﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Zhang, J
   Yu, ZK
   Liu, L
AF Zhang, Jie
   Yu, Zikui
   Liu, Lin
TI Multimodality Imaging in Diagnosing Polypoidal Choroidal Vasculopathy
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; indocyanine green angiography;
   optical coherence tomography; multispectral imaging; oxy-deoxy map
AB Purpose. Report a case of polypoidal choroidal vasculopathy (PCV) and reveal its characteristics in multispectral imaging (MSI), a novel modality that examines individual retinal layers and enhances visualization of deep retinal structures.
   Case Report. A 60-year-old Chinese woman presented with blurred vision in her left eye for over 1 week. Fundus examination revealed massive subretinal hemorrhage in the posterior pole with reddish orange polyp-like structure on the fovea of the left eye. Optical coherence tomography showed classic hyperreflectivity in the choroidal layer, known as the "double-layer'' sign, adjacent to a serous retinal pigment epithelial detachment, which was further confirmed in fluorescein angiography of the left eye. Indocyanine green angiography demonstrated the features of PCV, including multiple polyps arising out of inner choroidal vessels in the early phase as hyperfluorescent spots and ringlike silhouette staining of the polyps in the late phase. Multispectral imaging as a new modality was introduced to visualize the polypoidal lesion as a polyp-like cluster of hyperreflectance in the short-wavelength images (green and yellow) with subsequent highly defined ringlike hyperreflectance in the longer-wavelength images (near-infrared and infrared). According to the manifestations above, this patient's final diagnosis was PCV in the left eye.
   Conclusions. This is the first report using MSI as a novel imaging modality for the detection of PCV. Multispectral imaging can reveal highly defined hyperreflective polyp-like structures in the longer-wavelength images, which is compatible with the indocyanine green angiography findings, indicating preliminarily the advantages of noninvasiveness, simplicity, and effectiveness of MSI in diagnosing PCV.
C1 [Zhang, Jie; Yu, Zikui; Liu, Lin] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University
RP Liu, L (通讯作者)，Renji Hosp, Dept Ophthalmol, 160 Pujian Rd, Shanghai 200127, Peoples R China.
EM eyerenji@126.com
CR Calcagni A, 2011, EYE, V25, P1562, DOI 10.1038/eye.2011.202
   Everdell NL, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3478001
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   St Martin JM, 2013, OPTOMETRY VISION SCI, V90, pE293, DOI 10.1097/OPX.0000000000000079
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 11
TC 14
Z9 14
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JAN
PY 2015
VL 92
IS 1
BP E21
EP E26
DI 10.1097/OPX.0000000000000440
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1UW
UT WOS:000346732300004
PM 25397927
DA 2022-11-30
ER

PT J
AU Clark, AF
   Yorio, T
AF Clark, AF
   Yorio, T
TI Ophthalmic drug discovery
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; TRABECULAR MESHWORK CELLS; OPEN-ANGLE
   GLAUCOMA; RETINAL GANGLION-CELLS; INTRAOCULAR-PRESSURE; RAT MODEL;
   MATRIX METALLOPROTEINASES; DIABETIC-RETINOPATHY; OCULAR HYPERTENSION;
   GENE-THERAPY
AB Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.
C1 Alcon Res Ltd, Ft Worth, TX 76134 USA.
   Univ N Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Pharmcol & Neurosci, Ft Worth, TX 76107 USA.
C3 Novartis; Alcon; University of North Texas System; University of North
   Texas Health Science Center
RP Clark, AF (通讯作者)，Alcon Res Ltd, Ft Worth, TX 76134 USA.
EM abe.clark@alconlabs.com
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Agarwal N, 2002, EXP EYE RES, V74, P445, DOI 10.1006/exer.2001.1145
   Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   Aiello LP, 2002, SURV OPHTHALMOL, V47, pS263, DOI 10.1016/S0039-6257(02)00391-0
   Aihara M, 2002, INVEST OPHTH VIS SCI, V43, P146
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Alward WLM, 2003, SCIENCE, V299, P1527, DOI 10.1126/science.1082933
   Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503
   Alward WLM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1189
   ALWARD WLM, 2000, GLAUCOMA REQUISITES, P1
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794
   Avila MY, 2001, INVEST OPHTH VIS SCI, V42, P1841
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   Benson WE, 1999, OPHTHALMOLOGY
   Bielory L, 2002, DRUGS, V62, P1611, DOI 10.2165/00003495-200262110-00004
   Bielory Leonard, 2002, Expert Opin Pharmacother, V3, P541, DOI 10.1517/14656566.3.5.541
   Bodor N, 2001, PHARMAZIE, V56, pS67
   Borras T, 2002, INVEST OPHTH VIS SCI, V43, P2513
   Bradley JMB, 1998, INVEST OPHTH VIS SCI, V39, P2649
   Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5
   Calonge M, 2001, SURV OPHTHALMOL, V45, pS227, DOI 10.1016/S0039-6257(00)00205-8
   Campochiaro PA, 2002, EXPERT OPIN BIOL TH, V2, P537, DOI 10.1517/14712598.2.5.537
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Cioffi GA, 1995, CURR EYE RES, V14, P1147, DOI 10.3109/02713689508995821
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark Abbot F, 2002, Expert Opin Emerg Drugs, V7, P141
   Clark AF, 2000, EXPERT OPIN THER PAT, V10, P427, DOI 10.1517/13543776.10.4.427
   Clark AF, 2001, INVEST OPHTH VIS SCI, V42, P1769
   Clark AF, 1996, INVEST OPHTH VIS SCI, V37, P805
   CLARK AF, 1995, INVEST OPHTH VIS SCI, V36, P478
   CLARK AF, 1999, EMERG DRUGS, V4, P333
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   EDWARDS MG, 1999, OPHTHALMOLOGY
   ENGERMAN RL, 1995, ARCH OPHTHALMOL-CHIC, V113, P355, DOI 10.1001/archopht.1995.01100030111032
   Fanous MM, 1999, J OCUL PHARMACOL TH, V15, P51, DOI 10.1089/jop.1999.15.51
   Fauser S, 2002, SURV OPHTHALMOL, V47, P357, DOI 10.1016/S0039-6257(02)00314-4
   Fauss D, 1993, BASIC ASPECTS GLAUCO, VIII, P319
   Fautsch MP, 2000, INVEST OPHTH VIS SCI, V41, P4163
   FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Filla MS, 2002, INVEST OPHTH VIS SCI, V43, P151
   Fingert JH, 2002, SURV OPHTHALMOL, V47, P547, DOI 10.1016/S0039-6257(02)00353-3
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   Fingert JH, 2001, INVEST OPHTH VIS SCI, V42, P145
   Flammer J, 2001, PROG RETIN EYE RES, V20, P319, DOI 10.1016/S1350-9462(00)00028-8
   Fong DS, 2002, SURV OPHTHALMOL, V47, pS238, DOI 10.1016/S0039-6257(02)00389-2
   Foster CS, 1996, AM J OPHTHALMOL, V122, P171, DOI 10.1016/S0002-9394(14)72008-2
   FRASER S, 1999, OPHTHALMOLOGY
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Fujihara T, 2001, INVEST OPHTH VIS SCI, V42, P96
   Garcia CR, 2002, CURR EYE RES, V24, P33, DOI 10.1076/ceyr.24.1.33.5429
   GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Goldstein MH, 1999, OPHTHALMOLOGY, V106, P1313, DOI 10.1016/S0161-6420(99)00716-2
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   Guembel HOC, 1997, OPHTHALMOLOGICA, V211, P53, DOI 10.1159/000310887
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halpern D Lynn, 2002, Ophthalmol Clin North Am, V15, P61, DOI 10.1016/S0896-1549(01)00012-8
   Hare W, 2001, SURV OPHTHALMOL, V45, pS284, DOI 10.1016/S0039-6257(01)00200-4
   Howes JF, 2000, PHARMAZIE, V55, P178
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Ke TL, 1999, J OCUL PHARMACOL TH, V15, P513, DOI 10.1089/jop.1999.15.513
   Kim BS, 2001, MOL CELL BIOL, V21, P7707, DOI 10.1128/MCB.21.22.7707-7713.2001
   Kimura H, 2001, OPHTHALMOLOGICA, V215, P143, DOI 10.1159/000050849
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Ko ML, 2001, NEUROSCI LETT, V305, P139, DOI 10.1016/S0304-3940(01)01830-4
   Kowluru RA, 2002, CURR EYE RES, V24, P123, DOI 10.1076/ceyr.24.2.123.8158
   Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682
   Kunert KS, 2002, ARCH OPHTHALMOL-CHIC, V120, P330
   Lam DSC, 2000, INVEST OPHTH VIS SCI, V41, P1386
   Leibowitz HM, 1996, ARCH OPHTHALMOL-CHIC, V114, P933, DOI 10.1001/archopht.1996.01100140141005
   Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Lindsey JD, 1996, CURR EYE RES, V15, P869, DOI 10.3109/02713689609017628
   Loftsson T, 2002, ACTA OPHTHALMOL SCAN, V80, P144, DOI 10.1034/j.1600-0420.2002.800205.x
   Lund-Andersen H, 2002, SURV OPHTHALMOL, V47, pS270, DOI 10.1016/S0039-6257(02)00386-7
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   McKinnon SJ, 2002, MOL THER, V5, P780, DOI 10.1006/mthe.2002.0608
   Medeiros FA, 2002, DRUGS TODAY, V38, P563, DOI 10.1358/dot.2002.38.8.704676
   Mittag TW, 2000, INVEST OPHTH VIS SCI, V41, P3451
   Morrison JC, 1998, INVEST OPHTH VIS SCI, V39, P526
   Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184
   Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709
   Nakazawa T, 2002, INVEST OPHTH VIS SCI, V43, P3319
   *NAT EYE I, 2002, PREV BLINDN AM
   Nelson Mark L, 2003, Curr Opin Ophthalmol, V14, P39, DOI 10.1097/00055735-200302000-00007
   Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7
   Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944
   Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Panchapakesan J, 2003, BRIT J OPHTHALMOL, V87, P168, DOI 10.1136/bjo.87.2.168
   Pang IH, 1997, P SOC EXP BIOL MED, V215, P21
   Pang IH, 2000, J GLAUCOMA, V9, P468
   PANG IH, IN PRESS INVEST OPHT
   PARSHLEY DE, 1995, CURR EYE RES, V14, P537, DOI 10.3109/02713689508998400
   Parshley DE, 1996, INVEST OPHTH VIS SCI, V37, P795
   PEDERSON JE, 1984, ARCH OPHTHALMOL-CHIC, V102, P1689, DOI 10.1001/archopht.1984.01040031373030
   Penn JS, 1996, MICROVASC RES, V51, P126, DOI 10.1006/mvre.1996.0014
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Presta LG, 1997, CANCER RES, V57, P4593
   QUIGLEY HA, 1983, ARCH OPHTHALMOL-CHIC, V101, P1301
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   REENOR DL, IN PRESS INVEST OPHT
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   ROBISON WG, 1989, INVEST OPHTH VIS SCI, V30, P2285
   Sample P, 2001, SURV OPHTHALMOL, V45, pS273
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Sasaki H, 1999, CRIT REV THER DRUG, V16, P85
   Schoenwald Ronald D., 1997, P119
   Schwartz M, 2001, SURV OPHTHALMOL, V45, pS256, DOI 10.1016/S0039-6257(01)00208-9
   Seiler MJ, 2000, GRAEF ARCH CLIN EXP, V238, P599, DOI 10.1007/s004170000143
   SHAREEF SR, 1995, EXP EYE RES, V61, P379, DOI 10.1016/S0014-4835(05)80131-9
   SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47
   SIEVING PA, 1999, OPHTHALMOLOGY
   Smith A, 2001, DRUGS, V61, P747, DOI 10.2165/00003495-200161060-00004
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Stokely ME, 2002, INVEST OPHTH VIS SCI, V43, P3223
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Tamm ER, 2002, PROG RETIN EYE RES, V21, P395, DOI 10.1016/S1350-9462(02)00010-1
   Tatton WG, 1999, EUR J OPHTHALMOL, V9, pS22, DOI 10.1177/112067219900901S10
   Tatton WG, 2001, EUR J OPHTHALMOL, V11, pS12
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Thielen TL, 2000, ANN PHARMACOTHER, V34, P235, DOI 10.1345/aph.19136
   Ueda J, 1998, JPN J OPHTHALMOL, V42, P337, DOI 10.1016/S0021-5155(98)00026-4
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Vittitow JL, 2002, BIOCHEM BIOPH RES CO, V298, P67, DOI 10.1016/S0006-291X(02)02395-1
   Vorwerk CK, 1999, SURV OPHTHALMOL, V43, pS142, DOI 10.1016/S0039-6257(99)00017-X
   Wang RF, 2000, J GLAUCOMA, V9, P458
   Wax MB, 2001, J GLAUCOMA, V10, pS22, DOI 10.1097/00061198-200110001-00009
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weinreb RN, 1997, INVEST OPHTH VIS SCI, V38, P2772
   Wheeler LA, 2001, EUR J OPHTHALMOL, V11, pS30
   WIRTZ MK, 2003, GLAUCOMA SCI PRACTIC, P12
   Wong TTL, 2002, SURV OPHTHALMOL, V47, P239, DOI 10.1016/S0039-6257(02)00287-4
   Wood JPM, 2001, EXP EYE RES, V72, P79, DOI 10.1006/exer.2000.0929
   Wordinger RJ, 1999, PROG RETIN EYE RES, V18, P629, DOI 10.1016/S1350-9462(98)00035-4
   WuDunn Darrell, 2002, Curr Opin Ophthalmol, V13, P55, DOI 10.1097/00055735-200204000-00001
   Yamazaki H, 2002, INVEST OPHTH VIS SCI, V43, P919
   Yanni JM, 1999, ACTA OPHTHALMOL SCAN, V77, P33, DOI 10.1111/j.1600-0420.1999.tb01171.x
   Yorio T, 2002, J GLAUCOMA, V11, P259, DOI 10.1097/00061198-200206000-00016
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0
   Zhou ZH, 1999, HUM MOL GENET, V8, P2221, DOI 10.1093/hmg/8.12.2221
   ZHU MD, 1992, AUST NZ J OPHTHALMOL, V20, P225, DOI 10.1111/j.1442-9071.1992.tb00944.x
NR 169
TC 71
Z9 84
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD JUN
PY 2003
VL 2
IS 6
BP 448
EP 459
DI 10.1038/nrd1106
PG 12
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 683BZ
UT WOS:000183128300015
PM 12776220
DA 2022-11-30
ER

PT J
AU Sawa, M
   Ueno, C
   Gomi, F
   Nishida, K
AF Sawa, Miki
   Ueno, Chikaka
   Gomi, Fumi
   Nishida, Kohji
TI INCIDENCE AND CHARACTERISTICS OF NEOVASCULARIZATION IN FELLOW EYES OF
   JAPANESE PATIENTS WITH UNILATERAL RETINAL ANGIOMATOUS PROLIFERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; reticular pseudodrusen; retinal
   angiomatous proliferation; soft drusen; subretinal drusen; unilateral
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN; MACULAR
   DEGENERATION; TYPE-3 NEOVASCULARIZATION; CLINICAL CHARACTERISTICS;
   PREVALENCE; RISK
AB Purpose: To describe the incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation (RAP).
   Methods: We retrospectively studied patients with unilateral RAP in one center between 2003 and 2010. The minimal follow-up time was 2 years. The prevalence rates of soft drusen and reticular pseudodrusen in the fellow eyes at the first visit were examined in color fundus photographs and optical coherence tomography images. Stepwise analysis was performed to identify a correlation between the incidence of RAP in the fellow eyes and age, gender, follow-up time, soft drusen, and reticular pseudodrusen.
   Results: Twenty eyes were included in this study. The mean follow-up time was 49 months (range, 24-108 months). At the first visit, soft drusen was seen in 19 eyes (95%) and reticular pseudodrusen in 11 eyes (55%). Neovascular age-related macular degeneration developed in 10 eyes, including RAP in 9 eyes (45%) and polypoidal choroidal vasculopathy in 1 eye (5%). Stepwise analysis showed that reticular pseudodrusen and longer follow-up time were correlated significantly (P = 0.0384 and P = 0.0341, respectively) with the incidence of RAP.
   Conclusion: Bilateral RAP developed in almost half of the eyes initially diagnosed with unilateral RAP and the incidence increased with time. Reticular pseudodrusen is a risk factor for bilateral RAP.
C1 [Sawa, Miki; Ueno, Chikaka; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
   [Gomi, Fumi] Sumitomo Hosp, Div Ophthalmol, Osaka, Japan.
C3 Osaka University; Sumitomo Hospital
RP Sawa, M (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamadaoka,E-7, Suita, Osaka 5650871, Japan.
EM sawamiki@ophthal.med.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610; Gomi, Fumi/0000-0003-0807-8817
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuyama K, 2011, J OCUL PHARMACOL TH, V27, P379, DOI 10.1089/jop.2010.0194
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 17
TC 42
Z9 42
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2014
VL 34
IS 4
BP 761
EP 767
DI 10.1097/01.iae.0000434566.57189.37
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DO
UT WOS:000336960500024
PM 24100709
DA 2022-11-30
ER

PT J
AU Hsiao, YP
   Chen, C
   Lee, CM
   Chen, PY
   Chung, WH
   Wang, YP
   Hung, YC
   Cheng, CM
   Chen, C
   Ko, BH
   Hsu, MY
AF Hsiao, Yai-Ping
   Chen, Connie
   Lee, Chee-Ming
   Chen, Pei-Ying
   Chung, Wei-Heng
   Wang, Yu-Ping
   Hung, Yu-Chien
   Cheng, Chao-Min
   Chen, Chihchen
   Ko, Bei-Han
   Hsu, Min-Yen
TI Differences in the Quantity and Composition of Extracellular Vesicles in
   the Aqueous Humor of Patients with Retinal Neovascular Diseases
SO DIAGNOSTICS
LA English
DT Article
DE extracellular vesicle; exosome; aqueous humor; nanoparticle tracking
   analysis; retinal neovascular disease; angiogenesis
ID CELL-DERIVED EXOSOMES; PROTEINS; RELEASE; ROLES
AB Extracellular vesicles (EVs) are secreted by various cells in the body fluid system and have been found to influence vessel formation and inflammatory responses in a variety of diseases. However, which EVs and their subtypes are involved in vascular retinal diseases is still unclear. Therefore, the aim of this study was to explore the particle distribution of EVs in retinal neovascular diseases, including age-related macular degeneration, polypoidal choroidal vasculopathy, and central retinal vein occlusion. The aqueous humor was harvested from 20 patients with different retinal neovascular diseases and six patients with cataracts as the control group. The particle distribution was analyzed using nanoparticle tracking analysis (NTA) and transmitting electron microscopy (TEM). The results revealed that the disease groups had large amounts of EVs and their subtypes compared to the control group. After isolating exosomes, a higher expression of CD81(+) exosomes was shown in the disease groups using flow cytometry. The exosomes were then further classified into three subtypes of exomeres, small exosomes, and large exosomes, and their amounts were shown to differ depending on the disease type. To the best of our knowledge, this is the first study to elucidate the dynamics of EVs in retinal neovascular diseases using clinical cases. Our findings demonstrated the possible functionality of microvesicles and exosomes, indicating the potential of exosomes in the diagnosis and therapy of retinal neovascular diseases.
C1 [Hsiao, Yai-Ping; Chen, Connie; Lee, Chee-Ming; Chen, Pei-Ying; Chung, Wei-Heng; Ko, Bei-Han; Hsu, Min-Yen] Chung Shan Med Univ Hosp, Dept Ophthalmol, Taichung 402306, Taiwan.
   [Hsiao, Yai-Ping; Lee, Chee-Ming; Chen, Pei-Ying; Chung, Wei-Heng; Hsu, Min-Yen] Chung Shan Med Univ, Sch Med, Taichung 402306, Taiwan.
   [Chen, Connie] Chung Shan Med Univ, Dept Optometry, Taichung 402306, Taiwan.
   [Chen, Connie] Chung Shan Med Univ, Inst Optometry, Taichung 402306, Taiwan.
   [Wang, Yu-Ping] Taichung Vet Gen Hosp, Dept Radiol, Taichung 407219, Taiwan.
   [Hung, Yu-Chien] Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung 407219, Taiwan.
   [Cheng, Chao-Min] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 300044, Taiwan.
   [Chen, Chihchen] Natl Tsing Hua Univ, Inst Nanoengn & Microsyst, Hsinchu 30044, Taiwan.
   [Chen, Chihchen] Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu 300044, Taiwan.
   [Hsu, Min-Yen] Natl Chung Hsing Univ, Biotechnol Ctr, Taichung 402202, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University Hospital;
   Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University; Taichung Veterans General Hospital; Taichung
   Veterans General Hospital; National Tsing Hua University; National Tsing
   Hua University; National Tsing Hua University; National Chung Hsing
   University
RP Hsu, MY (通讯作者)，Chung Shan Med Univ Hosp, Dept Ophthalmol, Taichung 402306, Taiwan.; Hsu, MY (通讯作者)，Chung Shan Med Univ, Sch Med, Taichung 402306, Taiwan.; Hsu, MY (通讯作者)，Natl Chung Hsing Univ, Biotechnol Ctr, Taichung 402202, Taiwan.
EM amy1234575@gmail.com; cconnie7@gmail.com; cshy1886@csh.org.tw;
   rockinro11355@gmail.com; orien1168@gmail.com; drahcirxp@gmail.com;
   b92401086@gmail.com; chaomin@mx.nthu.edu.tw; chihchen23@gmail.com;
   bella37245@gmail.com; my.scott.hsu@gmail.com
RI Wang, Yu/GZL-9655-2022
OI Chen, Chihchen/0000-0002-2195-4802; Cheng, Chao-Min/0000-0002-8644-1960;
   Hsu, Min-Yen/0000-0002-5488-4257
FU Chung Shan Medical University Hospital [CSH-2020-C-027]; Ministry of
   Science and Technology of Taiwan [109-2636-E-04-001, 110-2636-E-040-001]
FX This study was supported in part by intramural grants from Chung Shan
   Medical University Hospital (Grant No. CSH-2020-C-027), and the Ministry
   of Science and Technology of Taiwan (109-2636-E-04-001,
   110-2636-E-040-001, Columbus program of MOST Young Scholar Fellowship).
CR Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Bar-Sela G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240994
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Davizon P, 2010, SEMIN THROMB HEMOST, V36, P857, DOI 10.1055/s-0030-1267039
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Dong X, 2021, THERANOSTICS, V11, P5107, DOI 10.7150/thno.54755
   Dutta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097580
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121
   Guduric-Fuchs J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-357
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Han KY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40548
   Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609
   Ju CW, 2018, J CARDIOVASC TRANSL, V11, P420, DOI 10.1007/s12265-018-9822-0
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004
   Lerner N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171153
   Liao Zhi-xiong, 2012, Zhejiang Da Xue Xue Bao Yi Xue Ban, V41, P315
   Liu J, 2020, INT J NANOMED, V15, P10519, DOI 10.2147/IJN.S277190
   Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Mead B, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100849
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Nojehdehi S, 2018, J CELL BIOCHEM, V119, P9433, DOI 10.1002/jcb.27260
   Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658
   Pan DY, 2019, J CHEM NEUROANAT, V96, P134, DOI 10.1016/j.jchemneu.2019.01.006
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev-biochem-013118-111902
   Qin S, 2019, FASEB J, V33, P6129, DOI 10.1096/fj.201802388R
   Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622
   Sahaboglu A, 2019, ADV EXP MED BIOL, V1185, P431, DOI 10.1007/978-3-030-27378-1_71
   Samaeekia R, 2018, INVEST OPHTH VIS SCI, V59, P5194, DOI 10.1167/iovs.18-24803
   Sanghani A, 2022, ACTA OPHTHALMOL, V100, P243, DOI 10.1111/aos.14932
   Seyedrazizadeh SZ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01702-x
   Stahl PD, 2019, PHYSIOLOGY, V34, P169, DOI 10.1152/physiol.00045.2018
   Tamkovich SN, 2016, BIOCHEM MOSC SUPPL S, V10, P163, DOI 10.1134/S1990747816020112
   Tokarz Aleksandra, 2015, Folia Med Cracov, V55, P35
   Tong Y, 2016, MED HYPOTHESES, V97, P98, DOI 10.1016/j.mehy.2016.10.027
   Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang WP, 2021, HUM GENE THER, V32, P707, DOI 10.1089/hum.2020.328
   Yu B, 2021, INT J BIOCHEM CELL B, V135, DOI 10.1016/j.biocel.2021.105975
   Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562
   Zhang HY, 2019, NAT PROTOC, V14, P1027, DOI 10.1038/s41596-019-0126-x
   Zhang HY, 2018, NAT CELL BIOL, V20, P332, DOI 10.1038/s41556-018-0040-4
   Zhang ZY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.643680
   Zhang ZH, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108626
NR 47
TC 2
Z9 2
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD JUL
PY 2021
VL 11
IS 7
AR 1276
DI 10.3390/diagnostics11071276
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TO4XU
UT WOS:000676917300001
PM 34359359
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Warrow, DJ
   Hoang, QV
   Freund, KB
AF Warrow, David J.
   Hoang, Quan V.
   Freund, K. Bailey
TI PACHYCHOROID PIGMENT EPITHELIOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE central; chorioretinopathy; choroidal; forme; fruste; serous; thickening
ID CENTRAL SEROUS CHORIORETINOPATHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE; VASCULAR
   HYPERPERMEABILITY; ANGIOGRAPHIC FINDINGS; PHOTODYNAMIC THERAPY;
   FOLLOW-UP
AB Purpose: To report nine cases of pachychoroid pigment epitheliopathy.
   Methods: An observational case series of nine patients who underwent comprehensive ophthalmic examination, fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, and enhanced depth imaging optical coherence tomography.
   Results: Eighteen eyes of 9 patients, aged 27 years to 89 years, were diagnosed with pachychoroid pigment epitheliopathy based on the characteristic funduscopic appearance of reduced fundus tessellation with overlying retinal pigment epithelial changes in one or both eyes, fundus autofluorescence abnormalities, and increased subfoveal choroidal thickness confirmed by enhanced depth imaging optical coherence tomography (mean, 460.2 mu m). The five older patients had been previously diagnosed with age-related macular degeneration, while the four younger subjects were referred for possible inflammatory chorioretinitis, pattern dystrophy, or nonspecific drusen. No subjects had a history of or subsequently developed subretinal fluid.
   Conclusion: Pachychoroid pigment epitheliopathy falls within a spectrum of diseases associated with choroidal thickening that includes central serous chorioretinopathy and polypoidal choroidal vasculopathy, and it should be suspected in eyes with a characteristic fundus appearance related to choroidal thickening and associated retinal pigment epithelial abnormalities but no history of subretinal fluid. Enhanced depth imaging optical coherence tomography confirming an abnormally thick choroid and characteristic retinal pigment epithelial changes on fundus autofluorescence support the diagnosis. Because these patients are frequently misdiagnosed, the recognition of pachychoroid pigment epitheliopathy may avoid unnecessary diagnostic testing and interventions.
C1 [Warrow, David J.] New York Eye & Ear Infirm, Dept Ophthalmol, New York, NY 10003 USA.
   [Hoang, Quan V.; Freund, K. Bailey] Macula Consultants New York, Retina, Vitreous, New York, NY 10022 USA.
   [Hoang, Quan V.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Hoang, Quan V.; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; Vitreous Retina Macula
   Consultants of New York; Manhattan Eye Ear & Throat Hospital; Columbia
   University; New York University
RP Freund, KB (通讯作者)，Macula Consultants New York, Retina, Vitreous, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retina Research Center, Manhattan Eye, Ear, and Throat
   Hospital; Macula Foundation Inc, New York, NY
FX Supported in part by the LuEsther T. Mertz Retina Research Center,
   Manhattan Eye, Ear, and Throat Hospital, and The Macula Foundation Inc,
   New York, NY.
CR Abe Sachi, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-76
   Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   [Anonymous], 1866, GRAEFES ARCH CLIN EX, DOI DOI 10.1007/BF02720786
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Bandello F, 2000, OPHTHALMOLOGICA, V214, P362, DOI 10.1159/000027522
   Bujarborua D, 2001, ACTA OPHTHALMOL SCAN, V79, P417, DOI 10.1034/j.1600-0420.2001.079004417.x
   COHEN D, 1983, J FR OPHTALMOL, V6, P339
   Dinc UA, 2011, CLIN EXP OPTOM, V94, P452, DOI 10.1111/j.1444-0938.2011.00598.x
   Fossarello M, 2004, EUR J OPHTHALMOL, V14, P568, DOI 10.1177/112067210401400620
   Framme C, 2005, ACTA OPHTHALMOL SCAN, V83, P161, DOI 10.1111/j.1600-0420.2005.00442.x
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gass JDM, 2005, RETINA-J RET VIT DIS, V25, P304, DOI 10.1097/00006982-200504000-00009
   GASS JDM, 1991, ARCH OPHTHALMOL-CHIC, V109, P677, DOI 10.1001/archopht.1991.01080050091036
   GASS JDM, 1987, STEREOSCOPIC ATLAS M, P46
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Goldenberg D, 2012, OPHTHAL SURG LAS IM, V43, P296, DOI 10.3928/15428877-20120426-02
   Gomez-Ulla F, 2000, ACTA OPHTHALMOL SCAN, V78, P232, DOI 10.1034/j.1600-0420.2000.078002232.x
   Goncu T, 2011, OPTOMETRY, V82, P556, DOI 10.1016/j.optm.2011.04.103
   Gupta Pawan, 2010, International Ophthalmology, V30, P175, DOI 10.1007/s10792-009-9302-2
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Iida Tomohiro, 1996, Nippon Ganka Gakkai Zasshi, V100, P817
   Iijima H, 1999, AM J OPHTHALMOL, V127, P477, DOI 10.1016/S0002-9394(98)00378-X
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   MAUMENEE A E, 1965, Trans Am Acad Ophthalmol Otolaryngol, V69, P605
   Mendrinos E, 2008, EUR J OPHTHALMOL, V18, P649, DOI 10.1177/112067210801800428
   Moisseiev J, 1989, Retina, V9, P153
   PICCOLINO FC, 1995, EYE, V9, P324, DOI 10.1038/eye.1995.63
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   PRUNTE C, 1995, INT OPHTHALMOL, V19, P77, DOI 10.1007/BF00133176
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Sun Jinghua, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P313
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   van Velthoven MEJ, 2005, BRIT J OPHTHALMOL, V89, P1483, DOI 10.1136/bjo.2005.073056
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Yannuzzi L A, 1992, Eur J Ophthalmol, V2, P103
   Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   YOSHIOKA H, 1991, Nippon Ganka Gakkai Zasshi, V95, P1181
NR 59
TC 309
Z9 324
U1 7
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1659
EP 1672
DI 10.1097/IAE.0b013e3182953df4
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200022
PM 23751942
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Ooto, S
   Yamashiro, K
   Tamura, H
   Otani, A
   Yoshimura, N
AF Tsujikawa, Akitaka
   Ooto, Sotaro
   Yamashiro, Kenji
   Tamura, Hiroshi
   Otani, Atsushi
   Yoshimura, Nagahisa
TI Treatment of polypoidal choroidal vasculopathy by intravitreal injection
   of bevacizumab
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; polypoidal choroidal
   vasculopathy
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; LASER
   PHOTOCOAGULATION; JAPANESE PATIENTS; RANIBIZUMAB; NEOVASCULARIZATION;
   VERTEPORFIN
AB To evaluate the efficacy of intravitreal bevacizumab (IVB) in eyes with polypoidal choroidal vasculopathy (PCV).
   Seventeen eyes of 16 patients with either subfoveal or juxtafoveal PCV were treated with IVB. As the initial treatment, ten eyes were treated with a single injection of bevacizumab and seven were treated with three monthly injections. Additional IVB injections were performed in 15 eyes when either a recurrent or residual exudative change was seen. Follow-up after initiation of IVB ranged from 12 to 30 months (mean, 20.7 +/- 5.7 months).
   The mean foveal thickness before IVB (492 +/- 205 mu m) decreased to 384 +/- 181 mu m at 3 months (P = 0.0008), and with additional IVB for recurrent exudative changes, the foveal thickness remained significantly reduced at 12 months (392 +/- 203 mu m, P = 0.0270). Mean visual acuity at baseline (0.54 +/- 0.38 in logMAR) somewhat improved to 0.45 +/- 0.32 at 3 months (P = 0.156). However, the improvement in visual acuity then subsided, and returned to the pretreatment value at 12 months (0.54 +/- 0.39).
   In eyes with PCV, IVB can reduce the exudative change and can maintain visual function for at least 1 year.
C1 [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   PAI SA, ACTA OPHTHA IN PRESS
   Peng CH, 2009, EYE, V23, P2126, DOI 10.1038/eye.2008.401
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zuo CG, 2009, DOC OPHTHALMOL, V119, P29, DOI 10.1007/s10633-009-9166-9
NR 36
TC 34
Z9 36
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2010
VL 54
IS 4
BP 310
EP 319
DI 10.1007/s10384-010-0813-1
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 637IS
UT WOS:000280811400010
PM 20700799
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Klufas, MA
   Yannuzzi, NA
   Pang, CE
   Srinivas, S
   Sadda, SR
   Freund, KB
   Kiss, S
AF Klufas, Michael A.
   Yannuzzi, Nicolas A.
   Pang, Claudine E.
   Srinivas, Sowmya
   Sadda, Srinivas R.
   Freund, K. Bailey
   Kiss, Szilard
TI FEASIBILITY AND CLINICAL UTILITY OF ULTRA-WIDEFIELD INDOCYANINE GREEN
   ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ultra-widefield imaging; ultra-widefield; wide-field; imaging; retinal
   imaging; indocyanine green angiography; wide-field fluorescein
   angiography; age-related macular degeneration; central serous
   chorioretinopathy; sarcoidosis; syphilis; bird-shot chorioretinopathy;
   multifocal choroiditis; acute zonal occult outer retinopathy; polypoidal
   choroidal vasculopathy
ID FIELD FLUORESCEIN ANGIOGRAPHY; INFRARED-ABSORPTION ANGIOGRAPHY; SCANNING
   LASER OPHTHALMOSCOPY; OCCULT OUTER RETINOPATHY; PERIPHERAL
   AUTOFLUORESCENCE; MULTIFOCAL CHOROIDITIS; MANAGEMENT; VIDEOANGIOGRAPHY;
   OCCLUSION; WHITE
AB Purpose: To evaluate the feasibility and clinical utility of a novel noncontact scanning laser ophthalmoscope-based ultra-widefield indocyanine green angiographic system.
   Methods: Ultra-widefield indocyanine green angiographic images were captured using a modified Optos P200Tx that produced high-resolution images of the choroidal vasculature with up to a 200 degrees field. Ultra-widefield indocyanine green angiography was performed on patients with a variety of retinal conditions to assess utility of this imaging technique for diagnostic purposes and disease treatment monitoring.
   Results: Ultra-widefield indocyanine green angiography was performed on 138 eyes of 69 patients. Mean age was 58 +/- 16.9 years (range, 24-85 years). The most common ocular pathologies imaged included central serous chorioretinopathy (24 eyes), uveitis (various subtypes, 16 eyes), age-related macular degeneration (12 eyes), and polypoidal choroidal vasculopathy (4 eyes). In all eyes evaluated with ultra-widefield indocyanine green angiography, high-resolution images of choroidal and retinal circulation were obtained with sufficient detail out to 200 degrees of the fundus.
   Conclusion: In this series of 138 eyes, scanning laser ophthalmoscope-based ultra-widefield indocyanine green angiography was clinically practical and provided detailed images of both the central and peripheral choroidal circulation. Future studies are needed to refine the clinical value of this imaging modality and the significance of peripheral choroidal vascular changes in the diagnosis, monitoring, and treatment of ocular diseases.
C1 [Klufas, Michael A.; Yannuzzi, Nicolas A.; Kiss, Szilard] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Srinivas, Sowmya; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
C3 Cornell University; Vitreous Retina Macula Consultants of New York;
   University of Southern California; New York University
RP Kiss, S (通讯作者)，NewYork Presbyterian Hosp, Weill Cornell Med Coll, Dept Ophthalmol, 1305 York Ave,11th Floor, New York, NY 10021 USA.
EM szk7001@med.cornell.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Kiss, Szilard/0000-0003-3433-8432
FU Research to Prevent Blindness (RPB) foundation; LuEsther T. Mertz
   Retinal Research Center, New York, NY
FX Weill Cornell Ophthalmology received an unrestricted departmental grant
   from the Research to Prevent Blindness (RPB) foundation. Supported in
   part by the LuEsther T. Mertz Retinal Research Center, New York, NY.
CR Anderson L, 2007, Semin Ophthalmol, V22, P43, DOI 10.1080/08820530601162867
   Baglivo E, 2003, CAN J OPHTHALMOL, V38, P401, DOI 10.1016/S0008-4182(03)80053-4
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Bodaghi Bahram, 2012, Presse Med, V41, pe349, DOI 10.1016/j.lpm.2012.04.004
   Campbell JP, 2012, AM J OPHTHALMOL, V154, P908, DOI 10.1016/j.ajo.2012.05.019
   Cho MHE, 2011, RETINA-J RET VIT DIS, V31, P738, DOI 10.1097/IAE.0b013e3181f049ec
   CHOROMOKOS E, 1969, J BIOL PHOTOGR ASSOC, V37, P100
   Coffee RE, 2009, SEMIN OPHTHALMOL, V24, P34, DOI 10.1080/08820530802520194
   Comander J, 2011, SEMIN OPHTHALMOL, V26, P329, DOI 10.3109/08820538.2011.588661
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Dhaliwal C, 2009, BRIT J OPHTHALMOL, V93, P355, DOI 10.1136/bjo.2008.148908
   Eandi CM, RETINA, V32, P1915
   Fine HF, 2009, ARCH OPHTHALMOL-CHIC, V127, P66, DOI 10.1001/archophthalmol.2008.530
   FLOWER RW, 1972, AM J OPHTHALMOL, V73, P458, DOI 10.1016/0002-9394(72)90079-7
   FLOWER RW, 1972, AM J OPHTHALMOL, V74, P600, DOI 10.1016/0002-9394(72)90819-7
   FLOWER RW, 1973, INVEST OPHTH VISUAL, V12, P248
   GASS JDM, 1990, OPHTHALMOLOGY, V97, P1288
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   GUYER DR, 1993, CURR OPIN OPHTHALMOL, V4, P3, DOI 10.1097/00055735-199306000-00002
   HAYASHI K, 1989, JPN J OPHTHALMOL, V33, P57
   Heussen FM, 2011, OPHTHAL SURG LAS IM, V42, P272, DOI 10.3928/15428877-20110505-01
   Iida T, 2002, AM J OPHTHALMOL, V133, P151, DOI 10.1016/S0002-9394(01)01251-X
   Jain A, 2009, SEMIN OPHTHALMOL, V24, P43, DOI 10.1080/08820530802520384
   Joseph A, 2007, EYE, V21, P1114, DOI 10.1038/sj.eye.6702504
   Kaines A, 2009, SEMIN OPHTHALMOL, V24, P19, DOI 10.1080/08820530802520095
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   KOGURE K, 1970, ARCH OPHTHALMOL-CHIC, V83, P209
   KULVIN S, 1970, SOUTHERN MED J, V63, P998, DOI 10.1097/00007611-197009000-00003
   Leder HA, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-30
   Manivannan A, 2005, AM J OPHTHALMOL, V140, P525, DOI 10.1016/j.ajo.2005.02.055
   Mantel I, 2012, AM J OPHTHALMOL, V153, P910, DOI 10.1016/j.ajo.2011.10.017
   Mudvari SS, 2010, OPHTHAL SURG LAS IM, V41, P311, DOI 10.3928/15428877-20100430-03
   Neri P, 2014, INT OPHTHALMOL, V34, P359, DOI 10.1007/s10792-013-9801-z
   Oliver SCN, 2010, SEMIN OPHTHALMOL, V25, P27, DOI 10.3109/08820538.2010.481239
   Orlin A, 2013, CLIN OPHTHALMOL, V7, P959, DOI 10.2147/OPTH.S43450
   Patel CK, 2013, EYE, V27, P589, DOI 10.1038/eye.2013.45
   POMERANTZEFF O, 1975, INVEST OPHTH VISUAL, V14, P401
   Prasad PS, 2010, OPHTHALMOLOGY, V117, P780, DOI 10.1016/j.ophtha.2009.09.019
   Puech C, 2010, GRAEF ARCH CLIN EXP, V248, P1623, DOI 10.1007/s00417-010-1481-z
   Reddy S, 2009, SEMIN OPHTHALMOL, V24, P9, DOI 10.1080/08820530802519899
   Reeves GMB, 2013, ACTA OPHTHALMOL, V91, P48, DOI 10.1111/j.1755-3768.2011.02200.x
   Ross A, 2011, CURR OPIN OPHTHALMOL, V22, P166, DOI 10.1097/ICU.0b013e3283459826
   Saito A, 2007, JPN J OPHTHALMOL, V51, P295, DOI 10.1007/s10384-007-0451-4
   SCHEIDER A, 1989, AM J OPHTHALMOL, V108, P458, DOI 10.1016/S0002-9394(14)73325-2
   Shields CL, 2003, ARCH OPHTHALMOL-CHIC, V121, P1603, DOI 10.1001/archopht.121.11.1603
   Silva PS, 2013, OPHTHALMOLOGY, V120, P2587, DOI 10.1016/j.ophtha.2013.05.004
   Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25
   Slakter JS, 1997, OPHTHALMOLOGY, V104, P1813, DOI 10.1016/S0161-6420(97)30022-0
   Soliman AZ, SEMIN OPHTHALMOL, V27, P221
   Spaide RF, 2004, AM J OPHTHALMOL, V138, P887, DOI 10.1016/j.ajo.2004.06.001
   Spaide RF, 1998, RETINA-J RET VIT DIS, V18, P44
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P829, DOI 10.1097/IAE.0b013e31820c841e
   Staurenghi G, 2005, ARCH OPHTHALMOL-CHIC, V123, P244, DOI 10.1001/archopht.123.2.244
   Takahashi K, 1996, OPHTHALMOLOGY, V103, P336
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Tsui I, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/464127
   Tsui I, 2013, OPHTHAL SURG LAS IM, V44, P59, DOI 10.3928/23258160-20121221-14
   Tsui I, 2012, OPHTHAL SURG LAS IM, V43, P257, DOI 10.3928/15428877-20120424-01
   Tsui I, 2011, RETINA-J RET VIT DIS, V31, P105, DOI 10.1097/IAE.0b013e3181e36c6d
   Tsui I, 2009, SEMIN OPHTHALMOL, V24, P29, DOI 10.1080/08820530802520186
   Vadala M, 2001, OPHTHALMOLOGICA, V215, P16, DOI 10.1159/000050820
   Wessel MM, 2012, RETINA-J RET VIT DIS, V32, P785, DOI 10.1097/IAE.0b013e3182278b64
   Wessel MM, BR J OPHTHALMOL, V96, P694
   Witmer MT, 2012, EYE, V26, P1209, DOI 10.1038/eye.2012.122
   Witmer MT, 2013, CLIN OPHTHALMOL, V7, P389, DOI 10.2147/OPTH.S41731
   Witmer MT, 2013, SURV OPHTHALMOL, V58, P143, DOI 10.1016/j.survophthal.2012.07.003
   Witmer MT, 2012, ACTA OPHTHALMOL, V90, pe428, DOI 10.1111/j.1755-3768.2012.02434.x
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 69
TC 26
Z9 30
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2015
VL 35
IS 3
BP 508
EP 520
DI 10.1097/IAE.0000000000000318
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC4AO
UT WOS:000350293100031
PM 25250480
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Hirami, Y
   Nakanishi, H
   Ojima, Y
   Aikawa, H
   Tamura, H
   Otani, A
   Yoshimura, N
AF Tsujikawa, Akitaka
   Hirami, Yasuhiko
   Nakanishi, Hideo
   Ojima, Yumiko
   Aikawa, Hiroko
   Tamura, Hiroshi
   Otani, Atsushi
   Yoshimura, Nagahisa
TI Retinal pigment epithelial tear in polypoidal choroidal vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; polypoidal
   choroidal vasculopathy; retinal pigment epithelial tear
ID PHOTODYNAMIC THERAPY; NEOVASCULARIZATION SECONDARY; INTRAVITREAL
   BEVACIZUMAB; DETACHMENT; VERTEPORFIN; MICRORIPS; FEATURES
AB Purpose: To study the clinical characteristics of tears of the retinal pigment epithelium (RPE) in eyes with polypoidal choroidal vasculopathy (PCV).
   Methods: The authors report eight eyes of eight patients with PCV that had tears of the RPE. These were examined with angiography and tomography.
   Results: Eight eyes of eight patients (seven men and one woman) had RPE tears at the margin of a serosanguineous pigment epithelial detachment (PED) associated with PCV. Tears of the RPE were detected at the initial visit in one eye and during follow-up without any treatment in five eyes. In two eyes, the RPE tears were detected 3 months and 6 months, respectively, after photodynamic therapy. In all eyes, the RPE tears were detected at the side opposite to the polypoidal lesions of the PEDs, and the fovea was not involved in the RPE tear. Visual acuity in the seven eyes without RPE tears on presentation ranged from 20/100 to 20/16 (median, 20/32). During follow-up, three of these eyes lost three or more lines of vision. At the final examination, while three of these eyes had visual acuity of 20/25 or better, the other four had visual acuity of 20/200 or worse.
   Conclusion: In eyes with PCV, RPE tears can occur at the margin of serosanguineous PEDs-either spontaneously or after photodynamic therapy.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   IE D, 1992, ARCH OPHTHALMOL-CHIC, V110, P1443, DOI 10.1001/archopht.1992.01080220105030
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Prakash M, 2006, AM J OPHTHALMOL, V142, P1079, DOI 10.1016/j.ajo.2006.06.059
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 32
TC 21
Z9 23
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 832
EP 838
DI 10.1097/IAE.0b013e318150d864
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600005
PM 17891005
DA 2022-11-30
ER

PT J
AU Heuberger, RA
   Fisher, AI
   Jacques, PF
   Klein, R
   Klein, BEK
   Palta, M
   Mares-Perlman, JA
AF Heuberger, RA
   Fisher, AI
   Jacques, PF
   Klein, R
   Klein, BEK
   Palta, M
   Mares-Perlman, JA
TI Relation of blood homocysteine and its nutritional determinants to
   age-related maculopathy in the third National Health and Nutrition
   Examination Survey
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE homocysteine; age-related maculopathy; third National Health and
   Nutrition Examination Survey; NHANES III; elderly; vitamin B-12; folate
ID SENILE MACULAR DEGENERATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   PLASMA HOMOCYSTEINE; DIETARY-FAT; MYOCARDIAL-INFARCTION;
   VASCULAR-DISEASE; HOMOCYST(E)INE; VITAMIN-B12; ASSOCIATION
AB Background: Blood homocysteine and its nutritional determinants folate and cyanocobalamin (vitamin B-12) have been shown to affect the risk of vascular disease. The pathogenesis of age-related maculopathy (ARM) is related to adverse vascular changes.
   Objective: The objective was to evaluate the associations between homocysteine, its nutritional determinants, and ARM in persons aged greater than or equal to 40 y participating in the third National Health and Nutrition Examination Survey.
   Design: A nonmydriatic fundus photograph of one eye, taken in a mobile examination center, was used to ascertain ARM status. Phlebotomy was performed for measurement of homocysteine, cyanocobalamin, and erythrocyte folate in participants of phase 2 of the survey (n = 3828). Logistic regressions were used to compute odds ratios and 95% CIs by quintile of serum analyte by using sample weights and jackknife replication methods to adjust for the complex survey design. The final analyses were adjusted for potential risk factors that influenced odds ratios.
   Results: Total serum homocysteine, red blood cell folate, and serum cyanocobalamin were unrelated to ARM in the overall sample. However, red blood cell folate was inversely related to one type of early ARM lesion (soft drusen) in non-Hispanic blacks.
   Conclusions: ARM does not appear to be associated with homocysteine or its dietary determinants in this survey. There is a need for further investigation to rule out potential associations in subgroups with low folate status that may not have been detected because of the cross-sectional survey design.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53705 USA.
   Univ Wisconsin, Dept Prevent Med, Sch Med, Madison, WI 53705 USA.
   Tufts Univ, Res Ctr Aging, Boston, MA 02111 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Tufts
   University
RP Mares-Perlman, JA (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,460 WARF, Madison, WI 53705 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NATIONAL EYE INSTITUTE [R01EY011722] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY11722] Funding Source: Medline
CR ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3
   ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704
   *BIOR LAB, 1987, INSTR MAN BIOR QUANT
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bostom AG, 1999, ARCH INTERN MED, V159, P1077, DOI 10.1001/archinte.159.10.1077
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   CHAVERS BM, 1984, KIDNEY INT, V25, P576, DOI 10.1038/ki.1984.57
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Dudman NPB, 1996, J NUTR, V126, pS1295, DOI 10.1093/jn/126.suppl_4.1295S
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Giles WH, 1998, STROKE, V29, P2473, DOI 10.1161/01.STR.29.12.2473
   Gunter E.W., 1996, LAB PROCEDURES USED
   Harpel PC, 1996, J NUTR, V126, pS1285, DOI 10.1093/jn/126.suppl_4.1285S
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAHN HA, 1973, DHEW PUBLICATION
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Malinow MR, 1996, J NUTR, V126, pS1238, DOI 10.1093/jn/126.suppl_4.1238S
   Malinow MR, 1999, CIRCULATION, V99, P178, DOI 10.1161/01.CIR.99.1.178
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   *NAT CTR HLTH STAT, 1994, VITAL HLTH STAT, V1, P32
   National Society to Prevent Blindness, 1980, VIS PROBL US DAT AN, P1
   NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526
   Potts A M, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P1058
   REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P
   SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131
   SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877
   TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369
   UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47
   Ubbink JB, 1996, J NUTR, V126, pS1254, DOI 10.1093/jn/126.suppl_4.1254S
   Ueland PM, 1996, J NUTR, V126, pS1281, DOI 10.1093/jn/126.suppl_4.1281S
   Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Woodside JV, 1998, AM J CLIN NUTR, V67, P858, DOI 10.1093/ajcn/67.5.858
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 45
TC 45
Z9 47
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 2002
VL 76
IS 4
BP 897
EP 902
DI 10.1093/ajcn/76.4.897
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 595GV
UT WOS:000178101000028
PM 12324306
OA Bronze
DA 2022-11-30
ER

PT J
AU Christen, WG
   Cook, NR
   Manson, JE
   Buring, JE
   Chasman, DI
   Lee, IM
   Bubes, V
   Li, CY
   Haubourg, M
   Schaumberg, DA
AF Christen, William G.
   Cook, Nancy R.
   Manson, JoAnn E.
   Buring, Julie E.
   Chasman, Daniel I.
   Lee, I-Min
   Bubes, Vadim
   Li, Chunying
   Haubourg, Margarette
   Schaumberg, Debra A.
TI Effect of Vitamin D and omega-3 Fatty Acid Supplementation on Risk of
   Age-Related Macular Degeneration An Ancillary Study of the VITAL
   Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; COMBINATION TREATMENT; BETA-CAROTENE;
   MACULOPATHY; CATARACT; SMOKING; RANIBIZUMAB; PROGRESSION; PREVALENCE;
   CANCER
AB IMPORTANCE Observational studies suggest that higher intake or blood levels of vitamin D and marine omega-3 fatty acids may be associated with lower risks of age-related macular degeneration (AMD). However, evidence from randomized trials is limited.
   OBJECTIVE To evaluate whether daily supplementation with vitamin D-3, marine omega-3 fatty acids, or both prevents the development or progression of AMD.
   DESIGN, SETTING, AND PARTICIPANTS This was a prespecified ancillary study of the Vitamin D and Omega-3 Trial (VITAL), a nationwide, placebo-controlled, 2 x 2 factorial design randomized clinical trial of supplementation with vitamin D and marine omega-3 fatty acids for the primary prevention of cancer and cardiovascular disease. Participants included 25 871 men and women in the US. Randomization was from November 2011 to March 2014, and study pill-taking ended as planned on December 31, 2017.
   INTERVENTIONS Vitamin D-3 (cholecalciferol), 2000 IU per day, and marine omega-3 fatty acids, 1 g per day.
   MAIN OUTCOMES AND MEASURES The primary end point was total AMD events, a composite of incident cases of AMD plus cases of progression to advanced AMD among participants with AMD at baseline, based on self-report confirmed by medical record review. Analyses were conducted using the intention-to-treat population.
   RESULTS In total, 25 871 participants with a mean (SD) age of 67.1 (7.0) years were included in the trial. Of them, 50.6% were women, 71.3% were self-declared non-Hispanic White participants, and 20.2% were Black participants. During a median (range) of 5.3 (3.8-6.1) years of treatment and follow-up, 324 participants experienced an AMD event (285 incident AMD and 39 progression to advanced AMD). For vitamin D-3, there were 163 events in the treated group and 161 in the placebo group (hazard ratio [HR], 1.02; 95% CI, 0.82-1.27). For omega-3 fatty acids, there were 157 events in the treated group and 167 in the placebo group (HR, 0.94; 95% CI, 0.76-1.17). In analyses of individual components for the primary end point, HRs comparing vitamin D-3 groups were 1.09 (95% CI, 0.86-1.37) for incident AMD and 0.63 (95% CI, 0.33-1.21) for AMD progression. For omega-3 fatty acids, HRs were 0.93 (95% CI, 0.73-1.17) for incident AMD and 1.05 (95% CI, 0.56-1.97) for AMD progression.
   CONCLUSION AND RELEVANCE Neither vitamin D-3 nor marine omega-3 fatty acid supplementation had a significant overall effect on AMD incidence or progression.
C1 [Christen, William G.; Cook, Nancy R.; Manson, JoAnn E.; Buring, Julie E.; Chasman, Daniel I.; Bubes, Vadim; Li, Chunying; Haubourg, Margarette; Schaumberg, Debra A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.
   [Cook, Nancy R.; Manson, JoAnn E.; Buring, Julie E.; Chasman, Daniel I.; Lee, I-Min] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Harvard T.H. Chan School of Public Health
RP Christen, WG (通讯作者)，Harvard Med Sch, Brigham & Womens Hosp, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
RI Lee, I-Min/ABD-5409-2021
FU National Eye Institute [R01 EY021900]; National Cancer Institute [U01
   CA138962, R01 CA138962]; National Heart, Lung, and Blood Institute;
   Office of Dietary Supplements; National Institute of Neurological
   Disorders and Stroke; National Center for Complementary and Integrative
   Health
FX This work was supported by grants from the National Eye Institute (R01
   EY021900), the National Cancer Institute (U01 CA138962 and R01
   CA138962), the National Heart, Lung, and Blood Institute, the Office of
   Dietary Supplements, the National Institute of Neurological Disorders
   and Stroke, and the National Center for Complementary and Integrative
   Health. Pharmavite donated vitamin D, and Pronova BioPharma and BASF
   donated the omega-3 fatty acids (Omacor); the companies also donated
   matching placebos and packaging in the form of calendar packs. Quest
   Diagnostics measured the serum 25-hydroxyvitamin D levels and plasma
   omega-3 index at no cost to the trial.
CR Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Bassuk SS, 2016, CONTEMP CLIN TRIALS, V47, P235, DOI 10.1016/j.cct.2015.12.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Dyck MC, 2011, MED HYPOTHESES, V77, P326, DOI 10.1016/j.mehy.2011.05.006
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foreman J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09421-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Harris WS, 2004, PREV MED, V39, P212, DOI 10.1016/j.ypmed.2004.02.030
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kouchaki E, 2018, J NUTR, V148, P1380, DOI 10.1093/jn/nxy116
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Manson JE, 2019, NEW ENGL J MED, V380, P23, DOI 10.1056/NEJMoa1811403
   Manson JE, 2012, CONTEMP CLIN TRIALS, V33, P159, DOI 10.1016/j.cct.2011.09.009
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Niramitmahapanya S, 2011, J CLIN ENDOCR METAB, V96, P3170, DOI 10.1210/jc.2011-1518
   Razavi M, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0236-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Yang J, 2017, CELL BIOL INT, V41, P890, DOI 10.1002/cbin.10806
NR 46
TC 12
Z9 13
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2020
VL 138
IS 12
BP 1280
EP 1289
DI 10.1001/jamaophthalmol.2020.4409
EA OCT 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PS6GH
UT WOS:000589772700006
PM 33119047
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Lee, YA
   Yang, CH
   Yang, CM
   Ho, TC
   Lin, CP
   Huang, JS
   Chen, MS
AF Lee, Yi-An
   Yang, Chang-Hao
   Yang, Chung-May
   Ho, Tzyy-Chang
   Lin, Chang-Ping
   Huang, Jen-Sheng
   Chen, Muh-Shy
TI Photodynamic Therapy With or Without Intravitreal Bevacizumab for
   Polypoidal Choroidal Vasculopathy: Two Years of Follow-Up
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; LASER PHOTOCOAGULATION; MACULAR DEGENERATION;
   INJECTION; EFFICACY; RANIBIZUMAB; VERTEPORFIN
AB PURPOSE; To compare the long-term results of the efficacy of photodynamic therapy (PDT) with or without intravitreal bevacizumab (IVB) injections for polypoidal choroidal vasculopathy.
   DESIGN: Retrospective, comparative, interventional case series.
   METHODS: We included 69 eyes of 69 patients with macula-involved polypoidal choroidal vasculopathy. All patients were followed up for more than 2 years. We compared the treatment outcomes between groups and investigated the factors influencing visual improvement at 24 months of follow-up.
   RESULTS: Thirty-six patients received PDT combined with IVB and 33 patients received PDT monotherapy. At 3 months, the mean logarithm of minimal angle of resolution (log,MAR) best-corrected visual acuity (BCVA) improved from 0.73 to 0.53 in the combined therapy group (P < .001) and from 0.79 to 0.72 in the PDT monotherapy group (P = .02), with a significant difference in treatment efficacy between the 2 groups (P < .001). However, the improvements in BCVA were not statistically significant after 21 months in the combined therapy group and 15 months in the monotherapy group. The difference in treatment efficacy between the 2 groups was not significant after 6 months. Initial BCVA (P = .005), lesion size (P = .011), patient age (P = .018), and location of polyps (P = .006) significantly predicted the final visual outcome rather than treatment modality (P = .243).
   CONCLUSIONS: PDT combined with IVB for symptomatic PCV was temporarily superior to PDT monotherapy, and the treatment efficacy decreased with time. Initial BCVA, lesion size, and location were more significant than treatment modality as the factors influencing final visual improvement. (Am J Ophthalmol 2012; 154:872-880. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Lee, Yi-An] Natl Taiwan Univ Hosp, Dept Ophthalmol, Yun Lin Branch, Yunlin, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan S Rd, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chung-May/AAV-3737-2020; Yang, Chang-Hao/AAR-3759-2021
OI LIN, CHANG-PING/0000-0003-0302-7711; YANG,
   CHANG-HAO/0000-0002-4328-8716; YANG, CHUNG-MAY/0000-0003-4082-420X
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Karacorlu SA, 2006, RETINA-J RET VIT DIS, V26, P752, DOI 10.1097/01.iae.0000231382.83491.c1
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 43
TC 42
Z9 49
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2012
VL 154
IS 5
BP 872
EP 880
DI 10.1016/j.ajo.2012.03.051
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 032ME
UT WOS:000310722200013
PM 22831838
DA 2022-11-30
ER

PT J
AU Akaza, E
   Mori, R
   Yuzawa, M
AF Akaza, Eriko
   Mori, Ryusaburo
   Yuzawa, Mitsuko
TI Long-term cults of photodynamic therapy of polypoidal choroidal
   vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE abnormal branching vascular network; photodynamic therapy; polypoidal
   choroidal vasculopathy; polypoidal lesion; recurrence
ID MACULAR DEGENERATION; VERTEPORFIN
AB Purpose: This study evaluated the results of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) 24 months or more after treatment.
   Methods: The study involved 47 eyes of 47 patients with PCV followed for 24 months or more after the first PDT. Fundus appearance, indocyanine green angiographic findings, and visual acuity (VA) were compared before PDT, and then at 3 months, 12 months, and the final visit after the first PDT.
   Results: At the final visit, VA was preserved or improved in 37 (79%) of the 47 eyes. Recurrence of polypoidal lesions was noted in 30 eyes (64%). An abnormal branching vascular network persisted in all subjects. In 26 of the 30 eyes exhibited recurrence of polypoidal lesions, which appeared in the periphery of the expanded abnormal branching vascular network.
   Conclusion: Patients with PCV need to be followed for long periods of time after PDT because of the high incidence of polypoidal lesion recurrence. However, since polypoidal lesions often recur outside the fovea, and thus have little effect on VA, PDT can be expected to exert long-term efficacy in treating PCV.
C1 [Akaza, Eriko; Mori, Ryusaburo; Yuzawa, Mitsuko] Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Sch Med,Chiyoda Ku, Tokyo 1018309, Japan.
C3 Nihon University
RP Akaza, E (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Sch Med,Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM merryeriko@hotmail.com
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mori R., 2004, GANKA, V46, P193
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A., 2005, GANKA, V47, P71
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   OTUJI T, 2000, OPHTHAL SURG LAS IM, V31, P210
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 26
TC 99
Z9 115
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2008
VL 28
IS 5
BP 717
EP 722
DI 10.1097/IAE.0b013e31816577cb
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 302KQ
UT WOS:000255967600007
PM 18463515
DA 2022-11-30
ER

PT J
AU Julien-Schraermeyer, S
   Illing, B
   Tschulakow, A
   Taubitz, T
   Guezguez, J
   Burnet, M
   Schraermeyer, U
AF Julien-Schraermeyer, Sylvie
   Illing, Barbara
   Tschulakow, Alexander
   Taubitz, Tatjana
   Guezguez, Jamil
   Burnet, Michael
   Schraermeyer, Ulrich
TI Penetration, distribution, and elimination of remofuscin/soraprazan in
   Stargardt mouse eyes following a single intravitreal injection using
   pharmacokinetics and transmission electron microscopic autoradiography:
   Implication for the local treatment of Stargardt's disease and dry
   age-related macular degeneration
SO PHARMACOLOGY RESEARCH & PERSPECTIVES
LA English
DT Review
DE autoradiography; high-performance liquid chromatography mass
   spectroscopy; intravitreal injection; pharmacokinetic; retinal pigment
   epithelium; Stargardt's disease; Transmission electron microscopy
ID RETINAL-PIGMENT EPITHELIUM; LIPOFUSCIN ACCUMULATION; MELANIN; MODEL;
   BISRETINOIDS; PROGRESSION; BINDING; ABCR
AB Age-related macular degeneration (AMD) is the leading cause of blindness in older people in the developed world while Stargardt's disease (SD) is a juvenile macular degeneration and an orphan disease. Both diseases are untreatable and are marked by accumulation of lipofuscin advancing to progressive deterioration of the retinal pigment epithelium (RPE) and retina and subsequent vision loss till blindness. We discovered that a small molecule belonging to the tetrahydropyridoether class of compounds, soraprazan renamed remofuscin, is able to remove existing lipofuscin from the RPE. This study investigated the drug penetration, distribution, and elimination into the eyes of a mouse model for increased lipofuscinogenesis, following a single intravitreal injection. We measured the time course of concentrations of remofuscin in different eye tissues using high-performance liquid chromatography combined with mass spectroscopy (HPLC-MS). We also visualized the penetration and distribution of H-3-remofuscin in eye sections up to 20 weeks post-injection using transmission electron microscopic (TEM) autoradiography. The distribution of silver grains revealed that remofuscin accumulated specifically in the RPE by binding to the RPE pigments (melanin, lipofuscin and melanolipofuscin) and that it was still detected after 20 weeks. Importantly, the melanosomes in choroidal melanocytes only rarely bind remofuscin emphasizing its potential to serve as an active ingredient in the RPE for the treatment of SD and dry AMD. In addition, our study highlights the importance of electron microscopic autoradiography as it is the only method able to show drug binding with a high intracellular resolution.
C1 [Julien-Schraermeyer, Sylvie; Illing, Barbara; Tschulakow, Alexander; Taubitz, Tatjana; Schraermeyer, Ulrich] Univ Tubingen, Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Tubingen, Germany.
   [Julien-Schraermeyer, Sylvie; Tschulakow, Alexander; Schraermeyer, Ulrich] STZ Ocutox Preclin Drug Assessment, Hechingen, Germany.
   [Guezguez, Jamil; Burnet, Michael] Synovo GmbH, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Synovo GmbH
RP Julien-Schraermeyer, S (通讯作者)，Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM Sylvie.Julien@med.uni-tuebingen.de
RI Taubitz, Tatjana/AAA-2941-2021
OI Taubitz, Tatjana/0000-0002-6747-4484; Julien-Schraermeyer,
   Sylvie/0000-0002-2322-511X
FU "Bundesministerium fur Bildung und Forschung", Bonn, Germany [01GQ1422B]
FX The authors thank Sigrid Schultheiss (Division of Experimental
   Vitreoretinal Surgery, Centre for Ophthalmology, University of
   Tuebingen, Germany) for her excellent technical assistance. This work
   was supported by "Bundesministerium fur Bildung und Forschung", Bonn,
   Germany (Grant 01GQ1422B).
CR Anderson DMG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17402-1
   Anderson DMG, 2020, J AM SOC MASS SPECTR
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   CARO LG, 1965, SCIENCE, V149, P60, DOI 10.1126/science.149.3679.60
   Cideciyan AV, 2015, INVEST OPHTH VIS SCI, V56, P5946, DOI 10.1167/iovs.15-17698
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   FANG Y, 2017, INVEST OPHTH VIS SCI, V58
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Julien S, 2010, INVEST OPHTH VIS SCI, V51, P481
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199
   Molday RS, 2010, PROG LIPID RES, V49, P476, DOI 10.1016/j.plipres.2010.07.002
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   North V, 2014, DEV OPHTHALMOL, V53, P44, DOI 10.1159/000357293
   Pauleikhoff D., 1996, Ophthalmologe, V93, P299
   Plattner H, 1987, ELEKTRONENMIKROSKOPI
   Racz B, 2018, J BIOL CHEM, V293, P11574, DOI 10.1074/jbc.RA118.002062
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rimpela AK, 2016, MOL PHARMACEUT, V13, P2977, DOI 10.1021/acs.molpharmaceut.5b00787
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P658, DOI 10.1111/j.1751-1097.2007.00291.x
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Simon WA, 2007, J PHARMACOL EXP THER, V321, P866, DOI 10.1124/jpet.107.120428
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taubit T, 2018, PEERJ, V6, DOI 10.7717/peerj.5215
   TAUBITZ T, 2015, INVEST OPHTH VIS SCI, V56
   Taubitz T, 2017, INVEST OPHTH VIS SCI, V58
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Vasireddy V, 2010, PROG RETIN EYE RES, V29, P191, DOI 10.1016/j.preteyeres.2010.01.001
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
NR 42
TC 9
Z9 9
U1 0
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2052-1707
J9 PHARMACOL RES PERSPE
JI Pharmacol. Res. Perspect.
PD DEC
PY 2020
VL 8
IS 6
AR e683
DI 10.1002/prp2.683
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PG9NH
UT WOS:000600052600028
PM 33164337
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zuo, CG
   Zhang, XZ
   Li, ML
   Peng, YT
   Mi, L
   Liu, B
   Wen, F
AF Zuo, Chengguo
   Zhang, Xiongze
   Li, Miaoling
   Peng, Yuting
   Mi, Lan
   Liu, Bing
   Wen, Feng
TI Case series of coexistence of polypoidal choroidal vasculopathy with
   other rare fundus diseases
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Myelinated nerve fiber; Branch
   retinal vein occlusion; Retinal angiomatous proliferation
ID PATIENT; SPECTRUM
AB PurposeTo record the coexistence of polypoidal choroidal vasculopathy (PCV) with other rare fundus diseases in a Chinese population.MethodIn this retrospective hospital-based study, a chart review of 861 patients with newly diagnosed PCV was performed. The clinical features of rare fundus comorbidities of PCV were recorded.ResultsFive eyes of 5 patients aged 63.411.22years (0.58%) had PCV coexisting with other fundus diseases in the same eye. Of the 5 PCV patients, 2 (0.23%) had myelinated nerve fiber, 2 (0.23%) had branch retinal vein occlusion, and 1 (0.12%) had retinal angiomatous proliferation.Conclusionp id=ParWe reported rare fundus comorbidities of PCV in a large Chinese cohort. These comorbidities included myelinated nerve fiber, branch retinal vein occlusion and retinal angiomatous proliferation. The combination might constitute an accidental occurrence.
C1 [Zuo, Chengguo; Zhang, Xiongze; Li, Miaoling; Peng, Yuting; Mi, Lan; Liu, Bing; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
FU National Natural Science Foundation of China [81400426, 81470647];
   Fundamental Research Funds for the Central Universities (the Young
   Teacher Training Project of Sun Yat-sen University) [15ykpy31]
FX This study was supported by the National Natural Science Foundation of
   China (Grant Numbers: 81400426, 81470647) and the Fundamental Research
   Funds for the Central Universities (the Young Teacher Training Project
   of Sun Yat-sen University, Grant Number: 15ykpy31).
CR Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Chin YC, 2014, LUPUS, V23, P319, DOI 10.1177/0961203313519160
   Ishida T, 2013, INT OPHTHALMOL, V33, P305, DOI 10.1007/s10792-012-9657-7
   Lee JH, 2016, OPHTHALMOLOGY, V123, P2066, DOI 10.1016/j.ophtha.2016.06.033
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Nakagawa S, 2013, RETINA-J RET VIT DIS, V33, P825, DOI 10.1097/IAE.0b013e31826b0bbe
   Nicolas El-Haddad M, 2002, ARCH SOC ESP OFTALMO, V77, P455
   Peiretti Enrico, 2008, Retin Cases Brief Rep, V2, P31, DOI 10.1097/01.iae.0000243064.91851.78
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   You QS, 2007, ACTA OPHTHALMOL SCAN, V85, P631, DOI 10.1111/j.1600-0420.2007.00909.x
NR 15
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAY
PY 2019
VL 39
IS 5
BP 987
EP 990
DI 10.1007/s10792-018-0900-8
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HX8IK
UT WOS:000467649400003
PM 29594794
DA 2022-11-30
ER

PT J
AU Najeeb, BH
   Deak, GG
   Schmidt-Erfurth, U
   Gerendas, BS
AF Haj Najeeb, Bilal
   Deak, Gabor G.
   Schmidt-Erfurth, Ursula
   Gerendas, Bianca S.
TI The RAP study, report 3: Discoloration of the macular region in patients
   with macular neovascularization type 3
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; dense exudates; intraretinal
   haemorrhage; macular neovascularization; retinal angiomatous
   proliferation
AB Background/Aims To explore whether the existence and pattern of distribution of macular haemorrhage or exudate can be valuable diagnostic markers for macular neovascularization type 3 (MNV3) in patients with neovascular age-related macular degeneration.
   Methods Eighty-three eyes of 83 consecutive treatment naive patients with stage 3 MNV3 were enrolled. The diagnosis was based on fluorescein angiography (FA) and optical coherence tomography (OCT). Subretinal and intraretinal haemorrhage and dense exudates were evaluated on colour fundus photography. Fluorescein angiography (FA) images and OCT scans were used to identify the axial location of the haemorrhage. 83 patients with MNV1 and 83 with MNV2 were included as two control groups.
   Results In the MNV3 group, 62 (75%) eyes had intraretinal haemorrhage and 52 (63%) had dense exudates. 73 (88%) eyes had intraretinal haemorrhage and/or dense exudates. 41 (49%) had both pathologies. The intraretinal haemorrhage was flame shaped over the lesion and punctate or semi-punctate further away from it and directed to the fovea. No subretinal haemorrhage was noticed. In the MNV1 and MNV2 groups, 11 (13%) and 24 (29%) eyes had subretinal haemorrhage or dense exudates, respectively. No intraretinal haemorrhage was seen in the two control groups. The prevalence of exudates and haemorrhage (irrespective of its location) was greater in MNV3 than in MNV1 or 2 (p < 0.0001).
   Conclusion The existence and pattern of distribution of intraretinal haemorrhage is pathognomonic of MNV3. It makes (alone or with dense exudates) the diagnose MNV3 possible using fundoscopy or colour fundus photo and without further diagnostic expenditure.
C1 [Haj Najeeb, Bilal; Deak, Gabor G.; Schmidt-Erfurth, Ursula; Gerendas, Bianca S.] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Vienna, Austria.
C3 Medical University of Vienna
RP Gerendas, BS (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM bianca.gerendas@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Gerendas, Bianca
   S./0000-0001-8940-8130; Haj Najeeb, Bilal/0000-0002-8147-1415
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Brar M, 2010, RETINA-J RET VIT DIS, V30, P383, DOI 10.1097/IAE.0b013e3181cd4803
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Najeeb BH, 2021, BRIT J OPHTHALMOL, V105, P113, DOI 10.1136/bjophthalmol-2019-315311
   Hajnajeeb B, 2012, BRIT J OPHTHALMOL, V96, P867, DOI 10.1136/bjophthalmol-2011-300629
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Lee JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186272
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Massacesi AL, 2008, GRAEF ARCH CLIN EXP, V246, P89, DOI 10.1007/s00417-007-0638-x
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Najeeb BH, 2020, RETINA-J RET VIT DIS, V40, P2255, DOI 10.1097/IAE.0000000000002774
   Najeeb BH, 2017, INVEST OPHTH VIS SCI, V58, P3986, DOI 10.1167/iovs.17-21510
   Ravera V, 2016, RETINA-J RET VIT DIS, V36, P2274, DOI 10.1097/IAE.0000000000001152
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wong TY, 2020, RETINA-J RET VIT DIS, V40, P599, DOI 10.1097/IAE.0000000000002768
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 30
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2022
VL 100
IS 1
BP E270
EP E277
DI 10.1111/aos.14866
EA APR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YD6LB
UT WOS:000636852600001
PM 33821577
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yuzawa, M
   Mori, R
   Haruyama, M
AF Yuzawa, M
   Mori, R
   Haruyama, M
TI A study of laser photocoagulation for polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE classic choroidal neovascularization; photocoagulation; polypoidal
   choroidal vasculopathy; serosanguineous detachment; visual outcome
AB Purpose: To evaluate the efficacy of laser photocoagulation for polypoidal choroidal vasculopathy (PCV) involving the macula,
   Methods: The records of 38 patients (47 eyes) undergoing laser photocoagulation for PCV causing serosanguineous detachment involving the fovea were reviewed and the results were evaluated. Ten eyes underwent photocoagulation to induce a fusion scar covering whole lesions consisting of both abnormal vessels and polypoidal lesions. Thirty-seven eyes underwent photocoagulation for only polypoidal lesions. When serosanguineous detachment recurred, additional photocoagulation was performed, targeting the causative lesions. Photocoagulation was performed with an argon dye laser or multicolor krypton laser. Final visual acuity, macular changes at the final visit, and the number of photocoagulations were evaluated. Follow-up period after the first photocoagulation was at least 1 year.
   Results: Of the 10 eyes undergoing photocoagulation of whole lesions, 9 showed absorption of exudate and/or blood after one photocoagulation, and maintained or improved visual acuity. Of the 37 eyes undergoing laser photocoagulation of only polypoidal lesions, 20 (54%) showed decreased visual acuity because of recurrent or persistent exudation and/or classic choroidal neovascularization or, alternatively, because of atrophy at the fovea; 32 of the 37 eyes had undergone photocoagulation at least twice or more.
   Conclusion: Photocoagulation is recommended only for whole lesions. (C) 2003 Japanese Ophthalmological Society.
C1 Nihon Univ, Dept Ophthalmol, Tokyo, Japan.
C3 Nihon University
RP Yuzawa, M (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018317, Japan.
CR Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   MORI R, 2001, NIHON GANKA KIYO, V52, P284
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yamanishi Akiko, 1998, Rinsho Ganka, V52, P1691
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 11
TC 62
Z9 69
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL-AUG
PY 2003
VL 47
IS 4
BP 379
EP 384
DI 10.1016/S0021-5155(03)00042-X
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699YU
UT WOS:000184085700010
PM 12842207
DA 2022-11-30
ER

PT J
AU Thavikulwat, AT
   De Silva, T
   Agron, E
   Keenan, TDL
   Toth, CA
   Chew, EY
   Cukras, CA
AF Thavikulwat, Alisa T.
   De Silva, Tharindu
   Agron, Elvira
   Keenan, Tiarnan D. L.
   Toth, Cynthia A.
   Chew, Emily Y.
   Cukras, Catherine A.
CA Age-Related Eye Dis Study 2 Ancill
TI MULTIMODAL ASSESSMENTS OF DRUSENOID PIGMENT EPITHELIAL DETACHMENTS IN
   THE AGE-RELATED EYE DISEASE STUDY 2 ANCILLARY SPECTRAL-DOMAIN OPTICAL
   COHERENCE TOMOGRAPHY STUDY COHORT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; optical coherence
   tomography
ID TYPE-3 NEOVASCULARIZATION; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   PHOTOGRAPHS; PROGRESSION
AB Purpose: To identify features correlating with drusenoid pigment epithelial detachment (DPED) progression in the Age-Related Eye Disease Study 2 Ancillary spectral-domain optical coherence tomography study cohort. Methods: In this retrospective analysis of a prospective longitudinal study, eyes with intermediate age-related macular degeneration and DPEDs were followed longitudinally with annual multimodal imaging. Results: Thirty-one eyes of 25 participants (mean age 72.6 years) in the Age-Related Eye Disease Study 2 Ancillary spectral-domain OCT substudy (A2A study) had DPED identified in color fundus images. Spectral-domain optical coherence tomography inspection confirmed a subretinal pigment epithelium drusenoid elevation of >= 433 mu m diameter in 25 eyes (80.6%). Twenty-four of these eyes were followed longitudinally (median 4.0 years), during which 7 eyes (29.2%) underwent DPED collapse (with 3/7 further progressing to geographic atrophy), 6 (25.0%) developing neovascular age-related macular degeneration, and 11 (45.8%) maintaining DPED persistence without late age-related macular degeneration. On Kaplan-Meier analysis, mean time to DPED collapse was 3.9 years. Both DPED collapse and progression to neovascular age-related macular degeneration were preceded by the presence of hyperreflective foci over the DPED. Conclusion: The natural history of DPED comprises collapse (sometimes followed by the development of atrophy), vascularization followed by exudation, or DPED persistence. Spectral-domain optical coherence tomography can confirm retinal pigment epithelial elevation caused by drusenoid accumulation and facilitate the identification of high-risk features that correlate with progression.
C1 [Thavikulwat, Alisa T.; De Silva, Tharindu; Agron, Elvira; Keenan, Tiarnan D. L.; Chew, Emily Y.; Cukras, Catherine A.] NEI, NIH, Bethesda, MD 20892 USA.
   [Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Duke University
RP Cukras, CA (通讯作者)，10 Ctr Dr, Bethesda, MD 20814 USA.
EM alisa.thavikulwat@gmail.com; tharindu.desilva@nih.gov; exa@nei.nih.gov;
   tiarnan.keenan@nih.gov; cynthia.toth@duke.edu; chewe@nei.nih.gov;
   cukrasc@nei.nih.gov
FU National Institutes of Health (NIH) intramural research program;
   National Eye Institute of the NIH; Department of Health and Human
   Services, Bethesda, Maryland [HHS-N-260-2005-00007-C, N01-EY-5-0007];
   AREDS2 Ancillary SDOCT Study
FX Supported by the National Institutes of Health (NIH) intramural research
   program. The Age-Related Eye Disease Study 2 (AREDS2) study was
   supported by the intramural program funds and contracts from the
   National Eye Institute of the NIH, Department of Health and Human
   Services, Bethesda, Maryland (Contract No. HHS-N-260-2005-00007-C; ADB
   Contract No. N01-EY-5-0007). The following sponsors supported the AREDS2
   Ancillary SDOCT Study and had no role in the design or conduct of this
   research: Genentech, San Francisco, California (research grant); Alcon,
   Fort Worth, Texas (research grant); and Bioptigen, Morrisville, North
   Carolina (research grant).
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim M, 2021, RETINA-J RET VIT DIS, V41, P402, DOI 10.1097/IAE.0000000000002844
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Pasricha MV, 2021, OPHTHALMOL RETINA, V5, P396, DOI 10.1016/j.oret.2020.12.010
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tvenning AO, 2020, ACTA OPHTHALMOL, V98, P701, DOI 10.1111/aos.14423
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
NR 23
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2022
VL 42
IS 5
BP 842
EP 851
DI 10.1097/IAE.0000000000003423
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0U0LT
UT WOS:000787351800005
PM 35174809
DA 2022-11-30
ER

PT J
AU Srour, M
   Querques, G
   Semoun, O
   El Ameen, A
   Miere, A
   Sikorav, A
   Zambrowski, O
   Souied, EH
AF Srour, Mayer
   Querques, Giuseppe
   Semoun, Oudy
   El Ameen, Ala
   Miere, Alexandra
   Sikorav, Anne
   Zambrowski, Olivia
   Souied, Eric H.
TI Optical coherence tomography angiography characteristics of polypoidal
   choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Imaging; Neovascularisation; Retina
ID NEOVASCULARIZATION
AB Purpose To analyse the morphological characteristics of polypoidal choroidal vasculopathy (PCV) on optical coherence tomography angiography (OCT-A).
   Methods Prospective study with consecutive patients affected with PCV were included. All patients underwent a complete ophthalmological examination including fundus photography, fluorescein angiography, indocyanine green angiography, spectral-domain OCT and OCT-A.
   Results Twelve eyes of 12 patients (mean age 72.610.5years; 4 men and 8 women) were included for analysis. In all eyes (12/12) the segmentation of the choriocapillaris layer on OCT-A revealed the branching vascular network (BVN) as a hyperflow lesion. OCT-A segmentation of the choriocapillaris layer in correspondence of the polypoidal lesion showed in 3/12 eyes (25%) a hyperflow round structure, surrounded by a hypointense halo, and in 9/12 eyes (75%) a hypoflow round structure.
   Conclusions The OCT-A is a non-invasive imaging modality allowing the visualisation of different structures in PCV. The BVN is constantly clearly detected. The hypoflow round structure appearance of the polyp in OCT-A, is probably due to an unusual blood flow inside the polypoidal lesions, contrasting with the BVN. Further improvement in OCT-A knowledge will provide information on the specificity of the different intensity characteristics in PCV.
C1 [Srour, Mayer; Querques, Giuseppe; Semoun, Oudy; El Ameen, Ala; Miere, Alexandra; Sikorav, Anne; Zambrowski, Olivia; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Querques,
   Giuseppe/0000-0002-3292-9581
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Muir ER, 2011, NMR BIOMED, V24, P216, DOI 10.1002/nbm.1576
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Puliafito CA, 2014, OSLI RETINA, V45, P360, DOI 10.3928/23258160-20140925-01
   Sa Ho-Seok, 2005, Korean J Ophthalmol, V19, P275
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 50
Z9 55
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2016
VL 100
IS 11
BP 1489
EP 1493
DI 10.1136/bjophthalmol-2015-307892
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC3DJ
UT WOS:000388004900009
PM 26837506
DA 2022-11-30
ER

PT J
AU Lee, MW
   Yeo, I
   Wong, D
   Ang, CL
AF Lee, M-W
   Yeo, I.
   Wong, D.
   Ang, C-L
TI Photodynamic therapy with verteporfin for polypoidal choroidal
   vasculopathy
SO EYE
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; verteporfin;
   age-related macular degeneration
ID LASER PHOTOCOAGULATION
AB Background To describe the efficacy of photodynamic therapy (PDT) with verteporfin for the treatment of polypoidal choroidal vasculopathy (PCV).
   Methods This is a retrospective interventional case series of 41 eyes of 40 patients with angiographic evidence of PCV, which had PDT with verteporfin. Pre-treatment best-corrected visual acuity (BCVA) was measured and patients were followed up for at least 12 months with BCVA recorded at each visit.
   Results The mean follow-up time was 23.7 months. Seven of 10 eyes (70%) with juxtafoveal lesions and 17 of 31 eyes (54.8%) with subfoveal lesions had stable or improved vision (loss of <= 3 lines) at the last follow-up. The mean number of treatments was 1.90. Thirty-three eyes (80.5%) had dry, quiescent scars at last follow-up, six eyes (14.6%) had persistent leakage, and two eyes (4.9%) had evidence of choroidal neovascularisation.
   Conclusion Our results indicate that 24 of 41 eyes (58.5%) with serosanguinous maculopathy secondary to PCV treated with PDT had stable or improved vision (loss of <= 3 lines) after a mean follow-up of almost 2 years. However, in view of the retrospective nature of this study, the true efficacy of PDT for PCV would have to be evaluated with a larger randomised controlled trial. Eye (2009) 23, 1417-1422; doi:10.1038/eye.2008.265; published online 29 August 2008
C1 [Lee, M-W; Yeo, I.; Wong, D.; Ang, C-L] Singapore Natl Eye Ctr, Dept Vitreoretinal Surg, Singapore 168751, Singapore.
C3 Singapore National Eye Center
RP Ang, CL (通讯作者)，Singapore Natl Eye Ctr, Dept Vitreoretinal Surg, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ang.chong.lye@snec.com.sg
OI Wong, Damon/0000-0003-4601-9121
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   LEE MW, 2007, EYE             0824
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vedantham V, 2005, EYE, V19, P915, DOI 10.1038/sj.eye.6701666
   Vilaplana D, 2005, Arch Soc Esp Oftalmol, V80, P597
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANUZZI LA, 1990, RETINA, V10, P1
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 27
TC 16
Z9 17
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2009
VL 23
IS 6
BP 1417
EP 1422
DI 10.1038/eye.2008.265
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 457BP
UT WOS:000266900500028
PM 18756283
OA Bronze
DA 2022-11-30
ER

PT J
AU LaRowe, TL
   Mares, JA
   Snodderly, DM
   Klein, ML
   Wooten, BR
   Chappell, R
AF LaRowe, Tara L.
   Mares, Julie A.
   Snodderly, D. Max
   Klein, Michael L.
   Wooten, Billy R.
   Chappell, Richard
CA CAREDS Mascular Pigment Study Grp
TI Macular pigment density and age-related maculopathy in the carotenoids
   in age-related eye disease study - An ancillary study of the women's
   health initiative
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-DENSITY; ZEAXANTHIN CONCENTRATIONS; ANTIOXIDANT INTAKE;
   FATTY-ACIDS; VITAMIN-E; LUTEIN; DEGENERATION; PLASMA; SERUM;
   IDENTIFICATION
AB Purpose: To examine the association between intermediate age-related macular degeneration (AMD) and the optical density of macular pigment (MPOD), which is composed of lutein and zeaxanthin from the diet.
   Design: Cross-sectional cohort study.
   Participants: We included 1698 of 2005 women ages 54 to 86 years and participating in the Carotenoids in Age-Related Eye Disease Study, an ancillary study of the Women's Health Initiative.
   Methods: The MPOD was measured noninvasively by heterochromatic flicker photometry. Fundus photographs were taken to document prevalent AMD.
   Main Outcome Measures: Intermediate AMD (n = 305) and two subtypes-large drusen (n = 233) and pigmentary abnormalities (n = 157).
   Results: After adjusting for covariates, the odds ratio (OR) and 95% confidence interval (CI) for AMD among women in quintile (Q) 5 (n = 339) versus 1 (n = 340) for MPOD was 1.4 (0.9, 2.1). However, after excluding women with possible unstable diets and recent supplement use due to chronic disease history, associations reversed (OR Q2-5 vs. 1, 0.8; 95% CI, 0.5-1.2), but remained nonsignificant. Associations also differed between middle-aged (54-69 years) and older ( 70 years) women (P-interaction = 0.09), but less so, after excluding women who were likely to have unstable diets: adjusted ORs (95% CI) were 0.5 (0.3-1.0; P = 0.08) for intermediate AMD among middle-aged women (n = 516) with MPOD in Q2 to Q5 versus 1 and 1.0 (0.5-2.0; P = 0.90) for older women (n = 422).
   Conclusions: The MPOD is not cross-sectionally associated with AMD. The inconsistency of relationships across age groups and in subgroups of women who are likely to have more stable diets suggests that cross-sectional associations maybe biased and highlights the need to study these relationships prospectively.
C1 [Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [LaRowe, Tara L.] Univ Wisconsin, Dept Family Med, Madison, WI USA.
   [Snodderly, D. Max] Univ Texas Austin, Dept Human Ecol Nutr Sci, Austin, TX 78712 USA.
   [Snodderly, D. Max] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA.
   [Snodderly, D. Max] Univ Texas Austin, Ctr Perceptual Syst, Austin, TX 78712 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
   [Wooten, Billy R.] Brown Univ, Dept Psychol, Providence, RI 02912 USA.
   [Chappell, Richard] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Texas System; University of Texas Austin; University of
   Texas System; University of Texas Austin; University of Texas System;
   University of Texas Austin; Oregon Health & Science University; Brown
   University; University of Wisconsin System; University of Wisconsin
   Madison
RP Mares, JA (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St 1063 WARF Bldg, Madison, WI 53726 USA.
EM Jmarespe@wisc.edu
OI Snodderly, Donald/0000-0002-3428-609X
FU NEI NIH HHS [R01 EY021532, EY 13018] Funding Source: Medline; NIDDK NIH
   HHS [DK07665] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY021532, U10EY013018] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007665]
   Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   BASIOTIS P, 2002, HELTH EATING INDEX 1
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MATHEWSROTH MM, 1974, PHOTOCHEM PHOTOBIOL, V19, P217, DOI 10.1111/j.1751-1097.1974.tb06501.x
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   ROSENTHAL FS, 1991, HEALTH PHYS, V61, P77, DOI 10.1097/00004032-199107000-00008
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   [USDA Nutrient Data Laboratory], USDA NAT NUTR DAT ST
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 47
TC 59
Z9 62
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2008
VL 115
IS 5
BP 876
EP 883
DI 10.1016/j.ophtha.2007.06.015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297KA
UT WOS:000255614400019
PM 17868874
DA 2022-11-30
ER

PT J
AU Scilley, K
   DeCarlo, DK
   Wells, J
   Owsley, C
AF Scilley, K
   DeCarlo, DK
   Wells, J
   Owsley, C
TI Vision-specific health-related quality of life in age-related
   maculopathy patients presenting for low vision services
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related maculopathy; health-related quality of life; low vision
   rehabilitation; NEI VFQ-25
ID VISUAL FUNCTION QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; DEPRESSIVE
   SYMPTOMS; DRIVING HABITS; OLDER DRIVERS; IMPAIRMENT; ACUITY; EYE;
   SENSITIVITY; DISABILITY
AB Few studies have examined the effectiveness of low vision rehabilitation for age-related maculopathy (ARM) patients and its impact on vision-specific health-related quality of life (HRQoL). However, before a multi-site clinical trial can be conducted, appropriate outcome measures need to be identified for ARM patients who seek out low vision rehabilitation, including a vision-specific HR QoL instrument. The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was developed to assess vision-specific HRQoL for low vision patients, including those with ARM. This study examines the performance of the NEI VFQ-25 among ARM patients who seek out low vision services and examines its relationship with visual acuity and self-reported use of low vision aids. One hundred and twenty-seven patients were recruited from a University-affiliated low vision clinic. During two telephone interviews, subjects completed the NEI VFQ-25 and a short cognitive test and provided information on general health and use of low vision aids. Additional information on visual acuity and eye health were collected from the medical record. Our results indicate that ARM patients who seek out low vision services report significant impairment in their vision-specific HRQoL. Their NEI VFQ-25 scores were lower compared to other ARM and low vision rehabilitation samples previously studied. The VFQ subscales with the largest deficits were near and distanced visual acuities and psychosocial issues (near vision, distance vision, role difficulties, dependency, social functioning, mental health). These subscale scores were lower for those with greater visual acuity impairment. The VFQ subscale scores most impacted by the disease had wide variability and were higher for those who used low vision aids, suggesting that the NEI VFQ-25 is suitable for measuring further decline and treatment-related improvements. Thus, it should be strongly considered for a multi-site clinical trial on the effectiveness of low vision rehabilitation.
C1 Univ Alabama Birmingham, Callahan Eye Fdn Hosp, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Nova SE Univ, Coll Optometry, Ft Lauderdale, FL 33314 USA.
C3 University of Alabama System; University of Alabama Birmingham; Nova
   Southeastern University
RP Scilley, K (通讯作者)，Univ Alabama Birmingham, Callahan Eye Fdn Hosp, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM kscilley@uab.edu
OI DeCarlo, Dawn/0000-0001-9078-9882
FU NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [P50AG011684] Funding Source: NIH RePORTER;
   NEI NIH HHS [R21-EY14071] Funding Source: Medline; NIA NIH HHS
   [P50-AG11684] Funding Source: Medline
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Broman AT, 2001, INVEST OPHTH VIS SCI, V42, P606
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   DEYO R, 1991, ANN INTERN MED, V338, P350
   ELLWEIN LB, 1994, INT OPHTHALMOL, V18, P263
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Fonda SJ, 2001, J GERONTOL B-PSYCHOL, V56, pS343, DOI 10.1093/geronb/56.6.S343
   GRESSET J, 1999, VISION REHAB ASSESSM, P152
   GUYATT G, 1991, CONTROL CLIN TRIALS, V12, pS81, DOI 10.1016/S0197-2456(05)80014-5
   JOSE R, 1983, UNDERSTANDING LOW VI, P61
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   *NATL ADV EY COUNC, 1999, VIS RES NAT PLAN 199, P99
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   PARDHAN S, 1991, EYE, V5, P31, DOI 10.1038/eye.1991.6
   PARDHAN S, 1991, CLIN VISION SCI, V6, P355
   PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018
   ROCCAFORTE WH, 1994, J GERIATR PSYCH NEUR, V7, P33, DOI 10.1177/089198879400700107
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STELMACK J, 1999, VISION REHAB ASSESSM, P774
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
NR 45
TC 29
Z9 29
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2004
VL 11
IS 2
BP 131
EP 146
DI 10.1076/opep.11.2.131.28159
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 815RG
UT WOS:000221058800003
PM 15255028
DA 2022-11-30
ER

PT J
AU Yu, SS
   Lu, J
   Cao, D
   Liu, RY
   Liu, BQ
   Li, T
   Luo, Y
   Lu, L
AF Yu, Shanshan
   Lu, Jing
   Cao, Di
   Liu, Ruyuan
   Liu, Bingqian
   Li, Tao
   Luo, Yan
   Lu, Lin
TI The role of optical coherence tomography angiography in fundus vascular
   abnormalities
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Optical coherence tomography angiography; Fundus vascular abnormalities;
   CNV; DR; BRVO; PCV
ID CHOROIDAL NEOVASCULARIZATION
AB Background: To evaluate the role of optical coherence tomography angiography (OCTA) in observation of fundus vascular abnormalities.
   Methods: Patients (n = 50, 10 in each group) with fundus disorders including branch retinal vein occlusion (BRVO), non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD), and polypoidal choroidal vasculopathy (PCV) were examined. They underwent imaging of OCTA and fluorescein angiography/indocyanine green angiography. The split-spectrum amplitude-decorrelation angiography algorithm was employed to obtain angiography within a 6 x 6 mm scanning area at the posterior retina. Segmentation algorithm was used to obtain 2-dimensional images from arbitrary layers. The OCTA features were analyzed and compared with the findings of conventional angiography. The contralateral eyes of the patients with BRVO and the eyes of 20 healthy volunteers served as controls.
   Results: OCTA showed precise images of normal and abnormal vasculature in the posterior retina and choroid by the given layers. Vascular abnormalities such as enlarged foveal avascular zone (FAZ), non-perfusion area of retina, microaneurysm, retinal neovascularization, choroidal neovascularization (CNV), branching vascular network and polypoidal lesions in choroid were clearly displayed by OCTA.
   Conclusions: OCTA provided a better projection of vascular pathologies of the posterior retina and choroid and could determine the precise location of the vascular lesion. The noninvasive OCTA can benefit the diagnosis of vascular abnormalities in the posterior retina and choroid.
C1 [Yu, Shanshan; Lu, Jing; Cao, Di; Liu, Ruyuan; Liu, Bingqian; Li, Tao; Luo, Yan; Lu, Lin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Zhongshan Image Reading Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Lu, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Zhongshan Image Reading Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM lulin888@126.com
RI yu, shanshan/AIC-2220-2022
OI yu, shanshan/0000-0001-6182-8328
FU National Basic Research Development Program of China (973 program)
   [2013CB967000]; National Natural Science Foundation of China [81371020]
FX This work was supported by grants from the National Basic Research
   Development Program of China (973 program: 2013CB967000) and the
   National Natural Science Foundation of China to YAN LUO (81371020). The
   funding organization had no role in the design or conduct of this
   research.
CR de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Hirooka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-73
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   LIPSON BK, 1989, INT OPHTHALMOL CLIN, V29, P200, DOI 10.1097/00004397-198902930-00011
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Nitta F, 2014, CLIN OPHTHALMOL, V8, P1119, DOI 10.2147/OPTH.S62022
   PACURARIU RI, 1982, ANN OPHTHALMOL, V14, P32
   Spaide RF, 2015, OPHTHALMOLOGY, V122, P2261, DOI 10.1016/j.ophtha.2015.07.025
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   TAMAKI Y, 1994, INVEST OPHTH VIS SCI, V35, P3825
   Wang XG, 2014, BRIT J OPHTHALMOL, V98, P1368, DOI 10.1136/bjophthalmol-2013-304547
   Yoshida A, 2003, AM J OPHTHALMOL, V135, P356, DOI 10.1016/S0002-9394(02)01949-9
NR 19
TC 29
Z9 31
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 13
PY 2016
VL 16
AR 107
DI 10.1186/s12886-016-0277-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0LR
UT WOS:000379599500001
PM 27412442
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chevreaud, O
   Oubraham, H
   Cohen, SY
   Jung, C
   Blanco-Garavito, R
   Gherdaoui, F
   Souied, EH
AF Chevreaud, Olivier
   Oubraham, Hassiba
   Cohen, Salomon Y.
   Jung, Camille
   Blanco-Garavito, Rocio
   Gherdaoui, Farah
   Souied, Eric H.
TI Ranibizumab for vascularized pigment epithelial detachment: 1-year
   anatomic and functional results
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age related macular degeneration; Anti-vascular endothelial growth
   factor; Pigment epithelial detachment; Ranibizumab
ID 2.0 MG RANIBIZUMAB; ANTI-VEGF THERAPY; MACULAR DEGENERATION;
   INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; TEARS; CLASSIFICATION;
   PREDICTORS; EFFICACY; OUTCOMES
AB To assess the anatomical and functional efficacy of ranibizumab on vascularized pigment epithelial detachment (V-PED) secondary to neovascular age-related macular degeneration (nAMD).
   One hundred and nine patients (116 eyes) were retrospectively selected from medical records of 2097 patients who benefited from intravitreal injection between January 2011 and June 2013 in a tertiary-care University-based Department of Ophthalmology. Inclusion criteria were: nAMD, treatment-naive eyes, presence of V-PED higher than 250 mu m, intravitreal ranibizumab with a loading phase, followed by a pro-re-nata regimen, and 1-year follow-up. Baseline characteristics and type of choroidal neovascularization (CNV) were analyzed. PED height, central macular thickness (CMT) and best-corrected visual acuity (BCVA, logMAR) were measured at baseline, months 3, 6 and 12.
   CNV was of type 1 in 91 eyes (78.4 %), type 2 in seven (6 %), type 3 in six (5.2 %), and polypoidal choroidal vasculopathy in 12 (10.3 %). Mean CMT at baseline was 572.1 mu m and decreased to 396.6 mu m (p < 0.0001) at 12 months. Mean height of PED was 458.2 mu m at baseline and 306.8 mu m (p < 0.0001) at 12 months. Mean BCVA improved from 0.46 at baseline to 0.39 at 12 months (p = 0.013).
   Treatment with ranibizumab improved visual and anatomical outcome in nAMD patients with V-PED.
C1 [Chevreaud, Olivier; Oubraham, Hassiba; Cohen, Salomon Y.; Blanco-Garavito, Rocio; Gherdaoui, Farah; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
   [Jung, Camille] Ctr Hosp Intercommunal, Clin Res Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Oubraham, H (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM oubraham@icloud.com
OI JUNG, Camille/0000-0001-8486-8939
CR Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giansanti F, 2014, EUR J OPHTHALMOL, V24, P402, DOI 10.5301/ejo.5000388
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Varshney N, 2013, CAN J OPHTHALMOL, V48, P210, DOI 10.1016/j.jcjo.2013.01.023
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 35
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2017
VL 255
IS 4
BP 743
EP 751
DI 10.1007/s00417-016-3564-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ER5DE
UT WOS:000398820800013
PM 27913869
DA 2022-11-30
ER

PT J
AU Patil, NS
   Mihalache, A
   Dhoot, AS
   Popovic, MM
   Muni, RH
   Kertes, PJ
AF Patil, Nikhil S.
   Mihalache, Andrew
   Dhoot, Arjan S.
   Popovic, Marko M.
   Muni, Rajeev H.
   Kertes, Peter J.
TI Association Between Visual Acuity and Residual Retinal Fluid Following
   Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for
   Neovascular Age-Related Macular Degeneration A Systematic Review and
   Meta-analysis
SO JAMA OPHTHALMOLOGY
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF TREATMENT; SUBRETINAL FLUID;
   RANIBIZUMAB; OUTCOMES; EXPERIENCE; PREDICTORS; EYES
AB IMPORTANCE The association between residual subretinal fluid (SRF) and intraretinal fluid (IRF) and visual acuity following anti-vascular endothelial growth factor (VEGF) treatment is not well understood.
   OBJECTIVE To examine the association of residual retinal fluid, SRF, and IRF with visual acuity following anti-VEGF treatment in patients with neovascular age-related macular degeneration (nAMD).
   DATA SOURCES A systematic literature search was performed from January 2005 to August 2021 using Ovid MEDLINE, Embase, and the Cochrane Library.
   STUDY SELECTION Peer-reviewed articles reporting on visual acuity stratified by the presence or absence of any residual SRF, IRF, or any retinal fluid at last study observation after intravitreal bevacizumab, ranibizumab, aflibercept, or brolucizumab in patients with nAMD were included. Studies that were noncomparative, included fewer than 10 eyes, or reported on other anti-VEGF agents were excluded.
   DATA EXTACTION AND SYNTHESIS Two independent reviewers conducted data extraction and synthesis. The Cochrane risk of bias tool 2 and ROBINS-I were used to assess risk of bias and GRADE evaluation was conducted to assess certainty of evidence.
   MAIN OUTCOMES AND MEASURES Primary outcomes were BCVA at last study observation, change in BCVA from baseline, and retinal thickness at last study observation.
   RESULTS In this systematic review and meta-analysis, 11 studies (6 randomized clinical trials [RCTs]) comprising 3092 eyes were included in our analysis. Across all included studies, the BCVA of eyes with residual SRF was better than eyes without SRF (weighted mean difference [WMD], 3.1 letter score; 95% CI, 0.05 to 6.18; P = .05; GRADE, low certainty of evidence; 6 studies; 1931 eyes) but similar in RCTs (WMD, 2.7 letter score; 95% CI, -2.40 to 7.84; P = .30; GRADE, low certainty of evidence; 3 studies; 1406 eyes). The BCVA of eyes with residual IRF was worse than that of eyes without IRF (WMD, -8.2 letter score; 95% CI, -11.79 to -4.50; P < .001; GRADE, low; 7 studies; 2114 eyes).
   CONCLUSIONS AND RELEVANCE The findings suggest that the presence of residual SRF was associated with slightly better BCVA at last study observation; however, baseline differences in BCVA existed and this conclusion was primarily driven by 1 study. The presence of residual IRF was associated with substantially worse BCVA at last study observation and less improvement of BCVA from baseline. The conclusions are limited by the inclusion of data from observational studies, heterogeneity, and a low certainty of evidence.
C1 [Patil, Nikhil S.] McMaster Univ, Michael DeGroote Sch Med, Hamilton, ON, Canada.
   [Mihalache, Andrew] Univ Western Ontario, Fac Sci, Dept Basic Med Sci, London, ON, Canada.
   [Dhoot, Arjan S.] Univ Toronto, Undergrad Med Educ, Temerty Fac Med, Toronto, ON, Canada.
   [Popovic, Marko M.; Muni, Rajeev H.; Kertes, Peter J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Muni, Rajeev H.] St Michaels Hosp, Unity Hlth Toronto, Dept Ophthalmol, Toronto, ON, Canada.
   [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202A, Toronto, ON M4N 3M5, Canada.
C3 McMaster University; Western University (University of Western Ontario);
   University of Toronto; University of Toronto; University of Toronto;
   University Toronto Affiliates; Saint Michaels Hospital Toronto;
   University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center
RP Kertes, PJ (通讯作者)，Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202A, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
OI Patil, Nikhil/0000-0003-3929-0482; Popovic, Marko/0000-0002-0370-5968
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Ebneter A, 2015, OPHTHALMOLOGICA, V234, P61, DOI 10.1159/000430103
   Guo Y, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.54
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heng LZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126557
   Higgins JPT., 2019, COCHRANE HDB SYSTEMA
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Holekamp NM, 2022, AM J OPHTHALMOL, V233, P8, DOI 10.1016/j.ajo.2021.06.029
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaiser PK, 2021, RETINA-J RET VIT DIS, V41, P1579, DOI 10.1097/IAE.0000000000003194
   Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.1136/bmj.l4898, 10.4084/MJHID.2010.005]
   Khanani AM, 2015, CLIN OPHTHALMOL, V9, P1315, DOI 10.2147/OPTH.S88624
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Khoshnood B, 2010, OPHTHAL PHYSL OPT, V30, P816, DOI 10.1111/j.1475-1313.2010.00766.x
   Kim KT, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02063-6
   Lee AY, 2021, JAMA OPHTHALMOL, V139, P741, DOI 10.1001/jamaophthalmol.2021.1284
   Melinscak M, 2021, AUTOMATIKA-UK, V62, P375, DOI 10.1080/00051144.2021.1973298
   Ohji M, 2021, GRAEF ARCH CLIN EXP, V259, P3637, DOI 10.1007/s00417-021-05293-y
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pron G, 2014, Ont Health Technol Assess Ser, V14, P1
   Qian TW, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022700
   Rezar S, 2015, ACTA OPHTHALMOL, V93, P719, DOI 10.1111/aos.12772
   Saenz-de-Viteri M, 2021, ACTA OPHTHALMOL, V99, P861, DOI 10.1111/aos.14786
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Visser MS, 2020, QUAL LIFE RES, V29, P3305, DOI 10.1007/s11136-020-02580-9
   Wang ZH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92458-8
   Wickremasinghe SS, 2014, RETINA-J RET VIT DIS, V34, P2367, DOI 10.1097/IAE.0000000000000258
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yorston David, 2014, Community Eye Health, V27, P44
   Yoshida I, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/5308597
   Zarbin MA, 2022, BRIT J OPHTHALMOL, V106, P1561, DOI 10.1136/bjophthalmol-2020-318688
NR 42
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2022
VL 140
IS 6
BP 611
EP 622
DI 10.1001/jamaophthalmol.2022.1357
EA MAY 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2E7EA
UT WOS:000794938900002
PM 35551359
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   SanGiovanni, JP
   Danis, R
   Ferris, FL
   Elman, M
   Antoszyk, A
   Ruby, A
   Orth, D
   Bressler, S
   Fish, G
   Hubbard, B
   Klein, M
   Chandra, S
   Blodi, B
   Domalpally, A
   Friberg, T
   Wong, W
   Rosenfeld, P
   Agron, E
   Toth, C
   Bernstein, P
   Sperduto, R
AF Chew, Emily Y.
   Clemons, Traci E.
   SanGiovanni, John Paul
   Danis, Ronald
   Ferris, Frederick L., III
   Elman, Michael
   Antoszyk, Andrew
   Ruby, Alan
   Orth, David
   Bressler, Susan
   Fish, Gary
   Hubbard, Baker
   Klein, Michael
   Chandra, Suresh
   Blodi, Barbara
   Domalpally, Amitha
   Friberg, Thomas
   Wong, Wai
   Rosenfeld, Philip
   Agron, Elvira
   Toth, Cynthia
   Bernstein, Paul
   Sperduto, Robert
CA Age-Related Eye Dis Study 2 AREDS2
TI Lutein plus Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular
   Degeneration The Age-Related Eye Disease Study 2 (AREDS2) Randomized
   Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID VITAMIN-C; DOCOSAHEXAENOIC ACID; DIETARY CAROTENOIDS; VISUAL FUNCTION;
   BETA-CAROTENE; SUPPLEMENTATION; PLACEBO; RISK; PREVALENCE; PREVENTION
AB Importance Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), or both might further reduce this risk.
   Objectives To determine whether adding lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation decreases the risk of developing advanced AMD and to evaluate the effect of eliminating beta carotene, lowering zinc doses, or both in the AREDS formulation.
   Design, Setting, and Participants The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, randomized, double-masked, placebo-controlled phase 3 study with a 2 x 2 factorial design, conducted in 2006-2012 and enrolling 4203 participants aged 50 to 85 years at risk for progression to advanced AMD with bilateral large drusen or large drusen in 1 eye and advanced AMD in the fellow eye.
   Interventions Participants were randomized to receive lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), lutein + zeaxanthin and DHA + EPA, or placebo. All participants were also asked to take the original AREDS formulation or accept a secondary randomization to 4 variations of the AREDS formulation, including elimination of beta carotene, lowering of zinc dose, or both.
   Main Outcomes and Measures Development of advanced AMD. The unit of analyses used was by eye.
   Results Median follow-up was 5 years, with 1940 study eyes (1608 participants) progressing to advanced AMD. Kaplan-Meier probabilities of progression to advanced AMD by 5 years were 31% (493 eyes [406 participants]) for placebo, 29% (468 eyes [399 participants]) for lutein + zeaxanthin, 31% (507 eyes [416 participants]) for DHA + EPA, and 30% (472 eyes [387 participants]) for lutein + zeaxanthin and DHA + EPA. Comparison with placebo in the primary analyses demonstrated no statistically significant reduction in progression to advanced AMD (hazard ratio [HR], 0.90 [98.7% CI, 0.76-1.07]; P=.12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P=.70 for DHA + EPA; 0.89 [98.7% CI, 0.75-1.06]; P=.10 for lutein + zeaxanthin and DHA + EPA). There was no apparent effect of beta carotene elimination or lower-dose zinc on progression to advanced AMD. More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P=.04), mostly in former smokers.
   Conclusions and Relevance Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not further reduce risk of progression to advanced AMD. However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.
   Trial Registration clinicaltrials.gov Identifier: NCT00345176
C1 [Chew, Emily Y.; SanGiovanni, John Paul; Ferris, Frederick L., III; Wong, Wai; Agron, Elvira] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Sperduto, Robert] EMMES Corp, Rockville, MD USA.
   [Danis, Ronald; Chandra, Suresh; Blodi, Barbara; Domalpally, Amitha] Univ Wisconsin, Fundus Reading Ctr, Madison, WI 53706 USA.
   [Elman, Michael] Elman Retina Grp, Baltimore, MD USA.
   [Antoszyk, Andrew] Charlotte Eye Ear Nose & Throat, Charlotte, NC USA.
   [Ruby, Alan] Vis Res Fdn, Royal Oak, MI USA.
   [Orth, David] Ingalls Mem Hosp, Harvey, IL USA.
   [Bressler, Susan] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Baltimore, MD 21218 USA.
   [Fish, Gary] Texas Retina Associates, Dallas, TX USA.
   [Hubbard, Baker] Emory Univ, Ctr Eye, Atlanta, GA 30322 USA.
   [Klein, Michael] Devers Eye Inst, Portland, OR USA.
   [Friberg, Thomas] Univ Pittsburgh, Med Ctr, Ctr Eye, Pittsburgh, PA USA.
   [Rosenfeld, Philip] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Toth, Cynthia] Duke Univ, Durham, NC USA.
   [Bernstein, Paul] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison; Johns Hopkins University; Johns Hopkins Medicine;
   Emory University; Devers Eye Institute; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; Bascom Palmer Eye
   Institute; Duke University; Utah System of Higher Education; University
   of Utah
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Toth, Cynthia/L-5534-2019; SanGiovanni, John Paul/AAU-3895-2020;
   Domalpally, Amitha/B-2367-2015; Wong, Wai/B-6118-2017
OI Toth, Cynthia/0000-0002-2324-0854; SanGiovanni, John
   Paul/0000-0001-7199-7053; Domalpally, Amitha/0000-0002-8145-9619; Elman,
   Michael/0000-0001-7726-9508; Wong, Wai/0000-0003-0681-4016; Ferris,
   Frederick/0000-0002-4933-0639
FU National Eye Institute (NEI), National Institutes of Health (NIH),
   Department of Health and Human Services, Bethesda, Maryland
   [HHS-N-260-2005-00007-C, N01-EY-5-0007]; NIH, Office of Dietary
   Supplements; NIH, National Center for Complementary and Alternative
   Medicine; NIH, National Institute on Aging; NIH, National Heart, Lung,
   and Blood Institute; NIH, National Institute of Neurological Disorders
   and Stroke; Southwest Clinical Research Associates LLC.; Genentech;
   Allergan; Bayer Healthcare; Lumenis Inc; Notal Vision Ltd; Novartis;
   Regeneron; Thrombogenics; sanofi-aventis; Bausch Lomb; Office of
   Research Administration; Texas Retina Associates; Carl Zeiss Meditec;
   Alexion; Potentia; GlaxoSmithKline; Topcon
FX All authors have completed and submitted the ICMJE Form for Disclosure
   of Potential Conflicts of Interest. Dr Ferris reported holding a patent
   for the Age-Related Eye Disease Study (AREDS) formulation with Bausch &
   Lomb. Dr Antoszyk reported receiving grant and travel support from
   Southwest Clinical Research Associates LLC. Dr Ruby reported receiving
   payment for lectures from Genentech. Dr Bressler reported receiving
   grant and travel support from the Emmes Corporation; serving as a
   consultant for GlaxoSmithKline; receiving grants or grants pending from
   Allergan, Bayer Healthcare, Genentech, Lumenis Inc, Notal Vision Ltd,
   Novartis, Regeneron, Thrombogenics, and sanofi-aventis; receiving
   payment for lectures from providers of continuing medical education
   materials; and serving as an investigator on a grant to The Johns
   Hopkins University sponsored by Bausch & Lomb; this grant is negotiated
   and administered by the School of Medicine, which receives the grant
   through the Office of Research Administration (individual investigators
   who participate in such sponsored projects are not directly compensated
   by the sponsor but may receive salary or other support from the
   institution to support their effort on the projects). Dr Fish reported
   receiving grant and travel support from Texas Retina Associates. Dr
   Rosenfeld reported serving as a consultant for Oraya, Novartis, Chengdu
   Kanghong Biotech, Acucela, Thrombogenics, and Canon; receiving grants or
   grants pending from Carl Zeiss Meditec, Alexion, Potentia, and
   GlaxoSmithKline; and receiving payment for lectures from Carl Zeiss
   Meditec, Allergan, and Topcon. Dr Toth reported receiving grant and
   travel support from the Emmes Corporation and serving as a consultant to
   ALCON. Dr Bernstein reported serving as a consultant for Kemin Health,
   Kalsec, DSM, and Science Based Health. No other authors reported
   disclosures.; This study was supported by the intramural program funds
   and contracts from the National Eye Institute (NEI), National Institutes
   of Health (NIH), Department of Health and Human Services, Bethesda,
   Maryland (contract HHS-N-260-2005-00007-C; ADB contract N01-EY-5-0007).
   Funds were generously contributed to these contracts by the following
   NIH institutes: Office of Dietary Supplements; National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; and National Institute of
   Neurological Disorders and Stroke. The study medications and raw
   materials were provided by Alcon, Bausch & Lomb, DSM, and Pfizer.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hambidge M, 2003, J NUTR, V133, p1438S, DOI 10.1093/jn/133.5.1438S
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mozaffarian D, 2012, JAMA-J AM MED ASSOC, V308, P2001, DOI 10.1001/jama.2012.28733
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Rauch B, 2010, CIRCULATION, V122, P2152, DOI 10.1161/CIRCULATIONAHA.110.948562
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Rotstein NP, 1996, J NEUROCHEM, V66, P1851
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Wang YM, 2010, EUR J NUTR, V49, P327, DOI 10.1007/s00394-009-0089-8
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Zhang XH, 2012, AM J CLIN NUTR, V95, P713, DOI 10.3945/ajcn.111.014415
NR 35
TC 647
Z9 669
U1 7
U2 180
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 15
PY 2013
VL 309
IS 19
BP 2005
EP 2015
DI 10.1001/jama.2013.4997
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 143GQ
UT WOS:000318855500023
OA Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Park, DH
   Kim, IT
AF Park, Dong Ho
   Kim, In Taek
TI LOC387715/HTRA1 VARIANTS AND THE RESPONSE TO COMBINED PHOTODYNAMIC
   THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; LOC387715/HTRA1 variants; photodynamic therapy; polypoidal
   choroidal vasculopathy
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; EPITHELIUM-DERIVED
   FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; JAPANESE
   POPULATION; ASSOCIATION; VERTEPORFIN; GENE; NEOVASCULARIZATION
AB Purpose: To investigate whether there was an association with the LOC387715/HTRA1 variants and a response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
   Methods: Combined photodynamic therapy with intravitreal bevacizumab was repeated every 3 months until the disappearance of angiographic signs in the active lesions of 51 eyes with polypoidal choroidal vasculopathy who were followed-up for at least 12 months. Patients were genotyped for LOC387715 and HTRA1 polymorphisms.
   Results: Although there was no significant difference in the baseline best-corrected visual acuity and fluorescein angiography-guided greatest linear dimension among the 3 genotypes in both genes, there was a significant difference at 12 months (P < 0.05, respectively). For LOC387715, the TT genotype showed greater fluorescein angiography-guided greatest linear dimension than the TG and GG genotypes (P = 0.035 and 0.006, respectively). The best-corrected visual acuity of the GG genotype was better than the TT and TG (P = 0.029 and 0.045, respectively). For HTRA1, the AA genotype showed greater fluorescein angiography-guided greatest linear dimension than AG and GG (P = 0.042 and 0.017, respectively). The best-corrected visual acuity of GG genotype was better than AA and AG (P = 0.018 and 0.040, respectively).
   Conclusion: After combined photodynamic therapy with intravitreal bevacizumab treatment, LOC387715 TT and HTRA1 AA genotype had poorer outcomes at 12 months, suggesting a pharmacogenetic relationship. RETINA 32:299-307, 2012
C1 [Park, Dong Ho; Kim, In Taek] Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, Taegu 700721, South Korea.
C3 Kyungpook National University
RP Kim, IT (通讯作者)，Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, 50 Samduk Dong,2 Ga, Taegu 700721, South Korea.
EM itkim@knu.ac.kr
FU Kyungpook National University
FX Supported by Kyungpook National University Research Fund, 2010.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Scholl HPN, 2007, MOL VIS, V13, P196
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
NR 39
TC 21
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2012
VL 32
IS 2
BP 299
EP 307
DI 10.1097/IAE.0b013e318225290f
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 890YJ
UT WOS:000300182700013
PM 21817962
DA 2022-11-30
ER

PT J
AU Lee, K
   Ra, H
   Lee, JH
   Baek, J
   Lee, WK
AF Lee, Kook
   Ra, Ho
   Lee, Jun Hyuk
   Baek, Jiwon
   Lee, Won Ki
TI Classification of Pachychoroid on Optical Coherence Tomographic En Face
   Images Using Deep Convolutional Neural Networks
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE choroid; deep learning; haller's layer; OCT; pachychoroid
ID CENTRAL SEROUS CHORIORETINOPATHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; EXTEND REGIMEN; AFLIBERCEPT;
   VASCULARITY; EYES
AB Purpose: To study the efficacy of deep convolutional neural networks (DCNNs) to differentiate pachychoroid from nonpachychoroid on en face optical coherence tomography (OCT) images at the large choroidal vessel.
   Methods: En face OCT images were collected from eyes with neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy. All images were prelabeled pachychoroid or nonpachychoroid based on quantitative and qualitative criteria for choroidal morphology on multimodal imaging by two retina specialists. In total, 1188 nonpachychoroid and 884 pachychoroid images were used for training (80%) and validation (20%). Accuracy for identification of pachychoroid by DCNN models was analyzed. Trained models were tested on a test set containing 79 nonpachychoroid and 93 pachychoroid images.
   Results: The accuracy on the validation set was 94.1%, 93.2%, 94.7%, and 94.4% in DenseNet, GoogLeNet, ResNet50, and Inception-v3, respectively. On a test set, each model demonstrated accuracy of 80.2%, 83.1%, 89.5%, and 90.1% and an F1 score of 0.782, 0.824, 0.904, and 0.901, respectively.
   Conclusions: DCNN models could classify pachychoroid and nonpachychoroid with good performance on OCT en face images. Automated classification of pachychoroid will be useful for tailored treatment of individual patients with exudative maculopathy.
   Translational Relevance: En face OCT images can be used by DCNN for classification of pachychoroid.
C1 [Lee, Kook] Catholic Univ Korea, Coll Med, Dept Ophthalmol, Seoul St Marys Hosp, Seoul, South Korea.
   [Ra, Ho; Lee, Jun Hyuk; Baek, Jiwon] Catholic Univ Korea, Coll Med, Dept Ophthalmol, Bucheon St Marys Hosp, 327 Sosa Ro, Bucheon 14647, Gyeonggi Do, South Korea.
   [Lee, Won Ki] Nune Eye Ctr, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea
RP Baek, J (通讯作者)，Catholic Univ Korea, Coll Med, Dept Ophthalmol, Bucheon St Marys Hosp, 327 Sosa Ro, Bucheon 14647, Gyeonggi Do, South Korea.
EM md.jiwon@gmail.com
FU Institute of Clinical Medicine Research of Bucheon St. Mary's Hospital,
   Research Fund; Korea Health Technology R&D Project through the Korea
   Health Industry Development Institute - Ministry of Health and Welfare,
   Republic of Korea [HI17C2012030018]
FX Supported by the Institute of Clinical Medicine Research of Bucheon St.
   Mary's Hospital, Research Fund, 2020 and a grant from the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute, funded by the Ministry of Health and Welfare, Republic of
   Korea (grant no: HI17C2012030018).
CR Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Baek J, 2020, RETINA-J RET VIT DIS, V40, P2166, DOI 10.1097/IAE.0000000000002723
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77566-1
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Hirahara S, 2016, AM J OPHTHALMOL, V166, P103, DOI 10.1016/j.ajo.2016.03.040
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Kim IK, 2021, BRIT J OPHTHALMOL, V105, P856, DOI 10.1136/bjophthalmol-2020-316108
   Kuroda Y, 2016, AM J OPHTHALMOL, V169, P199, DOI 10.1016/j.ajo.2016.06.043
   Lee WJ, 2017, BRIT J OPHTHALMOL, V101, P580, DOI 10.1136/bjophthalmol-2016-308428
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Vestias MP, 2019, ALGORITHMS, V12, DOI 10.3390/a12080154
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong RLM, 2021, EUR J OPHTHALMOL, V31, P536, DOI 10.1177/1120672120908719
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yang HL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215076
NR 32
TC 2
Z9 2
U1 2
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUN
PY 2021
VL 10
IS 7
AR 28
DI 10.1167/tvst.10.7.28
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TD3KJ
UT WOS:000669229500006
PM 34185057
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chan, WM
   Lim, TH
   Pece, A
   Silva, R
   Yoshimura, N
AF Chan, Wai Man
   Lim, Tock-Han
   Pece, Alfredo
   Silva, Rufino
   Yoshimura, Nagahisa
TI Verteporfin PDT for non-standard indications-a review of current
   literature
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Angioid streaks; Central serous chorioretinopathy; Choroidal
   haemangioma; Inflammatory CNV; Polypoidal choroidal vasculopathy;
   Verteporfin; Visudyne
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   PUNCTATE INNER CHOROIDOPATHY; INTRAVITREAL BEVACIZUMAB AVASTIN; ENHANCED
   PHOTODYNAMIC THERAPY; HALF-DOSE VERTEPORFIN; MACULAR DEGENERATION;
   NEOVASCULARIZATION SECONDARY; ANGIOID STREAKS; MULTIFOCAL CHOROIDITIS
AB Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the underlying pathology of ocular vascular disorders through its angio-occlusive mechanism of action, which reduces both visual acuity loss and the underlying leakage associated with lesions. Verteporfin PDT has also been associated with encouraging treatment outcomes in case studies involving patients with choroidal vascular disorders such as polypoidal choroidal vasculopathy, central serous chorioretinopathy, choroidal haemangioma, angioid streaks, and inflammatory CNV, i.e. conditions currently considered as non-standard indications of verteporfin PDT. In many studies, outcomes were better than expected based on the natural courses of each of these conditions. Although the anti-vascular endothelial growth factor (VEGF) therapies, ranibizumab and pegaptanib, have been approved for CNV due to AMD, their role in these other choroidal vascular disorders remains to be established. We summarize current literature that has documented the use of verteporfin PDT in these conditions.
   The complex pathogenesis of CNV provides a rationale for investigating combination approaches comprising verteporfin PDT and anti-VEGF therapies. Randomized controlled studies are warranted to confirm the preliminary results of verteporfin PDT as a monotherapy or in combination with anti-VEGF therapies in the treatment of a variety of choroidal vascular conditions.
C1 [Silva, Rufino] Hosp Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Pece, Alfredo] Osped Melegnano, Dept Ophthalmol, Milan, Italy.
   [Lim, Tock-Han] Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
   [Lim, Tock-Han] Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Chan, Wai Man] HK Sanat Hosp, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Kyoto University; Tan Tock Seng Hospital
RP Silva, R (通讯作者)，Hosp Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Silva, Rufino M/J-2817-2012
OI Silva, Rufino M/0000-0001-8676-0833
FU Novartis Pharma AG (Switzerland)
FX The authors would like to acknowledge Susanna Ryan of Chameleon
   Communications International for providing medical writing support with
   funding from Novartis Pharma AG (Switzerland). The authors also
   acknowledge Neelima Gundupalle and Aditi Gandhe from Novartis Healthcare
   Pvt. Ltd., (India) for their editorial assistance.
CR Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Anand R, 2003, AM J OPHTHALMOL, V136, P758, DOI 10.1016/S0002-9394(03)00423-9
   Arias L, 2006, GRAEF ARCH CLIN EXP, V244, P753, DOI 10.1007/s00417-005-0131-3
   Bandello F, 2001, J FR OPHTALMOL, V24, P448
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boixadera A, 2009, OPHTHALMOLOGY, V116, P100, DOI 10.1016/j.ophtha.2008.08.029
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown J, 1996, OPHTHALMOLOGY, V103, P1100, DOI 10.1016/S0161-6420(96)30561-7
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P71, DOI 10.1097/IAE.0b013e31815e9339
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coco RM, 2007, OCUL IMMUNOL INFLAMM, V15, P27, DOI 10.1080/09273940601174020
   Cooper BA, 2000, AM J OPHTHALMOL, V130, P187, DOI 10.1016/S0002-9394(00)00395-0
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Ergun E, 2004, ARCH OPHTHALMOL-CHIC, V122, P37, DOI 10.1001/archopht.122.1.37
   Fine HF, 2009, RETINA-J RET VIT DIS, V29, P8, DOI 10.1097/IAE.0b013e318187aff9
   Gerth C, 2006, EUR J OPHTHALMOL, V16, P111, DOI 10.1177/112067210601600118
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Guagnini AP, 2006, J FR OPHTALMOL, V29, P1013, DOI 10.1016/S0181-5512(06)73889-X
   Gupta M, 2004, EYE, V18, P139, DOI 10.1038/sj.eye.6700597
   Heimann H, 2005, GRAEF ARCH CLIN EXP, V243, P1115, DOI 10.1007/s00417-005-1193-y
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Huang S, 2009, OPTOMETRY VISION SCI, V86, P286, DOI 10.1097/OPX.0b013e318196a724
   Huiskamp EA, 2005, GRAEF ARCH CLIN EXP, V243, P727, DOI 10.1007/s00417-004-1102-9
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Jurklies B, 2006, OPHTHALMIC RES, V38, P209, DOI 10.1159/000093071
   Karacorlu M, 2002, AM J OPHTHALMOL, V134, P360, DOI 10.1016/S0002-9394(02)01626-4
   Kuo IC, 2000, INT OPHTHALMOL CLIN, V40, P111, DOI 10.1097/00004397-200004000-00009
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ladas ID, 2005, EUR J OPHTHALMOL, V15, P69, DOI 10.1177/112067210501500111
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Landau IME, 2002, ACTA OPHTHALMOL SCAN, V80, P531, DOI 10.1034/j.1600-0420.2002.800513.x
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lim JI, 2006, ANN ACAD MED SINGAP, V35, P198
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsushita S, 2008, J MED INVESTIG, V55, P231, DOI 10.2152/jmi.55.231
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mauget-Faysse M, 2006, RETINA-J RET VIT DIS, V26, P396, DOI 10.1097/00006982-200604000-00003
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   Michels S, 2005, RETINA-J RET VIT DIS, V25, P697, DOI 10.1097/00006982-200509000-00003
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Moon JW, 2009, GRAEF ARCH CLIN EXP, V247, P1315, DOI 10.1007/s00417-009-1104-8
   Ober MD, 2005, OPHTHALMOLOGY, V112, P2088, DOI 10.1016/j.ophtha.2005.06.026
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozmert E, 2009, OPHTHALMOLOGICA, V223, P263, DOI 10.1159/000210386
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Parodi MB, 2006, AM J OPHTHALMOL, V141, P123, DOI 10.1016/j.ajo.2005.07.045
   Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016/j.ajo.2004.03.029
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Postelmans L, 2005, OCUL IMMUNOL INFLAMM, V13, P361, DOI 10.1080/09273940590951124
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Sagong Min, 2009, Korean J Ophthalmol, V23, P127, DOI 10.3341/kjo.2009.23.2.127
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   Shaikh S, 2003, AM J OPHTHALMOL, V135, P1, DOI 10.1016/S0002-9394(02)01835-4
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singerman L J, 1981, Retina, V1, P75
   Singh AD, 2004, BRIT J OPHTHALMOL, V88, P1414, DOI 10.1136/bjo.2004.044396
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Tarantola RM, 2008, LASER SURG MED, V40, P671, DOI 10.1002/lsm.20720
   Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007/s00417-008-0906-4
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Verbraak FD, 2003, GRAEF ARCH CLIN EXP, V241, P891, DOI 10.1007/s00417-003-0765-y
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Xiong Ying, 2007, Zhonghua Yan Ke Za Zhi, V43, P1085
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Zhao MW, 2009, RETINA-J RET VIT DIS, V29, P1155, DOI 10.1097/IAE.0b013e3181a6c028
NR 96
TC 47
Z9 47
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2010
VL 248
IS 5
BP 613
EP 626
DI 10.1007/s00417-010-1307-z
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 575ML
UT WOS:000276071100001
PM 20162298
DA 2022-11-30
ER

PT J
AU Byon, IS
   Kwon, HJ
   Kim, SI
   Shin, MK
   Park, SW
   Lee, JE
AF Byon, Ik Soo
   Kwon, Han Jo
   Kim, Sung Il
   Shin, Min Kyu
   Park, Sung Who
   Lee, Ji Eun
TI Reduced-Fluence Photodynamic Therapy in Polypoidal Choroidal
   Vasculopathy Nonresponsive to Ranibizumab
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   BEVACIZUMAB; VERTEPORFIN; AFLIBERCEPT; EFFICACY; INJECTION; SAFETY
AB BACKGROUND AND OBJECTIVE: To evaluate the effect of reduced-fluence photodynamic therapy (PDT) on polypoidal choroidal vasculopathy (PCV) unresponsive to intravitreal ranibizumab.
   PATIENTS AND METHODS: Patients with PCV unresponsive to ranibizumab administered 3 months consecutively who then received reduced-fluence PDT were retrospectively surveyed. Nonresponders were defined as patients having no reduction in intraretinal and/or subretinal fluid after 3 consecutive treatments.
   RESULTS: In total, 22 of 104 eyes (21.2%) were nonresponders, and 16 of 22 nonresponders received reduced-fluence PDT. Nine eyes achieved complete fluid resolution, and six had reduced but persistent fluid. In one eye, fluid persisted at 6 months despite an additional anti-vascular endothelial growth factor (anti-VEGF) injection after reduced-fluence PDT. Mean macular thickness decreased significantly at 3 and 6 months after PDT, but the mean visual acuity was worse than baseline.
   CONCLUSION: Reduced-fluence PDT in nonresponders gradually decreased intraretinal and/or subretinal fluid over several months but did not maintain visual acuity.
C1 [Byon, Ik Soo] Pusan Natl Univ, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea.
   Yangsan Pusan Natl Univ Hosp, Res Inst Convergence Biomed Sci & Technol, Yangsan, South Korea.
   [Kwon, Han Jo; Kim, Sung Il; Shin, Min Kyu; Park, Sung Who; Lee, Ji Eun] Pusan Natl Univ Hosp, Dept Ophthalmol, 1-10 Ami Dong, Pusan, South Korea.
   [Lee, Ji Eun] Pusan Natl Univ, Sch Med, Inst Med, Pusan, South Korea.
C3 Pusan National University; Pusan National University Hospital; Pusan
   National University; Pusan National University; Pusan National
   University Hospital; Pusan National University; Pusan National
   University Hospital
RP Lee, JE (通讯作者)，Pusan Natl Univ Hosp, Dept Ophthalmol, 1-10 Ami Dong, Pusan, South Korea.
EM jlee@pusan.ac.kr
OI Byon, Iksoo/0000-0002-2638-8192; Han Jo, Kwon/0000-0003-2973-9725
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Goto S, 2012, AM J OPHTHALMOL, V154, P865, DOI 10.1016/j.ajo.2012.05.001
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Peyman GA, 2000, OPHTHALMOLOGY, V107, P29, DOI 10.1016/S0161-6420(99)00012-3
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P349
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 34
TC 7
Z9 9
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2014
VL 45
IS 6
BP 534
EP 541
DI 10.3928/23258160-20141118-08
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0PQ
UT WOS:000347299300008
PM 25423633
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Sacconi, R
   Klose, G
   de Sisternes, L
   Bandello, F
   Querques, G
AF Borrelli, Enrico
   Sacconi, Riccardo
   Klose, Gerd
   de Sisternes, Luis
   Bandello, Francesco
   Querques, Giuseppe
TI Rotational Three-dimensional OCTA: a Notable New Imaging Tool to
   Characterize Type 3 Macular Neovascularization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   ANGIOGRAPHY; CLASSIFICATION; DEGENERATION; DETACHMENT
AB This study explored whether rotational three-dimensional (3D) visualization of optical coherence tomography angiography (OCTA) volume data may yield valuable information regarding type 3 macular neovascularization (MNV). In this retrospective, cross-sectional study, we collected data from 15 eyes (13 patients) with treatment-naive type 3 MNV in their post-nascent stage and age-related macular degeneration (AMD). Subjects were imaged with the SS-OCT system (PLEX Elite 9000, Carl Zeiss Meditec Inc., Dublin, CA, USA). The OCTA volume data were processed with a prototype volume projection removal algorithm and then analyzed using volumetric visualization techniques in order to obtain a 3D visualization of the region occupied by type 3 MNV. The two-dimensional and three-dimensional OCTA images were investigated. Mean +/- SD age was 75.1 +/- 7.4 years. BCVA was 0.42 +/- 0.21 LogMAR in the study eyes. Considering the cohort of analyzed eyes, on rotational 3D OCTA images, a total of 35 neovascular lesions (vs 22 lesions detected on 2D OCTA images) rising from the deep vascular complex and variably spanning the outer retinal layers and eventually reaching the RPE/sub-RPE space were detected. Nine of 35 lesions had a saccular shape, while the remaining cases had a filiform shape. On rotational 3D OCTA images, these lesions were inclined on the three planes, instead of perpendicular to the RPE/Bruch's membrane. In conclusion, this study used an algorithm to obtain rotational three-dimensional visualization of type 3 MNV. This approach seems to increase the detection rate for these lesions and to be useful to offer new insight into type 3 MNV.
C1 [Borrelli, Enrico; Sacconi, Riccardo; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
   [Klose, Gerd] Carl Zeiss Meditec Inc, Tokyo, Japan.
   [de Sisternes, Luis] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Carl
   Zeiss AG; Carl Zeiss AG
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
EM giuseppe.querques@hotmail.it
RI bandello, francesco/AAH-2405-2019; Borrelli, Enrico/AAR-3693-2020
OI bandello, francesco/0000-0003-3238-9682; Borrelli,
   Enrico/0000-0003-2815-5031; Querques, Giuseppe/0000-0002-3292-9581;
   Sacconi, Riccardo/0000-0003-2891-2012
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Borrelli E, 2019, OPHTHALMOL THER, V8, P215, DOI 10.1007/s40123-019-0178-6
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Jalali A, 2016, J NEUROINTERV SURG, V8, P1056, DOI 10.1136/neurintsurg-2015-011963
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Li M., 2017, OPHTHALMOLOGY
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P424, DOI 10.1097/IAE.0000000000001344
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2421, DOI 10.1097/IAE.0000000000000721
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 31
TC 19
Z9 19
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 19
PY 2019
VL 9
AR 17053
DI 10.1038/s41598-019-53307-x
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JO6QJ
UT WOS:000497701800010
PM 31745216
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Lee, GKY
   Luk, FOJ
   Lam, DSC
AF Lai, Timothy Y. Y.
   Lee, Gary K. Y.
   Luk, Fiona O. J.
   Lam, Dennis S. C.
TI INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE
   TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; ranibizumab; photodynamic therapy;
   verteporfin
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; NEOVASCULAR MEMBRANES; BEVACIZUMAB AVASTIN; FOLLOW-UP;
   VERTEPORFIN; EXPRESSION; EFFICACY; OUTCOMES
AB Purpose: To evaluate the efficacy of intravitreal ranibizumab with or without verteporfin photodynamic therapy (PDT) in the treatment of symptomatic polypoidal choroidal vasculopathy.
   Methods: Twenty-three eyes of 23 patients received 3 monthly intravitreal ranibizumab injections with or without indocyanine green angiography-guided PDT at baseline. All patients had follow-up of >= 12 months. Visual and anatomical outcomes were compared between the two groups and a PDT monotherapy group.
   Results: Seven eyes had ranibizumab monotherapy, 16 had combined ranibizumab injections and verteporfin PDT, and 12 had PDT monotherapy. At 3 months, the mean logarithm of minimal angle of resolution best-corrected visual acuity improved from 0.92 to 0.74 in the ranibizumab group (P = 0.18), from 0.70 to 0.59 in the combined group (P = 0.037), and from 0.74 to 0.57 in the PDT monotherapy group (P = 0.014). Complete regression of polypoidal lesions in indocyanine green angiography was found in 1 (14.3%) eye in the ranibizumab group, compared with 15 (93.8%) eyes in the combined group (P = 0.001). Additional PDT and ranibizumab injections in eyes with persistent polyps and fluorescein leakage resulted in regression of polyps in all eyes. At 12 months, no significant difference in logarithm of minimal angle of resolution best-corrected visual acuity and visual change was found between eyes initially treated with ranibizumab monotherapy, combined ranibizumab and PDT, or PDT monotherapy (P = 1.00 and P = 0.11, respectively).
   Conclusion: Intravitreal ranibizumab appeared to result in stabilization of vision in patients with symptomatic polypoidal choroidal vasculopathy. However, combined ranibizumab and PDT appeared to be more effective in causing complete regression of the polypoidal lesions in indocyanine green angiography compared with ranibizumab monotherapy. RETINA 31: 1581-1588, 2011
C1 [Lai, Timothy Y. Y.; Lee, Gary K. Y.; Luk, Fiona O. J.; Lam, Dennis S. C.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 3-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lam, Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Oner A, 2005, DOC OPHTHALMOL, V111, P107, DOI 10.1007/s10633-005-4608-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 68
Z9 74
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1581
EP 1588
DI 10.1097/IAE.0b013e31820d3f3f
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100017
PM 21610566
DA 2022-11-30
ER

PT J
AU Wu, TT
   Kung, YH
   Hong, MC
AF Wu, Tsung-Tien
   Kung, Ya-Hsin
   Hong, May-Ching
TI VITREOUS HEMORRHAGE COMPLICATING INTRAVITREAL TISSUE PLASMINOGEN
   ACTIVATOR AND PNEUMATIC DISPLACEMENT OF SUBMACULAR HEMORRHAGE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE expansile gas; intravitreal injection; pneumatic displacement; risk
   factors; submacular hemorrhage; tissue plasminogen activator; vitreous
   hemorrhage
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; EXPERIMENTAL SUBRETINAL HEMORRHAGE;
   RETINAL TOXICITY; MANAGEMENT; INJECTION; GAS; SECONDARY
AB Purpose: To evaluate the clinical factors associated with vitreous hemorrhage (VH) complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage, and analyze visual outcomes.
   Methods: In this retrospective, comparative study, 120 consecutive eyes underwent intravitreal tissue plasminogen activator (50 mu g) and perfluoropropane (0.3 mL) injection for submacular hemorrhage secondary to different causes. We recorded their demographic data, visual acuity, complications, and further treatment after VH. Two groups created according to the occurrence of VH were compared to identify possible risk factors.
   Results: Breakthrough VH occurred in 18 eyes (15%). The size of submacular hemorrhage was significantly positively related to the occurrence of VH (P for trend <0.001). Among etiology, idiopathic polypoidal choroidal vasculopathy (IPCV) was associated with a significantly higher incidence of VH (odds ratio, 15.63; 95% confidence interval, 2.30-106.15; P = 0.005). Age-related macular degeneration was much less likely than other causes to result in VH (odds ratio, 0.121; 95% confidence interval, 0.023-0.642; P = 0.013). Best and final visual acuity improved significantly from initial visual acuity in both groups (P < 0.05).
   Conclusion: A large area of submacular hemorrhage (>= 10 disk areas) and IPCV were risk factors for VH after injection. The occurrence of VH did not affect final visual outcome. RETINA 31:2071-2077, 2011
C1 [Kung, Ya-Hsin] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung 813, Taiwan.
   Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
C3 Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung
   University
RP Kung, YH (通讯作者)，Kaohsiung Vet Gen Hosp, Dept Ophthalmol, 386 Ta Chung 1st Rd, Kaohsiung 813, Taiwan.
EM yhkung@vghks.gov.tw
FU Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan [VGHKS99-061]
FX Supported by the Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
   (grant VGHKS99-061).
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   HERIOT W, 1996, VAIL VITR M 10 15 MA
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kokame GT, 2000, AM J OPHTHALMOL, V129, P546, DOI 10.1016/S0002-9394(99)00474-2
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   RUIZLAPUENTE CJ, 1998, INVEST OPHTHALMOL  S, V39, P988
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wu TT, 2005, J OCUL PHARMACOL TH, V21, P62, DOI 10.1089/jop.2005.21.62
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 22
TC 21
Z9 22
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2011
VL 31
IS 10
BP 2071
EP 2077
DI 10.1097/IAE.0b013e31822528c8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 842AS
UT WOS:000296558500016
PM 21817964
DA 2022-11-30
ER

PT J
AU Fong, A
   Lee, G
AF Fong, Anthony
   Lee, Graham
TI Reducing vision loss in chronic eye disease
SO AUSTRALIAN FAMILY PHYSICIAN
LA English
DT Article
ID AGE-RELATED CATARACT; LONG-TERM INCIDENCE; BLUE MOUNTAINS EYE; MACULAR
   DEGENERATION; PRIMARY PREVENTION; CLINICAL-TRIAL; METAANALYSIS;
   SUPPLEMENTATION; PROGRESSION
AB Background
   Ocular disease in its early stages may be asymptomatic and insidious. Three of the leading causes of visual loss are cataract, age related macular degeneration and glaucoma.
   Objective
   This article discusses the presentation and treatment options for, and the management of, cataract, age related macular degeneration and glaucoma.
   Discussion
   Few primary prevention strategies are available as these ocular diseases are degenerative. The focus for reduction of visual loss is early detection and regular ophthalmic examination. The aim of management is to improve or maintain vision so as to preserve patient quality of life.
C1 [Lee, Graham] Univ Queensland, Brisbane, Qld 4072, Australia.
C3 University of Queensland
EM antfong@hotmail.com
OI Lee, Graham/0000-0002-9359-1473
CR *ACC EC PTY LTD, 2005, INV SIGHT STRAT INT
   *AUSTR I HLTH WELF, 2008, 99 AUS AIHW
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   Milton RC, 2006, OPHTHALMOLOGY, V113, P1264, DOI 10.1016/j.ophtha.2006.02.054
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   SPARROW JM, 1986, INT OPHTHALMOL, V9, P207, DOI 10.1007/BF00137534
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
NR 12
TC 5
Z9 5
U1 0
U2 1
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 0300-8495
J9 AUST FAM PHYSICIAN
JI Aust. Fam. Physician
PD OCT
PY 2009
VL 38
IS 10
BP 774
EP 779
PG 6
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 510YU
UT WOS:000271131200012
PM 19893815
DA 2022-11-30
ER

PT J
AU Tuncer, S
   Demirci, H
   Shields, CL
   Shields, JA
AF Tuncer, S.
   Demirci, H.
   Shields, C. L.
   Shields, J. A.
TI Polypoidal choroidal vasculopathy following photodynamic therapy for
   choroidal hemangioma
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroid; Eye; Hemangioma; Photodynamic therapy; Polypoidal choroidal
   vasculopathy
AB PURPOSE. To report a case of circumscribed choroidal hemangioma (CCH) that responded to photodynamic therapy (PDT) but 3 years later developed polypoidal choroidal vasculopathy (PCV) with exudative retinopathy.
   METHODS. Case report.
   RESULTS. A 59-year-old woman with a juxtapapillary CCH in her left eye was treated with a single 83-second, 7.5 mm PDT laser spot at 689 nm (50 J/cm(2)) 15 minutes after the injection of intravenous verteporfin (6 mg/m(2)). Three years later, the patient presented with photopsia in her left eye. Fundus examination of the left eye showed CCH regressed completely to a flat atrophic scar. There was diffuse macular edema and exudative retinopathy along the inferotemporal vascular arcade. On indocyanine green angiography, there were hyperfluorescent dilated choroidal vessels inferior to the foveola with late staining and leakage consistent with PCV. Hypofluorescence superior and nasal to the optic disc at the site of the treated hemangioma, consistent with choroidal ischemia, was observed. She was treated with 1.25 mg (0.05 cc) intravitreal bevacizumab. After 21 months of follow-up, the exudative retinopathy and macular edema completely regressed.
   CONCLUSIONS. PDT is an effective treatment for CCH. Side effects of PDT for CCH are rare but include PCV. (Eur J Ophthalmol 2009; 19: 159-62)
C1 [Tuncer, S.; Demirci, H.; Shields, C. L.; Shields, J. A.] Thomas Jefferson Univ, Ocular Oncol Serv, Wills Eye Inst, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Shields, CL (通讯作者)，Thomas Jefferson Univ, Ocular Oncol Serv, Wills Eye Inst, 840 Walnut St, Philadelphia, PA 19107 USA.
EM carolshields@gmail.com
RI Tuncer, Samuray/J-2596-2015
OI Demirci, Hakan/0000-0003-1593-1476
CR Landau IME, 2002, ACTA OPHTHALMOL SCAN, V80, P531, DOI 10.1034/j.1600-0420.2002.800513.x
   Leys AM, 2006, RETINA-J RET VIT DIS, V26, P693, DOI 10.1097/00006982-200607000-00018
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Michels S, 2005, RETINA-J RET VIT DIS, V25, P697, DOI 10.1097/00006982-200509000-00003
   Shields CL, 2001, OPHTHALMOLOGY, V108, P2237, DOI 10.1016/S0161-6420(01)00812-0
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P709, DOI 10.1016/S0002-9394(02)01331-4
   Vicuna-Kojchen J, 2006, OPHTHALMOLOGICA, V220, P351, DOI 10.1159/000095859
NR 7
TC 9
Z9 9
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2009
VL 19
IS 1
BP 159
EP 162
DI 10.1177/112067210901900127
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438ZV
UT WOS:000265596800027
PM 19123168
DA 2022-11-30
ER

PT J
AU Vugler, AA
AF Vugler, Anthony A.
TI PROGRESS TOWARD THE MAINTENANCE AND REPAIR OF DEGENERATING RETINAL
   CIRCUITRY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bipolar cell; channelrhodopsin; cone;
   dystrophy; Leber congenital amaurosis; macula; melanopsin; retinitis
   pigmentosa; RPE65
ID LEBER CONGENITAL AMAUROSIS; EMBRYONIC STEM-CELLS; CONTAINING
   GANGLION-CELLS; HUMAN GENE-THERAPY; VISUAL FUNCTION; CONE FUNCTION;
   MOUSE MODEL; PHOTORECEPTOR DEGENERATION; PIGMENT-EPITHELIUM; BIPOLAR
   CELLS
AB Background: Retinal diseases such as age-related macular degeneration and retinitis pigmentosa remain major causes of severe vision loss in humans. Clinical trials for treatment of retinal degenerations are underway and advancements in our understanding of retinal biology in health/disease have implications for novel therapies.
   Methods: A review of retinal biology is used to inform a discussion of current strategies to maintain/repair neural circuitry in age-related macular degeneration, retinitis pigmentosa, and Type 2 Leber congenital amaurosis.
   Results: In age-related macular degeneration/retinitis pigmentosa, a progressive loss of rods/cones results in corruption of bipolar cell circuitry, although retinal output neurons/photoreceptive melanopsin cells survive. Visual function can be stabilized/enhanced after treatment in age-related macular degeneration, but in advanced degenerations, reorganization of retinal circuitry may preclude attempts to restore cone function. In Type 2 Leber congenital amaurosis, useful vision can be restored by gene therapy where central cones survive. Remarkable progress has been made in restoring vision to rodents using light-responsive ion channels inserted into bipolar cells/retinal ganglion cells.
   Conclusion: Advances in genetic, cellular, and prosthetic therapies show varying degrees of promise for treating retinal degenerations. While functional benefits can be obtained after early therapeutic interventions, efforts should be made to minimize circuitry changes as soon as possible after rod/cone loss. Advances in retinal anatomy/physiology and genetic technologies should allow refinement of future reparative strategies. RETINA 30:983-1001, 2010
C1 UCL, Inst Ophthalmol, Dept Ocular Biol & Therapeut, London EC1V 9EL, England.
C3 University of London; University College London
RP Vugler, AA (通讯作者)，UCL, Inst Ophthalmol, Dept Ocular Biol & Therapeut, 11-43 Bath St, London EC1V 9EL, England.
EM a.vugler@ucl.ac.uk
FU Lincy Foundation; London Project to Cure Blindness
FX This work was funded by The Lincy Foundation and the London Project to
   Cure Blindness.
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Aguirre G D, 1998, Mol Vis, V4, P23
   Aleman TS, 2009, INVEST OPHTH VIS SCI, V50, P5944, DOI 10.1167/iovs.09-3982
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553
   BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0
   Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   BUSH RA, 1995, INVEST OPHTH VIS SCI, V36, P2054
   Cai X, 2009, OPHTHALMIC GENET, V30, P57, DOI 10.1080/13816810802626399
   Cai X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005290
   Cameron MA, 2009, EUR J NEUROSCI, V29, P761, DOI 10.1111/j.1460-9568.2009.06631.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489
   Chalupa LM, 2004, PROG RETIN EYE RES, V23, P31, DOI 10.1016/j.preteyeres.2003.10.001
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Chua J, 2009, J COMP NEUROL, V514, P473, DOI 10.1002/cne.22029
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cronin T, 2007, CURR GENE THER, V7, P121, DOI 10.2174/156652307780363143
   Cuenca N, 2004, NEUROSCIENCE, V127, P301, DOI 10.1016/j.neuroscience.2004.04.042
   Cuenca N, 2005, EUR J NEUROSCI, V22, P1057, DOI 10.1111/j.1460-9568.2005.04300.x
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Dacey DM, 2005, NATURE, V433, P749, DOI 10.1038/nature03387
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   DeVries SH, 2000, NEURON, V28, P847, DOI 10.1016/S0896-6273(00)00158-6
   Dkhissi-Benyabya O, 2006, INVEST OPHTH VIS SCI, V47, P1636, DOI 10.1167/iovs.05-1459
   Do MTH, 2009, NATURE, V457, P281, DOI 10.1038/nature07682
   Doyle SE, 2006, P NATL ACAD SCI USA, V103, P10432, DOI 10.1073/pnas.0600934103
   Dumitrescu ON, 2009, J COMP NEUROL, V517, P226, DOI 10.1002/cne.22158
   EISENFELD AJ, 1984, J COMP NEUROL, V223, P22, DOI 10.1002/cne.902230103
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Fan J, 2003, P NATL ACAD SCI USA, V100, P13662, DOI 10.1073/pnas.2234461100
   FOSTER KW, 1984, NATURE, V311, P756, DOI 10.1038/311756a0
   FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171
   Fu YB, 2005, P NATL ACAD SCI USA, V102, P10339, DOI 10.1073/pnas.0501866102
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Girman S, 2005, VISION RES, V45, P343, DOI 10.1016/j.visres.2004.08.023
   Gooley JJ, 2003, J NEUROSCI, V23, P7093, DOI 10.1523/JNEUROSCI.23-18-07093.2003
   GRAFSTEI.B, 1972, BRAIN RES, V44, P37, DOI 10.1016/0006-8993(72)90364-2
   Greferath U, 2009, INVEST OPHTH VIS SCI, V50, P5955, DOI 10.1167/iovs.09-3916
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609
   HATTAR S, 2009, ARVO ANN M, P5027
   Hattar S, 2006, J COMP NEUROL, V497, P326, DOI 10.1002/cne.20970
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Haverkamp S, 2006, J NEUROSCI, V26, P5248, DOI 10.1523/JNEUROSCI.4483-05.2006
   Hegemann P, 2008, ANNU REV PLANT BIOL, V59, P167, DOI 10.1146/annurev.arplant.59.032607.092847
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hoshi H, 2009, J NEUROSCI, V29, P8875, DOI 10.1523/JNEUROSCI.0912-09.2009
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Isoldi MC, 2005, P NATL ACAD SCI USA, V102, P1217, DOI 10.1073/pnas.0409252102
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jacobson SG, 2008, INVEST OPHTH VIS SCI, V49, P4573, DOI 10.1167/iovs.08-2121
   Jacobson SG, 2007, P NATL ACAD SCI USA, V104, P15123, DOI 10.1073/pnas.0706367104
   Jacobson SG, 2009, INVEST OPHTH VIS SCI, V50, P2368, DOI 10.1167/iovs.08-2696
   Jacobson SG, 2005, P NATL ACAD SCI USA, V102, P6177, DOI 10.1073/pnas.0500646102
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jimenez AJ, 1996, CELL TISSUE RES, V284, P193, DOI 10.1007/s004410050579
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   JOMARY C, 2009, INVEST OPHTH VIS SCI, V51, P1181
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jusuf PR, 2007, EUR J NEUROSCI, V26, P2906, DOI 10.1111/j.1460-9568.2007.05924.x
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Lin B, 2009, EXP EYE RES, V88, P589, DOI 10.1016/j.exer.2008.11.022
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443
   Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Machida S, 2008, INVEST OPHTH VIS SCI, V49, P442, DOI 10.1167/iovs.07-0291
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P322, DOI 10.1167/iovs.08-2301
   Maeda T, 2009, HUM MOL GENET, V18, P2277, DOI 10.1093/hmg/ddp163
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   McCall MA, 1996, EXP EYE RES, V63, P35, DOI 10.1006/exer.1996.0089
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Melyan Z, 2005, NATURE, V433, P741, DOI 10.1038/nature03344
   Michalakis S, 2005, INVEST OPHTH VIS SCI, V46, P1516, DOI 10.1167/iovs.04-1503
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Munch TA, 2009, NAT NEUROSCI, V12, P1308, DOI 10.1038/nn.2389
   NEWMAN NM, 1987, BRIT J OPHTHALMOL, V71, P21, DOI 10.1136/bjo.71.1.21
   NGUYENLEGROS J, 1988, PROG RET RES, V7, P114
   NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1
   Noseda R, 2010, NAT NEUROSCI, V13, P239, DOI 10.1038/nn.2475
   Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179
   Pang JJ, 2005, MOL VIS, V11, P152
   Parker RO, 2009, J NEUROSCI, V29, P4616, DOI 10.1523/JNEUROSCI.0063-09.2009
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pinilla I, 2005, NEUROSCI LETT, V382, P16, DOI 10.1016/j.neulet.2005.02.055
   Pinilla I, 2005, EXP EYE RES, V80, P51, DOI 10.1016/j.exer.2004.08.012
   Pires SS, 2009, J NEUROSCI, V29, P12332, DOI 10.1523/JNEUROSCI.2036-09.2009
   Porto FBO, 2003, ADV EXP MED BIOL, V533, P59
   Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a
   PROVENCIO I, 1994, VISION RES, V34, P1799, DOI 10.1016/0042-6989(94)90304-2
   Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000
   Pu ML, 2006, INVEST OPHTH VIS SCI, V47, P3579, DOI 10.1167/iovs.05-1450
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Rohrer B, 2005, INVEST OPHTH VIS SCI, V46, P3876, DOI 10.1167/iovs.05-0533
   Rohrer B, 2003, INVEST OPHTH VIS SCI, V44, P310, DOI 10.1167/iovs.02-0567
   Sakamoto K, 2004, J NEUROSCI, V24, P9693, DOI 10.1523/JNEUROSCI.2556-04.2004
   Samardzija M, 2008, HUM MOL GENET, V17, P281, DOI 10.1093/hmg/ddm304
   Samardzija M, 2009, HUM MOL GENET, V18, P1266, DOI 10.1093/hmg/ddp026
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Schmidt TM, 2009, J NEUROSCI, V29, P476, DOI 10.1523/JNEUROSCI.4117-08.2009
   Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712
   Semo M, 2003, EUR J NEUROSCI, V18, P3007, DOI 10.1111/j.1460-9568.2003.03061.x
   Semo M, 2007, EUR J NEUROSCI, V25, P2296, DOI 10.1111/j.1460-9568.2007.05461.x
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Simonelli F, 2007, INVEST OPHTH VIS SCI, V48, P4284, DOI 10.1167/iovs.07-0068
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Smith AJ, 2009, TRENDS GENET, V25, P156, DOI 10.1016/j.tig.2009.02.003
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Tomita H, 2007, INVEST OPHTH VIS SCI, V48, P3821, DOI 10.1167/iovs.06-1501
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Tomita H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007679
   Tu DC, 2006, P NATL ACAD SCI USA, V103, P10426, DOI 10.1073/pnas.0600917103
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Viney TJ, 2007, CURR BIOL, V17, P981, DOI 10.1016/j.cub.2007.04.058
   Vugler AA, 2007, J CHEM NEUROANAT, V33, P9, DOI 10.1016/j.jchemneu.2006.10.004
   Vugler AA, 2003, EXP NEUROL, V184, P464, DOI 10.1016/S0014-4886(03)00267-X
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Vugler AA, 2008, VISUAL NEUROSCI, V25, P125, DOI 10.1017/S0952523808080309
   Vugler AA, 2007, EXP NEUROL, V205, P26, DOI 10.1016/j.expneurol.2007.01.032
   Wang SM, 2005, J COMP NEUROL, V491, P400, DOI 10.1002/cne.20695
   Wang SM, 2000, INVEST OPHTH VIS SCI, V41, P537
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yang Y, 2009, MOL THER, V17, P787, DOI 10.1038/mt.2009.28
   Zaidi FH, 2007, CURR BIOL, V17, P2122, DOI 10.1016/j.cub.2007.11.034
   Zhang DQ, 2008, P NATL ACAD SCI USA, V105, P14181, DOI 10.1073/pnas.0803893105
   Zhang DQ, 2007, J NEUROSCI, V27, P692, DOI 10.1523/JNEUROSCI.4478-06.2007
   Zhang HB, 2008, J NEUROSCI, V28, P4008, DOI 10.1523/JNEUROSCI.0317-08.2008
   Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009
   Znoiko SL, 2005, INVEST OPHTH VIS SCI, V46, P1473, DOI 10.1167/iovs.04-0653
NR 180
TC 17
Z9 18
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2010
VL 30
IS 7
BP 983
EP 1001
DI 10.1097/IAE.0b013e3181e2a680
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622CE
UT WOS:000279635600001
PM 20616678
DA 2022-11-30
ER

PT J
AU Scilley, K
   Jackson, GR
   Cideciyan, AV
   Maguire, MG
   Jacobson, SG
   Owsley, C
AF Scilley, K
   Jackson, GR
   Cideciyan, AV
   Maguire, MG
   Jacobson, SG
   Owsley, C
TI Early age-related maculopathy and self-reported visual difficulty in
   daily life
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; DARK-ADAPTATION; MACULAR DEGENERATION; DRIVING
   CESSATION; CLINICAL RESEARCH; GRADING SYSTEM; OLDER DRIVERS; PREVALENCE;
   ACUITY; EYE
AB Purpose: To determine whether early age-related maculopathy (ARM) is associated with visual difficulty in daily activities beyond the difficulty that would be expected based on normal retinal aging; to determine whether scotopic sensitivity and visual acuity are associated with visual difficulties in these older adults.
   Study Design: Comparative, cross-sectional questionnaire study.
   Subjects: Ninety-two older adults with early ARM in at least one eye as defined by one or more large (>63 mum) drusen and/or focal hyperpigmentation but no choroidal neovascularization or geographic atrophy, acuity of 20/60 or better, and a reference group of 55 older adults in the same age range without these fundus features and acuity of 20/35 or better in each eye.
   Method. Tests of visual acuity and scotopic sensitivity and a general health questionnaire were carried out. The Activities of Daily Vision Scale (ADVS) was administered to assess self-reported visual difficulties in everyday tasks and expressed on a scale of 0 (extreme difficulty) to 100 (no difficulty). Fundus photographs were taken and graded to characterize the presence and severity of ARM to determine eligibility. Results: For purposes of analysis, the early ARM group was divided into those whose fellow eye (FE) was 20/60 or better and those whose FE was worse than 20/60. ADVS subscale scores were substantially lower in the early ARM group with FE worse than 20/60 (medians, 58-83) compared with the normal retinal health group (medians, 97-100). Even for those with early ARM with FE 20/60 or better, four of five subscale scores were lower (medians, 81-97), albeit slightly in some cases, than those of the reference group. For both ARM subgroups, the night driving subscale had the lowest scores of all subscales. Persons with early ARM with FE 20/60 or better were more likely to report difficulty on the night driving (odds ratio [OR], 4.3; 95% confidence interval [Cl], 1.6-11.4), near vision (OR, 5.0; 95% Cl, 1.9-12.9), and glare disability (OR, 2.7; 95% Cl, 1.1-6.3) subscales compared with those in normal retinal health, adjusting for age, gender, medical comorbidities, and lens density. For early ARM patients with FE worse than 20/60, there was widespread reporting of difficulty on all subscales (ORs ranging from 4.7-52.9). Poor scotopic sensitivity was highly associated with difficulty on the night driving subscale (OR, 6.6; 95% Cl, 1.2-35.5) but not with any other subscale. Acuity worse than 20/25 in both eyes was significantly associated with difficulty on all ADVS subscales; when this acuity impairment was present in one eye only, associations were still significantly present on some subscales, although they were weaker.
   Conclusions: Persons in the early phases of ARM, even when their fellow eye has relatively good acuity, are more likely to experience difficulty in night driving, near vision tasks, and glare disability compared with those in good retinal health. Scotopic dysfunction, a functional marker of early ARM, is linked to reported night driving problems. Even when acuity impairment occurs in one eye only, patients report difficulties with day driving and near and far vision tasks. Ophthalmology 2002,-109:1235-1242 (C) 2002 by the American Academy of Ophthalmology.
C1 Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Pennsylvania; Pennsylvania Medicine
RP Scilley, K (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
RI Cideciyan, Artur V/A-1075-2007
OI Cideciyan, Artur V/0000-0002-2018-0905; Jacobson,
   Samuel/0000-0003-2122-169X
FU NEI NIH HHS [T32-EY 07033, P30-EY 03039, R01-EY 05627, R01-EY 13203]
   Funding Source: Medline; NIA NIH HHS [R01-AG 04212] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R01EY013203, R01EY005627, T32EY007033,
   P30EY003039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   JACOBSON SG, 1991, HDB CLIN VISION TEST, P475
   JOHNSON CA, 1988, J OPT SOC AM A, V5, P2131, DOI 10.1364/JOSAA.5.002131
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KOSNIK W, 1988, J GERONTOL, V43, pP63, DOI 10.1093/geronj/43.3.P63
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MANGIONE CM, 1996, QUALITY LIFE PHARMAC, P1045
   Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   MASSIE DL, 1995, ACCIDENT ANAL PREV, V27, P73, DOI 10.1016/0001-4575(94)00050-V
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MORTIMER RG, 1989, ACCIDENT ANAL PREV, V21, P273, DOI 10.1016/0001-4575(89)90018-3
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, 1990, CLIN VISION SCI, V5, P325
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   SAMPLE PA, 1989, INVEST OPHTH VIS SCI, V30, P786
   SAMPLE PA, 1988, INVEST OPHTH VIS SCI, V29, P1306
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Sherwood MB, 1998, OPHTHALMOLOGY, V105, P561, DOI 10.1016/S0161-6420(98)93043-3
   SLOANE ME, 1992, NONINVASIVE ASSESSME, V1, P26
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Valbuena M, 1999, INVEST OPHTH VIS SCI, V40, P280
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 39
TC 110
Z9 111
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2002
VL 109
IS 7
BP 1235
EP 1242
DI 10.1016/S0161-6420(02)01060-6
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 568BK
UT WOS:000176522400014
PM 12093644
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Sasahara, M
   Otani, A
   Gotoh, N
   Kameda, T
   Iwama, D
   Yodoi, Y
   Tamura, H
   Mandai, M
   Yoshimura, N
AF Tsujikawa, Akitaka
   Sasahara, Manabu
   Otani, Atsushi
   Gotoh, Norimoto
   Kameda, Takanori
   Iwama, Daisuke
   Yodoi, Yuko
   Tamura, Hiroshi
   Mandai, Michiko
   Yoshimura, Nagahisa
TI Pigment epithelial detachment in polypoidal choroidal vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CLINICOPATHOLOGICAL CORRELATION;
   PATHOLOGICAL FEATURES
AB PURPOSE: To study the morphological features of serosanguineous pigment epithelial detachments (PEDs) with accompanying polypoidal lesions in eyes with polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective observational case series.
   METHODS: For this observational case study, we retrospectively reviewed 93 consecutive eyes of 85 patients with PCV. The lesions in eyes with PCV were examined with indocyanine green angiography (IA) and optical coherence tomography (OCT).
   RESULTS: Of 93 eyes with PCV, 51 eyes (55%) had serous or hemorrhagic PEDs. Of these 51 eyes, a notch in the PED was found in 27 eyes (53%) by angiography, most of which showed polypoidal lesions by IA that corresponded in location to the notch observed by angiography. Polypoidal lesions were detected outside the PED in one eye (2%), at the margin of the PED in 33 eyes (65%), and inside the PED in 12 eyes (24%). OCT revealed that PED had a notch observed tomographically in 29 eyes (57%), most of which corresponded in location to polypoidal lesions seen by IA. In eight eyes, polypoidal lesions, which were adherent to the inner surface of the serous PED, appeared to be detached from the Bruch membrane and the choroid.
   CONCLUSIONS: Polypoidal lesions are located at the margin of PED and make a notch in the accompanying PED that is visible by angiography and tomographically. When the polypoidal lesions have increased exudate, the fluid from the lesions infiltrates under the polypoidal lesions themselves, which results in the lesions detaching from the Bruch membrane and appearing to be located inside the PED.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ Hosp, Dept Expt Therapeut, Translat Res Ctr, Kyoto 606, Japan.
C3 Kyoto University; Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Mandai, Michiko/E-7986-2011; TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Mavrofrides EC, 2004, OPTICAL COHERENCE TO, P243
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 32
TC 87
Z9 94
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2007
VL 143
IS 1
BP 102
EP 111
DI 10.1016/j.ajo.2006.08.025
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123QY
UT WOS:000243311700014
PM 17101112
DA 2022-11-30
ER

PT J
AU Conley, YP
   Jakobsdottir, J
   Mah, T
   Weeks, DE
   Klein, R
   Kuller, L
   Ferrell, RE
   Gorin, MB
AF Conley, Yvette P.
   Jakobsdottir, Johanna
   Mah, Tammy
   Weeks, Daniel E.
   Klein, Ronald
   Kuller, Lewis
   Ferrell, Robert E.
   Gorin, Michael B.
TI CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to
   age-related maculopathy: AREDS and CHS cohorts and meta-analyses
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; APOLIPOPROTEIN-E;
   GENOMEWIDE-SCAN; ASSOCIATION; POLYMORPHISM; LINKAGE; VARIANT; FAMILY;
   Y402H
AB Age-related maculopathy (ARM) is an important cause of visual impairment in the elderly population. It is of crucial importance to identify genetic factors and their interactions with environmental exposures for this disorder. This study was aimed at investigating the CFH, ELOVL4, PLEKHA1 and LOC387715 genes in independent cohorts collected using different ascertainment schemes. The study used a case-control design with subjects originally recruited through the Cardiovascular Health Study (CHS) and the Age-Related Eye Disease Study (AREDS). CFH was significantly associated with ARM in both cohorts (P <= 0.00001). A meta-analysis confirmed that the risk allele in the heterozygous or homozygous state (OR, 2.4 and 6.2; 95% CI, 2.2-2.7 and 5.4-7.2, respectively) confers susceptibility. LOC387715 was also significantly associated with ARM in both cohorts (P <= 0.00001) and a meta-analysis confirmed that the risk allele in the heterozygous and homozygous state (OR, 2.5 and 7.3; 95% CI, 2.2-2.9 and 5.7-9.4, respectively) confers susceptibility. Both CFH and LOC387715 showed an allele-dose effect on the ARM risk, individuals homozygous at either locus were at more than two-fold risk compared to those heterozygous. PLEKHA1, which is closely linked to LOC387715, was significantly associated with ARM status in the AREDS cohort, but not the CHS cohort and ELOVL4 was not significantly associated with ARM in either cohort. Joint action of CFH and LOC387715 was best described by independent multiplicative effect without significant interaction in both cohorts. Interaction of both genes with cigarette smoking was insignificant in both cohorts. This study provides additional support for the CFH and LOC387715 genes in ARM susceptibility via the evaluation of cohorts that had different ascertainment schemes regarding ARM status and through the meta-analyses.
C1 Univ Pittsburgh, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Hlth Promot & Dev, Sch Nursing, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Ophthalmol, Sch Med, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53705 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Wisconsin System;
   University of Wisconsin Madison
RP Gorin, MB (通讯作者)，Univ Pittsburgh, Dept Human Genet, Grad Sch Publ Hlth, Eye & Ear Inst Bldg,203 Lothrop St, Pittsburgh, PA 15261 USA.
EM gorinmb@upmc.edu
RI Weeks, Daniel E/B-2995-2012
OI Weeks, Daniel E/0000-0001-9410-7228; Jakobsdottir,
   Johanna/0000-0002-8019-9683
FU DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC015103,
   N01HC085079, N01HC055222, N01HC035129, N01HC085086] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY009859] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080295]
   Funding Source: NIH RePORTER; NEI NIH HHS [R01EY009859] Funding Source:
   Medline; NHLBI NIH HHS [N01-HC-85086, N01 HC-55222, N01 HC-15103,
   N01-HC-85079, N01-HC-35129, U01 HL080295] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   CLAYTON DG, 2006, SNPHAP 1 3 1 PROGRAM
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   GAUDERMAN WJ, 2006, QUANTO 1 1 COMPUTER
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Howson JMM, 2005, GENET EPIDEMIOL, V29, P51, DOI 10.1002/gepi.20077
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P
   North BV, 2005, HUM HERED, V59, P79, DOI 10.1159/000085222
   Okamoto H, 2006, MOL VIS, V12, P156
   R Development Core Team, 2005, R LANG ENV STAT COMP
   Risch N, 2001, THEOR POPUL BIOL, V60, P215, DOI 10.1006/tpbi.2001.1538
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Souied EH, 2005, MOL VIS, V11, P1135
   Valdes AM, 1997, AM J HUM GENET, V60, P703
   van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 45
TC 118
Z9 124
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 1
PY 2006
VL 15
IS 21
BP 3206
EP 3218
DI 10.1093/hmg/ddl396
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 097EP
UT WOS:000241430000011
PM 17000705
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Arias, JD
   Hoyos, AT
   Parra, MM
   Gutierrez, AJ
   Sanchez-Avila, RM
AF Arias, Juan D.
   Hoyos, Andrea T.
   Margarita Parra, M.
   Gutierrez, Alvaro J.
   Sanchez-Avila, Ronald M.
TI Characteristics of Polypoidal Choroidal Vasculopathy in OCT Angiography
   in Latin American Patients
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; PHOTODYNAMIC THERAPY; JAPANESE PATIENTS; FEATURES
AB BACKGROUND AND OBJECTIVES: To describe the imaging characteristics of polypoidal choroidal vasculopathy (PCV) in optical coherence tomography angiography (OCTA) and demonstrate its use as diagnostic method for this pathology in a Latin American population.
   PATIENTS AND METHODS: A case series.
   RESULTS: Fourteen eyes were evaluated. At baseline, the most frequent morphology was the "oval" type (76.9%), obtaining a reduction of 53.8% after treatment. The intrinsic finding of the polyps was hyporeflective content prior to treatment (80.8%), which reduced after treatment (7.7%) (P = .016).
   CONCLUSIONS: OCTA is a useful imaging tool for detecting findings that can guide the diagnosis of PCV without contrast medium. Likewise, it provides signs that can suggest the behavior of the lesion prior to and after treatment, enriching the understanding of the pathology and therefore aiming to an efficient therapy. To the best of the authors' knowledge, this is the first study in a Latin American population.
C1 [Arias, Juan D.] Ctr Oftalmol Virgilio Galvis, Fdn Oftalmol Santander, Floridablanca, Colombia.
   [Arias, Juan D.; Margarita Parra, M.] FOSCAL Int, Floridablanca, Colombia.
   [Hoyos, Andrea T.; Gutierrez, Alvaro J.] Autonomous Univ Bucaramanga, FOSCAL Int, Floridablanca, Colombia.
   [Sanchez-Avila, Ronald M.] Univ Oviedo, Fdn Invest Oftalmol, Inst Univ Fernandez Vega, Oviedo, Spain.
C3 University of Oviedo
RP Parra, MM (通讯作者)，Fdn Oftalmol Santander, Clin Carlos Ardila Iulle FOSCAL, Floridablanca 181004, Colombia.
EM mariamargaritaparrac@gmail.com
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Guyomarch J, 2008, J FR OPHTALMOL, V31, P579, DOI 10.1016/S0181-5512(08)75458-5
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Uzun S, 2016, GRAEF ARCH CLIN EXP, V254, P1651, DOI 10.1007/s00417-016-3368-0
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 27
TC 2
Z9 2
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2018
VL 49
IS 10
BP 747
EP 756
DI 10.3928/23258160-20181002-02
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GY8AM
UT WOS:000448839800016
PM 30395660
DA 2022-11-30
ER

PT J
AU Thanos, A
   Miller, JB
   Ma, KN
   Subramanian, ML
   Kim, IK
   Eliott, D
AF Thanos, Aristomenis
   Miller, John B.
   Ma, Kelly N.
   Subramanian, Manju L.
   Kim, Ivana K.
   Eliott, Dean
TI A New Variant of Polypoidal Choroidal Vasculopathy With Annular
   Pigmentary Changes in Haitian Males
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID S-CONE SYNDROME
AB The authors report a new variant of idiopathic polypoidal choroidal vasculopathy (IPCV) in middle-aged Haitian men characterized by extramacular polypoidal lesions and bilateral extensive pigmentary alterations in the posterior pole in an annular wreath-like pattern surrounding the optic nerve and macular area. Two patients were seen at Massachusetts Eye and Ear Infirmary and one at Boston University Medical Center between 2010 and 2015. All three patients were middle-aged Haitian men who exhibited bilateral features of IPCV, including subretinal hemorrhages and serosanguinous pigment epithelial detachments. Indocyanine green angiography revealed extramacular polypoidal lesions located mostly along the major vascular arcades. Extensive pigmentary alterations were evident in the posterior pole surrounding the macula and optic nerve in an annular wreath-like pattern. These cases further expand the clinical spectrum of IPCV.
C1 [Thanos, Aristomenis; Miller, John B.; Kim, Ivana K.; Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
   [Ma, Kelly N.; Subramanian, Manju L.] Boston Univ, Med Ctr, Dept Ophthalmol, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Boston University
RP Eliott, D (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM dean_eliott@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Kim, Ivana/0000-0003-0310-6129
CR Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lotery AJ, 1996, EYE, V10, P759, DOI 10.1038/eye.1996.182
   Park DH, 2010, JPN J OPHTHALMOL, V54, P48, DOI 10.1007/s10384-009-0765-5
   Sharon D, 2003, ARCH OPHTHALMOL-CHIC, V121, P1316, DOI 10.1001/archopht.121.9.1316
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yzer S, 2013, JAMA OPHTHALMOL, V131, P1324, DOI 10.1001/jamaophthalmol.2013.4349
NR 14
TC 1
Z9 1
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2016
VL 47
IS 4
BP 381
EP 386
DI 10.3928/23258160-20160324-15
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9VJ
UT WOS:000378845400015
PM 27065382
DA 2022-11-30
ER

PT J
AU Nishide, T
   Hayakawa, N
   Nakanishi, M
   Ishii, M
   Okazaki, S
   Kimura, I
   Shibuya, E
   Mizuki, N
AF Nishide, Tadayuki
   Hayakawa, Natsuki
   Nakanishi, Misako
   Ishii, Mai
   Okazaki, Shinya
   Kimura, Ikuko
   Shibuya, Etsuko
   Mizuki, Nobuhisa
TI Reduction in choroidal thickness of macular area in polypoidal choroidal
   vasculopathy patients after intravitreal ranibizumab therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Polypoidal choroidal vasculopathy; Enhanced depth
   imaging; Optical coherence tomography; Ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; DEPTH; DEGENERATION
AB To evaluate changes in retinal and choroidal thickness changes after three intravitreal ranibizumab (IVR) injections for polypoidal choroidal vasculopathy (PCV) using enhanced depth-imaging-optical coherence tomography (EDI-OCT).
   In this retrospective, observational case series, EDI-OCT was used to measure changes in choroidal thickness at nine points in a lattice shape in the macula before and after introductory-stage IVR.
   Choroidal thickness was decreased at all nine points in the lattice shape, but was significantly decreased only at the fovea.
   The subfoveal choroidal thickness may be reduced by introductory-stage IVR in patients with PCV. In particular, choroidal thickness at the fovea was reduced during the early stage of treatment.
C1 [Nishide, Tadayuki; Hayakawa, Natsuki; Nakanishi, Misako; Ishii, Mai; Okazaki, Shinya; Kimura, Ikuko; Shibuya, Etsuko; Mizuki, Nobuhisa] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan.
C3 Yokohama City University
RP Nishide, T (通讯作者)，Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM nishide@abox3.so-net.ne.jp
CR Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2011, AM J OPHTHALMOL, V151, P297, DOI 10.1016/j.ajo.2010.08.014
   Kodach VM, 2010, BIOMED OPT EXPRESS, V1, P176, DOI 10.1364/BOE.1.000176
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Yeoh J, 2010, GRAEF ARCH CLIN EXP, V248, P1719, DOI 10.1007/s00417-010-1437-3
NR 15
TC 13
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2013
VL 251
IS 10
BP 2415
EP 2420
DI 10.1007/s00417-013-2419-z
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 220PW
UT WOS:000324598500015
PM 23864437
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Prakash, M
   Han, DP
AF Prakash, Manvi
   Han, Dennis P.
TI Recurrent bullous retinal detachments from photodynamic therapy for
   idiopathic polypoidal choroidal vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report the recurrent bullous retinal detachments as complications of photodynamic therapy (PDT) for idiopathic polypoidal choroidal vasculopathy (IPCV).
   DESIGN: Interventional case report.
   METHODS: A pseudophakic 84-year,old,woman had IPCV and decreased vision. Angiography demonstrated macular leakage. PDT with verteporfin was applied. Two days later, visual acuity decreased from 20/50 to 20/400. Examination revealed extensive inferior subretinal fluid, which mimicked a pseudophakic rhegmatogenous retinal detachment. A scleral buckle was placed; no retinal breaks were identified.
   RESULTS: Vision and fluid resolved over three weeks. Four months later, examination revealed decreased vision and persistent leakage. Two days after repeat PDT, bullous exudative macular detachment recurred. Detachment resolved over two weeks; visual acuity returned to 20/50.
   CONCLUSION: IPCV that is treated with PDT may be complicated by iatrogenic bullous exudative retinal detachments that resemble rhegmatogenous detachments. Modified treatment parameters may reduce the risk of recurrence. The natural history likely includes spontaneous resolution and visual recovery.
C1 Med Coll Wisconsin, Inst Eye, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Han, DP (通讯作者)，Med Coll Wisconsin, Inst Eye, 925 North 87th St, Milwaukee, WI 53226 USA.
EM dhan@mail.mcw.edu
CR Holz ER, 2003, ARCH OPHTHALMOL-CHIC, V121, P1649, DOI 10.1001/archopht.121.11.1649
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 5
TC 6
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 1079
EP 1081
DI 10.1016/j.ajo.2006.06.059
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100034
PM 17157602
DA 2022-11-30
ER

PT J
AU Assel, MJ
   Li, F
   Wang, Y
   Allen, AS
   Baggerly, KA
   Vickers, AJ
AF Assel, Melissa J.
   Li, Fan
   Wang, Ying
   Allen, Andrew S.
   Baggerly, Keith A.
   Vickers, Andrew J.
TI Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to
   Antioxidants and Zinc in Patients with Age-Related Macular Degeneration
   Independent Statistical Evaluations of Data from the Age-Related Eye
   Disease Study
SO OPHTHALMOLOGY
LA English
DT Article
ID CLINICALLY SIGNIFICANT ASSOCIATION; 38 OPHTHALMOLOGY 2014/121/2173-80;
   AREDS SUPPLEMENTS; GENOTYPES; NUMBER
AB Purpose: Considerable controversy has erupted in recent years regarding whether genotyping should be part of standard care for patients with age-related macular degeneration (AMD) who are being considered for treatment with antioxidants and zinc. We aimed to determine whether genotype predicts response to supplements in AMD.
   Design: Three separate statistical teams reanalyzed data derived from the Age-Related Eye Disease Study (AREDS), receiving data prepared by the AREDS investigators and, separately, data from investigators reporting findings that support the use of genotyping.
   Participants: The population of interest was AREDS participants with AMD worse than category 1 and genotyping data available. Data from the 2 groups overlap imperfectly with respect to measurements made: the largest common set involved 879 participants for whom the same CFH and ARMS2 single nucleotide polymorphisms were measured by both groups.
   Methods: Each team took a separate but complementary approach. One team focused on data concordance between conflicting studies. A second team focused on replicating the key claim of an interaction between genotype and treatment. The third team took a blank slate approach in attempting to find baseline predictors of treatment response.
   Main Outcome Measures: Progression to advanced AMD.
   Results: We found errors in the data used to support the initial claim of genotypeetreatment interaction. Although we found evidence that high-risk patients had more to gain from treatment, we were unable to replicate any genotypeetreatment interactions after adjusting for multiple testing. We tested 1 genotype claim on an independent set of data, with negative results. Even if we assumed that interactions in fact did exist, we did not find evidence to support the claim that supplementation leads to a large increase in the risk of advanced AMD in some genotype subgroups.
   Conclusions: Patients who meet criteria for supplements to prevent AMD progression should be offered zinc and antioxidants without consideration of genotype. (C) 2017 by the American Academy of Ophthalmology
C1 [Assel, Melissa J.; Vickers, Andrew J.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Li, Fan; Allen, Andrew S.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
   [Wang, Ying; Baggerly, Keith A.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
C3 Memorial Sloan Kettering Cancer Center; Duke University; University of
   Texas System; UTMD Anderson Cancer Center
RP Vickers, AJ (通讯作者)，Mem Sloan Kettering Canc Ctr, Epidemiol & Biostat, 485 Lexington Ave,2nd Floor, New York, NY 10017 USA.
EM vickersa@mskcc.org
RI Li, Fan/AAX-8565-2020
OI Li, Fan/0000-0001-6183-1893; Allen, Andrew/0000-0002-7232-2143
FU National Cancer Institute, National Institutes of Health, Bethesda,
   Maryland (Cancer Center Support grant) [P30-CA008748]; NATIONAL CANCER
   INSTITUTE [P30CA016672, P30CA008748] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): A.J.V.: Supported
   in part by the National Cancer Institute, National Institutes of Health,
   Bethesda, Maryland (Cancer Center Support grant to MSKCC, no.:
   P30-CA008748).
CR Awh CC, 2015, OPHTHALMOLOGY, V122, pE46, DOI 10.1016/j.ophtha.2014.12.042
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Chew EY, 2015, OPHTHALMOLOGY, V122, pE46, DOI 10.1016/j.ophtha.2015.01.023
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   EFRON B, 1977, J AM STAT ASSOC, V72, P557, DOI 10.2307/2286217
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Parekh DJ, 2015, EUR UROL, V68, P464, DOI 10.1016/j.eururo.2014.10.021
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
NR 12
TC 26
Z9 27
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2018
VL 125
IS 3
BP 391
EP 397
DI 10.1016/j.ophtha.2017.09.008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5SE
UT WOS:000425377300017
PM 29032853
OA Green Accepted
DA 2022-11-30
ER

PT J
AU van Asten, F
   Simmons, M
   Singhal, A
   Keenan, TD
   Ratnapriya, R
   Agron, E
   Clemons, TE
   Swaroop, A
   Lu, Z
   Chew, EY
AF van Asten, Freekje
   Simmons, Michael
   Singhal, Ayush
   Keenan, Tiarnan D.
   Ratnapriya, Rinki
   Agron, Elvira
   Clemons, Traci E.
   Swaroop, Anand
   Lu, Zhiyong
   Chew, Emily Y.
CA Age-Related Eye Dis Study Res Grp
TI A Deep Phenotype Association Study Reveals Specific Phenotype
   Associations with Genetic Variants in Age-related Macular Degeneration
   Age-Related Eye Disease Study 2 (AREDS2) Report No. 14
SO OPHTHALMOLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; EYE DISEASE; GEOGRAPHIC
   ATROPHY; RISK-FACTORS; LOC387715; RARE; OMEGA-3-FATTY-ACIDS;
   SUPPLEMENTATION; SUSCEPTIBILITY
AB Purpose: Age-related macular degeneration (AMD), a multifactorial disease with variable phenotypic presentation, was associated with 52 single nucleotide polymorphisms (SNPs) at 34 loci in a genome-wide association study (GWAS). These genetic variants could modulate different biological pathways involved in AMD, contributing to phenotypic variability. To better understand the effects of these SNPs, we performed a deep phenotype association study (DeePAS) in the Age-Related Eye Disease Study 2 (AREDS2), followed by replication using AREDS participants, to identify genotype associations with AMD and non-AMD ocular and systemic phenotypes.
   Design: Cohort study.
   Participants: AREDS and AREDS2 participants.
   Methods: AREDS2 participants (discovery cohort) had detailed phenotyping for AMD; other eye conditions; cardiovascular, neurologic, gastrointestinal, and endocrine disease; cognitive function; serum nutrient levels; and others (total of 139 AMD and non-AMD phenotypes). Genotypes of the 52 GWAS SNPs were obtained. The DeePAS was performed by correlating the 52 SNPs to all phenotypes using logistic and linear regression models. Associations that reached Bonferroni-corrected statistical significance were replicated in AREDS.
   Main Outcome Measures: Genotypeephenotype associations.
   Results: A total of 1776 AREDS2 participants had 5 years follow-up; 1435 AREDS participants had 10 years. The DeePAS revealed a significant association of the rs3750846 SNP at the ARMS2/HTRA1 locus with subretinal/suberetinal pigment epithelial (RPE) hemorrhage related to neovascular AMD (odds ratio 1.55 [95% confidence interval 1.31-1.84], P = 2.67 x 10(-7)). This novel association remained significant after conditioning on participants with neovascular AMD (P = 2.42 x 10(-4)). Carriers of rs3750846 had poorer visual acuity during follow-up (P = 6.82 x 10(-7)) and were more likely to have a first-degree relative with AMD (P = 5.38 x 10(-6)). Two SNPs at the CFH locus, rs10922109 and rs570618, were associated with the drusen area in the Early Treatment Diabetic Retinopathy Study Report (ETDRS) grid (P = 2.29 x 10(-11) and P = 3.20 x 10(-9), respectively) and the center subfield (P = 1.24 x 10(-9) and P = 6.68 x 10(-8), respectively). SNP rs570618 was additionally associated with the presence of calcified drusen (P = 5.38 x 10(-6)). Except for positive family history of AMD with rs3750846, all genotypeephenotype associations were significantly replicated in AREDS. No pleiotropic associations were identified.
   Conclusions: The association of the SNP at the ARMS2/HTRA1 locus with subretinal/sub-RPE hemorrhage and poorer visual acuity and of SNPs at the CFH locus with drusen area may provide new insights in pathophysiological pathways underlying different stages of AMD. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [van Asten, Freekje; Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Simmons, Michael; Singhal, Ayush; Lu, Zhiyong] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD USA.
   [Keenan, Tiarnan D.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10-CRC,Room 3-2531,10 Ctr Dr, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Library
   of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Emmes Corporation
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10-CRC,Room 3-2531,10 Ctr Dr, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020; van Asten, Freekje/P-6028-2015
OI van Asten, Freekje/0000-0002-8141-4234; Ratnapriya,
   Rinki/0000-0002-0469-4631
FU Bayer Global Ophthalmology Awards Program; National Eye Institute
   [EY000546, HHS-N-260-2005-00007-C, NO1-EY-5-0007, NOI-EY-0-2127];
   Nederlandse Oogonderzoek Stichting; Dr. P. Binkhorst Stichting;
   Stichting Dondersfonds; Prins Bernhard Cultuurfonds; Stichting A.F.
   Deutman Oogheelkunde Researchfonds; NIH Medical Research Scholars
   Program; NIH; Office of Dietary Supplements; National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke; NIH Intramural Program, National
   Library of Medicine; NATIONAL EYE INSTITUTE [ZIAEY000489, ZIAEY000546]
   Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [ZIALM091813]
   Funding Source: NIH RePORTER
FX The author(s) made the following disclosures: T.D.K.: Partly funded this
   year by an award from the Bayer Global Ophthalmology Awards Program.;
   F.v.A.: Funding-Intramural Research Program of the National Eye
   Institute (EY000546); Grants - Nederlandse Oogonderzoek Stichting, Dr.
   P. Binkhorst Stichting, Stichting Dondersfonds, Prins Bernhard
   Cultuurfonds, and Stichting A.F. Deutman Oogheelkunde Researchfonds;
   Support - NIH Medical Research Scholars Program, a public-private
   partnership supported jointly by the NIH and generous contributions to
   the Foundation for the NIH from the Doris Duke Charitable Foundation,
   the Howard Hughes Medical Institute, the American Association for Dental
   Research, the Colgate-Palmolive Company, and other private donors. No
   funds from the Doris Duke Charitable Foundation were used to support
   research that used animals. These organizations had no role in the
   design or conduct of this research.; Supported by the Intramural
   Research Program of the National Eye Institute (EY000546; AREDS2
   Contract HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007; AREDS
   Contract NOI-EY-0-2127). Funds contributed to AREDS2 contracts by the
   following NIH institutes: Office of Dietary Supplements, National Center
   for Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; and National Institute of
   Neurological Disorders and Stroke.; Supported by NIH Intramural Program,
   National Library of Medicine. The AREDS and AREDS2 sponsor and funding
   organization participated in the design and conduct of the study; data
   collection, management, analysis, and interpretation; and the
   preparation, review, and approval of the manuscript. HUMAN SUBJECTS:
   Human subjects were part of this study protocol. Institutional Review
   Board approval was obtained previously for both the AREDS and AREDS2
   populations. All participants provided written informed consent. This
   research was HIPAA-compliant and adhered to the tenets of the
   Declaration of Helsinki.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749
   Denny JC, 2010, BIOINFORMATICS, V26, P1205, DOI 10.1093/bioinformatics/btq126
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Domalpally A, 2013, INVEST OPHTH VIS SCI, V54, P5989, DOI 10.1167/iovs.13-12301
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Simmons M, 2016, ADV EXP MED BIOL, V939, P139, DOI 10.1007/978-981-10-1503-8_7
   Singhal A, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005017
   Singhal A, 2016, J AM MED INFORM ASSN, V23, P766, DOI 10.1093/jamia/ocw041
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Tong Y, 2010, MOL VIS, V16, P1958
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 45
TC 21
Z9 21
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2018
VL 125
IS 4
BP 559
EP 568
DI 10.1016/j.ophtha.2017.09.023
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ9HE
UT WOS:000427920000024
PM 29096998
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sato, T
   Kishi, S
   Watanabe, G
   Matsumoto, H
   Mukai, R
AF Sato, Taku
   Kishi, Shoji
   Watanabe, Goro
   Matsumoto, Hidetaka
   Mukai, Ryo
TI Tomographic features of branching vascular networks in polypoidal
   choroidal vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
AB Purpose: To identify the tomographic features of the branching vascular networks in patients with polypoidal choroidal vasculopathy (PCV).
   Methods: We prospectively performed third -generation optical coherence tomography (OCT) and fluorescein angiography for 44 eyes of 42 patients (mean age SID, 67.1 +/- 9.1 years) with PCV. All eyes had branching vascular networks and polypoidal lesions that were confirmed by indocyanine green angiography.
   Results: OCT showed double reflective layers that consisted of retinal pigment epithelium (RPE) and another highly reflective layer beneath the RPE ("double-layer sign") in the area of the branching network vessels in 26 (59%) of 44 eyes. The remaining 18 eyes had no double-layer sign, but 17 (94%) of 18 eyes had a slightly elevated RPE. A serous retinal detachment was present in 23 (88%) of 26 eyes with a double-layer sign, while only 1 (6%) of 18 eyes without the sign had a serous retinal detachment.
   Conclusions: In PCV, the double-layer sign is seen frequently in the area of the network vessels, particularly in eyes with a serous retinal detachment. The sign may reflect fluid accumulation between RPE and Bruch membrane resulting from leakage from the network of abnormal vessels.
C1 Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Sato, T (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3 Showamachi, Maebashi, Gunma 3718511, Japan.
EM takusato@showa.gunma-u.ac.jp
CR Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hogan M. J., 1971, HISTOLOGY HUMAN EYE, P328
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   PULIAFITO CA, 1995, OPTICAL COHERENCE TO, P187
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 17
TC 126
Z9 146
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2007
VL 27
IS 5
BP 589
EP 594
DI 10.1097/01.iae.0000249386.63482.05
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 178ZP
UT WOS:000247259400010
PM 17558321
DA 2022-11-30
ER

PT J
AU Ahmed, SS
   Lott, MG
   Marcus, DM
AF Ahmed, SS
   Lott, MG
   Marcus, DM
TI The macular xanthophylls
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; carotenoids; lutein; macular pigment;
   xanthophylls; zeaxanthin
ID AGE-RELATED MACULOPATHY; PIGMENT OPTICAL-DENSITY; BEAVER DAM EYE;
   NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; HUMAN RETINA;
   BETA-CAROTENE; RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; ZEAXANTHIN
   CONCENTRATIONS
AB The macular pigments are predominantly composed of three carotenoids: lutein, zeaxanthin, and meso-zeaxanthin. These carotenoids are concentrated and distributed in a selective manner. The properties of these pigments are further explored along with their methods of uptake, stabilization, and storage. The dual nature of these pigments as filters and antioxidants are elaborated upon in relation to their protective effects upon the macula, specifically in age-related macular degeneration. Evidence suggests that increased levels of macular pigment are correlated with a decreased risk of age-related macular degeneration. Many have Sought to exploit this therapeutic relation. Studies reveal that oral supplementation with lutein and zeaxanthin can increase the levels of macular pigments in the retina and plasma. The effects of such supplementation on actual ocular function have yet to be fully addressed. New and standardized methods of assessing macular pigment density are discussed and future areas of research to further our understanding of macular xanthophylls as they pertain to age-related macular degeneration are highlighted. (c) 2005 Elsevier Inc. All rights reserved.
C1 Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University
RP Marcus, DM (通讯作者)，Med Coll Georgia, Dept Ophthalmol, 1120 5th St,BA-2719, Augusta, GA 30912 USA.
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   ARMSTRONG D, 1990, JPN J OPHTHALMOL, V34, P158
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   COGDELL RJ, 1975, BIOCHIM BIOPHYS ACTA, V408, P189, DOI 10.1016/0005-2728(75)90122-X
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   de Pee S, 1998, AM J CLIN NUTR, V68, P1058, DOI 10.1093/ajcn/68.5.1058
   DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0
   DRASDO N, 1974, BRIT J OPHTHALMOL, V58, P709, DOI 10.1136/bjo.58.8.709
   Foote C.S, 1976, FREE RADICALS BIOL, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE, P508
   Holden Joanne M., 1999, Journal of Food Composition and Analysis, V12, P169, DOI 10.1006/jfca.1999.0827
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   JORGENSEN K, 1993, Z LEBENSM UNTERS FOR, V196, P423, DOI 10.1007/BF01190806
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   KHACHIK F, 1998, PHYTOCHEMICALS NEW P, P77
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MICHELS M, 1992, AM J OPHTHALMOL, V114, P287, DOI 10.1016/S0002-9394(14)71792-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   *NAT ADV EY COUNC, 1998, PUBLICATION NIH
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   OJIMA F, 1993, FREE RADICAL BIO MED, V15, P377, DOI 10.1016/0891-5849(93)90037-U
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   Schalch W, 1992, EXS, V62, P280
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1997, AM J OPHTHALMOL, V123, P750
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stewart JE, 1998, INT J BIOCHEM CELL B, V30, P407, DOI 10.1016/S1357-2725(97)00151-9
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   WERNER JS, 1979, J OPT SOC AM, V69, P422, DOI 10.1364/JOSA.69.000422
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 110
TC 94
Z9 99
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2005
VL 50
IS 2
BP 183
EP 193
DI 10.1016/j.survophthal.2004.12.009
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 909TE
UT WOS:000227882800004
PM 15749308
DA 2022-11-30
ER

PT J
AU Mason, JO
   Colagross, CC
   Feist, RM
   White, MF
   Thomley, ML
   Vail, RS
   McGwin, G
AF Mason, John O., III
   Colagross, Cheri C.
   Feist, Richard M.
   White, Milton F.
   Thomley, Martin L.
   Vail, Rachel S.
   McGwin, Gerald, Jr.
TI Risk Factors for Severe Vision Loss Immediately After Transpupillary
   Thermotherapy for Occult Subfoveal Choroidal Neovascularization
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID MACULAR DEGENERATION
AB BACKGROUND AND OBJECTIVE: To determine risk factors for immediate severe vision loss in patients with age-related macular degeneration after transpupillary thermotherapy for occult subfoveal choroidal neovascularization.
   PATIENTS AND METHODS: Retrospective review of 84 consecutive patients with age-related macular degeneration who received transpupillary thermotherapy for occult subfoveal choroidal neovascularization. Seven cases had severe vision loss and 77 were controls. All patients were treated with a diode infrared laser. Follow-up was completed on all patients 1, 3, and 6 months after treatment with transpupillary thermotherapy.
   RESULTS: Pretreatment visual acuity ranged from 20/40 to 1/200. Seven of 84 consecutive eyes had an immediate visual acuity loss of 6 or more Snellen lines after transpupillary thermotherapy.
   CONCLUSION: Transpupillary thermotherapy has a small but significant risk of immediate severe vision loss in patients with age-related macular degeneration with occult subfoveal choroidal neovascularization. Statistically significant risk factors include a subretinal hemorrhage 5 disc areas or greater in size, 9 disc areas or greater of subretinal fluid, and a laser power greater than 550 mW.
C1 [Mason, John O., III; Feist, Richard M.; White, Milton F.; Thomley, Martin L.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Retina Consultants Alabama, Sch Med, Callahan Eye Fdn Hosp,Dept Ophthalmol, Birmingham, AL 35233 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Mason, JO (通讯作者)，Univ Alabama Birmingham, Retina Consultants Alabama, Sch Med, Callahan Eye Fdn Hosp,Dept Ophthalmol, 700 S 8th St,Suite 707, Birmingham, AL 35233 USA.
FU Research to Prevent Blindness, Inc., New York, New York
FX Supported by an unrestricted departmental grant from Research to Prevent
   Blindness, Inc., New York, New York.
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   Desmettre T, 2001, INVEST OPHTH VIS SCI, V42, P2976
   GEERAETS WJ, 1962, INVEST OPHTH VISUAL, V1, P340
   Kaga T, 2001, RETINA-J RET VIT DIS, V21, P172, DOI 10.1097/00006982-200104000-00012
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Miller-Rivero NE, 2000, INVEST OPHTH VIS SCI, V41, pS179
   MORIMURA Y, 2001, JPN J OPHTHAL SURG, V14, P337
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P371, DOI 10.1097/00006982-200306000-00014
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Reichel E., 2005, INVEST OPHTH VIS SCI, V46, P2311
   Rogers AH, 2001, CURR OPIN OPHTHALMOL, V12, P212, DOI 10.1097/00055735-200106000-00012
   Sanders JB, 2001, INVEST OPHTH VIS SCI, V42, pS513
   Shields CL, 1996, OPHTHALMOLOGY, V103, P1642, DOI 10.1016/S0161-6420(96)30451-X
   Subramanian Manju L, 2003, Curr Opin Ophthalmol, V14, P155, DOI 10.1097/00055735-200306000-00008
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 23
TC 5
Z9 5
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2008
VL 39
IS 6
BP 460
EP 465
DI 10.3928/15428877-20081101-09
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 371TO
UT WOS:000260854400003
PM 19065975
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Alten, F
   Termuhlen, J
   Mihailovic, N
   Rosenberger, F
   Heiduschka, P
   Eter, N
AF Clemens, C. R.
   Alten, F.
   Termuehlen, J.
   Mihailovic, N.
   Rosenberger, F.
   Heiduschka, P.
   Eter, N.
TI Prospective PED-study of intravitreal aflibercept for refractory
   vascularized pigment epithelium detachment due to age-related macular
   degeneration: morphologic characteristics of non-responders in optical
   coherence tomography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pigment epithelium detachment;
   Spectral-domain optical coherence tomography; Aflibercept; Anti-vascular
   endothelial growth factor
ID CHOROIDAL NEOVASCULARIZATION; TACHYPHYLAXIS; RESISTANCE; THERAPY
AB Purpose The aim of this study was to investigate the outcomes of a fixed intravitreal aflibercept regimen in patients with vascular pigment epithelium detachment (vPED) secondary to age-related macular degeneration with refractory subretinal fluid.
   Methods A prospective, interventional case series involved 20 eyes of 20 patients with refractory subretinal fluid and vPED treated with at least three injections of intravitreal anti-VEGF prior to study inclusion. After study inclusion, patients were treated with three injections of intravitreal aflibercept 2 mg/0.05 mL monthly followed by injections every 8 weeks. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) were evaluated at all visits. Fluorescein angiography and indocyanine green angiography were performed at baseline and quarterly. Primary outcomes were effectivity of a fixed treatment as measured in change in BCVA, PED greatest linear diameter (GLD), and PED height from baseline to month 12. In an additional post hoc analysis, vPED patients were differentiated into two groups: (1) vPED lesions that showed persistence of subretinal fluid throughout 1 year of treatment and (2) vPED lesions that showed complete resolution of subretinal fluid at least at one of the monthly performed OCT volume scans. Reflectivity values were determined in the subretinal pigment epithelium (RPE) compartment in OCT scans at baseline, month 6 and 12.
   Results A total of 18 patients completed the study protocol. The mean age was 74.8 +/- 10.6 years, and six patients were female. The median BCVA of all patients was 72.0 +/- 8.0 EDTRS letters at baseline and 72.5 +/- 9.5 EDTRS letters at 12-month follow-up (p = 0.7420). The median PED height in all patients as measured in the OCT images significantly decreased from 372.0 +/- 140.0 mu m to 149.0 +/- 142.0 mu m after 12 months of treatment (p = 0.0020). Persistent subretinal fluid was present at every OCT control in six patients (group 1). Twelve patients showed resolution of subretinal fluid at least at one OCT control (group 2). Reflectivity values in the sub-RPE compartment in OCT scans were 41.48 +/- 4.48 (group 1) and 42.62 +/- 12.34 (group 2) at baseline (p = 0.854) and 65.88 +/- 6.74 and 50.87 +/- 14.11 at month 12 (p = 0.038).
   Conclusions Intravitreal aflibercept in refractory vPED leads to a significant reduction in PED height and disease activity as well as preservation of BCVA over 1 year. Persistent subretinal fluid was present in PED lesions with high values of reflectivity under the RPE, suggesting both a diffusion barrier and an increasing fibrovascular maturization of the choroidal neovascularization.
C1 [Clemens, C. R.; Alten, F.; Termuehlen, J.; Mihailovic, N.; Rosenberger, F.; Heiduschka, P.; Eter, N.] Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
C3 University of Munster
RP Clemens, CR (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM Christoph.Clemens@ukmuenster.de; Florian.Alten@ukmuenster.de;
   Julia.Termuehlen@ukmuenster.de; Natasa.Mihailovic@ukmuenster.de;
   Friederike.Rosenberger@ukmuenster.de; Peter.Heiduschka@ukmuenster.de;
   Nicole.Eter@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
FU Projekt DEAL - Bayer (Leverkusen, Germany)
FX Open Access funding provided by Projekt DEAL. This study was funded by
   Bayer (Leverkusen, Germany).
CR Arjamaa O, 2012, BRIT J OPHTHALMOL, V96, P1153, DOI 10.1136/bjophthalmol-2012-301823
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Kim K, 2019, RETINA-J RET VIT DIS, V39, P303, DOI 10.1097/IAE.0000000000001947
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Lu C, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.12.028
   Pachydaki SI, 2012, J OPHTHALMIC INFLAMM, V2, P29, DOI 10.1007/s12348-011-0050-x
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
NR 20
TC 3
Z9 4
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2020
VL 258
IS 7
BP 1411
EP 1417
DI 10.1007/s00417-020-04675-y
EA APR 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LZ6OV
UT WOS:000527902100001
PM 32306096
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Okubo, A
   Ito, M
   Sameshima, M
   Uemura, A
   Sakamoto, T
AF Okubo, A
   Ito, M
   Sameshima, M
   Uemura, A
   Sakamoto, T
TI Pulsatile blood flow in the polypoidal choroidal vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; PIGMENT EPITHELIAL DETACHMENTS
AB Objective: To describe patients with pulsatile polypoidal vessels in polypoidal choroidal vasculopathy (PCV).
   Design: Retrospective, observational case series.
   Participants: Eighty-four eyes of 74 patients with PCV.
   Methods: The medical records of patients diagnosed with PCV between 1998 and 2004 at Kagoshima University Hospital were reviewed.
   Main Outcome Measures: A pulsatile polypoidal vessel (PV) on indocyanine green angiography (ICGA).
   Results: Seven of 74 patients (9.5%) had PVs in the macula. Four eyes revealed pulsatile PVs on the day the diagnosis of PCV was first made, and PVs in the other 3 eyes showed pulsatile movement during the follow-up period. Two patterns of pulsatile movement were observed on ICGA: (1) a rhythmic variation in the caliber of a choroidal vessel (caliber variation pattern) and (2) a pulsatile blood flow in a tortuous and relatively narrow choroidal vessel (pulsatile blood flow pattern). Both patterns of pulsatile PVs appeared in the early frames of the ICGA, and some of them were observable even during the first 15 minutes after the ICG dye injection. The pulsatile movement disappeared spontaneously without treatment in some patients, and the period in which pulsatile PVs was detectable on ICGA was limited in each patient.
   Conclusions: We report the features of pulsatile PV in PCV. It is a unique and important characteristic that has not been reported with any other chorioretinal diseases and may provide a clue to understanding the pathogenesis of PCV.
C1 Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   Kagoshima City Hosp, Kagoshima, Japan.
C3 Kagoshima University; Kagoshima City Hospital
RP Okubo, A (通讯作者)，Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
CR AbuYousef MM, 1996, AM J ROENTGENOL, V167, P977, DOI 10.2214/ajr.167.4.8819397
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   ASHTON N, 1952, BRIT J OPHTHALMOL, V36, P465, DOI 10.1136/bjo.36.9.465
   Bischoff P, 1996, KLIN MONATSBL AUGENH, V208, P318, DOI 10.1055/s-2008-1035226
   Burns D, 1997, BASIC PATHOLOGY, P325
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   FRYCZKOWSKI AW, 1997, INDOCYANINE GREEN AN, P29
   FUJIWARA T, 2001, GANKA, V43, P1365
   FURUSHO F, 2000, ATARASHII GANKA, V17, P1695
   HAIMOVICI H, 1985, J VASC SURG, V2, P684, DOI 10.1067/mva.1985.avs0020684
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Moawad MR, 1998, LANCET, V352, P1030, DOI 10.1016/S0140-6736(98)04471-7
   Mori R., 2004, GANKA, V46, P193
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   RING HG, 1967, ARCH OPHTHALMOL-CHIC, V78, P431
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Schneider U, 1997, OPHTHALMOLOGICA, V211, P115, DOI 10.1159/000310775
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SHULTS WT, 1974, AM J OPHTHALMOL, V77, P304, DOI 10.1016/0002-9394(74)90734-X
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tanaka T, 1998, OPHTHALMOLOGY, V105, P1251, DOI 10.1016/S0161-6420(98)97030-0
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   WYBAR KC, 1954, J ANAT, V88, P94
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
NR 35
TC 27
Z9 28
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2005
VL 112
IS 8
BP 1436
EP 1441
DI 10.1016/j.ophtha.2005.03.017
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 949SL
UT WOS:000230808300019
PM 15996735
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Carriere, I
   Delage, M
   Barberger-Gateau, P
   Schalch, WF
AF Delcourt, Cicile
   Carriere, Isabelle
   Delage, Martine
   Barberger-Gateau, Pascale
   Schalch, Wolfgang
CA POLA Study Grp
TI Plasma lutein and zeaxanthin and other carotenoids as modifiable risk
   factors for age-related maculopathy and cataract: The POLA study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POSTERIOR SUBCAPSULAR CATARACTS; MACULAR DEGENERATION; ANTIOXIDANT
   INTAKE; 5-YEAR INCIDENCE; VITAMIN-C; NUCLEAR; PIGMENT; SERUM;
   CLASSIFICATION; IDENTIFICATION
AB PURPOSE. To assess the associations of plasma lutein and zeaxanthin and other carotenoids with the risk of age-related maculopathy (ARM) and cataract in the population-based Pathologies Oculaires Liees a l'Age (POLA) Study.
   METHODS. Retinal photographs were graded according to the international classification. ARM was defined by the presence of late ARM (neovascular ARM, geographic atrophy) and/or soft indistinct drusen (> 125 mu m) and/or soft distinct drusen (> 125 gm) associated with pigmentary abnormalities. Cataract classification was based on a direct standardized lens examination at the slit lamp, according to Lens Opacities Classification System III. Plasma carotenoids were measured by high-performance liquid chromatography (HPLC), in 899 subjects of the cohort.
   RESULTS. After multivariate adjustment, the highest quintile of plasma zeaxanthin was significantly associated with reduced risk of ARM (OR = 0.07; 95% CI: 0.01-0.58-1 P for trend = 0.005), nuclear cataract (OR = 0.23-1 95% CI: 0.08-0.68; P for trend = 0.003) and any cataract (OR = 0.53; 95% CI: 0.31-0.89; P for trend = 0.01). ARM was significantly associated with combined plasma lutein and zcaxanthin (OR = 0.21; 95% CI: 0.05-0.79; P for trend = 0.01), and tended to be associated with plasma lutein (OR = 0.31; 95% CI: 0.09-1.07; P for trend = 0.04), whereas cataract showed no such associations. Among other carotenoids, only beta-carotene showed a significant negative association with uncle at. cataract, but not ARM.
   CONCLUSIONS. These results are strongly suggestive of a protective role of the xanthophylls, in particular zeaxanthin, for the protection against ARM and cataract.
C1 Univ Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France.
   Univ Montpellier I, INSERM, E361, F-34006 Montpellier, France.
   Lapeyronie Univ Hosp, Biochem Lab, Montpellier, France.
   DSM Nutr Prod Ltd, Res & Dev, Kaiseraugst, Switzerland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; Universite de Montpellier; CHU de Montpellier; DSM NV
RP Delcourt, C (通讯作者)，Univ Bordeaux 2, INSERM, U593, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@isped.u-bordeaux2.fr
RI Delcourt, Cecile/I-2627-2013; Carrière, Isabelle/W-8728-2019
OI Delcourt, Cecile/0000-0002-2099-0481; Carriere,
   Isabelle/0000-0002-3617-0752
CR Aebischer CP, 1999, METHOD ENZYMOL, V299, P348
   Asbell PA, 2005, LANCET, V365, P599
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Delcourt C, 2005, ARCH OPHTHALMOL-CHIC, V123, P225, DOI 10.1001/archopht.123.2.225
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2000, ARCH OPHTHALMOL-CHIC, V118, P385, DOI 10.1001/archopht.118.3.385
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Lyle BJ, 1999, AM J CLIN NUTR, V69, P272
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Olmedilla B, 2002, J Nutr Health Aging, V6, P66
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SCHALCH W, 1999, CRC MOD NUT, P215
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1366
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1228
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1499
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   Valero MP, 2002, J NUTR, V132, P1299, DOI 10.1093/jn/132.6.1299
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 51
TC 183
Z9 190
U1 0
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2006
VL 47
IS 6
BP 2329
EP 2335
DI 10.1167/iovs.05-1235
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 048LQ
UT WOS:000237949000011
PM 16723441
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Jun, G
   Klein, BEK
   Klein, R
   Fox, K
   Millard, C
   Capriotti, J
   Russo, K
   Lee, KE
   Elston, RC
   Iyengar, SK
AF Jun, G
   Klein, BEK
   Klein, R
   Fox, K
   Millard, C
   Capriotti, J
   Russo, K
   Lee, KE
   Elston, RC
   Iyengar, SK
TI Genome-wide analyses demonstrate novel loci that predispose to drusen
   formation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; APOLIPOPROTEIN-E GENE; FACTOR-H POLYMORPHISM;
   MACULAR DEGENERATION; SUSCEPTIBILITY LOCI; QUANTITATIVE TRAIT;
   USHER-SYNDROME; ANIMAL-MODEL; SCAN; ASSOCIATION
AB PURPOSE. To test whether genes for drusen formation are independent of age-related macular degeneration (AMD) pathogenesis.
   METHODS. A genome-wide model-free linkage analysis was performed, using two semiquantitative drusen traits, size and type, on two sets of data: ( 1) 325 individuals ( 225 sib pairs) from the Beaver Dam Eye Study (BDES), and ( 2) 297 individuals ( 346 sib pairs) from the Family Age Related Maculopathy Study ( FARMS). Apolipoprotein E ( APOE) genotypes were used as a covariate in a multipoint sibpair analysis.
   RESULTS. The authors found evidence of linkage on 19q13.31 (D19S245), with size of drusen in both the BDES ( P = 0.0287) and the FARMS ( P = 0.0013; P = 0.0005, combined). In the BDES, type showed linkage evidence on 3p24.3 (D3S1768; P = 0.0189) and 3q25.1 (D3S2404; P = 0.0141); the linkage on 3p24.3 was also found with size ( D3S1768; P = 0.0264). In the FARMS, size showed evidence of linkage at 5q33.3 (D5S820; P = 0.0021), 14q32.33 (D14S1007; P = 0.0013), and 16p13.13 (D16S2616; P = 0.0015) and type at 21q21.2 (D21S2052; P = 0.0070). For size in the FARMS, there was a small increase in P-value at marker D19S245 from 0.0044 to 0.0111, and from 0.0044 to 0.0064, when the epsilon 4-carrier and the epsilon 3-carrier genotype were the covariates, respectively.
   CONCLUSIONS. The results show that APOE effects may be mediated early in the progression of ARM to AMD and thus may not be detected by standard genome scans for more severe disease.
C1 Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Case Western Reserve University; Case Western Reserve University;
   University of Wisconsin System; University of Wisconsin Madison
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Wolstein Res Bldg,1315,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM ski@case.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Jun, Gyungah/0000-0002-3230-8697
FU NCRR NIH HHS [RR 03655] Funding Source: Medline; NEI NIH HHS [EY 13438,
   EY 10605, EY 015810, U10 EY 06594] Funding Source: Medline; NIGMS NIH
   HHS [GM 28356] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH
   RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R03EY013438, R01EY015810, R01EY010605, U10EY006594] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R37GM028356, R01GM028356] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Astuto LM, 2000, AM J HUM GENET, V67, P1569, DOI 10.1086/316889
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Ballerini S, 2002, CLIN CHIM ACTA, V317, P71, DOI 10.1016/S0009-8981(01)00769-0
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher RH, 1950, STAT METHODS RES WOR, P99
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   LARGETPIET D, 1994, GENOMICS, V21, P138, DOI 10.1006/geno.1994.1235
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Shete S, 2003, HUM HERED, V55, P79, DOI 10.1159/000072312
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 42
TC 15
Z9 17
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2005
VL 46
IS 9
BP 3081
EP 3088
DI 10.1167/iovs.04-1360
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 959AH
UT WOS:000231488800011
PM 16123405
DA 2022-11-30
ER

PT J
AU Lee, SS
   Robinson, MR
AF Lee, Susan S.
   Robinson, Michael R.
TI Novel Drug Delivery Systems for Retinal Diseases A Review
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Corticosteroids; Drug delivery, eye; Retina
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; ENDOTHELIAL GROWTH-FACTOR;
   DIABETIC MACULAR EDEMA; INTRAOCULAR TISSUE DISTRIBUTION; ANTI-VEGF
   APTAMER; FLUOCINOLONE ACETONIDE; TRANSSCLERAL DELIVERY; BEVACIZUMAB
   AVASTIN; POSTERIOR SEGMENT; KINASE INHIBITOR
AB Introduction: Retinal diseases, such as macular edema from diabetic retinopathy and neovascular age-related macular degeneration, are important causes of visual impairment. Pharmacologic intervention has been employed, since laser can have limited success with improving vision. Topical eye drops and systemic therapy deliver low drug levels to the retina and the potential for systemic drug absorption and the accompanying side effects are high. As a result, transscleral and intravitreal drug delivery systems have had increasing importance in treating retinal diseases to deliver therapeutic drug concentrations and to limit the systemic drug exposure. Herein, we will review the novel drug delivery approaches for treating diabetic macular edema and neovascular age-related macular degeneration. Material and Methods: A Medline search was performed to identify articles that described novel drug delivery systems for treating diabetic macular edema and neovascular age-related macular degeneration. Our review was limited to intravitreal drug delivery systems that have recently completed phase II/III clinical trials and/or have been approved by the US Food and Drug Administration. Results: Journal articles were identified from the literature search and reviewed. Conclusions: Local administration of drugs using primarily intravitreal delivery systems is important in treating retinal diseases. Novel drug delivery approaches for treating diabetic macular edema currently are focused on sustained-release corticosteroids. For neovascular age-related macular degeneration, frequent intravitreal injections of anti-vascular endothelial growth factor compounds are the standard of care. Unmet needs in this population are therapies that reduce the treatment burden and improve visual acuity in a greater proportion of patients. Copyright (C) 2009 S. Karger AG, Basel
C1 [Lee, Susan S.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
   [Robinson, Michael R.] Allergan Pharmaceut Inc, Ophthalmol Clin Res, Irvine, CA USA.
C3 University of Southern California; AbbVie; Allergan
RP Lee, SS (通讯作者)，4660 Sunset Blvd,MS 81, Los Angeles, CA 90027 USA.
EM SLee@chla.usc.edu
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Antcliff R J, 1999, Semin Ophthalmol, V14, P223, DOI 10.3109/08820539909069541
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Araki M, 1976, Nippon Ganka Gakkai Zasshi, V80, P315
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayalasomayajula SP, 2004, PHARM RES-DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Bakri SJ, 2005, EYE, V19, P686, DOI 10.1038/sj.eye.6701602
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Batioglu Figen, 2007, International Ophthalmology, V27, P299, DOI 10.1007/s10792-007-9072-7
   BETHKE W, 2006, REV OPHTHALMOL, V13
   Bhavsar AR, 2007, AM J OPHTHALMOL, V144, P454, DOI 10.1016/j.ajo.2007.04.011
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   BILL A, 1964, EXP EYE RES, V3, P179, DOI 10.1016/S0014-4835(64)80033-6
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bonini MA, 2005, INVEST OPHTH VIS SCI, V46, P3845, DOI 10.1167/iovs.05-0297
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cardillo JA, 2005, OPHTHALMOLOGY, V112, P1557, DOI 10.1016/j.ophtha.2005.03.023
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Cukras Catherine, 2007, International Ophthalmology Clinics, V47, P75, DOI 10.1097/IIO.0b013e31802bda65
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   DAMICO DJ, 2003, OPHTHALMOLOGY, V10, P2384
   de Carvalho RAP, 2006, INVEST OPHTH VIS SCI, V47, P4532, DOI 10.1167/iovs.06-0030
   *DIAB RET CLIN RES, 2008, OPHTHALMOLOGY, V115, P1445
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   DUGEL PU, 2007, INVEST OPHTHALMOL VI, V48
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907
   Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226
   FRIEDMAN DM, 1980, J RHEUMATOL, V7, P850
   Furlani BA, 2007, EXPERT OPIN EMERG DR, V12, P591, DOI 10.1517/14728214.12.4.591
   Gilbert JA, 2003, J CONTROL RELEASE, V89, P409, DOI 10.1016/S0168-3659(03)00151-2
   Gilger BC, 2006, INVEST OPHTH VIS SCI, V47, P2596, DOI 10.1167/iovs.05-1540
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gregori NZ, 2006, RETINA-J RET VIT DIS, V26, P889, DOI 10.1097/01.iae.0000237111.82357.30
   Grover D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005656.pub2
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas Jost B, 2007, Dev Ophthalmol, V39, P96, DOI 10.1159/000098502
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Kramar M, 2007, CURR MED RES OPIN, V23, P1253, DOI 10.1185/030079907X187946
   KUPPERMANN BD, 2006, INVEST OPHTHALMOL VI, V47
   LEE SS, 2004, ENCY BIOMATERIALS BI
   Lee TWY, 2004, J OCUL PHARMACOL TH, V20, P55, DOI 10.1089/108076804772745464
   Liu XY, 2007, CAN J OPHTHALMOL, V42, P447, DOI 10.3129/i07-049
   Maia M, 2007, BRIT J OPHTHALMOL, V91, P1122, DOI 10.1136/bjo.2007.115386
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   MCCARTY DJ, 1964, ARTHRITIS RHEUM, V7, P359, DOI 10.1002/art.1780070402
   Mohammad DA, 2007, ANN PHARMACOTHER, V41, P449, DOI 10.1345/aph.1H540
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Morrison VL, 2006, RETINA-J RET VIT DIS, V26, P339, DOI 10.1097/00006982-200603000-00014
   Moshfeghi DM, 2005, OPHTHAL SURG LAS IM, V36, P24
   MRUTHYUNJAYA P, 2007, RETINAL PHYS
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Ohguro N, 2004, GRAEF ARCH CLIN EXP, V242, P444, DOI 10.1007/s00417-003-0853-z
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Okabe K, 2005, INVEST OPHTH VIS SCI, V46, P703, DOI 10.1167/iovs.03-0934
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   Olsen TW, 2007, AM J OPHTHALMOL, V144, P281, DOI 10.1016/j.ajo.2007.05.005
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   OLSEN TW, 2007, RETINA TODAY     MAR, P36
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Pearson PA, 2006, INVEST OPHTHALMOL VI, V47
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth DB, 2008, RETINA-J RET VIT DIS, V28, P66, DOI 10.1097/IAE.0b013e3181593e38
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   Schwartz SG, 2007, EXP DIABETES RES, DOI 10.1155/2007/52487
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Sultana Yasmin, 2006, Current Drug Delivery, V3, P207, DOI 10.2174/156720106776359186
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
   Vandervoort J, 2007, NANOMEDICINE-UK, V2, P11, DOI 10.2217/17435889.2.1.11
   Wakabayashi T, 2004, RETINA-J RET VIT DIS, V24, P964, DOI 10.1097/00006982-200412000-00020
   Wang GJ, 1996, PHARM RES-DORDR, V13, P1059, DOI 10.1023/A:1016062825360
   Wang LC, 2005, OCUL IMMUNOL INFLAMM, V13, P295, DOI 10.1080/09273940590951007
   WELTY D, 2007, 25 ANN M AM SOC RET
   WILLIAMS GA, 2006, JOINT M AM AC OPHTH
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zignani M, 2000, EUR J PHARM BIOPHARM, V50, P251, DOI 10.1016/S0939-6411(00)00107-7
NR 111
TC 42
Z9 42
U1 0
U2 26
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2009
VL 41
IS 3
BP 124
EP 135
DI 10.1159/000209665
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 432KL
UT WOS:000265131800001
PM 19321933
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Bordato, A
   Aragona, E
   Amato, A
   Vigano, C
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Bordato, Alessandro
   Aragona, Emanuela
   Amato, Alessia
   Vigano, Chiara
   Bandello, Francesco
   Battaglia Parodi, Maurizio
TI Macular neovascularization in AMD, CSC and best vitelliform macular
   dystrophy: quantitative OCTA detects distinct clinical entities
SO EYE
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY
AB Background To perform a quantitative optical coherence tomography (OCT) angiography (OCTA) analysis of macular neovascularization (MNV) secondary to age-related macular degeneration (AMD), central serous chorioretinopathy (CSC) and best vitelliform macular dystrophy (BVMD), with the aim of highlighting quantitative features indicating different clinical entities. Methods Study design: prospective, interventional. We recruited patients affected by AMD, CSC or BVMD, complicated by naive MNV. All patients underwent complete ophthalmologic examination and multimodal imaging. They were treated with anti-VEGF injections, following a pro-re-nata regimen. The ensuing follow-up lasted 1 year. Quantitative dye-based angiography, OCT, and OCTA parameters were analysed to obtain cutoff values able to distinguish two clinically different patient subgroups for each retinal disease. The main outcome measures were best-corrected visual acuity (BCVA), central macular thickness, vessel density of superficial, deep and choriocapillaris plexa, vessel tortuosity (VT) of MNV, vessel dispersion of MNV, number of injections, MNV/leakage ratio, MNV size, speckled fluorescence, and outer retinal atrophy. Results Ninety-eight eyes affected by MNV (98 patients) were analysed. These included 66 eyes affected by AMD, 18 displaying CSC, and 14 eyes with BVMD. BCVA was alike in the three groups, both at baseline and after 1 year (p > 0.05). An MNV VT cutoff of 8.40 at baseline detected two patient subgroups differing significantly in terms of morpho-functional features, found both at baseline and at the end of the follow-up. Conclusions Quantitative OCTA suggested that the MNV's VT might be able to provide a better characterization of two different morpho-functional manifestations in AMD, CSC and BVMD.
C1 [Arrigo, Alessandro; Bordato, Alessandro; Aragona, Emanuela; Amato, Alessia; Vigano, Chiara; Bandello, Francesco; Battaglia Parodi, Maurizio] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Ophthalmol, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Ophthalmol, Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961; bandello,
   francesco/0000-0003-3238-9682; Arrigo, Alessandro/0000-0003-4715-8414
CR Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Arrigo A, 2018, AM J OPHTHALMOL, V195, P233, DOI 10.1016/j.ajo.2018.08.001
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P901, DOI 10.1097/IAE.0000000000000804
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khan KN, 2017, RETINA-J RET VIT DIS, V37, P1360, DOI 10.1097/IAE.0000000000001357
   Lee GI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40406-y
   Lu HQ, 2016, EYE, V30, P15, DOI 10.1038/eye.2015.208
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
NR 14
TC 2
Z9 2
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2021
VL 35
IS 12
BP 3266
EP 3276
DI 10.1038/s41433-021-01396-2
EA JAN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA1VU
UT WOS:000611481700001
PM 33495568
DA 2022-11-30
ER

PT J
AU Millen, AE
   Nie, J
   Sahli, MW
   Mares, JA
   Meyers, KJ
   Klein, BEK
   Lamonte, MJ
   Lutsey, PL
   Andrews, CA
   Klein, R
AF Millen, A. E.
   Nie, J.
   Sahli, M. W.
   Mares, J. A.
   Meyers, K. J.
   Klein, B. E. K.
   Lamonte, M. J.
   Lutsey, P. L.
   Andrews, C. A.
   Klein, R.
TI VITAMIN D STATUS AND PREVALENT EARLY AGE-RELATED MACULAR DEGENERATION IN
   AFRICAN AMERICANS AND CAUCASIANS: THE ATHEROSCLEROSIS RISK IN
   COMMUNITIES (ARIC) STUDY
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Vitamin D; 25-hydroxyvitamin D; macular degeneration; retinal diseases;
   epidemiology; cohort studies
ID SERUM 25-HYDROXYVITAMIN D; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; D
   DEFICIENCY; HYPOVITAMINOSIS D; ASSOCIATION; QUESTIONNAIRE; POPULATION;
   INFLAMMATION; PREDICTORS
AB Objectives: Vitamin D status has been hypothesized to protect against development of early agerelated macular degeneration (AMD) via its anti-inflammatory properties and its possible beneficial influence on blood pressure control. We investigated the association between vitamin D status and prevalent early AMD in a community-based cohort. Design: This was a cross-sectional study. Setting: This was a secondary data analysis of already existing data from the Atherosclerosis Risk in Communities Study (ARIC) cohort collected from 1990 to 1995. Participants: There were 9,734 (7,779 Caucasians, 1,955 African American) ARIC participants (aged 46 to 70 at visit 2 [1990-1992]) with 25(OH) D data available at visit 2, AMD assessment at visit 3 (1993-1995), and complete covariate data. Measurements: Vitamin D status was assessed with serum 25-hydroxyvitamin D (25(OH) D) concentrations from bloods drawn at visit 2. Prevalent, early AMD (n=511) was assessed at visit 3 (1993-95) with nonmydriatic retinal photographs of one randomly chosen eye. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for early AMD by categories of 25(OH) D in nmol/L (deficient <30, inadequate 30-<50, and two categories of adequate status: 50-<75 and >= 75). Linear trend was estimated using continuous 25(OH) D concentrations. ORs were adjusted for age, race, and smoking status. We further adjusted for hypertension status to examine if vitamin D status influenced early AMD via its effects on blood pressure. Exploratory analyses of effect modification by age, sex, race and high risk genotypes [Y402H complement factor H (CFH) rs1061170 and the A69S age-related maculopathy susceptibility 2 (ARMS2) rs10490924 polymorphisms] were conducted. Results: The prevalence of early AMD was 5%, and 5% of participants were vitamin D deficient. The adjusted OR (95% CIs) for early AMD among those with adequate (>= 75 nmol/L) compared to deficient (<30 nmol/L) vitamin D status was 0.94 (0.59-1.50), p-trend=0.86. Further adjustment for hypertension status did not influence results (OR [95% CI]=0.95 [0.59-1.52], p-trend=0.84). Results did not vary significantly by age, race, sex, early AMD subtype (soft drusen or retinal pigment epithelium depigmentation), or ARMS2 genotype. Results did not vary significantly by CFH genotype in African Americans. The p for multiplicative interaction between 25(OH) D and CFH genotype was 0.06 in Caucasians, but OR [95% CIs] for AMD by vitamin D status were similar in each CFH genotype and not statistically significant. Conclusions: Vitamin D status was not associated with early AMD in this cohort sample.
C1 [Millen, A. E.; Nie, J.; Lamonte, M. J.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, 270 Farber Hall, Buffalo, NY 14214 USA.
   [Sahli, M. W.] Univ Michigan, Sch Hlth Profess & Studies, Dept Publ Hlth & Hlth Sci, Flint, MI 48503 USA.
   [Mares, J. A.; Meyers, K. J.; Klein, B. E. K.; Klein, R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Lutsey, P. L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Andrews, C. A.] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; University of Michigan System; University of Michigan;
   University of Michigan Flint; University of Wisconsin System; University
   of Wisconsin Madison; University of Minnesota System; University of
   Minnesota Twin Cities; University of Michigan System; University of
   Michigan
RP Millen, AE (通讯作者)，SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, 270 Farber Hall, Buffalo, NY 14214 USA.
EM aemillen@buffalo.edu
RI LaMonte, Mike/AAC-9953-2021
OI Lutsey, Pamela/0000-0002-1572-1340; Andrews, Chris/0000-0001-5130-6374
FU NIH National Institute on Aging [R01 AG041776]; NIH National Heart,
   Lung, and Blood Institute [R01 HL103706]; NIH Office of Dietary
   Supplements grant [R01 HL103706-S1]; Research to Prevent Blindness;
   National Heart, Lung, and Blood Institute [HHSN268201100005C,
   HHSN268201100006C, HHSN268201100007C, HHSN268201100008C,
   HHSN268201100009C, HHSN268201100010C, HHSN268201100011C,
   HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694]; National Human
   Genome Research Institute [U01HG004402]; National Institutes of Health
   [HHSN268200625226C, UL1RR025005]; NIH Roadmap for Medical Research;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086694, R01HL059367]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041776]
   Funding Source: NIH RePORTER
FX This research is supported by the NIH National Institute on Aging grant
   number. R01 AG041776, NIH National Heart, Lung, and Blood Institute
   grant number R01 HL103706, and the NIH Office of Dietary Supplements
   grant number R01 HL103706-S1 and an unrestricted grant from Research to
   Prevent Blindness. The Atherosclerosis Risk in Communities Study is
   carried out as a collaborative study supported by National Heart, Lung,
   and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C),
   R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research
   Institute contract U01HG004402; and National Institutes of Health
   contract HHSN268200625226C. The authors thank the staff and participants
   of the ARIC study for their important contributions. Infrastructure was
   partly supported by Grant Number UL1RR025005, a component of the
   National Institutes of Health and NIH Roadmap for Medical Research.
   Access to Data Statement(s), Data Analysis, Methods, and Contribution of
   Authors. Dr. Amy Millen had full access to all of the data in the study
   and takes responsibility for the integrity for the data and the accuracy
   of the data analysis.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1991, Ophthalmology, V98, P786
   Atherosclerosis Risk in Communities (ARIC) Study Research Group, 1991, MAN 8 LIP LIP DET
   Atherosclerosis Risk in Communities Study, 2010, EX 2 DER VAR DICT VE
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Feneis JF, 2010, AM J THERAPEUTICS
   Folsom AR, 2014, J THROMB HAEMOST, V12, P1455, DOI 10.1111/jth.12665
   Ganji V, 2012, J NUTR, V142, P498, DOI 10.3945/jn.111.151977
   Giovannucci E, 2006, JNCI-J NATL CANCER I, V98, P451, DOI 10.1093/jnci/djj101
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hofmann JN, 2010, CANCER EPIDEM BIOMAR, V19, P927, DOI 10.1158/1055-9965.EPI-09-1121
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Institute of Medicine, 2011, DIETARY REFERENCE IN, DOI [10.17226/13050, DOI 10.17226/13050]
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jorde R, 2010, AM J EPIDEMIOL, V171, P903, DOI 10.1093/aje/kwq005
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Kriegel MA, 2011, SEMIN ARTHRITIS RHEU, V40, P512, DOI 10.1016/j.semarthrit.2010.07.009
   Li YC, 2004, J STEROID BIOCHEM, V89-90, P387, DOI 10.1016/j.jsbmb.2004.03.004
   Meleth AD, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P65, DOI 10.1007/978-1-4614-0125-4_5
   Meng JE, 2012, CANCER EPIDEM BIOMAR, V21, P916, DOI 10.1158/1055-9965.EPI-12-0026
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Millen AE, 2010, AM J CLIN NUTR, V91, P1324, DOI 10.3945/ajcn.2009.28908
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   POLS MA, 1995, INT J EPIDEMIOL, V24, P381, DOI 10.1093/ije/24.2.381
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   RICHARDSON MT, 1995, INT J EPIDEMIOL, V24, P685, DOI 10.1093/ije/24.4.685
   Seddon JM, 2011, OPHTHALMOLOGY
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Zittermann A, 2003, BRIT J NUTR, V89, P552, DOI 10.1079/BJN2003837
NR 42
TC 12
Z9 12
U1 0
U2 6
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
EI 1760-4788
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD JUL
PY 2017
VL 21
IS 7
BP 772
EP 780
DI 10.1007/s12603-016-0827-6
PG 9
WC Geriatrics & Gerontology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA FB3NA
UT WOS:000406048200004
PM 28717807
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Clemons, TE
   Chew, EY
   Bressler, SB
   McBee, W
AF Clemons, TE
   Chew, EY
   Bressler, SB
   McBee, W
CA AREDS Res Grp
TI National Eye Institute Visual Function Questionnaire in the Age-Related
   Eye Disease Study (AREDS) - AREDS report no. 10
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; PEOPLE
AB Objectives: To describe the vision-targeted, health-related quality of life, measured with the National Eye Institute Visual Function Questionnaire (NEI-VFQ), in patients with age-related macular degeneration, cataract, or reduced visual acuity; to determine the relationship between the NEI-VFQ subscale scores and clinical measures of visual function; and to assess the internal consistency and reliability of the NEI-VFQ subscales.
   Design: The 39-item NEI-VFQ was administered at the 5-year clinic visit to 4077 Age-Related Eye Disease Study participants.
   Results: The subscales of the NEI-VFQ had moderate to high internal consistency (Cronbach's alpha = 0.58-0.91). The NEI-VFQ scores for participants with advanced age-related macular degeneration in 1 or both eyes, severe nuclear opacity, reduced visual acuity, or cataract surgery generally were lower than scores for disease-free participants (P<.001).
   Conclusion: These findings support the use of the NEI-VFQ as a measure of vision-targeted, health-related quality of life among patients with age-related macular degeneration, cataract, or reduced visual acuity.
RP Clemons, TE (通讯作者)，EMMES Corp, AREDS Coordinating Ctr, 401 N Washington St,Suite 700, Rockville, MD 20850 USA.
EM aredspub@emmes.com
FU NATIONAL EYE INSTITUTE [Z01EY000394] Funding Source: NIH RePORTER;
   Intramural NIH HHS [Z99 EY999999] Funding Source: Medline
CR *AG EYE DIS STUD R, 2001, AM J OPHTHALMOL, V131, P167
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cole SR, 2000, INVEST OPHTH VIS SCI, V41, P1017
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   GUYATT GH, 1986, CAN MED ASSOC J, V134, P889
   KAPLAN RM, 1996, QUALITY LIFE PHARMAC, P309
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MANGIONE CM, 1996, QUALITY LIFE PHARMAC, P1045
   MCNAIR D, 1980, PROFILE MOOD STATES
   Park W, 1999, INT OPHTHALMOL CLIN, V39, P143, DOI 10.1097/00004397-199903940-00010
   Parrish R K 2nd, 1996, Trans Am Ophthalmol Soc, V94, P919
   Schiffman RM, 2001, ARCH OPHTHALMOL-CHIC, V119, P841
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Spilker B., 1990, QUALITY LIFE ASSESSM
NR 22
TC 144
Z9 152
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2003
VL 121
IS 2
BP 211
EP 217
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 644AM
UT WOS:000180895800007
PM 12583787
DA 2022-11-30
ER

PT J
AU Friedrich, U
   Myers, CA
   Fritsche, LG
   Milenkovich, A
   Wolf, A
   Corbo, JC
   Weber, BHF
AF Friedrich, Ulrike
   Myers, Connie A.
   Fritsche, Lars G.
   Milenkovich, Andrea
   Wolf, Armin
   Corbo, Joseph C.
   Weber, Bernhard H. F.
TI Risk- and non-risk-associated variants at the 10q26 AMD locus influence
   ARMS2 mRNA expression but exclude pathogenic effects due to protein
   deficiency
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; CHROMOSOME 10Q26;
   SERINE-PROTEASE; APOLIPOPROTEIN-E; FACTOR-B; HTRA1; SUSCEPTIBILITY;
   GENE; HAPLOTYPE
AB Fifteen variants in 10q26 are in strong linkage disequilibrium and are associated with an increased risk for age-related macular degeneration (AMD), a frequent cause of blindness in developed countries. These variants tag a single-risk haplotype encompassing the genes ARMS2 (age-related maculopathy susceptibility 2) and part of HTRA1 (HtrA serine peptidase 1). To define the true AMD susceptibility gene in 10q26, several studies have focused on the influence of risk alleles on the expression of ARMS2 and/or HTRA1, but the results have been inconsistent. By heterologous expression of genomic ARMS2 variants, we now show that ARMS2 mRNA levels transcribed from the risk haplotype are significantly reduced compared with non-risk mRNA isoforms. Analyzing variant ARMS2 constructs, this effect could specifically be assigned to the known insertion/deletion polymorphism (c.(*)372_815del443ins54) in the 3'-untranslated region of ARMS2. Reporter gene assays with HTRA1 promoter sequences demonstrated the presence of a Muller glia-specific cis-regulatory region further upstream of the transcription start site. However, AMD risk alleles had little or no effect on HTRA1 promoter activity in the retina. Analysis of a large series of human postmortem retina/retinal pigment epithelial samples heterozygous for the risk haplotype confirmed the in vitro/ex vivo results and demonstrated that the risk haplotype affects ARMS2 but not HTRA1 mRNA expression. Furthermore, we provide in vivo evidence that a common non-risk-associated non-synonymous variant (rs2736911) also leads to decreased ARMS2 transcript levels. Consequently, our data suggest that pathogenic effects due to ARMS2 protein deficiency are unlikely to account for AMD pathology.
C1 [Friedrich, Ulrike; Fritsche, Lars G.; Milenkovich, Andrea; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Myers, Connie A.; Corbo, Joseph C.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA.
   [Wolf, Armin] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
C3 University of Regensburg; Washington University (WUSTL); University of
   Munich
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Corbo, Joseph/0000-0002-9323-7140;
   Weber, Bernhard H.F./0000-0002-8808-7723
FU National Health Institute (NIH) [EY018826]; American Health Assistance
   Foundation; Deutsche Forschungsgemeinschaft (DFG) [WE1259/18-1,
   WE1259/19-1]; Ruth and Milton Steinbach Foundation New York; Alcon
   Research Institute; NATIONAL EYE INSTITUTE [R01EY018826] Funding Source:
   NIH RePORTER
FX This work was supported in parts by grants from the National Health
   Institute (NIH) (EY018826 to J.C.), The American Health Assistance
   Foundation (to J.C.), the Deutsche Forschungsgemeinschaft (DFG)
   (WE1259/18-1, WE1259/19-1 to B. H. F. W.), The Ruth and Milton Steinbach
   Foundation New York (to B. H. F. W.) and the Alcon Research Institute
   (to B.H.F.W.).
CR Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Campioni M, 2010, MOL CANCER RES, V8, P1248, DOI 10.1158/1541-7786.MCR-09-0473
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chowers I, 2008, MOL VIS, V14, P2263
   De Luca A, 2004, J HISTOCHEM CYTOCHEM, V52, P1609, DOI 10.1369/jhc.4A6330.2004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Karlstetter M, 2010, J IMMUNOL, V185, P3379, DOI 10.4049/jimmunol.0903300
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037
   Lee J, 2010, GENE THER, V17, P1390, DOI 10.1038/gt.2010.77
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Polur I, 2010, HISTOL HISTOPATHOL, V25, P599, DOI 10.14670/HH-25.599
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roesch K, 2008, J COMP NEUROL, V509, P225, DOI 10.1002/cne.21730
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 52
TC 60
Z9 63
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2011
VL 20
IS 7
BP 1387
EP 1399
DI 10.1093/hmg/ddr020
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 733RB
UT WOS:000288279300013
PM 21252205
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Baek, J
   Dansingani, KK
   Lee, JH
   Lee, WK
   Freund, KB
AF Baek, Jiwon
   Dansingani, Kunal K.
   Lee, Jae Hyung
   Lee, Won Ki
   Freund, K. Bailey
TI CHOROIDAL MORPHOLOGY IN EYES WITH PERIPAPILLARY POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE peripapillary polypoidal choroidal vasculopathy; pachychoroid; choroidal
   morphology; dilated Haller vessel (pachyvessel)
ID SPECTRUM
AB Purpose: This study analyzes a subset of patients with peripapillary polypoidal choroidal vasculopathy (PCV) to determine whether quantifiable pachychoroid features colocalize with disease foci.
   Methods: Patients with PCV diagnosed by indocyanine green angiography were identified for the analysis of medical records and multimodal imaging and classified as having peripapillary or macular PCV. The ratio of Haller layer thickness to total choroidal thickness was calculated at the fovea and at the site of dilated Haller vessels that showed spatial correlation with the origin of neovascularization. Choroidal thickness was measured horizontally across the fovea and circumferentially around the temporal side of the disk to study its relationship to neovascularization.
   Results: Three hundred and fourteen eyes of 299 patients with PCV were identified, of which 17 eyes (5%) had peripapillary disease. Although eyes with peripapillary PCV exhibited thinner subfoveal choroids than those with macular PCV, at the extrafoveal disease foci, choroidal thickness, Haller's layer thickness, and its ratio to total choroidal thickness were relatively high.
   Conclusion: Quantitative indices of choroidal structure previously identified in macular PCV performed consistently when applied to a peripapillary PCV cohort, thus supporting the hypothesis that inner choroidal thinning and Haller vessel enlargement are mechanistically relevant to these related entities.
C1 [Baek, Jiwon] Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Dept Ophthalmol & Visual Sci, Kyung Gi, South Korea.
   [Dansingani, Kunal K.] Univ Pittsburgh, Dept Ophthalmol, Med Ctr, Pittsburgh, PA 15260 USA.
   [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England.
   [Lee, Jae Hyung; Lee, Won Ki] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 Catholic University of Korea; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Catholic University of Korea; Seoul St. Mary's Hospital; Vitreous Retina
   Macula Consultants of New York; New York University
RP Lee, WK (通讯作者)，Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol, 222 Banpo Daero, Seoul 06591, South Korea.
EM wklee@catholic.ac.kr
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   ARCHER D, 1970, AM J OPHTHALMOL, V69, P543, DOI 10.1016/0002-9394(70)91619-3
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2017, RETINA
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2893, DOI 10.1167/iovs.12-11085
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Squirrell DM, 2009, CLIN EXP OPHTHALMOL, V37, P368, DOI 10.1111/j.1442-9071.2009.02044.x
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 11
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2019
VL 39
IS 8
BP 1571
EP 1579
DI 10.1097/IAE.0000000000002188
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AL
UT WOS:000480763200021
PM 29683869
DA 2022-11-30
ER

PT J
AU Gryziewicz, L
AF Gryziewicz, L
TI Regulatory aspects of drug approval for macular degeneration
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE macular degeneration; AMD; neovascular form
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries with approximately 15 million people with the disease in the United States. AMD is characterized as a progressive degenerative disease of the macula. There are two forms of AMD: neovascular and non-neovascular. The non-neovascular form of AMD is more common and leads to a slow deterioration of the macula with a gradual loss of vision over a period of years. The neovascular form of the disease is responsible for the majority of cases of severe vision loss and is due to proliferation of abnormal blood vessels behind the retina. These blood vessels leak blood and fluid into the retina, which results in visual abnormalities. The development of these abnormal blood vessels is due in part to the activity of VEGF (vascular endothelial growth factor) and its inhibition is expected to impact on the onset and/or severity of vision loss associated with the proliferation of abnormal blood vessels.
   Age-related macular degeneration is an underserved treatment population. Visudyne (verteporfin for injection), Novartis Ophthalmics, is FDA approved for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. Pegaptanib sodium (Macugen, Eyetech Pharmaceuticals, Inc. and Pfizer, Inc.) is indicated for the treatment of neovascular (wet) age-related macular degeneration. This article will review the approval pathway for these two products and that required of future products indicated for macular degeneration. (c) 2005 Elsevier B.V. All rights reserved.
C1 Allergan Pharmaceut Inc, Global Regulatory Affairs, Irvine, CA 92612 USA.
C3 AbbVie; Allergan
RP Gryziewicz, L (通讯作者)，Allergan Pharmaceut Inc, Global Regulatory Affairs, 2525 Dupont Dr, Irvine, CA 92612 USA.
EM Gryziewicz_Lewis@allergan.com
CR *EYET PHARM INC, 2004 FDA ADV COMM M
   GUARINO RA, 2000, NEW DRUG APPROVAL PR
   MATTHIEU M, 2000, NEW DRUG DEV REGULAT
   *QLT PHOT INC, 2003, VIS PACK INS
   1996, GUIDELINE GOOD CLIN
   VISUDYNE CPMP REV
   FDA VISUDYNE SUMMARY
   2003, FED REG         0623, V68
   2004, FDA MANUAL STANDARD
   FDA MACUGEN SUMMARY
   VISUDYNE SUMMARY PRO
   2004 FDA ADV COMM M
NR 12
TC 23
Z9 28
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 13
PY 2005
VL 57
IS 14
BP 2092
EP 2098
DI 10.1016/j.addr.2005.09.009
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 996QD
UT WOS:000234188300009
PM 16316706
DA 2022-11-30
ER

PT J
AU Luke, M
   Ziemssen, F
   Volker, M
   Altpeter, E
   Beutel, J
   Besch, D
   Bartz-Schmidt, KU
   Gelisken, F
AF Lueke, Matthias
   Ziemssen, Focke
   Voelker, Michael
   Altpeter, Elke
   Beutel, Julia
   Besch, Dorothea
   Bartz-Schmidt, Karl Ulrich
   Gelisken, Faik
TI Full macular translocation (FMT) versus photodynamic therapy (PDT) with
   verteporfin in the treatment of neovascular age-related macular
   degeneration: 2-year results of a prospective, controlled, randomised
   pilot trial (FMT-PDT)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Macular translocation; Photodynamic
   therapy; Best corrected visual acuity; Near visual acuity; Contrast
   sensitivity; Vision-related quality of life
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; CONTRAST SENSITIVITY;
   RANIBIZUMAB; RETINECTOMY; RETINOTOMY; ACUITY
AB To report the outcome of best-corrected visual acuity (BCVA), near visual acuity (NVA), contrast sensitivity (CS) and vision-related quality of life (VRQOL) in patients 2 years after undergoing photodynamic therapy (PDT) or full macular translocation (FMT) for the treatment of neovascular age-related macular degeneration (AMD).
   Fifty patients with predominantly classic subfoveal choroidal neovascularisation (CNV) secondary to AMD were randomized to PDT or FMT. BCVA was determined according a standardized protocol with ETDRS charts. NVA were calculated after testing with SNAB (Swiss National Association of and for the Blind) visual acuity cards. CS was measured with Pelli-Robson charts. The 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25 plus supplement) was performed. Primary end points were the changes of BCVA, NVA, CS and VRQOL at 24-month examination.
   A stabilisation of BCVA (+0.3 letters) was found in the FMT group, whereas a decrease of more than 12 letters (-12.6 letters) was found in the PDT group (p = 0.052). Mean NVA improved by 7.0 letters in the FMT group and was superior to the PDT group (-9.6 letters, p = 0.036), while mean CS showed a time-dependent decrease in both treatment groups (FMT: -3.3 letters, PDT: -3.8 letters, p = 0.726). Considering the results of the VRQOL scores, the improvement of the subscales scores for general vision (p = 0.015), mental health (p = 0.028) and near activity (p = 0.020) were significantly higher in the FMT group.
   FMT can stabilise BCVA and improve NVA over a period of 2 years in patients with subfoveal classic CNV secondary to neovascular AMD, whereas a decrease of BCVA and NVA was found in the PDT group. CS did not differ between FMT and PDT. A significant increase of VRQOL scores was only found in the FMT group and not in the PDT group. FMT seems to be a therapeutic approach that can increase visual function resulting in an improvement of patient's VRQOL, but exhibits a higher number of severe complications compared to PDT.
C1 [Lueke, Matthias; Beutel, Julia] Univ Lubeck, Univ Eye Hosp, D-23538 Lubeck, Germany.
   [Lueke, Matthias; Ziemssen, Focke; Voelker, Michael; Altpeter, Elke; Beutel, Julia; Besch, Dorothea; Bartz-Schmidt, Karl Ulrich; Gelisken, Faik] Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, D-72076 Tubingen, Germany.
C3 University of Lubeck; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital
RP Luke, M (通讯作者)，Univ Lubeck, Univ Eye Hosp, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM Matthias.Lueke@uk-sh.de
RI Ziemssen, Focke/AAY-1686-2021; , Ziemssen/B-9564-2009
OI , Ziemssen/0000-0002-3873-0581
FU University of Tuebingen [46-0-0]
FX This study was supported in part by a grant (AKF project no. 46-0-0)
   from the University of Tuebingen.
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   COLENBRANDER A, 1990, J VIS REHAB, V4, P1
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Franke GH, 1998, Z MED PSYCHOL, P178
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee HKM, 2003, AGE AGEING, V32, P643, DOI 10.1093/ageing/afg110
   LORD SR, 1991, AGE AGEING, V20, P175, DOI 10.1093/ageing/20.3.175
   Luke M, 2007, GRAEF ARCH CLIN EXP, V245, P1831, DOI 10.1007/s00417-007-0558-9
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 2000, NEI VFQ 25 SCORING A
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Patel I, 2006, INVEST OPHTH VIS SCI, V47, P65, DOI 10.1167/iovs.05-0582
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Yang N, 2007, CELL PRESERV TECHNOL, V5, P48
   Ziemssen F, 2008, GRAEF ARCH CLIN EXP, V246, P653, DOI 10.1007/s00417-007-0726-y
NR 32
TC 12
Z9 12
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2009
VL 247
IS 6
BP 745
EP 754
DI 10.1007/s00417-009-1050-5
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 440MP
UT WOS:000265704700005
PM 19214552
DA 2022-11-30
ER

PT J
AU Si, JK
   Tang, K
   Bi, HS
   Guo, DD
   Guo, JG
   Du, YX
   Cui, Y
   Pan, XM
   Wen, Y
   Wang, RR
AF Si, Jun-Kang
   Tang, Kai
   Bi, Hong-Sheg
   Guo, Da-Dong
   Guo, Jun-Guo
   Du, Yu-Xiang
   Cui, Yan
   Pan, Xae-Mei
   Wen, Ying
   Wang, Ring-Rong
TI Combintion of ranibizumab with photodynamic therapy vsranibizumab
   rnonotherapy in the treatment of age-related macular degeneration: a
   systematic review and meta-analysis of randomized controlled trials
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE ranibizumab; photodynamic therapy; age-related macular degeneration;
   meta-analysis
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN PLUS RANIBIZUMAB;
   OPEN-LABEL EXTENSION; INTRAVITREAL RANIBIZUMAB; CLINICAL-TRIALS;
   COMBINATION; ENDOPHTHALMITIS; MONOTHERAPY; QUALITY
AB AIM: To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).
   METHODS: The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Pubmed, and Embase were searched. There were no language or data restrictions in the search for trials. Only randomized controlled trials (RCTs) were included. Methodological quality of the literatures was evaluated according to the Jadad Score. RevMan 5.2.6 software was used to do the meta-analysis.
   RESULTS: Seven studies were included in our systematic review, among which four of them were included in quantitative analysis. The result shows that the ranibizumab monotherapy group had a better mean best corrected visual acuity (BCVA) change vs baseline at month 12 compared with that of the combination treatment group, and the statistical difference was significant (WMD, -2.61; 95% Cl, -5.08 to -0.13; P=0.04). However, after the removal of one study, the difference between the two groups showed no significant difference (WMD, -2.29; 95% Cl, -4.81 to 0.23; P=0.07). Meanwhile, no significant central retinal thickness (CRT) reduction was found in the combination treatment group and the ranibizumab monotherapy group at 12 months follow-up. Nevertheless, the combination group tended to have a greater reduction in CRT (WMD, -4.13 mu m; 95%Cl, -25.88 to 17.63, P=0.71). The proportion of patients gaining more than 3 lines at month 12 in the ranibizumab group was higher than in the combination group and there was a significant difference (RR, 0.72; 95% Cl, 0.54 to 0.95; P= 0.02). Whereas there was no significant difference for the proportion of patients gaining more than 0 line at month 12 between the two groups (RR, 0.93; 95% Cl, 0.76 to 1.15; P=0.52). The general tendency shows a reduction in ranibizumab retreatment number in the combination treatment group compared with the ranibizumab monotherapy group. As major adverse events, the differences in the number of eye pain, endophthalmitis, hypertension and arterial thromboenibolic events were not significant between the two groups, and the incidence of serious adverse events in the two groups was very low.
   CONCLUSION: For the maintenance of vision, the comparison of the combination of ranibizumab with PDT vs ranibizumab monotherapy shows no apparent difference. Compared with the combination of ranibizumab and PDT, patients treated with ranibizumab monothearpy may gain more visual acuity (VA) improvement. The combination treatment group had a tendency to reduce the number of ranibizumab retreatment. Both the two treatment strategies were well tolerated.
C1 [Si, Jun-Kang; Tang, Kai; Du, Yu-Xiang] Shandong Univ Tradit Chinese Med, Dept Ophthalmol, Jinan 250002, Shandong, Peoples R China.
   [Bi, Hong-Sheg; Cui, Yan; Pan, Xae-Mei; Wen, Ying; Wang, Ring-Rong] Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Dept Ophthalmol, Jinan 250002, Shandong, Peoples R China.
   [Guo, Da-Dong; Guo, Jun-Guo] Shandong Univ Tradit Chinese Med, Inst Eye, Jinan 250002, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine; Shandong University of Traditional
   Chinese Medicine
RP Wang, RR (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Dept Ophthalmol, 48 Jinan Yingxiongshan Rd, Jinan 250002, Shandong, Peoples R China.
EM semxrw@163.com
OI Si, Junkang/0000-0003-3801-5868; Tang, Kai/0000-0001-6897-5857
FU National Natural Science Foundation of China [81072961, 81100658];
   Shandong Traditional Chinese Medicine Science and Technology Development
   Plans, China [2011-130]
FX National Natural Science Foundation of China (No.81072961 No.81100658);
   Shandong Traditional Chinese Medicine Science and Technology Development
   Plans, China (2011-130)
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1073, DOI 10.2147/OPTH.S13969
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Giustolisi Rosalia, 2011, Digit J Ophthalmol, V17, P23, DOI 10.5693/djo.01.2011.05.003
   Hussain N, 2006, JPN J OPHTHALMOL, V50, P524, DOI 10.1007/s10384-006-0367-4
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   McConnell V, 2005, Ulster Med J, V74, P82
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
NR 27
TC 17
Z9 19
U1 0
U2 8
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2014
VL 7
IS 3
BP 541
EP 549
DI 10.3980/j.issn.2222-3959.2014.03.28
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ4PN
UT WOS:000337658400028
PM 24967206
DA 2022-11-30
ER

PT J
AU Caramoy, A
   Ristau, T
   Lechanteur, YT
   Ersoy, L
   Muller, S
   Gelisken, F
   Hoyng, CB
   Kirchhof, B
   den Hollander, AI
   Fauser, S
AF Caramoy, Albert
   Ristau, Tina
   Lechanteur, Yara T.
   Ersoy, Lebriz
   Mueller, Sebastian
   Gelisken, Faik
   Hoyng, Carel B.
   Kirchhof, Bernd
   den Hollander, Anneke I.
   Fauser, Sascha
TI Environmental and genetic risk factors for retinal angiomatous
   proliferation
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; ARMS2; CFH; hypertension; retinal
   angiomatous proliferation; risk factor
ID MACULAR DEGENERATION; AGE; POLYMORPHISM; METAANALYSIS; ASSOCIATION
AB PurposeTo identify genetic and environmental risk factors in patients with retinal angiomatous proliferation (RAP), a clinical subtype of age-related macular degeneration (AMD).
   MethodsIn this case-control study, 108 AMD cases with RAP, 258 AMD patients with choroidal neovascularization (CNV) without RAP and 443 healthy controls were evaluated. Single nucleotide polymorphisms in age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) and various environmental risk factors were analysed. Statistical analysis was performed by univariate and multivariate regression analysis.
   ResultsHigh age, female sex and genetic variants in CFH and ARMS2 were identified as risk factors for developing any CNV. In RAP patients, arterial hypertension was also identified as a risk factor (OR 2.39; p=0.0005). Compared with the non-RAP' CNV group, the association with high age (OR 1.05; p=0.008) and arterial hypertension (OR 1.82; p=0.02) was significantly higher in RAP patients, while the association with CFH risk alleles (homozygous OR 0.40; p=0.003) was significantly lower, which was confirmed in a multivariate analysis (OR 0.41; p=0.03 for the heterozygous risk allele and OR 0.38; p=0.03 for the homozygous risk allele).
   ConclusionThe association with the CFH Y402 risk allele was less pronounced in RAP patients than in non-RAP' CNV patients, while the association with high age and arterial hypertension appeared to be stronger. These findings stress the importance of detailed phenotyping in AMD to identify homogeneous AMD subtypes and their different risk factors and disease mechanisms.
C1 [Caramoy, Albert; Ristau, Tina; Ersoy, Lebriz; Kirchhof, Bernd; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol3, D-50924 Cologne, Germany.
   [Lechanteur, Yara T.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Mueller, Sebastian; Gelisken, Faik] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany.
C3 University of Cologne; Radboud University Nijmegen; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol3, Kerpenerstr 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
RI Hoyng, C.B./H-8050-2014; Hollander, Anneke den/N-4911-2014; Lehtimäki,
   Terho/AAD-1094-2022; Lechanteur, Yara/ABB-6875-2020
OI Lehtimäki, Terho/0000-0002-2555-4427; Lechanteur,
   Yara/0000-0003-0951-4625
CR Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Hageman GS, 2005, HUM MOL GENET, V14, P3227
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Stoffelns BM, 2008, KLIN MONATSBL AUGENH, V225, P392, DOI 10.1055/s-2008-1027251
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Weger M, 2007, MOL VIS, V13, P1274
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 12
TC 18
Z9 19
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2014
VL 92
IS 8
BP 745
EP 748
DI 10.1111/aos.12437
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0WJ
UT WOS:000345342600031
PM 24847905
DA 2022-11-30
ER

PT J
AU Scholl, HPN
   Fleckenstein, M
   Fritsche, LG
   Schmitz-Valckenberg, S
   Gobel, A
   Adrion, C
   Herold, C
   Keilhauer, CN
   Mackensen, F
   Mossner, A
   Pauleikhoff, D
   Weinberger, AWA
   Mansmann, U
   Holz, FG
   Becker, T
   Weber, BHF
AF Scholl, Hendrik P. N.
   Fleckenstein, Monika
   Fritsche, Lars G.
   Schmitz-Valckenberg, Steffen
   Goebel, Arno
   Adrion, Christine
   Herold, Christine
   Keilhauer, Claudia N.
   Mackensen, Friederike
   Moessner, Andreas
   Pauleikhoff, Daniel
   Weinberger, Andreas W. A.
   Mansmann, Ulrich
   Holz, Frank G.
   Becker, Tim
   Weber, Bernhard H. F.
TI CFH, C3 and ARMS2 Are Significant Risk Loci for Susceptibility but Not
   for Disease Progression of Geographic Atrophy Due to AMD
SO PLOS ONE
LA English
DT Article
AB Background: Age-related macular degeneration (AMD) is a prevalent cause of blindness in Western societies. Variants in the genes encoding complement factor H (CFH), complement component 3 (C3) and age-related maculopathy susceptibility 2 (ARMS2) have repeatedly been shown to confer significant risks for AMD; however, their role in disease progression and thus their potential relevance for interventional therapeutic approaches remains unknown.
   Methodology/Principal Findings: Here, we analyzed association between variants in CFH, C3 and ARMS2 and disease progression of geographic atrophy (GA) due to AMD. A quantitative phenotype of disease progression was computed based on longitudinal observations by fundus autofluorescence imaging. In a subset of 99 cases with pure bilateral GA, variants in CFH (Y402H), C3 (R102G), and ARMS2 (A69S) are associated with disease (P = 1.6 x 10(-9), 3.2 x 10(-3), and P = 2.6 x 10(-12), respectively) when compared to 612 unrelated healthy control individuals. In cases, median progression rate of GA over a mean follow-up period of 3.0 years was 1.61 mm(2)/year with high concordance between fellow eyes. No association between the progression rate and any of the genetic risk variants at the three loci was observed (P>0.13).
   Conclusions/Significance: This study confirms that variants at CFH, C3, and ARMS2 confer significant risks for GA due to AMD. In contrast, our data indicate no association of these variants with disease progression which may have important implications for future treatment strategies. Other, as yet unknown susceptibilities may influence disease progression.
RP Scholl, HPN (通讯作者)，Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
EM bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019; Adrion, Christine/AAB-7247-2020
OI Fritsche, Lars G/0000-0002-2110-1690; Adrion,
   Christine/0000-0003-2408-2533; Weber, Bernhard H.F./0000-0002-8808-7723;
   Fleckenstein, Monika/0000-0001-8321-8037
CR Becker T, 2005, ANN HUM GENET, V69, P747, DOI 10.1111/j.1529-8817.2005.00198.x
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dreyhaupt J, 2007, METHOD INFORM MED, V46, P432, DOI 10.1160/ME0328
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 45
TC 73
Z9 74
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 12
PY 2009
VL 4
IS 10
AR e7418
DI 10.1371/journal.pone.0007418
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 505VX
UT WOS:000270728500016
PM 19823576
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Colby, KA
   Chang, DF
   Stulting, D
   Lane, SS
AF Colby, Kathryn A.
   Chang, David F.
   Stulting, Doyle
   Lane, Stephen S.
TI Surgical placement of an optical prosthetic device for end-stage macular
   degeneration - The implantable miniature telescope
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CATARACT-SURGERY
AB Objective: To describe the surgical procedure for placement of an implantable telescope prosthesis for endstage age-related macular degeneration.
   Methods: As part of a phase 2/3 clinical trial for patients with bilateral, irreversible age-related macular degeneration, the optimal procedure for monocular placement of the telescope prosthesis was determined.
   Results: Because of the unique configuration of the telescope prosthesis, proper wound construction, anterior chamber management, and device insertion after phacoemulsification are critical for successful surgery.
   Conclusion: A unique surgical technique ensures appropriate placement of the telescope prosthesis, while reducing surgical trauma to the corneal endothelium.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
   Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   Emory Univ, Emory Vis Ctr, Atlanta, GA 30322 USA.
   Associated Eye Care, Stillwater, MN USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; University of California System; University of California San
   Francisco; Emory University
RP Colby, KA (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St,Ste 808, Boston, MA 02114 USA.
EM kacolby@meei.harvard.edu
CR Arshinoff SA, 1999, J CATARACT REFR SURG, V25, P167, DOI 10.1016/S0886-3350(99)80121-7
   Beltrame G, 2002, J CATARACT REFR SURG, V28, P118, DOI 10.1016/S0886-3350(01)00983-X
   Bourne RRA, 2004, OPHTHALMOLOGY, V111, P679, DOI 10.1016/j.ophtha.2003.07.015
   BOURNE WM, 1994, OPHTHALMOLOGY, V101, P1014
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   KRAFF MC, 1980, ARCH OPHTHALMOL-CHIC, V98, P1782, DOI 10.1001/archopht.1980.01020040634009
   Lane SS, 2006, CURR OPIN OPHTHALMOL, V17, P94, DOI 10.1097/01.icu.0000193067.86627.a1
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
NR 8
TC 13
Z9 13
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2007
VL 125
IS 8
BP 1118
EP 1121
DI 10.1001/archopht.125.8.1118
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 197XO
UT WOS:000248590600017
PM 17698761
OA Bronze
DA 2022-11-30
ER

PT J
AU Sahni, J
   Dugel, PU
   Patel, SS
   Chittum, ME
   Berger, B
   Rubido, MD
   Sadikhov, S
   Szczesny, P
   Schwab, D
   Nogoceke, E
   Weikert, R
   Fauser, S
AF Sahni, Jayashree
   Dugel, Pravin U.
   Patel, Sunil S.
   Chittum, Mark E.
   Berger, Brian
   del Valle Rubido, Marta
   Sadikhov, Shamil
   Szczesny, Piotr
   Schwab, Dietmar
   Nogoceke, Everson
   Weikert, Robert
   Fauser, Sascha
TI Safety and Efficacy of Different Doses and Regimens of Faricimab vs
   Ranibizumab in Neovascular Age-Related Macular Degeneration The AVENUE
   Phase 2 Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; AFLIBERCEPT; ANGIOPOIETIN-2; ANGIOGENESIS; BEVACIZUMAB;
   OUTCOMES; THERAPY; VISION; EYE
AB Importance Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A).
   Objective To assess the efficacy and safety of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration (nAMD). Design,
   Setting, and Participants AVENUE was a 36-week, multiple-dose-regimen, active comparator-controlled, double-masked, phase 2 randomized clinical study performed at 58 sites in the United States. Eligible participants were anti-VEGF treatment naive with choroidal neovascularization secondary to nAMD and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 73 (Snellen equivalent, 20/40) to 24 (Snellen equivalent, 20/320). Data were collected from August 11, 2015, to January 12, 2017, with the final patient visit completed September 26, 2017. Data were analyzed from August 11, 2015, to October 4, 2019.
   Interventions Patients were randomized 3:2:2:2:3 to receive ranibizumab, 0.5 mg every 4 weeks (arm A [n = 68]); faricimab, 1.5 mg every 4 weeks (arm B [n = 47]); faricimab, 6.0 mg every 4 weeks (arm C [n = 42]); faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D [n = 47]); and ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E [n = 69]).
   Main Outcomes and Measures Mean change in BCVA from baseline to week 36, proportion of participants gaining at least 15 letters, BCVA of 20/40 or better or 20/200 or worse, and ocular coherence tomographic outcomes in anti-VEGF treatment-naive participants (arms A, B, C, D) and from weeks 12 to 36 in those with incomplete response (participants in arms A and E with week 12 BCVA ETDRS letter score of <= 68 [Snellen equivalent, 20/50 or worse]). Results A total of 263 participants were included in the analysis (172 [65.4%] female; 258 [98.1%] white; mean [SD] age, 78.3 [8.7] years). At week 36, adjusted mean change in BCVA vs ranibizumab was 1.6 (80% CI, -1.6 to 4.7) letters for arm B (P = .52), -1.6 (80% CI, -4.9 to 1.7) letters for arm C (P = .53), and -1.5 (80% CI, -4.6 to 1.6) letters for arm D (P = .53). For arm E, adjusted mean change from week 12 was -1.7 (80% CI, -3.8 to 0.4) letters (P = .30).
   Conclusions and Relevance AVENUE did not meet its primary end point of superiority of faricimab over ranibizumab in BCVA at week 36. Although not superior to monthly ranibizumab as given in this trial, overall visual and anatomical gains noted with faricimab support pursuing phase 3 trials for a potential alternative to monthly anti-VEGF therapy. Faricimab showed no new or unexpected safety signals.
C1 [Sahni, Jayashree; del Valle Rubido, Marta; Szczesny, Piotr; Schwab, Dietmar; Nogoceke, Everson; Weikert, Robert; Fauser, Sascha] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Grenzacherstr 124,Bldg 001-30,Room S666, CH-4070 Basel, Switzerland.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90007 USA.
   [Dugel, Pravin U.] IVERIC Bio, New York, NY USA.
   [Patel, Sunil S.] West Texas Retina Consultants, Abilene, TX USA.
   [Chittum, Mark E.] Retina Consultants Southern Colorado, Colorado Springs, CO USA.
   [Berger, Brian] Retina Res Ctr, Austin, TX USA.
   [Sadikhov, Shamil] F Hoffmann La Roche Ltd, Roche Prod Dev, Basel, Switzerland.
C3 Roche Holding; University of Southern California; Roche Holding
RP Sahni, J (通讯作者)，F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Grenzacherstr 124,Bldg 001-30,Room S666, CH-4070 Basel, Switzerland.
EM jayashree.sahni@roche.com
FU F. Hoffmann-La Roche Ltd.
FX This study was supported by F. Hoffmann-La Roche Ltd.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2019, PREF PRACT PATT GUID
   [Anonymous], 2018, LUC PRESCR INF
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Benest AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070459
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Danzig C, 2019, INVEST OPHTH VIS SCI, V60
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Frenkel REP, 2016, BRIT J OPHTHALMOL, V100, P1052, DOI 10.1136/bjophthalmol-2015-307575
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894
   Imhof BA, 2006, NAT MED, V12, P171, DOI 10.1038/nm0206-171
   IWATA D, 2014, INVEST OPHTH VIS SCI, V55
   Khanani A.M., 2020, JAMA OPHTHALMOL, DOI [10.1001/jamaophthalmol.2020.2699, DOI 10.1001/JAMA0PHTHALM0L.2020.2699]
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Regula JT, 2019, EMBO MOL MED, V11
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   US Food and Drug Administration, 2019, REG GOOD CLIN PRACT
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 41
TC 33
Z9 34
U1 2
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2020
VL 138
IS 9
BP 955
EP 963
DI 10.1001/jamaophthalmol.2020.2685
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NS2LN
UT WOS:000572098900005
PM 32729888
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yamagishi, T
   Koizumi, H
   Yamazaki, T
   Kinoshita, S
AF Yamagishi, Tetsuya
   Koizumi, Hideki
   Yamazaki, Taizo
   Kinoshita, Shigeru
TI Changes in fundus autofluorescence after treatments for polypoidal
   choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; OPHTHALMOSCOPE; LESIONS
AB Background/aims To evaluate changes in fundus autofluorescence (FAF) after treatments for polypoidal choroidal vasculopathy (PCV).
   Methods Thirty-six eyes of 35 patients with treatment-naive PCV underwent intravitreal injection of ranibizumab, photodynamic therapy, or a combination of both treatments. FAF and indocyanine green angiography (ICGA) at baseline were compared with those obtained 12 months later about the changes at the affected lesion.
   Results In the 36 eyes, 88 polyps were detected on ICGA at baseline, and 65 (73.9%) of those showed centred hypoautofluorescence and a circumferential hyperautofluorescent ring on FAF. Twelve months later, ICGA revealed resolution of 42 of those 65 polyps. Of those 42 resolved polyps, 30 hyperautofluorescent rings (71.4%) were eliminated concurrently with the resolution of polyp. Statistical analysis revealed that an elimination of the hyperautofluorescent ring was more frequently observed in association with the resolved polyps than with the persistent polyps (p<0.0001). All the hypoautofluorescent findings corresponding to branching vascular networks at baseline were unchanged during the follow-up period.
   Conclusions Elimination of the hyperautofluorescent ring is highly associated with the resolution of the polyp on ICGA. We propose that FAF has a potential as a non-invasive method of evaluating the therapeutic efficacy of treatments for PCV.
C1 [Yamagishi, Tetsuya; Koizumi, Hideki; Yamazaki, Taizo; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto 6020841, Japan.
C3 Kyoto Prefectural University of Medicine
RP Koizumi, H (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM hidekoiz@koto.kpu-m.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology-Japan
   [22791676]
FX Supported in part by Grant No. 22791676 from the Ministry of Education,
   Culture, Sports, Science and Technology-Japan (Dr Koizumi).
CR DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 14
TC 11
Z9 14
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2014
VL 98
IS 6
BP 780
EP 784
DI 10.1136/bjophthalmol-2013-303739
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6JI
UT WOS:000336979100016
PM 24515988
DA 2022-11-30
ER

PT J
AU Sheth, JU
   Narayanan, R
   Anantharaman, G
   Bhende, M
   Agarwal, A
   Chawla, S
   Rajendran, A
AF Sheth, Jay U.
   Narayanan, Raja
   Anantharaman, Giridhar
   Bhende, Muna
   Agarwal, Aniruddha
   Chawla, Shobhit
   Rajendran, Anand
TI Updated guidelines for the management of polypoidal choroidal
   vasculopathy: Recommendations from the Indian Polypoidal Choroidal
   Vasculopathy Panel and the Vitreoretinal Society of India
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Indocyanine green angiography; optical coherence tomography; polypoidal
   choroidal vasculopathy; vitreoretinal society of India
ID PHOTODYNAMIC THERAPY; INTRAVITREAL AFLIBERCEPT; HEMORRHAGIC
   COMPLICATIONS; RANIBIZUMAB; ANGIOGRAPHY; EYES
AB In Asians, polypoidal choroidal vasculopathy (PCV) is becoming more widely recognized as a significant cause of exudative maculopathy. The previous set of Indian guidelines on the management of PCV were published in 2018, with a literature search updated up to November 2015. As the treatment of PCV evolves, retinal physicians must constantly modify their current practice. The current guidelines are based on the most up-to-date information on PCV and are an update to the previous set of guidelines. These guidelines were developed by a panel of Indian retinal experts under the aegis of the Vitreoretinal Society of India (VRSI), based on a comprehensive search and assessment of literature up to September 2021. The final guidelines i) provide the updated nomenclature in PCV; ii) discusses the newer diagnostic imaging features of PCV, especially in the absence of indocyanine green angiography (ICGA); and iii) recommends the best possible therapeutic approach in the management of PCV, including the choice of anti-vascular endothelial growth factor (anti-VEGF) agents, treatment regimen, and the role of switching between the anti-VEGF agents. In the face of non-availability of photodynamic therapy (PDT) in India, we constructed practical recommendations on anti-VEGF monotherapy in PCV. The current updated recommendations would provide a broader framework to the treating retinal physician for the diagnosis and management of PCV for optimal therapeutic outcomes.
C1 [Sheth, Jay U.] Chaithanya Eye Hosp, Dept Clin Res, Trivandrum, Kerala, India.
   [Narayanan, Raja] Vitreoretinal Soc India, Vitreoretinal Soc India VRSI Gen Secretary, Bhubaneswar, India.
   [Anantharaman, Giridhar] Giridhar Eye Inst, Dept Vitreoretina, Kochi, Kerala, India.
   [Bhende, Muna] Med Res Fdn, Dept Vitreoretinal Serv, Sri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Agarwal, Aniruddha] Cleveland Clin Abu Dhabi, Dept Vitreoretina, Eye Inst, Abu Dhabi, U Arab Emirates.
   [Chawla, Shobhit] Vitreoretinal Soc India, Bhubaneswar, India.
   [Rajendran, Anand] Vitreoretinal Soc India, Vitreoretinal Soc India VRSI Convenor Sci Comm, Bhubaneswar, India.
C3 Cleveland Clinic Foundation
RP Narayanan, R (通讯作者)，LV Prasad Eye Inst, Room 603C,Banjara Hills, Hyderabad 500034, Telangana, India.
EM narayanan@lvpei.org
CR Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Bansal A, 2017, INDIAN J OPHTHALMOL, V65, P758, DOI 10.4103/ijo.IJO_1003_16
   Chakraborty D, 2021, CLIN OPHTHALMOL, V15, P3787, DOI 10.2147/OPTH.S328160
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kim K, 2020, AM J OPHTHALMOL, V217, P240, DOI 10.1016/j.ajo.2020.05.017
   Kim SW, 2009, OPHTHAL SURG LAS IM, V40, P300, DOI 10.3928/15428877-20090430-14
   Lee SE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37523-5
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
   Ogura Y, 2021, JPN J OPHTHALMOL, V65, P344, DOI 10.1007/s10384-020-00805-5
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Rishi P, 2017, INDIAN J OPHTHALMOL, V65, P712, DOI 10.4103/ijo.IJO_174_17
   Rouvas A, 2021, EUR J OPHTHALMOL, V31, P2868, DOI 10.1177/11206721211014717
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schnurrbusch UEK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1347, DOI 10.1001/archopht.123.10.1347
   Tamachi T, 2020, OPHTHALMOL THER, V9, P1069, DOI 10.1007/s40123-020-00312-3
   Teo KYC, 2021, OPHTHALMOL RETINA, V5, P945, DOI 10.1016/j.oret.2021.04.002
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
NR 34
TC 0
Z9 0
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD AUG
PY 2022
VL 70
IS 8
BP 3102
EP 3111
DI 10.4103/ijo.IJO_2985_21
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4D6HV
UT WOS:000847240800068
PM 35918981
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Marques, JP
   Lains, I
   Costa, MA
   Pires, I
   Cachulo, MD
   Figueira, J
   Silva, R
AF Marques, Joao Pedro
   Lains, Ines
   Costa, Miguel Angelo
   Pires, Isabel
   Cachulo, Maria da Luz
   Figueira, Joao
   Silva, Rufino
TI RETINAL ANGIOMATOUS PROLIFERATION A Quantitative Analysis of the
   Fundoscopic Features of the Fellow Eye
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   neovascular phenotypes; retina; retinal neovascularization; retinal
   angiomatous proliferation; type 3 neovascularization
ID MACULAR DEGENERATION; RETICULAR PSEUDODRUSEN; PHOTODYNAMIC THERAPY;
   CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; SEVERITY SCALE;
   RISK-FACTORS; AGE; NEOVASCULARIZATION; PREVALENCE
AB Purpose:To quantitatively analyze and compare the fundoscopic features between fellow eyes of retinal angiomatous proliferation and typical exudative age-related macular degeneration and to identify possible predictors of neovascularization.Methods:Retrospective case-control study. Seventy-nine fellow eyes of unilateral retinal angiomatous proliferation (n = 40) and typical exudative age-related macular degeneration (n = 39) were included. Fundoscopic features of the fellow eyes were assessed using digital color fundus photographs taken at the time of diagnosis of neovascularization in the first affected eye. Grading was performed by two independent graders using RetmarkerAMD, a computer-assisted grading software based on the International Classification and Grading System for age-related macular degeneration.Results:Baseline total number and area (square micrometers) of drusen in the central 1,000, 3,000, and 6,000 m were considerably inferior in the fellow eyes of retinal angiomatous proliferation, with statistically significant differences (P < 0.05) observed in virtually every location (1,000, 3,000, and 6,000 m). A soft drusen (125 m) area >510,196 m(2) in the central 6,000 m was associated with an increased risk of neovascularization (hazard ratio, 4.35; 95% confidence interval [1.56-12.15]; P = 0.005).Conclusion:Baseline fundoscopic features of the fellow eye differ significantly between retinal angiomatous proliferation and typical exudative age-related macular degeneration. A large area (>510,196 m(2)) of soft drusen in the central 6,000 m confers a significantly higher risk of neovascularization and should be considered as a phenotypic risk factor.
C1 [Marques, Joao Pedro; Lains, Ines; Pires, Isabel; Cachulo, Maria da Luz; Figueira, Joao; Silva, Rufino] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, P-3049 Coimbra, Portugal.
   [Marques, Joao Pedro; Costa, Miguel Angelo; Pires, Isabel; Cachulo, Maria da Luz; Figueira, Joao; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Lains, Ines; Pires, Isabel; Cachulo, Maria da Luz; Figueira, Joao; Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Marques, JP (通讯作者)，Ctr Hosp & Univ Coimbra, Dept Ophthalmol, P-3049 Coimbra, Portugal.
EM marquesjoaopedro@gmail.com
RI Marques, João Pedro/J-3584-2012; Silva, Rufino M/J-2817-2012
OI Marques, João Pedro/0000-0002-1014-0483; Silva, Rufino
   M/0000-0001-8676-0833; Lains, Ines/0000-0002-8136-4724; Cachulo, Maria
   Luz/0000-0002-0900-4548; Figueira, Joao P/0000-0002-3511-1515; Costa,
   Miguel Angelo/0000-0002-0362-1713; Pires, Isabel/0000-0002-5764-0178
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1189
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Fujimura S, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-013-2363-y
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Lim Eun-Hae, 2013, Korean J Ophthalmol, V27, P351, DOI 10.3341/kjo.2013.27.5.351
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marques J.P., 2013, ISRN OPHTHALMOL, V2013
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Montero JA, 2009, BRIT J OPHTHALMOL, V93, P166, DOI 10.1136/bjo.2008.141903
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Silva RM, 2007, GRAEF ARCH CLIN EXP, V245, P1131, DOI 10.1007/s00417-006-0532-y
   Sutter FK, 2006, KLIN MONATSBL AUGENH, V223, P376, DOI 10.1055/s-2006-926564
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 41
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1985
EP 1991
DI 10.1097/IAE.0000000000000619
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000009
PM 26035395
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Pan, Y
   Iejima, D
   Nakayama, M
   Suga, A
   Noda, T
   Kaur, I
   Das, T
   Chakrabarti, S
   Guymer, RH
   DeAngelis, MM
   Yamamoto, M
   Baird, PN
   Iwata, T
AF Pan, Yang
   Iejima, Daisuke
   Nakayama, Mao
   Suga, Akiko
   Noda, Toru
   Kaur, Inderjeet
   Das, Taraprasad
   Chakrabarti, Subhabrata
   Guymer, Robyn H.
   DeAngelis, Margaret M.
   Yamamoto, Megumi
   Baird, Paul N.
   Iwata, Takeshi
TI Binding of Gtf2i-beta/delta transcription factors to the ARMS2 gene
   leads to increased circulating HTRA1 in AMD patients and in vitro
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; FACTOR TFII-I; MACULAR DEGENERATION;
   TYROSINE KINASE; TGF-BETA; VARIANT; TARGET; SUSCEPTIBILITY;
   IDENTIFICATION; ENDOTHELIUM
AB The disease-initiating molecular events for age-related macular degeneration (AMD), a multifactorial retinal disease affecting many millions of elderly individuals worldwide, are still unknown. Of the over 30 risk and protective loci so far associated with AMD through whole genome-wide association studies (GWAS), the Age-Related Maculopathy Susceptibility 2 (ARMS2) gene locus represents one of the most highly associated risk regions for AMD. A unique insertion/deletion (in/del) sequence located immediately upstream of the High Temperature Requirement A1 ( HTRA1) gene in this region confers high risk for AMD. Using electrophoretic mobility shift assay (EMSA), we identified that two Gtf2i-beta/delta transcription factor isoforms bind to the cis-element 5'- ATTAATAACC-3' contained in this in/del sequence. The binding of these transcription factors leads to enhanced upregulation of transcription of the secretory serine protease HTRA1 in transfected cells and AMD patient-derived induced pluripotent stem cells (iPSCs). Overexpression of Htra1 in mice using a CAG-promoter demonstrated increased blood concentration of Htra1 protein, caused upregulation of vascular endothelial growth factor (VEGF), and produced a choroidal neovascularization (CNV)-like phenotype. Finally, a comparison of 478 AMD patients to 481 healthy, age-matched controls from Japan, India, Australia, and the USA showed a statistically increased level of secreted HTRA1 blood concentration in AMD patients compared with age-matched controls. Taken together, these results suggest a common mechanism across ethnicities whereby increased systemic blood circulation of secreted serine protease HTRA1 leads to subsequent degradation of Bruch's membrane and eventual CNV in AMD.
C1 [Pan, Yang; Iejima, Daisuke; Nakayama, Mao; Suga, Akiko; Yamamoto, Megumi; Iwata, Takeshi] Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Tokyo, Japan.
   [Noda, Toru] Natl Hosp Org Tokyo Med Ctr, Div Ophthalmol, Tokyo, Japan.
   [Kaur, Inderjeet; Das, Taraprasad; Chakrabarti, Subhabrata] LV Prasad Eye Inst, Prof Brien Holden Eye Res Ctr, Kallam Anji Reddy Mol Genet Lab, Hyderabad, India.
   [Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
   [Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Surg, Ophthalmol, East Melbourne, Vic, Australia.
   [DeAngelis, Margaret M.] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Ophthalmol, Buffalo, NY USA.
   [DeAngelis, Margaret M.] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Ira G Ross Eye Inst, Buffalo, NY USA.
   [Yamamoto, Megumi] JAC Ltd, Tokyo, Japan.
C3 L. V. Prasad Eye Institute; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; University of
   Melbourne; State University of New York (SUNY) System; State University
   of New York (SUNY) Buffalo; State University of New York (SUNY) System;
   State University of New York (SUNY) Buffalo
RP Iwata, T (通讯作者)，Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Tokyo, Japan.
EM takeshi.iwata@kankakuki.go.jp
RI Chakrabarti, Subhabrata/F-2468-2015; Kaur, Inderjeet/ABD-1833-2021
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; Pan,
   Yang/0000-0001-7673-2599; Suga, Akiko/0000-0001-6609-2647; Baird,
   Paul/0000-0002-1305-3502
FU Japan Agency for Medical Research and Development [19ek0109282h0003];
   Japan Society for the Promotion of Science (JSPS) [963552]; Department
   of Science & Technology and Australia-India Strategic Research Fund
   (AISRF) through the Department of Biotechnology (DBT), Government of
   India; Department of Science & Technology and Australia-India Strategic
   Research Fund (AISRF) through the Department of Innovation, Industry,
   Science and Research (DIISR), Government of Australia; National Health
   and Medical Research Council of Australia (NHMRC) [1138585, 1103013]
FX This work has been supported by research grant to T. I. by the Japan
   Agency for Medical Research and Development (19ek0109282h0003), T. I. by
   the Bilateral Program (2006-2007), Japan Society for the Promotion of
   Science (JSPS, 963552) with (D. B. and I. K.). Under the Bilateral
   Program (2006-2007), Department of Science & Technology and
   Australia-India Strategic Research Fund (AISRF) jointly funded through
   the Department of Biotechnology (DBT), Government of India (S. C. and I.
   K.) and the Department of Innovation, Industry, Science and Research
   (DIISR), Government of Australia (P. N. B. and R. H. G.). National
   Health and Medical Research Council of Australia (NHMRC) Research
   Fellowship 1138585 (P. N. B.) and 1103013 (R. H. G.). I. K. and S. C.
   would acknowledge the support of Retina consultants of LVPEI; Dr Nazimul
   Hussain, Dr Avinash Pathengay, Late Dr Annie Mathai and Dr Anjli Hussain
   for their help in recruitment of AMD patients and controls for this
   study. CERA receives Operational Infrastructure Support from the
   Victorian Government, Australia.
CR Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Chailangkarn T, 2018, MOL CELL PROBE, V40, P45, DOI 10.1016/j.mcp.2017.12.005
   Chen JG, 2005, J VIROL, V79, P4396, DOI 10.1128/JVI.79.7.4396-4406.2005
   Chen LJ, 2020, ASIA-PAC J OPHTHALMO, V9, P104, DOI 10.1097/01.APO.0000656976.47696.7d
   Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200
   Enkhmandakh B, 2009, P NATL ACAD SCI USA, V106, P181, DOI 10.1073/pnas.0811531106
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1
   Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hong M, 2005, J BIOL CHEM, V280, P16821, DOI 10.1074/jbc.M413753200
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Itoh F, 2012, BLOOD, V119, P5320, DOI 10.1182/blood-2011-12-395772
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kaur I, 2013, MOL VIS, V19, P822
   Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000
   Kim DW, 2001, MOL CELL BIOL, V21, P3387, DOI 10.1128/MCB.21.10.3387-3397.2000
   Ku MC, 2005, MOL CELL BIOL, V25, P7144, DOI 10.1128/MCB.25.16.7144-7157.2005
   Makeyev AV, 2009, GENE, V433, P16, DOI 10.1016/j.gene.2008.11.027
   Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765
   Misra UK, 2009, J CELL BIOCHEM, V106, P381, DOI 10.1002/jcb.22016
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Novina CD, 1999, MOL CELL BIOL, V19, P5014
   Oura Y, 2018, AM J PATHOL, V188, P2729, DOI 10.1016/j.ajpath.2018.08.012
   Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001
   Pena-Hernandez R, 2015, P NATL ACAD SCI USA, V112, pE677, DOI 10.1073/pnas.1416674112
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Roy AL, 2017, TRENDS MOL MED, V23, P501, DOI 10.1016/j.molmed.2017.04.002
   Sacristan C, 2009, EUR J IMMUNOL, V39, P2584, DOI 10.1002/eji.200839031
   Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480
   Seuntjens E, 2009, CYTOKINE GROWTH F R, V20, P449, DOI 10.1016/j.cytogfr.2009.10.005
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tipney HJ, 2004, EUR J HUM GENET, V12, P551, DOI 10.1038/sj.ejhg.5201174
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 50
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN-JUN
PY 2021
VL 296
AR 100456
DI 10.1016/j.jbc.2021.100456
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA TI5TQ
UT WOS:000672866400430
PM 33636181
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kustra, R
   Awh, CC
   Rojas-Fernandez, C
   Zanke, B
AF Kustra, Rafal
   Awh, Carl C.
   Rojas-Fernandez, Carlos
   Zanke, Brent
TI CFH and ARMS2 Polymorphisms Interact with Zinc Supplements in Cognitive
   Impairment in the Women's Health Initiative Hormone Trial
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Cognitive dysfunction; complement factor H; gene-environment
   interaction; genotype; macular degeneration; zinc
ID MACULAR DEGENERATION; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; RISK;
   ANTIOXIDANTS; ASSOCIATION; DEMENTIA; EYE; NEURODEGENERATION; GENETICS
AB Background: An interaction between genetic variants in complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) and high-dose zinc supplementation on progression to advanced age-related macular degeneration (AMD) exists. Because cognitive impairment (CI) is associated with AMD, we used data from the Women's Health Initiative (WHI) to search for a zinc/genetics interaction.
   Objective: To study the interaction of chronic zinc supplementation with genetic variants in CFH and ARMS2 on the development of CI.
   Methods: Zinc dietary supplements, CFH and ARMS2 genotypes, and serial mental status was analyzed in participants with available genetic data (n = 7,483). Cognition was assessed using the Modified Mini-Mental State Examination. The development of CI over 5 years was analyzed by genotype and zinc intake using a repeated measures logistic regression model.
   Results: Zinc supplementation of approximately 15 mg/day was associated with decreased development of CI in women with 1 or 2 CFH and no ARMS2 risk alleles (OR = 0.46: 1 CFH risk allele; 0.20: 2 CFH risk alleles; p = 0.002).
   Conclusion: Low-dose zinc (approximately 15 mg) is associated with reduced CI in women with 2 CFH and 0 ARMS2 AMD risk alleles. This interaction is opposite in direction to that observed in AMD, where patients with 2 CFH and 0 ARMS2 risk alleles had increased progression to neovascular AMD if treated with 80 mg/day of zinc. This may be due to a zinc dose-response or to a fundamental difference in the role of zinc in the progression of early CI versus advanced AMD.
C1 [Kustra, Rafal] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Awh, Carl C.] Tennessee Retina PC, Nashville, TN USA.
   [Rojas-Fernandez, Carlos] CRF Hlth Outcomes Res Consulting, Waterloo, ON, Canada.
   [Zanke, Brent] Univ Toronto, Fac Med, Div Hematol, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto
RP Zanke, B (通讯作者)，Arctic Med Labs, 801 Broadway Ave NW,Suite 303, Grand Rapids, MI 49504 USA.
EM bzanke@arcticdx.com
FU National Heart, Lung, and Blood Institute, National Institutes of
   Health, U.S. Department of Health and Human Services [N01WH22110, 24152,
   32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
   42107-26, 42129-32, 44221]
FX The Women's Health Initiative (WHI) program is funded by the National
   Heart, Lung, and Blood Institute, National Institutes of Health, U.S.
   Department of Health and Human Services through contracts N01WH22110,
   24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
   42107-26, 42129-32, and 44221. This manuscript was not prepared in
   collaboration with investigators of the WHI, has not been reviewed
   and/or approved by the WHI, and does not necessarily reflect the
   opinions of the WHI investigators or the NHLBI. No financial support was
   provided to the authors for the conduct of this study.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Chouraki V, 2014, ADV GENET, V87, P245, DOI 10.1016/B978-0-12-800149-3.00005-6
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Duncan TE, 2009, SOC PERSONAL PSYCHOL, V3, P979, DOI 10.1111/j.1751-9004.2009.00224.x
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hastie T., 1990, GEN ADDITIVE MODELS
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Rapp SR, 2003, AGING MENT HEALTH, V7, P217, DOI 10.1080/1360786031000101201
   Robitaille A, 2015, PSYCHOL AGING, V30, P712, DOI 10.1037/a0039333
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seripa D, 2011, REJUV RES, V14, P491, DOI 10.1089/rej.2011.1169
   Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947
   Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651
   Simon RM, 2009, J NATL CANCER I, V101, P1446, DOI 10.1093/jnci/djp335
   Tan LR, 2018, EXP DERMATOL, V27, P144, DOI 10.1111/exd.13463
   TENG EL, 1987, J CLIN PSYCHIAT, V48, P314
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x
   Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang DF, 2016, NEUROPSYCHOPHARMACOL, V41, P1034, DOI 10.1038/npp.2015.232
NR 34
TC 0
Z9 0
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2018
VL 66
IS 2
BP 707
EP 715
DI 10.3233/JAD-180673
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA HB6ZU
UT WOS:000451224700023
PM 30320589
DA 2022-11-30
ER

PT J
AU Kiss, S
   Malangone-Monaco, E
   Wilson, K
   Varker, H
   Stetsovsky, D
   Smith, D
   Garmo, V
AF Kiss, Szilard
   Malangone-Monaco, Elisabetta
   Wilson, Kathleen
   Varker, Helen
   Stetsovsky, Diana
   Smith, David
   Garmo, Vincent
TI Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept
   for the Treatment of Neovascular Age-Related Macular Degeneration and
   Diabetic Macular Edema
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; 2.0 MG RANIBIZUMAB; TREATMENT PATTERNS;
   VISUAL-ACUITY; PREVALENCE; EFFICACY; SAFETY
AB BACKGROUND: Ranibizumab and aflibercept are FDA-approved treatments for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although these agents differ in cost and labeled dosing, it is unclear whether these differences are reflected in clinical practice.
   OBJECTIVE: To compare the real-world frequency and cost of ranibizumab and aflibercept injections among treatment-naive and previously treated patients with nAMD and DME.
   METHODS: Claims data from MarketScan Research Databases were retrospectively reviewed to identify treatment-naive patients with nAMD who initiated intravitreal ranibizumab or aflibercept between January 1, 2014, and January 1, 2016, and treatment-naive patients with DME who initiated intravitreal ranibizumab or aflibercept between July 29, 2014, and July 1, 2016. Patients who switched to subsequent-line aflibercept or ranibizumab during the study period were eligible to enter previously treated subgroups. Multivariable regression models were derived to compare the per-patient frequency and cost of injections between ranibizumab- and aflibercept-treated patients with nAMD over 12 months (treatment-naive: n=1,087 and n=1,578; previously treated: n=221 and n=751) and 24 months (treatment-naive: n=454 and n=568; previously treated: n=93 and n=284) and in patients with DME over 6 months (treatment-naive: n=507 and n=681; previously treated: n=53 and n=223) and 12 months (treatment-naive: n=326 and n=382; previously treated: n=24 and n=122).
   RESULTS: After adjusting for patient demographics and clinical characteristics, per-patient injection frequency and cost were not significantly different between treatment-naive patients with nAMD who received ranibizumab versus aflibercept over 12 months (5.62 vs. 5.54; P=0.52, and $11,351 vs. $10,702; P=0.06, respectively) and 24 months (7.86 vs. 8.37; P=0.16, and $16,286 vs. $16,666; P=0.69, respectively). In previously treated patients with nAMD, injection frequency was significantly lower among ranibizumab- versus aflibercept-treated patients over 24 months (7.98 vs. 9.63; P=0.03), whereas treatment costs were comparable over 12 months ($11,512 vs. $12,050; P=0.44) and 24 months ($16,303 vs. $19,361; P=0.13). In treatment-naive patients with DME, ranibizumab was associated with significantly fewer injections and lower costs than aflibercept over 6 months (2.60 vs. 2.92 and $3,379 vs. $5,925, respectively; both P<0.001) and 12 months (3.33 vs. 3.87 and $4,136 vs. $7,656, respectively; both P<0.001). Similar cost savings were observed among previously treated patients with DME who received ranibizumab over 6 months ($3,834 vs. $6,775 for aflibercept; P=0.0001) and 12 months ($4,606 vs. $9,190; P=0.02), despite nonsignificant differences in injection frequency during follow-up.
   CONCLUSIONS: Although the frequency and cost of ranibizumab and aflibercept injections were generally comparable among patients treated for nAMD, ranibizumab was associated with estimated per-patient-per-year cost savings of $3,500-$4,500 in those treated for DME. Most patients received fewer injections than any FDA-indicated dosing schedule, suggesting potential undertreatment that may result in suboptimal vision outcomes. Copyright (C) 2020, Academy of Managed Care Pharmacy. All rights reserved.
C1 [Kiss, Szilard] Weill Cornell Med Coll, New York, NY USA.
   [Malangone-Monaco, Elisabetta; Wilson, Kathleen; Varker, Helen; Stetsovsky, Diana; Smith, David] IBM Watson Hlth, Cambridge, MA USA.
   [Garmo, Vincent] Genentech Inc, San Francisco, CA 94080 USA.
C3 Cornell University; Roche Holding; Genentech
RP Kiss, S (通讯作者)，New York Presbyterian Hosp, Weill Cornell Med Coll, 1305 York Ave, New York, NY 10021 USA.
EM szk7001@med.cornell.edu
OI Kiss, Szilard/0000-0003-3433-8432
FU Genentech
FX Writing assistance was provided by Karina Hamilton-Peel, PhD, of
   Envision Pharma Group, and funded by Genentech.
CR [Anonymous], 2016, MAC PEG SOD INJ INTR
   [Anonymous], 2019, EYL AFL INJ INTR US
   [Anonymous], 2019, AV BEV INJ INTR US
   [Anonymous], 2018, LUC RAN INJ INTR INJ
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Ferreras, 2014, J CLIN EXP OPHTHALMO, V5, P1
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Flaxel CJ, 2020, OPHTHALMOLOGY, V127, pP66, DOI [DOI 10.1016/j.ophtha.2019.09.025, DOI 10.1016/J.OPHTHA.2019.09.025, 10.1016/j.ophtha.2019.09.025]
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hoare T, 2014, INVEST OPHTH VIS SCI, V55
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kiss S, 2014, CLIN OPHTHALMOL, V8, P1611, DOI 10.2147/OPTH.S60893
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai TT, 2019, J FORMOS MED ASSOC, V118, P194, DOI 10.1016/j.jfma.2018.03.009
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   National Center for Health Statistics, 2020, INT CLASS DIS 10 REV
   National Center for Health Statistics and the Centers for Medicare and Medicaid Services, 2015, INT CLASS DIS 9 REV
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Stone T, 2015, AM SOC RETINA SPECIA
   Stone TW, 2018, AM SOC RETINA SPECIA
   U.S. Food & Drug Administration, 2019, NAT DRUG COD DIR
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 40
TC 10
Z9 10
U1 0
U2 2
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD MAR
PY 2020
VL 26
IS 3
BP 253
EP 266
DI 10.18553/jmcp.2020.19245
PG 14
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA KS2QF
UT WOS:000518154200007
PM 32020843
OA Bronze
DA 2022-11-30
ER

PT J
AU Wakabayashi, T
   Gomi, F
   Sawa, M
   Tsujikawa, M
   Tano, Y
AF Wakabayashi, T.
   Gomi, F.
   Sawa, M.
   Tsujikawa, M.
   Tano, Y.
TI Marked vascular changes of polypoidal choroidal vasculopathy after
   photodynamic therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; INDOCYANINE GREEN;
   CLINICAL CHARACTERISTICS; FLUORESCEIN ANGIOGRAPHY; JAPANESE PATIENTS;
   NEOVASCULARIZATION; VERTEPORFIN; FEATURES
AB Aims: To clarify vascular changes of polypoidal choroidal vasculopathy (PCV) after photodynamic therapy (PDT).
   Methods: Thirty-one eyes underwent PDT with verteporfin and were followed every 3 months with indocyanine green angiography (ICGA) using confocal scanning ophthalmoscope and optical coherence tomography (OCT) for over 15 months and the findings recorded.
   Results: The mean follow-up period was 19.2 months. Regression of the polypoidal lesions were confirmed once in 29 eyes (94%) on ICGA and OCT. Some lesions recurred at the initial regions (n= 5 eyes), at different regions connected to the branching vascular network (n= 4 eyes), and at both regions (n= 1 eye) (mean 11.4 (SD 1.9) months) after initial PDT. The branching vascular network remained in all eyes and enlarged in 13 eyes (42%) at the final visit. The vascular features of residual branching vascular networks changed (n= 7 eyes); fibrinous subretinal exudation developed (n= 4 eyes), and the retinal pigment epithelium was elevated similar to vascularised pigment epithelial detachment (n= 3 eyes).
   Conclusion: Polypoidal lesions of PCV are treatable with PDT; however, they often recur. The branching vascular networks do not regress and allow the recurrence of polypoidal lesions at the network termini. Alterations of the vascular features may occur; careful observation is needed after PDT.
C1 [Wakabayashi, T.; Gomi, F.; Sawa, M.; Tsujikawa, M.; Tano, Y.] Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 22
TC 56
Z9 57
U1 1
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2008
VL 92
IS 7
BP 936
EP 940
DI 10.1136/bjo.2007.132357
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318RL
UT WOS:000257109700016
PM 18577645
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Bunce, C
   Tufail, A
AF Patel, Praveen J.
   Bunce, Catey
   Tufail, Adnan
CA ABC Trial Investigators
TI A randomised, double-masked phase III/IV study of the efficacy and
   safety of Avastin (R) (Bevacizumab) intravitreal injections compared to
   standard therapy in subjects with choroidal neovascularisation secondary
   to age-related macular degeneration: clinical trial design
SO TRIALS
LA English
DT Article
ID RANIBIZUMAB
AB Background: The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data.
   Methods and design: The Avastin (R) (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining >= 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change.
   Discussion: The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy.
   Trial registration: Current controlled trials ISRCTN83325075
C1 [Patel, Praveen J.; Bunce, Catey; Tufail, Adnan] Moorfields Eye Hosp, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London, England.
EM praveenjpatel@yahoo.co.uk; catey.bunce@moorfields.nhs.uk;
   adnan.tufail@moorfields.nhs.uk
OI Bunce, Catey/0000-0002-0935-3713; Tufail, Adnan/0000-0001-6131-7640
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Mansfield J.S., 1993, OPT SOC AM TECHNOL D, V3, P232
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 15
TC 24
Z9 27
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 14
PY 2008
VL 9
AR 56
DI 10.1186/1745-6215-9-56
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 365UF
UT WOS:000260433500001
PM 18854025
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hodgson, N
   Wu, F
   Zhu, J
   Wang, WQ
   Ferreyra, H
   Zhang, K
   Wang, JW
AF Hodgson, Nickisa
   Wu, Frances
   Zhu, Jie
   Wang, Wenqui
   Ferreyra, Henry
   Zhang, Kang
   Wang, Jiawei
TI Economic and Quality of Life Benefits of Anti-VEGF Therapy
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE cost-effectiveness; macular degeneration; diabetic macular edema; VEGF;
   QALY
ID COST-EFFECTIVENESS ANALYSIS; MACULAR DEGENERATION; VISUAL IMPAIRMENT;
   DIABETIC-RETINOPATHY; UNITED-STATES; RANIBIZUMAB; BURDEN; HEALTH;
   DEVICE; TIME
AB Vision impairment and blindness create a significant impact on quality of life and loss of productivity. Health care expenditures for vision problems, including direct medical costs and indirect costs for support services and loss of productivity, amount to $139 billion annually. It is projected that by 2020, five million people will have visual impairment due to age related macular degeneration and diabetic macular edema. VEGF inhibitor therapy has been shown to be a cost-effective treatment for age related macular degeneration and diabetic macular edema that has reduced the incidence of vision loss and can reduce the associated economic and societal cost.
C1 [Hodgson, Nickisa; Wu, Frances; Zhu, Jie; Wang, Wenqui; Ferreyra, Henry; Zhang, Kang] Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Hodgson, Nickisa; Wu, Frances; Zhu, Jie; Wang, Wenqui; Ferreyra, Henry; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, Tissue Engn Ctr, La Jolla, CA 92093 USA.
   [Hodgson, Nickisa; Wu, Frances; Zhu, Jie; Wang, Wenqui; Ferreyra, Henry; Zhang, Kang] Univ Calif San Diego, Inst Engn Med, La Jolla, CA 92093 USA.
   [Zhu, Jie] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Wang, Wenqui] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai 20080, Peoples R China.
   [Zhang, Kang] Vet Adm Healthcare Syst, San Diego, CA 92093 USA.
   [Wang, Jiawei] Sun Yat Sen Univ, Zhongshan Opthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego; Air
   Force Military Medical University; Shanghai Jiao Tong University; Sun
   Yat Sen University
RP Wang, JW (通讯作者)，Sun Yat Sen Univ, Zhongshan Opthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
EM wangjw@mail.sysu.edu.cn
RI Zhu, Jie/AAD-1330-2022; Zhang, Kang/Y-2740-2019
OI Zhu, Jie/0000-0001-6862-9022; Zhang, Kang/0000-0002-4549-1697
CR [Anonymous], 2012, OEI031000360 DEP HHS
   Bressler NM, 2014, JAMA OPHTHALMOL, V132, P168, DOI 10.1001/jamaophthalmol.2013.6426
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Chaikitmongkol Voraporn, 2015, Retin Cases Brief Rep, V9, P33, DOI 10.1097/ICB.0000000000000085
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Gillick MR, 2004, NEW ENGL J MED, V350, P2199, DOI 10.1056/NEJMsb032612
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Heudebert GR, 2000, J GEN INTERN MED, V15, P175, DOI 10.1046/j.1525-1497.2000.02639.x
   Jampol LM, 2014, JAMA-J AM MED ASSOC, V311, P2269, DOI 10.1001/jama.2014.2536
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Li Hongchao, 2014, Zhonghua Yan Ke Za Zhi, V50, P426
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCannel C, 2001, RETINA, V31, P654
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Pershing S, 2014, ANN INTERN MED, V160, P18, DOI 10.7326/M13-0768
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russo A, 2015, AM J OPHTHALMOL, V159, P360, DOI 10.1016/j.ajo.2014.11.008
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Smiddy WE, 2011, OPHTHALMOLOGY, V118, P1827, DOI 10.1016/j.ophtha.2010.12.034
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Ting DSW, 2012, CLIN EXP OPHTHALMOL, V40, pE40, DOI 10.1111/j.1442-9071.2011.02732.x
   Varma R, 2012, AM AC OPHTH 2012 ANN
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wittenborn J, 2013, COST VISION PROBLEMS
   Zhao M, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.558
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 41
TC 14
Z9 16
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2016
VL 13
IS 9
BP 2877
EP 2880
DI 10.1021/acs.molpharmaceut.5b00775
PG 4
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DV1WV
UT WOS:000382713700002
PM 26836112
DA 2022-11-30
ER

PT J
AU Lai, K
   Landa, G
AF Lai, Kevin
   Landa, Gennady
TI Current choice of treatments for neovascular AMD
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE Avastin; Eylea; Lucentis; neovascular age-related macular degeneration;
   treatment
ID ARGON-LASER PHOTOCOAGULATION; SINGLE INTRAVITREAL INJECTION; VERTEPORFIN
   PLUS RANIBIZUMAB; RANDOMIZED CLINICAL-TRIALS; MACULAR DEGENERATION;
   CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS; PHOTODYNAMIC
   THERAPY; UNITED-STATES; TRAP-EYE
AB Age-related macular degeneration is the leading cause of irreversible blindness in developed countries with the neovascular form accounting for the majority of severe vision loss in the disease. The management of wet age-related macular degeneration has improved drastically in the past decade as anti-VEGF agents took its place at the forefront of treatment. As the choice of therapy is based on a number of factors, this review summarizes the pivotal studies that brought these agents to use and compares the different agents currently available. This review also briefly describes the promising new therapies that are in development.
C1 [Lai, Kevin; Landa, Gennady] New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY 10003 USA.
   [Landa, Gennady] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; Icahn School of Medicine at
   Mount Sinai
RP Landa, G (通讯作者)，New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY 10003 USA.
EM doctor.landa@gmail.com
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   HAWKINS BS, 1992, ARCH OPHTHALMOL-CHIC, V110, P761
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee J, 2007, RETINA-J RET VIT DIS, V27, P1205, DOI 10.1097/IAE.0b013e31815ec367
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P505
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ophthotech Corp, 2012, PHAS 1 SAF TOL PHARM
   Ophthotech Corp, 2012, SAF EFF STUD E10030
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 45
TC 18
Z9 19
U1 0
U2 24
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD JAN
PY 2015
VL 8
IS 1
BP 135
EP 140
DI 10.1586/17512433.2015.990379
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CC0JV
UT WOS:000350022500015
PM 25487081
DA 2022-11-30
ER

PT J
AU Wolf-Schnurrbusch, UEK
   Zinkernagel, MS
   Munk, MR
   Ebneter, A
   Wolf, S
AF Wolf-Schnurrbusch, Ute E. K.
   Zinkernagel, Martin S.
   Munk, Marion R.
   Ebneter, Andreas
   Wolf, Sebastian
TI Oral Lutein Supplementation Enhances Macular Pigment Density and
   Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty
   Acids
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular pigment; macular pigment; lutein; lutein; contrast sensitivity;
   contrast sensitivity
ID OPTICAL-DENSITY; SERUM CONCENTRATIONS; INTESTINAL-ABSORPTION;
   DEGENERATION; CAROTENOIDS; ZEAXANTHIN; PROGRESSION; OMEGA-3-FATTY-ACIDS;
   BIOAVAILABILITY; LIPOPROTEIN
AB PURPOSE. It has been shown that lutein and zeaxanthin accumulate in the macula where they enhance contrast sensitivity and may reduce the risk of progression to advanced age-related macular degeneration (AMD). Furthermore, omega-3 long-chain polyunsaturated fatty acids (PUFA) might further reduce this risk. However, controversy exists regarding whether PUFA may reduce the bioavailability of lutein.
   METHODS. This was a prospective 12-month, randomized, open label study evaluating the effect of supplementation with lutein, other antioxidants, and minerals on contrast sensitivity (CS) and macular pigment optical density (MPOD) in patients with age-related maculopathy. A total of 79 patients were randomized to either lutein (10 mg) and antioxidant supplement or lutein and antioxidant supplement in combination with PUFA. Patients received supplementation for a period of 6 months and were followed for a total of 12 months.
   RESULTS. Serum lutein and zeaxanthin increased significantly by the first follow-up visit at 1 month, and remained elevated throughout the intervention period of 6 months in the lutein-only group but not in the lutein+PUFA group. Macular pigment optical density and CS increased significantly in the lutein-only group (P < 0.005) but not in the lutein+PUFA group (P = 0.059) compared to baseline. Best-corrected visual acuity remained unchanged during the entire study period in both groups.
   CONCLUSIONS. Addition of PUFA may reduce the bioavailability of lutein and therefore lessen the beneficial effect on macular pigment and CS. This needs to be considered when prescribing lutein supplements to patients with low lutein levels. (ClinicalTrials. gov number, NCT00563979.)
C1 [Wolf-Schnurrbusch, Ute E. K.; Zinkernagel, Martin S.; Munk, Marion R.; Ebneter, Andreas; Wolf, Sebastian] Univ Bern, Inselspital, Univ Hosp Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Univ Hosp Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Zinkernagel, Martin/C-3799-2017; Ebneter, Andreas/C-5226-2017; Wolf,
   Sebastian/B-8782-2008
OI Zinkernagel, Martin/0000-0002-5622-114X; Ebneter,
   Andreas/0000-0001-6666-2558; Wolf, Sebastian/0000-0002-7467-7028;
   Zinkernagel, Martin S./0000-0003-3447-2359
FU Novartis; Swiss National Science Foundation [SNF 3200 Bo-109962/1];
   Velux Foundation Zurich [Velux 303]
FX Supported by Novartis, the Swiss National Science Foundation (SNF 3200
   Bo-109962/1) and Velux Foundation Zurich (Velux 303).
CR [Anonymous], 2008, Duke Med Health News, V14, P6
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Dagnelie G, 2000, Optometry, V71, P147
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019
   Goltz SR, 2012, MOL NUTR FOOD RES, V56, P866, DOI 10.1002/mnfr.201100687
   Gorusupudi A, 2012, EUR J LIPID SCI TECH, V114, P710, DOI 10.1002/ejlt.201100183
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Lakshminarayana R, 2009, LIPIDS, V44, P799, DOI 10.1007/s11745-009-3328-0
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Nagai N, 2015, RETINA-J RET VIT DIS, V35, P820, DOI 10.1097/IAE.0000000000000382
   Nidhi B, 2014, FOOD RES INT, V64, P256, DOI 10.1016/j.foodres.2014.06.034
   Nidhi B, 2014, EUR J NUTR, V53, P117, DOI 10.1007/s00394-013-0507-9
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sugawara T, 2001, J NUTR, V131, P2921, DOI 10.1093/jn/131.11.2921
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Wang TTY, 2013, J NUTR BIOCHEM, V24, P1538, DOI 10.1016/j.jnutbio.2013.01.001
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 46
TC 27
Z9 28
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2015
VL 56
IS 13
BP 8069
EP 8074
DI 10.1167/iovs.15-17586
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB1BU
UT WOS:000368243800058
PM 26720458
DA 2022-11-30
ER

PT J
AU Okubo, A
   Ito, M
   Kamisasanuki, T
   Sakamoto, T
AF Okubo, A
   Ito, M
   Kamisasanuki, T
   Sakamoto, T
TI Visual improvement following trans-Tenon's retrobulbar triamcinolone
   acetonide infusion for polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE triamcinolone acetonide; plypoidal choroidal vasculopathy; sub-Tenon's
   infusion
ID PHOTODYNAMIC THERAPY
AB Purpose: To report a case of polypoidal choroidal vasculopathy (PCV) that was successfully treated by sub-Tenon's infusion of triamcinolone acetonide (TA). Methods: A 56-year-old Japanese man had PCV in his left eye with vision of 20/32. Fluorescein angiography demonstrated a hyperfluorescent spot, and indocyanine green angiography showed marked leakage of dye from the polypoidal vessel. Optical coherence tomography showed anterior protrusion of highly reflective layers and subretinal fluid. Results: The patient underwent trans-Tenon's retrobulbar infusion of 12 mg TA. Subsequently, the reddish-orange lesion decreased in size and elevation with complete resolution of the serous retinal detachment, and visual acuity improved to 20/20. Visual acuity remained good through a 15-month follow-up during which the patient was free of endophthalmitis and elevated intraocular pressure. Conclusions: Trans-Tenon's retrobulbar TA infusion is potentially effective in treating PCV.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Martidis A, 1999, J OCUL PHARMACOL TH, V15, P425, DOI 10.1089/jop.1999.15.425
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Okada AA, 2004, BRIT J OPHTHALMOL, V88, P1097, DOI 10.1136/bjo.2003.039719
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 10
TC 16
Z9 17
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2005
VL 243
IS 8
BP 837
EP 839
DI 10.1007/s00417-005-1125-x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 958OP
UT WOS:000231457900018
PM 15761763
DA 2022-11-30
ER

PT J
AU Choudhry, N
   Giani, A
   Miller, JW
AF Choudhry, Netan
   Giani, Andrea
   Miller, Joan W.
TI Fundus Autofluorescence in Geographic Atrophy: A Review
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; fundus autoflourescence; geographic
   atrophy; lipofuscin
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; HUMAN RPE CELLS;
   MACULAR DEGENERATION; JUNCTIONAL ZONE; NATURAL-HISTORY; VISUAL-LOSS;
   LIPOFUSCIN; LASER; PROGRESSION
AB Fundus autofluorescence is a noninvasive imaging technology that provides information on the distribution of lipofuscin within the retinal pigment epithelial cell monolayer. Progressive accumulation of lipofuscin within retinal pigment epithelial cells is involved in the pathogenesis of geographic atrophy in age-related macular degeneration. This review contains an introduction to fundus autofluorescence, review of currently available imaging methods, and discussion of the role of autofluorescence imaging in geographic atrophy progression. The recent classification of geographic atrophy phenotypes by the Fundus Autofluorescence in Age-related Macular Degeneration Study (FAM) and the association of phenotype and atrophy progression are also summarized.
C1 [Choudhry, Netan; Giani, Andrea; Miller, Joan W.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02141 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Choudhry, N (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 12th Floor,243 Charles St, Boston, MA 02141 USA.
EM netan.choudhry@gmail.com
RI ; Giani, Andrea/L-5926-2017
OI Miller, Joan/0000-0003-2046-3996; Giani, Andrea/0000-0003-0682-1945
CR Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DITHMAR S, 1995, KLIN MONATSBL AUGENH, V207, P11, DOI 10.1055/s-2008-1035342
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   MACHEMER R, 1970, AM J OPHTHALMOL, V70, P1
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 38
TC 16
Z9 17
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2010
VL 25
IS 5-6
SI SI
BP 206
EP 213
DI 10.3109/08820538.2010.518121
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802HJ
UT WOS:000293499600008
PM 21091001
DA 2022-11-30
ER

PT J
AU Tan, CS
   Cheung, CMG
   Lai, TYY
   Pataluskaite, R
   Margaron, P
   Lim, TH
AF Tan, Colin S.
   Cheung, Chui Ming Gemmy
   Lai, Timothy Y. Y.
   Pataluskaite, Ramune
   Margaron, Philippe
   Lim, Tock Han
TI PREDICTORS AND IMPORTANCE OF COMPLETE POLYPOIDAL LESION REGRESSION IN
   THE EVEREST II STUDY Predictors of Polyp Regression in Polypoidal
   Choroidal Vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retina; polypoidal choroidal vasculopathy; ranibizumab; EVEREST study;
   ICGA
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB;
   COMBINATION; MULTICENTER; MANAGEMENT; EFFICACY; SAFETY
AB Purpose: To evaluate the predictors of complete polypoidal lesion regression (CPREG) in polypoidal choroidal vasculopathy. Methods: Post hoc analysis of EVEREST II-a 24-month, multicenter, randomized, controlled clinical trial of 322 patients with polypoidal choroidal vasculopathy, randomized to receive ranibizumab with or without photodynamic therapy. Images of indocyanine green angiography (ICGA) were graded by a central reading center. Multiple logistic regression analysis with significant baseline predictors then was conducted to assess adjusted odds ratios for CPREG at month (M) 12. Results: Baseline ICGA characteristics were comparable between the treatment groups. Patients treated with combination therapy had higher odds of achieving CPREG at M12 (adjusted odds ratio = 4.64; 95% confidence interval, 2.85-7.55; P < 0.001) compared with those in the monotherapy group. Absence of polypoidal lesion pulsation on ICGA was also associated with CPREG at M12 (adjusted odds ratio = 2.62; 95% confidence interval, 1.32-5.21; P = 0.006). The presence of CPREG at M3 had higher odds of maintaining CPREG at M12 (adjusted odds ratio = 6.60; 95% confidence interval, 3.77-11.57; P < 0.001) compared with those with persistent polypoidal lesions. Conclusion: At M12, treatment with combination therapy was associated with higher probability of achieving CPREG than with ranibizumab monotherapy. The results contribute to the further understanding of the response of polypoidal lesions to treatment.
C1 [Tan, Colin S.; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Tan, Colin S.] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Pataluskaite, Ramune] Novartis Ireland Ltd, Dublin, Ireland.
   [Margaron, Philippe] Novartis Pharma AG, Basel, Switzerland.
C3 Tan Tock Seng Hospital; National University of Singapore; Singapore
   National Eye Center; Chinese University of Hong Kong; Novartis; Novartis
RP Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM Colintan_eye@yahoo.com.sg
CR Chi SC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82316-y
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai KB, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0801-7
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan Colin S, 2022, Ophthalmol Sci, V2, P100082, DOI 10.1016/j.xops.2021.100082
   Tan CS, 2019, OPHTHALMOL RETINA, V3, P400, DOI 10.1016/j.oret.2019.01.009
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P614, DOI 10.1111/ceo.13464
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P621, DOI 10.1111/ceo.13462
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tan CS, 2018, OSLI RETINA, V49, P4, DOI 10.3928/23258160-20171215-01
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, OSLI RETINA, V46, P786, DOI 10.3928/23258160-20150909-02
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
   Zhao XY, 2021, GRAEF ARCH CLIN EXP, V259, P855, DOI 10.1007/s00417-020-04977-1
NR 28
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2022
VL 42
IS 11
BP 2091
EP 2098
DI 10.1097/IAE.0000000000003595
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5M0WB
UT WOS:000870825900012
PM 35963005
DA 2022-11-30
ER

PT J
AU Landrum, JT
   Bone, RA
AF Landrum, JT
   Bone, RA
TI Dietary lutein & zeaxanthin: reducing the risk for macular degeneration
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
ID CATARACT-EXTRACTION; BLUE-LIGHT; VITAMIN-C; PIGMENT; CAROTENOIDS;
   DENSITY; SERUM; EYES; MECHANISMS; CHEMISTRY
AB Lutein and zeaxanthin are isomeric carotenoids possessing two hydroxyl groups. They are accumulated in the human macula. The presence of these carotenoids in the eye and serum and their level of intake have been shown to be related to the risk of age-related macular degeneration. These carotenoids function as a filter of incoming light reducing the amount of high-energy, blue light capable of causing damage through the generation of free radicals and singlet oxygen. The addition of lutein and zeaxanthin as supplements in the diet can increase macular pigmentation and hopefully will significantly alter the risk for age-related macular degeneration.
C1 Florida Int Univ, Dept Chem, Miami, FL 33199 USA.
   Florida Int Univ, Dept Phys, Miami, FL 33199 USA.
C3 State University System of Florida; Florida International University;
   State University System of Florida; Florida International University
RP Landrum, JT (通讯作者)，Florida Int Univ, Dept Chem, Miami, FL 33199 USA.
CR *AG REL EYE DIS ST, 2000, RISK FACT ASS AG REL, V107, P2224
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   *AREDS GROUP, 2001, OPHTHALMOLOGY, V119, P1439
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   BRITTON G, 2004, HDB CAROTENOIDS, P670
   Britton G., 1983, BIOCH NATURAL PIGMEN
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036
   GOODWIN TW, 1992, METHOD ENZYMOL, V213, P167
   GOODWIN TW, 1980, BIOCH CAROTENOIDS, V1, P377
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   GROFF JL, 1993, ADV NUTR HUMAN METAB
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911
   JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3
   Landrum J, 2004, FASEB J, V18, pA532
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1994, OPHTHALMOLOGY, V101, P315
   Martin HD, 1999, PURE APPL CHEM, V71, P2253, DOI 10.1351/pac199971122253
   MATHEWSROTH MM, 1987, PHOTOCHEM PHOTOBIOL, V46, P507, DOI 10.1111/j.1751-1097.1987.tb04803.x
   MATHEWSROTH MM, 1986, PHOTOCHEM PHOTOBIOL, V43, P91, DOI 10.1111/j.1751-1097.1986.tb05596.x
   Moore T, 1929, LANCET, V2, P219
   MOORE T, 1930, BIOCH J, V24
   Moreland JD, 2004, ARCH BIOCHEM BIOPHYS, V430, P143, DOI 10.1016/j.abb.2004.06.024
   Mortensen A, 2001, ARCH BIOCHEM BIOPHYS, V385, P13, DOI 10.1006/abbi.2000.2172
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   Piccaglia R, 1998, IND CROP PROD, V8, P45, DOI 10.1016/S0926-6690(97)10005-X
   Schalch W, 2004, FASEB J, V18, pA532
   Schalch W., 2001, HKJ OPHTHALMOL, V4, P31
   SCHALCH W, 1999, CRC MOD NUT, P215
   Scott K.J., 1994, CAROTENOID COMPOSITI
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   WACKENRODER H, 1831, MAG PHARM, V33, P144
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   YANOFF M, 2002, OCULAR PATHOLOGY, P761
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   YOUNG RW, 1994, OPTOMETRY VISION SCI, V71, P125, DOI 10.1097/00006324-199402000-00013
   Zhang XY, 2002, GRAEF ARCH CLIN EXP, V240, P802, DOI 10.1007/s00417-002-0554-z
   1997, DIETARY REFERNECE IN
NR 64
TC 20
Z9 22
U1 1
U2 7
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
EI 2035-4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD NOV-DEC
PY 2004
VL 15
IS 6
BP 22
EP 25
PG 4
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 904NU
UT WOS:000227505800007
DA 2022-11-30
ER

PT J
AU Hanemoto, T
   Hikichi, Y
   Kikuchi, N
   Kozawa, T
AF Hanemoto, Tsukasa
   Hikichi, Yusuke
   Kikuchi, Norimasa
   Kozawa, Tadahiko
TI The impact of different anti-vascular endothelial growth factor
   treatment regimens on reducing burden for caregivers and patients with
   wet age-related macular degeneration in a single-center real-world
   Japanese setting
SO PLOS ONE
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT INJECTION; DISEASE BURDEN; RANIBIZUMAB;
   PREVALENCE; OUTCOMES
AB Objective
   To describe the burden associated with different anti-vascular endothelial growth factor (VEGF) treatment strategies for wet age-related macular degeneration (wAMD) in a real-word setting in Japan.
   Methods
   Single-center, cross-sectional survey of caregivers of patients with wAMD performed in a hospital in Mito-City, a rural area in Japan. Caregiver burden was evaluated using the Burden Index of Caregivers (BIC-11), and depressive symptoms were assessed by the Center for Epidemiologic Studies Depression scale. Retrospective medical chart review was conducted to monitor resource use and visual acuity outcomes in patients. The productivity loss of caregivers accompanying patients on hospital visits was estimated using the human capital method.
   Results
   Seventy-one patient-caregiver pairs were included. Most caregivers were female (74.6%), spouse/partner (54.9%), employed (46.5%), and the primary caregiver (85.9%). Patients received anti-VEGF treatment as follows: treat-and-extend (T & E; n = 42), switch (from as-needed [PRN] to T & E; n = 18), PRN (n = 10), and other (n = 1). Caregiver-related burden (total BIC-11 scores) were 4.29 (T&E) 4.60 (PRN), and 5.33 (switch) (p = NS).
   The mean number of hospital visits was lower with T&E than PRN (7.88 vs. 14.0 [p = 0.00674] in year 1 and 5.68 vs. 9.0 in year 2). For patients who switched from PRN to T&E, the mean number of hospital visits decreased from 13.21 to 7.43 (p<0.0001) in the first year after switch. The productivity loss associated with accompanying patients to the hospital was lower for caregivers of patients receiving T&E than PRN (mean differences: 74,456.04 JPY [p = 0.00284] in year 1 and 40843.14 JPY in year 2), and was also reduced for caregivers of patients who switched from PRN to T&E.
   Conclusion
   wAMD treatment with anti-VEGF agents via T&E reduced hospital visits compared with PRN, where associated monitoring visits are necessary to provide good patient outcomes. T&E was associated with a reduction trend in caregiver burden, including time and costs.
C1 [Hanemoto, Tsukasa; Kozawa, Tadahiko] Kozawa Eye Hosp, Dept Ophthalmol, Ibaraki, Japan.
   [Hikichi, Yusuke] Bayer Yakuhin Ltd, Market Access Hlth Econ & Outcomes Res, Tokyo, Japan.
   [Kikuchi, Norimasa] Clinical Study Support Inc, CR Div, Nagoya, Aichi, Japan.
C3 Bayer AG
RP Hanemoto, T (通讯作者)，Kozawa Eye Hosp, Dept Ophthalmol, Ibaraki, Japan.
EM hanemoto@tb3.so-net.ne.jp
OI Hikichi, Yusuke/0000-0002-1699-6821; Hanemoto,
   Tsukasa/0000-0002-2444-4234
FU Bayer Yakuhin, Ltd.; Clinical Study Support, Inc.; Bayer Pharmaceuticals
FX This study was funded by Bayer Yakuhin, Ltd. The funder provided support
   in the form of salary for YH, and was involved in the study design, data
   collection, data analysis, decision to publish, and preparation of the
   manuscript. Clinical Study Support, Inc., was contracted by Bayer
   Yakuhin, Ltd, and provided support in the form of salary for NK, and was
   involved in data collection and data analysis.; Medical writing
   assistance was provided by PAREXEL and was funded by Bayer
   Pharmaceuticals.
CR Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Braich PS, 2012, OPHTHALMOLOGY, V119, P221, DOI 10.1016/j.ophtha.2011.07.038
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Dilokthornsakul P, 2014, INT J OPHTHALMOL-CHI, V7, P145, DOI 10.3980/j.issn.2222-3959.2014.01.27
   Forbes A, 2007, CLIN REHABIL, V21, P563, DOI 10.1177/0269215507075035
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gopinath B, 2015, AGING MENT HEALTH, V19, P239, DOI 10.1080/13607863.2014.924477
   Hanemoto T., 2013, 67 ANN C JAP CLIN OP
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ministry of Health Labour and Welfare and Ministry of Education Culture Sports Science and Technology, 2015, CULT SPORTS SCI TECH
   Miyashita M, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-52
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Ohnaka M, 2016, GRAEFES ARCH CLIN EX
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shima S., 1985, CLIN PSYCHIATR, V27, P717, DOI DOI 10.11477/MF.1405203967
   Tsuchiya A, 2001, EC EVALUATION HLTH C, P22
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Weyer-Wendl H, 2016, HEALTH ECON REV, V6, DOI 10.1186/s13561-016-0116-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, ICD 10 VERS 2016 VIS
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 29
TC 22
Z9 23
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 8
PY 2017
VL 12
IS 12
AR e0189035
DI 10.1371/journal.pone.0189035
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FP2SV
UT WOS:000417469900028
PM 29220371
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Dysli, C
   Fink, R
   Wolf, S
   Zinkernagel, MS
AF Dysli, Chantal
   Fink, Rahel
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Fluorescence Lifetimes of Drusen in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE fluorescence lifetimes; fundus autofluorescence; retinal imaging; FLIO;
   age-related macular degeneration; AMD; deposits; drusen
ID FUNDUS AUTOFLUORESCENCE LIFETIMES; TIME-RESOLVED AUTOFLUORESCENCE;
   RETINAL-PIGMENT EPITHELIUM; IMAGING OPHTHALMOSCOPY; GEOGRAPHIC ATROPHY;
   RISK-FACTORS; DEPOSITS; DISEASE
AB PURPOSE. The purpose of this study was to characterize fundus autofluorescence lifetimes of retinal drusen in patients with AMD.
   METHODS. Patients with AMD and retinal drusen and healthy controls of similar age were examined. A fluorescence lifetime imaging ophthalmoscope was used. Retinal autofluorescence was excited using a 473-nm pulsed laser, and fundus autofluorescence lifetimes of the central retina (308) were measured in two distinct spectral channels (short: 498 to 560 nm [SSC]; long: 560 to 720 nm [LSC]). Mean retinal autofluorescence lifetimes, corresponding fundus autofluorescence intensity images, spectral domain optical coherence tomography, color fundus images, and clinical data were investigated. Patients were analyzed in two distinct groups (soft drusen and reticular pseudodrusen) and compared with control subjects.
   RESULTS. Sixty-four eyes of 64 patients with AMD and retinal drusen (age: mean 6 SD, 78 6 8.5 years; range, 59 to 94 years) were investigated and compared with a control group of 20 age-matched healthy subjects. Mean retinal autofluorescence lifetimes in patients with AMD was significantly prolonged compared with the healthy control eyes (mean 6 SEM: SSC, 486 6 18 vs. 332 6 11 ps, P < 0.0001; LSC: 493 6 9 vs. 382 6 17 ps, P < 0.0001). Areas of drusen featured a wide range of fluorescence lifetime values. Long lifetimes were identified in areas of atrophy and in areas of intraretinal hyperreflective deposits. Short lifetimes corresponded to deposits within the photoreceptor outer segment band.
   CONCLUSIONS. Mean retinal autofluorescence lifetimes in AMD patients are significantly prolonged. Intraretinal deposits cause prolonged lifetimes, whereas deposits in the area of the outer photoreceptor segments lead to short fluorescence lifetimes.
C1 [Dysli, Chantal; Fink, Rahel; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol,Dept BioMed Res, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Zinkernagel, MS (通讯作者)，Univ Bern, Bern Univ Hosp, CH-3010 Bern, Switzerland.
EM m.zinkernagel@gmail.com
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Zinkernagel, Martin
   S./0000-0003-3447-2359
FU Swiss National Science Foundation (Bern, Switzerland) [320030_156019]
FX Supported by Swiss National Science Foundation Grant 320030_156019
   (Bern, Switzerland). The sponsor or funding organization had no role in
   the design or conduct of this research.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Dysli C, 2017, RETINA-J RET VIT DIS, V37, P2151, DOI 10.1097/IAE.0000000000001452
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P6714, DOI 10.1167/iovs.16-20392
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Dysli C, 2015, INVEST OPHTH VIS SCI, V56, P3329, DOI 10.1167/iovs.14-16203
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   International Electrotechnical Commission, 2014, 6082512014 IEC
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klein R, 2015, J CLIN MED, V4, P425, DOI 10.3390/jcm4030425
   Korner-Stiefbold U, 2001, Ther Umsch, V58, P28, DOI 10.1024/0040-5930.58.1.28
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Reim M, 2004, DIAGNOSE AUGENHINTER
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sauer L, 2017, ACTA OPHTHALMOL, V95, P481, DOI 10.1111/aos.13269
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schmidt J, 2017, ACTA OPHTHALMOL, V95, P33, DOI 10.1111/aos.13174
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D, 2009, OPHTHALMOLOGE, V106, P714, DOI 10.1007/s00347-009-1975-4
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Schweitzer D, 2010, ESSENT OPHTHALMOL, P107, DOI 10.1007/978-3-540-85540-8_10
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Warburton S, 2005, MOL VIS, V11, P1122
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 42
Z9 42
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2017
VL 58
IS 11
BP 4856
EP 4862
DI 10.1167/iovs.17-22184
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5II
UT WOS:000414267700023
PM 28973332
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fan, DX
   Hua, R
AF Fan, Dongxia
   Hua, Rui
TI Different imaging characteristics between unilateral and bilateral
   polypoidal choroidal vasculopathy
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Indocyanine green angiography;
   Optical coherence tomography; Sub foveal choroidal thickness;
   Hyperfluorescent spots
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; EYES; THICKNESS; INJECTION; EFFICACY
AB Purpose: To investigate the different imaging characteristics between unilateral and bilateral polypoidal choroidal vasculopathy (PCV) cases, based on confocal scanning laser ophthalmoscope assessment.
   Methods: For this retrospective case series study, diagnostic indocyanine green angiography (ICGA) and spectral domain optical coherence tomography (SD-OCT) were performed to assess the eligible PCV eyes.
   Results: Among the 53 patients at baseline, 14 showed bilateral PCV lesions, including two cases of branching vessel network (BVN) without leakage. Concerning the subfoveal choroidal thickness (SFCT), unilateral PCV eyes (326 [155-547] mu m) were statistically comparable to their fellow eyes (330 [163-477] mu m) (p = 0.257). However, the SFCT (228[141-273] mu m) from the bilateral PCV group was significantly lower compared with both the PCV (p = 0.002) and fellow eyes (p < 0.001) from the unilateral group. Moreover, ICGA related hyperfluorescent spots were shown to have a significant positive correlation with SFCT in the unilateral PCV eyes and their fellow eyes, other than bilateral PCV cases. In addition, the drusens tended to prevail in the fellow eyes of the unilateral PCV group (46.2%), compared with bilateral cases.
   Conclusions: Our results indicate that SFCT, ICGA related hyperfluorescent spots, and drusen were the three main imaging characteristic differences between unilateral and bilateral PCV cases.
C1 [Fan, Dongxia; Hua, Rui] China Med Univ, Dept Ophthalmol, Hosp 1, Shenyang, Liaoning, Peoples R China.
C3 China Medical University
RP Hua, R (通讯作者)，155 Nanjingbei St, Shenyang 110001, Liaoning, Peoples R China.
EM woodshua@126.com
FU Fund for Scientific Research of The First Hospital of China Medical
   University [FSFH201712]; Natural Science Foundation of Liaoning Province
   [20170541041]; Clinical Genetics (Ophthalmology) Subject construction
   project of China Medical University [3110118049]
FX Fund for Scientific Research of The First Hospital of China Medical
   University (FSFH201712), Natural Science Foundation of Liaoning Province
   (No. 20170541041), and Clinical Genetics (Ophthalmology) Subject
   construction project of China Medical University (No.3110118049). No
   funders had any role in the study design, data collection, analysis,
   decision to publish, or preparation of the manuscript.
CR Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Hwang Hyun Ji, 2017, Korean J Ophthalmol, V31, P230, DOI 10.3341/kjo.2016.0035
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kim H, 2015, OSLI RETINA, V46, P423, DOI 10.3928/23258160-20150422-04
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Merle Harold, 2008, Retin Cases Brief Rep, V2, P181, DOI 10.1097/IAE.0b013e31802be7a3
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Ratanasukon M, 2018, CLIN OPHTHALMOL, V12, P2177, DOI 10.2147/OPTH.S178228
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Tateno Y, 2016, OPHTHALMIC GENET, V37, P177, DOI 10.3109/13816810.2015.1020557
   Thanos A, 2016, OSLI RETINA, V47, P381, DOI 10.3928/23258160-20160324-15
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2019
VL 26
BP 1
EP 7
DI 10.1016/j.pdpdt.2019.02.004
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IH2NB
UT WOS:000474330400001
PM 30738226
DA 2022-11-30
ER

PT J
AU Owsley, C
   McGwin, G
   Jackson, GR
   Heimburger, DC
   Piyathilake, CJ
   Klein, R
   White, MF
   Kallies, K
AF Owsley, C
   McGwin, G
   Jackson, GR
   Heimburger, DC
   Piyathilake, CJ
   Klein, R
   White, MF
   Kallies, K
TI Effect of short-term, high-dose retinol on dark adaptation in aging and
   early age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VITAMIN-A-DEFICIENCY; SORSBYS-FUNDUS-DYSTROPHY; BRUCHS MEMBRANE CHANGE;
   MACULAR DEGENERATION; PIGMENT EPITHELIUM; PHOTORECEPTOR-LOSS;
   STARGARDT-DISEASE; RHODOPSIN LEVELS; NIGHT BLINDNESS; BASAL DEPOSITS
AB PURPOSE. To examine the effect of a short course of high-dose retinol (preformed vitamin A) on dark adaptation in older adults with normal retinal health or early age-related maculopathy (ARM).
   METHODS. The study design was a randomized, double-masked, placebo-controlled experiment. Adults >= 50 years of age whose fundus photographs for. the eye to be tested psychophysically fell within steps 1 to 9 of the Age-Related Eye Disease Study (AREDS) Grading System were randomly assigned to a 30-day course of 50,000 IU oral retinol or a placebo. At baseline and 30-day follow-up, dark adaptation was tested and the Low Luminance Questionnaire (LLQ), all instrument for assessing difficulty with vision in reduced lighting, was administered. Primary Outcomes of interest were rod- and cone-mediated parameters of dark adaptation, with scores on the LLQ's six subscales as secondary outcomes.
   RESULTS. The sample consisted of 104 participants with 52 each in the intervention and placebo groups. There were no group differences in baseline variables. At 30-days, the dark-adaptation parameters of cone time-constant, cone threshold, rod-cone break, and rod threshold did not differ. The retinol intervention group had significantly larger (i.e., steeper) rod slopes, indicating faster sensitivity recovery, than did the placebo group (P = 0.0419). There were no group differences in scores on the LLQ subscales driving, extreme lighting, emotional distress, general lighting, or peripheral vision. The retinol group had a higher score by five points on the mobility sub-scale compared with the placebo group (P = 0.0141). Those who had the most self-reported change on the mobility sub-scale at day 30 were more likely to have greater change in the speed of dark adaptation, as indicated by the rod slope parameter (r = 0.24, P = 0.0141).
   CONCLUSIONS. A short-term, high-dose course of retinol in creased the rate of rod-mediated dark adaptation in older adults who were in the early phases of ARM or were exhibiting normal retinal aging. These results arc consistent with the hypothesis that depositions and other structural changes in the retinal pigment epithelium and Bruch's membrane in aging and early ARM cause a localized retinoid deficiency.
C1 Univ Alabama, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Surg, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Nutr Sci & Med, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Nutr Sci, Div Nutr Biochem & Genom, Birmingham, AL 35294 USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Wisconsin System; University of Wisconsin Madison
RP Owsley, C (通讯作者)，Univ Alabama, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
FU NEI NIH HHS [R21-EY14071] Funding Source: Medline; NIA NIH HHS
   [R01-AG04212] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R21EY014071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
CR ACOTT TS, 1995, NAT MED, V1, P884, DOI 10.1038/nm0995-884
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   Cideciyan AV, 1997, INVEST OPHTH VIS SCI, V38, P1786
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DELORI FC, 2000, INVEST OPHTH VIS SCI, V41, P464
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hecht S, 1939, J AMER MED ASSOC, V112, P1910, DOI 10.1001/jama.1939.02800190024006
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   KATZ ML, 1993, EXP EYE RES, V56, P671, DOI 10.1006/exer.1993.1084
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   KEMP CM, 1989, EXP EYE RES, V49, P49
   Kornzweig A. L., 1979, RETINAL PIGMENT EPIT, P478
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamb TD, 1998, J PHYSIOL-LONDON, V506P, p88P
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, IN PRESS INVEST OPHT
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P393, DOI 10.1113/jphysiol.1975.sp010981
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STAUBER PM, 1991, AM J CLIN NUTR, V54, P878, DOI 10.1093/ajcn/54.5.878
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
NR 63
TC 60
Z9 67
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2006
VL 47
IS 4
BP 1310
EP 1318
DI 10.1167/iovs.05-1292
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 029KI
UT WOS:000236560800009
PM 16565362
DA 2022-11-30
ER

PT J
AU Evereklioglu, C
   Er, H
   Doganay, S
   Cekmen, M
   Turkoz, Y
   Otlu, B
   Ozerol, E
AF Evereklioglu, C
   Er, H
   Doganay, S
   Cekmen, M
   Turkoz, Y
   Otlu, B
   Ozerol, E
TI Nitric oxide and lipid peroxidation are increased and associated with
   decreased antioxidant enzyme activities in patients with age-related
   macular degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antioxidant enzymes; lipid
   peroxidation; nitric oxide
ID GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; RISK-FACTORS; MACULOPATHY;
   PROTECTION; PEROXYNITRITE; CATALASE; DISEASE
AB Background: Nitric oxide (NO), hydroxyl radical (OH.), superoxide anion (02) and hydrogen peroxide (H2O2) are free-radicals released in oxidative stress. Superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and catalase (CAT) are antioxidant enzymes, mediating defense against oxidative stress. Excess NO and/or defective antioxidants cause lipid peroxidation, cellular dysfunction and death. Age-related maculopathy (ARM) or degeneration (ARMD) is the leading cause of irreversible blindness in developed countries. The etiology is unclear and the molecular factors contributing this disease remain to be specified. Aims: This multicenter, double-blind, cross-sectional study aimed to investigate plasma NO and lipid peroxidation levels with relation to antioxidant enzyme activities in erythrocyte and plasma of patients with ARMD compared with healthy control subjects. Methods: NO, lipid peroxidation (measured as plasma malondialdehyde [MDA] levels) and the catalytic activity of SOD, GSHPx and CAT were measured in a group of 41 patients with maculopathy (19 men, 22 women; 67.12 +/- 3.70 years) and compared with 25 age- and sex-matched healthy control subjects without maculopathy (12 men, 13 women; 68.04 +/- 3.02 years). NO and MDA levels were measured in plasma, CAT in red blood cells (RBCs), and SOD and GSHPx in both plasma and RBCs. Color fundus photographs were used to assess the presence of maculopathy, and the patients were divided into two groups using clinical examination and grading of photographs; early-ARM (n = 22) and late-ARMD (n = 19). Results: All patients with maculopathy had significantly (p < 0.001) higher plasma NO levels over control subjects (mean +/- SD, 48.58 +/- 8.81 vs. 28.22 +/- 3.39 mu mol/l). Plasma MDA levels in patients and control subjects were 4.99 +/- 1.00 and 2.16 +/- 0.24 mu mol/l, respectively, and the difference was significant (p < 0.001). On the other hand, SOD and GSHPx activities were significantly lower in both RBCs and plasma of patients with maculopathy than in control subjects (RBCs-SOD, 3509.30 +/- 478.22 vs. 5033.30 +/- 363.98 U/g Hb. p < 0.001; plasma-SOD, 560.95 +/- 52.52 vs. 704.76 +/- 24.59 U/g protein, p < 0.001; RBCs-GSHPx, 663.43 +/- 41.74 vs. 748.80 +/- 25.50 U/g Hb, p < 0.001; plasma-GSHPx, 98.26 +/- 15.67 vs. 131.80 +/- 8.73 U/g protein, p < 0.001). RBCs-CAT levels were not different between groups (131.68 +/- 12.89 vs. 133.00 +/- 13.29 k/g Hb, p = 0.811). Late-ARMD patients had significantly lower antioxidant enzyme levels and higher MDA levels when compared with early-ARM patients (for each, p < 0.001). In addition, plasma NO and MDA levels were negatively correlated with SOD and GSHPx activities. Conclusions: This study demonstrated for the first time that NO, the most abundant free-radical in the body, might be implicated in the pathophysiology of ARMD in association with decreased antioxidant enzymes and increased lipid peroxidation status.
C1 Erciyes Univ, Dept Ophthalmol, Kayseri, Turkey.
   Inonu Univ, Fac Med, Turgut Ozal Med Ctr, Malatya, Turkey.
   Gaziantep Univ, Fac Med, Res & Applicat Hosp, Gaziantep, Turkey.
C3 Erciyes University; Inonu University; Gaziantep University
RP Evereklioglu, C (通讯作者)，Erciyes Univ, Dept Ophthalmol, Kayseri, Turkey.
EM evereklioglu@hotmail.com
RI Evereklioğlu, Cem/A-5370-2018; cekmen, mustafa baki/G-6122-2011
OI Evereklioğlu, Cem/0000-0001-7889-4532; Otlu, Baris/0000-0002-6220-0521
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Alexander L J, 1993, J Am Optom Assoc, V64, P822
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Ben-Menachem E, 2000, EPILEPSY RES, V40, P33, DOI 10.1016/S0920-1211(00)00096-6
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   CHRISTEN WG, 1994, AM J MED, V97, pS14, DOI 10.1016/0002-9343(94)90293-3
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DEPAULET AC, 1990, ANN BIOL CLIN-PARIS, V48, P323
   Evereklioglu C, 2002, J AM ACAD DERMATOL, V46, P50, DOI 10.1067/mjd.2002.118338
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012
   Granger DL, 1996, METHOD ENZYMOL, V268, P142
   GUEMOURI L, 1991, CLIN CHEM, V37, P1932
   HALLIWELL B, 1991, AM J MED S3C, V91, P14, DOI DOI 10.1016/0002-9343(91)90279-7
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Muijsers RBM, 1997, LIFE SCI, V60, P1833, DOI 10.1016/S0024-3205(96)00651-0
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Pastor MC, 1998, CLIN CHEM, V44, P924
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sozmen EY, 2000, CLIN CHEM LAB MED, V38, P21, DOI 10.1515/CCLM.2000.004
   SUN Y, 1988, CLIN CHEM, V34, P497
   Tso M O, 1987, Trans Am Ophthalmol Soc, V85, P498
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WASOWICZ W, 1993, CLIN CHEM, V39, P2522
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 36
TC 82
Z9 97
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD MAR
PY 2003
VL 106
IS 2
BP 129
EP 136
DI 10.1023/A:1022512402811
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 698XM
UT WOS:000184025100005
PM 12678277
DA 2022-11-30
ER

PT J
AU Agorogiannis, EI
   Pearce, IA
   Yadav, S
   Parry, DG
   Beare, NAV
AF Agorogiannis, Eleftherios I.
   Pearce, Ian A.
   Yadav, Sohraab
   Parry, David G.
   Beare, Nicholas A. V.
TI Clinical outcomes in Caucasian patients with polypoidal choroidal
   vasculopathy
SO EYE
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL
   AFLIBERCEPT; RANIBIZUMAB; COMBINATION; EFFICACY; EVEREST; SAFETY; TRIAL
AB Purpose To describe treatment outcomes in a cohort of Caucasian patients with polypoidal choroidal vasculopathy (PCV).
   Methods Clinical charts from 48 eyes of 45 Caucasian patients with PCV were retrospectively reviewed. All cases were diagnosed with indocyanine green angiography. Best corrected visual acuity (BCVA) and optical coherence tomography (OCT) imaging were analyzed at baseline and final follow-up.
   Results Eyes were treated with a combination of verteporfin photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) (n = 24), or PDT monotherapy (n = 9), or anti-VEGF monotherapy (n = 8), or no treatment (n = 7). Aflibercept was the anti-VEGF agent in 30 out of 32 eyes. Sixteen out of 24 eyes in the combination treatment group received initial PDT at diagnosis. All treatments led to stabilization of BCVA at final visit with a trend for better visual acuity in the anti-VEGF monotherapy group. There was a substantial reduction in central retinal thickness associated with resolution of subfoveal fluid and improvement in retinal pigment epithelial detachment in all treatment groups. BCVA and OCT findings remained stable in eyes which received no treatment. The use of PDT was associated with 0.5 fewer intravitreal injections per annum, which was not statistically significant.
   Conclusions In the largest series of Caucasian patients with PCV presented to date, anti-VEGF monotherapy, PDT, or their combination preserved visual acuity and improved subfoveal exudative changes. Combination treatment was not superior to anti-VEGF monotherapy.
C1 [Agorogiannis, Eleftherios I.; Pearce, Ian A.; Yadav, Sohraab; Parry, David G.; Beare, Nicholas A. V.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool
RP Agorogiannis, EI (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
EM eleftherios.agorogiannis@gmail.com
RI Beare, Nicholas/AAG-4946-2019
OI Beare, Nicholas/0000-0001-8086-990X
FU Bayer
FX Ian A. Pearce has received consultancy fees from Bayer and Novartis and
   travel grants from Bayer. Nicholas A.V. Beare is a member of the NICE
   AMD Clinical Guidelines Development Committee, has participated in
   advisory boards for Santen Pharmaceuticals and AbbVie on uveitis, and
   has received a travel grant from Bayer.
CR Azuma K, 2016, RETINA-J RET VIT DIS, V36, P2158, DOI 10.1097/IAE.0000000000001047
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 7
Z9 7
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2018
VL 32
IS 11
BP 1731
EP 1739
DI 10.1038/s41433-018-0168-2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ6QB
UT WOS:000449564900008
PM 30002485
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wachtlin, J
   Eter, N
   Hasanbasic, Z
   Keramas, G
   Rech, C
   Sachs, H
   Schilling, H
   Wiedemann, P
   Framme, C
AF Wachtlin, Joachim
   Eter, Nicole
   Hasanbasic, Zoran
   Keramas, Georgios
   Rech, Christine
   Sachs, Helmut
   Schilling, Harald
   Wiedemann, Peter
   Framme, Carsten
TI Importance of continuous treatment with intravitreal aflibercept
   injections in patients with neovascular age-related macular
   degeneration-12-month post hoc analysis of the PERSEUS real-world
   evidence study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Intravitreal aflibercept;
   Intravitreal injection; Visual acuity
ID RANIBIZUMAB TREATMENT; VEGF TRAP
AB Purpose To investigate the influence of treatment regularity with intravitreal aflibercept injections (IVT-AFL injections) on visual acuity (VA) outcomes in patients with neovascular age-related macular degeneration (nAMD) enrolled in the PERSEUS trial who received at least 7 IVT-AFL injections during the first year. Methods This was a post hoc analysis of the PERSEUS trial, a prospective, non-interventional, multicenter cohort study, and included 370 patients with nAMD who had received >= 7 IVT-AFL injections during year 1. In addition to the prespecified subgroups of treatment-naive and previously treated patients, results were compared between patients with regular (n = 209) and irregular (n = 161) treatment. Regular treatment was defined as initial dosing with monthly IVT-AFL injections for 3 months, then bimonthly IVT-AFL injections until month 12. Irregular treatment was defined as any deviation from regular treatment (provided >= 7 injections were received). The outcome of primary interest was the mean change in VA from baseline after 12 months. Further outcomes of interest included VA gain or loss, proportion of patients achieving reading vision, and percentage of patients with fluid. Results At month 12, the mean (+/- standard deviation, SD) VA improvement from baseline was 6.1 +/- 15.6 Early Treatment Diabetic Retinopathy Study letters in the regular cohort and 2.5 +/- 16.7 letters in the irregular cohort with >= 7 IVT-AFL injections (P = 0.0514). Best results were obtained in the treatment-naive regular sub-cohort with a mean +/- SD VA improvement of 8.0 +/- 17.7 letters, whereas treatment-naive patients with irregular treatment experienced a considerably lower VA gain (2.8 +/- 20.0 letters). Irregular treatment consistently correlated with inferior results in treatment-naive patients. At month 12, the proportion of treatment-naive patients who had experienced a worsening of >= 5 letters was 29.6% in the irregular sub-cohort versus 13.6% in the regular sub-cohort (P = 0.0049). However, among the treatment-naive patients, the mean number of injections was significantly higher in the irregular than in the regular sub-cohort (8.0 +/- 1.2 vs. 7.4 +/- 0.6;P = 0.0001). Furthermore, compared with the treatment-naive, regular sub-cohort, patients in the irregular sub-cohort had more visits (19.1 +/- 8.6 vs. 16.1 +/- 5.7), VA tests (14.2 +/- 6.9 vs. 12.0 +/- 4.6), and optical coherence tomography examinations (5.1 +/- 3.7 vs. 3.4.0 +/- 3.0). Conclusions Although irregularly treated patients received more injections and more monitoring visits during the first year of IVT-AFL treatment, they experienced worse VA outcomes than regularly treated patients.
C1 [Wachtlin, Joachim] Sankt Gertrauden Krankenhaus, Abt Augenheilkunde, Paretzer Str 12, D-10713 Berlin, Germany.
   [Wachtlin, Joachim] Med Hsch Brandenburg, Neuruppin, Germany.
   [Eter, Nicole] Univ Klinikum Munster, Klin Augenheilkunde, Munster, Germany.
   [Hasanbasic, Zoran; Keramas, Georgios] Bayer Vital GmbH, Med Fachabt, Leverkusen, Germany.
   [Rech, Christine] Bayer Vital GmbH, Data Generat, Leverkusen, Germany.
   [Sachs, Helmut] Stadt Klinikum Dresden Friedrichstadt, Augenklin, Dresden, Germany.
   [Schilling, Harald] St Johannes Hosp, Klin Augenheilkunde, Dortmund, Germany.
   [Wiedemann, Peter] Univ Klinikum Leipzig, Klin & Poliklin Augenheilkunde, Leipzig, Germany.
   [Framme, Carsten] Hannover Med Sch, Klin Augenheilkunde, Hannover, Germany.
C3 University of Munster; Bayer AG; Bayer AG; Technische Universitat
   Dresden; Municipal Hospital Dresden; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; St. Johannes Hospital; Leipzig
   University; Hannover Medical School
RP Wachtlin, J (通讯作者)，Sankt Gertrauden Krankenhaus, Abt Augenheilkunde, Paretzer Str 12, D-10713 Berlin, Germany.; Wachtlin, J (通讯作者)，Med Hsch Brandenburg, Neuruppin, Germany.
EM augenheilkunde@sankt-gertrauden.de
OI Hasanbasic, Zoran/0000-0003-0673-012X
FU Bayer Vital GmbH [EY1313]
FX This study was funded by Bayer Vital GmbH (EY1313).
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Deutsche Ophthalmologische Gesellschaft RG Berufsverband der Augenarzte Deutschlands, 2014, STELL DTSCH OPHTH GE
   Ehlken C, 2018, RETINA-J RET VIT DIS, V38, P1134, DOI 10.1097/IAE.0000000000001681
   European Medicines Agency, 2020, ASS REP KEYTR
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Framme CEN, 2017, OPHTHALMOL RETINA, V2, P539, DOI [10.1016/j.oret.2017.09.017, DOI 10.1016/J.ORET.2017.09.017]
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Ohji M, 2017, EURETINA
   Ohji M, 2018, EURETINA
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
   Ziemssen F, 2017, ANN M ASS RES VIS OP
NR 20
TC 5
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2021
VL 259
IS 3
BP 601
EP 611
DI 10.1007/s00417-020-04803-8
EA AUG 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QM0ZA
UT WOS:000559145500001
PM 32789651
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Heier, JS
   Khanani, AM
   Ruiz, CQ
   Basu, K
   Ferrone, PJ
   Brittain, C
   Figueroa, MS
   Lin, H
   Holz, FG
   Patel, V
   Lai, TYY
   Silverman, D
   Regillo, C
   Swaminathan, B
   Viola, F
   Cheung, CMG
   Wong, TY
AF Heier, Jeffrey S.
   Khanani, Arshad M.
   Ruiz, Carlos Quezada
   Basu, Karen
   Ferrone, Philip J.
   Brittain, Christopher
   Figueroa, Marta S.
   Lin, Hugh
   Holz, Frank G.
   Patel, Vaibhavi
   Lai, Timothy Y. Y.
   Silverman, David
   Regillo, Carl
   Swaminathan, Balakumar
   Viola, Francesco
   Cheung, Chui Ming Gemmy
   Wong, Tien Y.
CA TENAYA Investigators
   LUCERNE Investigators
TI Efficacy, durability, and safety of intravitreal faricimab up to every
   16 weeks for neovascular age-related macular degeneration (TENAYA and
   LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
SO LANCET
LA English
DT Article
ID TREAT-AND-EXTEND; RANIBIZUMAB; THERAPY; EYE
AB Background Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for neovascular age-related macular degeneration (nAMD).
   Methods TENAYA and LUCERNE were randomised, double-masked, non-inferiority trials across 271 sites worldwide. Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6 center dot 0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2 center dot 0 mg every 8 weeks. Randomisation was performed through an interactive voice or web-based response system using a stratified permuted block randomisation method. Patients, investigators, those assessing outcomes, and the funder were masked to group assignments. The primary endpoint was mean change in bestcorrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non- inferiority margin of four letters), in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. These trials are registered with ClinicalTrials.gov (TENAYA NCT03823287 and LUCERNE NCT03823300).
   Findings Across the two trials, 1329 patients were randomly assigned between Feb 19 and Nov 19, 2019 (TENAYA n=334 faricimab and n=337 aflibercept), and between March 11 and Nov 1, 2019 (LUCERNE n=331 faricimab and n=327 aflibercept). BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5.8 letters [95% CI 4.6 to 7.1] and 5.1 letters [3.9 to 6.4]; treatment difference 0.7 letters [-1.1 to 2.5]) and LUCERNE (6.6 letters [5.3 to 7.8] and 6.6 letters [5.3 to 7.8]; treatment difference 0.0 letters [-1.7 to 1.8]). Rates of ocular adverse events were comparable between faricimab and aflibercept (TENAYA n=121 [36.3%] vs n=128 [38.1%], and LUCERNE n=133 [40.2%] vs n=118 [36.2%]).
   Interpretation Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD. Copyright (C) 2022 Elsevier Ltd. All rights reserved.
C1 [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA 02114 USA.
   [Khanani, Arshad M.] Sierra Eye Associates, Reno, NV USA.
   [Khanani, Arshad M.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Ruiz, Carlos Quezada] San Pedro Garza Garcia, San Pedro Garza Garcia, Nuevo Leon, Mexico.
   [Ruiz, Carlos Quezada; Brittain, Christopher; Lin, Hugh] Genentech Inc, San Francisco, CA USA.
   [Basu, Karen] Roche Prod Ireland, Dublin, Ireland.
   [Ferrone, Philip J.] Vitreoretinal Consultants New York, Great Neck, NY USA.
   [Figueroa, Marta S.] Ramon y Cajal Univ Hosp, Clin Baviera, Madrid, Spain.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Holz, Frank G.] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Patel, Vaibhavi; Silverman, David] Roche Prod, Welwyn Garden City, Herts, England.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Regillo, Carl] Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
   [Swaminathan, Balakumar] Hoffmann La Roche, Mississauga, ON, Canada.
   [Viola, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Viola, Francesco] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Cheung, Chui Ming Gemmy; Wong, Tien Y.] Natl Univ Singapore, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore, Singapore.
C3 Ophthalmic Consultants of Boston; Nevada System of Higher Education
   (NSHE); University of Nevada Reno; Roche Holding; Genentech; Hospital
   Universitario Ramon y Cajal; University of Bonn; University of Bonn;
   Roche Holding; Chinese University of Hong Kong; Jefferson University;
   Roche Holding; IRCCS Ca Granda Ospedale Maggiore Policlinico; University
   of Milan; National University of Singapore; Singapore National Eye
   Center
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
RI Sikorski, Bartosz L/AHD-2057-2022; Cagini, Carlo/H-3431-2019; Khoramnia,
   Ramin/AAR-8358-2020; Nowinska, Anna K/G-6165-2013; Virgili,
   Gianni/P-6607-2014
OI Sikorski, Bartosz L/0000-0001-5357-9560; Cagini,
   Carlo/0000-0002-3812-9219; Khoramnia, Ramin/0000-0002-6237-7773;
   Nowinska, Anna K/0000-0002-8418-3486; Talks, James/0000-0001-6126-6476;
   Silverman, David/0000-0003-1842-5739; Mones, Jordi/0000-0003-3685-2160;
   Virgili, Gianni/0000-0002-9960-2989; Lai, Chi-Chun/0000-0001-9547-7212
FU F Hoffmann-La Roche
FX F Hoffmann-La Roche.
CR American Academy of Ophthalmology Retina/Vitreous PPP Panel Hoskins Center for Quality Eye Care, 2019, PREF PRACT PATT AG R
   American Society of Retina Specialists,, 2020, MEMB UPD NOV SAF REV
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eylea, 2021, PRESCRIBING INFORM
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Khanani Arshad M, 2021, Ophthalmol Sci, V1, P100076, DOI 10.1016/j.xops.2021.100076
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 29
TC 22
Z9 22
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB
PY 2022
VL 399
IS 10326
BP 729
EP 740
DI 10.1016/S0140-6736(22)00010-1
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZE3NS
UT WOS:000758794200020
PM 35085502
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Sethia, A
   Sheth, J
   Gopalakrishnan, M
   Anantharaman, G
AF Sethia, Abhishek
   Sheth, Jay
   Gopalakrishnan, Mahesh
   Anantharaman, Giridhar
TI Spontaneous formation and closure of full thickness macular hole after
   treatment with anti-vascular endothelial growth factor therapy in
   polypoidal choroidal vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Full-thickness macular hole; intra-vitreal anti-vascular endothelial
   growth factor; polypoidal choroidal vasculopathy
ID RANIBIZUMAB; SECONDARY
AB Full-thickness macular hole (FTMH) formation in Polypoidal choroidal vasculopathy (PCV) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is a rare complication. Spontaneous closure of FTMH following anti-VEGF therapy has not been described in PCV till date. We present a case of Asian woman with PCV who developed a FTMH following treatment with intra-vitreal anti-VEGF injections which subsequently closed spontaneously on further course of treatment.
C1 [Sethia, Abhishek; Sheth, Jay; Gopalakrishnan, Mahesh; Anantharaman, Giridhar] Giridhar Eye Inst, Dept Vitreoretina, Kochi, Kerala, India.
RP Sethia, A (通讯作者)，New Lane, Bikaner 334401, Rajasthan, India.
EM dr.abhishekjain29@gmail.com
RI Sheth, Jay/AAZ-6612-2020
CR Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Baskaran P, 2017, MIDDLE EAST AFR J OP, V24, P159, DOI 10.4103/meajo.MEAJO_30_16
   Cho JH, 2011, CLIN EXP OPTOM, V94, P586, DOI 10.1111/j.1444-0938.2011.00614.x
   Oshima Y, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0021-3
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Raiji Veena R, 2013, Retin Cases Brief Rep, V7, P91, DOI 10.1097/ICB.0b013e31826f090d
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagara N, 2009, BRIT J OPHTHALMOL, V93, P1337, DOI 10.1136/bjo.2008.149195
   Storch MW, 2017, INDIAN J OPHTHALMOL, V65, P632, DOI 10.4103/ijo.IJO_818_16
   Wan Michael J, 2009, Retin Cases Brief Rep, V3, P86, DOI 10.1097/ICB.0b013e31815f3cd2
NR 10
TC 2
Z9 2
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD OCT
PY 2019
VL 67
IS 10
BP 1756
EP +
DI 10.4103/ijo.IJO_1597_18
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JA7FX
UT WOS:000488008300088
PM 31546555
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wong, TY
   Liew, G
   Mitchell, P
AF Wong, Tien Y.
   Liew, Gerald
   Mitchell, Paul
TI Clinical update: new treatments for age-related macular degeneration
SO LANCET
LA English
DT Article
ID RANIBIZUMAB; RISK
C1 Univ Melbourne, Ctr Eye Res, Melbourne, Vic 3002, Australia.
   Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
   Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
C3 University of Melbourne; National University of Singapore; Singapore
   National Eye Center; University of Sydney
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Mitchell, Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020; Liew,
   Gerald/AAB-6870-2022
OI Wong, Tien Yin/0000-0002-8448-1264; 
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   *GEN, 2007, SAF UPD LUC
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705
   *MAC AMD STUD GROU, 2007, PEG 1 YEAR SYST SAF, DOI DOI 10.1016/J.OPHTHA.2007.02.021
   *NAT EYE I, 2006, NIH STIM DEV TEST NE
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   *ROYAL COLL OPHTH, 2006, AMD INT GUID ROYAL C
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 18
TC 113
Z9 117
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 21
PY 2007
VL 370
IS 9583
BP 204
EP 206
DI 10.1016/S0140-6736(07)61104-0
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 194MG
UT WOS:000248347900010
PM 17658379
DA 2022-11-30
ER

PT J
AU Hopkins, J
   Walsh, A
   Chakravarthy, U
AF Hopkins, Jill
   Walsh, Alexander
   Chakravarthy, Usha
TI Fundus autofluorescence in age-related macular degeneration: An
   epiphenomenon?
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; IN-VIVO; GEOGRAPHIC ATROPHY; DYSTROPHY;
   DISEASE; LIPOFUSCIN; CLASSIFICATION; PATTERNS
C1 Queens Univ Belfast, Royal Hosp, Inst Clin Sci, Ctr Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
   Univ So Calif, Doheny Retina Inst, Los Angeles, CA 90089 USA.
C3 Queens University Belfast; University of Southern California
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Royal Hosp, Inst Clin Sci, Ctr Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Downes SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1373, DOI 10.1001/archopht.117.10.1373
   Downes SM, 2001, ARCH OPHTHALMOL-CHIC, V119, P96
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   FEHER J, 2005, NEUROBIOL AGING
   Holz FG, 2001, OPHTHALMOLOGE, V98, P10, DOI 10.1007/s003470170194
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   Rovati L, 2004, J BIOMED OPT, V9, P9, DOI 10.1117/1.1628241
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   von Ruckmann A, 1998, BRIT J OPHTHALMOL, V82, P346, DOI 10.1136/bjo.82.4.346
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
NR 27
TC 25
Z9 28
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2006
VL 47
IS 6
BP 2269
EP 2271
DI 10.1167/iovs.05-1482
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 048LQ
UT WOS:000237949000001
PM 16723433
DA 2022-11-30
ER

PT J
AU Zhou, H
   Chu, ZD
   Zhang, QQ
   Dai, YN
   Gregori, G
   Rosenfeld, PJ
   Wang, RKK
AF Zhou, Hao
   Chu, Zhongdi
   Zhang, Qinqin
   Dai, Yining
   Gregori, Giovanni
   Rosenfeld, Philip J.
   Wang, Ruikang K.
TI Attenuation correction assisted automatic segmentation for assessing
   choroidal thickness and vasculature with swept-source OCT
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FLUORESCEIN ANGIOGRAPHY;
   DIABETIC-RETINOPATHY; VOLUME; ENHANCEMENT; DENSITY; ATROPHY; IMAGES;
   TISSUE
AB Swept source optical coherence tomography (55-OCT) is being used more widely in clinical studies to investigate the choroid due to its deeper penetration under the retinal pigment epithelium and improved image quality compared with spectral domain OCT. However, automatic methods to reliably assess choroidal thickness and vasculature are still limited. This paper reports an approach that applies attenuation correction on SS-OCT structural scans to facilitate accurate automatic segmentation of the choroid and provides visualization of the choroidal vasculature without the necessity of OCT angiography. After attenuation correction, enhanced interlayer contrast at the choroidal-scleral interface was observed (from 0.13 +/- 0.05 to 0.29 +/- 0.10; P < 0.001). An algorithm that segmented the choroid from attenuation compensated B-scans achieved significantly higher accuracy when compared with an automated segmentation performed on regular OCT scans (91.8 +/- 3.7% vs.74.5 +/- 8.0%; P < 0.01). After attenuation correction, en film images of choroidal vessels were achieved with fewer artifacts from retinal vessels. Measurements of mean choroidal thickness and vessel density showed high repeatability. The attenuation correction assisted segmentation of the choroid and visualization of the choroidal vasculature will be helpful in studying the quantitative changes that occur in a myriad of diseases involving the choroid such as age-related macular degeneration, polypoidal choroidal vasculopathy, pathologic myopia, central serous chorioretinopathy, and inflammatory eye conditions. (C) 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Zhou, Hao; Chu, Zhongdi; Zhang, Qinqin; Dai, Yining; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98105 USA.
   [Dai, Yining] Shanxi Eye Hosp, Taiyuan, Shanxi, Peoples R China.
   [Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eve Inst, Miami, FL 33136 USA.
   [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98105 USA.
C3 University of Washington; University of Washington Seattle; Shanxi
   Medical University; Bascom Palmer Eye Institute; University of Miami;
   University of Washington; University of Washington Seattle
RP Wang, RKK (通讯作者)，Univ Washington, Dept Bioengn, Seattle, WA 98105 USA.; Wang, RKK (通讯作者)，Univ Washington, Dept Ophthalmol, Seattle, WA 98105 USA.
EM wangrk@uw.edu
RI Wang, Ruikang/L-3889-2019; Chu, Zhongdi/F-9604-2019; Dai,
   Yining/AAB-3658-2020; Zhou, Hao/U-7850-2017
OI Wang, Ruikang/0000-0001-5169-8822; Chu, Zhongdi/0000-0001-7430-5032;
   Zhou, Hao/0000-0003-0068-5102
FU National Eye Institute [R01EY024158, R01EY028753]; Salah Foundation;
   Research to Prevent Blindness; National Eye Institute Center Core Grant
   [P30EY014801]
FX National Eye Institute (R01EY024158, R01EY028753); the Salah Foundation;
   an unrestricted grant from the Research to Prevent Blindness; and the
   National Eye Institute Center Core Grant (P30EY014801) to the Department
   of Ophthalmology, University of Miami Miller School of Medicine.
CR Alonso-Caneiro D, 2013, BIOMED OPT EXPRESS, V4, P2795, DOI 10.1364/BOE.4.002795
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Baran U, 2016, J NEUROSCI METH, V270, P132, DOI 10.1016/j.jneumeth.2016.06.014
   Baran U, 2016, SCI REP-UK, V6, DOI 10.1038/srep21122
   Baran U, 2015, APPL OPTICS, V54, P6448, DOI 10.1364/AO.54.006448
   Beaton L, 2015, BIOMED OPT EXPRESS, V6, P1694, DOI 10.1364/BOE.6.001694
   BLOOME MA, 1980, VISION RES, V20, P1083, DOI 10.1016/0042-6989(80)90045-0
   Cauberg ECC, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3512206
   Chen CL, 2017, BIOMED OPT EXPRESS, V8, P1056, DOI 10.1364/BOE.8.001056
   Chen Q, 2015, OPT EXPRESS, V23, P8974, DOI 10.1364/OE.23.008974
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Chu ZD, 2017, INVEST OPHTH VIS SCI, V58
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dastiridou AI, 2017, OPHTHALMOLOGY, V124, P1186, DOI 10.1016/j.ophtha.2017.03.047
   Duan L, 2013, OPT EXPRESS, V21, P15787, DOI 10.1364/OE.21.015787
   Eilers PHC, 2006, COMPUT STAT DATA AN, V50, P61, DOI 10.1016/j.csda.2004.07.008
   Girard MJA, 2011, INVEST OPHTH VIS SCI, V52, P7738, DOI 10.1167/iovs.10-6925
   Haas P., INVEST OPHTHALMOL VI, V55, P2674
   HAYREH SS, 1969, BRIT J OPHTHALMOL, V53, P721, DOI 10.1136/bjo.53.11.721
   Huynh E, 2017, ASIA-PAC J OPHTHALMO, V6, P94, DOI 10.22608/APO.201698
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Kase S, 2016, EUR J OPHTHALMOL, V26, P158, DOI 10.5301/ejo.5000676
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kirby MA, 2018, PROC SPIE, V10474, DOI 10.1117/12.2291057
   Knighton RW, 2012, INVEST OPHTH VIS SCI, V53, P7412, DOI 10.1167/iovs.12-10515
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2016, RETINA-J RET VIT DIS, V36, P992, DOI 10.1097/IAE.0000000000000816
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Mazzaferri J, 2017, SCI REP-UK, V7, DOI 10.1038/srep42112
   Miller A. R., INVEST OPHTHALMOL VI, V58, P1499
   Nunes RP, 2015, OSLI RETINA, V46, P162, DOI 10.3928/23258160-20150213-17
   Ohsugi H, 2013, OPTOMETRY VISION SCI, V90, P599, DOI 10.1097/OPX.0b013e3182924017
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Scolaro L, 2012, BIOMED OPT EXPRESS, V3, P366, DOI 10.1364/BOE.3.000366
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Tomlins PH, 2005, J PHYS D APPL PHYS, V38, P2519, DOI 10.1088/0022-3727/38/15/002
   Vermeer KA, 2014, BIOMED OPT EXPRESS, V5, P322, DOI 10.1364/BOE.5.000322
   Vuong VS, 2016, AM J OPHTHALMOL, V169, P104, DOI 10.1016/j.ajo.2016.06.023
   Vupparaboina KK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24577-8
   Wang JC, 2017, AM J OPHTHALMOL, V184, P75, DOI 10.1016/j.ajo.2017.09.030
   Wang RKK, 2002, PHYS MED BIOL, V47, P2281, DOI 10.1088/0031-9155/47/13/307
   Xu CY, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2927464
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zhang QQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22017
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
NR 52
TC 38
Z9 39
U1 0
U2 7
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD DEC 1
PY 2018
VL 9
IS 12
BP 6067
EP 6080
DI 10.1364/BOE.9.006067
PG 14
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA HC5PQ
UT WOS:000451855300015
PM 31065413
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jelin, E
   Wisloff, T
   Moe, MC
   Heiberg, T
AF Jelin, Elma
   Wisloff, Torbjorn
   Moe, Morten C.
   Heiberg, Turid
TI Psychometric properties of the National Eye Institute Visual Function
   Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with
   neovascular age-related macular degeneration compared to a control
   population
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Age-related macular degeneration; Intravitreal injections; Anti-VEGF;
   Patient reported outcome measures; NEI-VFQ 25; Validation; Questionnaire
ID QUALITY-OF-LIFE; HEALTH; RELIABILITY; VERSION; VISION; VALIDATION;
   VALIDITY; DISEASE; RESPONSIVENESS; RANIBIZUMAB
AB Background Although visual acuity and optical coherence tomography (OCT) are most widely used as outcomes in treatment of neovascular age-related Macular Degeneration (nAMD), patient reported outcome measures are increasingly recognized. National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) was developed to capture the perceived visual function. Yet, evidence of psychometric performance in the target population is required. The aim of this study was to examine the psychometric properties of NEI-VFQ 25 in a Norwegian cohort of newly diagnosed nAMD patients followed with a Treat and Extend (T/E) protocol. Methods Patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection treatment according to a T/E protocol completed a Norwegian translation of NEI-VFQ 25, EuroQoL Health Questionnaire (EQ-5D), and Patient acceptable symptom state (PASS 5) at baseline, 3, 6 and 12 months. In addition, a control population completed the same questionnaires. Visual acuity was assessed with LogMar for best/treated eye. Validity testing comprised face validity by a 0-10 numeric rating scale about relevance of NEI-VFQ 25 as well as regression analyses and correlations between NEI-VFQ 25 and other relevant variables. Reliability was examined with Intraclass Correlation Coefficient (ICC) and Cronbach's alpha for internal consistency were performed. Responsiveness, discriminatory power and predictive value were also explored. Results Number of respondents at baseline, after 3, 6 and 12 months was 197, 186, 176 and 168, respectively. The control population comprised 26 individuals. Face validity of NEI-VFQ 25 had a mean (SD) of 7.8 (1.7) (n = 84). NEI-VFQ was significantly correlated to visual acuity and PASS 5 as well as EQ-5D at baseline. Reliability (ICC) of the overall and sub scores for the patients/controls ranged from 0.49-0.97/0.59-0.97. Cronbach's alpha was 0.61-0.85. Discriminatory power was confirmed by significant differences of the overall score between controls and patients (P < 0.001). NEI-VFQ 25 indicates responsiveness showing overall score improved significantly (P <= 0.001) from baseline to 3 months. NEI-VFQ 25, general health and visual acuity at baseline were the strongest predictors for how patients reported vision after 6 months follow-up. Conclusion NEI-VFQ 25 showed acceptable psychometric performance, which supports that the Norwegian version can be used to monitor patients treated for nAMD.
C1 [Jelin, Elma; Moe, Morten C.] Oslo Univ Hosp, Dept Ophthalmol, Postboks 4950 Nydalen, N-0424 Oslo, Norway.
   [Jelin, Elma; Moe, Morten C.] Univ Oslo, Inst Clin Med, Postboks 1171 Blindern, N-0318 Oslo, Norway.
   [Wisloff, Torbjorn] Norwegian Inst Publ Hlth, Postboks 222 Skoyen, N-0213 Oslo, Norway.
   [Wisloff, Torbjorn] Univ Oslo, Inst Hlth & Soc, Oslo, Norway.
   [Heiberg, Turid] Oslo Univ Hosp, Dept Reg Res Support, Sogn Arena, POB 4950, N-0424 Oslo, Norway.
   [Heiberg, Turid] Ostfold Univ Coll, Fac Hlth & Welf, POB 700, N-1757 Halden, Norway.
C3 University of Oslo; University of Oslo; Norwegian Institute of Public
   Health (NIPH); University of Oslo; University of Oslo; Ostfold
   University College
RP Jelin, E (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Postboks 4950 Nydalen, N-0424 Oslo, Norway.; Jelin, E (通讯作者)，Univ Oslo, Inst Clin Med, Postboks 1171 Blindern, N-0318 Oslo, Norway.
EM elmjel@ous-hf.no
RI Wisløff, Torbjørn/AFM-8289-2022
OI Wisløff, Torbjørn/0000-0002-7539-082X
FU Norwegian Nurses Organization
FX Research grant for PhD study is received from The Norwegian Nurses
   Organization and Division for Head, Neck and Reconstructive surgery.
CR Altman DG, 1991, PRACTICAL STAT MED R
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Clark MJ, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0104-5
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   COOK DJ, 1993, J CLIN EPIDEMIOL, V46, P529, DOI 10.1016/0895-4356(93)90125-K
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   de Vet HCW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2125
   Gnanasakthy A, 2017, VALUE HEALTH, V20, P420, DOI 10.1016/j.jval.2016.10.006
   GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N
   Heiberg T, 2008, ANN RHEUM DIS, V67, P967, DOI 10.1136/ard.2007.077503
   Hyman LG, 2005, OPHTHALMOLOGY, V112, P1505, DOI 10.1016/j.ophtha.2005.03.028
   Iyigun E, 2010, ACTA OPHTHALMOL, V88, pe115, DOI 10.1111/j.1755-3768.2009.01810.x
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kovac B, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0330-5
   Labiris G, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-4
   Lin JC, 2010, J EVAL CLIN PRACT, V16, P619, DOI 10.1111/j.1365-2753.2009.01253.x
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Matchar DB, 2006, AHRQ TECHNOLOGY ASSE
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Petrillo J, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0726-5
   Pettersen KI, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-28
   Revicki DA, 2007, QUAL LIFE RES, V16, P717, DOI 10.1007/s11136-006-9153-5
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Simao LM, 2008, ARQ BRAS OFTALMOL, V71, P540, DOI 10.1590/S0004-27492008000400014
   Solli O, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-18
   Sorensen MS, 2011, DAN MED BULL, V58
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stavem K, 2001, EPILEPSY RES, V44, P179, DOI 10.1016/S0920-1211(01)00201-7
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Weinberger M, 1996, J CLIN EPIDEMIOL, V49, P135, DOI 10.1016/0895-4356(95)00556-0
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 48
TC 6
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD AUG 14
PY 2019
VL 17
IS 1
AR 140
DI 10.1186/s12955-019-1203-0
PG 9
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA IQ5PW
UT WOS:000480805700001
PM 31412873
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI RATIONALE FOR COMBINATION THERAPY IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE angiogenesis; choroidal neovascularization; combination therapy;
   inflammation; normalization
ID TUMOR-ASSOCIATED MACROPHAGES; CHOROIDAL NEOVASCULARIZATION; VASCULATURE
AB Choroidal neovascularization (CNV) is typically characterized as an invasion of blood vessels, but it is important to recognize concurrent inflammatory and mesenchymal cell infiltration. A two component model of CNV can be thought to be composed of a vascular component and an extravascular component. Macular damage is possible through either. Given the redundancy and complex interaction among biologic systems involved in the production of CNV, it is likely that a monotherapeutic approach will not be fully effective. The vascular component of CNV arises through the orchestrated interaction of a number of growth factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which maintains pericyte viability. The vascular component of CNV can be selectively targeted with anti-VEGF and anti-PDGF drugs or nonselectively with such modalities as ionizing radiation. The extravascular component can be targeted selectively by inhibiting specific cytokines such as tumor necrosis factor a or nonselectively with antiinflammatory drugs such as corticosteroids. RETINA 29:S2-S4, 2009
C1 Vitreous Retina Macula Consultants, New York, NY 10458 USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants, 4600 Pk Ave,5th Floor, New York, NY 10458 USA.
EM rickspaide@yahoo.com
RI Spaide, Richard/ABD-7368-2020
CR Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867
   Schmid MC, 2008, METHOD ENZYMOL, V445, P343, DOI 10.1016/S0076-6879(08)03015-2
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   SPAIDE RF, 2007, MED RETINA ESSENTIAL, P90
NR 10
TC 1
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S2
EP S4
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700002
DA 2022-11-30
ER

PT J
AU Pallikaris, IG
   Kymionis, GD
   Ginis, HS
   Kounis, GA
   Christodoulakis, E
   Tsilimbaris, MK
AF Pallikaris, IG
   Kymionis, GD
   Ginis, HS
   Kounis, GA
   Christodoulakis, E
   Tsilimbaris, MK
TI Ocular rigidity in patients with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; SCLERAL RIGIDITY; RISK-FACTORS; MACULOPATHY; PREVALENCE;
   MEMBRANES; DISEASE
AB PURPOSE: To compare the ocular rigidity in vivo measurements of patients with age-related macular de, generation (AMD) and control subjects.
   DESIGN: Prospective comparative clinical study.
   METHODS: The pressure,volume relation and the ocular rigidity coefficient were compared among 32 patients with AMD (AMD group: 16 with neovascular and 16 with nonneovascular AMD) and 44 age,matched control patients (control group) who underwent operation for cataract. This was achieved by an injection of 200 mu l of a balanced salt solution (in steps of 4.5 mu l) through the limbus in the anterior chamber, while the intraocular pressure was monitored continually with a transducer, up to the limit of 30 mm Hg.
   RESULTS: The mean age (AMD group: 69.89 +/- 15.92 years vs control group: 65.28 +/- 12.34 years; P = .195), gender (AMD group: 13 female vs control group: 17 female; P = .513), eye's axial length (AMD group: 23.14 +/- 0.75 mm vs control group: 23.04 +/- 1.16 mm; P = .725) of patients with AMD and the healthy control subjects were comparable. No statistically significant difference in ocular rigidity measurements between patients with AMD and control subjects (AMD group: 0.0142 +/- 0.0077 mu l(-1) vs control group: 0.0125 +/- 0.0049 mu l(-1); P = .255) was found. When we examined separately the two subgroups of patients with AMD (neovascular and nonneovascular AMD), the average ocular rigidity measurements were higher in patients with neovascular AMD vs both control subjects and patients with nonneovascular AMD (neovascular AMD group: 0.0186 +/- 0.0078 mu l(-1) vs control group: 0.0125 +/- 0.0048 mu l(-1) [P = .014] vs nonneovascular AMD group: 0.0104 +/- 0.0053 mu l(-1) [P = .004]).
   CONCLUSIONS: Despite the limitations placed by the small sample of the examined cases, patients with neovascular AMD who are treated (with photodynamic therapy) have increased ocular rigidity measurements compared with patients with nonneovascular AMD and control patients.
C1 Univ Crete, Sch Med, Dept Ophthalmol, Inst Vis & Opt, Iraklion 71110, Crete, Greece.
C3 University of Crete
RP Kymionis, GD (通讯作者)，Univ Crete, Sch Med, Dept Ophthalmol, Inst Vis & Opt, Iraklion 71110, Crete, Greece.
EM kymionis@med.uoc.gr
OI Tsilimbaris, Miltiadis/0000-0002-0130-1150
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   DRANCE SM, 1960, ARCH OPHTHALMOL-CHIC, V63, P668
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedenwald J.S., 1937, AM J OPHTHALMOL, V20, P985, DOI [10.1016/s0002-9394(37)90425-2, DOI 10.1016/S0002-9394(37)90425-2, 10.1016/S0002-9394(37)90425-2]
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   JOHNSON MW, 1990, OPHTHALMOLOGY, V97, P190
   KAISERKUPFER MI, 1981, INVEST OPHTH VIS SCI, V20, P807
   Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SIMONE JN, 1990, OPHTHALMOLOGY, V97, P238
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 24
TC 47
Z9 53
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2006
VL 141
IS 4
BP 611
EP 615
DI 10.1016/j.ajo.2005.11.010
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030GG
UT WOS:000236621800001
PM 16564793
DA 2022-11-30
ER

PT J
AU Kivinen, N
AF Kivinen, Niko
TI The role of autophagy in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; ACTIVATED
   PROTEIN-KINASE; HEAT-SHOCK PROTEINS; UBIQUITIN-PROTEASOME PATHWAY;
   PROPHYLACTIC LASER TREATMENT; LIPID-PEROXIDATION PRODUCTS; TRANSCRIPTION
   FACTOR NRF2; NF-KAPPA-B; OXIDATIVE STRESS
C1 [Kivinen, Niko] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, Sch Med, Kuopio, Finland.
C3 University of Eastern Finland
RP Kivinen, N (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.; Kivinen, N (通讯作者)，Kuop Yliopistollinen Sairaala, PL 100, Kuopio 70029, Finland.
EM niko.kivinen@kuh.fi
CR Abdelmohsen K, 2009, EMBO J, V28, P1271, DOI 10.1038/emboj.2009.67
   Abdelmohsen K, 2008, P NATL ACAD SCI USA, V105, P20297, DOI 10.1073/pnas.0809376106
   AHLBERG J, 1982, LAB INVEST, V47, P523
   Aikio M, 2013, INVEST OPHTH VIS SCI, V54, P7450, DOI 10.1167/iovs.13-13039
   AKEO K, 1988, CURR EYE RES, V7, P961, DOI 10.3109/02713688809015141
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Amadio M, 2008, CURR PHARM DESIGN, V14, P2651, DOI 10.2174/138161208786264052
   Amadio M, 2009, J ALZHEIMERS DIS, V16, P409, DOI 10.3233/JAD-2009-0967
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2016, CURRENT CARE GUIDE L
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arjamaa O, 2012, BRIT J OPHTHALMOL, V96, P1153, DOI 10.1136/bjophthalmol-2012-301823
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   ARSTILA AU, 1969, VIRCHOWS ARCH B, V2, P85
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becker Silke, 2012, Cells, V1, P851, DOI 10.3390/cells1040851
   Behl T, 2015, LIFE SCI, V135, P131, DOI 10.1016/j.lfs.2015.06.017
   BELLHORN RW, 1981, INVEST OPHTH VIS SCI, V21, P771
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bonelli MA, 2004, EXP GERONTOL, V39, P423, DOI 10.1016/j.exger.2003.12.004
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407
   Braak H, 2011, J NEURAL TRANSM, V118, P809, DOI 10.1007/s00702-010-0508-2
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Caglayan AO, 2014, PEDIATR NEUROL, V51, P806, DOI 10.1016/j.pediatrneurol.2014.08.025
   CAHN RD, 1966, P NATL ACAD SCI USA, V55, P106, DOI 10.1073/pnas.55.1.106
   Calderwood SK, 2009, GERONTOLOGY, V55, P550, DOI 10.1159/000225957
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen CL, 2012, ACTA OPHTHALMOL, V90, pe389, DOI 10.1111/j.1755-3768.2012.02426.x
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ciechanover A, 2012, BBA-PROTEINS PROTEOM, V1824, P3, DOI 10.1016/j.bbapap.2011.03.007
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   da Silva KP, 2011, PROTEIN PEPTIDE LETT, V18, P132
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De los Rios P, 2006, P NATL ACAD SCI USA, V103, P6166, DOI 10.1073/pnas.0510496103
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Del Monte M A, 1980, Birth Defects Orig Artic Ser, V16, P327
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dokladny K, 2015, AUTOPHAGY, V11, P200, DOI 10.1080/15548627.2015.1009776
   Dokladny K, 2013, J BIOL CHEM, V288, P14959, DOI 10.1074/jbc.M113.462408
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Ferrington DA, 2012, PROG MOL BIOL TRANSL, V109, P75, DOI 10.1016/B978-0-12-397863-9.00003-1
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Geetha T, 2012, BIOMARKERS, V17, P99, DOI 10.3109/1354750X.2011.653986
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Goettsch S, 2002, FRONT BIOSCI-LANDMRK, V7, pA148, DOI 10.2741/goet
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gordon S, 2016, IMMUNITY, V44, P463, DOI 10.1016/j.immuni.2016.02.026
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gross-Jendroska M, 1998, AM J OPHTHALMOL, V126, P77, DOI 10.1016/S0002-9394(98)00061-0
   Guinez C, 2008, FASEB J, V22, P2901, DOI 10.1096/fj.07-102509
   Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317
   HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hurskainen M, 2005, FASEB J, V19, P1564, DOI 10.1096/fj.04-3101fje
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P
   Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Janer A, 2010, HUM MOL GENET, V19, P181, DOI 10.1093/hmg/ddp478
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jung T, 2009, MOL ASPECTS MED, V30, P191, DOI 10.1016/j.mam.2009.04.001
   Juuti-Uusitalo K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030089
   Kaarniranta K, 2005, MOL BRAIN RES, V137, P126, DOI 10.1016/j.molbrainres.2005.02.027
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta Kai, 2009, Duodecim, V125, P145
   Kaarniranta Kai, 2003, Duodecim, V119, P935
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khan AO, 2012, BRIT J OPHTHALMOL, V96, P890, DOI 10.1136/bjophthalmol-2011-301396
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002
   Kivinen N., 2014, J BIOCHEM, V2, P1
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klettner A, 2004, DRUG NEWS PERSPECT, V17, P299, DOI 10.1358/dnp.2004.17.5.829033
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner A., 2014, J BIOCH PHARM RES, V2, P8
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2014, NAT STRUCT MOL BIOL, V21, P336, DOI 10.1038/nsmb.2787
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Knaevelsrud H, 2010, FEBS LETT, V584, P2635, DOI 10.1016/j.febslet.2010.04.041
   Knobloch WH, 1971, J PEDIATR OPHTHALMOL, V8, P181
   Koh V, 2016, AM J OPHTHALMOL, V164, P69, DOI 10.1016/j.ajo.2016.01.005
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Korolchuk VI, 2009, AUTOPHAGY, V5, P862, DOI 10.4161/auto.8840
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107
   Lakshmanachetty S, 2016, EXP DERMATOL, V25, P346, DOI 10.1111/exd.12960
   Lee JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040361
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Luthra S, 2013, INDIAN J OPHTHALMOL, V61, P705, DOI 10.4103/0301-4738.124750
   Lytvynchuk L, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/934963
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MANNAGH J, 1973, INVEST OPHTH VISUAL, V12, P52
   Mannermaa Eliisa, 2007, Duodecim, V123, P2229
   Mannermaa E, 2009, PHARM RES-DORD, V26, P1785, DOI 10.1007/s11095-009-9890-6
   Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mei W., 2014, PLOS ONE, V9
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Miguel NCO, 2012, INVEST OPHTH VIS SCI, V53, P7904, DOI 10.1167/iovs.12-10283
   Mishra A, 2009, J BIOL CHEM, V284, P10537, DOI 10.1074/jbc.M806804200
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moseley PL, 1998, ANN NY ACAD SCI, V856, P206, DOI 10.1111/j.1749-6632.1998.tb08327.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029
   Nguyen TMB, 2009, J CELL MOL MED, V13, P3687, DOI 10.1111/j.1582-4934.2009.00722.x
   O'Brien CE, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0065-0
   O'Brien CE, 2014, J NEUROIMMUNE PHARM, V9, P285, DOI 10.1007/s11481-013-9519-8
   Ohlmann AV, 2005, CURR EYE RES, V30, P27, DOI 10.1080/02713680490894333
   Ojamo M, 2014, NAKOVAMMAREKISTERIN
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106
   Oskolkova OV, 2008, BLOOD, V112, P330, DOI 10.1182/blood-2007-09-112870
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Paimela T, 2011, PHARMACOL RES, V64, P501, DOI 10.1016/j.phrs.2011.05.027
   Paine MG, 2005, FEBS LETT, V579, P5029, DOI 10.1016/j.febslet.2005.08.010
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925
   Park D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21772
   Pascale A, 2012, CELL MOL LIFE SCI, V69, P501, DOI 10.1007/s00018-011-0810-7
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pascolini D, 2002, OPHTHAL EPIDEMIOL, V2004, P67
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Piri N, 2016, PROG RETIN EYE RES, V52, P22, DOI 10.1016/j.preteyeres.2016.03.001
   Qian J, 2011, RETINA-J RET VIT DIS, V31, P161, DOI 10.1097/IAE.0b013e3181e46ad8
   Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062
   RAKOCZY PE, 1994, INVEST OPHTH VIS SCI, V35, P4100
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rodgers KJ, 2009, REDOX REP, V14, P147, DOI 10.1179/135100009X392593
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   Salminen A, 2012, PROG NEUROBIOL, V96, P87, DOI 10.1016/j.pneurobio.2011.11.005
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758
   Sambrook J, 1990, MOL CLONING LAB MANU, P125
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schaljo B, 2009, J IMMUNOL, V183, P1197, DOI 10.4049/jimmunol.0803883
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schnichels S, 2013, BRIT J OPHTHALMOL, V97, P917, DOI 10.1136/bjophthalmol-2013-303130
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sniderman LC, 2000, AM J MED GENET, V90, P146, DOI 10.1002/(SICI)1096-8628(20000117)90:2<146::AID-AJMG11>3.0.CO;2-Z
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   TANAKA K, 1986, J BIOL CHEM, V261, P5197
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tokarz P, 2013, J BIOCH PHARM RES, V1, P106
   Tolentino MJ, 2014, EXPERT OPIN INV DRUG, V22, P1
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   van Doorn WG, 2013, AUTOPHAGY, V9, P1922, DOI 10.4161/auto.26275
   van Horssen J, 2002, BRAIN PATHOL, V12, P456
   Viana R, 2008, BIOCHEM BIOPH RES CO, V369, P964, DOI 10.1016/j.bbrc.2008.02.126
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Vladan Bajic, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P24
   Wang AM, 2013, NAT CHEM BIOL, V9, P112, DOI [10.1038/NCHEMBIO.1140, 10.1038/nchembio.1140]
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Xu W, 2010, MOL BIOL+, V44, P585, DOI 10.1134/S0026893310040138
   Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414
   Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088
   Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Ylikarppa R, 2003, FASEB J, V17, P2257, DOI 10.1096/fj.02-1001fje
   Yu Q, 2001, MOL VIS, V7, P48
   Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Zucal C, 2015, CURR DRUG TARGETS, V16, P499, DOI 10.2174/1389450116666150223163632
NR 314
TC 9
Z9 9
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD APR
PY 2018
VL 96
SU A110
SI SI
BP 1
EP 50
DI 10.1111/aos.13753
PG 50
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC1IK
UT WOS:000429534600001
PM 29633521
OA Bronze
DA 2022-11-30
ER

PT J
AU Klein, BEK
   Howard, KP
   Iyengar, SK
   Sivakumaran, TA
   Meyers, KJ
   Cruickshanks, KJ
   Klein, R
AF Klein, Barbara E. K.
   Howard, Kerri P.
   Iyengar, Sudha K.
   Sivakumaran, Theru A.
   Meyers, Kristin J.
   Cruickshanks, Karen J.
   Klein, Ronald
TI Sunlight Exposure, Pigmentation, and Incident Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE sunlight exposure; hair color; eye color; age-related macular
   degeneration; pigmentation
ID BEAVER-DAM-EYE; SKIN SUN SENSITIVITY; VISUAL-ACUITY; IRIS COLOR;
   RISK-FACTORS; MACULOPATHY; POPULATION; GENETICS; MONKEY; PERIOD
AB PURPOSE. Examine potential effects of sunlight exposure, hair color, eye color, and selected gene single-nucleotide polymorphisms (SNPs) on incidence of AMD.
   METHODS. Subjects participated in up to five examinations over a 20-year period. Eye color, self-reported hair color as a teenager, and sunlight exposure were ascertained at the baseline examination. Presence and severity of AMD and its lesions were determined via fundus photographs. Genetic data were available on a subset of participants. The SNPs CFH Y402H rs1061170 and ARMS2 A69S rs10490924 were used to analyze genetic risk of AMD; OCA2 rs4778241 and HERC2 rs12913832 represented genetic determinants of eye color.
   RESULTS. Incidence of early AMD was higher in blond/red-haired persons compared with brown/black-haired persons (hazard ratio [HR] 1.25, P = 0.02) and in persons with high sun exposure in their thirties (HR 1.41, P = 0.02). However, neither was significant after adjustment for multiple comparisons. Eye (HR 1.36, P = 0.006) and hair color (HR 1.42, P = 0.003) were associated with incidence of any retinal pigmentary abnormalities (RPAs). Both remained significant after adjustment for multiple comparisons. Neither presence of alleles for light-colored eyes nor those associated with high risk of late AMD altered the association of eye or hair color with early AMD. None of the characteristics studied were significantly associated with late AMD.
   CONCLUSIONS. Modest associations of eye color, hair color, and HERC2 genotype with any RPAs were found. Genes for AMD did not affect these associations. Eye color phenotype was more strongly associated with outcomes than HERC2 or OCA2 genotype.
C1 [Klein, Barbara E. K.; Howard, Kerri P.; Meyers, Kristin J.; Cruickshanks, Karen J.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
   [Cruickshanks, Karen J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Case Western Reserve University; Cincinnati
   Children's Hospital Medical Center; University of Wisconsin System;
   University of Wisconsin Madison
RP Klein, BEK (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinb@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X
FU National Institutes of Health [EY06594]; National Eye Institute;
   Research to Prevent Blindness, New York, New York
FX Supported by National Institutes of Health Grant EY06594 (BEKK, RK). The
   National Eye Institute provided funding for entire study, including
   collection and analyses of data. Additional support was provided by an
   unrestricted grant from Research to Prevent Blindness, New York, New
   York. The content is solely the responsibility of the authors and does
   not necessarily reflect the official views of the National Eye Institute
   or the National Institutes of Health.
CR BORGES J, 1990, ARCH OPHTHALMOL-CHIC, V108, P727, DOI 10.1001/archopht.1990.01070070113047
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Donnelly MP, 2012, HUM GENET, V131, P683, DOI 10.1007/s00439-011-1110-x
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Gao FY, 2001, J AM STAT ASSOC, V96, P127, DOI 10.1198/016214501750332749
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1991, NTIS PUBLICATION, V91-184267
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mogk L, 1999, MACULAR DEGENERATION, P88
   RITCHEY CL, 1970, AM J OPHTHALMOL, V70, P491
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Scholl HPN, 2007, MOL VIS, V13, P196
   Singer J. D., 2003, APPL LONGITUDINAL DA, DOI 10.1093/acprof:oso/9780195152968.001.0001
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sturm RA, 2004, TRENDS GENET, V20, P327, DOI 10.1016/j.tig.2004.06.010
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   TSO MOM, 1973, INVEST OPHTH VISUAL, V12, P17
   Wakamatsu K, 2012, PIGM CELL MELANOMA R, V25, P434, DOI 10.1111/j.1755-148X.2012.01011.x
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 41
TC 23
Z9 24
U1 0
U2 26
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2014
VL 55
IS 9
BP 5855
EP 5861
DI 10.1167/iovs.14-14602
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DX
UT WOS:000343146900051
PM 25125603
OA Green Published
DA 2022-11-30
ER

PT J
AU Mauschitz, MM
   Fonseca, S
   Chang, P
   Gobel, AP
   Fleckenstein, M
   Jaffe, GJ
   Holz, FG
   Schmitz-Valckenberg, S
AF Mauschitz, Matthias M.
   Fonseca, Sofia
   Chang, Petrus
   Goebel, Arno P.
   Fleckenstein, Monika
   Jaffe, Glenn J.
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
CA GAP Study Grp
TI Topography of Geographic Atrophy in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE PATTERNS; RETINAL-PIGMENT EPITHELIUM; RETICULAR
   DRUSEN; VISUAL-LOSS; MACULOPATHY; VULNERABILITY; EPIDEMIOLOGY;
   ENLARGEMENT; DYSFUNCTION; PROGRESSION
AB PURPOSE. To determine the topographic distribution and progression of geographic atrophy (GA) in patients with AMD.
   METHODS. Fundus autofluorescence images (excitation 488, emission 500-700 nm) from 413 eyes of 413 subjects (median age, 77.0 years; inter quartile range [IQR], 72.0-82.0 years) of the Geographic Atrophy Progression (GAP) study were retrospectively analyzed. Using a modified Early Treatment Diabetic Retinopathy Study grid to divide the posterior pole into nine different subfields plus periphery, the localization, size, and progression of atrophic patches were determined. Subfields, zones (center, inner and outer), and slices (nasal, temporal, inferior, superior) were compared using the Friedman test.
   RESULTS. The center and inner zones were involved in almost all eyes (>95%), while atrophy was less common in the outer zone subfields (76%). Inner zone atrophy size (median 4.00 mm(2)) and progression rate (0.67 mm(2)/year) were significantly greater than in the outer zone (0.60 mm(2) and 0.42 mm(2)/year; P < 0.001). There was a trend toward outer zone subfield and periphery involvement with increasing total size of atrophy. In addition, the superior outer subfield was significantly more affected by atrophy as compared with the other three outer subfields of the grid (P < 0.001).
   CONCLUSIONS. Distribution and progression of existing GA patches depended both on the eccentricity from the center and total GA size. Central macular areas appeared most susceptible for the occurrence and expansion of GA. Refined analysis of distribution and directional spread is important to understand the natural history of the disease. This information will likely be helpful to design interventional GA clinical trials and associated anatomical outcome measures. (ClinicalTrials. gov number, NCT00599846.) (Invest Ophthalmol Vis Sci. 2012;53:4932-4939) DOI:10.1167/iovs.12-9711
C1 [Mauschitz, Matthias M.; Fonseca, Sofia; Chang, Petrus; Goebel, Arno P.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Durham, NC USA.
C3 University of Bonn; Duke University
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; Fonseca,
   Sofia/0000-0001-5365-6220; Fleckenstein, Monika/0000-0001-8321-8037
FU Alcon Laboratories Inc., Fort Worth, Texas; Geographic Atrophy
   Progression (GAP)
FX Supported by Alcon Laboratories Inc., Fort Worth, Texas. The Geographic
   Atrophy Progression (GAP) Study was funded, designed, and conducted by
   the Sponsor. The data presented is an additional analysis that was
   conducted without extra funding by the sponsor. The manuscript was
   reviewed and approved by the Sponsor.
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHUANG EL, 1987, EYE, V1, P120, DOI 10.1038/eye.1987.18
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fleckenstein M, 2009, INVEST OPHTH VIS SCI, V51, P637
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Rohrschneider K, 1998, OPHTHALMOLOGE, V95, P706, DOI 10.1007/s003470050339
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Trauzettel-Klosinski S, 2010, J NEURO-OPHTHALMOL, V30, P73, DOI 10.1097/WNO.0b013e3181ce7e8f
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 32
TC 45
Z9 45
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2012
VL 53
IS 8
BP 4932
EP 4939
DI 10.1167/iovs.12-9711
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 983DA
UT WOS:000307096400072
PM 22661483
DA 2022-11-30
ER

PT J
AU Chang, MA
   Kapre, A
   Kaufman, D
   Kardatzke, DR
   Rabena, M
   Patel, S
   Bobbala, A
   Gune, S
   Fung, A
   Wallenstein, G
AF Chang, Margaret A.
   Kapre, Audrey
   Kaufman, Derrick
   Kardatzke, David R.
   Rabena, Melvin
   Patel, Shienal
   Bobbala, Ashwini
   Gune, Shamika
   Fung, Anne
   Wallenstein, Gene
TI Patient Preference and Treatment Satisfaction With a Port Delivery
   System for Ranibizumab vs Intravitreal Injections in Patients With
   Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID THERAPY; REGIMEN
AB IMPORTANCE The port delivery system (PDS) with ranibizumab has demonstrated noninferior and equivalent efficacy compared with monthly intravitreal injections of ranibizumab, an anti-vascular endothelial growth factor (VEGF) agent, in patients with neovascular age-related macular degeneration (nAMD), but evaluating patient preference is important to help inform clinical decision-making.
   OBJECTIVE Evaluate treatment satisfaction for ranibizumab delivered via PDS vs intravitreal injections as well as patient preference among those assigned to PDS.
   DESIGN, SETTING, AND PARTICIPANTS Archway was a phase 3 randomized active-comparator open-label clinical trial conducted at 78 sites in the US. Patients 50 years and older with nAMD diagnosed within 9 months of screening with a documented response to anti-VEGF therapy were included. Of 619 patients screened, 418 were enrolled; 415 were included in the primary analysis and 234 were included in the secondary exploratory analysis. The Archway study ran from September 12, 2019, through primary readout on May 22, 2020.
   INTERVENTIONS Patients were randomized 3:2 to PDS with ranibizumab, 100 mg/mL, with fixed refill exchanges every 24 weeks or intravitreal ranibizumab injections, 0.5 mg, every 4 weeks.
   MAIN OUTCOMES AND MEASURES Treatment satisfaction was measured using the Macular Disease Treatment Satisfaction Questionnaire in the PDS and intravitreal injection arms at week 40. Patient preference was assessed using the content-validated PDS Patient Preference Questionnaire (PPPQ), which measured the proportion of patients in the PDS arm with monthly monitoring who preferred treatment with the PDS at week 40 over previous intravitreal injections or concurrent fellow-eye injections. Both outcomes were exploratory end points.
   RESULTS The mean (SD) age of participants at baseline was 75.0 (7.9) years; 234 participants (59%) were women and 162 (41%) were men. At week 40, differences in overall treatment satisfaction scores were minimal for the PDS and intravitreal injection arms (mean, 68.0; 95% CI, 67.4-68.6: n = 237 and mean, 66.1; 95% CI, 64.9-67.3; n = 159, respectively: difference, 1.9; 95% CI, 0.7-3.1). A total of 234 of 248 patients (94.4%) in the PDS arm were included in the PPPQ analysis. At week 40, almost all patients in the PDS arm preferred treatment via PDS (218 of 234 [93.2%]) vs previous intravitreal injections (3 of 234 [1.3%]), including172 of 234 (73.5%) with a very strong preference for the PDS. In patients who received concurrent fellow-eye injections (n = 78), 72 (92.3%) preferred the PDS.
   CONCLUSIONS AND RELEVANCE Although PDS treatment was preferred by almost all patients assigned to PDS over previous intravitreal injections, both delivery methods have high treatment satisfaction. These findings provide further evidence for the PDS as a meaningful alternative treatment option for patients with nAMD.
C1 [Chang, Margaret A.] Retinal Consultants, Sacramento, CA USA.
   [Kapre, Audrey; Kaufman, Derrick; Kardatzke, David R.; Rabena, Melvin; Patel, Shienal; Bobbala, Ashwini; Gune, Shamika; Fung, Anne; Wallenstein, Gene] Genentech Inc, 1 DNAWay, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Wallenstein, G (通讯作者)，Genentech Inc, 1 DNAWay, San Francisco, CA 94080 USA.
EM wallensg@gene.com
FU Genentech, a member of the Roche Group
FX Funding for this study was provided by Genentech, a member of the Roche
   Group.
CR [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   [Anonymous], ICH HARM GUID INT AD
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Bhagat D, 2020, CLIN OPHTHALMOL, V14, P2975, DOI 10.2147/OPTH.S273564
   Braithwaite T, 2019, PATIENT-RELAT OUTCOM, V10, P9, DOI 10.2147/PROM.S162802
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dean S, 2017, BRIT J OPHTHALMOL, V101, P700, DOI 10.1136/bjophthalmol-2016-309955
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Ehlken C, 2020, GRAEF ARCH CLIN EXP, V258, P2077, DOI 10.1007/s00417-020-04798-2
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Lindhiem O, 2014, CLIN PSYCHOL REV, V34, P506, DOI 10.1016/j.cpr.2014.06.002
   McClard CK, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2020-000669
   McNamara M, 2020, PATIENT PREFER ADHER, V14, P781, DOI 10.2147/PPA.S239196
   Metz M, 2021, SUPPORT CARE CANCER, V29, P6633, DOI 10.1007/s00520-021-06230-9
   Mitchell J, 2018, J PATIENT-REP OUTCOM, V2, DOI 10.1186/s41687-018-0031-z
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Marin BP, 2022, EUR J OPHTHALMOL, V32, P385, DOI 10.1177/11206721211001716
   Pivot X, 2013, LANCET ONCOL, V14, P962, DOI 10.1016/S1470-2045(13)70383-8
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rummel M, 2017, ANN ONCOL, V28, P836, DOI 10.1093/annonc/mdw685
   Tschosik E, 2019, INVEST OPHTH VIS SCI, V60
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
NR 29
TC 3
Z9 3
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2022
VL 140
IS 8
BP 771
EP 778
DI 10.1001/jamaophthalmol.2022.1091
EA JUN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3Y5TL
UT WOS:000812370800005
PM 35708706
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Kim, M
   Park, YG
   Roh, YJ
AF Kim, Minhee
   Park, Young Gun
   Roh, Young-Jung
TI One-Year Functional and Anatomical Outcomes After Selective Retina
   Therapy With Real-Time Feedback-Controlled Dosimetry in Patients With
   Intermediate Age-Related Macular Degeneration: A Pilot Study
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE drusen; intermediate age-related macular degeneration; real-time
   feedback-controlled dosimetry; retinal sensitivity; selective retina
   therapy
ID SIMPLIFIED SEVERITY SCALE; PIGMENT EPITHELIUM; DRUSEN; RPE; SRT;
   VARIABILITY; NANOSECOND; MORPHOLOGY; DISEASES; EYES
AB Background and Objectives This pilot study sought to evaluate changes in macular function and drusen volume (DV) after selective retina therapy (SRT) in patients with intermediate age-related macular degeneration (iAMD). Study Design/Materials and Methods Twenty participants with bilateral iAMD were included in this prospective interventional case series study. After titrating pulse energy by real-time feedback-controlled dosimetry, SRT with a wavelength of 527 nm was applied around the macula of one eye of each patient. Changes in best-corrected visual acuity (BCVA), DV within the central 5-mm ring (C5), and retinal sensitivity (RS) of the SRT-treated eyes (treated eyes) and untreated fellow eyes (untreated eyes) were evaluated at baseline and then at 3, 6, 9, and 12 months after treatment using linear mixed models. Results The mean BCVA did not change significantly between baseline and 12 months in both treated and untreated eyes (P = 0.06,P = 0.24, respectively), whereas the BCVA increase rate was faster for treated than for untreated eyes at the 12-month visit (-0.072 logMAR; 95% confidence interval [CI], -0.085 to -0.059 logMAR;P = 0.006). The mean cube root transformation of DV (cube root DV) within C5 in the untreated eyes increased significantly from 0.278 +/- 0.115 at baseline to 0.295 +/- 0.132 mm (P = 0.027) at 12 months, whereas the cube root DV change in treated eyes was not significant (P = 0.553). The rate of increase in the cube root DV was lower in treated than in untreated eyes at the 12-month visit (-0.016 mm; 95% CI, -0.018 to -0.011 mm;P = 0.015). The mean RS was increased from 22.49 +/- 2.40 dB to 24.09 +/- 2.19 dB (P < 0.001) in the treated eyes, whereas the change of mean RS in the untreated eyes was not significant at the 12-month visit (P = 0.18). The treated eyes had a higher rate of increase in RS than untreated eyes at the 12-month visit (1.012 dB; 95% CI, 0.776-1.251 dB;P = 0.037). The RS change was significantly associated with the interaction between SRT treatment and time (P = 0.028), whereas it was not associated with cube root DV change (P = 0.106). No SRT-related adverse effects were observed in all participants during the 1-year follow-up. Conclusion Since SRT improved the mean RS and reduced the rate of change in drusen load in the treated eyes, as compared to the untreated eyes, SRT might slow the progression of iAMD. However, further large randomized clinical trials are necessary to confirm the efficacy of SRT for iAMD. Lasers Surg. Med. (c) 2020 Wiley Periodicals LLC
C1 [Kim, Minhee; Roh, Young-Jung] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Yeouido St Marys Hosp, Coll Med, 10,63 Ro, Seoul 07345, South Korea.
   [Park, Young Gun] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, 222 Banpo Daero, Seoul 06591, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Yeouido St Marys Hosp, Coll Med, 10,63 Ro, Seoul 07345, South Korea.; Roh, YJ (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Yeouido St Marys Hosp, Coll Med, 63 Ro 10, Seoul 07345, South Korea.
EM youngjungroh@hanmail.net
OI ROH, YOUNG JUNG/0000-0001-7294-6813
FU South Korean Government's Ministry of Trade, Industry, and Energy
   [M000004912-00192937]
FX The authors would like to thank Mr. Hyung Min Kim of the Department of
   Medical Informatics, College of Medicine, The Catholic University of
   Korea, Seoul, Republic of Korea, for his assistance in statistical data
   analysis. This study was supported by a grant from the South Korean
   Government's Ministry of Trade, Industry, and Energy
   (M000004912-00192937).
CR BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   Brinkmann R, 2006, OPHTHALMOLOGE, V103, P839, DOI 10.1007/s00347-006-1416-6
   Chhablani J, 2018, SURV OPHTHALMOL, V63, P307, DOI 10.1016/j.survophthal.2017.09.008
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Framme C, 2004, LASER SURG MED, V34, P206, DOI 10.1002/lsm.20022
   Framme C, 2002, BRIT J OPHTHALMOL, V86, P1099, DOI 10.1136/bjo.86.10.1099
   Framme C, 2008, LASER SURG MED, V40, P616, DOI 10.1002/lsm.20685
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Han RFC, 2017, CLIN EXP OPHTHALMOL, V45, P489, DOI 10.1111/ceo.12907
   Kang S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002524
   Kim HD, 2016, INVEST OPHTH VIS SCI, V57, P3486, DOI 10.1167/iovs.16-19508
   Kim HD, 2015, INVEST OPHTH VIS SCI, V56, P122, DOI 10.1167/iovs.14-15132
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee H, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2804078
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Minhee K, 2018, GRAEF ARCH CLIN EXP, V256, P1639, DOI 10.1007/s00417-018-4067-9
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Morales MU, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.6
   Neumann J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896969
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Park YG, 2017, GRAEF ARCH CLIN EXP, V255, P1375, DOI 10.1007/s00417-017-3672-3
   Park YG, 2016, GRAEF ARCH CLIN EXP, V254, P1703, DOI 10.1007/s00417-015-3262-1
   Park YG, 2014, CLIN EXP OPHTHALMOL, V42, P846, DOI 10.1111/ceo.12342
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Richert E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23163
   Roider J, 2000, BRIT J OPHTHALMOL, V84, P40, DOI 10.1136/bjo.84.1.40
   Roider J, 1999, GRAEF ARCH CLIN EXP, V237, P45, DOI 10.1007/s004170050193
   Roider J, 2010, GRAEF ARCH CLIN EXP, V248, P1263, DOI 10.1007/s00417-010-1356-3
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schuele G, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2136327
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seifert E, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.11.115002
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yasui A, 2017, GRAEF ARCH CLIN EXP, V255, P243, DOI 10.1007/s00417-016-3441-8
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 47
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD APR
PY 2021
VL 53
IS 4
BP 499
EP 513
DI 10.1002/lsm.23305
EA AUG 2020
PG 15
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology; Surgery
GA RN3CX
UT WOS:000555540600001
PM 32757324
DA 2022-11-30
ER

PT J
AU Neubauer, AS
   Holz, FG
   Sauer, S
   Wasmuth, T
   Hirneiss, C
   Kampik, A
   Schrader, W
AF Neubauer, Aljoscha S.
   Holz, Frank G.
   Sauer, Stefan
   Wasmuth, Timo
   Hirneiss, Christoph
   Kampik, Anselm
   Schrader, Wolfgang
TI Cost-Effectiveness of Ranibizumab for the Treatment of Neovascular
   Age-Related Macular Degeneration in Germany: Model Analysis From the
   Perspective of Germany's Statutory Health Insurance System
SO CLINICAL THERAPEUTICS
LA English
DT Article
DE choroidal neovascularization; cost utility; macular degeneration;
   value-based medicine; ranibizumab; quality-adjusted life-year; QALY;
   Germany
ID QUALITY-OF-LIFE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY;
   CONTRAST SENSITIVITY; RESOURCE UTILIZATION; UTILITY ANALYSIS; BURDEN;
   VERTEPORFIN; CARE; BLINDNESS
AB Background: In clinical trials, ranibizumab has been associated with stabilization and even improvement of visual acuity among patients with neovascular age-related macular degeneration (AMD), but its use is also associated with considerable costs.
   Objective: The aim of this work was to compare ranibizumab with best supportive care or photodynamic therapy (PDT) for AMD by means of economic cost-utility and cost-effectiveness analysis from the perspective of Germany's Statutory Health Insurance System.
   Methods: Visual acuity data from the Anti-VEGF (vascular endothelial growth factor) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) studies were applied, based on a ranibizumab dose of 0.5 mg. A Markov model simulated visual acuity and costs over 10 years (discounted at 3%). The base-case analysis assumed 5 injections per year over 2 years. Treatment costs were based on year-2008 euros (using German prices) and recommendations for procedure reimbursement from a public health insurance perspective. To assess cost-effectiveness, costs per year of legal blindness avoided (ie, vision-year gained [VYG]) and per quality-adjusted life-year (QALY) were calculated. The model assumed each patient's affected eye had better sight than the other eye, and the 2 comparators against which ranibizumab treatment was assessed were best supportive care and PDT. The robustness of the results was investigated in a univariate sensitivity analysis of all relevant parameters and a multivariate probabilistic sensitivity analysis. The multivariate 95% CIs for incremental cost-effectiveness ratios were obtained by conducting 1000 Monte Carlo simulations.
   Results: Compared with best supportive care, costs per VYG for ranibizumab were (sic)6767 in occult choroidal neovascularization (CNV) and (sic)6020 in minimally classic CNV. In classic CNV, costs were (sic)7341VYG for ranibizumab compared with supportive care and (sic)778NYG for ranibizumab compared with PDT. Costs per QALY for ranibizumab treatment for occult, minimally classic CNV, and classic CNV were (sic)22,320, (sic)22,538, and (sic)25,036, respectively, and (sic)3294 for classic CNV compared with PDT Results were sensitive to the cost of blindness, injection frequency, and duration. The multivariate 95% CIs for the incremental costeffectiveness ratios were (sic)14,438 to (sic)41,110/QALY for occult CNV, (sic)13,463 to (sic)43,614/QALY for minimally classic CNV, and (sic)15,634 to (sic)51,106/QALY for classic CNV.
   Conclusion: In this model analysis using costs and clinical trial data from Germany, ranibizumab appeared to be a cost-effective treatment option for all angiographic subtypes of neovascular AMD, from the perspective of Germany's Statutory Health Insurance System. (Chn Ther. 2010;32:1343-1356) (C) 2010 Excerpta Medica Inc.
C1 [Neubauer, Aljoscha S.; Hirneiss, Christoph; Kampik, Anselm] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Sauer, Stefan; Wasmuth, Timo] Novartis Pharma GmbH, Nurnberg, Germany.
   [Schrader, Wolfgang] Maximilians Augenklin Nurnberg, Nurnberg, Germany.
   [Schrader, Wolfgang] Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
C3 University of Munich; University of Bonn; Novartis; University of
   Wurzburg
RP Neubauer, AS (通讯作者)，Univ Munich, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM aljoscha.neubauer@med.uni-muenchen.de
FU Novartis Pharma GmbH
FX The update and revision of the model adaptation was performed by Andreas
   Beivers, PhD, Institut fur Gesundheitsokonomik Munchen, with funding
   from Novartis Pharma GmbH. The cost-utility model was also provided by
   Novartis. The authors have indicated that they have no other conflicts
   of interest regarding the content of this material. Dr. Neubauer had
   full access to the model and adaptation, and reviewed their structure
   and accuracy.
CR [Anonymous], 2009, AV BEV PACK INS
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2009, CURR OPIN OPHTHALMOL, V20, P147, DOI 10.1097/ICU.0b013e32832adf0c
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2008, CURR OPIN OPHTHALMOL, V19, P202, DOI 10.1097/ICU.0b013e3282fc9c35
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brown MM, 2009, CURR OPIN OPHTHALMOL, V20, P188, DOI 10.1097/ICU.0b013e328329cd59
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   BUSBEE BG, 2003, RETINA, V23, P297
   Busbee BG, 2003, RETINA, V23, P443
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   *EYET INC, 2008, MAC PEG SOD INJ PACK
   *FED OFF STAT, GERM DEATH TABL 2005
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   *GEN INC, 2010, LUC RAN INJ PACK INS
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Hirneiss C, 2003, OPHTHALMOLOGE, V100, P1091, DOI 10.1007/s00347-003-0884-1
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Knauer C, 2006, OPHTHALMOLOGE, V103, P735, DOI 10.1007/s00347-006-1411-y
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Marback RF, 2007, CLINICS, V62, P573, DOI 10.1590/S1807-59322007000500007
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Meyer CH, 2008, OPHTHALMOLOGE, V105, P143, DOI 10.1007/s00347-008-1701-7
   Meyer CH, 2008, OPHTHALMOLOGE, V105, P125, DOI 10.1007/s00347-008-1702-6
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   PFAU N, 2000, EPIDEMIOLOGY SOCIOEC
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *XRAT, 2010 EUR 1 USD
   GERMAN DRUG INFORM R
   KASSERNARZTLICHE BUN
NR 51
TC 23
Z9 24
U1 0
U2 4
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD JUL
PY 2010
VL 32
IS 7
BP 1343
EP 1356
DI 10.1016/j.clinthera.2010.07.010
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 637PF
UT WOS:000280829800011
PM 20678682
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
AF Schmidt-Erfurth, Ursula
TI Clinical safety of ranibizumab in age-related macular degeneration
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   Lucentis; ranibizumab; safety; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; ARTERIAL
   THROMBOEMBOLIC EVENTS; PIGMENT EPITHELIAL TEARS; CORONARY-HEART-DISEASE;
   CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTIONS; RISK;
   BEVACIZUMAB; VEGF
AB Importance of the field: Clinical safety of pharmaceutical products in the elderly is vital because of their increased risk of cardiac and other adverse events.
   Areas covered in this review: Search of the Medline database, including articles and abstracts from 1984 to 2009.
   What the reader will gain: Knowledge of ocular and systemic risks: The rate of endophthalmitis was 0.05% per injection (MARINA) and <0.1% per injection (ANCHOR), rates confirmed in a retrospective analysis of 14,320 injections. Moderate increases in intraocular pressure were transient, and incidences of intraocular inflammation were rarely serious. Systemic arterial thromboembolic events occurred in 4.6 and 0% of ranibizumab-treated patients and in 3.8 and 0% of sham-treated patients in MARINA (2 years) and PIER (1 year), respectively. In SAILOR, there was a numerically higher rate of cerebrovascular stroke with 0.5 mg ranibizumab compared with 0.3 mg ranibizumab (1.2 vs 0.7%), which was a non-statistically significant trend in patients with a history of stroke.
   Take home message: Although further studies to investigate the risk of stroke with ranibizumab therapy are required, repeated intravitreal ranibizumab was well tolerated and not associated with clinically significant safety risks during up to 2 years of treatment.
C1 Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
FU Novartis Pharma AG; Novartis; Bayer Healthcare; Alcon; Heidelberg
   Engineering; Carl Zeiss Meditec; Novartis Pharmaceuticals Corp.
FX Novartis Pharma AG provided the financial support for most of the
   studies of ranibizumab worldwide, but did not provide the author with
   financial support for this manuscript. S Ryan from Chameleon
   Communications International provided the author with writing support
   with funding from Novartis. U Schmidt-Erfurth has received research
   support from Novartis Pharma AG, Bayer Healthcare, Alcon, Heidelberg
   Engineering and Carl Zeiss Meditec. U Schmidt-Erfurth is a consultant
   Alcon Laboratories, Bayer Healthcare, Carl Zeiss Meditec, Heidelberg
   Engineering, Novartis Pharmaceuticals Corp., and Regeneron. She has
   received lecture fees from Bayer Healthcare, Carl Zeiss Meditec and
   Novartis Pharmaceuticals Corp., as well as grant support from Heidelberg
   Engineering.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   BAILEY CC, 2009, INVEST OPHTHALMOL VI, V50
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BOYER DS, 2008, AM AC OPHTH AAO 2008
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BUGGAGE RR, 2006, INVEST OPLITHALMOL V, V47
   BUSBEE BG, 2009, INVEST OPHTHALMOL VI, V50
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHEN E, 2009, INVEST OPHTHALMOL VI, V50
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Coote MA, 2008, J GLAUCOMA, V17, P517, DOI 10.1097/IJG.0b013e31815f5345
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   DRISCOLL SJ, 2009, INVEST OPHTHALMOL VI, V50
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   FUNK M, 2009, OPHTHALMOLO IN PRESS
   Galazios G, 2009, J MATERN-FETAL NEO M, V22, P371, DOI 10.1080/14767050802645035
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN INC, 2007, LETT HEALTHC PROV
   *GEN INC, 2008, AV BEV PRESCR INF
   GEORGALAS I, 2009, CLIN RISK MANAG, V5, P17
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   HAUGHNEY PC, 2005, INVEST OPHTH VIS SCI, V46, P1383
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HOLZ PC, 2009, INVEST OPHTHALMOL VI, V50
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   KWON O, 2009, INVEST OPHTH VIS SCI, V50, P2365
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   LARSEN BP, 2009, INVEST OPHTHAMOL VIS, V50
   LARSON TA, 2009, INVEST OPHTHALMOL VI, V50
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   MACULAR P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   MACULAR P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1023
   Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004
   Meyer CHEN, 2008, INVEST OPHTH VIS SCI, V49, P273
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Narukawa Mamoru, 2004, J Biopharm Stat, V14, P403, DOI 10.1081/BIP-120037189
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   *NOV PHARM AG, 2008, LUC RAN SUMM PROD CH
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   PRUCNTE C, 2009, INVEST OPTHALMOL VIS, V50
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   REGILLO CD, 2008, JOINT M AM AC OPHTH
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   *ROYAL COLL OPHTH, 2008, RAN CLIN GID COMM CO
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   SCHLINGEMANN RO, 2009, INVEST OPHTHALMOL VI, V50
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   SCOTT IU, 2006, INVEST OPHTHALMOL VI, V47
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SINGER M, 2009, INVEST OPHTHALMOL VI, V50
   SLAKTER JS, INVEST OPHTHALMOL VI
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   TANO Y, 2008, INVEST OPHTHALMOL VI, V49
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WEST ES, 2006, 24 ANN AM SOC RET SP
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 90
TC 39
Z9 43
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD JAN
PY 2010
VL 9
IS 1
BP 149
EP 165
DI 10.1517/14740330903418422
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 591QB
UT WOS:000277315700011
PM 20001757
DA 2022-11-30
ER

PT J
AU Lane, SS
   Kuppermann, BD
AF Lane, SS
   Kuppermann, BD
TI The implantable miniature telescope for macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; endothelial cell density; implantable
   miniature telescope; quality of life
ID ENDOTHELIAL-CELL LOSS
AB The function is described of the Implantable Miniature Telescope, which is completing clinical development for bilateral end-stage macular degeneration, and 6-month results of the Phase II/III IMT002 prospective, multicenter study are presented. Multispecialty patient management and implications of the study's findings are discussed. Recent findings No medical treatments are currently available for bilateral end-stage age-related macular degeneration (atrophic or disciform scar age-related macular degeneration). The visual prosthetic device discussed in this update is implanted in the posterior chamber to reduce the impact of the scotomata on the patient's central vision. The goal of treatment is to improve the patient's ability to perform everyday activities and participate in roles and hobbies that impact their quality of life. Patients implanted with the device experienced clinically significant gains in visual acuity and quality of life at 6 months, In total, 89% gained two or more lines of best-corrected near or distance visual acuity. The device was generally safe and well tolerated. The surgical technique is important to minimize surgically related reduction in endothelial cell density. Summary This age-related macular degeneration visual prosthesis has been shown to improve visual acuity and quality of life for the bilateral end-stage age-related macular degeneration patient population that at present has no other acceptable options. Endothelial cell density from baseline to 6 and 12 months after device implantation was reduced due to trauma from the surgical procedure, but was compatible with a healthy cornea. Meticulous surgical technique and a comprehensive, multispecialty approach to preoperative and postoperative patient management are essential for successful outcomes.
C1 Associated Eye Care, Stillwater, MN 55082 USA.
   Univ Minnesota, Dept Ophthalmol, Stillwater, MN USA.
   Univ Calif Irvine, Dept Ophthalmol, Irvine, CA USA.
C3 University of Minnesota System; University of California System;
   University of California Irvine
RP Lane, SS (通讯作者)，Associated Eye Care, 232 N Main St, Stillwater, MN 55082 USA.
EM sslane@associatedeyecare.com
CR Arias E, 2004, NATL VITAL STAT REPO, V53
   Armitage WJ, 2003, INVEST OPHTH VIS SCI, V44, P3326, DOI 10.1167/iovs.02-1255
   BATES AK, 1986, CURR EYE RES, V5, P363, DOI 10.3109/02713688609025174
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOURNE WM, 1994, OPHTHALMOLOGY, V101, P1014
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Domingues Flavia Guedes Pinto, 2005, Arq. Bras. Oftalmol., V68, P109, DOI 10.1590/S0004-27492005000100020
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kosrirukvongs P, 1997, J CATARACT REFR SURG, V23, P1006, DOI 10.1016/S0886-3350(97)80072-7
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   O'Brien PD, 2004, J CATARACT REFR SURG, V30, P839, DOI 10.1016/S0886-3350(03)00648-5
   OLSEN T, 1980, ACTA OPHTHALMOL, V58, P773
   Panton RW, 2000, J CATARACT REFR SURG, V26, P590, DOI 10.1016/S0886-3350(99)00398-3
   Peli E, 2002, OPTOMETRY VISION SCI, V79, P225, DOI 10.1097/00006324-200204000-00009
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   ZETTERSTROM C, 1995, J CATARACT REFR SURG, V21, P55, DOI 10.1016/S0886-3350(13)80480-4
NR 20
TC 24
Z9 24
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD FEB
PY 2006
VL 17
IS 1
BP 94
EP 98
DI 10.1097/01.icu.0000193067.86627.a1
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 023IX
UT WOS:000236121400014
PM 16436930
DA 2022-11-30
ER

PT J
AU Zhang, J
   Yan, Y
   Yu, ZK
   Liu, L
AF Zhang, Jie
   Yan, Yan
   Yu, Zikui
   Liu, Lin
TI Characteristics of Polypoidal Choroidal Vasculopathy Evaluated by
   Multispectral Imaging
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB BACKGROUND AND OBJECTIVE: To analyze the morphological and pathological characteristics of polypoidal choroidal vasculopathy (PCV) on multispectral imaging (MSI).
   PATIENTS AND METHODS: This prospective study included patients with a clinical diagnosis of treatment-naive PCV. All patients underwent a complete ophthalmological examination including fundus photography, fundus fluorescein angiography (FFA), indocyanine green angiography (ICCA), optical coherence tomography (OCT), and MSI. MSI was obtained by digital multispectral ophthalmoscope, which allows the visualization of retinal and choroidal structures progressively. The characteristics of PCV on MSI were analyzed and compared with ICCA.
   RESULTS: Sixteen eyes of 14 patients (mean age 60.9 years +/- 9.2 years; 11 male and three female) were included for analysis. Polypoidal lesions were detected in 15 eyes (93.8%) by MSI with nodular or nebulous hyperreflectance on choroidal oxy-deoxy map. MSI was able to reveal all the branching vascular networks (BVNs) detected by ICCA. Retinal pigment epithelial atrophy with melanin stacking was found with MSI infrared wavelengths around pigment epithelial detachment (PED) and in areas above the BVNs in 13 eyes (81.3%). The sensitivity and specificity of MSI were 93.8% and 100%, respectively, for identifying typical PCV with both BVN and polypoidal lesions.
   CONCLUSION: MSI appears to be a promising modality for detecting noninvasively the vascular and structural changes in PCV, especially for BVN. MSI may also be used to monitor the metabolic and functional changes of retinal pigment epithelium secondary to polypoidal lesions.
C1 [Zhang, Jie; Yan, Yan; Yu, Zikui; Liu, Lin] Shanghai Jiao Tong Univ, Dept Ophthalmol, Renji Hosp, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Liu, L (通讯作者)，Renji Hosp, Dept Ophthalmol, 160 Pujian Rd, Shanghai 200127, Peoples R China.
EM eyerenji@126.com
CR Bhavsar KV, 2015, OSLI RETINA, V46, P377, DOI 10.3928/23258160-20150323-14
   Calcagni A, 2011, EYE, V25, P1562, DOI 10.1038/eye.2011.202
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dugel PU, 2016, OSLI RETINA, V47, P134, DOI 10.3928/23258160-20160126-06
   Everdell NL, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3478001
   Freund K., 2014, RETINA TODAY, V9, P94
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wang Y, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7073083
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   Xu YP, 2015, LASER SURG MED, V47, P549, DOI 10.1002/lsm.22392
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang J, 2015, OPTOMETRY VISION SCI, V92, pE21, DOI 10.1097/OPX.0000000000000440
   Zhu XM, 2017, LASER SURG MED, V49, P498, DOI 10.1002/lsm.22619
NR 20
TC 7
Z9 7
U1 2
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD DEC
PY 2018
VL 49
IS 12
BP E249
EP E255
DI 10.3928/23258160-20181203-15
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HH7QQ
UT WOS:000455925900004
PM 30566710
DA 2022-11-30
ER

PT J
AU Michalska-Malecka, K
   Kaluzny, J
   Nowak, M
   Gosciniewicz, P
   Matysik-Wozniak, A
   Nowomiejska, K
   Karpe, J
   Rejdak, R
AF Michalska-Malecka, Katarzyna
   Kaluzny, Jakub
   Nowak, Mariusz
   Gosciniewicz, Poitr
   Matysik-Wozniak, Anna
   Nowomiejska, Katarzyna
   Karpe, Jacek
   Rejdak, Robert
TI Evaluation of retinal function improvement in neovascular age-related
   macular degeneration after intravitreal aflibercept injections with the
   use of the assessment of retinal sensitivity The use of the assessment
   of retinal sensitivity in anti-VEGF treatment - a STROBE-compliant
   observational study
SO MEDICINE
LA English
DT Article
DE aflibercept; age-related macular degeneration; fixation stability;
   microperimetric examination; microperimetry; retinal sensitivity
ID VISUAL-ACUITY; PERIMETRY MICROPERIMETRY; GEOGRAPHIC ATROPHY;
   PROGRESSION; MORPHOLOGY; AMD
AB This study compares 2 methods of macular function evaluation: the microperimetric examination (mean central retinal sensitivity and fixation stability) and the distance best-corrected visual acuity (BCVA) examination, which is the most frequently used method of assessing macular function in patients with newly diagnosed wet age-related macular degeneration (AMD) who have been treated with anti-vascular endothelial growth factor (VEGF) drug (aflibercept).
   Prospective analysis was conducted on 44 eyes of 44 patients treated with intravitreal injection of anti-VEGF (aflibercept) because of newly diagnosed neovascular AMD. According to the research protocol, all patients had a 6-month follow-up. The response to treatment was monitored functionally by MP-1 microperimetry, fixation, and distance BCVA assessment after injection. Improvement of retinal sensitivity and BCVA was found under aflibercept treatment. There was statistically significant improvement in retinal sensitivity in the MP-1 study 3 and 6 months from the beginning of anti-VEGF therapy. Moreover, a significant improvement in retinal sensitivity between 3 and 6 months of observation was demonstrated. At the same time, up to 3 months from the beginning of treatment, BCVA improved significantly compared to the baseline value. In the 6th month of the study BCVA remained stable without further significant improvement.
   Microperimetric examination with medium sensitivity and fixation stability assessment is a very valuable test determining the retinal function. It is clear that examining the macular morphology itself in modern diagnostics is not enough to assess retinal function. Microperimetry technique is a valuable tool for functional long-term evaluation of retinal function (also for a period of more than 3 months).
C1 [Michalska-Malecka, Katarzyna] Med Univ Silesia, Sch Med Katowice, Dept Ophthalmol, Ceglana 35, Katowice, Poland.
   [Michalska-Malecka, Katarzyna; Gosciniewicz, Poitr] Med Univ Silesia, Univ Hosp, Univ Clin Ctr, Katowice, Poland.
   [Kaluzny, Jakub] Nicolaus Copernicus Univ, Coll Med, Dept Optometry, Torun, Poland.
   [Kaluzny, Jakub] Oftalmika Eye Hosp, Bydgoszcz, Poland.
   [Nowak, Mariusz] Med Univ Silesia, Sch Med, Dept Pathophysiol & Endocrinol, Pathophysiol Div,Div Dent, Zabrze, Poland.
   [Matysik-Wozniak, Anna; Nowomiejska, Katarzyna; Rejdak, Robert] Med Univ, Dept Gen Ophthalmol, Lublin, Poland.
   [Karpe, Jacek] Med Univ Silesia, Sch Med, Dept Anaesthesiol & Intens Therapy, Div Dens, Zabrze, Poland.
C3 Medical University Silesia; Medical University Silesia; Nicolaus
   Copernicus University; Medical University Silesia; Medical University of
   Lublin; Medical University Silesia
RP Michalska-Malecka, K (通讯作者)，Med Univ Silesia, Sch Med Katowice, Dept Ophthalmol, Ceglana 35, Katowice, Poland.
EM k.michalska.malecka@gmail.com
OI MICHALSKA-MALECKA, KATARZYNA/0000-0002-0550-8386; Kaluzny,
   Jakub/0000-0003-1908-2141; Nowomiejska, Katarzyna/0000-0002-5805-8761;
   Karpe, Jacek/0000-0003-0578-2497; Nowak, Mariusz/0000-0003-1754-9959;
   Matysik-Wozniak, Anna/0000-0003-0865-6541
CR Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Denniss J, 2018, INVEST OPHTH VIS SCI, V59, P4590, DOI 10.1167/iovs.18-24861
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Grenga PL, 2013, CAN J OPHTHALMOL, V48, P394, DOI 10.1016/j.jcjo.2013.04.006
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lazzeri S, 2015, OPHTHALMOLOGICA, V233, P74, DOI 10.1159/000371393
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P347, DOI 10.1016/j.jcjo.2013.07.010
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Nagpal M, 2018, INDIAN J OPHTHALMOL, V66, P1790, DOI 10.4103/ijo.IJO_866_18
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Squirrell D, 2012, RETINAL PHYS, V9, P53
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tran BK, 2015, KLIN MONATSBL AUGENH, V232, P529, DOI 10.1055/s-0035-1545779
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   Wong EN, 2017, ASIA-PAC J OPHTHALMO, V6, P70, DOI 10.22608/APO.201643
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
NR 32
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV
PY 2019
VL 98
IS 44
AR e17599
DI 10.1097/MD.0000000000017599
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA JO7BV
UT WOS:000497731800023
PM 31689763
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Laine, M
   Jarva, H
   Seitsonen, S
   Haapasalo, K
   Lehtinen, MJ
   Lindeman, N
   Anderson, DH
   Johnson, PT
   Jarvela, I
   Jokiranta, TS
   Hageman, GS
   Immonen, I
   Meri, S
AF Laine, Matti
   Jarva, Hanna
   Seitsonen, Sanna
   Haapasalo, Karita
   Lehtinen, Markus J.
   Lindeman, Nina
   Anderson, Don H.
   Johnson, Patrick T.
   Jarvela, Irma
   Jokiranta, T. Sakari
   Hageman, Gregory S.
   Immonen, Ilkka
   Meri, Seppo
TI Y402H polymorphism of complement factor H affects binding affinity to
   C-reactive protein
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SHORT CONSENSUS REPEAT; MACULAR DEGENERATION; ALTERNATIVE PATHWAY;
   VISUAL IMPAIRMENT; BRUCHS MEMBRANE; AGE; COMMON; RISK; DRUSEN; GENES
AB Complement factor H (FH) is an important regulator of the alternative complement pathway. The Y402H polymorphism within the seventh short consensus repeat of FH was recently shown to be associated with age-related macular degeneration, the most common cause of irreversible blindness in the Western world. We examined the effects of this polymorphism on various FH functions. FH purified from sera of age-related macular degeneration patients homozygous for the FH402H variant showed a significantly reduced binding to C-reactive protein (CRP), an acute phase protein, as compared with FH derived from unaffected controls homozygous for the FH402Y variant. Strongly reduced binding to CRP was also observed with a recombinant fragment of FH (short consensus repeat 5-7) containing the same amino acid change. Because the interaction of CRP and FH promotes complement-mediated clearance of cellular debris in a noninflammatory fashion, we propose that the reduced binding of FH402H to CRP could lead to an impaired targeting of FH to cellular debris and a reduction in debris clearance and enhanced inflammation along the macular retinal pigmented epithelium-choroid interface in individuals with age-related macular degeneration.
C1 Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, FI-00014 Helsinki, Finland.
   Univ Helsinki, HUSLAB, Div Immunol, Cent Hosp Lab, FI-00014 Helsinki, Finland.
   Univ Helsinki, Dept Ophthalmol, FI-00014 Helsinki, Finland.
   Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland.
   Univ Helsinki Hosp, Lab Mol Genet, Helsinki, Finland.
   Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52240 USA.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   University of California System; University of California Santa Barbara;
   University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Iowa
RP Meri, S (通讯作者)，Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, POB 21,Haartmaninkatu 3, FI-00014 Helsinki, Finland.
EM seppo.meri@helsinki.fi
RI Jokiranta, T. Sakari/F-1906-2011; Jarvela, Irma E/L-5836-2013
OI Jarvela, Irma E/0000-0002-1770-6187; Jarva, Hanna/0000-0002-9154-354X;
   Haapasalo, Karita/0000-0002-9619-625X; Meri, Seppo/0000-0001-9142-501X
FU NATIONAL EYE INSTITUTE [R24EY017404, R01EY011515] Funding Source: NIH
   RePORTER; NEI NIH HHS [R24 EY017404, R01 EY011515, EY 11515] Funding
   Source: Medline
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aronen Merja, 1993, Immunology and Infectious Diseases (Oxford), V3, P83
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   GEWURZ H, 1982, ADV INTERNAL MED, V27, P345
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lehtinen MJ, 2004, J MOL BIOL, V344, P1385, DOI 10.1016/j.jmb.2004.10.017
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seitsonen S, 2006, MOL VIS, V12, P796
   Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346
   Taskinen S, 2005, BIOCHEM BIOPH RES CO, V329, P1208, DOI 10.1016/j.bbrc.2005.02.091
   VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820
   Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6
NR 37
TC 197
Z9 207
U1 0
U2 28
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 15
PY 2007
VL 178
IS 6
BP 3831
EP 3836
DI 10.4049/jimmunol.178.6.3831
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 146NX
UT WOS:000244942400057
PM 17339482
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Krishnaiah, S
   Das, TP
   Kovai, V
   Rao, GN
AF Krishnaiah, S.
   Das, T. P.
   Kovai, V.
   Rao, G. N.
TI Associated factors for age-related maculopathy in the adult population
   in southern India: the Andhra Pradesh Eye Disease Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; RISK-FACTORS; VISUAL IMPAIRMENT; LENS OPACITIES;
   CARDIOVASCULAR-DISEASE; JAPANESE POPULATION; RURAL-POPULATION;
   URBAN-POPULATION; PREVALENCE; BLINDNESS
AB Background: To assess prevalence, potential risk factors and population attributable risk percentage (PAR) for age-related maculopathy (ARM) in the Indian state of Andhra Pradesh.
   Methods: A population-based study, cross-sectional epidemiological study was conducted in the state of Andhra Pradesh in India during 1996 and 2000. Participants from 94 clusters in one urban and three rural areas representative of the population of Andhra Pradesh underwent a detailed interview and a detailed dilated ocular evaluation by trained professionals. This report presents the prevalence estimates of ARM and examines the association of ARM with potential risk factors in persons aged 40-102 years (n = 3723). ARM was defined as per the international classification and grading system.
   Results: ARM was present in 327 subjects, an age-gender-area-adjusted prevalence of 8.9% (95% confidence interval (CI), 8.1% to 9.9%). Multivariate analysis showed that, the adjusted prevalence of ARM was significantly higher in those 70 years of age or older (adjusted odds ratio (OR), 3.65; 95% CI 2.24 to 5.94) and in subjects with hypertension OR 1.30 (95% CI 1.02 to 1.65). The presence of any cataract and urban residence were significantly associated with increased prevalence of ARM (OR 1.67; 95% CI 1.27 to 2.21 and 2.30; 95% CI 1.79 to 2.96) respectively. Increased intraocular pressure (IOP) and increased cup-to-disc ratio (CDR) were also significantly associated with increased prevalence of ARM (OR 1.03; 95% CI 1.002 to 1.06 and 2.25; 95% CI 1.10 to 4.67) respectively. The PAR for hypertension and any cataract was 12% and 18% respectively in this population.
   Conclusion: The prevalence of ARM in this south Indian population is similar to those reported from other developed countries. Increased age, increased IOP and increased CDR were significantly associated with the increased risk of ARM.
C1 [Krishnaiah, S.; Kovai, V.; Rao, G. N.] LV Prasad Eye Inst, Int Ctr Adv Rural Eye Care, Hyderabad 500034, Andhra Pradesh, India.
   [Krishnaiah, S.; Rao, G. N.] Univ New S Wales, Vis Cooperat Res Ctr, Sydney, NSW, Australia.
   [Das, T. P.] LV Prasad Eye Inst, Bhubaneswar, Orissa, India.
C3 L. V. Prasad Eye Institute; University of New South Wales Sydney; Visa
   Inc; L. V. Prasad Eye Institute
RP Krishnaiah, S (通讯作者)，LV Prasad Eye Inst, Int Ctr Adv Rural Eye Care, Kallam Anji Reddy Campus, Hyderabad 500034, Andhra Pradesh, India.
EM krishnaiah@lvpei.org
RI Kovai, Vilas/V-4503-2017
OI Kovai, Vilas/0000-0002-2672-9970
FU Christoffel-Blindenmission, Bensheim, Germany; Hyderabad Eye Research
   Foundation, Hyderabad, India
FX Supported by grants from the Christoffel-Blindenmission, Bensheim,
   Germany, and the Hyderabad Eye Research Foundation, Hyderabad, India.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Dandona L, 1998, LANCET, V351, P1312, DOI 10.1016/S0140-6736(97)09509-3
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dandona Rakhi, 1997, Indian Journal of Ophthalmology, V45, P251
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nirmalan PK, 2003, INVEST OPHTH VIS SCI, V44, P4639, DOI 10.1167/iovs.03-0011
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PEARCE N, 1989, INT J EPIDEMIOL, V18, P976, DOI 10.1093/ije/18.4.976
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Taylor H, 1988, LENS RES, V5, P175
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 53
TC 15
Z9 16
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2009
VL 93
IS 9
BP 1146
EP 1150
DI 10.1136/bjo.2009.159723
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 498JL
UT WOS:000270135500006
PM 19429580
DA 2022-11-30
ER

PT J
AU Lama, P
AF Lama, P
TI HMG CoA reductase inhibitors and age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
ID 5-YEAR INCIDENCE; STATIN USE; MACULOPATHY; ASSOCIATION; EVENTS
CR Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926
   Dibra A, 2003, AM J MED, V114, P715, DOI 10.1016/S0002-9343(03)00183-9
   Forrester JS, 2002, ANN INTERN MED, V137, P823, DOI 10.7326/0003-4819-137-10-200211190-00012
   FRIEDMAN E, 1999, AGE RELATED MACULAR, P137
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711
   Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271
   Szczeklik A, 1999, J AM COLL CARDIOL, V33, P1286, DOI 10.1016/S0735-1097(99)00023-6
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2004
VL 49
IS 1
BP 123
EP 124
DI 10.1016/j.survophthal.2003.11.004
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 765UN
UT WOS:000188302300009
DA 2022-11-30
ER

PT J
AU Sheth, JU
   Gopal, L
   Gillies, M
   Khatri, M
   Kuppermann, B
   Roy, R
   Chawla, S
   Rajendran, A
   Narayanan, R
AF Sheth, Jay U.
   Gopal, Lingam
   Gillies, Mark
   Khatri, Manoj
   Kuppermann, Baruch
   Roy, Rupak
   Chawla, Shobhit
   Rajendran, Anand
   Narayanan, Raja
TI Vitreoretinal Society of India practice pattern survey 2020: Medical
   retina
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE As central serous chorioretinopathy; diabetic retinopathy; neovascular
   age related macular degeneration; polypoidal choroidal vasculopathy;
   practice patterns; retinal vein occlusions; vitreoretinal society of
   India
ID DIABETIC MACULAR EDEMA; CENTRAL SEROUS CHORIORETINOPATHY; INTRAVITREAL
   BEVACIZUMAB; RANIBIZUMAB INJECTIONS; PHOTOCOAGULATION; RETINOPATHY;
   EFFICACY; SAFETY; DEXAMETHASONE; ANGIOGRAPHY
AB Purpose: The aim of this study was to present the outcomes of the Vitreo-retinal Society of India (VRSI) Practice Pattern Survey 2020 in medical retina. Methods: An online survey of members of VRSI was conducted in April 2020 regarding their practice-patterns on varied medical and surgical retina topics concerning imaging and management approach. The results were evaluated by two independent experts in this field and compared with the evidence and other practice patterns in the world. Results: A total of 107 VRSI members participated in the online survey. Responses were obtained on management of wide-ranging chorioretinal disorders such as Central Serous Chorioretinopathy (CSCR), Polypoidal Choroidal Vasculopathy (PCV), Neovascular age related macular degeneration (n-AMD), Retinal Vein Occlusions (RVO), and Diabetic Retinopathy (DR). Participants were also surveyed regarding their attitudes and perceptions about anti-VEGF practice patterns and role of imaging in their current practice. Each of the survey question responses were then compared to contemporary literature, including evidence-based guidelines, randomized controlled trials (RCTs), real-world evidence and analogous international surveys. Comprehensive analysis related to this has been put forward in the article. Conclusion: This survey represents the contemporary practice patterns amongst vitreoretinal specialists in India. The survey results are vital for fellow practitioners to understand the 'standard of care' practice in medical retina. This will guide them to devise the best possible individualized treatment strategy for most favorable clinical outcomes.
C1 [Sheth, Jay U.] Surya Eye Inst & Res Ctr, Dept Vitreoretinal Serv, Mumbai, Maharashtra, India.
   [Gopal, Lingam] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.
   [Gillies, Mark] Univ Sydney, Save Sight Inst, Fac Med, Sydney, NSW, Australia.
   [Khatri, Manoj] Eydox Eye Hosp & Rajan Eye Care Hosp, Dept Vitreoretina, Chennai, Tamil Nadu, India.
   [Kuppermann, Baruch] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA.
   [Roy, Rupak] Aditya Birla Sankara Nethralaya, Dept Vitreo Retina, Kolkata, W Bengal, India.
   [Chawla, Shobhit] Prakash Netra Kendr, Lucknow, Uttar Pradesh, India.
   [Chawla, Shobhit; Rajendran, Anand; Narayanan, Raja] Vitreoretinal Soc India VRSI, Bangalore, Karnataka, India.
   [Rajendran, Anand] Aravind Eye Hosp, Retina Vitreous Serv, Chennai, Tamil Nadu, India.
   [Narayanan, Raja] LV Prasad Eye Inst, Suven Clin Res Ctr, Hyderabad, Telangana, India.
C3 National University of Singapore; University of Sydney; University of
   California System; University of California Irvine; L. V. Prasad Eye
   Institute
RP Narayanan, R (通讯作者)，LV Prasad Eye Inst, Room 603C,Banjara Hills, Hyderabad 500034, Telangana, India.
EM narayanan@lvpei.org
RI Narayanan, Raja/AAT-3098-2021
OI Narayanan, Raja/0000-0001-9688-5859
CR Ambiya V, 2017, OSLI RETINA, V48, P564, DOI 10.3928/23258160-20170630-07
   [Anonymous], Preferences and Trends (PAT) Survey
   [Anonymous], 1993, ONLINE J CURR CLIN T
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Baker CW, 2019, JAMA-J AM MED ASSOC, V321, P1880, DOI 10.1001/jama.2019.5790
   Brandl C, 2014, INT OPHTHALMOL, V34, P7, DOI 10.1007/s10792-013-9774-y
   Bressler SB, 2016, AM J OPHTHALMOL, V164, P57, DOI 10.1016/j.ajo.2015.12.025
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P2432, DOI 10.1016/j.ophtha.2014.06.011
   Chung YR, 2013, EYE, V27, P1339, DOI 10.1038/eye.2013.236
   Chung YR, 2018, RETINA-J RET VIT DIS, V38, P102, DOI 10.1097/IAE.0000000000001502
   Collins Jannette, 2007, J Am Coll Radiol, V4, P551, DOI 10.1016/j.jacr.2006.12.007
   Doble B, 2020, JAMA OPHTHALMOL, V138, P251, DOI 10.1001/jamaophthalmol.2019.5628
   Figueira J, 2018, OPHTHALMOLOGY, V125, P691, DOI 10.1016/j.ophtha.2017.12.008
   Fusi-Rubiano W, 2020, EYE, V34, P809, DOI 10.1038/s41433-019-0568-y
   Gawecki M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091398
   Gross JG, 2018, JAMA OPHTHALMOL, V136, P1138, DOI 10.1001/jamaophthalmol.2018.3255
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ho M, 2016, RETINA-J RET VIT DIS, V36, P432, DOI 10.1097/IAE.0000000000000843
   Horwitz RI, 2017, J CLIN EPIDEMIOL, V84, P14, DOI 10.1016/j.jclinepi.2017.02.003
   Iida-Miwa Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42982-5
   Ji SL, 2017, INT J CLIN PHARM-NET, V39, P514, DOI 10.1007/s11096-017-0460-4
   KLEIN ML, 1974, ARCH OPHTHALMOL-CHIC, V91, P247
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kwan CC, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1226-2
   Lam WC, 2015, CLIN OPHTHALMOL, V9, P1255, DOI 10.2147/OPTH.S80500
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maturi RK, 2018, JAMA OPHTHALMOL, V136, P29, DOI 10.1001/jamaophthalmol.2017.4914
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Sharma S, 2019, OPHTHALMOLOGICA, V241, P24, DOI 10.1159/000488602
   Siwek J, 2018, AM FAM PHYSICIAN, V98, P343
   Stattin M, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8491712
   Sundar D, 2020, INDIAN J OPHTHALMOL, V68, P1095, DOI 10.4103/ijo.IJO_1602_19
   Unsal E, 2015, PAK J MED SCI, V31, P510, DOI 10.12669/pjms.313.7218
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wessel MM, 2012, RETINA-J RET VIT DIS, V32, P785, DOI 10.1097/IAE.0b013e3182278b64
NR 41
TC 2
Z9 2
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2021
VL 69
IS 6
BP 1430
EP 1439
DI 10.4103/ijo.IJO_2573_20
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2LT
UT WOS:000658809500016
PM 34011714
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jin, J
   Shen, YC
   Chen, X
   Wang, J
   Chen, C
   Xu, X
   Huang, HY
   Liu, K
AF Jin Jing
   Shen Yinchen
   Chen Xia
   Wang Jing
   Chen Chong
   Xu Xun
   Huang Hengye
   Liu Kun
TI Pharmacogenomic study on anti-VEGF medicine in treatment of macular
   Neovascular diseases: a study protocol for a prospective observational
   study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; Macular neovascular diseases; Conbercept; Pharmacogenomic
ID MYOPIC CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL AFLIBERCEPT INJECTION;
   DEGENERATION; VASCULOPATHY; RANIBIZUMAB; EFFICACY; MONOTHERAPY;
   CONBERCEPT; PREVALENCE; SAFETY
AB Background: Macular neovascular diseases can cause severe vision loss. A newly approved anti-VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of Conbercept in real world clinical practice. Moreover, anti-VEGF drugs are expensive and often require multiple treatments, and some patients have poor or even no response to the drugs, this resulted enormous waste of medical resources. Therefore, how to find out those patients who have good response, and how to develop individualized therapeutic regimen in real world need to be urgently investigated in the aspect of pharmacogenomics and pharmacometabolomics.
   Methods: This study is a multicenter, prospective, observational study of Conbecept treating macular neovascular diseases in China. Patients suffered from age-related macular degeneration, polypoidal choroidal vasculopathy, and pathological myopia who already planned to receive Conbercept treatment will be recruited. We aimed to enroll more than 5000 patients from 43 ophthalmic centers in China. Patients' clinical data and blood samples will be collected during the oneyear follow-up period. Finally, the safety and efficacy of Conbercept, and the potential predictors of patients' response to Conbercept will be investigated by pharmacogenomics and pharmacometabolomics analysis.
   Discussion: This study will provide important data of Conbercept in treating macular neovascular diseases in real world. Besides, finding the predictor of patients' response will help doctor make more precise individualized therapeutic regimens.
C1 [Jin Jing; Shen Yinchen; Chen Xia; Wang Jing; Chen Chong; Xu Xun; Liu Kun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Jin Jing; Shen Yinchen; Chen Xia; Wang Jing; Chen Chong; Xu Xun; Liu Kun] Shanghai Key Lab Ocular Fundus Dis, Shanghai 200080, Peoples R China.
   [Jin Jing; Shen Yinchen; Chen Xia; Wang Jing; Chen Chong; Xu Xun; Liu Kun] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai 200080, Peoples R China.
   [Huang Hengye] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Liu, K (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.; Huang, HY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai 200025, Peoples R China.
EM huanghy1107@shsmu.edu.cn; drliukun@sjtu.edu.cn
FU National Key Research and Development Program of China [2016YFC0904800];
   National Natural Science Foundation of China [81570851]
FX This project is supported by National Key Research and Development
   Program of China (Grant No. 2016YFC0904800) and National Natural Science
   Foundation of China (Grant No. 81570851).
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Chan NSW, 2016, EYE CONTACT LENS, V42, P48, DOI 10.1097/ICL.0000000000000201
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P272, DOI 10.3341/kjo.2016.30.4.272
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Giuffre C, 2017, EUR J OPHTHALMOL, V27, pE39, DOI 10.5301/ejo.5000875
   Hashemi H, 2017, OPHTHAL EPIDEMIOL, V24, P222, DOI 10.1080/09286586.2016.1270335
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Kurt MM, 2017, OPHTHALMOLOGICA, V238, P147, DOI 10.1159/000477180
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Teo KYC, 2016, DRUGS, V76, P1119, DOI 10.1007/s40265-016-0605-0
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Wong CW, 2016, PROGRETIN EYE RES
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 26
TC 3
Z9 4
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 24
PY 2018
VL 18
AR 181
DI 10.1186/s12886-018-0812-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GO1FI
UT WOS:000439694300001
PM 30041608
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jiang, H
   Fan, YH
   Li, J
   Wang, JQ
   Kong, LY
   Wang, LA
   Li, ZF
   Ma, M
   Shi, X
   Liu, SJ
   Shi, J
   Zhu, HL
   Liu, XH
   Ma, L
AF Jiang, Hong
   Fan, Yahui
   Li, Juan
   Wang, Jiaqi
   Kong, Liyun
   Wang, Lina
   Li, Zhaofang
   Ma, Mei
   Shi, Xin
   Liu, Sijiao
   Shi, Jia
   Zhu, Hailu
   Liu, XiaoHong
   Ma, Le
TI The Associations of Plasma Carotenoids and Vitamins With Risk of
   Age-Related Macular Degeneration: Results From a Matched Case-Control
   Study in China and Meta-Analysis
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE carotenoids; vitamins; lutein; zeaxanthin; plasma; age-related macular
   degeneration
ID ANTIOXIDANT ACTIVITY; SERUM ANTIOXIDANTS; OXIDATIVE STRESS; EYE DISEASE;
   LUTEIN; ZEAXANTHIN; MACULOPATHY; SUPPLEMENTATION; INFLAMMATION;
   PROGRESSION
AB Background and PurposeData from studies support a beneficial effect of carotenoids and vitamins on an age-related macular degeneration (AMD) risk. However, studies on the relations between blood levels of these nutrients and AMD are limited and provided conflicting results. The objective of this case-control study and meta-analysis was to examine whether the blood concentrations of carotenoids and vitamins were associated with the risk of AMD. MethodsA total of 164 cases of AMD and an equal number of controls are individually matched according to age and gender among the participants, who provided blood samples in the Xi'an Eye Study. Plasma carotenoids and vitamins were measured using reversed-phase high-performance liquid chromatography. Bonferroni-corrected covariate-adjusted conditional logistic regression were used to estimate AMD risk by category of these nutrients in the multivariable-adjusted model. Nine studies were identified for the meta-analysis and calculated pooled risk estimates by means of a random-effects model. ResultsPlasma concentrations of examined carotenoids and vitamins were significantly lower in patients with AMD than those in controls. Plasma concentrations of examined carotenoids and vitamins were significantly lower in patients with AMD than those in controls. After a multivariate adjustment for body mass index, blood cholesterol, and other lifestyle risk factors, higher lutein/zeaxanthin content in plasma was significantly associated with a decreased risk of AMD, and the odds ratio (OR) comparing the top and bottom tertiles was 0.21 (95% CI: 0.05, 0.84; P-trend = 0.024). Associations for beta-carotenes (OR: 0.11; 95% CI: 0.02, 0.50; P-trend < 0.001), and beta-cryptoxanthin (OR: 0.08, 95% CI: 0.02, 0.39; P-trend < 0.001) were similar to that for lutein/zeaxanthin. Inverse associations were also observed for a higher level of retinol (OR: 0.14, 95% CI: 0.03, 0.61; P-trend = 0.006) and alpha-tocopherol (OR: 0.25, 95% CI: 0.06, 0.98; P-trend = 0.006). In the meta-analysis, a protective effect was detected for AMD among the participants with high blood lutein/zeaxanthin level (OR: 0.53, 95% CI: 0.40, 0.72, P < 0.001), compared to those with low level. Similar inverse associations were seen for beta-carotene (OR: 0.48, 95% CI: 0.28, 0.84, P = 0.010), beta-cryptoxanthin (OR: 0.48, 95% CI: 0.23, 1, P = 0.049), lycopene (OR: 0.70, 95% CI: 0.54, 0.90, P = 0.006) and alpha-tocopherol (OR: 0.50, 95% CI: 0.31, 0.81, P = 0.005). ConclusionsResults of the case-control study were consistent with findings from the meta-analysis, indicating that higher concentrations of carotenoids and vitamins were inversely associated with the AMD risk. Our finding supports the current notion that these nutrients are likely to affect the development of AMD and may help to refine the strategies for the prevention of age-related eye diseases.
C1 [Jiang, Hong; Liu, XiaoHong] Xi An Jiao Tong Univ, Hlth Sci Ctr, Affiliated Hosp 1, Xian, Peoples R China.
   [Jiang, Hong] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Peoples R China.
   [Jiang, Hong; Fan, Yahui; Wang, Jiaqi; Kong, Liyun; Wang, Lina; Li, Zhaofang; Ma, Mei; Shi, Xin; Liu, Sijiao; Shi, Jia; Zhu, Hailu; Ma, Le] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian, Peoples R China.
   [Li, Juan] Xi An Jiao Tong Univ, Hlth Sci Ctr, Affiliated Guangren Hosp, Xian Hosp 4,Xian Peoples Hosp,Shaanxi Eye Hosp, Xian, Peoples R China.
   [Ma, Le] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Xi'an Jiaotong University; Ministry of Education, China;
   Xi'an Jiaotong University
RP Liu, XH (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Affiliated Hosp 1, Xian, Peoples R China.; Ma, L (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian, Peoples R China.; Ma, L (通讯作者)，Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian, Peoples R China.
EM liuxiaoh@mail.xjtu.edu.cn; male@mail.xjtu.edu.cn
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   ALDER VA, 1990, GRAEF ARCH CLIN EXP, V228, P151
   ANDERSON RE, 1976, EXP EYE RES, V23, P149, DOI 10.1016/0014-4835(76)90198-6
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arunkumar R, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158617
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaulmann A, 2014, NUTR RES, V34, P907, DOI 10.1016/j.nutres.2014.07.010
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kipnis V, 2002, PUBLIC HEALTH NUTR, V5, P915, DOI 10.1079/PHN2002383
   Lee Hankil, 2017, Korean J Ophthalmol, V31, P557, DOI 10.3341/kjo.2017.0025
   Lietz G, 2012, J NUTR, V142, p161S, DOI 10.3945/jn.111.140756
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin H, 2017, OPHTHAL EPIDEMIOL, V24, P311, DOI 10.1080/09286586.2017.1290259
   Ma L, 2009, ASIA PAC J CLIN NUTR, V18, P318
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Marra KV, 2016, J AM GERIATR SOC, V64, P369, DOI 10.1111/jgs.13927
   Merle BMJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062047
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Olmedilla B, 2001, BRIT J NUTR, V85, P227, DOI 10.1079/BJN2000248
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Platel K, 2016, CRIT REV FOOD SCI, V56, P1608, DOI 10.1080/10408398.2013.781011
   Prentice RL, 2009, STAT BIOSCI, V1, P112, DOI 10.1007/s12561-009-9003-4
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   SCHOELLER DA, 1995, METABOLISM, V44, P18, DOI 10.1016/0026-0495(95)90204-X
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shang F, 2003, FREE RADICAL BIO MED, V34, P521, DOI 10.1016/S0891-5849(02)01304-7
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toniolo P, 2001, AM J EPIDEMIOL, V153, P1142, DOI 10.1093/aje/153.12.1142
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Winkler B S, 1999, Mol Vis, V5, P32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   ZAMAN Z, 1993, CLIN CHEM, V39, P2229
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
NR 56
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD FEB 11
PY 2022
VL 9
AR 745390
DI 10.3389/fnut.2022.745390
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ZI1XR
UT WOS:000761422400001
PM 35223939
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Evans, JR
   Fletcher, AE
   Wormald, RPL
AF Evans, JR
   Fletcher, AE
   Wormald, RPL
TI Age-related macular degeneration causing visual impairment in people 75
   years or older in Britain - An add-on study to the Medical Research
   Council Trial of Assessment and Management of Older People in the
   Community
SO OPHTHALMOLOGY
LA English
DT Article
ID MRC TRIAL; ACUITY; PREVALENCE; POPULATION; DESIGN
AB Purpose: Age-related macular degeneration (AMD) is the most commonly occurring cause of visual loss in people registered as blind or partially sighted. There are no nationally representative data on the prevalence of AMD in the British population. We aimed to estimate the prevalence of AMD causing visual impairment in people 75 years or older in Britain.
   Design: Population-based cross-sectional study.
   Participants: Thirteen thousand nine hundred people 75 years or older in 49 practices taking part in the Medical Research Council Trial of the Assessment and Management of Older People in the Community.
   Methods: Trial nurses tested visual acuity in everyone 75 years or older in participating practices. We collected data on the cause of visual loss for everyone who was visually impaired. We obtained these data from review of the general practice medical notes and by sending a questionnaire to the hospital ophthalmologist. Visual impairment was defined as a binocular acuity of less than 6/18.
   Main Outcome Measure: Prevalence of AMD causing visual impairment.
   Results: There were 976 visually impaired people for whom a cause of visual loss was established. Of these, 516 (53%) had AMD as a cause of visual loss. We estimate that 3.7% (95% confidence interval, 3.2%-4.2%) of the population 75 years or older and 14.4% (11.6%-17.2%) of the population 90 years or older are visually impaired due to AMD. There are an estimated 192 000 people 75 years or older visually impaired due to AMD in the United Kingdom (95% confidence interval, 144000-239000).
   Conclusion: Our results, from the largest and most representative study of the causes of vision loss in older people in the British population, confirm the substantial burden of AMD in people 75 years and older. As the population ages, this problem will get worse. The needs of this group for vision aids and other support in the community should be addressed; research on the causes of AMD and possible preventive measures should be given priority. (C) 2004 by the American Academy of Ophthalmology.
C1 London Sch Hyg & Trop Med, Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, London WC1, England.
   London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine
RP Evans, JR (通讯作者)，Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   ELTINGE JL, 1996, STATA TECHNICAL B, V31, P3
   EVANS J, 1995, STUDIES MED POPULATI
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   EVANS JR, IN PRESS J OPHTHALMO
   Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21
   MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x
   McGraw PV, 2000, OPHTHAL PHYSL OPT, V20, P173, DOI 10.1046/j.1475-1313.2000.00497.x
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Skinner C.J., 1989, ANAL COMPLEX SURVEYS
   van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
NR 14
TC 62
Z9 64
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2004
VL 111
IS 3
BP 513
EP 517
DI 10.1016/j.ophtha.2003.07.012
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 780BR
UT WOS:000189351800017
PM 15019328
DA 2022-11-30
ER

PT J
AU Zarranz-Ventura, J
   Nguyen, V
   Creuzot-Garcher, C
   Verbraaic, F
   O'Toole, L
   Inverntz, A
   Viola, F
   Squirrel, D
   Barthelmes, D
   Gillies, MC
AF Zarranz-Ventura, Javier
   Nguyen, Vuong
   Creuzot-Garcher, Catherine
   Verbraaic, Frank
   O'Toole, Louise
   Inverntz, Alessandro
   Viola, Francesco
   Squirrel, David
   Barthelmes, Daniel
   Gillies, Mark C.
CA FRB Int Comm
TI INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL
   THERAPY OUTCOMES Fight Retinal Blindness Registry
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE COVID-19; lockdown; intravitreal; VEGF; ranibizumab; aflibercept;
   bevacizumab; age-related macular degeneration; diabetic macular edema;
   retinal vein occlusion
ID MACULAR DEGENERATION; INJECTIONS; EXPERIENCE; MANAGEMENT; CARE
AB Purpose: To evaluate the impact of the COVID-19 pandemic lockdowns on the outcomes of eyes treated for neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion in eight countries. Methods: A multicenter international database study of 5,782 eyes (4,708 patients) receiving intravitreal antivascular endothelial growth factor injections before, during, and after national lockdowns. The baseline visit was defined as the last visit within 3 months before lockdown, and prelockdown and postlockdown periods were defined as 6 months before and after the lockdown date. Results: Eyes with neovascular age-related macular degeneration (n = 4,649) lost vision in all countries in proportion to the reduced number of injections. The mean visual acuity change postlockdown ranged from -0.4 to -3.8 logarithm of the minimum angle of resolution letters, and the median number of injections/visits decreased from 4-5/4-7 to 2-4/2-4 postlockdown. The diabetic macular edema (n = 654) and retinal vein occlusion (n = 479) eyes' mean visual acuity change ranged from -2.8 to +1.7 letters and -1.6 to +0.1 letters, and the median number of injections/visits decreased from 2.5-5/4-6 to 1-3/2-4 and from 3-5.5/4-5 to 1-3.5/2-3.5, respectively. The 6-month dropout rates postlockdown were 20% for neovascular age-related macular degeneration, 27% for diabetic macular edema, and 28% for retinal vein occlusion. Conclusion: This international study provides estimates of the impact of COVID-19 pandemic lockdown on intravitreal therapy and suggests that prioritizing neovascular age-related macular degeneration eyes seems appropriate.
C1 [Zarranz-Ventura, Javier] Hosp Clin Barcelona, Inst Clin Ophthalmol ICOF, Barcelona, Spain.
   [Zarranz-Ventura, Javier] August Pi & Sunyer Biomed Res Inst IDIBAPS, C Sabino Arana 1, Barcelona 08028, Spain.
   [Nguyen, Vuong; Inverntz, Alessandro; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Creuzot-Garcher, Catherine] Dijon Univ Hosp, Dept Ophthalmol, Dijon, France.
   [Verbraaic, Frank] Amsterdam Univ Med Ctr UMC, Amsterdam, Netherlands.
   [O'Toole, Louise] Mater Private Hosp, Dublin, Ireland.
   [Inverntz, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci L Sacco, Eye Clin, Milan, Italy.
   [Viola, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Viola, Francesco] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Squirrel, David] Greenlane Clin Ctr, Dept Ophthalmol, Auckland, New Zealand.
   [Squirrel, David] Dist Hlth Board, Auckland, New Zealand.
   [Barthelmes, Daniel] Univ Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Barthelmes, Daniel] Univ Zurich, Zurich, Switzerland.
C3 University of Barcelona; Hospital Clinic de Barcelona; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Sydney;
   CHU Dijon Bourgogne; Mater Private Hospital; University of Milan; Luigi
   Sacco Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Milan; Auckland District Health Board; University of
   Zurich; University Zurich Hospital; University of Zurich
RP Zarranz-Ventura, J (通讯作者)，Hosp Clin Barcelona, Inst Clin Ophthalmol ICOF, Barcelona, Spain.; Zarranz-Ventura, J (通讯作者)，August Pi & Sunyer Biomed Res Inst IDIBAPS, C Sabino Arana 1, Barcelona 08028, Spain.
EM zarranz@clinic.cat
RI Zarranz-Ventura, Javier/AAB-5390-2021
OI Zarranz-Ventura, Javier/0000-0003-2338-8143; Verbraak, Frank
   D/0000-0001-7560-1423
CR Antaki F, 2020, GRAEF ARCH CLIN EXP, V258, P1567, DOI 10.1007/s00417-020-04693-w
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Carnevali A, 2021, EUR J OPHTHALMOL, V31, P10, DOI 10.1177/1120672120962032
   Chaudhary V, 2020, CAN J OPHTHALMOL, V55, P452, DOI 10.1016/j.jcjo.2020.06.001
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   El Hamichi S, 2020, CLIN OPHTHALMOL, V14, P2593, DOI 10.2147/OPTH.S267950
   Figueras-Roca M, 2021, GRAEF ARCH CLIN EXP, V259, P1463, DOI 10.1007/s00417-020-05016-9
   Gegundez-Fernandez J A, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P300, DOI 10.1016/j.oftal.2020.04.002
   Gegundez-Fernandez JA, 2021, ACTA OPHTHALMOL, V99, pE973, DOI 10.1111/aos.14752
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Koh AHC, 2020, GRAEF ARCH CLIN EXP, V258, P2091, DOI 10.1007/s00417-020-04791-9
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Li JPO, 2020, OPHTHALMOLOGY, V127, P569, DOI 10.1016/j.ophtha.2020.03.037
   Li JPO, 2020, BRIT J OPHTHALMOL, V104, P297, DOI 10.1136/bjophthalmol-2020-315994
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Romano F, 2020, OPHTHALMOL RETINA, V4, P1209, DOI 10.1016/j.oret.2020.06.027
   Rutte M, NETHERLANDS PRIME MI
   Sevik MO, 2021, INT OPHTHALMOL, V41, P2951, DOI 10.1007/s10792-021-01854-6
   Sindal MD, 2021, INDIAN J OPHTHALMOL, V69, P730, DOI 10.4103/ijo.IJO_2807_20
   Team RC, 2018, R LANGUAGE ENV STAT
   Teo KYC, 2021, EYE, V35, P2793, DOI 10.1038/s41433-020-01315-x
   Viola F, 2021, RETINA-J RET VIT DIS, V41, P701, DOI 10.1097/IAE.0000000000002941
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 2
Z9 2
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2022
VL 42
IS 4
BP 616
EP 627
DI 10.1097/IAE.0000000000003368
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0A8RN
UT WOS:000774215200005
PM 34907129
DA 2022-11-30
ER

PT J
AU Wong, TY
   Shankar, A
   Klein, R
   Bray, MS
   Couper, DJ
   Klein, BEK
   Sharrett, AR
   Folsom, AR
AF Wong, TY
   Shankar, A
   Klein, R
   Bray, MS
   Couper, DJ
   Klein, BEK
   Sharrett, AR
   Folsom, AR
TI Apolipoprotein E gene and early age-related maculopathy - The
   atherosclerosis risk in communities study
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; E EPSILON-4;
   ALZHEIMER-DISEASE; ASSOCIATION; POPULATION; ALLELE; PREVALENCE; GENDER
AB Objective: To examine the association between the apolipoprotein E (APOE) gene and early age-related maculopathy (ARM) in middle-aged persons.
   Design: Population-based cross-sectional study.
   Participants: Participants from the Atherosclerosis Risk in Communities Study (n = 10 139; age range, 49-73 years).
   Methods: Retinal photography was performed on 1 randomly selected eye, and grading for presence of ARM was carried out using a modification of the Wisconsin ARM Grading System. Early ARM was defined as the presence of either soft drusen alone, retinal pigment epithelial depigmentation alone, or a combination of soft drusen with increased retinal pigment and/or depigmentation. DNA extracted from blood samples of participants were analyzed for common allelic variants of the APOE gene (is an element of 2, is an element of 3, and is an element of 4).
   Main Outcome Measures: Presence of early ARM on retinal photographs.
   Results: The prevalence of early ARM was similar in participants with different APOE genotypes: is an element of 2/is an element of 2 (5.9%), is an element of 2/is an element of 3 (5.2%), is an element of 2/is an element of 4 (3.2%), is an element of 3/is an element of 3 (5.2%), is an element of 3/is an element of 4 (4.9%), and is an element of 4/is an element of 4 (4.1%). After controlling for age, gender, race, cigarette smoking, and other factors, early ARM was not associated with APOE genotypes, with an odds ratio (OR) of 1.35 (95% confidence interval [Cl], 0.54-3.38) for is an element of 2/is an element of 2 genotype, an OR of 1.06 (95% Cl, 0.80-1.40) for is an element of 2/is an element of 3 genotype, an OR of 0.63 (95% Cl, 0.32-1.24) for is an element of 2/is an element of 4 genotype, an OR of 0.99 (95% Cl, 0.80-1.24) for is an element of 3/is an element of 4 genotype, and an OR of 0.88 (95% Cl, 0.47-1.63) for is an element of 4/is an element of 4 genotype, as compared with is an element of 3/is an element of 3 genotype (reference). No associations were found for specific early ARM signs or in analyses stratified by age, gender, race, or cigarette smoking status.
   Conclusions: These data provide no evidence of a strong association between the APOE gene and early ARM in middle-aged persons. This suggests that APOE is not likely a major determinant of the early stages of ARM in younger people. However, our study does not exclude the possibility of a weaker association or that APOE may influence only the development of late ARM in older populations, as reported in other studies.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117548, Singapore.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI 53706 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
   Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21218 USA.
   Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; Singapore National Eye Center; National
   University of Singapore; University of Wisconsin System; University of
   Wisconsin Madison; Baylor College of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; Johns Hopkins
   University; University of Minnesota System; University of Minnesota Twin
   Cities
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235
FU DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016,
   N01HC055015, N01HC055021, N01HC055018, N01HC055019, N01HC055020,
   N01HC055022] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R03EY013939] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R01HL073366] Funding Source: NIH RePORTER; NEI NIH HHS
   [EYO13939] Funding Source: Medline; NHLBI NIH HHS [N01-HC-55016,
   N01-HC-55018, N01-HC-55019, N01-HC-55015, HL073366, N01-HC-55020,
   N01-HC-55022, N01-HC-55021] Funding Source: Medline; ODCDC CDC HHS
   [UR6/CCU617218] Funding Source: Medline
CR *ATH RISK COMM STU, MAN 2 COH COMP PROC
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 25
TC 28
Z9 31
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2006
VL 113
IS 2
BP 255
EP 259
DI 10.1016/j.ophtha.2005.10.048
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 011HL
UT WOS:000235258800012
PM 16406547
DA 2022-11-30
ER

PT J
AU van der Made, SM
   Kelly, ER
   Berendschot, TTJM
   Kijlstra, A
   Lutjohann, D
   Plat, J
AF van der Made, Sanne M.
   Kelly, Elton R.
   Berendschot, Tos T. J. M.
   Kijlstra, Aize
   Luetjohann, Dieter
   Plat, Jogchum
TI Consuming a Buttermilk Drink Containing Lutein-Enriched Egg Yolk Daily
   for 1 Year Increased Plasma Lutein but Did Not Affect Serum Lipid or
   Lipoprotein Concentrations in Adults with Early Signs of Age-Related
   Macular Degeneration
SO JOURNAL OF NUTRITION
LA English
DT Article
ID SOLUBLE ANTIOXIDANT CONCENTRATIONS; APOPROTEIN-E PHENOTYPE;
   DIETARY-CHOLESTEROL; RANDOMIZED-TRIALS; LDL-CHOLESTEROL; PROTECTIVE
   ROLE; ZEAXANTHIN; METAANALYSIS; CAROTENOIDS; SUPPLEMENTS
AB Dietary lutein intake is postulated to interfere with the development of age-related macular degeneration (AMD). Because egg yolk-derived lutein has a high bioavailability, long-term consumption of lutein-enriched eggs might be effective in preventing AMD development, but alternatively might increase cardiovascular disease risk. Here, we report the effect of 1-y daily consumption of a buttermilk drink containing 1.5 lutein-rich egg yolks on serum lipid and lipoprotein and plasma lutein concentrations. Additionally, subgroups that could potentially benefit the most from the intervention were identified. Men and women who had early signs of AMD in at least 1 eye, but were otherwise healthy, participated in a 1-y randomized, placebo-controlled parallel intervention trial. At the start of the study, 101 participants were included: 52 in the experimental (Egg) group and 49 in the control (Con) group. Final analyses were performed with 45 participants in the Egg group and 43 participants in the Con group. As expected, the increase in plasma lutein concentrations in the Egg group was 83% higher than that in the Con group (P < 0.001). Changes in serum total, HDL, and LDL cholesterol, as well as the ratio of total cholesterol to HDL cholesterol, were not different between the 2 groups. Interestingly, participants classified as cholesterol absorbers had higher serum HDL cholesterol concentrations than participants classified as cholesterol synthesizers or participants with average campesterol-to-lathosterol ratios (P < 0.05) at baseline. In addition, cholesterol absorbers had a 229% higher increase in plasma lutein concentrations than participants who were classified as having an average campesterol-to-lathosterol ratio upon consumption of the lutein-enriched egg yolk drink (P < 0.05). Moreover, the change in serum HDL cholesterol upon consumption was significantly different between these 3 groups (P < 0.05). We suggest that cholesterol absorbers particularly might benefit from the lutein-enriched buttermilk drink. This study was registered at clinicaltrials.gov as NCT00902408.
C1 [van der Made, Sanne M.; Plat, Jogchum] Maastricht Univ, Med Ctr, Dept Human Biol, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands.
   [Kelly, Elton R.; Berendschot, Tos T. J. M.; Kijlstra, Aize] Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, Maastricht, Netherlands.
   [Luetjohann, Dieter] Univ Clin Bonn, Inst Clin Chem & Clin Pharmacol, Bonn, Germany.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Maastricht University; Maastricht University Medical Centre (MUMC);
   University of Bonn
RP Plat, J (通讯作者)，Maastricht Univ, Med Ctr, Dept Human Biol, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands.
EM j.plat@maastricht-university.nl
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X
FU Europees Fonds voor Regionale Ontwikkeling (OP-Zuid); Dutch Ministry of
   Economic Affairs; Province of Limburg; Newtricious RD B.V.
FX Supported by Europees Fonds voor Regionale Ontwikkeling (OP-Zuid), Dutch
   Ministry of Economic Affairs, the Province of Limburg, and Newtricious
   R&D B.V.
CR Applegate E, 2000, J AM COLL NUTR, V19, p495S, DOI 10.1080/07315724.2000.10718971
   Arsenault BJ, 2009, J AM COLL CARDIOL, V55, P35, DOI 10.1016/j.jacc.2009.07.057
   Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   Baumgartner S, 2013, NUTRITION, V29, P1237, DOI 10.1016/j.nut.2013.03.020
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Blanco-Molina A, 1998, AM J CLIN NUTR, V68, P1028, DOI 10.1093/ajcn/68.5.1028
   BOSNER MS, 1993, J LIPID RES, V34, P1047
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   DUANE WC, 1995, J LIPID RES, V36, P343
   GINSBERG HN, 1995, ARTERIOSCL THROM VAS, V15, P169, DOI 10.1161/01.ATV.15.2.169
   GINSBERG HN, 1994, ARTERIOSCLER THROMB, V14, P576, DOI 10.1161/01.ATV.14.4.576
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Herron KL, 2004, METABOLISM, V53, P823, DOI 10.1016/j.metabol.2003.12.030
   Herron KL, 2002, J AM COLL NUTR, V21, P250, DOI 10.1080/07315724.2002.10719218
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kromhout D, 2011, BRIT J NUTR, V106, P627, DOI 10.1017/S0007114511002236
   Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mensink RP, 2010, AM J CLIN NUTR, V92, P24, DOI 10.3945/ajcn.2009.29143
   MIETTINEN TA, 1988, LANCET, V2, P1261, DOI 10.1016/S0140-6736(88)90862-8
   Miettinen TA, 1998, BMJ-BRIT MED J, V316, P1127, DOI 10.1136/bmj.316.7138.1127
   Minihane AM, 2007, P NUTR SOC, V66, P183, DOI 10.1017/S0029665107005435
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Plat J, 2002, EUR J CLIN INVEST, V32, P242, DOI 10.1046/j.1365-2362.2002.00982.x
   Plat J, 2001, METABOLISM, V50, P520, DOI 10.1053/meta.2001.22509
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Rung Y, 2013, BMJ-BRIT MED J, V346, pe8539
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   SACKS FM, 1984, LANCET, V1, P647
   Silbernagel G, 2010, J LIPID RES, V51, P2384, DOI 10.1194/jlr.P002899
   Spence JD, 2012, ATHEROSCLEROSIS, V224, P469, DOI 10.1016/j.atherosclerosis.2012.07.032
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thuluva SC, 2005, INT J CLIN PHARM TH, V43, P305
   United States Department of Agriculture (USDA), 2010, DIET GUID AM
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weggemans RM, 2001, AM J CLIN NUTR, V73, P885
   Westerterp KR, 2002, CURR OPIN CLIN NUTR, V5, P489, DOI 10.1097/00075197-200209000-00006
   Zou ZY, 2011, ATHEROSCLEROSIS, V219, P789, DOI 10.1016/j.atherosclerosis.2011.08.006
NR 44
TC 18
Z9 18
U1 1
U2 28
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD SEP
PY 2014
VL 144
IS 9
BP 1370
EP 1377
DI 10.3945/jn.114.195503
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA AN6VK
UT WOS:000340736300004
PM 24991045
OA Bronze
DA 2022-11-30
ER

PT J
AU Sasaki, S
   Miyazaki, D
   Miyake, K
   Terasaka, Y
   Kaneda, S
   Ikeda, Y
   Funakoshi, T
   Baba, T
   Yamasaki, A
   Inoue, Y
AF Sasaki, Shin-ichi
   Miyazaki, Dai
   Miyake, Ken-ichiro
   Terasaka, Yuki
   Kaneda, Shuzo
   Ikeda, Yoshifumi
   Funakoshi, Taisaku
   Baba, Takashi
   Yamasaki, Atsushi
   Inoue, Yoshitsugu
TI Associations of IL-23 with Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H;
   C-REACTIVE PROTEIN; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   PHOTODYNAMIC THERAPY; GENE POLYMORPHISMS; NEOVASCULARIZATION; DISEASE
AB PURPOSE. To determine the relationship between the levels of intraocular inflammatory cytokines and polypoidal choroidal vasculopathy (PCV).
   METHODS. Prospective cohort study. Sixty-two patients with PCV and 36 control subjects were studied. The levels of cytokines, chemokines, and growth factors in the aqueous humor samples from PCV patients and control subjects were assessed for significant associations with PCV. Logistic regression analysis was used to compute the odds ratios (ORs) and 95% confidence intervals (CIs) after the study populations were divided into quartiles.
   RESULTS. In PCV patients, IL-4, IL-10, and IL-23 were significantly higher than in the controls. Logistic analyses showed a significantly high risk for IL-23 (OR for the highest quartile compared with the lowest quartile: 16.3; 95% CI: 3.5-75.2), VEGF (5.7; 1.2-26.1), and IL-4 (4.0; 1.3-12.7). IL-10 and IL-4, but not IL-23, were significantly correlated with the VEGF levels in PCV patients (IL-10: rho = 0.477, IL-4: rho = 0.281). The elevated levels of IL-5, IL-10, IL-4, IL-23, and IL-1 alpha were found to be significantly associated with exudative lesion(s) in the fluorescein angiograms.
   CONCLUSIONS. The significant associations between elevated levels of IL-23 with PCV and its activity strongly suggest an involvement of inflammatory processes in the etiology of PCV, presumably independent of VEGF. (www.umin.ac.jp/ctr number, UMIN000003854.) (Invest Ophthalmol Vis Sci. 2012;53:3424-3430) DOI:10.1167/iovs.11-7913
C1 [Sasaki, Shin-ichi; Miyazaki, Dai; Miyake, Ken-ichiro; Terasaka, Yuki; Kaneda, Shuzo; Ikeda, Yoshifumi; Funakoshi, Taisaku; Baba, Takashi; Yamasaki, Atsushi; Inoue, Yoshitsugu] Tottori Univ, Div Ophthalmol & Visual Sci, Fac Med, Yonago, Tottori 6838504, Japan.
C3 Tottori University
RP Miyazaki, D (通讯作者)，Tottori Univ, Div Ophthalmol & Visual Sci, Fac Med, 36-1 Nishi Cho, Yonago, Tottori 6838504, Japan.
EM dm@grape.med.tottori-u.ac.jp
FU Japanese Ministry of Education, Science, and Culture [20592076,
   23791984]; Grants-in-Aid for Scientific Research [23791984, 21592258]
   Funding Source: KAKEN
FX Supported by Grant-in-Aid 20592076 and 23791984 for Scientific Research
   from the Japanese Ministry of Education, Science, and Culture.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bosmann M, 2012, FASEB J, V26, P1640, DOI 10.1096/fj.11-199216
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59
   Ding CG, 2008, CURR OPIN INVEST DR, V9, P515
   Fang CY, 2009, BLOOD, V114, P1005, DOI 10.1182/blood-2009-01-198283
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Fyfe AI, 1997, CIRCULATION, V96, P2914, DOI 10.1161/01.CIR.96.9.2914
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   He R, 2006, J IMMUNOL, V177, P4072, DOI 10.4049/jimmunol.177.6.4072
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Isas JM, 2009, INVEST OPHTH VIS SCI, V51, P1304
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kaneda S, 2011, INVEST OPHTH VIS SCI, V52, P2982, DOI 10.1167/iovs.10-6299
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komatsu N, 2008, INVEST OPHTH VIS SCI, V49, P5307, DOI 10.1167/iovs.08-2154
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926
   Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Malle E, 1996, EUR J CLIN INVEST, V26, P427, DOI 10.1046/j.1365-2362.1996.159291.x
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Miyazaki D, 2009, INT IMMUNOL, V21, P187, DOI 10.1093/intimm/dxn137
   Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624
   Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Silvestre JS, 2008, CARDIOVASC RES, V78, P242, DOI 10.1093/cvr/cvn027
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   Zhang GC, 2009, J HUM GENET, V54, P624, DOI 10.1038/jhg.2009.97
NR 48
TC 18
Z9 19
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2012
VL 53
IS 7
BP 3424
EP 3430
DI 10.1167/iovs.11-7913
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 971CM
UT WOS:000306181200019
PM 22531705
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Ghiglione, D
   Calabria, G
AF Nicolo, M.
   Ghiglione, D.
   Calabria, G.
TI Retinal pigment epithelial tear following intravitreal injection of
   bevacizumab (Avastin)
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; age-relatedmacular degeneration; choroidal
   neovascularization; tear
ID MACULAR DEGENERATION
AB PURPOSE. To report one case of retinal pigment epithelium tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.
   METHODS. A 59-year-old patient presented with occult choroidal neovascularization associated with a serous pigment epithelial detachment secondary to age-related macular degeneration. The patient was treated with an intravitreal injection of bevacizumab.
   RESULTS. The patient developed a retinal pigment epithelium tear 60 days following the intravitreal injection.
   CONCLUSIONS. This report describes the development of retinal pigment epithelium tear after intravitreal bevacizumab injection. Future studies should be performed to evaluate which subtypes of lesions are most susceptible to this potential devastating visual complication.
C1 Univ Eye Clin, Dept Neurosci Ophthalmol & Genet, Genoa, Italy.
   Ist Biosan, Genoa, Italy.
C3 University of Genoa
RP Nicolo, M (通讯作者)，Via G Macaggi 25-3, I-16121 Genoa, Italy.
EM massimonicolo@occhioallaretina.it
OI Nicolo, Massimo/0000-0002-7824-3091
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GHASSEMIFAR R, 2005, CELL TISSUE RES, V15, P1
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
NR 6
TC 41
Z9 43
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2006
VL 16
IS 5
BP 770
EP 773
DI 10.1177/112067210601600521
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117TJ
UT WOS:000242895900023
PM 17061236
DA 2022-11-30
ER

PT J
AU Saha, R
   Chowdhury, AR
   Banerjee, S
   Chatterjee, T
AF Saha, R.
   Chowdhury, A. Roy
   Banerjee, S.
   Chatterjee, T.
TI DETECTION OF RETINAL ABNORMALITIES USING MACHINE LEARNING METHODOLOGIES
SO NEURAL NETWORK WORLD
LA English
DT Article
DE diabetic retinopathy; age related macular degeneration; multilevel
   thresholding; perceptron; support vector machine
ID DIABETIC-RETINOPATHY; AUTOMATIC DETECTION; SEGMENTATION; IMAGES;
   MICROANEURYSMS; CLASSIFICATION; LESIONS; DRUSEN
AB This paper presents an algorithm for the design of a computer aided diagnosis system to detect, quantify and classify the lesions of non-proliferative diabetic retinopathy as well as dry age related macular degeneration from the fundus retina images. Symptoms of non-proliferative diabetic retinopathy in images consist of bright lesions like hard exudates, cotton wool spots and dark lesions like microaneurysms, hemorrhages. Dry age related macular degeneration is manifested as a bright lesion called drusen. The proposed system consists of two parts: image processing, where preprocessed gray scale images are segmented to extract candidate lesions using a combination of Gaussian filtering and multilevel thresholding followed by classification of the different lesions in non-proliferative diabetic retinopathy and age related macular degeneration using perceptron, support vector machine and naive Bayes classifier. From the comparative performance analysis of the classification techniques, it is observed that comparable results are obtained from single layer perceptron and support vector machine and they both outperform naive Bayes classifier. The classification accuracy of support vector machine classifier for dark lesion class is 97.13% and the classification accuracy of single layer perceptron for bright lesion class is 95.13 % with optimal feature set.
C1 [Saha, R.; Chowdhury, A. Roy] Maulana Abul Kalam Azad Univ Technol, Comp Sci & Engn Dept, Kolkata, W Bengal, India.
   [Banerjee, S.] Maulana Abul Kalam Azad Univ Technol, Dept Nat Sci & IEM, Kolkata, W Bengal, India.
   [Chatterjee, T.] Calcutta Med Coll, Reg Inst Ophthalmol, Kolkata, W Bengal, India.
C3 Maulana Abul Kalam Azad University of Technology; Maulana Abul Kalam
   Azad University of Technology
RP Banerjee, S (通讯作者)，Maulana Abul Kalam Azad Univ Technol, Dept Nat Sci & IEM, Kolkata, W Bengal, India.
EM saha@gmail.com; amrita.me.cse@gmail.com; bsreep96@hotmail.com;
   drtamojit@gmail.com
RI Chatterjee, Tamojit/ABC-2605-2021
FU TEQIP; Department of Biotechnology, Government of India
   [BT/PR4256/BID/7/393/2012]
FX The authors would like to acknowledge a grant from TEQIP and Department
   of Biotechnology, Government of India (No. BT/PR4256/BID/7/393/2012
   dated 02.08.2012) for supporting this research. Authors would like to
   acknowledge Medical College, Kolkata for supplying images for this
   project and for their great support.
CR Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Agurto C, 2010, IEEE T MED IMAGING, V29, P502, DOI 10.1109/TMI.2009.2037146
   Akram MU, 2014, COMPUT BIOL MED, V45, P161, DOI 10.1016/j.compbiomed.2013.11.014
   Alshayeji M, 2017, MED BIOL ENG COMPUT, V55, P935, DOI 10.1007/s11517-016-1563-0
   Anitha J, 2013, NEURAL NETW WORLD, V23, P149, DOI 10.14311/NNW.2013.23.011
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Arora S, 2008, PATTERN RECOGN LETT, V29, P119, DOI 10.1016/j.patrec.2007.09.005
   Banerjee S, 2016, BIOCYBERN BIOMED ENG, V36, P679, DOI 10.1016/j.bbe.2016.07.001
   Banerjee S, 2015, PROCEDIA COMPUT SCI, V46, P402, DOI 10.1016/j.procs.2015.02.037
   Chowdhury A R., 2016, SCI J CIRCUITS SYST, V5, P1, DOI [10.11648/j.cssp.20160501.11, DOI 10.11648/J.CSSP.20160501.11]
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DASGUPTA M., 2014, INT J RES ELECT COMP, V2, P93
   Frame AJ, 1998, COMPUT BIOL MED, V28, P225, DOI 10.1016/S0010-4825(98)00011-0
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2009, IEEE T MED IMAGING, V28, P775, DOI 10.1109/TMI.2008.2012029
   Osareh A, 2003, BRIT J OPHTHALMOL, V87, P1220, DOI 10.1136/bjo.87.10.1220
   Rocha A, 2012, IEEE T BIO-MED ENG, V59, P2244, DOI 10.1109/TBME.2012.2201717
   ROSENBLATT F, 1958, PSYCHOL REV, V65, P386, DOI 10.1037/h0042519
   Roychowdhury S, 2014, IEEE J BIOMED HEALTH, V18, P1717, DOI 10.1109/JBHI.2013.2294635
   Saha R, 2016, LECT NOTES ARTIF INT, V9693, P734, DOI 10.1007/978-3-319-39384-1_65
   Sopharak A, 2008, COMPUT MED IMAG GRAP, V32, P720, DOI 10.1016/j.compmedimag.2008.08.009
   Spencer T, 1996, COMPUT BIOMED RES, V29, P284, DOI 10.1006/cbmr.1996.0021
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Wisaeng K., 2013, Applied Medical Informatics, V32, P33
   Witten IH, 2011, MOR KAUF D, P3, DOI 10.1016/B978-0-12-374856-0.00001-8
NR 26
TC 4
Z9 4
U1 0
U2 4
PU ACAD SCIENCES CZECH REPUBLIC, INST COMPUTER SCIENCE
PI 182 07 PRAGUE 8
PA POD VODARENSKOU VEZI 2, 182 07 PRAGUE 8, 00000, CZECH REPUBLIC
SN 1210-0552
J9 NEURAL NETW WORLD
JI Neural Netw. World
PY 2018
VL 28
IS 5
BP 457
EP 471
DI 10.14311/NNW.2018.28.025
PG 15
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA GZ5EK
UT WOS:000449440400003
OA Bronze
DA 2022-11-30
ER

PT J
AU Stern, J
   Temple, S
AF Stern, Jeffrey
   Temple, Sally
TI Retinal pigment epithelial cell proliferation
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Retinal pigment epithelium; retinal pigment epithelial proliferation;
   wound repair; stem cell; age-related macular degeneration; age-related
   macular degeneration; choroidal neovascularization; choroidal
   neovascularization; proliferative vitreoretinopathy; proliferative
   vitreoretinopathy
ID HUMAN BRUCHS MEMBRANE; PLURIPOTENT STEM-CELLS; ADULT HUMAN RPE;
   CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; MESENCHYMAL
   TRANSITION; DIRECTED DIFFERENTIATION; RETINITIS PIGMENTOSA; PROTEIN
   EXPRESSION; NATURAL-HISTORY
AB The human retinal pigment epithelium forms early in development and subsequently remains dormant, undergoing minimal proliferation throughout normal life. Retinal pigment epithelium proliferation, however, can be activated in disease states or by removing retinal pigment epithelial cells into culture. We review the conditions that control retinal pigment epithelial proliferation in culture, in animal models and in human disease and interpret retinal pigment epithelium proliferation in context of the recently discovered retinal pigment epithelium stem cell that is responsible for most in vitro retinal pigment epithelial proliferation. Retinal pigment epithelial proliferation-mediated wound repair that occurs in selected macular diseases is contrasted with retinal pigment epithelial proliferation-mediated fibroblastic scar formation that underlies proliferative vitreoretinopathy. We discuss the role of retinal pigment epithelial proliferation in age-related macular degeneration which is reparative in some cases and destructive in others. Macular retinal pigment epithelium wound repair and regression of choroidal neovascularization are more pronounced in younger than older patients. We discuss the possibility that the limited retinal pigment epithelial proliferation and latent wound repair in older age-related macular degeneration patients can be stimulated to promote disease regression in age-related macular degeneration.
C1 [Stern, Jeffrey; Temple, Sally] Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
   [Stern, Jeffrey] Capital Reg Retina PLLC, Albany, NY 12206 USA.
RP Stern, J (通讯作者)，Neural Stem Cell Inst, One Discovery Dr, Rensselaer, NY 12144 USA.
EM retina@nycap.rr.com
FU NEI [RO1-EY-022079]; NEI Audacious Goals Prize; NYSTEM Consortium Grant
   Award [CO028504]; NATIONAL EYE INSTITUTE [R01EY022079] Funding Source:
   NIH RePORTER
FX Funding from the NEI RO1-EY-022079 (ST), an NEI Audacious Goals Prize
   (JS), and a NYSTEM Consortium Grant Award CO028504 (ST, JS).
CR ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Blenkinsop TA, 2012, REGEN MED, V7, P32, DOI [10.2217/RME.12.77, 10.2217/rme.12.77]
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   BOK D, 1993, J CELL SCI, P189
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   CAMPOCHIARO PA, 1990, AM J OPHTHALMOL, V109, P668, DOI 10.1016/S0002-9394(14)72435-3
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   FLANNERY JG, 1989, INVEST OPHTH VIS SCI, V30, P191
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   Gass J D, 1994, Trans Am Ophthalmol Soc, V92, P91
   Gass JD, 1994, T AM OPHTHAL SOC, V92, P111
   Gass JD, STEREOSCOPIC ATLAS M, V4, P26
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Hasegawa M., 1958, EMBRYOLOGIA, V4, P1, DOI [10.1111/j.1440-169X.1958.tb00145.x, DOI 10.1111/J.1440-169X.1958.TB00145.X]
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Hu J, 2001, MOL VIS, V7, P14
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kaida M, 2000, INVEST OPHTH VIS SCI, V41, P3215
   KEEFE JR, 1973, J EXP ZOOL, V184, P239, DOI 10.1002/jez.1401840209
   KLEINER RC, 1988, RETINA-J RET VIT DIS, V8, P225, DOI 10.1097/00006982-198808040-00001
   Klimanskaya I, 2006, METHOD ENZYMOL, V418, P169, DOI 10.1016/S0076-6879(06)18011-8
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   LEFF SR, 1989, RETINA-J RET VIT DIS, V9, P267, DOI 10.1097/00006982-198909040-00005
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Li R, 2009, INVEST OPHTH VIS SCI, V50, P5988, DOI 10.1167/iovs.09-3591
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   MACHEMER R, 1975, AM J OPHTHALMOL, V80, P1
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mann I., 1949, DEV HUMAN EYE
   MANNAGH J, 1973, INVEST OPHTH VISUAL, V12, P52
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Milyushina LA, 2011, B EXP BIOL MED+, V151, P506, DOI 10.1007/s10517-011-1368-y
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750
   Rabin DM, 2013, AGING-US, V5, P51
   RODRIGUES MM, 1985, OPHTHALMOLOGY, V92, P1165
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505
   Shields JA, 2005, RETIN PHYS
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Spraul CW, 2004, OPHTHAL RES, V36, P166, DOI 10.1159/000077330
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Stern Jeffrey, 2014, F1000Res, V3, P293, DOI 10.12688/f1000research.5683.1
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   STROEVA OG, 1983, INT REV CYTOL, V83, P221, DOI 10.1016/S0074-7696(08)61689-7
   Sugino IK, 2014, DEV OPHTHALMOL, V53, P133, DOI 10.1159/000358531
   Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Veloso CE, 2007, EYE, V21, P1429, DOI 10.1038/sj.eye.6702940
   VERSTRAETEN TC, 1990, INVEST OPHTH VIS SCI, V31, P481
   WALLOW IHL, 1973, AM J OPHTHALMOL, V75, P32, DOI 10.1016/0002-9394(73)90651-X
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang H, 2006, J REHABIL RES DEV, V43, P713, DOI 10.1682/JRRD.2005.06.0114
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zinn KM, 1979, RETINAL PIGMENT EPIT
NR 78
TC 39
Z9 40
U1 0
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD AUG
PY 2015
VL 240
IS 8
BP 1079
EP 1086
DI 10.1177/1535370215587530
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CP2WP
UT WOS:000359738700009
PM 26041390
OA Green Published
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Teo, KYC
   Spaide, RF
AF Cheung, Chui Ming Gemmy
   Teo, Kelvin Yi Chong
   Spaide, Richard F.
TI PULSATILE FILLING OF DILATED CHOROIDAL VESSELS IN MACULAR WATERSHED
   ZONES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal blood flow; indocyanine green angiography; intervortex venous
   anastomoses; pachychoroid
ID INDOCYANINE GREEN ANGIOGRAPHY; VORTEX VEIN; BLOOD-FLOW; VASCULOPATHY;
   CIRCULATION; PRESSURES; OCCLUSION
AB Purpose: To describe pulsatile filling of dilated choroidal veins in the watershed zones and propose an alteration in choroidal perfusion pressure.
   Methods: Retrospective review of original and digital subtraction indocyanine green angiography.
   Results: We observed pulsating blood flow within choroidal vein segments in the posterior pole in 14 eyes (diagnosis of polypoidal choroidal vasculopathy, central serous chorioretinopathy, or neovascular age-related macular degeneration). Pulsating dye front was observed in single or multiple large choroidal vein(s) in a location that is ordinarily a watershed zone between the segmental areas of venous drainage, and vessels proximal and distal were often dilated. The pulsatile venous segments filled more slowly than the neighboring veins. In digital subtraction indocyanine green angiography, the dye front advanced in an incremental fashion or oscillated in a back-and-forth manner during several cardiac cycles during the filling of these larger choroidal veins. With indocyanine green angiography, we observed dilated choroidal veins that violated the macula watershed zone, localized bulbous dilations, and arteriole-over-vein crossings with apparent compression.
   Conclusion: These novel observations suggest the pressure gradient for flow in the affected veins varied from low gradients when the filling was slow to high gradients when the filling was faster. The vessels violated the physiological watershed zone and seem to function as anastomoses between the ordinarily segmented venous drainage of the choroid. The dilated segments may result in pooling of venous blood as part of venous outflow abnormalities that may be operative in these diseases.
C1 [Cheung, Chui Ming Gemmy; Teo, Kelvin Yi Chong] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Med Retina Dept, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Teo, Kelvin Yi Chong] Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Duke NUS Med Sch, Singapore, Singapore.
   [Spaide, Richard F.] Retina Consultants, Macula, Vitreous, New York, NY USA.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
OI Teo, Kelvin/0000-0002-7458-7081
CR BILL A, 1962, EXP EYE RES, V1, P193, DOI 10.1016/S0014-4835(62)80001-3
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   HAYREH SS, 1971, BRIT J OPHTHALMOL, V55, P649, DOI 10.1136/bjo.55.10.649
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kutoglu T, 2005, CLIN ANAT, V18, P269, DOI 10.1002/ca.20092
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li CY, 2018, INVEST OPHTH VIS SCI, V59, P5032, DOI 10.1167/iovs.18-24954
   LIM MC, 1995, OPHTHALMOLOGY, V102, P942, DOI 10.1016/S0161-6420(95)30930-X
   Lutjen-Drecoll E, 2006, EXP EYE RES, V82, P357, DOI 10.1016/j.exer.2005.09.015
   MAEPEA O, 1992, EXP EYE RES, V54, P731, DOI 10.1016/0014-4835(92)90028-Q
   Matsumoto H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75789-w
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   MCLEOD D, 1976, BRIT J OPHTHALMOL, V60, P419, DOI 10.1136/bjo.60.6.419
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Paques M, 2001, ARCH OPHTHALMOL-CHIC, V119, P1781, DOI 10.1001/archopht.119.12.1781
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Reiner A, 2018, PROG RETIN EYE RES, V64, P96, DOI 10.1016/j.preteyeres.2017.12.001
   SCHATZ H, 1991, OPHTHALMOLOGY, V98, P594
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P680, DOI 10.1016/S0161-6420(98)94024-6
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P231, DOI 10.1097/IAE.0000000000003057
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   Spaide RF, 2020, RETINA-J RET VIT DIS, V40, pE60, DOI 10.1097/IAE.0000000000002930
   Spaide RF, 2020, RETINA-J RET VIT DIS, V40, P1851, DOI 10.1097/IAE.0000000000002931
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
   Yu PK, 2010, INVEST OPHTH VIS SCI, V51, P6735, DOI 10.1167/iovs.10-5415
NR 35
TC 5
Z9 5
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2021
VL 41
IS 11
BP 2370
EP 2377
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB6BH
UT WOS:000756924700023
PM 34264572
DA 2022-11-30
ER

PT J
AU Rouvas, AA
   Papakostas, TD
   Ntouraki, A
   Douvali, M
   Vergados, I
   Ladas, ID
AF Rouvas, Alexandros A.
   Papakostas, Thanos D.
   Ntouraki, Amalia
   Douvali, Maria
   Vergados, Ioannis
   Ladas, Ioannis D.
TI PHOTODYNAMIC THERAPY, RANIBIZUMAB, AND RANIBIZUMAB WITH PHOTODYNAMIC
   THERAPY FOR THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy (PCV); ranibizumab; PDT; combination
ID INTRAVITREAL BEVACIZUMAB INJECTION; PIGMENT EPITHELIAL DETACHMENT;
   ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; LASER PHOTOCOAGULATION;
   JAPANESE PATIENTS; CLINICOPATHOLOGICAL CORRELATION; SUBMACULAR
   HEMORRHAGE; CHINESE PATIENTS; FOLLOW-UP
AB Purpose: The purpose of this study was to compare photodynamic therapy (PDT), ranibizumab, and ranibizumab with PDT in polypoidal choroidal vasculopathy.
   Methods: In this retrospective comparative study, 30 eyes of 30 patients with polypoidal choroidal vasculopathy were assigned to 1 of the 3 groups. The patients in Group 1 (n = 11) received 1 session of PDT. The patients in Group 2 (n = 10) received 3 monthly intravitreal injections of 0.5 mg ranibizumab, and the patients in Group 3 (n = 9) received 1 session of PDT and 3 injections of 0.5 mg ranibizumab. Retreatment, with the same therapeutic scheme in each group, was considered in case of leaking polyps on the indocyanine green angiography in Groups 1 and 3 and persistence or recurrence of subretinal fluid, intraretinal fluid, and/or hemorrhages in Group 2.
   Results: All the patients completed 12 months of follow-up. The visual acuity in the patients of Group 1 improved by 0.25 logarithm of the minimum angle of resolution units (P< 0.001), whereas the differences in the visual acuity in the other 2 groups were not statistically significant (0.04 logarithm of the minimum angle of resolution, P = 0.8118 in Group 2 and 0.18 logarithm of the minimum angle of resolution, P> 0.05 in Group 3). Of the patients in Group 1, 45.45% gained more than 3 lines (P = 0.0056), whereas no patient in Groups 2 and 3 experienced such a difference. No patient in Group 1 and 11.1% (n = 1) in Group 3 had angiographically evident polyps at 12 months, whereas 90% (n = 9) of the patients in Group 2 had persistent leakage. No extensive submacular hemorrhage or other complications were noted during the follow-up period.
   Conclusion: Photodynamic therapy resulted in a significantly better outcome at the end of the follow-up, whereas the patients who received ranibizumab or PDT and ranibizumab experienced a stabilization of the disease. RETINA 31: 464-474, 2011
C1 [Rouvas, Alexandros A.; Ntouraki, Amalia; Douvali, Maria; Vergados, Ioannis] Univ Athens, Sch Med, Dept Ophthalmol 2, GR-11527 Athens, Greece.
   [Papakostas, Thanos D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
   [Ladas, Ioannis D.] Univ Athens, Sch Med, Dept Ophthalmol 1, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Athens Medical School; National & Kapodistrian University of
   Athens
RP Rouvas, AA (通讯作者)，Univ Athens, Sch Med, Attikon Univ Hosp, Dept Ophthalmol 2, 1 Rimini St, GR-11527 Athens, Greece.
EM rallex@hol.gr
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BYEON SH, 2009, ACTA OPHTHALMOL
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pai SA, 2009, ACTA OPHTHALMOL, V87, P806, DOI 10.1111/j.1755-3768.2008.01330.x
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Torrón Fernández-Blanco C, 2003, Arch Soc Esp Oftalmol, V78, P471
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vilaplana D, 2005, Arch Soc Esp Oftalmol, V80, P597
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 69
TC 47
Z9 55
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2011
VL 31
IS 3
BP 464
EP 474
DI 10.1097/IAE.0b013e3181f274ec
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722YW
UT WOS:000287472400006
PM 20948458
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Bordato, A
   Amato, A
   Borghesan, F
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Bordato, Alessandro
   Amato, Alessia
   Borghesan, Federico
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Morphological and Functional Relationship Between OCTA and FA/ICGA
   Quantitative Features in AMD-Related Macular Neovascularization
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE age-related macular degeneration; OCT; OCTA; MNV; vessel density; vessel
   tortuosity
ID CHOROIDAL NEOVASCULARIZATION; NATURAL-HISTORY; DEGENERATION
AB Background: The aim was to study the relationship between quantitative information provided by optical coherence tomography (OCT) angiography (OCTA) and conventional angiography in macular neovascularization (MNV) secondary to age-related macular degeneration (AMD).
   Methods: The research was designed as an interventional, prospective study. We included 66 eyes (66 patients) affected by naive MNV. Multimodal imaging included structural OCT, OCTA, fluorescein angiography (FA), and indocyanine green angiography (ICGA). The follow-up lasted 1 year. Patients were treated by PRN anti-VEGF injections. Based on FA/ICGA examinations, we divided the patients into two categories: low vessel tortuosity (VT) (<8.40) and high VT (>8.40), correlating VT with the MNV area, leakage area, speckled fluorescence (SF) quadrants and MNV area/leakage area ratio.
   Results: Mean baseline BCVA was 0.50 +/- 0.61 LogMAR, improved to 0.31 +/- 0.29 LogMAR after 1 year (p < 0.01), with a mean number of 7 +/- 2 anti-VEGF injections. The patients revealed type-1 MNV in 36 eyes (55%), mixed type 1 and 2 MNV in 18 eyes (27%), and type-2 MNV in 12 eyes (18%). MNV eyes in high-VT MNV featured poorer BCVA, CMT, and OCTA parameters, higher SF quadrants, and less exudation, compared with low-VT MNV (p < 0.01). Moreover, 30% of high-VT MNV eyes developed outer retinal atrophy.
   Conclusions: Low VT MNV turned out to be more exudative at the baseline but less damaging to the outer retinal structures, whereas high VT MNV proved to be less exudative but more prone to lead to atrophic changes and visual function deterioration. VT may be usefully applied to artificial intelligence-based models designed to characterize MNV secondary to AMD.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Bordato, Alessandro; Amato, Alessia; Borghesan, Federico; Bandello, Francesco; Parodi, Maurizio Battaglia] Ist Sci San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Ist Sci San Raffaele, Dept Ophthalmol, Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR Adler P., 2013, POROUS MEDIA GEOMETR
   Arrigo A, 2021, RETINA-J RET VIT DIS, V41, P1463, DOI 10.1097/IAE.0000000000003065
   Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Arrigo A, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.26
   Arrigo A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091425
   Arrigo A, 2018, AM J OPHTHALMOL, V195, P233, DOI 10.1016/j.ajo.2018.08.001
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Goldman D, 2000, J THEOR BIOL, V206, P181, DOI 10.1006/jtbi.2000.2113
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Rabiolo A, 2016, EXPERT REV OPHTHALMO, V11, P243, DOI 10.1080/17469899.2016.1209409
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Tomita Y, 2005, J CEREBR BLOOD F MET, V25, P858, DOI 10.1038/sj.jcbfm.9600077
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 21
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD OCT 20
PY 2021
VL 8
AR 758668
DI 10.3389/fmed.2021.758668
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA WU6FY
UT WOS:000716640500001
PM 34746193
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Knudtson, MD
   Klein, R
   Klein, BEK
   Lee, KE
   Meuer, SM
   Tomany, SC
AF Knudtson, MD
   Klein, R
   Klein, BEK
   Lee, KE
   Meuer, SM
   Tomany, SC
TI Location of lesions associated with age-related maculopathy over a
   10-year period: The Beaver Dam Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-ACUITY; POPULATION; DRUSEN; RISK
AB PURPOSE. To describe cumulative incidence and changes in retinal lesions associated with age-related maculopathy ( ARM) by location over a 10-year period and to examine the relation of location of those lesions to progression of ARM.
   METHODS. Persons ranging in age from 43 to 84 years and living in Beaver Dam, Wisconsin, at the time of a census (1987-1988) were examined two to three times over a 10-year period (n = 3684). Drusen area, size, and type; retinal pigment epithelium depigmentation; increased pigment; geographic atrophy; and neovascular macular degeneration were determined in each of nine macular subfields: central, inner and outer superior, inner and outer nasal, inner and outer inferior, and inner and outer temporal by grading of stereoscopic color fundus photographs. Late ARM was defined as presence of either geographic atrophy or neovascular ARM.
   RESULTS. Lesions were more likely to change or develop in specific locations. Drusen area increased most in the central circle. Compared with other quadrants, drusen greater than 125 mum in diameter and soft indistinct or reticular drusen were most likely to develop in the superior or temporal quadrants, whereas pigmentary abnormalities were most likely to occur in the nasal or superior quadrants. In general, large drusen, soft indistinct drusen, and pigmentary abnormalities were more likely to develop in the inner circle versus the central and outer circles. The quadrant location of early ARM lesions in 72 persons in whom late ARM developed was generally similar to that in persons who did not have late ARM. However, persons who had geographic atrophy were more likely to have large drusen in the inner circle than in the outer circle, while those who did not have late ARM were more likely to have large drusen in the outer circle.
   CONCLUSIONS. Lesions associated with early ARM were more likely to develop in specific locations in the macular area, and persons with lesions closer to the fovea may be related to a higher risk of development of late ARM. The quadrant location of early ARM lesions does not appear to add additional information to the risk of development of late ARM.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Knudtson, MD (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM knudtson@epi.ophth.wisc.edu
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   [Anonymous], [No title captured]
   [Anonymous], 1999, SAS STAT US GUID VER
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS, DOI [10.1007/0-387-22747-4_1, DOI 10.1007/B98882]
   Prevent Blindness America, 2002, VIS PROBL US PREV AD, P1
   Sarks S., 1985, RETINAL DIS, P87
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sliney D H, 1999, J Epidemiol, V9, pS22
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
NR 22
TC 32
Z9 32
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2004
VL 45
IS 7
BP 2135
EP 2142
DI 10.1167/iovs.03-1085
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 833VH
UT WOS:000222367900012
PM 15223787
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Bordato, A
   Amato, A
   Saladino, A
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Bordato, Alessandro
   Amato, Alessia
   Saladino, Andrea
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI High Reflectivity and Low Reflectivity Properties on OCTA Influence the
   Detection of Macular Neovascularization in AMD
SO FRONTIERS IN PHYSICS
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography
   angiography; macular neovascularization; fluorescein angiography;
   indocyanine green angiography
ID TYPE-1
AB Background: In this study, we aimed to discriminate high reflectivity and low reflectivity macular neovascularization (MNV) lesions secondary to age-related macular degeneration (AMD)and to assess the influence of blood flow features on the amount of MNV detected by optical coherence tomography angiography (OCTA). Methods: The study was designed as observational, cross-sectional. Type 1 and type 2 MNV lesions were included. All the patients underwent fluorescein angiography (FA), indocyanine green angiography (ICGA) and OCTA. MNV size was calculated on early FA for type 2 MNV and on both early and late phases of ICGA for type 1 lesions. From OCTA, we calculated both MNV size and MNV reflectivity. We assessed the agreement between FA/ICGA and OCTA MNV sizes. Moreover, we studied the relationship between MNV reflectivity properties and MNV OCTA detection. Results: Fifty eyes (50 patients) were included. MNV was identified as follows: 35 /70%) type 1 and 15 (30%) type 2. We found a good agreement between early ICGA size and OCTA size for type 1 MNV (2.10 +/- 1.91 mm(2) vs 2.09 +/- 1.87 mm(2); p > 0.05), whereas MNV lesions turned out to be remarkably bigger on late ICGA phase (3.41 +/- 2.87 mm(2); p < 0.01). Interestingly, OCTA well-matched with FA in terms of MNV size for type 2 lesions (2.36 +/- 2.15 mm(2) vs 2.37 +/- 2.25 mm(2)). MNV reflectivity was higher in type 2 MNV and it was strongly associated with the OCTA ability to reconstruct the neovascular network. Conclusion: Our study quantitatively showed that MNV filling pattern and MNV blood flow reflectivity features influence the OCTA detection of the MNV in its entirety.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Bordato, Alessandro; Amato, Alessia; Saladino, Andrea; Bandello, Francesco; Parodi, Maurizio Battaglia] Univ Vita Salute, San Raffaele Hosp, Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute, San Raffaele Hosp, Sci Inst, Dept Ophthalmol, Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Haas AM, 2021, ACTA OPHTHALMOL, V99, pE260, DOI 10.1111/aos.14572
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Scharf J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040751
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
NR 9
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-424X
J9 FRONT PHYS-LAUSANNE
JI Front. Physics
PD JUN 17
PY 2021
VL 9
AR 694035
DI 10.3389/fphy.2021.694035
PG 7
WC Physics, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physics
GA TC4QI
UT WOS:000668624600001
OA gold
DA 2022-11-30
ER

PT J
AU Punjabi, OS
   Huang, J
   Rodriguez, L
   Lyon, AT
   Jampol, LM
   Mirza, RG
AF Punjabi, Omar S.
   Huang, Joyce
   Rodriguez, Lina
   Lyon, Alice T.
   Jampol, Lee M.
   Mirza, Rukhsana G.
TI Imaging characteristics of neovascular pigment epithelial detachments
   and their response to anti-vascular endothelial growth factor therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; Imaging; Macula
ID OCCULT CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; SECONDARY
AB Purpose
   To evaluate the imaging characteristics of macular neovascular pigment epithelial detachments (PEDs) and their response to anti-vascular endothelial growth factor (VEGF) therapy.
   Methods
   Patients with exudative age-related macular degeneration (AMD), idiopathic polypoidal choroidal vasculopathy, presumed ocular histoplasmosis syndrome (POHS) and central serous retinopathy (CSR) with choroidal neovascularisation (CNV) were included in the study. A retrospective chart review of 72 eyes of 64 patients was performed.
   Results
   Three types of PEDs were identified based on reflectivity of the material under the retinal pigment epithelium on optical coherence tomography: hollow (26 eyes with primarily hyporeflectivity under the PED), solid (30 eyes with primarily hyperreflective signal under the PED) and mixed (8 eyes with mixed reflectivity). The average number of anti-VEGF injections was 7 per eye and the average duration of follow-up was 16months. Among eyes with exudative AMD, 7/21 hollow PEDs flattened, 1/19 solid PEDs flattened and 2/6 mixed PEDs flattened after anti-VEGF therapy. POHS and CSR with CNV were associated with subfoveal solid PEDs and were unchanged after therapy. Overall, 46% (12/26) with hollow PEDs, 25% (2/8) with mixed PEDs and 3% (1/30) with solid PEDs had flattening after anti-VEGF therapy.
   Conclusions
   The likelihood of PED flattening was inversely related to the reflectivity of the PED. The more reflective the PED, the less likely resolution with anti-VEGF therapy occurred.
C1 [Punjabi, Omar S.; Huang, Joyce; Rodriguez, Lina; Lyon, Alice T.; Jampol, Lee M.; Mirza, Rukhsana G.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Mirza, RG (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 N Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM r-mirza@northwestern.edu
FU Research to Prevent Blindness, New York, NY, USA
FX Supported by an unrestricted grant from Research to Prevent Blindness,
   New York, NY, USA.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lumbroso B, 2011, RETINA-J RET VIT DIS, V31, P553, DOI 10.1097/IAE.0b013e3181eef3eb
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
NR 17
TC 21
Z9 22
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2013
VL 97
IS 8
BP 1024
EP 1031
DI 10.1136/bjophthalmol-2013-303155
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186JI
UT WOS:000322039400018
PM 23759437
DA 2022-11-30
ER

PT J
AU Qiu, BJ
   Zhang, XY
   Li, ZQ
   Chhablani, J
   Fan, H
   Wang, YH
   Xie, R
AF Qiu, Bingjie
   Zhang, Xinyuan
   Li, Zhiqing
   Chhablani, Jay
   Fan, Hao
   Wang, Yanhong
   Xie, Rui
TI Characterization of Choroidal Morphology and Vasculature in the
   Phenotype of Pachychoroid Diseases by Swept-Source OCT and OCTA
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE pachychoroid disorders; polypoidal choroidal vasculopathy; neovascular
   age-related macular degeneration; central serous chorioretinopathy;
   swept-source OCT; OCTA quantitative analysis
ID MACULAR DEGENERATION; VASCULOPATHY; AGE; EVEREST; MULTICENTER;
   THICKNESS; DIAGNOSIS; JAPANESE; SUBTYPES
AB The objective of this study was to characterize the choroidal morphology and vasculature in pachychoroid diseases (PCD). A total of 49 eyes with polypoidal choroidal vasculopathy (PCV), 43 eyes with neovascular age-related macular degeneration (nAMD), and 50 eyes with central serous chorioretinopathy (CSC), along with 80 healthy eyes, were enrolled in this nested case-control study. The swept-source optical coherent tomography (OCT), OCT angiography, and En face images were quantitatively analyzed. Multivariate logistic regression models showed that older age and increased vessel density (VD) in the choriocapillaris (CC) layer were independent risk factors for both PCV (p(age) < 0.001, p(VD) = 0.004), and nAMD (p(age) < 0.001, p(VD) = 0.005). Decreased VD in the Sattler's layer was an independent risk factor for PCV (p = 0.014). Increased VD in the Haller's layer was an independent risk factor for CSC (p = 0.001). The proportion of the diffuse type of collateral circulation in the Sattler' layer in CSC group was significantly higher than in the other three groups (p < 0.001). We concluded that the involvement of the blood flow in the CC, Haller's, and Sattler's layers are differently affected in CSC, nAMD, and PCV eyes, indicating the different pathological mechanism underlying the phenotype of PCD. The age-dependent establishment of collateral circulation in the Sattler's layer may play a compensatory role regarding ischemic injury in the development of PCD.
C1 [Qiu, Bingjie; Zhang, Xinyuan; Xie, Rui] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
   [Qiu, Bingjie; Zhang, Xinyuan; Xie, Rui] Beijing Retinal & Choroidal Vasc Disorders Study, Beijing 100730, Peoples R China.
   [Li, Zhiqing; Fan, Hao] Tianjin Med Univ, Tianjin Med Univ Eye Hosp, Tianjin 300392, Peoples R China.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15213 USA.
   [Wang, Yanhong] Chinese Acad Med Sci, Dept Epidemiol & Biostat, Inst Basic Med Sci, Beijing 100005, Peoples R China.
   [Wang, Yanhong] Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China.
C3 Capital Medical University; Tianjin Medical University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College
RP Zhang, XY (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.; Zhang, XY (通讯作者)，Beijing Retinal & Choroidal Vasc Disorders Study, Beijing 100730, Peoples R China.
EM qiubingjie16@mail.ccmu.edu.cn; mmzxy@mail.ccmu.edu.cn;
   drzhiqing_li@163.com; jay.chhablani@gmail.com; fh960316@163.com;
   wyhong826@pumc.edu.cn; sherry1996@ccmu.edu.cn
RI wang, yi/GVT-8516-2022; Wang, Yanbo/HFZ-8018-2022; wang,
   yan/GSE-6489-2022; Wang, Yin/HCI-9352-2022; Wang, Yu/GZL-9655-2022
OI Fan, Hao/0000-0002-7297-6526; Zhang, Xinyuan/0000-0002-3372-0798; Qiu,
   Bingjie/0000-0002-2527-4337; Chhablani, Jay/0000-0003-1772-3558
FU National Natural Science Foundation of China [81570850, 81170859,
   82070988]; Ministry of Science and Technology Foundation of China
   [2016YFC1305604]
FX This work is supported by the National Natural Science Foundation of
   China (Grant 81570850, 81170859 and 82070988) and the Ministry of
   Science and Technology Foundation of China (Grant 2016YFC1305604).
CR Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bartol-Puyal FD, 2020, INT OPHTHALMOL, V40, P3135, DOI 10.1007/s10792-020-01500-7
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Faber JE, 2014, ARTERIOSCL THROM VAS, V34, P1854, DOI 10.1161/ATVBAHA.114.303929
   Faber JE, 2011, ARTERIOSCL THROM VAS, V31, P1748, DOI 10.1161/ATVBAHA.111.227314
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim M, 2014, OPTOMETRY VISION SCI, V91, P491, DOI 10.1097/OPX.0000000000000229
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Nicolo M, 2017, INVEST OPHTH VIS SCI, V58, P2002, DOI 10.1167/iovs.17-21417
   Qiu BJ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.778283
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Waldstein SM, 2015, EYE, V29, P409, DOI 10.1038/eye.2014.319
   Wang JC, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.25
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   WEITER JJ, 1974, AM J OPHTHALMOL, V78, P583, DOI 10.1016/S0002-9394(14)76294-4
   Xie R, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.783519
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
NR 34
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2022
VL 11
IS 11
AR 3243
DI 10.3390/jcm11113243
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1Z5HH
UT WOS:000808855000001
PM 35683628
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Krebs, I
   Hagen, S
   Haas, P
   Glittenberg, C
   Binder, S
AF Krebs, I.
   Hagen, S.
   Haas, P.
   Glittenberg, C.
   Binder, S.
TI The vitreo-retinal interface in macular diseases
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Review
DE Detachment of the posterior hyaloid (PVD); anomalous vitreous
   detachment; macular hole; age-related macular degeneration; macular
   pucker; vitreomacular traction syndrome; diabetic macular edema
ID POSTERIOR VITREOUS DETACHMENT; VITREOMACULAR TRACTION SYNDROME;
   OPTICAL-COHERENCE-TOMOGRAPHY; PROLIFERATIVE DIABETIC-RETINOPATHY;
   PHARMACOLOGICAL VITREOLYSIS; INTRAVITREAL TRIAMCINOLONE; EPIRETINAL
   PATHOLOGY; HYALOIDAL TRACTION; GROWTH-FACTOR; EDEMA
AB Anomalous posterior vitreous detachment occurs, when the extent of vitreous liquefaction exceeds the degree of weakening of vitreo-retinal adherence and traction is exerted at the vitreo-retinal interface. In the macular region vitreo-macular traction is obviously correlated with macular disorders like macular pucker, epiretinal membrane, macular hole formation, and vitreo-macular traction syndrome. The pathogenesis of diabetic macular edema and exudative age-related macular degeneration is more complex. However, the effectivity of vitrectomy in diabetic macular edema and high incidence of vitreoretinal adhesions in exudative age-related macular degeneration underscore the important role of the vitreous in the pathogenesis of these diseases.
C1 [Krebs, I.; Hagen, S.; Haas, P.; Glittenberg, C.; Binder, S.] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, I.; Hagen, S.; Haas, P.; Glittenberg, C.; Binder, S.] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomikroskop Lase, A-1030 Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
CR Aaberg T. M., 1970, SURV OPHTHALMOL, V15, P139
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   APPIAH AP, 1988, AM J OPHTHALMOL, V106, P533, DOI 10.1016/0002-9394(88)90581-8
   AVILA MP, 1983, OPHTHALMOLOGY, V90, P1277
   Carpineto P, 2004, EUR J OPHTHALMOL, V14, P67, DOI 10.1177/112067210401400113
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Chu TG, 1996, OPHTHALMOLOGY, V103, P315
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ebato K, 2000, OPHTHALMIC SURG LAS, V31, P245
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   FOOS RY, 1978, AM J OPHTHALMOL, V86, P723, DOI 10.1016/0002-9394(78)90204-0
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200003000-00001
   Gandorfer A, 2005, AM J OPHTHALMOL, V139, P638, DOI 10.1016/j.ajo.2004.11.035
   Gandorfer A, 2002, BRIT J OPHTHALMOL, V86, P902, DOI 10.1136/bjo.86.8.902
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3
   Gaucher D, 2005, AM J OPHTHALMOL, V139, P807, DOI 10.1016/j.ajo.2004.12.084
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Harbour JW, 1996, AM J OPHTHALMOL, V121, P405, DOI 10.1016/S0002-9394(14)70437-4
   Hashimoto E, 1998, BRIT J OPHTHALMOL, V82, P326
   HIKICHI T, 1995, AM J OPHTHALMOL, V119, P55, DOI 10.1016/S0002-9394(14)73813-9
   Hikichi T, 1997, OPHTHALMOLOGY, V104, P473, DOI 10.1016/S0161-6420(97)30289-9
   HIKICHI T, 1995, RETINA-J RET VIT DIS, V15, P413, DOI 10.1097/00006982-199515050-00007
   Hirayama K, 2004, INVEST OPHTH VIS SCI, V45, P3896, DOI 10.1167/iovs.03-1330
   HISCOTT PS, 1984, BRIT J OPHTHALMOL, V68, P698, DOI 10.1136/bjo.68.10.698
   Ito Y, 2003, AM J OPHTHALMOL, V135, P351, DOI 10.1016/S0002-9394(02)01944-X
   JAFFE NS, 1968, ARCH OPHTHALMOL-CHIC, V79, P568
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Johnson MW, 2005, AM J OPHTHALMOL, V140, P184, DOI 10.1016/j.ajo.2005.01.033
   Kaiser PK, 2001, AM J OPHTHALMOL, V131, P44, DOI 10.1016/S0002-9394(00)00872-2
   KAKEHASHI A, 1994, OPHTHALMOLOGY, V101, P1515
   KISHI S, 1986, INT OPHTHALMOL, V9, P253, DOI 10.1007/BF00137539
   KISHI S, 1994, AM J OPHTHALMOL, V118, P451, DOI 10.1016/S0002-9394(14)75795-2
   Kita T, 2007, DIABETES, V56, P1421, DOI 10.2337/db06-1644
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   La Heij EC, 2001, GRAEF ARCH CLIN EXP, V239, P264, DOI 10.1007/s004170000251
   Larsson J, 2004, ACTA OPHTHALMOL SCAN, V82, P691, DOI 10.1111/j.1600-0420.2004.00344.x
   LARSSON L, 1985, GRAEF ARCH CLIN EXP, V223, P92, DOI 10.1007/BF02150952
   Lecleire-Collet A, 2007, ACTA OPHTHALMOL SCAN, V85, P795, DOI 10.1111/j.1600-0420.2007.00925.x
   Levy Jaime, 2004, Int Ophthalmol, V25, P247, DOI 10.1007/s10792-005-8249-1
   LEWIS H, 1992, OPHTHALMOLOGY, V99, P753
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Michels R G, 1982, Trans Am Ophthalmol Soc, V80, P580
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   NASRALLAH FP, 1989, OPHTHALMOLOGY, V96, P1511
   NASRALLAH FP, 1989, OPHTHALMOLOGY, V96, P1516
   NOVAK MA, 1984, AM J OPHTHALMOL, V97, P308, DOI 10.1016/0002-9394(84)90628-7
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Otani T, 2002, AM J OPHTHALMOL, V134, P214, DOI 10.1016/S0002-9394(02)01548-9
   Pendergast SD, 2000, AM J OPHTHALMOL, V130, P178, DOI 10.1016/S0002-9394(00)00472-4
   Qiao H, 2005, BRIT J OPHTHALMOL, V89, P513, DOI 10.1136/bjo.2004.050658
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Schumann RG, 2006, AM J OPHTHALMOL, V141, P1112, DOI 10.1016/j.ajo.2006.01.074
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P811, DOI 10.1007/s00417-004-1006-8
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Sebag J, 2002, EYE, V16, P429, DOI 10.1038/sj.eye.6700201
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   SEBAG J, 1994, INVEST OPHTH VIS SCI, V35, P2976
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   SEBAG J, 1998, DUANES FDN CLIN OPHT, V1, P16
   SEBAG J, 2008, ARV ANN M
   Sebag J, 2007, T AM OPHTHAL SOC, V105, P129
   Sebag Jerry, 2007, Trans Am Ophthalmol Soc, V105, P121
   SHIMADA H, 2008, INVEST OPHTHALM 1205
   Sivaprasad S, 2008, RETINA-J RET VIT DIS, V28, P1435, DOI 10.1097/IAE.0b013e31817f2dae
   SMIDDY WE, 1990, RETINA-J RET VIT DIS, V10, P288, DOI 10.1097/00006982-199010000-00012
   SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811
   Smiddy WE, 2004, AM J OPHTHALMOL, V137, P525, DOI 10.1016/j.ajo.2003.12.011
   Snead DRJ, 2004, GRAEF ARCH CLIN EXP, V242, P853, DOI 10.1007/s00417-004-1019-3
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   Stolba U, 2005, AM J OPHTHALMOL, V140, P295, DOI 10.1016/j.ajo.2005.03.045
   Tachi N, 1996, AM J OPHTHALMOL, V122, P258, DOI 10.1016/S0002-9394(14)72018-5
   TAMMEWAR A, 2008, BR J OPHTHALMOL 1119
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Uchino E, 2001, AM J OPHTHALMOL, V132, P122, DOI 10.1016/S0002-9394(00)00957-0
   Wang FH, 2004, INVEST OPHTH VIS SCI, V45, P3286, DOI 10.1167/iovs.04-0026
   Weber-Krause B, 1997, OPHTHALMOLOGE, V94, P619, DOI 10.1007/s003470050170
   WIZNIA RA, 1986, AM J OPHTHALMOL, V102, P196, DOI 10.1016/0002-9394(86)90144-3
   Yamada N, 2005, AM J OPHTHALMOL, V139, P112, DOI 10.1016/j.ajo.2004.08.055
   Yamaguchi Y, 2003, AM J OPHTHALMOL, V135, P116, DOI 10.1016/S0002-9394(02)01855-X
   Yamashita T, 2008, GRAEF ARCH CLIN EXP, V246, P333, DOI 10.1007/s00417-007-0745-8
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
NR 85
TC 5
Z9 5
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PD MAR
PY 2009
VL 23
IS 1
BP 2
EP 11
DI 10.1007/s00717-009-0309-x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438OK
UT WOS:000265564700002
DA 2022-11-30
ER

PT J
AU Spooner, KL
   Fraser-Bell, S
   Cozzi, M
   Staurenghi, G
   Invernizzi, A
   Monteduro, D
   Munk, MR
   Hong, T
   Chang, AA
AF Spooner, Kimberly L.
   Fraser-Bell, Samantha
   Cozzi, Mariano
   Staurenghi, Giovanni
   Invernizzi, Alessandro
   Monteduro, Davide
   Munk, Marion R.
   Hong, Thomas
   Chang, Andrew A.
TI Macular Atrophy Incidence and Progression in Eyes with Neovascular
   Age-Related Macular Degeneration Treated with Vascular Endothelial
   Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata
   Regimen
SO OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE PATTERNS; GEOGRAPHIC ATROPHY; 7-YEAR OUTCOMES;
   FELLOW EYE; VEGF; ASSOCIATION; BEVACIZUMAB; SECONDARY; ANCHOR; MARINA
AB Purpose: To compare the incidence and progression of macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents using either a treat-and-extend (T&E) or a pro re nata (PRN) regimen over 4 years in a real-world setting.
   Design: Four-year, multicenter, retrospective comparative study.
   Participants: Two hundred sixty-four patients with treatment-naive nAMD.
   Methods: Consecutive patients with nAMD received anti-VEGF therapy according to a T&E (n = 163) or PRN (n = 101) regimen. Eyes were included if they had received anti-VEGF injections for a period of at least 4 years and had undergone annual fundus autofluorescence (FAF) and OCT imaging using Heidelberg Spectralis. Two masked graders independently delineated areas of MA from serial FAF images using Heidelberg region finder software, and growth rates were calculated. Incident MA was assessed using proportional hazard ratios.
   Main Outcomes Measures: Macular atrophy incidence and progression over 4 years, association between treatment strategies, and number of injections.
   Results: At baseline, MA was present in 24% and 20% of study eyes in T&E and PRN groups, respectively (P = 0.45). At year 4, 27% (34/124) and 25% (20/81) of eyes without baseline MA showed detectable MA in the T&E and PRN groups, respectively. In those with MA at baseline, the mean square root area of MA progressed by a rate of 0.4 +/- 0.2 mm/year and 0.4 +/- 0.1 mm/year in the T&E and PRN groups, respectively (P = 0.23). Multivariate analysis for baseline predictors of MA growth demonstrated that older age, poorer baseline visual acuity, and presence of retinal angiomatous proliferation had a higher risk of greater MA progression (P = 0.03). Regression analysis demonstrated no association between T&E and PRN treatment strategies with the risk of new MA developing during the 4 years of follow-up or the progression of pre-existing MA at year 4 (P = 0.692).
   Conclusions: Over 4 years, neither incidence nor progression of MA in eyes with nAMD treated with anti-VEGF injections was influenced by the treatment regimen and injection frequency. Eyes treated with a T&E regimen received more injections and achieved better visual outcomes compared with those treated with a PRN approach. (C) 2020 by the American Academy of Ophthalmology
C1 [Spooner, Kimberly L.; Fraser-Bell, Samantha; Hong, Thomas; Chang, Andrew A.] Sydney Retina, Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Spooner, Kimberly L.; Fraser-Bell, Samantha; Invernizzi, Alessandro; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Cozzi, Mariano; Staurenghi, Giovanni; Invernizzi, Alessandro; Monteduro, Davide] Univ Milan, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Munk, Marion R.] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Munk, Marion R.] Univ Bern, Bern Univ Hosp, Bern Photog Reading Ctr, Bern, Switzerland.
C3 University of Sydney; University of Milan; Luigi Sacco Hospital;
   University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern
RP Chang, AA (通讯作者)，Sydney Retina, Level 13-187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
RI Staurenghi, Giovanni/K-4388-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251; Fraser-Bell,
   Samantha/0000-0001-5646-9359; Cozzi, Mariano/0000-0001-7777-2461
FU Bayer
FX The author(s) have made the following disclosure(s): K.L.S.: Financial
   support - Bayer.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Christakis PG, 2020, OPHTHALMOLOGY, V127, P784, DOI 10.1016/j.ophtha.2019.11.016
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mones J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.40
   Muller PL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.13
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Rebhun CB, 2020, RETINA-J RET VIT DIS, V40, P266, DOI 10.1097/IAE.0000000000002402
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Sikorav A, 2017, BRIT J OPHTHALMOL, V101, P438, DOI 10.1136/bjophthalmol-2015-308065
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Thalgott V, 2016, OPHTHALMOLOGE, V113, P668, DOI 10.1007/s00347-016-0228-6
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 50
TC 15
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2020
VL 127
IS 12
BP 1663
EP 1673
DI 10.1016/j.ophtha.2020.06.019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH9SN
UT WOS:000600742900018
PM 32544561
OA Green Published
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Agron, E
   Meleth, AD
   Reed, GF
   Sperduto, RD
   Clemons, TE
   Chew, EY
AF SanGiovanni, John Paul
   Agron, Elvira
   Meleth, A. Dhananjayan
   Reed, George F.
   Sperduto, Robert D.
   Clemons, Traci E.
   Chew, Emily Y.
CA AREDS Res Grp
TI omega-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence
   of neovascular age-related macular degeneration and central geographic
   atrophy: AREDS report 30, a prospective cohort study from the
   Age-Related Eye Disease Study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID DIETARY-FAT; DOCOSAHEXAENOIC ACID; FISH INTAKE; RISK; INFLAMMATION;
   ASSOCIATION; CONSUMPTION; HEALTH; CELL
AB Background: omega-3 (n-3) Long-chain polyunsaturated fatty acids (LCPUFAs) affect processes implicated in vascular and neural retinal pathogenesis and thus may influence the risk of developing age-related macular degeneration (AMD).
   Objective: We investigated whether omega-3 LCPUFA intake was associated with a reduced likelihood of developing central geographic atrophy (CGA) and neovascular (NV) AMD.
   Design: We undertook a nested cohort study within a multicenter phase 3 clinical trial, the Age-Related Eye Disease Study (AREDS), to study progression to advanced AMD in 1837 persons at moderate-to-high risk of this condition. The AREDS was designed to assess the clinical course, prognosis, risk factors, and nutrient-based treatments of AMD and ran from November 1992 to December 2005. We obtained baseline data on omega-3 LCPUFA intake with a validated food-frequency questionnaire. Trained fundus graders ascertained AMD status from annual stereoscopic color photographs by using standardized methods at a single reading center across a 12-y period. We applied multivariable repeated-measures logistic regression with the incorporation of generalized estimating equation methods, because this permitted determination of progression to outcome at each visit.
   Results: Participants who reported the highest omega-3 LCPUFA intake (median: 0.11% of total energy intake) were 30% less likely than their peers to develop CGA and NV AMD. The respective odds ratios were 0.65 (95% CI: 0.45, 0.92; P <= 0.02) and 0.68 (95% CI: 0.49, 0.94; P <= 0.02).
   Conclusions: The 12-y incidence of CGA and NV AMD in participants at moderate-to-high risk of these outcomes was lowest for those reporting the highest consumption of omega-3 LCPUFAs. If these results are generalizable, they may guide the development of low-cost and easily implemented preventive interventions for progression to advanced AMD. This trial was registered at clinicaltrials.gov as NCT00594672. Am J Clin Nutr 2009;90:1601-7.
C1 [SanGiovanni, John Paul] NEI, Clin Trials Branch, NIH, CRC, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Meleth, A. Dhananjayan] George Washington Univ, Dept Ophthalmol, Washington, DC USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; George Washington University
RP SanGiovanni, JP (通讯作者)，NEI, Clin Trials Branch, NIH, CRC, 10 Ctr Dr,MSC 1204,Bldg 10,Room 3-2521, Bethesda, MD 20892 USA.
EM jpsangio@post.harvard.edu
RI SanGiovanni, John Paul/AAU-3895-2020
OI SanGiovanni, John Paul/0000-0001-7199-7053
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, MD; NATIONAL EYE INSTITUTE
   [ZIAEY000489] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Department of Health and Human Services, Bethesda, MD.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2008, ADV EXP MED BIOL, V613, P39
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Institute of Medicine, 2005, DIETARY REFERENCE IN
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   NEURINGER M, 1993, RELATIONSHIP FATTY A
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni John Paul, 2009, V99, P105, DOI 10.1159/000193002
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   *USDA, 1935, USDA NAT FOOD SURV
   Weylandt KH, 2005, LANCET, V366, P618, DOI 10.1016/S0140-6736(05)67119-X
NR 32
TC 120
Z9 126
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC 1
PY 2009
VL 90
IS 6
BP 1601
EP 1607
DI 10.3945/ajcn.2009.27594
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 522XZ
UT WOS:000272034900022
PM 19812176
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Yakovleva, MA
   Radchenko, AS
   Kostyukov, AA
   Chagovets, VV
   Kononikhin, AS
   Khubetsova, MK
   Borzenok, SA
   Kuzmin, VA
   Nikolaev, EN
   Feldman, TB
   Ostrovsky, MA
AF Yakovleva, M. A.
   Radchenko, A. Sh
   Kostyukov, A. A.
   Chagovets, V. V.
   Kononikhin, A. S.
   Khubetsova, M. Kh
   Borzenok, S. A.
   Kuzmin, V. A.
   Nikolaev, E. N.
   Feldman, T. B.
   Ostrovsky, M. A.
TI Comparative Analysis of the Physicochemical Characteristics of
   Fluorophore Groups of Lipofuscin Granules from Cells of Retinal
   Pigmental Epithhelium of Human Cadader Eyes in the Norm and in a
   Pathology
SO RUSSIAN JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
DE lipofuscin granules; fluorophores; retinal pigment epithelium;
   autofluorescence; method of calculating time-correlatedtim photons
ID RPE LIPOFUSCIN; EPITHELIUM; BISRETINOIDS; AGE; PHOTOOXIDATION; PRODUCTS;
   A2E
AB A comparative study of individual groups of bisretinoids and their oxidation and degradation products in chloroform extracts from cells of the retinal pigment epithelium (RPE) of human cadaver eyes without signs of pathology (norm) and in the case of visualized age-related macular degeneration is carried out. Fluorescence analysis and high-performance liquid chromatography-mass spectrometry show that with age-related macular degeneration, an increased content of oxidation and degradation products of bisretinoids are observed in comparison with the norm. The results obtained allow us to conclude that the listed methods can be used in the preclinical diagnosis of degenerative diseases of the retina and the RPE of the human eye.
C1 [Yakovleva, M. A.; Radchenko, A. Sh; Kostyukov, A. A.; Kononikhin, A. S.; Kuzmin, V. A.; Feldman, T. B.; Ostrovsky, M. A.] Russian Acad Sci, Emanuel Inst Biochem Phys, Moscow, Russia.
   [Chagovets, V. V.] Minist Hlth Russian Federat, Kulakov Natl Med Res Ctr Obstet Gynecol & Perinat, Moscow, Russia.
   [Kononikhin, A. S.; Nikolaev, E. N.] Skolkovo Inst Sci & Technol, Moscow, Russia.
   [Khubetsova, M. Kh; Borzenok, S. A.] Minist Hlth Russian Federat, Fyodorov Eye Microsurg, Moscow, Russia.
   [Feldman, T. B.; Ostrovsky, M. A.] Moscow MV Lomonosov State Univ, Moscow, Russia.
C3 Russian Academy of Sciences; Emanuel Institute of Biochemical Physics;
   Ministry of Health of the Russian Federation; Skolkovo Institute of
   Science & Technology; Ministry of Health of the Russian Federation;
   Lomonosov Moscow State University
RP Yakovleva, MA (通讯作者)，Russian Acad Sci, Emanuel Inst Biochem Phys, Moscow, Russia.
EM lina.invers@gmail.com
FU Ministry of Science and Higher Education of the Russian Federation
   [075-15-2020-773]
FX This study was financially supported by a grant from the Ministry of
   Science and Higher Education of the Russian Federation (agreement no.
   075-15-2020-773). The equipment and resources of the Center for
   Collective Use of the Institute of Biochemical Physics, Russian Academy
   of Sciences "New Materials and Technologies" were used in this study.
CR BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Feldman TB, 2018, EYE, V32, P1440, DOI 10.1038/s41433-018-0109-0
   Feldman TB, 2015, ANAL BIOANAL CHEM, V407, P1075, DOI 10.1007/s00216-014-8353-z
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Ivanov DG, 2020, RUSS J PHYS CHEM B+, V14, P483, DOI 10.1134/S1990793120030173
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim SR, 2010, VISION RES, V50, P729, DOI 10.1016/j.visres.2009.09.015
   Kononikhin AS, 2019, RUSS J PHYS CHEM B+, V13, P951, DOI 10.1134/S1990793119060216
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Vasilyeva AD, 2020, RUSS J PHYS CHEM B+, V14, P468, DOI 10.1134/S1990793120030276
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yakovleva MA, 2020, RUSS J PHYS CHEM B+, V14, P462, DOI 10.1134/S199079312003029X
   Yakovleva MA, 2017, DOKL BIOCHEM BIOPHYS, V472, P19, DOI 10.1134/S1607672917010069
   Yakovleva M A, 2006, Dokl Biochem Biophys, V409, P223, DOI 10.1134/S1607672906040089
   Yakovleva MA, 2020, PHOTOCH PHOTOBIO SCI, V19, P920, DOI 10.1039/c9pp00406h
NR 23
TC 1
Z9 1
U1 0
U2 1
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1990-7931
EI 1990-7923
J9 RUSS J PHYS CHEM B+
JI Russ. J. Phys. Chem. B
PD FEB
PY 2022
VL 16
IS 1
BP 90
EP 96
DI 10.1134/S199079312201033X
PG 7
WC Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physics
GA 0P9LO
UT WOS:000784548800014
DA 2022-11-30
ER

PT J
AU Karasu, B
   Erdogan, G
AF Karasu, Bugra
   Erdogan, Gurkan
TI Autologous translocation of the choroid and retina pigment epitelial
   cells (RPE) in age-related macular degeneration: Monitoring the
   viability of choroid and RPE patch with indocyanine green
   angiography(ICGA) and fundus autofluorescence(FAF)
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Autologous translocation; RPE and choroid patch; ICGA; FFA and FAFF;
   Age-related macular degeneration
ID PHOTODYNAMIC THERAPY; OPHTHALMIC FINDINGS; READING CHART; EPITHELIUM;
   NEOVASCULARIZATION; VERTEPORFIN; REMOVAL; TRANSPLANTATION; SURGERY;
   LESIONS
AB Purpose: To investigate the functional and anatomical results of autologous retinal pigment epithelial(RPE) cells and choroidal translocation after removal of the subfoveal choroidal neovascular membrane(CNVM) in patients with exudative age-related macular degeneration(AMD). To monitor the viability of choroidal patch with indocyanine green angiography(ICGA) and fundus autofluorescence(FAF)
   Methods: This study was conducted as a retrospective, interventional case series, and evaluation of 8 patients; 4 patients had large (> 1 disk diameter) subfoveal choroidal membranes, 3 with massive subretinal hemorrhage and 1 case with suprachoroidal hemorrhage(SCH) + rhegmatogenous retinal detachment(RRD). After removal of the CNVM, the autologous full-thickness patch of the RPE, bruch's membrane, choriocapillaris, and choroid was excised from the midperiphery and placed under the macula. At the 1 st month, 3rd month, 6th month and final examination, color fundus pictures and optical coherence tomography (OCT) were performed by preferred fixation of the OCT-light. Visual test with the early treatment of diabetic retinopathy study(ETDRS), OCT imaging with fixation, scanning with laser ophthalmoscopy autofluorescence, and ICGA were performed to evaluate the viability of choroidal patch at each visits.
   Results: This study was carried out in 8 patients with a mean follow-up of 14.12 +/- 8.16 (range 7-30 months) months. The mean age was 73 +/- 7.17(range, 60-80 years) years. Pre-operative visual acuity ranged from hand motion (HM) (20/2000) to light perception (LP)(20/20000). Post-operative vision ranged from HM (20/2000) to 0.15(20/125). In 6 patients, autofluorescence was reflected in FAF imaging and lipofuscin activity was evaluated as viable. Post-operative subretinal hemorrhage was encountered in 1 (12.5%) patient and it also resolved spontaneously. There was a statistically significant increase in visual acuity at the postoperative final visit compared to baseline. (p = 0.027)
   Conclusions: After removal of the CNVM, translocation of a full-thickness patch with the autologous peripheral RPE and choroid can be performed at the macula, resulted in survival and functional graft for 6 months and moreover, hereby viability of the choroid and RPE patch were monitored by imaging methods such as FAF and ICGA.
C1 [Karasu, Bugra; Erdogan, Gurkan] Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Bereketzade Sok 2, Istanbul, Turkey.
C3 University of Health Sciences Turkey
RP Karasu, B (通讯作者)，Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Bereketzade Sok 2, Istanbul, Turkey.
EM bugra_karasu@hotmail.com
RI Erdogan, Gurkan/AAV-3972-2021; Karasu, Bugra/AFN-7793-2022
OI Erdogan, Gurkan/0000-0003-4155-0407; Karasu, Bugra/0000-0001-7362-4453
CR Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt Claus, 1996, Ophthalmologe, V93, P688, DOI 10.1007/s003470050059
   Eris E., 2019, J FR OPHTALMOL
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Romunde SHM, 2019, RETINA-J RET VIT DIS, V39, P288, DOI 10.1097/IAE.0000000000001945
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 30
TC 1
Z9 2
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2019
VL 28
BP 318
EP 323
DI 10.1016/j.pdpdt.2019.08.015
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JW2LR
UT WOS:000502889700054
PM 31454718
DA 2022-11-30
ER

PT J
AU Cheng, HC
   Liu, JH
   Lee, SM
   Lin, PK
AF Cheng, Hui-Chen
   Liu, Jorn-Hon
   Lee, Shui-Mei
   Lin, Po-Kang
TI Hyperhomocysteinemia in Patients with Polypoidal Choroidal Vasculopathy:
   A Case Control Study
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; MACULAR DEGENERATION; PLASMA HOMOCYSTEINE; CLINICAL
   CHARACTERISTICS; INFLAMMATORY MARKERS; RISK FACTOR; AGE; DISEASE;
   METAANALYSIS; FOLATE
AB Purpose: To determine whether elevated plasma homocysteine and serum high sensitivity C-reactive protein (hsCRP) levels, two established risk factors of vascular diseases, are associated with polypoidal choroidal vasculopathy (PCV).
   Design: Retrospective case-control study.
   Methods: One hundred and nineteen consecutive patients with PCV and 119 matched controls were enrolled in a tertiary hospital from September 2008 to June 2013. Plasma homocysteine and serum hsCRP levels were measured. Associations among plasma homocysteine, serum hsCRP levels and PCV were further evaluated using multivariable logistic regression analysis.
   Results: The median plasma homocysteine level was significantly higher in patients with PCV than in the controls (12.20 mu mol/L vs. 9.80 mu mol/ L, p<0.001). The median serum hsCRP level was slightly higher in the PCV group (0.16 mg/dl vs. 0.11 mg/dl in control group, p = 0.07). After multivariable logistic regression analysis, each 1 mmol/ L increase of plasma homocysteine was associated with a 1.5-fold increase in likelihood of having PCV (OR, 1.54; 95% confidence interval (CI), 1.33-1.79, p<0.001).
   Conclusions: Hyperhomocysteinemia was associated with PCV and might play a role in the pathogenesis of PCV.
C1 [Cheng, Hui-Chen; Liu, Jorn-Hon; Lee, Shui-Mei; Lin, Po-Kang] Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei 112, Taiwan.
   [Cheng, Hui-Chen; Liu, Jorn-Hon; Lee, Shui-Mei; Lin, Po-Kang] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Liu, Jorn-Hon] Cheng Hsin Rehabil Med Ctr, Dept Ophthalmol, Taipei, Taiwan.
   [Lin, Po-Kang] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 10764, Taiwan.
   [Lin, Po-Kang] Natl Chiao Tung Univ, Biomed Elect Translat Res Ctr, Hsinchu, Taiwan.
C3 National Yang Ming Chiao Tung University; Taipei Veterans General
   Hospital; National Taiwan University; National Yang Ming Chiao Tung
   University
RP Lin, PK (通讯作者)，Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei 112, Taiwan.
EM pklin123@hotmail.com
FU National Science Council of the Republic of China, Taiwan
   [NSC101-2220-E-010-001]; "Aim for the Top University Plan" of the
   National Chiao Tung University; Ministry of Education, Taiwan, R. O. C
FX The authors would like to thank the National Science Council of the
   Republic of China, Taiwan, for supporting this research under Contract
   No. NSC101-2220-E-010-001. This work was also supported by the "Aim for
   the Top University Plan" of the National Chiao Tung University and
   Ministry of Education, Taiwan, R. O. C. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2005, NIPPON GANKA GAKKAI, V109, P417
   [Anonymous], 2002, JAMA, V288, P2015
   [Anonymous], 2005, AM J CLIN NUTR, V82, P806
   Aydemir O, 2008, RETINA-J RET VIT DIS, V28, P741, DOI 10.1097/IAE.0b013e31816079fb
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   Hoh BL, 2004, ACTA NEUROCHIR, V146, P705, DOI 10.1007/s00701-004-0276-6
   Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   McGimpsey SJ, 2009, OPHTHALMOLOGY, V116, P1778, DOI 10.1016/j.ophtha.2009.02.033
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng MKC, 2002, ARTERIOSCL THROM VAS, V22, P1136, DOI 10.1161/01.ATV.0000022167.80130.A6
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634
   Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Russo GT, 2003, J NUTR, V133, P3416, DOI 10.1093/jn/133.11.3416
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tewari PC, 2004, CLIN CHIM ACTA, V342, P171, DOI 10.1016/j.cccn.2003.12.025
   Turgut B, 2010, CLIN INTERV AGING, V5, P133
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2014
VL 9
IS 10
AR e110818
DI 10.1371/journal.pone.0110818
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AR6DY
UT WOS:000343674800078
PM 25337797
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lee, SE
   Jang, JW
   Kang, SW
   Park, KH
   Lee, DW
   Kim, JH
   Bae, K
AF Lee, Sang Eun
   Jang, Jun Won
   Kang, Se Woong
   Park, Kyu Hyung
   Lee, Dong Won
   Kim, Jae Hui
   Bae, KunHo
TI Intravitreal aflibercept for active polypoidal choroidal vasculopathy
   without active polyps
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; VEGF TRAP-EYE; MACULAR DEGENERATION;
   RANIBIZUMAB INJECTIONS; EFFICACY; SAFETY; COMBINATION; MONOTHERAPY;
   BEVACIZUMAB; RECURRENT
AB The purpose of this study was to evaluate the efficacy of intravitreal aflibercept for active polypoidal choroidal vasculopathy (PCV) without active polyps and to identify prognostic factors. We enrolled 40 eyes from 40 patients who manifested PCV with exudation but without active polyps after prior treatment with photodynamic therapy (PDT) and/or anti-vascular endothelial growth factor (VEGF) other than aflibercept. Participants were initially given three consecutive intravitreal injections of aflibercept at 1-month intervals, followed by injections every 2 months in the maintenance phase. Spectral-domain optical coherence tomographic and indocyanine green angiographic features were assessed to determine associations between anatomical parameters and visual outcomes 14 months later. Mean visual acuity improved from 61.5 +/- 11.1 letters at baseline to 68.1 +/- 13.6 letters at 14 months (P = 0.001). Better vision and a smaller branching vascular network at baseline and 1 month after three monthly injections (visit 4) were associated with better final vision (P < 0.001). The presence of an inner retinal cyst at visit 4 was significantly related to worse final vision (P = 0.011). Intravitreal aflibercept improved the visual and anatomical outcomes of PCV with exudation from BVN after pre-treatment with PDT and/or anti-VEGF other than aflibercept. Better vision, smaller lesion size, and absence of an inner retinal cyst after induction therapy may predict better visual outcome.
C1 [Lee, Sang Eun; Jang, Jun Won; Kang, Se Woong; Bae, KunHo] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam, South Korea.
   [Lee, Dong Won; Kim, Jae Hui] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National
   University (SNU); Konyang University; Konyang University Hospital
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
EM swkang@skku.edu
FU Bayer Korea
FX Funding was provided by Bayer Korea for the overall study and medical
   writing and editorial assistance for this article.
CR Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Iida T., 2016, AS PAC VITR RET SOC, DOI [10.1097/iae.0000000000000499, DOI 10.1097/IAE.0000000000000499]
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Kang EC, 2017, GRAEF ARCH CLIN EXP, V255, P2157, DOI 10.1007/s00417-017-3776-9
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Saito M, 2013, EYE, V27, P931, DOI 10.1038/eye.2013.114
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 35
TC 3
Z9 3
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 6
PY 2019
VL 9
AR 1487
DI 10.1038/s41598-018-37523-5
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HK4CS
UT WOS:000457868400033
PM 30728380
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kim, YT
   Kang, SW
   Chung, SE
   Kong, MG
   Kim, JH
AF Kim, Yun Taek
   Kang, Se Woong
   Chung, Song Ee
   Kong, Min Gui
   Kim, Jae Hui
TI Development of polypoidal choroidal vasculopathy in unaffected fellow
   eyes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS;
   FEATURES
AB Purpose To assess longitudinal changes and determine their angiographic risk factors in the fellow eyes of patients with unilateral polypoidal choroidal vasculopathy (PCV).
   Methods We reviewed the medical records of 47 patients with unilateral PCV, all of whom had completed at least 12 months of follow-up. The angiographic features were evaluated including the development of active PCV over time, choroidal vessel dilation, choroidal vascular hyperpermeability, the branching vascular network (BVN) and late geographic hyperfluorescence (LGH), which was defined as a well-demarcated geographic hyperfluorescent lesion on late-phase on indocyanine green angiography (ICGA).
   Results The mean follow-up period was 30.3 +/- 12.2 months. Among 47 fellow eyes, 24 (51.1%) had choroidal vascular dilation, 27 (57.4%) had choroidal vascular hyperpermeability, six (12.8%) had BVN and 23 (48.9%) had LGH. The development of active PCV was noted in nine fellow eyes (19.1%), all of which had exhibited LGH at baseline. However, PCV did not develop in eyes without features of LGH at baseline (p< 0.001). The development of PCV was noted in three eyes with notification of BVN at baseline; however, PCV also developed in six eyes without apparent features of BVN (p=0.08).
   Conclusion The presence of LGH on ICGA in the fellow eye appears to be a significant risk factor for the development of active PCV and may constitute the diagnosis of preclinical PCV.
C1 [Kim, Yun Taek; Kang, Se Woong; Chung, Song Ee; Kong, Min Gui; Kim, Jae Hui] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Kim, Yun Taek] Ewha Womans Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
   [Chung, Song Ee] Doctor Lees Eye Clin, Suwon, Kyunggi Do, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Ewha Womans
   University
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
OI Kim, Yun Taek/0000-0001-9104-4241
CR Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 15
TC 14
Z9 14
U1 1
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2012
VL 96
IS 9
BP 1217
EP 1221
DI 10.1136/bjophthalmol-2012-301644
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004IH
UT WOS:000308674500013
PM 22760488
DA 2022-11-30
ER

PT J
AU Yang, SF
   Su, YC
   Lim, CC
   Huang, JY
   Hsu, SM
   Wu, LW
   Chang, YS
   Hung, JH
AF Yang, Shun-Fa
   Su, Yu-Chen
   Lim, Chen-Chee
   Huang, Jing-Yang
   Hsu, Sheng-Min
   Wu, Li-Wha
   Chang, Yi-Sheng
   Hung, Jia-Horung
TI Risk of dialysis in patients receiving intravitreal anti-vascular
   endothelial growth factor treatment: a population-based cohort study
SO AGING-US
LA English
DT Article
DE population-based cohort study; intravitreal anti-vascular endothelial
   growth factor; aflibercept; ranibizumab; dialysis
ID DIABETIC MACULAR EDEMA; FACTOR INHIBITORS; KIDNEY-DISEASE; FACTOR
   THERAPY; BEVACIZUMAB; VEGF; DEGENERATION; PROTEINURIA; INJECTION; TAIWAN
AB We utilized the Longitudinal Health Insurance Database which was stemmed from the Taiwan's National Health Insurance Research Database to conduct a retrospective cohort study investigating the risk of becoming dialysis dependent after receiving intravitreal anti-vascular endothelial growth factor (VEGF) agents for retinal diseases. Patients newly receiving intravitreal ranibizumab or aflibercept from 2000 to 2017 for age-related macular degeneration, polypoidal choroidal vasculopathy, diabetic macular edema, retinal vein occlusions, or myopic choroid neovascularization were included as the study group, and patients with same retinal diseases but did not receive intravitreal anti-VEGFs served as controls extracted by age-and sex-matched (1:4) and further propensity score matching (PSM). Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the risk of dialysis. A cohort of 2447 anti-VEGF users and 2447 controls by PSM were evaluated. Higher dialysis risks were observed among patients newly receiving anti-VEGF agents compared to controls (adjusted HR: 1.849; 95% CI: 1.378-2.482) in the PSM cohort. For subgroup analysis, patients newly receiving anti-VEGF treatment for diabetic macular edema had significant risk (adjusted HR: 1.834; 95% CI: 1.448-2.324) of becoming dialysis-dependent, while patients in other subgroups demonstrated similar risks as the controls. In conclusion, intravitreal anti-VEGF agents might increase the risk of becoming dialysis-dependent, especially in patients who are treated for diabetic macular edema.
C1 [Yang, Shun-Fa; Huang, Jing-Yang] Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
   [Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Su, Yu-Chen; Lim, Chen-Chee; Hsu, Sheng-Min; Chang, Yi-Sheng; Hung, Jia-Horung] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Ophthalmol, Tainan, Taiwan.
   [Wu, Li-Wha] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan.
   [Wu, Li-Wha] Kaohsiung Med Univ, Dept Lab Sci & Technol, Kaohsiung, Taiwan.
   [Hung, Jia-Horung] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University Hospital; National Cheng Kung University; National
   Cheng Kung University Hospital; National Cheng Kung University;
   Kaohsiung Medical University; National Cheng Kung University
RP Hung, JH (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Ophthalmol, Tainan, Taiwan.; Hung, JH (通讯作者)，Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.
EM hungjh@mail.ncku.edu.tw
RI Yang, Shun-Fa/AAN-1519-2020
OI Yang, Shun-Fa/0000-0002-0365-7927
FU National Cheng Kung University Hospital, Taiwan [NCKUH-11102004];
   Ministry of Science and Technology [MOST 110-2314-B-006-086-MY3]
FX This study was financially supported by funding from National Cheng Kung
   University Hospital, Taiwan [NCKUH-11102004] , and the Ministry of
   Science and Technology [MOST 110-2314-B-006-086-MY3] ; these grants were
   awarded to J.H. Hung.
CR Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Bagheri S, 2018, GALEN MED J, V7, DOI 10.22086/gmj.v0i0.1299
   Chang YS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25864-0
   Chen HL, 2014, J DIABETES COMPLICAT, V28, P612, DOI 10.1016/j.jdiacomp.2014.05.011
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Cheungpasitporn W, 2015, TRANSPLANTATION, V99, P2382, DOI 10.1097/TP.0000000000000750
   Chou YB, 2019, J CHIN MED ASSOC, V82, P659, DOI 10.1097/JCMA.0000000000000138
   Georgalas I, 2014, CURR DRUG SAF, V9, P156, DOI 10.2174/1574886309666140211113635
   Glassman AR, 2018, INVEST OPHTH VIS SCI, V59, P1199, DOI 10.1167/iovs.17-22853
   Hanhart J, 2018, GRAEF ARCH CLIN EXP, V256, P651, DOI 10.1007/s00417-018-3917-9
   Hanna RM, 2019, KIDNEY INT, V96, P572, DOI 10.1016/j.kint.2019.02.042
   Hanna RM, 2019, CLIN KIDNEY J, V12, P92, DOI 10.1093/ckj/sfy060
   Hsu CC, 2012, DIABETES CARE, V35, P2286, DOI 10.2337/dc11-2052
   Huang YF, 2017, J FORMOS MED ASSOC, V116, P490, DOI 10.1016/j.jfma.2016.09.010
   Karim ME, 2016, AM J EPIDEMIOL, V184, P325, DOI 10.1093/aje/kwv445
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Keller JJ, 2013, OSTEOPOROSIS INT, V24, P1835, DOI 10.1007/s00198-012-2185-5
   Khneizer Gebran, 2017, J Nephropathol, V6, P134, DOI 10.15171/jnp.2017.23
   Kuo CN, 2020, J FORMOS MED ASSOC, V119, P1731, DOI 10.1016/j.jfma.2019.08.023
   Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9
   Lo KJ, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4538135
   Majumder S, 2017, J DIABETES COMPLICAT, V31, P273, DOI 10.1016/j.jdiacomp.2016.10.020
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   O'Neill RA, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1650-1
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Risimic D, 2013, HELL J CARDIOL, V54, P435
   Saeed F, 2019, NEPHRON, V141, P98, DOI 10.1159/000494298
   Saran R, 2016, AM J KIDNEY DIS, V67, pS1, DOI 10.1053/j.ajkd.2015.12.014
   Sheu SJ, 2018, CLIN OPHTHALMOL, V12, P2189, DOI 10.2147/OPTH.S170089
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Taber SS, 2008, EXPERT OPIN DRUG SAF, V7, P679, DOI [10.1517/14740330802410462, 10.1517/14740330802410462 ]
   Touzani F, 2019, Case Rep Nephrol, V2019, P2919080, DOI 10.1155/2019/2919080
   Tsai MH, 2018, NEPHRON, V140, P175, DOI 10.1159/000491708
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Zhang Y, 2015, DRUG DES DEV THER, V9, P3413, DOI 10.2147/DDDT.S87920
NR 39
TC 0
Z9 0
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUN 30
PY 2022
VL 14
IS 12
BP 5116
EP 5130
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 3E1MS
UT WOS:000829754900015
PM 35724264
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Adenuga, O
   Okonkwo, ON
   Udoh, MM
   Ovienra, W
   Ibanga, A
   Agweye, C
   Nkanga, D
   Akanbi, T
   Oyekunle, I
AF Adenuga, O.
   Okonkwo, O. N.
   Udoh, M. M.
   Ovienra, W.
   Ibanga, A.
   Agweye, C.
   Nkanga, D.
   Akanbi, T.
   Oyekunle, I
TI Polypoidal Choroidal Vasculopathy Amongst Nigerians; A Multicenter Study
SO NIGERIAN JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
DE Indocyanine Green Angiography; Nigeria; polypoidal choroidal
   vasculopathy; retina diseases; vitreous hemorrhage
ID MACULAR DEGENERATION; CLINICAL-FEATURES; MANAGEMENT
AB Objective: To investigate the prevalence and presentation of polypoidal choroidal vasculopathy (PCV) in Nigerians. Methods: A cross-sectional, multicenter, hospital-based, descriptive study. Data were collected prospectively between January and December 2018, from consecutive patients diagnosed to have a retina disease at the general outpatient and retinal clinics of four eye departments in Nigeria. All participants had visual acuity, refraction, intraocular pressure, anterior segment examination, and dilated fundus examination. Some patients had fundus fluorescein angiography, optical coherence tomography (OCT), and OCT angiography (OCTA). Systemic comorbidity was determined by medical history and systemic evaluation. Diagnosis of PCV was based on clinical findings, and in some patients using OCT. Results: A total of 8,614 patients were seen and 15 patients (18 eyes) were diagnosed to have PCV giving a yearly hospital-based prevalence of 0.17%. The mean age at presentation was 63.27 +/- 11.5 years (range 44-84 years). There were nine females (60%). The male: female ratio was 1.5:1. Twelve (66.7%) of the 18 eyes were blind, 16.7% had severe visual impairment while 11.1% had mild visual impairment. Seven eyes (38.9%) had vitreous hemorrhage. Of the 12 blind eyes, 50% had vitreous hemorrhage (P = 0.463). Nine patients (60%) had systemic hypertensive as comorbidity (P = 0.016). Conclusion: PCV is a cause of vision loss among Nigerians. Majority of the eyes were blind and 50% of blind eyes had vitreous hemorrhage. Since Indocyanine Green Angiography is the most appropriate imaging technology and is mostly unavailable in Nigeria, efforts should be made to address this need and improve the diagnostic accuracy.
C1 [Adenuga, O.] Jos Univ Teaching Hosp, Dept Ophthalmol, Edo, Nigeria.
   [Okonkwo, O. N.; Akanbi, T.; Oyekunle, I] Eye Fdn Hosp, Dept Ophthalmol, Edo, Nigeria.
   [Udoh, M. M.; Ibanga, A.; Agweye, C.; Nkanga, D.] Univ Calabar Teaching Hosp, Dept Ophthalmol, Edo, Nigeria.
   [Ovienra, W.] Irrua Specialist Hosp, Dept Ophthalmol, Edo, Nigeria.
C3 University of Calabar
RP Okonkwo, ON (通讯作者)，Eye Fdn Retina Inst, 27 Isaac John St, Lagos, Nigeria.; Okonkwo, ON (通讯作者)，Eye Fdn Hosp, 27 Isaac John St, Lagos, Nigeria.
EM o_okonkwo@yahoo.com
OI Agweye, Chineze/0000-0001-7891-4177
CR Agorogiannis EI, 2018, EYE, V32, P1731, DOI 10.1038/s41433-018-0168-2
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Kabedi NN, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4103871
   Kim Joon-Bom, 2017, Curr Ophthalmol Rep, V5, P176, DOI 10.1007/s40135-017-0137-0
   Kleiner RC, 1984, OPHTHALMOLOGY S9, V94, P110
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Li ZX, 2019, INT J OPHTHALMOL-CHI, V12, P1859, DOI 10.18240/ijo.2019.12.07
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nkanga D, 2020, CLIN OPHTHALMOL, V14, P679, DOI 10.2147/OPTH.S226494
   Okonkwo ON, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000083
   Oluleye TS, 2013, CLIN OPHTHALMOL, V7, P1373, DOI 10.2147/OPTH.S47511
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tao Y, 2012, CHINESE J OCUL FUNDU, V28, P1005
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuda Miho, 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P97
NR 25
TC 0
Z9 0
U1 2
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1119-3077
J9 NIGER J CLIN PRACT
JI Niger. J. Clin. Pract.
PD SEP
PY 2021
VL 24
IS 9
BP 1321
EP 1325
AR PMID 34531344
DI 10.4103/njcp.njcp_682_20
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YT4UW
UT WOS:000751358000010
PM 34531344
DA 2022-11-30
ER

PT J
AU Wehrli, SJ
   Tawse, K
   Levin, MH
   Zaidi, A
   Pistilli, M
   Brucker, AJ
AF Wehrli, Sarah J.
   Tawse, Kirstin
   Levin, Marc H.
   Zaidi, Ali
   Pistilli, Maxwell
   Brucker, Alexander J.
TI A LACK OF DELAYED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS TREATED
   WITH INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF drug; bevacizumab;
   ranibizumab; choroidal neovascularization; intravitreal injection;
   intraocular pressure; toxicity
ID VERTEPORFIN
AB Purpose: The purpose of this study was to report the rate of intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth factor agents for exudative age-related macular degeneration.
   Methods: Retrospective chart review of all patients receiving intravitreal ranibizumab and/or bevacizumab injections for exudative age-related macular degeneration from November 2005 to June 2010. Delayed ocular hypertension (OHT) was defined as either an IOP >= 22 mmHg on 2 consecutive visits (with an increase from baseline > 6 mmHg) or an IOP >26 mmHg on a single visit with a concomitant initiation or augmentation of IOP-lowering treatment. Noninjected fellow eyes served as controls. Incidence of delayed OHT was analyzed using survival analyses, with risk assessed by Cox proportional hazards regression models. Eyes with glaucoma were evaluated separately.
   Results: Three hundred and two treated eyes and 226 control eyes met inclusion criteria. In eyes with exudative age-related macular degeneration without glaucoma, 3 of 270 injected eyes (0.51% incidence per eye-year) developed delayed OHT compared with 4 of 195 control eyes (1.00% incidence per eye-year), a difference that was not statistically significant (hazard ratio = 0.48; 95% confidence interval: 0.11-2.23). In eyes with exudative age-related macular degeneration and glaucoma, 2 of 32 injected eyes developed delayed OHT (3.1% incidence per eye-year) compared with 3 of 31 control eyes (5.7% incidence per eye-year), a difference that was not statistically significant (hazard ratio = 0.59; 95% confidence interval: 0.10-3.60).
   Conclusion: The incidence of delayed OHT after intravitreal anti-vascular endothelial growth factor injections was low and did not differ between injected and control eyes, including eyes with glaucoma. These results argue against a significant risk of IOP elevation because of repeated anti-vascular endothelial growth factor therapy. RETINA 32:1295-1301, 2012
C1 [Brucker, Alexander J.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Brucker, AJ (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM alexander.brucker@uphs.upenn.edu
OI Pistilli, Maxwell/0000-0002-4266-4150
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kempen JH, 2011, AM J OPHTHALMOL, V151, P7, DOI 10.1016/j.ajo.2010.08.047
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tseng JJ, 2011, J GLAUCOMA      0316
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wu HJ, 2009, SEMIN OPHTHALMOL, V24, P100, DOI 10.1080/08820530902800397
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 19
TC 53
Z9 57
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1295
EP 1301
DI 10.1097/IAE.0b013e31823f0c95
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100010
PM 22466465
DA 2022-11-30
ER

PT J
AU Introini, U
   Casalino, G
   Triolo, G
   O'Shaughnessy, D
   Shusterman, EM
   Chakravarthy, U
   Slakter, JS
   Bandello, F
AF Introini, Ugo
   Casalino, Giuseppe
   Triolo, Giacinto
   O'Shaughnessy, Denis
   Shusterman, E. Mark
   Chakravarthy, Usha
   Slakter, Jason S.
   Bandello, Francesco
TI Stereotactic Radiotherapy for Polypoidal Choroidal Vasculopathy: A Pilot
   Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Stereotactic radiotherapy;
   Intravitreal ranibizumab; Age-related macular degeneration; Indocyanine
   green angiography
ID X-RAY-IRRADIATION; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   RANIBIZUMAB THERAPY; VERTEPORFIN; EFFICACY; OUTCOMES; SAFETY
AB Purpose: To evaluate low-voltage X-ray stereotactic radiotherapy (SRT) delivered in conjunction with intravitreal ranibizumab for the treatment of active macular polypoidal choroidal vasculopathy (PCV). Methods: At baseline, all eyes received an intravitreal injection of ranibizumab, followed by 16-Gy X-ray SRT to the macula. Further ranibizumab injections were given pro re nata. The primary outcome measure was regression of the polyps assessed by indocyanine green angiography. Secondary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) changes on optical coherence tomography. Local or systemic adverse events were evaluated as well. Results: We examined 12 eyes of 12 patients with PCV. At month 12, an angiographic regression of the polyps was observed in 10 of the 12 eyes. The mean BCVA improved by 7.6 letters: from 65.08 +/- 11.4 to 72.7 +/- 14.75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean CFT decreased from 372.3 +/- 79.6 to 215.9 +/- 57.9 mu m (p < 0.01). No local or systemic adverse events were reported. Conclusions: The preliminary data support the safety of low-voltage X-ray SRT for the treatment of macular PCV and show polyp closure, reduction in CFT and improvement in the mean BCVA. Additional research is warranted to confirm the efficacy and longer-term safety of this therapy in this population. (C) 2014 S. Karger AG, Basel
C1 [Introini, Ugo; Casalino, Giuseppe; Triolo, Giacinto; Bandello, Francesco] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, IT-20132 Milan, Italy.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [O'Shaughnessy, Denis; Shusterman, E. Mark] Oraya Therapeut Inc, Newark, CA USA.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, New York, NY USA.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Queens
   University Belfast
RP Introini, U (通讯作者)，Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, IT-20132 Milan, Italy.
EM introini.ugo@hsr.it
RI Casalino, Giuseppe/I-1729-2019; bandello, francesco/AAH-2405-2019
OI Casalino, Giuseppe/0000-0002-0208-0740; bandello,
   francesco/0000-0003-3238-9682; Triolo, Giacinto/0000-0001-7681-8069;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Oraya Therapeutics, Inc.
FX This study was funded by Oraya Therapeutics, Inc.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi DM, 2013, RET SPEC DAY AM AC O
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 7
Z9 8
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 2
BP 82
EP 88
DI 10.1159/000368561
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC8AX
UT WOS:000350591400004
PM 25402871
DA 2022-11-30
ER

PT J
AU Imasawa, M
   Tsumura, T
   Sekine, A
   Kikuchi, T
   Iijima, H
AF Imasawa, Mitsuhiro
   Tsumura, Toyoaki
   Sekine, Arata
   Kikuchi, Toyohiko
   Iijima, Hiroyuki
TI Photodynamic therapy for polypoidal choroidal vasculopathy: Baseline
   perimetric results and visual outcomes
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE central visual field; Humphrey perimetry; photodynamic therapy;
   polypoidal choroidal vasculopathy; visual improvement
ID MACULAR DEGENERATION; VERTEPORFIN THERAPY; JAPANESE PATIENTS; LESION
   SIZE; NEOVASCULARIZATION
AB To investigate whether the baseline mean deviation (MD) of Humphrey perimetry has a predictive value for visual improvement after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).
   We retrospectively reviewed the records of 40 eyes of 39 PCV patients (28 men, 11 women) who underwent PDT. The follow-up period ranged from 12 to 42 months. Best-corrected visual acuity (BCVA) improved more than 0.2 logarithm of the minimum angle of resolution (logMAR) units at the final examination in 22 (55%) of the 40 eyes, which were classified into the "Improved group." The other 18 eyes with improvement of a parts per thousand currency sign0.2 logMAR units were classified into the "Not Improved group."
   The baseline MD in the Improved group was significantly better than that in the Not Improved group (P = 0.0144). Multivariate analysis confirmed that only the baseline MD was associated with improvement of the final BCVA, showing that eyes with better baseline MD tended to exhibit improvement of the final BCVA after PDT for PCV (odds ratio = 1.303; 95% confidence interval, 1.069-1.588).
   The baseline MD in Humphrey perimetry can be useful for predicting visual improvement after PDT for PCV.
C1 [Imasawa, Mitsuhiro; Tsumura, Toyoaki; Sekine, Arata; Kikuchi, Toyohiko; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Imasawa, M (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.
EM mimasawa@yamanashi.ac.jp
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Imasawa M, 2009, JPN J OPHTHALMOL, V53, P281, DOI 10.1007/s10384-008-0644-5
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 15
TC 6
Z9 7
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2009
VL 53
IS 6
BP 588
EP 592
DI 10.1007/s10384-009-0732-1
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 534NK
UT WOS:000272904200004
PM 20020236
DA 2022-11-30
ER

PT J
AU Boddu, S
   Lee, MD
   Marsiglia, M
   Marmok, M
   Freund, KB
   Smith, RT
AF Boddu, Sucharita
   Lee, Michele D.
   Marsiglia, Marcela
   Marmok, Michael
   Freund, K. Bailey
   Smith, R. Theodore
TI Risk Factors Associated With Reticular Pseudodrusen Versus Large Soft
   Drusen
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; CHOROIDAL BLOOD-FLOW;
   MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; BRUCHS MEMBRANE; DISEASE;
   PREVALENCE; DEPOSITS; EYES
AB PURPOSE: To investigate genetic, environmental, and systemic risk factors in prospectively identified subjects with the age-related macular degeneration (AMD) phenotypes of (1) reticular pseudodrusen without large soft drusen and (2) large soft drusen without reticular pseudodrusen.
   DESIGN: Prospective case-case comparison.
   METHODS: In a clinical practice setting, patients with AMD were sequentially screened using clinical examination and scanning laser ophthalmoscopy imaging to prospectively identify subjects (n = 73) with the phenotypes of (1) reticular pseudodrusen without large soft drusen (n = 30) or (2) large soft drusen without reticular pseudodrusen (n = 43). Subjects were genotyped for 2 alleles associated with AMD, age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH). A questionnaire was administered to collect history of smoking, hypertension, diabetes, and hyperlipidemia, as well as personal and family history of AMD.
   RESULTS: The reticular pseudodrusen group was older (median age 87 vs 81 years, P = .04) and had more female subjects (83.3% vs 48.8%, P = .003), later ages of AMD onset (83 vs 70 years, P = .0005), and a greater frequency of hypertension (76.7% vs 55.8%, P = .08). No significant differences were found in the distribution of the ARMS2 risk allele (P = .4) between the reticular pseudodrusen (homozygous = 20.0%; heterozygous = 56.7%) and large soft drusen (homozygous = 19.0%; heterozygous = 42.9%) phenotypes, or in the distribution of the CHF risk allele (P = .7) between the reticular pseudodrusen (homozygous = 26.7%; heterozygous = 56.7%) and large soft drusen (homozygous = 21.4%; heterozygous = 66.7%) phenotypes.
   CONCLUSIONS: The reticular pseudodrusen phenotype was associated with increased age, later age of AMD onset, and female sex. (C) 2014 Published by Elsevier Ltd.
C1 [Boddu, Sucharita; Lee, Michele D.; Marsiglia, Marcela; Freund, K. Bailey; Smith, R. Theodore] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Marmok, Michael] NYU, Sch Med, Dept Populat Hlth, New York, NY USA.
   [Boddu, Sucharita; Lee, Michele D.; Marsiglia, Marcela; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 New York University; New York University; Vitreous Retina Macula
   Consultants of New York
RP Smith, RT (通讯作者)，462 First Ave,NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
RI ; Freund, K. Bailey/V-7488-2018
OI Marmor, Michael/0000-0001-6605-2661; Lee, Michele/0000-0003-4772-1908;
   Freund, K. Bailey/0000-0002-7888-9773; smith,
   theodore/0000-0002-1693-943X
FU NIH/NEI; Research to Prevent Blindness; Foundation Fighting Blindness;
   National Institutes of Health (NIH)/National Eye Institute (NEI) [R01
   EY015520]; Macula Foundation, Inc; NATIONAL EYE INSTITUTE [R01EY015520]
   Funding Source: NIH RePORTER
FX Financial disclosures are as follows: K. Bailey Freund: Genentech, Inc
   (advisor); Regeneron Pharmaceuticals, Inc (advisor); Heidelberg
   Engineering (advisor); Optos plc (advisor); R. Theodore Smith: NIH/NEI
   (grant support); Research to Prevent Blindness (grant support);
   Foundation Fighting Blindness (grant support); Boehringer-Ingelheim
   (consultant). The research was supported by National Institutes of
   Health (NIH)/National Eye Institute (NEI) grant R01 EY015520 (R.T.S.),
   unrestricted funds from Research to Prevent Blindness (R.T.S.), an
   individual investigator research award from the Foundation Fighting
   Blindness (R.T.S.), and The Macula Foundation, Inc (K.B.F.).
   Contributions of authors: design of the study (R.T.S., K.B.F.); conduct
   of the study (R.T.S., K.B.F.); collection, management, analysis, and
   interpretation of the data (S.B., M.D.L., M.Marsiglia, M.Marmor, K.B.F.,
   R.T.S.); and preparation, review, or approval of the manuscript (S.B.,
   M.D.L., M.Marsiglia, M.Marmor, K.B.F., R.T.S.).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FOOS RY, 1982, ARCH OPHTHALMOL-CHIC, V100, P1492, DOI 10.1001/archopht.1982.01030040470020
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P161, DOI 10.1007/BF00127645
   HAYREH SS, 1981, OPHTHALMOLOGICA, V183, P11
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MANTEL N, 1963, J AM STAT ASSOC, V58, P690
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Megnien JL, 1996, HYPERTENSION, V27, P949, DOI 10.1161/01.HYP.27.4.949
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1978, 23 CONC OPHTH KYOT, P228
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 51
TC 51
Z9 51
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2014
VL 157
IS 5
BP 985
EP 993
DI 10.1016/j.ajo.2014.01.023
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG1TU
UT WOS:000335199900009
PM 24491417
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Otani, A
   Sasahara, M
   Yodoi, Y
   Aikawa, H
   Tamura, H
   Tsujikawa, A
   Yoshimura, N
AF Otani, Atsushi
   Sasahara, Manabu
   Yodoi, Yuko
   Aikawa, Hiroko
   Tamura, Hiroshi
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI Indocyanine green angiography: Guided photodynamic therapy for
   polypoidal choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; NEOVASCULARIZATION SECONDARY; VERTEPORFIN THERAPY;
   TRIAL
AB PURPOSE: To report the 12-month follow,up results of subfoveal polypoidal choroidal vasculopathy (PCV) pa-, tients treated with indocyanine green angiography (ICGA)-guided photodynamic therapy (PDT).
   DESIGN: Interventional, noncomparative cases series.
   METHODS: A retrospective analysis of the clinical and angiographic data related to 47 PCV eyes that were followed up for 12 months was carried out. The greatest linear dimension (GLD) for PDT was determined based on the ICGA findings. Optical coherence tomography (OCT) also was used to evaluate the therapeutic effects.
   RESULTS: The mean logarithm of the minimum angle of resolution visual acuity (VA; 0.58 +/- 0.37) signifi, cantly improved to 0.53 +/- 0.38 at three months (P =.04) and to 0.46 +/- 0.40 at 12 months (P = .02). The average ICGA GLD (2682.3 +/- 1026.9 mm) was significantly (P = .0001) smaller than the presumed fluores, cein angiography (FA) GLD (4043.6 +/- 1914.8 mm). In more than 80% of cases, complete resolution of retinal exudative changes was observed. Although polypoidal vascular lesions disappeared in 82.2% of eyes, the branched vascular networks showed little change. The initial VA and GLD had little correlation with the VA outcome.
   CONCLUSIONS: ICGA-guided PDT reduces the size of laser exposure and is an effective treatment for PCV. Because PCV may appear as occult choroidal neovascularization (CNV) on FA, PCV should be diagnosed using ICGA before treatment because PCV may respond dif- ferently than CNV to appropriate treatment.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Otani, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM otan@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   HIRAMI Y, IN PRESS RETINA
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Meyer CH, 2005, AM J OPHTHALMOL, V139, P214, DOI 10.1016/j.ajo.2004.07.034
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   TAP and VIP Study Group, 2002, RETINA, V22, P6
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   2005, RETINA, V25, P119
NR 32
TC 101
Z9 112
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2007
VL 144
IS 1
BP 7
EP 14
DI 10.1016/j.ajo.2007.03.014
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187SD
UT WOS:000247867800002
PM 17467649
DA 2022-11-30
ER

PT J
AU Van Leeuwen, R
   Tomany, SC
   Wang, JJ
   Klein, R
   Mitchell, P
   Hofman, A
   Klein, BEK
   Vingerling, JR
   Cumming, RG
   De Jong, PTVM
AF Van Leeuwen, R
   Tomany, SC
   Wang, JJ
   Klein, R
   Mitchell, P
   Hofman, A
   Klein, BEK
   Vingerling, JR
   Cumming, RG
   De Jong, PTVM
TI Is medication use associated with the incidence of early age-related
   maculopathy? Pooled findings from 3 continents
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; BLUE MOUNTAINS EYE; MACULAR DEGENERATION; RISK-FACTORS;
   5-YEAR INCIDENCE; CARDIOVASCULAR-DISEASE; GRADING SYSTEM; PREVALENCE;
   PROGRESSION; ROTTERDAM
AB Objective: To investigate whether there is an association between the use of medication and the incidence of early age-related maculopathy (ARM).
   Design: Pooled data from 3 prospective, population-based cohort studies.
   Participants: Subjects without early and late ARM at baseline who participated in the follow-up of the Beaver Dam Eye Study (n = 3012), the Rotterdam Study (n = 3434), and the Blue Mountains Eye Study (n = 2203).
   Methods: Stereoscopic color fundus photographs of all participants were graded according to a standardized protocol. At baseline, current use of prescription and over-the-counter medication was assessed by interview, and the drug name was confirmed at the research centers. Procedures and definitions were similar at both baseline and follow-up across the 3 study sites.
   Main Outcome Measures: Incidence of early ARM, defined as the presence at follow-up of either soft distinct drusen with pigmentary changes or soft indistinct or reticular drusen.
   Results: In the pooled cohort, 53.3% of participants used at least one of the medications selected for this study. Within a mean period of 5.6 years, a total of 683 subjects developed early ARM. Users of anti hypertensive medication in general, and beta-blockers in particular, had a borderline statistically significant increased risk of early ARM (odds ratio [OR] for beta-blockers, 1.3; 95% confidence interval [CI], 1.0-1.6) when adjusted for systolic (or diastolic) blood pressure and other confounders. A protective effect of borderline significance was found among women using hormone replacement therapy (OR, 0.6; 95% CI, 0.4-1.0) and in persons using tricyclic antidepressants (OR, 0.4; 95% CI, 0.2-1.0). In contrast with beta-blockers, the direction and magnitude of the association with hormone replacement therapy and tricyclic antidepressants were inconsistent among the 3 study populations.
   Conclusions: Pooled data from 3 population-based studies showed no strong associations between medication use and the incidence of early ARM. Of borderline significance were a slightly increased risk among users of beta-blockers and a reduced risk among users of hormone replacement therapy and users of tricyclic antidepressants. Although beta-blocker use could be a proxy for systemic hypertension, these findings warrant further investigations, preferably including information on the dosage and duration of drug exposure. (C) 2004 by the American Academy of Ophthalmology.
C1 Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia.
   Royal Netherlands Acad Arts & Sci, Netherlands Ophthalm Res Inst, Amsterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; University of Wisconsin System; University of Wisconsin
   Madison; University of Sydney; University of Sydney; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW)
RP De Jong, PTVM (通讯作者)，Netherlands Ophthalm Res Inst, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@ioi.knaw.nl
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022; Cumming, Robert G/R-1548-2016
OI Wang, Jie Jin/0000-0001-9491-4898; Cumming, Robert G/0000-0002-0261-6103
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FRAUNFELDER FT, 1989, DRUG INDUCED OCULAR
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   WOLFENSBERGER TJ, 1998, RETINAL PIGMENT EPIT, P621
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 32
TC 72
Z9 72
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2004
VL 111
IS 6
BP 1169
EP 1175
DI 10.1016/j.ophtha.2003.10.024
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824SY
UT WOS:000221708100014
PM 15177967
DA 2022-11-30
ER

PT J
AU Sugano, Y
   Iida, T
   Maruko, I
   Ojima, A
   Sekiryu, T
AF Sugano, Yukinori
   Iida, Tomohiro
   Maruko, Ichiro
   Ojima, Akira
   Sekiryu, Tetsuju
TI Choroidal thickness outside the laser irradiation area after
   photodynamic therapy in polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Photodynamic therapy; Polypoidal choroidal vasculopathy; Enhanced depth
   imaging spectral-domain optical coherence tomography; Choroidal
   thickness
ID MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN;
   RANIBIZUMAB; ANGIOGRAPHY; OCCLUSION
AB To evaluate changes in choroidal thickness adjacent to the area of laser application after photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV) using enhanced depth imaging spectral-domain optical coherence tomography.
   Masked observers measured the choroidal thickness at the subfovea and superior, inferior and temporal areas adjacent to the area of laser application before, 2 days, 1 week and 1 and 3 months after treatment.
   Thirty-seven patients with PCV treated with PDT with verteporfin were included. The mean subfoveal choroidal thickness decreased significantly (P < 0.001) from 256 +/- A 115 mu m at baseline to 207 +/- A 111 mu m at 3 months; the mean outside choroidal thickness including the superior, inferior and temporal areas decreased significantly (P < 0.001) from 240 +/- A 92 mu m at baseline to 209 +/- A 86 mu m at 3 months.
   PDT affected not only the subfoveal choroid, but also the choroid outside the area of laser application in PCV.
C1 [Sugano, Yukinori; Iida, Tomohiro; Maruko, Ichiro; Ojima, Akira; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Shinjuku Ku, Tokyo 1628666, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University
RP Iida, T (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM iida@oph.twmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022
OI Maruko, Ichiro/0000-0001-5647-6372; Sekiryu, Tetsuju/0000-0001-8042-2729
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Fujiwara A, 2012, JPN J OPHTHALMOL, V56, P230, DOI 10.1007/s10384-012-0128-5
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
NR 35
TC 5
Z9 6
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2013
VL 57
IS 3
BP 294
EP 300
DI 10.1007/s10384-013-0230-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 143BP
UT WOS:000318841600008
PM 23408087
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Li, E
   Donati, S
   Lindsley, KB
   Krzystotik, MG
   Virgili, G
AF Li, Emily
   Donati, Simone
   Lindsley, Kristina B.
   Krzystotik, Magdalena G.
   Virgili, Gianni
TI Treatment regimens for administration of anti-vascular endothelial
   growth factor agents for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID INTRAVITREAL AFLIBERCEPT INJECTION; 2.0 MG RANIBIZUMAB; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; BASE-LINE CHARACTERISTICS; FACTOR
   TRAP-EYE; PRO RE NATA; PHOTODYNAMIC THERAPY; GEOGRAPHIC ATROPHY;
   CIGARETTE-SMOKING; EXTEND PROTOCOL
AB Background
   Age-related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents: aflibercept, ranibizumab, and off-label bevacizumab. Injections can be given monthly, every two or three months ('extended-fixed'), or as needed (pro re nata (PRN)). A variant of PRN is 'treat-and-extend' whereby injections are resumed if recurrence is detected and then delivered with increasing intervals. Currently, injection frequency varies among practitioners, which underscores the need to characterize an optimized approach to nAMD management.
   Objectives
   To investigate the effects of monthly versus non-monthly intravitreous injection of an anti-VEGF agent in people with newly diagnosed nAMD.
   Search methods
   We searched CENTRAL, MEDLINE, Embase, LILACS, and three trials registers from 2004 to October 2019; checked references; handsearched conference abstracts; and contacted pharmaceutical companies to identify additional studies.
   Selection criteria
   We included randomized controlled trials (RCTs) that compared different treatment regimens for anti-VEGF agents in people with newly diagnosed nAMD. We considered standard doses only (ranibizumab 0.5 mg, bevacizumab 1.25 mg, aflibercept 2.0 mg, or a combination of these).
   Data collection and analysis
   We used standard Cochrane methods for trial selection, data extraction, and analysis.
   Main results
   We included 15 RCTs. The total number of participants was 7732, ranging from 37 to 2457 in each trial. The trials were conducted worldwide. Of these, six trials exclusively took place in the US, and three included centers from more than one country. Eight trials were at high risk of bias for at least one domain and all trials had at least one domain at unclear risk of bias.
   Seven trials (3525 participants) compared a PRN regimen with a monthly injection regimen, of which five trials delivered four to eight injections using standard PRN and three delivered nine or 10 injections using a treat-and-extend regimen in the first year. The overall mean change in best-corrected visual acuity (BCVA) at one year was +8.8 letters in the monthly injection group. Compared to the monthly injection, there was moderate-certainty evidence that the mean difference (MD) in BCVA change at one year for the standard PRN subgroup was -1.7 letters (95% confidence interval (CI) -2.8 to -0.6; 4 trials, 2299 participants), favoring monthly injections. There was low-certainty evidence of a similar BCVA change with the treat-and-extend subgroup (0.5 letters, 95% CI -3.1 to 4.2; 3 trials, 1226 participants).
   Compared to monthly injection, there was low-certainty evidence that fewer participants gained 15 or more lines of vision with standard PRN treatment at one year (risk ratio (RR) 0.87, 95% CI 0.76 to 0.99; 4 trials, 2299 participants) and low-certainty evidence of a similar gain with treat-and-extend versus monthly regimens (RR 1.11, 95% CI 0.91 to 1.36; 3 trials, 1169 participants).
   The mean change in central retinal thickness was a decrease of -166 mu m in the monthly injection group; the MD compared with standard PRN was 21 mu m (95% CI 6 to 32; 4 trials, 2215 participants; moderate-certainty evidence) and with treat-and extend was 22 mu m (95% CI 37 to -81 mu m; 2 trials, 635 participants; low-certainty evidence), in favor of monthly injection. Only one trial (498 participants) measured quality of life and reported no evidence of a difference between regimens, but data could not be extracted (low-certainty evidence).
   Both PRN regimens (standard and 'treat-and-extend') used fewer injections than monthly regimens (standard PRN: MD -4.6 injections, 95% CI -5.4 to -3.8; 4 trials, 2336 participants; treat-and-extend: -2.4 injections, 95% CI -2.7 to -2.1 injections; moderate-certainty evidence for both comparisons). Two trials provided cost data (1105 participants, trials conducted in the US and the UK). They found that cost differences between regimens were reduced if bevacizumab rather than aflibercept or ranibizumab were used, since bevacizumab was less costly (low-certainty evidence).
   PRN regimens were associated with a reduced risk of endophthalmitis compared with monthly injections (Peto odds ratio (OR) 0.13, 95% CI 0.04 to 0.46; 6 RCTs, 3175 participants; moderate-certainty evidence). Using data from all trials included in this review, we estimated the risk of endophthalmitis with monthly injections to be 8 in every 1000 people per year. The corresponding risk for people receiving PRN regimens was 1 in every 1000 people per year (95% CI 0 to 4).
   Three trials (1439 participants) compared an extended-fixed regimen (number of injections reported in only one large trial: 7.5 in one year) with monthly injections. There was moderate-certainty evidence that BCVA at one year was similar for extended-fixed and monthly injections (MD in BCVA change compared to extended-fixed group: -1.3 letters, 95% CI -3.9 to 1.3; RR of gaining 15 letters or more: 0.94, 95% CI 0.80 to 1.10). The change in central retinal thickness was a decrease of 137 mu m in the monthly group; the MD with the extended-fixed group was 8 mu m (95% CI -11 to 27; low-certainty evidence). The frequency of endophthalmitis was lower in the extended-fixed regimen compared to the monthly group, but this estimate was imprecise (RR 0.19, 95% CI 0.03 to 1.11; low-certainty evidence). If we assumed a risk of 8 cases of endophthalmitis in 1000 people receiving monthly injections over one year, then the corresponding risk with extended-fixed regimen was 2 in 1000 people (95% CI 0 to 9).
   Other evidence comparing different extended-fixed or PRN regimens yielded inconclusive results.
   Authors' conclusions
   We found that, at one year, monthly regimens are probably more effective than PRN regimens using seven or eight injections in the first year, but the difference is small and clinically insignificant. Endophthalmitis is probably more common with monthly injections and differences in costs between regimens are higher if aflibercept or ranibizumab are used compared to bevacizumab.
   This evidence only applies to settings in which regimens are implemented as described in the trials, whereas undertreatment is likely to be common in real-world settings. There are no data from RCTs on long-term effects of different treatment regimens.
C1 [Li, Emily] Signat Healthcare Brockton Hosp, Transit Year Residency Program, Brockton, MA USA.
   [Donati, Simone] Univ Insubria, Dept Surg & Morphol Sci, Sect Ophthalmol, Varese, Italy.
   [Lindsley, Kristina B.] IBM Watson Hlth, Life Sci Oncol & Genom, Baltimore, MD USA.
   [Krzystotik, Magdalena G.] Mass Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Providence, RI USA.
   [Virgili, Gianni] Univ Florence, Dept Neurosci, Psychol Drug Res & Child Hlth NEUROFARBA, Florence, Italy.
C3 University of Insubria; Harvard University; Massachusetts Eye & Ear
   Infirmary; University of Florence
RP Virgili, G (通讯作者)，Univ Florence, Dept Neurosci, Psychol Drug Res & Child Hlth NEUROFARBA, Florence, Italy.
EM gianni.virgili@unifi.it
RI Donati, Simone/K-4382-2019; Virgili, Gianni/P-6607-2014
OI Donati, Simone/0000-0002-6920-7021; Folk, James/0000-0002-6271-2906;
   Russell, Stephen/0000-0003-3776-1367; Virgili,
   Gianni/0000-0002-9960-2989
FU National Eye Institute, National Institutes of Health, USA [1 U01
   EY020522]; National institute for Health Research (NIHR), UK; Department
   of Health through National Institute for Health Research; NIHR
FX External sources; Methodological support provided by the Cochrane Eyes
   and Vision US Project, supported by co-operative agreement 1 U01
   EY020522, National Eye Institute, National Institutes of Health, USA;
   National institute for Health Research (NIHR), UK; Richard Wormald,
   Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges
   financial support for his CEV research sessions from the Department of
   Health through the award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology.; The NIHR also funds the CEV Editorial Base in
   London.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Airody A, 2018, INVEST OPHTH VIS SCI, V59
   Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold J, 2015, CLIN EXP OPHTHALMOL, V43, P108
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Avery RL, 2016, OPHTHALMOLOGY, V123, pE14, DOI 10.1016/j.ophtha.2015.08.031
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   BISHOP PN, 2014, INVESTIGATIVE OPHTHA, V55
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brader HS, 2015, INVEST OPHTH VIS SCI, V56
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brijesh T, 2016, AM J OPHTHALMOL, V162, P200, DOI 10.1016/j.ajo.2015.11.002
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2015, HLTH TECHNOLOGY ASSE, V19, P78
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Chong EW, 2017, CLIN EXP OPHTHALMOL, V45, P333, DOI 10.1111/ceo.12968
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CIULLA TA, 2015, INVESTIGATIVE OPHTHA, V56
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   DANIEL E, 2016, INVESTIGATIVE OPHTHA, V57
   Daniel E, 2017, OPHTHALMOL RETINA, V1, P25, DOI 10.1016/j.oret.2016.09.001
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Enseleit F, 2017, OPHTHALMOLOGICA, V238, P205, DOI 10.1159/000478665
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Feltgen N, 2014, INVEST OPHTH VIS SCI, V55
   Feltgen N, 2017, GRAEF ARCH CLIN EXP, V255, P923, DOI 10.1007/s00417-017-3589-x
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fiske A, 2009, ANNU REV CLIN PSYCHO, V5, P363, DOI 10.1146/annurev.clinpsy.032408.153621
   Foss AJE, 2016, BRIT J OPHTHALMOL, V100, P1662, DOI 10.1136/bjophthalmol-2015-307595
   Foss AJE, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0608-2
   FRENKEL REP, 2015, INVESTIGATIVE OPHTHA, V56
   Frenkel REP, 2016, BRIT J OPHTHALMOL, V100, P1052, DOI 10.1136/bjophthalmol-2015-307575
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gillies M, 2014, 46 ANN SCI C ROYAL A
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   GRUNWALD JE, 2014, INVESTIGATIVE OPHTHA, V55
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gunda Venugopal, 2013, J Cancer Sci Ther, V5, P417
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Harper RA, 2010, BASIC OPHTHALMOLOGY, P47
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   HUANG JY, 2014, INVESTIGATIVE OPHTHA, V55
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   KHANANI A, 2015, INVESTIGATIVE OPHTHA, V56
   KIM BJ, 2014, INVESTIGATIVE OPHTHA, V55
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kon-Jara V, 2007, INVEST OPHTHALMOL, V48, P3349
   KOROBELNIK JF, 2014, INVESTIGATIVE OPHTHA, V55
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li E, 2016, COCHRANE DATABASE OF, DOI [10.1002/14651858.CD012208, DOI 10.1002/14651858.CD012208]]
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   LOTERY A, 2014, INVESTIGATIVE OPHTHA, V55
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Maguire MG, 2015, INVEST OPHTH VIS SCI, V56
   Mahmood S, 2015, OPHTHALMOLOGY, V122, P1348, DOI 10.1016/j.ophtha.2015.03.017
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2012, OPHTHALMOLOGY, V119, P1388
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McMaster University (developed by Evidence Prime), 2019, GRADEPRO GDT
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell P, 2012, CLIN EXP OPHTHALMOL, V40, P44
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mones J, 2017, OPHTHALMIC RES, V58, P3
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Moshfeghi DM, 2016, OSLI RETINA, V47, P238, DOI 10.3928/23258160-20160229-06
   MOSHFEGHI DM, 2016, INVESTIGATIVE OPHTHA, V57
   National Eye Institute, 2000, NAT EYE I VIS FUNCT
   Nordic Cochrane Centre, 2014, COCHR COLL REV MAN 5
   NUNES RP, 2014, INVEST OPHTH VIS SCI, V55
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Ohnaka M, 2017, 49 ANN SCI C ROYAL A
   Penden MC, 2015, INVEST OPHTHALMOL, V56, P5362
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shah C, 2014, INVEST OPHTH VIS SCI, V55
   Shah N, 2016, OPHTHALMOLOGY, V123, P858, DOI 10.1016/j.ophtha.2015.11.030
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   SIMADER C, 2014, INVESTIGATIVE OPHTHA, V55
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   SINGER M, 2015, INVESTIGATIVE OPHTHA, V56
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Tempelaar S, 2015, VALUE HEALTH, V18, pA420, DOI 10.1016/j.jval.2015.09.554
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Veritas Health Innovation Covidence, VER HLTH INN COV
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   WALDSTEIN SM, 2014, INVESTIGATIVE OPHTHA, V55
   WIJEYAKUMAR W, 2015, INVESTIGATIVE OPHTHA, V56
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   World Health Organization, CAUS BLINDL VIS IMP
   Wormald R., 2007, COCHRANE DATABASE SY
   WYKOFF CC, 2015, INVESTIGATIVE OPHTHA, V56
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 146
TC 36
Z9 37
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2020
IS 5
AR CD012208
DI 10.1002/14651858.CD012208.pub2
PG 94
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LT4GU
UT WOS:000537031300022
PM 32374423
OA Green Published
DA 2022-11-30
ER

PT J
AU Conley, YP
   Thalamuthu, A
   Jakobsdottir, J
   Weeks, DE
   Mah, T
   Ferrell, RE
   Gorin, MB
AF Conley, YP
   Thalamuthu, A
   Jakobsdottir, J
   Weeks, DE
   Mah, T
   Ferrell, RE
   Gorin, MB
TI Candidate gene analysis suggests a role for fatty acid biosynthesis and
   regulation of the complement system in the etiology of age-related
   maculopathy
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; APOLIPOPROTEIN-E;
   SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; CHOLESTEROL TRANSPORT; LINKAGE
   ANALYSIS; VLDL RECEPTOR; HUMAN RETINA; ACE GENE
AB Age-related maculopathy (ARM) is a leading cause of visual impairment in elderly Americans and is a complex genetic disorder. Hypothesized pathways for the etiology of ARM include cholesterol and lipoprotein metabolism and transport, extracellular matrix integrity, oxidative stress and inflammatory/immunologic processes. This study investigates 21 polymorphisms within 15 candidate genes whose products function within these pathways by performing family and case-control genetic association studies using clearly affected familial cases (n=338 families, 796 individuals), clearly affected, unrelated sporadic cases (n=196) and clearly unaffected, unrelated controls (n=120). Two genes demonstrated significant association with ARM status. A Met299Val variant in the elongation of very long chain fatty acids-like 4 (ELOVL4) gene was significantly associated with ARM in the case-control allele (P=0.001), case-control genotype (P=0.001) and case-control family (P < 0.0001) tests. A Tyr402His variant in exon 9 in the complement factor H (CFH) gene was also significantly associated with ARM in the case-control allele (P < 0.0001), case-control genotype (P < 0.0001) and case-control family (P < 0.0001) tests. All of these results remain significant after adjusting for false discovery rates to control for the impact of multiple testing. In addition, the CFH variant appears to play a role in exudative and atrophic disease, whereas the ELOVL4 variant may play a greater role in exudative disease in our population. These results support a potential role for multiple pathways in the etiology of ARM, including pathways involved with fatty acid biosynthesis and the complement system.
C1 Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Gorin, MB (通讯作者)，Univ Pittsburgh, Sch Med, Dept Ophthalmol, Eye & Ear Inst Bldg,203 Lothrop St, Pittsburgh, PA 15213 USA.
EM gorinmb@upmc.edu
RI Thalamuthu, Anbupalam/Z-5545-2019; Weeks, Daniel E/B-2995-2012
OI Thalamuthu, Anbupalam/0000-0002-7114-1260; Weeks, Daniel
   E/0000-0001-9410-7228; Jakobsdottir, Johanna/0000-0002-8019-9683
FU FIC NIH HHS [5D43TW006180] Funding Source: Medline; NEI NIH HHS
   [R01EY009859] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER
   [D43TW006180] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY009859] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   AREDS SG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943
   Browning SR, 2005, GENET EPIDEMIOL, V28, P110, DOI 10.1002/gepi.20051
   Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DiScipio RG, 1998, J IMMUNOL, V160, P4057
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EMIGH TH, 1980, BIOMETRICS, V36, P627, DOI 10.2307/2556115
   FOKIANOS K, 2005, GENETS MICROARRAY TI
   Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200
   Goodship T, 2004, Bull Mem Acad R Med Belg, V159, P195
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gu WK, 1999, INVEST OPHTH VIS SCI, V40, P1229
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Indelman M, 2002, J INVEST DERMATOL, V119, P1210, DOI 10.1046/j.1523-1747.2002.19528.x
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Jonkman MF, 2002, J INVEST DERMATOL, V119, P1275, DOI 10.1046/j.1523-1747.2002.19609.x
   Jozsi M, 2004, HISTOL HISTOPATHOL, V19, P251, DOI 10.14670/HH-19.251
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KONTULA K, 1990, CLIN CHEM, V36, P2087
   Lange K, 2001, AM J HUM GENET, V69, P504
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mukhopadhyay N, 2005, BIOINFORMATICS, V21, P2556, DOI 10.1093/bioinformatics/bti364
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   OKUIZUMI K, 1995, NAT GENET, V11, P207, DOI 10.1038/ng1095-207
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Priglinger SG, 2003, INVEST OPHTH VIS SCI, V44, P355, DOI 10.1167/iovs.02-0224
   R Development Core Team, 2004, R LANG ENV STAT COMP
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sato Y, 1999, BIOCHEM BIOPH RES CO, V259, P349, DOI 10.1006/bbrc.1999.0797
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x
   Slager SL, 2000, GENET EPIDEMIOL, V18, P143, DOI 10.1002/(SICI)1098-2272(200002)18:2<143::AID-GEPI4>3.0.CO;2-5
   Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sprecher E, 2001, NAT GENET, V29, P134, DOI 10.1038/ng716
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Tacken PJ, 2001, CURR OPIN LIPIDOL, V12, P275, DOI 10.1097/00041433-200106000-00006
   TIRET L, 1992, AM J HUM GENET, V51, P197
   Toti P, 1997, NEUROMUSCULAR DISORD, V7, P21, DOI 10.1016/S0960-8966(96)00399-9
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vogel BE, 2001, DEVELOPMENT, V128, P883
   WARNES G, 2004, POPULATION GENETICS
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wu F, 1998, INVEST OPHTH VIS SCI, V39, P476
   Yamamoto C, 1998, GRAEF ARCH CLIN EXP, V236, P41, DOI 10.1007/s004170050040
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 80
TC 125
Z9 144
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 15
PY 2005
VL 14
IS 14
BP 1991
EP 2002
DI 10.1093/hmg/ddi204
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 941HL
UT WOS:000230205800008
PM 15930014
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Akaza, E
   Yuzawa, M
   Mori, R
AF Akaza, Eriko
   Yuzawa, Mitsuko
   Mori, Ryusaburo
TI Three-year follow-up results of photodynamic therapy for polypoidal
   choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE indocyanine green angiography; photodynamic therapy; polypoidal
   choroidal vasculopathy; visual acuity
ID MACULAR DEGENERATION; JAPANESE PATIENTS; CLINICOPATHOLOGICAL
   CORRELATION; CLINICAL CHARACTERISTICS; VERTEPORFIN; NEOVASCULARIZATION
AB To evaluate the visual outcomes and changes in abnormal vascular networks and polypoidal lesions of polypoidal choroidal vasculopathy (PCV) 3 years after photodynamic therapy (PDT).
   We studied 43 eyes of 43 patients with PCV for 3 years. Fundus appearance, fluorescein angiography (FA) and indocyanine green angiography (IA) findings, and visual acuity (VA) before the initial PDT were compared with those 3 months, 1 year, 2 years, and 3 years after treatment.
   In 24 of the 43 eyes, enlargement of the abnormal vascular network continued in a manner similar to that before PDT on IA; in eight eyes, transformation into polypoidal choroidal neovascularization (CNV) with enlargement was detected; and two eyes had the appearance of classic CNV on FA. Polypoidal lesions recurred at 3 years in 33 of the 43 eyes (77%). Mean VA (logarithm of the minimum angle of resolution) of all 43 eyes decreased to below baseline at 3 years after the initial PDT. This decrease can be explained by foveal atrophy after absorption of recurrent hemorrhagic or exudative detachment.
   Long-term visual outcomes were not good owing to the high frequency of recurrent polypoidal lesions, as well as enlargement and neovascular changes involving abnormal vascular networks.
C1 [Akaza, Eriko] Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, Tokyo 1018309, Japan.
C3 Nihon University
RP Akaza, E (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Suru Gadai, Tokyo 1018309, Japan.
EM merryeriko@hotmail.com
FU Research Committee on Chorioretinal Degeneration and Optic Atrophy,
   Ministry of Health, Labour and Welfare of Japan
FX This study was funded in part by the Research Committee on Chorioretinal
   Degeneration and Optic Atrophy, Ministry of Health, Labour and Welfare
   of Japan.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mori R., 2004, GANKA, V46, P193
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A., 2005, GANKA, V47, P71
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 31
TC 55
Z9 67
U1 0
U2 2
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2011
VL 55
IS 1
BP 39
EP 44
DI 10.1007/s10384-010-0886-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 723WQ
UT WOS:000287538400008
PM 21331691
DA 2022-11-30
ER

PT J
AU Querques, G
   Merle, BMJ
   Pumariega, NM
   Benlian, P
   Delcourt, C
   Zourdani, A
   Leisy, HB
   Lee, MD
   Smith, RT
   Souied, EH
AF Querques, Giuseppe
   Merle, Benedicte M. J.
   Pumariega, Nicole M.
   Benlian, Pascale
   Delcourt, Cecile
   Zourdani, Alain
   Leisy, Heather B.
   Lee, Michele D.
   Smith, R. Theodore
   Souied, Eric H.
TI Dynamic Drusen Remodelling in Participants of the Nutritional AMD
   Treatment-2 (NAT-2) Randomized Trial
SO PLOS ONE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; POLYUNSATURATED FATTY-ACIDS; MACULAR
   DEGENERATION; DIETARY-FAT; FISH INTAKE; DOCOSAHEXAENOIC ACID; GEOGRAPHIC
   ATROPHY; 5-YEAR INCIDENCE; RISK; AUTOFLUORESCENCE
AB Purpose
   To evaluate the dynamic remodeling of drusen in subjects with unilateral neovascular age-related macular degeneration (AMD) receiving a three-year course of oral docosahexaenoic acid (DHA) or placebo.
   Setting
   Institutional setting.
   Methods
   Three hundred subjects with age-related maculopathy and neovascular AMD in the fellow eye were randomly assigned to receive either 840 mg/day DHA or placebo for 3 years. Main outcome measures of this post-hoc sub-group analysis were progression of drusen number, total diameter, and total area on fundus photography, and their association with DHA supplementation, socio-demographic and genetic characteristics.
   Results
   Drusen progression was analyzed in 167 subjects that did not develop CNV (87 that received DHA and 80 that received placebo). None of the drusen remodeling outcomes were significantly associated with DHA supplementation. Total drusen diameter reduction in the inner subfield was significantly associated with age (older patients: r = -0.17; p = 0.003). Women showed a tendency to decreased total drusen diameter in the inner subfield with CFH polymorphism (p = 0.03), where women with TT genotype tended to have a greater reduction in drusen diameter than other genotypes (CC and CT). Drusen area in the inner subfield was more reduced in older patients (r = -0.17) and in women (p = 0.01). Drusen number showed no significant trends.
   Conclusions
   Dynamic drusen remodeling with net reduction in drusen load over three years was found in patients with exudative AMD in one eye and drusen in the other eye (study-eye). This reduction was correlated with increased age and female gender, and showed a tendency to be influenced by CFH genotype, but did not appear to be affected by DHA supplementation.
C1 [Querques, Giuseppe; Merle, Benedicte M. J.; Zourdani, Alain; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Pumariega, Nicole M.; Leisy, Heather B.; Lee, Michele D.; Smith, R. Theodore] NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.
   [Benlian, Pascale] Hop St Antoine, APHP, Biochem & Mol Biol Dept, F-75012 Paris, France.
   [Benlian, Pascale] Univ Lille 2, INSERM, UMRS 1011, Lille, France.
   [Delcourt, Cecile] INSERM, Ctr INSERM, Epidemiol Biostat U897, Bordeaux, France.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, Bordeaux, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; New York
   University; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Antoine
   - APHP; UDICE-French Research Universities; Sorbonne Universite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Lille - ISITE; Universite de Lille; Institut National de
   la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
EM giuseppe.querques@hotmail.it
RI Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/F-1247-2015; Merle,
   Benedicte MJ/AAQ-5021-2021; Benlian, Pascale/I-7964-2016
OI Delcourt, Cecile/0000-0002-2099-0481; Merle, Benedicte
   MJ/0000-0003-1332-0954; Merle, Benedicte MJ/0000-0003-1332-0954;
   Querques, Giuseppe/0000-0002-3292-9581; Benlian,
   Pascale/0000-0002-3423-8979; Lee, Michele/0000-0003-4772-1908
FU Laboratoire Bausch & Lomb - Chauvin, Clinical Research, Montpellier,
   Cedex 2, France
FX This study was supported by a grant from Laboratoire Bausch & Lomb -
   Chauvin, Clinical Research, 416, rue Samuel Morse, CS 99535, 34961
   Montpellier, Cedex 2, France. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Age-Related Eye Disease Study 2 Research G, 2003, JAMA-J AM MED ASSOC, V309, P2005
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2009, PROSTAG LEUKOTR ESS, V81, P205, DOI 10.1016/j.plefa.2009.05.024
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016
   Marik PE, 2009, CLIN CARDIOL, V32, P365, DOI 10.1002/clc.20604
   Merle B, 2001, INVEST OPHTH VIS SCI, V52, P6004
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   OMS, 2018, TOP 10 CAUS DEATH
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pepe S, 2005, EXP GERONTOL, V40, P369, DOI 10.1016/j.exger.2005.03.005
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2005, INVEST OPHTH VIS SCI, V46, P2940, DOI 10.1167/iovs.04-0778
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Smith RT, 2004, J BIOMED OPT, V9, P162, DOI 10.1117/1.1630604
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
NR 47
TC 18
Z9 18
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2016
VL 11
IS 2
AR e0149219
DI 10.1371/journal.pone.0149219
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF3VL
UT WOS:000371276100046
PM 26901353
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ooto, S
   Tsujikawa, A
   Mori, S
   Tamura, H
   Yamashiro, K
   Otani, A
   Yoshimura, N
AF Ooto, Sotaro
   Tsujikawa, Akitaka
   Mori, Satoshi
   Tamura, Hiroshi
   Yamashiro, Kenji
   Otani, Atsushi
   Yoshimura, Nagahisa
TI RETINAL MICROSTRUCTURAL ABNORMALITIES IN CENTRAL SEROUS
   CHORIORETINOPATHY AND POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE central serous chorioretinopathy; optical coherence tomography;
   polypoidal choroidal vasculopathy
ID OPTICAL COHERENCE TOMOGRAPHY; AUTOFLUORESCENCE; FLUORESCEIN;
   ANGIOGRAPHY; LESIONS
AB Purpose: To compare retinal morphologic alterations in eyes with polypoidal choroidal vasculopathy (PCV) and central serous chorioretinopathy (CSC) using speckle noise-reduced spectral-domain optical coherence tomography.
   Methods: We retrospectively reviewed 63 eyes of 62 patients with active PCV and 38 eyes of 38 patients with active CSC. Patients underwent fundus photography, angiography, and speckle noise-reduced spectral-domain optical coherence tomography examinations, and retinal morphologic alterations were evaluated.
   Results: Cystoid macular edema, lipid deposits, subretinal hemorrhage, and hemorrhagic pigment epithelial detachment were not seen in any eye with CSC but were seen in eyes with PCV. In PCV, mean visual acuity was significantly poorer in eyes with fibrin infiltration (P = 0.027) or hemorrhagic infiltration (P = 0.002) in the fovea than in eyes without fibrin or hemorrhagic infiltration.
   Conclusion: Differentiating factors between PCV and CSC noted on spectral-domain optical coherence tomography include a lack of cystoid macular edema, lipid deposition, subretinal hemorrhage, and hemorrhagic pigment epithelial detachment in eyes with CSC, which makes spectral-domain optical coherence tomography helpful in differentiating CSC from PCV. More severe retinal alterations were seen in PCV than in CSC because of infiltration of fibrin and hemorrhage in the outer retina, which also correlated with poorer vision. RETINA 31: 527-534, 2011
C1 [Ooto, Sotaro] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science [21791679]
FX Supported in part by a Grant-in-Aid for Scientific Research (21791679)
   from the Japan Society for the Promotion of Science.
CR Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Iida T, 2000, AM J OPHTHALMOL, V129, P16, DOI 10.1016/S0002-9394(99)00272-X
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kon Y, 2008, RETINA-J RET VIT DIS, V28, P864, DOI 10.1097/IAE.0b013e3181669795
   LEVINE R, 1989, OPHTHALMOLOGY, V96, P854
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Matsumoto H, 2008, AM J OPHTHALMOL, V145, P162, DOI 10.1016/j.ajo.2007.08.024
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ojima Y, 2007, OPHTHALMOLOGY, V114, P2197, DOI 10.1016/j.ophtha.2007.02.015
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SCHEIDER A, 1993, AM J OPHTHALMOL, V115, P50, DOI 10.1016/S0002-9394(14)73524-X
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 29
TC 10
Z9 12
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2011
VL 31
IS 3
BP 527
EP 534
DI 10.1097/IAE.0b013e3181eef2db
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722YW
UT WOS:000287472400014
PM 20890237
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Fung, AT
   Kumar, N
   Vance, SK
   Slakter, JS
   Klancnik, JM
   Spaide, RS
   Freund, KB
AF Fung, A. T.
   Kumar, N.
   Vance, S. K.
   Slakter, J. S.
   Klancnik, J. M.
   Spaide, R. S.
   Freund, K. B.
TI Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the
   management of neovascular age-related macular degeneration in patients
   with perSistent/recurrenT macular fluid < 30 days following treatment
   with intravitreal anti-VEGF therapy (the LAST Study)
SO EYE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularisation; vascular
   endothelial growth factor; ranibizumab
ID TACHYPHYLAXIS
AB Purpose To determine the efficacy of intravitreal ranibizumab 2.0 mg in patients with recalcitrant neovascular age-related macular degeneration (AMD).
   Methods This single-masked, randomized, prospective, pilot study enrolled patients with subfoveal neovascular AMD. All study eyes had persistent subretinal (SRF) or intraretinal fluid (IRF) on spectral-domain optical coherence tomography (SD-OCT) <30 days following at least 6 monthly intravitreal injections of ranibizumab or bevacizumab. Patients were randomized 2 : 1 to receive either ranibizumab 2.0 or 0.5 mg. Following three-loading treatments 4-weeks apart, both groups were treated using a 'treat and extend' regimen guided by eye-tracked SD-OCT through month 12. The primary end point was the mean change in best-corrected visual acuity (BCVA) at month 6.
   Results Nine eyes of 9 patients (mean age +/- SD, 82.0 +/- 5.8 years) were enrolled. Seven eyes received ranibizumab 2.0 mg and two eyes received 0.5 mg. Owing to the small number of patients enrolled, no statistical comparison could be made between the two dosages. At month 6, the mean improvement in BCVA was +6.1 +/- 3.7 (W=0, P<0.001) ETDRS letters and +2.0 ETDRS letters in the 2.0 and 0.5 mg groups, respectively. In the 2.0 mg group, there was a statistically significant decline in central foveal thickness, SRF and maximum pigment epithelial detachment height at 6 months compared with baseline. No adverse events were reported in either group.
   Conclusion Ranibizumab 2.0 mg has the potential to maintain or improve BCVA in some patients with persistent or recurrent SRF or IRF secondary to neovascular AMD despite prior monthly intravitreal anti-vascular endothelial growth factor therapy with the standard dose. Eye (2012) 26, 1181-1187; doi:10.1038/eye.2012.174; published online 10 August 2012
C1 [Fung, A. T.; Kumar, N.; Vance, S. K.; Slakter, J. S.; Klancnik, J. M.; Spaide, R. S.; Freund, K. B.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Fung, A. T.; Kumar, N.; Vance, S. K.; Slakter, J. S.; Klancnik, J. M.; Spaide, R. S.; Freund, K. B.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10022 USA.
   [Freund, K. B.] NYU, Dept Ophthalmol, New York, NY 10016 USA.
   [Freund, K. B.] Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University; Columbia University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Spaide, Richard/ABD-7368-2020
FU Macula Foundation, Inc.; Genentech, Inc.; Genentech; Regeneron; Novartis
FX This work was supported by the Macula Foundation, Inc. and Genentech,
   Inc. K Bailey Freund is an advisor to Genentech and Regeneron. Jason S
   Slakter receives support from Genentech, Regeneron and Novartis; James M
   Klancnik (Jnr) by Genentech and Regeneron; Richard S Spaide by
   Genentech.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan C, 2011, HIGH DOSE 2 0 MG VS
   Chen E, 2011, SAVE SUPERDOSE ANTIV
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Ho AC, 2011, EFFICACY SAFETY 2 0
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld P, 2003, INVEST OPHTHALMOL VI, V44
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
NR 13
TC 38
Z9 42
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2012
VL 26
IS 9
BP 1181
EP 1187
DI 10.1038/eye.2012.174
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004NN
UT WOS:000308688500003
PM 22878451
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kortvely, E
   Hauck, SM
   Behler, J
   Ho, N
   Ueffing, M
AF Kortvely, Elod
   Hauck, Stefanie M.
   Behler, Jennifer
   Ho, Nurulain
   Ueffing, Marius
TI The unconventional secretion of ARMS2
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID ENDOPLASMIC-RETICULUM; MACULAR DEGENERATION; PROTEIN SECRETION;
   CONTAINING EXOSOMES; INCLUSION-BODIES; MESSENGER-RNA; EXPRESSION;
   MEMBRANE; LOC387715; RESIDENT
AB Age-related maculopathy susceptibility 2 (ARMS2) is a small (11 kDa), primate-specific protein found in the extracellular matrix of the choroid layer in the eye. Variants in the corresponding genetic locus are highly associated with age-related macular degeneration, a leading cause of blindness in the elderly. So far, the physiological function of ARMS2 has remained enigmatic. It has been demonstrated that ARMS2 is a genuine secreted protein devoid of an N-terminal leader sequence, yet the mechanism how it exits the cells and enters the choroidal matrix is not understood. Here, we show that ARMS2 efficiently recruits lectin chaperones from the cytosol and colocalizes with calnexin-positive and protein disulfide isomerase-negative vesicle-like structures. Site-directed mutagenesis revealed critical elements for this interaction. Mutant forms proving unable to interact with the calnexin/calreticulin system failed secretion. On the other hand, blocking the endoplasmic reticulum to Golgi transport with brefeldin A had no effect on ARMS2 secretion. As we found ARMS2 colocalizing with GRASP65, a marker for unconventional protein secretion, autophagic factors are likely to be key in its export. Interleukin-1 beta (IL-1 beta) is the most established example of secretory autophagy. Co-expression experiments, however, suggest that the transport of ARMS2 is different from that of IL-1 beta. In conclusion, in this work we show that ARMS2 is externalized via an unconventional pathway bypassing Golgi. Its intracellular separation from the classical secretion pathway suggests that the maturation of the protein requires a specific biochemical niche and/or may be needed to impede the premature formation of unwanted protein-protein interactions.
C1 [Kortvely, Elod; Ho, Nurulain; Ueffing, Marius] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, Rontgenweg 11, D-72076 Tubingen, Germany.
   [Hauck, Stefanie M.; Behler, Jennifer] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Dept Prot Sci, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Helmholtz Association; Helmholtz-Center Munich - German
   Research Center for Environmental Health
RP Kortvely, E (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, Rontgenweg 11, D-72076 Tubingen, Germany.
EM eloed.koertvely@uni-tuebingen.de
RI Hauck, Stefanie/B-3300-2013
OI Hauck, Stefanie/0000-0002-1630-6827
FU Kerstan Foundation; European Union [634479]
FX This work was supported by grants from the Kerstan Foundation and by the
   European Union's Horizon 2020 Research and Innovation Programme under
   EYE-RISK (Grant Agreement No 634479) to M. U.
CR Arasaki K, 2010, TRAFFIC, V11, P587, DOI 10.1111/j.1600-0854.2010.01050.x
   Asea A, 2008, J REPROD IMMUNOL, V79, P12, DOI 10.1016/j.jri.2008.06.001
   Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9
   Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800
   Butler J, 2011, J CELL BIOCHEM, V112, P3543, DOI 10.1002/jcb.23281
   Caramelo JJ, 2008, J BIOL CHEM, V283, P10221, DOI 10.1074/jbc.R700048200
   Caramelo JJ, 2015, FEBS LETT, V589, P3379, DOI 10.1016/j.febslet.2015.07.021
   D'Angelo G, 2009, J BIOL CHEM, V284, P34849, DOI 10.1074/jbc.M109.068403
   DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804
   Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046
   Gomes C, 2007, NEUROSCI LETT, V428, P43, DOI 10.1016/j.neulet.2007.09.024
   Granell S, 2008, MOL BIOL CELL, V19, P572, DOI 10.1091/mbc.E07-06-0587
   Ito D, 2012, HUM MOL GENET, V21, P635, DOI 10.1093/hmg/ddr497
   Jiang S, 2013, J INNATE IMMUN, V5, P471, DOI 10.1159/000346707
   Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kinseth MA, 2007, CELL, V130, P524, DOI 10.1016/j.cell.2007.06.029
   Kortvely E, 2016, ADV EXP MED BIOL, V854, P23, DOI 10.1007/978-3-319-17121-0_4
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lamriben L, 2016, TRAFFIC, V17, P308, DOI 10.1111/tra.12358
   Lasser C, 2011, AM J RHINOL ALLERGY, V25, P89, DOI 10.2500/ajra.2011.25.3573
   Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9
   Lukashova V, 2011, J BIOL CHEM, V286, P11456, DOI 10.1074/jbc.M110.182881
   Mason AK, 2008, J BIOL CHEM, V283, P5973, DOI 10.1074/jbc.M709756200
   Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876
   Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617
   Rabouille C, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00001
   Rabouille C, 2012, J CELL SCI, V125, P5251, DOI 10.1242/jcs.103630
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schotman H, 2008, DEV CELL, V14, P171, DOI 10.1016/j.devcel.2007.12.006
   Tooze SA, 2013, ESSAYS BIOCHEM, V55, P29, DOI [10.1042/BSE0550029, 10.1042/bse0550029]
   VanLeeuwen D, 2003, J BIOL CHEM, V278, P15935, DOI 10.1074/jbc.M211546200
   Wendeler MW, 2007, EMBO REP, V8, P258, DOI 10.1038/sj.embor.7400893
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhang M, 2013, SCIENCE, V340, P559, DOI 10.1126/science.1234740
   Zhang XZ, 2016, PROCEEDINGS 2016 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P2016, DOI 10.1109/ICIT.2016.7475077
NR 41
TC 14
Z9 14
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2016
VL 25
IS 15
BP 3143
EP 3151
DI 10.1093/hmg/ddw162
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EJ2YK
UT WOS:000393077300001
PM 27270414
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Ohji, M
   Okada, AA
   Sasaki, K
   Moon, SC
   Machewitz, T
   Takahashi, K
AF Ohji, Masahito
   Okada, Annabelle A.
   Sasaki, Koji
   Moon, SungChul Charles
   Machewitz, Tobias
   Takahashi, Kanji
CA ALTAIR Investigators
TI Relationship between retinal fluid and visual acuity in patients with
   exudative age-related macular degeneration treated with intravitreal
   aflibercept using a treat-and-extend regimen: subgroup and post-hoc
   analyses from the ALTAIR study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Exudative age-related macular degeneration; Ophthalmology;
   Treat-and-extend; Post-hoc
ID MORPHOLOGY; EFFICACY
AB Purpose To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study. Methods Outcomes were investigated according to overall fluid status at week 16 (predefined) and the relationship between any fluid, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment with BCVA at baseline, and weeks 16, 52, and 96 (post-hoc). The analyses involved treatment-naive patients (N = 246) with exudative age-related macular degeneration (AMD), aged >= 50 years with BCVA of 73-25 Early Treatment Diabetic Retinopathy Study letters, who participated in the ALTAIR study. Results The mean (standard deviation) change in BCVA from baseline to week 52 was + 10.6 (10.9) and + 6.5 (16.0) letters in patients without and with fluid at week 16, respectively; and to week 96 was + 9.1 (14.3) and + 4.3 (16.1) letters in patients without and with fluid at week 16, respectively. The last injection interval was 16 weeks in 33.6% and 2.0% (week 52), and 62.9% and 17.6% (week 96) of patients without or with fluid at week 16, respectively. At baseline, 35.7% of patients had IRF and 85.2% of patients had SRF, which decreased to 11.8% (IRF) and 31.7% (SRF) of patients, 8.5% (IRF) and 18.7% (SRF), and 6.5% (IRF) and 20.7% (SRF) at weeks 16, 52, and 96, respectively. Presence of IRF at all timepoints was associated with poorer BCVA than if IRF was absent, while the presence of SRF was not associated with poorer BCVA compared with the absence of SRF. Conclusion IVT-AFL T&E dosing was effective at clearing fluid regardless of fluid type in similar to 80% of patients with exudative AMD. Patients without fluid at week 16 had numerically better BCVA than those with fluid at week 16. Over 60% of patients without fluid at week 16 achieved the maximum treatment interval of 16 weeks by study end, compared with < 20% of patients with fluid at week 16. IRF (weeks 16, 52, 96), although evident in a small number of patients, was associated with poorer BCVA, whereas SRF was not.
C1 [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Okada, Annabelle A.] Kyorin Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Sasaki, Koji; Moon, SungChul Charles] Bayer Yakuhin Ltd, Osaka, Japan.
   [Machewitz, Tobias] Bayer AG, Berlin, Germany.
   [Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Osaka, Japan.
C3 Shiga University of Medical Science; Kyorin University; Bayer AG; Bayer
   AG; Kansai Medical University
RP Ohji, M (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
EM eye.ohji@gmail.com
FU Bayer Consumer Care AG, Basel, Switzerland
FX These predefined and post-hoc analyses were funded by Bayer Consumer
   Care AG, Basel, Switzerland. Bayer, in conjunction with the ALTAIR
   steering committee (who are all authors), participated in the design of
   the study; analysis and interpretation of the data; preparation, review,
   and approval of the manuscript; and decision to submit the manuscript
   for publication. Additionally, Bayer was responsible for the conduct of
   the study and oversight of the collection and management of data.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sharma A, 2020, RETINA-J RET VIT DIS, V40, P1451, DOI 10.1097/IAE.0000000000002870
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
NR 13
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2021
VL 259
IS 12
BP 3637
EP 3647
DI 10.1007/s00417-021-05293-y
EA JUL 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6CP
UT WOS:000675140800003
PM 34283294
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Qian, TW
   Li, XX
   Zhao, MY
   Xu, X
AF Qian, Tianwei
   Li, Xinxin
   Zhao, Mengya
   Xu, Xun
TI Polypoidal choroidal vasculopathy treatment options: A meta-analysis
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
DE combination therapy; intravitreal anti-VEGF; meta-analysis; photodynamic
   therapy; polypoidal choroidal vasculopathy
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   INTRAVITREAL RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT; EFFICACY;
   COMBINATION; OUTCOMES; INJECTIONS
AB BackgroundCombined treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF) and verteporfin photodynamic therapy (PDT) is widely used for patients with polypoidal choroidal vasculopathy (PCV), although clinical evidence regarding the therapeutic efficacy and safety of such treatment remains lacking.
   Design/MethodsWe performed a meta-analysis of previously reported studies comparing combination treatment, PDT monotherapy, and anti-VEGF monotherapy. Primary outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). The proportion of patients with polyp regression was regarded as the secondary outcome measure.
   ResultsTwenty studies (three RCTs and 19 retrospective studies) involving 1,178 patients with PCV were selected. Significant differences in the proportion of patients with polyps were observed between the PDT and anti-VEGF monotherapy groups at 3 and 6 months (P < .00001; and P = .0001, respectively). Significantly greater reductions in CRT were observed in the anti-VEGF than in the PDT group at the 3-month follow-up (P = .04). Significantly greater improvements in BCVA were observed in the combined therapy group than in the PDT monotherapy group at 3, 6, 12, and 24 months (P = .03; P = .005; P = .02; and P < .00001, respectively). Combined treatment also resulted in significantly greater improvements in BCVA than monotherapy with anti-VEGF at 6 and 24 months (P = .001; P < .00001, respectively), and significantly greater polyp regression than that observed following anti-VEGF treatment at 3 and 6 months (P < .00001; P < .0001, respectively).
   ConclusionsCombined therapy involving anti-VEGF agents and PDT may be more effective in improving long-term outcomes for patients with PCV than monotherapy.
C1 [Qian, Tianwei; Li, Xinxin; Zhao, Mengya; Xu, Xun] Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
RP Xu, X (通讯作者)，Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
EM drxuxun@sjtu.edu.cn
OI qian, tian wei/0000-0002-7359-911X
FU National Natural Science Foundation of China [81570851]
FX Supported by the National Natural Science Foundation of China (No.
   81570851).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Ho M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36870
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kikushima W, 2016, GRAEFES ARCH CLIN EX, V255, P1
   Kim Jae Hui, 2015, Korean J Ophthalmol, V29, P404, DOI 10.3341/kjo.2015.29.6.404
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Liang IC, 2017, J OCUL PHARMACOL TH, V33, P42, DOI 10.1089/jop.2015.0150
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Morimoto M, 2017, GRAEFES ARCH CLIN EX, V2017, P1
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simera I, 2010, EUR J CLIN INVEST, V40, P35, DOI 10.1111/j.1365-2362.2009.02234.x
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   TANG K, 1056, INT J OPHTHALMOL, V2015, P8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang K, 2008, BIOL PHARM BULL, V31, P1541, DOI 10.1248/bpb.31.1541
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 54
TC 15
Z9 16
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD JAN
PY 2018
VL 48
IS 1
AR e12840
DI 10.1111/eci.12840
PG 14
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA FR1ZO
UT WOS:000418866800001
PM 28981139
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Okubo, A
   Abematsu, N
   Sakamoto, T
AF Okubo, Akiko
   Abematsu, Noriko
   Sakamoto, Taiji
TI Nasal and independent polypoidal lesions in polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
AB Polypoidal vessels in polypoidal choroidal vasculopathy (PCV) are known to occur frequently in the macular and peripapillary regions. The aim of this study is to describe patients with polypoidal vessels that are nasal to the optic disc, being independent of macular polypoidal lesions.
   A 75-year-old man and a 65-year-old man with polypoidal vessels in the macula of both eyes were followed up through routine examinations including indocyanine green angiography and optical coherence tomography.
   A polypoidal vessel located 1.5 disc diameters to the nasal margin of the disc was found in the right eye during the first examination in one case, and in the other case it developed during the follow-up period, after successful treatment using photodynamic therapy for the polypoidal lesion in the macula of the left eye. Indocyanine green angiography disclosed no continuity between the polypoidal vessels nasal to the disc and the polypoidal vessels in the macula region in either case. The nasal polypoidal vessels were not associated with exudative changes in either case, and the vessel in one case disappeared spontaneously without any treatment.
   The findings of this study demonstrate that PCV could involve regions outside the macula and occur in multiple areas independently. The results also indicate the dynamic nature and transitory appearance of polypoidal vessels. Polypoidal vessels nasal to the disc might be overlooked, especially in cases that are not associated with exudative changes, and careful examination might disclose more subclinical nasal polypoidal vessels. Further detailed examination would be helpful to gain a better understanding of the pathogenesis of PCV.
C1 [Okubo, Akiko] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
FU Japanese Ministry of Education, Science, Sports, and Culture [19592028]
FX This work was supported by research grant number 19592028 from the
   Japanese Ministry of Education, Science, Sports, and Culture.
CR Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Merle H, 2007, CAN J OPHTHALMOL, V42, P631, DOI 10.3129/i07-102
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
NR 10
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2009
VL 247
IS 3
BP 421
EP 425
DI 10.1007/s00417-008-0953-x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 403CZ
UT WOS:000263061200017
PM 18850106
DA 2022-11-30
ER

PT J
AU Zhang, K
   Zhang, LF
   Weinreb, RN
AF Zhang, Kang
   Zhang, Liangfang
   Weinreb, Robert N.
TI Ophthalmic drug discovery: novel targets and mechanisms for retinal
   diseases and glaucoma
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; CILIARY NEUROTROPHIC FACTOR; OPEN-ANGLE
   GLAUCOMA; AQUEOUS-HUMOR DYNAMICS; EPITHELIUM-DERIVED FACTOR;
   PROTEIN-KINASE INHIBITOR; GENOME-WIDE ASSOCIATION; RANIBIZUMAB PLUS
   PROMPT; AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM
AB Blindness affects 60 million people worldwide. The leading causes of irreversible blindness include age-related macular degeneration, retinal vascular diseases and glaucoma. The unique features of the eye provide both benefits and challenges for drug discovery and delivery. During the past decade, the landscape for ocular drug therapy has substantially changed and our knowledge of the pathogenesis of ophthalmic diseases has grown considerably. Anti-angiogenic drugs have emerged as the most effective form of therapy for age-related macular degeneration and retinal vascular diseases. Lowering intraocular pressure is still the mainstay for glaucoma treatment but neuroprotective drugs represent a promising next-generation therapy. This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities.
C1 [Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Mol Med Res Ctr, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Zhang, Kang; Weinreb, Robert N.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Zhang, Kang; Weinreb, Robert N.] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Zhang, Kang; Zhang, Liangfang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Zhang, Liangfang] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA.
C3 Sichuan University; Sichuan University; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego
RP Zhang, K (通讯作者)，Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
EM kang.zhang@gmail.com
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU Chinese National 985 Project; National Eye Institute; US National
   Institutes of Health, VA Merit Award, Research to Prevent Blindness,
   King Abdulaziz City for Science and Technology (through the University
   of California San Diego Center of Excellence in Nanomedicine centre
   grant); BWF (Burroughs Wellcome Fund) Clinical Scientist Award in
   Translational Research; National Science Foundation (NSF) [CMMI1031239,
   DMR1216461]; US National Institutes of Health [EY019692]; Research to
   Prevent Blindness, New York, USA; NATIONAL EYE INSTITUTE [R01EY019692]
   Funding Source: NIH RePORTER; Direct For Mathematical & Physical Scien
   [1216461] Funding Source: National Science Foundation
FX We thank J. Ambati, S. Ding, I. Kozak, J. Lee, L. Zhao and P. Shaw for
   their helpful comments. K.Z. is supported by grants from the Chinese
   National 985 Project to Sichuan University and West China Hospital, the
   National Eye Institute and the US National Institutes of Health, VA
   Merit Award, Research to Prevent Blindness, King Abdulaziz City for
   Science and Technology (through the University of California San Diego
   Center of Excellence in Nanomedicine centre grant) and the BWF
   (Burroughs Wellcome Fund) Clinical Scientist Award in Translational
   Research. L.Z. is supported by the National Science Foundation (NSF)
   grants CMMI1031239 and DMR1216461; R.N.W. is supported by grants from
   the National Eye Institute and the US National Institutes of Health
   (EY019692) and an unrestricted grant from Research to Prevent Blindness,
   New York, USA. We apologize for the omission of references owing to page
   limitations.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Anderson RE, 2002, MOL VIS, V8, P351
   Arar NH, 2008, INVEST OPHTH VIS SCI, V49, P3839, DOI 10.1167/iovs.07-1633
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barnebey HS, 2005, AM J OPHTHALMOL, V140, P1, DOI 10.1016/j.ajo.2005.02.043
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2009, INVEST OPHTHALMOL VI, V50
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Burnham CM, 2003, DRUG DISCOV TODAY, V8, P146, DOI 10.1016/S1359-6446(03)02604-7
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Campochiaro PA, 2010, AM J OPHTHALMOL, V149, P839, DOI 10.1016/j.ajo.2009.12.005
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Chen J, 2011, CLIN OPHTHALMOL, V5, P667, DOI 10.2147/OPTH.S15971
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chien FY, 2003, ARCH OPHTHALMOL-CHIC, V121, P87
   Choudhri S, 2000, AM J OPHTHALMOL, V130, P832, DOI 10.1016/S0002-9394(00)00717-0
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Craven ER, 2005, J OCUL PHARMACOL TH, V21, P337, DOI 10.1089/jop.2005.21.337
   Dark GG, 1997, CANCER RES, V57, P1829
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Deng WT, 2012, INVEST OPHTH VIS SCI, V53, P1895, DOI 10.1167/iovs.11-8831
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   DRANCE SM, 1981, ARCH OPHTHALMOL-CHIC, V99, P1019, DOI 10.1001/archopht.1981.03930011019007
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   du Toit LC, 2011, EXPERT OPIN DRUG DEL, V8, P71, DOI 10.1517/17425247.2011.542142
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2003, J COMP NEUROL, V461, P111, DOI 10.1002/cne.10701
   FUHRMANN S, 1995, DEVELOPMENT, V121, P2695
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Goldberg DF., 2012, INVEST OPHTHALMOL VI, V53
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676
   HEPLER RS, 1971, J AMER MED ASSOC, V217, P1392, DOI 10.1001/jama.1971.03190100074024
   Hernandez M, 2008, EXP EYE RES, V86, P798, DOI 10.1016/j.exer.2008.02.008
   Hietala K, 2008, DIABETES, V57, P2176, DOI 10.2337/db07-1495
   Hiett J A, 1992, Optom Clin, V2, P97
   Higginbotham EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P915, DOI 10.1001/archopht.120.7.915
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hommer A, 2007, EUR J OPHTHALMOL, V17, P53, DOI 10.1177/112067210701700108
   Honjo M, 2007, INVEST OPHTH VIS SCI, V48, P5549, DOI 10.1167/iovs.07-0878
   Honjo Megumi, 2009, Nippon Ganka Gakkai Zasshi, V113, P1071
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Hsiung SC, 2005, J NEUROCHEM, V95, P1653, DOI 10.1111/j.1471-4159.2005.03496.x
   Hu CMJ, 2011, P NATL ACAD SCI USA, V108, P10980, DOI 10.1073/pnas.1106634108
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kim J, 2011, P NATL ACAD SCI USA, V108, P7838, DOI 10.1073/pnas.1103113108
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Krauss AHP, 2011, EXP EYE RES, V93, P250, DOI 10.1016/j.exer.2011.03.001
   Krupin T, 2011, AM J OPHTHALMOL, V151, P671, DOI 10.1016/j.ajo.2010.09.026
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambert WS, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-4
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu JHK, 2004, AM J OPHTHALMOL, V138, P389, DOI 10.1016/j.ajo.2004.04.022
   Liu JHK, 2011, BRIT J OPHTHALMOL, V95, P599, DOI 10.1136/bjo.2010.199737
   Liu JHK, 2010, OPHTHALMOLOGY, V117, P2075, DOI 10.1016/j.ophtha.2010.03.026
   Liu JHK, 2009, OPHTHALMOLOGY, V116, P449, DOI 10.1016/j.ophtha.2008.09.054
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mauler F, 2005, J CEREBR BLOOD F MET, V25, P451, DOI 10.1038/sj.jcbfm.9600038
   Medeiros FA, 2002, DRUGS TODAY, V38, P563, DOI 10.1358/dot.2002.38.8.704676
   Migdal C, 2000, EYE, V14, P515, DOI 10.1038/eye.2000.138
   Mizuno K, 2011, INVEST OPHTHALMOL VI, V52
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   NATHANSON JA, 1981, INVEST OPHTH VIS SCI, V21, P798
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nilsson SFE, 2006, INVEST OPHTH VIS SCI, V47, P4042, DOI 10.1167/iovs.05-1627
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Orecchia A, 2003, J CELL SCI, V116, P3479, DOI 10.1242/jcs.00673
   Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Patel S, 2008, CURR DIABETES REP, V8, P257, DOI 10.1007/s11892-008-0046-6
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peterson JA, 2000, INVEST OPHTH VIS SCI, V41, P1749
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299
   Pfeiffer N, 2002, GRAEF ARCH CLIN EXP, V240, P893, DOI 10.1007/s00417-002-0553-0
   Pieramici D. J., 2012, ANN M ASS RES VIS OP
   Pons M, 2010, INVEST OPHTH VIS SCI, V51
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ramdas WD, 2011, HUM MOL GENET, V20, P2464, DOI 10.1093/hmg/ddr120
   Ramos AJ, 2004, BRAIN RES, V1030, P201, DOI 10.1016/j.brainres.2004.10.019
   Rao PV, 2001, INVEST OPHTH VIS SCI, V42, P1029
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rheaume MA, 2010, SEMIN OPHTHALMOL, V25, P295, DOI 10.3109/08820538.2010.518865
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruz V., 2011, INVEST OPHTHALMOL VI, V52
   Sagara T, 1999, ARCH OPHTHALMOL-CHIC, V117, P794
   Schachar RA, 2010, INVEST OPHTH VIS SCI, V51
   Schachar RA, 2011, CURR EYE RES, V36, P809, DOI 10.3109/02713683.2011.593725
   Schuman JS, 2005, AM J OPHTHALMOL, V140, P242, DOI 10.1016/j.ajo.2005.02.058
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Shih TY, 2011, SEX TRANSM DIS, V38, P299, DOI 10.1097/OLQ.0b013e31820b8bb4
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Sit AJ, 2006, AM J OPHTHALMOL, V141, P1131, DOI 10.1016/j.ajo.2006.01.049
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Sugiyama T, 2011, INVEST OPHTH VIS SCI, V52, P64, DOI 10.1167/iovs.10-5265
   Sultana Y, 2011, DRUG TODAY, V47, P441, DOI 10.1358/dot.2011.47.6.1549023
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tian BH, 1997, EXP EYE RES, V64, P979, DOI 10.1006/exer.1997.0296
   Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105
   TORIS CB, 1995, ARCH OPHTHALMOL-CHIC, V113, P1514, DOI 10.1001/archopht.1995.01100120044006
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Varma R, 2007, OPHTHALMOLOGY, V114, P1332, DOI 10.1016/j.ophtha.2006.10.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang RF, 2005, EXP EYE RES, V80, P629, DOI 10.1016/j.exer.2004.11.012
   Watterson KR, 2007, WOUND REPAIR REGEN, V15, P607, DOI 10.1111/j.1524-475X.2007.00292.x
   Weinreb RN, 2004, AM J OPHTHALMOL, V138, P458, DOI 10.1016/j.ajo.2004.04.054
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Weinreb RN, 2002, INVEST OPHTH VIS SCI, V43, P716
   Weinreb RN, 2009, OCULAR BLOOD FLOW GL
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wen R, 1996, J NEUROSCI, V16, P5986
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P30, DOI 10.1001/archopht.125.1.30
   Williams RD, 2011, AM J OPHTHALMOL, V152, P834, DOI 10.1016/j.ajo.2011.04.012
   Wirostko B.M., 2011, INVEST OPHTHALMOL VI, V52
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Yamamoto T, 2011, INVEST OPHTHALMOL VI, V52
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
   Yang ZL, 2008, J CLIN INVEST, V118, P2908, DOI 10.1172/JCI35891
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang K, 2011, NEW ENGL J MED, V365, P370, DOI 10.1056/NEJMcibr1105280
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang R, 2011, RETINA-J RET VIT DIS, V31, P785, DOI 10.1097/IAE.0b013e3181f27509
NR 205
TC 225
Z9 235
U1 10
U2 148
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD JUL
PY 2012
VL 11
IS 7
BP 541
EP 559
DI 10.1038/nrd3745
PG 19
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 968HU
UT WOS:000305969300023
PM 22699774
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Francis, PJ
   Zhang, H
   DeWan, A
   Hoh, J
   Klein, ML
AF Francis, Peter J.
   Zhang, Hong
   DeWan, Andrew
   Hoh, Josephine
   Klein, Michael L.
TI Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH
   genes on AMD in a Caucasian population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; CIGARETTE-SMOKING; JAPANESE
   POPULATION; RISK; DISEASE; VARIANT; ASSOCIATION
AB Purpose: To estimate the joint effects of single nucleotide polymorphysms (SNPs) in the genes complement factor H (CFH), HtrA serine peptidase I (HTRA1), and age-related maculopathy susceptibility 2 (LOC387715/ARMS2) in a Caucasian age related macular degeneration (AMD) case-control cohort.
   Methods: We genotyped three SNPs,rs1061170 (exon9, CFH),rs1 1200638 (HTRA1 promoter, -512bp), and rs10490924 (6.6 kb upstream of HTRA1 in LOC387715/ARMS2) in 333 cases with advanced AMD (choroidal neovascularization [CNV] and geographic atrophy) and 171 age-matched examined controls. Association tests were performed for individual SNPs and jointly with the CFH SNP Y402H. Analyses for interaction were also performed.
   Results: The linkage disequilibrium measure for two SNPs on 10q26, rs10490924 and rs1 1200638, is D'=0.8 and all four possible haplotypes of the two SNPs were detected in the samples. The allelic association test for rs1 1200638 on the promoter of HTRA1 yielded p-values less than 10(-10) for geographic atrophy, less than 10(-16) for neovascularization, and less than 10(-19) for the pooled phenotypes (with an odds ration [OR] of 3.973-, 95% confidence interval [Cl] 2.928, 5.390). Disease risk is conferred in a dosage-dependent fashion. Similar figures were observed for the LOC387715/ARMS2 SNP. No interaction was detected between either between the 10q26 SNPs or the CFH SNP.
   Conclusions: This is the first analysis to show that the two 10q26 SNPs are not in complete linkage disequilibrium. Our studies however show that both the HTRA1 and LOC387715/ARMS2 SNP appear to contribute equally to disease risk (both geographic atrophy and choroidal neovascularization) with no evidence of interaction with CFH.
C1 [Zhang, Hong; DeWan, Andrew; Hoh, Josephine] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Francis, Peter J.; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
C3 Yale University; Oregon Health & Science University
RP Hoh, J (通讯作者)，Yale Univ, Dept Epidemiol & Publ Hlth, 60 Coll St,Room 416, New Haven, CT 06520 USA.
EM josephine.hoh@yale.edu
OI DeWan, Andrew/0000-0002-7679-8704
FU NATIONAL EYE INSTITUTE [R01EY015771, R01EY012203, R21EY018127] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY012203, R21 EY018127,
   R01-EY015771, R01-EY12203, R21-EY018127, R01 EY015771] Funding Source:
   Medline
CR Akaike H., 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15
   Armitage P, 1971, STAT METHODS MED RES
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DEWAN A, 2006, SCIENCE
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scheffe H., 1959, ANAL VARIANCE
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Weger M, 2007, MOL VIS, V13, P1274
   YANG Z, 2006, SCIENCE
   Yoshida T, 2007, MOL VIS, V13, P545
NR 21
TC 55
Z9 59
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 4
PY 2008
VL 14
IS 167-73
BP 1395
EP 1400
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 336EC
UT WOS:000258346100002
PM 18682806
DA 2022-11-30
ER

PT J
AU Giorgi, D
   Contestabile, MT
   Pacella, E
   Gabrieli, CB
AF Giorgi, D
   Contestabile, MT
   Pacella, E
   Gabrieli, CB
TI An instrument for biofeedback applied to vision
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Article
DE biofeedback; low vision; macular degeneration; central scotoma; visual
   rehabilitation; improved biofeedback integrated system (Ibis)
ID CONGENITAL NYSTAGMUS; ECCENTRIC FIXATION; ACCOMMODATION; BLEPHAROSPASM;
   SCOTOMA; MYOPIA
AB One hundred and ten patients (179 eyes) with reduced visual acuity caused by different ocular disorders underwent visual rehabilitation with an instrument for biofeedback: improved biofeedback integrated system (Ibis). One hundred and fourteen eyes had age-related macular degeneration, 39 eyes had myopic macular degeneration, and 26 eyes were affected by different ocular disorders. A placebo training was developed on 34 patients (47 eyes). Thirty-three eyes had age-related macular degeneration and 15 eyes had myopic macular degeneration. Visual acuity was found to be improved in 130/179 eyes (72.62%). Mean visual acuity was 0.24 before training and 0.36 at the last follow-up. A review of the literature and possible mechanisms are discussed.
C1 Univ Roma La Sapienza, Dept Ophthalmol Sci, I-00176 Rome, Italy.
C3 Sapienza University Rome
RP Giorgi, D (通讯作者)，Univ Roma La Sapienza, Dept Ophthalmol Sci, Via Guglielmo Ubertini 64, I-00176 Rome, Italy.
EM lupusunit@tin.it
OI PACELLA, ELENA/0000-0002-5431-6399
CR ABADI RV, 1980, BRIT J OPHTHALMOL, V64, P2, DOI 10.1136/bjo.64.1.2
   ALLEN M J, 1954, Am J Optom Arch Am Acad Optom, V31, P297
   BALLIET R, 1978, INVEST OPHTH VIS SCI, V17, P303
   BANGERTER A, 1955, AMBLYOPIEBEHANDLUNG
   BOHME G, 1955, Klin Monbl Augenheilkd Augenarztl Fortbild, V126, P694
   CIUFFREDA KJ, 1982, AM J OPTOM PHYS OPT, V59, P396
   Contestabile MT, 2002, EYE, V16, P472, DOI 10.1038/sj.eye.6700046
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   FLOM MC, 1980, INVEST OPHTH VIS SCI, V19, P1371
   FOSSETTI A, 1962, MANAGEMENT MYOPIA BI
   IORIO P, 1998, OTTICA FIRSTOPATOLOG, V3, P39
   Leung V, 1996, OPTOMETRY VISION SCI, V73, P114, DOI 10.1097/00006324-199602000-00007
   MONCADA A, 1995, BIOFEEDBACK VISIVO O, P6
   ROTBERG MH, 1983, SURV OPHTHALMOL, V27, P381, DOI 10.1016/0039-6257(83)90195-9
   ROWAN GE, 1981, AM J PSYCHIAT, V138, P1487
   ROXANAS MR, 1978, CAN MED ASSOC J, V119, P48
   RUSS KL, 1978, BIOFEEDBACK SELF-REG, V3, P231
   TRACHTMAN JN, 1978, AM J OPTOM PHYS OPT, V55, P400
   TRACHTMAN JN, 1987, AM J OPTOM PHYS OPT, V64, P639
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 20
TC 18
Z9 21
U1 0
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
EI 1573-3270
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD DEC
PY 2005
VL 30
IS 4
BP 389
EP 395
DI 10.1007/s10484-005-8424-1
PG 7
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA 998DW
UT WOS:000234299800005
PM 16385426
DA 2022-11-30
ER

PT J
AU Kiernan, DF
   Zelkha, R
   Hariprasad, SM
   Lim, JI
   Blair, MP
   Mieler, WF
AF Kiernan, Daniel F.
   Zelkha, Ruth
   Hariprasad, Seenu M.
   Lim, Jennifer I.
   Blair, Michael P.
   Mieler, William F.
TI EN FACE SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY OUTER RETINAL
   ANALYSIS AND RELATION TO VISUAL ACUITY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE en face optical coherence tomography; macular edema; optical coherence
   tomography; visual acuity; spectral-domain optical coherence tomography
ID DIABETIC MACULAR EDEMA; FOVEAL PHOTORECEPTOR LAYER;
   ULTRAHIGH-RESOLUTION; EPIRETINAL MEMBRANE; INTRAVITREAL TRIAMCINOLONE;
   SEGMENT JUNCTION; VEIN OCCLUSION; HIGH-SPEED; THICKNESS; INNER
AB Purpose: To describe a method of en face visualization and quantification of the photoreceptor inner segment/outer segment junction area, using spectral-domain optical coherence tomography, and association with visual acuity.
   Methods: Case series of 74 eyes in 53 patients. Central 1-mm and 400-mu m en face areas were analyzed with a computer algorithm.
   Results: The presence or absence of inner segment/outer segment junction was visible on both spectral-domain optical coherence tomography en face and retinal cross sections. Thirty eyes (40.6%) had no retinal pathology and an average logMAR visual acuity of 0.116. Twenty-five eyes (33.8%) had intraretinal edema, with visual acuity of 0.494. Nineteen eyes had nonneovascular age-related macular degeneration (dry age-related macular degeneration, 25.6%), with visual acuity of 0.392. In all eyes, central 1-mm and 400-mm en face areas were 58.3 +/- 25.0% and 56.4 +/- 26.0%, which showed significant correlation with visual acuity (Pearson correlation, r = -0.66 and -0.56, both P < 0.001). This correlation was greater than correlation of visual acuity with central subfield thickness (r = 0.39, P < 0.001), macular volume (r = 0.36, P = 0.002), and average macular thickness (r = 0.37, P = 0.001). However, no variables were significantly correlated with dry age-related macular degeneration eyes.
   Conclusion: Central en face inner segment/outer segment junction areas are significantly correlated with visual acuity in most eyes. This may correlate better with visual acuity than other spectral-domain optical coherence tomography values, as a reflection of photoreceptor integrity. Dry age-related macular degeneration may disrupt the plane used to formulate the en face display. Advancements in spectral-domain optical coherence tomography may provide routine en face visualization analysis. RETINA 32:1077-1086, 2012
C1 [Kiernan, Daniel F.; Zelkha, Ruth; Lim, Jennifer I.; Blair, Michael P.; Mieler, William F.] Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Hariprasad, Seenu M.] Univ Chicago, Dept Surg, Sect Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Chicago
RP Mieler, WF (通讯作者)，Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA.
EM wmieler@uic.edu
FU University of Illinois at Chicago [EY01792]; Research from Prevent
   Blindness; Gerhard Cless Retina Research Fund; NATIONAL EYE INSTITUTE
   [P30EY001792] Funding Source: NIH RePORTER
FX Supported in part by University of Illinois at Chicago core grant
   EY01792, an unrestricted grant from Research from Prevent Blindness, and
   the Gerhard Cless Retina Research Fund (J.I.L.).
CR Arichika S, 2010, RETINA-J RET VIT DIS, V30, P503, DOI 10.1097/IAE.0b013e3181bd2d65
   Barkana Y, 2009, AM J OPHTHALMOL, V147, P260, DOI 10.1016/j.ajo.2008.08.008
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Chang LK, 2008, RETINA-J RET VIT DIS, V28, P969, DOI 10.1097/IAE.0b013e3181744165
   Choi SS, 2008, J NEURO-OPHTHALMOL, V28, P120, DOI 10.1097/WNO.0b013e318175c6f5
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3
   Forooghian F, 2010, RETINA-J RET VIT DIS, V30, P63, DOI 10.1097/IAE.0b013e3181bd2c5a
   Gibran SK, 2007, OPHTHALMOLOGY, V114, P890, DOI 10.1016/j.ophtha.2006.11.026
   Hofer H, 2005, J NEUROSCI, V25, P9669, DOI 10.1523/JNEUROSCI.2414-05.2005
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiernan Daniel F, 2010, Retin Cases Brief Rep, V4, P339, DOI 10.1097/ICB.0b013e3181d42801
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Mitamura Y, 2009, BRIT J OPHTHALMOL, V93, P171, DOI 10.1136/bjo.2008.146381
   Mizota A, 2007, CLIN EXP OPHTHALMOL, V35, P220, DOI 10.1111/j.1442-9071.2007.01456.x
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Oh J, 2010, INVEST OPHTH VIS SCI, V51, P1651, DOI 10.1167/iovs.09-4420
   Oster SF, 2010, RETINA-J RET VIT DIS, V30, P713, DOI 10.1097/IAE.0b013e3181c596e3
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   RIPPS H, 1965, NATURE, V205, P52, DOI 10.1038/205052a0
   Rosen RB, 2009, OPT EXPRESS, V17, P4112, DOI 10.1364/OE.17.004112
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   VANNORREN D, 1989, VISION RES, V29, P1825, DOI 10.1016/0042-6989(89)90163-6
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Zambarakji HJ, 1998, OPHTHALMOLOGY, V105, P1051, DOI 10.1016/S0161-6420(98)96007-9
NR 32
TC 13
Z9 13
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2012
VL 32
IS 6
BP 1077
EP 1086
DI 10.1097/IAE.0b013e31823c23bc
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 948VY
UT WOS:000304532100005
PM 22466459
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Plastino, F
   Pesce, NA
   Andre, H
AF Plastino, Flavia
   Pesce, Noemi Anna
   Andre, Helder
TI MicroRNAs and the HIF/VEGF axis in ocular neovascular diseases
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age&#8208; related macular degeneration; angiogenesis; corneal
   neovascularization; hypoxamiR; proliferative diabetic retinopathy;
   retinopathy of prematurity
ID ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; MACULAR DEGENERATION;
   RNA-INTERFERENCE; NUCLEAR EXPORT; DIABETIC-RETINOPATHY; GEOGRAPHIC
   ATROPHY; GENE-REGULATION; FACTOR 1-ALPHA; HYPOXIA
AB Ocular neovascular diseases, such as proliferative diabetic retinopathy, retinopathy of prematurity and neovascular age-related macular degeneration, are the leading causes of visual impairment worldwide. The hypoxia-inducible factors and vascular endothelial growth factors are key molecular promoters of ocular neovascularization. Moreover, the role of microRNAs as regulators of angiogenesis has been expanding, particularly hypoxia-associated microRNA; hypoxamiRs. This review provides a summary of hypoxamiRs that directly and specifically target HIF1A and VEGF mRNAs, thus critically involved in the regulation of ocular neovascular pathologies. The discussed microRNAs highlight putative diagnostic markers and therapeutic agents in choroidal and retinal angiogenic diseases, including proliferative diabetic retinopathy, retinopathy of prematurity and neovascular age-related macular degeneration.
C1 [Plastino, Flavia; Pesce, Noemi Anna; Andre, Helder] Karolinska Inst, St Erik Eye Hosp, Div Eye & Vis, Dept Clin Neurosci, Stockholm, Sweden.
C3 Karolinska Institutet
RP Andre, H (通讯作者)，Karolinska Inst, St Erik Eye Hosp, Div Eye & Vis, Dept Clin Neurosci, Stockholm, Sweden.
EM Helder.Andre@ki.se
OI Pesce, Noemi Anna/0000-0002-5836-8575; Plastino,
   Flavia/0000-0001-8160-3273; Andre, Helder/0000-0002-2926-2376
CR Abu El-Asrar AM, 2007, BRIT J OPHTHALMOL, V91, P822, DOI 10.1136/bjo.2006.109876
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bashinsky Alice L, 2017, N C Med J, V78, P124, DOI 10.18043/ncm.78.2.124
   Beaujean O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180235
   Beebe DC, 2008, SEMIN CELL DEV BIOL, V19, P125, DOI 10.1016/j.semcdb.2007.08.014
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bezzi M, 2017, CELL RES, V27, P1401, DOI 10.1038/cr.2017.136
   Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Chen HX, 2014, ONCOTARGET, V5, P11873, DOI 10.18632/oncotarget.2662
   Chen N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095665
   Cheng YQ, 2020, GENES-BASEL, V11, DOI 10.3390/genes11080868
   Crosby ME, 2009, CELL CYCLE, V8, P4009, DOI 10.4161/cc.8.24.10211
   Daniel E, 2020, JAMA OPHTHALMOL, V138, P510, DOI 10.1001/jamaophthalmol.2020.0437
   De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602
   DelMonte DW, 2011, J CATARACT REFR SURG, V37, P588, DOI 10.1016/j.jcrs.2010.12.037
   Desjarlais M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218282
   Ehrlich R., 2010, ENCY EYE, P73, DOI [10.1016/B978-0-12-374203-2.00136-6, DOI 10.1016/B978-0-12-374203-2.00136-6]
   El Baroudi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014742
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Forooghian F, 2007, AM J OPHTHALMOL, V144, P761, DOI 10.1016/j.ajo.2007.07.022
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gee HE, 2010, CANCER-AM CANCER SOC, V116, P2148, DOI 10.1002/cncr.25009
   Ghini F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05182-9
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Han F, 2015, MED SCI MONITOR, V21, P1642, DOI 10.12659/MSM.893068
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hartnett ME, 2013, J AAPOS, V17, P229, DOI 10.1016/j.jaapos.2012.12.155
   Hasegawa T, 2007, DEV DYNAM, V236, P2089, DOI 10.1002/dvdy.21231
   Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Jeong YC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160662
   Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
   Kim LA, 2015, MOL VIS, V21, P673
   Kim SJ, 2018, SURV OPHTHALMOL, V63, P618, DOI 10.1016/j.survophthal.2018.04.002
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Kuehbacher A, 2008, TRENDS PHARMACOL SCI, V29, P12, DOI 10.1016/j.tips.2007.10.014
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Kvanta A, 2008, ACTA OPHTHALMOL, V86, P468, DOI 10.1111/j.1755-3768.2008.01283.x
   Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Li C, 2017, ONCOL RES, V25, P1169, DOI 10.3727/096504017X14847395834985
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Ling SK, 2013, CELL SIGNAL, V25, P2840, DOI 10.1016/j.cellsig.2013.08.039
   Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   Lutty GA, 2018, PROG RETIN EYE RES, V62, P58, DOI 10.1016/j.preteyeres.2017.10.001
   Madanecki P, 2013, CELL MOL BIOL LETT, V18, P47, DOI 10.2478/s11658-012-0037-0
   Maddula S, 2011, OPHTHALMOLOGY, V118, P591, DOI 10.1016/j.ophtha.2011.01.041
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Mammadzada P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122217
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   Melincovici CS, 2018, ROM J MORPHOL EMBRYO, V59, P455
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Migault M, 2017, METHODS, V117, P35, DOI 10.1016/j.ymeth.2016.11.012
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nunes DN, 2015, P NATL ACAD SCI USA, V112, P3770, DOI 10.1073/pnas.1500008112
   Park KH, 2004, RETINA-J RET VIT DIS, V24, P368, DOI 10.1097/00006982-200406000-00006
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Peet DJ, 2017, EXP CELL RES, V356, P136, DOI 10.1016/j.yexcr.2017.03.030
   Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rodrigues Gustavo B, 2016, Int J Retina Vitreous, V2, P26
   Rodrigues M, 2013, DIABETES, V62, P3863, DOI 10.2337/db13-0014
   Ruas JL, 2005, SEMIN CELL DEV BIOL, V16, P514, DOI 10.1016/j.semcdb.2005.04.001
   Ryan D, 2006, MOL VIS, V12, P1175
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389
   Shah Parag K, 2016, World J Clin Pediatr, V5, P35, DOI 10.5409/wjcp.v5.i1.35
   Sharif Zuhair, 2019, Rom J Ophthalmol, V63, P15
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83
   Smith RO, 2020, ELIFE, V9, DOI 10.7554/eLife.54056
   Sundermeier TR, 2012, CELL MOL LIFE SCI, V69, P2739, DOI 10.1007/s00018-012-0976-7
   Takemoto A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42186
   Teppo S, 2017, RNA BIOL, V14, P827, DOI 10.1080/15476286.2017.1312228
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Ullah S, 2014, MOL BIOL REP, V41, P225, DOI 10.1007/s11033-013-2855-1
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Wang YP, 2017, MOL MED REP, V15, P146, DOI 10.3892/mmr.2016.5993
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   Wilusz JE, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1478
   Wu L, 2013, WORLD J DIABETES, V4, P290, DOI 10.4239/wjd.v4.i6.290
   Yang C, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755-5922.12329
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   York Jackie R, 2004, J Perinatol, V24, P82, DOI 10.1038/sj.jp.7211040
   Yue BL, 2017, J CELL BIOCHEM, V118, P2387, DOI 10.1002/jcb.25901
   Zhang XP, 2018, EXP EYE RES, V167, P122, DOI 10.1016/j.exer.2017.12.001
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zong RR, 2016, INVEST OPHTH VIS SCI, V57, P1398, DOI 10.1167/iovs.15-17417
NR 123
TC 8
Z9 8
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2021
VL 99
IS 8
BP E1255
EP E1262
DI 10.1111/aos.14845
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW9GS
UT WOS:000629650400001
PM 33729690
OA hybrid
DA 2022-11-30
ER

PT J
AU Stahl, A
   Krohne, TU
   Sapieha, P
   Chen, J
   Hellstrom, A
   Chew, E
   Holz, FG
   Smith, LEH
AF Stahl, Andreas
   Krohne, Tim U.
   Sapieha, Przemyslaw
   Chen, Jing
   Hellstrom, Ann
   Chew, Emily
   Holz, Frank G.
   Smith, Lois E. H.
TI Lipid metabolites in the pathogenesis and treatment of neovascular eye
   disease
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RETINAL MICROVASCULAR DEGENERATION; POLYUNSATURATED FATTY-ACIDS;
   OXYGEN-INDUCED RETINOPATHY; PEROXIDATION PRODUCTS; PROTEIN
   MODIFICATIONS; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; OXIDATIVE
   DAMAGE; ENDOTHELIAL-CELLS; END-PRODUCTS
AB Lipids and lipid metabolites have long been known to play biological roles that go beyond energy storage and membrane structure. In age-related macular degeneration and diabetes, for example, dysregulation of lipid metabolism is closely associated with disease onset and progression. At the same time, some lipids and their metabolites can exert beneficial effects in the same disorders. This review summarises our current knowledge of the contributions of lipids to both the pathogenesis and treatment of neovascular eye disease. The clinical entities covered are exudative age-related macular degeneration, diabetic retinopathy and retinopathy of prematurity, with a special emphasis on the potential therapeutic effects of omega 3- (also known as n-3) polyunsaturated fatty acids.
C1 [Stahl, Andreas; Chen, Jing; Smith, Lois E. H.] Harvard Univ, Sch Med, Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Stahl, Andreas] Univ Eye Hosp Freiburg, Freiburg, Germany.
   [Krohne, Tim U.; Holz, Frank G.] Univ Eye Hosp Bonn, Bonn, Germany.
   [Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada.
   [Hellstrom, Ann] Univ Gothenburg, Inst Neurosci & Physiol, Gothenburg, Sweden.
   [Chew, Emily] NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Freiburg; University of Bonn; Universite de Montreal;
   University of Gothenburg; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Smith, LEH (通讯作者)，Harvard Univ, Sch Med, Childrens Hosp Boston, 300 Longwood Ave, Boston, MA 02115 USA.
EM lois.smith@childrens.harvard.edu
RI Krohne, Tim/AAG-4412-2020; Krohne, Tim/D-1497-2013
OI Krohne, Tim/0000-0003-2280-925X; Hellstrom, Ann/0000-0002-9259-1244
FU Deutsche Forschungsgemeinschaft; Canadian Institutes of Health Research;
   Canadian National Institute for the Blind; Juvenile Diabetes Research
   Foundation International; NIH [EY017017, EY017017-S1]; V. Kann Rasmussen
   Foundation; Roche Foundation for Anemia Research; Children's Hospital
   Boston Mental Retardation and Developmental Disabilities Research
   Center; Research to Prevent Blindness Senior Investigator Award; Alcon
   Research Institute Award; MacTel Foundation; NATIONAL EYE INSTITUTE
   [R01EY022275, R01EY017017] Funding Source: NIH RePORTER
FX Deutsche Forschungsgemeinschaft (AS); Canadian Institutes of Health
   Research, Canadian National Institute for the Blind (PS); Juvenile
   Diabetes Research Foundation International (JC); NIH (EY017017,
   EY017017-S1), V. Kann Rasmussen Foundation, Roche Foundation for Anemia
   Research, Children's Hospital Boston Mental Retardation and
   Developmental Disabilities Research Center, Research to Prevent
   Blindness Senior Investigator Award, Alcon Research Institute Award,
   MacTel Foundation (LEHS).
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barnett JM, 2010, INVEST OPHTH VIS SCI, V51, P1136, DOI 10.1167/iovs.09-3691
   Bartoli M, 2009, INVEST OPHTH VIS SCI, V50, P4934, DOI 10.1167/iovs.08-2158
   Bazan N G, 1976, Adv Exp Med Biol, V72, P317
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beauchamp MH, 2001, J APPL PHYSIOL, V90, P2279, DOI 10.1152/jappl.2001.90.6.2279
   Bonventre JV, 1996, J LIPID MEDIAT CELL, V14, P15, DOI 10.1016/0929-7855(96)00503-2
   BREM SS, 1977, SCIENCE, V195, P880, DOI 10.1126/science.402692
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calandria JM, 2010, ADV EXP MED BIOL, V664, P663, DOI 10.1007/978-1-4419-1399-9_76
   Calandria JM, 2009, J BIOL CHEM, V284, P17877, DOI 10.1074/jbc.M109.003988
   Campbell WB, 2010, PFLUG ARCH EUR J PHY, V459, P881, DOI 10.1007/s00424-010-0804-6
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Cheung HM, 2009, CLIN NUTR, V28, P209, DOI 10.1016/j.clnu.2009.02.004
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chew Emily Y, 2010, Retina, V30, P459, DOI 10.1097/IAE.0b013e3181bcf1a0
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2010, OPHTHALMOLOGY, V117, P1279, DOI 10.1016/j.ophtha.2010.03.011
   de Meijer VE, 2009, JPEN-PARENTER ENTER, V33, P541, DOI 10.1177/0148607109332773
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Ferris FL, 1996, DIABETES CARE, V19, P1291, DOI 10.2337/diacare.19.11.1291
   FLOWER RW, 1984, PEDIATRICS, V73, P440
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Good WV, 2001, OPHTHALMOLOGY, V108, P1013, DOI 10.1016/S0161-6420(01)00540-1
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hardy P, 2005, PHARMACOL REP, V57, P169
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jenkins AJ, 2004, CURR PHARM DESIGN, V10, P3395, DOI 10.2174/1381612043383188
   Jin YP, 2009, INVEST OPHTH VIS SCI, V50, P4743, DOI 10.1167/iovs.08-2462
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Jones Marcus, 2009, Paediatr Respir Rev, V10 Suppl 1, P9, DOI 10.1016/S1526-0542(09)70005-3
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kermorvant-Duchemin E, 2005, NAT MED, V11, P1339, DOI 10.1038/nm1336
   Kesavulu MM, 2000, DIABETES METAB, V26, P387
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lapillonne A, 2009, PROSTAG LEUKOTR ESS, V81, P143, DOI 10.1016/j.plefa.2009.05.014
   Le HD, 2009, PROSTAG LEUKOTR ESS, V81, P165, DOI 10.1016/j.plefa.2009.05.020
   Leduc M, 2006, SEMIN PERINATOL, V30, P129, DOI 10.1053/j.semperi.2006.04.004
   Lee CTC, 2010, OPHTHALMOLOGY, V117, P71, DOI 10.1016/j.ophtha.2009.06.040
   Lin CI, 2008, CELL SIGNAL, V20, P1804, DOI 10.1016/j.cellsig.2008.06.008
   Lyons TJ, 2004, INVEST OPHTH VIS SCI, V45, P910, DOI 10.1167/iovs.02-0648
   Matsuo Y, 1996, BRAIN RES, V709, P296, DOI 10.1016/0006-8993(95)01324-5
   Michaelis UR, 2003, FASEB J, V17, P770, DOI 10.1096/fj.02-0640fje
   Negre-Salvayre A, 2008, BRIT J PHARMACOL, V153, P6, DOI 10.1038/sj.bjp.0707395
   Pazdro R, 2010, MECH AGEING DEV, V131, P276, DOI 10.1016/j.mad.2010.03.005
   Phillis JW, 2004, BRAIN RES REV, V44, P13, DOI 10.1016/j.brainresrev.2003.10.002
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schwartzman ML, 2010, DIABETES, V59, P1780, DOI 10.2337/db10-0110
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Sheets KG, 2010, MOL VIS, V16, P320
   Shen LQ, 2008, ARCH OPHTHALMOL-CHIC, V126, P793, DOI 10.1001/archopht.126.6.793
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   STEVENS MK, 1988, J CEREBR BLOOD F MET, V8, P790, DOI 10.1038/jcbfm.1988.134
   Szymczak M, 2008, BLOOD, V111, P3514, DOI 10.1182/blood-2007-08-109934
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Ucgun NI, 2007, ANN NY ACAD SCI, V1100, P213, DOI 10.1196/annals.1395.021
   Verdejo C, 1999, EYE, V13, P183, DOI 10.1038/eye.1999.48
   Weinberger B, 2006, PEDIATR INT, V48, P479, DOI 10.1111/j.1442-200X.2006.02257.x
   Winterbourn CC, 2000, PEDIATR RES, V48, P84, DOI 10.1203/00006450-200007000-00015
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200
   Zhu Y, 1998, EXP EYE RES, V67, P357, DOI 10.1006/exer.1998.0535
NR 91
TC 21
Z9 21
U1 1
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2011
VL 95
IS 11
BP 1496
EP 1501
DI 10.1136/bjo.2010.194241
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 837VK
UT WOS:000296233900004
PM 21421650
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Tian, LF
   Kazmierkiewicz, KL
   Bowman, AS
   Li, MY
   Curcio, CA
   Stambolian, DE
AF Tian, Lifeng
   Kazmierkiewicz, Krista L.
   Bowman, Anita S.
   Li, Mingyao
   Curcio, Christine A.
   Stambolian, Dwight E.
TI Transcriptome of the human retina, retinal pigmented epithelium and
   choroid
SO GENOMICS
LA English
DT Review
DE Age-related macular degeneration; cDNA microarray; Glaucoma; Retina;
   Retinal pigmented epithelium; Choroid; RNA-Seq; Serial analysis of gene
   expression; Transcriptome
ID SUBRETINAL DRUSENOID DEPOSITS; GENE-EXPRESSION; RETICULAR PSEUDODRUSEN;
   SERIAL ANALYSIS; GRADING SYSTEM; HUMAN MACULA; RNA; GENOMICS; EYES;
   REPRODUCIBILITY
AB The retina and its adjacent supporting tissues - retinal pigmented epithelium (RPE) and choroid - are critical structures in human eyes required for normal visual perception. Abnormal changes in these layers have been implicated in diseases such as age-related macular degeneration and glaucoma. With the advent of high-throughput methods, such as serial analysis of gene expression, cDNA microarray, and RNA sequencing, there is unprecedented opportunity to facilitate our understanding of the normal retina, RPE, and choroid. This information can be used to identify dysfunction in age-related macular degeneration and glaucoma. In this review, we describe the current status in our understanding of these transcriptomes through the use of high-throughput techniques. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Tian, Lifeng] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA.
   [Kazmierkiewicz, Krista L.; Bowman, Anita S.; Stambolian, Dwight E.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Li, Mingyao] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; University of Pennsylvania;
   University of Alabama System; University of Alabama Birmingham
RP Stambolian, DE (通讯作者)，Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
EM tianl@email.chop.edu; kristakazmar@gmail.com;
   anitabow@mail.med.upenn.edu; mingyao@mail.med.upenn.edu; curcio@uab.edu;
   stamboli@mail.med.upenn.edu
OI Bowman, Anita S./0000-0002-8651-5317
FU NEI [EY06109, EY023164, EY020483]; Arnold and Mabel Beckman Initiative
   for Macular Research; EyeSight Foundation of Alabama, Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY023164, P30EY001583,
   R01EY006109, R01EY020483] Funding Source: NIH RePORTER
FX We thank our laboratory members for helpful discussion of the
   manuscript. CAC acknowledges support from: NEI EY06109; Arnold and Mabel
   Beckman Initiative for Macular Research; EyeSight Foundation of Alabama,
   Research to Prevent Blindness. DES acknowledges support from: NEI
   EY023164 and EY020483; Arnold and Mabel Beckman Initiative for Macular
   Research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bagheri N, 2012, ADV EXP MED BIOL, V723, P479, DOI 10.1007/978-1-4614-0631-0_60
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Brown NH, 2009, GRAEF ARCH CLIN EXP, V247, P1069, DOI 10.1007/s00417-009-1044-3
   Cai H, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00008
   Cheung VG, 2003, NAT GENET, V33, P422, DOI 10.1038/ng1094
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Daiger S.P., 1997, INVEST OPHTH VIS SCI, V12, P295
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Heinzen EL, 2008, PLOS BIOL, V6, P2869, DOI 10.1371/journal.pbio.1000001
   Hornan DM, 2007, INVEST OPHTH VIS SCI, V48, P5388, DOI 10.1167/iovs.07-0355
   Kalathur RKR, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-208
   Katsanis N, 2002, P NATL ACAD SCI USA, V99, P14326, DOI 10.1073/pnas.222409099
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Liu YT, 2013, INVEST OPHTH VIS SCI, V54, P6382, DOI 10.1167/iovs.13-12128
   Malik KF, 2003, INVEST OPHTH VIS SCI, V44, P2730, DOI 10.1167/iovs.02-1120
   Malone JH, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-34
   Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Schulz HL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-50
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239
   Sirbu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050986
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Swaroop A, 2002, GENOME BIOL, V3
   van Soest SS, 2007, MOL VIS, V13, P1608
   VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484
   Wagner AH, 2013, EXP EYE RES, V111, P105, DOI 10.1016/j.exer.2013.03.004
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Young TL, 2013, EXP EYE RES, V116, P265, DOI 10.1016/j.exer.2013.08.009
   Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 53
TC 40
Z9 40
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD MAY
PY 2015
VL 105
IS 5-6
BP 253
EP 264
DI 10.1016/j.ygeno.2015.01.008
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CG2TD
UT WOS:000353127100001
PM 25645700
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Chung, SE
   Kang, SW
   Kim, JH
   Kim, YT
   Park, DY
AF Chung, Song Ee
   Kang, Se Woong
   Kim, Jae Hui
   Kim, Yun Taek
   Park, Do Young
TI ENGORGEMENT OF VORTEX VEIN AND POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; vascular dilation; vortex vein;
   wide-angle indocyanine angiography
ID CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; UVEAL EFFUSION
AB Purpose: The purpose of this study was to identify a correlation between engorgement of the vortex vein and the development of polypoidal choroidal vasculopathy (PCV).
   Methods: Engorgement of the vortex vein was evaluated by masked observers using a montage of indocyanine green angiography images. Sixty-three eyes with PCV, 27 uninvolved fellow eyes with PCV, and 30 eyes of age-matched control subjects were included. The incidence and distribution pattern of engorgement were evaluated.
   Results: Thirty-three eyes (52.4%) of PCV evidenced engorgement of the vortex vein, whereas such engorgement was detected in only 7 of the 30 eyes (30.4%) of the control subjects (P = 0.016). Among 27 fellow eyes with PCV, it was detected in 11 (40.7%) (P = 0.706 vs. control eyes). In all groups, it was most frequently detected at the inferior temporal quadrant. In eyes with PCV, mean (+/-standard deviation) choroidal thickness of the eyes evidencing vortex vein engorgement was 338.1 +/- 131.3 mm and the thickness of those not evidencing vortex vein engorgement was 275.1 +/- 107.7 mm. When the choroidal thickness increased to 10 mm in the eyes with PCV, the odds of detecting the engorgement was multiplied by a factor of 1.05 (P = 0.042). The incidence of the engorgement of vortex vein was correlated with the presence of choroidal vascular hyperpermeability (P = 0.009).
   Conclusion: This study demonstrates that engorgement of the vortex vein was observed more frequently in the eyes with PCV. Such a finding was associated with choroidal thickening and choroidal vascular hyperpermeability. These indicate that the engorgement of the vortex vein might be involved in the pathogenic mechanisms of PCV. RETINA 33:834-840, 2013
C1 [Chung, Song Ee; Kang, Se Woong; Kim, Jae Hui; Park, Do Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Kim, Yun Taek] Ewha Womans Univ, Sch Med, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Ewha Womans
   University
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
OI Kim, Yun Taek/0000-0001-9104-4241; Park, Do Young/0000-0001-6089-6898
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   BROCKHURST RJ, 1980, ARCH OPHTHALMOL-CHIC, V98, P1987
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   GASS JDM, 1983, RETINA-J RET VIT DIS, V3, P159, DOI 10.1097/00006982-198300330-00003
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   HAYREH SS, 1973, BRIT J OPHTHALMOL, V57, P217, DOI 10.1136/bjo.57.4.217
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 19
TC 36
Z9 38
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 834
EP 840
DI 10.1097/IAE.0b013e31826af540
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900022
PM 23117282
DA 2022-11-30
ER

PT J
AU Nakajima, M
   Yuzawa, M
   Shimada, H
   Mori, R
AF Nakajima, M
   Yuzawa, M
   Shimada, H
   Mori, R
TI Correlation between indocyanine green angiographic findings and
   histopathology of polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; histopathology; indocyanine green
   angiography; polypoidal choroidal vasculopathy
ID MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; IPCV
AB Purpose: To analyze the histopathology of polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV) developing from PCV, the authors evaluated correlations between pathological findings and the findings of preoperative indocyanine green angiography (IA).
   Methods: Two specimens were obtained during CNV excision associated with PCV. PCV tissue was excised with the CNV. The specimens were examined by light microscopy.
   Results: In one case, IA revealed polypoidal lesions exhibiting hyperfluorescence in both the early and the late phase, and in the affected area, abnormally dilated vessels were identified histologically underneath relatively healthy retinal pigment epithelium (RPE). In the other case, the polypoidal lesions seen on IA showed early hyperfluorescence and late isofluorescence, and dilated vessels were observed under the RPE; perivascular amorphous material was present. The RPE adhered to the side of the choroid, and there was CNV under the neurosensory retina in both cases. The CNV had numerous vascular lumens, was not surrounded by the RPE, and exhibited few fibrous components.
   Conclusions: IA findings vary depending on the condition of the RPE located above the PCV and the extent of amorphous material around the PCV. (C) Japanese Ophthalmological Society 2004.
C1 Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku,Sch Med, Tokyo 1018039, Japan.
C3 Nihon University
RP Nakajima, M (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku,Sch Med, 1-8-13 Surugadai, Tokyo 1018039, Japan.
EM masamin@mail.med.nihon-u.ac.jp
CR Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Nakajima M, 2000, JPN J OPHTHALMOL, V44, P360, DOI 10.1016/S0021-5155(00)00180-5
   Nakajima Masami, 1999, Nippon Ganka Gakkai Zasshi, V103, P252
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1997, INDOCYANINE GREEN AN, P130
NR 16
TC 46
Z9 52
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY-JUN
PY 2004
VL 48
IS 3
BP 249
EP 255
DI 10.1007/s10384-003-0057-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824SN
UT WOS:000221706900010
PM 15175917
DA 2022-11-30
ER

PT J
AU Hirami, Y
   Tsujikawa, A
   Otani, A
   Yodoi, Y
   Aikawa, H
   Mandai, M
   Yoshimura, N
AF Hirami, Yasuhiko
   Tsujikawa, Akitaka
   Otani, Atsushi
   Yodoi, Yuko
   Aikawa, Hiroko
   Mandai, Michiko
   Yoshimura, Nagahisa
TI Hemorrhagic complications after photodynamic therapy for polypoidal
   choroidal vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; subretinal
   hemorrhage; vitreous hemorrhage
ID VERTEPORFIN
AB Purpose: To evaluate the clinical features and risk factors of hemorrhagic complications in eyes with polypoidal choroidal vasculopathy (PCV) after photodynamic therapy (PDT).
   Methods: We retrospectively reviewed data for 91 consecutive eyes of 85 patients who underwent PDT for the treatment of PCV. The diagnosis of PCV was based on indocyanine green angiographic findings, showing a branching vascular network terminating in polypoidal swelling. The greatest linear dimension included all polypoidal lesions, leaking vascular network, and type 2 choroidal neovascularization.
   Results: During the follow-up period after PDT, postoperative subretinal hemorrhage was seen in 28 (30.8%) of 91 eyes. In 22 (78.6%) of these 28 eyes, subretinal hemorrhage was absorbed without treatment. In 6 eyes (21.4%), however, bleeding resulted in vitreous hemorrhage, and 2 eyes underwent pars plana vitrectomy. Although visual acuity was maintained or increased in 18 (81.8%) of 22 eyes with subretinal hemorrhage alone, it decreased significantly in 3 (50.0%) of 6 eyes with postoperative vitreous hemorrhage. Various systemic diseases and medication with an anticoagulant had no correlation with these hemorrhagic complications. Laser irradiation spot size for PDT was significantly larger in eyes with postoperative vitreous hemorrhage (P = 0.017) than in those without.
   Conclusion: Subretinal hemorrhage after PDT can be a common complication in patients with PCV and may have a minor effect on visual outcome. However, postoperative hemorrhage is occasionally so massive that it leads to vitreous hemorrhage and poor visual prognosis. When considering PDT for eyes with a large PCV lesion, ophthalmologists should be aware of the risk of serious hemorrhagic complications.
C1 Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ Hosp, Dept Expt Therapeut, Translat Res Ctr, Kyoto 606, Japan.
C3 Kyoto University; Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI Mandai, Michiko/E-7986-2011
OI Tsujikawa, Akitaka/0000-0003-0779-7799
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   *VAM STUD WRIT COM, 2004, RETINA, V24, P512
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 21
TC 127
Z9 147
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2007
VL 27
IS 3
BP 335
EP 341
DI 10.1097/01.iae.0000233647.78726.46
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AT
UT WOS:000246985100009
PM 17460589
DA 2022-11-30
ER

PT J
AU Fletcher, EL
   Wang, AY
   Jobling, AI
   Rutar, MV
   Greferath, U
   Gu, B
   Vessey, KA
AF Fletcher, Erica L.
   Wang, Anna Y.
   Jobling, Andrew I.
   Rutar, Matthew V.
   Greferath, Ursula
   Gu, Ben
   Vessey, Kirstan A.
TI Targeting P2X7 receptors as a means for treating retinal disease
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID INDUCED PHOTORECEPTOR DEATH; P2X(7) RECEPTORS; EXTRACELLULAR ATP;
   RHEUMATOID-ARTHRITIS; INNATE PHAGOCYTOSIS; SUSTAINED ELEVATION;
   SCAVENGER ACTIVITY; POTENT ANTAGONIST; GANGLION-CELLS; AQUEOUS-HUMOR
AB Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood-brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.
C1 [Fletcher, Erica L.; Wang, Anna Y.; Jobling, Andrew I.; Rutar, Matthew V.; Greferath, Ursula; Vessey, Kirstan A.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia.
   [Gu, Ben] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia.
C3 University of Melbourne; Florey Institute of Neuroscience & Mental
   Health
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia.
EM elf@unimelb.edu.au
RI ; Jobling, Andrew/C-8221-2015
OI Greferath, Ursula/0000-0003-1028-648X; Rutar,
   Matthew/0000-0002-8893-5120; Jobling, Andrew/0000-0002-7827-3135;
   Vessey, Kirstan/0000-0003-1031-1964; Gu, Ben/0000-0001-5500-4453
FU National Health and Medical Research Council of Australia [1061418,
   1061419]
FX This work was supported by the National Health and Medical Research
   Council of Australia (#1061418 to E.L.F. and A.I.J.; #1061419 to E.L.F.
   and K.A.V.).
CR Abdi MH, 2010, BIOORG MED CHEM LETT, V20, P5080, DOI 10.1016/j.bmcl.2010.07.033
   Ali Z, 2013, BRIT J CLIN PHARMACO, V75, P197, DOI 10.1111/j.1365-2125.2012.04320.x
   Aplin FP, 2014, INVEST OPHTH VIS SCI, V55, P8319, DOI 10.1167/iovs.14-15732
   Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003
   Bhattacharya A, 2018, NEUROPSYCHOPHARMACOL, V43, P2586, DOI 10.1038/s41386-018-0141-6
   Brandle U, 1998, MOL BRAIN RES, V62, P106, DOI 10.1016/S0169-328X(98)00254-X
   Chua J, 2012, MOL VIS, V18, P431
   Coddou C, 2011, PHARMACOL REV, V63, P641, DOI 10.1124/pr.110.003129
   Danquah W, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8463
   Di Virgilio F, 2018, TRENDS CELL BIOL, V28, P392, DOI 10.1016/j.tcb.2018.01.005
   Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265
   Donnelly-Roberts DL, 2009, NEUROPHARMACOLOGY, V56, P223, DOI 10.1016/j.neuropharm.2008.06.012
   Dvoriantchikova G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031991
   Eser A, 2015, INFLAMM BOWEL DIS, V21, P2247, DOI 10.1097/MIB.0000000000000514
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081
   Gu BJ, 2016, ACTA NEUROPATHOL, V132, P377, DOI 10.1007/s00401-016-1596-3
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Ho T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00389
   Ho T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029892
   Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Innocenti B, 2004, J NEUROSCI, V24, P8577, DOI 10.1523/JNEUROSCI.2812-04.2004
   Kaczmarek-Hajek K, 2018, ELIFE, V7, DOI 10.7554/eLife.36217
   Karasawa A, 2016, ELIFE, V5, DOI 10.7554/eLife.22153
   Keystone EC, 2012, ANN RHEUM DIS, V71, P1630, DOI 10.1136/annrheumdis-2011-143578
   Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347
   Letavic MA, 2017, J MED CHEM, V60, P4559, DOI 10.1021/acs.jmedchem.7b00408
   Li A, 2011, EXP EYE RES, V93, P528, DOI 10.1016/j.exer.2011.06.020
   Lord B, 2014, J PHARMACOL EXP THER, V351, P628, DOI 10.1124/jpet.114.218487
   Lu WN, 2015, INVEST OPHTH VIS SCI, V56, P3075, DOI 10.1167/iovs.14-15891
   Mitchell CH, 2009, PURINERG SIGNAL, V5, P241, DOI 10.1007/s11302-009-9142-6
   Mugisho O. O, 1862, BIOCH BIOPHYS ACTA G, V3, P385, DOI [10.1016/j.bbagen.2017.11.015, DOI 10.1016/J.BBAGEN.2017.11.015]
   Newman E A, 2001, Prog Brain Res, V132, P241
   Niittykoski M, 2010, INVEST OPHTH VIS SCI, V51, P6387, DOI 10.1167/iovs.09-3816
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Ou A, 2018, BBA-MOL BASIS DIS, V1864, P1051, DOI 10.1016/j.bbadis.2018.01.012
   Pannicke T, 2000, J NEUROSCI, V20, P5965, DOI 10.1523/JNEUROSCI.20-16-05965.2000
   Puthussery T, 2004, J COMP NEUROL, V472, P13, DOI 10.1002/cne.20045
   Puthussery T, 2006, EUR J NEUROSCI, V24, P7, DOI 10.1111/j.1460-9568.2006.04895.x
   Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964
   Resta V, 2007, EUR J NEUROSCI, V25, P2741, DOI 10.1111/j.1460-9568.2007.05528.x
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874
   Stokes L, 2006, BRIT J PHARMACOL, V149, P880, DOI 10.1038/sj.bjp.0706933
   Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434
   Timmers M, 2018, J PSYCHOPHARMACOL, V32, P1341, DOI 10.1177/0269881118800067
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052
   Zhao Da, 2017, Front Neurosci, V11, P41, DOI 10.3389/fnins.2017.00041
NR 60
TC 14
Z9 14
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD AUG
PY 2019
VL 24
IS 8
SI SI
BP 1598
EP 1605
DI 10.1016/j.drudis.2019.03.029
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IX7GP
UT WOS:000485852100018
PM 30954685
DA 2022-11-30
ER

PT J
AU Maya-Vetencourt, JF
   Manfredi, G
   Mete, M
   Colombo, E
   Bramini, M
   Di Marco, S
   Shmal, D
   Mantero, G
   Dipalo, M
   Rocchi, A
   DiFrancesco, ML
   Papaleo, ED
   Russo, A
   Barsotti, J
   Eleftheriou, C
   Di Maria, F
   Cossu, V
   Piazza, F
   Emionite, L
   Ticconi, F
   Marini, C
   Sambuceti, G
   Pertile, G
   Lanzani, G
   Benfenati, F
AF Maya-Vetencourt, Jose Fernando
   Manfredi, Giovanni
   Mete, Maurizio
   Colombo, Elisabetta
   Bramini, Mattia
   Di Marco, Stefano
   Shmal, Dmytro
   Mantero, Giulia
   Dipalo, Michele
   Rocchi, Anna
   DiFrancesco, Mattia L.
   Papaleo, Ermanno D.
   Russo, Angela
   Barsotti, Jonathan
   Eleftheriou, Cyril
   Di Maria, Francesca
   Cossu, Vanessa
   Piazza, Fabio
   Emionite, Laura
   Ticconi, Flavia
   Marini, Cecilia
   Sambuceti, Gianmario
   Pertile, Grazia
   Lanzani, Guglielmo
   Benfenati, Fabio
TI Subretinally injected semiconducting polymer nanoparticles rescue vision
   in a rat model of retinal dystrophy
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID ROYAL-COLLEGE; STIMULATION; PROSTHESIS; INTERFACE;
   POLY(3-HEXYLTHIOPHENE); IMPLANTATION; DEPRIVATION; PLASTICITY; CELLS;
   GENE
AB Semiconducting polymer nanoparticles can act as light-sensitive interfaces with retinal neurons, and on microinjection in the eye, rescue vision in retinas affected by photoreceptor degeneration, offering a potential new treatment option for inherited retinal dystrophies and late-stage age-related macular degeneration.
   Inherited retinal dystrophies and late-stage age-related macular degeneration, for which treatments remain limited, are among the most prevalent causes of legal blindness. Retinal prostheses have been developed to stimulate the inner retinal network; however, lack of sensitivity and resolution, and the need for wiring or external cameras, have limited their application. Here we show that conjugated polymer nanoparticles (P3HT NPs) mediate light-evoked stimulation of retinal neurons and persistently rescue visual functions when subretinally injected in a rat model of retinitis pigmentosa. P3HT NPs spread out over the entire subretinal space and promote light-dependent activation of spared inner retinal neurons, recovering subcortical, cortical and behavioural visual responses in the absence of trophic effects or retinal inflammation. By conferring sustained light sensitivity to degenerate retinas after a single injection, and with the potential for high spatial resolution, P3HT NPs provide a new avenue in retinal prosthetics with potential applications not only in retinitis pigmentosa, but also in age-related macular degeneration.
C1 [Maya-Vetencourt, Jose Fernando; Colombo, Elisabetta; Bramini, Mattia; Di Marco, Stefano; Shmal, Dmytro; Mantero, Giulia; Rocchi, Anna; DiFrancesco, Mattia L.; Papaleo, Ermanno D.; Eleftheriou, Cyril; Benfenati, Fabio] Ist Italiano Tecnol, Ctr Synapt Neurosci & Technol, Genoa, Italy.
   [Maya-Vetencourt, Jose Fernando; Colombo, Elisabetta; Di Marco, Stefano; Rocchi, Anna; Cossu, Vanessa; Emionite, Laura; Ticconi, Flavia; Sambuceti, Gianmario; Benfenati, Fabio] Osped Policlin San Martino, IRCCS, Genoa, Italy.
   [Maya-Vetencourt, Jose Fernando] Univ Pisa, Dept Biol, Pisa, Italy.
   [Manfredi, Giovanni; Barsotti, Jonathan; Lanzani, Guglielmo] Ist Italiano Tecnol, Ctr Nano Sci & Technol, Milan, Italy.
   [Mete, Maurizio; Russo, Angela; Pertile, Grazia] Osped Sacro Cuore Don Calabria, Ophthalmol Dept, IRCCS, Negrar, Italy.
   [Dipalo, Michele] Ist Italiano Tecnol, Plasmon Nanotechnol, Genoa, Italy.
   [Di Maria, Francesca] CNR, Inst Organ Synth & Photoreact ISOF, Bologna, Italy.
   [Cossu, Vanessa; Ticconi, Flavia; Sambuceti, Gianmario] Univ Genoa, Dept Hlth Sci, Nucl Med, Genoa, Italy.
   [Piazza, Fabio] ASST Mantova, ENT Dept, Mantua, Italy.
   [Marini, Cecilia] CNR, Inst Bioimages & Mol Physiol, Milan Genoa Sect, Genoa, Italy.
   [Lanzani, Guglielmo] Politecn Milan, Dept Phys, Milan, Italy.
   [Bramini, Mattia] Univ Granada, Dept Appl Phys, Granada, Spain.
   [Eleftheriou, Cyril] Cornell Univ, Weil Med Coll, Dept Ophthalmol, White Plains, NY USA.
   [Eleftheriou, Cyril] Cornell Univ, Weil Med Coll, Dept Neurol, White Plains, NY USA.
   [Ticconi, Flavia] Faenza Hosp, Dept Oncohematol, Nucl Med Unit, Faenza, Italy.
C3 Istituto Italiano di Tecnologia - IIT; University of Pisa; Istituto
   Italiano di Tecnologia - IIT; IRCCS Sacro Cuore Don Calabria; Istituto
   Italiano di Tecnologia - IIT; Consiglio Nazionale delle Ricerche (CNR);
   Istituto per la Sintesi Organica e la Fotoreattivita (ISOF-CNR);
   University of Genoa; Consiglio Nazionale delle Ricerche (CNR);
   Polytechnic University of Milan; University of Granada; Cornell
   University; Cornell University
RP Benfenati, F (通讯作者)，Ist Italiano Tecnol, Ctr Synapt Neurosci & Technol, Genoa, Italy.; Benfenati, F (通讯作者)，Osped Policlin San Martino, IRCCS, Genoa, Italy.; Lanzani, G (通讯作者)，Ist Italiano Tecnol, Ctr Nano Sci & Technol, Milan, Italy.; Lanzani, G (通讯作者)，Politecn Milan, Dept Phys, Milan, Italy.
EM guglielmo.lanzani@iit.it; fabio.benfenati@iit.it
RI Maya-Vetencourt, JF/AAT-5130-2020; Bramini, Mattia/Q-6130-2016; Di
   Maria, Francesca/E-9931-2012; Lanzani, Guglielmo/AAC-4500-2022; Pertile,
   Grazia/AAC-4956-2022; Dipalo, Michele/D-6708-2014; Rocchi,
   Anna/AAA-7748-2019; Mete, Maurizio/C-2149-2018; DiFrancesco, Mattia
   Lorenzo/AAC-1029-2022
OI Bramini, Mattia/0000-0002-0381-9391; Di Maria,
   Francesca/0000-0001-5557-3816; Dipalo, Michele/0000-0002-1823-8231;
   Rocchi, Anna/0000-0002-1334-9063; DiFrancesco, Mattia
   Lorenzo/0000-0002-7511-4438; Maya-Vetencourt, Jose
   Fernando/0000-0003-3808-8944; Papaleo, Ermanno
   Donato/0000-0001-8455-2133; Shmal, Dmytro/0000-0001-6770-6364; MANFREDI,
   GIOVANNI/0000-0003-0682-0731; lanzani, guglielmo/0000-0002-2442-4495;
   Cossu, Vanessa/0000-0002-7302-7429
FU Italian Ministry of Health [RF-2013-02358313]; Fondazione Cariplo
   [2018-0505]; Compagnia di San Paolo [9798]; H2020-MSCA-ITN 2019 "Entrain
   Vision" [861423]; EuroNanoMed3 [2019-132]; Ra.Mo. Foundation; Rare
   Partners srl; Fondazione 13 Marzo
FX We thank M. M. La Vail (Beckman Vision Centre, University of California
   San Francisco) for providing non-dystrophic RCS-rdy+ and dystrophic RCS
   rats, N. De Petrocellis and N. Forte (CNR Institute for Biomolecular
   Chemistry) for stably hTRPV1-transfected HEK293 clones, E. Lingueglia
   (CNRS Institute of Molecular and Cellular Pharmacology) for providing
   the complementary DNA for the ASIC1a channel, A. Desii, S. Francia and
   M. Salerno (Istituto Italiano di Tecnologia) for help in the preparation
   and characterization of NPs, M. Cilli and A. Buschiazzo (IRCCS Ospedale
   Policlinico San Martino) for assistance in the surgical procedures and
   help in positron emission tomography imaging and R. Ciancio, I.
   Dallorto, A. Mehilli, R. Navone and D. Moruzzo (Istituto Italiano di
   Tecnologia for technical assistance. The work was supported by the
   Italian Ministry of Health (project RF-2013-02358313 to G.P., G.L. and
   F.B.), Fondazione Cariplo (project 2018-0505 to G.L., F.B. and G.P.),
   Compagnia di San Paolo (project 9798 to J.F.M.-V.), H2020-MSCA-ITN 2019
   "Entrain Vision" (project 861423 to F.B.) and EuroNanoMed3 (project
   2019-132 "NanoLight" to F.B.). The support of the Ra.Mo. Foundation,
   Rare Partners srl and Fondazione 13 Marzo is also acknowledged.
CR Antognazza MR, 2016, ADV HEALTHC MATER, V5, P2271, DOI 10.1002/adhm.201600318
   BARBARELLA G, 1994, MACROMOLECULES, V27, P3039, DOI 10.1021/ma00089a022
   Benfenati F, 2018, LAB ANIMAL, V47, P71, DOI 10.1038/s41684-018-0003-1
   Bloch E, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841418817501
   Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3
   Carvalho-de-Souza JL, 2015, NEURON, V86, P207, DOI 10.1016/j.neuron.2015.02.033
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chen S, 2018, SCIENCE, V359, P679, DOI 10.1126/science.aaq1144
   Colombo E, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00105
   Dagnelie G, 2017, CLIN EXP OPHTHALMOL, V45, P152, DOI 10.1111/ceo.12812
   Di Maria F, 2018, CHEM SOC REV, V47, P4757, DOI 10.1039/c7cs00860k
   Fendyur Anna, 2011, Front Neuroeng, V4, P14, DOI 10.3389/fneng.2011.00014
   Feng LH, 2013, CHEM SOC REV, V42, P6620, DOI 10.1039/c3cs60036j
   Feyen P, 2016, SCI REP-UK, V6, DOI 10.1038/srep22718
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gautam V, 2014, ADV MATER, V26, P1751, DOI 10.1002/adma.201304368
   Ghezzi D, 2013, NAT PHOTONICS, V7, P400, DOI [10.1038/nphoton.2013.34, 10.1038/NPHOTON.2013.34]
   Ghezzi D, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1164
   Hanson L, 2012, NANO LETT, V12, P5815, DOI 10.1021/nl303163y
   Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Hustinx R, 1999, EUR J NUCL MED, V26, P1501, DOI 10.1007/s002590050487
   Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260
   Krzywinski M, 2013, NAT METHODS, V10, P1139, DOI 10.1038/nmeth.2738
   LAVAIL MM, 1975, EXP EYE RES, V21, P167, DOI 10.1016/0014-4835(75)90080-9
   Lorach H, 2018, SCI REP, V8
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293
   Ma YQ, 2019, CELL, V177, P243, DOI 10.1016/j.cell.2019.01.038
   Maeda A, 2019, ANNU REV GENOM HUM G, V20, P201, DOI 10.1146/annurev-genom-083118-015043
   Manfredi G, 2019, ANNU REV PHYS CHEM, V70, P99, DOI 10.1146/annurev-physchem-042018-052445
   Martino N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08911
   Maya-Vetencourt JF, 2017, NAT MATER, V16, P681, DOI [10.1038/NMAT4874, 10.1038/nmat4874]
   Maya-Vetencourt JF, 2012, J PHYSIOL-LONDON, V590, P4777, DOI 10.1113/jphysiol.2012.234237
   Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516
   McGill TJ, 2004, INVEST OPHTH VIS SCI, V45, P932, DOI 10.1167/iovs.03-0964
   Morimoto T, 2007, INVEST OPHTH VIS SCI, V48, P4725, DOI 10.1167/iovs.06-1404
   Mosconi E, 2016, ACS ENERGY LETT, V1, P454, DOI 10.1021/acsenergylett.6b00197
   Pardue MT, 2005, INVEST OPHTH VIS SCI, V46, P674, DOI 10.1167/iovs.04-0515
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PHELPS ME, 1981, SEMIN NUCL MED, V11, P32, DOI 10.1016/S0001-2998(81)80051-7
   PITMAN E. J. G., 1937, J. Roy. Statist. Soc. 1937., (Suppl.), V4, P119
   Pizzorusso T, 2006, P NATL ACAD SCI USA, V103, P8517, DOI 10.1073/pnas.0602657103
   Porciatti V, 1999, VISION RES, V39, P3071, DOI 10.1016/S0042-6989(99)00022-X
   Porciatti Vittorio, 2002, Documenta Ophthalmologica, V104, P69, DOI 10.1023/A:1014463212001
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Pu ML, 2006, INVEST OPHTH VIS SCI, V47, P3579, DOI 10.1167/iovs.05-1450
   Rivnay J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601649
   Rossi EA, 2010, NAT NEUROSCI, V13, P156, DOI 10.1038/nn.2465
   Santoro F, 2017, ACS NANO, V11, P8320, DOI 10.1021/acsnano.7b03494
   Schmiedel U, 2018, REL GLOB MIGRATION, P297, DOI 10.1007/978-3-319-67961-7_16
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Shapiro MG, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1742
   Shimizu H, 2008, POLYM J, V40, P33, DOI 10.1295/polymj.PJ2007043
   Shmoel N, 2016, SCI REP, V6
   Simunovic MP, 2019, EXP EYE RES, V178, P15, DOI 10.1016/j.exer.2018.09.003
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Tian BZ, 2018, PHYS BIOL, V15, DOI 10.1088/1478-3975/aa9f34
   Tuncel D, 2010, NANOSCALE, V2, P484, DOI 10.1039/b9nr00374f
   Zangoli M, 2017, NANOSCALE, V9, P9202, DOI 10.1039/c7nr01793f
   Zhou WT, 2012, EXP NEUROL, V238, P192, DOI 10.1016/j.expneurol.2012.08.029
   Ziccardi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225722
NR 62
TC 65
Z9 65
U1 11
U2 49
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD AUG
PY 2020
VL 15
IS 8
BP 698
EP +
DI 10.1038/s41565-020-0696-3
EA JUN 2020
PG 30
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA MW4ST
UT WOS:000544174700007
PM 32601447
DA 2022-11-30
ER

PT J
AU Pelletier, AL
   Thomas, J
   Shaw, FR
AF Pelletier, Allen L.
   Thomas, Jeremy
   Shaw, Fawwaz R.
TI Vision Loss in Older Persons
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID FOLLOW-UP; VISUAL IMPAIRMENT; BLOOD-PRESSURE; RISK-FACTORS; RETINOPATHY;
   DISEASE; TRIAL; PROGRESSION; PREVALENCE; PREVENTION
AB Family physicians have an essential role in assessing, identifying, treating, and preventing or delaying vision loss in the aging population. Approximately one in 28 U.S. adults older than 40 years is visually impaired. Vision loss is associated with depression, social isolation, falls, and medication errors, and it can cause disturbing hallucinations. Adults older than 65 years should be screened for vision problems every one to two years, with attention to specific disorders, such as diabetic retinopathy, refractive error, cataracts, glaucoma, and age-related macular degeneration. Vision-related adverse effects of commonly used medications, such as amiodarone or phosphodiesterase inhibitors, should be considered when evaluating vision problems. Prompt recognition and management of sudden vision loss can be vision saving, as can treatment of diabetic retinopathy, refractive error, cataracts, glaucoma, and age-related macular degeneration. Aggressive medical management of diabetes, hypertension, and hyperlipidemia; encouraging smoking cessation; reducing ultraviolet light exposure; and appropriate response to medication adverse effects can preserve and protect vision in many older persons. Antioxidant and mineral supplements do not prevent age-related macular degeneration, but may play a role in slowing progression in those with advanced disease. (Am Fam Physician. 2009;79(11):963-970. Copyright (C) 2009 American Academy of Family Physicians.)
C1 [Pelletier, Allen L.] Med Coll Georgia, Dept Family Med HB 2020, Augusta, GA 30912 USA.
   [Thomas, Jeremy; Shaw, Fawwaz R.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA.
C3 University System of Georgia; Augusta University; University of
   Tennessee System; University of Tennessee Health Science Center
RP Pelletier, AL (通讯作者)，Med Coll Georgia, Dept Family Med HB 2020, Augusta, GA 30912 USA.
EM apelletier@mcg.edu
OI SHAW, FAWWAZ/0000-0002-9873-8390
CR *AM AC FAM PHYS, 2009, REC CLIN PREV SERV
   *AM AC OPHTH, PREF PRACT PATT COMP
   American Academy of Ophthalmology, PREF PRACT PATT DIAB
   Brezin AP, 2004, BRIT J OPHTHALMOL, V88, P1330, DOI 10.1136/bjo.2003.039180
   Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Fernandez MM, 2008, CURR OPIN OPHTHALMOL, V19, P66, DOI 10.1097/ICU.0b013e3282f2d7b6
   Field TS, 2007, J AM GERIATR SOC, V55, P271, DOI 10.1111/j.1532-5415.2007.01047.x
   Fontal MR, 2007, SEMIN NEUROL, V27, P221, DOI 10.1055/s-2007-979686
   Fraunfelder FW, 2005, AM J OPHTHALMOL, V140, P723, DOI 10.1016/j.ajo.2005.02.049
   GOLDBLOOM R, 1995, CAN MED ASSOC J, V152, P1211
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Holman RR, 2008, NEW ENGL J MED, V359, P1565, DOI 10.1056/NEJMoa0806359
   *ICSI, PREV SERV AD
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Kniestedt Christoph, 2003, Ophthalmol Clin North Am, V16, P155, DOI 10.1016/S0896-1549(03)00013-0
   Kohner EM, 2008, DIABETIC MED, V25, P20, DOI 10.1111/j.1464-5491.2008.02505.x
   LASSMANNVAGUE V, 2005, DIABETES METAB
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   *NAT EYE I, AMSL GRID
   Pokhrel PK, 2007, AM FAM PHYSICIAN, V76, P829
   Rosenberg EA, 2008, AM FAM PHYSICIAN, V77, P1431
   Rowe S, 2004, JAMA-J AM MED ASSOC, V291, P1487, DOI 10.1001/jama.291.12.1487
   Salomon O, 1999, OPHTHALMOLOGY, V106, P739, DOI 10.1016/S0161-6420(99)90159-8
   Santaella RM, 2007, DRUGS, V67, P75, DOI 10.2165/00003495-200767010-00006
   Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594
   *US PREV SERV TASK, 1996, SCREEN VIS IMP
   *US PREV SERV TASK, 2005, SCREEN GLAUC REC STA
   Warrington KJ, 2007, CLIN EXP RHEUMATOL, V25, pS137
   Weintraub JM, 2002, AM J EPIDEMIOL, V155, P72, DOI 10.1093/aje/155.1.72
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   ZIMMERMAN TJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P551
   2008, DRUG FACTS COMP, P1725
NR 47
TC 19
Z9 20
U1 1
U2 6
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD JUN 1
PY 2009
VL 79
IS 11
BP 963
EP 970
PG 8
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 456RP
UT WOS:000266865500006
PM 19514694
DA 2022-11-30
ER

PT J
AU Rauf, A
   Malik, R
   Bunce, C
   Wormald, R
AF Rauf, Abdul
   Malik, Rizwan
   Bunce, Catey
   Wormald, Richard
TI The British Asian Community Eye Study: Outline of results on the
   prevalence of eye disease in British Asians with origins from the Indian
   subcontinent
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE British Asians; eye disease prevalence; eye health care planning; Indian
   subcontinent
ID OPEN-ANGLE GLAUCOMA; LENS OPACITIES; VISUAL IMPAIRMENT; CATARACT;
   POPULATION; AGE; LEICESTER; PROFILE
AB Background: Asians from the Indian Subcontinent form the largest ethnic minority in the United Kingdom. Data on the prevalence of visually-impairing eye conditions in this population are vital for planning eye health care services. Materials and Methods: This survey was based in the two London boroughs with the largest Asian populations. Subjects originating from the Indian Subcontinent were identified from GP practice records. All subjects were asked about demographic details and were given a full ophthalmological examination. The severity of cataract, glaucoma, diabetic retinopathy, and age-related maculopathy was recorded. Blindness was defined as logMAR visual acuity of 0.99 (Snellen equivalence 20/200 in the better eye) or worse, 'low vision' was defined as Snellen equivalence of 20/63 or worse (logMAR 0.5 or higher), and visual impairment was defined as visual acuity worse than 20/40. Results: The median age was 56 years. Two hundred and eighty four subjects did not attend for eye examination. Of the 922 examined, 128 subjects (13.9%) were 'visually impaired,' 39 (4.2%) had 'low vision,' and 6 (0.7%) were bilaterally blind. The overall prevalence of cataract, open-angle glaucoma, age-related macular degeneration, and diabetic retinopathy were 77%, 1.0%, 8.7%, and 8.8%, respectively. Conclusion: Visual impairment rates amongst Asians seem to be similar to Caucasian populations in the UK. The prevalence of cataract and diabetic retinopathy is higher, while the risk of ARMD and OAG are comparable. In view of the high cataract prevalence, a more detailed assessment of the visual profile and factors limiting healthcare accessibility in this community are needed.
C1 [Rauf, Abdul] Queens Hosp, Burton Upon Trent, Staffs, England.
   [Malik, Rizwan] Moorfields Eye Hosp Fdn NHS Trust, NIHR Biomed Res Ctr Ophthalmol, Glaucoma Res Unit, London, England.
   [Malik, Rizwan] UCL Inst Ophthalmol, London, England.
   [Bunce, Catey; Wormald, Richard] Moorfields Eye Hosp, London, England.
   [Wormald, Richard] London Sch Hyg & Trop Med, London WC1, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; London School of Hygiene & Tropical Medicine
RP Malik, R (通讯作者)，Moorfields Eye Hosp Fdn NHS Trust, NIHR Biomed Res Ctr Ophthalmol, Glaucoma Res Unit, London, England.
EM rizimalik@googlemail.com
OI Bunce, Catey/0000-0002-0935-3713
FU Thomas Pocklington Trust
FX This study was supported by the Thomas Pocklington Trust.
CR BROWN NAP, 1993, EYE, V7, P63, DOI 10.1038/eye.1993.14
   CHATTERJEE A, 1982, BRIT J OPHTHALMOL, V66, P35, DOI 10.1136/bjo.66.1.35
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   COFFEY M, 1993, BRIT J OPHTHALMOL, V77, P17, DOI 10.1136/bjo.77.1.17
   DAS BN, 1990, EYE, V4, P723, DOI 10.1038/eye.1990.102
   DAS BN, 1994, J ROY SOC MED, V87, P219
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P893, DOI 10.1136/bjo.83.8.893
   Evans JR, 1998, INVEST OPHTH VIS SCI, V39, P1740
   Gray PJ., 1994, J ROY SOC MED, V87, P219
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Malik R, 2005, EYE, V19, P406, DOI 10.1038/sj.eye.6701511
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   NICOLL A, 1986, J EPIDEMIOL COMMUN H, V40, P364, DOI 10.1136/jech.40.4.364
   Nirmalan PK, 2003, INVEST OPHTH VIS SCI, V44, P4639, DOI 10.1167/iovs.03-0011
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pardhan S, 2002, EYE, V16, P572, DOI 10.1038/sj.eye.6700164
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   RAUF A, 1994, J ROY SOC MED, V87, P78
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   Stocks N, 2002, EYE, V16, P275, DOI 10.1038/sj.eye.6700106
   The Age-Related Eye Disease Research Group, 2001, 9 AREDS, V119, P1439
   THOMPSON JR, 1989, BRIT J OPHTHALMOL, V73, P950, DOI 10.1136/bjo.73.12.950
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   UK Census, 1991, UK CENS 1991
   UK Census, 2001, UK CENS 2001
   Wong TY, 2001, ARCH OPHTHALMOL-CHIC, V119, P727, DOI 10.1001/archopht.119.5.727
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
NR 29
TC 9
Z9 9
U1 0
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD FEB
PY 2013
VL 61
IS 2
BP 53
EP 58
DI 10.4103/0301-4738.107191
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 116GY
UT WOS:000316872200002
PM 23412521
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lin, P
AF Lin, Phoebe
TI Importance of the intestinal microbiota in ocular inflammatory diseases:
   A review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; microbiome; uveitis
ID GUT MICROBIOTA; PROTECTION; ASSOCIATION; METABOLITES; CELLS
AB The purpose of this article is to review the literature on relationships between the intestinal microbiota and ocular inflammatory disease, specifically non-infectious uveitis and age-related macular degeneration. The importance of the intestinal microbiota in uveitis pathogenesis has been shown by multiple groups demonstrating that alterations in the microbiota induced by certain oral antibiotics results in reduced uveitis severity, and another group demonstrating that a commensal intestinal bacterial antigen activates retina-specific autoreactive T cells, potentially indicating a commensal trigger for uveitis. Additionally, commensal intestinal bacterial metabolite short chain fatty acids can be utilized to suppress autoimmune uveitis. Age-related macular degeneration is associated with intestinal dysbiosis, which is partially influenced by genetic risk alleles and AREDS supplementation. Strategies for therapeutically targeting the intestinal microbiota might involve several approaches, including the use of antibiotics, dietary changes, drugs that supplement beneficial bacterial metabolites or target causative bacterial strains, dietary strategies or faecal microbial transplantation. In summary, the intestinal microbiota are at the cross-roads of genetic and environmental factors that can promote ocular conditions such as non-infectious uveitis and age-related macular degeneration, partially via its dynamic influence on mucosal and systemic immunity. The intestinal microbiome thus represents a salient potential target for therapeutic modulation to treat these potentially blinding conditions.
C1 [Lin, Phoebe] Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Lin, P (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM linp@ohsu.edu
OI Lin, Phoebe/0000-0002-2918-5470
FU National Institutes of Health [P30 EY010572]; Alcon Research Institute;
   Collins Medical Trust; Edward N. and Della L. Thome Memorial Foundation;
   National Eye Institute [P30 EY010572, K08 EY022948]; Oregon Health &
   Science University; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [P30EY010572, K08EY022948] Funding Source: NIH RePORTER
FX National Institutes of Health, Grant/Award Number: P30 EY010572; Alcon
   Research Institute, Grant/Award Number: Young Investigator Award;
   Collins Medical Trust, Grant/Award Number: Award; Edward N. and Della L.
   Thome Memorial Foundation, Grant/Award Number: Program in Age-Related
   Macular Degeneration Researh; National Eye Institute, Grant/Award
   Numbers: K08 EY022948, P30 EY010572; Oregon Health & Science University,
   Grant/Award Number: Physician-Scientist Award; Research to Prevent
   Blindness, Grant/Award Numbers: Career Development Award, Unrestricted
   departmental funding
CR Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469
   Berer K, 2017, P NATL ACAD SCI USA, V114, P10719, DOI 10.1073/pnas.1711233114
   Brown JM, 2017, J BIOL CHEM, V292, P8560, DOI 10.1074/jbc.R116.765388
   Costello ME, 2015, ARTHRITIS RHEUMATOL, V67, P686, DOI 10.1002/art.38967
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heissigerova J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5065703
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033
   Janowitz C, 2019, INVEST OPHTH VIS SCI, V60, P420, DOI 10.1167/iovs.18-24813
   Li XSM, 2017, EUR HEART J, V38, P814, DOI 10.1093/eurheartj/ehw582
   Lin P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105684
   Maeda Y, 2016, ARTHRITIS RHEUMATOL, V68, P2646, DOI 10.1002/art.39783
   Manasson J, 2018, ARTHRITIS RHEUMATOL, V70, P242, DOI 10.1002/art.40359
   Miyake S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137429
   Nakamura YK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12163-3
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Ochoa-Reparaz J, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029017
   Ochoa-Reparaz J, 2010, J IMMUNOL, V185, P4101, DOI 10.4049/jimmunol.1001443
   Okai S, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.103, 10.1038/nmicrobiol.2016.103]
   Picchianti-Diamanti A, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02696
   Rosenbaum JT, 2018, NAT REV RHEUMATOL, V14, P704, DOI 10.1038/s41584-018-0097-2
   Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Tan TG, 2016, P NATL ACAD SCI USA, V113, pE8141, DOI 10.1073/pnas.1617460113
   Ye Z, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0520-6
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 32
TC 24
Z9 26
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2019
VL 47
IS 3
SI SI
BP 418
EP 422
DI 10.1111/ceo.13493
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW6NW
UT WOS:000466807900010
PM 30834680
DA 2022-11-30
ER

PT J
AU Li, RY
   Yang, ZW
   Zhang, Y
   Bai, WL
   Du, YF
   Sun, RZ
   Tang, JJ
   Wang, NL
   Liu, HR
AF Li, Ruyue
   Yang, Ziwei
   Zhang, Yue
   Bai, Weiling
   Du, Yifan
   Sun, Runzhou
   Tang, Jianjun
   Wang, Ningli
   Liu, Hanruo
TI Cost-effectiveness and cost-utility of traditional and telemedicine
   combined population-based age-related macular degeneration and diabetic
   retinopathy screening in rural and urban China
SO LANCET REGIONAL HEALTH-WESTERN PACIFIC
LA English
DT Article
DE Cost-effectiveness; Cost-utility; Age-related macular degeneration;
   Diabetic retinopathy; Telemedicine screening
ID VISION LOSS; PREVALENCE; MACULOPATHY; DISEASE; SYSTEM; ZINC
AB Background To assess the cost-effectiveness and cost-utility of a population-level traditional and telemedicine combined age-related macular degeneration (AMD) and diabetic retinopathy (DR) screening program in rural and urban China.
   Methods Decision-analytic Markov models were conducted to evaluate the costs and benefits of traditional and telemedicine combined AMD and DR screening from a societal perspective. A cohort of all participants aged 50 years old and above was followed through a total of 30 1-year Markov cycles. Separate analyses were performed for rural and urban settings. Relevant parameters such as the prevalence of AMD and DR, transition probability, compliance with screening and treatment, screening sensitivity, specificity, utility, and mortality were collected from published studies specific to China, other Asian counties' studies, or unpublished data sources such as the National Committee for the Prevention of Blindness. Costs of screening, full examination, and treatment come from the real medical environments and unified pricing of Beijing Municipal Medical Insurance Bureau. Primary outcomes were incremental cost-utility ratios (ICURs) using quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) using years of blindness avoided. One-way deterministic and simulated probabilistic sensitivity analyses were conducted to reflect uncertainty.
   Findings Under the status quo, the total expected medical costs for a 50-year-old patient with AMD or DR were $869.59 and $1,514.18 in rural and urban settings, respectively. Both traditional and telemedicine screening were highly cost-effective. In rural settings, ICURs were $191 (95% confidence interval [CI]: $66 to $239) and $199 (95% CI: $-12 to $217), and ICERs were $2,436 (95% CI: $1,089 to $3,254) and $2,441 (95% CI: $1,452 to $3,900) for traditional and telemedicine screening separately. Even more surprising, both screening strategies dominated no screening in urban settings. Our results were insensitive and robust to extensive sensitivity analyses. Among all acceptable screening intervals (from 1 to 5 years), annual screening could not only produce biggest benefits but also keep ICERs less than three times and one time the per capita gross domestic product (GDP) in rural and urban settings separately. When compared with traditional screening, ICERs of telescreening were less than three times the per capita GDP in rural settings ($2,559 to $8,809) and less than one time the per capita GDP in urban settings (less than $5,564), annual telescreening produced the biggest benefits, it could avert 119 and 270 years of blindness in rural and urban areas separately when 100,000 people were screened.
   Interpretation We performed decision-analytic Markov models for combined AMD and DR screening in rural and urban China, and the results showed that population-level combined screening for AMD and DR is likely to be highly cost-effective in both rural and urban China for people over 50 years old. Optimal screening may have an interval of every year based on teleophthalmology platforms. In the future, China should pay more attention to chronic eye diseases and the government should establish a sound chronic disease management system and make every patient enjoy equal medical services. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
C1 [Wang, Ningli; Liu, Hanruo] Beijing Inst Ophthalmol, Beijing 100000, Peoples R China.
   [Li, Ruyue; Zhang, Yue; Bai, Weiling; Du, Yifan; Sun, Runzhou; Wang, Ningli; Liu, Hanruo] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100000, Peoples R China.
   [Yang, Ziwei; Tang, Jianjun] Renmin Univ China, Sch Agr Econ & Rural Dev, Beijing 100000, Peoples R China.
   [Wang, Ningli; Liu, Hanruo] Beijing Inst Technol, Sch Informat & Elect, Beijing 100000, Peoples R China.
C3 Capital Medical University; Renmin University of China; Beijing
   Institute of Technology
RP Tang, JJ (通讯作者)，Renmin Univ China, Sch Agr Econ & Rural Dev, Beijing 100000, Peoples R China.; Wang, NL; Liu, HR (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr,Beijing Inst Technol, Beijing Inst Ophthalmol,Beijing Key Lab Ophthalmo, Beijing 100000, Peoples R China.
EM j.tang@ruc.edu.cn; wningli@vip.163.com; hanruo.liu@hotmail.co.uk
OI Li, Ruyue/0000-0001-9219-5332
FU National Natural Science Foundation of China; NSFC [82171051]; Major
   Innovation Platform of Public Health & Disease Control and Prevention,
   Renmin University of China; Beijing Nova program [Z191100001119072]
FX National Natural Science Foundation of China, NSFC (82171051); the Major
   Innovation Platform of Public Health & Disease Control and Prevention,
   Renmin University of China and Beijing Nova program (Z191100001119072).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ben AJ, 2020, APPL HEALTH ECON HEA, V18, P57, DOI 10.1007/s40258-019-00528-w
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chen H, 2021, JAMA OPHTHALMOL, V139, P975, DOI 10.1001/jamaophthalmol.2021.2312
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Corcostegui B, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/8234186
   Davies R, 2002, DIABETIC MED, V19, P762, DOI 10.1046/j.1464-5491.2002.00773.x
   GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study, 2021, LANCET GLOB HEALTH, V9, P144
   Harding S, 2003, DIABETIC MED, V20, P965, DOI 10.1111/j.1464-5491.2003.01077.x
   Ho R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206690
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Hutubessy Raymond, 2003, Cost Eff Resour Alloc, V1, P8, DOI 10.1186/1478-7547-1-8
   Jin GM, 2018, INVEST OPHTH VIS SCI, V59, P5067, DOI 10.1167/iovs.18-24280
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lai KHW, 2018, OPHTHALMOLOGY, V125, P1027, DOI 10.1016/j.ophtha.2018.03.027
   Li JPO, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100900
   Lian JX, 2016, BRIT J OPHTHALMOL, V100, P151, DOI 10.1136/bjophthalmol-2015-307382
   Lian JX, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019989
   Maa AY, 2020, OPHTHALMOLOGY, V127, P38, DOI 10.1016/j.ophtha.2019.07.026
   Nguyen HV, 2016, OPHTHALMOLOGY, V123, P2571, DOI 10.1016/j.ophtha.2016.08.021
   Peng JJ, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-250
   Rachapelle S, 2013, OPHTHALMOLOGY, V120, P566, DOI 10.1016/j.ophtha.2012.09.002
   Romero-Aroca P, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0318-x
   Rothman KJ., 2012, EPIDEMIOLOGY INTRO
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Tang JJ, 2019, LANCET GLOB HEALTH, V7, pE968, DOI 10.1016/S2214-109X(19)30201-3
   Thomas RL, 2020, EUR J HEALTH ECON, V21, P993, DOI 10.1007/s10198-020-01191-y
   Thomas S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137913
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   UK National Screening Committee, 2009, NATL SCREENING PROGR
   Ullah W, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020306
   Vijan S, 2000, JAMA-J AM MED ASSOC, V283, P889, DOI 10.1001/jama.283.7.889
   Walsh L, 2021, CLIN OPHTHALMOL, V15, P4015, DOI 10.2147/OPTH.S294428
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   WILSON JMG, 1968, B OFIC SANIT PANAM, V65, P281
   Wong TY, 2018, OPHTHALMOLOGY, V125, P1608, DOI 10.1016/j.ophtha.2018.04.007
   Wu B, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001989
   Xu TL, 2020, LANCET PUBLIC HEALTH, V5, pE682, DOI 10.1016/S2468-2667(20)30254-1
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhang W, 2016, POPUL J, V38, P18
NR 47
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
EI 2666-6065
J9 LANCET REG HEALTH-W
JI Lancet Reg. Health-W. Pac.
PD JUN
PY 2022
VL 23
AR 100435
DI 10.1016/j.lanwpc.2022.100435
PG 15
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 1D2OS
UT WOS:000793645700004
PM 35355615
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Spielberg, L
   Leys, A
AF Spielberg, Leigh
   Leys, Anita
TI Treatment of neovascular age-related macular degeneration with a
   variable ranibizumab dosing regimen and one-time reduced-fluence
   photodynamic therapy: the TORPEDO trial at 2 years
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascular membrane;
   Lucentis (ranibizumab injection); Photodynamic therapy; Vascular
   endothelial growth factor (VEGF)
ID OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL INJECTION; COMBINATION THERAPY; VERTEPORFIN; BEVACIZUMAB;
   EFFICACY
AB The combination of verteporfin photodynamic therapy (PDT) and anti-angiogenics has been shown to be safe and efficacious in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The purpose of this study is to demonstrate long-term prevention of vision loss and improvement in best-corrected visual acuity (BCVA) after treatment with one-time reduced-fluence-rate PDT followed by administration of ranibizumab on a variable dosing regimen over 24 months in patients with neovascular AMD. Secondary outcome measures included the change in central macular thickness (CMT), reinjection frequency, and safety.
   This prospective, nonrandomized, open-label, single-center study enrolled 27 consecutive patients (27 eyes) presenting at the Leuven University Eye Hospital with previously untreated, active neovascular AMD between September 2006 and January 2007. All patients were treated with one-time, reduced-fluence-rate verteporfin PDT, followed by intravitreal ranibizumab 0.5 mg on the same day. A second and third ranibizumab injection were given at weeks 4 and 8, respectively, after which patients were followed up monthly for 24 months. Additional treatment with ranibizumab was administered to eyes with active neovascularization as indicated clinically and on imaging studies. Retreatment was based on the following criteria: (1) presence of subretinal fluid (SRF), intraretinal edema or sub-retinal pigment epithelial fluid, as seen on OCT; (2) increase of CMT by > 100 mm on OCT; (3) signs of active CNV leakage on fluorescein angiography; (4) new sub- or intraretinal hemorrhage; and (5) BCVA decreased of a parts per thousand yen5 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. If any single criterion for reinjection was fulfilled, retreatment with ranibizumab was administered.
   Twenty-five patients completed the 2-year study. Occult CNV was present in 64% and retinal angiomatous proliferative (RAP) lesions were present in 24% of the study eyes. The remaining three eyes had lesions classified as classic (one eye) or predominantly classic (two eyes) CNV. Month 24 data are available for 25 eyes (25 patients; age 55-86 years; mean 77; standard deviation (SD) = 7.2). Mean baseline VA was 58.6 letters (range: 35-70; SD = 8.4); 24-month VA was 66.2 letters (35-82; 12.7), not including one warfarin-treated patient who suffered vitreous hemorrhage. The mean visual acuity improved by 7.2 letters (p < 0.05) and the mean CMT decreased by 146 mu m. VA improved > 3 lines (15 letters) in 16%; improved 1-3 lines in 20%; remained within one line of baseline in 32%, decreased 1-3 lines in 16%, and decreased > 3 lines in 16%. Losses of > 3 lines were due to vitreous hemorrhage, geographic atrophy, fibrosis, and growth of an initially small CNV lesion. An average of 5.1 injections (range: 3-9) were administered during the first 12 months, and 7.1 injections (3-13) over 24 months. A total of 178 injections were performed; no systemic side-effects, uveitis, or choroidal collateral vascular damage were observed. Two patients were lost to follow-up.
   Combined PDT and ranibizumab injection the same day was well tolerated in all patients. Eighty-four percent of patients had stable or improved vision at month 24.
C1 [Spielberg, Leigh; Leys, Anita] Univ Hosp Leuven, Dept Ophthalmol, B-3000 Louvain, Belgium.
C3 KU Leuven; University Hospital Leuven
RP Spielberg, L (通讯作者)，Univ Hosp Leuven, Dept Ophthalmol, Kapucijnenvoer 33, B-3000 Louvain, Belgium.
EM spielz01@hotmail.com
FU Novartis Inc, Basel, Switzerland; Department of Ophthalmology at the
   Leuven University Hospital, Leuven, Belgium
FX The authors would like to thank Carol Heughebaert for her editorial
   assistance and Adrian Loehwing for her help with the statistical
   analysis. This study was supported by Novartis Inc, Basel, Switzerland,
   and the Department of Ophthalmology at the Leuven University Hospital,
   Leuven, Belgium. Dr. Leys has received research grants from Novartis
   Inc, has participated in competing scientific advisory boards, and has
   received honorarium and reimbursement for travel expenses from Novartis.
   We thank the following: those involved in design of study (A. L.);
   conduct of study (A. L., L. S.); data collection (L. S., A. L.);
   management (L. S., A. L.); analysis (L. S., A. L), and interpretation of
   data (L. S., A. L.); and preparation (L. S.), review and approval of the
   manuscript (L. S., A. L.). Before the initiation of the study, approval
   to perform the TORPEDO Study was obtained from the Institutional Review
   Board at the Leuven University Hospital. The study was registered with
   https://eudract.emea.europa.eu (no. 2006-003976-36). The study adhered
   to the tenets of the Declaration of Helsinki.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2007, DRUG AGING, V24, P979, DOI 10.2165/00002512-200724120-00002
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carpineto P, 2010, EYE, V24, P251, DOI 10.1038/eye.2009.76
   Casey R, 1997, AM J OPHTHALMOL, V124, P521, DOI 10.1016/S0002-9394(14)70868-2
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   DURBIN MAT, 2009, RETINAL MEASUREMENTS
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kiernan DF, 2009, AM J OPHTHALMOL, V147, P267, DOI 10.1016/j.ajo.2008.08.018
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Miller LS, 1999, J CLIN CHILD PSYCHOL, V28, P2, DOI 10.1207/s15374424jccp2801_1
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Peters S, 2007, BRIT J OPHTHALMOL, V91, P827, DOI 10.1136/bjo.2006.109702
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Volcker M, 2006, OPHTHALMOLOGE, V103, P476, DOI 10.1007/s00347-006-1356-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 41
TC 23
Z9 25
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2010
VL 248
IS 7
BP 943
EP 956
DI 10.1007/s00417-009-1256-6
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 602JB
UT WOS:000278134300004
PM 20204659
DA 2022-11-30
ER

PT J
AU Sjostrand, J
   Laatikainen, L
   Hirvela, H
   Popovic, Z
   Jonsson, R
AF Sjostrand, Johan
   Laatikainen, Leila
   Hirvela, Heli
   Popovic, Zoran
   Jonsson, Robert
TI The decline in visual acuity in elderly people with healthy eyes or eyes
   with early age-related maculopathy in two Scandinavian population
   samples
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ageing; early age-related maculopathy; healthy eyes; visual acuity
ID CATARACT-SURGERY; PREVALENCE; OLDER; IMPAIRMENT; SENSITIVITY; PERIMETRY;
   BLINDNESS; RISK
AB Purpose: This study aimed to analyse the decline in visual acuity (VA) during normal ageing in two Scandinavian population samples of subjects aged >= 70 years and to study the age-specific decline in VA in eyes with early age-related maculopathy (ARM).
   Methods: We carried out a cross-sectional analysis of data pertaining to VA in the better eye in one population sample from Oulu (OU), Finland (aged 70-82 years) and a second population sample from Gothenburg (GG), Sweden (aged 82 or 88 years). The change in VA with age was evaluated in healthy eyes (OU, n = 119; GG, n = 40) and in eyes with early ARM (OU-ARM, n = 22; GG-ARM, n = 114) using linear regression or logistic regression. The results were compared with those of previous reports.
   Results: Our population samples showed a significant decrease with age in VA in healthy eyes in subjects aged >= 44 years using both statistical models. Comparisons with previous reports demonstrated a homogeneity in the decline in VA with age. On average, 0.3 logMAR are lost from middle age up to 88 years, presumably as a result of physiological ageing. In early ARM, the rate of age-specific decline in VA more than doubled and the prevalence of VA < 0.5 markedly increased.
   Conclusions: Visual acuity in healthy eyes declines with age from middle age onwards. The decrease in VA possibly accelerates in subjects aged > 70 years, although no significant evidence for this was found. An age-specific decline in VA is shown in eyes with early ARM. These results are important for the evaluation of age-specific treatment results.
C1 [Sjostrand, Johan; Popovic, Zoran] Univ Gothenburg, Dept Ophthalmol, Gothenburg, Sweden.
   [Laatikainen, Leila] Univ Helsinki, Dept Ophthalmol, Helsinki, Finland.
   [Laatikainen, Leila; Hirvela, Heli] Univ Oulu, Dept Ophthalmol, SF-90220 Oulu, Finland.
   [Jonsson, Robert] Univ Gothenburg, Dept Stat, Gothenburg, Sweden.
C3 University of Gothenburg; University of Helsinki; University of Oulu;
   University of Gothenburg
RP Sjostrand, J (通讯作者)，Sahlgrenska Univ Hosp Molndal, Inst Neurosci & Physiol, Dept Ophthalmol, SE-43180 Molndal, Sweden.
EM johan.sjostrand@oft.gu.se
RI Popovic, Zoran/J-2976-2013
OI Popovic, Zoran/0000-0002-5616-9847
FU Gothenburg Medical Society
FX The authors thank Birgitta Bergman, Lars Frisen and David B. Elliott for
   allowing the use of their published data. This research was supported by
   grants from the Gothenburg Medical Society.
CR Alio JL, 2005, OPHTHALMOLOGY, V112, P2022, DOI 10.1016/j.ophtha.2005.04.034
   Applegate RA, 2006, OPTOMETRY VISION SCI, V83, P635, DOI 10.1097/01.opx.0000232842.60932.af
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bergman B, 1999, ACTA OPHTHALMOL SCAN, V77, P286, DOI 10.1034/j.1600-0420.1999.770308.x
   Bergman B, 2004, ACTA OPHTHALMOL SCAN, V82, P166, DOI 10.1111/j.1600-0420.2004.00182.x
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   CONNOVER WJ, 1980, PRACTICAL NONPARAMET, P64
   CRAMER H, 1957, MATH METHODS STAT, P248
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Elliott BE, 1995, OPTOMETRY VISION SCI, V72, P186
   ELLIOTT DB, 1989, APPL OPTICS, V28, P1914, DOI 10.1364/AO.28.001914
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   FRISEN L, 1991, ACTA OPHTHALMOL, V69, P511
   FRISEN L, 1981, A GRAEF ARCH KLIN EX, V215, P149, DOI 10.1007/BF00413146
   Guirao A, 1999, INVEST OPHTH VIS SCI, V40, P203
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Harwerth RS, 2008, GRAEF ARCH CLIN EXP, V246, P305, DOI 10.1007/s00417-007-0691-5
   Hermann A, 2008, ACTA OPHTHALMOL, V86, P446, DOI 10.1111/j.1600-0420.2007.01055.x
   HIRVELA H, 1995, ACTA OPHTHALMOL SCAN, V73, P111
   HIRVELA H, 1995, ACTA OPHTHALMOL SCAN, V73, P99
   Hosmer DW., 1989, APPL LOGISTIC REGRES
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   KLEINBAUM DG, 1978, APPLIED REGRESSION A, P45
   Kruskal WH, 1978, INT ENCY STAT, V2
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Panchapakesan J, 2004, EYE, V18, P278, DOI 10.1038/sj.eye.6700641
   Pesudovs K, 2004, J REFRACT SURG, V20, pS491
   Petersen A, 2004, OPHTHAL RES, V36, P25, DOI 10.1159/000076106
   Sjostrand JB, 2004, INVEST OPHTH VIS SCI, V45, pU657
   SPEAR PD, 1993, VISION RES, V33, P2589, DOI 10.1016/0042-6989(93)90218-L
   Van den Berg TJTP, 2007, AM J OPHTHALMOL, V144, P358, DOI 10.1016/j.ajo.2007.05.037
   van Leeuwen R, 2007, BRIT J OPHTHALMOL, V91, P1450, DOI 10.1136/bjo.2006.113670
   Westcott MC, 2000, BRIT J OPHTHALMOL, V84, P1380, DOI 10.1136/bjo.84.12.1380
NR 38
TC 24
Z9 24
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2011
VL 89
IS 2
BP 116
EP 123
DI 10.1111/j.1755-3768.2009.01653.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 725RV
UT WOS:000287664700030
PM 19845558
DA 2022-11-30
ER

PT J
AU Seitsonen, S
   Lemmela, S
   Holopainen, J
   Tommila, P
   Ranta, P
   Kotamies, A
   Moilanen, J
   Palosaari, T
   Kaarniranta, K
   Meri, S
   Immonen, I
   Jarvela, I
AF Seitsonen, Sanna
   Lemmela, Susanna
   Holopainen, Juha
   Tommila, Petri
   Ranta, Paivi
   Kotamies, Antti
   Moilanen, Jukka
   Palosaari, Tapani
   Kaarniranta, Kai
   Meri, Seppo
   Immonen, Ilkka
   Jarvela, Irma
TI Analysis of variants in the complement factor H, the elongation of very
   long chain fatty acids-like 4 and the hemicentin 1 genes of age-related
   macular degeneration in the Finnish population
SO MOLECULAR VISION
LA English
DT Article
ID SHORT CONSENSUS REPEAT; C-REACTIVE PROTEIN; SUSCEPTIBILITY LOCI;
   GENOMEWIDE-SCAN; FAMILIAL AGGREGATION; EXTENDED FAMILIES; DISEASE
   HERITAGE; APOLIPOPROTEIN-E; MACULOPATHY; RISK
AB PURPOSE: A strong association of a Tyr402His polymorphism in the complement factor H (CFH) gene and a Met299Val polymorphism in the elongation of very long chain fatty acids-like 4 (ELOVL4) gene with age-related macular degeneration (AMD) has been identified in Caucasian populations in the United States. Earlier a Gln5345Arg variant in the hemicentin 1 (HMCN1) gene was reported in a large AMD family in the United States. We wanted to investigate whether the polymorphisms of the CFH and the ELOVL4 genes or the mutation of the HMCN1 gene are associated with AMD in patients originating from the Finnish population with characteristics of a genetic isolate.
   METHODS: The material consisted of familial (n=181) and sporadic cases (n=154) with AMD, a control group with no AMD (non-AMD controls, n=105), and a control group of anonymous blood donors (blood donor controls, n =350). The DNA of the subjects was sequenced to analyze the variants of the three genes.
   RESULTS: We detected a strong association between the C/C-genotype compared to the T/T-genotype of Tyr402His polymorphism (first base of the Tyr-codon changes) of the CFH gene and AMD in the AMD cases compared to the non-AMD (p=8.86x10(-12)) or to blood donor controls (p=2.02x10(-13)). The frequency of the C/C genotype was significantly increased in both familial cases compared to non-AMD controls with non-adjusted odds ratio (OR) 10.1 (confidence intervals [CI] 95% 4.64-22.2) or compared to blood donor controls with non-adjusted OR 5.50 (CI 95% 3.17-9.55) and in sporadic cases with non-adjusted OR 9.33 (CI 95% 4.10-21.3; non-AMD-controls), OR 5.06 (CI 95% 2.75-9.28; blood donor controls). Frequency of C allele differed significantly between cases and controls (p=1.32x10(-11); non-AMD-controls and p=3.94x10(-14); blood donor controls). No association with AMD was detected with Met299Val polymorphism in the ELOVL4 gene in the familial or sporadic cases compared to non-AMD or blood donor controls. None of our subjects (258 AMD cases, 72 non-AMD controls) had the Gln5345Arg variant in the HMCN1 gene.
   CONCLUSIONS: The CFH gene polymorphism seems to be an important etiologic factor for AMD also in the isolated Finnish population.
C1 Univ Helsinki, Cent Hosp, Mol Genet Lab, FIN-00029 Helsinki, Finland.
   Univ Helsinki, Dept Ophthalmol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland.
   Oulu Univ, Helsinki Ctr Econ Res, SF-90220 Oulu, Finland.
   Oulu Univ, Dept Ophthalmol, SF-90220 Oulu, Finland.
   Univ Kuopio, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; University of Helsinki; Aalto University; University of
   Oulu; University of Oulu; University of Eastern Finland
RP Jarvela, I (通讯作者)，Univ Helsinki, Cent Hosp, Mol Genet Lab, Haartmaninkatu 2, FIN-00029 Helsinki, Finland.
EM irma.jarvela@hus.fi
RI Jarvela, Irma E/L-5836-2013
OI Jarvela, Irma E/0000-0002-1770-6187; Meri, Seppo/0000-0001-9142-501X;
   Kaarniranta, Kai/0000-0003-2600-8679
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   AYYAGARI R, 2002, OPHTHALMIC GENET, V23, P198
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Edwards AO, 2001, INVEST OPHTH VIS SCI, V42, P2652
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Kenealy SJ, 2004, MOL VIS, V10, P57
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Norio R, 2003, HUM GENET, V112, P441, DOI 10.1007/s00439-002-0875-3
   Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
NR 48
TC 55
Z9 57
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 20
PY 2006
VL 12
IS 88-90
BP 796
EP 801
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 069QU
UT WOS:000239464100002
PM 16885922
DA 2022-11-30
ER

PT J
AU Arden, GB
   Wolf, JE
AF Arden, GB
   Wolf, JE
TI Differential effects of light and alcohol on the electro-oculographic
   responses of patients with age-related macular disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COLOR CONTRAST SENSITIVITY; DEGENERATION;
   MACULOPATHY; PATTERN; DRUSEN
AB PURPOSE. Alcohol (EtOH) affects the electro-oculogram (EOG) in ways very similar to fight, although the two agents act on the RPE through different routes. Are the EOGs to light and to alcohol affected similarly in age-related macular degeneration (AMD) and age-related maculopathy (ARM)?
   METHODs. Standard eye movements and recording of FOGS were used. After 26 minutes of baseline recording in darkness, subjects were either exposed to 30 cd/m(2) light or drank 226 mg/kg alcohol (7.1% vol/vol) in water.
   RESULTS. In 17 patients with ARM and AMD (aged 67-86 years; mean, 77), the light-EOG was slowed in comparison to normal, and the voltage changes were somewhat reduced. The mean reduction in the alcohol-EOG (EtOH-EOG) was much greater. The reduction was equal in the two eyes, regardless of uniocular foveal impairment. Some EtOH-EOG loss occurred in patients with minor fundus changes and no loss of acuity, but the loss was greater in patients with "wet" or "dry" ARM and AMD. Grading of RPE changes correlated with the decrease in EtOH-EOG responsiveness, but not with light-EOG responsiveness.
   CONCLUSIONS. EtOH- and light-EOGs are affected differentially. In ARM, even with minor fundus changes, patients appear to have a general abnormality in the RPE. The alcohol response abnormality is correlated to the fundus appearance, but not with age. These results provide further evidence that EtOH acts by a pathway different from that governing the action of fight. These results support histologic and other evidence that in ARM there is a functional barrier between the choroid and the RPE- retina.
C1 City Univ London, Appl Vis Res Ctr, London EC1V 0HB, England.
C3 City University London
RP Arden, GB (通讯作者)，City Univ London, Appl Vis Res Ctr, London EC1V 0HB, England.
EM g.arden@city.ac.uk
OI Arden, Geoffrey/0000-0001-7334-2026
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arden G B, 1962, Br J Ophthalmol, V46, P468, DOI 10.1136/bjo.46.8.468
   ARDEN GB, 1988, CLIN VISION SCI, V2, P303
   ARDEN GB, 1991, OPHTHALMOLOGY, V98, P567
   ARDEN GB, 1962, J PHYSIOL-LONDON, V161, P189, DOI 10.1113/jphysiol.1962.sp006881
   Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366
   Arden GB, 2000, INVEST OPHTH VIS SCI, V41, P2730
   Arden GB, 2000, INVEST OPHTH VIS SCI, V41, P2722
   Arden GB, 1995, EYE, V9, P686, DOI 10.1038/eye.1995.180
   ARDEN GB, 1984, BRIT J OPHTHALMOL, V68, P878, DOI 10.1136/bjo.68.12.878
   Arden GB, 2000, BRIT J OPHTHALMOL, V84, P881, DOI 10.1136/bjo.84.8.881
   ARDEN GB, 2003, OPTICIAN, V225, P12
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRANCOIS J, 1956, Br J Ophthalmol, V40, P108, DOI 10.1136/bjo.40.2.108
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Green W R, 1999, Mol Vis, V5, P27
   Greenstein VC, 2000, INVEST OPHTH VIS SCI, V41, P3643
   Gupta LY, 1995, DOC OPHTHALMOL, V91, P101, DOI 10.1007/BF01203689
   GUPTA LY, 1994, DOC OPHTHALMOL, V88, P49, DOI 10.1007/BF01203701
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Knoblauch K, 2001, VISION RES, V41, P23, DOI 10.1016/S0042-6989(00)00205-4
   LINSENMEIER RA, 1982, J PHYSIOL-LONDON, V331, P653, DOI 10.1113/jphysiol.1982.sp014396
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   MADACHIYAMAMOTO S, 1984, DOC OPHTHALMOL, V57, P153, DOI 10.1007/BF00143079
   MADACHIYAMAMOTO S, 1984, ACTA SOC OPHTHALMOL, V88, P1267
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   Marmor MF, 1998, RETINAL PIGMENT EPIT, P199
   MEDINA E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Miyake Y, 1996, JPN J OPHTHALMOL, V40, P511
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   OUSLEY C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pinckers A, 1996, OPHTHALMIC GENET, V17, P103, DOI 10.3109/13816819609057112
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   SKOOG KO, 1975, ACTA OPHTHALMOL, V53, P710
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   STEINBERG RH, 1983, VISION RES, V23, P1315, DOI 10.1016/0042-6989(83)90107-4
   Steinberg RH, 1985, PROG RETIN RES, V4, P33, DOI [10.1016/0278-4327(85)90004-5, DOI 10.1016/0278-4327(85)90004-5]
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Sunness JS, 1999, MOL VIS, V5
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   WEINSTEIN GW, 1988, ARCH OPHTHALMOL-CHIC, V106, P923
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 53
TC 25
Z9 26
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2003
VL 44
IS 7
BP 3226
EP 3232
DI 10.1167/iovs.02-0998
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 694VL
UT WOS:000183795800059
PM 12824275
DA 2022-11-30
ER

PT J
AU Liang, ST
   Shi, X
   Rosenfeld, PJ
   Li, XX
AF Liang, Shuting
   Shi, Xuan
   Rosenfeld, Philip J.
   Li, Xiaoxin
TI Type 2 choroidal neovascularisation in polypoidal choroidal
   vasculopathy: a retrospective case series
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal Choroidal Vasculopathy (PCV); neovascular Age-related Macular
   Degeneration (nAMD); Optical Coherence Tomography Angiography (OCTA)
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; PHOTODYNAMIC THERAPY; EVEREST
AB Background and objective To demonstrate the coexistence of polypoidal choroidal vasculopathy (PCV) with type 2 neovascularisation (NV), we used multimodal imaging, including spectral-domain optical coherence tomography angiography (SD-OCTA), to identify both types of lesions in the same eye.
   Study design This retrospective case series reviewed patients with PCV diagnosed with indocyanine green angiography (ICGA), fluorescein angiography (FA), SD-OCT and SD-OCTA.
   Results 15 eyes of 14 patients were imaged and diagnosed with PCV by ICGA. ICGA identified polyps in all these eyes, while SD-OCTA imaging identified polypoidal lesions in only 11 (73%) of these eyes with PCV. Branching vascular networks (BVNs) were detected in 12 eyes (80%) by ICGA and SD-OCTA. Type 2 NV was detected in four eyes (27%) by FA and SD-OCTA. In these eyes, a combination of polyps, BVNs and type 2 NV were detected using FA, ICGA and SD-OCTA.
   Conclusion BVN and type 2 NV can coexist in the same PCV eye and communicate with each other. This suggests that polyps may represent a structural variant of neovascular tissue rather than a distinct pathogenic process in NV.
C1 [Liang, Shuting; Shi, Xuan; Li, Xiaoxin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Liang, Shuting; Shi, Xuan; Li, Xiaoxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
   [Liang, Shuting; Shi, Xuan; Li, Xiaoxin] Peking Univ, Collage Optometry, Hlth Sci Ctr, Beijing, Peoples R China.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Peking University; Peking University; Bascom Palmer Eye Institute;
   University of Miami
RP Shi, X (通讯作者)，Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
EM drxuanshi@163.com
FU Bethune - Langmu Ophthalmic Foundation for Young and Middle-aged
   [BJ-LM2015001L]
FX Bethune - Langmu Ophthalmic Foundation for Young and Middle-aged
   Researchers (BJ-LM2015001L)
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1572, DOI 10.1136/bjo.2006.112318corr1
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 3
Z9 3
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2018
VL 102
IS 11
BP 1570
EP 1574
DI 10.1136/bjophthalmol-2017-311518
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD3UI
UT WOS:000452446800018
PM 29436399
DA 2022-11-30
ER

PT J
AU Gelisken, F
   Karim-Zoda, K
   Grisanti, S
   Bartz-Schmidt, KU
AF Gelisken, F
   Karim-Zoda, K
   Grisanti, S
   Bartz-Schmidt, KU
TI Macular translocation with 360 degrees retinotomy for retinal pigment
   epithelial tear
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; complication; macular translocation;
   retinal pigment epithelial tear; therapy
ID DEGENERATION; FOVEA
AB Purpose: To report a case of retinal pigment epithelial tear treated by macular translocation with 360 degrees retinotomy. Methods: Interventional case report. A 75-year-old woman with neovascular age-related macular degeneration and retinal pigment epithelial tear underwent macular translocation with 360 degrees retinotomy and silicone oil tamponade. After 3 months, pars plana vitrectomy, silicone oil removal, and muscle surgery were performed. Results: Twenty-two months after macular translocation surgery, the visual acuity of the patient had improved to 20/50 ( preoperative 20/200). No proliferative vitreoretinopathy or recurrence of the choroidal neovascularisation was observed. Conclusions: Macular translocation surgery with 360 degrees retinotomy can improve vision in retinal pigment epithelial tear secondary to neovascular age-related macular degeneration.
C1 Univ Tubingen, Augenklin, D-72076 Tubingen, Germany.
   Univ Tubingen, Dept Ophthalmol 1, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; University of Hamburg; University Medical Center
   Hamburg-Eppendorf; Eberhard Karls University of Tubingen
RP Gelisken, F (通讯作者)，Univ Tubingen, Augenklin, D-72076 Tubingen, Germany.
EM Faik.Gelisken@med.uni-Tuebingen.de
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Yoshitani S, 2003, OPHTHALMIC SUR LA IM, V34, P217, DOI 10.3928/1542-8877-20030501-12
NR 11
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2005
VL 243
IS 6
BP 619
EP 621
DI 10.1007/s00417-004-1098-1
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 937DA
UT WOS:000229903600018
PM 15650855
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   Agron, E
   Domalpally, A
   Keenan, TDL
   Vitale, S
   Weber, C
   Smith, DC
   Christen, W
AF Chew, Emily Y.
   Clemons, Traci E.
   Agron, Elvira
   Domalpally, Amitha
   Keenan, Tiarnan D. L.
   Vitale, Susan
   Weber, Claire
   Smith, Douglas C.
   Christen, William
CA AREDS2 Res Grp
TI Long-term Outcomes of Adding Lutein/Zeaxanthin and omega-3 Fatty Acids
   to the AREDS Supplements on Age-Related Macular Degeneration Progression
   AREDS2 Report 28
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BASE-LINE-CHARACTERISTICS; BETA-CAROTENE; LUNG-CANCER; EYE DISEASE;
   COMBINATION; TRIAL
AB IMPORTANCE After the Age-Related Eye Disease Study 2 (ARED52) study, the beta carotene component was replaced by lutein/zeaxanthin for the development of the revised AREDS supplement. However, it is unknown if the increased risk of lung cancer observed in those assigned beta carotene persists beyond the conclusion of the AREDS2 trial and if there is a benefit of adding lutein/zeaxanthin to the original AREDS supplement that can be observed with long-term follow-up.
   OBJECTIVE To assess 10-year risk of developing lung cancer and late age-related macular degeneration (AMD).
   DESIGN, SETTING, AND PARTICIPANTS This was a multicenter epidemiologic follow-up study of the AREDS2 clinical trial, conducted from December 1, 2012, to December 31, 2018. Included in the analysis were participants with bilateral or unilateral intermediate AMD for an additional 5 years after clinical trial. Eyes/participants were censored at the time of late AMD development, death, or loss to follow-up. Data were analyzed from November 2019 to March 2022.
   INTERVENTIONS During the clinical trial, participants were randomly assigned primarily to lutein/zeaxanthin and/or omega-3 fatty acids or placebo and secondarily to no beta carotene vs beta carotene and low vs high doses of zinc. In the epidemiologic follow-up study, all participants received AREDS2 supplements with lutein/zeaxanthin, vitamins C and E, and zinc plus copper. Outcomes were assessed at 6-month telephone calls. Analyses of AMD progression and lung cancer development were conducted using proportional hazards regression and logistic regression, respectively.
   MAIN OUTCOMES AND MEASURES Self-reported lung cancer and late AMD validated with medical records.
   RESULTS This study included 3882 participants (mean [SD] baseline age, 72.0 [7.7] years; 2240 women [57.7%]) and 6351 eyes. At 10 years, the odds ratio (OR) of having lung cancer was 1.82 (95% CI, 1.06-3.12; P = .02) for those randomly assigned to beta carotene and 1.15 (95% CI, 0.79-1.66; P = .46) for lutein/zeaxanthin. The hazard ratio (HR) for progression to late AMD comparing lutein/zeaxanthin with no lutein/zeaxanthin was 0.91(95% CI, 0.84-0.99; P = .02) and comparing omega-3 fatty acids with no omega-3 fatty acids was 1.01(95% CI, 0.93-1.09; P = .91). When the lutein/zeaxanthin main effects analysis was restricted to those randomly assigned to beta carotene, the HR was 0.80 (95% CI, 0.68-0.92; P = .002). A direct analysis of lutein/zeaxanthin vs beta carotene showed the HR for late AMD was 0.85 (95% CI, 0.73-0.98; P = .02). The HR for low vs high zinc was 1.04 (95% CI, 0.94-1.14; P = .49), and the HR for no beta carotene vs beta carotene was 1.04 (95% CI, 0.94-1.15; P = .48).
   CONCLUSIONS AND RELEVANCE Results of this long-term epidemiologic follow-up study of the AREDS2 cohort suggest that lutein/zeaxanthin was an appropriate replacement for beta carotene in AREDS2 supplements. Beta carotene usage nearly doubled the risk of lung cancer, whereas there was no statistically significant increased risk with lutein/zeaxanthin. When compared with beta carotene, lutein/zeaxanthin had a potential beneficial association with late AMD progression.
C1 [Chew, Emily Y.; Agron, Elvira; Keenan, Tiarnan D. L.; Vitale, Susan; Weber, Claire] NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,Bldg 10 Clin Res Ctr,Room 3-2531, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Domalpally, Amitha] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   [Smith, Douglas C.; Christen, William] Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,Bldg 10 Clin Res Ctr,Room 3-2531, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Weber, Claire/0000-0002-2352-8479
FU National Eye Institute [EY000546, HHS-N-260-2005-00007-C, NO1-EY-5-0007,
   NOI-EY-0-2127]; Office of Dietary Supplements, the National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke; National Eye Institute/National
   Institutes of Health [HHSN263201300005C]; Research to Prevent Blindness
   Inc
FX This research was supported in part by grants EY000546, Age-Related Eye
   Disease Study 2 (AREDS2) contract HHS-N-260-2005-00007-C, ADB contract
   NO1-EY-5-0007, and AREDS contract NOI-EY-0-2127 from the Intramural
   Research Program of the National Eye Institute; the Office of Dietary
   Supplements, the National Center for Complementary and Alternative
   Medicine; the National Institute on Aging; the National Heart, Lung, and
   Blood Institute; and the National Institute of Neurological Disorders
   and Stroke. For the AREDS2 10-year follow-up portion, further support
   included contract No. HHSN263201300005C from the National Eye
   Institute/National Institutes of Health; and an unrestricted grant from
   Research to Prevent Blindness Inc to the University of Wisconsin Madison
   Department of Ophthalmology and Visual Sciences (Dr Domalpally).
CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christen WG, 2020, JAMA OPHTHALMOL, V138, P1280, DOI 10.1001/jamaophthalmol.2020.4409
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Satia JA, 2009, AM J EPIDEMIOL, V169, P815, DOI 10.1093/aje/kwn409
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 12
TC 4
Z9 4
U1 5
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2022
VL 140
IS 7
BP 692
EP 698
DI 10.1001/jamaophthalmol.2022.1640
EA JUN 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3C7IR
UT WOS:000805556800003
PM 35653117
DA 2022-11-30
ER

PT J
AU Wightman, AJ
   Guymer, RH
AF Wightman, Antony J.
   Guymer, Robyn H.
TI Reticular pseudodrusen: current understanding
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age-related macular degeneration; reticular pseudodrusen
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED
   MACULOPATHY; OUTER RETINAL ATROPHY; MACULAR DEGENERATION;
   GEOGRAPHIC-ATROPHY; CHOROIDAL THICKNESS; ADAPTIVE OPTICS; RISK-FACTOR;
   PREVALENCE
AB Reticular pseudodrusen (RPD), also known as subretinal drusenoid deposits, represent a morphological change to the retina distinct from other subtypes of drusen by being located above the level of the retinal pigment epithelium. Although they can infrequently appear in individuals with no other apparent pathology, their highest rates of occurrence are in association with age-related macular degeneration (AMD), for which they hold clinical significance by being highly correlated with end-stage disease sub-types, choroidal neovascularisation and geographic atrophy. Reticular pseudodrusen are also found in other diseases, most notably Sorsby's fundus dystrophy, pseudoxanthoma elasticum and acquired vitelliform lesions. They are found more frequently in females, with increased age and more commonly bilaterally than unilaterally. Increased risk of RPD formation is conveyed by genetic variants known to increase risk of AMD development, including complement factor H, age-related maculopathy susceptibility 2, and high-temperature requirement A serine peptidase 1; however, to date, no genetic factor has been found to predispose to RPD independent of those that carry risks for AMD. They have typical features visible on multimodal imaging, identifiable either as single lesions or more commonly in yellowish-white net-like patterns on colour fundus photography and are particularly distinguishable using spectral domain optical coherence tomography, fundus auto-fluorescence, and near infrared reflectance imaging. On histological examination, RPD have been shown to have distinct compositions in comparison to typical drusen, suggesting different pathways of pathogenesis. Although their aetiology remains unclear, presence of opsin within lesions, a high topographic association with areas of highest rod-photoreceptor concentration and functional deficits most pronounced within the scotopic range, has implicated rod photoreceptor dysfunction as a component of RPD.
C1 [Wightman, Antony J.; Guymer, Robyn H.] Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wightman, Antony J.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Wightman, Antony J.; Guymer, Robyn H.] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wightman, AJ (通讯作者)，Ctr Eye Res Australia, Melbourne, Vic, Australia.; Wightman, AJ (通讯作者)，Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.; Wightman, AJ (通讯作者)，Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
EM antony.wightman@gmail.com
FU National Health and Medical Research Council (NHMRC) Fellowship
   [1103013]
FX Supported by National Health and Medical Research Council (NHMRC)
   Fellowship (#1103013, RHG). The Centre for Eye Research Australia (CERA)
   receives Operational Infrastructure Support from the Victorian
   Government, Australia.
CR Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Badal J, 2018, INT OPHTHALMOL, V38, P199, DOI 10.1007/s10792-017-0448-z
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chassaing N, 2005, J MED GENET, V42, P881, DOI 10.1136/jmg.2004.030171
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cukras C, 2016, RETINA-J RET VIT DIS, V36, P2348, DOI 10.1097/IAE.0000000000001113
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Gliem Martin, 2013, Frontiers in Genetics, V4, P14, DOI 10.3389/fgene.2013.00014
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Ho CYD, 2018, CLIN EXP OPHTHALMOL, V46, P485, DOI 10.1111/ceo.13131
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lally DR, 2014, JAMA OPHTHALMOL, V132, P775, DOI 10.1001/jamaophthalmol.2014.387
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nghiem-Buffet S, 2017, RETINA-J RET VIT DIS, V37, P53, DOI 10.1097/IAE.0000000000001134
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Paavo M, 2017, INVEST OPHTH VIS SCI, V58, P4769, DOI 10.1167/iovs.17-22338
   Paulus TVMJ, 2016, OPHTHALMOL EYE DI S1, V8s1, P5
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schaal KB, 2017, OPHTHALMOLOGY, V124, P205, DOI 10.1016/j.ophtha.2016.10.009
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vemala R, 2017, INVEST OPHTH VIS SCI, V58, P247, DOI 10.1167/iovs.17-21771
   Vessey KA, 2011, J COMP NEUROL, V519, P506, DOI 10.1002/cne.22530
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wilde C, 2016, EYE, V30, P817, DOI 10.1038/eye.2016.46
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   Witmer MT, 2012, ACTA OPHTHALMOL, V90, pe428, DOI 10.1111/j.1755-3768.2012.02434.x
   Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2), 2017, Ophthalmology, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 76
TC 26
Z9 26
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2019
VL 102
IS 5
BP 455
EP 462
DI 10.1111/cxo.12842
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU4MT
UT WOS:000483561900003
PM 30298528
DA 2022-11-30
ER

PT J
AU Maloney, SC
   Antecka, E
   Granner, T
   Fernandes, B
   Lim, LA
   Orellana, ME
   Burnier, MN
AF Maloney, Shawn C.
   Antecka, Emilia
   Granner, Tamara
   Fernandes, Bruno
   Lim, Li-Anne
   Orellana, Maria E.
   Burnier, Miguel N., Jr.
TI EXPRESSION OF SIRT1 IN CHOROIDAL NEOVASCULAR MEMBRANES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   nicotinamide; retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; SMALL-MOLECULE ACTIVATORS; MACULAR
   DEGENERATION; INTRAVITREAL RANIBIZUMAB; SACCHAROMYCES-CEREVISIAE; DOSING
   REGIMEN; LIFE-SPAN; CELLS; GROWTH; CHORIOCAPILLARIS
AB Purpose: SIRT1 is a deacetylase that has been shown to be instrumental in embryonic and pathologic vascular formation. The purpose of this study was to evaluate the potential role of SIRT1 in the pathogenesis of choroidal neovascularization in age-related macular degeneration.
   Methods: The expression of SIRT1 was assessed via immunohistochemistry in nine excised human choroidal neovascularization membranes and seven non-age-related macular degeneration donor eyes. Enzyme-linked immunosorbent assay-based angiogenesis arrays were used to assess the potential of an SIRT1 inhibitor, nicotinamide, to reduce secretion of 10 unique proangiogenic cytokines from retinal pigment epithelial cells.
   Results: SIRT1 was expressed more frequently in choroidal neovascularization membranes than donor eyes about vascular endothelial cells (78 vs. 29% positive cases) and retinal pigment epithelial cells (57 vs. 14% positive cases). SIRT1 inhibition in retinal pigment epithelial cells correlated with significantly decreased secretion of three potent proangiogenic cytokines: angiogenin, platelet-derived growth factor BB, and vascular endothelial growth factor A.
   Conclusion: SIRT1 levels appear elevated in human choroidal neovascularization membranes compared with control eyes. Moreover, inhibition of SIRT1 activity is correlated with decreased secretion of potent proangiogenic cytokines. Collectively, these data support a potential role for SIRT1 in the pathogenesis of neovascular age-related macular degeneration. RETINA 33:862-866, 2013
C1 [Maloney, Shawn C.; Antecka, Emilia; Granner, Tamara; Fernandes, Bruno; Lim, Li-Anne; Orellana, Maria E.; Burnier, Miguel N., Jr.] McGill Univ, Dept Ophthalmol, Henry C Witelson Ocular Pathol Lab, Montreal, PQ H3A 2T5, Canada.
C3 McGill University
RP Maloney, SC (通讯作者)，3775 Univ St,Room 216, Montreal, PQ H3A 2B4, Canada.
EM shawn.maloney@mail.mcgill.ca
RI Fernandes, Bruno F./ABA-3567-2020
OI Fernandes, Bruno F./0000-0002-5385-3571; Orellana Torres, Maria
   Eugenia/0000-0001-7412-7352; Burnier, Miguel/0000-0002-2335-7470
CR [Anonymous], 2011, VASCULAR ENDOTHELIAL
   Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   KORTE GE, 1986, ACTA ANAT, V127, P171
   Lee HI, 2008, BIOCHEM BIOPH RES CO, V368, P298, DOI 10.1016/j.bbrc.2008.01.082
   Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Potente M, 2008, CELL CYCLE, V7, P2117, DOI 10.4161/cc.7.14.6267
   Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
NR 28
TC 13
Z9 16
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 862
EP 866
DI 10.1097/IAE.0b013e31826af556
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900026
PM 23135526
DA 2022-11-30
ER

PT J
AU Mckay, GJ
   Dasari, S
   Patterson, CC
   Chakravarthy, U
   Silvestri, G
AF Mckay, Gareth J.
   Dasari, Shilpa
   Patterson, Christopher C.
   Chakravarthy, Usha
   Silvestri, Giuliana
TI Complement Component 3: an assessment of association with AMD and
   analysis of gene-gene and gene-environment interactions in a Northern
   Irish cohort
SO MOLECULAR VISION
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   RISK; VARIANT; SUSCEPTIBILITY; HTRA1; LOC387715; INCREASES; HAPLOTYPE
AB Purpose: A non-synonymous single nucleotide polymorphism ( SNP) in complement component 3 has been shown to increase the risk of age-related macular degeneration (AMD). We assess its effect on AMD risk in a Northern Irish sample, test for gene-gene and gene-environment interaction, and review a risk prediction model.
   Methods: SNP rs2230199 was genotyped in 1,358 samples, which comprised 437 cases, 436 no-disease controls, and 485 participants randomly sampled from the Northern Ireland population. Allele frequencies were assessed in cases and controls. Logistic regression analysis was used to assess interaction and develop a risk prediction model.
   Results: We report a minor allele frequency of 0.248 for rs2230199 in the population (n=485), 0.296 in cases (n=437), and 0.221 in controls (n=436; odds ratio [OR]=1.48; confidence interval [CI]: 1.19-1.85; p=0.0003). The significant association is retained following multivariate analysis with adjustment for age, smoking status, Complement Factor H (CFH), Age-Related Maculopathy Susceptibility 2 (ARMS2), Complement Component 2 (CC2), and Complement Factor B (CFB; OR=1.45; CI: 1.10-1.91; p=0.009). No evidence to support an interaction between any of the covariates within the regression model was found. The area under the receiver operator characteristic curve calculated for the fully adjusted model, including all variables, was 0.86 for late AMD.
   Conclusions: Our study confirmed the association between Complement Component 3 (C3) and late-stage AMD. There was no evidence for an interaction with environmental exposures, nor did we find data to support a gene-gene effect.
C1 [Mckay, Gareth J.; Dasari, Shilpa; Chakravarthy, Usha; Silvestri, Giuliana] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [Patterson, Christopher C.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Mckay, GJ (通讯作者)，Royal Victoria Hosp, Ctr Vis & Vasc Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM g.j.mckay@qub.ac.uk
RI McKay, Gareth/AAZ-2601-2020
OI McKay, Gareth/0000-0001-8197-6280; Chakravarthy,
   Usha/0000-0002-2606-3734; Silvestri, Giuliana/0000-0001-5662-5374
FU Guide Dogs for the Blind Association UK [2008-5a]; Research and
   Development Office, Northern Ireland Health and Personal Social Services
   [RRG 4.5]; European Union [FP6]
FX The authors are indebted to those who have participated in this study.
   We thank Evelyn Moore and Vittorio Silvestri for technical assistance.
   This research was funded by The Guide Dogs for the Blind Association UK
   (2008-5a); Research and Development Office, Northern Ireland Health and
   Personal Social Services (RRG 4.5); EVI-GENORET, an integrated project
   funded through the European Union Research Project (FP6).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   CDC (Cent. Dis. Control Prev.), 2004, MMWR-MORBID MORTAL W, V53, P1069
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   REID DD, 1976, LANCET, V2, P979
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 26
TC 23
Z9 25
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 10
PY 2010
VL 16
IS 22-26
BP 194
EP 199
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 570ZG
UT WOS:000275716800003
PM 20157618
DA 2022-11-30
ER

PT J
AU Gunes, A
   Yasar, C
   Tok, L
   Tok, O
AF Gunes, Alime
   Yasar, Cigdem
   Tok, Levent
   Tok, Ozlem
TI Prevalence of Pseudoexfoliation Syndrome in Turkish Patients with Senile
   Cataract
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; cataract; mixed type; prevalence;
   pseudoexfoliation syndrome
ID EXFOLIATION SYNDROME; SYSTEMIC ASSOCIATIONS; DIABETES-MELLITUS; SURGERY;
   GLAUCOMA; EPIDEMIOLOGY; POPULATION; DISEASE; RISK; LENS
AB Purpose: To investigate the prevalence of pseudoexfoliation syndrome (PEX) among Turkish patients with senile cataract. Materials and Methods: Records of 352 eyes of 352 patients who underwent cataract surgery were analyzed in this retrospective study. The presence of PEX, type of cataract, intraocular pressure (IOP), glaucoma, age-related macular degeneration, and systemic diseases (coronary artery disease, hypertension, diabetes mellitus) were recorded. Results: The overall prevalence of PEX syndrome was detected to be 11%. The mean age of PEX patients was significantly higher than without PEX (74.4 +/- 7.2 years and 69.3 +/- 11.4 years, respectively, p=0.004). The most common cataract type in the PEX patients was mixed-type cataract determined in 51.2% of patients. IOP was significantly higher in eyes with PEX than in eyes without it (16.1 +/- 4.5mmHg and 14.7 +/- 3.8mmHg, respectively; p=0.03). Moreover, the prevalence of age-related macular degeneration was found to be significantly higher, and prevalence of glaucoma slightly higher in PEX patients than without PEX. Conclusion: Pseudoexfoliation syndrome is a common condition in Turkish people. PEX is associated with mixed type of cataract, age-related macular degeneration, and elevated IOP. Therefore, PEX patients should be checked for concomitant diseases.
C1 [Gunes, Alime; Yasar, Cigdem; Tok, Levent; Tok, Ozlem] Suleyman Demirel Univ, Fac Med, Dept Ophthalmol, TR-32260 Isparta, Turkey.
C3 Suleyman Demirel University
RP Gunes, A (通讯作者)，Suleyman Demirel Univ, Fac Med, Dept Ophthalmol, TR-32260 Isparta, Turkey.
EM dralimesefer@hotmail.com
CR Andrikopoulos GK, 2009, EYE, V23, P442, DOI 10.1038/sj.eye.6702992
   Belovay GW, 2010, CURR OPIN OPHTHALMOL, V21, P25, DOI 10.1097/ICU.0b013e328332f814
   Bojic L, 2005, GRAEF ARCH CLIN EXP, V243, P446, DOI 10.1007/s00417-004-1074-9
   Cahill M, 2002, EYE, V16, P261, DOI 10.1038/sj.eye.6700011
   FORSIUS H, 1979, T OPHTHAL SOC UK, V99, P296
   Forsius H, 1988, Acta Ophthalmol Suppl, V184, P71
   HIETANEN J, 1992, ACTA OPHTHALMOL, V70, P440
   Kaljurand K, 2004, ACTA OPHTHALMOL SCAN, V82, P259, DOI 10.1111/j.1600-0420.2004.00256.x
   Konstas Anastasios G P, 2006, Compr Ophthalmol Update, V7, P131
   Kovac B, 2014, VOJNOSANIT PREGL, V71, P839, DOI 10.2298/VSP121208018K
   KOZART DM, 1982, OPHTHALMOLOGY, V89, P214
   Kozobolis VP, 1997, ACTA OPHTHALMOL SCAN, V75, P726
   Krishnadas R, 2003, AM J OPHTHALMOL, V135, P830, DOI 10.1016/S0002-9394(02)02271-7
   Lindberg JG, 1979, ACTA OPHTHALMOL SCAN, V67, P190
   Linner E, 2001, ACTA OPHTHALMOL SCAN, V79, P283, DOI 10.1034/j.1600-0420.2001.790314.x
   Mitchell P, 1997, AM J OPHTHALMOL, V124, P685, DOI 10.1016/S0002-9394(14)70908-0
   MORRENOMONTANES J, 1989, ACTA OPHTHALMOL, V67, P383
   NETLAND PA, 1995, OPHTHALMOLOGY, V102, P878, DOI 10.1016/S0161-6420(95)30939-6
   PSILAS KG, 1991, ACTA OPHTHALMOL, V69, P664
   Puska P, 2001, J CATARACT REFR SURG, V27, P1992, DOI 10.1016/S0886-3350(01)00972-5
   REPO LP, 1993, OPHTHALMOLOGY, V100, P352
   Ringvold A, 1999, ACTA OPHTHALMOL SCAN, V77, P371, DOI 10.1034/j.1600-0420.1999.770401.x
   Ritch R, 1994, J Glaucoma, V3, P176
   Ritland JS, 2004, ACTA OPHTHALMOL SCAN, V82, P401, DOI 10.1111/j.1395-3907.2004.00297.x
   Schlotzer-Schrehardt U, 2006, AM J OPHTHALMOL, V141, P921, DOI 10.1016/j.ajo.2006.01.047
   SCHLOTZERSCHREHARDT UM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1752, DOI 10.1001/archopht.1992.01080240092038
   Schumacher S, 2001, LANCET, V357, P359, DOI 10.1016/S0140-6736(00)03645-X
   Sekeroglu MA, 2008, EUR J OPHTHALMOL, V18, P551, DOI 10.1177/112067210801800408
   SELAND JH, 1982, T OPHTHAL SOC UK, V102, P375
   STREETEN BW, 1992, ARCH OPHTHALMOL-CHIC, V110, P1757, DOI 10.1001/archopht.1992.01080240097039
   TAYLOR HR, 1979, T OPHTHAL SOC UK, V99, P302
   Teshome T, 2004, ACTA OPHTHALMOL SCAN, V82, P254, DOI 10.1111/j.1395-3907.2004.00263.x
   WALINDER PEK, 1989, J CATARACT REFR SURG, V15, P526, DOI 10.1016/S0886-3350(89)80109-9
   Wood SD, 2011, J GLAUCOMA, V20, P278, DOI 10.1097/IJG.0b013e3181e3d483
   Young AL, 2004, BRIT J OPHTHALMOL, V88, P193, DOI 10.1136/bjo.2003.021816
NR 35
TC 6
Z9 6
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2017
VL 32
IS 3
BP 297
EP 301
DI 10.3109/08820538.2015.1068344
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES8KZ
UT WOS:000399807200009
PM 26795697
DA 2022-11-30
ER

PT J
AU Bartsch, DU
   El-Bradey, MH
   El-Musharaf, A
   Freeman, WR
AF Bartsch, DU
   El-Bradey, MH
   El-Musharaf, A
   Freeman, WR
TI Improved visualisation of choroidal neovascularisation by scanning laser
   ophthalmoscope using image averaging
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; ORAL FLUORESCEIN ANGIOGRAPHY; MEMBRANE
   DEFORMABLE MIRROR; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; HUMAN
   EYE; NOISE; PHOTOCOAGULATION; COMPENSATION; ENHANCEMENT
AB Aims: To improve visualisation of angiographic features in patients with age related macular degeneration associated with choroidal neovascularisation (CNV) and related complications. To evaluate if image averaging can achieve this goal.
   Methods: 27 eyes of 20 sequential patients with age related macular degeneration over a 3 month period were studied. Indocyanine green angiograms (ICGA), fluorescein angiograms ( FA), and oral fluorescein angiograms were recorded with a confocal scanning laser ophthalmoscope. Software was used to average multiple images from a 10 - 20 image series ( over 0.5 - 1.0 seconds). Image quality was assessed by two masked observers and graded on a scale of 0 - 3. A more quantifiable grading method was devised by adding a variable amount of Gaussian noise to the improved image until the original and image averaged image appeared equal.
   Results: Masked review showed mild to strong improvement of visualisation of structures including borders of CNV. Improvement varied depending on the type and phase of the angiogram. Improvement was highest in late phase FA, mid and late phase ICGA, and all phases of oral FA.
   Conclusion: Image averaging using software based algorithms improves the quality of angiographic images, particularly late ICGA images and oral FAs. This method may assist in the visualisation of choroidal neovascularisation in age related macular degeneration.
C1 Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   Tanta Univ, Fac Med, Tanta, Egypt.
C3 University of California System; University of California San Diego;
   Egyptian Knowledge Bank (EKB); Tanta University
RP Bartsch, DU (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM dbartsch@ucsd.edu
FU NATIONAL EYE INSTITUTE [R01EY013304, R01EY007366] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY07366, EY13304] Funding Source: Medline
CR *ANSI, 1993, Z1361 ANSI, P1
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   BARTSCH DU, 1994, EXP EYE RES, V58, P161, DOI 10.1006/exer.1994.1004
   BARTSCH DU, 1993, NEUROSCI BIOBEHAV R, V17, P459
   Ferguson RD, 2004, OPT EXPRESS, V12, P5198, DOI 10.1364/OPEX.12.005198
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Freeman WR, 1998, ARCH OPHTHALMOL-CHIC, V116, P455, DOI 10.1001/archopht.116.4.455
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Garcia CR, 1999, OPHTHALMOLOGY, V106, P1114, DOI 10.1016/S0161-6420(99)90264-6
   Gelfand YA, 1997, OPHTHALMIC SURG LAS, V28, P823
   George LD, 1999, BRIT J OPHTHALMOL, V83, P911, DOI 10.1136/bjo.83.8.911
   Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032
   Kavanaugh K M, 1990, Int J Card Imaging, V5, P233, DOI 10.1007/BF01797840
   Lee W K, 2000, Korean J Ophthalmol, V14, P60
   LESZCZYNSKI KW, 1990, PHYS MED BIOL, V35, P429, DOI 10.1088/0031-9155/35/3/011
   LIANG J, 1996, C LAS EL, V9, P74
   Madore B, 1996, MED PHYS, V23, P109, DOI 10.1118/1.597687
   Marcos S, 1996, J OPT SOC AM A, V13, P897, DOI 10.1364/JOSAA.13.000897
   Newsom R, 2000, EYE, V14, P579, DOI 10.1038/eye.2000.146
   Newsom RSB, 2000, EYE, V14, P318, DOI 10.1038/eye.2000.80
   Ofverstedt LG, 1997, J STRUCT BIOL, V120, P329, DOI 10.1006/jsbi.1997.3915
   RAJAPAKSHE R, 1994, MED PHYS, V21, P1263, DOI 10.1118/1.597360
   Rivero ME, 1999, OPHTHALMOLOGY, V106, P2296, DOI 10.1016/S0161-6420(99)90529-8
   SCHEIDER A, 1989, AM J OPHTHALMOL, V108, P458, DOI 10.1016/S0002-9394(14)73325-2
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   SWINDELL W, 1995, MED PHYS, V22, P1405, DOI 10.1118/1.597618
   Torok B, 1996, KLIN MONATSBL AUGENH, V208, P333, DOI 10.1055/s-2008-1035230
   WEINREB RN, 1993, ARCH OPHTHALMOL-CHIC, V111, P636, DOI 10.1001/archopht.1993.01090050070031
   WOODWARD JT, 1995, J MICROSC-OXFORD, V178, P86, DOI 10.1111/j.1365-2818.1995.tb03583.x
   YEE T, 1991, BIOTECHNIQUES, V10, P786
   Zhu LJ, 1999, APPL OPTICS, V38, P168, DOI 10.1364/AO.38.000168
   Zhu LJ, 1998, OPTOMETRY VISION SCI, V75, P827, DOI 10.1097/00006324-199811000-00025
   Zhu LJ, 1999, APPL OPTICS, V38, P6019, DOI 10.1364/AO.38.006019
NR 34
TC 8
Z9 8
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2005
VL 89
IS 8
BP 1026
EP 1030
DI 10.1136/bjo.2004.057364
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 946CK
UT WOS:000230549500027
PM 16024859
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Sambhav, K
   Grover, S
   Chalam, KV
AF Sambhav, Kumar
   Grover, Sandeep
   Chalam, Kakarla V.
TI The application of optical coherence tomography angiography in retinal
   diseases
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; diabetic
   retinopathy; motion contrast; optical coherence tomography angiography
   (OCTA); OCT-based optical microangiography (OMAG); OCT angiography ratio
   analysis (OCTARA); split-spectrum amplitude decorrelation angiography
   (SSADA)
ID DIABETIC MACULAR EDEMA; FOVEAL AVASCULAR ZONE; MYOPIC CHOROIDAL
   NEOVASCULARIZATION; AMPLITUDE-DECORRELATION ANGIOGRAPHY; CENTRAL SEROUS
   CHORIORETINOPATHY; SICKLE-CELL-DISEASE; OCT ANGIOGRAPHY;
   FLUORESCEIN-ANGIOGRAPHY; CAPILLARY NONPERFUSION; VASCULAR ABNORMALITIES
AB Optical coherence tomography angiography (OCTA) is a new, noninvasive imaging technique that generates real-time volumetric data on chorioretinal vasculature and its flow pattern. With the advent of high-speed optical coherence tomography, established en face chorioretinal segmentation, and efficient algorithms, OCTA generates images that resemble an angiogram. The principle of OCTA involves determining the change in backscattering between consecutive B-scans and then attributing the differences to the flow of erythrocytes through retinal blood vessels. OCTA has shown promise in the evaluation of common ophthalmologic diseases such as diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusions. It quantifies vascular compromise reflecting the severity of diabetic retinopathy. OCTA detects the presence of choroidal neovascularization in exudative age-related macular degeneration and maps loss of choriocapillaris in nonexudative age-related macular degeneration. We describe principles of OCTA and findings in common and some uncommon retinal pathologies. Finally, we summarize its potential future applications. Its current limitations include a relatively small field of view, inability to show leakage, and a tendency for image artifacts. Further larger studies will define OCTAs utility in clinical settings and establish if the technology may offer its utility in decreasing morbidity through early detection and guide therapeutic interventions in retinal diseases. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Sambhav, Kumar; Grover, Sandeep; Chalam, Kakarla V.] Univ Florida, Coll Med, Dept Ophthalmol, 580 W 8th St,Tower 2,3rd Floor, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, 580 W 8th St,Tower 2,3rd Floor, Jacksonville, FL 32209 USA.
EM kvchalam@aol.com
RI Sambhav, Kumar/AAR-7929-2021; Chalam, kakarla/K-7507-2019
OI Chalam, K V/0000-0002-0004-9416; Grover, Sandeep/0000-0002-3771-7510
CR Adhi M, 2016, INVEST OPHTH VIS SCI, V57, pOCT486, DOI 10.1167/iovs.15-18907
   Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Ophthalmology, V98, P807
   AREND O, 1991, BRIT J OPHTHALMOL, V75, P514, DOI 10.1136/bjo.75.9.514
   Bonini MA, 2015, RETINA-J RET VIT DIS, V35, P2339, DOI 10.1097/IAE.0000000000000850
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Brar M, 2010, RETINA-J RET VIT DIS, V30, P383, DOI 10.1097/IAE.0b013e3181cd4803
   BRESNICK GH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1286
   Cardoso JN, 2016, AM J OPHTHALMOL, V163, P93, DOI 10.1016/j.ajo.2015.11.025
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chan G, 2012, INVEST OPHTH VIS SCI, V53, P5502, DOI 10.1167/iovs.12-10265
   Chidambara L, 2016, BRIT J OPHTHALMOL, V100, P1482, DOI 10.1136/bjophthalmol-2015-307941
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cole ED, INVEST OPHTHALMOL VI
   Coscas F, 2016, INVEST OPHTH VIS SCI, V57, pOCT211, DOI 10.1167/iovs.15-18793
   Coscas F, 2016, AM J OPHTHALMOL, V161, P160, DOI 10.1016/j.ajo.2015.10.008
   Coscas G, 2016, DEV OPHTHALMOL, V56, P1, DOI 10.1159/000442768
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   de Carlo TE, 2016, OSLI RETINA, V47, P128, DOI 10.3928/23258160-20160126-05
   de Carlo TE, 2016, OSLI RETINA, V47, P108, DOI 10.3928/23258160-20160126-02
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2364, DOI 10.1097/IAE.0000000000000882
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   de Castro-Abeger AH, 2015, OSLI RETINA, V46, P1052, DOI 10.3928/23258160-20151027-12
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feucht N, 2016, OSLI RETINA, V47, P322, DOI 10.3928/23258160-20160324-03
   Finger PT, 2005, BRIT J OPHTHALMOL, V89, P730, DOI 10.1136/bjo.2004.052159
   Gangaputra S, 2013, RETINA-J RET VIT DIS, V33, P1393, DOI 10.1097/IAE.0b013e318286c952
   Grover S, 1999, OPHTHALMOLOGY, V106, P1780, DOI 10.1016/S0161-6420(99)90342-1
   Grover S, AM J
   Grover S, 2016, EUR J OPHTHALMOL, V26, pE121, DOI 10.5301/ejo.5000765
   Han IC, 2015, JAMA OPHTHALMOL, V133, P1337, DOI 10.1001/jamaophthalmol.2015.2824
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hasegawa N, INVEST OPHTHALMOL VI
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Horgan N, 2010, CURR OPIN OPHTHALMOL, V21, P233, DOI 10.1097/ICU.0b013e3283386687
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Inoue M, INVEST OPHTHALMOL VI
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   IWASAKI M, 1986, INVEST OPHTH VIS SCI, V27, P1698
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   John D, 2011, INDIAN J OPHTHALMOL, V59, P9, DOI 10.4103/0301-4738.73706
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2016, OPHTHALMOLOGY, V123, P2368, DOI 10.1016/j.ophtha.2016.07.010
   Leitgeb RA, 2003, OPT EXPRESS, V11, P3116, DOI 10.1364/OE.11.003116
   Liang MC, 2016, DEV OPHTHALMOL, V56, P62, DOI 10.1159/000442780
   Liu B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003264
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Macdonald D, 2014, CLIN EXP OPTOM, V97, P311, DOI 10.1111/cxo.12120
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Minvielle W, 2016, AM J OPHTHALMOL, V164, P137, DOI 10.1016/j.ajo.2015.12.023
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Morgan JIW, 2016, OPHTHAL PHYSL OPT, V36, P218, DOI 10.1111/opo.12289
   Motaghiannezam R, 2012, BIOMED OPT EXPRESS, V3, P503, DOI 10.1364/BOE.3.000503
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Murthy RK, 2011, ARCH OPHTHALMOL-CHIC, V129, P247, DOI 10.1001/archophthalmol.2010.357
   Nagasawa T, 2013, INVEST OPHTH VIS SCI, V54, P7068, DOI 10.1167/iovs.13-12350
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Novais EA, 2016, DEV OPHTHALMOL, V56, P132, DOI 10.1159/000442805
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Parodi MB, 2017, BRIT J OPHTHALMOL, V101, P428, DOI 10.1136/bjophthalmol-2016-308925
   Parodi MB, 2017, BRIT J OPHTHALMOL, V101, P780, DOI 10.1136/bjophthalmol-2016-308869
   Podoleanu AG, 1998, OPT LETT, V23, P147, DOI 10.1364/OL.23.000147
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Puliafito CA, IMAGING MACULAR DISE
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2016, DEV OPHTHALMOL, V56, P101, DOI 10.1159/000442800
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Samara WA, 2015, RETINA-J RET VIT DIS, V35, P2188, DOI 10.1097/IAE.0000000000000847
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Schaudig UH, 2000, OPHTHALMIC SURG LAS, V31, P182
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Seregard S, 2013, DEV OPHTHALMOL, V52, P114, DOI 10.1159/000351088
   SHAHIDI M, 1991, ARCH OPHTHALMOL-CHIC, V109, P1115, DOI 10.1001/archopht.1991.01080080075032
   Shahlaee A, 2016, AM J OPHTHALMOL, V165, P39, DOI 10.1016/j.ajo.2016.02.018
   Shen WY, 2012, J NEUROSCI, V32, P15715, DOI 10.1523/JNEUROSCI.2841-12.2012
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   SNODDERLY DM, 1990, J COMP NEUROL, V297, P145
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P1200, DOI 10.1016/j.ajo.2015.09.010
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2181, DOI 10.1097/IAE.0000000000000764
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P113, DOI 10.1159/000442802
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Takase N, RETINA
   Tan CS, 2016, INVEST OPHTH VIS SCI, V57, pOCT224, DOI 10.1167/iovs.15-18869
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   Tan PEZ, 2012, INVEST OPHTH VIS SCI, V53, P5728, DOI 10.1167/iovs.12-10017
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Toto L, 2016, INVEST OPHTH VIS SCI, V57, P6360, DOI 10.1167/iovs.16-20544
   Van Velthoven MEJ, 2006, RETINA-J RET VIT DIS, V26, P129, DOI 10.1097/00006982-200602000-00001
   Veverka KK, 2015, RETINA-J RET VIT DIS, V35, P2400, DOI 10.1097/IAE.0000000000000844
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Witmer MT, 2013, CLIN OPHTHALMOL, V7, P389, DOI 10.2147/OPTH.S41731
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   WU LZ, 1985, JPN J OPHTHALMOL, V29, P406
   Yang ZY, 2015, AM J OPHTHALMOL, V159, P193, DOI 10.1016/j.ajo.2014.10.019
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Yazdanfar S, 2003, ARCH OPHTHALMOL-CHIC, V121, P235
   Yoshikawa M, 2014, INVEST OPHTH VIS SCI, V55, P477, DOI 10.1167/iovs.13-11897
   Zeimer M, 2015, RETINA-J RET VIT DIS, V35, P2307, DOI 10.1097/IAE.0000000000000868
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
   Zhang M, 2016, INVEST OPHTH VIS SCI, V57, P5101, DOI 10.1167/iovs.16-19776
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
NR 151
TC 69
Z9 72
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD NOV-DEC
PY 2017
VL 62
IS 6
BP 838
EP 866
DI 10.1016/j.survophthal.2017.05.006
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL0FR
UT WOS:000413887500007
PM 28579550
DA 2022-11-30
ER

PT J
AU Tsai, ASH
   Cheung, N
   Gan, ATL
   Jaffe, GJ
   Sivaprasad, S
   Wong, TY
   Cheung, CMG
AF Tsai, Andrew S. H.
   Cheung, Ning
   Gan, Alfred T. L.
   Jaffe, Glenn J.
   Sivaprasad, Sobha
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Retinal angiomatous proliferation
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; retinal angiomatous proliferation;
   choroidal neovascularization; anti-vascular endothelial growth factor;
   photodynamic therapy; pigment epithelial detachment; optical coherence
   tomography; fundus fluorescein angiography
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN ANGIOGRAPHY; PIGMENT
   EPITHELIAL DETACHMENT; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   DEGENERATION TREATMENTS TRIALS; BEVACIZUMAB AVASTIN TREATMENT; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY
AB Retinal angiomatous proliferation (RAP) is a unique variant of neovascular age-related macular degeneration. Published studies have estimated that up to 15% of patients with neovascular age-related macular degeneration have RAP. Clinical features frequently associated with RAP include bilateral disease, presence of pigment epithelial detachments, and reticular pseuclodrusen. RAP is more frequently associated with the development of retinal pigment epithelial tears and geographic atrophy that can lead to severe vision loss. Recent advances in retinal and choroidal imaging technology have furthered our understanding of RAP. Although indocyanine green angiography remains the gold standard diagnostic tool, optical coherence tomography has improved the precision by which neovascular age-related macular degeneration with RAP lesions can be diagnosed, staged, and monitored. Anti vascular endothelial growth factor therapy is currently the first line of treatment. Other treatment options including combination of photodynamic therapy with antiangiogenic agent intravitreal injections or corticosteroids may also achieve a reasonable therapeutic outcome; however, RAP may portend a more guarded visual prognosis than typical choroidal neovascularization because of variable treatment response and dependence on the disease stage. Future basic and clinical research is needed to clarify the pathophysiology, definition and classification, optimal treatment regimen, and long-term outcome of RAP. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Tsai, Andrew S. H.; Cheung, Ning; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Tsai, Andrew S. H.; Cheung, Ning; Gan, Alfred T. L.; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Tsai, Andrew S. H.; Cheung, Ning; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London, England.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore; Duke
   University; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wong.tien.yin@singhealth.com.sg
RI Sivaprasad, S./D-6876-2015; Wong, Tien Yin/AAC-9724-2020
OI Sivaprasad, S./0000-0001-8952-0659; Wong, Tien Yin/0000-0002-8448-1264;
   Tufail, Adnan/0000-0001-6131-7640; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Novartis; Bayer; Roche
FX Dr Jaffe has served as a consultant for Alcon/Novartis; Neurotech; and
   Roche/Genentech. Dr Sivaprasad has served as a consultant for Novartis,
   Bayer, and Allergan; Dr Wong is on the advisory board for Allergan,
   Novartis, and Bayer; and Dr Cheung is on the advisory board of Novartis
   and Bayer and has received research grants from Novartis, Bayer, and
   Roche.
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Amarakoon S, 2015, AM J OPHTHALMOL, V160, P1044, DOI 10.1016/j.ajo.2015.07.026
   Amselem L., 2008, Arch Soc Esp Oftalmol, V83, P53
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Bearelly S, 2008, BRIT J OPHTHALMOL, V92, P191, DOI 10.1136/bjo.2007.118760
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Forooghian F, 2008, CAN J OPHTHALMOL, V43, P246, DOI 10.3129/i08-017
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gharbiya M, 2009, RETINA-J RET VIT DIS, V29, P740, DOI 10.1097/IAE.0b013e3181a0be1d
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Gomez-Ulla F, 2006, OPTOMETRY VISION SCI, V83, P546, DOI 10.1097/01.opx.0000230279.95171.71
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Hufendiek Katerina, 2012, International Ophthalmology, V32, P259, DOI 10.1007/s10792-012-9562-0
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Inoue M, 2014, BRIT J OPHTHALMOL, V98, P956, DOI 10.1136/bjophthalmol-2013-304251
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Kerbs I, 2009, OPHTHAL SURG LAS IM, V40, P285, DOI [10.9999/15428877-20090430-10, 10.3928/15428877-20090430-10]
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Kramann CA, 2012, ACTA OPHTHALMOL, V90, P487, DOI 10.1111/j.1755-3768.2010.01952.x
   Krieglstein TR, 2006, BRIT J OPHTHALMOL, V90, P1357, DOI 10.1136/bjo.2006.092536
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lee MY, 2011, RETINA-J RET VIT DIS, V31, P65, DOI 10.1097/IAE.0b013e3181e586e3
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lo Giudice G, 2009, RETINA-J RET VIT DIS, V29, P949, DOI 10.1097/IAE.0b013e3181af106d
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Mahmood S, 2009, EYE, V23, P530, DOI 10.1038/eye.2008.101
   Maier M, 2013, OPHTHALMOLOGE, V110, P1171, DOI 10.1007/s00347-012-2732-7
   Mantel I, 2006, EUR J OPHTHALMOL, V16, P705, DOI 10.1177/112067210601600507
   Marques JP, 2015, RETINA-J RET VIT DIS, V35, P1985, DOI 10.1097/IAE.0000000000000619
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2015, RETINA-J RET VIT DIS, V35, P648, DOI 10.1097/IAE.0000000000000486
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Mendis R, 2008, BRIT J OPHTHALMOL, V92, P1154, DOI 10.1136/bjo.2007.122119
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Miller JW, 1997, AM J PATHOL, V151, P13
   Mones J, 2013, CLIN OPHTHALMOL, V7, P1089, DOI 10.2147/OPTH.S45155
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Montero JA, 2009, BRIT J OPHTHALMOL, V93, P166, DOI 10.1136/bjo.2008.141903
   Montero JA, 2009, EUR J OPHTHALMOL, V19, P448, DOI 10.1177/112067210901900320
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nakano S, 2012, CLIN OPHTHALMOL, V6, P277, DOI 10.2147/OPTH.S29718
   Nakata M, 2006, AM J OPHTHALMOL, V141, P968, DOI 10.1016/j.ajo.2005.12.029
   Nicolo M, 2006, GRAEF ARCH CLIN EXP, V244, P1336, DOI 10.1007/s00417-006-0306-6
   Ohkuma Y, 2014, CLIN OPHTHALMOL, V8, P143, DOI 10.2147/OPTH.S56483
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Olea J.L., 2007, Arch Soc Esp Oftalmol, V82, P27
   Panagiotidis D, 2006, EUR J OPHTHALMOL, V16, P326, DOI 10.1177/112067210601600221
   Park YG, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0172-2
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Petrarca Robert, 2012, Retin Cases Brief Rep, V6, P353, DOI 10.1097/ICB.0b013e31823c12a3
   Phasukkijwatana N, 2016, BR J OPHTHALMOL
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P165, DOI 10.1007/s00417-011-1804-8
   Reche-Frutos J, 2007, EUR J OPHTHALMOL, V17, P979, DOI 10.1177/112067210701700619
   Reche-Frutos J, 2011, EUR J OPHTHALMOL, V21, P783, DOI 10.5301/EJO.2011.6526
   Roth DB, 2007, RETINA-J RET VIT DIS, V27, P1201, DOI 10.1097/IAE.0b013e3180ed45a6
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Rouvas AA, 2010, EYE LOND, V24, P1643
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Saito M, 2012, AM J OPHTHALMOL, V153
   Saito M, 2016, JPN J OPHTHALMOL, V60, P42, DOI 10.1007/s10384-015-0417-x
   Saito M, 2013, JPN J OPHTHALMOL, V57, P211, DOI 10.1007/s10384-012-0215-7
   Saito M, 2012, CLIN OPHTHALMOL, V6, P1385, DOI 10.2147/OPTH.S36333
   Saito M, 2010, AM J OPHTHALMOL, V149, P472, DOI 10.1016/j.ajo.2009.09.016
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Sakimoto S, 2005, AM J OPHTHALMOL, V139, P917, DOI 10.1016/j.ajo.2004.10.046
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seidel G, 2013, ACTA OPHTHALMOL, V91, pe482, DOI 10.1111/aos.12111
   Shimada H, 2005, GRAEF ARCH CLIN EXP, V243, P519, DOI 10.1007/s00417-004-1073-x
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Shiragami C, 2007, RETINA-J RET VIT DIS, V27, P198, DOI 10.1097/01.iae.0000224938.61915.f0
   Shirakata Y, 2012, JPN J OPHTHALMOL, V56, P599, DOI 10.1007/s10384-012-0183-y
   Silva RM, 2007, GRAEF ARCH CLIN EXP, V245, P1131, DOI 10.1007/s00417-006-0532-y
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   Steigerwalt Robert D Jr, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100325-12
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Tsaousis KT, 2015, GRAEF ARCH CLIN EXP, V253, P663, DOI 10.1007/s00417-014-2835-8
   van de Moere A, 2007, AM J OPHTHALMOL, V143, P701, DOI 10.1016/j.ajo.2006.10.045
   Viola F, 2010, EYE, V24, P1344, DOI 10.1038/eye.2010.33
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 135
TC 43
Z9 44
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2017
VL 62
IS 4
BP 462
EP 492
DI 10.1016/j.survophthal.2017.01.008
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX8WB
UT WOS:000403529800004
PM 28189495
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Lee, DW
   Cho, SW
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Lee, Dong Won
   Cho, Sung Won
   Kim, Chul Gu
   Kim, Jong Woo
TI Hemorrhagic complications after intravitreal ranibizumab injection for
   polypoidal choroidal vasculopathy
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; BEVACIZUMAB; TEARS
AB Objective: To evaluate clinical features and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy (PCV) after intravitreal ranibizumab injection.
   Design: Retrospective case series.
   Participants: The charts of 54 patients with PCV who had received intravitreal ranibizumab 0.5 mg.
   Methods: The study was conducted as a retrospective chart review of 54 patients with PCV who had received intravitreal ranibizumab 0.5 mg. Analysis of 2 groups was based on mean PCV lesion size: < 15mm(2) (n = 24); or 15mm(2) (n = 32). The occurrence of fresh postoperative subretinal hemorrhage, best corrected visual acuity, systemic disease, and medication history were documented and analyzed.
   Results: The mean injection number was 3.3 +/- 0.7 (range, 1 to 6), with a mean follow-up of 7.4 +/- 2.8 months (range, 4 to 14 months). During the follow-up period, postoperative subretinal hemorrhage was observed in 5 (8.9%) of 56 eyes. Occurrence of postoperative hemorrhage was significantly increased in the group with large PCV size (p = 0.01). Pars plana vitrectomy was performed for postoperative bleeding that resulted in vitreous hemorrhage in 1 eye (1.8%). Various systemic diseases and medication with an anticoagulant had no correlation with occurrence of hemorrhagic complications.
   Conclusions: Subretinal hemorrhage after ranibizumab injection can occur in patients with PCV. When considering ranibizumab injection for treatment of a large PCV lesion, the risk for hemorrhagic complications should be considered.
C1 [Cho, Han Joo; Lee, Dong Won; Cho, Sung Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Konyang University
RP Cho, HJ (通讯作者)，Konyang Univ Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156,4Ga, Seoul, South Korea.
EM ccnnrr@naver.net
OI Cho, Han Joo/0000-0001-7336-5762
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 9
Z9 12
U1 1
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2012
VL 47
IS 2
BP 170
EP 175
DI 10.1016/j.jcjo.2012.01.005
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953RI
UT WOS:000304890100016
PM 22560424
DA 2022-11-30
ER

PT J
AU Yamamoto, A
   Okada, AA
   Kano, M
   Koizumi, H
   Saito, M
   Maruko, I
   Sekiryu, T
   Iida, T
AF Yamamoto, Akiko
   Okada, Annabelle A.
   Kano, Mariko
   Koizumi, Hideki
   Saito, Masaaki
   Maruko, Ichiro
   Sekiryu, Tetsuju
   Iida, Tomohiro
TI One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal
   Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID SHORT-TERM EFFICACY; VEGF TRAP-EYE; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; JAPANESE PATIENTS; RANIBIZUMAB INJECTIONS; CLINICAL
   CHARACTERISTICS; VISUAL-ACUITY; VERTEPORFIN; BEVACIZUMAB
AB Purpose: To investigate 1-year outcomes of intravitreal aflibercept for polypoidal choroidal vasculopathy (PCV).
   Design: Retrospective, multicenter, consecutive case series.
   Participants: A total of 90 eyes of 87 patients with treatment-naive PCV followed at 3 tertiary centers.
   Methods: Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening.
   Main Outcome Measures: Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year.
   Results: The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months (P < 0.001). The mean central retinal thickness decreased from 315 mm at baseline to 204 mm at 12 months (P < 0.001). At 12 months, 64 eyes (71.1%) achieved a dry macula, defined as absence of intraretinal or subretinal fluid on OCT. Of 83 eyes that underwent indocyanine green angiography at both baseline and 12 months, 46 (55.4%) showed complete and 27 (32.5%) showed partial resolution of polypoidal lesions. Eleven of 82 eyes (13.4%) showed decreased size of branching choroidal vascular networks.
   Conclusions: Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naive eyes with PCV. (C) 2015 by the American Academy of Ophthalmology.
C1 [Yamamoto, Akiko; Okada, Annabelle A.] Kyorin Univ, Sch Med, Dept Ophthalmol, Mitaka, Tokyo 1818611, Japan.
   [Kano, Mariko; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Koizumi, Hideki; Maruko, Ichiro; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 Kyorin University; Fukushima Medical University; Tokyo Women's Medical
   University
RP Okada, AA (通讯作者)，Kyorin Univ, Sch Med, Dept Ophthalmol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.
EM aokada@eye-center.org
RI Maruko, Ichiro/AFP-1311-2022; Saito, Masaaki/ABI-2783-2020
OI Maruko, Ichiro/0000-0001-5647-6372; Saito, Masaaki/0000-0003-1494-6350;
   Sekiryu, Tetsuju/0000-0001-8042-2729
FU Novartis Pharma K.K. (Japan); Bayer Yakuhin, Ltd. (Japan); Santen
   Pharmaceutical Co., Ltd. (Japan); Pfizer Japan, Inc.; Novartis AG; Bayer
   Healthcare AG; Mitsubishi Tanabe Pharma Corporation (Japan)
FX The author(s) have made the following disclosure(s): A.Y.: Personal fees
   - Novartis Pharma K.K. (Japan), Bayer Yakuhin, Ltd. (Japan), Santen
   Pharmaceutical Co., Ltd. (Japan), outside the submitted work.; A.A.O.:
   Personal fees - Novartis Pharma K.K. (Japan), Bayer Yakuhin, Ltd.
   (Japan); Pfizer Japan, Inc., Santen Pharmaceutical Co., Ltd. (Japan),
   Novartis AG, Bayer Healthcare AG; Grants and personal fees - Mitsubishi
   Tanabe Pharma Corporation (Japan), outside the submitted work.; T.I.:
   Personal fees - Bayer Yakuhin, Ltd. (Japan); Grants and personal fees -
   Novartis Pharma K.K. (Japan), Santen Pharmaceutical Co., Ltd. (Japan),
   outside the submitted work.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BR J OPHTHALMOL
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Yamamoto A, 2013, CLIN OPHTHALMOL, V7, P757, DOI 10.2147/OPTH.S42189
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 44
TC 98
Z9 98
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2015
VL 122
IS 9
BP 1866
EP 1872
DI 10.1016/j.ophtha.2015.05.024
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP8BU
UT WOS:000360116900028
PM 26088619
DA 2022-11-30
ER

PT J
AU Singh, SR
   Chakurkar, R
   Goud, A
   Rasheed, MA
   Vupparaboina, KK
   Chhablani, J
AF Singh, Sumit Randhir
   Chakurkar, Renuka
   Goud, Abhilash
   Rasheed, Mohammed Abdul
   Vupparaboina, Kiran Kumar
   Chhablani, Jay
TI Pachydrusen in polypoidal choroidal vasculopathy in an Indian cohort
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness (CT); large choroidal vessel thickness (LCVT);
   optical coherence tomography (OCT); pachydrusen; polypoidal choroidal
   vasculopathy (PCV); soft drusen
ID MACULAR DEGENERATION; DRUSEN; THICKNESS; DIAGNOSIS
AB Purpose: To report the prevalence of pachydrusen and their relationship with subfoveal choroidal thickness (SFCT) and large choroidal vessel layer thickness (SF-LCVT) in eyes with polypoidal choroidal vasculopathy (PCV) and their fellow eyes. Methods: The case records of 50 patients (99 eyes; 59 PCV and 40 fellow eyes) were retrospectively analyzed for the presence of pachydrusen and other drusen types such as soft drusen. The diagnosis was established using colour fundus photography and optical coherence tomography (OCT). SFCT and SF-LCVT were measured and correlated with the different types of drusen. Results: The mean age of the study cohort was 62.26 +/- 10.67 years and included 27 males and 23 females. Pachydrusen and soft drusen were seen in 14 (PCV: 8 and fellow eyes: 6) and 8 eyes (PCV: 2 and fellow eyes: 6) respectively. The mean SFCT and SF-LCVT in the eyes with and without pachydrusen was not significanty different (280.29 +/- 103.11 mu vs. 292.63 +/- 87.17 mu; P = 0.63 and 180.57 +/- 59.20 vs. 173.73 +/- 54.86 mu; P = 0.67, respectively). The pachydrusen were most commonly located near the vascular arcades and showed scattered distribution pattern. Though SFCT and SF-LCVT was lower in the eyes with soft drusen compared to eyes with pachydrusen, it failed to reach statistical significance (SFCT, P = 0.1 and SF-LCVT, P = 0.06). Conclusion: The prevalence of pachydrusen in PCV and their fellow eyes is lower in Indian population suggestive of ethnic variations. SFCT and SF-LCVT was not noted to vary signifcantly in eyes with and without pachydrusen in this study cohort.
C1 [Singh, Sumit Randhir; Chakurkar, Renuka; Goud, Abhilash; Rasheed, Mohammed Abdul; Vupparaboina, Kiran Kumar; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 34, Telangana, India.
   [Singh, Sumit Randhir] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 34, Telangana, India.
EM jay.chhablani@gmail.com
OI Chhablani, Jay/0000-0003-1772-3558; Abdul Rasheed,
   Mohammed/0000-0002-6417-2552
CR Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Friedman D, 2012, RETINA-J RET VIT DIS, V32, P19, DOI 10.1097/IAE.0b013e318219e5e9
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Green W R, 1999, Mol Vis, V5, P27
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoshimura Nagahisa, 2016, Nippon Ganka Gakkai Zasshi, V120, P163
NR 31
TC 9
Z9 9
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2019
VL 67
IS 7
BP 1121
EP +
DI 10.4103/ijo.IJO_1757_18
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IG3FI
UT WOS:000473687700031
PM 31238425
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kameda, T
   Tsujikawa, A
   Otani, A
   Sasahara, M
   Gotoh, N
   Tamura, H
   Yoshimura, N
AF Kameda, Takanori
   Tsujikawa, Akitaka
   Otani, Atsushi
   Sasahara, Manabu
   Gotoh, Norimoto
   Tamura, Hiroshi
   Yoshimura, Nagahisa
TI Polypoidal choroidal vasculopathy examined with en face optical
   coherence tomography
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal vasculopathy; idiopathic
   polypoidal choroidal vasculopathy; optical coherence tomography;
   retinal-imaging
ID CENTRAL SEROUS CHORIORETINOPATHY; PIGMENT EPITHELIAL DETACHMENTS;
   CLINICOPATHOLOGICAL CORRELATION; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; JAPANESE PATIENTS; FEATURES; IPCV
AB Background: To study the morphologic features of polypoidal choroidal vasculopathy (PCV) with the use of en face optical coherence tomography (OCT).
   Methods: We reviewed retrospectively 57 eyes of 57 patients with PCV. The macular region was examined with OCT en face planes scanned at different sequential depths, following which detailed scanning was performed of arbitrarily selected longitudinal planes.
   Results: In 48 of the cases (84.2%), en face OCT allowed us to detect round protrusions of the retinal pigment epithelium (RPE) that corresponded to the polypoidal lesions seen on indocyanine green angiography (ICGA); the branching vascular networks seen on ICGA often induced slight elevation of the overlying RPE, which typically assumed a geographical shape. In 30 cases (52.6%), branching vascular networks were detected as elevations of the RPE. With en face OCT, serous pigment epithelial detachments, most of which were seen as round protrusions of the RPE, were often accompanied by adjacent smaller round protrusions of the RPE, consistent with polypoidal lesions. These protrusions of the RPE were often fused and typically appeared as a 'snowman'. Subsequent longitudinal examination revealed the polypoidal lesions to be sharp protrusions of the RPE with moderate inner reflectivity. Consistent with the location of the branching vascular network, a highly reflective line was seen often just beneath the slightly elevated reflective line of RPE.
   Conclusions: En face examination using OCT has an advantage in screening lesions of PCV and in examination of the detailed relationship of each component of these lesions.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Hirami Y, 2007, CLIN EXP OPHTHALMOL, V35, P225, DOI 10.1111/j.1442-9071.2006.01447.x
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mavrofrides EC, 2004, OPTICAL COHERENCE TO, P243
   Mitarai K, 2006, GRAEF ARCH CLIN EXP, V244, P1415, DOI 10.1007/s00417-006-0277-7
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Velthoven MEJ, 2005, BRIT J OPHTHALMOL, V89, P1483, DOI 10.1136/bjo.2005.073056
   Van Velthoven MEJ, 2006, RETINA-J RET VIT DIS, V26, P129, DOI 10.1097/00006982-200602000-00001
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 33
TC 22
Z9 23
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP-OCT
PY 2007
VL 35
IS 7
BP 596
EP 601
DI 10.1111/j.1442-9071.2007.01554.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 213XJ
UT WOS:000249700300003
PM 17894678
DA 2022-11-30
ER

PT J
AU Wong, CW
   Cheung, CMG
   Mathur, R
   Li, X
   Chan, CM
   Yeo, I
   Wong, E
   Lee, SY
   Wong, D
   Wong, TY
AF Wong, Chee Wai
   Cheung, Chui Ming Gemmy
   Mathur, Ranjana
   Li, Xiang
   Chan, Choi Mun
   Yeo, Ian
   Wong, Edmund
   Lee, Shu Yen
   Wong, Doric
   Wong, Tien Yin
TI THREE-YEAR RESULTS OF POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH
   PHOTODYNAMIC THERAPY Retrospective Study and Systematic Review
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   photodynamic therapy; vision; outcome
ID ENDOTHELIAL GROWTH-FACTOR; SUBMACULAR HEMORRHAGE SECONDARY; INDOCYANINE
   GREEN ANGIOGRAPHY; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   TRIAMCINOLONE ACETONIDE; FOLLOW-UP; JAPANESE PATIENTS; VISUAL OUTCOMES;
   CLINICAL CHARACTERISTICS
AB Purpose:To evaluate the 3-year outcome in eyes with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy with verteporfin.Methods:Retrospective study and review of the literature. We performed a retrospective study of patients with PCV who were treated with photodynamic therapy between January 2007 and December 2008. Patients were excluded if they had received photodynamic therapy before the study period, but those who received previous treatment with other modalities (thermal laser or intravitreal therapies) were allowed. The main outcome measures were best-corrected visual acuity, repeat photodynamic therapy, and recurrence of PCV at the end of Years 1, 2, and 3. We further conducted a systematic review of the literature using the terms polypoidal choroidal vasculopathy and photodynamic therapy and compared the visual outcome of studies over 3 years using meta-analytical methods.Results:The retrospective study included 68 eyes. The mean best-corrected visual acuity was 0.73 0.56 logMAR (20/107, Snellen equivalent) at baseline, 0.73 +/- 0.70 logMAR (20/107, Snellen equivalent) at 1 year, 0.96 +/- 0.76 logMAR (20/182, Snellen equivalent) at 2 years, and 1.07 +/- 0.81 logMAR (20/235, Snellen equivalent) at 3 years. The cumulative recurrence rates of PCV were 16.1% (1 year), 34.9% (2 years), and 52.7% (3 years) and eyes with recurrence were more likely to suffer 3 lines loss compared with eyes without recurrence (63.2 vs. 17.6%, P = 0.006). The systematic review summarized results from 48 published studies and our retrospective study. The pooled analysis from 29 studies (316 eyes reporting the 3-year visual outcome) reported mean best-corrected visual acuity improvement of 0.115 logMAR at 1 year (n = 1,669), 0.066 logMAR at 2 years (n = 701), and 0.027 logMAR at 3 years (n = 316). Reported recurrence rates were 5.9% to 50.0% after 1 year, 9.1% to 83.3% after 2 years, and 40.0% to 78.6% after 3 years or longer of follow-up.Conclusion:The visual outcome in eyes with PCV was stable until 2 years, but the outcome at 3 years worsened, particularly in eyes that experienced recurrence.
C1 [Wong, Chee Wai; Cheung, Chui Ming Gemmy; Mathur, Ranjana; Li, Xiang; Chan, Choi Mun; Yeo, Ian; Wong, Edmund; Lee, Shu Yen; Wong, Doric; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Li, Xiang; Wong, Tien Yin] Duke NUS Grad Med Sch, Acad Clin Program Ophthalmol & Visual Sci, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Li, Xiang; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Li, Xiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2014, GRAEFES ARCH CLIN EX
   Hata Masayuki, 2012, Nippon Ganka Gakkai Zasshi, V116, P937
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imasawa M, 2009, JPN J OPHTHALMOL, V53, P588, DOI 10.1007/s10384-009-0732-1
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Miki A, 2013, JPN J OPHTHALMOL, V57, P301, DOI 10.1007/s10384-013-0237-9
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Saito K, 2009, JPN J OPHTHALMOL, V53, P512, DOI 10.1007/s10384-009-0703-6
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yanagidaira Tomoko, 2008, Nippon Ganka Gakkai Zasshi, V112, P1068
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 77
TC 45
Z9 46
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2015
VL 35
IS 8
BP 1577
EP 1593
DI 10.1097/IAE.0000000000000499
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP4HX
UT WOS:000359843700011
PM 25719986
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Silver, RE
   Rosner, B
AF Seddon, Johanna M.
   Silver, Rachel E.
   Rosner, Bernard
TI Response to AREDS supplements according to genetic factors: survival
   analysis approach using the eye as the unit of analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ADVANCED MACULAR DEGENERATION; HIGH-RISK; PROGRESSION; CFH;
   ANTIOXIDANTS; ZINC; ASSOCIATION; OMEGA-3-FATTY-ACIDS; SUSCEPTIBILITY;
   GENOTYPES
AB Background/aims The Age-Related Eye Disease Study (AREDS) reported the beneficial impact of antioxidant and zinc supplements on the risk of progression to advanced stages of age-related macular degeneration (AMD). We evaluated the role of genetic variants in modifying the relationship between supplementation and progression to advanced AMD.
   Methods Among 4124 eyes (2317 subjects with a genetic specimen), 882 progressed from no AMD, early or intermediate AMD to overall advanced disease, including geographic atrophy (GA) and neovascular disease (NV) over the course of the clinical trial. Survival analysis using individual eyes as the unit of analysis was used to assess the effect of supplementation on AMD outcomes, with adjustment for demographic, environmental, ocular and genetic covariates. Interaction effects between supplement groups and individual complement factor H (CFH) Y402H and age-related maculopathy susceptibility 2 (ARMS2) genotypes, and composite genetic risk groups combining the number of risk alleles for both loci, were evaluated for their association with progression.
   Results Among antioxidant and zinc supplement users compared with the placebo group, subjects with a nonrisk genotype for CFH (TT) had a lower risk of progression to advanced AMD (HR: 0.55, 95% CI 0.32 to 0.95, p=0.033). No significant treatment effect was apparent among subjects who were homozygous for the CFH risk allele (CC). A protective effect was observed among high-risk ARMS2 (TT) carriers (HR: 0.52, 95% CI 0.33 to 0.82, p=0.005). Similar results were seen for the NV subtype but not GA.
   Conclusions The effectiveness of antioxidant and zinc supplementation appears to differ by genotype. Further study is needed to determine the biological basis for this interaction.
C1 [Seddon, Johanna M.; Silver, Rachel E.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Rosner, Bernard] Harvard Univ, Harvard Med Sch, Channing Div Network Med, Boston, MA 02115 USA.
C3 Tufts Medical Center; Tufts University; Tufts University; Harvard
   University; Harvard Medical School
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health [R01-EY11309, R01-EY022445]; Massachusetts
   Lions Eye Research Fund, New Bedford, MA; Research to Prevent Blindness,
   New York, NY; Age-Related Macular Degeneration Research Fund, Ophthalmic
   Epidemiology and Genetics Service, Tufts Medical Center, Tufts
   University School of Medicine, Boston, MA; NATIONAL EYE INSTITUTE
   [R01EY011309, R01EY022445] Funding Source: NIH RePORTER
FX This work is supported by R01-EY11309 and R01-EY022445 from the National
   Institutes of Health; the Massachusetts Lions Eye Research Fund, New
   Bedford, MA; unrestricted grants from Research to Prevent Blindness, New
   York, NY and the Age-Related Macular Degeneration Research Fund,
   Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center,
   Tufts University School of Medicine, Boston, MA.
CR Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 27
TC 39
Z9 39
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1731
EP 1737
DI 10.1136/bjophthalmol-2016-308624
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500026
PM 27471039
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ladas, ID
   Karagiannis, DA
   Georgalas, I
   Rouvas, AA
   Moschos, MM
   Apostolopoulos, M
AF Ladas, ID
   Karagiannis, DA
   Georgalas, I
   Rouvas, AA
   Moschos, MM
   Apostolopoulos, M
TI Polypoidal choroidal vasculopathy associated with Doyne's familial
   choroiditis: treatment with thermal laser
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; Doyne's familial honeycomb
   choroiditis; indocyanine green angiography; choroidal neovascularization
AB PURPOSE. To report the unusual occurrence of polypoidal choroidal vasculopathy (PCV) in a patient with Doyne's familial honeycomb choroiditis (DFHC) and its course after laser treatment.
   DESIGN. Interventional case report.
   METHODS. Indocyanine green (ICG) angiography guided laser was performed on active polypoidal lesions.
   RESULTS. A 45-year-old man with a 15-year history of bilateral DFCH and a scarred macular choroidal neovascularization in the right eye (RE) was referred to us with exudative maculopathy in the left eye (LE). His best-corrected visual acuity (BCVA) was 201800 in the RE and 20140 in the LE. ICG angiography revealed a picture that was characteristic for PCV in both eyes. ICG guided argon green laser was performed on the active parapapillary and perifoveal polypoidal lesions of the LE. Eight months after the laser photocoagulation treatment, the macular exudative lesions had subsided and the BCVA improved to 20/20. The favorable anatomic and functional results have remained stable over 3 years.
   CONCLUSIONS. This is, to our knowledge, the first case of a PCV that occurred secondary to DFHC.
C1 Univ Athens, Sch Med, Dept Ophthalmol, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens
RP Ladas, ID (通讯作者)，8 Meg Alexandrou Str, GR-15236 Athens, Greece.
EM ladas@ath.forthnet.gr
RI Georgalas, Ilias/AAD-5946-2019
OI Georgalas, Ilias/0000-0002-6171-5865
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas DD, 2003, OPHTHALMOLOGICA, V217, P194, DOI 10.1159/000068973
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   PEARCE WG, 1988, BR J OPHTHALMOL, V528, P73
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 10
TC 5
Z9 5
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2004
VL 14
IS 3
BP 264
EP 268
DI 10.1177/112067210401400313
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 829CD
UT WOS:000222019900013
PM 15206654
DA 2022-11-30
ER

PT J
AU Kim, JY
   Son, WY
   Kim, RY
   Kim, M
   Park, YG
   Park, YH
AF Kim, Joo Young
   Son, Woo Young
   Kim, Rae Young
   Kim, Mirinae
   Park, Young Gun
   Park, Young-Hoon
TI Recurrence and visual prognostic factors of polypoidal choroidal
   vasculopathy: 5-year results
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; BINARIZATION; ASSOCIATION;
   EYES
AB This retrospective study aimed to evaluate the factors affecting recurrence and visual prognosis in patients with treatment-naive subfoveal polypoidal choroidal vasculopathy (PCV). Patients who had received three consecutive intravitreal injections of ranibizumab or aflibercept and had reached remission were enrolled. They were divided into a group without recurrence (group 1, 26 eyes) and a group with recurrence (group 2, 121 eyes) and followed up for at least 5 years. Patients in group 2 received additional treatment for worsening. Logistic regression analysis revealed that a young age of onset (P = 0.001), high choroidal vascularity index (CVI; P = 0.019), and presence of choroidal vascular hyperpermeability (CVH; P = 0.037) were associated with a low risk of recurrence. Multiple regression analysis revealed that recurrence (P = 0.001), greatest linear dimension (P = 0.003), and polyp configuration (single or cluster; P = 0.043) were associated with final visual acuity. Patients without recurrence had a lower age of onset and higher CVI than those with recurrence, and they tended to have CVH. In addition, patients with recurrence, large lesion, and cluster polyps had worse final visual acuity than those without these factors. CVI and CVH may be used to predict recurrence of PCV.
C1 [Kim, Joo Young; Son, Woo Young; Kim, Rae Young; Kim, Mirinae; Park, Young Gun; Park, Young-Hoon] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, 222 Banpo Daero, Seoul 06591, South Korea.
   [Kim, Joo Young; Kim, Rae Young; Kim, Mirinae; Park, Young Gun; Park, Young-Hoon] Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea
RP Park, YH (通讯作者)，Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, 222 Banpo Daero, Seoul 06591, South Korea.; Park, YH (通讯作者)，Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul, South Korea.
EM parkyh@catholic.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea [NRF-2020R1F1A1074898]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF-2020R1F1A1074898). The
   funders had no role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agrawal R., 2010, SCI REP UK, V6, P1023
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Liu B, 2019, CLIN EXP OPHTHALMOL, V47, P631, DOI 10.1111/ceo.13467
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 1
Z9 1
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 3
PY 2021
VL 11
IS 1
AR 21572
DI 10.1038/s41598-021-00904-4
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WR3PJ
UT WOS:000714415600020
PM 34732787
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Lee, TG
   Chang, YS
   Kim, CG
   Cho, SW
AF Kim, Jae Hui
   Lee, Tae Gon
   Chang, Young Suk
   Kim, Chul Gu
   Cho, Sung Won
TI Short-term choroidal thickness changes in patients treated with either
   ranibizumab or aflibercept: a comparative study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION; MACULAR
   DEGENERATION RANIBIZUMAB; GROWTH-FACTOR THERAPY; VASCULAR
   HYPERPERMEABILITY; INTRAVITREAL AFLIBERCEPT; HEALTHY-SUBJECTS;
   VASCULOPATHY; EFFICACY; BEVACIZUMAB
AB Purpose To compare, in neovascular age-related macular degeneration (AMD) patients, short-term choroidal thickness changes in eyes treated using ranibizumab with those in eyes treated using aflibercept.
   Methods This retrospective, observational study included 240 eyes from 240 patients who had been diagnosed with treatment-naive neovascular AMD and treated using three monthly injections of either ranibizumab (ranibizumab group) or aflibercept (aflibercept group). The choroidal thickness change between the time of diagnosis and 3 months later was compared between the two groups. Eyes were then classified into three disease groups: typical neovascular AMD, polypoidal choroidal vasculopathy (PCV) and retinal angiomatous proliferation (RAP). Within each disease group, choroidal thickness change was again compared between the two treatment groups.
   Results In the ranibizumab group (n=155), the mean choroidal thicknesses at diagnosis and at 3 months were 255.3 +/- 103.9 mu m and 242.9 +/- 104.8 mu m, respectively. In the aflibercept group (n=85), the values were 277.5 +/- 119.1 mu m and 254.7 +/- 114.5 mu m, respectively. The decrease was significantly greater in the aflibercept group (p<0.001). In the PCV group, the decrease was greater in the aflibercept group (p=0.001), whereas the difference was not significant in either the typical neovascular AMD group or the RAP group.
   Conclusions A greater decrease in choroidal thickness was noted in eyes treated with aflibercept than in eyes treated with ranibizumab. This difference was more marked in PCV than in other subtypes of neovascular AMD.
C1 [Kim, Jae Hui; Lee, Tae Gon; Kim, Chul Gu; Cho, Sung Won] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Lee, TG (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM tglee85@naver.com
FU Kim's Eye Hospital Research Center
FX This study is supported by Kim's Eye Hospital Research Center.
CR Akay F, 2016, EUR J OPHTHALMOL, V26, P152, DOI 10.5301/ejo.5000675
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Vural AD, 2014, RETINA-J RET VIT DIS, V34, P1223, DOI 10.1097/IAE.0000000000000043
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 31
TC 28
Z9 28
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1634
EP 1639
DI 10.1136/bjophthalmol-2015-308074
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500009
PM 26951770
DA 2022-11-30
ER

PT J
AU Blinder, KJ
   Bradley, S
   Bressler, NM
   Bressler, SB
   Donati, G
   Hao, Y
   Ma, C
   Menchini, U
   Miller, J
   Potter, MJ
   Pournaras, JC
   Reaves, A
   Rosenfeld, PJ
   Strong, HA
   Stur, M
   Su, XY
   Virgili, G
AF Blinder, KJ
   Bradley, S
   Bressler, NM
   Bressler, SB
   Donati, G
   Hao, Y
   Ma, C
   Menchini, U
   Miller, J
   Potter, MJ
   Pournaras, JC
   Reaves, A
   Rosenfeld, PJ
   Strong, HA
   Stur, M
   Su, XY
   Virgili, G
CA TAP Study Grp
   VIP Study Grp
TI Effect of lesion size, visual acuity, and lesion composition on visual
   acuity change with and without verteporfin therapy for choroidal
   neovascularization secondary to age-related macular degeneration: TAP
   and VIP report no. 1
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; PHOTODYNAMIC THERAPY; PHOTOCOAGULATION
AB PURPOSE: To determine whether differences in base. line lesion size and visual acuity might explain differing results found in three different lesion compositions (predominantly classic, minimally classic, and occult with no classic) among three placebo-controlled, randomized clinical trials evaluating photodynamic therapy with verteporfin (Visudyne, Novartis AG), also termed verteporfin therapy, in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   .METHODS: Exploratory analyses were conducted in patients with predominantly classic or minimally classic lesions at enrollment in the Treatment of AMD with Photodynamic Therapy (TAP) Investigation and in AMD patients with occult with no classic CNV in the Verteporfin In Photodynamic Therapy (VIP) Trial. Baseline characteristics of patients among these three lesion compositions were compared. In addition, multiple linear regression modeling was used to explore the effect of baseline lesion size, visual acuity, and lesion composition on mean change in visual acuity from baseline to 24 months. .
   RESULTS: At baseline, the mean size of predominantly classic lesions (3-4 disk areas) was smaller than that of minimally classic (4.7 disk areas) and occult with no classic lesions (4.3 disk areas). In the multiple linear regression model of individual lesion compositions, there was a significant treatment by-lesion,size interaction for minimally classic and occult with no classic lesions, but not for predominantly classic lesions. Interaction between treatment and baseline visual acuity was not significant for any lesion composition. Small verteporfin treated lesions lost less vision than large verteporfin-treated lesions in each lesion composition. In the multiple linear regression model that included all lesion compositions, lesion size was a more significant predictive factor for the magnitude of treatment benefit than either lesion composition or visual acuity. Smaller (4.0 disk areas or less) minimally classic and occult with no classic lesions had similar visual acuity outcomes to those observed in predominantly classic lesions.
   CONCLUSIONS: Based on exploratory analyses, lesion size in the TAP Investigation and VIP Trial was an important predictor of the magnitude of treatment benefit with verteporfin therapy in occult with no classic and minimally classic lesion compositions. In patients with AMD, treating smaller rather than larger neovascular lesions, regardless of lesion composition, likely will result in a better level of visual acuity. (C) 2003 by Elsevier Inc. All rights reserved.
RP Bressler, NM (通讯作者)，550 N Broadway,Suite 115, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
RI Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989; Miller, Joan/0000-0003-2046-3996
CR *AM AC OPHTH RET, 2002, PREF PRACT PATT AG R
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   *SAS I INC, 1989, SAS STAT US GUID VER, V2, P891
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 11
TC 240
Z9 257
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2003
VL 136
IS 3
BP 407
EP 418
DI 10.1016/S0002-9394(03)00223-X
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 714XT
UT WOS:000184940100001
PM 12967792
DA 2022-11-30
ER

PT J
AU Hua, R
   Duan, JN
   Zhang, MX
AF Hua, Rui
   Duan, Jianan
   Zhang, Meixia
TI Pachychoroid Spectrum Disease: Underlying Pathology, Classification, and
   Phenotypes
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Aneurysms; polypoidal choroidal vasculopathy; pachychoroid spectrum
   disease; subretinal fluid; type-2 choroidal neovascularization
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY; CENTRAL
   SEROUS CHORIORETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; NEOVASCULARIZATION; EYES; ANGIOGRAPHY; FEATURES;
   NEOVASCULOPATHY
AB Purpose Pachychoroid spectrum disease encompasses a set of macular disorders secondary to an abnormally thick choroid. However, the pathological process underlying pachychoroid spectrum disease and its overlap with age-related macular degeneration (AMD) remain unclear. This review aimed to understand the underlying pathology, classification, and phenotypes of pachychoroid spectrum disease. Methods This comprehensive literature review was performed based on a search of peer-reviewed published papers relevant to the current knowledge of pachychoroid disease spectrum. Results Pachychoroid is primarily a bilateral phenomenon; the main pathological lesions include choriocapillaris attenuation and abnormally dilated pachyvessels. Chronic central serous chorioretinopathy (CSC) and pachychoroid neovasculopathy (PNV) show similar morphological changes and angiogenic cytokine levels. The subretinal fluid in PNV may not accurately indicate PNV activity. Besides, types 1 and 2 of choroidal neovascularization (CNV) may be involved in primary pachychoroidal disease. Both choroidal arteriosclerosis and higher hydrostatic pressure contribute to hyalinized choroidal arteries and aneurysmal dilatations, resulting in PNV progression to polypoidal choroidal vasculopathy (PCV). Thus, pachychoroid-related type 2 CNV and chronic CSC could be considered as PNV (IIIc) and as a precursor of PNV (IIIa), respectively. Tangled PCV on optical coherence tomography angiography that fails to develop aneurysms should be classified as a subtype of PNV or a forme fruste of PCV. Conclusions Multiple disorders of the pachychoroid spectrum are considered as a continuous disease process, ultimately stimulated by choroidal malfunction. PCV overlaps both AMD and pachychoroid disease, especially for thin-choroid and bilateral types. The terminology and classification of pachychoroid spectrum disease should be used cautiously.
C1 [Hua, Rui; Duan, Jianan; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
   [Hua, Rui] China Med Univ, Dept Ophthalmol, Hosp 1, Shenyang, Peoples R China.
   [Hua, Rui; Duan, Jianan; Zhang, Meixia] Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.
C3 Sichuan University; China Medical University; Sichuan University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Ophthalmol, 37 Guoxue Lane, Chengdu 610041, Peoples R China.
EM coretina@gmail.com
FU Beijing Bethune Charitable Foundation [AF-OG-03-1.1-03]; 1.3.5 project
   for disciplines of excellence, West China Hospital, Sichuan University
   [ZYJC21025]
FX This study was funded by the Beijing Bethune Charitable Foundation
   [AF-OG-03-1.1-03], and 1.3.5 project for disciplines of excellence, West
   China Hospital, Sichuan University [ZYJC21025].
CR Afanasyeva M A, 2019, Vestn Oftalmol, V135, P293, DOI 10.17116/oftalma2019135052293
   Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Anzidei Rossella, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-225571
   Ayachit G, 2018, INDIAN J OPHTHALMOL, V66, P1022, DOI 10.4103/ijo.IJO_180_18
   Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Baek J, 2019, GRAEF ARCH CLIN EXP, V257, P1863, DOI 10.1007/s00417-019-04388-x
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Baek J, 2019, RETINA-J RET VIT DIS, V39, P1571, DOI 10.1097/IAE.0000000000002188
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Batioglu F, 2019, TURK OFTALMOL DERG, V49, P226, DOI 10.4274/tjo.galenos.2019.38073
   Bicer O, 2020, OSLI RETINA, V51, P640, DOI 10.3928/23258160-20201104-06
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77566-1
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Chen ZJ, 2021, BRIT J OPHTHALMOL, V105, P1035, DOI 10.1136/bjophthalmol-2019-315746
   Chen ZY, 2019, GRAEF ARCH CLIN EXP, V257, P2111, DOI 10.1007/s00417-019-04374-3
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Demirel S, 2021, EUR J OPHTHALMOL, V31, P184, DOI 10.1177/1120672119887095
   Demirel S, 2017, GRAEF ARCH CLIN EXP, V255, P2317, DOI 10.1007/s00417-017-3793-8
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Ersoz MG, 2018, BRIT J OPHTHALMOL, V102, P473, DOI 10.1136/bjophthalmol-2017-310724
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P957, DOI 10.1097/IAE.0000000000001655
   Eymard P, 2021, ACTA OPHTHALMOL, V99, P533, DOI 10.1111/aos.14664
   Fan DX, 2019, PHOTODIAGN PHOTODYN, V26, P1, DOI 10.1016/j.pdpdt.2019.02.004
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   Ghadiali Quraish, 2016, Retin Cases Brief Rep, V10, P293, DOI 10.1097/ICB.0000000000000301
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hikichi T, 2021, EYE, V35, P3367, DOI 10.1038/s41433-021-01418-z
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Hwang H, 2020, RETINA-J RET VIT DIS, V40, P1724, DOI 10.1097/IAE.0000000000002662
   Iacono P, 2021, EUR J OPHTHALMOL, V31, pNP15, DOI 10.1177/1120672119892428
   Ijuin N, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01443-8
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Jung JJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.50
   Kang NY, 2021, GRAEF ARCH CLIN EXP, V259, P1803, DOI 10.1007/s00417-021-05104-4
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Kato Y, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.39
   Kim IK, 2021, BRIT J OPHTHALMOL, V105, P856, DOI 10.1136/bjophthalmol-2020-316108
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lavinsky Fabio, 2016, Int J Retina Vitreous, V2, P25
   Lee A, 2020, GRAEF ARCH CLIN EXP, V258, P1921, DOI 10.1007/s00417-020-04772-y
   Lee GW, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83650-x
   Lee JH, 2016, OPHTHALMOLOGY, V123, P2066, DOI 10.1016/j.ophtha.2016.06.033
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee MW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229134
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lee SY, 2017, JAMA OPHTHALMOL, V135, P1177, DOI 10.1001/jamaophthalmol.2017.3790
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Lim HB, 2021, ACTA OPHTHALMOL, V99, pE117, DOI 10.1111/aos.14522
   Lotery A, 2020, LANCET, V395, P294, DOI 10.1016/S0140-6736(19)32981-2
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Matsumoto H, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246115
   Matsumoto H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75789-w
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   Mikhail Mikel, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS98, DOI 10.1097/ICB.0000000000000426
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nagia L, 2016, INVEST OPHTH VIS SCI, V57, P4679, DOI 10.1167/iovs.16-19315
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Pichi F, 2018, INT OPHTHALMOL, V38, P975, DOI 10.1007/s10792-017-0547-x
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Ryan, 2006, RETINA-J RET VIT DIS, V1
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Saito M, 2015, INVEST OPHTH VIS SCI, V56, P6515, DOI 10.1167/iovs.15-17246
   Saito M, 2013, BRIT J OPHTHALMOL, V97, P775, DOI 10.1136/bjophthalmol-2012-302349
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Savastano MC, 2021, RETINA-J RET VIT DIS, V41, P302, DOI 10.1097/IAE.0000000000002810
   Schworm B, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65370-w
   Seo EJ, 2021, RETINA-J RET VIT DIS, V41, P987, DOI 10.1097/IAE.0000000000002980
   Sheth J, 2018, INDIAN J OPHTHALMOL, V66, P1796, DOI 10.4103/ijo.IJO_377_18
   Sia DIT, 2013, INT OPHTHALMOL, V33, P67, DOI 10.1007/s10792-012-9681-7
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Simao Jorge M, 2021, Ophthalmologica, V244, P315, DOI 10.1159/000515295
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P679, DOI 10.1097/IAE.0000000000002988
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   Tagawa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73303-w
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tateno Y, 2016, OPHTHALMIC GENET, V37, P177, DOI 10.3109/13816810.2015.1020557
   Terao N, 2018, INVEST OPHTH VIS SCI, V59, P5924, DOI 10.1167/iovs.18-25517
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YOSHIOKA H, 1982, OPHTHALMOLOGICA, V185, P168, DOI 10.1159/000309239
   Yun C, 2019, GRAEF ARCH CLIN EXP, V257, P57, DOI 10.1007/s00417-018-4179-2
   Zhang Fuyan, 2018, Retin Cases Brief Rep, V12 Suppl 1, pS110, DOI 10.1097/ICB.0000000000000658
NR 109
TC 2
Z9 2
U1 4
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2021
VL 46
IS 10
BP 1437
EP 1448
DI 10.1080/02713683.2021.1942073
EA AUG 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YZ2DH
UT WOS:000680264500001
PM 34114902
DA 2022-11-30
ER

PT J
AU Xu, YP
   Yan, K
   Kim, JM
   Wang, XY
   Li, CY
   Su, L
   Yu, SQ
   Xu, X
   Feng, DD
AF Xu, Yupeng
   Yan, Ke
   Kim, Jinman
   Wang, Xiuying
   Li, Changyang
   Su, Li
   Yu, Suqin
   Xu, Xun
   Feng, Dagan David
TI Dual-stage deep learning framework for pigment epithelium detachment
   segmentation in polypoidal choroidal vasculopathy
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; RETINAL LAYER;
   AUTOMATIC SEGMENTATION; EXUDATIVE AMD; IMAGES; QUANTIFICATION; NETWORKS
AB Worldwide, polypoidal choroidal vasculopathy (PCV) is a common vision-threatening exudative maculopathy, and pigment epithelium detachment (PED) is an important clinical characteristic. Thus, precise and efficient PED segmentation is necessary for PCV clinical diagnosis and treatment. We propose a dual-stage learning framework via deep neural networks (DNN) for automated PED segmentation in PCV patients to avoid issues associated with manual PED segmentation (subjectivity, manual segmentation errors, and high time consumption). The optical coherence tomography scans of fifty patients were quantitatively evaluated with different algorithms and clinicians. Dual-stage DNN outperformed existing PED segmentation methods for all segmentation accuracy parameters, including true positive volume fraction (85.74 +/- 8.69%), dice similarity coefficient (85.69 +/- 8.08%), positive predictive value (86.02 +/- 8.99%) and false positive volume fraction (0.38 +/- 0.18%). Dual-stage DNN achieves accurate PED quantitative information, works with multiple types of PEDs and agrees well with manual delineation, suggesting that it is a potential automated assistant for PCV management. (C) 2017 Optical Society of America
C1 [Xu, Yupeng; Su, Li; Yu, Suqin; Xu, Xun] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp, Shanghai 200080, Peoples R China.
   [Xu, Yupeng; Su, Li; Yu, Suqin; Xu, Xun] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.
   [Yan, Ke; Kim, Jinman; Wang, Xiuying; Li, Changyang; Feng, Dagan David] Univ Sydney, Biomed & Multimedia Informat Technol BMIT Res Grp, Sydney, NSW 2006, Australia.
C3 Shanghai Jiao Tong University; University of Sydney
RP Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp, Shanghai 200080, Peoples R China.; Xu, X (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.
EM drxuxun@sjtu.edu.cn
RI 俞, 素勤/HDO-8369-2022
OI Wang, Xiu Ying/0000-0001-7160-5929; kim, jinman/0000-0001-5960-1060; Xu,
   Yupeng/0000-0002-4788-7003
FU National Natural Science Foundation of China (NSFC) [81570851,
   81273424]; Project of the National Key Research Program on Precision
   Medicine [2016YFC0904800]
FX National Natural Science Foundation of China (NSFC) (81570851, 81273424)
   and Project of the National Key Research Program on Precision Medicine
   (2016YFC0904800)
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Buades A, 2005, PROC CVPR IEEE, P60, DOI 10.1109/cvpr.2005.38
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chan EW, 2017, AM J OPHTHALMOL, V177, P195, DOI 10.1016/j.ajo.2016.12.008
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Cohen SM, 1996, RETINA-J RET VIT DIS, V16, P467, DOI 10.1097/00006982-199616060-00001
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Doi K, 2007, COMPUT MED IMAG GRAP, V31, P198, DOI 10.1016/j.compmedimag.2007.02.002
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2013, IEEE T MED IMAGING, V32, P2034, DOI 10.1109/TMI.2013.2271904
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gass JDM, 2005, RETINA-J RET VIT DIS, V25, P304, DOI 10.1097/00006982-200504000-00009
   Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guo YR, 2016, IEEE T MED IMAGING, V35, P1077, DOI 10.1109/TMI.2015.2508280
   Hu PJ, 2016, PHYS MED BIOL, V61, P8676, DOI 10.1088/1361-6560/61/24/8676
   Huang L, 2017, COMPUT METH PROG BIO, V143, P67, DOI 10.1016/j.cmpb.2017.02.013
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li GB, 2016, PROC CVPR IEEE, P478, DOI 10.1109/CVPR.2016.58
   Li H., 2014, ARXIV PREPRINT ARXIV
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Milletari F, 2016, INT CONF 3D VISION, P565, DOI 10.1109/3DV.2016.79
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Roberts P., INVEST OPHTHALMOL VI, V57, P1595
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Sun C., 2017, RTIF INTELL IN PRESS
   Sun ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21739
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Vedaldi A, 2015, MM'15: PROCEEDINGS OF THE 2015 ACM MULTIMEDIA CONFERENCE, P689, DOI 10.1145/2733373.2807412
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Yan K, 2016, IEEE ENG MED BIO, P635, DOI 10.1109/EMBC.2016.7590782
   Yu HC, 2016, OPT LETT, V41, P994, DOI 10.1364/OL.41.000994
   Yuan Y., 2017, IEEE T MED IMAGING, V99, P2695
   Zhang F, 2015, IEEE T GEOSCI REMOTE, V53, P2175, DOI 10.1109/TGRS.2014.2357078
NR 49
TC 36
Z9 38
U1 0
U2 25
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD SEP 1
PY 2017
VL 8
IS 9
BP 4061
EP 4076
DI 10.1364/BOE.8.004061
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA FF5IS
UT WOS:000409020600012
PM 28966847
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Haas, P
   Steindl, K
   Aggermann, T
   Schmid-Kubista, K
   Krugluger, W
   Hageman, GS
   Binder, S
AF Haas, Paulina
   Steindl, Kerstin
   Aggermann, Tina
   Schmid-Kubista, Katharina
   Krugluger, Walter
   Hageman, Gregory S.
   Binder, Susanne
TI Serum VEGF and CFH in Exudative Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Complement; Genetics; Neovascular;
   Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULAR
   MEMBRANES; RETINAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY;
   NITRIC-OXIDE; VARIANT; POLYMORPHISM; EXPRESSION; Y402H
AB Methods: Sixty-six AMD patients and 66 healthy age- and gender-matched controls were included in this case-control study. The serum VEGF165 was assayed by ELISA (R&D). Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism analysis. Chi-squared tests were used regarding the polymorphism, a t-test regarding the VEGF-levels.
   Results: Levels of serum VEGF165 were similar in both groups (p-value == 0.2112). Genotype frequency differed significantly between patients with exudative AMD and the healthy control group (p == 0.003136). The serum VEGF165 levels were similar irrespective of the presence of the CFH Y402H polymorphism (p == 0.4113) and independent of the specific genotype (p == 0.9634).
   Conclusion: In the present study, exudative AMD is not associated to serum VEGF165 levels; furthermore, our data does not establish a statistical link between VEGF165 and the CFH Y402H polymorphism.
C1 [Haas, Paulina; Steindl, Kerstin; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Rudolf Fdn Clin, A-1030 Vienna, Austria.
   [Haas, Paulina; Aggermann, Tina; Schmid-Kubista, Katharina; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, Vienna, Austria.
   [Krugluger, Walter] Rudolf Fdn Clin, Dept Clin Chem, Vienna, Austria.
   [Hageman, Gregory S.] Univ Utah, Ctr Translat Med Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 Ludwig Boltzmann Institute; Utah System of Higher Education; University
   of Utah
RP Haas, P (通讯作者)，Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Rudolf Fdn Clin, Juchgasse 25, A-1030 Vienna, Austria.
EM paulina.haas@wienkav.at
FU Med. wissenschaftlicher Fond des Buergermeisters der Stadt Wien [BGM
   07068]; NATIONAL EYE INSTITUTE [P30EY014800, R24EY017404] Funding
   Source: NIH RePORTER
FX This study was funded through govermental funding-Med.
   wissenschaftlicher Fond des Buergermeisters der Stadt Wien-BGM 07068.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   McColm J, 2004, MOL VIS, V10, P512
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlingemann RO, 1997, BRIT J OPHTHALMOL, V81, P501, DOI 10.1136/bjo.81.6.501
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Steinbrugger I, 2009, SPEKTRUM AUGENHEILKD, V23, P353, DOI 10.1007/s00717-009-0355-4
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 29
TC 10
Z9 10
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB
PY 2011
VL 36
IS 2
BP 143
EP 148
DI 10.3109/02713683.2010.533808
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 717XK
UT WOS:000287080800009
PM 21158586
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sorbera, LA
   Leeson, PA
   Castaner, J
   Bayes, M
AF Sorbera, LA
   Leeson, PA
   Castaner, J
   Bayes, M
TI Anecortave acetate - Treatment of age-related macular degeneration
   angiogenesis inhibitor
SO DRUGS OF THE FUTURE
LA English
DT Article
ID ANGIOSTATIC STEROIDS; CORNEAL NEOVASCULARIZATION; INTEGRINS; RAT
AB Angiogenesis is a normal process that is strictly controlled. If this is strictly controlled. If this fine control is disrupted, chronic activation can occur resulting in inappropriate tissue responses that can lead to pathologic neovascularization. Many chronic ocular diseases are due to chronic stimulation of angiogenesis and they are they major cause of blindness worldwide. Treatment for these ocular neovascular disorders should involve delay, arrest or prevention of new capillary proliferation with the absence of or the presence of only minimal adverse events. To date, surgery, last photocoagulation and glucocorticoid therapy are the usual treatment options. However, they may be ineffective, worsen the condition or, in the case of glucocorticoids, be associated with steroid-induced adverse events. Several classes of antiangiogenic agents have been described and they include antibiotics, polypeptides, polycations, polyanions, steroids, VEGF antagonists and integrin antagonists. Angiostatic steroids in particular have been shown to inhibit angiogenesis without the typical steroid activity that is associated with side effects. One such novel angiostatic steroid chosen for further development is anecortave acetate. It has shown excellent preclinical antiangiogenic efficacy and promising clinical activity as a treatment for ocular neovascular disorders.
C1 Prous Sci, Barcelona 08080, Spain.
RP Sorbera, LA (通讯作者)，Prous Sci, POB 540, Barcelona 08080, Spain.
CR BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   BENEZRA D, 1994, ANGIOGENESIS MOL BIO, P27282
   BULLARD LE, 1999, INVEST OPHTH VIS SCI, V40, P3255
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   CLARK AF, 2000, INVEST OPHTHALMOL VI, V41
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   DAMICO DJ, 2001, ANN M ASS RES VIS OP
   DAMICO DJ, 2002, ANN M ASS RES VIS OP
   DESMET MD, 2002, 4 INT S OC PHARM PHA, P47
   FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HESSLER EJ, Patent No. 4216159
   HOFMEISTER H, Patent No. 0181442
   HOFMEISTER H, Patent No. 4708823
   HOFMEISTER H, Patent No. 3434448
   LI WW, 1991, INVEST OPHTH VIS SCI, V32, P2898
   MA D, 1995, INVEST OPHTH VIS SCI, V36, P2265
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MILLER JW, 1993, OPHTHALMOLOGY, V100, P9
   Mousa SA, 1996, MOL MED TODAY, V2, P140, DOI 10.1016/1357-4310(96)88781-8
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   PROIA AD, 1993, EXP EYE RES, V57, P693, DOI 10.1006/exer.1993.1177
   REID JG, 1990, TETRAHEDRON LETT, V31, P3669
   ROBERTSON S, 1999, 12 C EUR SOC OPHTH J
   SACKS CE, Patent No. 0186948
   SANTOS CI, 1999, INVEST OPHTH VIS SCI, V40, P1778
   SHEPHARD KP, Patent No. 630394
   SHEPHARD KP, Patent No. 4041055
   SINGERMAN LJ, 2001, ANN M ASS RES VIS OP
   SLAKTER JS, 2002, ANN M ASS RES VIS OP
   SLAKTER JS, 2001, ANN M ASS RES VIS OP
   TOLMAN BL, 1995, INVEST OPHTH VIS SCI, V36, P454
   VANRHEENEN V, 1979, J ORG CHEM, V44, P1582, DOI 10.1021/jo01323a054
   WALKER JA, Patent No. 4568492
   WALKER JA, Patent No. 4600538
   WALKER JA, Patent No. 4357279
   2002, ALCON WEB SITE  1008
   2002, DAILYDRUGNEWS C 1002
NR 44
TC 0
Z9 0
U1 0
U2 1
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0377-8282
J9 DRUG FUTURE
JI Drug Future
PD NOV
PY 2002
VL 27
IS 11
BP 1039
EP 1048
DI 10.1358/dof.2002.027.11.707396
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 641WB
UT WOS:000180769100002
DA 2022-11-30
ER

PT J
AU Arruabarrena, C
   Toro, MD
   Onen, M
   Malyugin, BE
   Rejdak, R
   Tognetto, D
   Zweifel, S
   Giglio, R
   Teus, MA
AF Arruabarrena, Carolina
   Toro, Mario Damiano
   Onen, Mehmet
   Malyugin, Boris E.
   Rejdak, Robert
   Tognetto, Danielle
   Zweifel, Sandrine
   Giglio, Rosa
   Teus, Miguel A.
TI Impact on Visual Acuity in Neovascular Age Related Macular Degeneration
   (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; AMD; SARS-CoV-2; neovascular age related macular degeneration
ID ANTI-VEGF AGENTS; PROGNOSIS; OUTCOMES; DELAY; EYES
AB This is a retrospective, multicenter study of consecutive patients with nAMD scheduled for a visit and/or a treatment with an intravitreal injection (IVI) during the 3 months before lockdown in the Ophthalmology Departments of six centers of Europe.The study was conducted on 546 patients, of which 55.13% were females, almost 100% of the patients were White/Caucasian race, and 71.53% of the patients presented a type 1 macular neovascularization (NVM). A total of 62.82% of patients (343 patients) that were on scheduled clinic visits and/or intravitreal injection treatment during the 3 months before the quarantine did not attend either to visit or for treatment during the lockdown. The mean number of injections during the lockdown was significantly reduced. This was followed by a significant reduction in the mean best-corrected visual acuity (BCVA) between the 3 months before the lockdown (mean BCVA of 60.68 +/- 19.77 letters) and 6 months after lockdown (mean BCVA of 56.98 +/- 22.59 letters). Patients with better BCVA before the lockdown and the ones showing neovascular activity were more likely to attend their scheduled visits and/or IVI treatments. The COVID-19 pandemic and the lockdown have led to a decrease in the number of IVI treatments in patients with nAMD, evidencing a significant vision loss at 6 months.
C1 [Arruabarrena, Carolina; Teus, Miguel A.] Univ Alcala, Univ Hosp Alcala de Henares, Dept Ophthalmol, Alcala De Henares 28802, Spain.
   [Toro, Mario Damiano; Zweifel, Sandrine] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Toro, Mario Damiano] Cardinal Stefan Wyszynski Univ, Coll Med, Fac Med Sci, PL-01815 Warsaw, Poland.
   [Toro, Mario Damiano; Rejdak, Robert] Med Univ Lublin, Chair & Dept Gen & Pediat Ophthalmol, PL-20079 Lublin, Poland.
   [Onen, Mehmet] Ankara City Hosp, Dept Ophthalmol, TR-06800 Ankara, Turkey.
   [Malyugin, Boris E.] S Fyodorov Eye Microsurg Fed State Inst, Moscow 127486, Russia.
   [Tognetto, Danielle; Giglio, Rosa] Univ Trieste, Dept Med Surg & Hlth Sci, Eye Clin, I-34134 Trieste, Italy.
C3 Prince of Asturias University Hospital; Universidad de Alcala;
   University of Zurich; University Zurich Hospital; Cardinal Stefan
   Wyszynski University in Warsaw; Medical University of Lublin; City
   Hospital Ankara; University of Trieste
RP Arruabarrena, C (通讯作者)，Univ Alcala, Univ Hosp Alcala de Henares, Dept Ophthalmol, Alcala De Henares 28802, Spain.
EM carruabarrenas@gmail.com; toro.mario@email.it; mehmetonenster@gmail.com;
   boris.malyugin@gmail.com; robertrejdak@yahoo.com; tognetto@units.it;
   sandrine.zweifel@usz.ch; giglio.rosam@gmail.com; miguelteus@gmail.com
OI Rejdak, Robert/0000-0003-3321-2723; Teus, Miguel/0000-0002-3835-9882;
   Arruabarrena, Carolina/0000-0002-5312-8900; Giglio,
   Rosa/0000-0001-9755-0786
FU Fundacion de Investigacion Biomedica del Hospital Universitario Principe
   de Asturias [2-2021]
FX Funded in part by a grant (2-2021) of the Fundacion de Investigacion
   Biomedica del Hospital Universitario Principe de Asturias.
CR American Academy of Ophthalmology, 2020, IMP COR UPD OPHTH
   [Anonymous], 51 WHOC
   [Anonymous], 2020, REC URG NON PAT CAR
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Deutsche Opthalmologische Gesellschaft, 2020, COR COVID 19
   Elfalah M, 2021, CLIN OPHTHALMOL, V15, P661, DOI 10.2147/OPTH.S289068
   Ferrara M, 2020, EYE, V34, P2089, DOI 10.1038/s41433-020-1061-3
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Lestable L, 2020, J FR OPHTALMOL, V43, P761, DOI 10.1016/j.jfo.2019.11.016
   Li JPO, 2020, OPHTHALMOLOGY, V127, P569, DOI 10.1016/j.ophtha.2020.03.037
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Ophthalmologists RCo, 2020, CLIN GUIDELINES HYDR
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Shmueli O, 2020, EYE, V34, P1165, DOI 10.1038/s41433-020-0925-x
   SociUtU Franthaised'Ophtalmologie, QUELL COND TEN AD VI
   Song WL, 2021, OPHTHALMOL RETINA, V5, P975, DOI 10.1016/j.oret.2020.12.020
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   The Royal College of Ophthalmologists, 2020, MED RET MAN PLANS CO
   Thomas DS, 2020, ESTIMATING EXCESS VI, DOI 10.1101/2020.06.02.20120642
   Tognetto D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10121035
   Toro M, 2020, CLIN OPHTHALMOL, V14, P2879, DOI 10.2147/OPTH.S260960
   Toro MD, 2021, EUR J OPHTHALMOL, V31, P5, DOI 10.1177/1120672120960339
   Viola F, 2021, RETINA-J RET VIT DIS, V41, P701, DOI 10.1097/IAE.0000000000002941
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Wong RLM, 2020, ASIA-PAC J OPHTHALMO, V9, P59, DOI 10.1097/APO.0000000000000283
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu D, 2020, CURR OPIN OPHTHALMOL, V31, P427, DOI 10.1097/ICU.0000000000000692
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
   Zweifel S.A., 2021, CORRELATION OUTER RE, DOI [10.1097/IAE.0000000000003135, DOI 10.1097/IAE.0000000000003135]
NR 36
TC 15
Z9 15
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2021
VL 10
IS 15
AR 3281
DI 10.3390/jcm10153281
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TV9TY
UT WOS:000682057500001
PM 34362066
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Preti, RC
   Monteiro, MLR
   Morita, C
   Helal, J
   Zacharias, LC
   Ferraz, DA
   Pelayes, DE
   Takahashi, WY
AF Preti, Rony Carlos
   Ribeiro Monteiro, Mario Luiz
   Morita, Celso
   Helal Junior, John
   Zacharias, Leandro Cabral
   Ferraz, Daniel Araujo
   Pelayes, David E.
   Takahashi, Walter Yukihiko
TI Idiopathic polypoidal choroidal vasculopathy masquerading as choroidal
   tumors: one year follow-up of a peripheral lesion
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Choroid hemorrhage/etiology; Choroid diseases/pathology; Fluorescein
   angiography; Indocyanine green/diagnostic use; Choroid/blood supply;
   Peripheral vascular diseases; Pigment epithelium of eye; Tomography;
   optical cohe-rence; Case reports
AB This case report describes peripheral idiopathic polypoidal choroidal vasculopathy (IPCV) with a collection of small aneurysmal dilations that masqueraded as choroidal tumors in an elderly patient. A 68-year-old African American woman was referred to us with a suspected diagnosis of asymptomatic vascular choroidal tumor and choroidal capillary hemangioma, affecting the temporal peripheral fundus. Upon examination, optical coherence tomography (OCT) revealed two large hemorrhagic pigment epithelium detachments (PED), and indocyanine green angiography (ICG) confirmed the diagnosis of IPCV. One year later, there was reduction in the hemorrhagic pigment epithelium detachments and the lesion took on a different appearance, resembling a choroidal osteoma. No treatment was necessary despite the presence of multiple polyps. IPCV is a rare condition that can resemble other choroidal diseases depending on the stage of presentation. OCT is the best tool to determine the characteristics of the lesions, and indocyanine green angiography should be used to confirm the diagnosis. Not all cases require treatment.
C1 [Preti, Rony Carlos; Ribeiro Monteiro, Mario Luiz; Morita, Celso; Helal Junior, John; Zacharias, Leandro Cabral; Ferraz, Daniel Araujo; Takahashi, Walter Yukihiko] Univ Sao Paulo, Fac Med, Div Ophthalmol, Sao Paulo, SP, Brazil.
   [Pelayes, David E.] Univ Buenos Aires, Area Ophthalmol, Buenos Aires, DF, Argentina.
   [Pelayes, David E.] Univ Maimonides, Ctr Appl Res & High Complex Ophthalmol, Buenos Aires, DF, Argentina.
C3 Universidade de Sao Paulo; University of Buenos Aires
RP Preti, RC (通讯作者)，Av Ramalho Ortigao 269-54, BR-04130010 Sao Paulo, SP, Brazil.
EM preti@usp.br
RI Preti, Rony Carlos/N-4584-2013; MONTEIRO, MARIO L R/C-8891-2012;
   Zacharias, Leandro C/G-3960-2013
OI Preti, Rony Carlos/0000-0002-4395-6761; MONTEIRO, MARIO L
   R/0000-0002-7281-2791; Zacharias, Leandro C/0000-0003-2965-3315
CR Andrade Rafael Ernane, 2002, Arq. Bras. Oftalmol., V65, P363, DOI 10.1590/S0004-27492002000300016
   Barreira Ieda Maria Alexandre, 2005, Arq. Bras. Oftalmol., V68, P253, DOI 10.1590/S0004-27492005000200019
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 10
TC 1
Z9 1
U1 0
U2 6
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2015
VL 78
IS 3
BP 187
EP 189
DI 10.5935/0004-2749.20150048
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN9MD
UT WOS:000358772000013
PM 26222111
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular
   Degeneration
SO MEDICAL LETTER ON DRUGS AND THERAPEUTICS
LA English
DT Article
CR [Anonymous], 2022, MED LETT DRUGS THER, V64, P45
   [Anonymous], 2020, MED LETT DRUGS THER, V62, P23
   [Anonymous], 2019, MED LETT DRUGS THER, V61, P187
   [Anonymous], 2006, MED LETT DRUGS THER, V48, P85
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
NR 7
TC 0
Z9 0
U1 0
U2 0
PU MED LETTER INC
PI NEW ROCHELLE
PA 145 HUGUENOT ST, SUITE 312, NEW ROCHELLE, NY 10801-7537 USA
SN 0025-732X
EI 1523-2859
J9 MED LETT DRUGS THER
JI Med. Lett. Drugs Ther.
PD MAY 2
PY 2022
VL 64
IS 1649
BP 71
EP 72
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0X1LO
UT WOS:000789476500005
PM 35471228
DA 2022-11-30
ER

PT J
AU Terasaki, H
   Miyake, Y
   Suzuki, T
   Nakamura, M
   Nagasaka, T
AF Terasaki, H
   Miyake, Y
   Suzuki, T
   Nakamura, M
   Nagasaka, T
TI Polypoidal choroidal vasculopathy treated with macular translocation:
   clinical pathological correlation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; BLACK-WOMEN; DEGENERATION; IPCV
AB Aims: To report the histopathology of two specimens of polypoidal choroidal vasculopathy (PCV) obtained from two eyes of Japanese, patients.
   Methods: Specimens were obtained under direct visualisation during macular translocation surgery with 360 degree retinotomy. The clinical findings were correlated with the light microscopic findings of the two specimens.
   Results: One specimen from a 77 year old man was the central portion of the lesion that lay under the sensory retina on the retinal pigment epithelium (RPE). The specimen was made up mainly of fibrous tissue with small, thin walled vessels. Indocyanine green angiography after surgery revealed that active leaking polypoidal element remained under the RPE. Another specimen obtained from a 62 year old man was made up of a fibrovascular membrane situated within Bruch's membrane. The part of this specimen inferior to the foveal region included a collection of dilated, thin walled blood vessels without pericytes, surrounded by macrophages that stained positive for CD68. The dilated vessels appeared to be correlated with the orange coloured polyps observed by ophthalmoscopy, the polypoidal structure seen in indocyanine green angiograms, and the pyramidal elevation with intermediate reflectivity by optical coherence tomography.
   Conclusion: Polypoidal structures are located within Bruch's space. They are composed of clusters of dilated, thin walled blood vessels surrounded by macrophages and fibrin material. The positive immunohistochemical staining for vascular endothelial growth factor in the RPE and the vascular endothelial cells suggests that this fibrovascular complex is a subretinal choroidal neovascularisation.
C1 Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   Nagoya Univ Hosp, Clin Lab, Div Pathol, Nagoya, Aichi, Japan.
C3 Nagoya University; Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
RI Terasaki, Hiroko/M-5054-2014
OI Nakamura, Makoto/0000-0002-6464-4302
CR GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Sheibani K, 1984, Semin Diagn Pathol, V1, P235
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   YANNUZZI LA, 1982 MAC SOC M
NR 19
TC 129
Z9 137
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2002
VL 86
IS 3
BP 321
EP 327
DI 10.1136/bjo.86.3.321
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 529CK
UT WOS:000174282300021
PM 11864892
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Oshima, Y
   Kimoto, K
   Yoshida, N
   Fujisawa, K
   Sonoda, S
   Kubota, T
   Murata, T
   Sakamoto, T
   Yoshida, S
   Sonoda, KH
   Ishibashi, T
AF Oshima, Yuji
   Kimoto, Kenichi
   Yoshida, Noriko
   Fujisawa, Kimihiko
   Sonoda, Shozo
   Kubota, Toshiaki
   Murata, Toshinori
   Sakamoto, Taiji
   Yoshida, Shigeo
   Sonoda, Koh-Hei
   Ishibashi, Tatsuro
TI One-Year Outcomes following Intravitreal Aflibercept for Polypoidal
   Choroidal Vasculopathy in Japanese Patients: The APOLLO Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Aflibercept; 1-year outcome
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; VEGF TRAP; RANIBIZUMAB;
   COMBINATION; VERTEPORFIN; MONOTHERAPY; INJECTION; EFFICACY; SAFETY
AB Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naive PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001).Mean central foveal thickness decreased from 356 to 239 mu m (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients. (c) 2017 S. Karger AG, Basel
C1 [Oshima, Yuji; Yoshida, Shigeo; Sonoda, Koh-Hei; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Oshima, Yuji] Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Fukuoka, Japan.
   [Kimoto, Kenichi; Kubota, Toshiaki] Oita Univ, Fac Med, Dept Ophthalmol, Oita, Japan.
   [Yoshida, Noriko; Murata, Toshinori] Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano, Japan.
   [Fujisawa, Kimihiko] Japan Community Healthcare Org Kyushu Hosp, Dept Ophthalmol, Kitakyushu, Fukuoka, Japan.
   [Sonoda, Shozo; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan.
C3 Kyushu University; Fukuoka University; Oita University; Shinshu
   University; Kagoshima University
RP Oshima, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM yoshima1@kyudai.jp
RI Kubota, Toshiaki/AAN-4334-2021
OI Yoshida, Shigeo/0000-0003-1049-8909; Murata,
   Toshinori/0000-0001-6577-5032; Kubota, Toshiaki/0000-0001-6177-549X
FU Bayer Japan (Tokyo, Japan); JSPS KAKENHI [C26462641]
FX This work was supported by Bayer Japan (Tokyo, Japan) and a JSPS KAKENHI
   Grant (# Kiban C26462641 [to Y.O.]).
CR Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 17
Z9 20
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 3
BP 163
EP 171
DI 10.1159/000477448
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG4EA
UT WOS:000410182000007
PM 28697497
DA 2022-11-30
ER

PT J
AU Treharne, AJ
   Grossel, MC
   Lotery, AJ
   Thomson, HA
AF Treharne, Andrew J.
   Grossel, Martin C.
   Lotery, Andrew J.
   Thomson, Heather A.
TI The chemistry of retinal transplantation: the influence of polymer
   scaffold properties on retinal cell adhesion and control
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID IRIS PIGMENT-EPITHELIUM; LEBER CONGENITAL AMAUROSIS; EMBRYONIC
   STEM-CELLS; MACULAR DEGENERATION; SURFACE MODIFICATION; IN-VITRO;
   RETINITIS-PIGMENTOSA; PHOTORECEPTOR TRANSPLANTATION; TOPOGRAPHICAL
   CONTROL; PLASMA TREATMENT
AB Age-related macular degeneration is the most common cause of blindness in the UK. Cellular replacement of retinal pigment epithelium cells is a potential therapeutic option to treat the cellular loss and dysfunction which is characteristic of age-related macular degeneration and other progressive retinopathies. A supportive scaffold, natural or artificial, may be required to facilitate cell delivery to the eye. Research to improve the biomimetic properties of such scaffolds, in order to optimise cell attachment and functionality following implantation, is ongoing. This short review will focus on the potential of biomaterials for ocular tissue engineering and how surface modification and the physical properties of these scaffolds can be tailored to help realise the full clinical potential of retinal pigment epithelium cell transplantation.
C1 [Lotery, Andrew J.; Thomson, Heather A.] Univ Southampton, Southampton Gen Hosp, Clin Neurosci Div, Sch Med, Southampton SO16 6YD, Hants, England.
   [Treharne, Andrew J.; Grossel, Martin C.] Univ Southampton, Sch Chem, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew J.] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO9 4XY, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Gen Hosp, Clin Neurosci Div, Sch Med, Mailpoint 806, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI , Martin/AAV-9496-2021
OI , Martin/0000-0001-7869-037X; Lotery, Andrew/0000-0001-5541-4305
FU National Institute for Health Research; National Eye Research Centre;
   British Retinitis Pigmentosa Society; Foresight RP; National Institute
   for Health Research [NF-SI-0507-10094, II-FS-0109-11028] Funding Source:
   researchfish
FX Financial support was provided by the National Institute for Health
   Research, National Eye Research Centre, British Retinitis Pigmentosa
   Society and Foresight RP.
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abrams GA, 2000, CELL TISSUE RES, V299, P39, DOI 10.1007/s004410050004
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Asami M, 2007, DEV BIOL, V304, P433, DOI 10.1016/j.ydbio.2006.12.047
   Atala A, 2000, WORLD J UROL, V18, P364, DOI 10.1007/s003450000152
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   Berthiaume F, 1996, FASEB J, V10, P1471, DOI 10.1096/fasebj.10.13.8940293
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Britland S., 1997, EXP BIOL ONLINE, V1, P1
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chacko DM, 2003, VISION RES, V43, P937, DOI 10.1016/S0042-6989(02)00688-0
   Chen GP, 2009, J BIOMED MATER RES B, V90B, P864, DOI 10.1002/jbm.b.31356
   CLARK P, 1987, DEVELOPMENT, V99, P439
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Djojosubroto M, 2009, INVEST OPHTH VIS SCI, V50, P5975, DOI 10.1167/iovs.08-3091
   Djordjevic I, 2008, APPL SURF SCI, V254, P1929, DOI 10.1016/j.apsusc.2007.07.199
   Duan XD, 2007, BIOMATERIALS, V28, P78, DOI 10.1016/j.biomaterials.2006.08.034
   DUNN GA, 1986, J CELL SCI, V83, P313
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Fittkau MH, 2005, BIOMATERIALS, V26, P167, DOI 10.1016/j.biomaterials.2004.02.012
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Gao JM, 1998, J BIOMED MATER RES, V42, P417, DOI 10.1002/(SICI)1097-4636(19981205)42:3<417::AID-JBM11>3.3.CO;2-N
   Gias C, 2007, EUR J NEUROSCI, V25, P1940, DOI 10.1111/j.1460-9568.2007.05459.x
   Guillemette MD, 2009, INTEGR BIOL, V1, P196, DOI 10.1039/b820208g
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Han D, 2006, NANOMED-NANOTECHNOL, V2, P37, DOI 10.1016/j.nano.2006.01.002
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142-9612(03)00343-0
   Huang YC, 2007, J BIOMED MATER RES A, V82A, P842, DOI 10.1002/jbm.a.31036
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JENKINS DHR, 1977, J BONE JOINT SURG BR, V59, P53, DOI 10.1302/0301-620X.59B1.845228
   Jozwiak AB, 2008, J MATER CHEM, V18, P2240, DOI 10.1039/b719025e
   Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012
   Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537
   Khorasani MT, 2009, J APPL POLYM SCI, V112, P3429, DOI 10.1002/app.29813
   Krishna Y, 2007, J BIOMED MATER RES A, V80A, P669, DOI 10.1002/jbm.a.30953
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lee CJ, 2007, BIOMATERIALS, V28, P2192, DOI 10.1016/j.biomaterials.2007.01.018
   Limb GA, 2008, BRIT MED BULL, V85, P47, DOI 10.1093/bmb/ldn008
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   MacNeil A, 2007, STEM CELLS, V25, P2430, DOI 10.1634/stemcells.2007-0035
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mart RJ, 2006, SOFT MATTER, V2, P822, DOI 10.1039/b607706d
   Mooney DJ, 2008, CELL STEM CELL, V2, P205, DOI 10.1016/j.stem.2008.02.005
   Moroni L, 2006, BIOMATERIALS, V27, P4911, DOI 10.1016/j.biomaterials.2006.05.027
   Nelea V, 2005, J BIOMED MATER RES A, V75A, P216, DOI 10.1002/jbm.a.30402
   Ohno-Matsui K, 2006, MOL VIS, V12, P1022
   Ohta K, 2008, DEV GROWTH DIFFER, V50, P253, DOI [10.1111/j.1440-169x.2008.01006.x, 10.1111/j.1440-169X.2008.01006.x]
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Prabhakaran MP, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/45/455102
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Ren YJ, 2009, BIOMATERIALS, V30, P1036, DOI 10.1016/j.biomaterials.2008.10.028
   Ryu GH, 2005, SURF COAT TECH, V193, P60, DOI 10.1016/j.surfcoat.2004.07.062
   Saha K, 2008, BIOPHYS J, V95, P4426, DOI 10.1529/biophysj.108.132217
   Santiago LY, 2006, BIOMATERIALS, V27, P2962, DOI 10.1016/j.biomaterials.2006.01.011
   Schraermeyer U, 2000, GRAEF ARCH CLIN EXP, V238, P979, DOI 10.1007/s004170000194
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Shin K, 2007, J BIOMED MATER RES A, V83A, P1076, DOI 10.1002/jbm.a.31437
   Stile RA, 1999, MACROMOLECULES, V32, P7370, DOI 10.1021/ma990130w
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sun GW, 2006, DEV BIOL, V289, P243, DOI 10.1016/j.ydbio.2005.10.035
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thissen H, 2006, J BIOMED MATER RES A, V77A, P590, DOI 10.1002/jbm.a.30612
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   Verrier S, 2002, BIOMATERIALS, V23, P585, DOI 10.1016/S0142-9612(01)00145-4
   West EL, 2009, PROG BRAIN RES, V175, P3, DOI 10.1016/S0079-6123(09)17501-5
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Yang J, 2002, BIOMATERIALS, V23, P2607, DOI 10.1016/S0142-9612(01)00400-8
NR 100
TC 37
Z9 39
U1 0
U2 21
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2011
VL 95
IS 6
BP 768
EP 773
DI 10.1136/bjo.2010.184002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 766OJ
UT WOS:000290793600006
PM 20807710
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Singh, MS
   MacLaren, RE
AF Singh, Mandeep S.
   MacLaren, Robert E.
TI Stem Cell Treatment for Age-Related Macular Degeneration: the Challenges
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE regeneration; age-related macular degeneration; retinal degeneration;
   stem cells
ID RETINAL-PIGMENT EPITHELIUM; CONE PHOTORECEPTORS; SUBRETINAL
   IMPLANTATION; INTRAVITREAL INJECTION; HOST PHOTORECEPTORS; GEOGRAPHIC
   ATROPHY; BRUCHS MEMBRANE; VISUAL FUNCTION; TRANSPLANTATION; RESTORATION
C1 [Singh, Mandeep S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
   [MacLaren, Robert E.] Univ Oxford, Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [MacLaren, Robert E.] NHS Fdn Trust, Oxford Univ Hosp, NIHR Biomed Res Ctr, Oxford, England.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Oxford;
   Oxford University Hospitals NHS Foundation Trust; University of Oxford
RP Singh, MS (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM mandeep@jhmi.edu
RI Singh, Mandeep/AAS-8842-2021
OI Singh, Mandeep/0000-0003-1749-0088
CR Arai S, 2004, EXP EYE RES, V79, P331, DOI 10.1016/j.exer.2004.05.013
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P328
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hofer H, 2005, J NEUROSCI, V25, P9669, DOI 10.1523/JNEUROSCI.2414-05.2005
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kim Ju Young, 2017, Retin Cases Brief Rep, V11, P227, DOI 10.1097/ICB.0000000000000327
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kruczek K, 2017, STEM CELL REP, V8, P1659, DOI 10.1016/j.stemcr.2017.04.030
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lazow MA, 2011, INVEST OPHTH VIS SCI, V52, P9581, DOI 10.1167/iovs.11-8554
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ortin-Martinez A, 2017, STEM CELLS, V35, P932, DOI 10.1002/stem.2552
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pennington BO, 2016, J OCUL PHARMACOL TH, V32, P261, DOI 10.1089/jop.2015.0153
   Roorda A, 1999, NATURE, V397, P520, DOI 10.1038/17383
   Rossi EA, 2013, BIOMED OPT EXPRESS, V4, P2527, DOI 10.1364/BOE.4.002527
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Santos-Ferreira T, 2016, INVEST OPHTH VIS SCI, V57, P3509, DOI 10.1167/iovs.16-19087
   Santos-Ferreira T, 2015, STEM CELLS, V33, P79, DOI 10.1002/stem.1824
   Saraf SS, 2017, OSLI RETINA, V48, P772, DOI 10.3928/23258160-20170829-16
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Seiler MJ, 2005, EUR J NEUROSCI, V21, P161, DOI 10.1111/j.1460-9568.2004.03851.x
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   SINGH MS, 2014, INVEST OPHTH VIS SCI, V55
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sugino IK, 2014, DEV OPHTHALMOL, V53, P133, DOI 10.1159/000358531
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Verdina T, 2017, GRAEF ARCH CLIN EXP, V255, P1307, DOI 10.1007/s00417-017-3637-6
   Waldron PV, 2018, STEM CELL REP, V10, P406, DOI 10.1016/j.stemcr.2017.12.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
   Zhang TR, 2009, INVEST OPHTH VIS SCI, V50, P2982, DOI 10.1167/iovs.08-2131
   Zhong X., 2014, NAT COMMUN, V5
   Zhou SF, 2015, DEVELOPMENT, V142, P3294, DOI 10.1242/dev.125385
NR 71
TC 9
Z9 9
U1 3
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD78
EP AMD82
DI 10.1167/iovs.18-24426
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GN7JZ
UT WOS:000439314600003
PM 30025109
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Wong, TY
   Tomany, SC
   Cruickshanks, KJ
AF Klein, R
   Klein, BEK
   Wong, TY
   Tomany, SC
   Cruickshanks, KJ
TI The association of cataract and cataract surgery with the long-term
   incidence of age-related maculopathy - The Beaver Dam Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAOCULAR-LENS IMPLANTATION; MACULAR DEGENERATION; VISUAL-ACUITY;
   RISK-FACTORS; EXTRACTION; PREVALENCE; POPULATION; OPACITIES;
   PROGRESSION; EXPOSURE
AB Objective: To examine the association between cataract and cataract surgery and the 10-year incidence of age-related maculopathy (ARM).
   Methods: A population-based cohort study of persons aged 43 to 86 years at baseline, living in Beaver Dam, Wis, of whom 3684 participated in a 5-year and 2764 in a 10-year follow-up. We used standardized protocols for physical examination, blood collection, health history, slitlamp and retroillumination photography of the lenses to determine the presence of cataract, and stereoscopic color fundus photography to determine the presence of ARM. We used the Kaplan-Meier (product-limit) survival approach and discrete linear logistic regression in analyses.
   Main Outcome Measures: The risk ratios (RRs) of persons with cataract or cataract surgery at baseline.
   Results: While controlling for age, sex, systolic blood pressure, history of heavy drinking and smoking, and vitamin use, cataract at baseline was associated with incidence of early ARM (RR, 1.30; 95% confidence interval [CI], 1.04-1.63), soft indistinct drusen (RR, 1.38; 95% CI, 1.08-1.75), increased retinal pigment (RR, 1.38; 95% CI, 1.07-1.79), and progression of ARM (RR, 1.37; 95% CI, 1.06-1.77). We found no association with the incidence of late ARM. In contrast, cataract surgery before baseline was associated with incidence of late ARM (RR, 3.81; 95% CI, 1.89-7.69), increased retinal pigment (RR, 1.89; 95% CI, 1.18-3.03), retinal pigment epithelial depigmentation (RR, 1.95; 95% CI, 1.17-3.25), pure geographic atrophy (RR, 3.18; 95% CI, 1.33-7.60), exudative macular degeneration (RR, 4.31; 95% CI, 1.71-10.9), and progression of ARM (RR, 1.97; 95% CI, 1.29-3.02), but not with the incidence of early ARM.
   Conclusions: These findings indicate an association of cataract with subsequent risk for early ARM. Cataract surgery increased the risk for late ARM.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53726 USA.
   Univ Wisconsin, Dept Populat Hlth Sci, Sch Med, Madison, WI 53726 USA.
   Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   National University of Singapore
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,460 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR ALLEN AW, 1987, ANN OPHTHALMOL, V19, P329
   [Anonymous], [No title captured]
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   El Mallah MK, 2001, OPTOMETRY VISION SCI, V78, P683, DOI 10.1097/00006324-200109000-00014
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   HEIBA IM, 1993, AM J MED GENET, V47, P1208, DOI 10.1002/ajmg.1320470816
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HOSMER DW, 1989, APPL LOGISTIC REGRES, P90
   JAFFE NS, 1982, AUST J OPHTHALMOL, V10, P115, DOI 10.1111/j.1442-9071.1982.tb00369.x
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN BEK, 1990, WISCONSIN SYSTEM CLA
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Kleinmann G, 2002, OPHTHALMOLOGY, V109, P334, DOI 10.1016/S0161-6420(01)00924-1
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, AM J EPIDEMIOL, V141, P322, DOI 10.1093/aje/141.4.322
   MCDONALD HR, 1983, OPHTHALMOLOGY, V90, P945
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   *SAS I INC, 1990, SAS US GUID STAT VER
   SEVERIN T D, 1988, Ophthalmic Surgery, V19, P116
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   SPERDUTO RD, 1980, AM J OPHTHALMOL, V90, P86, DOI 10.1016/S0002-9394(14)75081-0
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Tielsch JA, 1995, VISION PROBLEMS US R, P1
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Vingerling J. R., 1997, Investigative Ophthalmology and Visual Science, V38, pS472
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   1976, PREV MED, V5, P207
NR 53
TC 158
Z9 170
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2002
VL 120
IS 11
BP 1551
EP 1558
DI 10.1001/archopht.120.11.1551
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 614RE
UT WOS:000179203400017
PM 12427071
OA Bronze
DA 2022-11-30
ER

PT J
AU Rahimy, E
   Freund, KB
   Larsen, M
   Spaide, RF
   Costa, RA
   Hoang, Q
   Christakopoulos, C
   Munch, IC
   Sarraf, D
AF Rahimy, Ehsan
   Freund, K. Bailey
   Larsen, Michael
   Spaide, Richard F.
   Costa, Rogerio A.
   Quan Hoang
   Christakopoulos, Christos
   Munch, Inger C.
   Sarraf, David
TI MULTILAYERED PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; ranibizumab; choroidal neovascularization; vascularized pigment
   epithelial detachment; retinal pigment epithelialtears; spectral domain
   optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   ANGIOGRAPHY; TEARS; CLASSIFICATION; DRUSEN; CELLS
AB Purpose: To describe the spectral domain optical coherence tomography findings in eyes with chronic fibrovascular pigment epithelial detachment (PED) receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.
   Methods: Retrospective observational case series of patients with chronic fibrovascular PEDs receiving serial intravitreal anti-VEGF therapy. Corresponding spectral domain optical coherence tomography scans of chronic PEDs were studied in detail over multiple visits. The internal structure within the sub-PED compartment was analyzed, characteristic features were identified, and then correlated with visual outcome.
   Results: Thirty-eight eyes of 34 patients with fibrovascular PEDs were included. Mean and median Snellen visual acuity was 20/50 (range, 20/20-20/400). Eyes received a mean of 28.2 intravitreal anti-VEGF injections (median, 23.0; range, 3-70) administered over a mean of 36.9 months (median, 37.5; range, 6-84). A fusiform, or spindle-shaped, complex of highly organized layered hyperreflective bands was noted within each PED. Nineteen eyes demonstrated heterogenous, dilated, irregular neovascular tissue adherent to the undersurface of the retinal pigment epithelium. Additionally, 25 eyes demonstrated a hyporeflective cavity separating the choroidal neovascularization complex from the underlying choroid.
   Conclusion: Chronic fibrovascular PEDs receiving serial anti-VEGF therapy demonstrate a characteristic fusiform complex of highly organized, layered, hyperreflective bands, termed a "multilayered PED," which is often seen in conjunction with neovascular tissue adherent to the undersurface of the retinal pigment epithelium monolayer. On the basis of previous histopathologic correlations, these bands may represent a fibrous tissue complex with contractile properties. An associated hyporeflective space, termed a "pre-choroidal cleft," separates the fusiform complex from the underlying choroid and may be due to contraction, the exudation of fluid, or both. Many of these eyes maintain good visual acuity, presumably because the neovascular and cicatricial process is suppressed within the sub-retinal pigment epithelium space by chronic anti-VEGF therapy, thus permitting the viability of the photoreceptor population through preservation of the retinal pigment epithelium.
C1 [Rahimy, Ehsan; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Freund, K. Bailey; Spaide, Richard F.; Quan Hoang] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Larsen, Michael; Christakopoulos, Christos; Munch, Inger C.] Univ Copenhagen, Roskilde Hosp, Glostrup Hosp, Copenhagen, Denmark.
   [Costa, Rogerio A.] Ctr Brasileiro Ciencias Visuais, Belo Horizonte, MG, Brazil.
   [Quan Hoang] Columbia Univ, Med Ctr, Edward S Harkness Eye Inst, New York, NY USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Vitreous Retina Macula Consultants of New York;
   University of Copenhagen; Columbia University
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Munch, Inger Christine/E-9652-2010; Larsen, Michael/E-9620-2010; Spaide,
   Richard/ABD-7368-2020; Freund, K. Bailey/V-7488-2018
OI Larsen, Michael/0000-0002-5172-5891; Rahimy, Ehsan/0000-0001-8446-7078;
   Freund, K. Bailey/0000-0002-7888-9773
FU NATIONAL EYE INSTITUTE [P30EY019007] Funding Source: NIH RePORTER
CR Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   Bressler Neil M, 2005, Retina, V25, P130, DOI 10.1097/00006982-200507001-00016
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Taarnhoj NCBB, 2003, INVEST OPHTH VIS SCI, V44, P1680, DOI 10.1167/iovs.01-1132
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 26
TC 41
Z9 42
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2014
VL 34
IS 7
BP 1289
EP 1295
DI 10.1097/IAE.0000000000000130
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK9UG
UT WOS:000338772600005
PM 24675391
DA 2022-11-30
ER

PT J
AU Zuo, CG
   Wen, F
   Li, JQ
   Liu, Y
   Long, SX
   Huang, SZ
   Li, M
AF Zuo, Chengguo
   Wen, Feng
   Li, Jiaqing
   Liu, Yan
   Long, Shixian
   Huang, Shizhou
   Li, Meng
TI Functional changes following combined intravitreal bevacizumab and
   photodynamic therapy for polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Contrast sensitivity; Color vision; Intravitreal bevacizumab;
   Photodynamic therapy; Polypoidal choroidal vasculopathy
ID CONTRAST SENSITIVITY; MACULAR DEGENERATION; NEOVASCULAR MEMBRANES;
   INDIAN POPULATION; VISUAL FUNCTION; VERTEPORFIN; ACUITY; ASSOCIATION;
   AVASTIN; TRIAL
AB To assess the functional changes of retina in patients affected by polypoidal choroidal vasculopathy (PCV) after combined intravitreal bevacizumab and photodynamic therapy (PDT) by means of contrast sensitivity (CS) test and color vision test.
   Twelve eyes of 12 patients were included in the study. The CS and color vision were measured and compared before the combined treatment and 1, 3 and 6 months after the treatment.
   The patients had an improvement in CS over pre-treatment values at the all of the five spatial frequencies. And the differences at 1.5 cycle per degree (cpd) at 1 and 3 months after treatment (p = 0.04 and 0.007 respectively) were statistically significant. The mean square root of total error score for color vision of the FM 100-hue test decreased after treatment and the change was significant at 3 and 6 months after treatment (p < 0.001 and 0.011 respectively).
   Combined intravitreal bevacizumab and PDT can improve the CS at low spatial frequency and color vision in patients affected by PCV, although the significant increases of CS were no longer found at 6-month follow-up.
C1 [Zuo, Chengguo; Wen, Feng; Li, Jiaqing; Liu, Yan; Long, Shixian; Huang, Shizhou; Li, Meng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Basic Research Program of China [2007CB512206]
FX This study was supported by the National Basic Research Program of China
   (Grant No. 2007CB512206).
CR Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   HYVARINEN L, 1983, ACTA OPHTHALMOL, V61, P161
   KINNEAR PR, 1970, VISION RES, V10, P423, DOI 10.1016/0042-6989(70)90123-9
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   MARMOR MF, 1988, OPHTHALMOLOGY, V95, P139
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Meyer CH, 2005, AM J OPHTHALMOL, V139, P214, DOI 10.1016/j.ajo.2004.07.034
   MITRA S, 1985, DOC OPHTHALMOL, V59, P247, DOI 10.1007/BF00159263
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rocha KM, 2006, AM J OPHTHALMOL, V142, P750, DOI 10.1016/j.ajo.2006.06.031
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   SJOSTRAND J, 1979, ACTA OPHTHALMOL, V57, P832
   Stifter E, 2006, INVEST OPHTH VIS SCI, V47, P5412, DOI 10.1167/iovs.05-1564
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ziemssen F, 2008, GRAEF ARCH CLIN EXP, V246, P653, DOI 10.1007/s00417-007-0726-y
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
NR 28
TC 6
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2010
VL 248
IS 2
BP 191
EP 196
DI 10.1007/s00417-009-1210-7
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 540EF
UT WOS:000273313100006
PM 19830442
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Uji, A
   Sarraf, D
   Sadda, SR
AF Borrelli, Enrico
   Uji, Akihito
   Sarraf, David
   Sadda, SriniVas R.
TI Alterations in the Choriocapillaris in Intermediate Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; image analysis; choriocapillaris;
   retina
ID OPTICAL COHERENCE TOMOGRAPHY; BEAVER DAM EYE; SWEPT-SOURCE; INTRAVITREAL
   BEVACIZUMAB; OCT ANGIOGRAPHY; QUANTITATIVE-ANALYSIS; GEOGRAPHIC ATROPHY;
   MOTION CORRECTION; ULTRAHIGH-SPEED; BRUCHS MEMBRANE
AB PURPOSE. The purpose of this study was to compare the choriocapillaris plexus in eyes with intermediate AMD (iAMD), with or without neovascular AMD in the fellow eye, using optical coherence tomography angiography (OCTA).
   METHODS. We collected data from 42 eyes with iAMD from 42 patients who had obtained OCTA. This cohort was divided into two subgroups according to the status of the fellow eye, yielding a group of 20 cases with bilateral intermediate AMD (bilateral iAMD group) and 22 cases with neovascular AMD in the fellow eye (unilateral iAMD group). An additional control group of 20 eyes from 20 healthy subjects was included for comparison. Main outcome measures were: (1) the percent of nondetectable perfused choriocapillaris area and (2) the average choriocapillaris signal void size.
   RESULTS. No differences in the percent of nondetectable perfused choriocapillaris area were found among the three groups (2.3 +/- 1.4% in the unilateral iAMD group, 1.5 +/- 0.9% in the bilateral iAMD group, and 1.7 6 1.4% in the control group, respectively). The average choriocapillaris signal void size, however, was significantly increased in unilateral iAMD eyes (293.7 +/- 71.2 mu m(2)) compared to both bilateral iAMD (241.5 +/- 51.6 mu m(2), P = 0.031) and control (212.7 +/- 48.6 mu m(2), P = 0.001) eyes.
   CONCLUSIONS. Intermediate AMD eyes of patients with neovascular AMD in the fellow eye have an increased average choriocapillaris signal void size compared to eyes without neovascular AMD in the fellow eye. If replicated in future studies, choriocapillaris signal void size may prove to be a useful parameter for evaluating eyes with AMD.
C1 [Borrelli, Enrico; Uji, Akihito; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Borrelli, Enrico; Uji, Akihito; Sadda, SriniVas R.] UCLA, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Borrelli, Enrico] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Sarraf, David] UCLA, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; G d'Annunzio University
   of Chieti-Pescara; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System
RP Sadda, SR (通讯作者)，1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Borrelli, Enrico/AAR-3693-2020
OI Borrelli, Enrico/0000-0003-2815-5031
FU Retina Research Foundation
FX The authors thank the Retina Research Foundation for awarding E.
   Borrelli the Lawrence Travel Grant to present part of this study at the
   2017 ARVO annual meeting.
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Velez-Montoya R, 2009, RETINA-J RET VIT DIS, V29, P20, DOI 10.1097/IAE.0b013e318186c64e
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 42
TC 104
Z9 105
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2017
VL 58
IS 11
BP 4792
EP 4798
DI 10.1167/iovs.17-22360
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5II
UT WOS:000414267700004
PM 28973325
OA gold
DA 2022-11-30
ER

PT J
AU Reznicek, L
   Wasfy, T
   Stumpf, C
   Kampik, A
   Ulbig, M
   Neubauer, AS
   Kernt, M
AF Reznicek, Lukas
   Wasfy, Tamer
   Stumpf, Carmen
   Kampik, Anselm
   Ulbig, Michael
   Neubauer, Aljoscha S.
   Kernt, Marcus
TI Peripheral Fundus Autofluorescence Is Increased in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPY; GEOGRAPHIC
   ATROPHY; IN-VIVO; CONTRAST SENSITIVITY; ADVANCED GLYCATION; HIGH-RISK;
   MACULOPATHY; LIPOFUSCIN; LESIONS
AB PURPOSE. To evaluate peripheral fundus autofluorescence (FAF) in patients with AMD.
   METHODS. A consecutive series of 71 normal eyes, 71 eyes with neovascular AMD having received anti-VEGF treatment, and 43 eyes with untreated AMD were investigated. In all subjects, wide-field FAF imaging was performed, applying a wide-field scanning laser ophthalmoscope. FAF was quantified by image analysis software after defining peripheral and perifoveal central measurement zones with a grid scheme; age correction was performed by regression model.
   RESULTS. Fundus autofluorescence increased with age not only in the perifoveal retinal area, but also in the retinal periphery. For age-corrected measurements, peripheral FAF was significantly increased for both, treated and untreated AMD groups compared with normal subjects. No significant difference was observed in peripheral FAF between AMD eyes having received anti-VEGF treatment and those without treatment. Age-corrected normal FAF in the retinal center differed significantly from the anti-VEGF-treated group (P < 0.01), but not the untreated AMD group. Age-corrected peripheral FAF irregularity, defined as the standard deviation in the measurement field, was significantly increased in both AMD groups compared with normal subjects.
   CONCLUSIONS. Detection of peripheral in addition to central FAF may provide additional information potentially helpful to detect and monitor the development of AMD. No differences in autofluorescence were observed in the retinal periphery between anti-VEGF-treated and untreated eyes. (Invest Ophthalmol Vis Sci. 2012; 53: 2193-2198) DOI:10.1167/iovs.11-8483
C1 [Reznicek, Lukas; Stumpf, Carmen; Kampik, Anselm; Ulbig, Michael; Neubauer, Aljoscha S.; Kernt, Marcus] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
   [Wasfy, Tamer] Tanta Univ, Dept Ophthalmol, Tanta, Egypt.
C3 University of Munich; Egyptian Knowledge Bank (EKB); Tanta University
RP Kernt, M (通讯作者)，Univ Munich, Klinikum Univ Munchen, Dept Ophthalmol, Campus Innenstadt,Mathildenstr 8, D-80336 Munich, Germany.
EM marcus.kernt@med.uni-muenchen.de
OI Wasfy, Tamer/0000-0001-9918-6834
CR Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barr D B, 1995, Eur J Ophthalmol, V5, P155
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   Datta A, 2008, OPHTHALMOLOGY, V115, P1853, DOI 10.1016/j.ophtha.2008.06.028
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Dolar-Szczasny Joanna, 2007, Klin Oczna, V109, P176
   DOREY CK, 1990, EXP EYE RES, V50, P1, DOI 10.1016/0014-4835(90)90003-D
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V364, P396
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Hammer M, 2008, GRAEF ARCH CLIN EXP, V246, P105, DOI 10.1007/s00417-007-0639-9
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   Kernt M, 2010, CIRCULATION, V121, P1459, DOI 10.1161/CIR.0b013e3181d99c22
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Neubauer AS, 2008, GRAEF ARCH CLIN EXP, V246, P229, DOI 10.1007/s00417-007-0631-4
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   SCHRAERMEYER U, 1994, CELL TISSUE RES, V276, P273, DOI 10.1007/BF00306113
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 61
TC 25
Z9 25
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2012
VL 53
IS 4
BP 2193
EP 2198
DI 10.1167/iovs.11-8483
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 937PC
UT WOS:000303669400057
PM 22410571
DA 2022-11-30
ER

PT J
AU Buschini, E
   Piras, A
   Nuzzi, R
   Vercelli, A
AF Buschini, Elisa
   Piras, Antonio
   Nuzzi, Raffaele
   Vercelli, Alessandro
TI Age related macular degeneration and drusen: Neuroinflammation in the
   retina
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE Aging; Retinal pigmented epithelium; Inflammation; Complement;
   Microglia; Autophagy
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIAL-CELLS; IMMUNE PRIVILEGE; BRUCHS
   MEMBRANE; GENE-EXPRESSION; AMYLOID-BETA; MICROGLIAL ACTIVATION;
   CHOROIDAL MACROPHAGES; MOLECULAR MACHINERY; POTENTIAL ROLE
AB Inflammation protects from dangerous stimuli, restoring normal tissue homeostasis. Inflammatory response in the nervous system ("neuroinflammation") has distinct features, which are shared in several diseases. The retina is an immune-privileged site, and the tight balance of immune reaction can be disrupted and lead to age-related macular disease (AMD) and to its peculiar sign, the druse. Excessive activation of inflammatory and immunological cascade with subsequent induction of damage, persistent activation of resident immune cells, accumulation of byproducts that exceeds the normal capacity of clearance giving origin to a chronic local inflammation, alterations in the activation of the complement system, infiltration of macrophages, T-lymphocytes and mast-cells from the bloodstream, participate in the mechanisms which originate the drusen. In addition, aging of the retina and AMD involve also para-inflammation, by which immune cells react to persistent stressful stimuli generating low-grade inflammation, aimed at restoring function and maintaining tissue homeostasis by varying the set point in relation to the new altered conditions. This mechanism is also seen in the normal aging retina, but, in the presence of noxious stimuli as in AMD, it can become chronic and have an adverse outcome. Finally, autophagy may provide new insights to understand AMD pathology, due to its contribution in the removal of defective proteins. Therefore, the AMD retina can represent a valuable model to study neuroinflammation, its mechanisms and therapy in a restricted and controllable environment. Targeting these pathways could represent a new way to treat and prevent both exudative and dry forms of AMD. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Buschini, Elisa; Piras, Antonio; Vercelli, Alessandro] Univ Turin, Neurosci Inst Cavalieri Ottolenghi Fdn, NICO, Orbassano, TO, Italy.
   [Buschini, Elisa; Nuzzi, Raffaele] Univ Turin, Dept Clin Pathophysiol, Ophthalm Sect, I-10121 Turin, Italy.
C3 University of Turin; University of Turin
RP Buschini, E (通讯作者)，Univ Turin, Neurosci Inst Cavalieri Ottolenghi Fdn, NICO, Reg Gonzole 10, Orbassano, TO, Italy.
EM elisa.buschini@tiscali.it
RI Vercelli, Alessandro E/A-1926-2012; Mohammed, Imran/J-8271-2012; du,
   zhao jiang/F-6229-2011
OI Vercelli, Alessandro E/0000-0002-5909-2128; Mohammed,
   Imran/0000-0002-8412-0768; Nuzzi, Raffaele/0000-0002-5381-832X; Piras,
   Antonio/0000-0003-3052-1715
FU MIUR; Compagnia di San Paolo
FX Supported by MIUR and Compagnia di San Paolo grants to AV. In partial
   fulfillment for the requirements of the Doctoral Thesis of AP.
CR Abela GS, 2010, J CLIN LIPIDOL, V4, P156, DOI 10.1016/j.jacl.2010.03.003
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   AHLBERG J, 1982, LAB INVEST, V47, P523
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   ATKINSON J P, 1991, Clinical and Experimental Immunology, V86, P27
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   BARKER CF, 1977, ADV IMMUNOL, V25, P1
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   BENSON MT, 1992, CURR EYE RES, V11, P173, DOI 10.3109/02713689208999529
   Bian ZM, 2004, INVEST OPHTH VIS SCI, V45, P1887, DOI 10.1167/iovs.03-0608
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   DANNO K, 1982, BRIT J DERMATOL, V106, P129, DOI 10.1111/j.1365-2133.1982.tb00921.x
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   DONDERS FC, 1854, GRAEFES ARCH CLIN EX, V1, P106
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   ELNER VM, 1990, AM J PATHOL, V136, P745
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Eskelinen EL, 2005, CELL DEATH DIFFER, V12, P1468, DOI 10.1038/sj.cdd.4401721
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Forrester JV, 2005, BRIT J OPHTHALMOL, V89, P369, DOI 10.1136/bjo.2004.054197
   Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47
   GASQUE P, 1995, J IMMUNOL, V154, P4726
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   Green W R, 1999, Mol Vis, V5, P27
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Khalyfa A, 2007, MOL VIS, V13, P293
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Koevary, 2000, Clin Eye Vis Care, V12, P97, DOI 10.1016/S0953-4431(00)00041-2
   KOKOTAS H, 2010, CLIN CHEM LAB MED
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   KUPPNER MC, 1995, IMMUNOLOGY, V84, P265
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liszewski MK, 1996, ADV IMMUNOL, V61, P201
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Niederkorn JY, 2003, J INVEST DERM SYMP P, V8, P168, DOI 10.1046/j.1087-0024.2003.00803.x
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514
   PLANCK SR, 1992, INVEST OPHTH VIS SCI, V33, P78
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Ryhanen T, 2008, EUR J PHARMACOL, V584, P229, DOI 10.1016/j.ejphar.2008.02.010
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Skerka C, 2008, VACCINE, V26, pI9, DOI 10.1016/j.vaccine.2008.11.021
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Streilein J W, 1999, Chem Immunol, V73, P11
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VEERHUIS R, 2010, CURR ALZHEIMER RES
   Vega JL, 2009, AM J PATHOL, V175, P1218, DOI 10.2353/ajpath.2009.090264
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6
   Wang AL, 2010, VISION RES, V50, P638, DOI 10.1016/j.visres.2009.08.029
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yang Y, 2006, INT J OBESITY, V30, P439, DOI 10.1038/sj.ijo.0803173
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang C, 2005, MOL VIS, V11, P887
NR 146
TC 165
Z9 177
U1 0
U2 62
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
EI 1873-5118
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD SEP 15
PY 2011
VL 95
IS 1
BP 14
EP 25
DI 10.1016/j.pneurobio.2011.05.011
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 820ZC
UT WOS:000294943600002
PM 21740956
DA 2022-11-30
ER

PT J
AU Foster, Z
   Kini, A
   Al Othman, B
   Lee, AG
   Vaphiades, M
AF Foster, Zane
   Kini, Ashwini
   Al Othman, Bayan
   Lee, Andrew G.
   Vaphiades, Michael
TI Seeing is not believing
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE pure alexia; alexia without agraphia; occipital lobe; splenium of corpus
   callosum; stroke; reading problems
ID ALEXIA; AGRAPHIA
AB An 84-year-old woman with a history of dry age-related macular degeneration presented with an acute inability to read, but intact writing ability (pure alexia or alexia without agraphia). She denied any difficulty speaking, paresthesias, or hemiparesis. Her visual acuity was 20/20 in each eye. Macular examination, optical coherence tomography, and fluorescein angiography demonstrated the previously diagnosed macular drusen and geographic atrophy of the retinal pigment epithelium consistent with the dry form of age-related macular degeneration both eyes. Automated perimetry revealed a right homonymous hemianopsia. Neuroimaging confirmed a left occipital ischemic infarction with involvement of the splenium of the corpus callosum producing the classic disconnection syndrome of alexia without agraphia. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Foster, Zane] Baylor Coll Med, Houston, TX 77030 USA.
   [Kini, Ashwini; Al Othman, Bayan; Lee, Andrew G.] Houston Methodist Hosp, Blanton Eye Inst, Dept Ophthalmol, Houston, TX 77030 USA.
   [Lee, Andrew G.] UTMB, Dept Ophthalmol, Galveston, TX USA.
   [Lee, Andrew G.] UT MD Anderson Canc Ctr, Texas A&M Coll Med, Bryan, TX USA.
   [Vaphiades, Michael] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Vaphiades, Michael] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA.
   [Vaphiades, Michael] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA.
C3 Baylor College of Medicine; The Methodist Hospital System; The Methodist
   Hospital - Houston; University of Texas System; University of Texas
   Medical Branch Galveston; Texas A&M University System; Texas A&M
   University College Station; Texas A&M Health Science Center; University
   of Texas System; UTMD Anderson Cancer Center; University of Alabama
   System; University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham
RP Lee, AG (通讯作者)，Houston Methodist Hosp, Blanton Eye Inst, 6560 Fannin St,Suite 450, Houston, TX 77030 USA.
EM aglee@houstonmethodist.org
RI Lee, Andrew/GVU-2817-2022
CR [Anonymous], AM ORTHOPTIC J
   [Anonymous], OPHTHALMOLOGY
   Bub D, 2003, NEUROL CLIN, V21, P549, DOI 10.1016/S0733-8619(02)00099-3
   COGAN D G, 1965, Arch Ophthalmol, V73, P2
   Haque S, 2018, J NEURO-OPHTHALMOL, V38, P379, DOI 10.1097/WNO.0000000000000556
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Mani J, 2008, NEUROLOGY, V71, P1621, DOI 10.1212/01.wnl.0000334755.32850.f0
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Millington RS, 2017, NEUROIMAGE-CLIN, V14, P242, DOI 10.1016/j.nicl.2017.01.012
   PILLON B, 1987, ARCH NEUROL-CHICAGO, V44, P1257, DOI 10.1001/archneur.1987.00520240039009
   Robinson JS, 2016, APPL NEUROPSYCH-ADUL, V23, P65, DOI 10.1080/23279095.2014.973495
   Rodriguez-Lopez C, 2018, J NEUROL, V265, P436, DOI 10.1007/s00415-017-8691-9
   Rupareliya C, 2017, CUREUS, V9, DOI 10.7759/cureus.1304
   Sharma B, 2014, AM J EMERG MED, V32, DOI 10.1016/j.ajem.2014.04.046
   Strbian D, 2010, STROKE, V41, P712, DOI 10.1161/STROKEAHA.109.571976
   Yong KXX, 2015, NEUROLOGY, V85, P339, DOI 10.1212/WNL.0000000000001782
NR 16
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2020
VL 65
IS 3
BP 386
EP 390
DI 10.1016/j.survophthal.2019.03.008
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KY8CL
UT WOS:000522799100009
PM 30953621
DA 2022-11-30
ER

PT J
AU Wong, TY
   Ogura, Y
   Lee, WK
   Iida, T
   Chen, SJ
   Mitchell, P
   Cheung, CMG
   Zhang, ZQ
   Leal, S
   Ishibashi, T
AF Wong, Tien Yin
   Ogura, Yuichiro
   Lee, Won Ki
   Iida, Tmohiro
   Chen, Shih-Jen
   Mitchell, Paul
   Cheung, Chui Ming Gemmy
   Zhang, Zhongqi
   Leal, Sergio
   Ishibashi, Tatsuro
CA PLANET Investigators
TI Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal
   Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal
   Choroidal Vasculopathy Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; DAILY CLINICAL-PRACTICE; VISUAL-ACUITY
   OUTCOMES; SHORT-TERM EFFICACY; MACULAR DEGENERATION; TRAP-EYE;
   RANIBIZUMAB; INJECTIONS; DIAGNOSIS
AB PURPOSE: We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with polypoidal choroidal vasculopathy (PCV).
   DESIGN: This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers.
   METHODS: In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73-24 Early Treatment Diabetic Retinopathy Study letters (20/40-20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated.
   RESULTS: Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained ( +10.7 vs +9.1, P =.48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed.
   CONCLUSION: IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit. (Am J Ophthalmol 2019;204:80-89. (C) 2019 Published by Elsevier Inc.)
C1 [Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, 20 Coll Rd, Singapore 169856, Singapore.
   [Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke Natl Univ Singapore, Med Sch, Singapore, Singapore.
   [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
   [Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Iida, Tmohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Chen, Shih-Jen] Natl Yang Ming Univ Taipei, Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ Taipei, Sch Med, Taipei, Taiwan.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Zhang, Zhongqi; Leal, Sergio] Bayer Pharmaceut, Berlin, Germany.
   [Ishibashi, Tatsuro] Kyushu Univ Hosp, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; National University of Singapore; Nagoya
   City University; Catholic University of Korea; Seoul St. Mary's
   Hospital; Tokyo Women's Medical University; National Yang Ming Chiao
   Tung University; Taipei Veterans General Hospital; National Yang Ming
   Chiao Tung University; University of Sydney; Westmead Institute for
   Medical Research; Bayer AG; Bayer Healthcare Pharmaceuticals; Kyushu
   University
RP Wong, TY (通讯作者)，Singapore Eye Res Inst, 20 Coll Rd, Singapore 169856, Singapore.
EM wong.tien.yin@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2018, JAMA OPHTHALMOL, V136, P794, DOI 10.1001/jamaophthalmol.2018.1799
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Eylea Bayer, BAYER EYL PRESCR INF
   Genentech Lucentis, GEN LUC PRESCR INF 2
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong TY, 2019, RETINA-J RET VIT DIS, V39, P537, DOI 10.1097/IAE.0000000000001986
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 40
TC 47
Z9 50
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2019
VL 204
BP 80
EP 89
DI 10.1016/j.ajo.2019.02.027
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN7KD
UT WOS:000478859400010
PM 30849345
DA 2022-11-30
ER

PT J
AU Ho, M
   Lo, ECF
   Young, AL
   Liu, DTL
AF Ho, M.
   Lo, E. C. F.
   Young, A. L.
   Liu, D. T. L.
TI Outcome of polypoidal choroidal vasculopathy at 1 year by combined
   therapy of photodynamic therapy with ranibizumab and predictive factors
   governing the outcome
SO EYE
LA English
DT Article
ID COMBINED INTRAVITREAL RANIBIZUMAB; OPTICAL COHERENCE TOMOGRAPHY;
   AS-NEEDED REINJECTIONS; MACULAR DEGENERATION; JAPANESE PATIENTS;
   VERTEPORFIN; INJECTIONS; BEVACIZUMAB; THICKNESS; EFFICACY
AB Aim To report the visual outcome of polypoidal choroidal vasculopathy receiving combined treatment with photodynamic therapy using Visudyne and intravitreal ranibizumab injections, and to analyze the predictive factors of visual outcome at 1 year post treatment.
   Methods Seventy-four consecutive patients with newly diagnosed polypoidal choroidal vasculopathy were treated with photodynamic therapy using Visudyne and three loading doses of intravitreal ranibizumab. The final visual outcome and polyp eradication rate at 1 year were reported. A stepwise regression model was used to estimate the baseline clinical factors predictive of better visual outcome and polyp eradication.
   Results Visual acuities at 12-months follow-up improved significantly compared with baseline from 0.828 logMAR to 0.728 logMAR (P = 0.026). The mean foveal thickness decreased from 380 +/- 175 to 278 +/- 117 mu m. In all 29.7% of eyes improved at least by 0.3 logMAR, and 55.4% remained stable in visual acuity with less than 0.3 logMAR change. Overall, 85% of eyes achieved at least stable vision, 20.2% (15/74) cases achieved polyp eradication on angiogram, and 60.8% (45/74) achieved polyp size reduction on angiogram at 1 year. Regarding predictive factors, the baseline visual acuity (P = 0.003), no foveal involvement by abnormal choroidal vasculature (P<0.0001), absence of hard exudates (0.001) or subretinal fluid (<0.0001) are important clinical factors affecting the final visual outcome.
   Conclusions Combination therapy with photodynamic therapy using Visudyne and three loading doses of intravitreal ranibizumab injections resulted in 85% success rate on visual stabilization and 81% success rate in polypoidal lesion control.
C1 [Ho, M.; Lo, E. C. F.; Young, A. L.; Liu, D. T. L.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin 12345, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital
RP Liu, DTL (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin 12345, Hong Kong, Peoples R China.
EM david_tlliu@yahoo.com
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Ho M, 2013, OPHTHALMOLOGY, V120, P1909, DOI 10.1016/j.ophtha.2013.02.005
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 32
TC 16
Z9 18
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2014
VL 28
IS 12
BP 1469
EP 1476
DI 10.1038/eye.2014.222
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW6FQ
UT WOS:000346365600010
PM 25257771
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Singh, SR
   Hariprasad, SM
   Khanani, AM
   Chhablani, J
AF Singh, Sumit Randhir
   Hariprasad, Seenu M.
   Khanani, Arshad M.
   Chhablani, Jay
TI Unsuccessful Trials That Investigated Therapies for Age-Related Macular
   Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANKYRIN REPEAT PROTEIN; RANIBIZUMAB; VEGF;
   PDGF
C1 [Singh, Sumit Randhir] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Hariprasad, Seenu M.] Univ Chicago, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave,Room S-439, Chicago, IL 60637 USA.
   [Khanani, Arshad M.] Sierra Eye Associates, Reno, NV 89502 USA.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
C3 University of California System; University of California San Diego;
   University of Chicago; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh
RP Singh, SR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Dept Ophthalmol, La Jolla, CA 92093 USA.
EM sumit.jipmer@gmail.com; retina@uchicago.edu; arshad.khanani@gmail.com;
   jay.chhablani@gmail.com
OI Chhablani, Jay/0000-0003-1772-3558
CR [Anonymous], 2017, CISION PR NEWSW 1127
   [Anonymous], 2014, STUD INTR IMPL NT 50
   [Anonymous], 2016, REGENERON       0930
   [Anonymous], 2018, HCPLIVE         1204
   [Anonymous], 2020, HEALIO          0626
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Poor SH, 2018, INVEST OPHTH VIS SCI, V59
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1488, DOI 10.1016/j.ophtha.2018.06.002
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV
PY 2020
VL 51
IS 11
BP 608
EP 611
DI 10.3928/23258160-20201104-01
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA PA2RK
UT WOS:000595480800001
PM 33231692
DA 2022-11-30
ER

PT J
AU Casparis, H
   Lindsley, K
   Kuo, IC
   Sikder, S
   Bressler, NM
AF Casparis, Heather
   Lindsley, Kristina
   Kuo, Irene C.
   Sikder, Shameema
   Bressler, Neil M.
TI Surgery for cataracts in people with age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Cataract [complications]; Cataract Extraction [adverse effects]; Disease
   Progression; Macular Degeneration [complications; pathology]; Randomized
   Controlled Trials as Topic
ID QUALITY-OF-LIFE; INTRAOCULAR-LENS; VISUAL-ACUITY; RISK-FACTORS; BEAVER
   DAM; MACULOPATHY; EXTRACTION; RANIBIZUMAB; PROGRESSION; IMPACT
AB Background
   Cataract and age-relatedmacular degeneration (AMD) are common causes of decreased vision that often occur simultaneously in people over age 50. Although cataract surgery is an effective treatment for cataract-induced visual loss, some clinicians suspect that such an intervention may increase the risk of worsening of underlying AMD and thus have deleterious effects on vision.
   Objectives
   The objective of this review was to evaluate the effectiveness and safety of cataract surgery compared with no surgery in eyes with AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 11), Ovid MEDLINE, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to December 2016), Embase (January 1980 toDecember 2016), Latin American and Caribbean Literature onHealth Sciences (LILACS) (January 1982 toDecember 2016), the ISRCTN registry (www. isrctn. com/editAdvancedSearch), ClinicalTrials. gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2 December 2016.
   Selection criteria
   We included randomized controlled trials (RCTs) and quasi-randomized trials that enrolled participants whose eyes were affected by both cataract and AMD in which cataract surgery was compared with no surgery.
   Data collection and analysis
   Two review authors independently evaluated the search results against the inclusion and exclusion criteria. Two review authors independently extracted data, assessed risk of bias for included studies, and graded the certainty of evidence. We followed methods as recommended by Cochrane.
   Main results
   We included two RCTs with a total of 114 participants (114 study eyes) with visually significant cataract and AMD. We identified no ongoing trials. Participants in each RCT were randomized to immediate cataract surgery (within two weeks of enrollment) or delayed cataract surgery (six months after enrollment). The risk of bias was unclear for most domains in each study; one study was registered prospectively.
   In one study conducted in Australia outcomes were reported only at six months (before participants in the delayed-surgery group had cataract surgery). At six months, the immediate-surgery group showed mean improvement in best-corrected visual acuity (BCVA) compared with the delayed-surgery group (mean difference (MD) -0.15 LogMAR, 95% confidence interval (CI) -0.28 to -0.02; 56 participants; moderate-certainty evidence). In the other study, conducted in Austria, outcomes were reported only at 12 months (12 months after participants in the immediate-surgery group and six months after participants in the delayed-surgery group had cataract surgery). There was uncertainty as to which treatment group had better improvement in distance visual acuity at 12 months (unit of measure not reported; very low-certainty evidence).
   At 12 months, the mean change from baseline between groups in cumulated drusen or geographic atrophy area size was small and there was uncertainty which, if either, of the groups was favored (MD 0.76, 95% CI -8.49 to 10.00; 49 participants; low-certainty evidence). No participant in one study had exudative AMD develop in the study eye during 12 months of follow-up; in the other study, choroidal neovascularization developed in the study eye of 1 of 27 participants in the immediate-surgery group versus 0 of 29 participants in the delayed-surgery group at six months (risk ratio 3.21, 95% CI 0.14 to 75.68; 56 participants; very low-certainty evidence). Quality of life was measured using two different questionnaires. Scores on the Impact of Vision Impairment (IVI) questionnaire suggested that the immediate-surgery group fared better regarding vision-related quality of life than the delayed-surgery group at six months (MD in IVI logit scores 1.60, 95% CI 0.61 to 2.59; low-certainty evidence). However, we could not analyze scores from the Visual Function14 (VF-14) questionnaire from the other study due to insufficient data. No postoperative complication was reported from either study.
   Authors' conclusions
   At this time, it is not possible to draw reliable conclusions from the available data as to whether cataract surgery is beneficial or harmful in people with AMD after 12 months. Although cataract surgery provides short-term (six months) improvement in BCVA in eyes with AMD compared with no surgery, it is unclear whether the timing of surgery has an effect on long-term outcomes. Physicians must make recommendations to their AMD patients regarding cataract surgery based on experience and clinical judgment until large controlled trials are conducted and their findings published.
   There is a need for prospective RCTs in which cataract surgery is compared with no surgery in people with AMD to better evaluate whether cataract surgery is beneficial or harmful in all or a subset of AMDpatients. However, ethical considerations precludewithholding surgery, or delaying it for several years, if it may be a potentially beneficial treatment. Designers of future trials are encouraged to utilize existing standardized systems for grading cataract and AMD and for measuring key outcomes: visual acuity, change in visual acuity, worsening of AMD, quality of life measures, and adverse events.
C1 [Casparis, Heather] Private practice, Ophthalmol, Via Antonio Ciseri 13, CH-6600 CH- Locarno, Switzerland.
   [Lindsley, Kristina] Johns Hopkins Bloomberg Sch PublicHealth, Dept Epidemiol, Baltimore, MD USA.
   [Kuo, Irene C.] Johns Hopkins Univ Sch Med, Wilmer Eye Inst, Dept ofOphthalmol, Baltimore, MD USA.
   [Sikder, Shameema; Bressler, Neil M.] Johns Hopkins Univ Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD USA.
   [Casparis, Heather] Heather Casparis, Private practice, Ophthalmol, Via Antonio Ciseri 13, CH-6600 CH- Locarno, Switzerland.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Casparis, H (通讯作者)，Heather Casparis, Private practice, Ophthalmol, Via Antonio Ciseri 13, CH-6600 CH- Locarno, Switzerland.
EM studiocasparis@gmail.com
FU Johns Hopkins University, USA; National Eye Institute, National
   Institutes of Health, USA [1 U01 EY020522]; National Institute for
   Health Research (NIHR), UK; Department of Health through NIHR to
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology; NATIONAL EYE INSTITUTE [U01EY020522] Funding Source: NIH
   RePORTER
FX Internal sources; Johns Hopkins University, USA.; External sources;
   Grant 1 U01 EY020522, National Eye Institute, National Institutes of
   Health, USA.; National Institute for Health Research (NIHR), UK.;
   Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision
   (CEV) acknowledges financial support for his CEV research sessions from
   the Department of Health through the award made by the NIHR to
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology.; The NIHR also funds the CEV editorial base in London.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1471
   Albrecht S, 2011, US PHARM, V36, P29
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ang M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008811.pub2
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Benson WB., 2009, EVIDENCE BASED OPHTH, V10, P158
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2008, EVIDENCE BASED OPHTH, V9, P158
   Brunner S, 2005, INVEST OPHTH VIS SCI, V46
   BRUNNER S, 2001, SPEKTRUM AUGENHEILKU, V15, P178
   Brunner S, 2013, OPHTHALMOLOGICA, V229, P86, DOI 10.1159/000345492
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Casparis H, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006757, DOI 10.1002/14651858.CD006757]
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Casparis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub2
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chew EY., 2001, EVIDENCE BASED EYE C, V2, P136
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GRADE Working Group McMaster University, 2014, GRADEPRO
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hiller R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1113, DOI 10.1001/archopht.1997.01100160283003
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Jacques PF, 2005, ARCH OPHTHALMOL-CHIC, V123, P517, DOI 10.1001/archopht.123.4.517
   Javitt JC, 2000, OPHTHALMOLOGY, V107, P2040, DOI 10.1016/S0161-6420(00)00368-7
   Javitt JC, 2001, EVIDENCE BASED EYE C, V2, P138
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kertes PJ., 2003, EVIDENCE BASED EYE C, V4, P110
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kuo IC, 2011, CAN J OPHTHALMOL, V46, P391, DOI 10.1016/j.jcjo.2011.07.008
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nordic Cochrane Centre, 2014, REV MAN REVMAN COMP
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Prajna  NV, 1998, AM J OPHTHALMOL, V125, P14, DOI 10.1016/S0002-9394(99)80230-X
   Riaz Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001323.pub2
   Rohart C, 2008, J FR OPHTALMOL, V31, P571, DOI 10.1016/S0181-5512(08)75457-3
   Rosen E, 2009, EYE, V23, P1120, DOI 10.1038/eye.2008.203
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Talukder Abdul Khaleque, 2009, Mymensingh Med J, V18, pS15
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P2120, DOI 10.1016/j.ophtha.2010.03.005
NR 65
TC 28
Z9 28
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2017
IS 2
AR CD006757
DI 10.1002/14651858.CD006757.pub4
PG 35
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EN6EF
UT WOS:000396096600023
PM 28206671
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Luu, CD
   Guymer, RH
AF Wu, Zhichao
   Ayton, Lauren N.
   Luu, Chi D.
   Guymer, Robyn H.
TI Microperimetry of Nascent Geographic Atrophy in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; microperimetry;
   optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPE; RETICULAR
   PSEUDODRUSEN; RETINAL SENSITIVITY; PERIMETRY; DRUSEN; EYES
AB PURPOSE. To determine the microperimetric retinal sensitivity in areas with nascent geographic atrophy (nGA) compared with other pathological features in eyes with intermediate AMD.
   METHODS. Participants with bilateral intermediate AMD underwent microperimetry examinations and high-resolution spectral-domain optical coherence tomography (SD-OCT) scans in a prospective study. Twenty-two participants (24 eyes) identified as having a microperimetric stimulus sampling an atrophic area (nGA or drusen-associated atrophy detected on SD-OCT) in an eye were analyzed, using three neighboring nonatrophic regions (with or without AMD-associated features) in the same eye as reference areas.
   RESULTS. On average, the mean microperimetric retinal sensitivity was worse in areas with nGA than nonatrophic reference areas (P <= 0.008), but better than areas with drusen-associated atrophy (P = 0.008). Considering all the microperimetry points in an eye, there were only 6 out of 16 eyes (37.5%) where the retinal sensitivity over nGA was the worst performing point in the eye, while all eight out of eight eyes (100.0%) with an area of drusen-associated atrophy detected on SD-OCT had the worst-performing point over that area.
   CONCLUSIONS. Areas of nGA were characterized by worse microperimetric retinal sensitivity compared with nonatrophic areas in eyes with intermediate AMD, but better retinal sensitivity compared with areas of drusen-associated atrophy detected on SD-OCT. Areas of nGA were also not always the worst performing point in an eye. These findings further our understanding of the functional changes occurring in novel SD-OCT identified pathological changes in intermediate AMD.
C1 [Wu, Zhichao; Ayton, Lauren N.; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097
FU National Health and Medical Research Council (NHMRC) [1027624]; NHMRC
   [529905]; Macular Disease Foundation Australia (MDFA); Bupa Health
   Foundation (Australia); Menzies Foundation; University of Melbourne
   [1350114]; Macular Vision Loss Support Society of Australia, Inc.;
   NH&MRC Centre for Clinical Research Excellence [529923]
FX Supported by the National Health and Medical Research Council (NH&MRC)
   Project Grant (1027624); NH&MRC Practitioner Fellowship (RHG, #529905);
   Macular Disease Foundation Australia (MDFA) Research Grant; Bupa Health
   Foundation (Australia); The Menzies Foundation; a University of
   Melbourne Early Career Research grant (LNA, #1350114); and the Macular
   Vision Loss Support Society of Australia, Inc. CERA receives Operational
   Infrastructure Support from the Victorian Government and is supported by
   a NH&MRC Centre for Clinical Research Excellence award (#529923).
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 17
TC 36
Z9 37
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 115
EP 121
DI 10.1167/iovs.14-15614
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800013
PM 25515578
DA 2022-11-30
ER

PT J
AU Bloch, SB
AF Bloch, Sara Brandi
TI Implementation studies of ranibizumab for neovascular age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; COMPLEMENT FACTOR-H; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; VERTEPORFIN PHOTODYNAMIC THERAPY; BODY-MASS INDEX;
   SUBRETINAL MICROGLIA; DIABETIC-RETINOPATHY; INCREASED EXPRESSION
C1 [Bloch, Sara Brandi] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Bloch, Sara Brandi] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Bloch, SB (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM sara.brandi.bloch@regionh.dk
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BESHARSE JC, 1998, RETINAL PIGMENT EPIT, P152
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Bressler NM, 2006, RETINA, P1075
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   BUTTERY RG, 1991, VISION RES, V31, P169, DOI 10.1016/0042-6989(91)90110-Q
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Friedman SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004700
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Genentech, 2010, AV PRESCR INF
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2006, OPHTHALMOLOGY, V113, P267, DOI 10.1016/j.ophthzi.2005.10.031
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2009, RETINA-J RET VIT DIS, V29, P592, DOI 10.1097/IAE.0b013e31819b17a5
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kent D, 2003, MOL VIS, V9, P747
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   La Cour M., 2003, ADLERS PHYSL EYE, V10, P348
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   Luo C, 2011, MOL VIS, V17, P1588
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Martin J, 2005, CARDIOVASC RES, V65, P694, DOI 10.1016/j.cardiores.2004.10.041
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazawa K, 1995, ATHEROSCLEROSIS, V118, P213, DOI 10.1016/0021-9150(95)05607-6
   Novartis, 2010, LUC PRESCR INF
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ophthotech Corp, 2013, OPHTH NOV ANT PDGF C
   PARVER LM, 1982, RETINA-J RET VIT DIS, V2, P117, DOI 10.1097/00006982-198200220-00008
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Rabin DM, 2013, AGING-US, V5, P51
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Saari J.C., 1987, ADLERS PHYSL EYE CLI, P356
   Schmitz-Valskenberg S, 2007, ATLAS FUNDUS AUTOFLU, P147
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Statistics Denmark, 2011, STATBANK DENM POP EL
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Ward MR, 1998, ATHEROSCLEROSIS, V137, P267, DOI 10.1016/S0021-9150(97)00275-X
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   YAMADA H, 1994, J BIOCHEM-TOKYO, V116, P892, DOI 10.1093/oxfordjournals.jbchem.a124612
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1979, MACULA COMPREHENSIVE
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   YU DY, 1994, AM J PHYSIOL-HEART C, V267, pH2498, DOI 10.1152/ajpheart.1994.267.6.H2498
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhao SH, 2010, CHINESE MED J-PEKING, V123, P713, DOI 10.3760/cma.j.issn.0366-6999.2010.06.014
NR 147
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2013
VL 91
SU THEI7
SI SI
BP 1
EP 22
DI 10.1111/aos.12272
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 247XS
UT WOS:000326658400001
PM 24206851
OA Bronze
DA 2022-11-30
ER

PT J
AU Tan, ACS
   Simhaee, D
   Balaratnasingam, C
   Dansingani, KK
   Yannuzzi, LA
AF Tan, Anna C. S.
   Simhaee, Daniel
   Balaratnasingam, Chandrakumar
   Dansingani, Kunal K.
   Yannuzzi, Lawrence A.
TI A Perspective on the Nature and Frequency of Pigment Epithelial
   Detachments
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL
   SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   NEOVASCULARIZATION; ANGIOGRAPHY; RANIBIZUMAB; ASSOCIATION; ANASTOMOSIS
AB PURPOSE: To describe and compare the clinical and imaging characteristics of pigment epithelial detachments (PEDs) in age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), and central serous chorioretinopathy (CSC) as seen in a clinical setting of a tertiary retinal practice.
   DESIGN: A perspective supported by clinical and imaging characteristics of a consecutive cohort of patients with strictly defined PEDs.
   RESULTS: One hundred seventy-four eyes of 113 patients with-PEDs were studied with comprehensive clinical retinal examination and multimodal imaging; PEDs were differentiated into nonvascularized and vascularized forms with 3 main underlying etiologies: AMD (76%), PCV (9%), and CSC (3%). AMD was the most common diagnosis, with both nonvascularized PEDs (drusenoid and serous) and vascularized PEDs (type 1 and type 3 neovascularization) associated with drusen and a thin choroid. PCV patients had large, vascularized, peaked PEDs associated with polyps and a variable choroidal thickness, while CSC patients had a thick choroid and predominantly nonvascularized, serous PEDs with an overlying neurosensory detachment. The combined clinical and imaging characteristics form a profile for each PED subtype related to their underlying disease. However, atypical features noted in 11% of patients may complicate the underlying diagnosis.
   CONCLUSION: Typical phenotypic manifestations of PEDs and other features seen with multimodal imaging were associated with specific underlying etiologies. As suggested by our study, identification of these features help clinicians to determine the precise underlying etiology and manage both vascularized PEDs, where evidence-based treatment exists, and nonvascularized PEDs, where current treatment is not supported by convincing evidence. ((C) 2016 Elsevier Inc. All rights reserved.)
C1 [Tan, Anna C. S.; Balaratnasingam, Chandrakumar; Dansingani, Kunal K.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
   [Tan, Anna C. S.; Simhaee, Daniel; Balaratnasingam, Chandrakumar; Dansingani, Kunal K.; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Tan, Anna C. S.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Lions Eye Inst, Dept Physiol & Pharmacol, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Dansingani, Kunal K.] Univ Nebraska, Truhlseq Eye Inst, Omaha, NE 68182 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; National University of Singapore; Singapore National
   Eye Center; Lions Eye Institute; University of Western Australia;
   University of Nebraska System
RP Tan, ACS (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM annacstan@gmail.com
FU MACULA FOUNDATION INC.
FX SUPPORT FROM THE MACULA FOUNDATION INC.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Constantinides G, 2000, J FR OPHTALMOL, V23, P649
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dansingani KK, 2015, RETINA, V36, P499
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Querques G, 2012, RETINA-J RET VIT DIS, V32, P458, DOI 10.1097/IAE.0b013e3182205960
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
NR 35
TC 31
Z9 33
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2016
VL 172
BP 13
EP 27
DI 10.1016/j.ajo.2016.09.004
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE5AF
UT WOS:000389616400004
PM 27637783
DA 2022-11-30
ER

PT J
AU Nashine, S
   Kanodia, R
   Nesburn, AB
   Soman, G
   Kuppermann, BD
   Kenney, MC
AF Nashine, Sonali
   Kanodia, Raj
   Nesburn, Anthony B.
   Soman, Girish
   Kuppermann, Baruch D.
   Kenney, M. Cristina
TI Nutraceutical effects of Emblica officinalis in age-related macular
   degeneration
SO AGING-US
LA English
DT Article
DE Emblica officinalis; Phyllanthus emblica; Indian gooseberry; Amla;
   nutraceutical; age-related macular degeneration; AMD
ID ALDOSE REDUCTASE EXPRESSION; OXIDATIVE STRESS; TANNOID PRINCIPLES; AMLA;
   GAERTN.; EXTRACT; INHIBITION; APOPTOSIS; MODEL; CELL
AB Emblica officinalis Gaetrn (i.e., Phyllanthus emblica/ Indian gooseberry/ Amla) (EO) has been used extensively as a nutraceutical in several diseases since it is known to boost immunity and offers numerous health benefits such as antioxidant, anti-inflammatory, and anti-aging effects. The goal of our study was to test the hypothesis that EO will rescue human AMD RPE transmitochondrial cells from mitochondria-induced cellular damage. AMD RPE transmitochondrial cell lines were created by fusing mitochondria DNA-deficient APRE-19 (Rho0) cells with platelets isolated from AMD patients, and therefore had identical nuclei but differed in mitochondrial DNA content. These AMD RPE cells were treated with EO extract followed by characterization of effects of EO using cellular and molecular assays. Herein, EO significantly improved live cell number and mitochondrial membrane potential, reduced apoptosis and oxidative stress, down-regulated VEGF, and up-regulated PGC-1 alpha. In conclusion, EO improved cellular and mitochondrial health, thereby playing a key cytoprotective role in AMD in vitro. Further studies are required to examine the mechanisms that mediate the cytoprotective effects of EO.
C1 [Nashine, Sonali; Nesburn, Anthony B.; Kuppermann, Baruch D.; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Kanodia, Raj] Dr Raj Kanodia Med Grp, Beverly Hills, CA 90210 USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Soman, Girish] Nisarga Biotech Pvt Ltd, Satara 415004, Maharashtra, India.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; Cedars
   Sinai Medical Center; University of California System; University of
   California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM mkenney@uci.edu
RI NASHINE, SONALI/AAG-1474-2020
FU 2017 Genentech/ARVO AMD Translational Research Fellowship; RPB (Research
   to Prevent Blindness) pilot research grant; Arnold and Mabel Beckman
   Foundation; UCI School of Medicine; Discovery Eye Foundation; Guenther
   Foundation; Beckman Initiative for Macular Research; Polly and Michael
   Smith Foundation; Max Factor Family Foundation; Iris and B. Gerald
   Cantor Foundation; RPB; 2016 RPB pilot research grant; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001414] Funding Source: NIH
   RePORTER
FX This research work was supported by the 2017 Genentech/ARVO AMD
   Translational Research Fellowship, RPB (Research to Prevent Blindness)
   pilot research grant, Arnold and Mabel Beckman Foundation, UCI School of
   Medicine, Discovery Eye Foundation, Guenther Foundation, Beckman
   Initiative for Macular Research, Polly and Michael Smith Foundation, Max
   Factor Family Foundation, Iris and B. Gerald Cantor Foundation; research
   was supported in part by an unrestricted grant from RPB. SN is a
   recipient of the 2017 Genentech/ARVO AMD Translational Research
   Fellowship and the 2016 RPB pilot research grant.
CR Agte V, 2014, BRIT J PHARM RES, V4, P2575, DOI 10.9734/BJPR/2014/6643
   Akhtar MS, 2011, INT J FOOD SCI NUTR, V62, P609, DOI 10.3109/09637486.2011.560565
   Allsop D, 2014, ESSAYS BIOCHEM, V56, P99, DOI [10.1042/BSE0560099, 10.1042/bse0560099]
   Carlsen MH, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-37
   Chandrasekaran A, 2017, REDOX BIOL, V11, P91, DOI 10.1016/j.redox.2016.11.005
   Chang KC, 2016, BIOCHEM BIOPH RES CO, V473, P565, DOI 10.1016/j.bbrc.2016.03.122
   Charoenteeraboon J., 2010, Songklanakarin Journal of Science and Technology, V32, P599
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De la Fuente M, 2009, CURR PHARM DESIGN, V15, P3003, DOI 10.2174/138161209789058110
   Golechha M, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/178408
   Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jacob KD, 2013, MECH AGEING DEV, V134, P139, DOI 10.1016/j.mad.2013.02.008
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joshi S., 2012, NATL J PHYSL PHARM, V2, P172
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kanthe PS, 2017, J CLIN DIAGN RES, V11, pCC5, DOI 10.7860/JCDR/2017/28474.10628
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   KINOSHITA JH, 1979, METABOLISM, V28, P462, DOI 10.1016/0026-0495(79)90057-X
   Kumari P, 2016, J FOOD SCI TECH MYS, V53, P3093, DOI 10.1007/s13197-016-2282-0
   Lim DW, 2016, NUTRIENTS, V8, DOI 10.3390/nu8120760
   Lu K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043934
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Md Hasan R., 2016, INT CURR PHARM J, V5, P14, DOI [DOI 10.3329/ICPJ.V5I2.26441, 10.3329/icpj.v5i2.26441]
   Middha SK, 2015, PHARMACOGN MAG, V11, pS427, DOI 10.4103/0973-1296.168982
   Murphy MP, 2010, J ALZHEIMERS DIS, V19, P311, DOI [10.3233/JAD-2009-1221, 10.3233/JAD-2010-1221]
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Ngamkitidechakul C, 2010, PHYTOTHER RES, V24, P1405, DOI 10.1002/ptr.3127
   Ram MS, 2003, PHYTOTHER RES, V17, P430, DOI 10.1002/ptr.1157
   Rao TP, 2013, BRIT J NUTR, V110, P2201, DOI 10.1017/S0007114513001669
   Rao TP, 2005, J MED FOOD, V8, P362, DOI 10.1089/jmf.2005.8.362
   Sairam K, 2002, J ETHNOPHARMACOL, V82, P1, DOI 10.1016/S0378-8741(02)00041-7
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Singh MK, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-193
   Singh Manish Kumar, 2014, Toxicol Int, V21, P8, DOI 10.4103/0971-6580.128784
   Snow A, 2015, CHEM-BIOL INTERACT, V234, P247, DOI 10.1016/j.cbi.2014.12.017
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Suryanarayana P, 2004, MOL VIS, V10, P148
   Tahir I, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1387-3
   Thenmozhi AJ, 2016, NUTR NEUROSCI, V19, P269, DOI 10.1179/1476830515Y.0000000016
   Thilakchand KR, 2013, FOOD FUNCT, V4, P1431, DOI 10.1039/c3fo60237k
   VINORES SA, 1988, DIABETES, V37, P1658, DOI 10.2337/diabetes.37.12.1658
   Wang W, 2016, ANTIOXID REDOX SIGN, V25, P534, DOI 10.1089/ars.2016.6739
   Yadav UCS, 2010, CURR MOL MED, V10, P540
   Yamamoto H, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1735841
   Yokozawa T, 2007, BRIT J NUTR, V97, P1187, DOI 10.1017/S0007114507691971
   Yokozawa T, 2007, J AGR FOOD CHEM, V55, P7744, DOI 10.1021/jf072105s
NR 51
TC 14
Z9 14
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD FEB 28
PY 2019
VL 11
IS 4
BP 1177
EP 1188
DI 10.18632/aging.101820
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA HN2QG
UT WOS:000460029300015
PM 30792375
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Joshi, D
   Field, J
   Murphy, J
   Abdelrahim, M
   Schonherr, H
   Sparrow, JR
   Ellestad, G
   Nakanishi, K
   Zask, A
AF Joshi, Dharati
   Field, James
   Murphy, John
   Abdelrahim, Mohammed
   Schoenherr, Heike
   Sparrow, Janet R.
   Ellestad, George
   Nakanishi, Koji
   Zask, Arie
TI Synthesis of Antioxidants for Prevention of Age-Related Macular
   Degeneration
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID LIGHT-INDUCED DAMAGE; LIPOFUSCIN FLUOROPHORE; EPITHELIAL-CELLS; PIGMENT
   A2-E; A2E; ANALOGS
AB Photooxidation of A2E may be involved in diseases of the macula, and antioxidants could serve as therapeutic agents for these diseases. Inhibitors of A2E photooxidation were prepared by Mannich reaction of the antioxidant quercetin. These compounds contain water-solubilizing amine groups, and several were more potent inhibitors of A2E photooxidation than quercetin.
C1 [Joshi, Dharati; Field, James; Murphy, John; Abdelrahim, Mohammed; Ellestad, George; Nakanishi, Koji; Zask, Arie] Columbia Univ, Dept Chem, New York, NY 10027 USA.
   [Schoenherr, Heike; Sparrow, Janet R.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Zask, A (通讯作者)，Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM AZ2280@columbia.edu
OI Zask, Arie/0000-0002-1991-1328
FU National Institutes of Health [RO1 EY12951]; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH
   RePORTER
FX J.R.S. and H.S. were supported by National Institutes of Health grant
   RO1 EY12951 (J.R.S.) and by a grant from Research to Prevent Blindness
   to the Department of Ophthalmology, Columbia University.
CR Amorati R, 2006, J AGR FOOD CHEM, V54, P2932, DOI 10.1021/jf053159+
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Lange J, 2000, HETEROCYCLES, V53, P197
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Reddy MVB, 2008, BIOORGAN MED CHEM, V16, P7358, DOI 10.1016/j.bmc.2008.06.018
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Wright JS, 2001, J AM CHEM SOC, V123, P1173, DOI 10.1021/ja002455u
   Yanase E, 2011, HETEROCYCLES, V82, P1151, DOI 10.3987/COM-10-S(E)102
   Zhang SX, 2008, BIOORGAN MED CHEM, V16, P7127, DOI 10.1016/j.bmc.2008.06.055
NR 18
TC 29
Z9 30
U1 7
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD MAR
PY 2013
VL 76
IS 3
BP 450
EP 454
DI 10.1021/np300769c
PG 5
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Plant Sciences; Pharmacology & Pharmacy
GA 114WO
UT WOS:000316773900022
PM 23346866
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Faes, L
   Bodmer, NS
   Locher, S
   Keane, PA
   Balaskas, K
   Bachmann, LM
   Schlingemann, RO
   Schmid, MK
AF Faes, Livia
   Bodmer, Nicolas S.
   Locher, Silvan
   Keane, Pearse A.
   Balaskas, Konstantinos
   Bachmann, Lucas M.
   Schlingemann, Reinier O.
   Schmid, Martin K.
TI Test performance of optical coherence tomography angiography in
   detecting retinal diseases: a systematic review and meta-analysis
SO EYE
LA English
DT Review
ID CENTRAL SEROUS CHORIORETINOPATHY; CHOROIDAL NEOVASCULARIZATION;
   DIABETIC-RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; DIAGNOSTIC-ACCURACY;
   FEATURES; TOOL
AB Objective To investigate the diagnostic accuracy of optical coherence tomography angiography (OCTA) in detecting vascular characteristics of chorio-retinal disease.
   Methods Evidence acquisition: We searched Web of Science, Scopus, and Medline by the citation of references and complemented these electronic searches by checking the list of references of included and review articles. Screening, selection, assessment, and extraction was performed in parallel by two authors.
   Results Evidence synthesis: Systematic review and exploratory meta-analysis. The ten studies that contributed to the meta-analysis enrolled 440 eyes and allowed constructing ten two-by-two tables. The tables reported on detection of choroidal neovascularization (CNV) in eyes suffering from either age-related macular degeneration (4), central serous chorioretinopathy (2), myopia (2), foveomacular vitelliform dystrophy (1), or a mixed cohort suffering from multiple retinal diseases (1). Of the ten studies, six used a cohort and four a case-control design. We found a pooled sensitivity of 0.90 (95% confidence intervals (CIs): 0.82-0.95) and a pooled specificity of 0.97 (95% CI: 0.89-0.99). Corresponding positive and negative likelihood ratios were 32.3 (95% CI: 7.4-141.6) and 0.10 (95% CI: 0.06-0.20), respectively. No pooling was possible for retinal vascular parameters of diabetic retinopathy, polypoidal choroidal vasculopathy, or detection of CNV activity.
   Conclusions The results of highly biased and heterogeneous studies assessing the diagnostic performance of OCTA high-light the need for further analyses of methodologically sound and sufficiently sized clinical evaluations.
C1 [Faes, Livia; Locher, Silvan; Schmid, Martin K.] Cantonal Hosp Lucerne, Eye Clin, Luzern, Switzerland.
   [Faes, Livia; Keane, Pearse A.; Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, Med Retina Dept, London, England.
   [Bodmer, Nicolas S.; Bachmann, Lucas M.] Medignition Inc, Zurich, Switzerland.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London, England.
   [Schlingemann, Reinier O.] Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Lucerne Cantonal Hospital; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London;
   University of Amsterdam; Academic Medical Center Amsterdam
RP Bodmer, NS (通讯作者)，Medignition Inc, Zurich, Switzerland.
EM bodmer@medignition.ch
RI Balaskas, Konstantinos/ABD-5979-2020; Keane, Pearse/AAE-5709-2019
OI Balaskas, Konstantinos/0000-0002-7690-6277; Keane,
   Pearse/0000-0002-9239-745X
FU Novartis AG
FX The research program of the Eye Clinic of the Cantonal Hospital Lucerne,
   funded by Novartis AG to assess the role of OCTA in screening,
   diagnosis, and prognosis of retinal diseases.
CR Bachmann LM, 2006, BRIT MED J, V332, P1127, DOI 10.1136/bmj.38793.637789.2F
   Bhanushali D, 2016, INVEST OPHTH VIS SCI, V57, pOCT519, DOI 10.1167/iovs.15-18901
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   de Carlo TE, 2016, OSLI RETINA, V47, P128, DOI 10.3928/23258160-20160126-05
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2364, DOI 10.1097/IAE.0000000000000882
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Freiberg FJ, 2016, GRAEF ARCH CLIN EXP, V254, P1051, DOI 10.1007/s00417-015-3148-2
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Harbord RM, 2008, J CLIN EPIDEMIOL, V61, P1095, DOI 10.1016/j.jclinepi.2007.09.013
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P1411, DOI 10.1001/jamaophthalmol.2016.4272
   Khan HA, 2017, EXPERT REV OPHTHALMO, V12, P373, DOI 10.1080/17469899.2017.1356229
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Lupidi M, 2015, INVEST OPHTH VIS SCI, V56, P7638, DOI 10.1167/iovs.15-17603
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Optovue, 2014, OPT INTR 1 SOFTW ASS
   Querques L, 2017, BRIT J OPHTHALMOL, V101, P609, DOI 10.1136/bjophthalmol-2016-309162
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Salz DA, 2016, JAMA OPHTHALMOL, V134, P644, DOI 10.1001/jamaophthalmol.2016.0600
   Shaimov T B, 2015, Vestn Oftalmol, V131, P4, DOI 10.17116/oftalma201513154-12
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2161, DOI 10.1097/IAE.0000000000000881
   Tan ACS, 2018, EYE, V32, P262, DOI 10.1038/eye.2017.181
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wylegala A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004907
   Zwinderman AH, 2008, STAT MED, V27, P687, DOI 10.1002/sim.2992
NR 39
TC 7
Z9 7
U1 0
U2 11
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2019
VL 33
IS 8
BP 1327
EP 1338
DI 10.1038/s41433-019-0421-3
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP8ZQ
UT WOS:000480336800020
PM 30971815
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Simonett, JM
   Chan, EW
   Chou, J
   Skondra, D
   Colon, D
   Chee, CK
   Lingam, G
   Fawzi, AA
AF Simonett, Joseph M.
   Chan, Errol W.
   Chou, Jonathan
   Skondra, Dimitra
   Colon, Daniel
   Chee, Caroline K.
   Lingam, Gopal
   Fawzi, Amani A.
TI Quantitative Analysis of En Face Spectral-Domain Optical Coherence
   Tomography Imaging in Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN
AB BACKGROUND AND OBJECTIVE: Spectral-domain optical coherence tomography (SD-OCT) imaging can be used to visualize polypoidal choroidal vasculopathy (PCV) lesions in the en face plane. Here, the authors describe a novel lesion quantification technique and compare PCV lesion area measurements and morphology before and after anti-vascular endothelial growth factor (VEGF) treatment.
   PATIENTS AND METHODS: Volumetric SD-OCT scans in eyes with PCV before and after induction anti-VEGF therapy were retrospectively analyzed. En face SD-OCT images were generated and a pixel intensity thresholding process was used to quantify total lesion area.
   RESULTS: Thirteen eyes with PCV were analyzed. En face SD-OCT PCV lesion area quantification showed good intergrader reliability (intraclass correlation coefficient = 0.944). Total PCV lesion area was significantly reduced after anti-VEGF therapy (2.22 mm(2) vs. 2.73 mm(2); P =.02). The overall geographic pattern of the branching vascular network was typically preserved.
   CONCLUSION: PCV lesion area analysis using en face SD-OCT is a reproducible tool that can quantify treatment related changes.
C1 [Simonett, Joseph M.; Chou, Jonathan; Skondra, Dimitra; Colon, Daniel; Fawzi, Amani A.] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave, Chicago, IL 60611 USA.
   [Chan, Errol W.] McGill Univ, McGill Univ Hlth Ctr, Dept Ophthalmol, Montreal, PQ, Canada.
   [Chan, Errol W.; Chee, Caroline K.] Natl Univ Singapore, Hlth Syst, Dept Ophthalmol, Singapore, Singapore.
   [Chan, Errol W.; Chee, Caroline K.] Yong Loo Lin Sch Med, Singapore, Singapore.
   [Chou, Jonathan] Massachusetts Eye & Ear Infirm, Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA.
C3 Northwestern University; Feinberg School of Medicine; McGill University;
   National University of Singapore; National University of Singapore;
   Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Fawzi, AA (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave, Chicago, IL 60611 USA.
EM afawzimd@gmail.com
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558
FU National University Health System Clinician-Scientist Program Grant
   (Singapore)
FX This study is supported by the National University Health System
   Clinician-Scientist Program Grant (Singapore).
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 19
TC 3
Z9 3
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2017
VL 48
IS 2
BP 126
EP +
DI 10.3928/23258160-20170130-06
PG 11
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EP2TG
UT WOS:000397235600006
PM 28195615
DA 2022-11-30
ER

PT J
AU Farooq, A
   Frazier, H
   Marcus, WB
   Fechter, C
   Singh, H
   Marcus, DM
AF Farooq, Amina
   Frazier, Heather
   Marcus, William B.
   Fechter, Chelsea
   Singh, Harinderjit
   Marcus, Dennis M.
TI Intravitreal Aflibercept for Neovascular Polypoidal Choroidal
   Vasculopathy in a Predominantly Non-Asian Population: RIVAL Results
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL
   GROWTH-FACTOR; OBSTRUCTIVE SLEEP-APNEA; MACULAR DEGENERATION;
   PHOTODYNAMIC THERAPY; BLOOD-FLOW; RANIBIZUMAB MONOTHERAPY; JAPANESE
   PATIENTS; VERTEPORFIN
AB BACKGROUND AND OBJECTIVE: To evaluate safety and efficacy of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injection (IAI) for the treatment of neovascular polypoidal choroidal vasculopathy (PCV) in a predominantly non-Asian population.
   PATIENTS AND METHODS: This was an open-label, prospective, unmasked, nonrandomized clinical trial. Twenty eyes with neovascular PCV received monthly 2.0 mg IAI for 3 months followed by mandatory IAI every 2 months for 12 months.
   RESULTS: The mean change in ETDRS best-corrected visual acuity from baseline to 1 year was +11 letters in the treatment-naive group, +5 letters in the treatment non-naive group, and +9 letters overall. There was an overall mean reduction of 70 mu m from baseline central subfield thickness (CST) at 1 year. Patients received a mean of 6.2 mandatory and 0.7 additional IAI injections overall during the course of 1 year. No serious ocular adverse events were reported.
   CONCLUSION: At 1 year, neovascular PCV in a predominantly non-Asian population treated with IAI demonstrated favorable visual, anatomic, and safety outcomes.
C1 [Farooq, Amina; Frazier, Heather; Marcus, William B.; Singh, Harinderjit; Marcus, Dennis M.] Southeast Retina Ctr, Augusta, GA USA.
   [Fechter, Chelsea] Mercer Univ, Sch Med, Macon, GA 31207 USA.
C3 Mercer University
RP Marcus, DM (通讯作者)，3685 Wheeler Rd, Augusta, GA 30909 USA.
EM dmarcus@southeastretina.com
FU Genentech; Regeneron; Acucela; Alcon Laboratories; Allergan;
   GlaxoSmithKline; Ophthotech; Pfizer; Roche; ThromboGenics; Del Mar
   Pharmaceuticals; Chiltern International; Neurotech Pharmaceuticals;
   Xcovery; Alimera Sciences
FX Dr. Dennis M. Marcus has served as an advisor or consultant for
   Genentech, Regeneron, and ThromboGenics; served as a speaker or member
   of a speakers bureau for Alimera Sciences, Genentech, and Regeneron;
   received grants for clinical research from Genentech and Regeneron; and
   received pharmaceutical-sponsored clinical research from Acucela, Alcon
   Laboratories, Allergan, Genentech, GlaxoSmithKline, Ophthotech, Pfizer,
   Regeneron, Roche, ThromboGenics, Del Mar Pharmaceuticals, Chiltern
   International, Neurotech Pharmaceuticals, and Xcovery. Dr. Singh has
   received grants for clinical research from Genentech and Regeneron, and
   pharmaceutical-sponsored clinical research from Acucela, Alcon
   Laboratories, Alimera Sciences, Allergan, Genentech, GlaxoSmithKline,
   Ophthotech, Pfizer, Regeneron, Roche, Del Mar Pharmaceuticals,
   ThromboGenics, Chiltern International, Neurotech Pharmaceuticals, and
   Xcovery. The remaining authors have no relevant financial disclosures.
CR Abraham A, 2013, CLIN NEUROL NEUROSUR, V115, P1379, DOI 10.1016/j.clineuro.2012.12.037
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Kergoat H, 1999, INVEST OPHTH VIS SCI, V40, P2906
   Khayi H, 2011, INVEST OPHTH VIS SCI, V52, P9489, DOI 10.1167/iovs.11-7936
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Marcus DM, 2015, EYE, V29, P1427, DOI 10.1038/eye.2015.150
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tonini M, 2010, SLEEP, V33, P811, DOI 10.1093/sleep/33.6.811
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 34
TC 2
Z9 2
U1 1
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2017
VL 48
IS 1
BP 34
EP U189
DI 10.3928/23258160-20161219-05
PG 19
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EO1OH
UT WOS:000396467300005
PM 28060392
DA 2022-11-30
ER

PT J
AU Sallo, FB
   Rechtman, E
   Peto, T
   Stanescu-Segall, D
   Vogt, G
   Bird, AC
   Fitzke, FW
AF Sallo, F. B.
   Rechtman, E.
   Peto, T.
   Stanescu-Segall, D.
   Vogt, G.
   Bird, A. C.
   Fitzke, F. W.
TI Functional aspects of drusen regression in age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; MACULOPATHY;
   OPHTHALMOSCOPE; ABNORMALITIES; PERIMETRY; AREAS
AB Aims: To investigate the functional implications of macular soft drusen regression in AMD eyes.
   Methods: Patients were selected from a large ongoing collection of clinical data at Moorfields Eye Hospital. Phenotyping based on standard colour fundus images was performed according to the system defined by the International Classification for ARM, by certified graders masked to the main aim of the study. Fundus autofluorescence (FA) was recorded using a Heidelberg Retina Angiograph 2. Where drusen regression was confirmed by independent grading, the patient was invited for photopic and scotopic fine matrix mapping (FMM). Phenotype and functional data were analysed for correlations between fundus appearance, autofluorescence and retinal sensitivity.
   Results: Fundus and FA images of 960 patients were screened, soft drusen regression was detected in 34 cases, and 14 patients agreed to participate in the study, ranging in age from 52 to 84 years (median 72). The mean follow-up period was 5.9 years (range 2.8-14.4 years). FMM showed generalised threshold elevation relative to normal controls both under photopic and scotopic conditions. Scotopic sensitivity loss exceeded photopic loss in all cases. Sensitivity loss over areas with drusen or regressed drusen did not differ significantly from that over non-drusen areas.
   Conclusion: Macular soft drusen may fade or disappear without detectable ophthalmoscopic, FA or psychophysical signs of local dysfunction. This phenomenon is a potential source of misclassification. The prognosis for cases with true regression of drusen compared with those without needs to be considered in future studies on AMD.
C1 [Sallo, F. B.] Moorfields Eye Hosp, Dept Res & Dev, Reading Ctr, London EC1V 2PD, England.
   [Sallo, F. B.; Bird, A. C.; Fitzke, F. W.] UCL Inst Ophthalmol, London, England.
   [Rechtman, E.] Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
   [Vogt, G.] State Hlth Ctr, Minist Def, Budapest, Hungary.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Chaim Sheba Medical Center
RP Sallo, FB (通讯作者)，Moorfields Eye Hosp, Dept Res & Dev, Reading Ctr, 162 City Rd, London EC1V 2PD, England.
EM fbsallo@yahoo.com
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   FITZKE FW, 1995, BRIT J OPHTHALMOL, V79, P207, DOI 10.1136/bjo.79.3.207
   FITZKE FW, 1989, EYE, V3, P84, DOI 10.1038/eye.1989.12
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Westcott MC, 1997, BRIT J OPHTHALMOL, V81, P452, DOI 10.1136/bjo.81.6.452
   WU D, 1995, CHUNG HUA YEN KO TSA, V31, P243
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 26
TC 23
Z9 23
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2009
VL 93
IS 10
BP 1345
EP 1350
DI 10.1136/bjo.2008.150334
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 498JN
UT WOS:000270135700016
PM 19535356
DA 2022-11-30
ER

PT J
AU Voigt, AP
   Mulfaul, K
   Mullin, NK
   Flamme-Wiese, MJ
   Giacalone, JC
   Stone, EM
   Tucker, BA
   Scheetz, TE
   Mullins, RF
AF Voigt, Andrew P.
   Mulfaul, Kelly
   Mullin, Nathaniel K.
   Flamme-Wiese, Miles J.
   Giacalone, Joseph C.
   Stone, Edwin M.
   Tucker, Budd A.
   Scheetz, Todd E.
   Mullins, Robert F.
TI Single-cell transcriptomics of the human retinal pigment epithelium and
   choroid in health and macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE choroid; choriocapillaris; single cell; age-related macular degeneration
ID HUMAN CHORIOCAPILLARIS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; HUMAN EYES;
   PATHOGENESIS; NEURONS; ICAM-1; FLOW
AB The human retinal pigment epithelium (RPE) and choroid are complex tissues that provide crucial support to the retina. Disease affecting either of these supportive tissues can lead to irreversible blindness in the setting of age-related macular degeneration. In this study, single-cell RNA sequencing was performed on macular and peripheral regions of RPE-choroid from 7 human donor eyes in 2 independent experiments. In the first experiment, total RPE/choroid preparations were evaluated and expression profiles specific to RPE and major choroidal cell populations were identified. As choroidal endothelial cells represent a minority of the total RPE/choroidal cell population but are strongly implicated in age-related macular degeneration (AMD) pathogenesis, a second single-cell RNA-sequencing experiment was performed using endothelial cells enriched by magnetic separation. In this second study, we identified gene expression signatures along the choroidal vascular tree, classifying the transcriptome of human choriocapillaris, arterial, and venous endothelial cells. We found that the choriocapillaris highly and specifically expresses the regulator of cell cycle gene (RGCC), a gene that responds to complement activation and induces apoptosis in endothelial cells. In addition, RGCC was the most upregulated choriocapillaris gene in a donor diagnosed with AMD. These results provide a characterization of the human RPE and choriocapillaris transcriptome, offering potential insight into the mechanisms of choriocapillaris response to complement injury and choroidal vascular disease in age-related macular degeneration.
C1 [Voigt, Andrew P.; Mulfaul, Kelly; Mullin, Nathaniel K.; Flamme-Wiese, Miles J.; Giacalone, Joseph C.; Stone, Edwin M.; Tucker, Budd A.; Scheetz, Todd E.; Mullins, Robert F.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Voigt, Andrew P.; Mulfaul, Kelly; Mullin, Nathaniel K.; Flamme-Wiese, Miles J.; Giacalone, Joseph C.; Stone, Edwin M.; Tucker, Budd A.; Scheetz, Todd E.; Mullins, Robert F.] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.; Mullins, RF (通讯作者)，Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
EM mullinsrf@gmail.com
RI Mullins, Robert F/I-6717-2013; Mullin, Nathaniel/AAY-6875-2020
OI Mullin, Nathaniel/0000-0003-4320-2852; Giacalone,
   Joseph/0000-0003-4404-9749; Scheetz, Todd/0000-0002-1965-5811; Mullins,
   Robert/0000-0002-5006-0891; Stone, Edwin M./0000-0003-3343-4414; Tucker,
   Budd/0000-0003-2178-1742; Voigt, Andrew/0000-0001-8107-8317
FU NIH [T32 GM007337, EY024605, EY027038, P30 EY025580]; Elmer and Sylvia
   Sramek Charitable Foundation; Research to Prevent Blindness; Martin and
   Ruth Carver Chair in Ocular Cell Biology; Carver College of Medicine;
   Holden Comprehensive Cancer Center; Iowa City Veteran's Administration
   Medical Center; NATIONAL EYE INSTITUTE [P30EY025580, R21EY027038]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [T32GM007337] Funding Source: NIH RePORTER
FX We thank the donors, their families, and the Iowa Lions Eye Bank for
   their generous role in this research. This work was supported in part by
   NIH Grants T32 GM007337, EY024605, EY027038, and P30 EY025580; the Elmer
   and Sylvia Sramek Charitable Foundation; Research to Prevent Blindness;
   and the Martin and Ruth Carver Chair in Ocular Cell Biology. The RGCC
   monoclonal antibody developed by Johns Hopkins University/CDI was
   obtained from the Developmental Studies Hybridoma Bank, created by the
   National Institute of Child Health and Human Development of the NIH and
   maintained at the Department of Biology, The University of Iowa (Iowa
   City, IA). The data presented herein were obtained at the Flow Cytometry
   Facility, which is a Carver College of Medicine/Holden Comprehensive
   Cancer Center Core Research Facility at the University of Iowa. The
   facility is funded through user fees and the generous financial support
   of the Carver College of Medicine, Holden Comprehensive Cancer Center,
   and Iowa City Veteran's Administration Medical Center.
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   An XJ, 2009, CIRCULATION, V120, P617, DOI 10.1161/CIRCULATIONAHA.108.841502
   Aran A, 2016, NEUROLOGY, V86, P2016, DOI 10.1212/WNL.0000000000002704
   Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200
   Ban Y, 2000, DEV BRAIN RES, V121, P89
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Buschmann I, 2010, DEVELOPMENT, V137, P2187, DOI 10.1242/dev.045351
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Casey CS, 2015, J BIOL CHEM, V290, P14208, DOI 10.1074/jbc.M114.625251
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2018, EYE, V32, P1740, DOI 10.1038/s41433-018-0170-8
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Fang JS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01742-7
   FLUGEL C, 1994, INVEST OPHTH VIS SCI, V35, P592
   Giacalone JC, 2019, MICROVASC RES, V123, P50, DOI 10.1016/j.mvr.2018.12.002
   GOLDBLUM SE, 1994, P NATL ACAD SCI USA, V91, P3448, DOI 10.1073/pnas.91.8.3448
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   Hasegawa T, 2007, DEV DYNAM, V236, P2089, DOI 10.1002/dvdy.21231
   Hayashi Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0088-z
   Herrnberger L, 2012, EXP EYE RES, V105, P27, DOI 10.1016/j.exer.2012.09.011
   Hochgrebe TT, 1999, EXP CELL RES, V249, P13, DOI 10.1006/excr.1999.4459
   Hu YQ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000365
   Hwang B, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0071-8
   Lu J, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-015-0109-9
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nguyen DV, 2013, GROWTH HORM IGF RES, V23, P45, DOI 10.1016/j.ghir.2013.03.001
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nork TM, 2006, ARCH OPHTHALMOL-CHIC, V124, P860, DOI 10.1001/archopht.124.6.860
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Reiner A, 2018, PROG RETIN EYE RES, V64, P96, DOI 10.1016/j.preteyeres.2017.12.001
   Rheaume BA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05134-3
   Sabbagh MF, 2018, ELIFE, V7, DOI 10.7554/eLife.36187
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054
   Shibuya M, 2007, INVEST OPHTH VIS SCI, V48, P516, DOI 10.1167/iovs.06-0434
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Sun HY, 2010, BIOCHEM BIOPH RES CO, V395, P361, DOI 10.1016/j.bbrc.2010.04.019
   Thiriot A, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0381-7
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   van Soest SS, 2007, MOL VIS, V13, P1608
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Voigt A. P., GENE EXPRESSION OMNI
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wilkerson BA, 2014, BBA-MOL CELL BIOL L, V1841, P1403, DOI 10.1016/j.bbalip.2014.06.012
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yuan K, 2016, AM J PATHOL, V186, P2500, DOI 10.1016/j.ajpath.2016.05.016
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049
   Zheng PP, 2010, ANN NEUROL, V68, P835, DOI 10.1002/ana.22318
NR 66
TC 107
Z9 106
U1 2
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 26
PY 2019
VL 116
IS 48
BP 24100
EP 24107
DI 10.1073/pnas.1914143116
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JQ7DI
UT WOS:000499101100039
PM 31712411
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Sunness, JS
   Rubin, GS
   Zuckerbrod, A
   Applegate, CA
AF Sunness, Janet S.
   Rubin, Gary S.
   Zuckerbrod, Abraham
   Applegate, Carol A.
TI Foveal-Sparing Scotomas in Advanced Dry Age-Related Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; VISUAL-ACUITY LOSS; GEOGRAPHIC ATROPHY;
   ENLARGEMENT; LOCI
AB Foveal-sparing scotomas are common in advanced dry macular degeneration (geographic atrophy). Foveal preservation may be present for a number of years. Despite good visual acuity, these patients have reduced reading rates. Magnification may not be effective if the text becomes too large to "fit" within the central spared area.
C1 [Sunness, Janet S.; Applegate, Carol A.] Greater Baltimore Med Ctr, Richard E Hoover Rehabil Serv Low Vis & Blindness, Hoover Serv, Baltimore, MD 21204 USA.
   [Rubin, Gary S.] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Zuckerbrod, Abraham] SUNY, Coll Optometry, New York, NY 10036 USA.
C3 Greater Baltimore Medical Center; University of London; University
   College London; State University of New York (SUNY) System; SUNY
   Community College; SUNY Maritime College; SUNY Optometry
RP Sunness, JS (通讯作者)，Greater Baltimore Med Ctr, Richard E Hoover Rehabil Serv Low Vis & Blindness, Hoover Serv, 6569 N Charles St,PPW 305, Baltimore, MD 21204 USA.
EM jsunness@gbmc.org; g.rubin@ucl.ac.uk; azuckerbrod@sunyopt.edu;
   capplegate@gbmc.org
OI Sunness, Janet/0000-0001-8823-0780
FU NATIONAL EYE INSTITUTE [R03EY014148, R01EY008552] Funding Source: NIH
   RePORTER; NEI NIH HHS [R03 EY014148, R01 EY008552-06A1] Funding Source:
   Medline
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HART WM, 1983, OPHTHALMOLOGY, V90, P1028
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P205, DOI 10.1097/ICB.0b013e31806011e6
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SUNNESS JS, J VISUAL IM IN PRESS
   SUNNESS JS, RETINAL CAS IN PRESS
NR 18
TC 59
Z9 59
U1 0
U2 0
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2008
VL 102
IS 10
SI SI
BP 600
EP 610
PG 11
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 365YI
UT WOS:000260445400004
PM 20224750
DA 2022-11-30
ER

PT J
AU Gertner, M
   Chell, E
   Pan, KH
   Hansen, S
   Kaiser, PK
   Moshfeghi, DM
AF Gertner, Michael
   Chell, Erik
   Pan, Kuang-Hung
   Hansen, Steve
   Kaiser, Peter K.
   Moshfeghi, Darius M.
TI Stereotactic targeting and dose verification for age-related macular
   degeneration
SO MEDICAL PHYSICS
LA English
DT Article
DE eye; radiation therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXTERNAL-BEAM RADIOTHERAPY;
   RADIATION-THERAPY; SR-90 BRACHYTHERAPY; RETINOPATHY; SECONDARY; TRIAL;
   GY
AB Methods: Ten human cadaver eyes were obtained for this study and mounted in the IRay (TM) system. Using gel and vacuum, an I-Guide (TM) immobilization device was coupled to the eyes and radiochromic film was affixed to the posterior aspect of the globes. Three narrow x-ray beams were delivered through the pars plana to overlap on the predicted nominal fovea. A needle was placed through the center of the film's beam spot and into the eye to register the film and the inner retina. The process was performed three times for each of the ten eyes (30 simulated treatments; 90 individual beams). The globes were dissected to assess the targeting accuracy by measuring the distances from the needles to the fovea. The dose to the fovea was calculated from the radiochromic film.
   Results: X-ray targeting on the retina averaged 0.6 +/- 0.4 mm from the fovea. Repeated treatments on the same eye showed a reproducibility of 0.4 +/- 0.4 mm. The optic nerve was safely avoided, with the 90% isodose edge of the beam spot between 0.4 and 2.6 mm from the edge of the optic disk. Measured dose matched that prescribed.
   Conclusions: This study provides confidence that the IRay (TM), with an average accuracy of 0.6 mm and a precision of 0.4 mm, can reliably treat most AMD lesions centered on the fovea. With the exception of motion, all sources of error are included.
C1 [Gertner, Michael; Chell, Erik; Pan, Kuang-Hung; Hansen, Steve] Oraya Therapeut Inc, Newark, CA 94560 USA.
   [Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44915 USA.
   [Moshfeghi, Darius M.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 Cleveland Clinic Foundation; Stanford University
RP Moshfeghi, DM (通讯作者)，1225 Crane St,Ste 202 Menlo Pk, Menlo Pk, CA 94025 USA.
EM dariusm@stanford.edu
OI Kaiser, Peter/0000-0001-5126-045X; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
CR Akmansu M, 1998, INT J RADIAT ONCOL, V40, P923, DOI 10.1016/S0360-3016(97)00859-6
   Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Donati G, 1999, BRIT J OPHTHALMOL, V83, P646, DOI 10.1136/bjo.83.6.646
   Eter N, 1998, GRAEF ARCH CLIN EXP, V236, P806, DOI 10.1007/s004170050164
   Eter Nicole, 2001, International Ophthalmology, V24, P13, DOI 10.1023/A:1014445524293
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   Girkin CA, 1997, OPHTHALMOLOGY, V104, P1634, DOI 10.1016/S0161-6420(97)30084-0
   Gripp S, 2002, INT J RADIAT ONCOL, V52, P489, DOI 10.1016/S0360-3016(01)02611-6
   Haas A, 2002, OPHTHALMOLOGY, V109, P909, DOI 10.1016/S0161-6420(02)01011-4
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hoeller U, 2005, EYE, V19, P1151, DOI 10.1038/sj.eye.6701743
   Hoyng CB, 2002, GRAEF ARCH CLIN EXP, V240, P337, DOI 10.1007/s00417-002-0428-4
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Lambooij AC, 2001, GRAEF ARCH CLIN EXP, V239, P539, DOI 10.1007/s004170100314
   LEE AWM, 1999, NASOPHARYNGEAL CARCI, P255
   Lisc Ak Roman, 2007, Prog Neurol Surg, V20, P324, DOI 10.1159/000100176
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 1999, RETINA-J RET VIT DIS, V19, P525, DOI 10.1097/00006982-199911000-00008
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   Munshi Anusheel, 2007, J Cancer Res Ther, V3, P12
   Niroomand-Rad A, 1998, MED PHYS, V25, P2093, DOI 10.1118/1.598407
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Postelmans L, 1999, Bull Soc Belge Ophtalmol, V271, P73
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   Roos DE, 1999, INT J RADIAT ONCOL, V43, P1071, DOI 10.1016/S0360-3016(98)00493-3
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   Schulte RW, 2000, INT J RADIAT ONCOL, V47, P1105, DOI 10.1016/S0360-3016(00)00551-4
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V18
   Staar S, 1999, INT J RADIAT ONCOL, V45, P467, DOI 10.1016/S0360-3016(99)00186-8
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Valmaggia C, 1997, DOC OPHTHALMOL, V93, P317, DOI 10.1007/BF02569069
   van Ginderdeuren R, 2005, BRIT J OPHTHALMOL, V89, P1306, DOI 10.1136/bjo.2005.068460
   Vinh-Hung V, 1998, INT J RADIAT ONCOL, V41, P721, DOI 10.1016/S0360-3016(98)00070-4
NR 42
TC 23
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD FEB
PY 2010
VL 37
IS 2
BP 600
EP 606
DI 10.1118/1.3291648
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 549SW
UT WOS:000274075600020
PM 20229868
DA 2022-11-30
ER

PT J
AU Wiecek, E
   Jackson, ML
   Dakin, SC
   Bex, P
AF Wiecek, Emily
   Jackson, Mary Lou
   Dakin, Steven C.
   Bex, Peter
TI Visual Search with Image Modification in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID QUALITY-OF-LIFE; OBJECT RECOGNITION; NATURAL SCENES; FACE RECOGNITION;
   OLDER-ADULTS; READING PERFORMANCE; SPATIAL-FREQUENCY; EYE-MOVEMENTS;
   LOW-VISION; ENHANCEMENT
AB PURPOSE. AMD results in loss of central vision and a dependence on low-resolution peripheral vision. While many image enhancement techniques have been proposed, there is a lack of quantitative comparison of the effectiveness of enhancement. We developed a natural visual search task that uses patients' eye movements as a quantitative and functional measure of the efficacy of image modification.
   METHODS. Eye movements of 17 patients (mean age = 77 years) with AMD were recorded while they searched for target objects in natural images. Eight different image modification methods were implemented and included manipulations of local image or edge contrast, color, and crowding. In a subsequent task, patients ranked their preference of the image modifications.
   RESULTS. Within individual participants, there was no significant difference in search duration or accuracy across eight different image manipulations. When data were collapsed across all image modifications, a multivariate model identified six significant predictors for normalized search duration including scotoma size and acuity, as well as interactions among scotoma size, age, acuity, and contrast (P < 0.05). Additionally, an analysis of image statistics showed no correlation with search performance across all image modifications. Rank ordering of enhancement methods based on participants' preference revealed a trend that participants preferred the least modified images (P < 0.05).
   CONCLUSIONS. There was no quantitative effect of image modification on search performance. A better understanding of low-and high-level components of visual search in natural scenes is necessary to improve future attempts at image enhancement for low vision patients. Different search tasks may require alternative image modifications to improve patient functioning and performance. (Invest Ophthalmol Vis Sci. 2012;53:6600-6609) DOI:10.1167/iovs.12-10012
C1 [Wiecek, Emily; Jackson, Mary Lou; Bex, Peter] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Wiecek, Emily; Bex, Peter] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Wiecek, Emily; Dakin, Steven C.] UCL, Inst Ophthalmol, London, England.
   [Dakin, Steven C.] Moorfields Eye Hosp NHS Fdn Trust, NIHR, Biomed Res Ctr, London, England.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; University of London; University
   College London; University of London; King's College London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Wiecek, E (通讯作者)，20 Staniford St, Boston, MA 02118 USA.
EM emily.wiecek@schepens.harvard.edu
RI Dakin, Steven C/B-7610-2008
OI Dakin, Steven C/0000-0002-3548-9104
FU National Institute of Health [R01EY018664, R01EY019281]; NIHR Biomedical
   Research Centre at Moorfields Eye Hospital NHS Foundation Trust;
   NATIONAL EYE INSTITUTE [R01EY019281, R01EY018664] Funding Source: NIH
   RePORTER
FX Supported by National Institute of Health Grants R01EY018664 and
   R01EY019281, and by the NIHR Biomedical Research Centre at Moorfields
   Eye Hospital NHS Foundation Trust (SCD).
CR Al-Atabany WI, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-27
   Alvarez GA, 2004, PSYCHOL SCI, V15, P106, DOI 10.1111/j.0963-7214.2004.01502006.x
   Anstey KJ, 2005, CLIN PSYCHOL REV, V25, P45, DOI 10.1016/j.cpr.2004.07.008
   BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Bex PJ, 2009, J VISION, V9, DOI 10.1167/9.10.1
   BIEDERMAN I, 1988, J EXP PSYCHOL LEARN, V14, P456, DOI 10.1037/0278-7393.14.3.456
   BIEDERMAN I, 1982, COGNITIVE PSYCHOL, V14, P143, DOI 10.1016/0010-0285(82)90007-X
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   BOYCE SJ, 1989, J EXP PSYCHOL HUMAN, V15, P556, DOI 10.1037/0096-1523.15.3.556
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Bravo MJ, 2004, PERCEPTION, V33, P643, DOI 10.1068/p5244
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chun MM, 1998, COGNITIVE PSYCHOL, V36, P28, DOI 10.1006/cogp.1998.0681
   Chung STL, 2001, VISION RES, V41, P1833, DOI 10.1016/S0042-6989(01)00071-2
   COCKRELL JR, 1988, PSYCHOPHARMACOL BULL, V24, P689
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   ERICKSON RA, 1964, HUM FACTORS, V6, P165
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FINE EM, 1995, J OPT SOC AM A, V12, P1439, DOI 10.1364/JOSAA.12.001439
   Firestone A, 2007, AGING NEUROPSYCHOL C, V14, P594, DOI 10.1080/13825580600899717
   Fosse P, 2001, VISUAL IMPAIRMENT RE, V3, P111
   Foster JK, 1995, AGING COGNITION, V2, P279, DOI 10.1080/13825589508256604
   Fullerton M, 2006, J SOC INF DISPLAY, V14, P15, DOI 10.1889/1.2166829
   Gegenfurtner KR, 2000, CURR BIOL, V10, P805, DOI 10.1016/S0960-9822(00)00563-7
   Geisler WS, 2008, ANNU REV PSYCHOL, V59, P167, DOI 10.1146/annurev.psych.58.110405.085632
   Gold J, 1999, VISION RES, V39, P3537, DOI 10.1016/S0042-6989(99)00080-2
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hayhoe M, 2005, TRENDS COGN SCI, V9, P188, DOI 10.1016/j.tics.2005.02.009
   Ho G, 2001, HUM FACTORS, V43, P194, DOI 10.1518/001872001775900922
   Jacko J. A., 2002, Universal Access in the Information Society, V1, P197, DOI 10.1007/s102090100015
   JOHNSON MA, 1986, AM J OPTOM PHYS OPT, V63, P97
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   Lawton TA, 1998, VISION RES, V38, P153, DOI 10.1016/S0042-6989(97)00140-5
   Leat SJ, 2009, OPHTHAL PHYSL OPT, V29, P397, DOI 10.1111/j.1475-1313.2008.00633.x
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Lott LA, 2001, OPTOMETRY VISION SCI, V78, P316, DOI 10.1097/00006324-200105000-00015
   MADDEN DJ, 1983, DEV PSYCHOL, V19, P499, DOI 10.1037/0012-1649.19.4.499
   MANDLER JM, 1976, J EXP PSYCHOL-HUM L, V2, P529, DOI 10.1037/0278-7393.2.5.529
   Neider MB, 2006, VISION RES, V46, P614, DOI 10.1016/j.visres.2005.08.025
   Over EAB, 2007, VISION RES, V47, P2272, DOI 10.1016/j.visres.2007.05.002
   Owsley C, 2000, GERONTOLOGY, V46, P300, DOI 10.1159/000022181
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   PALMER SE, 1975, MEM COGNITION, V3, P519, DOI 10.3758/BF03197524
   Peli E, 2005, OPHTHAL PHYSL OPT, V25, P543, DOI 10.1111/j.1475-1313.2005.00340.x
   PELI E, 1994, J OPT SOC AM A, V11, P1929, DOI 10.1364/JOSAA.11.001929
   Peli E, 2004, J OPT SOC AM A, V21, P937, DOI 10.1364/JOSAA.21.000937
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Querques G, 2011, CLIN OPHTHALMOL, V5, P593, DOI 10.2147/OPTH.S10161
   Russell BC, 2008, INT J COMPUT VISION, V77, P157, DOI 10.1007/s11263-007-0090-8
   SOLOMON JA, 1994, NATURE, V369, P395, DOI 10.1038/369395a0
   STEEDMAN WC, 1960, HUM FACTORS, V2, P120, DOI 10.1177/001872086000200302
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Vlaskamp BNS, 2006, VISION RES, V46, P417, DOI 10.1016/j.visres.2005.04.006
   Whitney D, 2011, TRENDS COGN SCI, V15, P160, DOI 10.1016/j.tics.2011.02.005
   Wichmann FA, 2002, J EXP PSYCHOL LEARN, V28, P509, DOI 10.1037//0278-7393.28.3.509
   WILLIAMS LG, 1966, PERCEPT PSYCHOPHYS, V1, P315, DOI 10.3758/BF03207398
   Wolfe JM, 2002, VISION RES, V42, P2985, DOI 10.1016/S0042-6989(02)00388-7
   WURM LH, 1993, J EXP PSYCHOL HUMAN, V19, P899, DOI 10.1037/0096-1523.19.4.899
NR 64
TC 16
Z9 16
U1 0
U2 19
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6600
EP 6609
DI 10.1167/iovs.12-10012
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 016NQ
UT WOS:000309526200078
PM 22930725
OA Green Published
DA 2022-11-30
ER

PT J
AU Kaji, Y
   Oshika, T
   Takazawa, Y
   Fukayama, M
   Fujii, N
AF Kaji, Yuichi
   Oshika, Tetsuro
   Takazawa, Yutaka
   Fukayama, Masashi
   Fujii, Noriko
TI Accumulation of D-beta-Aspartic Acid-Containing Proteins in Age-Related
   Ocular Diseases
SO CHEMISTRY & BIODIVERSITY
LA English
DT Article
ID GLYCATION END-PRODUCTS; ALPHA-A-CRYSTALLIN; D-AMINO-ACID; HUMAN LENS;
   MACULAR DEGENERATION; IMMUNOHISTOCHEMICAL LOCALIZATION; SIMULTANEOUS
   STEREOINVERSION; ALZHEIMER-DISEASE; ELASTIC FIBERS; RACEMIZATION
AB Transparency is essential for eyes, which serve as cameras. However, decreased transparency caused by accumulation of abnormal proteins is commonly observed especially in elderly people. However, the mechanism of accumulation of abnormal proteins in various ocular diseases is still unclear. In the present study, we investigated the role of D-amino acids in the development of accumulation of abnormal proteins in age-related ocular diseases.
   Whole eyes with age-related macular degeneration were excised from four patients. Surgical specimens with pinguecula were excised from eight patients, and specimens with climatic droplet keratopathy were excised from three patients. Polyclonal antibody to the D-beta-Asp-containing peptide was prepared. Using the antibody, immunohistochemical localization of D-beta-Asp-containing proteins was determined.
   In eyes with age-related macular degeneration, accumulation of abnormal proteins was observed between the retinal pigment epithelial cells and Bruch's membrane. The accumulated abnormal proteins were positive for D-beta-Asp-containing peptides. In surgical specimens with pinguecula and climatic droplet keratopathy, abnormal accumulation of proteins seen in the superficial layer of the stroma was positive for D-beta-Asp-containing peptide.
   The results indicate that development of D-beta-Asp-containing proteins in vivo have a central role in the development of accumulation of abnormal proteins in age-related macular degeneration, pinguecula, and climatic drop-like dystrophy.
C1 [Kaji, Yuichi; Oshika, Tetsuro] Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tsukuba, Ibaraki 3058575, Japan.
   [Takazawa, Yutaka; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Human Pathol, Tokyo, Japan.
   [Fujii, Noriko] Kyoto Univ, Inst Res Reactor, Osaka 59004, Japan.
C3 University of Tsukuba; University of Tokyo; Kyoto University
RP Kaji, Y (通讯作者)，Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058575, Japan.
EM kajiyuichi@hotmail.com
FU Ministry of Education, Science, Sports and Culture, Japan [21592216]
FX This work is supported by the Ministry of Education, Science, Sports and
   Culture, Grant-in-Aid for Scientific Research, 21592216 (2009-2011),
   Japan.
CR Bellotti V, 1999, CELL MOL LIFE SCI, V55, P977, DOI 10.1007/s000180050348
   Biroccio A, 2006, PROTEOMICS, V6, P2305, DOI 10.1002/pmic.200500285
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Fujii N, 2005, BIOL PHARM BULL, V28, P1585, DOI 10.1248/bpb.28.1585
   Fujii N, 2004, CHEM REC, V4, P267, DOI 10.1002/tcr.20020
   Fujii N, 1999, BIOCHEM BIOPH RES CO, V263, P322, DOI 10.1006/bbrc.1999.1279
   Fujii N, 2000, MOL VIS, V6, P1
   Fujii N, 2003, MOL VIS, V9, P315
   FUJII N, 1994, J BIOCHEM-TOKYO, V116, P663, DOI 10.1093/oxfordjournals.jbchem.a124577
   Fujii N, 2002, BIOCHEM BIOPH RES CO, V294, P1047, DOI 10.1016/S0006-291X(02)00597-1
   FUJII N, 1994, BBA-PROTEIN STRUCT M, V1204, P157, DOI 10.1016/0167-4838(94)90003-5
   Fujii N, 2002, ORIGINS LIFE EVOL B, V32, P103, DOI 10.1023/A:1016031014871
   Fujii N, 1999, MECH AGEING DEV, V107, P347, DOI 10.1016/S0047-6374(98)00129-8
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kaji Y, 2009, BRIT J OPHTHALMOL, V93, P977, DOI 10.1136/bjo.2008.144212
   Kaji Y, 2009, BRIT J OPHTHALMOL, V93, P974, DOI 10.1136/bjo.2007.135889
   Kaji Y, 2007, INVEST OPHTH VIS SCI, V48, P3923, DOI 10.1167/iovs.06-1284
   Kubo T, 2003, J NEUROPATH EXP NEUR, V62, P248, DOI 10.1093/jnen/62.3.248
   MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460
   Murata T, 1997, DIABETOLOGIA, V40, P764, DOI 10.1007/s001250050747
   Ohtani S, 1998, GROWTH DEVELOP AGING, V62, P141
   POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z
   Ritz-Timme S, 2003, INT J LEGAL MED, V117, P96, DOI 10.1007/s00414-002-0355-2
   SHAPIRA R, 1987, BIOCHEM BIOPH RES CO, V146, P1342, DOI 10.1016/0006-291X(87)90797-2
   SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204
   TOMIYAMA T, 1994, J BIOL CHEM, V269, P10205
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766
NR 28
TC 13
Z9 14
U1 0
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1612-1872
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PY 2010
VL 7
IS 6
BP 1364
EP 1370
DI 10.1002/cbdv.200900329
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 643PN
UT WOS:000281310800005
PM 20564555
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Kitamei, H
   Shioya, S
AF Hikichi, Taiichi
   Kitamei, Hirokuni
   Shioya, Shoko
TI Retinal pigment epithelial atrophy over polypoidal choroidal
   vasculopathy lesions during ranibizumab monotherapy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Retinal pigment
   epithelial atrophy
ID GEOGRAPHIC ATROPHY; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   OUTCOMES; PROGRESSION; EXPRESSION; ANCHOR; GROWTH; MARINA; VEGF
AB Background: To evaluate the quantitative changes of retinal pigment epithelial (RPE) atrophy during 3-year follow-up period of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV).
   Methods: We retrospectively reviewed consecutive 100 Japanese patients with unilateral symptomatic treatment-naive PCV who received ranibizumab monotherapy for 3 years. Color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence were evaluated for RPE atrophy. Multiple regression analysis was performed to investigate the predictive factors found during univariate analysis to identify an association with increased RPE atrophic areas. RPE atrophic areas overlapping PCV lesions were measured.
   Results: The mean (standard deviation) number of injections was 11.4 (4.50). RPE atrophic area enlarged to 2.91 (5.41 mm(2)) 3 years after the first injection from 1.22 (1.72 mm(2)) at baseline, which differed significantly (P = 0.012). Multiple regression analysis showed that larger PCV lesions and larger RPE atrophic areas at baseline were associated with increased RPE atrophic areas. RPE atrophic area overlapping the baseline PCV lesions significantly increased during 3-year follow-up period, whereas RPE atrophic area not overlapping the baseline PCV lesions did not increase significantly.
   Conclusion: RPE atrophy progresses in eyes with PCV during ranibizumab monotherapy and the tendency for development of RPE atrophy within the PCV lesions.
C1 [Hikichi, Taiichi] Hikichi Eye Clin, Kita Ku, Kita 7 Nishi 5 7-1 Kita Sky Bild 14F, Sapporo, Hokkaido 0600807, Japan.
   [Hikichi, Taiichi; Kitamei, Hirokuni; Shioya, Shoko] Ohtsuka Eye Hosp, Sapporo, Hokkaido, Japan.
RP Hikichi, T (通讯作者)，Hikichi Eye Clin, Kita Ku, Kita 7 Nishi 5 7-1 Kita Sky Bild 14F, Sapporo, Hokkaido 0600807, Japan.; Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Sapporo, Hokkaido, Japan.
EM thikichi@hikichi-eye.jp
FU Novartis Pharma Japan; Bayer Japan; Abott Japan
FX Dr. Hikichi received lecture fees from Novartis Pharma Japan, Bayer
   Japan, and Abott Japan. Dr. Kitamei received lecture fee from Novartis
   Pharma Japan. Dr. Shioya received lecture fees from Novartis Pharma
   Japan.
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 21
TC 6
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 16
PY 2016
VL 16
AR 55
DI 10.1186/s12886-016-0237-x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN0EN
UT WOS:000376737300001
PM 27184489
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lee, A
   Ra, H
   Baek, J
AF Lee, Anna
   Ra, Ho
   Baek, Jiwon
TI Choroidal vascular densities of macular disease on ultra-widefield
   indocyanine green angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal vascular density; Haller vessel; Pachyvessel; Ultra-widefield
   indocyanine green (UWF ICGA); Pachychoroid
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   THICKNESS; AGE; DEGENERATION; EYES
AB Purpose We sought to compare choroidal vascular characteristics of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), and age-related macular degeneration (AMD) using quantitative analyses of ultra-widefield indocyanine green (UWF ICGA) images. Methods Eyes with CSC (n = 57), thick-choroid PCV (n = 29), thin-choroid PCV (n = 25), neovascular AMD (n = 45), and pachychoroid neovasculopathy (PNV) (n = 28) were enrolled. On UWF ICGA images, choroidal vascular density (CVD) was assessed using binarization in the total area, posterior pole, each quadrant, and vortex ampullae. Subfoveal choroidal thickness (SFCT) was measured using optical coherence tomography. Results The CVDs of thin-choroid PCV and typical AMD were lower than those of CSC (P = 0.002 and P < 0.001, respectively; P = 0.010 and P = 0.016 when adjusted for age.), whereas the CVDs of CSC, thick-choroid PCV, and PNV did not differ from each other (all P >= 0.161; all P >= 0.424 when adjusted for age). The CVD of the total area showed a positive correlation with SFCT in each also a whole group (all P <= 0.001). Meanwhile, the CVD of each ampullae positively correlated with that of the corresponding quadrant in total eyes and in each group (all P <= 0.001). Conclusions The mean CVD on UWF ICGA was increased in CSC, thick-choroid PCV, and PNV, whereas it was relatively low in thin-choroid PCV and typical AMD. Congestion at the vortex ampulla might be a cause of increased CVD, therefore increasing the SFCT in pachychoroid eyes.
C1 [Lee, Anna; Ra, Ho; Baek, Jiwon] Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Dept Ophthalmol, 327 Sosa Ro, Bucheon 14647, Gyeonggi Do, South Korea.
C3 Catholic University of Korea
RP Baek, J (通讯作者)，Catholic Univ Korea, Coll Med, Bucheon St Marys Hosp, Dept Ophthalmol, 327 Sosa Ro, Bucheon 14647, Gyeonggi Do, South Korea.
EM md.jiwon@gmail.com
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute - Ministry of Health and Welfare, Republic of
   Korea [HI17C2012030018]
FX This work was supported by a grant from the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute, funded
   by the Ministry of Health and Welfare, Republic of Korea (grant no:
   HI17C2012030018).
CR Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   CastroCorreia J, 1995, INT OPHTHALMOL, V19, P135
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung YR, 2016, RETINA-J RET VIT DIS, V36, P1652, DOI 10.1097/IAE.0000000000000998
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   GASS JDM, 1983, RETINA-J RET VIT DIS, V3, P159, DOI 10.1097/00006982-198300330-00003
   Gupta MP, 2016, CLIN OPHTHALMOL, V10, P1275, DOI 10.2147/OPTH.S105080
   Hanumunthadu D, 2019, J OPHTHAL VIS RES, V14, P164, DOI 10.4103/jovr.jovr_152_17
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   Hirahara S, 2016, AM J OPHTHALMOL, V166, P103, DOI 10.1016/j.ajo.2016.03.040
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kuroda Y, 2016, AM J OPHTHALMOL, V169, P199, DOI 10.1016/j.ajo.2016.06.043
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Ryan SJ, 2013, RETINA, P1
   Shinojima A, 2012, AVIAT SPACE ENVIR MD, V83, P388, DOI 10.3357/ASEM.3191.2012
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
NR 25
TC 10
Z9 10
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2020
VL 258
IS 9
BP 1921
EP 1929
DI 10.1007/s00417-020-04772-y
EA JUN 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ND8ON
UT WOS:000537670600003
PM 32494872
DA 2022-11-30
ER

PT J
AU Pieramici, DJ
   Bressler, SB
   Koester, JM
   Bressler, NM
AF Pieramici, DJ
   Bressler, SB
   Koester, JM
   Bressler, NM
CA Writing Comm VIP Study Grp
TI Occult with no classic subfoveal choroidal neovascular lesions in
   age-related macular degeneration - Clinically relevant natural history
   information in larger lesions with good vision from the Verteporfin in
   Photodynamic Therapy (VIP) Trial: VIP report No. 4
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID INCLUDING LESIONS; GUIDELINES; TAP
AB Objective: To determine whether data from patients with age-related macular degeneration (AMD) assigned to the placebo group in the Verteporfin in Photodynamic Therapy ( VIP) Trial provide a rationale for continuation or cessation of follow-up of individuals with subfoveal occult choroidal neovascularization (CNV) with no classic lesions, presumed recent disease progression, larger lesion size (> 4 disc areas), and a higher level of visual acuity ( approximate Snellen equivalent, >= 20/50 in the affected eye) in whom no treatment is given at initial examination.
   Methods: In a prospective, noncomparative case series, angiograms of participants assigned to a placebo group who had occult with no classic lesion composition at baseline were reviewed to identify conversion to minimally classic (area of classic CNV > 0% but < 50% of the entire lesion area) or predominantly classic (area of CNV >= 50% of the entire lesion area) composition.
   Results: Of the 114 patients with AMD assigned to the placebo group, 89 were judged to have occult with no classic lesion composition at baseline in the study eye when fluorescein angiograms were reviewed in late 2001 for this report. By 24 months, 7 ( 8%) of the 89 patients had lesions that converted to predominantly classic composition, and 41 (46%) had minimally classic composition. Among the 24 patients with a baseline visual acuity better than 20/50(-1) and lesion size greater than 4 disc areas whose lesions did not convert to predominantly classic composition, the visual acuity of 18 (75%) dropped below 20/50. Six of these 18 continued to have occult with no classic CNV with a visual acuity of 20/100 or better and had a lesion size no greater than 9 disc areas at the time that visual acuity dropped below 20/50.
   Conclusions: Continued monitoring, rather than cessation of follow-up, is recommended for patients with occult with no classic lesions, similar to those patients enrolled in the VIP Trial who did not initially receive treatment when they had relatively large lesions with good visual acuity. In these cases, if visual acuity decreases or predominantly classic features develop, photodynamic therapy with verteporfin or pegaptanib sodium injections may be considered.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Suita 115,550 N Broadway, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
CR *AM AC OPHTH, 2004, PREF PRACT PATT AG R
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   *SST, 2005, RETINA, V125, P253
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 11
TC 25
Z9 26
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2006
VL 124
IS 5
BP 660
EP 664
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 040GP
UT WOS:000237367300004
PM 16682587
DA 2022-11-30
ER

PT J
AU De Niro, JE
   McDonald, HR
   Johnson, RN
   Jumper, JM
   Fu, AD
   Cunningham, ET
   Lujan, BJ
AF De Niro, Jennifer E.
   McDonald, H. Richard
   Johnson, Robert N.
   Jumper, J. Michael
   Fu, Arthur D.
   Cunningham, Emmett T., Jr.
   Lujan, Brandon J.
TI SENSITIVITY OF FLUID DETECTION IN PATIENTS WITH NEOVASCULAR AMD USING
   SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY HIGH-DEFINITION LINE SCANS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; sensitivity; Cirrus;
   macular cube; intraretinal fluid; subretinal fluid
ID MACULAR DEGENERATION; RANIBIZUMAB
AB Purpose: To determine the sensitivity of the Cirrus high-definition (HD) 5-line raster scans for detecting retinal fluid in neovascular age-related macular degeneration when using the spectral domain optical coherence tomography macular cubes as a gold standard.
   Methods: Patients were retrospectively identified from their initial follow-up visit after being newly diagnosed with neovascular age-related macular degeneration in at least one eye. Patients were imaged with Cirrus spectral domain optical coherence tomography using the 512 x 128 macular cube scan and HD 5-line raster scan settings. Patients with other diseases that cause subretinal or intraretinal fluid, or who had an epiretinal membrane causing macular traction were excluded from the analysis. We recorded the presence or absence of subretinal or intraretinal fluid in the macular cube and on the HD 5-line raster scans.
   Results: Seventy-nine patients met the study requirements. Of the 63 patients who had fluid present on the macular cube, 1 did not seem to have fluid on the HD 5-line raster scans. Taking the macular cube as a gold standard, the sensitivity of the HD 5-line raster scans for detecting retinal fluid in this cohort was 98.4%.
   Conclusion: The Cirrus HD 5-line raster scans have a high sensitivity for detecting fluid in the macular cube in patients with neovascular age-related macular degeneration.
C1 [De Niro, Jennifer E.; Cunningham, Emmett T., Jr.] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA.
   [McDonald, H. Richard; Johnson, Robert N.; Jumper, J. Michael; Fu, Arthur D.; Cunningham, Emmett T., Jr.; Lujan, Brandon J.] West Coast Retina Med Grp, San Francisco, CA 94109 USA.
   [Cunningham, Emmett T., Jr.] Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Lujan, Brandon J.] Univ Calif Berkeley, Dept Vis Sci, Berkeley, CA 94720 USA.
C3 California Pacific Medical Center; Stanford University; University of
   California System; University of California Berkeley
RP Lujan, BJ (通讯作者)，West Coast Retina Med Grp, 1445 Bush St, San Francisco, CA 94109 USA.
EM blujan@westcoastretina.com
FU National Institute of Health [EY017269-04]; NATIONAL EYE INSTITUTE
   [K12EY017269] Funding Source: NIH RePORTER
FX Supported by the National Institute of Health (Grant EY017269-04).
CR Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
NR 7
TC 17
Z9 17
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2014
VL 34
IS 6
BP 1163
EP 1166
DI 10.1097/IAE.0000000000000077
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI8GP
UT WOS:000337149000018
PM 24406389
DA 2022-11-30
ER

PT J
AU Canas, RV
   Liatsis, P
AF Vargas Canas, Rubiel
   Liatsis, Panos
TI Interactive retinal blood flow estimation from fluorescein angiograms
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART C-JOURNAL OF
   MECHANICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluorescein retinal vessel segmentation; retinal registration; retinal
   blood transit-time estimation; retinal blood flow estimation
ID MACULAR DEGENERATION; DIABETIC-RETINOPATHY; TRANSIT-TIME; HUMAN EYE;
   CIRCULATION; FUNDUS; IMAGES; PRESSURE; GLAUCOMA; VESSELS
AB It is well-known that age-related macular degeneration is the main cause of visual impairment in industrialised countries affecting around 239,000 people in UK while demonstrating an increasing trend. Fluorescein angiography is the most widely used technique in the diagnosis, prognosis and in following up the development of the disease. The interpretation of fluorescein angiograms depends upon the detection of abnormal fluorescence and clinical assessment of the functional integrity of retinal circulation, which is primarily based on subjective evaluation of the dye transit-time. This study presents a prototype system for quantitative analysis of the retinal haemodynamics. It analyses retinal blood flow based on the estimation of parameters such as mean transit-time, arteriovenous passage time and mean dye velocity. These parameters are estimated using densitometry and analysis of the vascular response. The prototype system consists of three main stages: vessel segmentation, image registration and blood flow estimation. The performance of the system is demonstrated on a comprehensive dataset, which contains images of normal retinas and retinas with pathologies such as wet age-related macular degeneration and branch retinal vein occlusion. The presented framework aims to demonstrate the technical feasibility for automated extraction of retinal blood flow parameters and contributes towards the development of a clinically proven computer vision system for quantitative analysis of fluorescein angiograms to assist NHS clinicians in the early diagnosis of age-related macular degeneration.
C1 [Vargas Canas, Rubiel; Liatsis, Panos] City Univ London, Informat Engn & Med Imaging Grp, Sch Engn & Math Sci, London EC1V 0HB, England.
   [Vargas Canas, Rubiel] Cauca Univ, Dept Phys, Cauca, Colombia.
C3 City University London; Universidad del Cauca
RP Liatsis, P (通讯作者)，City Univ London, Informat Engn & Med Imaging Grp, Sch Engn & Math Sci, Northampton Sq, London EC1V 0HB, England.
EM p.liatsis@city.ac.uk
RI Canas, Rubiel Vargas/V-6577-2019; Liatsis, Panos/AAF-9675-2020
OI Canas, Rubiel Vargas/0000-0003-1548-942X; Liatsis,
   Panos/0000-0002-5490-6030
FU Programme AlBan; European Union Programme of High Level Scholarships for
   Latin America [07D403130CO]; Cauca University-Colombia; Colombia's
   National Department of Science, Technology and Innovation - COLCIENCIAS
FX This study is supported by the Programme AlBan, the European Union
   Programme of High Level Scholarships for Latin America, scholarship no.
   [07D403130CO], Cauca University-Colombia and Colombia's National
   Department of Science, Technology and Innovation - COLCIENCIAS.
CR Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Bjarnhall G, 2002, ACTA OPHTHALMOL SCAN, V80, P652, DOI 10.1034/j.1600-0420.2002.800617.x
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BULPITT CJ, 1971, CARDIOVASC RES, V5, P406, DOI 10.1093/cvr/5.3.406
   Bursell SE, 1996, INVEST OPHTH VIS SCI, V37, P886
   Can A, 1999, IEEE Trans Inf Technol Biomed, V3, P125, DOI 10.1109/4233.767088
   Caprioli J, 2010, AM J OPHTHALMOL, V149, P704, DOI 10.1016/j.ajo.2010.01.018
   Charles N, 2007, BRIT J VISUAL IMPA, V25, P199, DOI 10.1177/0264619607079793
   Chen JA, 2010, IEEE T BIO-MED ENG, V57, P1707, DOI 10.1109/TBME.2010.2042169
   Choe TE, 2008, MED IMAGE ANAL, V12, P174, DOI 10.1016/j.media.2007.10.002
   Chutatape O, 1998, P ANN INT IEEE EMBS, V20, P3144, DOI 10.1109/IEMBS.1998.746160
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Garcia JPS, 2002, OPHTHALMIC RES, V34, P295, DOI 10.1159/000065600
   Garzozi HJ, 2001, ISRAEL MED ASSOC J, V3, P443
   Gilmore ED, 2006, THESIS WATERLOO
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   HICKAM JOHN B., 1965, INVEST OPHTHALMOL, V4, P876
   Hipwell JH, 1998, PHYSIOL MEAS, V19, P165, DOI 10.1088/0967-3334/19/2/004
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   JAGOE R, 1993, INVEST OPHTH VIS SCI, V34, P2881
   JUNG F, 1983, GRAEF ARCH CLIN EXP, V221, P133, DOI 10.1007/BF02133853
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KOVESI P, 1999, J COMPUTER VISION RE, V1, P1
   KOYAMA T, 1990, GRAEF ARCH CLIN EXP, V228, P442, DOI 10.1007/BF00927258
   Kurokawa T, 1998, ELECTRON LETT, V34, P976, DOI 10.1049/el:19980689
   Lin G, 2004, IEEE T BIO-MED ENG, V51, P115, DOI 10.1109/TBME.2003.820332
   Lovie-Kitchin JE., 1985, SENILE MACULAR DEGEN
   Mengko TR, 2009, P 9 IAPR C MACH VIS, P451
   Montoliu R, 2008, LECT NOTES COMPUT SC, V5112, P660, DOI 10.1007/978-3-540-69812-8_65
   Narasimha-Iyer H, 2006, IEEE T BIO-MED ENG, V53, P1084, DOI 10.1109/TBME.2005.863971
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Quek FKH, 2001, IEEE T MED IMAGING, V20, P117, DOI 10.1109/42.913178
   Rao B, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2967986
   Rechtman E, 2003, CURR EYE RES, V27, P329, DOI 10.1076/ceyr.27.6.329.18193
   Schmetterer L, 2007, SURV OPHTHALMOL, V52, pS134, DOI 10.1016/j.survophthal.2007.08.008
   SCHMETTERER LF, 1995, OPT ENG, V34, P711, DOI 10.1117/12.193292
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   SILVER DM, 1989, ACTA OPHTHALMOL, V67, P25
   Silver DM, 2000, CURR EYE RES, V20, P115, DOI 10.1076/0271-3683(200002)20:2;1-D;FT115
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   SPAETH GL, 1977, PATHOGENESIS NERVE D
   Sperber GO, 1997, ACTA OPHTHALMOL SCAN, V75, P532
   Takerkart S, 2008, I S BIOMED IMAGING, P1457, DOI 10.1109/ISBI.2008.4541282
   Tikellis G, 2007, DIABETOLOGIA, V50, P2263, DOI 10.1007/s00125-007-0822-x
   Tomic L, 2005, ACTA OPHTHALMOL SCAN, V83, P705, DOI 10.1111/j.1600-0420.2005.00522.x
   Tsai CL, 2010, IEEE T MED IMAGING, V29, P636, DOI 10.1109/TMI.2009.2030324
   Vargas R, 2010, Proceedings of the Third International Conference on Developments in eSystems Engineering (DESE 2010), P23, DOI 10.1109/DeSE.2010.11
   Vargas R, 2011, P 18 INT C SYST SIGN, P1
   Venkataraman ST, 2005, MICROVASC RES, V69, P149, DOI 10.1016/j.mvr.2005.02.003
   Wang R, 2010, BIOMED OPT MED IMAGI, DOI [10.1117/2.1201002.002571, DOI 10.1117/2.1201002.002571.SPIE]
   WOLF S, 1989, GRAEF ARCH CLIN EXP, V227, P145, DOI 10.1007/BF02169788
   Yanuzzi LA, 1979, MACULA COMPREHENSIVE, P31
   Zhu I, 2002, PROCEEDINGS OF THE IEEE 28TH ANNUAL NORTHEAST BIOENGINEERING CONFERENCE, P3, DOI 10.1109/NEBC.2002.999436
NR 54
TC 4
Z9 4
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954-4062
EI 2041-2983
J9 P I MECH ENG C-J MEC
JI Proc. Inst. Mech. Eng. Part C-J. Eng. Mech. Eng. Sci.
PY 2012
VL 226
IS C10
BP 2521
EP 2537
DI 10.1177/0954406211435195
PG 17
WC Engineering, Mechanical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 011ZX
UT WOS:000309206200012
DA 2022-11-30
ER

PT J
AU Chen, FK
   Viljoen, RD
   Bukowska, DM
AF Chen, Fred K.
   Viljoen, Rian D.
   Bukowska, Danuta M.
TI Classification of image artefacts in optical coherence tomography
   angiography of the choroid in macular diseases
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal vasculature; image artefact; optical coherence tomography
   angiography; retinal diseases
ID SOURCE OCT ANGIOGRAPHY; RETINAL VASCULAR LAYERS; THICKNESS; TRACKING;
   SPEED
AB BackgroundTo evaluate and classify image artefacts in optical coherence tomography (OCT) angiography (OCTA) of the choroid in a group of patients with macular diseases.
   DesignRetrospective observational study.
   ParticipantsFive patients with age-related macular degeneration, three with central serous retinopathy, one with polypoidal choroidal vasculopathy and one with multiple evanescent white dot syndrome.
   MethodsOCTA and OCT reflectivity (OCTR) maps were reviewed along with their fluorescein angiography and indocyanine green angiography. Sixty OCTA images (20 outer retina, 20 Sattler and 20 Haller layers) were graded for image artefacts by two examiners independently.
   Main Outcome MeasuresOCTA artefacts and their correlation with OCTR maps, angiography and OCT B-scans.
   ResultsArtefacts (frequency) were classified into (i) motion (70-100%), (ii) fringe washout (100%), (iii) decorrelation projection (0-20%), (iv) masking and unmasking (50-65%) and (v) stromal decorrelation signal (100%). Motion artefact in OCTA is characterized by horizontal dark lines or bands not apparent on OCTR map. Fringe washout creates signal void within choroidal vessels because of fast blood flow. Decorrelation projection from retinal vasculature and choroidal new vessels above the Bruch's membrane are seen within the choroidal OCTA image. Masking and unmasking artefacts occur in regions of pigment epithelial detachment and atrophy. Decorrelation signals can also be seen in the choroidal stroma.
   ConclusionsOur classification system of artefact in choroidal OCTA establishes a common terminology for clinical interpretation. This is important in enhancing our understanding of the principles of OCTA acquisition, and it also serves as a bench mark for reading centres.
C1 [Chen, Fred K.; Bukowska, Danuta M.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Incorp Lions Eye Inst, Perth, WA, Australia.
   [Chen, Fred K.; Viljoen, Rian D.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
C3 Lions Eye Institute; University of Western Australia; Royal Perth
   Hospital; University of Western Australia
RP Bukowska, DM (通讯作者)，Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM dankabukowska@lei.org.au
RI , Fred/B-8158-2013; Sampson, Danuta/AAN-6075-2021; Sampson, Danuta
   M/A-5873-2016
OI , Fred/0000-0003-2809-9930; Sampson, Danuta M/0000-0003-4737-6606
FU NH&MRC Early Career Fellowship
FX NH&MRC Early Career Fellowship (Fred K Chen)
CR Browning DJ, 2008, AM J OPHTHALMOL, V145, P889, DOI 10.1016/j.ajo.2008.01.007
   Chan G, 2015, MICROVASC RES, V100, P32, DOI 10.1016/j.mvr.2015.04.006
   Chhablani J, 2014, SAUDI J OPHTHALMOL, V28, P81, DOI 10.1016/j.sjopt.2014.02.010
   Choi W, 2013, OPT LETT, V38, P338, DOI 10.1364/OL.38.000338
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Enfield J, 2011, BIOMED OPT EXPRESS, V2, P1184, DOI 10.1364/BOE.2.001184
   Ferguson RD, 2004, OPT LETT, V29, P2139, DOI 10.1364/OL.29.002139
   Fingler J, 2008, INVEST OPHTH VIS SCI, V49, P5055, DOI 10.1167/iovs.07-1627
   Ho J, 2010, INVEST OPHTH VIS SCI, V51, P3714, DOI 10.1167/iovs.09-4057
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Ricco S, 2009, LECT NOTES COMPUT SC, V5761, P100
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Sheehy CK, 2012, BIOMED OPT EXPRESS, V3, P2611, DOI 10.1364/BOE.3.002611
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Tan PEZ, 2015, INVEST OPHTH VIS SCI, V56, P3989, DOI 10.1167/iovs.14-15879
   Thorell MR, 2014, OSLI RETINA, V45, P369, DOI 10.3928/23258160-20140909-06
   Wang RK, 2009, OPT EXPRESS, V17, P8926, DOI 10.1364/OE.17.008926
   Yousefi S, 2011, IEEE T BIO-MED ENG, V58, DOI 10.1109/TBME.2011.2152839
   Zhang GL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080969, 10.1371/journal.pone.0063486, 10.1371/journal.pone.0059428, 10.1371/journal.pone.0064689, 10.1371/journal.pone.0059254]
   Zhang Q, 2015, J BIOMED OPT, V20, P1
NR 36
TC 59
Z9 69
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2016
VL 44
IS 5
BP 388
EP 399
DI 10.1111/ceo.12683
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR5JG
UT WOS:000379938700005
PM 26584465
DA 2022-11-30
ER

PT J
AU Shin, MK
   Lee, JE
   Byon, IS
   Park, SW
AF Shin, Min Kyu
   Lee, Ji Eun
   Byon, Ik Soo
   Park, Sung Who
TI Choroidal Watershed Zone and Growth of Polypoidal Choroidal Vasculopathy
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Choroidal watershed zone (CWZ); choroidal circulation; choroidal
   hypoxia; indocyanine green angiography (ICGA); polypoidal choroidal
   vasculopathy (PCV)
ID VERTEPORFIN PHOTODYNAMIC THERAPY; POSTERIOR CILIARY ARTERY; MACULAR
   DEGENERATION; RANIBIZUMAB; THICKNESS; NEOVASCULARIZATION; COMBINATION;
   OCCLUSION; ISCHEMIA; DISEASE
AB Purpose: To investigate the topographic relationship between polypoidal choroidal vasculopathy (PCV) growth and choroidal watershed zones (CWZ) by using indocyanine green angiography (ICGA).Materials and Methods: We evaluated PCV lesions smaller than the CWZ at baseline and followed up more than 6 months. The CWZ was traced in the early phase ICGA at baseline. The vascular lesion of PCV was traced in baseline and follow-up ICGA. These traces were overlapped and topographic relationships between CWZs and PCV growth were evaluated.Results: Among 31 eyes of 31 patients, enlargement of a PCV lesion was observed in 20 patients (64.5%) at mean follow-up of 30.4 months (6-68 months). A topographical relationship between the CWZ and PCV growth was demonstrated in 14 eyes (70.0%), as the shape of the PCV lesion conformed to the boundary of the CWZ, and/or the growth of the branching vascular network was aligned to the direction of the CWZ extension to the periphery. Growth beyond the boundary of the CWZ was noted in 9 eyes (45.0%), however growth area was greater inside the CWZ than outside in all eyes. Of 15 eyes of extrafoveal lesion at baseline, 8 eyes in which the vascular lesion progressed to the fovea had the CWZ involving the fovea, whereas PCV in three eyes with an extrafoveal CWZ remained as a non-subfoveal disease after mean follow-up of 17.0 months (p = 0.019).Conclusions: A subfoveal CWZ was related to PCV growth to the fovea. Topographical relationships between PCV growth and the CWZ suggest that choroidal circulation is a predisposition for PCV growth.
C1 [Shin, Min Kyu; Lee, Ji Eun; Byon, Ik Soo; Park, Sung Who] Pusan Natl Univ, Dept Ophthalmol, Coll Med, Yangsan, South Korea.
   [Lee, Ji Eun; Park, Sung Who] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea.
   [Byon, Ik Soo] Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan, South Korea.
C3 Pusan National University; Pusan National University; Pusan National
   University Hospital; Pusan National University; Pusan National
   University Hospital
RP Lee, JE (通讯作者)，Pusan Natl Univ Hosp, Dept Ophthalmol, 179 Gudeok Ro, Busan, South Korea.
EM jlee@pusan.ac.kr
OI Byon, Iksoo/0000-0002-2638-8192
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1972, BRIT J OPHTHALMOL, V56, P719, DOI 10.1136/bjo.56.10.719
   HAYREH SS, 1973, BRIT J OPHTHALMOL, V57, P217, DOI 10.1136/bjo.57.4.217
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lee JE, 2016, BRIT J OPHTHALMOL, V100, P652, DOI 10.1136/bjophthalmol-2015-306678
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z
   Leung Loh-Shan B, 2012, Ophthalmic Surg Lasers Imaging, V43 Online, pe73, DOI 10.3928/15428877-20120712-05
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   MATSUO N, 1980, Nippon Ganka Gakkai Zasshi, V84, P2147
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SHIMIZU K, 1981, OPHTHALMOLOGICA, V183, P5, DOI 10.1159/000309126
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   WYBAR KC, 1954, BRIT J OPHTHALMOL, V38, P513, DOI 10.1136/bjo.38.9.513
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 36
TC 4
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 2
BP 252
EP 259
DI 10.1080/02713683.2016.1183794
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM3AL
UT WOS:000395186800014
PM 27400136
DA 2022-11-30
ER

PT J
AU Mohamad, NA
   Ramachandran, V
   Ismail, P
   Isa, HM
   Chan, YM
   Ngah, NF
   Bakri, NM
   Ching, SM
   Hoo, FK
   Sulaiman, WAW
AF Mohamad, Nur Afiqah
   Ramachandran, Vasudevan
   Ismail, Patimah
   Isa, Hazlita Mohd
   Chan, Yoke Mun
   Ngah, Nor Fariza
   Bakri, Norshakimah Md
   Ching, Siew Mooi
   Hoo, Fan Kee
   Sulaiman, Wan Aliaa Wan
TI Prevalence and treatment patterns of ranibizumab and photodynamic
   therapy in a tertiary care setting in Malaysia
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE anti-vascular endothelial growth factor therapy; photodynamic therapy;
   ranibizumab; treatment patterns
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; RISK-FACTORS; FOLLOW-UP; MEDICARE BENEFICIARIES;
   VERTEPORFIN; NEOVASCULARIZATION; COMBINATION; MONOTHERAPY
AB AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014.
   METHODS: Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded.
   RESULTS: The five-year analysis included 821 patients with a mean age of 65.9 +/- 11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy (P<0.001) while PCV was associated with more likely to have received PDT (P<0.001) and PDT combined with ranibizumab therapy (P<0.001).
   CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.
C1 [Mohamad, Nur Afiqah; Ramachandran, Vasudevan; Chan, Yoke Mun; Bakri, Norshakimah Md] Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang 43400, Selangor De, Malaysia.
   [Ismail, Patimah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Selangor De, Malaysia.
   [Isa, Hazlita Mohd] Univ Kebangsaan Malaysia, Med Ctr, Dept Ophthalmol, Kuala Lumpur 56000, Malaysia.
   [Chan, Yoke Mun] Univ Putra Malaysia, Dept Nutr & Dietet, Fac Med & Hlth Sci, Serdang 43400, Selangor De, Malaysia.
   [Ngah, Nor Fariza] Hosp Selayang, Dept Ophthalmol, Lebuhraya Selayang Kepon 68100, Batu Caves, Malaysia.
   [Ching, Siew Mooi] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Serdang 43400, Selangor De, Malaysia.
   [Hoo, Fan Kee; Sulaiman, Wan Aliaa Wan] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Serdang 43400, Selangor De, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti
   Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti Putra
   Malaysia; Universiti Putra Malaysia
RP Ramachandran, V (通讯作者)，Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang 43400, Selangor De, Malaysia.; Chan, YM (通讯作者)，Univ Putra Malaysia, Dept Nutr & Dietet, Fac Med & Hlth Sci, Serdang 43400, Selangor De, Malaysia.
EM vasuphd@gmail.com; cym@upm.edu.my
RI Chan, Yoke Mun Yoke/L-2965-2015; Wan Sulaiman, Wan Aliaa
   Binti/AAF-8072-2021; Ching, Siew Mooi/I-5817-2013; ramachandran,
   vasudevan/C-3395-2008; Hoo, Fan Kee/J-2591-2013
OI Chan, Yoke Mun Yoke/0000-0002-3853-736X; Wan Sulaiman, Wan Aliaa
   Binti/0000-0003-4969-0308; Ching, Siew Mooi/0000-0002-4425-7989;
   ramachandran, vasudevan/0000-0003-0044-1626; Isa,
   Hazlita/0000-0002-2731-8233; Mohamad, Nur Afiqah/0000-0002-9015-0525;
   Hoo, Fan Kee/0000-0003-1687-627X
FU Putra Grant from Universiti Putra Malaysia [9409800, 9432700]
FX Supported by Putra Grant from Universiti Putra Malaysia (No.9409800;
   No.9432700).
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chan WM, 2016, HONG KONG J OPHTHALM, V14, P14
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P13, DOI 10.1097/00006982-200402000-00002
   Erikitola OC, 2014, EYE, V28, P944, DOI 10.1038/eye.2014.134
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Ip MS, 2015, OPHTHALMOLOGY, V122, P367, DOI 10.1016/j.ophtha.2014.08.048
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Koh A, 2011, SINGAP MED J, V52, P232
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee JY, 2016, J KOR OPHTHALMOL SOC, V57, P1071, DOI 10.3341/jkos.2016.57.7.1071
   Lloyd R, 2008, CURR OPIN OPHTHALMOL, V19, P190, DOI 10.1097/ICU.0b013e3282f97fa1
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mohamad AZ, 2012, 4 REPORT NATL EYE DA
   Ng WY, 2014, OPTOMETRY VISION SCI, V91, P872, DOI 10.1097/OPX.0000000000000283
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2004, OPHTHALMOLOGY, V111, P1725, DOI 10.1016/j.ophtha.2004.02.014
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Salam A, 2011, ACTA OPHTHALMOL, V89, P405, DOI 10.1111/j.1755-3768.2010.02079.x
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Teo KYC, 2014, ANN ACAD MED SINGAP, V43, P192
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
NR 59
TC 3
Z9 3
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2017
VL 10
IS 12
BP 1889
EP 1897
DI 10.18240/ijo.2017.12.16
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP9AB
UT WOS:000417937800016
PM 29259909
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Choo, HG
   Lee, JH
   Oh, HS
   Kim, SH
   You, YS
   Kwon, OW
AF Choo, Hun Gu
   Lee, Jin Hae
   Oh, Hyun Sub
   Kim, Soon Hyun
   You, Yong Sung
   Kwon, Oh Woong
TI One-year outcomes of fixed-dosing Aflibercept therapy for pre treated
   and naive polypoidal choroidal vasculopathy patient
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Age-related macular degeneration;
   Aflibercept; Fixed-dosing regimen
AB BackgroundPolypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV.MethodsThis was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naive patients. The patients were treated and monitored for 12months. Each patient was administered with an aflibercept (2.0mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12months.ResultsAfter 12months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p<0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-naive patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant.ConclusionsThe fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naive patients than in pre-treated patients.Trial registrationClinical Research Information Service (CRiS), Republic of Korea. Identifer: KCT0005798, Registered: Jan 20, 2021. Retrospectively registered, URL: https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546
C1 [Choo, Hun Gu] Yonsei Univ, Wonju Coll Med, Dept Ophthalmol, Wonju, South Korea.
   [Lee, Jin Hae] First St Marys Eye Clin, Dept Ophthalmol, Seoul, South Korea.
   [Oh, Hyun Sub; Kim, Soon Hyun; You, Yong Sung; Kwon, Oh Woong] Nune Eye Hosp, Dept Ophthalmol, Noon Bldg 404,Seonreung Ro, Seoul 06198, South Korea.
C3 Yonsei University
RP Kwon, OW (通讯作者)，Nune Eye Hosp, Dept Ophthalmol, Noon Bldg 404,Seonreung Ro, Seoul 06198, South Korea.
EM owkwon0301@yuhs.ac
FU Bayer Korea
FX This study conducted with the support of Bayer Korea, the manufacturer
   of aflibercept. The funding bodies played no role in the design of the
   study and collection, analysis, and interpretation of data and in
   writing the manuscript.
CR Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
NR 16
TC 0
Z9 0
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 18
PY 2021
VL 21
IS 1
AR 94
DI 10.1186/s12886-021-01829-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QL4KO
UT WOS:000621047800003
PM 33602156
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Bubeck, F
   Grimm, D
AF Bubeck, Felix
   Grimm, Dirk
TI 'Hit and run' therapy averts macular degeneration
SO NATURE BIOMEDICAL ENGINEERING
LA English
DT Article
AB Subretinal delivery of lentiviruses bearing Cas9 mRNA and a guide RNA targeting the Vegfa gene reduces the development of choroidal neovascularization in a mouse model of wet age-related macular degeneration.
C1 [Bubeck, Felix; Grimm, Dirk] Heidelberg Univ, Fac Med, Dept Infect Dis Virol, Heidelberg, Germany.
   [Bubeck, Felix; Grimm, Dirk] Heidelberg Univ, BioQuant, Heidelberg, Germany.
   [Grimm, Dirk] German Ctr Infect Res DZIF, Heidelberg, Germany.
   [Grimm, Dirk] German Ctr Cardiovasc Res DZHK, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; German Center for Infection Research; German Centre for
   Cardiovascular Research
RP Grimm, D (通讯作者)，Heidelberg Univ, Fac Med, Dept Infect Dis Virol, Heidelberg, Germany.; Grimm, D (通讯作者)，Heidelberg Univ, BioQuant, Heidelberg, Germany.; Grimm, D (通讯作者)，German Ctr Infect Res DZIF, Heidelberg, Germany.; Grimm, D (通讯作者)，German Ctr Cardiovasc Res DZHK, Heidelberg, Germany.
EM dirk.grimm@bioquant.uni-heidelberg.de
CR Anzalone AV, 2020, NAT BIOTECHNOL, V38, P824, DOI 10.1038/s41587-020-0561-9
   ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916
   Cai YJ, 2014, ELIFE, V3, DOI 10.7554/eLife.01911
   Cai YJ, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gkt1163
   He C, 2014, GENE THER, V21, P759, DOI 10.1038/gt.2014.51
   Li A, 2020, MOL THER, V28, P1432, DOI 10.1016/j.ymthe.2020.04.017
   Ling SK, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00656-y
   Lyu P, 2020, LIFE-BASEL, V10, DOI 10.3390/life10120366
   Michel G, 2010, MOL THER, V18, P1814, DOI 10.1038/mt.2010.150
   Nguyen GN, 2021, NAT BIOTECHNOL, V39, P47, DOI 10.1038/s41587-020-0741-7
   Prel A, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.39
   Rulli SJ, 2007, J VIROL, V81, P6623, DOI 10.1128/JVI.02833-06
   Wesselhoeft RA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05096-6
   Yin D, 2021, NAT BIOTECHNOL, V39, P567, DOI 10.1038/s41587-020-00781-8
NR 14
TC 0
Z9 0
U1 1
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2157-846X
J9 NAT BIOMED ENG
JI Nat. Biomed. Eng
PD FEB
PY 2021
VL 5
IS 2
BP 132
EP 133
DI 10.1038/s41551-021-00690-4
PG 2
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA QG4HB
UT WOS:000617547300004
PM 33580229
DA 2022-11-30
ER

PT J
AU Aksoy, NO
   Bursali, O
   Cakir, B
   Dogan, E
   Celik, E
   Alagoz, G
AF Aksoy, Nilgun Ozkan
   Bursali, Ozlem
   Cakir, Burcin
   Dogan, Emine
   Celik, Erkan
   Alagoz, Gursoy
TI THE ETIOLOGY OF UNILATERAL AND BILATERAL BLINDNESS IN THE ELDERLY AND
   THE DIFFERENCES BY GENDER
SO TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
LA English
DT Article
DE Blindness; Aged; Gender Identity
ID VISUAL IMPAIRMENT; POPULATION
AB Introduction: The aim of this study was to investigate the causes of unilateral and bilateral blindness in elderly patients and to evaluate its distribution by gender.
   Materials and Methods: Data from 22055 patients examined in the Ophthalmology Department between 2013-2020 were retrospectively analyzed. Patients 65 years or older were selected, and the causes of unilateral and bilateral blindness were evaluated. The patients were divided into two groups: 65-74 years old were presenile and 75 years or older were senile group. The factors causing blindness were evaluated separately by gender and age group.
   Results: 452 patients (213 females, 239 males) were 65 years or older with unilateral and bilateral low vision. A total of 193(42.7%) were in the presenile, and 259(57.3%) were in the senile group. Age-related macular degeneration was the most common cause of unilateral and bilateral blindness in both genders, followed by diabetic retinopathy in females and glaucoma in males. The most common cause of blindness in both presenile and senile groups was age-related macular degeneration, followed by diabetic retinopathy in the presenile, glaucoma in the senile group.
   Conclusions: In the presenile and senile groups, age-related macular degeneration was the most common cause of unilateral and bilateral blindness in females and males. Other leading causes were diabetic retinopathy in females and glaucoma in males.
C1 [Aksoy, Nilgun Ozkan; Bursali, Ozlem; Cakir, Burcin; Dogan, Emine; Celik, Erkan; Alagoz, Gursoy] Sakarya Univ, Training & Res Hosp, Tip Fak, Egitim & Arastirma Hastanesi,Ophthalmol Dept, Sakaya, Turkey.
C3 Corum Training & Research Hospital; Sakarya Training & Research
   Hospital; Sakarya University
RP Aksoy, NO (通讯作者)，Sakarya Univ, Training & Res Hosp, Tip Fak, Egitim & Arastirma Hastanesi,Ophthalmol Dept, Sakaya, Turkey.
EM nilgun_ozkan@yahoo.com
CR Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Ceyhan D, 2017, TURKIYE KLINIKLERI J, V10, P87
   Doyal L, 2018, BMJ OPEN OPHTHALMOL, V3, DOI 10.1136/bmjophth-2017-000135
   Esteban JJN, 2008, QUAL LIFE RES, V17, P37, DOI 10.1007/s11136-007-9280-7
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Kalayci M, 2020, TURK OFTALMOL DERG, V50, P288, DOI 10.4274/tjo.galenos.2020.82504
   Khanna RC, 2020, AM J OPHTHALMOL, V29
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Mirza E, 2019, EURASIAN J MED, V51, P242, DOI 10.5152/eurasianjmed.2019.18312
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pizzarello L, 2004, ARCH OPHTHALMOL-CHIC, V122, P615, DOI 10.1001/archopht.122.4.615
   Sabanayagam C, 2017, LANCET GLOB HEALTH, V5, pE1164, DOI 10.1016/S2214-109X(17)30412-6
   Sahli E, 2019, TURK OFTALMOL DERG, V49, P89, DOI 10.4274/tjo.galenos.2018.65928
   Tunay ZO, 2016, TURK OFTALMOL DERG, V46, P118, DOI 10.4274/tjo.68878
   WHO, BLINDN VIS 2020 GLOB
   World Health Organization, BLINDN VIS IMP
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 17
TC 0
Z9 0
U1 0
U2 1
PU GUNES KITABEVI LTD STI
PI ANKARA
PA M RAUF INAN SOK NO 3, ANKARA, SIHHIYE 06410, TURKEY
SN 1304-2947
EI 1307-9948
J9 TURK J GERIATR
JI Turk. J. Geriatr.
PY 2021
VL 24
IS 2
BP 196
EP 203
DI 10.31086/tjgeri.2021.215
PG 8
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA SW9ZM
UT WOS:000664872200011
OA gold
DA 2022-11-30
ER

PT J
AU Schimel, AM
   Abraham, L
   Cox, D
   Sene, A
   Kraus, C
   Dace, DS
   Ercal, N
   Apte, RS
AF Schimel, Andrew M.
   Abraham, Linu
   Cox, Douglas
   Sene, Abdoulaye
   Kraus, Courtney
   Dace, Dru S.
   Ercal, Nuran
   Apte, Rajendra S.
TI N-Acetylcysteine Amide (NACA) Prevents Retinal Degeneration by
   Up-Regulating Reduced Glutathione Production and Reversing Lipid
   Peroxidation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; TERT-BUTYL HYDROPEROXIDE; LIGHT-INDUCED
   APOPTOSIS; MACULAR DEGENERATION; OXIDATIVE STRESS; BRUCHS MEMBRANE;
   THIOL ANTIOXIDANT; MORPHOMETRIC-ANALYSIS; RETINITIS-PIGMENTOSA; INDUCED
   CYTOTOXICITY
AB Oxidative stress plays a critical role in accelerating retinal pigment epithelial dysfunction and death in degenerative retinal diseases, including age-related macular degeneration. Given the key role of oxidative stress-induced retinal pigment epithelial cell death and secondary photoreceptor loss in the pathogenesis of age-related macular degeneration, we hypothesized that a novel thiol antioxidant, N-acetylcysteine amide (NACA), might ameliorate cellular damage and subsequent loss of vision. Treatment of human retinal pigment epithelial cells with NACA protected against oxidative stress-induced cellular injury and death. NACA acted mechanistically by scavenging existing reactive oxygen species while halting production of reactive oxygen species by reversing lipid peroxidation. Furthermore, NAGA functioned by increasing the levels of reduced glutathione and the phase II detoxification enzyme glutathione peroxidase. Treatment of mice exposed to phototoxic doses of light with NACA maintained retinal pigment epithelial cell integrity and prevented outer nudear layer cell death as examined by histopathologic methods and rescued photoreceptor function as measured by electroretinography. These observations indicate that NACA protects against oxidative stress-induced retinal pigment epithelial and photoreceptor cell death in vitro and in vivo. The data suggest that NACA may be a novel treatment in rescuing retinal function and preventing vision loss secondary to retinal degenerative diseases, including age-related macular degeneration. (AmJ Pathol 2011, 178: 2032-2043; DOI: 10.1016/j.ajpath.2011.01.036)
C1 [Schimel, Andrew M.; Cox, Douglas; Sene, Abdoulaye; Kraus, Courtney; Dace, Dru S.; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Abraham, Linu; Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL); University
   of Missouri System; Missouri University of Science & Technology
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
RI Sene, Abdoulaye/D-3342-2015
OI Sene, Abdoulaye/0000-0001-9194-7264
FU NIH [K08EY016139, R01EY019287, P30 EY 02687]; Carl Marshall Reeves and
   Mildred Almen Reeves Foundation Inc.; Research to Prevent Blindness
   Inc.; International Retina Research Foundation; American Federation for
   Aging Research; American Retina Foundation; International Retinal
   Research Foundation; Lacey Foundation; NIH and National Institute on
   Drug Abuse [R15DA023409]; NATIONAL EYE INSTITUTE [K08EY016139,
   P30EY002687, R01EY019287] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON DRUG ABUSE [R15DA023409] Funding Source: NIH RePORTER
FX Supported by NIH grants K08EY016139 and R01EY019287 (R.S.A.), NIH Vision
   core grant P30 EY 02687, a Carl Marshall Reeves and Mildred Almen Reeves
   Foundation Inc. Award (R.S.A.), a Research to Prevent Blindness Inc.
   Career Development Award (R.S.A.), the International Retina Research
   Foundation (R.S.A.), an American Federation for Aging Research grant
   (R.S.A.), the American Retina Foundation (R.S.A.), an International
   Retinal Research Foundation Callahan Award (D.S.D.), a Lacey Foundation
   Research Award (A.S.), NIH and National Institute on Drug Abuse award
   R15DA023409 (N.E.), and a Research to Prevent Blindness Inc.
   unrestricted grant to Washington University.
CR Abler AS, 1996, RES COMMUN MOL PATH, V92, P177
   ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   AM J, 2008, BIOCHIM BIOPHYS ACTA, V1780, P249
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   COMPORTI M, 1987, CHEM PHYS LIPIDS, V45, P143, DOI 10.1016/0009-3084(87)90064-8
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   GONG X, AM J NEPHROL, V31, P178
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grinberg L, 2005, FREE RADICAL BIO MED, V38, P136, DOI 10.1016/j.freeradbiomed.2004.09.025
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Heverly-Coulson GS, 2010, J PHYS CHEM A, V114, P1996, DOI 10.1021/jp910368u
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Marc RE, 2008, MOL VIS, V14, P782
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7
   Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821
   Nelson KC, 2002, INVEST OPHTH VIS SCI, V43, P3550
   Offen D, 2004, J NEUROCHEM, V89, P1241, DOI 10.1111/j.1471-4159.2004.02428.x
   Omatsu T, 2009, J GASTROENTEROL, V44, P30, DOI 10.1007/s00535-008-2293-3
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Peachey NS, 2003, DOC OPHTHALMOL, V107, P13, DOI 10.1023/A:1024448314608
   Penugonda S, 2005, BRAIN RES, V1056, P132, DOI 10.1016/j.brainres.2005.07.032
   Penugonda S, 2006, TOXICOL APPL PHARM, V216, P197, DOI 10.1016/j.taap.2006.05.002
   Price TO, 2006, EXP NEUROL, V201, P193, DOI 10.1016/j.expneurol.2006.03.030
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197
   Terman Alexei, 2006, Molecular Aspects of Medicine, V27, P471, DOI 10.1016/j.mam.2006.08.006
   THORNALLEY PJ, 1983, BIOCHIM BIOPHYS ACTA, V759, P16, DOI 10.1016/0304-4165(83)90183-6
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   WANG XM, 1993, HUM IMMUNOL, V37, P264
   Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000
   WINTERS RA, 1995, ANAL BIOCHEM, V227, P14, DOI 10.1006/abio.1995.1246
   Wu W, 2008, LIFE SCI, V82, P1122, DOI 10.1016/j.lfs.2008.03.016
   Wu ZH, 2006, J CELL PHYSIOL, V209, P996, DOI 10.1002/jcp.20819
   Yanoff M., 2004, OPHTHALMOLOGY
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu DY, 2000, INVEST OPHTH VIS SCI, V41, P3999
   Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zeitz O, 2007, GRAEF ARCH CLIN EXP, V245, P276, DOI 10.1007/s00417-006-0384-5
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhu YL, 2007, INVEST OPHTH VIS SCI, V48, P1735, DOI 10.1167/iovs.06-1037
NR 76
TC 38
Z9 44
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2011
VL 178
IS 5
BP 2032
EP 2043
DI 10.1016/j.ajpath.2011.01.036
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 865JI
UT WOS:000298306800011
PM 21457933
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jordan-Yu, JM
   Teo, KYC
   Chakravarthy, U
   Gan, A
   Tan, ACS
   Cheong, KX
   Wong, TY
   Cheung, CMG
AF Jordan-Yu, Janice Marie
   Teo, Kelvin Yi Chong
   Chakravarthy, Usha
   Gan, Alfred
   Tan, Anna Cheng Sim
   Cheong, Kai Xiong
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI POLYPOIDAL CHOROIDAL VASCULOPATHY FEATURES VARY ACCORDING TO SUBFOVEAL
   CHOROIDAL THICKNESS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal thickness; neovascular age-related macular degeneration;
   multimodal imaging; pachychoroid; pachyvessels; polypoidal lesions;
   polypoidal choroidal vasculopathy; subfoveal choroidal thickness
ID MACULAR DEGENERATION; RANIBIZUMAB; PROTOCOL; EYES
AB Purpose: To evaluate associations between choroidal thickness and features of polypoidal choroidal vasculopathy (PCV) lesions based on multimodal imaging. Methods: This cross-sectional analysis included treatment-naive PCV eyes from a prospectively recruited observational cohort. Associations between of subfoveal choroidal thickness (SFCT) and qualitative and quantitative morphologic features of PCV lesions on color fundus photographs, indocyanine green and fluorescein angiography, and spectral-domain optical coherence tomography were evaluated. Results: We included 100 eyes with indocyanine green angiography-proven PCV. Subfoveal choroidal thickness showed a bimodal distribution with peaks at 170 mu m and 350 mu m. There was a significant linear increase in the total lesion area (P-trend = 0.028) and the polypoidal lesion area (P-trend = 0.030 and P-continuous = 0.037) with increasing SFCT. Pairwise comparisons between quartiles showed that the total lesion area (4.20 +/- 2.61 vs. 2.89 +/- 1.43 mm(2), P = 0.024) and the polypoidal lesion area (1.03 +/- 1.01 vs. 0.59 +/- 0.45 mm(2), P = 0.042) are significantly larger in eyes in Q4 (SFCT >= 350 mu m) than eyes in Q1 (SFCT <= 170 mu m). Although there was no significant linear trend relating SFCT to best-corrected visual acuity, pairwise comparisons showed that eyes in Q4 (SFCT >= 350 mu m) have significantly worse vision (0.85 +/- 0.63 vs. 0.55 +/- 0.27 logMAR, P = 0.030) than eyes in Q2 (SFCT 170-260 mu m). Conclusion: Total lesion areas and polypoidal lesion areas tend to be larger in eyes with increasing SFCT. Choroidal background may influence the phenotype or progression pattern of PCV.
C1 [Jordan-Yu, Janice Marie; Teo, Kelvin Yi Chong; Gan, Alfred; Tan, Anna Cheng Sim; Cheong, Kai Xiong; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Med Retina Dept, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Tan, Anna Cheng Sim; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Program, Duke NUS Med Sch, Singapore, Singapore.
   [Chakravarthy, Usha] Queens Univ, Ophthalmol & Vis Sci, Belfast, Antrim, North Ireland.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Queens University Belfast
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Teo, Kelvin/0000-0002-7458-7081
FU National Medical Research Council Open Fund Large Collaborative Grant
   [NMRC/LGC/004/2018]
FX Supported by the National Medical Research Council Open Fund Large
   Collaborative Grant: NMRC/LGC/004/2018. The funding organization had no
   role in the design or conduct of this research.
CR Azuma K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65346-w
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2021, RETINA-J RET VIT DIS, V41, P387, DOI 10.1097/IAE.0000000000002902
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Jang JW, 2019, RETINA-J RET VIT DIS, V39, P1995, DOI 10.1097/IAE.0000000000002259
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Peiretti E, 2015, RETINA-J RET VIT DIS, V35, P1360, DOI 10.1097/IAE.0000000000000529
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Zhang QQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22017
NR 30
TC 6
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2021
VL 41
IS 5
BP 1084
EP 1093
DI 10.1097/IAE.0000000000002966
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2UF
UT WOS:000658831500027
PM 32858669
DA 2022-11-30
ER

PT J
AU Zeng, RP
   Zhang, XZ
   Li, M
   Wen, F
AF Zeng, Renpan
   Zhang, Xiongze
   Li, Meng
   Wen, Feng
TI Pilot study of inactive polypoidal lesions in polypoidal choroidal
   vasculopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Inactive polypoidal lesions; Indocyanine green angiography; Polypoidal
   choroidal vasculopathy
ID PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; JAPANESE PATIENTS; CHINESE PATIENTS; BLACK-WOMEN;
   POLYMORPHISMS; ANGIOGENESIS; GENE; PEDF
AB Purpose: This pilot study was conducted to describe the angiographic characteristics of inactive polypoidal lesions that were observed during indocyanine green angiography (ICGA) in polypoidal choroidal vasculopathy (PCV).
   Methods: This was a retrospective study involving 40 eyes of 39 consecutive Chinese patients with PCV with inactive polypoidal lesions. All patients underwent fundus fluorescein angiography and ICGA examinations. We used ICGA to make a definitive diagnosis of PCV in each patient. The clinical and angiographic characteristics of inactive polypoidal lesions were recorded and analyzed.
   Results: In the 40 eyes that were studied, the time between receiving an injection of indocyanine green and the initial appearance of inactive polypoidal lesions ranged from 8.2 minutes to 25.1 minutes, with a mean time of 15.1 +/- 5.6 minutes. Inactive polypoidal lesions were divided into 4 groups: 5 eyes (12.5%) in the asymptomatic group; 8 eyes (20.0%) in the atrophic and/or cicatricial group; 24 eyes (60.0%) in the combined group (coexisting with active polypoidal lesions); and 3 eyes (7.5%) in the mixed group (coexisting with choroidal neovascularization). Twelve of the 40 eyes were followed up for 9 to 29 months (mean 12.4 +/- 5.3 months). Over this time period, inactive polypoidal lesions completely regressed (not observed in ICGA) in 3 eyes (25.0%), partially regressed in 3 eyes (25.0%), and were stable (the same as the first visit) in 6 eyes (50.0%).
   Conclusions: Inactive polypoidal lesions in patients with PCV most commonly appeared during the middle phase of ICGA and were manifested in 4 groups. These lesions represented the sites of PCV in a regressed or quiescent stage.
C1 [Zeng, Renpan; Zhang, Xiongze; Li, Meng; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zeng, Renpan] Sichuan Prov Corps Hosp, Chinese Peoples Armed Police Forces, Dept Ophthalmol, Leshan, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81271011, 81200705]
FX Supported by the National Natural Science Foundation of China (grant
   numbers 81271011 and 81200705).
CR Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Park DH, 2010, JPN J OPHTHALMOL, V54, P48, DOI 10.1007/s10384-009-0765-5
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zuo CG, 2010, GRAEF ARCH CLIN EXP, V248, P191, DOI 10.1007/s00417-009-1210-7
   Zuo CG, 2009, DOC OPHTHALMOL, V119, P29, DOI 10.1007/s10633-009-9166-9
NR 38
TC 1
Z9 1
U1 0
U2 3
PU WICHTIG PUBL
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2015
VL 25
IS 3
BP 222
EP 228
DI 10.5301/ejo.5000532
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2IN
UT WOS:000361151700097
PM 25363854
DA 2022-11-30
ER

PT J
AU He, S
   Jin, ML
   Worpel, V
   Hinton, DR
AF He, S
   Jin, ML
   Worpel, V
   Hinton, DR
TI A role for connective tissue growth factor in the pathogenesis of
   choroidal neovascularization
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VASCULAR ENDOTHELIAL-CELLS; FACTOR GENE-EXPRESSION; PIGMENT
   EPITHELIAL-CELLS; ANGIOGENESIS IN-VIVO; MACULAR DEGENERATION;
   FACTOR-BETA; MEMBRANES; MIGRATION; MATRIX; PROLIFERATION
AB Objective: To evaluate the expression of connective tissue growth factor (CTGF) in choroidal neovascular membranes from patients with age-related macular degeneration and the effect of CTGF on choroidal endothelial cell (CEC) function.
   Methods: Using immunohistochemical methods, we analyzed CTGF expression in 13 surgically excised choroidal neovascular membranes related to age-related macular degeneration. The expression of CTGF in retinal pigment epithelial and CEC cultures was determined by means of reverse transcriptase polymerase chain reaction and Western blot, and its regulation by vascular endothelial growth factor and transforming growth factor P was determined. The effects of CTGF on bovine CEC proliferation, attachment, migration, and tube formation were measured.
   Results: Vascularized human choroidal neovascular membranes showed strong CTGF immunoreactivity. Double staining disclosed colocalization of CTGF with retinal pigment epithelial cells and CECs. The CTGF induced a significant increase in attachment and migration of CECs; however, it did not stimulate CEC proliferation. The CTGF protein was up-regulated in retinal pigment epithelial cells and CECs by stimulation with transforming growth factor P and vascular endothelial growth factor, respectively.
   Conclusions: The expression of CTGF in choroidal neovascular membranes, its regulation by angiogenic growth factors, and its proangiogenic effects on CEC function suggest that CTGF may play a role in the pathogenesis of choroidal neovascularization.
   Clinical Relevance: Multiple growth factors are involved in the pathogenesis of choroidal neovascularization in age-related macular degeneration.
C1 Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.
   Doheny Eye Inst, Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   Doheny Eye Institute
RP Hinton, DR (通讯作者)，Dept Pathol & Ophthalmol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
FU NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY03040] Funding Source: Medline
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Babic AM, 1999, MOL CELL BIOL, V19, P2958
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   Boes M, 1999, ENDOCRINOLOGY, V140, P1575, DOI 10.1210/en.140.4.1575
   BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Craig LE, 1998, MICROVASC RES, V55, P65, DOI 10.1006/mvre.1997.2045
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389
   Ghitescu L, 2002, MICROSC RES TECHNIQ, V57, P381, DOI 10.1002/jemt.10091
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469
   He PM, 1998, BIOCHEM BIOPH RES CO, V249, P253, DOI 10.1006/bbrc.1998.9087
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465
   Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Meyer P, 2002, OPHTHALMOLOGICA, V216, P284, DOI 10.1159/000063843
   Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K
   Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059
   Oemar BS, 1997, CIRCULATION, V95, P831
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57
   Schild C, 2002, EXP CELL RES, V274, P83, DOI 10.1006/excr.2001.5458
   Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414
   Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071
   Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200
   Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8
   Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141
   Wunderlich K, 2000, GRAEF ARCH CLIN EXP, V238, P910, DOI 10.1007/s004170000199
NR 40
TC 71
Z9 75
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2003
VL 121
IS 9
BP 1283
EP 1288
DI 10.1001/archopht.121.9.1283
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 721QT
UT WOS:000185327600008
PM 12963611
OA Bronze
DA 2022-11-30
ER

PT J
AU Vinores, SA
AF Vinores, SA
TI Anecortave Alcon Laboratories
SO IDRUGS
LA English
DT Article
ID MACULAR DEGENERATION; AGE; NEOVASCULARIZATION; RETINOPATHY; STEROIDS;
   THERAPY
AB Anecortave, an angiostatic steroid administered as a posterior juxtascleral depot, is under development by Alcon Laboratories Inc for the potential prevention and treatment of ocular diseases, in particular age-related macular degeneration.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Vinores, SA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 825 Maumenee Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM svinores@jhmi.edu
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   BINGAMAN DP, 2004, ANN M ASS RES VIS OP
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   DAHLIN DC, 2003, ANN M ASS RES VIS OP
   DAMICO DJ, 2002, ANN M ASS RES VIS OP
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Frank R N, 1998, Trans Am Ophthalmol Soc, V96, P635
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fujii GY, 2003, AM J OPHTHALMOL, V135, P109, DOI 10.1016/S0002-9394(02)01854-8
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HUDSON HL, 2003, INVEST OPHTHALMOL VI, V44
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   KITCHENS JW, 2003, ANN M ASS RES VIS OP
   KORNZWEIG AL, 1965, AM J OPHTHALMOL, V60, P835, DOI 10.1016/0002-9394(65)92002-7
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   LUTTY G, 1999, INVEST OPHTH VIS SCI, V3, P35
   McBee Wendy L, 2003, Curr Opin Ophthalmol, V14, P159, DOI 10.1097/00055735-200306000-00009
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MOUSA SA, 2001, ANGIOGENESIS NOVEL T
   MURRAY TG, 2004, ANN M ASS RES VIS OP, P45
   MURRAY TG, 2003, ANN M ASS RES VIS OP
   OLSEN TW, 2003, ANN M ASS RES VIS OP
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   RUSSELL SR, 2004, ANN M ASS RES VIS OP
   Santos CI, 1999, INVEST OPHTH VIS SCI, V40, pS335
   SLAKTER JS, 2004, ANN M ASS RES VIS OP
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   TORIS C, 2005, ASS OC PHARM THER 7
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   YACCOBI Y, 2003, ANN M ASS RES VIS OP
   YANG R, 2004, ANN M ASS RES VIS OP
   1993, Patent No. 09310141
   1992, Patent No. 00941485
   1991, Patent No. 00796169
   2002, FDC REPORTS PINK SHE, V64, P24
   1992, Patent No. 00892448
   1999, Patent No. 9903503
NR 48
TC 2
Z9 4
U1 0
U2 1
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1369-7056
EI 2040-3410
J9 IDRUGS
JI IDrugs
PD APR
PY 2005
VL 8
IS 4
BP 327
EP 334
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 916VK
UT WOS:000228414300015
PM 15800808
DA 2022-11-30
ER

PT J
AU Zuo, CG
   Wen, F
   Li, JQ
   Liu, Y
   Li, M
AF Zuo, Chengguo
   Wen, Feng
   Li, Jiaqing
   Liu, Yan
   Li, Meng
TI Transitions of multifocal electroretinography following combined
   intravitreal bevacizumab and photodynamic therapy for polypoidal
   choroidal vasculopathy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Bevacizumab;
   Multifocal electroretinography
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; NEOVASCULAR MEMBRANES; VERTEPORFIN; ERG; EXPRESSION;
   AVASTIN; RETINA
AB To investigate the changes in the multifocal electroretinography (ERG) after combined intravitreal bevacizumab and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Thirteen eyes of 13 patients were included in the study. The latencies and average response densities of all the six ring retinal regions were measured and compared before treatment and 1, 3, and 6 months after treatment. The latencies of the N1 and P1 waves in all the six rings remained unchanged compared with pre-treatment. Significant increase of average response densities of both P1 in ring 1 (P = 0.023) and N1, P1 in ring 2 (P = 0.028 and 0.046, respectively) were detected at 3 months post-treatment. The increase of P1 amplitude densities in ring 1 (P = 0.015) and N1, P1 amplitude densities in ring 2 (P = 0.031 and 0.034, respectively) were also significant at 6 months post-treatment. In conclusion, combined intravitreal bevacizumab and PDT is associated with an increase of multifocal ERG centrally in PCV patients.
C1 [Zuo, Chengguo; Wen, Feng; Li, Jiaqing; Liu, Yan; Li, Meng] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
FU National Basic Research Program of China [2007CB512206]
FX This study was supported by the National Basic Research Program of China
   (grant no. 2007CB512206).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Meyer CH, 2005, AM J OPHTHALMOL, V139, P214, DOI 10.1016/j.ajo.2004.07.034
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Shetty R, 2008, DOC OPHTHALMOL, V116, P129, DOI 10.1007/s10633-007-9090-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsunoda K, 2004, INVEST OPHTH VIS SCI, V45, P3820, DOI 10.1167/iovs.04-0394
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wakusawa R, 2008, AM J OPHTHALMOL, V146, P235, DOI 10.1016/j.ajo.2008.03.019
   Yamashiro K, 2007, JPN J OPHTHALMOL, V51, P368, DOI 10.1007/s10384-007-0465-y
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ziemssen F, 2008, GRAEF ARCH CLIN EXP, V246, P653, DOI 10.1007/s00417-007-0726-y
NR 37
TC 6
Z9 9
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD AUG
PY 2009
VL 119
IS 1
BP 29
EP 36
DI 10.1007/s10633-009-9166-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461TK
UT WOS:000267294200005
PM 19184153
DA 2022-11-30
ER

PT J
AU Ryu, G
   Moon, C
   van Hemert, J
   Sagong, M
AF Ryu, Gahyung
   Moon, Cheolwon
   van Hemert, Jano
   Sagong, Min
TI Quantitative analysis of choroidal vasculature in polypoidal choroidal
   vasculopathy using ultra-widefield indocyanine green angiography
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Polypoidal choroidal vasculopathy (PCV) is a common choroidal vascular disease particularly in Asians. However, the underlying pathogenesis of PCV is still yet to be fully elucidated, and the correlation between choroidal vasculature and treatment response of PCV are poorly understood. Accordingly, we sought to find clues to understand the pathogenesis and prognosis of PCV by quantitatively evaluating choroidal vasculature from the entire fundus using ultra-widefield (UWF) indocyanine green angiography (ICGA). In this study, 32 eyes from 29 patients with treatment naive PCV and 30 eyes from 30 healthy control participants were enrolled. Choroidal vascular density (CVD) of PCV eyes was higher than normal eyes in majority regions including the periphery. CVD was positively correlated with choroidal thickness and choroidal hyperpermeability, supporting that the pathogenesis of PCV may include choroidal congestion and dilatation. Thicker choroid and higher CVD were also correlated with poor treatment response after anti-VEGF injections. The CVD, quantified from UWF ICGA can also be used as an effective image biomarker to predict the treatment response in PCV.
C1 [Ryu, Gahyung; Moon, Cheolwon; Sagong, Min] Yeungnam Univ, Dept Ophthalmol, Coll Med, 170 Hyunchungro, Daegu 42415, South Korea.
   [Ryu, Gahyung; Moon, Cheolwon; Sagong, Min] Yeungnam Univ Hosp, Yeungnam Eye Ctr, Daegu, South Korea.
   [van Hemert, Jano] Optos PLC, Dunfermline, Fife, Scotland.
C3 Yeungnam University; Yeungnam University; Yeungnam University Hospital
RP Sagong, M (通讯作者)，Yeungnam Univ, Dept Ophthalmol, Coll Med, 170 Hyunchungro, Daegu 42415, South Korea.; Sagong, M (通讯作者)，Yeungnam Univ Hosp, Yeungnam Eye Ctr, Daegu, South Korea.
EM msagong@ynu.ac.kr
RI van Hemert, Jano/C-3094-2009
OI van Hemert, Jano/0000-0003-0834-7079
FU Yeungnam University
FX This work was supported by the 2018 Yeungnam University research grant.
CR Aboshiha J, 2015, OPHTHALMOLOGY, V122, P864, DOI 10.1016/j.ophtha.2014.11.016
   Baek J, 2020, RETINA-J RET VIT DIS, V40, P2166, DOI 10.1097/IAE.0000000000002723
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   DICOM Standards Committee, DIGITAL IMAGING COMM
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Hirahara S, 2016, AM J OPHTHALMOL, V166, P103, DOI 10.1016/j.ajo.2016.03.040
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jung JJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.50
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee A, 2020, GRAEF ARCH CLIN EXP, V258, P1921, DOI 10.1007/s00417-020-04772-y
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu B, 2019, CLIN EXP OPHTHALMOL, V47, P631, DOI 10.1111/ceo.13467
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yannuzzi L. A., 2012, AGE RELATED MACUL DE, DOI [10.1201/b14548-14, DOI 10.1201/B14548-14]
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 34
TC 3
Z9 3
U1 0
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 26
PY 2020
VL 10
IS 1
AR 18272
DI 10.1038/s41598-020-75506-7
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QD2QW
UT WOS:000615370600004
PM 33106565
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wolkow, N
   Song, Y
   Wu, TD
   Qian, J
   Guerquin-Kern, JL
   Dunaief, JL
AF Wolkow, Natalie
   Song, Ying
   Wu, Ting-Di
   Qian, Jiang
   Guerquin-Kern, Jean-Luc
   Dunaief, Joshua L.
TI Aceruloplasminemia Retinal Histopathologic Manifestations and
   Iron-Mediated Melanosome Degradation
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID HEREDITARY CERULOPLASMIN DEFICIENCY; INCREASED LIPID-PEROXIDATION;
   MACULAR DEGENERATION; PIGMENT EPITHELIUM; BRUCHS MEMBRANE; DRUSEN
   FORMATION; HUMAN RPE; GENE; FERRITIN; MELANIN
AB Objective: To examine the retinal histopathologic manifestation of aceruloplasminemia, an autosomal recessive disease caused by mutation of the ferroxidase ceruloplasmin, resulting in tissue iron overload.
   Methods: The morphologic features of the human aceruloplasminemic retina were studied with light and electron microscopy. Retinal iron accumulation was assessed with Perls Prussian blue staining, immunohistochemistry, and secondary ion mass spectrometry.
   Results: Light and electron microscopic analysis revealed several ocular pathologic findings that resembled age-related macular degeneration, including retinal pigment epithelium (RPE) depigmentation, atrophy and hypertrophy, nodular and diffuse drusen, and lipofuscin and melanolipofuscin granules. Complement deposition was detected in drusen. The RPE cells and neural retina had increased levels of iron. Two major types of RPE cells were observed: melanosome rich and melanosome poor. Melanosome-rich cells had increased levels of iron and melanolipofuscin. The melanolipofuscin granules were observed in large aggregates, where some of the melanosomes were degrading. Melanosome-poor cells lacked melanosomes, melanolipofuscin, and lipofuscin but contained electron-dense aggregates high in iron, phosphorus, and sulfur.
   Conclusions: The findings in the aceruloplasminemic retina resemble some of those found in age-related macular degeneration. Also, they suggest that melanosomes in the RPE can be degraded via iron-mediated reactive oxygen species production.
   Clinical Relevance: Mechanisms underlying the pathologic mechanisms found in aceruloplasminemia also may be important in age-related macular degeneration.
C1 [Wolkow, Natalie; Song, Ying; Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Wu, Ting-Di; Guerquin-Kern, Jean-Luc] Inst Curie, Lab Microscopie Ion, F-91405 Orsay, France.
   [Wu, Ting-Di; Guerquin-Kern, Jean-Luc] Univ Paris 11, INSERM, F-91405 Orsay, France.
   [Qian, Jiang] Albany Med Coll & Ctr, Affiliated Pathol Serv Inc, Dept Pathol & Lab Med, Albany, NY USA.
C3 University of Pennsylvania; Pennsylvania Medicine; UDICE-French Research
   Universities; PSL Research University Paris; UNICANCER; Institut Curie;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Saclay; Albany
   Medical College
RP Dunaief, JL (通讯作者)，Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
RI Guerquin-Kern, Jean-Luc/M-5000-2018
OI Guerquin-Kern, Jean-Luc/0000-0002-8610-0146; Wolkow,
   Natalie/0000-0003-1524-115X; WU, Ting-Di/0000-0002-6398-0363
FU National Institutes of Health [R01EY015240, EY012211, EY012261,
   EY012279, 1F30AG037289-01]; Research to Prevent Blindness,; F. M. Kirby
   Foundation; NATIONAL EYE INSTITUTE [R01EY015240, U10EY012279] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F30AG037289] Funding
   Source: NIH RePORTER
FX This study was supported by National Institutes of Health grants
   R01EY015240, EY012211, EY012261, and EY012279 (Dr Dunaief) and
   1F30AG037289-01 (Dr Wolkow), an unrestricted grant from Research to
   Prevent Blindness, the F. M. Kirby Foundation, a gift from L. Stanley
   Mauger, JD, in memory of Lee F. Mauger, MD, and the Paul and Evanina
   Bell Mackall Foundation Trust.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BHATNAGAR V, 1993, ARCH BIOCHEM BIOPHYS, V307, P183, DOI 10.1006/abbi.1993.1577
   Borovansky J, 2003, PIGM CELL RES, V16, P280, DOI 10.1034/j.1600-0749.2003.00040.x
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   COOPER PJ, 1988, HISTOCHEM J, V20, P499, DOI 10.1007/BF01002648
   De Domenico I, 2007, EMBO J, V26, P2823, DOI 10.1038/sj.emboj.7601735
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1979, DEV BIOL, V72, P73, DOI 10.1016/0012-1606(79)90099-X
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   GARCIA RI, 1983, EXPERIENTIA, V39, P391, DOI 10.1007/BF01963141
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guerquin-Kern JL, 2005, BBA-GEN SUBJECTS, V1724, P228, DOI 10.1016/j.bbagen.2005.05.013
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   IANCU TC, 1992, ELECTRON MICROSC REV, V5, P209, DOI 10.1016/0892-0354(92)90011-E
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kim I T, 1998, Korean J Ophthalmol, V12, P85
   Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989
   Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768
   Kohno S, 2000, J NEUROL SCI, V182, P57, DOI 10.1016/S0022-510X(00)00452-4
   Koorts A. M., 2007, Archives of Physiology and Biochemistry, V113, P30, DOI 10.1080/13813450701318583
   KORYTOWSKI W, 1990, J BIOL CHEM, V265, P12410
   Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Miyajima H, 1999, NEUROLOGY, V53, P617, DOI 10.1212/WNL.53.3.617
   Miyajima H, 2002, BLOOD CELL MOL DIS, V29, P433, DOI 10.1006/bcmd.2002.0561
   Miyajima H, 2003, NEUROPATHOLOGY, V23, P345, DOI 10.1046/j.1440-1789.2003.00521.x
   MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761
   MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   RICHTER GW, 1984, LAB INVEST, V50, P26
   RICHTER GW, 1958, J BIOPHYS BIOCHEM CY, V4, P55, DOI 10.1083/jcb.4.1.55
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Wixom R L, 1980, Int Rev Exp Pathol, V22, P193
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yoshida K, 2000, J NEUROL SCI, V175, P91, DOI 10.1016/S0022-510X(00)00295-1
   YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
NR 58
TC 44
Z9 45
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2011
VL 129
IS 11
BP 1466
EP 1474
DI 10.1001/archophthalmol.2011.309
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 848JK
UT WOS:000297047600010
PM 22084216
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zuo, CG
   Wen, F
   Huang, SZ
   Luo, GW
   Yan, H
   Wu, WJ
   Wu, DZ
AF Zuo Cheng-guo
   Wen Feng
   Huang Shi-zhou
   Luo Guang-wei
   Yan Hong
   Wu Wei-ju
   Wu De-zheng
TI Angiographic leakage of polypoidal choroidal vasculopathy on indocyanine
   angiography
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE classification; indocyanine green angiography; polypidal choroidal
   vasculopathy
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; CHINESE PATIENTS; FEATURES;
   NEOVASCULARIZATION; GREEN; HEMORRHAGE; LESIONS
AB Background There is no detailed report about the angiographic leakage of polypoidal choroidal vasculopathy (PCV) lesions on indocyanine green (ICG) angiography. This study aimed to investigate the angiographic leakage of polypoidal lesions in PCV on ICG angiography.
   Methods One hundred and forty-four eyes of 137 patients diagnosed as PCV were prospectively observed. Fundus examination, fluorescein angiography, and ICG angiography were performed. Leakage of polypoidal lesions and clinical features were recorded according to the angiograms.
   Results In all 144 eyes, 110 eyes showed angiographic leakage (leakage group) on ICG angiography and three subtypes of leakage group were noted, which were polypoidal dilations leakage (47 eyes, 42.7%), branching vascular networks leakage (14 eyes, 12.7%) and leakage of both (49 eyes, 44.5%). The other 34 eyes showed regression of polypoidal lesions (regression group). In leakage group, the rates of pigment epithelial detachment (PED), best corrected visual acuity (BCVA) <0.1 and old subretinal hemorrhages were 56.4% (62 eyes), 19.1% (21 eyes), and 4.6% (5 eyes) respectively, compared with 8.8% (3 eyes), 50% (17 eyes) and 38.2% (13 eyes) of regression group (P <0.001). The history of regression group was significantly longer (P <0.001).
   Conclusions Angiographic leakage and regression can be observed in PCV lesions. Leakage of both polypoidal dilations and branching vascular networks is the most common subtype in leakage group. PCV in leakage group is more likely to be related to PED, better BCVA and shorter history, while PCV regression group tends to relevant to old subretinal hemorrhage, worse BCVA and longer history. This may reflect that the former is active or in the early course while the later is resting or in the late phase of PCV. Chin Med J 2010;123(12):1548-1552
C1 [Zuo Cheng-guo; Wen Feng; Huang Shi-zhou; Luo Guang-wei; Yan Hong; Wu Wei-ju; Wu De-zheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
FU National Basic Research Program of China [2007CB512206]
FX This work was supported by a grant from the National Basic Research
   Program of China (No. 2007CB512206).
CR Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Obana A, 1999, BRIT J OPHTHALMOL, V83, P429, DOI 10.1136/bjo.83.4.429
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 21
TC 2
Z9 2
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD JUN 20
PY 2010
VL 123
IS 12
BP 1548
EP 1552
DI 10.3760/cma.j.issn.0366-6999.2010.12.013
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 623PK
UT WOS:000279754100013
PM 20819510
DA 2022-11-30
ER

PT J
AU Mantel, I
   Schalenbourg, A
   Zografos, L
AF Mantel, Irmela
   Schalenbourg, Ann
   Zografos, Leonidas
TI Peripheral Exudative Hemorrhagic Chorioretinopathy: Polypoidal Choroidal
   Vasculopathy and Hemodynamic Modifications
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; JAPANESE PATIENTS;
   DETACHMENT; ANGIOGRAPHY; RETINOPATHY; FEATURES; LESIONS; LASER; EYES
AB PURPOSE: To investigate choroidal vascular abnormalities in peripheral exudative hemorrhagic chorioretinopathy, using dynamic ultrawide-field fluorescein angiography (FA) and indocyanine green angiography (ICGA).
   DESIGN: Prospective observational case series.
   METHODS: This institutional study comprised a consecutive series of 40 patients (48 eyes) with peripheral exudative hemorrhagic chorioretinopathy. Choroidal vascular abnormalities were assessed with dynamic ultrawide-field (150-degree) FA and ICGA, using the Staurenghi 230 SLO Retina Lens and the Heidelberg scanning laser ophthalmoscope. The main outcome measures were morphologic descriptions of structural vascular abnormalities and choroidal hemodynamics (comparison with 30 normal eyes).
   RESULTS: The peripheral mass lesions were highly exudative and hemorrhagic, and usually associated with a pigment epithelium detachment. FA revealed nonspecific alterations corresponding to the visible fundoscopic changes (window defects, blockage, staining), but no neovascular membrane. However, despite frequent masking, ICGA showed hyperfluorescent polyp-like structures in the choroid of the lesion area in 33 eyes (69%) and an abnormal choroidal vascular network in 24 eyes (50%). The abnormal choroidal vascular network filled in the arterial or early venous phase, while the polyp-like structures filled some seconds later. Optical coherence tomography revealed the typical dome-shaped elevation of the pigment epithelium over the vascular polyps. Peripheral choriocapillaris closure was observed as well as dilated shunting vessels.
   CONCLUSION: Peripheral exudative hemorrhagic chorioretinopathy shares many characteristics (polyp-like choroidal telangiectases, abnormal choroidal vascular networks, exudative and hemorrhagic presentation) with polypoidal choroidal vasculopathy. Clarification of the precise role of these abnormalities requires further studies. (Am J Ophthalmol 2012;153:910-922. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Mantel, Irmela; Schalenbourg, Ann; Zografos, Leonidas] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Av France Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Annesley W H Jr, 1980, Trans Am Ophthalmol Soc, V78, P321
   BARDENSTEIN DS, 1992, OPHTHALMOLOGY, V99, P944
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   BEC P, 1979, J FR OPHTALMOL, V2, P329
   Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kim YT, 2010, JPN J OPHTHALMOL, V54, P227, DOI 10.1007/s10384-009-0794-0
   KINGHAM JD, 1978, ANN OPHTHALMOL, V10, P175
   Ladas ID, 2004, EUR J OPHTHALMOL, V14, P264, DOI 10.1177/112067210401400313
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Mantel I, 2009, AM J OPHTHALMOL, V148, P932, DOI 10.1016/j.ajo.2009.06.032
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   McCourt Emily A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS28, DOI 10.3928/15428877-20101031-14
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   POTTER JW, 1985, AM J OPTOM PHYS OPT, V62, P161
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shields CL, 2009, OPHTHALMOLOGY, V116, P529, DOI 10.1016/j.ophtha.2008.10.015
   SHIELDS JA, 1980, OPHTHALMOLOGY, V87, P518
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SILVA VB, 1976, ARCH OPHTHALMOL-CHIC, V94, P1295
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Staurenghi G, 2005, ARCH OPHTHALMOL-CHIC, V123, P244, DOI 10.1001/archopht.123.2.244
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Tsujikawa A, 2008, CLIN EXP OPHTHALMOL, V36, P817, DOI 10.1111/j.1442-9071.2009.01907.x
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vine A K, 1996, Eur J Ophthalmol, V6, P44
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 38
TC 26
Z9 26
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2012
VL 153
IS 5
BP 910
EP 922
DI 10.1016/j.ajo.2011.10.017
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941LN
UT WOS:000303964800017
PM 22310077
DA 2022-11-30
ER

PT J
AU Roh, MI
   Kim, HS
   Song, JH
   Lim, JB
   Koh, HJ
   Kwon, OW
AF Roh, Mi In
   Kim, Hong Suk
   Song, Ji Hun
   Lim, Jong Baek
   Koh, Hyoung Jun
   Kwon, Oh Woong
TI CONCENTRATION OF CYTOKINES IN THE AQUEOUS HUMOR OF PATIENTS WITH NAIVE,
   RECURRENT AND REGRESSED CNV ASSOCIATED WITH AMD AFTER BEVACIZUMAB
   TREATMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; aqueous humor; bevacizumab;
   interleukin-2; interleukin-6; interleukin-8; tumor necrosis
   factor-alpha; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN;
   MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; DIABETIC-RETINOPATHY;
   VITREOUS LEVELS; INTERLEUKIN-6; ANGIOGENESIS; EXPRESSION
AB Purpose: To evaluate the concentration of various cytokines in the aqueous humor of patients with naive, recurrent, and regressed choroidal neovascularization (CNV) of age-related macular degeneration after bevacizumab treatment.
   Methods: Aqueous humor samples were collected from 36 eyes with age-related macular degeneration and 10 controls during cataract surgery. Of 36 patients with age-related macular degeneration, 5 eyes were naive to bevacizumab injection, 14 eyes had recurrent CNV after bevacizumab treatment, and 17 eyes had regressed CNV after bevacizumab treatment. Cytokines were measured by an immunoassay using multianalyte biochip array technology (Evidence investigator cytokine and growth factor biochip array, RANDOX laboratories Ltd., Crumlin, UK).
   Results: No significant difference in the cytokine levels was noted between the control group and the naive CNV group (all P > 0.05). Vascular endothelial growth factor in both naive (66.8 +/- 35.1 pg/mL) and recurrent CNV groups (55.7 +/- 63.0 pg/mL) was significantly higher compared with regressed CNV group (9.8 +/- 12.8 pg/mL, P = 0.025 and P = 0.004, respectively) but was not statistically different from the control group (81.8 +/- 43.7 pg/mL, P = 0.310 and P = 0.212, respectively). The aqueous humor level of tumor necrosis factor-a and interleukin (IL)-2 was significantly lower in recurrent CNV group (P = 0.036 and P = 0.019) compared with the control group. In the active CNV patients (recurrent and naive CNV groups), the aqueous humor levels of IL-6 and IL-8 significantly correlated with the size of CNV (rho = 0.692, P = 0.001 and rho = 0.745, P < 0.001, respectively).
   Conclusion: Levels of Vascular endothelial growth factor measured in the aqueous humor were significantly related to the disease activity of CNV in age-related macular degeneration. Moreover, IL-2, IL-6, IL-8, and tumor necrosis factor-a may be related to the activity of CNV.
C1 [Roh, Mi In; Kim, Hong Suk; Song, Ji Hun; Koh, Hyoung Jun; Kwon, Oh Woong] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
   [Lim, Jong Baek] Yonsei Univ, Coll Med, Dept Lab Med, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kwon, OW (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM owkwon0301@yuhs.ac
OI Roh, Miin/0000-0003-3346-754X; Lim, Jong-Baeck/0000-0003-0419-0422; Koh,
   Hyoung Jun/0000-0002-5932-8516
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   ELASRAR AM, 1992, AM J OPHTHALMOL, V114, P731, DOI 10.1016/S0002-9394(14)74052-8
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funatsu H, 2001, RETINA-J RET VIT DIS, V21, P469, DOI 10.1097/00006982-200110000-00009
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   Isaacs TW, 2006, CLIN EXP OPHTHALMOL, V34, P802, DOI 10.1111/j.1442-9071.2006.01378.x
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Lacomba MS, 2001, OPHTHALMIC RES, V33, P251
   Lacomba MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P768, DOI 10.1001/archopht.118.6.768
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Molloy RM, 2005, CLIN CHEM LAB MED, V43, P1303, DOI 10.1515/CCLM.2005.224
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohtani K, 2008, INT J ONCOL, V32, P397
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015
   Yuuki T, 2001, J DIABETES COMPLICAT, V15, P257, DOI 10.1016/S1056-8727(01)00155-6
NR 36
TC 90
Z9 93
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2009
VL 29
IS 4
BP 523
EP 529
DI 10.1097/IAE.0b013e318195cb15
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 433KX
UT WOS:000265203800015
PM 19262441
DA 2022-11-30
ER

PT J
AU Huang, JD
   Amaral, J
   Lee, JW
   Larrayoz, IM
   Rodriguez, IR
AF Huang, Jiahn-Dar
   Amaral, Juan
   Lee, Jung Wha
   Larrayoz, Ignacio M.
   Rodriguez, Ignacio R.
TI Sterculic acid antagonizes 7-ketocholesterol-mediated inflammation and
   inhibits choroidal neovascularization
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE ER stress; 7-ketocholesterol; Inflammation; Sterculic acid; CHOP; RPE
AB Sterculic acid is a cyclopropene fatty acid with numerous biological activities. In this study we demonstrate that sterculic acid is a potent inhibitor of endoplasmic reticulum (ER) stress and related inflammation caused by 7-ketocholesterol (7KCh). 7KCh is a highly toxic oxysterol suspected in the pathogenesis of various age-related diseases such as atherosclerosis, Alzheimer's disease and age-related macular degeneration. Sterculic acid demonstrated to be 5-10 times more effective than other anti-inflammatory fatty acids at inhibiting 7KCh-mediated inflammatory responses in cultured cells. In vivo, sterculic acid was effective at inhibiting the formation of choroidal neovascularization (CNV) in the laser-injury rat model. Our data suggests that sterculic acid may be useful in treating CNV in certain forms of age-related macular degeneration. Published by Elsevier B.V.
C1 [Huang, Jiahn-Dar; Amaral, Juan; Lee, Jung Wha; Larrayoz, Ignacio M.; Rodriguez, Ignacio R.] NEI, NIH, Sect Mech Retinal Dis, LRCMB, Bethesda, MD 20892 USA.
   [Larrayoz, Ignacio M.] Ctr Biomed Res La Rioja CIBIR, Angiogenesis Unit, La Rioja, Spain.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Rodriguez, IR (通讯作者)，NEI, NIH, Sect Mech Retinal Dis, LRCMB, 6 Ctr Dr,MSC0608,Bldg 6 Rm 136, Bethesda, MD 20892 USA.
EM rodriguezi@nei.nih.gov
RI Larrayoz, Ignacio M/I-5613-2012
OI Larrayoz, Ignacio M/0000-0003-1629-152X; Amaral,
   Juan/0000-0001-8755-9170
FU National Eye Institute; NATIONAL EYE INSTITUTE [ZIAEY000307] Funding
   Source: NIH RePORTER
FX The authors would like to thank Dr. Maria Campos at the NEI's Biological
   Imaging Core facility for her assistance in imaging of the laser
   lesions. This work is supported by National Eye Institute Intramural
   Research Program.
CR Badimon L, 2010, CARDIOVASC THER, V28, P202, DOI 10.1111/j.1755-5922.2010.00189.x
   Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Brown AJ, 1997, J LIPID RES, V38, P1730
   Busch TP, 2010, J AM OIL CHEM SOC, V87, P955, DOI 10.1007/s11746-010-1572-3
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Garcia-Cruset S, 2001, FREE RADICAL RES, V35, P31, DOI 10.1080/10715760100300571
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lee WH, 2009, Z NATURFORSCH C, V64, P307
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200
   Ong WY, 2003, BRAIN PATHOL, V13, P250
   Park PW, 1996, J AM OIL CHEM SOC, V73, P623, DOI 10.1007/BF02518118
   Pase MP, 2011, AM J CLIN NUTR, V93, P446, DOI 10.3945/ajcn.110.002725
   Poli G, 2009, MOL ASPECTS MED, V30, P180, DOI 10.1016/j.mam.2009.02.003
   Psota TL, 2006, AM J CARDIOL, V98, p3I, DOI 10.1016/j.amjcard.2005.12.022
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Saito E, 2008, J ATHEROSCLER THROMB, V15, P130, DOI 10.5551/jat.E556
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Salminen A, 2009, J CLIN IMMUNOL, V29, P397, DOI 10.1007/s10875-009-9296-6
   Salun J., 2000, TOP CURR CHEM, P1
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sanson M, 2009, CIRC RES, V104, P328, DOI 10.1161/CIRCRESAHA.108.183749
   Sasaki H, 2007, METABOLISM, V56, P357, DOI 10.1016/j.metabol.2006.10.017
   Smith LL, 1996, LIPIDS, V31, P453, DOI 10.1007/BF02522641
   Sottero B, 2009, CURR MED CHEM, V16, P685, DOI 10.2174/092986709787458353
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766
   VARMA JP, 1957, J AM OIL CHEM SOC, V34, P452, DOI 10.1007/BF02638003
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
NR 44
TC 28
Z9 29
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 1879-2618
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD APR
PY 2012
VL 1821
IS 4
BP 637
EP 646
DI 10.1016/j.bbalip.2012.01.013
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 921OI
UT WOS:000302486500009
PM 22342272
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sato, T
   Kanda, T
   Iida, T
   Takahashi, T
   Kishi, S
   Hoshino, Y
AF Sato, T
   Kanda, T
   Iida, T
   Takahashi, T
   Kishi, S
   Hoshino, Y
TI Immunohistochemical study of surgically excised choroidal neovascular
   membranes
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE choroidal neovascular membranes; idiopathic choroidal
   neovascularization; basic transcriptional element binding protein-2;
   age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; SMEMB/NMHC-B GENE; MACULAR DEGENERATION;
   MODEL
AB We carried out an immunohistochemical investigation of the choroidal neovascular membranes from 12 eyes surgically excised as a result of age-related macular degeneration (n = 6) or idiopathic choroidal neovascularization (n = 6). Immunohistochemical staining was performed with antibodies specific for basic transcriptional element binding protein-2, actin or smooth muscle cell 1. In all membranes, the endothelial cells and stromal components around the vessels were immunoreactive for expression of basic transcriptional element binding protein-2, while immunoreactive expression of actin and smooth muscle cell type 1 was found in the surrounding stromal cells. These results suggest that basic transcriptional element binding protein-2, a zinc finger transcription factor, may contribute to the establishment of the choroidal neovascularization observed in the pathogenesis of age-related macular degeneration and idiopathic choroidal neovascularization.
C1 Kanazawa Med Univ, Dept Gen Med, Uchinada, Ishikawa 9200293, Japan.
   Gunma Univ, Sch Med, Dept Ophthalmol, Gunma, Japan.
   Gunma Univ, Sch Med, Dept Internal Med 2, Gunma, Japan.
C3 Kanazawa Medical University; Gunma University; Gunma University
RP Kanda, T (通讯作者)，Kanazawa Med Univ, Dept Gen Med, Daigaku 1-1, Uchinada, Ishikawa 9200293, Japan.
OI Takahashi, Takashi/0000-0003-4131-2062
CR EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Manabe I, 1997, BIOCHEM BIOPH RES CO, V239, P598, DOI 10.1006/bbrc.1997.7512
   NAKAJIMA M, 1997, J JPN OPHTHALMOL SOC, V101, P584
   Takahashi T, 1998, RES EXP MED, V197, P319, DOI 10.1007/s004330050080
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
NR 11
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE MED PUBL
PI WORTHING
PA WICKER HOUSE, HIGH ST, WORTHING BN11 1DJ, W SUSSEX, ENGLAND
SN 0300-0605
J9 J INT MED RES
JI J. Int. Med. Res.
PD SEP-OCT
PY 2003
VL 31
IS 5
BP 402
EP 406
DI 10.1177/147323000303100507
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 735DX
UT WOS:000186098100007
PM 14587307
DA 2022-11-30
ER

PT J
AU Lin, HC
   Yang, CH
   Yang, CM
AF Lin, H-C
   Yang, C-H
   Yang, C-M
TI Visual outcomes of vitrectomy for polypoidal choroidal
   vasculopathy-related breakthrough vitreous haemorrhage
SO EYE
LA English
DT Article
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; ASSOCIATION;
   COMPLICATIONS; SECONDARY; INJECTION; SURGERY
AB Purpose To evaluate the long-term visual outcomes of pars plana vitrectomy (PPV) for polypoidal choroidal vasculopathy (PCV)-associated vitreous haemorrhage (VH).
   Method We retrospectively reviewed the records of patients with PCV-related VH who underwent PPV. The main outcome measures were best-corrected visual acuity (BCVA) and fundus findings at 3 months postoperatively and final visit.
   Results Seventeen eyes of 17 patients with massive subretinal haemorrhage (16.7 +/- 7.1 disc size of mean subretinal haemorrhage area) were enrolled. The mean postoperative follow-up period was 25.2 months. Four eyes received intravitreal bevacizumab injections, and three eyes underwent photodynamic therapy before the onset of VH. The mean BCVA improved from logarithm of the minimum angle of resolution (LogMAR) of 2.63 +/- 0.57 preoperatively to 1.43 +/- 0.82 at final visit (P<0.001). Among the eyes with initial polyps at subfoveal or juxtafoveal area, 16.70% achieved final BCVA >= 20/400 (LogMAR 1.3), whereas 87.50% of eyes with initial polyps at extrafoveal area had final BCVA >= 20/400 (Fisher's exact test, P = 0.026).
   Conclusions PCV with massive subretinal haemorrhage is at risk for breakthrough VH. The visual prognosis in eyes with PCV-related breakthrough VH is variable after vitrectomy. Initial polyps at the extrafoveal area led to better functional outcomes. Early vitrectomy may be beneficial for visual recovery after PCV-related VH.
C1 [Lin, H-C; Yang, C-H; Yang, C-M] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei 100, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chung-May/AAV-3737-2020; Yang, Chang-Hao/AAR-3759-2021
OI Lin, Hsuan-Chieh/0000-0002-8942-4613; YANG,
   CHANG-HAO/0000-0002-4328-8716; YANG, CHUNG-MAY/0000-0003-4082-420X
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Azzolini C, 1991, Eur J Ophthalmol, V1, P142
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen HY, 2012, MOL VIS, V18, P816
   Cho HJ, 2012, CAN J OPHTHALMOL, V47, P170, DOI 10.1016/j.jcjo.2012.01.005
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   ORTH DH, 1982, RETINA-J RET VIT DIS, V2, P89, DOI 10.1097/00006982-198200220-00006
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Roufail E, 2008, CLIN EXP OPHTHALMOL, V36, P36, DOI 10.1111/j.1442-9071.2007.01651.x
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 6
Z9 8
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2014
VL 28
IS 7
BP 797
EP 807
DI 10.1038/eye.2014.124
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL5LT
UT WOS:000339175900005
PM 24924445
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Sharma, MC
   Lai, WW
   Shapiro, MJ
AF Sharma, MC
   Lai, WW
   Shapiro, MJ
TI Pseudohypopyon following intravitreal triamcinolone acetonide injection
SO CORNEA
LA English
DT Article
DE endophthalmitis; hypopyon; intravitreal injection; pseudohypopyon;
   triamcinolone acetonide
ID CRYSTALLINE CORTISONE; ADJUNCTIVE TREATMENT
AB Objective: To report a case of a pseudohypopyon that developed after intravitreal injection of triamcinolone acetonide for choroidal neovascularization from age-related macular degeneration.
   Methods: Observational case report.
   Results: A 62-year-old woman received an intravitreal injection of triamcinolone acetonide for the treatment of a choroidal neovascular membrane that developed as a result of age-related macular degeneration. A layer of yellowish deposits was observed in the anterior chamber I day after the injection. The patient denied any pain or reduced vision, and there was no redness noted on examination. The deposits cleared spontaneously on the fourth postoperative day.
   Conclusions: Pseudohypopyon may develop after intravitreal injection of triamcinolone acetonide. Distinguishing this from a true hypopyon is important because the treatment and prognosis are very different for the two conditions.
C1 Univ Illinois, Chicago Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Sharma, MC (通讯作者)，Univ Illinois, Chicago Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, 1905 W Taylor St, Chicago, IL 60612 USA.
EM sharmamc@hotmail.com
RI CLIHON, Residencia Medica/K-4896-2013
OI CLIHON, Residencia Medica/0000-0001-6734-2513
CR AYLIFFE W, 1995, AM J OPHTHALMOL, V119, P361
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Kresloff MS, 1998, SURV OPHTHALMOL, V43, P193, DOI 10.1016/S0039-6257(98)00036-8
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
NR 5
TC 20
Z9 20
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD MAY
PY 2004
VL 23
IS 4
BP 398
EP 399
DI 10.1097/00003226-200405000-00016
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815WW
UT WOS:000221073400016
PM 15097137
DA 2022-11-30
ER

PT J
AU Palanki, MSS
   Akiyama, H
   Campochiaro, P
   Cao, J
   Chow, CP
   Dellamary, L
   Doukas, J
   Fine, R
   Gritzen, C
   Hood, JD
   Hu, S
   Kachi, S
   Kang, X
   Klebansky, B
   Kousba, A
   Lohse, D
   Mak, CC
   Martin, M
   McPherson, A
   Pathak, VP
   Renick, J
   Soll, R
   Umeda, N
   Yee, S
   Yokoi, K
   Zeng, B
   Zhu, H
   Noronha, G
AF Palanki, Moorthy S. S.
   Akiyama, Hideo
   Campochiaro, Peter
   Cao, Jianguo
   Chow, Chun P.
   Dellamary, Luis
   Doukas, John
   Fine, Richard
   Gritzen, Colleen
   Hood, John D.
   Hu, Steven
   Kachi, Shu
   Kang, Xinshan
   Klebansky, Boris
   Kousba, Ahmed
   Lohse, Dan
   Mak, Chi Ching
   Martin, Michael
   McPherson, Andrew
   Pathak, Ved P.
   Renick, Joel
   Soll, Richard
   Umeda, Naoyasu
   Yee, Shiyin
   Yokoi, Katsutoshi
   Zeng, Binqi
   Zhu, Hong
   Noronha, Glenn
TI Development of prodrug
   4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}1,2,4-b
   enzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered
   therapeutic candidate in clinical trials for the treatment of
   age-related macular degeneration
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; VEGF-INDUCED
   ANGIOGENESIS; CHOROIDAL NEOVASCULARIZATION; NEW-MODEL; PHOSPHORYLATION;
   TYROSINE-861; RANIBIZUMAB; SUPPRESSION; INHIBITION
AB Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeting the VEGFr pathway may be effective for the treatment of AMD. Recent studies using Src/YES knockout mice suggest that along with VEGF, Src and YES play a crucial role in vascular leak and might be useful in treating edema associated with AMD. Therefore, we have developed several potent benzotriazine inhibitors designed to target VEGFr2, Src, and YES. One of the most potent compounds is 4-chloro-3-{5-methyl-3-[4-(2-pytrolidin-1-yl-ethoxy)phenylamino]benzo[1,2,4]triazin-7-yl}phenol (5), a dual inhibitor of both VEGFr2 and the Src family (Src and YES) kinases. Several ester analogues of 5 were prepared as prodrugs to improve the concentration of 5 at the back of the eye after topical administration. The thermal stability of these esters was studied, and it was found that benzoyl and substituted benzoyl esters of 5 showed good thermal stability. The hydrolysis rates of these prodrugs were studied to analyze their ability to undergo conversion to 5 in vivo so that appropriate concentrations of 5 are available in the back-of-the-eye tissues. From these studies, we identified 4-chloro-3-(5-methyl-3-{[4(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotfazin-7-yl)phenyl benzoate (12), a topically administered prodrug delivered as an eye drop that is readily converted to the active compound 5 in the eye. This topically delivered compound exhibited excellent ocular pharmacokinetics and poor systemic circulation and showed good efficacy in the laser induced choroidal neovascularization model. On the basis of its superior profile, compound 12 was advanced. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD.
C1 [Palanki, Moorthy S. S.; Cao, Jianguo; Chow, Chun P.; Dellamary, Luis; Doukas, John; Gritzen, Colleen; Hood, John D.; Hu, Steven; Kousba, Ahmed; Lohse, Dan; Mak, Chi Ching; Martin, Michael; McPherson, Andrew; Pathak, Ved P.; Renick, Joel; Soll, Richard; Yee, Shiyin; Zeng, Binqi; Zhu, Hong; Noronha, Glenn] TargeGen Inc, San Diego, CA 92121 USA.
   [Akiyama, Hideo; Campochiaro, Peter; Kachi, Shu; Umeda, Naoyasu; Yokoi, Katsutoshi] Johns Hopkins Univ Hosp, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Fine, Richard; Kang, Xinshan; Klebansky, Boris] BioPredict Inc, Oradell, NJ 07649 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Palanki, MSS (通讯作者)，TargeGen Inc, 9380 Judicial Dr, San Diego, CA 92121 USA.
EM Palanki@targegen.com
OI Umeda, Naoyasu/0000-0001-5814-8356; McPherson,
   Andrew/0000-0001-8579-8709
CR Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255
   AGUILAR E, 2006, ANN M ASS RES VIS OP
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ATTAR M, 2005, EXPERT OPIN DRUG DEL, V2, P908
   Bainbridge JWB, 2003, BIOCHEM BIOPH RES CO, V302, P793, DOI 10.1016/S0006-291X(03)00222-5
   BEALS CR, 2006, Patent No. 200611766
   Breitenlechner CB, 2005, J MOL BIOL, V353, P222, DOI 10.1016/j.jmb.2005.08.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714
   Dalgarno D, 2006, CHEM BIOL DRUG DES, V67, P46, DOI 10.1111/j.1747-0285.2005.00316.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   DOUKAS J, 2008, J CELL PHYSL, V215
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079
   ESILVA RL, 2006, EXP EYE RES, V83, P1260
   Fernando NH, 2004, ONCOLOGIST, V9, P11, DOI 10.1634/theoncologist.9-suppl_1-11
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   FRIEDLANDER M, COMMUNICATION
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   KOUSBA AA, 2007, 8 SCI M ASS OC PHARM
   Kudo N, 2006, ANGEW CHEM INT EDIT, V45, P1282, DOI 10.1002/anie.200503479
   Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200
   MASON JC, 1970, J CHEM SOC B, P911, DOI 10.1039/j29700000911
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   NORONHA G, 2007, FRONTIERS DRUG DESIG, V3, P121
   Noronha G, 2007, BIOORG MED CHEM LETT, V17, P602, DOI 10.1016/j.bmcl.2006.11.006
   Noronha G, 2006, BIOORG MED CHEM LETT, V16, P5546, DOI 10.1016/j.bmcl.2006.08.035
   PEER J, 1995, LAB INVEST, V72, P638
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SOUBRANE G, 1994, CURR EYE RES, V13, P183, DOI 10.3109/02713689408995776
   Sultana Yasmin, 2006, Current Drug Delivery, V3, P207, DOI 10.2174/156720106776359186
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Tundel RE, 2006, J ORG CHEM, V71, P430, DOI 10.1021/jo052131u
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   VERBEKE G, 2000, LINEAR MIXED MODELS, P93
   WAND F, 2003, INVEST OPHTH VIS SCI, V44, P781
   Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130
   WOLF FJ, 1954, J AM CHEM SOC, V76, P3551, DOI 10.1021/ja01642a060
   Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0
NR 52
TC 38
Z9 49
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 27
PY 2008
VL 51
IS 6
BP 1546
EP 1559
DI 10.1021/jm7011276
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 277JZ
UT WOS:000254209800004
PM 18311895
DA 2022-11-30
ER

PT J
AU Sorensen, JO
   Subhi, Y
   Molbech, CR
   Nielsen, MK
   Sorensen, TL
AF Sorensen, Jakob Orskov
   Subhi, Yousif
   Molbech, Christopher R.
   Nielsen, Marie Krogh
   Sorensen, Torben L.
TI Plasma levels of inflammatory chemokines in patients with polypoidal
   choroidal vasculopathy
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Chemokines; CX3CL1; Fractalkine; Plasma; Polypoidal choroidal
   vasculopathy
ID C-REACTIVE PROTEIN; MACULAR DEGENERATION; RECEPTOR; CX3CR1;
   ACCUMULATION; EXPRESSION; MONOCYTES
AB Purpose Chemokines are a group of cytokines that guide immune cell migration. We studied plasma levels of inflammatory chemokines in patients with polypoidal choroidal vasculopathy (PCV) and compared with healthy age-matched control individuals.
   Methods This was a clinic-based prospective case-control study of participants (n = 60) with either PCV (n = 26) or age-matched healthy controls (n = 34). We sampled fresh venous blood and isolated plasma for analysis. We used U-PLEX Human Assays to quantify concentrations of the inflammatory chemokines MCP-1/CCL2, RANTES/CCL5, eotaxin/CCL11, IP-10/CXCL10 and fractalkine/CX3CL1.
   Results Plasma levels of fractalkine was significantly higher in patients with PCV when compared to healthy controls (mean +/- SD: 7291 +/- 2461 pg/ml versus 5879 +/- 2001 pg/ml; p = 0.021). Plasma levels of MCP-1 (p = 0.846), RANTES (p = 0.288), eotaxin (p = 0.496) and IP-10 (p = 0.352) did not differ significantly between the groups. To evaluate possible biomarker quality of fractalkine, we used a ROC analysis and found a positive but weak discriminatory ability (AUC = 0.68).
   Conclusion Patients with PCV have a higher plasma level of fractalkine. Although the differences do not possess strong biomarker qualities, they inform on disease processes of a poorly understood disease and suggest that the fractalkine-CX3CR1 axis may be involved. As this study did not investigate local chemokine concentrations, we are unable to confirm or disprove any local chorioretinal interaction, and our findings should be interpreted with such caution.
C1 [Sorensen, Jakob Orskov; Subhi, Yousif; Molbech, Christopher R.; Nielsen, Marie Krogh; Sorensen, Torben L.] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Sorensen, Jakob Orskov; Subhi, Yousif] Rigshosp Glostrup, Dept Ophthalmol, Glostrup, Denmark.
   [Molbech, Christopher R.; Sorensen, Torben L.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Call DR, 2001, AM J PATHOL, V158, P715, DOI 10.1016/S0002-9440(10)64014-X
   Clover AJP, 2011, BURNS, V37, P1386, DOI 10.1016/j.burns.2011.08.001
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Falk M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109104
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moussa Kareem, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS128, DOI 10.1097/ICB.0000000000000464
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rifai N, 2001, CLIN CHEM, V47, P28
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Shimizu K, 2011, HYPERTENS RES, V34, P747, DOI 10.1038/hr.2011.23
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Subhi Y, 2019, INVEST OPHTH VIS SCI, V60, P2583, DOI 10.1167/iovs.19-26882
   Subhi Y, 2019, JAMA OPHTHALMOL, V137, P515, DOI 10.1001/jamaophthalmol.2019.0010
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yannuzzi L., 1982, MAC SOC M MIAM FL FE
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 4
Z9 4
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2020
VL 98
IS 4
BP 384
EP 389
DI 10.1111/aos.14295
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LN3HJ
UT WOS:000532832600009
PM 31680415
DA 2022-11-30
ER

PT J
AU Hu, ZZ
   Xie, P
   Ding, YZ
   Yuan, DQ
   Liu, QH
AF Hu, Zizhong
   Xie, Ping
   Ding, Yuzhi
   Yuan, Dongqing
   Liu, Qinghuai
TI Association between variants A69S in ARMS2 gene and response to
   treatment of exudative AMD: a meta-analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; GROWTH-FACTOR TREATMENT; MACULAR DEGENERATION;
   INTRAVITREAL RANIBIZUMAB; LOC387715/HTRA1 VARIANTS; PHOTODYNAMIC
   THERAPY; SUSCEPTIBILITY; BEVACIZUMAB
AB A study was undertaken to investigate the association between A69S in age-related maculopathy susceptibility 2 (ARMS2) and the response to anti-angiogenesis treatment in exudative age-related macular degeneration (AMD). A literature-based meta-analysis was performed of studies relevant to A69S and the response to anti-angiogenesis treatment. PubMed, Web of Science, China National Knowledge Infrastructure (CNKI) and Sinomed databases were used to retrieve articles up to July 2014. Pooled ORs and 95% CIs were estimated using fixed and random effects models in Stata V.9.0. Q-statistic testing was used to assess heterogeneity. Twelve articles comprising 2389 cases were included in the final meta-analysis. The analysis of the overall population indicated a statistically significant association between A69S and the response to anti-angiogenesis treatment in exudative AMD (GG vs TT: OR 1.34 (95% CI 1.01 to 1.77), p=0.039; GT vs TT: OR 1.58 (95% CI 1.08 to 2.31), p=0.018; GG+GT vs TT: OR 1.74 (95% CI 1.19 to 2.52), p=0.004). In subgroup analysis, A69S appeared more likely to be a predictor for anti-angiogenic response in the East Asian population (GG vs TT: OR 1.65 (95% CI 1.02 to 2.68), p=0.042; GT vs TT: OR 1.66 (95% CI 1.17 to 2.37), p=0.005; GG+GT vs TT: OR 1.82 (95% CI 1.07 to 3.10), p=0.027; G vs T: OR 1.56 (95% CI 1.01 to 2.41)). However, no statistical significance was found in the Caucasian subgroup analysis. This study shows an association between A69S polymorphism in the ARMS2 gene and the anti-angiogenesis treatment response. A69S could be considered predictive of the anti-angiogenic effects, especially in Asian populations.
C1 [Hu, Zizhong; Xie, Ping; Ding, Yuzhi; Yuan, Dongqing; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964; hu, zizhong/0000-0001-6289-1804; Xie,
   Ping/0000-0003-4257-8970
FU National Basic Research Program of China (973 Program) [2013CB967500,
   2011CB510200]; National Natural Science Fund [81170855]; Jiangsu
   Provincial Special Program of Medical Science [BL2014089]
FX This research was supported by the National Basic Research Program of
   China (973 Program, No. 2013CB967500 and No. 2011CB510200,
   http://www.973.gov.cn/English/Index.aspx), General Project of the
   National Natural Science Fund (No. 81170855, http://www.nsfc.gov.cn) and
   Jiangsu Provincial Special Program of Medical Science (BL2014089).
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   dos Reis Veloso CE, 2013, OPHTHALMIC RES, V51, P1
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ingleheam CF, 2012, INVEST OPHTH VIS SCI, V53, P3325
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Teper SJ, 2010, MOL VIS, V16, P2598
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yu KD, 2001, BREAST CANC RES TREA, V127, P577
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
NR 46
TC 22
Z9 22
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2015
VL 99
IS 5
BP 593
EP 598
DI 10.1136/bjophthalmol-2014-305488
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5BR
UT WOS:000353305800005
PM 25185256
DA 2022-11-30
ER

PT J
AU Wang, M
   Zhou, Y
   Gao, SS
   Liu, W
   Huang, YH
   Huang, D
   Jia, YL
AF Wang, Min
   Zhou, Yao
   Gao, Simon S.
   Liu, Wei
   Huang, Yongheng
   Huang, David
   Jia, Yali
TI Evaluating Polypoidal Choroidal Vasculopathy With Optical Coherence
   Tomography Angiography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography angiography; polypoidal choroidal
   vasculopathy; branching vascular network
ID AMPLITUDE-DECORRELATION ANGIOGRAPHY; INDOCYANINE GREEN;
   ADVERSE-REACTIONS; NEOVASCULARIZATION
AB PURPOSE. We observed and analyzed the morphologic characteristics of polypoidal lesions and abnormal branching vascular network (BVN) in patients with polypoidal choroidal vasculopathy (PCV) by optical coherence tomography angiography (OCTA).
   METHODS. A retrospective observational case series was done of patients with PCV. All patients were scanned with a 70-kHz spectral-domain OCT system using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm to distinguish blood flow from static tissue. The OCTA images of these patients were compared to those from indocyanine green angiography (ICGA). Semiautomated segmentation was used to further analyze the polypoidal lesion and the BVN.
   RESULTS. We studied 13 eyes of 13 patients 51 to 69 years old. A total of 11 patients were treatment-naive. Two patients had multiple anti-VEGF injections and one underwent photodynamic therapy (PDT). Optical coherence tomography angiography was able to detect the BVN in all cases. Using cross-sectional OCTA, BVN locations were shown to be in the space between the RPE and Bruch's membrane. Using en face OCTA, the BVN vascular pattern could be shown more clearly than by ICGA. Polypoidal lesions showed high flow signals in different patterns in 12 cases in the outer retina slab. Using cross-sectional OCTA, the polyps were shown to be just below the top of the pigment epithelial detachment (PED). In one case, the polypoidal lesion was not detectable at the outer retina slab.
   CONCLUSIONS. Optical coherence tomography angiography is a noninvasive imaging tool for detecting vascular changes in PCV. Branching vascular networks showed more clearly on OCTA than on ICGA. Polypoidal lesions had variable patterns on OCTA and were not always detected. The OCTA patterns of the polypoidal lesions and the BVN are helpful in understanding the pathology of PCV.
C1 [Wang, Min; Zhou, Yao; Liu, Wei; Huang, Yongheng] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol & Vis Sci, Shanghai, Peoples R China.
   [Wang, Min; Liu, Wei] Key Lab Visual Impairment & Restorat Shanghai, Shanghai, Peoples R China.
   [Gao, Simon S.; Huang, David; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
C3 Fudan University; Oregon Health & Science University
RP Wang, M (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol & Vis Sci, Shanghai, Peoples R China.; Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM wangmin83@yahoo.com; jiaya@ohsu.edu
OI Jia, Yali/0000-0002-2784-1905; Gao, Simon/0000-0002-7020-037X
FU Shanghai Science and Technology Committee [14411965500]; Natural Science
   Foundation of Shanghai Municipal Science and Technology Commission
   [13ZR1406100]; Shanghai Key Laboratory of Visual Impairment and
   Restoration, National Institutes of Health (NIH; Bethesda, MD, USA) [DP3
   DK104397, R01EY024544, R01EY023285, P30 EY010572]; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [R01EY023285, R01EY024544,
   P30EY010572, T32EY023211] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [DP3DK104397]
   Funding Source: NIH RePORTER
FX Supported in part by research grants from Shanghai Science and
   Technology Committee (14411965500), The Natural Science Foundation of
   Shanghai Municipal Science and Technology Commission (13ZR1406100),
   Shanghai Key Laboratory of Visual Impairment and Restoration, National
   Institutes of Health (NIH; Bethesda, MD, USA) Grants DP3 DK104397,
   R01EY024544, R01EY023285, P30 EY010572, and an unrestricted grant from
   Research to Prevent Blindness. Oregon Health & Science University
   (OHSU), David Huang and Yali Jia have a significant financial interest
   in Optovue, Inc. David Huang also has a financial interest in Carl Zeiss
   Meditec, Inc. These potential conflicts of interest have been reviewed
   and managed by OHSU.
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   BENYA R, 1989, CATHETER CARDIO DIAG, V17, P231, DOI 10.1002/ccd.1810170410
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 22
TC 58
Z9 66
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2016
VL 57
IS 9
BP OCT526
EP OCT532
DI 10.1167/iovs.15-18955
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9MY
UT WOS:000383985400056
PM 27472276
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, KM
   Kim, HS
   Il Han, J
   Kim, CG
   Lee, TG
   Kim, JW
AF Cho, Han Joo
   Kim, Kyoung Min
   Kim, Hyoung Seok
   Il Han, Jung
   Kim, Chul Gu
   Lee, Tae Gon
   Kim, Jong Woo
TI Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal
   Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF TRAP-EYE; MACULAR DEGENERATION; VASCULAR HYPERPERMEABILITY;
   PHOTODYNAMIC THERAPY; MULTICENTER; THICKNESS; EFFICACY
AB PURPOSE: To compare the effectiveness of intravitreal injection of aflibercept and ranibizumab for patients with polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective, interventional case series.
   METHODS: Ninety-eight treatment-naive PCV eyes were included. The eyes had received intravitreal aflibercept or ranibizumab injections. All patients were treated using an initial series of 3 monthly loading injections, followed by further injections as required. The visual and anatomic outcomes of treatment were evaluated after 12 months.
   RESULTS: The mean best-corrected visual acuity (BCVA) in the aflibercept-treated group (38 eyes), expressed as the logarithm of the minimal angle of resolution (logMAR), had decreased from 0.63 +/- 0.49 to 0.44 +/- 0.37 after 12 months of treatment (P =.012). Similarly, in the ranibizumab-treated group (60 eyes), the BCVA had decreased from 0.66 +/- 0.43 to 0.49 +/- 0.36 (P =.018). The central foveal thickness had decreased in the aflibercept-treated group from 396 +/- 167 mu m to 212 +/- 144 mu m, and in the ranibizumab-treated group from 402 +/- 198 mu m to 240 +/- 183 mu m (P <.001 in both cases). However, there was no significant difference between the groups with regard to either BCVA improvement or decrease in central foveal thickness. Polyp regression was significantly more frequent in the aflibercept-treated group, occurring in 39.5% of eyes, than in the ranibizumab-treated group (21.6% of eyes; P =.007).
   CONCLUSIONS: In PCV patients, the visual acuity improvement achieved after 12 months of intravitreal aflibercept did not differ significantly from that achieved using intravitreal ranibizumab. However, aflibercept treatment more often led to polyp regression than did treatment using ranibizumab. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Cho, Han Joo; Kim, Kyoung Min; Kim, Hyoung Seok; Il Han, Jung; Kim, Chul Gu; Lee, Tae Gon; Kim, Jong Woo] Konyang Univ, Coll Med, Myung Gok Eye Res Inst, Dept Ophthalmol,Kims Eye Hosp, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4Ga, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tan CS, 2015, OSLI RETINA, V46, P786, DOI 10.3928/23258160-20150909-02
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 52
Z9 53
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2016
VL 165
BP 1
EP 6
DI 10.1016/j.ajo.2016.02.019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM3EF
UT WOS:000376228900003
PM 26921806
DA 2022-11-30
ER

PT J
AU Tomiyasu, T
   Nozaki, M
   Yoshida, M
   Ogura, Y
AF Tomiyasu, Taneto
   Nozaki, Miho
   Yoshida, Munenori
   Ogura, Yuichiro
TI Characteristics of Polypoidal Choroidal Vasculopathy Evaluated by
   Optical Coherence Tomography Angiography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; optical coherence tomography
   angiography; indocyanine green angiography
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; FLUORESCEIN-ANGIOGRAPHY; MACULAR
   TELANGIECTASIA; DIABETIC-RETINOPATHY; NEOVASCULARIZATION; PIGMENT
AB PURPOSE. The purpose of this study was to compare the angiographic findings of polypoidal choroidal vasculopathy (PCV) detected by indocyanine green angiography (ICGA) and en face optical coherence tomography angiography (OCTA). METHODS. The study design was a retrospective chart review of 20 eyes with a clinical diagnosis of treatment-naive PCV, seen at Nagoya City University Hospital between December 2014 and January 2016. Indocyanine green angiography was performed with Heidelberg Retina Angiography 2 and OCTA was performed by using Avanti RTVue XR. RESULTS. Twenty eyes of 20 patients (18 male, 2 female) were studied. Average age was 71.9 years. Manual segmentation was required to detect the pathologic lesions of PCV in all cases. The polypoidal lesions were detected in 20 eyes (100%) by ICGA, and in 17 eyes (85%) by OCTA. The number of polypoidal lesions detected by OCTA averaged 2.6 +/- 1.9, with an average of 2.0 +/- 1.1 by ICGA (P < 0.05). The branching vascular network (BVN) was detected in 14 eyes (70%) by ICGA and in 14 eyes (70%) by OCTA. All of the BVNs detected by OCTA were located between the RPE and Bruch's membrane.
   CONCLUSIONS. Despite the manual segmentation required, en face OCTA enabled us to analyze the angiographic features of PCV combined with longitudinal image (B-scan). En face OCTA may be useful for understanding the pathogenesis of PCV and managing PCV.
C1 [Tomiyasu, Taneto; Nozaki, Miho; Yoshida, Munenori; Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
C3 Nagoya City University
RP Nozaki, M (通讯作者)，Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.
EM nozakim@med.nagoya-cu.ac.jp
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Mashayekhi Arman, 2013, J Ophthalmic Vis Res, V8, P264
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Suzuki N, 2016, AM J OPHTHALMOL, V161, P126, DOI 10.1016/j.ajo.2015.09.038
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zeimer M, 2015, RETINA-J RET VIT DIS, V35, P2307, DOI 10.1097/IAE.0000000000000868
NR 34
TC 44
Z9 50
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2016
VL 57
IS 9
BP OCT324
EP OCT330
DI 10.1167/iovs.15-18898
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9MY
UT WOS:000383985400031
PM 27409489
OA gold
DA 2022-11-30
ER

PT J
AU de Carlo, TE
   Kokame, GT
   Shantha, JG
   Lai, JC
   Wee, R
AF de Carlo, Talisa E.
   Kokame, Gregg T.
   Shantha, Jessica G.
   Lai, James C.
   Wee, Raymond
TI Spectral-Domain Optical Coherence Tomography Angiography for the
   Diagnosis and Evaluation of Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Optical coherence tomography;
   Indocyanine green angiography; Age-related macular degeneration
ID MACULAR DEGENERATION; NEOVASCULARIZATION; RANIBIZUMAB; THERAPY
AB Purpose: To compare the diagnostic ability of optical coherence tomography angiography (OCTA) with indocyanine green angiography (ICGA) in polypoidal choroidal vasculopathy (PCV). Methods: Retrospective review of 47 eyes with PCV imaged with ICGA and OCTA. For each eye, it was determined which imaging modality better delineated the PCV complex. The presence of a branching vascular network (BVN) and polyp(s) were noted. Results: PCV was better visualized with ICGA in 21 eyes (44.7%) and with OCTA in 9 eyes (19.2%). The results were comparable in 17 eyes (36.2%). Of the 44 eyes with BVN on ICGA, 41 eyes (93.2%) also showed BVN on OCTA. Of the 28 eyes with polyp(s) on ICGA, 22 eyes (78.6%) also showed polyp(s) on OCTA. Polyps were high-flow lesions or faint low-flow dilations on OCTA. Conclusion: OCTA readily detects BVNs and can detect most polyps, but in many cases ICGA is better able to detect the PCV complex. (c) 2017 S. Karger AG, Basel.
C1 [de Carlo, Talisa E.] Univ Hawaii, Sch Med, Dept Med, Transit Residency Program, Honolulu, HI 96822 USA.
   [de Carlo, Talisa E.] Univ Hawaii, John A Burns Sch Med, Sch Med, Honolulu, HI 96822 USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Shantha, Jessica G.; Lai, James C.; Wee, Raymond] Retina Ctr Pali Momi, Aiea, HI USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Shantha, Jessica G.; Lai, James C.; Wee, Raymond] Retina Consultants Hawaii, Honolulu, HI USA.
   [de Carlo, Talisa E.; Kokame, Gregg T.; Shantha, Jessica G.; Lai, James C.; Wee, Raymond] Hawaii Macula & Retina Inst, Aiea, HI USA.
   [Kokame, Gregg T.; Lai, James C.] Univ Hawaii, Dept Surg, Div Ophthalmol, Sch Med, Honolulu, HI 96822 USA.
C3 University of Hawaii System; University of Hawaii System; University of
   Hawaii System
RP Kokame, GT (通讯作者)，Retina Consultants Hawaii, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
FU EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENT [K12HD085850] Funding Source: NIH RePORTER
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2016, 10 APVRS C BANGK
   Kokame GT, 2016, OSLI RETINA, V47, P737, DOI 10.3928/23258160-20160808-07
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kokame GT, 2015, JAMA OPHTHALMOL, V133, DOI 10.1001/jamaophthalmol.2015.1886
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 9
Z9 9
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 239
IS 2-3
BP 103
EP 109
DI 10.1159/000481540
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ0QL
UT WOS:000427276000005
PM 29227980
DA 2022-11-30
ER

PT J
AU Kim, H
   Lee, JH
   Kwon, KY
   Byeon, SH
   Lee, SC
   Lee, CS
AF Kim, Hyesun
   Lee, Ji Hwan
   Kwon, Kye Yoon
   Byeon, Suk Ho
   Lee, Sung Chul
   Lee, Christopher Seungkyu
TI Punctate Hyperfluorescent Spots Associated With Polypoidal Choroidal
   Vasculopathy on Indocyanine Green Angiography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; VASCULAR
   HYPERPERMEABILITY; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS;
   MACULAR DEGENERATION; CUTICULAR DRUSEN; NEOVASCULARIZATION; RANIBIZUMAB;
   VERTEPORFIN
AB BACKGROUND AND OBJECTIVE: To evaluate punctate hyperfluorescent spots on indocyanine green angiography (ICGA) in eyes with polypoidal choroidal vasculopathy (PCV).
   PATIENTS AND METHODS: Retrospective observation case series of 88 eyes of 81 patients (63 men and 18 women) analyzing fundus photography, fluorescein angiography, ICGA, and spectral-domain optical coherence tomography (OCT) findings at baseline.
   RESULTS: Seven patients (9%) had bilateral PCV lesions. Mean age was 68.44 +/- 5.94 years (range: 45 to 86 years). Macular-type PCV was found in 72 eyes (81.8%), peripapillary-type PCV in 12 eyes (13.6%), and combined-type PCV in four eyes (4.5%). Choroidal vascular hyperpermeability was observed in 38 eyes (43.2%), and punctate hyperfluorescent spots on ICGA in 47 eyes (53.4%). ICGA of unaffected fellow eyes of 74 patients with unilateral PCV revealed choroidal hyperpermeability in 23 eyes (31.1%) and punctate hyperfluorescent spots in 38 eyes (51.4%). Presence of punctate hyperfluorescent spots was significantly associated with choroidal vascular hyperpermeability (P < .001).
   CONCLUSION: Punctate hyperfluorescent spots were frequently observed in eyes with PCV in late-phase ICGA, as previously described in eyes with central serous chorioretinopathy, which may represent leakage from punctate hyperpermeable inner choroid spots or late staining of forme fruste drusen or drusen-like subretinal pigment epithelium deposits associated with choroidal hyperpermeability.
C1 [Kim, Hyesun; Lee, Ji Hwan; Kwon, Kye Yoon; Byeon, Suk Ho; Lee, Sung Chul; Lee, Christopher Seungkyu] Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Coll Med, Severance Hosp, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM sklee219@yuhs.ac
OI Lee, Ji Hwan/0000-0003-1759-8195; , Sung Chul/0000-0001-9438-2385; Lee,
   Christopher/0000-0001-5054-9470; Byeon, suk ho/0000-0001-8101-0830
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P300, DOI 10.1046/j.1442-9071.2003.00664.x
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Friedman D, 2012, RETINA-J RET VIT DIS, V32, P19, DOI 10.1097/IAE.0b013e318219e5e9
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi L A, 1992, Eur J Ophthalmol, V2, P103
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 31
TC 4
Z9 4
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2015
VL 46
IS 4
BP 423
EP 427
DI 10.3928/23258160-20150422-04
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UP
UT WOS:000359292300004
PM 25970862
DA 2022-11-30
ER

PT J
AU Ito, A
   Maruyama-Inoue, M
   Kitajima, Y
   Ikeda, S
   Inoue, T
   Kadonosono, K
AF Ito, Arisa
   Maruyama-Inoue, Maiko
   Kitajima, Yoko
   Ikeda, Shoko
   Inoue, Tatsuya
   Kadonosono, Kazuaki
TI One-year outcomes of intravitreal brolucizumab injections in patients
   with polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID AFLIBERCEPT; RANIBIZUMAB; THERAPY
AB To evaluate the 1-year visual outcomes and anatomic responses of Japanese patients who received intravitreal brolucizumab (IVBr) injections for polypoidal choroidal vasculopathy (PCV). This was a retrospective study of 17 treatment-naive eyes with PCV that were treated with IVBr. We evaluated the best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT) and number of injections for 1 year. The eradication of polypoidal lesions was also evaluated using by indocyanine green angiography during the 1-year follow-up. Non-infectious intraocular inflammation developed in two (11.8%) eyes; 15 eyes were assessed at the 1-year follow-up examination. The mean BCVA improved significantly from 0.28 at baseline to 0.13 (P < 0.05) at 1 year. The CMT and CCT decreased significantly after 1 year. The mean number of injections was 6.4 +/- 0.13. The rate of complete resolution of polypoidal lesions at 1 year was 93.3%. A dry macula was achieved in 13 eyes (86.6%) after the loading phase and in 11 eyes (73.3%) at 1 year. The IVBr injections appeared to be effective for improving both functional and anatomic outcomes in Japanese patients with PCV, with a high regression rate of polypoidal lesions.
C1 [Ito, Arisa; Maruyama-Inoue, Maiko; Ikeda, Shoko; Inoue, Tatsuya; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
   [Kitajima, Yoko] Sakae Kyosai Hosp, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
C3 Yokohama City University
RP Maruyama-Inoue, M (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Choi EY, 2020, OPHTHALMOLOGICA, V243, P136, DOI 10.1159/000501724
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fukuda Y, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091164
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Ito A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235213
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 2
Z9 2
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 14
PY 2022
VL 12
IS 1
AR 7987
DI 10.1038/s41598-022-12216-2
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 1G8CL
UT WOS:000796077900023
PM 35568780
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Algvere, PV
   Kvanta, A
   Seregard, S
AF Algvere, Peep V.
   Kvanta, Anders
   Seregard, Stefan
TI Drusen maculopathy: a risk factor for visual deterioration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related eye disease study; age-related maculopathy; antioxidants;
   drusen; lipofuscin; pathogenetic features; photoelectric effect;
   reactive oxygene species
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; OXIDATIVE STRESS;
   BRUCHS MEMBRANE; AGE; COMPLEMENT; ARMS2; RPE; CFH; DISEASE
AB Age-related macular degeneration (AMD), the most common cause of visual loss after the age of 65, displays a degeneration of the retinal pigment epithelial (RPE) cells and photoreceptors in the retinal centre (macula). The central macula (fovea) that contains mostly cone photoreceptors mediates the high visual acuity. Drusen maculopathy may lead to visual deterioration. Drusen are extracellular deposits of debris that accumulate on Bruchs membrane. Drusen attract inflammatory, immunological and vasoactive stimuli. RPE and photoreceptor cells overlying drusen exhibit biochemical and morphological signs of degeneration. Strong and intermittent light exposure (photons) induces the formation of free radicals in the very high oxygen tension milieu of the retina. The negative effects of irradiation stimulate accumulation of lipofuscin in RPE and photoreceptor cells leading to mitochondrial dysfunction and apoptotic cell death. A hydrophobic barrier is built up in Bruchs membrane reducing diffusion to the choroid. Hereditary and inflammatory factors modify the risk for AMD. There is a genetic dysregulation of the complement system leading to inappropriate complement activation. The genetic polymorphism of complement factor H (CFH) and age-related maculopathy susceptibilty 2 (ARMS2) increase the risk of progression to advanced AMD. The photoelectric effect creates free radicals, resulting in a continuous increase of lipofuscin formation and impairing mitochondrial activity. In addition, inflammation and complement dysregulation contribute to the formation of drusen and vasoproliferative reactions with neovascularization. Antioxidants neutralize reactive oxygen species and reduce lipofuscin accumulation in RPE and photoreceptor cells. For prophylactic treatment of drusen maculopathy, high doses of antioxidants such as vitamins C and E, lutein, zeaxanthine and zinc are used according to the Age-Related Eye Disease Study 2 (AREDS 2). The risk of developing advanced AMD was reduced by 27% at 10years follow-up. No adverse events were noted.
C1 [Algvere, Peep V.; Kvanta, Anders; Seregard, Stefan] Karolinska Inst, St Erik Eye Hosp, Stockholm, Sweden.
C3 Karolinska Institutet
RP Seregard, S (通讯作者)，Karolinska Inst, St Erik Eye Hosp, Stockholm, Sweden.
EM stefan.seregard@sankterik.se
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Marshall J, 2015, EYE, V29, P46, DOI 10.1038/eye.2014.240
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P8325, DOI 10.1167/iovs.13-13214
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
   Wu JM, 2002, INVEST OPHTH VIS SCI, V43, P3349
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 64
TC 29
Z9 30
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2016
VL 94
IS 5
BP 427
EP 433
DI 10.1111/aos.13011
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR8IZ
UT WOS:000380142900030
PM 27009526
OA Bronze
DA 2022-11-30
ER

PT J
AU Sonoda, S
   Sakamoto, T
   Otsuka, H
   Yoshinaga, N
   Yamashita, T
   Ki-I, Y
   Okubo, A
   Yamashita, T
   Arimura, N
AF Sonoda, Shozo
   Sakamoto, Taiji
   Otsuka, Hiroki
   Yoshinaga, Narimasa
   Yamashita, Toshifumi
   Ki-, Yuya, I
   Okubo, Akiko
   Yamashita, Takehiro
   Arimura, Noboru
TI Responsiveness of eyes with polypoidal choroidal vasculopathy with
   choroidal hyperpermeability to intravitreal ranibizumab
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE AMD; Drug; Enhanced depth imaging optical coherence tomography
   interventional immunology; Ranibizumab
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN ANGIOGRAPHY;
   COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   CLINICAL CHARACTERISTICS; THICKNESS; PATHOPHYSIOLOGY; ASSOCIATION;
   VERTEPORFIN
AB Background: To determine the role played by vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV) based on an interventional immunology theory.
   Methods: Eyes with PCV were divided in a masked fashion into those with choroidal hyperpermeability (HP group) and those with normal choroidal permeability (NP group) based on the indocyanine green angiograms. The inter-rater agreement rate was evaluated using Fleiss' kappa. Patients were treated by intravitreal ranibizumab (IVB). The central choroidal thickness and central foveal thickness (CFT) at the baseline and 7 days after the treatment were measured by optical coherence tomography.
   Results: Among the 57 consecutive eyes diagnosed with PCV, 42 eyes of 42 patients met the inclusion criteria (21 eyes/HP group vs 21 eyes /NP group). Central choroidal thickness in HP group was significantly thicker than that in the NP group (P < .001, Mann-Whitney U test). The inter-rater agreement was high with a Fleiss' kappa = 0.95, P < .0001. The percentage reduction in the CFT in HP group (14.0%) was significantly less than that in NP group (20.4%; P = .013, Mann-Whitney U test).
   Conclusions: Eyes with PCV that are associated with choroidal hyper-permeability may not be strongly associated with VEGF-related pathology, and may not respond favorably to anti-VEGF monotherapy.
C1 [Sonoda, Shozo; Sakamoto, Taiji; Otsuka, Hiroki; Yoshinaga, Narimasa; Yamashita, Toshifumi; Ki-, Yuya, I; Okubo, Akiko; Yamashita, Takehiro; Arimura, Noboru] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
C3 Kagoshima University
RP Sakamoto, T (通讯作者)，Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
EM tsakamot@m3.kufm.kagoshima-u.ac.jp
CR Arimura N, 2009, OPHTHALMOLOGY, V116, P921, DOI 10.1016/j.ophtha.2008.12.024
   Bae SH, 2011, AM J OPHTHALMOL, V152, P784, DOI 10.1016/j.ajo.2011.04.008
   Bessho H, 2012, MOL VIS, V18, P121
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ehrenstein MR, 2007, J EXP MED, V204, P2249, DOI 10.1084/jem.20071737
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hafler DA, 2007, NAT REV IMMUNOL, V7, P423, DOI 10.1038/nri2101
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lai TY, 2001, RETINA, V31, P1581
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim JW, 2011, GRAEF ARCH CLIN EXP, V249, P969, DOI 10.1007/s00417-010-1581-9
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2013, GRAEFES ARCH CLIN EX
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 1999, RETINA-J RET VIT DIS, V19, P12, DOI 10.1097/00006982-199901000-00003
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yamashita T, 2012, INVEST OPHTH VIS SCI, V53, P1102, DOI 10.1167/iovs.11-8836
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 39
TC 38
Z9 41
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 20
PY 2013
VL 13
AR 43
DI 10.1186/1471-2415-13-43
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 206FT
UT WOS:000323504900001
PM 23962072
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jiang, JJ
   Wu, X
   Zhou, P
   Yu, WZ
   Huang, LZ
   Li, XX
AF Jiang, J. J.
   Wu, X.
   Zhou, P.
   Yu, W. Z.
   Huang, L. Z.
   Li, X. X.
TI Meta-analysis of the relationship between the LOC387715/ARMS2
   polymorphism and polypoidal choroidal vasculopathy
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Polypoidal choroidal vasculopathy; LOC387715/ARMS2; Gene polymorphism;
   Meta-analysis
ID HTRA1 PROMOTER POLYMORPHISM; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; CIGARETTE-SMOKING; VISUAL PROGNOSIS; ASSOCIATION; CFH;
   JAPANESE; GENE; A69S
AB We investigated the association between the LOC387715/ARMS2 polymorphism (rs10490924 G>T) and susceptibility to polypoidal choroidal vasculopathy (PCV) through a meta-analysis of 1446 cases and 3255 controls from eight case-control studies. The genetic effect of the LOC387715/ARMS2 rs10490924 G>T polymorphism on PCV was assessed by calculating pooled odds ratios (ORs) with 95% confidence intervals (95% CIs). We found that elevated PCV risk was significantly associated with the GG genotype (GG vs TT, OR = 4.23, 95%CI = 3.53-5.06), and heterozygous genotype TG appeared to have a minor effect on PCV risk (TG vs TT, OR = 1.47, 95% CI = 1.26-1.71). Patients with the T allele were 2.09 times more likely to have PCV than those with the G allele (95% CI = 1.906-2.288). A further subgroup analysis by ages also showed that the genetic effect of the LOC387715/ARMS2 rs10490924 G>T polymorphism on PCV is stronger among patients with mean age <73 years. Our meta-analysis strengthened the evidence that the LOC387715/ARMS2 rs10490924 G>T polymorphism plays an important role in PCV susceptibility.
C1 [Jiang, J. J.; Wu, X.; Zhou, P.; Yu, W. Z.; Huang, L. Z.; Li, X. X.] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
   [Jiang, J. J.] China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Zhou, P.] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai 200433, Peoples R China.
C3 Peking University; China-Japan Friendship Hospital; Fudan University
RP Li, XX (通讯作者)，Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
EM drlixiaoxin@163.com
OI Jiang, Jingjing/0000-0002-5077-1204
FU National Basic Research Program of China (973 Program) [2011CB510200]
FX Research supported by the National Basic Research Program of China (973
   Program; #2011CB510200).
CR Bessho H, 2011, MOL VIS, V17, P977
   Chang YC, 2007, DIABETES, V56, P2631, DOI 10.2337/db07-0421
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Machida S, 2010, CLIN OPHTHALMOL, V4, P793
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wittke-Thompson JK, 2005, AM J HUM GENET, V76, P967, DOI 10.1086/430507
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoshida T, 2007, MOL VIS, V13, P545
NR 30
TC 4
Z9 6
U1 0
U2 5
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
EI 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2012
VL 11
IS 4
BP 4256
EP 4267
DI 10.4238/2012.December.17.1
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 076ML
UT WOS:000313960500070
PM 23315805
OA Bronze
DA 2022-11-30
ER

PT J
AU Huang, CH
   Yeh, PT
   Hsieh, YT
   Ho, TC
   Yang, CM
   Yang, CH
AF Huang, Chu-Hsuan
   Yeh, Po-Ting
   Hsieh, Yi-Ting
   Ho, Tzyy-Chang
   Yang, Chung-May
   Yang, Chang-Hao
TI Characterizing Branching Vascular Network Morphology in Polypoidal
   Choroidal Vasculopathy by Optical Coherence Tomography Angiography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; CLASSIFICATION; SPECIFICITY; THICKNESS; DIAGNOSIS;
   SUBTYPES; THERAPY
AB This study analyze the morphological characteristics of branching vascular networks (BVN) in polypoidal choroidal vasculopathy (PCV) using optical coherence tomography angiography (OCTA), and correlate imaging characteristics with clinical presentations. We presented a retrospective observational case series for fifty cases of PCV confirmed by indocyanine green angiography. Macular OCTA were done by the AngioVue. The PCV cases were classified by distinct morphologic patterns of BVN by two retina specialists and clinical features were analyzed. The sensitivity of polyp detection by OCTA was 86% after manual segmentation and that of BVN was 90%. Three distinct morphologic patterns of BVN were identified. (1) The "Trunk" pattern (47%) exhibited major vessel trunk with features including presence of drusens, thin choroid, and larger BVN area. (2) The "Glomeruli" pattern (33%) showed anastomotic vascular network without major trunk. (3) The "Stick" pattern (20%) had localized BVN and the thickest choroid. Subtypes 2 and 3 held higher recurrence rate. In conclusions, the precise visualization of BVN on OCTA supported that OCTA might be a noninvasive tool to study the morphology of BVN in PCV, which exhibits three different morphological types. Identifying the morphology of BVN has the potential to prognosticate outcomes in PCV patients.
C1 [Huang, Chu-Hsuan; Yeh, Po-Ting; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Yeh, Po-Ting; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.; Yang, CH (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chung-May/AAV-3737-2020; Yang, Chang-Hao/AAR-3759-2021
OI YANG, CHUNG-MAY/0000-0003-4082-420X; Yeh, Po-Ting/0000-0002-0461-8778;
   YANG, CHANG-HAO/0000-0002-4328-8716
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Bessho H, 2011, MOL VIS, V17, P977
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 13
Z9 14
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 24
PY 2019
VL 9
AR 595
DI 10.1038/s41598-018-37384-y
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HI6HI
UT WOS:000456554600034
PM 30679701
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miura, M
   Muramatsu, D
   Hong, YJ
   Yasuno, Y
   Iwasaki, T
   Goto, H
AF Miura, Masahiro
   Muramatsu, Daisuke
   Hong, Young-Joo
   Yasuno, Yoshiaki
   Iwasaki, Takuya
   Goto, Hiroshi
TI Noninvasive Vascular Imaging of Polypoidal Choroidal Vasculopathy by
   Doppler Optical Coherence Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; optical coherence tomography;
   Doppler; OCT angiography; polypoidal lesion
ID EXUDATIVE MACULAR DISEASES; CLINICOPATHOLOGICAL CORRELATION; HUMAN
   RETINA; ANGIOGRAPHY; CLASSIFICATION; VISUALIZATION; PATTERNS; LESIONS
AB PURPOSE. To noninvasively investigate the vascular architecture of polypoidal lesions in polypoidal choroidal vasculopathy (PCV) using Doppler optical coherence tomography (OCT), and to evaluate the clinical usefulness of Doppler OCT for the assessment of therapeutic effects in PCV.
   METHODS. Fifteen eyes of 15 patients with treatment-naive PCV were prospectively studied. Vascular imaging was obtained using 1060-nm swept-source Doppler OCT, and compared with indocyanine green angiography (ICGA) images. The therapeutic effect of three consecutive intravitreal aflibercept injections was evaluated with ICGA and Doppler OCT.
   RESULTS. In Doppler OCT images, polypoidal lesions were clearly detected at the corresponding locations of lesions in the ICGA images. By being insensitive to dye leakage, Doppler OCT identified the complicated vascular structure in the polypoidal lesions. The identified mean area of the polypoidal lesions in the Doppler OCT images (0.04 mm(2)) was significantly smaller than that of the ICGA images (0.13 mm(2)). Polypoidal lesions were located in the retinal pigment epithelial detachment in 13 eyes, in the choroid in one eye, and in both the retinal pigment epithelial detachment and choroid in one eye. After intravitreal aflibercept treatment, areas of polypoidal lesions in the ICGA images were decreased in 14 of 15 eyes. This therapeutic effect was clearly confirmed in the Doppler OCT images.
   CONCLUSIONS. Doppler OCT imaging clearly detected fine vascular structures at the polypoidal lesions in PCV. Doppler OCT might be useful for the diagnosis and evaluation of therapeutic effects in PCV.
C1 [Miura, Masahiro; Muramatsu, Daisuke; Iwasaki, Takuya] Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, Inashiki, Ibaraki 3000395, Japan.
   [Miura, Masahiro; Muramatsu, Daisuke; Iwasaki, Takuya; Goto, Hiroshi] Tokyo Med Univ, Dept Ophthalmol, Inashiki, Ibaraki 3000395, Japan.
   [Hong, Young-Joo; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki, Japan.
C3 Tokyo Medical University; Tokyo Medical University; University of
   Tsukuba
RP Miura, M (通讯作者)，Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, 3-20-1 Chuo, Inashiki, Ibaraki 3000395, Japan.
EM m-miura@tokyo-med.ac.jp
RI Yasuno, Yoshiaki/F-2586-2011
OI Yasuno, Yoshiaki/0000-0003-1645-7948
FU KAKENHI [24592682]; Japan Science and Technology Agency
FX This project was supported in part by KAKENHI (24592682) and the Japan
   Science and Technology Agency through a program of the Development of
   Systems and Technology for Advanced Measurement and Analysis.
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   BARTSCH DU, 1994, EXP EYE RES, V58, P161, DOI 10.1006/exer.1994.1004
   Blatter C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.070505
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Hong YJ, 2012, OPT EXPRESS, V20, P2740, DOI 10.1364/OE.20.002740
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Mariampillai A, 2010, OPT LETT, V35, P1257, DOI 10.1364/OL.35.001257
   Miura M, 2015, AM J OPHTHALMOL, V159, P528, DOI 10.1016/j.ajo.2014.12.002
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Nagase Satoko, 2012, Ophthalmic Surg Lasers Imaging, V43 Online, pe5, DOI 10.3928/15428877-20120130-02
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Szkulmowska A, 2009, OPT EXPRESS, V17, P10584, DOI 10.1364/OE.17.010584
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 35
TC 15
Z9 17
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2015
VL 56
IS 5
BP 3179
EP 3186
DI 10.1167/iovs.14-16252
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK7UJ
UT WOS:000356439200051
PM 26024101
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Yanagisawa, S
   Sakurada, Y
   Miki, A
   Matsumiya, W
   Imoto, I
   Honda, S
AF Yanagisawa, Suiho
   Sakurada, Yoichi
   Miki, Akiko
   Matsumiya, Wataru
   Imoto, Issei
   Honda, Shigeru
TI The Association of Elastin Gene Variants with Two Angiographic Subtypes
   of Polypoidal Choroidal Vasculopathy
SO PLOS ONE
LA English
DT Article
ID FACTOR-H CFH; MACULAR DEGENERATION; SUSCEPTIBILITY; ARMS2; POLYMORPHISM;
   FEATURES
AB Objective
   To compare the association of elastin (ELN) gene variants between two different angiographic phenotypes of polypoidal choroidal vasculopathy (PCV).
   Methods
   We included 411 treatment-naive PCV patients and 350 controls in the present study. PCV was classified into two phenotypes (152 Type 1 and 259 Type 2) according to the presence or absence of feeding vessels found in indocyanine-green angiography. Single nucleotide polymorphisms (SNPs) in the ELN region including rs868005, rs884843, rs2301995, rs13239907 and rs2856728 were genotyped using TaqMan Genotyping Assays.
   Results
   In the allelic association analyses, rs868005 showed the strongest association with Type 2 PCV (allelic odds ratio 1.56; p = 7.4x10(-6)), while no SNP was significantly associated with Type 1 PCV. Genotype association analyses revealed the significant association of rs868005 with Type 2 PCV in log additive model and predominant model (odds ratio 1.75; p = 1.5x10(-6) and odds ratio 1.60; p = 0.0044, respectively), but not with Type 1 PCV. These findings were further corroborated by another control group in the literature.
   Conclusions
   There may be significantly different associations in genetic variants of elastin between two angiographic phenotypes of PCV.
C1 [Yanagisawa, Suiho; Miki, Akiko; Matsumiya, Wataru; Honda, Shigeru] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Sakurada, Yoichi] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Kofu, Yamanashi 4093898, Japan.
   [Imoto, Issei] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Human Genet, Tokushima 7708503, Japan.
C3 Kobe University; University of Yamanashi; Tokushima University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019; Imoto, Issei/AAD-5799-2020
OI Imoto, Issei/0000-0002-4150-7938
FU Ministry of Education, Science and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 23592567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S.H.), and by
   a grant from the Takeda Science Foundation, Osaka, Japan (S.H.). The
   funding organization had no role in the design or conduct of this
   research.
CR Akagawa H, 2006, HUM MOL GENET, V15, P1722, DOI 10.1093/hmg/ddl096
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 28
TC 12
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2015
VL 10
IS 3
AR e0120643
DI 10.1371/journal.pone.0120643
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CD6EY
UT WOS:000351183500187
PM 25775011
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ijuin, N
   Tsujinaka, H
   Hirai, H
   Jimura, H
   Nakao, S
   Yamashita, M
   Nishi, T
   Ueda, T
   Ogata, N
AF Ijuin, Nobuo
   Tsujinaka, Hiroki
   Hirai, Hiromasa
   Jimura, Hironobu
   Nakao, Shigeya
   Yamashita, Mariko
   Nishi, Tomo
   Ueda, Tetsuo
   Ogata, Nahoko
TI Clinical implications of pachyvessels in polypoidal choroidal
   vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Pachychoroid; Pachyvessels
ID MACULAR DEGENERATION; VASCULAR HYPERPERMEABILITY; VORTEX VEIN;
   THICKNESS; AGE; SPECTRUM
AB Background Polypoidal choroidal vasculopathy (PCV) is one of the disorders within the pachychoroid spectrum diseases. The presence of pachyvessels is one of the characteristics of pachychoroid disorders. However, the relationship between the presence of pachyvessels and the clinical characteristics of PCV eyes has not been determined. The purpose of this study was to determine the relationship between the presence of choroidal pachyvessels and the clinical characteristics of eyes with PCV. Methods The medical records of patients who were diagnosed with PCV and were treatment-naive were reviewed. Fluorescein and indocyanine green angiography, fundus photography, spectral domain optical coherence tomography (SD-OCT), and enhanced depth imaging OCT (EDI-OCT) were used to obtain images of the choroid. The presence of pathologically dilated outer choroidal vessels, pachyvessels, was determined by ICGA images. These pachyvessels were confirmed to correspond with the large choroidal vessels in the EDI OCT images. The PCV eyes were divided into two groups based on the presence or absence of pachyvessels and clinical features and subfoveal choroidal thickness (SFCT) were evaluated between the two groups. Results Eighty-six eyes of 84 patients with PCV were evaluated. Pachyvessels were detected in 48 eyes (55.8%). The mean SFCT was 203.9 +/- 83.9 mu m in all 86 eyes, and it was significantly thinner in eyes with pachyvessels (+) than without pachyvessels (-) (183.2 +/- 58.4 mu m vs 230.2 +/- 103.1 mu m; P = 0.01). The differences in the incidence of subretinal fluid, pigment epithelial detachments, and hemorrhages between the two groups were not significant. However, the PCV eyes in pachyvessels (+) group with hemorrhage had the thinnest choroid (P = 0.047). The choroidal features of the fellow eyes were similar to those of the PCV affected eyes, that is, the fellow eyes in pachyvessels (+) group had pachyvessels and the fellow eyes in pachyvessels (-) group did not have pachyvessels. Conclusions Pachyvessels were presented 55.8% in eyes with PCV, and these eyes had the thin SFCT. The presence of pachyvessels and attenuation of the inner choroid were probably due to the pathological changes in the eyes with PCV.
C1 [Ijuin, Nobuo; Yamashita, Mariko] Nara City Hosp, Dept Ophthalmol, Nara, Japan.
   [Tsujinaka, Hiroki; Hirai, Hiromasa; Jimura, Hironobu; Nakao, Shigeya; Nishi, Tomo; Ueda, Tetsuo; Ogata, Nahoko] Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.
C3 Nara Medical University
RP Ogata, N (通讯作者)，Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.
EM ogata@naramed-u.ac.jp
OI Hirai, Hiromasa/0000-0002-7607-0975
CR Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu PK, 2013, EXP EYE RES, V115, P144, DOI 10.1016/j.exer.2013.07.006
NR 27
TC 5
Z9 5
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 29
PY 2020
VL 20
IS 1
AR 170
DI 10.1186/s12886-020-01443-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL1SK
UT WOS:000531334600001
PM 32349707
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Tateno, Y
   Sakurada, Y
   Yoneyama, S
   Kikushima, W
   Mabuchi, F
   Sugiyama, A
   Tanabe, N
   Kubota, T
   Iijima, H
AF Tateno, Yasushi
   Sakurada, Yoichi
   Yoneyama, Seigo
   Kikushima, Wataru
   Mabuchi, Fumihiko
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Kubota, Takeo
   Iijima, Hiroyuki
TI Risk Factors for Second Eye Involvement in Eyes with Unilateral
   Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC GENETICS
LA English
DT Article
DE ARMS2 A69S; polypoidal choroidal vasculopathy; second eye involvement
ID MACULAR DEGENERATION; JAPANESE PATIENTS; BILATERAL INVOLVEMENT;
   GENETIC-VARIANTS; LOC387715 A69S; FELLOW EYES; ASSOCIATION; POPULATION;
   GENOTYPE; SUSCEPTIBILITY
AB Purpose: To investigate risk factors associated with developing polypoidal choroidal vasculopathy (PCV) lesions in the unaffected fellow eye of patients with unilateral PCV.
   Methods: We studied 179 patients with initial unilateral PCV who were followed up for a period of 24 months or longer to monitor for second eye involvement. All patients underwent genotyping for CFH I62V (rs800292) and ARMS2 A69S (rs10490924) using TaqMan technology.
   Results: During the follow-up period ranging from 5-180 months, 20 (11.2%) of 179 patients developed PCV in the initially unaffected fellow eye. The risk allele (T) of ARMS2 A69S was significantly more prevalent in patients with second eye involvement compared to those without PCV in the fellow eye (p = 0.0046). Cox regression analysis demonstrated that the ARMS2 A69S genotype is a risk factor for developing PCV in the fellow eye (p = 0.027, odds ratio 2.53, confidence interval 1.11-5.73). Survival analysis revealed that the fellow eye of patients with the risk-associated homozygous genotype (TT) of ARMS2 A69S was affected significantly earlier than those with other genotypes (p = 0.0177, log rank test).
   Conclusions: Development of PCV in the unaffected fellow eye is associated with ARMS2 A69S genotype in patients with unilateral PCV.
C1 [Tateno, Yasushi; Sakurada, Yoichi; Yoneyama, Seigo; Kikushima, Wataru; Mabuchi, Fumihiko; Sugiyama, Atsushi; Tanabe, Naohiko; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
   [Kubota, Takeo] Univ Yamanashi, Fac Med, Dept Epigenet, Kofu, Yamanashi, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Kofu, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR Bessho H, 2011, MOL VIS, V17, P977
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
NR 24
TC 6
Z9 6
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2016
VL 37
IS 2
BP 177
EP 182
DI 10.3109/13816810.2015.1020557
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA DK2HD
UT WOS:000374734400008
PM 26332911
DA 2022-11-30
ER

PT J
AU Hosokawa, M
   Shiraga, F
   Yamashita, A
   Shiragami, C
   Ono, A
   Shirakata, Y
   Kimura, S
   Shiode, Y
   Kawata, T
   Hosogi, M
   Fujiwara, A
   Morizane, Y
AF Hosokawa, Mio
   Shiraga, Fumio
   Yamashita, Ayana
   Shiragami, Chieko
   Ono, Aoi
   Shirakata, Yukari
   Kimura, Shuhei
   Shiode, Yusuke
   Kawata, Tetsuhiro
   Hosogi, Mika
   Fujiwara, Atsushi
   Morizane, Yuki
TI Six-month results of intravitreal aflibercept injections for patients
   with polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; GROWTH-FACTOR; VEGF-TRAP;
   RANIBIZUMAB; BEVACIZUMAB; EFFICACY; VERTEPORFIN; PERICYTES; SAFETY
AB Background This study aims to evaluate the therapeutic effect of intravitreal aflibercept injection for polypoidal choroidal vasculopathy (PCV).
   Methods Eighteen eyes of 17 consecutive patients with PCV received three consecutive monthly intravitreal injections of aflibercept and one additional injection 2 months later (four injections totally). All patients underwent eye examinations, which included bestcorrected visual acuity (BCVA), fluorescein angiography, indocyanine green angiography, and optical coherence tomography. The primary endpoint of the study was the regression of polypoidal lesions. The secondary endpoints were BCVA, central retinal thickness (CRT) and changes in retinal exudation.
   Results Six months after the first aflibercept injection, the polypoidal lesions were completely resolved in 14 eyes (77.7%) and partially resolved in 4 eyes (22.2%). Although branching choroidal vascular networks were still present in all eyes, retinal exudative changes had completely resolved in 17 eyes (94.4%), and the mean CRT decreased significantly from 407.2 +/- 100.1 mu m to 229.1 +/- 57.2 mu m (p < 0.0001). BCVA (logarithm of the minimal angle of resolution, logMAR) improved significantly from 0.414 +/- 0.384 at baseline to 0.297 +/- 0.334 after 6 months (p = 0.016).
   Conclusions At 6 months, aflibercept monotherapy effectively reduced polyps, retinal exudation and CRT in patients with PCV.
C1 [Hosokawa, Mio; Shiraga, Fumio; Kimura, Shuhei; Shiode, Yusuke; Kawata, Tetsuhiro; Hosogi, Mika; Fujiwara, Atsushi; Morizane, Yuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Okayama, Okayama 7008558, Japan.
   [Yamashita, Ayana; Shiragami, Chieko; Ono, Aoi; Shirakata, Yukari] Kagawa Univ, Fac Med, Dept Ophthalmol, Takamatsu, Kagawa 760, Japan.
C3 Okayama University; Kagawa University
RP Hosokawa, M (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan.
EM hmo529@okayama-u.ac.jp
CR Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 25
TC 18
Z9 18
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2015
VL 99
IS 8
BP 1087
EP 1091
DI 10.1136/bjophthalmol-2014-305275
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN3BC
UT WOS:000358297200015
PM 25712826
DA 2022-11-30
ER

PT J
AU Kokame, GT
   Yeung, L
   Lai, JC
AF Kokame, Gregg T.
   Yeung, Ling
   Lai, James C.
TI Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal
   vasculopathy: 6-month results
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN;
   COMPLICATIONS; MEMBRANES; FEATURES
AB Aim To evaluate the short-term efficacy and safety of monthly intravitreal injections of ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and active exudation or haemorrhage.
   Methods A prospective, open-label trial of monthly intravitreal ranibizumab (0.5 mg) injections for PCV in 12 eyes of 12 patients was performed. The primary outcome measures were stabilisation of vision (loss < 15 ETDRS letters). Secondary outcome measures included incidence of ocular and systemic adverse events, and changes in subretinal haemorrhage, central foveal thickness (CFT) and polypoidal complexes on indocyanine green angiography at 6 months.
   Results Baseline findings included eight eyes with subretinal fluid, six eyes with subretinal haemorrhage and five eyes with macular oedema (CFT > 275 mu m). No patient lost >= 15 letters in visual acuity at 6 months. Subretinal fluid decreased in 5/8 eyes (63%). Subretinal haemorrhage resolved in 6/6 eyes (100%). Macular oedema improved in 4/5 eyes (80%). Polypoidal complexes decreased in 4/12 (33%) eyes. There were no ocular or systemic adverse events.
   Conclusions Continuous monthly intravitreal ranibizumab is safe and well tolerated in eyes with PCV. Preliminary results show stabilisation of vision, resolution of subretinal haemorrhage and a decrease in macular oedema. Polypoidal lesions decreased in 4/12 (33%) eyes, but branching choroidal vessels persisted.
C1 [Kokame, Gregg T.; Yeung, Ling; Lai, James C.] Hawaii Pacific Hlth, Retina Ctr Pali Momi, Aiea, HI 96701 USA.
   [Kokame, Gregg T.; Yeung, Ling; Lai, James C.] Univ Hawaii, Sch Med, Dept Surg, Div Ophthalmol, Honolulu, HI 96822 USA.
   [Yeung, Ling] Chang Gung Mem Hosp, Dept Ophthalmol, Chilung, Taiwan.
C3 University of Hawaii System; Chang Gung Memorial Hospital
RP Kokame, GT (通讯作者)，Hawaii Pacific Hlth, Retina Ctr Pali Momi, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
FU Genentech
FX This study was supported in part by a research grant from Genentech for
   an investigator-sponsored trial.
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fukushima Y, 2007, JPN J OPHTHALMOL, V51, P307, DOI 10.1007/s10384-007-0444-3
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 25
TC 140
Z9 151
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2010
VL 94
IS 3
BP 297
EP 301
DI 10.1136/bjo.2008.150029
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 566BZ
UT WOS:000275346200010
PM 19726427
DA 2022-11-30
ER

PT J
AU Rodriguez, AA
   Olson, MD
   Miller, KM
AF Rodriguez, AA
   Olson, MD
   Miller, KM
TI Bilateral blindness in a monocular patient after cataract surgery
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID OUTCOMES; EXTRACTION
AB We present the case of a 74-year-old monocular man who went blind in his sighted eye from complications of exudative age-related macular degeneration several months after cataract surgery. He is now bilaterally blind.
C1 Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Miller, KM (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol, 100 Stein Pl, Los Angeles, CA 90095 USA.
EM miller@jsei.ucla.edu
RI Miller, Kevin/ABB-5906-2021
OI Miller, Kevin/0000-0002-5128-0685
CR Bergwerk KL, 2000, J CATARACT REFR SURG, V26, P1631, DOI 10.1016/S0886-3350(00)00440-5
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   MASKET S, 2001, PREFERRED PRACTICE P
   Pomberg ML, 2004, AM J OPHTHALMOL, V138, P125, DOI 10.1016/j.ajo.2004.02.022
   Trotter WL, 2002, J CATARACT REFR SURG, V28, P1348, DOI 10.1016/S0886-3350(01)01320-7
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 6
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD FEB
PY 2005
VL 31
IS 2
BP 438
EP 440
DI 10.1016/j.jcrs.2004.05.055
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 907TX
UT WOS:000227742000041
PM 15767171
DA 2022-11-30
ER

PT J
AU Patterson, VL
   Thompson, BS
   Cherry, C
   Wang, SB
   Chen, B
   Hoh, J
AF Patterson, Victoria L.
   Thompson, Brian S.
   Cherry, Catherine
   Wang, Shao-bin
   Chen, Bo
   Hoh, Josephine
TI A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes
   Implicated in Human Diseases of Aging
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 113; Parkinson's disease; age-related macular
   degeneration; mitochondria; HtrA1; HtrA2; HtrA3; HtrA4; complement
   factor H (CFH)
ID COMPLEMENT FACTOR-H; SERINE-PROTEASE HTRA1; MACULAR DEGENERATION; A3
   HTRA3; VARIANT; IDENTIFICATION; FAMILY; LOC387715/ARMS2;
   PHOSPHORYLATION; OVEREXPRESSION
AB Age-related diseases are becoming increasingly prevalent and the burden continues to grow as our population ages. Effective treatments are necessary to lessen the impact of debilitating conditions but remain elusive in many cases. Only by understanding the causes and pathology of diseases associated with aging, can scientists begin to identify potential therapeutic targets and develop strategies for intervention. The most common age-related conditions are neurodegenerative disorders such as Parkinson's disease and blindness. Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. Genome wide association studies have previously identified loci that are associated with increased susceptibility to this disease and identified two regions of interest: complement factor H (CFH) and the 10q26 locus, where the age-related maculopathy susceptibility 2 (ARMS2) and high-temperature requirement factor A1 (HtrA1) genes are located. CFH acts as a negative regulator of the alternative pathway (AP) of the complement system while HtrA1 is an extracellular serine protease. ARMS2 is located upstream of HtrA1 in the primate genome, although the gene is absent in mice. To study the effects of these genes, humanized knock-in mouse lines of Cfh and ARMS2, knockouts of Cfh, HtrA1, HtrA2, HtrA3 and HtrA4 as well as a conditional neural deletion of HtrA2 were generated. Of all the genetically engineered mice produced only mice lacking HtrA2, either systemically or in neural tissues, displayed clear phenotypes. In order to examine these mice thoroughly and systematically, an initial phenotyping schedule was established, consisting of a series of tests related to two main diseases of interest: AMD and Parkinson's. Genetically modified mice can be subjected to appropriate experiments to identify phenotypes that may be related to the associated diseases in humans. A phenotyping regimen with a mitochondrial focus is presented here alongside representative results from the tests of interest.
C1 [Patterson, Victoria L.; Thompson, Brian S.; Cherry, Catherine; Hoh, Josephine] Yale Univ, Sch Med, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
   [Wang, Shao-bin; Chen, Bo; Hoh, Josephine] Yale Univ, Sch Med, Dept Ophthalmol, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP Patterson, VL (通讯作者)，Yale Univ, Sch Med, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
EM josephine.hoh@yale.edu
RI Wang, Shaobin/C-5507-2008; WANG, SHAO-BIN/Z-1810-2018
OI Wang, Shaobin/0000-0002-1751-9162; WANG, SHAO-BIN/0000-0002-6699-9406;
   Cherry, Catherine/0000-0001-5246-1245; Thompson,
   Brian/0000-0003-0983-2762
FU Rosebay Medical Foundation; Yale Medical School Dean's Research Fund;
   NATIONAL EYE INSTITUTE [R01EY024986, R01EY021502] Funding Source: NIH
   RePORTER
FX Funding for this research came from Rosebay Medical Foundation and a
   Yale Medical School Dean's Research Fund (JH). We thank Dr. Claire
   Koenig for help with behavioral experiments. Genetically engineered
   mouse lines were generated at Ozgene (Perth, Australia).
CR Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Beleford D, 2010, J BIOL CHEM, V285, P12011, DOI 10.1074/jbc.M109.097790
   Bogaerts V, 2008, HUM MUTAT, V29, P832, DOI 10.1002/humu.20713
   Bowden MA, 2006, GYNECOL ONCOL, V103, P253, DOI 10.1016/j.ygyno.2006.03.006
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   CHANCE B, 1955, J BIOL CHEM, V217, P439
   Chen YY, 2014, J BIOL CHEM, V289, P22958, DOI 10.1074/jbc.M114.576744
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dynon K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045956
   El-Khodor BF, 2008, EXP NEUROL, V212, P29, DOI 10.1016/j.expneurol.2008.02.025
   Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b
   Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986
   Francis PJ, 2008, MOL VIS, V14, P1395
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gage G. J., 2012, J VIS EXP
   Glaza P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131142
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Inagaki A, 2012, PLACENTA, V33, P919, DOI 10.1016/j.placenta.2012.08.003
   Jo H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115362
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052
   KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang S, 2013, CELL DEATH DIFFER, V20, P259, DOI 10.1038/cdd.2012.117
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lecha M, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-19
   Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795
   Liu J., 2015, MOL MED REP
   Liu J, 2015, INVEST OPHTH VIS SCI, V56, P1387, DOI 10.1167/iovs.14-15914
   Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200
   Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Patterson VL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115789
   Runyon ST, 2007, PROTEIN SCI, V16, P2454, DOI 10.1110/ps.073049407
   Singh H, 2013, J CANCER, V4, P152, DOI 10.7150/jca.5702
   Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   WAHLSTEN D, 1974, BRAIN RES, V72, P251, DOI 10.1016/0006-8993(74)90863-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 55
TC 3
Z9 3
U1 0
U2 5
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2016
IS 113
AR e54136
DI 10.3791/54136
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DZ1TG
UT WOS:000385622600047
PM 27500671
DA 2022-11-30
ER

PT J
AU Li, J
   Sun, JH
   Li, B
   Liu, ZL
AF Li, Jia
   Sun, Jianhua
   Li, Bing
   Liu, Zheli
TI Intravitreal ranibizumab injection combined with photodynamic therapy
   for polypoidal choroidal vasculopathy
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy; intravitreal ranibizumab injection;
   photodynamic therapy; combination therapy
ID FLUENCE; COMBINATION; MONOTHERAPY
AB The aim of the present study was to evaluate the efficacy of combination treatment with intravitreal ranibizumab (IVR) injection and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). A total of 64 patients with PCV were included in the present study, which were divided into the IVR monotherapy group (Group A) and combination treatment groups (Groups B-D) with different treatment intervals. All subjects were followed-up at 1, 3, 6 and 12 months following treatment, and subjected to the detection of best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Compared with the monotherapy group, more significant BCVA improvement was observed for the combination treatment groups, with the most evident effect exhibited in Group C. At the end of the follow-up period, visual acuity improvement rates were markedly elevated in the combination treatment groups, as compared with the monotherapy group. According to optical coherence tomography, the CFT for the combination treatment groups was thinner than the monotherapy group. Among the combination groups, CFT improvement for Group C was superior to other groups. Fundus angiography demonstrated that, compared with monotherapy, combination treatment may significantly promote the regression and prevent the recurrence of polyps and BVN. The most efficient effectiveness was observed for Group C. In addition, combination treatment may significantly reduce the IVR injection numbers required to treat PCV. Patients receiving combination treatment with IVR injection and PDT have greater vision improvements, reduced macular degeneration and decreased injection numbers. Combination therapy may therefore, represent an effective and safe therapeutic strategy for PCV clinical treatment.
C1 [Li, Jia; Li, Bing] Jinzhou Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Jinzhou 121000, Liaoning, Peoples R China.
   [Sun, Jianhua] Cent Hosp Jinzhou, Dept Otorhinolaryngol, Jinzhou 121000, Liaoning, Peoples R China.
   [Liu, Zheli] China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 155 Nanjing North Rd, Shenyang 110000, Liaoning, Peoples R China.
C3 Jinzhou Medical University; China Medical University
RP Liu, ZL (通讯作者)，China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 155 Nanjing North Rd, Shenyang 110000, Liaoning, Peoples R China.
EM lijia820323@163.com
FU Joint Grant of Liaoning Province Science and Technology Department
   [2015020351]
FX The present study was supported by the Joint Grant of Liaoning Province
   Science and Technology Department (grant no. 2015020351).
CR Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Chung WH, 2017, CLIN OPHTHALMOL, V11, P63, DOI 10.2147/OPTH.S122568
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Miki A, 2013, JPN J OPHTHALMOL, V57, P301, DOI 10.1007/s10384-013-0237-9
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI [10. 1016/j. ajo. 2011. 09. 031 22265146, DOI 10.1016/J.AJ0.2011.09.03122265146]
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI [10. 1016/j. ajo. 2009. 12. 038 20346441, DOI 10.1016/J.AJ0.2009.12.03820346441]
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Watanabe R, 2010, CLIN OPHTHALMOL, V4, P1243, DOI 10.2147/OPTH.S14550
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI [10. 1016/j. ajo. 2012. 06. 027 22995028, DOI 10.1016/J.AJ0.2012.06.02722995028]
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 26
TC 1
Z9 1
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD FEB
PY 2018
VL 15
IS 2
BP 1546
EP 1551
DI 10.3892/etm.2017.5565
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FT5VP
UT WOS:000423221600052
PM 29434739
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, B
   Cong, CY
   Li, ZE
   Hao, LL
   Yuan, XM
   Wang, WQ
   Shi, YM
   Liu, TT
AF Liu, Bing
   Cong, Chenyang
   Li, Zhongen
   Hao, Linlin
   Yuan, Xiaomeng
   Wang, Wenqi
   Shi, Yanmei
   Liu, Tingting
TI Analysis of the aqueous humor lipid profile in patients with polypoidal
   choroidal vasculopathy
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Polypoidalchoroidalvasculopathy; Lipid; Aqueoushumor; Biomarker
ID MACULAR DEGENERATION; AGE; CHOLESTEROL; LYSOPHOSPHATIDYLGLYCEROL;
   ACCUMULATION
AB This study aimed to investigate the lipid profiles of aqueous humor from polypoidal choroidal vasculopathy (PCV) patients and identify potential biomarkers to increase the understanding of PCV pathomechanism. An ultra-high performance liquid chromatography-tandem mass spectrometry based untargeted lipidomic analysis was performed to acquire lipid profiles of aqueous humor of PCV patients and control subjects. Differentially expressed lipids were identified by univariate and multivariate analyses. A receiver operator characteristic curve (ROC) analysis was conducted to confirm the potential of identified lipids as biomarkers. Sixteen PCV patients and twenty-eight control subjects were enrolled in this study. In total, we identified 33 lipid classes and 639 lipid species in aqueous humor using the LipidSearch software. Of them, 50 differential lipids were obtained by combining univariate and multivariate statistical analyses (VIP>1 and P < 0.05), and 19 potential lipid bio-markers were identified by ROC analysis. In addition, significant alterations were found in several metabolic pathways, including glycerophospholipid, glycerolipid, and glycosylphosphatidylinositol-anchor biosynthesis. This study is the first to systematically characterize the alterations in lipid profiles in aqueous humor of PCV patients and screen for the potential lipid biomarkers for PCV diagnosis and treatment intervention. The results of this study are likely to broaden our understanding of the pathogenesis of PCV and contribute to improvements in the diagnosis and treatment of the disease.
C1 [Liu, Bing; Hao, Linlin] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Ophthalmol, Jinan 250033, Peoples R China.
   [Cong, Chenyang; Li, Zhongen] Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Jinan 250002, Peoples R China.
   [Li, Zhongen] Shandong Univ Tradit Chinese Med, Jinan 250002, Peoples R China.
   [Yuan, Xiaomeng; Wang, Wenqi; Shi, Yanmei; Liu, Tingting] Shandong First Med Univ, Eye Inst Shandong Med Univ 1, Eye Hosp Shandong Med Univ 1, Shandong Eye Hosp,State Key Lab Cultivat Base, Jinan 250021, Peoples R China.
C3 Shandong University; Shandong University of Traditional Chinese
   Medicine; Shandong University of Traditional Chinese Medicine; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Liu, TT (通讯作者)，Shandong First Med Univ, Eye Inst Shandong Med Univ 1, Eye Hosp Shandong Med Univ 1, Shandong Eye Hosp,State Key Lab Cultivat Base, Jinan 250021, Peoples R China.
EM liutteye@163.com
RI Liu, Bing/GRX-5962-2022
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Azbukina NV, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10070658
   Cabrerizo J, 2017, J GLAUCOMA, V26, P349, DOI 10.1097/IJG.0000000000000603
   Calzada E, 2016, INT REV CEL MOL BIO, V321, P29, DOI 10.1016/bs.ircmb.2015.10.001
   Chen XL, 2018, GRAEF ARCH CLIN EXP, V256, P1449, DOI 10.1007/s00417-018-4020-y
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312
   Deng YH, 2021, AGING-US, V13, P13968, DOI 10.18632/aging.203006
   Fu YH, 2021, CELL RES, V31, P965, DOI 10.1038/s41422-021-00532-7
   Guziewicz KE, 2017, PROG RETIN EYE RES, V58, P70, DOI 10.1016/j.preteyeres.2017.01.005
   JAHN CE, 1983, OPHTHALMIC RES, V15, P220, DOI 10.1159/000265263
   Kato Y, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.39
   Kwa Faith A, 2019, F1000Res, V8, P1067, DOI 10.12688/f1000research.19598.1
   Lee SY, 2007, BIOCHEM BIOPH RES CO, V363, P490, DOI 10.1016/j.bbrc.2007.08.194
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Liu K, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0161-2
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rinsky B, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.18
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sorensen JO, 2020, ACTA OPHTHALMOL, V98, P384, DOI 10.1111/aos.14295
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Vance JE, 2015, TRAFFIC, V16, P1, DOI 10.1111/tra.12230
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wu KX, 2022, BMC BIOL, V20, DOI 10.1186/s12915-022-01244-z
   Xu ND, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226763
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
   Zhang Y, 2017, CAN J PHYSIOL PHARM, V95, P1283, DOI 10.1139/cjpp-2017-0127
NR 34
TC 0
Z9 0
U1 3
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2022
VL 222
AR 109160
DI 10.1016/j.exer.2022.109160
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E5ON
UT WOS:000830032700004
PM 35753432
DA 2022-11-30
ER

PT J
AU Feldman-Billard, S
   Dupas, B
AF Feldman-Billard, Sylvie
   Dupas, Benedicte
TI Eye disorders other than diabetic retinopathy in patients with diabetes
SO DIABETES & METABOLISM
LA English
DT Review
DE Acute anterior ischemic neuropathy; Age-related macular degeneration;
   Cataract; Diabetes; Glaucoma; Retinal vascular occlusion
ID OPEN-ANGLE GLAUCOMA; CATARACT-SURGERY; VISUAL OUTCOMES; RISK-FACTORS;
   MELLITUS; ASSOCIATION; RATES; METFORMIN; UK
AB Aim: While diabetic retinopathy is the most specific complication of chronic hyperglycaemia, numerous other ocular conditions also can involve the eyes of people with diabetes. Cataract, glaucoma, age-related macular degeneration, retinal vascular occlusion, and acute ischaemic optic neuropathy combine to impair vision in people with diabetes, especially when they are old. This report provides a critical analysis and an overview of the current knowledge of the main ocular disorders (excluding diabetic retinopathy) and their association in patients with diabetes. Methods: A literature search strategy was conducted for all English-language literature with a systematic review of key references until 2021. Results: Patients with diabetes have a high-to-moderate increased risk for most of the usual ocular disorders we reviewed with the exception of age-related macular degeneration. Exposure to chronic hyperglycaemia promotes the development of many eye disorders while acute glucose changes are involved in refractive disorders, diabetic papillopathy and acute cataract. Conclusion: Diabetes, beyond diabetic retinopathy, increases the risk of numerous eye disorders leading to low vision with implications for daily diabetes management. Even in the absence of clearly demonstrated benefit from glucose control in all eye conditions, achieving good glycaemic control and adherence to diabetes treatment will likely help avoid an additional risk of visual impairment in people with diabetes. In perspective, interesting findings suggesting a preventive effect of metformin use on age-related macular degeneration occurrence justify further studies. (c) 2021 Elsevier Masson SAS. All rights reserved.
C1 [Feldman-Billard, Sylvie] CHNO Quinze Vingts, Serv Med Interne, 28 Rue Charenton, F-75571 Paris 12, France.
   [Dupas, Benedicte] Ctr Ophtalmol Sorbonne St Michel, Paris, France.
   [Dupas, Benedicte] Hop Lariboisiere, Serv Ophtalmol, Paris, France.
C3 CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne
   Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite
RP Feldman-Billard, S (通讯作者)，CHNO Quinze Vingts, Serv Med Interne, 28 Rue Charenton, F-75571 Paris 12, France.
EM sfeldman@15-20.fr
CR Abikoye TM, 2020, INT OPHTHALMOL, V40, P3233, DOI 10.1007/s10792-020-01507-0
   Ansari AS, 2017, DIABETES CARE, V40, pE30, DOI 10.2337/dc16-2320
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Baudin F, 2018, JAMA OPHTHALMOL, V136, P1352, DOI 10.1001/jamaophthalmol.2018.3939
   Bayraktar Z, 2002, RETINA-J RET VIT DIS, V22, P752, DOI 10.1097/00006982-200212000-00011
   Becker C, 2018, EYE, V32, P1028, DOI 10.1038/s41433-017-0003-1
   Bikbov MM, 2020, AM J OPHTHALMOL, V210, P146, DOI 10.1016/j.ajo.2019.10.004
   Biousse V, 2015, NEW ENGL J MED, V372, P2428, DOI 10.1056/NEJMra1413352
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chancellor J, 2021, AM J OPHTHALMOL, V225, P47, DOI 10.1016/j.ajo.2020.12.027
   Chang YS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201627
   Chen HY, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024209
   Chen L, 2020, DIABETOLOGIA, V63, P1718, DOI 10.1007/s00125-020-05199-0
   Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076653
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Choi JA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239529
   Chu CJ, 2016, OPHTHALMOLOGY, V123, P316, DOI 10.1016/j.ophtha.2015.10.001
   De Freitas GR, 2021, PRIM CARE DIABETES, V15, P184, DOI 10.1016/j.pcd.2020.01.011
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   Drinkwater JJ, 2019, DIABETES CARE, V42, P288, DOI 10.2337/dc18-1556
   Feldman-Billard S, 2013, DIABETES METAB, V39, P271, DOI 10.1016/j.diabet.2012.10.009
   Ferdousi M, 2021, DIABETES CARE, V44, P150, DOI 10.2337/dc20-1482
   Gao Y, 2015, INT J OPHTHALMOL-CHI, V8, P358, DOI 10.3980/j.issn.2222-3959.2015.02.26
   Giusti C, 2003, SWISS MED WKLY, V133, P200
   Greco D, 2009, ACTA DIABETOL, V46, P23, DOI 10.1007/s00592-008-0053-8
   Hainsworth DP, 2021, OPHTHALMOLOGY, V128, P554, DOI 10.1016/j.ophtha.2020.09.014
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Huntjens B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052947
   Ismail-Beigi F, 2010, LANCET, V376, P419, DOI 10.1016/S0140-6736(10)60576-4
   Jeganathan VSE, 2008, DIABETES CARE, V31, P1905, DOI 10.2337/dc08-0342
   Johnson NA, 2021, OPHTHALMOL GLAUCOMA, V4, P216, DOI 10.1016/j.ogla.2020.09.013
   Jung Y, 2018, DIABETES METAB, V44, P328, DOI 10.1016/j.diabet.2017.09.007
   Kastelan S, 2018, SEMIN OPHTHALMOL, V33, P838, DOI 10.1080/08820538.2018.1519582
   Koh YY, 2020, GRAEF ARCH CLIN EXP, V258, P1367, DOI 10.1007/s00417-020-04679-8
   Lim HB, 2019, JAMA OPHTHALMOL, V137, P1125, DOI 10.1001/jamaophthalmol.2019.2537
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Ostri C, 2014, ACTA OPHTHALMOL, V92, DOI 10.1111/aos.12364
   Park Jung Hyun, 2017, J Med Case Rep, V11, P107, DOI 10.1186/s13256-017-1268-5
   Patel SV, 2005, OPHTHALMOLOGY, V112, P760, DOI 10.1016/j.ophtha.2004.11.057
   Rim TH, 2018, ACTA OPHTHALMOL, V96, pE1025, DOI 10.1111/aos.13805
   Santiago JG, 2014, EYE, V28, P259, DOI 10.1038/eye.2014.1
   Scott IU, 2020, LANCET, V396, P1927, DOI 10.1016/S0140-6736(20)31559-2
   Sebai I, 2019, REV MED INTERNE, V40, P188, DOI 10.1016/j.revmed.2018.08.007
   Sharma S, 2017, OPHTHALMOLOGY, V124, P450, DOI 10.1016/j.ophtha.2016.11.029
   SIVALINGAM A, 1989, INT OPHTHALMOL, V13, P187, DOI 10.1007/BF02028208
   Song BJ, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0815-6
   Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405
   Tham YC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8035
   Thilen SR, 2014, JAMA INTERN MED, V174, P380, DOI 10.1001/jamainternmed.2013.13426
   Tilleul J, 2009, J FR OPHTALMOL, V32, P513, DOI 10.1016/j.jfo.2009.06.006
   Wang Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019319
   Wu J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012874
   Yoo TK, 2019, INT OPHTHALMOL, V39, P2611, DOI 10.1007/s10792-019-01110-y
   Zhao D, 2015, OPHTHALMOLOGY, V122, P72, DOI 10.1016/j.ophtha.2014.07.051
   Zou XR, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0781-7
NR 59
TC 4
Z9 5
U1 2
U2 7
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 1262-3636
EI 1878-1780
J9 DIABETES METAB
JI Diabetes Metab.
PD NOV
PY 2021
VL 47
IS 6
AR 101279
DI 10.1016/j.diabet.2021.101279
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA XJ1CW
UT WOS:000726536200017
PM 34534696
DA 2022-11-30
ER

PT J
AU Busbee, BG
   Brown, MM
   Brown, GC
   Sharma, S
AF Busbee, BG
   Brown, MM
   Brown, GC
   Sharma, S
TI CME review: A cost-utility analysis of laser photocoagulation for
   extrafoveal choroidal neovascularization
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; cost-utility analysis; extrafoveal
   choroidal neovascularization; laser therapy
ID THERAPY
AB Purpose: The purpose of this study was to perform a reference case (average case), cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization associated with age-related macular degeneration using a model incorporating patient preferences.
   Methods: Visual acuity data for patients treated and observed over a 5-year period were obtained from previously reported studies by the Macular Photocoagulation Study Group. The results from this prospective, randomized trial were incorporated in a cost-utility model using time-trade-off utility analysis and decision analysis with Markov modeling according to the recommendations of the Panel on Cost-Effectiveness in Health and Medicine. Expenditures and health care benefits were each discounted at a 3% yearly rate.
   Results: Laser photocoagulation therapy for extrafoveal choroidal neovascularization in age-related macular degeneration, compared with observation, resulted in a mean gain of 0.0740 quality-adjusted life-year per patient treated. The mean cost of treatment for the average patient totaled $1,715. The cost divided by the health care benefit resulted in $23,176 year 2001 US dollars per quality-adjusted life-year gained for this procedure for a reference case. Sensitivity analyses, varying the cost, utility values, and discount parameters, resulted in dollars per quality-adjusted life-year gained ranging from $16,117 to $49,766.
   Conclusion: Laser photocoagulation for extrafoveal choroidal neovascularization associated with age-related macular degeneration appears to be cost-effective when compared with interventions across multiple medical specialties.
C1 Ctr Value Based Med, Flourtown, PA 19031 USA.
   Tufts Univ New England Med Ctr, Ctr Value Based Med, Boston, MA 02111 USA.
   Tufts Univ New England Med Ctr, Dept Ophthalmol, Boston, MA 02111 USA.
   Wills Eye Hosp & Res Inst, Cataract & Primary Eye Care Serv, Philadelphia, PA 19107 USA.
   Wills Eye Hosp & Res Inst, Ctr Value Based Med, Philadelphia, PA 19107 USA.
   Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
   Hop Hotel Dieu, Hlth Policy Unit, Kingston, ON, Canada.
   Queens Univ, Dept Ophthalmol, Kingston, ON, Canada.
   Queens Univ, Dept Epidemiol, Kingston, ON, Canada.
C3 Tufts Medical Center; Tufts Medical Center; Jefferson University;
   Jefferson University; Jefferson University; Queens University - Canada;
   Queens University - Canada; Queens University - Canada
RP Brown, MM (通讯作者)，Ctr Value Based Med, 1107 Bethlehem Pike,Suite 210, Flourtown, PA 19031 USA.
EM Gary0514@aol.com
CR Anderson R N, 1999, Natl Vital Stat Rep, V47, P1
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown G C, 2000, Qual Manag Health Care, V9, P23
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, RETINA-J RET VIT DIS, V20, P331, DOI 10.1097/00006982-200007000-00002
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   BROWN GC, 1999, J HLTH CARE FINANCE, V26, P1
   Brown M M, 1999, Curr Opin Ophthalmol, V10, P221, DOI 10.1097/00055735-199906000-00012
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   DAVIS JB, 2000, MED FEES US NATIONWI
   Detsky AS, 1997, MED DECIS MAKING, V17, P126, DOI 10.1177/0272989X9701700202
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   KIRSCHNER CG, 2000, PHYSICIANS CURRENT P
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   REDELMEIER DA, 1995, PRIMARY CARE, V22, P271
   ROTHWELL PM, 1988, BMJ-BRIT MED J, V95, P1147
   Schrader GD, 1997, PSYCHOTHER PSYCHOSOM, V66, P258, DOI 10.1159/000289144
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409
   Stein J D, 2002, J Clin Hypertens (Greenwich), V4, P181, DOI 10.1111/j.1524-6175.2002.00970.x
   Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559
   *TREEAG SOFTW INC, 1999, DAT TM 3 5 HEALTHC U
   United States Department of Labor, CONS PRIC IND
   Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253
NR 29
TC 26
Z9 26
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2003
VL 23
IS 3
BP 279
EP 287
DI 10.1097/00006982-200306000-00001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 697FY
UT WOS:000183932600001
PM 12824826
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Tadarati, M
   Bressler, NM
AF Chaikitmongkol, Voraporn
   Tadarati, Mongkol
   Bressler, Neil M.
TI Recent approaches to evaluating and monitoring geographic atrophy
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; geographic atrophy; monitoring;
   retinal imaging; screening
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; FUNDUS
   AUTOFLUORESCENCE; MICROPERIMETRY; PROGRESSION; SEGMENTATION; SECONDARY;
   GROWTH; IMAGES; DRUSEN
AB Purpose of review
   Given the increasing prevalence of geographic atrophy from age-related macular degeneration as the number of individuals over 85 increases throughout the world, as well as the recent increase in potential treatments to slow growth of geographic atrophy, this article discusses recent findings regarding retinal imaging of geographic atrophy to detect its presence or expansion over time.
   Recent findings
   During the review period, the COMPLETE (Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration) and the GATE (Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration) studies, respectively, reported no beneficial effects of intravenous eculizumab or tandospirone eye drops, respectively, identified on the growth of geographic atrophy. Several imaging and visual function studies have evaluated the role of various techniques using fundus autofluorescence, optical coherence tomography, microperimetry, or other investigator-initiated tools to assess geographic atrophy growth or progression over time, although the ideal imaging for geographic atrophy remains unknown. Some predictive factors for geographic atrophy growth recently suggested include genetic features, geographic atrophy characteristics in the fellow eye, or the presence of outer retinal tubulation on optical coherence tomography.
   Summary
   Quantification of geographic atrophy is important for evaluating growth of geographic atrophy. Numerous new imaging techniques of geographic atrophy beyond human grading of fundus photographs or fluorescein angiograms have emerged, but the ideal imaging for geographic atrophy has yet to be determined.
C1 [Chaikitmongkol, Voraporn] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai 50000, Thailand.
   [Tadarati, Mongkol] Rangsit Univ, Coll Med, Rajavithi Hosp, Retina Div,Dept Ophthalmol, Bangkok, Thailand.
   [Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
C3 Chiang Mai University; Rajavithi Hospital; Rangsit University; Johns
   Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
OI Chaikitmongkol, Voraporn/0000-0003-0426-7602
FU AMA - JAMA Ophthalmology; Bayer Healthcare Pharmaceuticals, Inc.;
   Genentech/Roche, Inc.; National Eye Institute of the National Institutes
   of Health; Novartis Pharma AG; Regeneron Pharmaceuticals, Inc.; Emmes
   Corporation
FX V.C.: None; M.T.: None; N.M.B.: PI of grants at the Johns Hopkins
   University School of Medicine sponsored by the following entities AMA -
   JAMA Ophthalmology; Bayer Healthcare Pharmaceuticals, Inc.;
   Genentech/Roche, Inc.; National Eye Institute of the National Institutes
   of Health; Novartis Pharma AG; Regeneron Pharmaceuticals, Inc.; The
   Emmes Corporation.
CR Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Chen Q, 2014, RETINA-J RET VIT DIS, V34, P2346, DOI 10.1097/IAE.0000000000000249
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Regillo C, 2013, 117 ANN M AM AC OPHT
   Sayegh RG, 2015, INVEST OPHTH VIS SCI, V56, P5246, DOI 10.1167/iovs.14-15114
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Wallsh Josh, 2015, Retin Cases Brief Rep, V9, P88, DOI 10.1097/ICB.0000000000000092
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Yaspan B, 2014, INVEST OPHTH VIS SCI, V55
   Yehoshua Z, 2015, OSLI RETINA, V46, P772, DOI 10.3928/23258160-20150730-15
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 26
TC 15
Z9 16
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2016
VL 27
IS 3
BP 217
EP 223
DI 10.1097/ICU.0000000000000259
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK2TJ
UT WOS:000374767000007
PM 26866953
DA 2022-11-30
ER

PT J
AU Tatlipinar, S
   Dinc, UA
   Yenerel, NM
   Gorgun, E
AF Tatlipinar, Sinan
   Dinc, Umut Asli
   Yenerel, N. Melda
   Gorgun, Ebru
TI Short-term effects of a single intravitreal bevacizumab injection on
   retinal vessel calibre
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE anti-VEGF; bevacizumab; intravitreal injection; retinal vessel diameter;
   vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; VISUAL IMPAIRMENT;
   BLOOD-FLOW; PHARMACOKINETICS; RETINOPATHY; EXPRESSION; DISEASE; VEGF
AB Purpose: The aim was to investigate the short-term effects of a single intravitreal bevacizumab injection on the retinal vessel calibre in patients with neovascular age-related macular degeneration and in patients with diabetic macular oedema.
   Methods: Twelve patients with neovascular age-related macular degeneration and eight patients with diabetic macular oedema were included in the study. All patients received an intravitreal injection of 1.25 mg bevacizumab. Red-free fundus photographs (35) were acquired with a fundus camera at baseline and one day, one week and one month after the intravitreal injection. Measurements of retinal vessel diameter were made of the supero-temporal retinal venule and arteriole using the software available on the IMA-GEnet program.
   Results: Although there appeared to be a trend towards vasoconstriction for the measurements in the diabetic macular oedema group (both for arterioles and venules at day 7) and the age-related macular degeneration group (for venules at day 1 and for arterioles at day 7), it did not reach statistical significance (p > 0.05). Optical coherence tomography revealed a significant decrease in foveal thickness measurements in both groups at the one month visit compared with baseline.
   Conclusion: The results suggest that intravitreal injection of bevacizumab might induce retinal vasoconstriction; however, low numbers of subjects might have prevented the difference from reaching statistical significance. Further studies with a larger number of subjects would reveal the effect of intravitreal anti-vascular endothelial growth factor treatment on retinal vessel diameters more clearly.
C1 [Tatlipinar, Sinan] Yeditepe Univ, Ctr Eye, Fac Med, Dept Ophthalmol, Istanbul, Turkey.
C3 Yeditepe University
RP Tatlipinar, S (通讯作者)，Yeditepe Univ, Ctr Eye, Fac Med, Dept Ophthalmol, Sakir Kesebir Cd Gazi Umur Pasa Sk 28, Istanbul, Turkey.
EM statlipi@yahoo.com
CR Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Harris A, 1998, ARCH OPHTHALMOL-CHIC, V116, P1491, DOI 10.1001/archopht.116.11.1491
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   Klein R, 2006, OPHTHALMOLOGY, V113, P1488, DOI 10.1016/j.ophtha.2006.03.028
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Yokoyama K, 2008, ACTA OPHTHALMOL, V86, P927, DOI 10.1111/j.1755-3768.2008.01187.x
NR 19
TC 26
Z9 27
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0816-4622
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JAN
PY 2012
VL 95
IS 1
BP 94
EP 98
DI 10.1111/j.1444-0938.2011.00662.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 869HQ
UT WOS:000298589400015
PM 21954975
OA Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Lee, SJ
   Kim, KW
   Yu, YS
   Kim, JH
AF Kim, Jin Hyoung
   Lee, Sung-Joon
   Kim, Kyu-Won
   Yu, Young Suk
   Kim, Jeong Hun
TI Oxidized low density lipoprotein-induced senescence of retinal pigment
   epithelial cells is followed by outer blood-retinal barrier dysfunction
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Outer blood-retinal barrier; Oxidized low density lipoprotein; Retinal
   pigment epithelial cell; Senescence
ID MACULAR DEGENERATION; OXIDATIVE STRESS; RISK-FACTORS; VERTEBRATE RETINA;
   PATHWAYS; APOPTOSIS; DISEASE; WNT; EYE
AB Age-related macular degeneration is the most common cause of vision loss in the elderly, which starts from aging processes of retinal pigment epithelial cells. Among variable risk factors in occurrence and progression of age-related macular degeneration, oxidized low density lipoprotein could be causally involved in pathobiological changes of RPE cells. Herein we showed that oxidized low density lipoprotein-induced senescence of retinal pigment epithelial cells is followed by outer blood-retinal barrier dysfunction. Under sub-lethal concentration, oxidized low density lipoprotein could promote advanced senescence of retinal pigment epithelial cells. Interestingly expression of CRALBP and RPE 65, indicators of retinal pigment epithelial cell differentiation, was decreased by oxidized low density lipoprotein. In addition, oxidized low density lipoprotein induced reactive oxygen species production and up-regulated inflammatory factors such as tumor necrosis factor-a and vascular endothelial growth factor, when beta-catenin, a critical mediator of the canonical Wnt pathway, was also elevated. Oxidized low density lipoprotein increased paracellular permeability of retinal pigment epithelial cells, when zonula occludens-1 at intercellular junctions markedly decreased as well. Furthermore, in retinal pigment epithelial cells and choriocapillaris of human apolipoprotein E2 transgenic mouse eye, increased vascular endothelial growth factor and decreased zonula occludens-1 expression was observed. Therefore, our results suggest that oxidized low density lipoprotein could promote senescence of retinal pigment epithelial cells which leads to induce outer blood-retinal barrier dysfunction as an early pathogenesis of age-related macular degeneration. (c) 2012 Elsevier Ltd. All rights reserved.
C1 Seoul Natl Univ, Fight Angiogenesis Related Blindness FARB Lab, Clin Res Inst, Seoul Natl Univ Hosp,Coll Med, Seoul 110744, South Korea.
   [Lee, Sung-Joon] Korea Univ, Div Food Biosci & Technol, Coll Life Sci & Biotechnol, Inst Biomed Sci & Safety, Seoul 136713, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, NeuroVasc Coordinat Res Ctr, Coll Pharm, Seoul 151742, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
   [Yu, Young Suk; Kim, Jeong Hun] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Korea University; Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ, Fight Angiogenesis Related Blindness FARB Lab, Clin Res Inst, Seoul Natl Univ Hosp,Coll Med, Seoul 110744, South Korea.
EM steph25@snu.ac.kr; steph25@snu.ac.kr
RI Kim, Kyu Won/AAJ-7213-2020; Lee, Sung-Joon/F-2435-2013; Yu, Young
   Suk/J-5551-2012; Kim, Jeong Hun/J-2748-2012
OI Kim, Jeong Hun/0000-0003-2957-1766
FU Ministry of Health & Welfare, Republic of Korea [A101329]
FX This study was supported by a grant of the Korea Healthcare Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea (A101329).
CR Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen CH, 2003, CIRCULATION, V107, P2102, DOI 10.1161/01.CIR.0000065220.70220.F7
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406
   Ho TC, 2006, BIOCHEM BIOPH RES CO, V342, P372, DOI 10.1016/j.bbrc.2006.01.164
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Kim JH, 2009, J NEUROSCI RES, V87, P653, DOI 10.1002/jnr.21884
   Kim JH, 2010, AM J PATHOL, V176, P1517, DOI 10.2353/ajpath.2010.090398
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963
   Steindl-Kuscher K, 2009, INVEST OPHTH VIS SCI, V50, P4471, DOI 10.1167/iovs.08-3139
   Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 32
TC 26
Z9 26
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD MAY
PY 2012
VL 44
IS 5
BP 808
EP 814
DI 10.1016/j.biocel.2012.02.005
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 935YR
UT WOS:000303558600021
PM 22349216
DA 2022-11-30
ER

PT J
AU Doggrell, SA
AF Doggrell, SA
TI Pegaptanib: the first antiangiogenic agent approved for neovascular
   macular degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE age-related macular degeneration; antiangiogenesis; clinical trial;
   neovascularisation; pegaptanib; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; INHIBITION
AB Age-related macular degeneration is the leading cause of irreversible visual loss in the industrialised world. Angiogenesis underlies the neovascularisation, and vascular endothelial growth factor (VEGF) is an angiogenesis growth factor. in the VEGF Inhibition Study in Ocular Neovascularisation-1 (VISION-1) trial, pegaptanib (an aptamer inhibitor of VEGF) was tested in neovascular age-related macular degeneration. The 1186 patients received a sham injection or intravitreous injection of pegaptanib (0.3, 1.0 or 3.0 mg) every 6 weeks over a period of 48 weeks. The primary end point was the proportion of patients who lost < 15 letters of visual acuity between baseline and 54 weeks, and this occurred in 164/296 patients (55%) who received the sham injection. A higher percentage of patients maintained this visual acuity if they were treated with pegaptanib 0.3 mg (54/206 patients, 70%). There was no evidence that pegaptanib 1 or 3 mg was more effective than 0.3 mg. There was no excess of systemic adverse effects with pegaptanib, but ocular adverse effects occurred more commonly with pegaptanib than with sham injection; vitreous floaters (33 versus 8%), vitreous opacities (18 versus 10%) and anterior chamber inflammation (14 versus 6%). Although these results represent a new, beneficial and relatively safe approach to age-related macular degeneration, the progression was not halted or reversed, and further improvement to treatment for this condition should be sought.
C1 Auckland Univ Technol, Sch Nursing, Auckland, New Zealand.
C3 Auckland University of Technology
RP Doggrell, SA (通讯作者)，Auckland Univ Technol, Sch Nursing, Akoranga Campus, Auckland, New Zealand.
EM s_doggrell@yahoo.com
CR Doggrell SA, 2004, EXPERT OPIN PHARMACO, V5, P2621, DOI 10.1517/14656566.5.12.2621
   Farhadi MR, 2005, J NEUROSURG, V102, P363, DOI 10.3171/jns.2005.102.2.0363
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 5
TC 60
Z9 62
U1 0
U2 3
PU ASHLEY PUBLICATIONS LTD
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1465-6566
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD JUL
PY 2005
VL 6
IS 8
BP 1421
EP 1423
DI 10.1517/14656566.6.8.1421
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 952GG
UT WOS:000230991400013
PM 16013991
DA 2022-11-30
ER

PT J
AU von Leithner, PL
   Kam, JH
   Bainbridge, J
   Catchpole, I
   Gough, G
   Coffey, P
   Jeffery, G
AF von Leithner, Peter Lundh
   Kam, Jaimie Hoh
   Bainbridge, James
   Catchpole, Ian
   Gough, Gerald
   Coffey, Peter
   Jeffery, Glen
TI Complement Factor H Is Critical in the Maintenance of Retinal Perfusion
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; PIGMENT EPITHELIUM; BRUCHS MEMBRANE; RISK;
   ACTIVATION; RAT; GLOMERULONEPHRITIS; POLYMORPHISM
AB Vascular pathologies are known to be associated with age-related macular degeneration. Recently, age-related macular degeneration was associated with a single-nucleotide substitution of the complement factor H (CFH) gene, part of the alternative pathway of the complement system, a critical element in the innate immune response. Such polymorphisms are found in more than 50% of cases of age-related macular degeneration. Here we show that the absence of CFH causes an autoimmune response that targets the vascular endothelium of both the inner and outer retinal vascular networks. In CFH-knockout (cfh(-/-)) mice, Q and C3b, key components of the complement system, are progressively deposited on retinal vessels, which subsequently become restricted and wither, resulting in a reduction of retinal blood supply. This result leads to increased oxygen stress. While such effects are not systemic, these structural changes are mirrored in functional changes with a substantial decline in retinal blood flow dynamics. When the system is challenged functionally by laser-induced choroidal neovascularization, fluorescein leakage was significantly smaller in cfh(-/-) mice compared with controls, likely due to reduced retinal perfusion. These data reveal that in both the presence and absence of exogenous challenge to the innate immune system, CFH is required to maintain normal levels of retinal perfusion. It is likely that C3 and Ob accumulation in the aged CFH-deficient retina is associated with complement-mediated retinal endothelium destruction. (Am J Pathol 2009, 175:412-421; DOI. 10.2353/ajpath.2009.080927)
C1 [von Leithner, Peter Lundh; Kam, Jaimie Hoh; Bainbridge, James; Coffey, Peter; Jeffery, Glen] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Catchpole, Ian; Gough, Gerald] GlaxoSmithKline Med Res Ctr, BioPharm CEDD Biol, Stevenage, Herts, England.
C3 University of London; University College London; GlaxoSmithKline
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Bainbridge,
   James/0000-0003-1318-8201; Coffey, Peter/0000-0002-5427-2939
FU GlaxoSmith Kline, UK
FX Supported by GlaxoSmith Kline, UK.
CR Abrera-Abeleda MA, 2007, KIDNEY INT, V71, P1142, DOI 10.1038/sj.ki.5002235
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hofman P, 2001, ARCH OPHTHALMOL-CHIC, V119, P861
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hunigen H, 2008, ACTA HISTOCHEM, V110, P462, DOI 10.1016/j.acthis.2008.02.006
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001
   MATTER J, 2006, NAT GENET, V38, P1055
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Noris M, 2006, PLOS MED, V3, P1719, DOI 10.1371/journal.pmed.0030432
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   SCHMIDSCHONBEIN GW, 1990, BIORHEOLOGY, V27, P859
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   Takemura M, 1996, J COMP NEUROL, V365, P511, DOI 10.1002/(SICI)1096-9861(19960219)365:4<511::AID-CNE1>3.0.CO;2-7
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 34
TC 42
Z9 45
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2009
VL 175
IS 1
BP 412
EP 421
DI 10.2353/ajpath.2009.080927
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 464MG
UT WOS:000267508600038
PM 19541934
OA Green Published
DA 2022-11-30
ER

PT J
AU Sun, TT
   Wan, ZQ
   Gao, Y
   Zhang, L
   Peng, Q
AF Sun, Tingting
   Wan, Zhongqi
   Gao, Yan
   Zhang, Li
   Peng, Qing
TI Fundus imaging features of massive hemorrhaging in polypoidal choroidal
   vasculopathy after treatment
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Polypoidal choroidal vasculopathy (PCV); photodynamic therapy (PDT);
   anti-vascular endothelial growth factor (Anti-VEGF); massive subretinal
   hemorrhage (MSH); vitreous hemorrhage (VH)
ID MACULAR DEGENERATION
AB To explore the fundus imaging features of massive subretinal or vitreous hemorrhages in polypoidal choroidal vasculopathy (PCV) patients after treatment. This is a retrospective, non-controlled clinical study. We collected 9 PCV patients (9 eyes) with more than 6000 mu m subretinal or vitreous massive hemorrhaging. Two patients who underwent combination therapy had massive subretinal hemorrhage (MSH) at day 75 and 82 post-treatment. Three patients who underwent PDT alone had MSH on postoperative day 22, 25 and 60. In addition, among four patients who underwent intravitreal injection of Conbercept alone, one patient developed MSH on day 30 after injection, while the other 3 patients suffered from vitreous hemorrhaging on day 1, 3 and 12 after injection, respectively. OCT showed several hill-shaped pigment epithelium detachments (PED), subretinal hyperreflective mass and cystoid hyporeflection fluid. FFA showed three hyperfluorescent spots in the early phase and gradually enhanced, diffused in the late phase. Visual acuity of 7 patients with MSH was improved after medical treatment. However, the visual acuity of another two patients with vitreous hemorrhaging showed no improved in one patient and slightly improved in another patient by vitrectomy. Therefore, the risk of subretinal and vitreous hemorrhaging in PCV patients was higher when the lesions were more than 6000 mu m after PDT alone or in combination with anti-VEGF therapy.
C1 [Sun, Tingting] Shanxi Med Univ, Dept Ophthalmol, Taiyuan 030001, Shanxi, Peoples R China.
   [Wan, Zhongqi] Nanjing Med Univ, Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China.
   [Gao, Yan] Shanxi Eye Hosp, Dept Vitreoretinol, 100 Fudong St, Taiyuan, Shanxi, Peoples R China.
   [Zhang, Li] Shanxi Med Univ, Affiliated Peoples Hosp, Dept Ophthalmol, Shanxi Prov Peoples Hosp, Taiyuan 030001, Shanxi, Peoples R China.
   [Peng, Qing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Yanchang Rd M, Shanghai 200072, Peoples R China.
C3 Shanxi Medical University; Nanjing Medical University; Shanxi Medical
   University; Shanxi Medical University; Shanxi People's Hospital; Tongji
   University
RP Zhang, L (通讯作者)，Shanxi Med Univ, Affiliated Peoples Hosp, Dept Ophthalmol, Shanxi Prov Peoples Hosp, Taiyuan 030001, Shanxi, Peoples R China.; Peng, Q (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Yanchang Rd M, Shanghai 200072, Peoples R China.
EM zhangli63930@163.com; pengqing@tongji.edu.cn
FU National Natural Science Foundation [81570852]
FX This study was supported by the National Natural Science Foundation
   (Grant No.: 81470025) and National Natural Science Foundation (Grant
   No.: 81570852). They supported the data collection, interpretation and
   writing the manuscript.
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim H, 2015, OSLI RETINA, V46, P423, DOI 10.3928/23258160-20150422-04
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Shin YI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28938-1
   Talany G, 2017, EYE, V31, P628, DOI 10.1038/eye.2016.265
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang KY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012464
NR 21
TC 0
Z9 0
U1 2
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2020
VL 13
IS 8
BP 5736
EP 5744
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA NS8GZ
UT WOS:000572495600022
DA 2022-11-30
ER

PT J
AU Tamminen, T
   Koskela, A
   Toropainen, E
   Gurubaran, IS
   Winiarczyk, M
   Liukkonen, M
   Paterno, JJ
   Lackman, P
   Sadeghi, A
   Viiri, J
   Hyttinen, JMT
   Koskelainen, A
   Kaarniranta, K
AF Tamminen, Toni
   Koskela, Ali
   Toropainen, Elisa
   Gurubaran, Iswariyaraja Sridevi
   Winiarczyk, Mateusz
   Liukkonen, Mikko
   Paterno, Jussi J.
   Lackman, Petri
   Sadeghi, Amir
   Viiri, Johanna
   Hyttinen, Juha M. T.
   Koskelainen, Ari
   Kaarniranta, Kai
TI Pinosylvin Extract Retinari (TM) Sustains Electrophysiological Function,
   Prevents Thinning of Retina, and Enhances Cellular Response to Oxidative
   Stress in NFE2L2 Knockout Mice
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID COMPLEMENT FACTOR-H; ANTIOXIDANT RESPONSE; AGE; NRF2; RESVERATROL;
   AUTOPHAGY; INFLAMMATION; RPE; DEGENERATION; ACTIVATION
AB Chronic oxidative stress eventually leads to protein aggregation in combination with impaired autophagy, which has been observed in age-related macular degeneration. We have previously shown an effective age-related macular degeneration disease model in mice with nuclear factor-erythroid 2-related factor-2 (NFE2L2) knockout. We have also shown pinosylvin, a polyphenol abundant in bark waste, to increase human retinal pigment epithelium cell viability in vitro. In this work, the effects of commercial natural pinosylvin extract, Retinari (TM), were studied on the electroretinogram, optical coherence tomogram, autophagic activity, antioxidant capacity, and inflammation markers. Wild-type and NFE2L2 knockout mice were raised until the age of 14.8 +/- 3.8 months. They were fed with either regular or Retinari (TM) chow (141 +/- 17.0 mg/kg/day of pinosylvin) for 10 weeks before the assays. Retinari (TM) treatment preserved significant retinal function with significantly preserved a- and b-wave amplitudes in the electroretinogram responses. Additionally, the treatment prevented thinning of the retina in the NFE2L2 knockout mice. The NFE2L2 knockout mice showed reduced ubiquitin-tagged protein accumulation in addition to local upregulation of complement factor H and antioxidant enzymes superoxide dismutase 1 and catalase. Therefore, the treatment in the NFE2L2 KO disease model led to reduced chronic oxidative stress and sustained retinal function and morphology. Our results demonstrate that pinosylvin supplementation could potentially lower the risk of age-related macular degeneration onset and slow down its progression.
C1 [Tamminen, Toni; Koskela, Ali; Gurubaran, Iswariyaraja Sridevi; Liukkonen, Mikko; Paterno, Jussi J.; Viiri, Johanna; Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1627, FI-70211 Kuopio, Finland.
   [Toropainen, Elisa; Sadeghi, Amir] Univ Eastern Finland, Sch Pharm, POB 1627, FI-70211 Kuopio, Finland.
   [Winiarczyk, Mateusz] Med Univ Lublin, Dept Vitreoretinal Surg, Lublin, Poland.
   [Paterno, Jussi J.; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, FI-70029 Kuopio, Finland.
   [Lackman, Petri] Eevia Hlth Oy, FI-60100 Seinajoki, Finland.
   [Koskelainen, Ari] Aalto Univ, Dept Neurosci & Biomed Engn, FI-00067 Aalto, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Medical
   University of Lublin; Kuopio University Hospital; University of Eastern
   Finland; Aalto University
RP Tamminen, T (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1627, FI-70211 Kuopio, Finland.
EM toni.tamminen@uef.fi
OI Koskela, Ali/0000-0003-1194-275X; Sridevi Gurubaran,
   Iswariyaraja/0000-0003-1863-9550; Hyttinen, Juha/0000-0002-3414-4032;
   Liukkonen, Mikko/0000-0002-4259-4041
FU Finnish Eye Foundation [20180014]; Kuopio University Hospital [5503743];
   Health Research Council of the Academy of Finland [296840]; Paivikki ja
   Sakari Sohlbergin Saatio; Sigrid Juselius Foundation; Finnish Eye and
   Tissue Bank Foundation [20180041]; Friends of the Blind Foundation;
   Finnish Medical Foundation [2326]; Finnish Cultural Foundation - North
   Savo regional fund; University of Eastern Finland; Finnish Funding
   Agency for Technology and Innovation
FX We thank our Laboratory Technician Anne Seppanen for the assistance in
   the laboratory work. This study was supported by the Finnish Eye
   Foundation (grant number 20180014), Kuopio University Hospital (grant
   number 5503743), Finnish Funding Agency for Technology and Innovation,
   Health Research Council of the Academy of Finland (grant number 296840),
   Paivikki ja Sakari Sohlbergin Saatio, Sigrid Juselius Foundation,
   Finnish Eye and Tissue Bank Foundation (grant number 20180041), Friends
   of the Blind Foundation, Finnish Medical Foundation (grant number 2326),
   Finnish Cultural Foundation - North Savo regional fund, and University
   of Eastern Finland strategical support.
CR Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Bauerova K, 2015, AUTOIMMUNITY, V48, P46, DOI 10.3109/08916934.2014.939268
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dinkova-Kostova AT, 2015, FREE RADICAL BIO MED, V88, P179, DOI 10.1016/j.freeradbiomed.2015.04.036
   Erasalo H, 2018, J NAT PROD, V81, P1131, DOI 10.1021/acs.jnatprod.7b00384
   Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008
   Farkhondeh T, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110234
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fonseca-Kelly Zoe, 2012, Front Neurol, V3, P84, DOI 10.3389/fneur.2012.00084
   Fu YH, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/4181084
   Giordano S, 2014, REDOX BIOL, V2, P82, DOI 10.1016/j.redox.2013.12.013
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001
   Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Kang JH, 2016, ARCH PHARM RES, V39, P1703, DOI 10.1007/s12272-016-0839-0
   Kapuy O, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7030039
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Koskela A, 2014, MOL VIS, V20, P760
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Laavola M, 2015, J AGR FOOD CHEM, V63, P3445, DOI 10.1021/jf504606m
   Ladewig M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1557, DOI 10.1001/archopht.121.11.1557
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Z, 2017, ONCOTARGET, V8, P65778, DOI 10.18632/oncotarget.19473
   Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118
   Meng X, 2020, FOODS, V9, DOI 10.3390/foods9030340
   Mishra R, 2021, J BIOMOL STRUCT DYN, V39, P1766, DOI 10.1080/07391102.2020.1738958
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moilanen LJ, 2016, BASIC CLIN PHARMACOL, V118, P238, DOI 10.1111/bcpt.12485
   Moldogazieva NT, 2018, FREE RADICAL RES, V52, P507, DOI 10.1080/10715762.2018.1457217
   Mudo G, 2012, CELL MOL LIFE SCI, V69, P1153, DOI 10.1007/s00018-011-0850-z
   National Center for Biotechnology Information, 2020, PUBCHEM COMP SUMM CI
   Nimse SB, 2015, RSC ADV, V5, P27986, DOI 10.1039/c4ra13315c
   Park EJ, 2012, J NUTR BIOCHEM, V23, P946, DOI 10.1016/j.jnutbio.2011.04.021
   Perkins SJ, 2010, ADV EXP MED BIOL, V703, P25, DOI 10.1007/978-1-4419-5635-4_3
   Pugh EN, 1998, PHOTOSTASIS AND RELATED PHENOMENA, P93, DOI 10.1007/978-1-4899-1549-8_7
   Reinisalo M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/340520
   Roupe K, 2005, J PHARMACEUT BIOMED, V38, P148, DOI 10.1016/j.jpba.2004.12.015
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Thiel G, 2014, MOL NUTR FOOD RES, V58, P1402, DOI 10.1002/mnfr.201300913
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Wu J, 2020, SCI TOTAL ENVIRON, V734, DOI 10.1016/j.scitotenv.2020.139425
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Xiao WS, 2020, ANTIOXID REDOX SIGN, V32, P1330, DOI 10.1089/ars.2019.7803
   Xu H, 2020, J FUNCT FOODS, V71, DOI 10.1016/j.jff.2020.104019
   Yun HR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093289
   Zeng Y, 2015, BIOCHEM BIOPH RES CO, V468, P167, DOI 10.1016/j.bbrc.2015.10.139
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157
NR 71
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD DEC 7
PY 2021
VL 2021
AR 8028427
DI 10.1155/2021/8028427
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA ZJ5BM
UT WOS:000762319700001
PM 34917233
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Brogan, AP
   Dickerson, TJ
   Boldt, GE
   Janda, KD
AF Brogan, AP
   Dickerson, TJ
   Boldt, GE
   Janda, KD
TI Altered retinoid homeostasis catalyzed by a nicotine metabolite:
   Implications in macular degenerationand and normal development
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE organocatalysis; retinal isomerization
ID FACTOR-H POLYMORPHISM; ACID RECEPTORS RARS; VITAMIN-A; PIGMENT
   EPITHELIUM; CIGARETTE-SMOKING; DOUBLE MUTANTS; PUBLIC-HEALTH; VISUAL
   CYCLE; AGE; NORNICOTINE
AB Retinoids (vitamin A) serve two distinct functions in higher animals: light absorption for vision and gene regulation for growth and development. Cigarette smoking is a contributing factor for diseases that affect vision such as age-related macular degeneration and increases the risk of birth defects; however, altered retinoid homeostasis has received little attention as a potential mechanism for smoking-associated toxicities. Herein, we demonstrate that nornicotine, a nicotine metabolite and component of cigarette smoke, catalyzes the Z-to-E alkene isomerization of unsaturated aldehydes and ketones, including retinals. Despite the recent explosion in the use of organic compounds as chemical catalysts, minimal effort has been devoted to biologically relevant organocatalysis. Our study demonstrates a system in which a lowest unoccupied molecular orbital-lowering intermediate similar to the endogenous protein rhodopsin effectively catalyzes isomerization under biologically relevant conditions. The product of retinal isomerization is all-E-retinal, which in the eye is a biosynthetic precursor to N-retinylidene-N-retinylethanolamine, a hallmark of age-related macular degeneration. Furthermore, 9-Z- and all-E-retinal isomers are biosynthetic precursors to 9-Z- and all-E-retinoic acids, ligands that mediate specific cellular responses by binding to transcriptional regulatory proteins critical in growth and development. Strict maintenance of retinal isomer composition is essential for proper transcriptional regulation. Nornicotine-catalyzed retinal isomerization implies an underlying molecular mechanism for age-related macular degeneration, the birth defects associated with smoking, and other smoking-associated abnormalities that stem from disruption of retinoid metabolism.
C1 Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.
C3 Scripps Research Institute; Scripps Research Institute; Scripps Research
   Institute
RP Janda, KD (通讯作者)，Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM kdjanda@scripps.edu
CR Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cia D, 1999, J CHROMATOGR A, V864, P257, DOI 10.1016/S0021-9673(99)01024-9
   Crooks PA, 1997, DRUG METAB DISPOS, V25, P47
   Dalko PI, 2004, ANGEW CHEM INT EDIT, V43, P5138, DOI 10.1002/anie.200400650
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Dickerson TJ, 2003, P NATL ACAD SCI USA, V100, P8182, DOI 10.1073/pnas.1332847100
   Dickerson TJ, 2002, P NATL ACAD SCI USA, V99, P15084, DOI 10.1073/pnas.222561699
   Dickerson TJ, 2002, J AM CHEM SOC, V124, P3220, DOI 10.1021/ja017774f
   Dickerson TJ, 2004, J ORG CHEM, V69, P6603, DOI 10.1021/jo048894j
   Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Fujita T., 1971, PESTIC BIOCHEM PHYS, V1, P151
   FUTORYAN T, 1994, NUTR REV, V52, P299, DOI 10.1111/j.1753-4887.1994.tb01461.x
   Gerster H, 1997, INT J VITAM NUTR RES, V67, P71
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harbige Laurence S., 1996, Nutrition and Health (Bicester), V10, P285
   Hinds TS, 1997, J CLIN PHARMACOL, V37, P551, DOI 10.1002/j.1552-4604.1997.tb04336.x
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   KANDORI H, 1995, J AM CHEM SOC, V117, P2669, DOI 10.1021/ja00114a040
   KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7
   Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512
   Keegan BR, 2005, SCIENCE, V307, P247, DOI 10.1126/science.1101573
   KISAKI T, 1961, ARCH BIOCHEM BIOPHYS, V94, P252, DOI 10.1016/0003-9861(61)90038-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LOHNES D, 1994, DEVELOPMENT, V120, P2723
   MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749
   Nagao A, 2004, J NUTR, V134, p237S, DOI 10.1093/jn/134.1.237S
   Ouellet SG, 2005, J AM CHEM SOC, V127, P32, DOI 10.1021/ja043834g
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   Rogers CJ, 2005, J ORG CHEM, V70, P3705, DOI 10.1021/jo050161r
   Ross AC, 1996, FASEB J, V10, P979, DOI 10.1096/fasebj.10.9.8801180
   ROSS AC, 1994, ADV EXP MED BIOL, V352, P187
   Ross DA, 1998, P NUTR SOC, V57, P159, DOI 10.1079/PNS19980022
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Semba RD, 1998, NUTR REV, V56, pS38, DOI 10.1111/j.1753-4887.1998.tb01643.x
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, P NATL ACAD SCI USA, V100, P4353, DOI 10.1073/pnas.1031478100
   Stephens D, 1996, Pediatr Nurs, V22, P377
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tanaka Y, 2005, NATURE, V435, P172, DOI 10.1038/nature03494
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vermot J, 2005, SCIENCE, V308, P563, DOI 10.1126/science.1108363
   Vermot J, 2005, NATURE, V435, P215, DOI 10.1038/nature03488
   YAMAMOTO I, 1962, AGR BIOL CHEM TOKYO, V26, P709, DOI 10.1080/00021369.1962.10858034
   Yang JW, 2004, ANGEW CHEM INT EDIT, V43, P6660, DOI 10.1002/anie.200461816
NR 52
TC 21
Z9 26
U1 1
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 26
PY 2005
VL 102
IS 30
BP 10433
EP 10438
DI 10.1073/pnas.0504721102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 950JL
UT WOS:000230853300007
PM 16014706
OA Green Published
DA 2022-11-30
ER

PT J
AU Imasawa, M
   Sakurada, Y
   Iijima, H
AF Imasawa, Mitsuhiro
   Sakurada, Yoichi
   Iijima, Hiroyuki
TI Classic choroidal neovascularization developing after photodynamic
   therapy in eyes with polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Classic choroidal neovascularization; Photodynamic therapy; Polypoidal
   choroidal vasculopathy; Risk factors
ID MACULAR DEGENERATION; JAPANESE PATIENTS; VERTEPORFIN; RANIBIZUMAB;
   ANGIOGRAPHY; MEMBRANES
AB To investigate the characteristics of eyes with polypoidal choroidal vasculopathy (PCV) which develop secondary classic choroidal neovascularization (CNV) after photodynamic therapy (PDT).
   We retrospectively reviewed the records of 64 eyes of 64 PCV patients (43 men, 21 women; mean age +/- A standard deviation, 72.7 +/- A 8.6 years), who were followed-up for at least 1 year after the initial PDT. There was no evidence of classic CNV in any of the subject eyes on fluorescein angiography (FA) at the first PDT. Eyes which developed of secondary classic CNV after PDT were classified as the CNV group and the other eyes as the No-CNV group.
   Secondary classic CNV developed after PDT in 10 (15.6%) of the 64 eyes. Six patients developed CNV within 1 year after the first PDT. Multivariate logistic regression analysis for the baseline factors related to CNV development, including age, gender, greatest linear dimension, and the lesion components, revealed that in the CNV group the age was significantly younger (p = 0.037) and the incidence of retinal edema was significantly greater (p = 0.041) than in the No-CNV group.
   Secondary classic CNV tends to develop after PDT in PCV eyes in younger patients with retinal edema.
C1 [Imasawa, Mitsuhiro; Sakurada, Yoichi; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Imasawa, M (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.
EM mimasawa@yamanashi.ac.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busch T, 2009, RETINA-J RET VIT DIS, V29, pS36, DOI 10.1097/IAE.0b013e3181ad25e8
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 24
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2011
VL 55
IS 3
BP 241
EP 247
DI 10.1007/s10384-011-0006-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778XI
UT WOS:000291742300010
PM 21559909
DA 2022-11-30
ER

PT J
AU Lee, ET
   Russell, D
   Morris, T
   Warn, A
   Kingsley, R
   Ogola, G
AF Lee, ET
   Russell, D
   Morris, T
   Warn, A
   Kingsley, R
   Ogola, G
TI Visual impairment and eye abnormalities in Oklahoma Indians
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; AMERICAN-INDIANS; RISK-FACTORS; PREVALENCE;
   POPULATION; PTERYGIUM; DISEASE
AB Objective: To determine the prevalence of visual impairment and eye abnormalities in Oklahoma Indians.
   Methods: The cross-sectional study included 1019 Oklahoma Indians, aged 48 to 82 years; 60.2% were women. All participants gave a personal inter-view, and all underwent an eye examination, including the determination of best-corrected visual acuity and an ophthalmoscopic examination. In addition, two 45 degrees fundus photographs were taken of each eye, and these photographs were graded by the Fundus Photography Reading Center at the University of Wisconsin, Madison.
   Results: Among the 1019 participants, 77.4% had a visual acuity of 20/20 or better, 19.5% and 2.5% had visual acuities of between 20/25 and 20/40 and between 20/50 and 20/190, respectively; and 0.6% were legally blind, all in the better eye. Cataract was the most frequent contributing cause and age-related macular degeneration the second most frequent contributing cause of visual impairment. The overall prevalence proportions of age-related macular degeneration, cataract, diabetic retinopathy, and definite glaucoma were 33.6%, 39.6%, 20.1%, and 5.6%, respectively. Most of the other eye abnormalities were rare in the study participants, except for pinguecula (42.4%) and dermatochalasis (30.1%).
   Conclusions: Oklahoma Indians have a higher prevalence of visual impairment, age-related macular degeneration, and diabetic retinopathy than other ethnic groups. The implementation of adequate treatment and prevention programs for eye diseases is indicated.
C1 Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Ctr Amer India Hlth Res, Oklahoma City, OK 73104 USA.
   Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK 73104 USA.
   McGee Eye Inst, Lawton, OK USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center
RP Lee, ET (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Ctr Amer India Hlth Res, 801 NE 13th St, Oklahoma City, OK 73104 USA.
FU NATIONAL EYE INSTITUTE [U10EY009898] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL041654] Funding Source:
   NIH RePORTER; NEI NIH HHS [EY-09898] Funding Source: Medline; NHLBI NIH
   HHS [U01-HL041654] Funding Source: Medline
CR ADLERGRINBERG D, 1986, AM J OPTOM PHYS OPT, V63, P553
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Berinstein DM, 1997, DIABETES CARE, V20, P757, DOI 10.2337/diacare.20.5.757
   BETTMAN JW, 1972, ARCH OPHTHALMOL-CHIC, V88, P263, DOI 10.1001/archopht.1972.01000030265009
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fishbaugh J, 1995, Insight, V20, P11
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   KLEIN R, 1986, OPHTHALMOLOGY, V93, P1183
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LEE ET, 1990, AM J EPIDEMIOL, V132, P1141, DOI 10.1093/oxfordjournals.aje.a115757
   LEE ET, 1995, DIABETES CARE, V18, P599, DOI 10.2337/diacare.18.5.599
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   Luthra R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1827, DOI 10.1001/archopht.119.12.1827
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Panchapakesan J, 1998, AUST NZ J OPHTHALMOL, V26, pS2, DOI 10.1111/j.1442-9071.1998.tb01362.x
   SHOEMAKER JA, 2002, VISION PROBLEMS US P
   STODDART M, 2000, AM INDIAN ALSK NATIV, V90, P20
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
NR 24
TC 16
Z9 16
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2005
VL 123
IS 12
BP 1699
EP 1704
DI 10.1001/archopht.123.12.1699
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991BS
UT WOS:000233787800010
PM 16344442
OA Bronze
DA 2022-11-30
ER

PT J
AU Yamada, K
   Kaneko, H
   Shimizu, H
   Suzumura, A
   Namba, R
   Takayama, K
   Ito, S
   Sugimoto, M
   Terasaki, H
AF Yamada, Kazuhisa
   Kaneko, Hiroki
   Shimizu, Hideyuki
   Suzumura, Ayana
   Namba, Rina
   Takayama, Kei
   Ito, Seina
   Sugimoto, Masataka
   Terasaki, Hiroko
TI Lamivudine Inhibits Alu RNA-induced Retinal Pigment Epithelium
   Degeneration via Anti-inflammatory and Anti-senescence Activities
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; NLRP3
   inflammasome; lamivudine; senescence
ID NLRP3 INFLAMMASOME ACTIVATION; MACULAR DEGENERATION; CELLS; MECHANISMS;
   CGAS; BETA
AB Purpose: Accumulation of the long noncoding Alu element RNA activates the NLRP3 inflammasome and leads to retinal pigment epithelium (RPE) cell death, a key event in the pathogenesis of geographic atrophy during late-stage age-related macular degeneration. Lamivudine (3TC) is a nucleoside analog reverse transcriptase inhibitor known to inhibit the NLRP3 inflammasome. Currently, the intracellular response of the senescence-marker p16(Ink4a) to the long noncoding RNA is being actively studied. The present study aimed to assess the efficacy of 3TC against Alu RNA-induced RPE inflammation and senescence by evaluating changes in expression of the proinflammatory cytokines IL-18 and IL-1 beta and of p16(INK4a) in RPE cells.
   Methods: Cultured human RPE cells and in vivo mouse RPE cells were transfected with an in vitro-transcribed Alu RNA, and changes in IL-18, IL-1 beta, and p16(Ink4a) expression measured in the presences of 3TC or 3,4-(M)CA as a negative control.
   Results: Treatment with 3TC markedly reduced Alu RNA-induced expression of IL-18 and IL-1 beta in human and mouse RPE cells compared with the negative control. Further, Alu RNA-induced p16(INK4a) expression was suppressed by 3TC in human RPE cells.
   Conclusions: Our data suggest that Alu RNA accumulation contributes to RPE cell senescence in age-related macular degeneration and that this pathogenic process can be suppressed by 3TC.
   Translational Relevance: Further verifying this study leads to potential targets for age-related macular degeneration therapy.
C1 [Yamada, Kazuhisa; Kaneko, Hiroki; Shimizu, Hideyuki; Suzumura, Ayana; Namba, Rina; Ito, Seina; Terasaki, Hiroko] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
   [Takayama, Kei] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Sugimoto, Masataka] Natl Ctr Geriatr & Gerontol, Dept Mech Aging, Obu, Aichi, Japan.
C3 Nagoya University; National Defense Medical College - Japan; National
   Center for Geriatrics & Gerontology
RP Kaneko, H (通讯作者)，Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465
FU Japan Society for the Promotion of Science [19K09988]; Takeda Science
   Foundation; Eye Research Foundation for the Aged; Charitable Trust Fund
   for Ophthalmic Research in Commemoration of Santen Pharmaceutical's
   Founder
FX Partially supported by Grants-in-Aid for Scientific Research C (H.K.;
   19K09988) from Japan Society for the Promotion of Science
   (http://www.jsps.go.jp/), Takeda Science Foundation, The Eye Research
   Foundation for the Aged, and Charitable Trust Fund for Ophthalmic
   Research in Commemoration of Santen Pharmaceutical's Founder.
CR Ahn H, 2014, IMMUNOBIOLOGY, V219, P315, DOI 10.1016/j.imbio.2013.11.003
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Brestovac B, 2013, COMP CLIN PATHOL, V24, P9
   Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640
   De Cecco M, 2019, NATURE, V566, P73, DOI 10.1038/s41586-018-0784-9
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Hasler J, 2006, NUCLEIC ACIDS RES, V34, P2374, DOI 10.1093/nar/gkl246
   He Y, 2014, J BIOL CHEM, V289, P1142, DOI 10.1074/jbc.M113.515080
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Jadeja RN, 2018, AGING-US, V10, P1306, DOI 10.18632/aging.101469
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Lan YY, 2019, AGING CELL, V18, DOI 10.1111/acel.12901
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315
   McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401
   Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967
   Philipot D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4494
   Price AL, 2004, GENOME RES, V14, P2245, DOI 10.1101/gr.2693004
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Sawicka M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053313
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   SINNETT D, 1991, J BIOL CHEM, V266, P8675
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Takahashi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03555-8
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114
   Yin YL, 2017, INT J BIOCHEM CELL B, V84, P22, DOI 10.1016/j.biocel.2017.01.001
NR 43
TC 5
Z9 6
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2020
VL 9
IS 8
AR 1
DI 10.1167/tvst.9.8.1
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MY9JT
UT WOS:000558736500002
PM 32855848
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kokame, GT
   Shantha, JG
   Hirai, K
   Ayabe, J
AF Kokame, Gregg T.
   Shantha, Jessica G.
   Hirai, Kelsi
   Ayabe, Julia
TI En Face Spectral-Domain Optical Coherence Tomography for the Diagnosis
   and Evaluation of Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; FEATURES; RANIBIZUMAB; THERAPY; EVEREST
AB BACKGROUND AND OBJECTIVE: To evaluate the diagnostic capability of en face spectral-domain optical coherence tomography (SD-OCT) in patients with polypoidal choroidal vasculopathy (PCV) diagnosed by indocyanine green angiography (ICGA).
   PATIENTS AND METHODS: A retrospective, consecutive case series of 100 eyes diagnosed with PCV by ICGA were imaged with en face SD-OCT. Evaluation of the PCV complex on en face SD-OCT was performed on the ability to diagnose PCV by the characteristic configuration of the PCV complex and the extent and size of the PCV lesion.
   RESULTS: The PCV complex was better visualized on ICGA in 45 eyes, on en face SD-OCT in 44 eyes, and equally well in 11 eyes. The extent of the PCV complex was larger on en face SD-OCT in 65 eyes, larger on ICGA in 23 eyes, and equal in size in 12 eyes.
   CONCLUSION: En face SD-OCT images the characteristic findings of PCV and provides a noninvasive way to diagnose and treat PCV when ICGA is not available.
C1 [Kokame, Gregg T.] Univ Hawaii, Sch Med, Div Ophthalmol, Dept Surg, Honolulu, HI 96822 USA.
   [Kokame, Gregg T.; Shantha, Jessica G.] Retina Ctr Pali Momi, Aiea, HI USA.
   [Kokame, Gregg T.; Shantha, Jessica G.] Retina Consultants Hawaii, Honolulu, HI USA.
   [Kokame, Gregg T.; Shantha, Jessica G.] Hawaii Macula & Retina Inst, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
   [Hirai, Kelsi; Ayabe, Julia] Univ Hawaii, John A Burns Sch Med, Sch Med, Honolulu, HI 96822 USA.
C3 University of Hawaii System; University of Hawaii System
RP Kokame, GT (通讯作者)，Hawaii Macula & Retina Inst, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
FU Bayer and Regeneron; Zeiss; Bausch + Lomb; Allergan; Santen
FX Dr. Kokame has received speaker and consulting fees from Bayer and
   Regeneron, as well as consultant fees from Zeiss, Bausch + Lomb,
   Allergan, and Santen. The remaining authors report no relevant financial
   disclosures.
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Semoun O, 2015, BR J OPHTHALMOL, DOI [10.1136/bjophthalmol-2015-307494, DOI 10.1136/BJOPHTHALMOL-2015-307494]
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
NR 24
TC 7
Z9 7
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD AUG
PY 2016
VL 47
IS 8
BP 737
EP 744
DI 10.3928/23258160-20160808-07
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3GQ
UT WOS:000393101000007
PM 27548451
DA 2022-11-30
ER

PT J
AU Honda, S
   Miki, A
   Yanagisawa, S
   Matsumiya, W
   Nagai, T
   Tsukahara, Y
AF Honda, Shigeru
   Miki, Akiko
   Yanagisawa, Suiho
   Matsumiya, Wataru
   Nagai, Takayuki
   Tsukahara, Yasutomo
TI Comparison of the Outcomes of Photodynamic Therapy between Two
   Angiographic Subtypes of Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Photodynamic therapy; 12 months' outcome; Polypoidal choroidal
   vasculopathy; Indocyanine green angiography
ID FACTOR-H CFH; MACULAR DEGENERATION; VISUAL PROGNOSIS; LESION SIZE;
   ASSOCIATION; GENOTYPE; MULTICENTER; PHENOTYPE; FEATURES; HYOGO
AB Background: To compare the outcomes of photodynamic therapy (PDT) between two different angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: Ninety-three consecutive cases of PCV were classified into two phenotypes (42 type 1 and 51 type 2) according to the presence or absence of feeding vessels found on indocyanine green angiography. Full-dose PDT and retreatments were performed every 3 months as needed based on the findings on angiography. The best-corrected visual acuity (BCVA) was compared as the main outcome between type 1 and type 2 PCV up to 12 months after the initial PDT. Results: The baseline greatest linear dimension (GLD) was significantly larger in type 1 PCV than type 2 PCV. The mean BCVA was significantly improved from baseline in type 2 PCV, while no improvement was found in type 1 PCV. Analysis with matching the GLD between both PCV subtypes did not change the original results. Conclusions: There may be a significantly different response to PDT between two angiographic phenotypes of PCV. (C) 2014 S. Karger AG, Basel
C1 [Honda, Shigeru; Miki, Akiko; Yanagisawa, Suiho; Matsumiya, Wataru; Nagai, Takayuki; Tsukahara, Yasutomo] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
FU Ministry of Education, Science and Culture, Tokyo, Japan [23592567];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a grant-in-aid (C) 23592567 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (to S.H.), and
   by a grant from the Takeda Science Foundation, Osaka, Japan (to S.H.).
   The funding organization had no role in the design or conduct of this
   research.
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bessho H, 2011, MOL VIS, V17, P977
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 29
TC 17
Z9 18
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 232
IS 2
BP 92
EP 96
DI 10.1159/000360308
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO1LI
UT WOS:000341073200004
PM 24993059
DA 2022-11-30
ER

PT J
AU Pawloff, M
   Bogunovic, H
   Gruber, A
   Michl, M
   Riedl, S
   Schmidt-Erfurth, U
AF Pawloff, Maximilian
   Bogunovic, Hrvoje
   Gruber, Anastasiia
   Michl, Martin
   Riedl, Sophie
   Schmidt-Erfurth, Ursula
TI SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID
   VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR
   DISEASES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AI; CRT; CSFT; deep learning; DME; IRF; nAMD; retinal thickness; RVO;
   SRF
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT; SUBRETINAL
   FLUID; VISUAL-ACUITY; RANIBIZUMAB; DEGENERATION; OUTCOMES; THERAPY;
   REGIMEN; EDEMA
AB Purpose: To investigate the correlation of volumetric measurements of intraretinal (IRF) and subretinal fluid obtained by deep learning and central retinal subfield thickness (CSFT) based on optical coherence tomography in retinal vein occlusion, diabetic macular edema, and neovascular age-related macular degeneration. Methods: A previously validated deep learning-based approach was used for automated segmentation of IRF and subretinal fluid in spectral domain optical coherence tomography images. Optical coherence tomography volumes of 2.433 patients obtained from multicenter studies were analyzed. Fluid volumes were measured at baseline and under antivascular endothelial growth factor therapy in the central 1, 3, and 6 mm. Results: Patients with neovascular age-related macular degeneration generally demonstrated the weakest association between CSFT and fluid volume measurements in the central 1 mm (0.107-0.569). In patients with diabetic macular edema, IRF correlated moderately with CSFT (0.668-0.797). In patients with retinal vein occlusion, IRF volumes showed a moderate correlation with CSFT (0.603-0.704). Conclusion: The correlation of CSFT and fluid volumes depends on the underlying pathology. Although the amount of central IRF seems to partly drive CSFT in diabetic macular edema and retinal vein occlusion, it has only a limited impact on patients with neovascular age-related macular degeneration. Our findings do not support the use of CSFT as a primary or secondary outcome measure for the quantification of exudative activity or treatment guidance.
C1 [Pawloff, Maximilian; Bogunovic, Hrvoje; Michl, Martin; Riedl, Sophie; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
   [Gruber, Anastasiia] Med Univ Vienna, Dept Stat, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM maximilian.pawloff@meduniwien.ac.at; hrvoje.bogunovic@meduniwien.ac.at;
   anastasiia.gruber@meduniwien.ac.at; Martin.michl@meduniwien.ac.at;
   sophie.riedl@meduniwien.ac.at; ursula.schmidt-erfurth@meduniwien.ac.at
CR Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Bressler NM, 2018, JAMA OPHTHALMOL, V136, P257, DOI 10.1001/jamaophthalmol.2017.6565
   Browning DJ, 2008, OPHTHALMOLOGY, V115, P1366, DOI 10.1016/j.ophtha.2007.12.004
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Deak GG, 2018, JAMA OPHTHALMOL, V136, P1215, DOI 10.1001/jamaophthalmol.2018.3848
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gerendas BS, 2018, BRIT J OPHTHALMOL, V102, P195, DOI 10.1136/bjophthalmol-2017-310483
   Hawkes N, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3275
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Joltikov KA, 2017, INVEST OPHTH VIS SCI, V58, P277, DOI 10.1167/iovs.17-21863
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Maturi RK, 2018, JAMA OPHTHALMOL, V136, P29, DOI 10.1001/jamaophthalmol.2017.4914
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma A, 2020, RETINA-J RET VIT DIS, V40, P1451, DOI 10.1097/IAE.0000000000002870
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Song PG, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010427
   Tadayoni R, 2017, OPHTHALMOLOGY, V124, P1778, DOI 10.1016/j.ophtha.2017.06.027
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
NR 30
TC 3
Z9 3
U1 3
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2022
VL 42
IS 5
BP 831
EP 841
DI 10.1097/IAE.0000000000003385
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0U0LT
UT WOS:000787351800004
PM 34934034
DA 2022-11-30
ER

PT J
AU Yeong, JL
   Loveman, E
   Colquitt, JL
   Royle, P
   Waugh, N
   Lois, N
AF Yeong, Jian Lee
   Loveman, Emma
   Colquitt, Jill L.
   Royle, Pamela
   Waugh, Norman
   Lois, Noemi
TI Visual cycle modulators versus placebo or observation for the prevention
   and treatment of geographic atrophy due to age-related macular
   degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID EMIXUSTAT HYDROCHLORIDE
AB Background
   Age-related macular degeneration (AMD) is a highly prevalent condition in an ever-increasing elderly population. Although insidious in the early stages, advanced AMD (neovascular and atrophic forms) can cause significant visual disability and economic burden on health systems worldwide. The most common form, geographic atrophy, has no effective treatment to date, whereas neovascular AMD can be treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Geographic atrophy has a slow disease progression and patients tend to have preserved central vision until the final stages. This tendency, coupled with the use of modern imaging modalities, provides a large window of opportunity to intervene with validated methods to assess treatment efficacy. As geographic atrophy is an increasingly common condition with no effective intervention, many treatments are under investigation, one of which is visual cycle modulators. These medications have been shown to reduce lipofuscin accumulation in pre-clinical studies that have led to several clinical trials, reviewed herein.
   Objectives
   To assess the efficacy and safety of visual cycle modulators for the prevention and treatment of geographic atrophy secondary to AMD.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2020, Issue 1); MEDLINE Ovid; Embase Ovid; Web of Science Core Collection; Scopus; Association for Research in Vision and Ophthalmology (ARVO) website; ClinicalTrials.gov and the WHO ICTRP to 11 January 2020 with no language restrictions. We also searched using the reference lists of reviews and existing studies and the Cited Reference Search function in Web of Science to identify further relevant studies.
   Selection criteria
   We included randomised controlled trials (RCTs) and quasi-randomised clinical studies (if available) that compared visual cycle modulators to placebo or no treatment (observation) in people diagnosed with AMD (early, intermediate or geographic atrophy).
   Data collection and analysis
   Two authors independently assessed risk of bias in the included studies and extracted data. Both authors entered data into RevMan 5. We resolved discrepancies through discussion. We graded the certainty of the evidence using the GRADE approach.
   Main results
   We included three RCTs from the USA; one of these had clinical sites in Germany. Two studies compared emixustat to placebo while the other compared fenretinide to placebo. All assigned one study eye per participant and, combined, have a total of 821 participants with a majority white ethnicity (97.6%). All participants were diagnosed with geographic atrophy due to AMD based on validated imaging modalities. All three studies have high risk of attrition bias mainly due to ocular adverse effects of emixustat and fenretinide. We considered only one study to be adequately conducted and reported with high risk of bias in only one domain (attrition bias). We considered the other two studies to be poorly reported and to have high risk of attrition bias and reporting bias.
   People with geographic atrophy treated with emixustat may not experience a clinically important change in best-corrected visual acuity (BCVA) between baseline and 24 months compared to people treated with placebo (mean difference (MD) 1.9 Early Treatment Diabetic Retinopathy Study (ETDRS) Eaters, 95% confidence interval (CI) -2.34 to 6.14, low-certainty evidence). Emixustat may also result in little or no difference in loss of 15 ETDRS letters or more of BCVA compared with placebo at 24 months (16.4% versus 18%) (risk ratio (RR) 0.91, 95% CI 0.59 to 1.4, low-certainty evidence). In terms of disease progression, emixustat may result in little or no difference in the annual growth rate of geographic atrophy compared with placebo (mean difference MD 0.09 mm(2)/year (95% CI -0.26 to 0.44, low-certainty evidence).
   All three studies reported adverse events of both drugs (emixustat: moderate-certainty evidence; fenretinide: low-certainty evidence). The main adverse events were ocular in nature and associated with the mechanism of action of the drugs. Delayed dark adaptation (emixustat: 54.5%; fenretinide: 39.3%) and chromatopsia (emixustat: 22.6%; fenretinide: 25.2%) were the most common adverse events reported, and were the most prevalent reasons for study dropout in emixustat trials. These effects were dose-dependent and resolved after drug cessation. No specific systemic adverse events were considered related to emixustat; only pruritus and rash were considered to be due to fenretinide. One emixustat study reported six deaths, none deemed related to the drug.
   None of the included RCTs reported the other pre-specified outcomes, including proportion of participants losing 10 letters or more, and mean change in macular sensitivity. We planned to investigate progression to advanced AMD (geographic atrophy or neovascular AMD) in prevention studies, including participants with early or intermediate AMD, but we identified no such studies.
   Two of the included studies reported an additional outcome - incidence of choroidal neovascularisation (CNV) - that was not in our published protocol. CNV onset may be reduced in those treated with emixustat but the evidence was uncertain (risk ratio (RR) 0.67, 95% CI 0.27 to 1.65, low-certainty evidence), or fenretinide (RR 0.5, 95% CI 0.26 to 0.98, low-certainty evidence) compared to placebo. A dose dependent relationship was observed with emixustat.
   Authors' conclusions
   There is limited evidence to support the use of visual cycle modulators (emixustat and fenretinide) for the treatment of established geographic atrophy due to AMD. The possible reduction in the incidence of CNV observed with fenretinide, and to a lesser extent, emixustat, requires formal assessment in focused studies.
C1 [Yeong, Jian Lee] Royal Victoria Hosp, Belfast & Social Care Trust, Belfast, Antrim, North Ireland.
   [Loveman, Emma; Colquitt, Jill L.] Effect Evidence LLP, Waterlooville, England.
   [Royle, Pamela] Univ Warwick, Warwick Med Sch, Hlth Sci Res Inst, Warwick Evidence, Coventry, W Midlands, England.
   [Waugh, Norman] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry, W Midlands, England.
   [Lois, Noemi] Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
C3 University of Warwick; University of Warwick; Queens University Belfast
RP Lois, N (通讯作者)，Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
EM n.lois@qub.ac.uk
CR Boman N., 2010, RETINA TODAY, P76
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Holz F, 2016, OPHTHALMOLOGICA, V236, P4
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
NR 4
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2020
IS 12
AR CD013154
DI 10.1002/14651858.CD013154.pub2
PG 49
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PO0TJ
UT WOS:000604884100009
PM 33331670
OA Green Published
DA 2022-11-30
ER

PT J
AU St Martin, JM
   Rodman, J
   Pizzimenti, JJ
   Duchnowski, E
AF St Martin, Jamie M.
   Rodman, Julie
   Pizzimenti, Joseph J.
   Duchnowski, Eva
TI The "Double-Layer Sign": In Vivo Imaging of Polypoidal Choroidal
   Vasculopathy
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE double-layer sign; polypoidal choroidal vasculopathy; indocyanine green
   angiography; serosanguineous; optical coherence tomography
ID FEATURES
AB Purpose. Polypoidal choroidal vasculopathy (PCV), a disease of the choroidal vascular network, presents clinically with polyp-like reddish orange lesions, as well as retinal pigment epithelial (RPE) and/or neurosensory retinal detachments. Optical coherence tomography (OCT) is a useful diagnostic tool that provides cross-sectional and volumetric imaging of posterior segment microstructure. Typical OCT findings in PCV may reveal a classic hyperreflectivity in the choroidal layers known as the "double-layer" sign. This sign is indicative of an abnormal choroidal vascular network. Indocyanine green angiography is also useful for the diagnosis of PCV and clearly identifies the polyp-like lesions arising from the choroidal vasculature.
   Case Report. A 53-year-old African American woman presented with complaints of gradually decreasing vision in the left eye (OS). Clinical examination revealed moderately reduced acuity OS with a small central scotoma found on Amsler grid testing. Dilated fundus examination revealed a hemorrhagic RPE detachment with suspicion of a choroidal neovascular membrane in the foveal region of the OS. Exudative leakage appeared circumferentially around the macula OS. Optical coherence tomography of the OS also revealed two highly reflective layers: one at the level of the RPE and another beneath the RPE ("double-layer" sign). The patient was referred to a retina subspecialist for angiography and treatment consideration.
   Conclusions. It is important to distinguish PCV from other variants of choroidal neovascularization. The polyp-like lesions found in the PCV are a unique and classic characteristic. Proper diagnostic workup includes stereoscopic posterior fundus evaluation and imaging studies, including OCT and indocyanine green angiography.
C1 [St Martin, Jamie M.; Rodman, Julie; Pizzimenti, Joseph J.; Duchnowski, Eva] Nova SE Univ, Ft Lauderdale, FL 33328 USA.
C3 Nova Southeastern University
RP St Martin, JM (通讯作者)，Nova SE Univ, 3200 S Univ Dr, Ft Lauderdale, FL 33328 USA.
EM jstmartin12@yahoo.com
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Besada E, 2012, CLIN REFRACT OPTOM, V5, P160
   Chan WM, 2010, HKJ OPHTHALMOLOGY, V14, P14
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lai TY, 2010, INVEST OPHTH VIS SCI, V51
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   McCleary Christa D, 2004, Optometry, V75, P756, DOI 10.1016/S1529-1839(04)70235-3
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 1982, MAC SOC M MIAM FLOR
   Zeng RP, 2013, MOL VIS, V19, P729
NR 21
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD DEC
PY 2013
VL 90
IS 12
BP E293
EP E300
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 298UO
UT WOS:000330350200001
PM 24162896
DA 2022-11-30
ER

PT J
AU Gu, XY
   Yu, XB
   Dai, H
AF Gu, Xiaoya
   Yu, Xiaobing
   Dai, Hong
TI Therapeutic effects of ranibizumab in patients with polypoidal choroidal
   vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; Photodynamic therapy; Polypoidal choroidal vasculopathy
ID VERTEPORFIN PHOTODYNAMIC THERAPY; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL
   GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; NEOVASCULAR MEMBRANES; MACULAR
   DEGENERATION; EFFICACY; BEVACIZUMAB; INJECTIONS; EXPRESSION
AB Background: There is no consensus on the optimal initial treatment for polypoidal choroidal vasculopathy (PCV). Our study aimed to report the efficacy of repeated injections of intravitreal ranibizumab with or without photodynamic therapy for the treatment of PCV and to determine the possible factors predictive of visual outcomes.
   Methods: The results of the initial treatment of 40 patients with PCV with 3 monthly injections of ranibizumab were retrospectively reviewed. We compared the results in terms of the best corrected visual acuity (BCVA), the central retinal thickness (CRT), the number of injections, the regression rates of polyps and the rates of the reduction of subretinal fluid.
   Results: At the 3-month follow-up, the mean BCVA was significantly increased by 7.312.4 letters compared to baseline (p<0.01). At the 12-month follow-up, the mean BCVA was increased by 3.4 +/- 15.4 letters compared to baseline, and there was no significant difference (p>0.05). The mean CRT at the 12-month follow-up was 593.58 +/- 243.64 mu m, with an average decrease of 101.55 +/- 256.07 mu m compared to baseline (p<0.01). Fifteen eyes (18.8%) showed the complete regression of polyps, and 22 eyes (27.5%) showed a reduction in polyps. The baseline VA, the reduction in subretinal fluids and the greatest lesion diameter were significant independent factors that were predictive of improved VA at the final follow-up.
   Conclusions: Three monthly injections of ranibizumab as an initial treatment could significantly improve VA in PCV patients in the short term. At 12 months postinjection, ranibizumab treatment could stabilize VA in most PCV patients. The baseline VA, the reduction in subretinal fluids and the greatest lesion diameter were predictive factors for the relative improvement of VA at the final follow-up.
C1 [Gu, Xiaoya; Yu, Xiaobing; Dai, Hong] Beijing Hosp, Natl Ctr Gerontol, Dept Ophthalmol, 1 Dahua Rd, Beijing, Peoples R China.
C3 Beijing Hospital
RP Dai, H (通讯作者)，Beijing Hosp, Natl Ctr Gerontol, Dept Ophthalmol, 1 Dahua Rd, Beijing, Peoples R China.
EM dai-hong@x263.net
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kim Jae Hui, 2015, Korean J Ophthalmol, V29, P404, DOI 10.3341/kjo.2015.29.6.404
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 34
TC 4
Z9 4
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 19
PY 2019
VL 19
AR 153
DI 10.1186/s12886-019-1156-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IK3NE
UT WOS:000476494900003
PM 31324161
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kang, HM
   Kim, YM
   Koh, HJ
AF Kang, Hae Min
   Kim, Yong Min
   Koh, Hyoung Jun
TI Five-Year Follow-up Results of Photodynamic Therapy for Polypoidal
   Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN;
   NEOVASCULARIZATION; EFFICACY; RANIBIZUMAB
AB PURPOSE: To. evaluate the 5-year efficacy of photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective study.
   METHODS: Forty-two eyes of 36 patients with PCV followed up for at least 60 months after PDT were reviewed. All eyes were primarily treated with PDT. Main outcome measure was best-corrected visual acuity (BCVA; logMAR [logarithm of minimal angle of resolution]) at baseline and at each follow-up visit. We also classified the eyes into 3 groups: improved (improvement >= 0.3 logMAR), decreased (deterioration >= 0.3 logMAR), and stable.
   RESULTS: During the mean follow-up duration, 73.64 +/- 13.47 months, the mean number of PDT was 2.21 +/- 1.62 treatments. Recurrence was noted in 33 eyes (78.6%) during follow-up. The mean baseline BCVA was 0.78 +/- 0.48 logMAR (20/120 Snellen equivalent), and the final BCVA at 60 months was 0.67 +/- 0.52 logMAR (20/93 Snellen equivalent) (P = .050, paired t test). On the final evaluation at 60 months, the mean BCVA was improved in 14 eyes (33.3%), stable in 23 eyes (54.8%), and decreased in 5 eyes (11.9%).
   CONCLUSION: At 60 months after initial PDT, 88.1% of PCV patients showed stable or improved BCVA after PDT. Despite a high recurrence rate, PDT remained effective for 5 years, and represents a good therapeutic approach to PCV. (Am J Ophthalmol 2013;155:438-447. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Kang, Hae Min; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120749, South Korea.
   [Kim, Yong Min] Siloam Eye Hosp, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120749, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
FU QLT; Lux Biosciences; Allergan; Physician Recommended Nutriceuticals
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Dr Garg is a paid consultant for QLT
   and Lux Biosciences, and receives lecture fees from Allergan. Dr Fineman
   is a paid consultant for, and holds stock or stock options with,
   Physician Recommended Nutriceuticals. The authors indicate no funding
   support. Contributions of authors: involved in design and conduct
   (P.S.B., S.J.G.); collection, management, analysis, and interpretation
   (P.S.B., S.J.G., M.S.F., J.B., G.C.B., A.C., R.A.A.); and preparation,
   review, or approval of the article (P.S.B., S.J.G., M.S.F., J.B.,
   G.C.B., A.C., R.A.A.).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Eong KGA, 2006, ANN ACAD MED SINGAP, V35, P133
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2011, SINGAP MED J, V52, P232
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 30
Z9 33
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2013
VL 155
IS 3
BP 438
EP 447
DI 10.1016/j.ajo.2012.09.020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 096TA
UT WOS:000315426000005
PM 23218705
DA 2022-11-30
ER

PT J
AU Pak, KY
   Park, SW
   Byon, IS
   Lee, JE
AF Pak, Kang Yeun
   Park, Sung Who
   Byon, Ik Soo
   Lee, Ji Eun
TI TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL
   VASCULOPATHY One-Year Results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; treat-and-extend
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION
AB Purpose: To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV).
   Methods: We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose $ 3 best-corrected visual acuity (BCVA) lines. The number of intravitreal injections and recurrences as well as the maximum treatment interval without recurrence were analyzed.
   Results: The mean BCVA improved from 0.64 +/- 0.42 logMAR (median, 20/80) at baseline to 0.30 +/- 0.31 logMAR (median, 20/30) at 12 months (P < 0.001). The mean central subfield macular thickness improved from 307.0 +/- 70.2 mu m to 237.5 +/- 64.4 mu m (P < 0.001). None of the subjects lost $ 3 lines, and 15 (51.7%) gained >= 3 lines. The mean number of injections was 7.0. The mean maximum treatment interval without recurrence was 10.0 weeks. After the loading phase, 12 eyes (41.4%) showed no recurrence. Seven eyes (24.1%) demonstrated disease activity at 12 months, and 4 (13.8%) of them were never dry during the entire 12-month follow-up duration.
   Conclusion: The TER effectively improved visual acuity in PCV while reducing the number of injections.
C1 [Pak, Kang Yeun; Park, Sung Who; Byon, Ik Soo; Lee, Ji Eun] Pusan Natl Univ, Sch Med, Dept Ophthalmol, Yangsan, South Korea.
   [Pak, Kang Yeun; Park, Sung Who; Lee, Ji Eun] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea.
   [Byon, Ik Soo] Pusan Natl Univ, Yangsan Hosp, Res Inst Convergence Biomed Sci & Technol, Yangsan, South Korea.
C3 Pusan National University; Pusan National University Hospital; Pusan
   National University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital
RP Lee, JE (通讯作者)，Pusan Natl Univ Hosp, Ami Dong 1-10, Busan 49241, South Korea.
EM jlee@pusan.ac.kr
OI Byon, Iksoo/0000-0002-2638-8192
FU Bayer
FX J. E. Lee: Research fund from Bayer, and Consultation and honorarium
   from Novartis, Bayer, and Allergan. The other authors have no
   financial/conflicting interests to disclose.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stone TW, 2014, 2014 PREFERENCES TRE
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 13
Z9 13
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2017
VL 37
IS 3
BP 561
EP 567
DI 10.1097/IAE.0000000000001195
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ3QM
UT WOS:000397987600030
PM 27454224
DA 2022-11-30
ER

PT J
AU Siu, AL
   Bibbins-Domingo, K
   Grossman, DC
   Baumann, LC
   Davidson, KW
   Ebell, M
   Garcia, FAR
   Gillman, M
   Herzstein, J
   Kemper, AR
   Krist, AH
   Kurth, AE
   Owens, DK
   Phillips, WR
   Phipps, MG
   Pignone, MP
AF Siu, Albert L.
   Bibbins-Domingo, Kirsten
   Grossman, David C.
   Baumann, Linda Ciofu
   Davidson, Karina W.
   Ebell, Mark
   Garcia, Francisco A. R.
   Gillman, Matthew
   Herzstein, Jessica
   Kemper, Alex R.
   Krist, Alex H.
   Kurth, Ann E.
   Owens, Douglas K.
   Phillips, William R.
   Phipps, Maureen G.
   Pignone, Michael P.
CA USPSTF
TI Screening for Impaired Visual Acuity in Older Adults US Preventive
   Services Task Force Recommendation Statement
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID INTRAOCULAR-LENS IMPLANTATION; RANDOMIZED CONTROLLED-TRIAL; EYE
   CATARACT-SURGERY; MACULAR DEGENERATION; UNITED-STATES; CONTRAST
   SENSITIVITY; HEALTH-STATUS; PEOPLE; FALLS; RISK
AB DESCRIPTION Update of the US Preventive Services Task Force (USPSTF) recommendation on screening for impaired visual acuity in older adults.
   METHODS The USPSTF reviewed the evidence on screening for visual acuity impairment associated with uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in the primary care setting; the benefits and harms of screening; the accuracy of screening; and the benefits and harms of treatment of early vision impairment due to uncorrected refractive error, cataracts, and age-related macular degeneration.
   POPULATION This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care clinician with vision problems.
   RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement)
C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA.
   [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA.
   [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI 53706 USA.
   [Davidson, Karina W.] Columbia Univ, New York, NY USA.
   [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA.
   [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA.
   [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA.
   [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
   [Kemper, Alex R.] Duke Univ, Durham, NC USA.
   [Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA.
   [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
   [Kurth, Ann E.] NYU, New York, NY USA.
   [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA.
   [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA.
   [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA.
   [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA.
C3 Icahn School of Medicine at Mount Sinai; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); James J. Peters VA
   Medical Center; University of California System; University of
   California San Francisco; University of Wisconsin System; University of
   Wisconsin Madison; Columbia University; University System of Georgia;
   University of Georgia; Harvard University; Harvard Medical School;
   Harvard Pilgrim Health Care; Duke University; Virginia Commonwealth
   University; New York University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Palo Alto Health Care System;
   Stanford University; University of Washington; University of Washington
   Seattle; Brown University; University of North Carolina; University of
   North Carolina Chapel Hill
RP Siu, AL (通讯作者)，Mt Sinai Sch Med, New York, NY USA.; Siu, AL (通讯作者)，James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
EM chair@uspstf.net
RI Davidson, Karina/GWC-0996-2022; Davidson, Karina/AAG-2388-2019;
   Phillips, William R./V-1065-2017
OI Davidson, Karina/0000-0002-9162-477X; Davidson,
   Karina/0000-0002-9162-477X; Phillips, William R./0000-0003-2802-4349;
   Kemper, Alex/0000-0001-5491-3997
FU Agency for Healthcare Research and Quality (AHRQ)
FX The USPSTF is an independent, voluntary body. The US Congress mandates
   that the Agency for Healthcare Research and Quality (AHRQ) support the
   operations of the USPSTF.
CR American Academy of Family Physicians, CLIN PREV SERV REC V
   [Anonymous], AG 65 YEARS OLD HLTH
   [Anonymous], AD VIS 19 40 YEARS A
   Centers for Disease Control and Prevention, IMPR NAT VIS HLTH CO
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chou R, 2016, AHRQ PUBLICATION
   Chou R., 2009, AHRQ PUBLICATION
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Eekhof JAH, 2000, FAM PRACT, V17, P329, DOI 10.1093/fampra/17.4.329
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Foss AJE, 2006, AGE AGEING, V35, P66, DOI 10.1093/ageing/afj005
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478
   Jessa Z, 2012, OPHTHAL PHYSL OPT, V32, P332, DOI 10.1111/j.1475-1313.2012.00919.x
   Lord SR, 2002, J AM GERIATR SOC, V50, P1760, DOI 10.1046/j.1532-5415.2002.50502.x
   Lum F, 2016, OPHTHALMOLOGY, V123, P928, DOI [10.1016/j.ophtha.2016.01.024, 10.1016/j.ophtha.2015.10.047]
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2
   MURRAY A, 2005, SYSTEMATIC REV SAFET
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P228, DOI 10.1001/archopht.1994.01090140104032
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3
   Smeeth L, 2003, BMJ-BRIT MED J, V327, P1027
   Swanson MW, 2009, J AM GERIATR SOC, V57, P486, DOI 10.1111/j.1532-5415.2008.02144.x
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Zhang XZ, 2007, ARCH OPHTHALMOL-CHIC, V125, P411, DOI 10.1001/archopht.125.3.411
NR 31
TC 27
Z9 27
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 1
PY 2016
VL 315
IS 9
BP 908
EP 914
DI 10.1001/jama.2016.0763
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DF1DB
UT WOS:000371077500021
PM 26934260
OA Bronze
DA 2022-11-30
ER

PT J
AU Tamura, H
   Tsujikawa, A
   Otani, A
   Gotoh, N
   Sasahara, M
   Kameda, T
   Iwama, D
   Yodoi, Y
   Mandai, M
   Yoshimura, N
AF Tamura, Hiroshi
   Tsujikawa, Akitaka
   Otani, Atsushi
   Gotoh, Norimoto
   Sasahara, Manabu
   Kameda, Takanori
   Iwama, Daisuke
   Yodoi, Yuko
   Mandai, Michiko
   Yoshimura, Nagahisa
TI Polypoidal choroidal vasculopathy appearing as classic choroidal
   neovascularisation on fluorescein angiography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; VERTEPORFIN; MEMBRANES; FEATURES
AB Aims: To study the visual prognosis and ocular characteristics of eyes with polypoidal choroidal vasculopathy (PCV) that appear to have classic choroidal neovascularisation (CNV) on fluorescein angiography (FA).
   Methods: The authors reviewed retrospectively 38 eyes with PCV that appear to have classic CNV on FA. Lesions were examined with indocyanine green angiography, FA and optical coherence tomography (OCT).
   Results: In all cases OCT showed subretinal material with moderate reflectivity that corresponded in location to classic CNV. At the final visit, the subretinal material resolved completely in 14 eyes (36.8%, resolved group), but resolved only incompletely in 24 eyes (63.2%, persisted group) after photodynamic therapy (PDT). Mean ( standard deviation) visual acuity in the resolved group (0.35 (0.41) in log MAR) was significantly better than that in the persisted group (0.84 (0.24)) at the final visit ( p < 0.001). The subretinal material seen before treatment was more frequently seen in subfovea in the persisted group (87.5% vs 42.9%, p = 0.007). Also, this material was located adjacent to polypoidal lesions more often in the resolved group (92.9% vs 58.3%, p = 0.030).
   Conclusions: Eyes with PCV sometimes show classic CNV with subretinal material apparent on OCT, and PCV is thus attributed to type 2 CNV or to pure fibrinous tissue without CNV. Visual prognosis in eyes with type 2 CNV is poor, and although it is difficult to discriminate type 2 CNV from pure fibrin deposition before treatment, type 2 CNV is seen more often in the subfovea and is typically separate from the polypoidal lesions.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tamura, H (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Shogoin Kawahra Cho 54 Sakyo, Kyoto 6068507, Japan.
RI Mandai, Michiko/E-7986-2011; TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Iida T, 2000, AM J OPHTHALMOL, V129, P16, DOI 10.1016/S0002-9394(99)00272-X
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   OTSUJI T, 2006, J JPN OPHTHALMOL SOC, V110, P454
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 29
TC 38
Z9 44
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2007
VL 91
IS 9
BP 1152
EP 1159
DI 10.1136/bjo.2006.112318
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202EN
UT WOS:000248884900019
PM 17314148
OA Green Published
DA 2022-11-30
ER

PT J
AU Koh, A
   Lee, WK
   Chen, LJ
   Chen, SJ
   Hashad, Y
   Kim, H
   Lai, TY
   Pilz, S
   Ruamviboonsuk, P
   Tokaji, E
   Weisberger, A
   Lim, TH
AF Koh, Adrian
   Lee, Won Ki
   Chen, Lee-Jen
   Chen, Shih-Jen
   Hashad, Yehia
   Kim, Hakyoung
   Lai, Timothy Y.
   Pilz, Stefan
   Ruamviboonsuk, Paisan
   Tokaji, Erika
   Weisberger, Annemarie
   Lim, Tock H.
TI EVEREST STUDY Efficacy and Safety of Verteporfin Photodynamic Therapy in
   Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in
   Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE angio-occlusion; confocal scanning laser ophthalmoscope; indocyanine
   green angiography; polypoidal choroidal vasculopathy; polyp regression;
   ranibizumab; verteporfin PDT
ID INTRAVITREAL BEVACIZUMAB; SUBMACULAR HEMORRHAGE; JAPANESE PATIENTS;
   DEGENERATION; NEOVASCULARIZATION; OUTCOMES
AB Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
   Methods: In this multicenter, double-masked, primarily indocyanine green angiography-guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3-5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography-assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety.
   Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%;P < 0.01); mean change +/- standard deviation in best-corrected visual acuity (letters) was 10.9 +/- 10.9 (verteporfin PDT + ranibizumab), 7.5 +/- 10.6 (verteporfin PDT), and 9.2 +/- 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination.
   Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months.
C1 [Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul 137701, South Korea.
   [Koh, Adrian] Camden Med Ctr, Eye & Retina Surg Clin, Singapore, Singapore.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Hashad, Yehia] Allergan Pharmaceut Inc, Clin Res & Dev, Retina, Irvine, CA 92715 USA.
   [Kim, Hakyoung] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lai, Timothy Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Pilz, Stefan; Tokaji, Erika] Novartis Pharma AG, Basel, Switzerland.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Weisberger, Annemarie] Novartis Pharmaceut, E Hanover, NJ USA.
   [Lim, Tock H.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Mackay Memorial
   Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao
   Tung University; AbbVie; Allergan; Hallym University; Chinese University
   of Hong Kong; Novartis; Rajavithi Hospital; Novartis; Tan Tock Seng
   Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
RI Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 413
Z9 441
U1 6
U2 38
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2012
VL 32
IS 8
BP 1453
EP 1464
DI 10.1097/IAE.0b013e31824f91e8
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004HN
UT WOS:000308672300004
PM 22426346
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Tisi, A
   Passacantando, M
   Ciancaglini, M
   Maccarone, R
AF Tisi, A.
   Passacantando, M.
   Ciancaglini, M.
   Maccarone, R.
TI Nanoceria neuroprotective effects in the light-damaged retina: A focus
   on retinal function and microglia activation
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Cerium oxide nanoparticles; Oxidative stress; Macular degeneration;
   Light damage; Electroretinogram; Microglia
ID CERIUM OXIDE NANOPARTICLES; OXIDATIVE STRESS; PHOTORECEPTOR
   DEGENERATION; INTRAVITREAL INJECTION; TUBBY MICE; AGE; INFLAMMATION;
   MECHANISMS; EXPOSURE; IMPACT
AB The use of nanomaterials is an emerging therapeutic approach for the treatment of several pathologies. Cerium oxide nanoparticles have been studied for biomedical application, including neurodegenerative disorders, such as age-related macular degeneration in several animal models. The light damage model is characterised by oxidative stress upregulation followed by photoreceptor death and microglia activation in the outer retina. For this reason, the light damage model mimics some aspects involved in human age-related macular degeneration pathogenesis. In this review, we focus on the neuroprotective effects on retinal function and microglia activation in the light damage model, considering the administration of the nanoparticles both before and after the injury. The electrical responses of the retina and the microglia number and morphology are clearly modulated by the treatment, supporting the beneficial effects of cerium oxide nanoparticles to counteract the degeneration processes in the retina.
C1 [Tisi, A.; Maccarone, R.] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
   [Passacantando, M.] Univ Aquila, Dept Phys & Chem Sci, Via Vetoio,Coppito 1, I-67100 Laquila, Italy.
   [Ciancaglini, M.] Univ Aquila, Dept Life Hlth & Environm Sci, Piazzale Salvatore Tommasi 1,Blocco 11, I-67100 Laquila, Italy.
C3 University of L'Aquila; University of L'Aquila; University of L'Aquila
RP Maccarone, R (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
EM annamaria.tisi@graduate.univaq.it;
   maurizio.passacantando@aquila.infn.it; marco.ciancaglini@cc.univaq.it;
   rita.maccarone@univaq.it
RI Nanozymes, Nanozymes/D-8197-2019
OI MACCARONE, Rita/0000-0003-0648-3771; Tisi,
   Annamaria/0000-0002-8592-2412; Ciancaglini, Marco/0000-0001-5888-7976
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai X, 2016, MOL VIS, V22, P1176
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Cai X, 2012, BIOMATERIALS, V33, P8771, DOI 10.1016/j.biomaterials.2012.08.030
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Das S, 2013, NANOMEDICINE-UK, V8, P1483, DOI [10.2217/NNM.13.133, 10.2217/nnm.13.133]
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fiorani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140387
   Forest V, 2017, TOXICOL IN VITRO, V38, P136, DOI 10.1016/j.tiv.2016.09.022
   Heckenlively J. R., 2006, PRINCIPLES PRACTICE, V2nd
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kong L, 2006, NEUROBIOL DIS, V21, P468, DOI 10.1016/j.nbd.2005.08.017
   Kong L, 2011, NEUROBIOL DIS, V42, P514, DOI 10.1016/j.nbd.2011.03.004
   Korsvik C, 2007, CHEM COMMUN, P1056, DOI 10.1039/b615134e
   Kumari M, 2014, MUTAGENESIS, V29, P467, DOI 10.1093/mutage/geu038
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   LaVail MM, 2018, EXP EYE RES, V167, P56, DOI 10.1016/j.exer.2017.10.023
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Lloyd RV, 1997, FREE RADICAL BIO MED, V22, P885, DOI 10.1016/S0891-5849(96)00432-7
   Marc RE, 2008, MOL VIS, V14, P782
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Montalban-Soler L, 2012, MOL VIS, V18, P675
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Park K, 2018, ARCH PHARM RES, V41, P1108, DOI 10.1007/s12272-018-1074-7
   Passacantando M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1785-0
   Portioli C, 2013, NANOSCI NANOTECH LET, V5, P1174, DOI 10.1166/nnl.2013.1715
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   Roberts LJ, 2009, J LIPID RES, V50, pS219, DOI 10.1194/jlr.R800037-JLR200
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Singh R, 2016, LANGMUIR, V32, P12202, DOI 10.1021/acs.langmuir.6b03022
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Tisi A, 2019, EXP EYE RES, V182, P30, DOI 10.1016/j.exer.2019.03.003
   Trovarelli A., 2013, CATALYTIC SCI SERIES, DOI [10.1142/p870, DOI 10.1142/P870]
   Tseng MT, 2012, TOXICOL APPL PHARM, V260, P173, DOI 10.1016/j.taap.2012.02.008
   Virlet B, 2011, LCTES 11: PROCEEDINGS OF THE ACM SIGPLAN/SIGBED 2011 CONFERENCE ON LANGUAGES, COMPILERS, TOOLS AND THEORY FOR EMBEDDED SYSTEMS, P1
   Wachtmeister L, 1998, PROG RETIN EYE RES, V17, P485, DOI 10.1016/S1350-9462(98)00006-8
   Walkey C, 2015, ENVIRON SCI-NANO, V2, P33, DOI 10.1039/c4en00138a
   Wong LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121977
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 50
TC 12
Z9 12
U1 2
U2 18
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2019
VL 188
AR 107797
DI 10.1016/j.exer.2019.107797
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JJ9XC
UT WOS:000494503700003
PM 31520599
DA 2022-11-30
ER

PT J
AU Au, A
   Gupta, O
AF Au, Angela
   Gupta, Omesh
TI The economics of telemedicine for vitreoretinal diseases
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE cost-effectiveness; macular degeneration; retinal disease and diabetic
   retinopathy; retinopathy of prematurity; telemedicine and
   teleophthalmology
ID COST-EFFECTIVENESS ANALYSIS; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   FUNDUS PHOTOGRAPHY; SCREENING-PROGRAM; PREMATURITY; OPHTHALMOSCOPY
AB Purpose of review
   A literature review was conducted presenting the current data on the economics of telemedicine in vitreoretinal diseases.
   Recent findings
   There have been an increasing number of studies evaluating the cost-effectiveness of telemedicine for vitreoretinal diseases. The availability of ophthalmologists able to screen for these conditions is limited. Teleophthalmology has been playing a larger role in screening for diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration. Many telemedicine programs are currently being investigated and implemented.
   Summary
   Telemedicine is a cost-effective means for screening diabetic retinopathy and retinopathy of prematurity. It can alleviate some of the burden of this growing public health problem. However, the large initial cost associated with beginning a teleophthalmology retinal screening program is a barrier to implementation. Additional studies are needed in the area of telemedicine for age-related macular degeneration.
C1 [Gupta, Omesh] Wills Eye Inst, Philadelphia, PA 19107 USA.
   [Au, Angela; Gupta, Omesh] Temple Univ Hosp & Med Sch, Dept Ophthalmol, Philadelphia, PA 19140 USA.
C3 Jefferson University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University
RP Gupta, O (通讯作者)，Wills Eye Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM ogupta@hotmail.com
CR [Anonymous], 2007, NATL DIABETES FACT S
   Aoki N, 2004, DIABETES CARE, V27, P1095, DOI 10.2337/diacare.27.5.1095
   Brown GC, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.4.e47
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Castillo-Riquelme MC, 2004, INT J TECHNOL ASSESS, V20, P201, DOI 10.1017/S0266462304000984
   Fleming AD, 2010, BRIT J OPHTHALMOL, V94, P1606, DOI 10.1136/bjo.2009.176784
   Gomez-Ulla F, 2008, TELEMED J E-HEALTH, V14, P912, DOI 10.1089/tmj.2008.0013
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jackson KM, 2008, ARCH OPHTHALMOL-CHIC, V126, P493, DOI 10.1001/archopht.126.4.493
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Maberley D, 2003, CAN MED ASSOC J, V168, P160
   Philip S, 2007, BRIT J OPHTHALMOL, V91, P1512, DOI 10.1136/bjo.2007.119453
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   *RET GROUP WA, 2010, RET GROUP WASH INTR
   Richter GM, 2009, SURV OPHTHALMOL, V54, P671, DOI 10.1016/j.survophthal.2009.02.020
   Scotland GS, 2007, BRIT J OPHTHALMOL, V91, P1518, DOI 10.1136/bjo.2007.120972
   Scotland GS, 2010, BRIT J OPHTHALMOL, V94, P712, DOI 10.1136/bjo.2008.151126
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Silva PS, 2009, CURR DIABETES REP, V9, P265, DOI 10.1007/s11892-009-0041-6
   Whited JD, 2005, TELEMED J E-HEALTH, V11, P641, DOI 10.1089/tmj.2005.11.641
   Whitten PS, 2002, BRIT MED J, V324, P1434, DOI 10.1136/bmj.324.7351.1434
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
NR 24
TC 32
Z9 32
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2011
VL 22
IS 3
BP 194
EP 198
DI 10.1097/ICU.0b013e3283459508
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YQ
UT WOS:000289508400010
PM 21460727
DA 2022-11-30
ER

PT J
AU Kokame, GT
   Yeung, L
   Teramoto, K
   Lai, JC
   Wee, R
AF Kokame, Gregg T.
   Yeung, Ling
   Teramoto, Kyla
   Lai, James C.
   Wee, Raymond
TI Polypoidal Choroidal Vasculopathy Exudation and Hemorrhage: Results of
   Monthly Ranibizumab Therapy at One Year
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Hemorrhage; Exudation
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL
   BEVACIZUMAB; NEOVASCULARIZATION; EFFICACY
AB Purpose: To evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and active exudation or hemorrhage. Methods: A prospective, single practice, open label trial of monthly intravitreal ranibizumab (0.5 mg) injections for PCV in 13 eyes of 13 patients who completed the 1-year study. The primary outcome measure was stabilization of vision (loss of <15 ETDRS letters). Secondary outcome measures included incidence of ocular and systemic adverse events, changes in subretinal hemorrhage, central foveal thickness, and polypoidal complexes on indocyanine green angiography at 1 year. Results: No patient lost >= 15 letters in visual acuity at 1 year. Three patients (23%) gained >= 15 letters at 12 months. Subretinal hemorrhage resolved in 9/9 eyes (100%). Macular edema improved in 5/5 eyes (100%). Subretinal fluid completely resolved in 4/9 eyes (44%), decreased in 2/9 eyes (22%), and increased in 3/9 eyes (33%). Polypoidal complexes decreased in 5/13 eyes (38%). Conclusion: Continuous monthly intravitreal ranibizumab decreases leakage and hemorrhage in eyes with exudative and hemorrhagic complications of PCV. Branching vascular networks persisted, and polypoidal complexes decreased in only 5/13 (38%) eyes with continuous antiangiogenic therapy at 1 year. (C) 2013 S. Karger AG, Basel
C1 [Kokame, Gregg T.; Yeung, Ling; Teramoto, Kyla; Lai, James C.] Univ Hawaii, John A Burns Sch Med, Dept Surg, Div Ophthalmol, Honolulu, HI 96822 USA.
   [Kokame, Gregg T.; Lai, James C.; Wee, Raymond] Retina Consultants Hawaii, Honolulu, HI USA.
   [Kokame, Gregg T.; Lai, James C.; Wee, Raymond] Hawaii Pacific Hlth, Retina Ctr Pali Momi, Aiea, HI USA.
   [Yeung, Ling] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
C3 University of Hawaii System; Chang Gung Memorial Hospital
RP Kokame, GT (通讯作者)，Retina Ctr Pali Momi, 98-1079 Moanalua Rd,Suite 470, Aiea, HI 96701 USA.
EM retinahi@aol.com
FU Genentech
FX This was an investigator-sponsored trial; a grant was provided by
   Genentech.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2011, RETINA-J RET VIT DIS, V31, P209, DOI 10.1097/IAE.0b013e31820a69db
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Jalil A, 2009, EUR J OPHTHALMOL, V19, P490, DOI 10.1177/112067210901900330
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 31
Z9 33
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 2
BP 94
EP 102
DI 10.1159/000354072
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296AE
UT WOS:000330156700005
PM 24135557
DA 2022-11-30
ER

PT J
AU Wakusawa, R
   Abe, T
   Sato, H
   Yoshida, M
   Kunikata, H
   Sato, Y
   Nishida, K
AF Wakusawa, Ryosuke
   Abe, Toshiaki
   Sato, Hajime
   Yoshida, Madoka
   Kunikata, Hiroshi
   Sato, Yasufumi
   Nishida, Kohji
TI Expression of vasohibin, an antiangiogenic factor, in human choroidal
   neovascular membranes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; ANGIOGENESIS INHIBITOR; CELLS; VASCULOPATHY; VEGF;
   RECEPTOR-2; DISEASES
AB PURPOSE: To determine whether vasohibin, an antiangiogenic factor produced by vascular endothelial cells, is expressed in the choroidal neovascular (CNV) membranes obtained from human eyes with age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
   DESIGN: Retrospective, interventional case series.
   METHODS: The medical charts of 21 eyes of 21 patients with AMD or PCV who underwent surgical removal of the CNV membrane were reviewed. The removed tissues were immunostained for von Willebrand Factor (vWF), vascular endothelial growth factor (VEGF), and vasohibin. The levels of the messenger ribonucleic acid of VEGF, VEGFR2, and vasohibin were determined by real,time reverse-transcriptase polymerase chain reaction (RT-PCR) from the CNV membranes excised from nine AMD and nine PCV patients.
   RESULTS: The patients were divided into three groups; four patients were placed in the most active group (Group S), 13 in the less active group (Group E), and four in the nonactive group (Group S). Immunohistochemistry showed that vasohibin, vWF, and VEGF were expressed in the vascular endothelial cells in the CNV membranes and in the polypoidal vessels. RT,PCR showed that there was a strong correlation between the level of expression of VEGFR2 and vasohibin (P = .0002). Eyes with a lower vasohibin-to-VEGF ratio tended to have larger subretinal hemorrhages or vitreous hemorrhages, whereas eyes with higher vasohibin-to-VEGF ratio had subretinal fibrosislike lesions. Statistical analysis of the vasohibin-to-VEGF ratio among the three groups was significant (P = .0209).
   CONCLUSIONS: Vasohibin is expressed in human CNV membranes. Our results indicate that the vasohibin-to-VEGF ratio may be related with the activity of the CNV.
C1 [Wakusawa, Ryosuke] Tohoku Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Aoba Ku, Sendai, Miyagi 9808574, Japan.
   [Abe, Toshiaki] Tohoku Univ, Grad Sch Med, Div Clin Cell Therapy, Ctr Translat & Adv Anim Res, Sendai, Miyagi 9808574, Japan.
   [Sato, Yasufumi] Tohoku Univ, Grad Sch Med, Dept Vasc Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9808574, Japan.
C3 Tohoku University; Tohoku University; Tohoku University
RP Wakusawa, R (通讯作者)，Tohoku Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Aoba Ku, 1-1 Seiryo Cho, Sendai, Miyagi 9808574, Japan.
EM ckd19390@rio.odn.ne.jp
RI Sato, Yasufumi/AAF-3367-2019
OI Nishida, Kohji/0000-0001-9069-3610
CR Abe T, 2001, GRAEF ARCH CLIN EXP, V239, P927, DOI 10.1007/s00417-001-0393-3
   Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hofer E, 2007, THROMB HAEMOSTASIS, V97, P355, DOI 10.1160/TH06-08-0470
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shen JK, 2006, FASEB J, V20, P723, DOI 10.1096/fj.05-5046fje
   Shimizu K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI 10.1016/j.bbrc.2004.12.073
   Singh AJ, 2005, MOL BIOL CELL, V16, P2106, DOI 10.1091/mbc.E04-08-0749
   Sonoda H, 2006, BIOCHEM BIOPH RES CO, V342, P640, DOI 10.1016/j.bbrc.2006.01.185
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 30
Z9 32
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2008
VL 146
IS 2
BP 235
EP 243
DI 10.1016/j.ajo.2008.03.019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 333CD
UT WOS:000258128700013
PM 18486097
DA 2022-11-30
ER

PT J
AU Horz, FG
AF Horz, Frank G.
TI Practical aspects of biopharmaceutical therapy: the example of
   ranibizumab
SO EJHP PRACTICE
LA English
DT Article
ID MACULAR DEGENERATION; COST-EFFECTIVENESS; LUCENTIS; PHARMACOKINETICS;
   VERTEPORFIN; MANAGEMENT; FRAGMENT; AVASTIN
AB The introduction of ranibizumab is an important advance in the management of age-related macular degeneration. Achieving the best clinical outcomes and optimal use of existing resources requires careful consideration of the properties of this novel biopharmaceutical agent.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Horz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, 2 Ernst Abbe Str, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
CR Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   BOLZ M, 2008, 8 EURETINA C VIENN A
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAUGHNEY PC, 2005, INVEST OPHTH VIS SCI, V46, P1383
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Keam SJ, 2003, DRUGS, V63, P2521, DOI 10.2165/00003495-200363220-00016
   LALWANI GA, 2007, INVEST OPHTH VIS SCI, V48, P1834
   Meyer CHEN, 2008, INVEST OPHTH VIS SCI, V49, P273
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nagle PC, 2008, AM J MANAG CARE, V14, P226
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Singh Rishi P., 2007, Indian Journal of Ophthalmology, V55, P421
NR 23
TC 0
Z9 0
U1 0
U2 1
PU PHARMA PUBLISHING & MEDIA EUROPE-PPM EUROPE
PI MOL
PA POSTBUS 10001, MOL, B-2400, BELGIUM
SN 1781-9989
EI 2030-3769
J9 EJHP PRACT
JI EJHP Pract.
PY 2008
VL 14
IS 6
BP 22
EP 24
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 394CU
UT WOS:000262424000016
DA 2022-11-30
ER

PT J
AU Wang, YL
   Chen, Z
   Yu, WH
   Chen, YX
AF Wang, Yuelin
   Chen, Zhe
   Yu, Weihong
   Chen, Youxin
TI Activation of quiescent polypoidal choroidal vasculopathy after membrane
   peeling vitrectomy for epiretinal membrane: a case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Epiretinal membrane; Vitrectomy; Case
   report
ID LASER PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; ARGON-LASER; RANIBIZUMAB;
   AFLIBERCEPT; DIAGNOSIS; EFFICACY
AB Background Regular membrane peeling vitrectomy for epiretinal membrane (ERM) patients seldom causes large pigment epithelial detachment (PED). We presented an unusual case of the activation of quiescent polypoidal choroidal vasculopathy (PCV) after membrane peeling vitrectomy for ERM, with an uneven therapeutic process. Case presentation A 75-year-old female patient complained of metamorphopsia in her left eye for 2 years. Her best-corrected visual acuity was 20/160 with a moderate nuclear cataract. An irregular ERM and slight PED were shown in optical coherence tomography (OCT). No obvious orange-red lesion was detected. The patient underwent vitrectomy + ERM peeling + cataract surgery. After the operation, large PED emerged, and indocyanine green angiography (ICGA) confirmed PCV. Four monthly injections of intravitreal ranibizumab were administered, but PED persisted. After focal laser therapy targeted to the polyps combined with ranibizumab treatment, PED was absorbed. Conclusions Careful evaluation for PCV before membrane peeling vitrectomy for ERM is important, as indolent PCV may be activated postoperatively. Anti-VEGF therapy accompanied by laser photocoagulation may be more effective for PCV polyps located away from the fovea.
C1 [Wang, Yuelin; Chen, Zhe; Yu, Weihong; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Wang, Yuelin; Chen, Zhe; Yu, Weihong; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
FU Non-profit Central Research Institute Fund of the Chinese Academy of
   Medical Sciences [2018PT32029]
FX This work was supported by The Non-profit Central Research Institute
   Fund of the Chinese Academy of Medical Sciences (2018PT32029).
CR Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Fang XL, 2017, BRIT J OPHTHALMOL, V101, P1535, DOI 10.1136/bjophthalmol-2016-309768
   Flaxel CJ, 2020, OPHTHALMOLOGY, V127, pP145, DOI 10.1016/j.ophtha.2019.09.022
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Gagnier JJ, 2013, DTSCH ARZTEBL INT, V110, P603, DOI [10.3238/arztebl.2013.0603, 10.1136/bcr-2013-201554, 10.7453/gahmj.2013.008, 10.1186/1752-1947-7-223]
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Hussnain SA, 2019, AM J OPHTHALMOL, V207, P304, DOI 10.1016/j.ajo.2019.06.003
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Steel DHW, 2013, EYE, V27, pS1, DOI 10.1038/eye.2013.212
   Yeo JH, 2020, GRAEF ARCH CLIN EXP, V258, P1379, DOI 10.1007/s00417-020-04684-x
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 17
TC 0
Z9 0
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 6
PY 2021
VL 21
IS 1
AR 321
DI 10.1186/s12886-021-02080-5
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UN3YI
UT WOS:000693953200003
PM 34488669
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Berrow, EJ
   Bartlett, HE
   Eperjesi, F
   Gibson, JM
AF Berrow, Emma J.
   Bartlett, Hannah E.
   Eperjesi, Frank
   Gibson, Jonathan M.
TI The effects of a lutein-based supplement on objective and subjective
   measures of retinal and visual function in eyes with age-related
   maculopathy - a randomised controlled trial
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Lutein; Macular degeneration; Electroretinography; Electrophysiology
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; CONTRAST SENSITIVITY; PIGMENT
   EPITHELIUM; VITAMIN-A; RELIABILITY; ELECTRORETINOGRAM; ANTIOXIDANTS;
   PATHOGENESIS; CAROTENOIDS
AB Lutein and zeaxanthin are lipid-soluble antioxidants found within the macula region of the retina. Links have been suggested between increased levels of these carotenoids and reduced risk for age-related macular disease (ARMD). Therefore, the effect of lutein-based supplementation on retinal and visual function in people with early stages of ARMD (age-related maculopathy, ARM) was assessed using multifocal electroretinography (mfERG), contrast sensitivity and distance visual acuity. A total of fourteen participants were randomly allocated to either receive a lutein-based oral supplement (treated group) or no supplement (non-treated group). There were eight participants aged between 56 and 81 years (65.50 (SD 9.27) years) in the treated group and six participants aged between 61 and 83 years (69.67 (SD 7.52) years) in the non-treated group. Sample sizes provided 80% power at the 5% significance level. Participants attended for three visits (0, 20 and 40 weeks). At 60 weeks, the treated group attended a fourth visit following 20 weeks of supplement withdrawal. No changes were seen between the treated and non-treated groups during supplementation. Although not clinically significant, mfERG ring 3 N2 latency (P=0.041) and ring 4 P1 latency (P=0.016) increased, and a trend for reduction of mfERG amplitudes was observed in rings 1, 3 and 4 on supplement withdrawal. The statistically significant increase in mfERG latencies and the trend for reduced mfERG amplitudes on withdrawal are encouraging and may suggest a potentially beneficial effect of lutein-based supplementation in ARM-affected eyes.
C1 [Berrow, Emma J.; Bartlett, Hannah E.; Eperjesi, Frank; Gibson, Jonathan M.] Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
   [Berrow, Emma J.; Gibson, Jonathan M.] Heart England NHS Trust, Birmingham, W Midlands, England.
C3 Aston University; Heart of England NHS Foundation Trust
RP Berrow, EJ (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
EM berrowej@aston.ac.uk
OI Bartlett Eperjesi, Hannah E/0000-0002-7531-6902; Gibson, Jonathan
   M/0000-0002-9281-5244; Eperjesi, Frank/0000-0003-4358-0095
FU Bausch and Lomb, Kingston-Upon- Thames, Surrey, UK
FX The authors would like to thank Bausch and Lomb, Kingston-Upon- Thames,
   Surrey, UK for funding the research position and supplying the Ocuvite
   Duo nutritional supplement. E. J. B. completed the data collection,
   performed statistical analysis of the data and wrote the manuscript. H.
   E. B. and F. E. conceptualised and supervised the research, and edited
   the manuscript. J. M. G. supervised the research and edited the
   manuscript. The authors declare no competing financial interests.
CR Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Crabtree DV, 1996, INVEST OPHTH VIS SCI, V37, P61
   Dolan FM, 2006, DOC OPHTHALMOL, V112, P31, DOI 10.1007/s10633-006-0002-1
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   FSA, 2003, EXP GROUP VIT MIN SA
   Hahn SR, 2009, OPHTHALMOLOGY, V116, pS37, DOI 10.1016/j.ophtha.2009.06.023
   Hood DC, 2003, J NEURO-OPHTHALMOL, V23, P225, DOI 10.1097/00041327-200309000-00008
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Korobelnik JF, 2006, INVEST OPHTH VIS SCI, V47, P4270, DOI 10.1167/iovs.05-1467
   Lakshminarayana R, 2009, LIPIDS, V44, P799, DOI 10.1007/s11745-009-3328-0
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Meyer-Ruesenberg B, 2010, KLIN MONATSBL AUGENH, V227, P646, DOI 10.1055/s-0029-1245118
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   O'Connell O, 2008, INT J VITAM NUTR RES, V78, P238, DOI [10.1024/0300-9831.78.45.238, 10.1024/0300-9831.78.4/5.238]
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   SUTTER EE, 1991, SIAM J COMPUT, V20, P686, DOI 10.1137/0220043
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   World Medical Association Inc, 2009, J Indian Med Assoc, V107, P403
   Yong VK, 2006, OPHTHAL EPIDEMIOL, V13, P35, DOI 10.1080/09286580500473779
NR 46
TC 19
Z9 19
U1 0
U2 16
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN 14
PY 2013
VL 109
IS 11
BP 2008
EP 2014
DI 10.1017/S0007114512004187
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 146WT
UT WOS:000319126700010
PM 23084077
OA Bronze
DA 2022-11-30
ER

PT J
AU Xue, Y
   Cai, QH
AF Xue, Yin
   Qinhua Cai
TI Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients
   Treated With Intravitreal Aflibercept or Conbercept
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE aflibercept; conbercept; polypoidal choroidal vasculopathy;
   best-corrected visual acuity; polyp regression
ID CLASSIFICATION; DIAGNOSIS; THERAPY
AB PurposeTo compare the short-term efficacy in patients with polypoidal choroidal vasculopathy (PCV) treated using either aflibercept or conbercept. MethodsThis prospective study included 41 patients with treatment-naive PCV (42 eyes). All the patients were treated with either aflibercept or conbercept using an initial series of 3 monthly loading injections. Changes in the best-corrected logMAR visual acuity (BCVA) and anatomic outcomes were evaluated at 3 months. ResultsBCVA was improved with reduction in central choroidal thickness (CCT), central foveal thickness (CFT), and subretinal fluid (SRF) after 3 monthly loading injections in both aflibercept (IVA) and conbercept (IVC) groups. There was no significant difference in either visual or anatomic outcomes between the two groups after 3 months of treatment. However, compared with the IVC group, significantly higher BCVA improvement was observed in the patients in the IVA group with baseline BCVA better than 1. A visual outcome improved >= 3 lines in 13 patients in the IVA group (59%), and 9 patients in the IVC group (45%). A relatively high proportion of polyp regression was observed in the IVA group (63%) compared with the IVC group (55%) via OCTA. ConclusionsVisual and anatomic outcomes were significantly improved in both IVA and IVC groups, but the results suggest a potentially superior short-term response in the IVA group.
C1 [Xue, Yin; Qinhua Cai] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, Suzhou, Peoples R China.
C3 Soochow University - China
RP Cai, QH (通讯作者)，Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, Suzhou, Peoples R China.
EM 3173695856@qq.com
FU National Natural Science Foundation in China [82101120]; Jiangsu
   Provincial Natural Science Foundation [BK20210095]; Soochow Livelihood
   Technology Project [SYS2020114]
FX Funding This study was supported by the National Natural Science
   Foundation in China (Grant No. 82101120), the Jiangsu Provincial Natural
   Science Foundation (Grant No. BK20210095), and the Soochow Livelihood
   Technology Project (Grant No. SYS2020114).
CR Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Cheng Y, 2016, CHINESE MED J-PEKING, V129, P2610, DOI 10.4103/0366-6999.192779
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Juncal VR, 2020, J OCUL PHARMACOL TH, V36, P697, DOI 10.1089/jop.2020.0038
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim K, 2020, AM J OPHTHALMOL, V217, P240, DOI 10.1016/j.ajo.2020.05.017
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Marcus DM, 2015, EYE, V29, P1427, DOI 10.1038/eye.2015.150
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sorensen JO, 2020, ACTA OPHTHALMOL, V98, P384, DOI 10.1111/aos.14295
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ye LH, 2021, GRAEF ARCH CLIN EXP, V259, P1455, DOI 10.1007/s00417-020-04988-y
NR 26
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD FEB 17
PY 2022
VL 9
AR 835255
DI 10.3389/fmed.2022.835255
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZM7JN
UT WOS:000764528900001
PM 35252267
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dansingani, KK
   Gal-Or, O
   Sadda, SR
   Yannuzzi, LA
   Freund, KB
AF Dansingani, Kunal K.
   Gal-Or, Orly
   Sadda, Srinivas R.
   Yannuzzi, Lawrence A.
   Freund, K. Bailey
TI Understanding aneurysmal type 1 neovascularization (polypoidal choroidal
   vasculopathy): a lesson in the taxonomy of "expanded spectra' - a review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE imaging; macular degeneration; neovascularization; pachychoroid;
   polypoidal
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENTS; MACULAR
   DEGENERATION; CLASSIFICATION; FEATURES; ANGIOGRAPHY; EYES
AB The term aneurysmal type 1 neovascularization is derived from terminology, which is established in the literature but has fallen out of use. We believe that aneurysmal type 1 neovascularization accurately describes the lesions which define the entity known as polypoidal choroidal vasculopathy (PCV). Over the last three decades, the clinical spectrum of PCV has expanded to recognize the occurrence of the aneurysmal (polypoidal) lesions in different contexts, resulting in a complex and unwieldy taxonomy based sometimes on circumstantial findings rather than mechanistic considerations. Advances in multimodal imaging provides increasingly convincing evidence that the lesions which define various forms of PCV are indeed vascular and arise from type 1 neovascular networks. The understanding of PCV as type 1 neovascularization with aneurysms renews focus on the question as to why some patients with type 1 neovascularization develop aneurysms while others do not. Conceptual themes and potential for further study are discussed.
C1 [Dansingani, Kunal K.] Univ Pittsburgh, Dept Ophthalmol, Med Ctr, Pittsburgh, PA 15260 USA.
   [Gal-Or, Orly; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
   [Gal-Or, Orly; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England.
   [Gal-Or, Orly] Rabin Med Ctr, Petah Tiqwa, Israel.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Vitreous Retina Macula Consultants of New York; Manhattan
   Eye Ear & Throat Hospital; Doheny Eye Institute; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; Rabin Medical Center
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Dansingani, Kunal K/D-1025-2015; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, New York; Macula Foundation,
   Inc., New York
FX The LuEsther T. Mertz Retinal Research Center and The Macula Foundation,
   Inc., New York. The funding entities had no role in the conception,
   design or preparation of this manuscript.
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bousquet E, 2017, RETINA
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Coscas F, 2011, EUR J OPHTHALMOL, V21, P331, DOI 10.5301/EJO.2010.2803
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Naysan J, 2015, INT J RETIN VITR, V1, P909
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Spaide R. F., 2017, RETINA
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P709, DOI 10.1016/S0002-9394(02)01331-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P1544, DOI 10.1097/IAE.0000000000001402
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 62
TC 96
Z9 102
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAR
PY 2018
VL 46
IS 2
SI SI
BP 189
EP 200
DI 10.1111/ceo.13114
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GA5NY
UT WOS:000428382000010
PM 29178419
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Mauget-Faysse, M
   Vuillaume, M
   Quaranta, M
   Moullan, N
   Angele, S
   Friesen, MD
   Hall, J
AF Mauget-Faysse, M
   Vuillaume, M
   Quaranta, M
   Moullan, N
   Angele, S
   Friesen, MD
   Hall, J
TI Idiopathic and radiation-induced ocular telangiectasia: The involvement
   of the ATM gene
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ATAXIA-TELANGIECTASIA; BREAST-CANCER;
   MACULAR DEGENERATION; RISK-FACTOR; MUTATIONS; FAMILIES; DNA;
   NEOVASCULARIZATION; HETEROZYGOTES
AB PURPOSE. To investigate whether individuals, with no family history of ataxia telangiectasia (AT), in whom idiopathic or radiation-induced ocular telangiectasia developed are carriers of ATM gene mutations.
   METHODS. The ATM cDNA from lymphoblastoid cell lines established from 16 patients with idiopathic retinal or choroidal telangiectasia. and 14 patients with radiation-induced telangiectasia after radiotherapy for age-related macular degeneration (AMD) was screened using the restriction endonuclease fingerprinting technique. The frequency of each detected variant was determined in the French population by either a mass spectrometry-based technique or variant-specific endonuclease digestion.
   RESULTS. Twenty-one ATM missense alterations, at 10 different sites, 8 of which would result in an amino acid substitution at a conserved position in the ATM protein were found. Four were novel changes, three of which were not detected in the 128 French control subjects screened. Eleven of 16 of the individuals with either idiopathic polypoidal choroidal vasculopathy or juxtafoveolar retinal telangiectasis and 6 of 14 individuals that had choroidal telangiectasis after radiotherapy for AMD carried ATM sequence variants. These latter six individuals had a significantly shorter delay time before the presentation of this vasculopathy compared with those individuals who had a wild-type ATM (11.8 +/- 3.4 months vs. 17.5 +/- 4.5 months, P = 0.024). They had also received a lower average dose of X-rays, although this difference did not reach statistical significance (18.7 +/- 3.9 Gy vs. 23.7 +/- 5.6 Gy, P = 0.09).
   CONCLUSIONS. ATM missense variants could confer an AT-like phenotype and influence the formation of retinal and choroidal vascular abnormalities.
C1 Int Agcy Res Canc, DNA Repair Grp, F-69372 Lyon 08, France.
   Int Agcy Res Canc, Nutr & Canc Unit, F-69372 Lyon, France.
   Rabelais Ophthalmol Ctr, Lyon, France.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); World Health Organization; International Agency for Research on
   Cancer (IARC)
RP Hall, J (通讯作者)，Int Agcy Res Canc, DNA Repair Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM hall@iarc.fr
RI Friesen, Marlin D/D-7328-2012; hall, janet/G-1372-2013
OI hall, janet/0000-0002-4397-6295
CR Angele S, 2000, MUTAT RES-REV MUTAT, V462, P167, DOI 10.1016/S1383-5742(00)00034-X
   Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
   CHEW EY, 1986, ARCH OPHTHALMOL-CHIC, V104, P71
   Dork T, 2001, CANCER RES, V61, P7608
   Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942
   Gilad S, 1998, HUM MUTAT, V11, P69, DOI 10.1002/(SICI)1098-1004(1998)11:1<69::AID-HUMU11>3.3.CO;2-P
   Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433
   Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382
   Hall EJ, 1998, CANCER J, V4, P385
   ISSACS TW, 1996, EYE, V10, P639
   Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874
   Laake K, 2000, HUM MUTAT, V16, P232, DOI 10.1002/1098-1004(200009)16:3<232::AID-HUMU6>3.0.CO;2-L
   Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352, DOI 10.1038/4333
   Larson GP, 1997, GENET TEST, V1, P165, DOI 10.1089/gte.1997.1.165
   Leys A, 2000, RETINA-J RET VIT DIS, V20, P184, DOI 10.1097/00006982-200003000-00011
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   LIU Q, 1995, BIOTECHNIQUES, V18, P470
   Maberley DAL, 1999, OPHTHALMOLOGY, V106, P2248, DOI 10.1016/S0161-6420(99)90523-7
   Maillet P, 1999, MOL CELL PROBE, V13, P67, DOI 10.1006/mcpr.1998.0219
   Maillet P, 2000, INT J CANCER, V88, P928, DOI 10.1002/1097-0215(20001215)88:6<928::AID-IJC14>3.0.CO;2-P
   Mauget-Faysse M, 2000, J FR OPHTALMOL, V23, P127
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   McConville CM, 1996, AM J HUM GENET, V59, P320
   Menchini U, 2000, AM J OPHTHALMOL, V129, P401, DOI 10.1016/S0002-9394(99)00380-3
   MILLAY RH, 1986, AM J OPHTHALMOL, V102, P363, DOI 10.1016/0002-9394(86)90012-7
   Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555
   Sandoval N, 1999, HUM MOL GENET, V8, P69, DOI 10.1093/hmg/8.1.69
   SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600
   SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347
   Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spurdle AB, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr534
   Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706
   SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101
   SWIFT M, 1986, AM J HUM GENET, V39, P573
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   WOODS CG, 1990, HUM GENET, V84, P555
   Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 17
Z9 17
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2003
VL 44
IS 8
BP 3257
EP 3262
DI 10.1167/iovs.02-1269
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 705EV
UT WOS:000184383500001
PM 12882767
DA 2022-11-30
ER

PT J
AU Manayath, GJ
   Shah, VS
   Saravanan, VR
   Narendran, V
AF Manayath, George J.
   Shah, Vanee Sheth
   Saravanan, Veerappan R.
   Narendran, Venkatapathy
TI POLYPOIDAL CHOROIDAL VASCULOPATHY ASSOCIATED WITH CENTRAL SEROUS
   CHORIORETINOPATHY Pachychoroid Spectrum of Diseases
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE central serous chorioretinopathy; pachychoroid; polypoidal choroidal
   vasculopathy
ID MACULAR DEGENERATION; UPDATE
AB Purpose: To study multimodal imaging features of polypoidal choroidal vasculopathy (PCV) associated with central serous chorioretinopathy (CSC) in the same eye.
   Methods: A retrospective observational study of cases of suspected PCV which underwent indocyanine green angiography, fundus fluorescein angiography and optical coherence tomography was done, to look for simultaneous typical CSC-like active leak in the same eye. The relevant history, best-corrected visual acuity, optical coherence tomography, fundus fluorescein angiography, and indocyanine green angiography findings were analyzed.
   Results: From 226 patients reviewed, 195 patients had PCV from which 6 eyes (3.07%) with features of PCV associated with typical CSC-like active leak in the same eye were identified; 3 men and 3 women with a mean age of 62.6 years. Optical coherence tomography showed notched pigment epithelial detachment in two and irregular peaked pigment epithelial detachment in four cases with subretinal fluid and/or subretinal haemorrhage over a thick choroid with dilated outer choroidal vessels. Fundus fluorescein angiography showed stippled hyperfluorescence at polyp area and a separate typical CSC-like active leak-Inkblot in three and Smokestack in three cases. On indocyanine green angiography, multiple polyps were noted with choroidal hyperpermeability in late phase at the site of CSC leak.
   Conclusion: The coexistence of PCV with typical CSC-like active leaks and a thick choroid in the same eye simultaneously provides strong evidence that these diseases have an association and support the hypothesis that these conditions may originate from predisposed thick choroid.
C1 [Manayath, George J.; Shah, Vanee Sheth; Saravanan, Veerappan R.; Narendran, Venkatapathy] Aravind Eye Hosp, Dept Vitreoretina Serv, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India.
RP Shah, VS (通讯作者)，Aravind Eye Hosp, Dept Vitreoretina Serv, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India.; Shah, VS (通讯作者)，Postgrad Inst Ophthalmol, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India.
EM vanee.sheth@gmail.com
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Liegl R, 2014, OPHTHALMOLOGICA, V232, P65, DOI 10.1159/000360014
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Okushiba Utako, 1997, Nippon Ganka Gakkai Zasshi, V101, P74
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 2010, THE RETINAL ATLAS
NR 21
TC 30
Z9 31
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2018
VL 38
IS 6
BP 1195
EP 1204
DI 10.1097/IAE.0000000000001665
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CC
UT WOS:000440627100019
PM 28445211
DA 2022-11-30
ER

PT J
AU Wu, HJ
   Sugano, Y
   Itagaki, K
   Kasai, A
   Shintake, H
   Sekiryu, T
AF Wu, Huajui
   Sugano, Yukinori
   Itagaki, Kanako
   Kasai, Akihito
   Shintake, Hiroaki
   Sekiryu, Tetsuju
TI The characteristics of choriocapillaris flow void in the unilateral
   polypoidal choroidal vasculopathy fellow eyes
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; NEOVASCULARIZATION; DEGENERATION;
   ARTIFACTS; FEATURES
AB To evaluate the morphological characteristics of flow void (FV) in the fellow eyes of the unilateral polypoidal choroidal vasculopathy (PCV). Fifty PCV fellow eyes (PCVF) and 31 age-matched normal ocular circulation controls were recruited in this retrospective study. The number of FV was analyzed according to the size in a centered 5 x 5 mm swept source optical coherence tomography angiography scans. We used indocyanine green angiography images to determine whether choroidal vascular hyperpermeability (CVH) has occurred. For the PCVF, the prevalence rate of CVH was 70% (35 of 50) The number of FVs was significantly lower in 400-25,000 mu m(2) (P = 0.005), 400-500 mu m(2) (P = 0.001), 525-625 mu m(2) (P = 0.001) and 650-750 mu m(2) (P = 0.018). compared to the controls. And showed no difference in size from 775 to 1125 mu m(2) between the two groups. The area under the receiver operating characteristic curve of PCVF with CVH and controls was 0.94 (95% CI 0.88-1.00) (P < 0.001). We found that the number of small FVs was significantly lower in the PCV fellow eyes than that in the eyes with control group.
C1 [Wu, Huajui; Sugano, Yukinori; Itagaki, Kanako; Kasai, Akihito; Shintake, Hiroaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, 1 Hikariga Oka, Fukushima, Japan.
C3 Fukushima Medical University
RP Sekiryu, T (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, 1 Hikariga Oka, Fukushima, Japan.
EM sekiryu@fmu.ac.jp
CR Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Bosch AJ, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0732-x
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Cao D, 2018, ACTA DIABETOL, V55, P469, DOI 10.1007/s00592-018-1115-1
   Chu ZD, 2021, AM J OPHTHALMOL, V222, P92, DOI 10.1016/j.ajo.2020.08.045
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Dodo Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05663-9
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Jumar A, 2016, J CLIN HYPERTENS, V18, P1112, DOI 10.1111/jch.12851
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kim K, 2020, AM J OPHTHALMOL, V20, P20
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Luo MY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01386-0
   Mammo Z, 2016, AM J OPHTHALMOL, V170, P41, DOI 10.1016/j.ajo.2016.07.015
   Moussa Kareem, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS128, DOI 10.1097/ICB.0000000000000464
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Newman MEJ, 2005, CONTEMP PHYS, V46, P323, DOI 10.1080/00107510500052444
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Ryu G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75506-7
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SOILLE P, 1990, P SOC PHOTO-OPT INS, V1360, P240, DOI 10.1117/12.24211
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P679, DOI 10.1097/IAE.0000000000002988
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Sun C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66736-w
   Thompson IA, 2019, EYE, V33, P648, DOI 10.1038/s41433-018-0286-x
   Wu HJ, 2021, QUANT IMAG MED SURG, V11, P3146, DOI 10.21037/qims-20-1027
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yarmohammadi A, 2016, INVEST OPHTH VIS SCI, V57, pOCT451, DOI 10.1167/iovs.15-18944
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
   YOSHIOKA H, 1991, Nippon Ganka Gakkai Zasshi, V95, P1181
   Yun C, 2020, INT OPHTHALMOL, V40, P325, DOI 10.1007/s10792-019-01182-w
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 50
TC 0
Z9 0
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 29
PY 2021
VL 11
IS 1
AR 23059
DI 10.1038/s41598-021-02377-x
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XF0MF
UT WOS:000723772800060
PM 34845281
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Corvi, F
   Chandra, S
   Invernizzi, A
   Pace, L
   Viola, F
   Sivaprasad, S
   Staurenghi, G
   Cheung, CMG
   Teo, KYC
AF Corvi, Federico
   Chandra, Shruti
   Invernizzi, Alessandro
   Pace, Lucia
   Viola, Francesco
   Sivaprasad, Sobha
   Staurenghi, Giovanni
   Cheung, Chui Ming Gemmy
   Teo, Kelvin Yi Chong
TI Multimodal Imaging Comparison of Polypoidal Choroidal Vasculopathy
   Between Asian and Caucasian Populations
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; GENETIC-VARIANTS;
   ASSOCIATION; RESISTANCE; DIAGNOSIS; EYES
AB PURPOSE: Differences in multimodal imaging features between Asian and Caucasian eyes may contribute to our understanding of the etiology of the polypoidal choroidal vasculopathy (PCV). The purpose of this study was to compare the multimodal imaging features of Asian and Caucasian eyes with PCV.
   DESIGN: Cross-sectional, retrospective, multicenter, observational case series.
   METHODS: Consecutive treatment-naive patients diagnosed with PCV based on indocyanine green angiography in accordance with published guidelines. Demographic and multimodal imaging findings based on color fundus photography, spectral domain optical coherence tomography, fluorescein angiography, and indocyanine green angiography were graded.
   RESULTS: A total of 250 participants with PCV (128 Asian vs 122 Caucasian participants) were included. Asian participants presented with lower best-corrected visual acuity (mean +/- SD: 0.7 +/- 0.6 logMAR vs 0.4 +/- 0.3 logMAR; P < .001) compared with Caucasian participants. More Asian eyes had subretinal hemorrhage (mean +/- SD: 53.9% vs 24.6%; P < .001) and larger areas of hemorrhage (mean +/- SD: 7.5 +/- 15.2 mm(2) vs 1.3 +/- 3.3 mm(2); P < .001). More Asian eyes had pachyvessels (84.4% vs 28.7%; P < .001), choroidal vascular hyperpermeability (70.3% vs 17.2%; P < .001), and widespread polypoidal lesions (19.5% vs 8.2%; P = .005), and Caucasian eyes had more drusen (79.5% vs 49.2%; P = .02).
   CONCLUSIONS: Multimodal imaging analysis revealed ethnic differences in disease characteristics of PCV, suggesting pathophysiologic mechanism of the disease vary based on ethnicity. (C) 2021 Elsevier Inc. All rights reserved.
C1 Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res Moorfields Biomed Res Ctr, London, England.
   UCL Inst Ophthalmol, London, England.
   Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   Natl Univ Singapore, Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore.
C3 University of Milan; Luigi Sacco Hospital; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of Sydney;
   IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Invernizzi, A (通讯作者)，Univ Milan, Luigi Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci, Via GB Grassi 74, I-20157 Milan, Italy.
EM alessandro.invernizzi@gmail.com
OI Corvi, Federico/0000-0002-2661-5500; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Sivaprasad, Sobha/0000-0001-8952-0659;
   Chandra, Shruti/0000-0002-2634-9775
FU ORNATE-India grant [MR/P207881/1]
FX Shruti Chandra is funded by ORNATE-India grant (Ref: GCRF UKRI
   (MR/P207881/1). Alessandro Invernizzi reports consultancy fees, grants,
   travel support, and speaker fees from Bayer, Allergan, and Novartis
   outside the submitted work. Francesco Viola reports consultancy fees,
   honorarium, grants, travel support,and speaker fees from Bayer,
   Novartis, Allergan, and Roche outside the submitted work. Sobha
   Sivaprasad reports personal fees and grants from Bayer, Allergan,
   Novartis, Roche, Boehringer Ingleheim, Optos, Apellis, Opthea, Oculis,
   Oxurion, and Heidelberg Engineering outside the submitted work. Giovanni
   Staurenghi reports personal fees and other from Heidelberg Engineering,
   grants, personal fees, and other from Zeiss Meditec, grants from
   Optovue, grants, and other from Optos, grants, personal fees, and other
   from Centervue, grants from Nidek, grants, personal fees, and other from
   Novartis, personal fees and other from Bayer, other from Boeheringer,
   other from Allergan, and other from Alcon, outside the submitted work.
   Chui Ming Gemmy Cheung reports grants, personal fees, and nonfinancial
   support from Bayer, grants, personal fees, and nonfinancial support from
   Novartis, grants from Roche, grants from GlaxoSmith Kline, nonfinancial
   support from Allergan, and nonfinancial support from Topcon, outside the
   submitted work. Kelvin Yi Chong Teo reports consultancy fees,
   honorarium, travel support, and speaker fees from Bayer and Novartis
   outside the submitted work. The remaining authors indicate no financial
   support or conflicts of interest. All authors attest that they meet the
   current ICMJE criteria for authorship.
CR Azuma K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65346-w
   Chen LJ, 2020, ASIA-PAC J OPHTHALMO, V9, P104, DOI 10.1097/01.APO.0000656976.47696.7d
   Chen YFN, 2017, CAN J OPHTHALMOL, V52, P475, DOI 10.1016/j.jcjo.2017.02.014
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435
   Kokame GT, 2020, OPHTHALMOLOGICA, V243, P178, DOI 10.1159/000503834
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Nieblas-Bedolla E, 2020, ACAD MED, V95, P1802, DOI 10.1097/ACM.0000000000003496
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Teo KYC, 2021, OPHTHALMOL RETINA, V5, P945, DOI 10.1016/j.oret.2021.04.002
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 35
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2022
VL 234
BP 108
EP 116
DI 10.1016/j.ajo.2021.08.006
EA NOV 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XI3TM
UT WOS:000726038400007
PM 34450112
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Hykin, P
AF Sivaprasad, Sobha
   Hykin, Phil
TI The role of photodynamic therapy in ophthalmology
SO BRITISH JOURNAL OF HOSPITAL MEDICINE
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE;
   VERTEPORFIN THERAPY; SUBRETINAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; FUNDUS DYSTROPHY; IMPROVEMENT; HEMANGIOMA
AB Photodynamic therapy has become an established therapy for certain subtypes of wet age-related macular degeneration. It is increasingly being recognized as a treatment modality for other ocular conditions. This review summarizes the current clinical applications of photodynamic therapy in ophthalmology.
C1 Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Hykin, P (通讯作者)，Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
CR Andrade RE, 2003, AM J OPHTHALMOL, V136, P1179, DOI 10.1016/S0002-9394(03)00711-6
   ARIAS L, 2005, GRAEFES ARCH CLIN EX, V14, P1
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Barbazetto IA, 2004, AM J OPHTHALMOL, V138, P183, DOI 10.1016/j.ajo.2004.04.007
   Blaise P, 2005, ACTA OPHTHALMOL SCAN, V83, P515, DOI 10.1111/j.1600-0420.2005.00479.x
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brooks BJ, 2004, BRIT J OPHTHALMOL, V88, P840, DOI 10.1136/bjo.2003.035071
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Donaldson MJ, 2005, CLIN EXP OPHTHALMOL, V33, P548, DOI 10.1111/j.1442-9071.2005.01083.x
   Ergun E, 2004, AM J OPHTHALMOL, V138, P434, DOI 10.1016/j.ajo.2004.04.055
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P399, DOI 10.1097/00006982-200406000-00010
   Ergun E, 2004, ARCH OPHTHALMOL-CHIC, V122, P37, DOI 10.1001/archopht.122.1.37
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Harissi-Dagher M, 2005, AM J OPHTHALMOL, V139, P726, DOI 10.1016/j.ajo.2004.10.009
   Heimann H, 2005, GRAEF ARCH CLIN EXP, V243, P1115, DOI 10.1007/s00417-005-1193-y
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krebs I, 2005, AM J OPHTHALMOL, V140, P416, DOI 10.1016/j.ajo.2005.03.050
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Michels S, 2005, RETINA-J RET VIT DIS, V25, P697, DOI 10.1097/00006982-200509000-00003
   *NAT I CLIN EXC, 2003, FULL GUID US PHOT TH
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Parodi MB, 2005, OPHTHALMOLOGY, V112, P1844, DOI 10.1016/j.ophtha.2005.03.011
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P171, DOI 10.1097/00006982-200304000-00006
   Parodi MB, 2005, RETINA-J RET VIT DIS, V25, P438, DOI 10.1097/00006982-200506000-00007
   Peiretti E, 2005, RETINA-J RET VIT DIS, V25, P377, DOI 10.1097/00006982-200504000-00024
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Shields CL, 2005, OPHTHAL SURG LAS IM, V36, P237, DOI 10.3928/1542-8877-20050501-10
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Szabo A, 2005, ACTA OPHTHALMOL SCAN, V83, P512, DOI 10.1111/j.1600-0420.2005.00476.x
   Taban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043
   THOMAS EL, 2005, INVEST OPHTHALMOL E
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Wong SC, 2003, BRIT J OPHTHALMOL, V87, P796, DOI 10.1136/bjo.87.6.796
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
NR 46
TC 2
Z9 2
U1 0
U2 3
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 1750-8460
EI 1759-7390
J9 BRIT J HOSP MED
JI Br. J. Hosp. Med.
PD DEC
PY 2006
VL 67
IS 12
BP 647
EP 650
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 117SF
UT WOS:000242892900005
PM 17328448
DA 2022-11-30
ER

PT J
AU Yanase, E
   Jang, YP
   Nakanishi, K
AF Yanase, Emiko
   Jang, Young P.
   Nakanishi, Koji
TI SYNTHESES OF ANTIOXIDANT FLAVONOID DERIVATIVES
SO HETEROCYCLES
LA English
DT Article
DE Age-Related Macular Degeneration (AMD); Antioxidant; Quercetin; Caffeic
   Acid; Curcumin
AB Quercetin-caffeic acid and quercetin-curcumin conjugates have been synthesized as potent antioxidants to prevent age-related macular degeneration. Thus, the widely disributed plant antioxidant quercetin was linked to other plant antioxidants, caffeic acid and curucumin, to enhance its antioxidative properties.
C1 [Yanase, Emiko; Jang, Young P.; Nakanishi, Koji] Columbia Univ, Dept Chem, New York, NY 10027 USA.
C3 Columbia University
RP Yanase, E (通讯作者)，Gifu Univ, Fac Appl Biol Sci, Gifu 5011193, Japan.
EM kn5@columbia.edu
RI Jang, Young Pyo/AAJ-8782-2020
OI Jang, Young Pyo/0000-0001-5865-9228; Yanase, Emiko/0000-0002-6652-4259
FU NIH [GM36564]; Shionogi Co.
FX The studies were supported by NIH GM36564 and a grant from Shionogi &
   Co.
CR Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Harbome J. B., 1994, FLAVONOIDS ADV RES 1
   Haslam E, 1989, PLANT POLYPHENOLS VE
   HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   JONG YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529
   PETER GM, 2007, GREENES PROTECTIVE G
   Ramesh C, 2003, TETRAHEDRON, V59, P1049, DOI 10.1016/S0040-4020(02)01635-6
   ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sugiyama Y, 1996, BIOCHEM PHARMACOL, V52, P519, DOI 10.1016/0006-2952(96)00302-4
   TAKAHAMA U, 1984, PHOTOBIOCH PHOTOBIOP, V7, P175
NR 14
TC 2
Z9 2
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0385-5414
EI 1881-0942
J9 HETEROCYCLES
JI Heterocycles
PD MAR 1
PY 2011
VL 82
IS 2
BP 1151
EP +
DI 10.3987/COM-10-S(E)102
PG 6
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA 743VU
UT WOS:000289047600014
DA 2022-11-30
ER

PT J
AU Zhang, XY
   Sivaprasad, S
AF Zhang, Xinyuan
   Sivaprasad, Sobha
TI Drusen and pachydrusen: the definition, pathogenesis, and clinical
   significance
SO EYE
LA English
DT Review
ID AGE-RELATED MACULOPATHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR
   DEGENERATION FINDINGS; 15-YEAR CUMULATIVE INCIDENCE; RETICULAR
   PSEUDODRUSEN; BRUCHS MEMBRANE; BASAL DEPOSITS; AGING CHANGES;
   PREVALENCE; CHOLESTEROL
AB The pachychoroid disease spectrum encompasses seven major retinal conditions including central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), and pachychoroid neovasculopathy or type I macular neovascularisation (MNV) secondary to chronic persistent thickening and dysfunction of the choroidal vasculature. Drusen are focal yellow-white deposits of extracellular debris, which consist of complement proteins, esterified and nonesterified cholesterol, apolipoproteins, carbohydrates, and trace elements, above the retinal pigment epithelium (RPE) or between the RPE and Bruch's membrane. Although drusen are an essential disease precursor of advanced age-related macular degeneration (AMD), a new entity "pachydrusen" has been identified to be associated with some of the enitites that constitute the pachychoroid spectrum. It remains to be determined what the exact differences are between soft drusen, pseudodrusen, and pachydrusen in terms of phenotype, genotype, and pathogenesis. Improving our knowledge in these areas will inevitably improve our understanding of their clinical significance especially as in disease prediction in AMD and the pachychroid spectrum disorders. It remains controversial whether PCV is a subtype of AMD. Understanding the pathogenesis of different types of drusen may also help in addressing if phenotype and/or genotype of type 1 MNV associated with pachychoroid are similar to type 1 MNV related to AMD. Furthermore, because pachydrusen links two pachychoroid diseases, CSC and PCV, it is also of great interest to investigate if CSC is an early stage or a predictor of PCV in future research. In this review, we share our experience in clinical practice and the latest published evidence-based literature to emphasize the differences and similarities in morphology, pathogenesis, and clinical significance of drusen and pachydrusen, a new member of the pachychoroid spectrum disorders.
C1 [Zhang, Xinyuan] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
   [Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London, England.
C3 Capital Medical University; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Zhang, XY (通讯作者)，Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
EM mmzxy2010@163.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Zhang, Xinyuan/0000-0002-3372-0798
FU National Natural Science Foundation of China [81570850, 81170859];
   Ministry of Science and Technology Foundation of China [2016YFC1305604]
FX This work is supported by the National Natural Science Foundation of
   China [Grant 81570850; Grant 81170859] and the Ministry of Science and
   Technology Foundation of China [Grant 2016YFC1305604].
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Anatomische HM, 1856, GRAEFES ARCH CLIN EX, V2, P1, DOI [10.1007/BF02720657, DOI 10.1007/BF02720657]
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Armstrong J, 2005, INVEST OPHTHALMOL VI, P46
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler SBBN, 2006, AGE RELATED MACULAR
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fukuda Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082459
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hirata C, 1997, BIOCHEM BIOPH RES CO, V236, P712, DOI 10.1006/bbrc.1997.7036
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   John Wiley and Sons, 1975, TECHNIQUES BIOCH BIO
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Matsubara M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237330
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Meng JJ, 2017, J ENERG MATER, V35, P385, DOI 10.1080/07370652.2016.1201172
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Sartini F, 2020, INT OPHTHALMOL, V40, P3577, DOI 10.1007/s10792-020-01522-1
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Shen JH, 2016, DISCOV MED, V22, P129
   Silvestri G, 2012, EYE, V26, P1357, DOI 10.1038/eye.2012.165
   Singh SR, 2020, INDIAN J OPHTHALMOL, V68, P118, DOI 10.4103/ijo.IJO_528_19
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P371, DOI 10.4103/ijo.IJO_1173_18
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   TAKAHASHI A, 2019, INVEST OPHTH VIS SCI, V60
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Uchida A, 2020, OSLI RETINA, V51, P22, DOI 10.3928/23258160-20191211-03
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ugarte M, 2014, METALLOMICS, V6, P189, DOI 10.1039/c3mt00291h
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van Kuijk Frederik J G M, 2017, Trans Am Ophthalmol Soc, V115, pT3
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wedl C, 1854, GRUNDZUGE PATHOLOGIS
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 115
TC 16
Z9 17
U1 2
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2021
VL 35
IS 1
BP 121
EP 133
DI 10.1038/s41433-020-01265-4
EA NOV 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PI7BU
UT WOS:000599036200002
PM 33208847
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Farid, M
AF Farid, Marjan
TI Transscleral suturing of the implantable miniature telescope
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID MACULAR DEGENERATION
AB A technique is described for transscleral suturing of the implantable miniature telescope device for end-stage age-related macular degeneration. It provides stabilization and centration of the implantable miniature telescope device in the case of capsule rupture or severe zonular dialysis.
C1 Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Farid, M (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, 118 MedSurge 1, Irvine, CA 92697 USA.
EM mfarid@uci.edu
FU Research to Prevent Blindness, New York, New York; Foundation Fighting
   Blindness, Columbia, Maryland, USA
FX Supported in part by a grant from Research to Prevent Blindness, New
   York, New York, and by the Foundation Fighting Blindness, Columbia,
   Maryland, USA.
CR Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   Colby KA, 2007, ARCH OPHTHALMOL-CHIC, V125, P1118, DOI 10.1001/archopht.125.8.1118
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Lane SS, 2006, CURR OPIN OPHTHALMOL, V17, P94, DOI 10.1097/01.icu.0000193067.86627.a1
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
NR 5
TC 0
Z9 0
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUL
PY 2013
VL 39
IS 7
BP 979
EP 983
DI 10.1016/j.jcrs.2013.05.014
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 184ZR
UT WOS:000321935200003
PM 23707409
DA 2022-11-30
ER

PT J
AU Park, DH
   Kim, IT
AF Park, Dong Ho
   Kim, In Taek
TI Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a
   Korean population
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Single nucleotide polymorphism;
   Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; NEOVASCULAR MEMBRANES; CLINICAL CHARACTERISTICS;
   RANIBIZUMAB; ASSOCIATION; EXPRESSION; THERAPY; GENES
AB The aim of this study was to investigate whether polymorphisms in the vascular endothelial growth factor A gene (VEGF-A) are associated with polypoidal choroidal vasculopathy (PCV) in a Korean population and whether they are associated with PCV phenotypes.
   This was a case-control study comprising 111 patients with PCV and 123 control participants. The PCV and control groups were genotyped for five polymorphisms in VEGF-A. Clinical characteristics were evaluated, including best-corrected visual acuity, fundus findings, and angiography findings at the first visit. Main outcome measures were the genotypes of variants and association with phenotypes.
   Only rs833069 in VEGF-A generated significant allelic associations with PCV (P = 2.24 x 10(-5)). As compared with the AA group, the GG genotype group in rs833069 had a 6.25-fold increased risk of PCV [P = 7.45 x 10(-5), 95% confidence interval (CI) 2.52-15.46] and the AG group had a 1.82-fold increased risk (P = 0.029, 95% CI 1.03-3.24). The haplotype CCGC in VEGF-A showed an association with PCV (P = 2.90 x 10(-5)). However, the phenotypic characteristics of PCV did not show an association with the rs833069 genotypes.
   The rs833069 polymorphism in VEGF-A was significantly associated with the risk of PCV in a Korean population.
C1 [Park, Dong Ho; Kim, In Taek] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Jung Gu 700721, Daegu, South Korea.
C3 Kyungpook National University
RP Kim, IT (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, 50 Samduk Dong 2 Ga, Jung Gu 700721, Daegu, South Korea.
EM itkim@knu.ac.kr
FU Kyungpook National University Hospital
FX This work was supported by a Biomedical Research Institute Grant from
   Kyungpook National University Hospital (2011).
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fang AM, 2009, MOL VIS, V15, P2710
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 28
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2012
VL 56
IS 2
BP 145
EP 151
DI 10.1007/s10384-012-0119-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 908IY
UT WOS:000301485300007
PM 22307775
DA 2022-11-30
ER

PT J
AU Hong, YJ
   Miura, M
   Ju, MJ
   Makita, S
   Iwasaki, T
   Yasuno, Y
AF Hong, Young-Joo
   Miura, Masahiro
   Ju, Myeong Jin
   Makita, Shuichi
   Iwasaki, Takuya
   Yasuno, Yoshiaki
TI Simultaneous Investigation of Vascular and Retinal Pigment Epithelial
   Pathologies of Exudative Macular Diseases by Multifunctional Optical
   Coherence Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography; exudative macular disease; retinal pigment
   epithelium; OCT angiography; polarization-sensitive OCT
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR;
   HIGH-PENETRATION; BLOOD-FLOW; IMAGING POLARIMETRY; HUMAN RPE; DOPPLER;
   ANGIOGRAPHY; MELANIN; AUTOFLUORESCENCE
AB PURPOSE. To investigate exudative macular disease, multifunctional optical coherence tomography (MF-OCT) using a 1-mu m probe band was developed. The clinical utility of MF-OCT was examined in a descriptive case series.
   METHODS. Ten eyes of nine subjects with exudative macular disease, including one eye with age-related macular degeneration (AMD), one eye with idiopathic neovascular maculopathy, and eight eyes with polypoidal choroidal vasculopathy (PCV), were investigated. Areas of 6 3 6 mm(2) around the pathologic region were scanned with 512 x 1024 depth scans in 6.6 seconds. Structural OCT, Doppler optical coherence angiography (OCA), and cumulative phase retardation images were obtained with a single measurement. Each MF-OCT image visualized the structure, vasculature, and birefringence. Degree of polarization uniformity values were also obtained for selective visualization of the retinal pigment epithelium (RPE). The MF-OCT images were compared with conventional ophthalmic images.
   RESULTS. Abnormal vasculatures were observed with Doppler OCA in all eyes, which presented high similarity to indocyanine green angiography in the midphase. The RPE and exudation in the pathologic regions were discriminated in one eye with AMD and five of eight eyes with PCV. Cumulative phase retardation visualized fibrosis scars in two of the PCV cases.
   CONCLUSIONS. Multifunctional OCT revealed depth-resolved abnormal vasculatures, the integrity of the RPE and choroid, discrimination of the RPE and exudation, and existence of fibrosis scars in exudative macular diseases. Interpretation of MF-OCT examination is well matched with conventional ophthalmic examination. These results suggest that MF-OCT can be used as a noninvasive ophthalmic examination tool prior to conventional examinations in clinical routines.
C1 [Hong, Young-Joo; Makita, Shuichi; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki 3058571, Japan.
   [Hong, Young-Joo; Miura, Masahiro; Makita, Shuichi; Yasuno, Yoshiaki] Computat Opt & Ophthalmol Grp, Tsukuba, Ibaraki, Japan.
   [Miura, Masahiro; Iwasaki, Takuya] Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, Ami, Ibaraki, Japan.
   [Ju, Myeong Jin] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
C3 University of Tsukuba; Tokyo Medical University; University of British
   Columbia
RP Yasuno, Y (通讯作者)，Univ Tsukuba, Computat Opt Grp, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058571, Japan.
EM yasuno@optlab2.bk.tsukuba.ac.jp
RI Yasuno, Yoshiaki/F-2586-2011; Makita, Shuichi/G-3806-2011
OI Yasuno, Yoshiaki/0000-0003-1645-7948; Makita,
   Shuichi/0000-0002-6614-3640; JU, MYEONG JIN/0000-0002-4907-3732
FU Japan Society for the Promotion of Science (JSPS) KAKENHI [11J01600,
   24592682]
FX Supported in part by the Japan Society for the Promotion of Science
   (JSPS) KAKENHI Grants 11J01600 and 24592682.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baumann B, 2010, OPTICAL COHERENCE TO, V7554
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2011, BIOMED OPT EXPRESS, V2, P1539, DOI 10.1364/BOE.2.001539
   Blatter C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.070505
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Braaf B, 2012, OPT EXPRESS, V20, P20516, DOI 10.1364/OE.20.020516
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chen ZP, 1997, OPT LETT, V22, P64, DOI 10.1364/OL.22.000064
   deBoer JF, 1997, OPT LETT, V22, P934, DOI 10.1364/OL.22.000934
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   HATA Y, 1995, VIRCHOWS ARCH, V426, P479
   HEE MR, 1992, J OPT SOC AM B, V9, P903, DOI 10.1364/JOSAB.9.000903
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Hong YJ, 2012, OPT EXPRESS, V20, P2740, DOI 10.1364/OE.20.002740
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jaillon F, 2011, BIOMED OPT EXPRESS, V2, P1147, DOI 10.1364/BOE.2.001147
   Ju MJ, 2013, OPT EXPRESS, V21, P19412, DOI 10.1364/OE.21.019412
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Leitgeb RA, 2004, OPT LETT, V29, P171, DOI 10.1364/OL.29.000171
   Leitgeb RA, 2003, OPT EXPRESS, V11, P3116, DOI 10.1364/OE.11.003116
   Lim Y, 2012, OPT LETT, V37, P1958, DOI 10.1364/OL.37.001958
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Mariotti SP., GLOBAL DATA VISUAL I
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2012, INVEST OPHTH VIS SCI, V53, P7137, DOI 10.1167/iovs.12-10666
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park BH, 2005, OPT EXPRESS, V13, P3931, DOI 10.1364/OPEX.13.003931
   Park BH, 2004, OPT LETT, V29, P2512, DOI 10.1364/OL.29.002512
   Park BH, 2003, OPT EXPRESS, V11, P782, DOI 10.1364/OE.11.000782
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Yamanari M, 2006, OPT EXPRESS, V14, P6502, DOI 10.1364/OE.14.006502
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA., 2010, RETINAL ATLAS, P544
   Yasuno Y, 2002, OPT LETT, V27, P1803, DOI 10.1364/OL.27.001803
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 52
TC 34
Z9 34
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 5016
EP 5031
DI 10.1167/iovs.14-14005
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500042
PM 25052993
DA 2022-11-30
ER

PT J
AU Saito, M
   Kano, M
   Itagaki, K
   Ise, S
   Imaizumi, K
   Sekiryu, T
AF Saito, Masaaki
   Kano, Mariko
   Itagaki, Kanako
   Ise, Shigeyuki
   Imaizumi, Kimihiro
   Sekiryu, Tetsuju
TI Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after
   switching to intravitreal aflibercept injection
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Aflibercept; Choroidal thickness;
   Ranibizumab; Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY;
   EPITHELIUM-DERIVED FACTOR; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; NEOVASCULAR MEMBRANES; PHOTODYNAMIC THERAPY;
   RANIBIZUMAB; VERTEPORFIN; EXPRESSION
AB Purpose To investigate the changes in subfoveal thickness after switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy (PCV).
   Methods We retrospectively reviewed 66 eyes of 65 PCV patients (mean age 75.7 years) which were refractory to ranibizumab. The choroidal thickness was measured by optical coherence tomography (OCT) using an enhanced depth imaging technique. Intravitreal aflibercept (2 mg/0.05 ml) was administered with three consecutive monthly injections as a loading dose, followed by further injections bimonthly (every two months).
   Results The mean subfoveal choroidal thickness significantly decreased from 203 mu m at baseline to 171 mu m at month 6 (P < 0.0001). The mean logMAR best-corrected visual acuity levels significantly improved from 0.40 at baseline to 0.33 at 6 months (P < 0.001). The central retinal thickness significantly decreased from 249 mu m at baseline to 161 mu m at 6 months (P < 0.0001). At month 6, 41 (62.1 %) eyes had dry macula by OCT. Of 46 eyes with polypoidal lesions at baseline, complete regression of polypoidal lesions was achieved in 26 (56.5 %) eyes at 3 months.
   Conclusions The choroidal thickness in PCV eyes significantly decreased after switching to intravitreal aflibercept injection. Aflibercept may help prevent choroidal neovascularization near or under the retinal pigment epithelium, which might help achieve greater occlusion of polypoidal lesions compared with ranibizumab.
C1 [Saito, Masaaki; Kano, Mariko; Itagaki, Kanako; Ise, Shigeyuki; Imaizumi, Kimihiro; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Saito, Masaaki] Akita Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 1-1-1 Hondo Akita, Akita 0108543, Japan.
C3 Fukushima Medical University; Akita University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.; Saito, M (通讯作者)，Akita Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 1-1-1 Hondo Akita, Akita 0108543, Japan.
EM masaaki@med.akita-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Sekiryu, Tetsuju/0000-0001-8042-2729
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 35
TC 19
Z9 19
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2016
VL 60
IS 1
BP 35
EP 41
DI 10.1007/s10384-015-0411-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF3UZ
UT WOS:000371274900006
PM 26350229
DA 2022-11-30
ER

PT J
AU Nakai, S
   Honda, S
   Miki, A
   Matsumiya, W
   Nakamura, M
AF Nakai, Shunichiro
   Honda, Shigeru
   Miki, Akiko
   Matsumiya, Wataru
   Nakamura, Makoto
TI Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between
   Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-vascular endothelial growth factor; Polypoidal choroidal
   vasculopathy; Indocyanine green angiography
ID FACTOR-H CFH; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   PROGNOSTIC-FACTORS; VERTEPORFIN; VARIANTS; EFFICACY; ARMS2
AB Background: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective cohort study of 38 treatment-naive PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR. Results: The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 +/- 1.7 in type 1 PCV and 1.2 +/- 1.3 in type 2 PCV. Conclusions: The outcomes of IVR may be different between two angiographic subtypes of PCV. (C) 2017 S. Karger AG, Basel
C1 [Nakai, Shunichiro; Honda, Shigeru; Miki, Akiko; Matsumiya, Wataru; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Nakamura, Makoto/0000-0002-6464-4302
FU Ministry of Education, Science and Culture, Tokyo, Japan [16K11286];
   Takeda Science Foundation, Osaka, Japan
FX This study was supported by a Grant-in Aid (C) 16K11286 from the
   Ministry of Education, Science and Culture, Tokyo, Japan (S.H.), and by
   a grant from the Takeda Science Foundation, Osaka, Japan (S.H.). The
   funding organization had no role in the design or conduct of this
   research.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeong S, 2016, BR J OPHTHALMOL
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 26
TC 9
Z9 10
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 237
IS 3
BP 123
EP 127
DI 10.1159/000455273
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES9UA
UT WOS:000399905700001
PM 28324878
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Kubota, T
   Mabuchi, F
   Imasawa, M
   Tanabe, N
   Iijima, H
AF Sakurada, Yoichi
   Kubota, Takeo
   Mabuchi, Fumihiko
   Imasawa, Mitsuhiro
   Tanabe, Naohiko
   Iijima, Hiroyuki
TI Association of LOC387715 A69S with vitreous hemorrhage in polypoidal
   choroidal vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID HTRA1 PROMOTER POLYMORPHISM; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   JAPANESE POPULATION; GENE; TRANSLOCATION; RETINOTOMY; OUTCOMES; SURGERY
AB PURPOSE: To investigate whether the LOC387715 polymorphism is associated with polypoidal choroidal vasculopathy (PCV) and with vitreous hemorrhage (VH), one of the most severe clinical phenotypes, in the Japanese population.
   DESIGN: Cross-sectional case,control association study.
   METHODS: One hundred and nine Japanese patients with PCV, composed of nine patients associated with VH (VH group) and 100 patients without VH (non-VH group), and 85 control subjects were analyzed for the LOC387715 polymorphism (rs = 10490924), using denaturing high,performance chromatography.
   RESULTS: There was a significant difference in the T allele frequency between PCV patients and control subjects (P < .0001). In comparison with wild-type homozygosity (GG), homozygosity for the at-risk allele genotype (TT) increased the likelihood for PCV 8.4-fold (3.6 to 19.5, 95% confidence interval [CI]) and heterozygosity for the at-risk allele genotype (TG) increased the likelihood for PCV 4.0-fold (1-9 to 8.4, 95% CI). There was a significant difference in the genotypic frequency at the LOC387715 site between the VH and non,VH groups (P = .0099, Chi-square test) with the TT genotype occurring in 88.9% in the VH group and 37.0% in the non,VH group. The frequency of the T allele in the VH group was significantly greater than that in the non,VH group (0.944 vs 0.610; P = .0039, Fisher exact test).
   CONCLUSIONS: The LOC387715 polymorphism is associated with PCV and clinical severity in the sub, groups of PCV in the Japanese population.
C1 [Sakurada, Yoichi; Mabuchi, Fumihiko; Imasawa, Mitsuhiro; Tanabe, Naohiko; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo City, Yamanashi, Japan.
   [Kubota, Takeo] Univ Yamanashi, Dept Epigenet Med, Fac Med, Chuo City, Yamanashi, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Iijima, H (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Shimokato 1110, Yamanashi 4093898, Japan.
EM hiijimar@yamanashi.ac.jp
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Guzowski Dorothy, 2005, J Biomol Tech, V16, P154
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Marx J, 2006, SCIENCE, V314, P405
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 23
TC 46
Z9 51
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2008
VL 145
IS 6
BP 1058
EP 1062
DI 10.1016/j.ajo.2008.02.007
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307PS
UT WOS:000256331400019
PM 18400199
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Shaikh, A
   Goud, A
   Kawasaki, R
   Kwon, OW
   Chang, A
   Lam, D
   Das, T
AF Chhablani, Jay
   Shaikh, Adnan
   Goud, Abhilash
   Kawasaki, Ryo
   Kwon, Oh W.
   Chang, Andrew
   Lam, Dennis
   Das, Taraprasad
TI Asia-Pacific Technology and Trend Survey 2016-2017
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Asia-Pacific; AP-TAT survey; PAT survey; practice; retina specialists
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION;
   ANTIBIOTIC-PROPHYLAXIS; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   RANIBIZUMAB; ENDOPHTHALMITIS; EFFICACY; SAFETY
AB Purpose: To report the results of a survey conducted among retina specialists in the Asia-Pacific region on real-life practice patterns in the management of vitreoretinal diseases.
   Design: Prospective questionnaire-based study.
   Methods: In 2016 and 2017. a link was sent to 1400 retinal specialists across the Asia-Pacific region by e-mail, which directed to a web-based questionnaire (Google forms or Survey Monkey) with secure confidential access. Answers to some of the common questions were compared with the domestic and global trends results of the 2016 American Society of Retina Specialists Preferences and Trends survey.
   Results: Of 1400 retinal specialists who received the email broadcast, 539 (38.5%) and 200 (14.3%) completed the survey in 2016 and 2017. respectively. Among those who completed the survey, approximately 85% practiced combined medical and surgical retina. In the management of wet age-related macular degeneration, ranibizumab was the drug of choice (41% of respondents) in 2016. and bevacizumab (48%) in 2017. In the management of polypoidal choroidal vasculopathy, both combination of verteporfin photodynamic therapy and anti-vascular endothelial growth factor (VEGF) (59% of respondents) and intravitreal aflibercept monotherapy (53%) were preferred. Anti-VEGF treatment remained the first choice for center-involving diabetic macular edema (DME) (78% in 2016 and 87% in 2017) and switching to dexamethasone implant in nonresponding DME was preferred after 6 anti-VEGF injections (42% in 2016 and 53% in 2017).
   Conclusions: The survey revealed information that may be close to real-world practices in the Asia-Pacific region and could be of help to understand the transformation of global trends and practices due to evolving evidence and technologies.
C1 [Chhablani, Jay; Shaikh, Adnan; Goud, Abhilash; Das, Taraprasad] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 34, Telangana, India.
   [Kawasaki, Ryo] Osaka Univ, Grad Sch Med, Dept Vis Informat Topcon, Osaka, Japan.
   [Kwon, Oh W.] Nune Eye Hosp, Retina Ctr, Seoul, South Korea.
   [Chang, Andrew] Univ Sydney, Sydney Retina Clin, Sydney, NSW, Australia.
   [Lam, Dennis] Dennis Lam & Partners Eye Ctr, Cent, Hong Kong, Peoples R China.
C3 L. V. Prasad Eye Institute; Osaka University; University of Sydney
RP Das, T (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 34, Telangana, India.
EM tpdbei@gmail.com
RI Lam, Dennis/AAL-1211-2020; Kawasaki, Ryo/B-7266-2009
OI Kawasaki, Ryo/0000-0002-7492-6303; Chhablani, Jay/0000-0003-1772-3558
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee WK, 2017, INVEST OPHTH VIS SCI, V58
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Pan CW, 2015, OPTOMETRY VISION SCI, V92, P258, DOI 10.1097/OPX.0000000000000516
   Rayat JS, 2016, CAN J OPHTHALMOL, V51, P233, DOI 10.1016/j.jcjo.2015.10.014
   Rezaei K, GLOBAL TRENDS RETINA
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
NR 17
TC 5
Z9 5
U1 0
U2 0
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD JAN-FEB
PY 2019
VL 8
IS 1
BP 43
EP 54
DI 10.22608/APO.2018136
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JT1SL
UT WOS:000500777600008
PM 30188025
OA gold
DA 2022-11-30
ER

PT J
AU Sarangarajan, R
   Apte, SP
AF Sarangarajan, R
   Apte, SP
TI Melanin aggregation and polymerization: Possible implications in
   age-related macular degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE melanin aggregation; polymerization; age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; MELANOSOMAL PROTEINS;
   5,6-DIHYDROXYINDOLE-2-CARBOXYLIC ACID; HUMAN RPE; LIPOFUSCIN;
   MELANOGENESIS; TYROSINASE; ACCUMULATION; MECHANISMS; OXYGEN
AB The state of aggregation of the polymer melanin may determine its propensity to act either as an antioxidant or as a pro-oxidant. Age-related alterations in its state of aggregation are suggested to alter the degree of polymerization so as to confer increased pro-oxidant propensity to the melanin polymer. Degradative processes in/of melanosomes and lysosomes in the retinal pigment epithelium (RPE) appear to be intimately connected so that they may involve exchange of contents between these two organelles. An increased pro-oxidant environment inside lysosomes has been associated with preventing the digestion of cellular components including photoreceptor outer rod segments partly by altering function of lysosomal hydrolases. It is speculated that age-related accumulation of low-molecular-weight phototoxic pro-oxidant melanin oligomers within lysosomes in the RPE may be partly responsible for decreasing the digestive rate of incorporated cellular components (including photoreceptor outer rod segments) which may lead to lipofuscin formation. More work is required to definitively refute or support such a hypothesis. Copyright (C) 2005 S. Karger AG, Basel.
C1 Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Worcester, MA USA.
RP Apte, SP (通讯作者)，2313 Welch Pl, Mansfield, TX 76063 USA.
EM Shireeshpapte@msn.com
CR Ancans J, 2000, FEBS LETT, V478, P57, DOI 10.1016/S0014-5793(00)01795-6
   Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251
   AROCA P, 1992, EUR J BIOCHEM, V208, P155, DOI 10.1111/j.1432-1033.1992.tb17169.x
   BHATNAGAR V, 1993, ARCH BIOCHEM BIOPHYS, V307, P183, DOI 10.1006/abbi.1993.1577
   Blarzino C, 1999, FREE RADICAL BIO MED, V26, P446, DOI 10.1016/S0891-5849(98)00225-1
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Borovansky J, 2003, PIGM CELL RES, V16, P280, DOI 10.1034/j.1600-0749.2003.00040.x
   BOROVANSKY J, 1977, CELL BIOL INT REP, V1, P549, DOI 10.1016/0309-1651(77)90093-5
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Clancy CMR, 2000, J PHYS CHEM B, V104, P7871, DOI 10.1021/jp001630q
   Dayhaw-Barker P, 2002, INT J TOXICOL, V21, P451, DOI 10.1080/10915810290169873
   DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213
   DONATIEN PD, 1995, EUR J BIOCHEM, V232, P159, DOI 10.1111/j.1432-1033.1995.tb20794.x
   Dutkiewicz R, 2000, EXP EYE RES, V70, P563, DOI 10.1006/exer.1999.0819
   ENDO H, 1973, DEV BIOL, V32, P69, DOI 10.1016/0012-1606(73)90220-0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Fuller BB, 2001, EXP CELL RES, V262, P197, DOI 10.1006/excr.2000.5092
   Gallas JM, 1999, BIOPHYS J, V77, P1135, DOI 10.1016/S0006-3495(99)76964-X
   GARCIA RI, 1983, EXPERIENTIA, V39, P391, DOI 10.1007/BF01963141
   Geng LJ, 1999, EXP EYE RES, V69, P539, DOI 10.1006/exer.1999.0735
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hegedus ZL, 2000, TOXICOLOGY, V145, P85, DOI 10.1016/S0300-483X(00)00157-8
   Ivy GO, 1996, ANN NY ACAD SCI, V786, P12, DOI 10.1111/j.1749-6632.1996.tb39048.x
   KATO T, 1986, BIOCHIM BIOPHYS ACTA, V881, P415, DOI 10.1016/0304-4165(86)90034-6
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   KENNEDY CJ, 1994, EXP CELL RES, V210, P209, DOI 10.1006/excr.1994.1031
   KIKUGAWA K, 1989, ADV EXP MED BIOL, V266, P345
   Kim I T, 1998, Korean J Ophthalmol, V12, P85
   KOLLIAS N, 1987, J INVEST DERMATOL, V89, P384, DOI 10.1111/1523-1747.ep12471764
   KONO R, 1984, CANCER RES, V44, P4337
   Lindquist NG, 1999, EXP EYE RES, V69, P431, DOI 10.1006/exer.1999.0718
   Littrell KC, 2003, PHOTOCHEM PHOTOBIOL, V77, P115, DOI 10.1562/0031-8655(2003)077<0115:SSOBMB>2.0.CO;2
   Mani I, 2001, PIGM CELL RES, V14, P170, DOI 10.1034/j.1600-0749.2001.140306.x
   Metodiewa D, 1999, FREE RADICAL BIO MED, V26, P107, DOI 10.1016/S0891-5849(98)00167-1
   MISHIMA Y, 1994, PIGM CELL RES, V7, P376, DOI 10.1111/j.1600-0749.1994.tb00065.x
   Nofsinger JB, 2002, FREE RADICAL BIO MED, V32, P720, DOI 10.1016/S0891-5849(02)00763-3
   Nohl H, 1998, FREE RADICAL BIO MED, V25, P666, DOI 10.1016/S0891-5849(98)00105-1
   ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291
   Ozeki H, 1997, ANAL BIOCHEM, V248, P149, DOI 10.1006/abio.1997.2079
   PASCUTTI PG, 1992, J PHOTOCH PHOTOBIO B, V16, P257, DOI 10.1016/1011-1344(92)80014-M
   Pawlak A, 2002, ARCH BIOCHEM BIOPHYS, V403, P59, DOI 10.1016/S0003-9861(02)00260-6
   Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7
   RODRIGUEZLOPEZ JN, 1991, BIOCHIM BIOPHYS ACTA, V1076, P379
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Sarangarajan R, 2004, OPHTHALMIC RES, V36, P303, DOI 10.1159/000081632
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Sharma AK, 2001, PROTEINS, V45, P229, DOI 10.1002/prot.1143
   Sharma S, 2002, PIGM CELL RES, V15, P127, DOI 10.1034/j.1600-0749.2002.1o076.x
   SIMON JD, 2002, SPECTRUM-J STATE GOV, V15, P1
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   TAKEUCHI YK, 1975, J EXP ZOOL, V192, P391, DOI 10.1002/jez.1401920312
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X
   Wagh S, 2000, PIGM CELL RES, V13, P442, DOI 10.1034/j.1600-0749.2000.130606.x
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   ZAJAC GW, 1994, BBA-GEN SUBJECTS, V1199, P271, DOI 10.1016/0304-4165(94)90006-X
NR 61
TC 14
Z9 15
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2005
VL 37
IS 3
BP 136
EP 141
DI 10.1159/000085533
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 946UD
UT WOS:000230597700004
PM 15867475
DA 2022-11-30
ER

PT J
AU Dewi, NA
   Yuzawa, M
   Tochigi, K
   Kawamura, A
   Mori, R
AF Dewi, Nadia Artha
   Yuzawa, Mitsuko
   Tochigi, Kasumi
   Kawamura, Akiyuki
   Mori, Ryusaburo
TI Effects of photodynamic therapy on the choriocapillaris and retinal
   pigment epithelium in the irradiated area
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; hypofluorescence; indocyanine green
   angiography; photodynamic therapy; polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR DEGENERATION;
   NEOVASCULARIZATION; VERTEPORFIN
AB Purpose: To evaluate the effect of photodynamic therapy (PDT) on the choriocapillaris and retinal pigment epithelium (RPE) in the irradiated area surrounding choroidal neovascularization (CNV) during 12 months of follow-up.
   Methods: We reviewed the medical records, and indocyanine green angiography (IA), fluorescein angiography (FA), and fundus photographic findings of 72 eyes (72 patients) with CNV associated with age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV). Patients were divided into three groups based on the number of PDT sessions. Twelve months after PDT, we evaluated the relationship between the number of sessions and both the presence of hypofluorescence in the late phase of IA and window defects observed on FA in the irradiated areas.
   Results: Twenty-three patients had one PDT session (group I), 25 had two (group II), and 24 had three or four (group III). IA revealed hypofluorescence indicating a choriocapillaris filling defect within the irradiated area in 11 eyes (48%) in group I, 18 (72%) in group II, and 22 (91%) in group III. The correlation between the number of PDT sessions and hypofluorescence in the irradiated areas was significant. FA showed window defects surrounding CNV in 26%, 52%, and 71% of eyes from groups I, II, and III, respectively. Subretinal hemorrhages had been present in 23 eyes (32%) and exudation in 13 (18%) prior to PDT. Areas without hemorrhages or exudation prior to PDT had a normal appearance within the irradiated area in all 72 eyes.
   Conclusions: Although the RPE in the irradiated area was preserved, 12 months after PDT, mild choriocapillaris occlusion was detected in the irradiated area in eyes that had undergone multiple PDT sessions.
C1 [Dewi, Nadia Artha; Yuzawa, Mitsuko; Tochigi, Kasumi; Kawamura, Akiyuki; Mori, Ryusaburo] Nihon Univ, Dept Ophthalmol, Sch Med, Tokyo 1018309, Japan.
C3 Nihon University
RP Yuzawa, M (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM yuzawam@med.nihon-u.ac.jp
OI DEWI, NADIA/0000-0002-6077-170X
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research, from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (Mitsuko Yuzawa).
CR BARQUET LA, 2006, AGE RELATED MACULAR, P200
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Hussain Nazimul, 2004, Indian Journal of Ophthalmology, V52, P227
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Kroll P, 2006, BRIT J OPHTHALMOL, V90, P128, DOI 10.1136/bjo.2005.083337
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   MAHESH S, 2005, INDIAN J OPHTHALMOL, V53, P61
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Obana A, 2000, ARCH OPHTHALMOL-CHIC, V118, P650
   Parodi MB, 2003, BRIT J OPHTHALMOL, V87, P177, DOI 10.1136/bjo.87.2.177
   Paskowitz DM, 2004, INVEST OPHTH VIS SCI, V45, P4190, DOI 10.1167/iovs.04-0676
   REINKE MH, 2004, PHOTODYNAMIC THERAPY, P107
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 19
TC 16
Z9 18
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2008
VL 52
IS 4
BP 277
EP 281
DI 10.1007/s10384-008-0551-9
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 344XI
UT WOS:000258960200006
PM 18773265
DA 2022-11-30
ER

PT J
AU Derham, AM
   Chen, E
   Bunya, VY
   O'Malley, RE
AF Derham, Angeline M.
   Chen, Eric
   Bunya, Vatinee Y.
   O'Malley, Ronan E.
TI Bilateral Herpetic Keratitis After Bilateral Intravitreal Bevacizumab
   for Exudative Macular Degeneration
SO CORNEA
LA English
DT Article
DE age-related macular degeneration; bevacizumab; diabetes mellitus; herpes
   simplex epithelial keratitis; intravitreal injection
ID TRIAMCINOLONE ACETONIDE; EPITHELIAL KERATITIS; INJECTION
AB Purpose: To report a case of bilateral herpetic epithelial keratitis after bilateral intravitreal bevacizumab injections for the treatment of exudative age-related macular degeneration.
   Methods: A 66-year-old man with diabetes and an extensive history of bilateral anti-vascular endothelial growth factor treatments for exudative age-related macular degeneration received an intravitreal bevacizumab injection in the right eye and triple therapy ( bevacizumab, photodynamic therapy, and triamcinolone acetonide) in the left eye. After 4 days, he presented with pain, photophobia, tearing, and decreased vision in both eyes. Slit-lamp examination revealed bilateral dendritic epithelial lesions with terminal bulbs, and he was diagnosed with bilateral herpes simplex epithelial keratitis.
   Results: The patient was treated with ganciclovir ophthalmic ointment and oral acyclovir with resolution of signs and symptoms.
   Conclusions: To our knowledge, this is the first documented account of bilateral herpetic epithelial keratitis after bilateral intravitreal bevacizumab injections.
C1 [Derham, Angeline M.; Chen, Eric; O'Malley, Ronan E.] Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
   [Bunya, Vatinee Y.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX USA.
   [Bunya, Vatinee Y.] Weill Cornell Med Coll, Houston, TX USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; Cornell
   University
RP Chen, E (通讯作者)，Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM ecmd@houstonretina.com
CR Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Gulkilik G, 2007, CORNEA, V26, P1000, DOI 10.1097/ICO.0b013e3180cab659
   Hashizume K, 2009, CORNEA, V28, P463, DOI 10.1097/ICO.0b013e31818a7d9a
   Inoue H., 2014, OPHTHALMOLOGY, V5, P277
   Kaiserman I, 2005, OPHTHALMOLOGY, V112, P2184, DOI 10.1016/j.ophtha.2005.07.014
   Khalili MR, 2009, CORNEA, V28, P360, DOI 10.1097/ICO.0b013e318189137a
   Liesegang TJ, 2001, CORNEA, V20, P1, DOI 10.1097/00003226-200101000-00001
   Mitchell BM, 2003, J NEUROVIROL, V9, P194, DOI 10.1080/13550280390194000
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Shtein RM, 2007, CORNEA, V26, P641, DOI 10.1097/ICO.0b013e318041f0c0
   Yoon KC, 2010, CORNEA, V29, P465, DOI 10.1097/ICO.0b013e3181b53310
NR 11
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3740
EI 1536-4798
J9 CORNEA
JI Cornea
PD JUL
PY 2017
VL 36
IS 7
BP 878
EP 879
DI 10.1097/ICO.0000000000001233
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX5HM
UT WOS:000403270200021
PM 28489722
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Jager, R
   Ong, J
   Lohrenz, R
   Hamilton, RJ
   Stea, B
   Drew, M
   Kokame, G
AF Chhablani, Jay
   Jager, Rama
   Ong, Joshua
   Lohrenz, Ryan
   Hamilton, Russell J.
   Stea, Baldassare
   Drew, Mary
   Kokame, Gregg
CA Doheny Retina Study Grp
TI Two-year outcomes of episcieral brachytherapy adjunct to anti-VEGF
   therapy for treatment-resistant nAMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Episcleral brachytherapy; Neovascular age-related macular degeneration;
   Retina; Anti-vascular endothelial growth factor; Polypoidal choroidal
   vasculopathy
AB Purpose This study was designed to demonstrate the safety and feasibility of episcleral brachytherapy (ESB) for the treatment of anti-vascular endothelial growth factor (anti-VEGF) resistant neovascular age-related macular degeneration (nAMD) in a 6-subject cohort adjunct to anti-VEGF therapy.
   Methods Six eyes of six subjects with anti-VEGF resistant nAMD (persistent fluid or hemorrhage despite frequent antiVEGF treatment) were treated with ESB between May 2018 and July 2018 as part of a larger early feasibility trial. Baseline and follow-up exams with multi-modal imaging were conducted.
   Results In this analysis, six eyes were included. The mean age was 74.7 years; 33% were female; 67% had polypoidal choroidal vasculopathy. The mean number of lifetime anti-VEGF injections received prior to the study enrollment was 33.9 injections and 10 injections in the year prior to the study enrollment. In the first and second years following ESB, the mean number of injections was 8.5 and 8, respectively. No evidence of radiation-induced toxicity through 2 years following ESB was observed. The mean baseline VA was 55.3 letters. At 1 year, the mean VA increased by 3.2 letters and 1.7 letters at year 2. At 2 years, the mean change in vascular complex on ICGA was -18%, -43% on OCTA, and-5% on FA. The subjects also experienced a mean decrease in CRT on OCT of 21% after 2 years.
   Conclusions The results from this six-subject cohort with 2-year data support additional investigations of ESB for nAMD, specifically those with persistent disease activity and treatment resistant nAMD.
C1 [Chhablani, Jay; Ong, Joshua] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   [Jager, Rama] Univ Retina & Macula Associates, Oak Forest, IL USA.
   [Jager, Rama] Univ Illinois, Chicago, IL USA.
   [Lohrenz, Ryan; Drew, Mary] SalutarisMD, Tucson, AZ USA.
   [Hamilton, Russell J.; Stea, Baldassare] Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA.
   [Stea, Baldassare] Univ Arizona, Canc Ctr, Tucson, AZ USA.
   [Kokame, Gregg] Univ Hawaii, Div Ophthalmol, Dept Surg, John A Burns Sch Med, Honolulu, HI 96822 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Illinois System; University of Illinois
   Chicago; University of Illinois Chicago Hospital; University of Arizona;
   University of Arizona; University of Hawaii System
RP Chhablani, J (通讯作者)，Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
EM jay.chhablani@gmail.com
FU Salutaris Medical Devices, Inc.
FX This study was financially sponsored by Salutaris Medical Devices, Inc.
CR Balaggan K, 2016, WORLD OPHTHALMOLOGY
   Chalam KV, 2011, RETINA-J RET VIT DIS, V31, P169, DOI 10.1097/IAE.0b013e3181dee621
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Friedman WA, 2011, NEUROL RES, V33, P803, DOI 10.1179/1743132811Y.0000000043
   Heussen FM, 2011, INVEST OPHTH VIS SCI, V52, P7792, DOI 10.1167/iovs.11-8023
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Schneider BF, 1997, J NEUROSURG, V87, P352, DOI 10.3171/jns.1997.87.3.0352
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Sirks MJ, 2022, ACTA OPHTHALMOL, V100, pE1522, DOI 10.1111/aos.15148
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2022
VL 260
IS 12
BP 3791
EP 3798
DI 10.1007/s00417-022-05736-0
EA JUN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6F8MV
UT WOS:000812453300001
PM 35713709
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Lee, TG
   Kim, HS
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Lee, Tae Gon
   Kim, Hyoung Seok
TI DIAGNOSIS OF TYPE 3 NEOVASCULARIZATION BASED ON OPTICAL COHERENCE
   TOMOGRAPHY IMAGES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Type 3 neovascularization; retinal angiomatous proliferation; optical
   coherence tomography; age-related macular degeneration; diagnosis
ID RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; RETICULAR PSEUDODRUSEN;
   PREVALENCE; DRUSEN; RANIBIZUMAB; ASSOCIATION; ANGIOGRAPHY
AB Purpose: To evaluate the concordance of an optical coherence tomography (OCT)based diagnosis of Type 3 neovascularization and an indocyanine green angiography (ICGA)-based diagnosis in neovascular age-related macular degeneration (AMD).
   Methods: This observational case series includes 263 eyes from 263 patients who were diagnosed with treatment-naive neovascular AMD. Patients exhibiting at least three of the following OCT features were diagnosed with Type 3 neovascularization: subfoveal choroidal thickness <200 mu m, presence of intraretinal fluid accumulation, absence of sub-retinal fluid, gently-sloping dome-shaped retinal pigment epithelial detachment or trapezoid-shaped retinal pigment epithelial detachment without an obvious peak, and intraretinal mass lesion. The incidence of cases exhibiting three or more OCT features was compared among different subtypes of neovascular AMD. Additionally, the concordance of OCT-based diagnosis and ICGA-based diagnosis was evaluated.
   Results: Three or more OCT features were noted in 8 of 82 (9.8%) eyes with typical neovascular AMD, 4 of 147 (2.7%) eyes with polypoidal choroidal vasculopathy, and 30 of 34 (88.2%) eyes with Type 3 neovascularization, respectively. The incidence was significantly greater in Type 3 neovascularization than in the other subtypes of neovascular AMD (P < 0.001). Of patients diagnosed with Type 3 neovascularization using ICGA-based methods, 88.2% were also diagnosed with Type 3 neovascularization using OCT-based methods. Only 5.2% of patients diagnosed with other subtypes of neovascular AMD using ICGA-based methods were diagnosed with Type 3 neovascularization using OCT-based methods.
   Conclusion: Optical coherence tomography-based diagnosis of Type 3 neovascularization showed relatively high concordance compared with ICGA-based diagnosis. This method may be useful in clinical practice.
C1 [Kim, Jae Hui; Kim, Jong Woo; Lee, Tae Gon; Kim, Hyoung Seok] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX Supported by Kim's Eye Hospital Research Center.
CR Bearelly S, 2008, BRIT J OPHTHALMOL, V92, P191, DOI 10.1136/bjo.2007.118760
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kerbs I, 2009, OPHTHAL SURG LAS IM, V40, P285, DOI [10.9999/15428877-20090430-10, 10.3928/15428877-20090430-10]
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 29
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1506
EP 1515
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200029
PM 27359259
DA 2022-11-30
ER

PT J
AU Hutton-Smith, LA
   Gaffney, EA
   Byrne, HM
   Maini, PK
   Schwab, D
   Mazer, NA
AF Hutton-Smith, Laurence A.
   Gaffney, Eamonn A.
   Byrne, Helen M.
   Maini, Philip K.
   Schwab, Dietmar
   Mazer, Norman A.
TI A Mechanistic Model of the Intravitreal Pharmacokinetics of Large
   Molecules and the Pharmacodynamic Suppression of Ocular Vascular
   Endothelial Growth Factor Levels by Ranibizumab in Patients with
   Neovascular Age-Related Macular Degeneration
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE intravitreal; pharmacokinetics; VEGF; ranibizumab; neovascular
   age-related macular degeneration; mechanistic modeling
ID INTRAOCULAR PHARMACOKINETICS; INJECTION; BEVACIZUMAB; BINDING;
   BEVACKUMAB; DIFFUSION; TRANSPORT; THERAPY; LIGANDS; VOLUME
AB Intravitreal injection of anti-VEGF (vascular endothelial growth factor) antibodies or antibody fragments has been shown to be a highly effective treatment for neovascular age-related macular degeneration (wet AMD). The ocular half-life (t(1/2)) of these large molecules, determined in ocular fluids or derived from serum levels, varies with molecular size and is larger in humans than in preclinical animal species. The high affinity binding of VEGF to these molecules lowers the free concentration of VEGF and reduces its occupancy on VEGF receptors in ocular tissues. To understand the biophysical determinants of t(1/2) for anti-VEGF antibodies and the time-course of VEGF in ocular fluids, we developed a mechanistic model of intravitreal pharmacokinetics (IVT PK) for anti-VEGF antibodies and combined it with a mechanistic model of the pharrnacodynamics (RVR PD) of VEGF suppression by ranibizumab, an anti-VEGF recombinant, humanized monoclonal antibody fragment (Fab). Our IVT PK model predicts that the ocular t(1/2) of a large molecule will be approximately four-times the calculated value of its vitreous diffusion time (T-diff), defined as r(vit)(2)/6D, where r(vit) is the radius of the vitreous chamber in that species (modeled as a sphere), and D is the diffusion coefficient of the molecule in physiological saline at 37 degrees C obtained from the Stokes Einstein relation. This prediction is verified from a compilation of data and calculations on various large molecules in the human, monkey, rabbit, and rat and is consistent with the reported t(1/2) values of ranibizumab in humans (mean value 7.9 days) and the calculated T-diff of 1.59 days. Our RVR PD model is based on the publication of Saunders et al. (Br. J. Ophthalmol. 2015, 99, 1554-1559) who reported data on the time course of VEGF levels in aqueous humor samples obtained from 31 patients receiving ranibizumab treatment for wet AMD and developed a compartmental mathematical model to describe the VEGF suppression profiles. We modified Saunders' model with the known 2:1 stoichiometry of ranibizumab-VEGF binding and included the association and dissociation kinetics of the binding reactions. Using the RVR PD model, we reanalyzed Saunders' data to estimate the in vivo dissociation constant (K-D) between ranibizumab and VEGF. Our analysis demonstrates the delicate interrelationship between the in vivo K-D value and the intravitreal half-life and yields an in vivo K-D estimate that is appreciably larger than the in vitro K-D estimates reported in the literature. Potential explanations for the difference between the in vivo and in vitro K-D values, which appear to reflect the different methodologies and experimental conditions, are discussed. We conclude that the combined mechanistic model of IVT PK and RVR PD provides a useful framework for simulating the effects of dose, K-D, and the molecular weight of VEGF-binding molecules on the duration of VEGF suppression.
C1 [Hutton-Smith, Laurence A.; Gaffney, Eamonn A.; Byrne, Helen M.; Maini, Philip K.] Univ Oxford, Wolfson Ctr Math Biol, Math Inst, Radcliffe Observ Quarter, Andrew Wiles Bldg,Woodstock Rd, Oxford OX2 6GG, England.
   [Schwab, Dietmar; Mazer, Norman A.] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Clin Pharmacol, Bldg 663-2130-12,Hochstr 16, CH-4070 Basel, Switzerland.
C3 University of Oxford; Roche Holding
RP Hutton-Smith, LA (通讯作者)，Univ Oxford, Wolfson Ctr Math Biol, Math Inst, Radcliffe Observ Quarter, Andrew Wiles Bldg,Woodstock Rd, Oxford OX2 6GG, England.; Mazer, NA (通讯作者)，Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Clin Pharmacol, Bldg 663-2130-12,Hochstr 16, CH-4070 Basel, Switzerland.
EM laurence.hutton-smith@pmb.ox.ac.uk; norman.mazer@roche.com
OI Gaffney, Eamonn/0000-0002-6888-4362; Byrne, Helen/0000-0003-1771-5910
FU EPSRC; MRC [EP/L016044/1]; Roche Pharma Research and Early Development
FX N.A.M. wishes to acknowledge Dr. Daniel Serafin for assistance using the
   plot digitizer and for helpful discussions related to this work. Funding
   provided to Wolfson Centre of Mathematical Biology by EPSRC and MRC
   (Grant No. EP/L016044/1). Additional funding provided by Roche Pharma
   Research and Early Development.
CR [Anonymous], 2015, MATLAB US GUID R2015
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressloff PC, 2013, REV MOD PHYS, V85, P135, DOI 10.1103/RevModPhys.85.135
   Chuang LH, 2011, OPHTHALMIC RES, V45, P31, DOI 10.1159/000315617
   Davuluri G, 2009, ARCH OPHTHALMOL-CHIC, V127, P613, DOI 10.1001/archophthalmol.2009.88
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FONTANA ST, 1980, ARCH OPHTHALMOL-CHIC, V98, P1803
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Macchioni A, 2008, CHEM SOC REV, V37, P479, DOI 10.1039/b615067p
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, P68, DOI 10.1111/j.1755-3768.2009.01842.x
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park J, 2005, J CONTROL RELEASE, V105, P279, DOI 10.1016/j.jconrel.2005.03.010
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006-3495(02)73933-7
   Reille-Seroussi M, 2015, BIOCHEMISTRY-US, V54, P5147, DOI 10.1021/acs.biochem.5b00722
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saunders DJ, 2015, BRIT J OPHTHALMOL, V99, P1554, DOI 10.1136/bjophthalmol-2015-306771
   Sha O., 2006, Neuroembryology and Aging, V4, P183, DOI 10.1159/000118928
   Stuttfeld E., 2012, THESIS
   Tasman W., 2013, DUANES OPHTHALMOLOGY
   Toris CB, 1999, AM J OPHTHALMOL, V127, P407, DOI 10.1016/S0002-9394(98)00436-X
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 37
TC 45
Z9 45
U1 2
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2016
VL 13
IS 9
BP 2941
EP 2950
DI 10.1021/acs.molpharmaceut.5b00849
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DV1WV
UT WOS:000382713700009
PM 26726925
DA 2022-11-30
ER

PT J
AU Friberg, TR
   Huang, L
   Palaiou, M
   Bremer, R
AF Friberg, Thomas R.
   Huang, Linda
   Palaiou, Maria
   Bremer, Rob
TI Computerized detection and measurement of drusen in age-related macular
   degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID IMAGES; FUNDUS; PHOTOGRAPHS; DIAGNOSIS; PROGNOSIS; DISEASE
AB BACKGROUND AND OBJECTIVE: The authors used a drusen detection algorithm to quantitate drusen on digitized images and determined its precision and accuracy.
   PATIENTS AND METHODS: Fundus images from 349 participants in the Age-Related Eye Disease Study trial were digitized and analyzed with the Drusen Analyzer (IRIDEX Corporation, Mountain View, CA). The size, number, and area of the drusen in two macular regions were computed by two readers using an interactive approach. Measurements were compared to data generated by reading center methods.
   RESULTS: For the Analyzer, inter-observer agreement was 0.79 (SE = 0.02) and 0.86 (SE = 0.01) (kappa statistic). Intra-observer precision was 0.835 and 0.880 (Spearman coefficients). Categorical agreement (weighted kappa) between the Analyzer and reading center results for the two regions was (0.76, 0.58) and (0.68, 0.68) for readers A and B. The time required to quantitate an image using the Analyzer was 105 +/- 52 and 218 +/- 102 seconds for the two regions, respectively.
   CONCLUSIONS: Quantitative detection of drusen can be performed reproducibly and efficiently. Comparisons to more labor intensive reading center techniques suggest that the results are similar but that the algorithm is more sensitive and precise.
C1 Univ Pittsburgh, Sch Med, UPMC Eye Ctr, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Friberg, TR (通讯作者)，Univ Pittsburgh, Sch Med, UPMC Eye Ctr, Dept Ophthalmol, 203 Lothrop St,Suite 824, Pittsburgh, PA 15213 USA.
FU NEI NIH HHS [R03 EY13807-01] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R03EY013807] Funding Source: NIH RePORTER
CR *AG REL EYE DIS ST, 2006, ARCH OPHTHALMOL-CHIC, V124, P289
   *AG REL EYE DIS ST, 2001, OPHTHALMOLOGY, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   FRIBERG TR, 1989, GRAEF ARCH CLIN EXP, V227, P201, DOI 10.1007/BF02172748
   FRIBERG TR, 1987, RETINA-J RET VIT DIS, V7, P246, DOI 10.1097/00006982-198707040-00010
   FRIBERG TR, 1992, OCULAR MICROCIRCULAT, P131
   FRIBERT TR, 1992, OCULAR MICROCIRCULAT, P173
   GOLDBAUM MH, 1990, INVEST OPHTH VIS SCI, V31, P617
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   SHIN BS, 1999, AGE RELATED MACULAR, P207
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
NR 16
TC 11
Z9 11
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2007
VL 38
IS 2
BP 126
EP 134
DI 10.3928/15428877-20070301-07
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 147PK
UT WOS:000245014700007
PM 17396693
DA 2022-11-30
ER

PT J
AU Xu, ZH
   Sun, T
   Li, WN
   Sun, XJ
AF Xu, Zhihan
   Sun, Tao
   Li, Weinan
   Sun, Xiangjun
TI Inhibiting effects of dietary polyphenols on chronic eye diseases
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Review
DE Dietary polyphenols; Chronic eye diseases; Oxidative stress;
   Inflammation; Angiogenesis
ID RETINAL ENDOTHELIAL-CELLS; INDUCED OXIDATIVE STRESS; FACTOR-KAPPA-B;
   DIABETIC CATARACT; ALDOSE REDUCTASE; IN-VITRO; OCULAR
   NEOVASCULARIZATION; EPIGALLOCATECHIN-GALLATE; LIPID-PEROXIDATION; VISUAL
   FUNCTION
AB The prevalence of many eye diseases, including cataracts, age-related macular degeneration and diabetic retinopathy, is expected to increase and has become leading causes of irreversible vision loss in the elderly population. Recent experimental and clinical studies have increased awareness of the potential health benefits of polyphenol consumption, including for the prevention of chronic eye diseases. This review focuses on recent findings regarding the beneficial effects of polyphenols for treatment/prevention of cataracts, age-related macular degeneration, diabetic retinopathy and glaucoma, and discusses possible mechanisms of action. The results of studies presented in this review show that polyphenols suppress formation of reactive oxygen species, increase antioxidant defense systems, ameliorate pro-inflammatory cytokines, and decrease vascular endothelial growth factor in retinal cells and ocular tissues. Based on these results, polyphenols may be an effective and safe component of functional foods used to address chronic eye disease.
C1 [Xu, Zhihan; Sun, Tao; Li, Weinan; Sun, Xiangjun] Shanghai Jiao Tong Univ, Coll Agr & Biol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Sun, XJ (通讯作者)，Shanghai Jiao Tong Univ, Coll Agr & Biol, Shanghai, Peoples R China.
EM xjsun@sjtu.edu.cn
FU National Natural Science Foundation of China [31571837]
FX This research was supported by the National Natural Science Foundation
   of China (No. 31571837).
CR Abengozar-Vela A, 2015, INVEST OPHTH VIS SCI, V56, P2709, DOI 10.1167/iovs.15-16595
   Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Asbell PA, 2005, LANCET, V365, P599
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563
   Biju PG, 2007, J MED FOOD, V10, P308, DOI 10.1089/jmf.2006.054
   Boeing H, 2012, EUR J NUTR, V51, P637, DOI 10.1007/s00394-012-0380-y
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Bringmann A, 2005, ACTA OPHTHALMOL SCAN, V83, P528, DOI 10.1111/j.1600-0420.2005.00565.x
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chan E, 2010, CLIN EXP OPTOM, V93, P379, DOI 10.1111/j.1444-0938.2010.00516.x
   Chen M, 2010, EXP EYE RES, V90, P437, DOI 10.1016/j.exer.2009.12.004
   Chethan S, 2008, BIOORGAN MED CHEM, V16, P10085, DOI 10.1016/j.bmc.2008.10.003
   Chiu C. J., 2014, AM DIETARY PATTERNS, V158, P119
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Choi EJ, 2008, ARCH PHARM RES, V31, P1457, DOI 10.1007/s12272-001-2130-1
   Chou WW, 2012, CELL IMMUNOL, V273, P79, DOI 10.1016/j.cellimm.2011.11.003
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Cornish KM, 2002, FREE RADICAL BIO MED, V33, P63, DOI 10.1016/S0891-5849(02)00843-2
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Del Rio D, 2010, BRIT J NUTR, V104, pS67, DOI 10.1017/S0007114510003958
   Di Girolamo N, 2002, INVEST OPHTH VIS SCI, V43, P3430
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Doganay S, 2002, J CATARACT REFR SURG, V28, P1457, DOI 10.1016/S0886-3350(02)01242-7
   Duan YW, 2015, COLLOID SURFACE B, V128, P322, DOI 10.1016/j.colsurfb.2015.02.007
   Duarte DA, 2015, J NUTR BIOCHEM, V26, P64, DOI 10.1016/j.jnutbio.2014.09.003
   Dung N. X., 1993, Journal of Essential Oil Research, V5, P553
   Durukan AH, 2006, J CATARACT REFR SURG, V32, P1041, DOI 10.1016/j.jcrs.2006.02.041
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Evans J.R., 2000, COCHRANE DB SYST REV, V2
   Falsini B, 2009, GRAEF ARCH CLIN EXP, V247, P1223, DOI 10.1007/s00417-009-1064-z
   Fangueiro JF, 2016, INT J PHARMACEUT, V502, P161, DOI 10.1016/j.ijpharm.2016.02.039
   Fangueiro JF, 2015, EUR J PHARM BIOPHARM, V95, P307, DOI 10.1016/j.ejpb.2014.12.023
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fiorentini D, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/196914
   Ghosh D, 2007, ASIA PAC J CLIN NUTR, V16, P200
   Ha JH, 2014, J NUTR, V144, P799, DOI 10.3945/jn.113.186957
   Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1
   Hsuuw YD, 2005, J CELL PHYSIOL, V205, P379, DOI 10.1002/jcp.20408
   Hu ST, 2017, J FUNCT FOODS, V30, P108, DOI 10.1016/j.jff.2017.01.009
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Huang RH, 2007, EXP BIOL MED, V232, P118
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jain SK, 2006, FREE RADICAL BIO MED, V41, P92, DOI 10.1016/j.freeradbiomed.2006.03.008
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kador P. F., 2017, FUNCTIONAL FOODS HLT, V7, P17
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Kang MK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8120782
   Kang SW, 2010, J NUTR BIOCHEM, V21, P55, DOI 10.1016/j.jnutbio.2008.10.004
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Khan AA, 2010, AM J PATHOL, V177, P481, DOI 10.2353/ajpath.2010.090836
   Kim CS, 2011, ARCH PHARM RES, V34, P847, DOI 10.1007/s12272-011-0519-z
   Kim MH, 2003, J CELL BIOCHEM, V89, P529, DOI 10.1002/jcb.10543
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kowalska K, 2016, J FUNCT FOODS, V20, P171, DOI 10.1016/j.jff.2015.11.001
   Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kubota S, 2009, INVEST OPHTH VIS SCI, V50, P3512, DOI 10.1167/iovs.08-2666
   Kumar B, 2014, EXP EYE RES, V125, P193, DOI 10.1016/j.exer.2014.06.009
   Kumar B, 2013, MICROVASC RES, V87, P65, DOI 10.1016/j.mvr.2013.01.002
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kyselova Z, 2012, J FOOD NUTR RES-SLOV, V51, P185
   Laabich A, 2007, EXP EYE RES, V85, P154, DOI 10.1016/j.exer.2007.04.003
   LAURENS A, 1983, THERAPIE, V38, P659
   Lee HS, 2014, MOLECULES, V19, P12150, DOI 10.3390/molecules190812150
   Lee Sung Min, 2010, Korean J Ophthalmol, V24, P101, DOI 10.3341/kjo.2010.24.2.101
   Liu RH, 2003, AM J CLIN NUTR, V78, p517S, DOI 10.1093/ajcn/78.3.517S
   Liu YX, 2017, J AGR FOOD CHEM, V65, P3179, DOI 10.1021/acs.jafc.7b00844
   London DS, 2015, NUTR RES, V35, P107, DOI 10.1016/j.nutres.2014.12.007
   Luna C, 2009, FOOD CHEM TOXICOL, V47, P198, DOI 10.1016/j.fct.2008.10.029
   Manikandan R, 2009, CHEM-BIOL INTERACT, V181, P202, DOI 10.1016/j.cbi.2009.05.011
   Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509
   Marc RE, 2008, MOL VIS, V14, P782
   Mares JA, 2004, NUTR REV, V62, P28, DOI 10.1301/nr.2004.jan.28-32
   Matsumoto H, 2003, J AGR FOOD CHEM, V51, P3560, DOI 10.1021/jf034132y
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Mirzaei H, 2017, BIOMED PHARMACOTHER, V85, P102, DOI 10.1016/j.biopha.2016.11.098
   Moeller SM, 2004, J NUTR, V134, P1812, DOI 10.1093/jn/134.7.1812
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mohammadian A., 2016, J HERBMED PHARM, V5, P29
   Moreau KL, 2012, TRENDS MOL MED, V18, P273, DOI 10.1016/j.molmed.2012.03.005
   MORIMITSU Y, 1995, BIOSCI BIOTECH BIOCH, V59, P2018, DOI 10.1271/bbb.59.2018
   Morimitsu Y, 2002, INT CONGR SER, V1245, P503, DOI 10.1016/S0531-5131(02)00919-6
   Morton L. W., 2002, CLIN EXPT PHARM PHYS, V27, P152
   Mueller D, 2017, FOOD CHEM, V231, P275, DOI 10.1016/j.foodchem.2017.03.130
   Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623
   Muthenna P, 2012, BRIT J NUTR, V107, P941, DOI 10.1017/S0007114511004077
   Nasri H, 2015, J RES MED SCI, V20, P491
   Neto CC, 2007, MOL NUTR FOOD RES, V51, P652, DOI 10.1002/mnfr.200600279
   Ong KC, 1997, GEN PHARMACOL-VASC S, V29, P121, DOI 10.1016/S0306-3623(96)00421-1
   Osakabe N, 2004, EXP BIOL MED, V229, P33, DOI 10.1177/153537020422900104
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel S, 2015, GRAEF ARCH CLIN EXP, V253, P1841, DOI 10.1007/s00417-015-3168-y
   Paysant J, 2008, INT ANGIOL, V27, P81
   Peng W, 2013, J ETHNOPHARMACOL, V148, P729, DOI 10.1016/j.jep.2013.05.007
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Quaranta L, 2003, OPHTHALMOLOGY, V110, P359, DOI 10.1016/S0161-6420(02)01745-1
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Roupe KA, 2006, CURR CLIN PHARMACOL, V1, P81, DOI 10.2174/157488406775268246
   Sakakibara H, 2009, J AGR FOOD CHEM, V57, P7681, DOI 10.1021/jf901341b
   Sakthivel M, 2008, EXP EYE RES, V86, P251, DOI 10.1016/j.exer.2007.10.016
   Sanderson J, 1999, FREE RADICAL BIO MED, V26, P639, DOI 10.1016/S0891-5849(98)00262-7
   Satici A, 2003, EUR J OPHTHALMOL, V13, P779, DOI 10.1177/1120672103013009-1008
   Shayganni E, 2016, PHYTOMEDICINE, V23, P1119, DOI 10.1016/j.phymed.2015.11.004
   Shearer T R, 1997, Mol Vis, V3, P8
   Shi M, 2017, J FUNCT FOODS, V30, P16, DOI 10.1016/j.jff.2016.12.036
   Sohn E, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030140
   Soufi FG, 2012, PHARMACOL REP, V64, P1505, DOI 10.1016/S1734-1140(12)70948-9
   Srinivasan K, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P413, DOI 10.1016/B978-0-12-401717-7.00042-3
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   Sunkireddy P, 2013, COLLOID SURFACE B, V112, P554, DOI 10.1016/j.colsurfb.2013.07.068
   Suryanarayana P, 2005, INVEST OPHTH VIS SCI, V46, P2092, DOI 10.1167/iovs.04-1304
   Szumny D, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/939402
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Tang L, 2011, EXP BIOL MED, V236, P1051, DOI 10.1258/ebm.2011.010400
   Taylor A, 2001, NUTRITION, V17, P845, DOI 10.1016/S0899-9007(01)00655-4
   Tokuda K, 2007, EXP EYE RES, V84, P537, DOI 10.1016/j.exer.2006.11.005
   Tzeng TF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090572
   Tzeng TF, 2015, NUTRIENTS, V7, P7821, DOI 10.3390/nu7095369
   Tzeng TF, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/340645
   Wang DF, 2014, J CARDIOVASC PHARM, V64, P218, DOI 10.1097/FJC.0000000000000109
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.243S, 10.1093/ajcn/81.1.230S]
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zhou, 1995, CHINESE J INTEGRATED, V1, P84
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
   Zhou Q, 2013, J AGR FOOD CHEM, V61, P6693, DOI 10.1021/jf401191q
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P425, DOI 10.1089/jop.2006.22.425
NR 141
TC 19
Z9 20
U1 2
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD DEC
PY 2017
VL 39
BP 186
EP 197
DI 10.1016/j.jff.2017.10.031
PG 12
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA FQ2RW
UT WOS:000418206000023
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Han, SY
   Kim, HS
   Lee, TG
   Kim, JW
AF Cho, Han Joo
   Han, Sang Yoon
   Kim, Hyoung Seok
   Lee, Tae Gon
   Kim, Jong Woo
TI Factors associated with polyp regression after intravitreal ranibizumab
   injections for polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Vascular endothelial growth factor
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; PHOTODYNAMIC THERAPY; VASCULAR
   HYPERPERMEABILITY; CLINICAL CHARACTERISTICS; MACULAR DEGENERATION;
   VERTEPORFIN
AB To investigate the predictive factors of polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy (PCV).
   Sixty-nine eyes (69 patients) with treatment-na < ve PCV received an initial series of 3-monthly intravitreal ranibizumab injections, followed by as-needed injections. Polyp regression was determined after 6 months from baseline by means of indocyanine angiography and correlated with clinical characteristics at baseline.
   After treatment, 26.1 % (18 out of 69 eyes) achieved complete polyp regression and 73.9 % (51 out of 69 eyes) showed persistent polyps. The mean logarithm of the minimum angle of resolution (logMAR) of best-corrected visual acuity (BCVA) was significantly improved in both groups (P = 0.02). No statistically significant difference in BCVA improvement was observed between the groups. However, the proportion of subjects with BCVA improvement by more than three lines was significantly higher in the polyp regression group (P = 0.02). Univariate analysis of the baseline characteristics identified the number of polyps (P = 0.02), the total polyp area (P = 0.009) and the polyp pattern (P = 0.01) as predictive factors for polyp regression. Multivariate logistic regression identified the total polyp area (P = 0.01) as an independent predictor for polyp regression after intravitreal ranibizumab injections.
   The regression of polypoidal lesions in PCV patients after intravitreal ranibizumab injections was associated with a smaller total polyp area. This result could be helpful in predicting polypoidal changes after ranibizumab treatment and in deciding the best treatment strategy for PCV patients.
C1 [Cho, Han Joo; Han, Sang Yoon; Kim, Hyoung Seok; Lee, Tae Gon; Kim, Jong Woo] Konyang Univ, Myung Gok Eye Res Inst, Kims Eye Hosp, Dept Ophthalmol,Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Lee, TG (通讯作者)，Konyang Univ, Myung Gok Eye Res Inst, Kims Eye Hosp, Dept Ophthalmol,Coll Med, 156,4ga Yeoungdeungpo Dong, Seoul, South Korea.
EM idoc@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 23
TC 10
Z9 10
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2015
VL 59
IS 1
BP 29
EP 35
DI 10.1007/s10384-014-0349-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5TM
UT WOS:000348282600005
PM 25373450
DA 2022-11-30
ER

PT J
AU Sassmannshausen, M
   Steinberg, JS
   Fimmers, R
   Pfau, M
   Thiele, S
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Sassmannshausen, Marlene
   Steinberg, Julia S.
   Fimmers, Rolf
   Pfau, Maximilian
   Thiele, Sarah
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Structure-Function Analysis in Patients With Intermediate Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE fundus-controlled perimetry; microperimetry; scotopic; mesopic; MP-1S;
   drusen; age-related macular degeneration; SD-OCT; retinal imaging
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS-CONTROLLED PERIMETRY; OUTER RETINAL
   THICKNESS; GEOGRAPHIC ATROPHY; VISUAL-ACUITY; MICROPERIMETRY; DRUSEN;
   SENSITIVITY; AUTOFLUORESCENCE; EYES
AB PURPOSE. To examine the topographic correlation between retinal morphology and retinal sensitivity by mesopic and scotopic fundus-controlled perimetry (FCP) in eyes with intermediate AMD.
   METHODS. Thirty-five eyes from 32 patients (mean age 70.9 years) and 29 age-matched controls prospectively underwent spectral-domain optical coherence tomography (SD-OCT) imaging. Mesopic (Goldman III, 200 ms, 4-2 strategy) and scotopic (Goldman V, 200 ms, 4-2 strategy) FCP with a 56-stimulus point grid was performed in AMD patients with the MP-1S. Thickness values of different retinal layers were measured at each stimulus point and compared, topographically corresponding to values in controls of similar age for pointwise structural-functional analysis.
   RESULTS. The overall mean sensitivity in patients was 16.9 +/- 3.0 dB for mesopic and 14.0 +/- 3.7 dB for scotopic testing. Within the central 48 of the macula, reduced mesopic and scotopic sensitivity values were found (P < 0.0001). These findings correlated to central increasing retinal pigment epithelium-drusen complex (RPEDC) thickness and central decreasing outer nuclear layer (ONL) and photoreceptor (PR)-segments thickness (P < 0.0001, respectively). Structure-function correlations revealed that a reduction of mesopic and scotopic sensitivity was associated with increasing thickness of the total retina and the RPEDC and a decrease of the ONL and the PR-segments (P < 0.001, respectively).
   CONCLUSIONS. Accumulation of sub-RPE material in patients with intermediate AMD is spatially associated to quantifiable structural alterations in various retinal layers and to corresponding retinal dysfunction. The topographic analysis of retinal thickness and retinal sensitivity will be helpful for a better understanding of the disease process and for the evaluation of new interventional approaches.
C1 [Sassmannshausen, Marlene; Steinberg, Julia S.; Pfau, Maximilian; Thiele, Sarah; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Fimmers, Rolf] Univ Bonn, Med Fac, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Pfau, Maximilian/N-1888-2019
OI Pfau, Maximilian/0000-0001-9761-9640
FU Gertrud-Kusen Foundation; University of Bonn: Bonfor Grant [O-137.0021,
   O-137.0022]; German Research Foundation (DFG) [658/4-1, 658/4-2]
FX Supported by Gertrud-Kusen Foundation (JSS), University of Bonn: Bonfor
   Grant No. O-137.0021 (JSS), University of Bonn: Bonfor Grant No.
   O-137.0022 (JSS), and the German Research Foundation (DFG) Grants
   658/4-1 and 658/4-2 (MF). The sponsors or funding organizations had no
   role in the design or conduct of this research.
CR Balasubramanian S, 2018, BRIT J OPHTHALMOL, V102, P109, DOI 10.1136/bjophthalmol-2017-310258
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fragiotta Serena, 2017, Int J Retina Vitreous, V3, P8, DOI 10.1186/s40942-017-0061-3
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu HT, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.5.3
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nakagawa S, 2013, METHODS ECOL EVOL, V4, P133, DOI 10.1111/j.2041-210x.2012.00261.x
   NEBBIOSO M, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/671529
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Tepelus TC, 2017, OSLI RETINA, V48, P312, DOI 10.3928/23258160-20170329-05
   Wu ZC, 2015, OPHTHALMOLOGY, V122, pE53, DOI 10.1016/j.ophtha.2015.03.011
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
NR 40
TC 17
Z9 17
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 3
BP 1599
EP 1608
DI 10.1167/iovs.17-22712
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB4CA
UT WOS:000429006700010
PM 29625486
OA gold
DA 2022-11-30
ER

PT J
AU Tezel, TH
   Del Priore, LV
   Berger, AS
   Kaplan, HJ
AF Tezel, Tongalp H.
   Del Priore, Lucian V.
   Berger, Adam S.
   Kaplan, Henry J.
TI Adult retinal pigment epithelial transplantation in exudative
   age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; RANDOMIZED CLINICAL-TRIAL; HUMAN BRUCHS MEMBRANE; PRESUMED
   OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION;
   OPHTHALMIC FINDINGS; SUBMACULAR SURGERY; SURGICAL EXCISION
AB PURPOSE: To improve visual function by retinal pig, ment epithelial (RPE) cell transplantation and systemic immunosuppression at the time of surgical removal of subfoveal choroidal neovascularization in exudative agerelated macular degeneration (AMD).
   center dot DESIGN: An interventional case series of RPE transplantation in exudative AMD.
   center dot METHODS: Twelve patients (one eye only) underwent subfoveal membranectomy with transplantation of a sheet of adult human allogeneic RPE cells at a single institution and were followed for one year. Eligibility criteria included age > 60, best,corrected acuity <= 20/63 and subfoveal neovascularization <= 9 disk areas on preop, erative fluorescein angiography. All patients were started on triple immunosuppression postoperatively. The pri, mary outcome measure was best-corrected vision, with contrast sensitivity and reading speed as secondary outcome measures.
   center dot RESULTS: The best-corrected visual acuity (P = .085), contrast sensitivity (P = .204), and the reading speed (P = .077) did not change significantly at one year compared with preoperative values. Transplants showed no signs of rejection in patients who were able to continue the immunosuppressants for six months. Post, operative surgical complications included cataract pro, gression requiring surgery (three of eight phakic eyes), retinal detachment (three eyes), intraoperative retinal breaks (two eyes), and macular pucker (two eyes). None of the patients developed cystoid macular edema on postoperative fluorescein angiography or postoperative inflammation.
   center dot CONCLUSIONS: A sheet of adult human allogeneic RPE can be transplanted into the subretinal space in AMD patients at the time of subfoveal membranectomy. Systemic immune suppression appeared to prevent rejection of the transplanted tissue, but did not lead to an improvement in visual function.
C1 Univ Louisville, Dept Ophthalmol & Visual Sci, Sch Med, Kentucky Lions Eye Ctr, Louisville, KY 40202 USA.
   Columbia Univ, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10027 USA.
   Vitreous & Retina Consultants, Winter Haven, FL USA.
C3 University of Louisville; Columbia University
RP Kaplan, HJ (通讯作者)，Univ Louisville, Dept Ophthalmol & Visual Sci, Sch Med, Kentucky Lions Eye Ctr, 301 E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM hank.kaplan@louisville.edu
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Akduman L, 1997, AM J OPHTHALMOL, V123, P90, DOI 10.1016/S0002-9394(14)70997-3
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   ALMOND PS, 1992, TRANSPLANTATION, V53, P46, DOI 10.1097/00007890-199201000-00008
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Berger AS, 1997, ARCH OPHTHALMOL-CHIC, V115, P991, DOI 10.1001/archopht.1997.01100160161004
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1
   DANIEL W, 2004, BIOSTATISTICS FDN AN, V8, P303
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DELPRIORE LV, 1997, SEMIN OPHTHALMOL, V12, P45
   DELPRIORE LV, 1993, EUR J IMPLANT REF SU, V5, P128, DOI DOI 10.1016/S0955-3681(13)80263-8
   DUTT K, 1989, CURR EYE RES, V8, P435, DOI 10.3109/02713688909000023
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P194, DOI 10.1089/jop.2006.22.194
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Ma Anlun, 2002, Current Drug Targets - Cardiovascular & Haematological Disorders, V2, P57, DOI 10.2174/1568006023337466
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   POLINER LS, 1993, OPHTHALMOLOGY, V100, P1417
   Pollack JS, 1996, BRIT J OPHTHALMOL, V80, P314, DOI 10.1136/bjo.80.4.314
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P660, DOI 10.1097/00006982-200408000-00039
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   YE JJ, 1993, CURR EYE RES, V12, P629, DOI 10.3109/02713689309001842
   ZAVAZAVA N, 1991, CLIN EXP IMMUNOL, V84, P163
NR 66
TC 74
Z9 81
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2007
VL 143
IS 4
BP 584
EP 595
DI 10.1016/j.ajo.2006.12.007
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 154WE
UT WOS:000245537800004
PM 17303061
DA 2022-11-30
ER

PT J
AU Buitendijk, GHS
   Amin, N
   Hofman, A
   van Duijn, CM
   Vingerling, JR
   Klaver, CCW
AF Buitendijk, Gabrielle H. S.
   Amin, Najaf
   Hofman, Albert
   van Duijn, Cornelia M.
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
TI Direct-to-Consumer Personal Genome Testing for Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; AMD; prediction; DTC-tests; personal
   genome testing
ID COMPLEMENT FACTOR-H; COMPONENT 3; FACTOR-B; RISK; MACULOPATHY; VARIANT;
   MODEL; GENES; CFH; SUSCEPTIBILITY
AB PURPOSE. Genetic testing may be the next step in clinical medicine for a more personalized approach in determining risk of disease. Direct-to-consumer (DTC) personal genome tests may fulfill this role. We explored the practicability and predictive value of DTC tests from four companies (23andMe, deCODEme, Easy DNA, Genetic Testing Laboratories) for AMD.
   METHODS. Body specimens of three individuals were collected and sent to four companies for DNA genotyping and disease risk estimation. In addition, DNA was also genotyped using Illumina HumanOmniExpress 12v1 array in the Rotterdam Study laboratory, and risk estimates of AMD were calculated using the validated prediction model from the population-based Three Continent AMD Consortium.
   RESULTS. Genotyped results of the four DTC tests matched genotyping performed by the Rotterdam Study laboratory. The estimated risks provided by the companies varied considerably in the tested individuals, from a 1.6-fold difference for overall relative risk to an up to 12-fold difference for lifetime risk. The lifetime risks for the individuals ranged from 1.4% to 16.1% in the DTC tests, while they varied from 0.5% to 4.2% in the validated prediction model. Most important reasons for the differences in risks were the testing of only a limited set of genetic markers, the choice of the reference population, and the methodology applied for risk calculation.
   CONCLUSIONS. Direct-to-consumer personal genome tests are not suitable for clinical application as yet. More comprehensive genetic testing and inclusion of environmental risk factors may improve risk prediction of AMD.
C1 [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Amin, Najaf; Hofman, Albert; van Duijn, Cornelia M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
   [Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, The Hague, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Klaver, Caroline C.W./A-2013-2016
OI Amin, Najaf/0000-0002-8944-1771; Klaver, Caroline/0000-0002-2355-5258;
   Van Duijn, Cornelia/0000-0002-2374-9204
FU Stichting Nederlands Oog Onderzoek (SNOO) Rotterdam, The Netherlands;
   stichting UITZICHT, The Netherlands; Netherlands Organization for
   Scientific Research, The Hague; Swart van Essen, Rotterdam, the
   Netherlands; Bevordering van Volkskracht, Rotterdam, The Netherlands;
   Rotterdamse Blindenbelangen Association, Rotterdam, The Netherlands;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Doorn, The
   Netherlands; Oogfonds Nederland, Utrecht, The Netherlands; MDFonds,
   Utrecht, The Netherlands; Vereniging Trustfonds Erasmus Universiteit
   Rotterdam, Rotterdam, The Netherlands; Lijf en Leven, Krimpen aan de
   IJssel, The Netherlands; Topcon Europe BV, Capelle aan den IJssel, The
   Netherlands
FX Supported by grants from the Stichting Nederlands Oog Onderzoek (SNOO)
   Rotterdam, The Netherlands; stichting UITZICHT, The Netherlands;
   Netherlands Organization for Scientific Research, The Hague; Swart van
   Essen, Rotterdam, the Netherlands; Bevordering van Volkskracht,
   Rotterdam, The Netherlands; Rotterdamse Blindenbelangen Association,
   Rotterdam, The Netherlands; Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid, Doorn, The Netherlands; Oogfonds Nederland,
   Utrecht, The Netherlands; MDFonds, Utrecht, The Netherlands; Vereniging
   Trustfonds Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands;
   and Lijf en Leven, Krimpen aan de IJssel, The Netherlands. An
   unrestricted grant was obtained from Topcon Europe BV, Capelle aan den
   IJssel, The Netherlands.
CR [Anonymous], 2010, R LANG ENV STAT COMP
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   deCODEme, RISK CALC
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   ENIGMA2 GENETICS Support Team, ENIGMA2 1KGP COOKB V
   FDA: US Food and Drug Administration, 2014, MED DEV
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kalf RRJ, 2014, GENET MED, V16, P85, DOI 10.1038/gim.2013.80
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Macpherson MNB, 2007, ESTIMATING GENOTYPE
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mckay GJ, 2010, MOL VIS, V16, P194
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Prioux F, 2012, POPULATION ENGL ED, V67
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   WHO, LIF EXP BIRTH 2011
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 50
TC 13
Z9 13
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2014
VL 55
IS 10
BP 6167
EP 6174
DI 10.1167/iovs.14-15142
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DY
UT WOS:000343147100006
PM 25146986
DA 2022-11-30
ER

PT J
AU Lim, PCC
   Layton, CJ
AF Lim, Paul C. C.
   Layton, Christopher J.
TI Prognostic implications of imaging in atrophic macular degeneration and
   its use in clinical practice and clinical trial design
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE atrophic age-related macular degeneration; clinical trials; fundus
   autofluorescence; optical coherence tomography; phenotypes
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE PATTERNS; GEOGRAPHIC ATROPHY; SPATIAL-DISTRIBUTION;
   VISUAL IMPAIRMENT; NATURAL-HISTORY; BRUCHS MEMBRANE; JUNCTIONAL ZONE;
   HIGH-RESOLUTION
AB Clinical prognostic markers in atrophic age-related macular degeneration include the extent of existing atrophy, fundus autofluorescence (FAF) patterns and optical coherence tomography changes in the outer retina/retinal pigment epithelium interface. The prognostic implications of these findings may be used to determine not just the rate of disease progression but also influence the likelihood, magnitude and clinical relevance of therapy responses. FAF phenotypes have been extensively investigated; however, the pathophysiological mechanisms behind their appearance have not been fully elucidated. Optical coherence tomography imaging is additive to FAF imaging in atrophic age-related macular degeneration, allowing the visualization of detail not available through FAF imaging whilst also displaying subtle changes correlating with the FAF phenotypes themselves, thereby giving clues to their histological determinates. The developing understanding of these imaging modalities and consequent development of prognostically useful classification systems have widespread implication in clinical care and clinical trial design.
C1 [Lim, Paul C. C.; Layton, Christopher J.] Univ Queensland, Mayne Med Sch, Sch Med, Herston, Qld, Australia.
   [Layton, Christopher J.] Gallipoli Med Res Inst, Newdegate St, Greenslopes, Australia.
   [Layton, Christopher J.] Greenslopes Private Hosp, Greenslopes, Australia.
   [Layton, Christopher J.] Greenslopes Private Hosp, Ophthalmol Dept, Brisbane, Qld, Australia.
C3 University of Queensland
RP Layton, CJ (通讯作者)，Greenslopes Private Hosp, Ophthalmol Res Unit, Gallipoli Med Res Inst, Greenslopes Specialty Clin, Newdegate St, Greenslopes, Qld 4120, Australia.
EM c.layton@uq.edu.au
RI Layton, Christopher J/I-5888-2012
OI Layton, Christopher J/0000-0001-6933-9991
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Biarnes M, 2014, INVEST OPHTH VIS SCI, V55, P8302, DOI 10.1167/iovs.13-13542
   Biarnes M, 2012, GRAEF ARCH CLIN EXP, V250, P485, DOI 10.1007/s00417-011-1846-y
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Deloitte Access Economics, 2011, EHEALTH BENCHM 3 SMA, P1
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Formann A K, 1996, Stat Methods Med Res, V5, P179, DOI 10.1177/096228029600500205
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Hammer M, 2006, MOL VIS, V12, P1348
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li JQ, 2011, BIOCHEM BIOPH RES CO, V404, P349, DOI 10.1016/j.bbrc.2010.11.122
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schachar IH, 2013, JAMA OPHTHALMOL, V131, P1009, DOI 10.1001/jamaophthalmol.2013.4014
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Smith RT, 2013, INVEST OPHTH VIS SCI, V54, P5543, DOI 10.1167/iovs.13-12798
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P8325, DOI 10.1167/iovs.13-13214
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 82
TC 1
Z9 1
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2016
VL 44
IS 5
BP 410
EP 421
DI 10.1111/ceo.12671
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR5JG
UT WOS:000379938700007
PM 26468964
DA 2022-11-30
ER

PT J
AU Yang, SS
   Fu, AD
   McDonald, HR
   Johnson, RN
   Ai, E
   Jumper, JM
AF Yang, SS
   Fu, AD
   McDonald, HR
   Johnson, RN
   Ai, E
   Jumper, JM
TI Massive spontaneous choroidal hemorrhage
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; suprachoroidal hemorrhage;
   thrombolytic therapy; warfarin
ID PARS-PLANA VITRECTOMY; SPONTANEOUS SUPRACHOROIDAL HEMORRHAGE;
   TISSUE-PLASMINOGEN ACTIVATOR; RETINAL ARTERY-OCCLUSION; MACULAR
   DEGENERATION; VALSALVA MANEUVER; RISK-FACTORS; THERAPY; AGE; OUTCOMES
AB Purpose: To describe the course, management, and prognosis of massive spontaneous choroidal hemorrhage.
   Methods: The presenting visual acuity, ocular findings, duration to surgical intervention, and outcomes of five patients were retrospectively reviewed.
   Results: Five eyes from four patients (median age, 80 years; range, 66-85 years) were studied. The patients were observed from 4 to 72 months (median, 33 months). Three patients were on anticoagulation therapy with warfarin; one patient had bilateral involvement with no history of anticoagulation therapy. Three patients were hypertensive, and three of the four had been diagnosed with age-related macular degeneration. Four eyes underwent choroidal drainage procedures, and one was observed. In all patients whose choroids were drained, the final vision was no light perception.
   Conclusions: Massive spontaneous choroidal hemorrhage may be associated with hypertension, systemic anticoagulation, advanced age, and age-related macular degeneration. Final visual acuities are generally poor.
C1 Calif Pacific Med Ctr, San Francisco, CA USA.
   St Marys Hosp, Retina Res Fund, San Francisco, CA USA.
C3 California Pacific Medical Center
RP McDonald, HR (通讯作者)，1 Daniel Burnham Court,Suite 210C, San Francisco, CA 94109 USA.
CR Alexandrakis G, 1998, RETINA-J RET VIT DIS, V18, P485, DOI 10.1097/00006982-199805000-00023
   Beatty S, 1998, EYE, V12, P815, DOI 10.1038/eye.1998.210
   BERO CJ, 1995, J VASC INTERV RADIOL, V6, P571, DOI 10.1016/S1051-0443(95)71138-1
   BEYER CF, 1989, ARCH OPHTHALMOL-CHIC, V107, P1648, DOI 10.1001/archopht.1989.01070020726036
   BROWN GC, 1982, CAN J OPHTHALMOL, V17, P227
   Chorich LJ, 1998, OPHTHALMOLOGY, V105, P428, DOI 10.1016/S0161-6420(98)93023-8
   Chu TG, 1999, SURV OPHTHALMOL, V43, P471, DOI 10.1016/S0039-6257(99)00037-5
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   KESSLER CM, 1988, ANN EMERG MED, V17, P1216, DOI 10.1016/S0196-0644(88)80073-8
   Khawly JA, 1996, AM J OPHTHALMOL, V121, P577, DOI 10.1016/S0002-9394(14)75438-8
   KOLEHLER MP, 1983, ANN OPHTHALMOL, V15, P958
   LAKHANPAL V, 1990, OPHTHALMOLOGY, V97, P1114
   Lakhanpal V, 1993, Trans Am Ophthalmol Soc, V91, P545
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   PIPER JG, 1993, OPHTHALMOLOGY, V100, P699
   Pollack AL, 2001, AM J OPHTHALMOL, V132, P383, DOI 10.1016/S0002-9394(01)01049-2
   SCHMIDT D, 1992, AM J OPHTHALMOL, V113, P429, DOI 10.1016/S0002-9394(14)76167-7
   SCHUMACHER M, 1993, NEURORADIOLOGY, V35, P600, DOI 10.1007/BF00588405
   Scott IU, 1997, OPHTHALMOLOGY, V104, P2039, DOI 10.1016/S0161-6420(97)30042-6
   Sharma T, 1997, OPHTHALMIC SURG LAS, V28, P640
   SHEPHERD AMM, 1977, BRIT J CLIN PHARMACO, V4, P315, DOI 10.1111/j.1365-2125.1977.tb00719.x
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P202
   STEINEMANN T, 1988, AM J OPHTHALMOL, V106, P752, DOI 10.1016/0002-9394(88)90722-2
   Tabandeh H, 1999, OPHTHALMOLOGY, V106, P236, DOI 10.1016/S0161-6420(99)90062-3
   VANMEURS JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1025, DOI 10.1001/archopht.1993.01090080021008
   WOLTER JR, 1988, OPHTHALMIC SURG LAS, V19, P344
   Wong JS, 1999, AUST NZ J OPHTHALMOL, V27, P433
NR 29
TC 35
Z9 37
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2003
VL 23
IS 2
BP 139
EP 144
DI 10.1097/00006982-200304000-00001
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 679AK
UT WOS:000182898700001
PM 12707590
DA 2022-11-30
ER

PT J
AU van Leeuwen, EM
   Emri, E
   Merle, BMJ
   Colijn, JM
   Kersten, E
   Cougnard-Gregoire, A
   Dammeier, S
   Meester-Smoor, M
   Pool, FM
   de Jong, EK
   Delcourt, C
   Rodrigez-Bocanegra, E
   Biarnes, M
   Luthert, PJ
   Ueffing, M
   Klaver, CCW
   Nogoceke, E
   den Hollander, AI
   Lengyel, I
AF van Leeuwen, Elisabeth M.
   Emri, Eszter
   Merle, Benedicte M. J.
   Colijn, Johanna M.
   Kersten, Eveline
   Cougnard-Gregoire, Audrey
   Dammeier, Sascha
   Meester-Smoor, Magda
   Pool, Frances M.
   de Jong, Eiko K.
   Delcourt, Cecile
   Rodrigez-Bocanegra, Eduardo
   Biarnes, Marc
   Luthert, Philip J.
   Ueffing, Marius
   Klaver, Caroline C. W.
   Nogoceke, Everson
   den Hollander, Anneke I.
   Lengyel, Imre
TI A new perspective on lipid research in age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration (AMD); High-density lipoprotein
   cholesterol (HDL-C); Dietary lipids; Circulating lipoproteins; Retinal
   lipids; Genetics
ID HIGH-DENSITY-LIPOPROTEIN; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; C-REACTIVE-PROTEIN; POLYUNSATURATED FATTY-ACIDS;
   APOLIPOPROTEIN-A-I; FACTOR GENE POLYMORPHISMS; GENOME-WIDE ASSOCIATION;
   CORONARY-HEART-DISEASE; ESTER TRANSFER PROTEIN
AB There is an urgency to find new treatment strategies that could prevent or delay the onset or progression of AMD. Different classes of lipids and lipoproteins metabolism genes have been associated with AMD in a multiple ways, but despite the ever-increasing knowledge base, we still do not understand fully how circulating lipids or local lipid metabolism contribute to AMD. It is essential to clarify whether dietary lipids, systemic or local lipoprotein metabolismtrafficking of lipids in the retina should be targeted in the disease. In this article, we critically evaluate what has been reported in the literature and identify new directions needed to bring about a significant advance in our understanding of the role for lipids in AMD. This may help to develop potential new treatment strategies through targeting the lipid homeostasis.
C1 [van Leeuwen, Elisabeth M.; Colijn, Johanna M.; Meester-Smoor, Magda; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [van Leeuwen, Elisabeth M.; Colijn, Johanna M.; Meester-Smoor, Magda; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Emri, Eszter; Lengyel, Imre] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Merle, Benedicte M. J.; Cougnard-Gregoire, Audrey; Delcourt, Cecile] Univ Bordeaux, INSERM, UMR 1219, Bordeaux Populat Hlth Res Ctr,Team LEHA, F-33000 Bordeaux, France.
   [Kersten, Eveline; de Jong, Eiko K.; Klaver, Caroline C. W.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Dammeier, Sascha; Ueffing, Marius] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Tubingen, Germany.
   [Pool, Frances M.; Luthert, Philip J.] UCL Inst Ophthalmol, London, England.
   [Nogoceke, Everson] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Rodrigez-Bocanegra, Eduardo; Biarnes, Marc] Barcelona Macula Fdn, Barcelona, Spain.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Queens University Belfast; Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux; Radboud University Nijmegen; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; University
   of London; University College London; Roche Holding; Radboud University
   Nijmegen
RP Lengyel, I (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Expt Med, Room 01-057,Wellcome Wolfson Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM i.lengyel@qub.ac.uk
RI COUGNARD-GREGOIRE, Audrey/T-4443-2019; Klaver, Caroline
   C.W./A-2013-2016; Delcourt, Cecile/I-2627-2013; Kersten,
   Eveline/P-8173-2015; Hollander, Anneke den/N-4911-2014; Merle, Benedicte
   MJ/F-1247-2015; Lengyel, Imre/B-5217-2009; Merle, Benedicte
   MJ/AAQ-5021-2021; Emri, Eszter/ABE-9363-2020
OI COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   Lengyel, Imre/0000-0001-7467-2174; Merle, Benedicte
   MJ/0000-0003-1332-0954; Rodriguez Bocanegra,
   Eduardo/0000-0003-3019-8911; Biarnes, Marc/0000-0003-2584-4894;
   Dammeier, Sascha/0000-0003-0714-9409
FU Eye-Risk project from the European Union's Horizon 2020 research and
   innovation programme [634479]
FX The work was supported by the Eye-Risk project funded from the European
   Union's Horizon 2020 research and innovation programme under grant
   agreement No 634479. The authors would like to thank Soufiane Ajana,
   Blanca Arango-Gonzalez, Angela Armento, Verena Arndt, Vaibhav Bhatia,
   Shomi S. Bhattacharya, Anna Borrell, Sebastian Buhren, Sofia M. Calado,
   Berta De la Cerda, Francisco J. Diaz-Corrales, Sigrid Diether, Tanja
   Endermann, Lucia L. Ferraro, Miriam Garcia, Thomas J. Heesterbeek,
   Sabina Honisch, Carel B. Hoyng, Ellen Kilger, Elod Kortvely, Hanno
   Langen, Cyrille Maugeais, Jordi Mones, Tunde Peto, Karl U. Ulrich
   Bartz-Schmidt, Vassil, Vassilev, Timo Verzijden, Markus Zumbansen for
   invaluable comments during the preparation of this manuscript.
CR Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Ajadi Rasheed Adetola, 2016, Niger J Physiol Sci, V31, P77
   Al-Mashhadi RH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004853
   Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9
   Albert AD, 1996, BBA-PROTEIN STRUCT M, V1297, P77, DOI 10.1016/0167-4838(96)00102-1
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Anderson DMG, 2014, J AM SOC MASS SPECTR, V25, P1394, DOI 10.1007/s13361-014-0883-2
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Ashikawa Y, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00266
   Asztalos BF, 2003, AM J CARDIOL, V91, p12E, DOI 10.1016/S0002-9149(02)03383-0
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   BETTGER WJ, 1979, J NUTR, V109, P480, DOI 10.1093/jn/109.3.480
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200
   Boesze-Battaglia K, 1997, J EXP BIOL, V200, P2927
   Boesze-Battaglia K, 2002, INT REV CYTOL, V217, P183
   BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   Boomsma DI, 2014, EUR J HUM GENET, V22, P221, DOI 10.1038/ejhg.2013.118
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bowden JA, 2017, J LIPID RES, V58, P2275, DOI 10.1194/jlr.M079012
   Briand F, 2014, EUR J PHARMACOL, V740, P135, DOI 10.1016/j.ejphar.2014.06.022
   BROWN MS, 1980, J LIPID RES, V21, P505
   Brunham LR, 2015, PROG LIPID RES, V58, P14, DOI 10.1016/j.plipres.2015.01.001
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgoyne T, 2015, P NATL ACAD SCI USA, V112, P15922, DOI 10.1073/pnas.1509285113
   BUSH RA, 1991, EXP EYE RES, V53, P741, DOI 10.1016/0014-4835(91)90109-R
   Calvo D, 1998, J LIPID RES, V39, P777
   Casamassima D, 2017, J ANIM PHYSIOL AN N, V101, pe175, DOI 10.1111/jpn.12584
   Chakradhar S, 2016, NAT MED, V22, P116, DOI 10.1038/nm0216-116
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007
   Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chevrier G, 2015, J NUTR, V145, P1415, DOI 10.3945/jn.114.208215
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choi SE, 2009, ENDOCRINOLOGY, V150, P126, DOI 10.1210/en.2008-0483
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Connelly MA, 2016, TRANSL RES, V173, P7, DOI 10.1016/j.trsl.2016.01.006
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CUNNANE S C, 1981, Progress in Lipid Research, V20, P157, DOI 10.1016/0163-7827(81)90029-1
   CUNNANE SC, 1988, BRIT J NUTR, V59, P273, DOI 10.1079/BJN19880034
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Da Silva MS, 2017, LIPIDS, V52, P315, DOI 10.1007/s11745-017-4243-4
   Davis BT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093457
   de Grooth GJ, 2004, J LIPID RES, V45, P1967, DOI 10.1194/jlr.R400007-JLR200
   De Lorgeril Michel, 2007, Subcell Biochem, V42, P283
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   den Hollander A. I., 2014, COLD SPRING HARB PER, V5
   DETURCO EBR, 1990, J NEUROSCI RES, V27, P522, DOI 10.1002/jnr.490270413
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DOWNS LG, 1993, RES VET SCI, V54, P63, DOI 10.1016/0034-5288(93)90012-5
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   EDER K, 1995, BIOL TRACE ELEM RES, V48, P215, DOI 10.1007/BF02789404
   Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008
   Fitzgerald ML, 2004, J BIOL CHEM, V279, P48477, DOI 10.1074/jbc.M409848200
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Foresti O, 2013, ELIFE, V2, DOI 10.7554/eLife.00953
   Francioli LC, 2014, NAT GENET, V46, P818, DOI 10.1038/ng.3021
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Friedman E, 2005, IOVS, V46, P199
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   German OL, 2006, J NEUROCHEM, V98, P1507, DOI 10.1111/j.1471-4159.2006.04061.x
   Gistera A, 2017, NAT REV NEPHROL, V13, DOI 10.1038/nrneph.2017.51
   Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Gordon SM, 2010, J PROTEOME RES, V9, P5239, DOI 10.1021/pr100520x
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Graham MJ, 2013, CIRC RES, V112, P1479, DOI 10.1161/CIRCRESAHA.111.300367
   Green PS, 2008, CIRCULATION, V118, P1259, DOI 10.1161/CIRCULATIONAHA.108.770669
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gruffat D, 1996, REPROD NUTR DEV, V36, P375, DOI 10.1051/rnd:19960404
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gunness P, 2016, MOL NUTR FOOD RES, V60, P642, DOI 10.1002/mnfr.201500686
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Haapasalo K, 2015, J BIOL CHEM, V290, P28977, DOI 10.1074/jbc.M115.669226
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Hall Nigel F, 2002, Expert Opin Pharmacother, V3, P803
   Hals PA, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0411-z
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Handa James T, 2015, Trans Am Ophthalmol Soc, V113, pT5
   HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   He JP, 2017, FEBS J, V284, P1324, DOI 10.1111/febs.14055
   Hegele RA, 2009, NAT REV GENET, V10, P109, DOI 10.1038/nrg2481
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   HIGH O.B., 1984, LIPID HISTOCHEMISTRY
   Hime NJ, 2008, J LIPID RES, V49, P2113, DOI 10.1194/jlr.M700564-JLR200
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holland WL, 2011, J CLIN INVEST, V121, P1858, DOI 10.1172/JCI43378
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Houten SM, 2016, ANNU REV PHYSIOL, V78, P23, DOI 10.1146/annurev-physiol-021115-105045
   HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Huang CX, 2013, CURR PHARM BIOTECHNO, V14, P623, DOI 10.2174/138920101131400228
   Huang C, 2013, MOL VIS, V19, P1211
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Huang WC, 2016, MOLECULES, V21, DOI 10.3390/molecules21030313
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Ishikawa M, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0104-4
   Jaishy B, 2016, J LIPID RES, V57, P1619, DOI 10.1194/jlr.R067520
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   JENNE DE, 1991, J BIOL CHEM, V266, P11030
   Jeusette IC, 2005, AM J VET RES, V66, P81, DOI 10.2460/ajvr.2005.66.81
   Jialal I, 2001, CIRCULATION, V103, P1933
   Johnson I.D., 2010, MOL PROBES HDB GUIDE
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jones PH, 2010, AM J CARDIOVASC DRUG, V10, P73, DOI 10.2165/10061630-000000000-00000
   Jorgensen MJ, 2013, J AM ASSOC LAB ANIM, V52, P448
   Justus J, 2014, BIOL TRACE ELEM RES, V158, P365, DOI 10.1007/s12011-014-9940-8
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kang JX, 2007, PROSTAG LEUKOTR ESS, V77, P263, DOI 10.1016/j.plefa.2007.10.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kee P, 2006, ARTERIOSCL THROM VAS, V26, P884, DOI 10.1161/01.ATV.0000201064.89581.35
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim EH, 2012, BIOCHEM PHARMACOL, V84, P1359, DOI 10.1016/j.bcp.2012.08.029
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Komprda T, 2017, J ANIM PHYSIOL AN N, V101, P1093, DOI 10.1111/jpn.12581
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Kontush A, 2015, HANDB EXP PHARMACOL, V224, P3, DOI 10.1007/978-3-319-09665-0_1
   Koo E, 2014, AM J CLIN NUTR, V100, p336S, DOI 10.3945/ajcn.113.071563
   Kostogrys R. B., 2017, PHARM REP, V2016, P112
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LAGARDE M, 1984, IN VITRO CELL DEV B, V20, P33
   Laguerre M, 2007, PROG LIPID RES, V46, P244, DOI 10.1016/j.plipres.2007.05.002
   LAMBA OP, 1994, BIOCHEMISTRY-US, V33, P1704, DOI 10.1021/bi00173a012
   Lambert C, 2014, ARTHRITIS RHEUMATOL, V66, P960, DOI 10.1002/art.38315
   Lambert G, 2001, J BIOL CHEM, V276, P15090, DOI 10.1074/jbc.M008466200
   Landgraf Kathrin, 2017, BMC Physiology, V17, DOI 10.1186/s12899-017-0031-x
   Lange LA, 2014, AM J HUM GENET, V94, P233, DOI 10.1016/j.ajhg.2014.01.010
   Leiva A, 2017, MOL ASPECTS MED, V55, P26, DOI 10.1016/j.mam.2017.01.007
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li FT, 2014, OPHTHALMIC RES, V51, P210, DOI 10.1159/000357978
   Li SJ, 2013, MOL METAB, V2, P256, DOI 10.1016/j.molmet.2013.06.001
   Li YB, 2017, BIOCHEM BIOPH RES CO, V486, P364, DOI 10.1016/j.bbrc.2017.03.047
   Li YX, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002779
   Liang H, 2012, J PHARMACOL EXP THER, V340, P228, DOI 10.1124/jpet.111.187419
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Lin PY, 2017, INT J CARDIOL, V227, P938, DOI 10.1016/j.ijcard.2016.09.040
   Lincoff AM, 2017, NEW ENGL J MED, V376, P1933, DOI 10.1056/NEJMoa1609581
   Liu YH, 2017, FOOD FUNCT, V8, P291, DOI 10.1039/c6fo01207h
   Lizaso A, 2013, AUTOPHAGY, V9, P1228, DOI 10.4161/auto.24893
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mao YQ, 2015, CELL PHYSIOL BIOCHEM, V37, P563, DOI 10.1159/000430377
   Marazzi J, 2011, J IMMUNOL METHODS, V373, P219, DOI 10.1016/j.jim.2011.08.021
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Martin C, 2008, NAT MED, V14, P1011, DOI 10.1038/nm1008-1011a
   Mazein A, 2013, BIOCHEM PHARMACOL, V86, P56, DOI 10.1016/j.bcp.2013.03.021
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGill TJ, 2016, INVEST OPHTH VIS SCI, V57, P1361, DOI 10.1167/iovs.15-18596
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   McLaughlin T, 2002, CIRCULATION, V106, P2908, DOI 10.1161/01.CIR.0000041046.32962.86
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mishra S, 2016, MOL VIS, V22, P1387
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mori N, 2015, FRONT VET SCI, V2, DOI 10.3389/fvets.2015.00034
   Morishita S, 2016, BIOSCI BIOTECH BIOCH, V80, P295, DOI 10.1080/09168451.2015.1091713
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P395, DOI 10.1001/archopht.1964.00970020395018
   Navab M, 2006, NAT CLIN PRACT CARD, V3, P540, DOI 10.1038/ncpcardio0661
   Navab M, 2006, CURR OPIN LIPIDOL, V17, P440, DOI 10.1097/01.mol.0000236371.27508.d4
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Noratto GD, 2017, FOOD CHEM, V227, P305, DOI 10.1016/j.foodchem.2017.01.097
   Ogita M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163055
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Packard CJ, 1998, EUR HEART J, V19, pA62
   Pahan K, 2006, CELL MOL LIFE SCI, V63, P1165, DOI 10.1007/s00018-005-5406-7
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054
   Park CT, 2000, BLOOD, V95, P198, DOI 10.1182/blood.V95.1.198.001k31_198_204
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Peloso GM, 2014, AM J HUM GENET, V94, P223, DOI 10.1016/j.ajhg.2014.01.009
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pertl L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154397
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667
   Pool F, 2018, J THEOR BIOL, V443, P157, DOI 10.1016/j.jtbi.2017.12.023
   Preedy V., 2014, HDB NUTR
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Quehenberger O, 2010, J LIPID RES, V51, P3299, DOI 10.1194/jlr.M009449
   Rallidis LS, 2002, CLIN CARDIOL, V25, P505, DOI 10.1002/clc.4960251106
   Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029
   Rao V. S., 2011, CHOLESTEROL, V2011
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reddy ST, 2014, CURR OPIN LIPIDOL, V25, P304, DOI 10.1097/MOL.0000000000000092
   Reiner Z, 2011, EUR HEART J, V32, P1769, DOI [10.1093/eurheartj/ehr158, 10.1016/j.atherosclerosis.2011.06.012]
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Richardson AJ, 2007, MOL VIS, V13, P2148
   ROSENFELD SI, 1983, J CLIN INVEST, V71, P795, DOI 10.1172/JCI110833
   Rosenson RS, 2016, NAT REV CARDIOL, V13, P48, DOI 10.1038/nrcardio.2015.124
   Rosenson RS, 2013, CIRCULATION, V128, P1256, DOI 10.1161/CIRCULATIONAHA.113.000962
   Rosenson RS, 2011, CLIN CHEM, V57, P392, DOI 10.1373/clinchem.2010.155333
   ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554
   Rudolf M, 2004, OPHTHALMOLOGE, V101, P715, DOI 10.1007/s00347-003-0942-8
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Rye KA, 2014, CIRC RES, V114, P143, DOI 10.1161/CIRCRESAHA.114.300632
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018
   Samuel W, 2017, MOL VIS, V23, P60
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793
   Scantlebury T, 1998, J BIOL CHEM, V273, P20903, DOI 10.1074/jbc.273.33.20903
   Schlegel A, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00159
   Schlegel A, 2015, CELL MOL LIFE SCI, V72, P2249, DOI 10.1007/s00018-014-1816-8
   Schnebelen C, 2009, OPHTHALMIC RES, V41, P216, DOI 10.1159/000217726
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sekula P, 2016, J AM SOC NEPHROL, V27, P3253, DOI 10.1681/ASN.2016010098
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shi Q, 2013, AM J CARDIOVASC DIS, V3, P107
   Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   Small D M, 1988, Agents Actions Suppl, V26, P135
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Soffientini U, 2016, CLIN SCI, V130, P1843, DOI 10.1042/CS20160339
   SOUIED E, 2013, INVESTIG OPHTHALMOL, V54
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spencer CCA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000477
   SRIVASTAVA RAK, 1995, J LIPID RES, V36, P1434
   Stoger JL, 2016, THROMB HAEMOSTASIS, V116, P565, DOI 10.1160/TH16-01-0043
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   STREETEN D H, 1961, N Y State J Med, V61, P3431
   Suhre K, 2011, NATURE, V477, P54, DOI 10.1038/nature10354
   Surakka I, 2015, NAT GENET, V47, P589, DOI 10.1038/ng.3300
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tai LM, 2016, ACTA NEUROPATHOL, V131, P709, DOI 10.1007/s00401-016-1547-z
   Tall AR, 2018, CIRC RES, V122, P106, DOI 10.1161/CIRCRESAHA.117.311978
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tepaamorndech S, 2016, FEBS J, V283, P378, DOI 10.1111/febs.13582
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   TSCHOPP J, 1993, J IMMUNOL, V151, P2159
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Usui S, 2014, J VET MED SCI, V76, P269, DOI 10.1292/jvms.13-0369
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   Valdes J, 2016, ALTEX-ALTERN ANIM EX, V33, P459, DOI 10.14573/altex.1603111
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van der Valk J, 2010, TOXICOL IN VITRO, V24, P1053, DOI 10.1016/j.tiv.2010.03.016
   van Leeuwen EM, 2015, NPJ AGING MECH DIS, V1, DOI 10.1038/npjamd.2015.11
   van Leeuwen EM, 2016, J MED GENET, V53, P441, DOI 10.1136/jmedgenet-2015-103439
   van Leeuwen EM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7065
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   von Zychlinski A, 2011, J PROTEOMICS, V74, P2881, DOI 10.1016/j.jprot.2011.07.008
   Waldeyer C, 2017, EUR HEART J, V38, P2490, DOI 10.1093/eurheartj/ehx166
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang JH, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0376
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang L, 2014, SCI REP-UK, V4, DOI 10.1038/srep04582
   WANG N, 1993, EXP EYE RES, V57, P225, DOI 10.1006/exer.1993.1118
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Watanabe J, 2012, ARTHRITIS RHEUM-US, V64, P1828, DOI 10.1002/art.34363
   Watson CE, 2011, J LIPID RES, V52, P361, DOI 10.1194/jlr.M011098
   Weir JM, 2013, J LIPID RES, V54, P2898, DOI 10.1194/jlr.P035808
   WEISGRABER KH, 1990, J LIPID RES, V31, P1503
   Welch L., 2015, DEV CELL, V2015, P657
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wong BH, 2016, J BIOL CHEM, V291, P10501, DOI 10.1074/jbc.M116.721340
   Wu J, 2017, AM J CLIN NUTR, V105, P1483, DOI 10.3945/ajcn.116.143453
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Ye D, 2011, CURR DRUG TARGETS, V12, P647, DOI 10.2174/138945011795378522
   Yin W, 2012, J LIPID RES, V53, P51, DOI 10.1194/jlr.M019927
   Yokoyama S, 2005, CURR OPIN LIPIDOL, V16, P269, DOI 10.1097/01.mol.0000169346.15450.90
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yue F, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0280-x
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zheng J, 2016, ATHEROSCLEROSIS, V255, P156, DOI 10.1016/j.atherosclerosis.2016.08.022
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
NR 418
TC 85
Z9 85
U1 5
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2018
VL 67
BP 56
EP 86
DI 10.1016/j.preteyeres.2018.04.006
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD5OJ
UT WOS:000452579500003
PM 29729972
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Askou, AL
AF Askou, Anne Louise
TI Development of gene therapy for treatment of age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
C1 Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark.
C3 Aarhus University
RP Askou, AL (通讯作者)，Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus, Denmark.
EM anne.louise.askou@hum-gen.au.dk
RI Askou, Anne/AGW-2995-2022
OI Askou, Anne Louise/0000-0002-5512-1796
CR Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Pihlmann M, 2012, J GENE MED, V14, P328, DOI 10.1002/jgm.2623
NR 3
TC 0
Z9 0
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2014
VL 92
IS 7
BP 709
EP 709
DI 10.1111/aos.12569
PG 1
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS3FN
UT WOS:000344162700039
OA Bronze
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Armstrong, D
   Browne, R
AF Spaide, RF
   Armstrong, D
   Browne, R
TI Choroidal neovascularization in age-related macular degeneration - What
   is the cause?
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; angiogenesis; apoptosis; Bruch
   membrane; choroidal neovascularization; drusen; geographic atrophy;
   ischemia; lipid metabolism; oxidative damage; p53; peroxidized lipids;
   reactive oxygen species; scavenger receptors; senescence; vascular
   endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; GLYCATION
   END-PRODUCTS; VASCULAR-PERMEABILITY FACTOR; LOW-DENSITY-LIPOPROTEIN;
   MONOCYTE-DERIVED MACROPHAGES; NITRIC-OXIDE SYNTHASE; ROD OUTER SEGMENTS;
   INDUCIBLE FACTOR-I; DISEASE GENE ABCR
C1 Vitreous Retina Macula Consultants New York, New York, NY 10021 USA.
   SUNY Buffalo, Dept Biotech & Clin Lab Sci, Buffalo, NY 14260 USA.
   SUNY Buffalo, Dept Biotech & Clin Lab Sci, Buffalo, NY 14260 USA.
C3 Vitreous Retina Macula Consultants of New York; State University of New
   York (SUNY) System; State University of New York (SUNY) Buffalo; State
   University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 519 E 72nd St, New York, NY 10021 USA.
EM rickspaide@yahoo.com
RI Spaide, Richard/ABD-7368-2020
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ARDELT BK, 1994, TOXICOLOGY, V89, P127, DOI 10.1016/0300-483X(94)90221-6
   Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Asayama Nobuya, 2000, Nippon Ganka Gakkai Zasshi, V104, P390
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211
   Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Bonne C, 1998, GEN PHARMACOL, V30, P275, DOI 10.1016/S0306-3623(97)00357-1
   Boullier A, 2001, ANN NY ACAD SCI, V947, P214
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337
   Chen QM, 2000, ANN NY ACAD SCI, V908, P111
   Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8
   CHUMBLEY LC, 1977, S AFR MED J, V52, P316
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dorey CK, 1996, ARCH OPHTHALMOL-CHIC, V114, P1210, DOI 10.1001/archopht.1996.01100140410008
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Folkman J, 1997, EXS, V79, P1
   Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982
   FUKUZUMI K, 1986, J ENVIRON PATHOL TOX, V6, P25
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gillotte KL, 2000, J LIPID RES, V41, P824
   Gohil K, 2002, ANN NY ACAD SCI, V957, P70, DOI 10.1111/j.1749-6632.2002.tb02906.x
   Gohil K, 2000, FREE RADICAL RES, V33, P831, DOI 10.1080/10715760000301351
   Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HASHIMOTO E, 1994, BIOCHEM BIOPH RES CO, V204, P318, DOI 10.1006/bbrc.1994.2462
   Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161
   HAUGH LM, 1990, ANN BIOMED ENG, V18, P19, DOI 10.1007/BF02368415
   HAYASAKA S, 1989, JPN J OPHTHALMOL, V33, P36
   Hirata C, 1997, BIOCHEM BIOPH RES CO, V236, P712, DOI 10.1006/bbrc.1997.7036
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1997, ARCH OPHTHALMOL-CHIC, V115, P788, DOI 10.1001/archopht.1997.01100150790017
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Honda S, 2002, BRIT J OPHTHALMOL, V86, P159, DOI 10.1136/bjo.86.2.159
   Horiuchi S, 1996, DIABETES, V45, pS73, DOI 10.2337/diab.45.3.S73
   HRUSZKEWYCZ AM, 1988, BIOCHEM BIOPH RES CO, V153, P191, DOI 10.1016/S0006-291X(88)81207-5
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108
   Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   ISHIBASHI T, 1986, OPHTHALMOLOGICA, V192, P179, DOI 10.1159/000309639
   Ishikawa Y, 2000, KIDNEY INT, V58, P1078, DOI 10.1046/j.1523-1755.2000.00265.x
   Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5
   Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953
   Jeziorska M, 1999, HUM PATHOL, V30, P919, DOI 10.1016/S0046-8177(99)90245-9
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATOH O, 1995, CANCER RES, V55, P5687
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776
   KIKUGAWA K, 1989, ADV EXP MED BIOL, V266, P345
   KIKUGAWA K, 1987, CHEM PHYS LIPIDS, V44, P277, DOI 10.1016/0009-3084(87)90054-5
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955
   KORTE GE, 1988, ACTA ANAT, V133, P224
   KRAKAU CET, 1995, GRAEF ARCH CLIN EXP, V233, P112, DOI 10.1007/BF00241481
   KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   Kubo H, 2000, BLOOD, V96, P546
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kuzuya M, 2001, ARTERIOSCL THROM VAS, V21, P765, DOI 10.1161/01.ATV.21.5.765
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lelkes PI, 1998, ADV EXP MED BIOL, V454, P295
   Li WY, 1999, MECH AGEING DEV, V110, P137, DOI 10.1016/S0047-6374(99)00047-0
   Linnane AW, 2002, FREE RADICAL RES, V36, P445, DOI 10.1080/10715760290021306
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   MATSUMURA M, 1985, OPHTHALMIC RES, V17, P148, DOI 10.1159/000265366
   MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35
   Miquel J, 1998, EXP GERONTOL, V33, P113, DOI 10.1016/S0531-5565(97)00060-0
   Monte M, 1997, EUR J CANCER, V33, P676, DOI 10.1016/S0959-8049(96)00506-0
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Muller K, 2002, FREE RADICAL RES, V36, P791, DOI 10.1080/10715760290032539
   Murata T, 1997, DIABETOLOGIA, V40, P764, DOI 10.1007/s001250050747
   Nicholson AC, 2000, ANN NY ACAD SCI, V902, P128
   Nose K, 2000, BIOL PHARM BULL, V23, P897
   OBRIEN ER, 1994, AM J PATHOL, V145, P883
   PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peters S, 1999, GRAEF ARCH CLIN EXP, V237, P976, DOI 10.1007/s004170050333
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Piotrowski JJ, 1996, LIFE SCI, V58, P735, DOI 10.1016/0024-3205(95)02351-8
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Ramos MA, 1998, ARTERIOSCL THROM VAS, V18, P1188, DOI 10.1161/01.ATV.18.7.1188
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rao DV, 2003, MECH AGEING DEV, V124, P55, DOI 10.1016/S0047-6374(02)00170-7
   REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021
   Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   RUNGGERBRANDLE E, 1987, INVEST OPHTH VIS SCI, V28, P2026
   RYAN SJ, 2001, CHOROIDAL NEOVASCULA, P1005
   Ryeom SW, 1996, J CELL SCI, V109, P387
   SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265
   Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789
   Saretzki G, 2002, ANN NY ACAD SCI, V959, P24, DOI 10.1111/j.1749-6632.2002.tb02079.x
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sasaki H, 2000, TOXICOLOGY, V155, P27, DOI 10.1016/S0300-483X(00)00274-2
   Schmidt S, 2000, MOL VIS, V6, P287
   SCHOTT RJ, 1993, CARDIOVASC RES, V27, P1155, DOI 10.1093/cvr/27.7.1155
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Segawa Y, 1998, OPHTHALMIC RES, V30, P333, DOI 10.1159/000055493
   Senger DR, 1996, AM J PATHOL, V149, P293
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Shi WB, 2000, CIRCULATION, V102, P75, DOI 10.1161/01.CIR.102.1.75
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7
   Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652
   Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53
   Skulachev VP, 2002, ANN NY ACAD SCI, V959, P214, DOI 10.1111/j.1749-6632.2002.tb02095.x
   Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Soussi T, 2000, ANN NY ACAD SCI, V910, P121
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Suarna C, 1997, FREE RADICAL RES, V27, P397, DOI 10.3109/10715769709065779
   SUBCZYNSKI WK, 1991, BIOCHEMISTRY-US, V30, P8578, DOI 10.1021/bi00099a013
   SUBCZYNSKI WK, 1992, BIOPHYS J, V63, P573, DOI 10.1016/S0006-3495(92)81612-0
   SUBCZYNSKI WK, 1989, P NATL ACAD SCI USA, V86, P4474, DOI 10.1073/pnas.86.12.4474
   SUBCZYNSKI WK, 1992, J GEN PHYSIOL, V100, P69, DOI 10.1085/jgp.100.1.69
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P2165
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
   Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   UEDA T, 1998, ANGIOGENESIS, V2, P174
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   Vinores SA, 2000, ADV EXP MED BIOL, V476, P129
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   WANG GL, 1993, J BIOL CHEM, V268, P21513
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Wihlmark U, 1996, APMIS, V104, P265, DOI 10.1111/j.1699-0463.1996.tb00716.x
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wintergerst ES, 2000, EUR J BIOCHEM, V267, P6050, DOI 10.1046/j.1432-1327.2000.01682.x
   WOLF G, 1993, NUTR REV, V51, P205, DOI 10.1111/j.1753-4887.1993.tb03104.x
   YAN SD, 1994, J BIOL CHEM, V269, P9889
   YANCEY CM, 1989, INVEST OPHTH VIS SCI, V30, P600
   YANCEY CM, 1988, INVEST OPHTH VIS SCI, V29, P700
   Yang YC, 1997, J GLAUCOMA, V6, P175
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   Yin JH, 2000, BIOCHEM BIOPH RES CO, V279, P30, DOI 10.1006/bbrc.2000.3896
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
NR 223
TC 91
Z9 99
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2003
VL 23
IS 5
BP 595
EP 614
DI 10.1097/00006982-200310000-00001
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 736MM
UT WOS:000186174600001
PM 14574243
DA 2022-11-30
ER

PT J
AU Kessel, L
   Erngaard, D
   Flesner, P
   Andresen, J
   Tendal, B
   Hjortdal, J
AF Kessel, Line
   Erngaard, Ditte
   Flesner, Per
   Andresen, Jens
   Tendal, Britta
   Hjortdal, Jesper
TI Cataract surgery and age-related macular degeneration. An evidence-based
   update
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; cataract surgery; exudative
   age-related macular degeneration; outcome; visual acuity
ID QUALITY-OF-LIFE; ENDOTHELIAL GROWTH-FACTOR; VISUAL-ACUITY;
   INTRAOCULAR-LENS; BEAVER DAM; 5-YEAR INCIDENCE; RISK-FACTORS;
   MACULOPATHY; EXTRACTION; IMPLANTATION
AB PurposeAge-related macular degeneration (AMD) and cataract often coexist in patients and concerns that cataract surgery is associated with an increased risk of incidence or progression of existing AMD has been raised. This systematic review and meta-analysis is focused on presenting the evidence concerning progression of AMD in patients undergoing cataract surgery.
   MethodsWe performed a systematic literature search in the PubMed, Medline, Cochrane Library and CINAHL databases. Two randomized trials and two case-control trials were identified. Quality of the studies was assessed using the Cochrane risk of bias tool, data were extracted, and meta-analyses were performed. Quality of the available evidence was evaluated using the GRADE system.
   ResultsWe found that visual acuity at 6-12months follow-up was significantly better (6.5-7.5 letters) in eyes that had undergone cataract surgery than in unoperated eyes, but the included number of subjects was small, and hence, the quality of evidence was downgraded to moderate. We did not find an increased risk of progression to exudative AMD 6-12months after cataract surgery [RR 3.21 (0.14-75.68)], but the included number of subjects was small, and thus, the quality of the evidence was moderate.
   ConclusionCataract surgery increases visual acuity without an increased risk of progression to exudative AMD, but further research with longer follow-up is encouraged.
C1 [Kessel, Line] Univ Copenhagen, Glostrup Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Kessel, Line; Tendal, Britta] Danish Hlth & Med Author, Copenhagen, Denmark.
   [Erngaard, Ditte] Naestved Hosp, Dept Ophthalmol, Naestved, Denmark.
   [Flesner, Per] Odense Eye Clin, Odense, Denmark.
   [Andresen, Jens] Skanderborg Eye Clin, Skanderborg, Denmark.
   [Tendal, Britta] Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen, Denmark.
   [Hjortdal, Jesper] Aarhus Univ Hosp NBG, Dept Ophthalmol, Aarhus, Denmark.
C3 University of Copenhagen; Naestved Hospital; University of Southern
   Denmark; Odense University Hospital; Rigshospitalet; University of
   Copenhagen; Aarhus University
RP Kessel, L (通讯作者)，Univ Copenhagen, Glostrup Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM line.kessel@dadlnet.dk
OI Kessel, Line/0000-0002-9375-1510
FU National Danish Health and Medicines Authority
FX The study was initiated and financed by the National Danish Health and
   Medicines Authority. The authors would like to thank information
   specialist Birgitte Holm Pedersen for assistance with the literature
   search.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brunner S, 2013, OPHTHALMOLOGICA, V229, P86, DOI 10.1159/000345492
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chen J, 2012, NAT MED, V18, P658, DOI 10.1038/nm.2761
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2007, OPHTHAL EPIDEMIOL, V14, P408, DOI 10.1080/09286580701316124
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Demirel S, 2014, GRAEF ARCH CLIN EXP, V252, P213, DOI 10.1007/s00417-013-2424-2
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Fong CSU, 2011, BRIT J OPHTHALMOL, V95, P1652, DOI 10.1136/bjo.2010.197517
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   GRADE profiler, 2011, GRAD WORK GROUP 2004
   Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725
   Grixti A, 2014, ISRN OPHTHALMOL, V2014
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P395, DOI 10.1016/j.jclinepi.2010.09.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Howard KP, 2013, OPHTHALMOLOGY, V120, P1509, DOI 10.1016/j.ophtha.2013.03.025
   Iwami Hisashi, 2011, Osaka City Med J, V57, P49
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kessel L, 2010, J CATARACT REFR SURG, V36, P308, DOI 10.1016/j.jcrs.2009.08.035
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Kovacevic D, 2010, COLLEGIUM ANTROPOL, V34, P21
   Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P9
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Pham TQ, 2007, EYE, V21, P324, DOI 10.1038/sj.eye.6702171
   Pham TQ, 2005, CLIN EXP OPHTHALMOL, V33, P360, DOI 10.1111/j.1442-9071.2005.01031.x
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Potgieter FJ, 2014, J CATARACT REFR SURG, V40, P1085, DOI 10.1016/j.jcrs.2013.10.049
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Review Manager (RevMan), 2014, REV MAN REVMAN
   Rohart C, 2008, J FR OPHTALMOL, V31, P571, DOI 10.1016/S0181-5512(08)75457-3
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Ruiz-Moreno JM, 2010, INT J OPHTHALMOL, V10, P1245
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   STOLBA U, 1989, J FR OPHTALMOL, V12, P897
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Tovey D, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4508
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 82
TC 33
Z9 33
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2015
VL 93
IS 7
BP 593
EP 600
DI 10.1111/aos.12665
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU9UG
UT WOS:000363890500015
PM 25601333
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kim, M
   Yu, SY
   Kwak, HW
AF Kim, Moosang
   Yu, Seung-Young
   Kwak, Hyung-Woo
TI Association between hyperacuity defects and retinal microstructure in
   polypoidal choroidal vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; preferential hyperacuity perimetry;
   spectral-domain optical coherence tomography
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; FOVEAL
   PHOTORECEPTOR LAYER; OCCULT OUTER RETINOPATHY; VISUAL-ACUITY; MACULAR
   DEGENERATION; VEIN OCCLUSION; RETINITIS-PIGMENTOSA; PERIMETER; SEGMENT
AB Purpose: To improve our understanding of hyperacuity defects measured with preferential hyperacuity perimetry (PHP) by correlating PHP findings with the retinal microstructural changes visible on spectral-domain optical coherence tomography (OCT) in patients with polypoidal choroidal vasculopathy (PCV). Materials and Methods: Twenty-eight eyes of 28 patients with PCV were retrospectively reviewed. All patients underwent a complete ophthalmologic examination, including best-corrected visual acuity (logMAR) testing, PHP, and OCT. The functional 'PHP test score' and 'total volume of hyperacuity defect zone' were also analyzed. Results: Patients were classified based on the hyperacuity defect by PHP, as follows: Hyperacuity defect (n = 17 eyes) group and hyperacuity intact (n = 11 eyes) group. The mean best-corrected visual acuity in the hyperacuity intact group (0.46 +/- 0.39) was better than that in the hyperacuity defect group (0.82 +/- 0.37) (P = 0.014). The presence of serous retinal detachment and retinal pigment epithelial detachment did not differ significantly between groups (P = 0.120 and P = 0.689, respectively). A disrupted photoreceptor layer was more common in the hyperacuity defect group compared with the hyperacuity intact group (P = 0.0001). Among 17 eyes with a hyperacuity defect, 9 eyes showing intra-retinal pathology (intra-retinal cyst or hard exudates) and had a significantly higher PHP test score and larger total volume of the hyperacuity defect zone than 8 eyes without intra-retinal pathology (P = 0.006 and P = 0.021, respectively). Conclusion: A hyperacuity defect in PCV was associated with photoreceptor disarrangement. Furthermore, PCV lesions on the inner retina that invaded the photoreceptor layer were associated with a more severe hyperacuity defect.
C1 [Kim, Moosang] Kangwon Natl Univ, Sch Med, Kangwon Natl Univ Hosp, Dept Ophthalmol, Chunchon, Gangwon Do, South Korea.
   [Yu, Seung-Young; Kwak, Hyung-Woo] Kyung Hee Univ, Coll Med, Seoul, South Korea.
C3 Kangwon National University; Kangwon National University Hospital; Kyung
   Hee University
RP Yu, SY (通讯作者)，1 Hoegi Dong, Seoul 130702, South Korea.
EM syyu@khu.ac.kr
FU Kangwon National University
FX This study was supported by 2012 Research Grant from Kangwon National
   University.
CR Aizawa S, 2009, EYE, V23, P304, DOI 10.1038/sj.eye.6703076
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Anderson C, 2009, RETINA-J RET VIT DIS, V29, P1188, DOI 10.1097/IAE.0b013e3181a3b8d4
   Baba T, 2008, RETINA-J RET VIT DIS, V28, P453, DOI 10.1097/IAE.0b013e3181571398
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Hangai Masanori, 2007, Nippon Ganka Gakkai Zasshi, V111, P509
   Li D, 2007, ARCH OPHTHALMOL-CHIC, V125, P1194, DOI 10.1001/archopht.125.9.1194
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Massey S.C., 2006, RETINA-J RET VIT DIS, VFourth Edition, P43, DOI 10.1016/b978-0-323-02598-0.50010-0
   Murakami T, 2007, AM J OPHTHALMOL, V143, P171, DOI 10.1016/j.ajo.2006.08.030
   Oishi A, 2009, EYE, V23, P299, DOI 10.1038/sj.eye.6703077
   Ojima Y, 2008, AM J OPHTHALMOL, V146, P77, DOI 10.1016/j.ajo.2008.02.016
   Ojima Y, 2007, OPHTHALMOLOGY, V114, P2197, DOI 10.1016/j.ophtha.2007.02.015
   Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P111, DOI 10.1016/j.ajo.2008.02.027
   Watanabe A, 2009, OPHTHALMOLOGY, V116, P1788, DOI 10.1016/j.ophtha.2009.04.046
   WESTHEIMER G, 1987, AM J OPTOM PHYS OPT, V64, P567
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 4
Z9 4
U1 0
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2014
VL 62
IS 6
BP 702
EP 706
DI 10.4103/0301-4738.121132
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ9WP
UT WOS:000348565200011
PM 24212209
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Eraydin, B
   Kocak, N
   Birinci, H
AF Eraydin, Bilge
   Kocak, Nurullah
   Birinci, Hakki
TI The comparison of spectral domain optical coherence tomography and
   indocyanine green angiography in the diagnosis of polypoidal choroidal
   vasculopathy
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; SD-OCT; ICGA
AB Objectives To evaluate the diagnostic capability of spectral domain optical coherence tomography (SD-OCT) in patients with potential diagnostic findings for polypoidal choroidal vasculopathy (PCV). Materials and methods Ninety-three eyes with potential diagnostic findings for PCV were prospectively evaluated. Patients with multiple retinal pigment epithelial detachment (RPED), sharp RPED peak, RPED notch, hyporeflective lumen representing polyps, double-layer sign and the presence of hyperreflective intraretinal hard exudate were considered as PCV in SD-OCT. The sensitivity and specificity of SD-OCT in the diagnosis of PCV were determined by comparing SD-OCT-based diagnosis with indocyanine green angiography (ICGA). Results Sixty-nine (74.2%) of 93 eyes included in the study were confirmed with ICGA and diagnosed as PCV. The sensitivity and specificity of SD-OCT for the diagnosis of PCV were 75.3% and 75%, respectively. Conclusion The SD-OCT-based method helps clinicians to develop appropriate diagnostic and treatment strategies for patients in whom ICGA cannot be used.
C1 [Eraydin, Bilge] Tokat Erbaa State Hosp, Tokat, Turkey.
   [Kocak, Nurullah; Birinci, Hakki] Ondokuz Mayis Univ, Dept Ophthalmol, Samsun, Turkey.
C3 Erbaa State Hospital; Ondokuz Mayis University
RP Eraydin, B (通讯作者)，Tokat Erbaa State Hosp, Tokat, Turkey.
EM bilgeraydin@hotmail.com
RI KOÇAK, NURULLAH/AAI-9905-2021
OI Eraydin, Bilge/0000-0003-0036-056X
CR Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2021
VL 41
IS 2
BP 659
EP 665
DI 10.1007/s10792-020-01622-y
EA OCT 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG9RC
UT WOS:000577849800001
PM 33057916
DA 2022-11-30
ER

PT J
AU Yamada, Y
   Miyamura, N
   Suzuma, K
   Kitaoka, T
AF Yamada, Yoshihisa
   Miyamura, Noritake
   Suzuma, Kiyoshi
   Kitaoka, Takashi
TI Long-term Follow-up of Full Macular Translocation for Choroidal
   Neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; PHOTODYNAMIC THERAPY; INTRAVITREAL
   TRIAMCINOLONE; PERIPHERAL RETINECTOMY; 360-DEGREE RETINOTOMY; VISUAL
   FUNCTION; DEGENERATION; VERTEPORFIN; SURGERY; MANAGEMENT
AB PURPOSE: To report the long-term (>5 years) results of full macular translocation in patients with choroidal neovascularization (CNV).
   DESIGN: Retrospective, interventional case series.
   METHODS: This study involved 32 eyes of 32 patients who had undergone full macular translocation for CNV. The median follow-up was 6.5 years (range, 5.2 to 7.7 years). We evaluated the best-corrected visual acuity, fundus examination results obtained before and 1 and 5 years after operation, and postoperative complications.
   RESULTS: At the 1-year follow-up, foveal retinal pigment epithelium atrophy was observed in only 3 eyes (12%), and the mean logarithm of the minimal angle of resolution (logMAR) visual acuity (VA) at that time (1.39 +/- 0.67) was not significantly changed from that before surgery (logMAR, 1.31 +/- 0.66) in 25 eyes with age-related macular degeneration (AMD). However, at 5-year follow-up, foveal retinal pigment epithelium atrophy increased (18 eyes; 72%), and final mean logMAR VA (1.88 +/- 0.76) was significantly lower (P < .01). Five eyes with myopic CNV maintained their VA from before operation (mean logMAR, 0.88 +/- 0.35) until final follow-up (mean logMAR, 0.73 +/- 0.31). The final VA was significantly better in myopic CNV than in exudative age-related macular degeneration on multiple regression analysis (P = .019).
   CONCLUSIONS: Long-term follow-up of full macular translocation showed that the final VA was poor in age-related macular degeneration, but relatively better in myopic CNV. (Am J Ophthalmol 2010;149:453-457. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Yamada, Yoshihisa; Miyamura, Noritake; Suzuma, Kiyoshi; Kitaoka, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Nagasaki 8528501, Japan.
C3 Nagasaki University
RP Yamada, Y (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.
EM y-yoshi@nagasaki-u.ac.jp
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Aisenbrey S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1367, DOI 10.1001/archopht.125.10.1367
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Suesskind D, 2008, EYE, V22, P834, DOI 10.1038/sj.eye.6702738
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
NR 20
TC 12
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2010
VL 149
IS 3
BP 453
EP 457
DI 10.1016/j.ajo.2009.09.014
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 565MD
UT WOS:000275296400015
PM 20035923
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Ojima, Y
   Yamashiro, K
   Nakata, I
   Ooto, S
   Tamura, H
   Nakanishi, H
   Hayashi, H
   Otani, A
   Yoshimura, N
AF Tsujikawa, Akitaka
   Ojima, Yumiko
   Yamashiro, Kenji
   Nakata, Isao
   Ooto, Sotaro
   Tamura, Hiroshi
   Nakanishi, Hideo
   Hayashi, Hisako
   Otani, Atsushi
   Yoshimura, Nagahisa
TI Association of Lesion Size and Visual Prognosis to Polypoidal Choroidal
   Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; INDOCYANINE GREEN; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; LASER PHOTOCOAGULATION; ANGIOGRAPHIC LESION;
   FEATURES
AB PURPOSE: To investigate the progression of vascular lesions of polypoidal choroidal vasculopathy (PCV) as viewed with indocyanine green angiography and the visual prognosis of these eyes.
   DESIGN: Retrospective case study.
   METHODS: We reviewed retrospectively the medical records of 88 consecutive patients (88 eyes) with PCV who had been examined with indocyanine green angiography for more than 2 years.
   RESULTS: Depending on the initial area of the vascular lesion, eyes were divided into smaller PCV (baseline area of lesion being < 1 disc area [DA], n = 22) and larger PCV (baseline area of lesion being >= 1 DA, n = 66). In larger PCV, the mean area of the lesion progressed significantly from 6.49 +/- 8.96 mm(2) to 16.27 +/- 14.19 mm(2) (P < .0001) with marked deterioration of visual acuity (P < .0001) during follow-up. In contrast, smaller PCV often showed minimal progression of the lesion, only limited exudative change, and the eyes maintained their initially good vision to the final visit. Smaller PCV lesions rarely progressed to extensive PCV lesions. Severe vision-threatening complications (ie, suprachoroidal hemorrhage, vitreous hemorrhage, and tears of the retinal pigment epithelium) were seen only in eyes with larger PCV, and in studying single nucleotide polymorphisms A69S of ARMS2 genes, there was a significant difference in T allele frequency between individuals with smaller PCV and those with larger PCV (20.2% vs 79.8%; P = .0235).
   CONCLUSIONS: PCV with small vascular lesions shows minimal progression and no vision-threatening complications, and these eyes often maintain good visual acuity for a long time. (Am J Ophthalmol 2011;151: 961-972. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Tsujikawa, Akitaka; Ojima, Yumiko; Yamashiro, Kenji; Nakata, Isao; Ooto, Sotaro; Tamura, Hiroshi; Nakanishi, Hideo; Hayashi, Hisako; Otani, Atsushi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21592256]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED IN PART BY GRANT-IN-AID FOR
   SCIENTIFIC RESEARCH NO. 21592256 FROM the Japan Society for the
   Promotion of Science (JSPS), Tokyo, Japan; and the Japan National
   Society for the Prevention of Blindness, Tokyo, Japan. The authors
   indicate no financial conflict of interest. Involved in Conception and
   design of study (AT., Y.O., N.Y.); Data collection (A.T., Y.O., K.Y.,
   I.N., SO., H.T., H.N., H.H., A.O.); Analysis and interpretation of data
   (K.Y., IN., S.O., H.T., H.N.,. H.H., A.O.); writing of article (A.T.,
   Y.O.); critical revision of article (K.Y., IN., SO,, H.T., H.N., H.H.,
   A.O., N.Y.); and Final approval of article (A.T., Y.O., K.Y., IN., SO.,
   H.T., H.N., H.H., A.O., N.Y.). This study was approved by the
   Institutional Review Board at Kyoto University Graduate School of
   Medicine and adhered to the tenets of the Declaration of Helsinki. In
   the guidelines, it is not mandatory to obtain informed consent from
   patients for a retrospective study in which the researchers review only
   medical records.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akman A, 2000, EYE, V14, P680, DOI 10.1038/eye.2000.175
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut B A, 2000, Bull Soc Belge Ophtalmol, P49
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 48
TC 48
Z9 49
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2011
VL 151
IS 6
BP 961
EP 972
DI 10.1016/j.ajo.2011.01.002
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 773GQ
UT WOS:000291295400008
PM 21457926
OA Green Published
DA 2022-11-30
ER

PT J
AU Markowitz, M
   Daibert-Nido, M
   Markowitz, SN
AF Markowitz, Michelle
   Daibert-Nido, Monica
   Markowitz, Samuel N.
TI Rehabilitation of reading skills in patients with age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
ID LOW-VISION REHABILITATION; PERIPHERAL-VISION; PSYCHOPHYSICS; DISEASE;
   PRISMS; SPEED
AB Reading is the most frequent clinical complaint and the primary goal for patients with macular degeneration seeking vision rehabilitation. The current prevalent methods for reading skills training across the globe are still magnification and basic scotoma awareness training. More recent studies showed that specific eccentric training, comprehension ability training, and specific oculomotor training are all beneficial to reading skills rehabilitation. In clinical practice, ophthalmologists should strive to implement reading skills methods that include assessment of cognitive skills, optimal eyewear, optimal reading material, PRL assessment, training of better oculomotor control, and efficient perceptual training.
C1 [Daibert-Nido, Monica; Markowitz, Samuel N.] Univ Toronto, Dept Opthalmol & Vis Sci, Univ Hlth Network Hosp, Low Vis Serv, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
CR Allen M, 2012, M AM OPT ASS OPT JUN
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Chung STL, 2010, OPTOMETRY VISION SCI, V87, P276, DOI 10.1097/OPX.0b013e3181c91347
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   Jasper Ridge Inc, LUXQ 2 TINT LIGHTING
   KLEEN SR, 1981, AM J OPTOM PHYS OPT, V58, P200
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   Markowitz M, 2006, CAN J OPHTHALMOL, V41, P340, DOI 10.1139/I06-020
   Markowitz S N., 2008, P 9 INT C LOW VIS VI
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Markowitz SN, 2013, ACTA OPHTHALMOL, V91, P207, DOI 10.1111/j.1755-3768.2011.02336.x
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Midena E, 2013, MICROPERIMETRY MULTI
   Mikhail D, 2015, CAN J OPHTHALMOL, V50, P19, DOI 10.1016/j.jcjo.2014.08.002
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Reyes SV, 2013, CAN J OPHTHALMOL, V48, P427, DOI 10.1016/j.jcjo.2013.03.001
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Tarita-Nistor L, 2013, CAN J OPHTHALMOL, V48, P57, DOI 10.1016/j.jcjo.2012.09.017
   *VIS GWSSB, 2004, TRAIN ECC FIX READ I
   WARREN M, 1996, PREREADING WRITING E
   WATSON GR, 1992, J VISUAL IMPAIR BLIN, V86, P37
   WATSON GR, 1995, LEARN USE YOUR VISIO
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
NR 27
TC 7
Z9 7
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2018
VL 53
IS 1
BP 3
EP 8
DI 10.1016/j.jcjo.2017.10.042
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX2XB
UT WOS:000425927500018
PM 29426437
DA 2022-11-30
ER

PT J
AU Fazelat, A
   Bahrani, H
   Buzney, S
   Lashkari, K
   Weiter, JJ
AF Fazelat, Ahad
   Bahrani, Hasan
   Buzney, Sheldon
   Lashkari, Kameran
   Weiter, John J.
TI Autoimmunity and Age-related Macular Degeneration: A Review of the
   Literature
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Drusen; Choroidal Neovascular Membranes; Autoantibodies; Autoimmunity;
   Complement; Inflammation
ID FACTOR-H POLYMORPHISM; ANIMAL-MODEL; DRUSEN; RISK; AUTOANTIBODIES;
   INFLAMMATION; ACTIVATION; ANTIBODIES; MONOCYTE; DISEASES
C1 [Fazelat, Ahad; Bahrani, Hasan; Buzney, Sheldon; Weiter, John J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
   [Lashkari, Kameran] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Schepens Eye
   Research Institute
RP Fazelat, A (通讯作者)，2285 Massachusetts Ave, Cambridge, MA USA.
EM Ahad_Fazelat@meei.harvard.edu
OI Lashkari, Kameran/0000-0003-3855-0246
CR Adamus G, 2003, AUTOIMMUN REV, V2, P63, DOI 10.1016/S1568-9972(02)00127-1
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koevary SB, 1999, OCULAR IMMUNOLOGY HL
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Niederkorn Jerry Y, 2007, Chem Immunol Allergy, V92, P1, DOI 10.1159/000099234
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Rahman I, 1999, ANTIOXID REDOX SIGN, V1, P425, DOI 10.1089/ars.1999.1.4-425
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 40
TC 3
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JUL-SEP
PY 2011
VL 26
IS 4-5
BP 304
EP 311
DI 10.3109/08820538.2011.588666
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 826VO
UT WOS:000295383800011
PM 21958179
DA 2022-11-30
ER

PT J
AU Lazic, R
   Gabric, N
   Dekaris, I
   Saric, B
   Gavric, M
AF Lazic, Ratimir
   Gabric, Nikica
   Dekaris, Iva
   Saric, Borna
   Gavric, Morena
TI Intravitreal bevacizumab (avastin) in treatment of neovascular
   age-related macular degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE bevacizumab; ranibizumab; pegaptanib
ID CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; THERAPY;
   VERTEPORFIN; INJECTION
AB To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this prospective, noncomparative, interventional case series. Median follow-up was 18 weeks (6-24). Intravitreal bevacizumab injection of 0.05 mL (1.25 mg) was administered at baseline and in 6 week intervals until leakage resolved, and repeated in case of leakage recurrence. Visual acuity (VA) improved in the majority of patients (mean baseline VA=1.078 log MAR) by mean increase of 1.32 lines (last follow-up) (p=0.001). Central foveal thickness and total macular volume decreased by 51 mu m (p=0.01) and 0.84 mm(3) (p < 0.0001) respectively. No serious complications were observed. As initial therapy, intravitreal bevacizumab appears to be safe and effective. A significant functional and anatomical improvement was noted in majority of patients and maintained during follow-up.
C1 Eye Clin Svjetlost, Zagreb 10000, Croatia.
RP Lazic, R (通讯作者)，Eye Clin Svjetlost, Bukovacka 27, Zagreb 10000, Croatia.
EM ratimir.lazic@svjetlost.hr
RI Dekaris, Iva/AAM-8799-2020
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 2001, RETINA, V3, P2030
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   He Aiwu Ruth, 2005, Clin Adv Hematol Oncol, V3, P555
   Ignoffo RJ, 2004, AM J HEALTH-SYST PH, V61, pS21, DOI 10.1093/ajhp/61.suppl_5.S21
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   WORMALD R, 2003, COCHRANE DB SYST REV
NR 22
TC 9
Z9 9
U1 0
U2 2
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 77
EP 81
PG 5
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800019
PM 17469757
DA 2022-11-30
ER

PT J
AU Patil, NS
   Dhoot, AS
   Popovic, MM
   Kertes, PJ
   Muni, RH
AF Patil, Nikhil S.
   Dhoot, Arjan S.
   Popovic, Marko M.
   Kertes, Peter J.
   Muni, Rajeev H.
TI RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR
   ENDOTHELIAL GROWTH FACTOR AGENTS A Meta-analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; intraocular inflammation;
   brolucizumab; endophthalmitis
ID MACULAR DEGENERATION; RANIBIZUMAB; BEVACIZUMAB; BROLUCIZUMAB;
   AFLIBERCEPT
AB Purpose: This meta-analysis investigates the incidence of intraocular inflammation (IOI) after intravitreal antivascular endothelial growth factor injections in neovascular age-related macular degeneration. Methods: A systematic search was performed on Ovid MEDLINE, Embase, and Cochrane Central from January 2005 to April 2021. Randomized controlled trials comparing IOI after intravitreal bevacizumab, ranibizumab, brolucizumab, or aflibercept in neovascular age-related macular degeneration were included. Primary outcomes were sight-threatening IOI, final best-corrected visual acuity, and change in best-corrected visual acuity from baseline. Secondary outcomes included the incidence of other IOI events. Meta-analysis was performed using a random-effects model. Results: Overall, 11,460 unique studies were screened, of which 14 randomized controlled trials and 6,759 eyes at baseline were included. There was no difference between agents for the risk of endophthalmitis and retinal vascular occlusion. Compared with aflibercept, brolucizumab had a higher incidence of generalized IOI (risk ratio = 6.24, 95% confidence interval = [1.40-27.90]) and vitreous haze/floaters (risk ratio = 1.64, 95% confidence interval = [1.00-2.67]). There were no significant differences between comparators for other secondary end points. Conclusion: There was no difference in the risk of severe sight-threatening IOI outcomes between intravitreal antivascular endothelial growth factor agents. There was a significantly higher risk of generalized IOI after brolucizumab relative to aflibercept. Our results alongside other recent safety findings suggest the need for further investigation in the risk-benefit profile of brolucizumab for the treatment of neovascular age-related macular degeneration.
C1 [Patil, Nikhil S.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada.
   [Dhoot, Arjan S.] Univ Toronto, Fac Med, Toronto, ON, Canada.
   [Popovic, Marko M.; Kertes, Peter J.; Muni, Rajeev H.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, Toronto, ON, Canada.
   [Muni, Rajeev H.] St Michaels Hosp, Dept Ophthalmol, Unity Hlth Toronto, 30 Bond St,8th Floor, Toronto, ON M5B 1W8, Canada.
C3 McMaster University; University of Toronto; University of Toronto;
   University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center; University of Toronto;
   University Toronto Affiliates; Saint Michaels Hospital Toronto
RP Muni, RH (通讯作者)，St Michaels Hosp, Dept Ophthalmol, Unity Hlth Toronto, 30 Bond St,8th Floor, Toronto, ON M5B 1W8, Canada.
EM rajeev.muni@utoronto.ca
OI Patil, Nikhil/0000-0003-3929-0482
CR Agostini H, 2020, CURR EYE RES, V45, P1298, DOI 10.1080/02713683.2020.1731832
   Anderson WJ, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00307-7
   [Anonymous], EYEWIRE
   [Anonymous], COCHRANE HDB SYSTEMA
   [Anonymous], NOVARTIS
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Ip M., 2020, AM ACAD OPHTHALMOLOG
   Iyer Prashanth G, 2020, Am J Ophthalmol Case Rep, V20, P100989, DOI 10.1016/j.ajoc.2020.100989
   Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.1136/bmj.l4898, 10.4084/MJHID.2010.005]
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Nunes RP, 2019, ARQ BRAS OFTALMOL, V82, P225, DOI 10.5935/0004-2749.20190043
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yorston David, 2014, Community Eye Health, V27, P44
NR 27
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2022
VL 42
IS 11
BP 2134
EP 2142
DI 10.1097/IAE.0000000000003582
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5M0WB
UT WOS:000870825900017
PM 36269802
DA 2022-11-30
ER

PT J
AU Ishikawa, K
   Sreekumar, PG
   Spee, C
   Nazari, H
   Zhu, DH
   Kannan, R
   Hinton, DR
AF Ishikawa, Keijiro
   Sreekumar, Parameswaran G.
   Spee, Christine
   Nazari, Hossein
   Zhu, Danhong
   Kannan, Ram
   Hinton, David R.
TI alpha B-Crystattin Regulates Subretinal Fibrosis by Modulation of
   Epithelial-Mesenchymat Transition
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; PROLIFERATIVE DIABETIC-RETINOPATHY; BONE
   MORPHOGENETIC PROTEINS; HEAT-SHOCK PROTEINS; MACULAR DEGENERATION;
   CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR; CRYSTALLIN DISTRIBUTION;
   NUCLEAR-LOCALIZATION; ENDOTHELIAL-CELLS
AB Subretinal fibrosis is an end stage of neovascular age-related macular degeneration, characterized by fibrous membrane formation after choroidal neovascularization. An initial step of the pathogenesis is an epithelial-mesenchymal transition (EMT) of retinal pigment epithelium cells. alpha B-crystallin plays multiple roles in age-related macular degeneration, including cytoprotection and angiogenesis. However, the role of alpha B-crystallin in subretinal EMT and fibrosis is unknown. Herein, we showed attenuation of subretinal fibrosis after regression of Laser-induced choroidal neovascularization and a decrease in mesenchymal retinal pigment epithelium cells in aB-crystallin knockout mice compared with wild-type mice. alpha B-crystallin was prominently expressed in subretinal fibrotic lesions in mice. In vitro, overexpression of alpha B-crystallin induced EMT, whereas suppression of alpha B-crystallin induced a mesenchymal-epithelial transition. Transforming growth factor-beta 2 induced EMT was further enhanced by overexpression of alpha B-crystallin but was inhibited by suppression of alpha B-crystallin. Silencing of alpha B-crystallin inhibited multiple fibrotic processes, including cell proliferation, migration, and fibronectin production. Bone morphogenetic protein 4 up regulated alpha B-crystallin, and its EMT induction was inhibited by knockdown of alpha B-crystallin. Furthermore, inhibition of alpha B-crystallin enhanced monotetraubiquitination of SMAD4, which can impair its nuclear localization. Overexpression of alpha B-crystallin enhanced nuclear translocation and accumulation of SMAD4 and SMAD5. Thus, alpha B-crystallin is an important regulator of EMT, acting as a molecular chaperone for SMAD4 and as its potential therapeutic target for preventing subretinal fibrosis development in neovascular age-related macular degeneration.
C1 [Ishikawa, Keijiro; Sreekumar, Parameswaran G.; Kannan, Ram] Doheny Eye Inst, Arnold & Mabel Beckman Macula Res Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Ishikawa, Keijiro; Spee, Christine; Nazari, Hossein; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Zhu, Danhong; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Ophthalmol, Hoffman Med Res 209, 2011 Zonal Ave, Los Angeles, CA 90033 USA.; Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, Hoffman Med Res 209, 2011 Zonal Ave, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020; Nazari, Hossein/GOK-8161-2022
OI kannan, ram/0000-0002-1583-3414; Nazari, Hossein/0000-0002-8945-9680;
   /0000-0002-9425-3986
FU NIH [EY03040, EY01545]; Arnold and Mabel Beckman Foundation; Japanese
   Society for the Promotion of Science; Japan Society for the Promotion of
   Science Postdoctoral Fellowships; NATIONAL EYE INSTITUTE [P30EY003040,
   R01EY001545] Funding Source: NIH RePORTER
FX Supported by NIH grants EY03040 and EY01545, the Arnold and Mabel
   Beckman Foundation, the Japanese Society for the Promotion of Science,
   and a Japan Society for the Promotion of Science Postdoctoral
   Fellowships for Research Abroad fellowship (K.I.).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Azmi AS, 2013, CURR CANCER DRUG TAR, V13, P906, DOI 10.2174/15680096113136660096
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   Basha E, 2012, TRENDS BIOCHEM SCI, V37, P106, DOI 10.1016/j.tibs.2011.11.005
   Bellaye PS, 2015, AM J RESP CELL MOL, V52, P244, DOI 10.1165/rcmb.2014-0011OC
   Bellaye PS, 2014, J PATHOL, V232, P458, DOI 10.1002/path.4314
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924
   Burke JM, 1999, INVEST OPHTH VIS SCI, V40, P2963
   Chen ZJ, 2014, BREAST CANCER RES TR, V145, P45, DOI 10.1007/s10549-014-2940-8
   Ciumas M, 2013, ARTERIOSCL THROM VAS, V33, P2577, DOI 10.1161/ATVBAHA.113.301976
   Cutroneo KR, 2003, J CELL BIOCHEM, V90, P1, DOI 10.1002/jcb.10599
   Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Deng M, 2010, BBA-MOL BASIS DIS, V1802, P621, DOI 10.1016/j.bbadis.2010.04.004
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8
   Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Huang XY, 2013, HEPATOLOGY, V57, P2235, DOI 10.1002/hep.26255
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Jiang DF, 2014, BLOOD, V123, P86, DOI 10.1182/blood-2013-07-515254
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kent D, 2003, MOL VIS, V9, P747
   Kudelka MR, 2013, EXPERT REV OPHTHALMO, V8, P475, DOI 10.1586/17469899.2013.840095
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li H, 2014, BIOCHEM BIOPH RES CO, V446, P347, DOI 10.1016/j.bbrc.2014.02.119
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nurgazieva D, 2015, J IMMUNOL, V194, P709, DOI 10.4049/jimmunol.1300272
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   van den Bosch MH, 2014, CELL SIGNAL, V26, P951, DOI 10.1016/j.cellsig.2014.01.021
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Wettstein G, 2012, INT J BIOCHEM CELL B, V44, P1680, DOI 10.1016/j.biocel.2012.05.024
   Wree A, 2014, J MOL MED, V92, P1069, DOI 10.1007/s00109-014-1170-1
   Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212
   Xing CC, 2015, J MOL CELL BIOL, V7, P48, DOI 10.1093/jmcb/mjv004
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094743
NR 59
TC 36
Z9 37
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2016
VL 186
IS 4
BP 859
EP 873
DI 10.1016/j.ajpath.2015.11.014
PG 15
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DI3QP
UT WOS:000373413900012
PM 26878210
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Petrarca, R
   Richardson, M
   Douiri, A
   Nau, J
   Mchugh, D
   Stangos, AN
   Jackson, TL
AF Petrarca, Robert
   Richardson, Matthew
   Douiri, Abdel
   Nau, Jeffrey
   Mchugh, Dominic
   Stangos, Alexandros N.
   Jackson, Timothy L.
TI SAFETY TESTING OF EPIMACULAR BRACHYTHERAPY WITH MICROPERIMETRY AND
   INDOCYANINE GREEN ANGIOGRAPHY 12-Month Results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE epimacular brachytherapy; indocyanine green angiography; microperimetry;
   neovascular age-related macular degeneration
ID POSTERIOR VITREOMACULAR ADHESION; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS PERIMETRY; SUBRETINAL NEOVASCULARIZATION;
   RADIATION RETINOPATHY; BEVACIZUMAB; PHYSIOLOGY; SECONDARY; RISK
AB Purpose: To determine if epimacular brachytherapy is associated with reduced retinal sensitivity or choroidal nonperfusion.
   Methods: A prospective intervention case series of 12 participants with neovascular age-related macular degeneration requiring frequent ranibizumab underwent vitrectomy and epimacular brachytherapy. The Strontium 90/Yttrium 90 source delivered a single 24-Gy dose at the center of the treatment zone. The dose attenuated with increasing distance from the source. Microperimetry and indocyanine green angiography were performed at baseline and 12 months. The main outcome measures were mean sensitivity and choroidal nonperfusion. A linear mixed model was used to assess the association between the dose of radiation and the change in mean sensitivity.
   Results: Mean visual acuity remained within 1 letter of baseline at 12 months (-0.33 +/- 13.2 letters). There was no statistically significant change in mean sensitivity within the neovascular age-related macular degeneration lesion area (gain of 0.94 +/- 3.25 dB; P = 0.339) or in neighboring unaffected retina (0.66 +/- 4.14 dB; P = 0.594), defined using fluorescein angiography. Within the lesion area, mean sensitivity improved by an average of 0.23 +/- 0.16 dB (P = 0.006) for every additional gray of radiation received. Indocyanine green angiography failed to demonstrate any choroidal nonperfusion or radiation damage at 12 months after the treatment.
   Conclusion: Stable retinal sensitivity in areas not manifestly affected by neovascular age-related macular degeneration suggests that epimacular brachytherapy does not damage retinal function. The presence of a dose response suggests that the positive effect of epimacular brachytherapy relates more to beta irradiation than vitrectomy.
C1 [Petrarca, Robert; Richardson, Matthew; Mchugh, Dominic; Stangos, Alexandros N.; Jackson, Timothy L.] Kings Coll Hosp London, London SE5 9RS, England.
   [Petrarca, Robert; Douiri, Abdel; Jackson, Timothy L.] Univ London, Univ London Kings Coll, London SW3 6LX, England.
   [Nau, Jeffrey] NeoVista, Newark, CA USA.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Douiri, Abdel/0000-0002-4354-4433; Petrarca, Robert/0000-0001-8693-3423;
   Jackson, Timothy/0000-0001-7618-1555; Richardson,
   Matthew/0000-0002-7390-9480
FU NeoVista, Inc.; Department of Health via the National Institute for
   Health Research (NIHR) comprehensive Biomedical Research Centre award;
   King's College London; King's College Hospital NHS Foundation Trust
FX King's College Hospital received a research grant from NeoVista, Inc.;
   A. Douiri receives financial support from the Department of Health via
   the National Institute for Health Research (NIHR) comprehensive
   Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation
   Trust in partnership with King's College London and King's College
   Hospital NHS Foundation Trust. J. Nau was an employee of NeoVista, Inc,
   and is presently employed by Genentech.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   BOOZALIS GT, 1987, RETINA-J RET VIT DIS, V7, P156, DOI 10.1097/00006982-198700730-00004
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   GORDON KB, 1995, INT J RADIAT ONCOL, V31, P1123, DOI 10.1016/0360-3016(95)00062-4
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Jaakkola A, 1998, BRIT J OPHTHALMOL, V82, P763, DOI 10.1136/bjo.82.7.763
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Midena E, 2006, Arch Soc Esp Oftalmol, V81, P183
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Navarro Rafael, 2011, Retin Cases Brief Rep, V5, P352, DOI 10.1097/ICB.0b013e3181fff2a6
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SOARES CG, 1991, MED PHYS, V18, P787, DOI 10.1118/1.596632
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Varano M, 1997, RETINA-J RET VIT DIS, V17, P300, DOI 10.1097/00006982-199707000-00004
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 30
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2013
VL 33
IS 6
BP 1232
EP 1240
DI 10.1097/IAE.0b013e3182794b22
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 151IU
UT WOS:000319454700021
PM 23508075
DA 2022-11-30
ER

PT J
AU Desai, P
   Minassian, DC
   Reidy, A
   Allen, N
   Sudlow, C
AF Desai, Parul
   Minassian, Darwin C.
   Reidy, Angela
   Allen, Naomi
   Sudlow, Cathie
TI Number of incident cases of the main eye diseases of ageing in the UK
   Biobank cohort, projected over a 25-year period from time of recruitment
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE epidemiology; public health
ID OPEN-ANGLE GLAUCOMA; PREVALENCE
AB Objectives To estimate the number of new cases of age-related macular degeneration, cataract and glaucoma accruing in the UK Biobank cohort, over a period of 25 years from time of recruitment. Our secondary objective was to assess the statistical power of nested case-control studies of these eye diseases. We aimed to provide quantitative information relevant to UK Biobank's eye disease case ascertainment efforts and to the potential for UK Biobank-based research into the causes of eye disease.
   Methods We constructed a Markov discrete-time state transition model to simulate the population dynamics of the eye disorders within the UK Biobank cohort, using prevalence data from population-based epidemiological studies to derive incidence, and Office for National Statistics data on mortality and migration overseas.
   Results By 2023, >900 new cases of each of wet' (neovascular) and dry' age-related macular degeneration, >1200 cases of primary open angle glaucoma and almost 15000 cases of cataracts are expected to have accrued in the subcohort of 68500 participants who had ocular assessment at baseline, with around seven times as many cases of each disease in the whole cohort of 500000 participants. These predicted incident case numbers generate good or substantial statistical power for a range of nested case-control studies of potential genetic, lifestyle and environmental determinants of disease.
   Conclusions Over the next few years, UK Biobank is expected to generate sufficient numbers of new cases for statistically well-powered studies of the determinants of the major causes of sight loss: age-related macular degeneration, vision-impairing cataract and glaucoma.
C1 [Desai, Parul] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Minassian, Darwin C.; Reidy, Angela] EpiVision, Penn, England.
   [Minassian, Darwin C.] UCL Inst Ophthalmol, London, England.
   [Allen, Naomi; Sudlow, Cathie] UK Biobank, Stockport, Lancs, England.
   [Allen, Naomi] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
   [Sudlow, Cathie] Univ Edinburgh, Med Informat Ctr, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Oxford; University of Edinburgh
RP Desai, P (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London, England.
EM parul.desai@moorfields.nhs.uk
OI Sudlow, Cathie/0000-0002-7725-7520
FU UK Biobank
FX The study was funded by a grant from the UK Biobank to Moorfields Eye
   Hospital R&D Directorate.
CR Biobank, AB UK BIOB
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burton PR, 2005, UK BIOBANK TECHNICAL
   Elandt-Johnson RC., 1980, SURVIVAL MODELS DATA
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Kapetanakis VV, 2016, BRIT J OPHTHALMOL, V100, P86, DOI 10.1136/bjophthalmol-2015-307223
   LESKE MC, 1981, AM J EPIDEMIOL, V113, P606, DOI 10.1093/oxfordjournals.aje.a113138
   National Eye Institute National Institutes of Health USA, 2012, VIS RES NEEDS GAPS O
   ONS, 2014, LONG TERM INT MIGR T
   ONS, HIST PROJ MORT RAT
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Sightsavers UK, 2016, EV GAP MAP CAT
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   UK Biobank, 2006, PROT LARG PROSP EP R
   UK Biobank Showcase, REG APPL
NR 16
TC 3
Z9 3
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2018
VL 102
IS 11
BP 1533
EP 1537
DI 10.1136/bjophthalmol-2017-311289
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD3UI
UT WOS:000452446800012
PM 29437582
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ozkaya, A
   Alagoz, C
   Garip, R
   Alkin, Z
   Perente, I
   Yazici, AT
   Taskapili, M
AF Ozkaya, A.
   Alagoz, C.
   Garip, R.
   Alkin, Z.
   Perente, I.
   Yazici, A. T.
   Taskapili, M.
TI The role of indocyanine green angiography imaging in further
   differential diagnosis of patients with nAMD who are morphologically
   poor responders to ranibizumab in a real-life setting
SO EYE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; INTRAVITREAL RANIBIZUMAB;
   NEOVASCULARIZATION; PHOTOCOAGULATION; VERTEPORFIN; INJECTION; OUTCOMES
AB Purpose To evaluate the neovascular age-related macular degeneration (nAMD) in patients who were morphologically poor responders to intravitreal ranibizumab (IVR) treatment using indocyanine green angiography (ICGA) for further investigation.
   Methods This was a cross-sectional, retrospective study. The patients with an initial diagnosis of nAMD who made through the clinical examination, optical coherence tomography, and fluorescein angiography imaging, and were treated with at least three monthly IVR injections that resulted with a morphological poor response, were included. ICGA was obtained from the patients and evaluated in regard to differential diagnosis of other macular diseases, which might mimic nAMD.
   Results The study included 132 eyes of 117 patients. The mean age was 67.4 +/- 9.4 years. After ICGA imaging, 13 eyes (9.8%) were diagnosed as true nAMD, 74 eyes (56.1%) as polypoidal choroidal vasculopathy (PCV), 35 eyes (26.5%) as chronic central serous chorioretinopathy (CSC), 3 eyes (2.3%) as retinal angiomatous proliferation (RAP), 3 eyes (2.3%) as choroidal neovascularization secondary to CSC, 2 eyes (1.5%) as adult-onset vitelliform macular dystrophy, and 2 eyes (1.5%) as drusenoid pigment epithelial detachment with vitelliform material, respectively. The duration between the initial diagnosis and the revised diagnosis was 15.6 +/- 10.5 months in the non-AMD group, and the mean injection number of these patients was 6.6 +/- 4.4.
   Conclusions Most of the nAMD patients who were thought to be morphologically poor responders to IVR were diagnosed as having non-AMD diseases via ICGA. A detailed differential diagnostic work-up is needed before considering these patients as poor responders.
C1 [Ozkaya, A.; Alagoz, C.; Garip, R.; Alkin, Z.; Perente, I.; Yazici, A. T.; Taskapili, M.] Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research Hospital
RP Ozkaya, A (通讯作者)，Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
EM abdozkaya@gmail.com
RI Alkin, Zeynep/V-7252-2017
OI Alkin, Zeynep/0000-0002-5363-1944
CR Alkin Z, 2014, J OCUL PHARMACOL TH, V30, P359, DOI 10.1089/jop.2013.0162
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cazet-Supervielle A, 2015, OPHTHALMOLOGICA, V234, P26, DOI 10.1159/000430470
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Garcia-Finana M, 2010, EYE, V24, P1213, DOI 10.1038/eye.2009.319
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grob S, 2014, SAUDI J OPHTHALMOL, V28, P104, DOI 10.1016/j.sjopt.2014.02.001
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hogan AC, 2006, EYE, V20, P649, DOI 10.1038/sj.eye.6702028
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Kapran Z, 2013, OSLI RETINA, V44, P471, DOI 10.3928/23258160-20130909-09
   Lee JE, 2015, RETINA-J RET VIT DIS, V35, P999, DOI 10.1097/IAE.0000000000000432
   Manoj S., 2011, KERALA J OPHTHALMOL, V3, P282
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Ozkaya Abdullah, 2014, Retina, V34, P853, DOI 10.1097/IAE.0000000000000024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROY M, 1990, Eye (London), V4, P813
   SINGERMAN LJ, 1989, RETINA-J RET VIT DIS, V9, P247, DOI 10.1097/00006982-198909040-00002
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   TORNAMBE PE, 1992, RETINA-J RET VIT DIS, V12, P305, DOI 10.1097/00006982-199212040-00003
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 29
TC 13
Z9 16
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2016
VL 30
IS 7
BP 958
EP 965
DI 10.1038/eye.2016.71
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0GS
UT WOS:000379586600009
PM 27080484
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Hoerster, R
   Muether, PS
   Sitnilska, V
   Kirchhof, B
   Fauser, S
AF Hoerster, Robert
   Muether, Philipp S.
   Sitnilska, Vasilena
   Kirchhof, Bernd
   Fauser, Sascha
TI FIBROVASCULAR PIGMENT EPITHELIAL DETACHMENT IS A RISK FACTOR FOR
   LONG-TERM VISUAL DECAY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERETION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   anti-vascular endothelial growth factor therapy; prognosis; optical
   coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; DEGENERATION; RANIBIZUMAB; ACUITY;
   BEVACIZUMAB; DELAY; AMD
AB Background: The individual outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration is variable. To investigate the prognostic value of spectral domain optical coherence tomography structures for best-corrected visual acuity (BCVA) outcome, volumetric analysis of spectral domain optical coherence tomography structures was performed in neovascular age-related macular degeneration correlated with BCVA after 24 months.
   Methods: At the Department of Ophthalmology, University of Cologne, Germany, 75 patients with neovascular age-related macular degeneration were analyzed prospectively over 24 months. Patients received three initial consecutive monthly intravitreal ranibizumab injections followed by monthly spectral domain optical coherence tomography controls. Therapy was continued as a pro re nata regimen. Volumetric analysis of spectral domain optical coherence tomography images was performed using commercially available software (3D-Doctor).
   Results: Subretinal tissue, subretinal fluid, serous pigment epithelial detachment, and fibrovascular pigment epithelial detachment (FPED) were identified. By contrast to all other structures, FPED did not respond to ranibizumab therapy. Volume of FPED at baseline and after the loading phase correlated most with impaired BCVA after 24 months (r = -0.0215, P = 0.9263 [subretinal tissue]; r = -0.3120, P = 0.0216 [subretinal fluid]; r = -0.0757, P = 0.6470 [serous pigment epithelial detachment]; r = -0.4182, P = 0.0111 (FPED baseline); r = -0.4768; P = 0.0002 [FPED after loading phase]).
   Conclusion: Of all identified structures, FPED was most deleterious for BCVA after 24 months. The knowledge about possible BCVA course can influence the decision for more intense treatment regimens.
C1 [Hoerster, Robert; Muether, Philipp S.; Sitnilska, Vasilena; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Hoerster, R (通讯作者)，Univ Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM robert.hoerster@uk-koeln.de
FU Gilen Foundation, Cologne, Germany; Nolting Foundation, Cologne,
   Germany; Gilen Foundation; Nolting Foundation; Novartis; Bayer;
   Heidelberg Engineering
FX Supported by grants from the Gilen and Nolting Foundations, Cologne,
   Germany. S. Fauser received grants from the Gilen and Nolting
   Foundations and from Novartis. The funding organizations had no role in
   the design or conduct of this research.; S. Fauser is a consultant to
   Novartis and Alimera and received payment for lectures from Bayer and
   Novartis. P. Muether received payment for lectures from Novartis,
   Heidelberg Engineering, and Bayer. B. Kirchhof is a consultant to Bayer
   and Novartis and received payments for lectures and educational
   presentations from Bayer and Novartis. The other authors have no
   conflicting interests to disclose.
CR Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Gass J Donald, 2003, Retina, V23, P990
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
NR 14
TC 23
Z9 24
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1767
EP 1773
DI 10.1097/IAE.0000000000000188
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400011
PM 24936942
DA 2022-11-30
ER

PT J
AU Hoang, QV
   Tsuang, AJ
   Gelman, R
   Mendonca, LS
   Della Torre, KE
   Jung, JJ
   Freund, KB
AF Hoang, Quan V.
   Tsuang, Angela J.
   Gelman, Rony
   Mendonca, Luis S.
   Della Torre, Kara E.
   Jung, Jesse J.
   Freund, K. Bailey
TI CLINICAL PREDICTORS OF SUSTAINED INTRAOCULAR PRESSURE ELEVATION DUE TO
   INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE avastin; bevacizumab; glaucoma; IOP; lucentis; ranibizumab; VEGF
ID MACULAR DEGENERATION; RANIBIZUMAB; BEVACIZUMAB; INJECTIONS; PEGAPTANIB
AB Purpose: We assess for frequency and predictive factors related to sustained intraocular pressure (IOP) elevation in eyes with neovascular age-related macular degeneration receiving intravitreal injections of ranibizumab and/or bevacizumab.
   Methods: A total of 328 patients with neovascular age-related macular degeneration (449 eyes) who presented to a single physician over a 6-month period were retrospectively assessed for baseline demographic/clinical information, total number of bevacizumab and/or ranibizumab injections, and sustained IOP elevation on 2 or more consecutive visits (absolute IOP >25 mmHg, increase above baseline >10 mmHg, or IOP of >21 mmHg and increase of >5 mmHg). Cox regression survival analysis and multivariate logistic regression were performed to assess the influence of intravitreal injections on experiencing sustained IOP elevation.
   Results: Overall, 32 eyes (7.1%) experienced sustained IOP elevation. Survival analysis showed a significant effect of the number of anti-vascular endothelial growth factor injections on sustained IOP elevation (hazard ratio, 1.085; 95% confidence interval: 1.06-1.11, P < 0.001). Also, there was an increased odds ratio (16.1, P = 0.008) of sustained IOP elevation in eyes receiving >= 29 injections compared with <= 12 injections. After controlling for the confounder (prior intravitreal steroid injection), total number of injections still showed a statistically significant association (P = 0.002).
   Conclusion: A greater number of intravitreal anti-vascular endothelial growth factor injections is associated with an increased risk for sustained IOP elevation in eyes with neovascular age-related macular degeneration receiving intravitreal ranbizumab and/or bevacizumab. RETINA 33:179-187, 2013
C1 [Hoang, Quan V.; Gelman, Rony; Mendonca, Luis S.; Della Torre, Kara E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Hoang, Quan V.; Gelman, Rony; Mendonca, Luis S.; Della Torre, Kara E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Hoang, Quan V.; Gelman, Rony; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Hoang, Quan V.; Tsuang, Angela J.; Gelman, Rony; Della Torre, Kara E.; Jung, Jesse J.; Freund, K. Bailey] NYU, Dept Ophthalmol, Med Ctr, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Columbia University; New
   York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Institute; Macula Foundation Inc, New York, NY; Genentech; Alcon;
   Regeneron; Alimera
FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear, and Throat Institute, and The Macula Foundation Inc, New York,
   NY; Genentech, Alcon, Regeneron, and Alimera (to K.B.F.).
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2010, OPHTHALMOLOGE, V107, P1123, DOI 10.1007/s00347-010-2299-0
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Ladas JG, 2001, INVEST OPHTH VIS SCI, V42, P2584
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Loukianou Eleni, 2011, International Ophthalmology, V31, P211, DOI 10.1007/s10792-010-9410-z
   Meyer CH, 2011, ACTA OPHTHALMOL
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
NR 25
TC 68
Z9 72
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 179
EP 187
DI 10.1097/IAE.0b013e318261a6f7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069GE
UT WOS:000313422500023
PM 22990314
DA 2022-11-30
ER

PT J
AU Ouchi, M
   Ikeda, T
   Nakamura, K
   Harino, S
   Kinoshita, S
AF Ouchi, M
   Ikeda, T
   Nakamura, K
   Harino, S
   Kinoshita, S
TI A novel relation of fatty acid with age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; fatty acid; radical; peroxide lipid
ID DIETARY-FAT; VITAMIN-E; RETINAL DEGENERATION; VERTEBRATE RETINA;
   ACCUMULATION; DEFICIENCY; DAMAGE; RISK; RAT
AB To evaluate the relation between fatty acids and agerelated macular degeneration (ARMD), the fatty acid fractions within the red blood cell (RBC) membrane and plasma of 11 ARMD patients and 10 healthy individuals (controls) were determined and compared. RBC arachidonic acid (AA) and docosahexaenoic acid (DHA) exhibited significantly higher values in the ARMD patients than in the controls. RBC levels of palmitic, palmitoleic, oleic and linoleic acids, however, showed significantly higher values in the controls than in the ARMD patients. No significant variations were observed between the two groups in terms of plasma levels of AA, DHA, palmitic, palmitoleic, oleic and linoleic acids. Our findings indicate that polyunsaturated fatty acids, vulnerable to free radicals and reactive oxygen species, and easily peroxidized, may be related to ARMD induction. Copyright (C) 2002 S. Karger AG, Basel.
C1 Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6028566, Japan.
   Osaka Med Coll, Dept Ophthalmol, Osaka, Japan.
   Nakamura Eye Clin, Nagano, Japan.
   Yodogawa Christians Hosp, Dept Ophthalmol, Osaka, Japan.
C3 Kyoto Prefectural University of Medicine; Osaka Medical College
RP Ouchi, M (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kawaramachi,Hirokoji Agaru,Kajiicho, Kyoto 6028566, Japan.
CR AMEMIYA T, 1978, J JPN OPHTHALMOL SOC, V82, P822
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   ARMSTRONG D, 1982, EXP EYE RES, V35, P157, DOI 10.1016/S0014-4835(82)80063-8
   ARMSTRONG D, 1989, J CLIN BIOCHEM NUTR, V7, P211
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   BERSON EL, 1980, VISION RES, V20, P1179, DOI 10.1016/0042-6989(80)90057-7
   BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2365
   BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   FARNSWORTH CC, 1979, BIOCHIM BIOPHYS ACTA, V552, P281, DOI 10.1016/0005-2736(79)90283-9
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   HIRAMITSU T, 1988, Folia Ophthalmologica Japonica, V39, P1911
   HIRAMITSU T, 1976, EXPERIENTIA, V32, P622, DOI 10.1007/BF01990199
   HIRAMITSU T, 1978, J JPN OPHTHALMOL SOC, V78, P819
   KATZ ML, 1984, MECH AGEING DEV, V25, P149, DOI 10.1016/0047-6374(84)90137-4
   KUBO K, 1995, JHD, V10, P72
   KUIJK F, 1992, INVEST OPHTH VIS SCI, V33, P3493
   NIMI K, 1985, J JPN OPHTHALMOL SOC, V89, P379
   NISIDA T, 1984, JPN J OPHTHALMOL, V28, P377
   PAZ MDL, 1992, INVEST OPHTH VIS SCI, V33, P3497
   REDDY TS, 1985, NEUROSCI LETT, V59, P67, DOI 10.1016/0304-3940(85)90216-2
   ROBISON WG, 1980, INVEST OPHTH VIS SCI, V19, P1030
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SUGAWARA H, 1981, Journal of the Japan Diabetes Society, V24, P891
   WILLIAMS J, 1985, BR J OPHTHALMOL, V69, P15
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 27
TC 14
Z9 15
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD SEP-OCT
PY 2002
VL 216
IS 5
BP 363
EP 367
DI 10.1159/000066178
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 616DV
UT WOS:000179287200012
PM 12424405
DA 2022-11-30
ER

PT J
AU Yoon, J
   Yoon, W
   Na, SK
   Lee, J
   Kim, CG
   Kim, JW
   Cho, HJ
AF Yoon, Jihyun
   Yoon, Wontae
   Na, Seung Kwan
   Lee, Jihyun
   Kim, Chul Gu
   Kim, Jong Woo
   Cho, Han Joo
TI Long-term outcome of intravitreal anti-vascular endothelial growth
   factor treatment for pachychoroid neovasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; RANIBIZUMAB INJECTIONS; GEOGRAPHIC
   ATROPHY; EXTEND REGIMEN; AFLIBERCEPT; NEOVASCULARIZATION; RELEVANT;
   EFFICACY
AB To compare the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). Forty-one eyes with PNV, 68 eyes with PCV/AT1, and 56 eyes with typical nAMD were retrospectively included for analysis. All patients were treatment-naive and received a three-monthly loading injection of anti-VEGF, followed by further injections, as required. The visual and anatomical outcomes after treatment were evaluated up to 36 months from baseline. No significant intergroup difference was found in terms of best-corrected visual acuity (BCVA) and changes in central foveal thickness at 12, 24, and 36 months after the baseline. In addition, no significant difference was found between the groups regarding the proportions of improved or worsened (increased or decreased more than 3-lines) visual acuity. However, the PNV group participants received significantly fewer anti-VEGF injections (11.7 +/- 6.9) than those in the PCV/AT1 (12.4 +/- 7.0; P=0.031) and typical nAMD groups (13.2 +/- 7.4; P=0.016). The incidence of macular atrophy (MA) development was also significantly lower for the PNV (4/41 eyes, 9.8%) than the typical nAMD (15/56 eyes, 26.8%; P=0.033) eyes. There was no significant difference between PNV, PCV/AT1, and typical nAMD regarding visual acuity improvement after anti-VEGF treatment over 36 months. However, the number of injections for PNV was significantly lower compared to that for PCV/AT1 and typical nAMD, and the incidence of MA development was significantly lower than in typical nAMD.
C1 [Yoon, Jihyun; Yoon, Wontae; Na, Seung Kwan; Lee, Jihyun; Kim, Chul Gu; Kim, Jong Woo; Cho, Han Joo] Konyang Univ, Kims Eye Hosp, Coll Med, 156,4Ga,Yeoungdeungpo Dong, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Kims Eye Hosp, Coll Med, 156,4Ga,Yeoungdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2020, BRIT J OPHTHALMOL, V104, P1443, DOI 10.1136/bjophthalmol-2019-315496
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Demirel S, 2018, GRAEF ARCH CLIN EXP, V256, P1559, DOI 10.1007/s00417-018-4019-4
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hikichi T, 2021, EYE, V35, P3367, DOI 10.1038/s41433-021-01418-z
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kato Y, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.39
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
NR 31
TC 2
Z9 2
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 8
PY 2021
VL 11
IS 1
AR 12052
DI 10.1038/s41598-021-91589-2
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SU3AD
UT WOS:000663012100003
PM 34103603
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kung, YH
   Wu, TT
   Hong, MC
   Sheu, SJ
AF Kung, Ya-Hsin
   Wu, Tsung-Tien
   Hong, May-Ching
   Sheu, Shwu-Jiuan
TI Intravitreal Tissue Plasminogen Activator and Pneumatic Displacement of
   Submacular Hemorrhage
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID EXPERIMENTAL SUBRETINAL HEMORRHAGE; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   MACULAR DEGENERATION; MANAGEMENT; INJECTION; GAS; SURGERY
AB Purpose: We sought to evaluate the efficacy, safety, and visual outcome of intravitreal tissue plasminogen activator (t-pa) and pneumatic displacement to treat submacular hemorrhage.
   Methods: In this retrospective, interventional case series, 46 consecutive eyes of 45 patients received intravitreal t-pa (50 mu g in 0.1 mL) and expansile gas (0.3 mL perfluoropropane) injection for submacular hemorrhage. Hemorrhages were secondary to exudative age-related macular degeneration in 28 eyes, idiopathic polypoidal choroidal vasculopathy (IPCV) in 11 eyes, retinal arterial macroaneurysm in 2 eyes, pathologic myopia in 3 eyes, and trauma in 1 eye. After surgery, patients maintained a supine position for the first 6 h and then remained prone for about 1 week. Outcome measures were visual acuity, displacement of submacular hemorrhage, and surgical complications.
   Results: Complete displacement of thick blood out of the fovea was achieved in 40 of 45 eyes (89%), and partial displacement was achieved in 5 eyes (11%). Best postoperative visual acuity improved by 2 Snellen lines or greater in 21 of 45 eyes (46.67%). At a mean follow up of 15.64 months, final visual acuity improved by 2 Snellen lines or greater in 16 eyes (35.6%). The complication of breakthrough vitreous hemorrhage occurred in nine eyes (20%). Eyes with nonage-related macular degeneration tended to have better final visual recovery, especially eyes with IPCV over extended follow up (P=0.035).
   Conclusions: Intravitreal injection of t-pa and expansile gas was an effective and safe treatment for submacular hemorrhage. Our study features a considerable number of patients with IPCV, and the outcomes are favorable.
C1 [Kung, Ya-Hsin; Wu, Tsung-Tien; Hong, May-Ching; Sheu, Shwu-Jiuan] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung 813, Taiwan.
   [Kung, Ya-Hsin; Wu, Tsung-Tien; Hong, May-Ching; Sheu, Shwu-Jiuan] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
C3 Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung
   University
RP Wu, TT (通讯作者)，Kaohsiung Vet Gen Hosp, Dept Ophthalmol, 386 Ta Chung 1st Rd, Kaohsiung 813, Taiwan.
EM ttwu@vghks.gov.tw
FU Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan [VGHKS98-061]
FX This study was supported by the Kaohsiung Veterans General Hospital,
   Kaohsiung, Taiwan (grant VGHKS98-061).
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen W L, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P268
   Cheng Xiang-rong, 2007, ACTA BOTANICA BOREALI-OCCIDENTALIA SINICA, V27, P321
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Heriot W, 1996, AM AC OPHTH ANN VITR
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   JAFFE GJ, 1990, OPHTHALMOLOGY, V97, P184
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   Kokame GT, 2000, AM J OPHTHALMOL, V129, P546, DOI 10.1016/S0002-9394(99)00474-2
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wu TT, 2009, EYE, V23, P101, DOI 10.1038/sj.eye.6702984
   Wu TT, 2005, J OCUL PHARMACOL TH, V21, P62, DOI 10.1089/jop.2005.21.62
NR 21
TC 16
Z9 16
U1 1
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2010
VL 26
IS 5
BP 469
EP 474
DI 10.1089/jop.2010.0066
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 660LI
UT WOS:000282643800009
PM 20925578
DA 2022-11-30
ER

PT J
AU Wiggins, MN
   Uwaydat, SH
AF Wiggins, MN
   Uwaydat, SH
TI Age-related macular degeneration: Options for earlier detection and
   improved treatment
SO JOURNAL OF FAMILY PRACTICE
LA English
DT Article
ID BEAVER DAM EYE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; 5-YEAR
   INCIDENCE; MACULOPATHY; RISK; DISEASE
C1 Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Wiggins, MN (通讯作者)，Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, 4301 W Markham St Slot 523, Little Rock, AR 72205 USA.
EM wigginsmichael@uams.edu
CR American Academy of Ophthalmology, 2004, BAS CLIN SCI COURS
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Ebell MH, 2004, J FAM PRACTICE, V53, P111
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Yanoff M., 2004, OPHTHALMOLOGY
NR 20
TC 0
Z9 0
U1 1
U2 1
PU DOWDEN PUBLISHING CORP
PI MONTVALE
PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA
SN 0094-3509
J9 J FAM PRACTICE
JI J. Fam. Pract.
PD JAN
PY 2006
VL 55
IS 1
BP 22
EP 27
PG 6
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 008IK
UT WOS:000235033200007
PM 16388763
DA 2022-11-30
ER

PT J
AU Marko, CK
   Miller, JW
AF Marko, Christina Kaiser
   Miller, Joan W.
TI Opportunities and Challenges in Translational Research: The Development
   of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor
   Drugs
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
DE Ophthalmology; Macular Degeneration; AMD; VEGF; PDT; Industry; academia
ID VASCULAR-PERMEABILITY FACTOR; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; IRIS NEOVASCULARIZATION; VERTEPORFIN; ANGIOGENESIS;
   RANIBIZUMAB; BEVACIZUMAB
AB The development of photodynamic therapy and anti-vascular endothelial growth factor agents have revolutionized the treatment of retinal diseases, transforming the retina subspecialty by ushering in an age of pharmacological treatments for a wide range of diseases, including age-related macular degeneration (AMD).
C1 [Marko, Christina Kaiser; Miller, Joan W.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Marko, Christina Kaiser] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Miller, Joan W.] Harvard Med Sch, Ophthalmol, Boston, MA 02115 USA.
   [Miller, Joan W.] Massachusetts Eye & Ear, Ophthalmol, Boston, MA USA.
   [Miller, Joan W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Miller, Joan W.] Brigham & Womens Hosp, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University;
   Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical
   School; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Massachusetts General Hospital; Harvard University; Brigham
   & Women's Hospital
RP Marko, CK (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.; Marko, CK (通讯作者)，Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Adams JU, 2008, NAT REV DRUG DISCOV, V7, P463, DOI 10.1038/nrd2609
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2009, MASS EYE EAR INFIRMA, P57
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   ENGLER CB, 1993, ACTA OPHTHALMOL, V71, P27
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Klagsbrun M, 2008, NATURE, V451, P781, DOI 10.1038/451781a
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mazzucato M, 2018, IND CORP CHANGE, V27, P803, DOI 10.1093/icc/dty034
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
NR 26
TC 1
Z9 1
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PY 2021
VL 49
IS 1
SI SI
BP 19
EP 24
AR PII S1073110521000048
DI 10.1017/jme.2021.4
PG 6
WC Ethics; Law; Medical Ethics; Medicine, Legal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
   Medicine
GA TG4FW
UT WOS:000671362600004
PM 33966647
DA 2022-11-30
ER

PT J
AU Jue, A
AF Jue, Andrea
TI Angiogenesis: Trabeculectomy and Bevacizumab
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; MITOMYCIN-C; NEOVASCULAR GLAUCOMA; FILTERING
   SURGERY; FLUOROURACIL; 5-FLUOROURACIL; ANTIBODY; BLEB
AB The use of bevacizumab for the treatment of proliferative diabetic retinopathy, neovascular glaucoma, neovascular age related macular degeneration, and cystoid macular edema has been extensively reported upon. From the published case reports available, bevacizumab may be a useful adjunct to the trabeculectomy procedure.
C1 Massachusetts Eye & Ear Infirm, Fellows Course 2009, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary
RP Jue, A (通讯作者)，Massachusetts Eye & Ear Infirm, Fellows Course 2009, Boston, MA 02114 USA.
CR Alward WLM, 1996, AM J OPHTHALMOL, V121, P349
   CAIRNS JE, 1970, BIBL OPHTHALMOL, P143
   Chen CW, 1986, ACTA OPHTHALMOL SCAN, V25, P1487
   Coote MA, 2008, J GLAUCOMA, V17, P517, DOI 10.1097/IJG.0b013e31815f5345
   Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P2225
   CORNISH KS, 2008, EYE IN PRESS    0502
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Gheith ME, 2007, J OCUL PHARMACOL TH, V23, P487, DOI 10.1089/jop.2007.0036
   Grewal DS, 2008, OPHTHALMOLOGY, V115, P2141, DOI 10.1016/j.ophtha.2008.06.009
   Jonas JB, 2007, OPHTHAL RES, V39, P121, DOI 10.1159/000099248
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P148, DOI 10.3928/1542-8877-20060301-12
   KHAW PT, 1993, ARCH OPHTHALMOL-CHIC, V111, P263, DOI 10.1001/archopht.1993.01090020117035
   KHAW PT, 1994, EYE, V8, P188, DOI 10.1038/eye.1994.44
   KHAW PT, 1992, ARCH OPHTHALMOL-CHIC, V110, P1150, DOI 10.1001/archopht.1992.01080200130040
   Lama PJ, 2003, SURV OPHTHALMOL, V48, P314, DOI 10.1016/S0039-6257(03)00038-9
   Miki A, 2008, BRIT J OPHTHALMOL, V92, P1431, DOI 10.1136/bjo.2007.129833
   PALANCACAPISTRA.AM, 2008, OPHTHALMOLO IN PRESS
   SALMON SE, 1987, BASIC CLIN PHARM, P676
   SALMON SE, 1987, BASIC CLIN PHARM, V3, P680
   Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301
   Singh K, 2000, OPHTHALMOLOGY, V107, P2305, DOI 10.1016/S0161-6420(00)00391-2
   Smith MF, 1997, J GLAUCOMA, V6, P104
   TRIPATHI RC, 1994, EXP EYE RES, V59, P723, DOI 10.1006/exer.1994.1158
   Vogel R, 2007, OPHTHALMOLOGY, V114, P1822, DOI 10.1016/j.ophtha.2007.03.050
   WONG J, 1994, EXP EYE RES, V58, P439, DOI 10.1006/exer.1994.1037
NR 25
TC 10
Z9 10
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2009
VL 24
IS 2
BP 122
EP 125
DI 10.1080/08820530902801015
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18RA
UT WOS:000208020700013
PM 19373697
DA 2022-11-30
ER

PT J
AU Campbell, RJ
   Bronskill, SE
   Bell, CM
   Paterson, JM
   Whitehead, M
   Gill, SS
AF Campbell, Robert J.
   Bronskill, Susan E.
   Bell, Chaim M.
   Paterson, J. Michael
   Whitehead, Marlo
   Gill, Sudeep S.
TI Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008
   A Population-Based Analysis
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; RANIBIZUMAB; AVASTIN(R)
AB Objective: To evaluate patterns of care for age-related macular degeneration following the introduction of vascular endothelial growth factor inhibitors.
   Methods: Using a population-based retrospective design, we studied monthly fee claims for intravitreal injections submitted to the Ontario Health Insurance Plan between January 1, 2000, and March 30, 2008, and linked procedures to the physicians who performed them. This database records physician services provided as part of universal health care insurance coverage in Ontario, Canada. This program covers all residents of Ontario, which had an average population of 12.1 million during the study period.
   Results: Following regulatory approval of bevacizumab for colorectal cancer in 2005, off-label use of this drug for the treatment of retinal disease, particularly age-related macular degeneration, became increasingly common. The rate of intravitreal injections in Ontario rapidly grew 8-fold, and this growth preceded the availability of ranibizumab by more than a year. Moreover, in 2007, more than 50% of intravitreal injections in Ontario were performed by 3% of ophthalmologists.
   Conclusions: The development of vascular endothelial growth factor inhibitors has revolutionized the treatment of age-related macular degeneration. To our knowledge, this study is the first to quantify the dramatic uptake of these treatments at a population level. Our findings also suggest that off-label injection of bevacizumab was highly prevalent in Ontario. Serial intravitreal injections requiring direct physician administration and the concentration of injection procedures in the hands of a small number of ophthalmologists have the potential to affect services for other vision-threatening conditions.
C1 [Campbell, Robert J.; Whitehead, Marlo] Queens Univ, Dept Ophthalmol, Kingston, ON K7L 5G2, Canada.
   [Gill, Sudeep S.] Queens Univ, Div Geriatr Med, Kingston, ON K7L 5G2, Canada.
   [Campbell, Robert J.] Hop Hotel Dieu, Dept Ophthalmol, Kingston, ON K7L 5G2, Canada.
   [Gill, Sudeep S.] St Marys Lake Hosp, Div Geriatr Med, Kingston, ON, Canada.
   [Campbell, Robert J.; Bronskill, Susan E.; Bell, Chaim M.; Paterson, J. Michael; Whitehead, Marlo; Gill, Sudeep S.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON M5S 1A1, Canada.
   [Bronskill, Susan E.; Bell, Chaim M.; Paterson, J. Michael] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada.
   [Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada.
   [Bell, Chaim M.] St Michaels Hosp, Dept Med, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
   [Bell, Chaim M.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Paterson, J. Michael] McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens
   University - Canada; University of Toronto; University of Toronto;
   University of Toronto; University of Toronto; Li Ka Shing Knowledge
   Institute; University Toronto Affiliates; Saint Michaels Hospital
   Toronto; University of Toronto; Li Ka Shing Knowledge Institute;
   University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster
   University
RP Campbell, RJ (通讯作者)，Queens Univ, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM rob.campbell@queensu.ca
RI Bell, Chaim/C-4611-2015
OI Bell, Chaim/0000-0002-3778-9469
FU E. A. Baker Foundation for the Prevention of Blindness; Queen's
   University; Institute for Clinical Evaluative Sciences; Ontario Ministry
   of Health and Long-Term Care; Institute of Aging; Canadian Institutes of
   Health Research; Canadian Patient Safety Institute Chair in Patient
   Safety and Continuity of Care
FX This study was supported by research grants from the E. A. Baker
   Foundation for the Prevention of Blindness and Queen's University and by
   the Institute for Clinical Evaluative Sciences, a nonprofit research
   corportation sponsored by the Ontario Ministry of Health and Long-Term
   Care. Dr Campbell is supported by the E. A. Baker Foundation for the
   Prevention of Blindness. Dr Bronskill is supported by a Canadian
   Institutes of Health Research New Investigator Award from the Institute
   of Aging. Dr Bell is supported by a Canadian Institutes of Health
   Research and Canadian Patient Safety Institute Chair in Patient Safety
   and Continuity of Care. Dr Gill is supported by an Ontario Ministry of
   Health and Long-Term Care Career Scientist Award.
CR Bellan L, 2007, CAN J OPHTHALMOL, V42, P34, DOI 10.3129/canjophthalmol.06-115
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   *CAN I HLTH INF, 2008, SURG VOL TRENDS 2008
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   Hatch WV, 2009, OPHTHALMOLOGY, V116, P425, DOI 10.1016/j.ophtha.2008.09.039
   *HLTH CAN, REP EYE INFL END TOX
   Hsu J, 2007, CURR OPIN OPHTHALMOL, V18, P235, DOI 10.1097/ICU.0b013e3281108000
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   *NAT EYE I, COMP AG REL MAC DEG
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Williams JI, 1996, PATTERNS HLTH CARE O, P339
NR 13
TC 51
Z9 53
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2010
VL 128
IS 3
BP 359
EP 362
DI 10.1001/archophthalmol.2010.19
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 565QC
UT WOS:000275308100013
PM 20212208
OA Bronze
DA 2022-11-30
ER

PT J
AU Goverdhan, SV
   Gibbs, FA
   Lotery, AJ
AF Goverdhan, SV
   Gibbs, FA
   Lotery, AJ
TI Radiotherapy for age-related macular degeneration: no more pilot studies
   please
SO EYE
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXTERNAL-BEAM RADIOTHERAPY;
   RANDOMIZED CLINICAL-TRIAL; TIME-DOSE FACTORS; RADIATION-THERAPY;
   SUBRETINAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; LASER
   PHOTOCOAGULATION; IRRADIATION; MEMBRANES
C1 Univ Southampton, Southampton SO9 5NH, Hants, England.
   Southampton Eye Unit, Southampton, Hants, England.
   Diacor Inc, Salt Lake City, UT USA.
C3 University of Southampton
RP Lotery, AJ (通讯作者)，Southampton Gen Hosp, Div Human Genet, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
CR Akmansu M, 1998, INT J RADIAT ONCOL, V40, P923, DOI 10.1016/S0360-3016(97)00859-6
   Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   Archambeau JO, 1998, INT J RADIAT ONCOL, V40, P1125, DOI 10.1016/S0360-3016(97)00919-X
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   BERGINK GJ, 1994, GRAEF ARCH CLIN EXP, V232, P591, DOI 10.1007/BF00193119
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   BESSELL EM, 1987, EYE, V1, P90, DOI 10.1038/eye.1987.14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1986, BRIT J OPHTHALMOL, V70, P561, DOI 10.1136/bjo.70.8.561
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Chakravarthy U, 2000, EYE, V14, P151, DOI 10.1038/eye.2000.45
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   CHAUVEL, 2004, ESTRO M NIC APR
   *DOH, 2003, NAT STAT
   EVANS J, 1995, CAUSES BLINDNESS PAR, P57
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel, 2000, Am J Ophthalmol, V130, P541, DOI 10.1016/S0002-9394(00)00741-8
   Freire J, 1997, FRONT RADIAT THER ON, V30, P247
   Gibbs FA, 2001, FRONT RADIAT THER ON, V35, P94
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hollick EJ, 1996, EYE, V10, P609, DOI 10.1038/eye.1996.139
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hoyng CB, 2002, GRAEF ARCH CLIN EXP, V240, P337, DOI 10.1007/s00417-002-0428-4
   *INT PROC GUID, 2004, IPG0049
   Kacperek A, 2001, PHYS MEDICA, V17, P7
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Martin P, 1997, Cancer Radiother, V1, P227, DOI 10.1016/S1278-3218(97)89769-7
   Mauget-Faysse M, 2000, J FR OPHTALMOL, V23, P127
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P755, DOI 10.1016/0360-3016(94)90346-8
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Staar S, 1999, INT J RADIAT ONCOL, V45, P467, DOI 10.1016/S0360-3016(99)00186-8
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Subasi M, 1999, Radiat Med, V17, P169
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   YONEMOTO LT, 2000, J RADIOSURG, V3, P47
   Zur C, 2001, J FR OPHTALMOL, V24, P949
NR 54
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2005
VL 19
IS 11
BP 1137
EP 1141
DI 10.1038/sj.eye.6701744
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982EZ
UT WOS:000233142000001
PM 15543181
OA Bronze
DA 2022-11-30
ER

PT J
AU Richer, SP
   Stiles, W
   Graham-Hoffman, K
   Levin, M
   Ruskin, D
   Wrobel, J
   Park, DW
   Thomas, C
AF Richer, Stuart P.
   Stiles, William
   Graham-Hoffman, Kelly
   Levin, Marc
   Ruskin, Dennis
   Wrobel, James
   Park, Dong-Wouk
   Thomas, Carla
TI Randomized, double-blind, placebo-controlled study of zeaxanthin and
   visual function in patients with atrophic age-related macular
   degeneration The Zeaxanthin and Visual Function Study (ZVF) FDA IND #78,
   973
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Zeaxanthin; Lutein; Carotenoids; Macular pigment; Atrophic age-related
   macular degeneration
ID PIGMENT OPTICAL-DENSITY; RISK-FACTORS; FUNDUS AUTOFLUORESCENCE; CONTRAST
   SENSITIVITY; SERUM CONCENTRATIONS; LUTEIN; CAROTENOIDS; ANTIOXIDANTS;
   MACULOPATHY; SUPPLEMENTATION
AB BACKGROUND: The purpose of this study is to evaluate whether dietary supplementation with the carotenoid zeaxanthin (Zx) raises macula pigment optical density (MPOD) and has unique visual benefits for patients with early atrophic macular degeneration having visual symptoms but lower-risk National Institute of Health/National Eye Institute/Age-Related Eye Disease Study characteristics.
   METHODS: This was a 1-year, n = 60 (57 men, 3 women), 4-visit, intention-to-treat, prospective, randomized controlled clinical trial of patients (74.9 years, standard deviation [SD] 10) with mild-to-moderate age-related macular degeneration (AMD) randomly assigned to 1 of 2 dietary supplement carotenoid pigment intervention groups: 8 mg Zx (n = 25) and 8 mg Zx plus 9 mg lutein (L) (n = 25) or 9 mg L ("Faux Placebo," control group, n = 10). Analysis was by Bartlett's test for equal variance, 3-way repeated factors analysis of variance, independent t test (P < 0.05) for variance and between/within group differences, and post-hoc Scheffe's tests. Estimated foveal heterochromic flicker photometry, 1 degrees macular pigment optical density (MPOD QuantifEye (R)), low- and high-contrast visual acuity, foveal shape discrimination (Retina Foundation of the Southwest), 10 yellow kinetic visual fields (KVF), glare recovery, contrast sensitivity function (CSF), and 6 degrees blue cone ChromaTest (R) color thresholds were obtained serially at 4, 8, and 12 months.
   RESULTS: Ninety percent of subjects completed >= 2 visits with an initial Age-Related Eye Disease Study report #18 retinopathy score of 1.4(1.0 SD)/4.0 and pill intake compliance of 96% with no adverse effects. There were no intergroup differences in 3 major AMD risk factors: age, smoking, and body mass index as well as disease duration and Visual Function Questionnaire 25 composite score differences. Randomization resulted in equal MPOD variance and MPOD increasing in each of the 3 groups from 0.33 density units (du) (0.17 SD) baseline to 0.51 du (0.18 SD) at 12 m, (P = 0.03), but no between-group differences (Analysis of Variance; P = 0.47). In the Zx group, detailed high-contrast visual acuity improved by 1.5 lines, Retina Foundation of the Southwest shape discrimination sharpened from 0.97 to 0.57 (P = 0.06, 1-tail), and a larger percentage of Zx patients experienced clearing of their KVF central scotomas (P = 0.057). The "Faux Placebo" L group was superior in terms of low-contrast visual acuity, CSF, and glare recovery, whereas Zx showed a trend toward significance.
   CONCLUSION: In older male patients with AMD, Zx-induced foveal MPOD elevation mirrored that of L and provided complementary distinct visual benefits by improving foveal cone-based visual parameters, whereas L enhanced those parameters associated with gross detailed rod-based vision, with considerable overlap between the 2 carotenoids. The equally dosed (atypical dietary ratio) Zx plus L group fared worse in terms of raising MPOD, presumably because of duodenal, hepatic-lipoprotein or retinal carotenoid competition. These results make biological sense based on retinal distribution and Zx foveal predominance. Optometry 2011;82:667-680
C1 [Richer, Stuart P.; Stiles, William; Graham-Hoffman, Kelly; Levin, Marc; Thomas, Carla] Captain James A Lovell Fed Hlth Care Facil, N Chicago, IL 60064 USA.
   [Richer, Stuart P.; Wrobel, James; Park, Dong-Wouk] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL USA.
C3 Chicago Medical School; Rosalind Franklin University Medical & Science
RP Richer, SP (通讯作者)，Captain James A Lovell Fed Hlth Care Facil, 3001 Green Bay Rd, N Chicago, IL 60064 USA.
EM Stuart.Richer1@va.gov
FU Captain James A. Lovell Federal Health Care Facility, North Chicago,
   Illinois; Department of Veterans Affairs Research Service/CARES (Hines,
   Illinois); Chrysantis, Inc. (West Chicago, Illinois); Kowa Optimed, Inc.
   (Torrance, California and Tokyo, Japan); Stereo Optical, Inc. (Chicago,
   Illinois); Rush Ophthalmics, Inc. (Gold Beach, Oregon); Pharmanex, Inc.
   (Provo, Utah); ZeaVision, Inc. (Chesterfield, Missouri); Heidelberg
   Instruments, Inc. (Heidelberg, Germany); RTVue (Fremont, California)
FX This material is based on original work supported by the Captain James
   A. Lovell Federal Health Care Facility, North Chicago, Illinois, and the
   Department of Veterans Affairs Research Service/CARES (Hines, Illinois).
   Chrysantis, Inc. (West Chicago, Illinois) is the primary ZVF granting
   sponsor. Kowa Optimed, Inc. (Torrance, California and Tokyo, Japan),
   Stereo Optical, Inc. (Chicago, Illinois), Rush Ophthalmics, Inc. (Gold
   Beach, Oregon), Pharmanex, Inc. (Provo, Utah), ZeaVision, Inc.
   (Chesterfield, Missouri), Heidelberg Instruments, Inc. (Heidelberg,
   Germany), and RTVue (Fremont, California) all provided instrumentation
   as secondary sponsors in support of both ZVF and our Ocular Nutrition
   Laboratory.
CR [Anonymous], 2007, ARCH OPHTHALMOL-CHIC, V125, P671
   [Anonymous], SIMULEYES MACULAR FI
   ARDEN G, 1988, DOC OPHTHALMOL, V69, P167, DOI 10.1007/BF00153698
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Baum SJ, 2010, NEW ENGL J MED, V363, P22
   Beatty S, 2008, INVEST OPHTH VIS SCI, V49, P843, DOI 10.1167/iovs.07-1276
   Bernstein P, 2011, J MAYER USDA HUM NUT
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bone RA, 2003, J NUTR, V133, P1953
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   CHYLACK LT, 1999, CRC MOD NUT, P25
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Haddad W M, 2006, Bull Soc Belge Ophtalmol, P15
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kirby ML, 2011, BRIT J NUTR, V105, P1036, DOI 10.1017/S0007114510004721
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Makridaki M, 2009, OPHTHAL PHYSL OPT, V29, P338, DOI 10.1111/j.1475-1313.2009.00667.x
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Margrain TH, 2002, OPHTHAL PHYSL OPT, P2261
   Mayne ST, 2010, AM J CLIN NUTR, V92, P794, DOI 10.3945/ajcn.2010.29707
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Murray IJ, 2011, BRIT J OPHTHALMOL, V95, P431, DOI 10.1136/bjo.2010.195321
   National Eye Institute, AG REL EYE DIS STUD
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Peralta E, 2011, AM SOC RET SPEC 2011
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Richer S, 1999, J Am Optom Assoc, V70, P13
   Richer S, 2000, INT OPHTHALMOL CLIN, V40, P1, DOI 10.1097/00004397-200010000-00002
   RICHER S, 1996, J AM OPTOMETRIC ASS, V0067
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer S P, 1993, J Am Optom Assoc, V64, P838
   Richer S.P., 2011, OPTOMETRY, V82, P680
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schneck Marilyn E, 2003, Ophthalmol Clin North Am, V16, P269, DOI 10.1016/S0896-1549(03)00008-7
   Sharifzadeh M, 2006, J OPT SOC AM A, V23, P2373, DOI 10.1364/JOSAA.23.002373
   SIVAGNANAVEL V, 2005, INVEST OPHTH VIS S S, V46
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Stiles WR, 2010, ASS RES VIS OPHTH M
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   Wang Yu-feng, 2011, Instrument Techniques and Sensor, P52
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Wong R, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-15
   Wood S, 2008, 15 INT S CAR OK JAP
NR 69
TC 65
Z9 66
U1 1
U2 35
PU AMER OPTOMETRIC ASSN INC
PI ST LOUIS
PA 243 N LINDBERGH BLVD, ST LOUIS, MO 63141 USA
SN 1529-1839
EI 1558-1527
J9 OPTOMETRY
JI Optometry
PD NOV
PY 2011
VL 82
IS 11
BP 667
EP 680
DI 10.1016/j.optm.2011.08.008
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 843QL
UT WOS:000296687200005
PM 22027699
DA 2022-11-30
ER

PT J
AU Weinberg, DV
   Shapiro, H
   Ehrlich, JS
AF Weinberg, David V.
   Shapiro, Howard
   Ehrlich, Jason S.
TI Ranibizumab Treatment Outcomes in Phakic versus Pseudophakic Eyes An
   Individual Patient Data Analysis of 2 Phase 3 Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; MACULAR DEGENERATION; CATARACT-SURGERY;
   SUBGROUP ANALYSIS; ANCHOR; MARINA
AB Objective: To compare visual outcomes in phakic and pseudophakic eyes treated with monthly intravitreal ranibizumab for exudative age-related macular degeneration (AMD).
   Design: Meta-analysis of individual patient data from 2 phase 3 clinical trials of intravitreal ranibizumab in neovascular AMD (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration [ANCHOR], ClinicalTrials.gov number, NCT00061594; and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration [MARINA], ClinicalTrials.gov number NCT00056836).
   Participants and Controls: A total of 1137 patients from 2 phase 3 clinical trials.
   Methods: Phakic and pseudophakic eyes were treated with monthly intravitreal ranibizumab (0.3 mg or 0.5 mg), sham injections plus verteporfin photodynamic therapy (ANCHOR), or sham injections alone (MARINA).
   Main Outcome Measures: Mean change from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and the proportion of patients gaining or losing 15 or more ETDRS letters.
   Results: After adjusting for baseline covariates, no differences were seen in mean change in VA for phakic versus pseudophakic eyes. Pseudophakic eyes were more likely to lose 15 or more letters of vision than phakic eyes at 12 months, but not at 24 months.
   Conclusions: Overall, in this analysis, lens status did not demonstrate an independent influence on mean VA for eyes treated with monthly ranibizumab. It is possible that phakic eyes may be less prone to severe vision loss. (C) 2013 by the American Academy of Ophthalmology.
C1 [Weinberg, David V.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
   [Shapiro, Howard; Ehrlich, Jason S.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Medical College of Wisconsin; Roche Holding; Genentech
RP Weinberg, DV (通讯作者)，Med Coll Wisconsin, Dept Ophthalmol, 925 North 87th St, Milwaukee, WI 53226 USA.
EM dweinber@mcw.edu
OI Weinberg, David/0000-0002-1974-9252
FU Research to Prevent Blindness, Inc., New York, New York
FX Supported in part by an unrestricted grant to the Medical College of
   Wisconsin from Research to Prevent Blindness, Inc., New York, New York.
   Dr. Weinberg has received no financial support. The design and conduct
   of the study as well as collection, management, analysis, and
   interpretation of the data were supported by Genentech, Inc. Third-party
   medical writing assistance was supported by Genentech, Inc.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Harocopos GJ, 2004, INVEST OPHTH VIS SCI, V45, P77, DOI 10.1167/iovs.03-0820
   Hilford D, 2009, EYE, V23, P1388, DOI 10.1038/eye.2008.273
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klein BEK, 2009, ARCH OPHTHALMOL-CHIC, V127, P1528, DOI 10.1001/archophthalmol.2009.258
   Mirshahi A, 2009, J CATARACT REFR SURG, V35, P987, DOI 10.1016/j.jcrs.2009.02.016
   Neal RE, 2005, EXP EYE RES, V80, P337, DOI 10.1016/j.exer.2004.09.015
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
NR 11
TC 11
Z9 12
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2013
VL 120
IS 6
BP 1278
EP 1282
DI 10.1016/j.ophtha.2012.11.042
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 167RJ
UT WOS:000320650700035
PM 23453513
DA 2022-11-30
ER

PT J
AU Silva, JN
   Filipe, P
   Morliere, P
   Maziere, JC
   Freitas, JP
   Gomes, MM
   Santus, R
AF Silva, Joao N.
   Filipe, Paulo
   Morliere, Patrice
   Maziere, Jean-Claude
   Freitas, Joao P.
   Gomes, Manuel Marques
   Santus, Rene
TI Photodynamic therapy: Dermatology and ophthalmology as main fields of
   current applications in clinic
SO BIO-MEDICAL MATERIALS AND ENGINEERING
LA English
DT Article
DE Photodynamic therapy; verteporfin; aminolevulinic acid; age-related
   macular degeneration; actinic keratosis; basal cell carcinoma; squamous
   cell carcinoma; cutaneous T-cell lymphoma
ID TOPICAL METHYL AMINOLEVULINATE; INDUCED SKIN TUMORS; ACTINIC KERATOSES;
   RANDOMIZED MULTICENTER; CELL CARCINOMA; ACID DELAYS; LIPOPROTEINS;
   CRYOTHERAPY; APPEARANCE; DISEASE
AB Photodynamic therapy (PDT) of skin tumors or pre-cancerous lesions and of age-related macular degeneration combines the administration of porphyrins or porphyrin precursors and illumination with red light at the diseased sites. Photosensitizers absorbing light beyond 630 nm where tissues have the highest transmittance produce singlet oxygen, a highly reactive activated oxygen species and a major cytotoxin. The PDT of age-related macular degeneration is performed with red laser light after i.v. injection of verteporfin (Visudyne (R)) a hydrophobic porphyrin carried by serum lipoproteins whose endocytosis leads to accumulation of the porphyrin in endothelial cells of choroidal neo-vessels. In the PDT of skin cancers, local synthesis of the photosensitizer occurs after topical application of the natural protoporphyrin IX precursor delta-aminolevulinic acid (or its ester forms) on the lesions. In all the cases, the photosensitizers should be rapidly excreted to avoid a long lasting skin photosensitivity.
C1 [Silva, Joao N.; Filipe, Paulo; Freitas, Joao P.; Gomes, Manuel Marques] Clin Univ Dermatol, Hosp Santa Maria, P-1600 Lisbon, Portugal.
   [Morliere, Patrice; Maziere, Jean-Claude] CHU Amiens, Biochim Lab, INSERM, ERI 12, Amiens, France.
   [Santus, Rene] Hop St Louis, INSERM, Inst Rech Peau, U 697, Paris, France.
   [Santus, Rene] Museum Natl Hist Nat, F-75231 Paris, France.
C3 Universidade de Lisboa; Hospital Santa Maria; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Picardie Universites;
   Universite de Picardie Jules Verne (UPJV); CHU Amiens; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis -
   APHP; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite Paris Cite;
   Museum National d'Histoire Naturelle (MNHN)
RP Silva, JN (通讯作者)，Clin Univ Dermatol, Hosp Santa Maria, P-1600 Lisbon, Portugal.
EM maiasilva@fm.ul.pt
OI Silva, Joao/0000-0003-2583-9518; Filipe, Paulo/0000-0001-6917-527X;
   Filipe, Paulo/0000-0002-7337-6493
FU La Ligue contre le Cancer, Comite de la Somme; Sociedade Portuguesa de
   Dermatologia e Venereologia
FX We gratefully acknowledge grants from "La Ligue contre le Cancer, Comite
   de la Somme". J.N. Silva and P. Filipe thank the "Sociedade Portuguesa
   de Dermatologia e Venereologia" for travel grants.
CR Basset-Seguin N, 2006, J INVEST DERMATOL, V126, pS34
   Berg K., 1996, FUNDAMENTAL BASES PH, P181
   Berking C, 2007, DERMATOL SURG, V33, P825, DOI 10.1111/j.1524-4725.2007.33176.x
   Caty V, 2006, BRIT J DERMATOL, V154, P740, DOI 10.1111/j.1365-2133.2005.07056.x
   CHANG CS, 1985, MOL BIOCHEM PARASIT, V16, P267, DOI 10.1016/0166-6851(85)90069-6
   de Graaf YGL, 2006, J INVEST DERMATOL, V126, P569, DOI 10.1038/sj.jid.5700098
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Dragieva G, 2004, BRIT J DERMATOL, V151, P196, DOI 10.1111/j.1365-2133.2004.06054.x
   Dragieva G, 2004, TRANSPLANTATION, V77, P115, DOI 10.1097/01.TP.0000107284.04969.5C
   Gardlo K, 2003, J AM ACAD DERMATOL, V48, P893, DOI 10.1067/mjd.2003.218
   Geze M, 1996, NATO ADV SCI I A-LIF, V286, P113
   Ghaffarifar F., 2006, Eastern Mediterranean Health Journal, V12, P902
   Horn M, 2003, BRIT J DERMATOL, V149, P1242, DOI 10.1111/j.1365-2133.2003.05600.x
   JORI G, 1984, CANCER LETT, V24, P291, DOI 10.1016/0304-3835(84)90025-9
   Kelty CJ, 2002, PHOTOCH PHOTOBIO SCI, V1, P158, DOI 10.1039/b201027p
   Kohen E., 1995, PHOTOBIOLOGY, P23, DOI DOI 10.1016/B978-012417755-0/50003-7
   Mennel S, 2007, OPHTHALMOLOGICA, V221, P216, DOI 10.1159/000101922
   Morton C, 2006, BRIT J DERMATOL, V155, P1029, DOI 10.1111/j.1365-2133.2006.07470.x
   MORTON CA, 2005, 10 WORLD C CANC SKIN
   Pariser DM, 2003, J AM ACAD DERMATOL, V48, P227, DOI 10.1067/mjd.2003.49
   Perrett CM, 2007, BRIT J DERMATOL, V156, P320, DOI 10.1111/j.1365-2133.2006.07616.x
   REYFTMANN JP, 1984, PHOTOCHEM PHOTOBIOL, V40, P721, DOI 10.1111/j.1751-1097.1984.tb04643.x
   Rhodes LE, 2007, ARCH DERMATOL, V143, P1131, DOI 10.1001/archderm.143.9.1131
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sharfaei S, 2001, BRIT J DERMATOL, V144, P1207, DOI 10.1046/j.1365-2133.2001.04232.x
   Sharfaei S, 2002, ARCH DERMATOL RES, V294, P237, DOI 10.1007/s00403-002-0320-4
   Silva JN, 2006, BIO-MED MATER ENG, V16, pS147
   Stender IM, 1997, PHOTOCHEM PHOTOBIOL, V66, P493, DOI 10.1111/j.1751-1097.1997.tb03178.x
   Szeimies RM, 2002, J AM ACAD DERMATOL, V47, P258, DOI 10.1067/mjd.2002.119649
   Tarstedt M, 2005, ACTA DERM-VENEREOL, V85, P424, DOI 10.1080/00015550510032887
   Tope W, 2004, J EUR ACAD DERMATOL, V18, P413
   VINCIULLO C, 2004, INT SKIN CANC C 2004
   Zane C, 2006, PHOTODERMATOL PHOTO, V22, P254, DOI 10.1111/j.1600-0781.2006.00246.x
NR 33
TC 28
Z9 28
U1 0
U2 14
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0959-2989
EI 1878-3619
J9 BIO-MED MATER ENG
JI Bio-Med. Mater. Eng.
PY 2008
VL 18
IS 4-5
BP 319
EP 327
DI 10.3233/BME-2008-0546
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 394MO
UT WOS:000262451000026
PM 19065042
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Narayanan, R
   Mathai, A
   Yogi, R
   Stewart, M
AF Chhablani, Jay
   Narayanan, Raja
   Mathai, Annie
   Yogi, Rohit
   Stewart, Michael
CA Ziv-Aflibercept Study Grp
TI SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; anti-VEGF; bevacizumab; ranibizumab; ziv-aflibercept; AMD;
   CNV
ID MACULAR DEGENERATION; INTRAOCULAR INFLAMMATION; PIGMENT-EPITHELIUM;
   INJECTION; NONRESPONDERS; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; SWITCH;
   EDEMA
AB Aim: To evaluate the safety of intravitreal ziv-aflibercept (Zaltrap) in the treatment choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Eligible eyes with choroidal neovascularization secondary to age-related macular degeneration each received a single intravitreal injection of ziv-aflibercept. Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injection, and International Society for Clinical Electrophysiology of Vision standard electroretinography was performed at baseline and Day 30. Primary outcome measures were safety parameters that included signs of clinical and electroretinographic toxicity. Secondary outcome measures included changes in best-corrected visual acuity and central subfield thickness.
   Results: Twelve eyes of 12 patients were treated. None of the patients complained of blurred vision, ocular pain, or bulbar injection at any of the follow-up visits, nor was intraocular inflammation noted. There were no significant differences in implicit times, "a" and "b" wave amplitudes, or b/a ratios at 1 month when compared with baseline (P = 0.4). None of the patients experienced serious ocular or systemic adverse events. Mean best-corrected visual acuity improved only slightly at 30 days (LogMAR 0.45 +/- 0.31 [Snellen equivalent: 20/60]) compared with baseline (LogMAR 0.37 +/- 0.24 [Snellen equivalent: 20/50]; P = 0.51).
   Conclusion: Single intravitreal injections of ziv-aflibercept into eyes with neovascular age-related macular degeneration appear to be safe through 1 month. Ziv-aflibercept could become a safe, low-cost therapy for macular diseases in developing countries and in those where intravitreal aflibercept (Eylea) is not available.
C1 [Chhablani, Jay; Narayanan, Raja; Mathai, Annie; Yogi, Rohit] LV Prasad Eye Inst, Hyderabad Eye Res Fdn, Srimati Kanuri Santhamma Ctr Vitreo Retinal Dis, Kallam Anji Reddy Campus, Hyderabad 500034, Telangana, India.
   [Stewart, Michael] Mayo Clin, Dept Ophthalmol, Jacksonville, FL 32224 USA.
C3 L. V. Prasad Eye Institute; Mayo Clinic
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Srimati Kanuri Santhamma Ctr Vitreo Retinal Dis, Kallam Anji Reddy Campus,LV Prasad Marg, Hyderabad 500034, Telangana, India.
EM jay.chhablani@gmail.com
RI Narayanan, Raja/AAT-3098-2021
OI Narayanan, Raja/0000-0001-9688-5859
CR Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Fine HF, 2015, RETINA-J RET VIT DIS, V35, P681, DOI 10.1097/IAE.0000000000000398
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Hahn P, 2015, JAMA OPHTHALMOL, V133, P421, DOI 10.1001/jamaophthalmol.2014.5650
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Moustafa MTM, 2014, ASS RES VIS OPHTH AN
   Patel A, 2014, BIOL-TARGETS THER, V8, P13, DOI 10.2147/BTT.S39360
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
NR 23
TC 32
Z9 32
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2016
VL 36
IS 6
BP 1126
EP 1131
DI 10.1097/IAE.0000000000000913
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN5VJ
UT WOS:000377139100026
PM 26655620
DA 2022-11-30
ER

PT J
AU Kernt, M
   Thiele, S
   Neubauer, AS
   Koenig, S
   Hirneiss, C
   Haritoglou, C
   Ulbig, MW
   Kampik, A
AF Kernt, Marcus
   Thiele, Sarah
   Neubauer, Aljoscha S.
   Koenig, Susanna
   Hirneiss, Christoph
   Haritoglou, Christos
   Ulbig, Michael W.
   Kampik, Anselm
TI INHIBITORY ACTIVITY OF RANIBIZUMAB, SORAFENIB, AND PAZOPANIB ON
   LIGHT-INDUCED OVEREXPRESSION OF PLATELET-DERIVED GROWTH FACTOR AND
   VASCULAR ENDOTHELIAL GROWTH FACTOR A AND THE VASCULAR ENDOTHELIAL GROWTH
   FACTOR A RECEPTORS 1 AND 2 AND NEUROPILIN 1 AND 2
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   multikinase inhibitors; pazopanib; platelet-derived growth factor;
   ranibizumab; sorafenib; vascular endothelial growth factor A
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULAR MEMBRANES; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; IN-VIVO; OCULAR NEOVASCULARIZATION;
   MULTIKINASE INHIBITOR; DIABETIC-RETINOPATHY; KINASE INHIBITOR; VEGF
AB Background: Cumulative light exposure is significantly associated with progression of age-related macular degeneration. Growth factors and growth factor receptor signaling are known to have a substantial impact on the development of age-related macular degeneration. This study explored the effects of ranibizumab, sorafenib, and pazopanib on vascular endothelial growth factor A (VEGF) receptors 1 and 2 and neuropilin 1 and 2 expression in human retinal pigment epithelial cells. In addition, their effects on light-induced overexpression of VEGF and platelet-derived growth factor were investigated.
   Methods: Primary human retinal pigment epithelial cells were exposed to white light and then treated with ranibizumab (0.125 mg/mL), sorafenib (1 mu g/mL), or pazopanib (1 mu g/mL). Viability of cells, expression of VEGF receptors 1 and 2 and neuropilin 1 and 2 and their mRNA, and secretion of VEGF and platelet-derived growth factor were investigated by reverse transcription-polymerase chain reactions, immunohistochemistry, and enzyme-linked immunosorbent assays.
   Results: Treatment with sorafenib or pazopanib reduced the expression of VEGF receptors 1 and 2 and neuropilin 1, and sorafenib also reduced neuropilin 2. Light exposure decreased cell viability and increased expression and secretion of VEGF and platelet-derived growth factor. Sorafenib and pazopanib significantly reduced light-induced overexpression and secretion of VEGF and platelet-derived growth factor. Ranibizumab reduced secreted VEGF in cell culture supernatants only.
   Conclusion: Our in vitro results suggest that multikinase inhibitors have promising properties as a potential antiangiogenic treatment for age-related macular degeneration.
C1 [Kernt, Marcus; Thiele, Sarah; Neubauer, Aljoscha S.; Koenig, Susanna; Hirneiss, Christoph; Haritoglou, Christos; Ulbig, Michael W.; Kampik, Anselm] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
C3 University of Munich
RP Kernt, M (通讯作者)，Univ Munich, Dept Ophthalmol, Mathilden St 8, D-80336 Munich, Germany.
EM marcus.kernt@med.uni-muenchen.de
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Antcliff R J, 1999, Semin Ophthalmol, V14, P223, DOI 10.3109/08820539909069541
   Barber AJ, 2003, INVEST OPHTH VIS SCI, V44, P5410, DOI 10.1167/iovs.03-0244
   BARISHAK Y. ROBERT, 1960, ACTA OPHTHALMOL, V38, P339
   Bukowski RM, 2010, EXPERT REV ANTICANC, V10, P635, DOI 10.1586/ERA.10.38
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Freyberger H, 2000, EXP CLIN ENDOCR DIAB, V108, P106, DOI 10.1055/s-2000-5803
   Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hamberg P, 2010, ONCOLOGIST, V15, P539, DOI 10.1634/theoncologist.2009-0274
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kernt M, 2011, OPHTHALMOLOGE, V108, P445, DOI 10.1007/s00347-010-2304-7
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Kernt M, 2010, GROWTH FACTORS, V28, P211, DOI 10.3109/08977191003604505
   Kernt M, 2010, OPHTHALMOLOGE, V107, P150, DOI 10.1007/s00347-009-1945-x
   Kernt M, 2008, ACTA OPHTHALMOL, V86, P456, DOI 10.1111/j.1600-0420.2007.01014.x
   Kernt M, 2009, J CATARACT REFR SURG, V35, P354, DOI 10.1016/j.jcrs.2008.10.052
   Kinose F, 2005, MOL VIS, V11, P366
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8
   Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlingemann RO, 1996, J PATHOL, V179, P436
   Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shen JK, 2004, MOL MED, V10, P12, DOI 10.2119/2004-00017.Campochiaro
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8
   Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Veikkola T, 2000, CANCER RES, V60, P203
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 66
TC 15
Z9 16
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2012
VL 32
IS 8
BP 1652
EP 1663
DI 10.1097/IAE.0b013e318240a558
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004HN
UT WOS:000308672300028
PM 22466477
DA 2022-11-30
ER

PT J
AU Klettner, A
AF Klettner, Alexa
TI Fucoidan as a Potential Therapeutic for Major Blinding Diseases-A
   Hypothesis
SO MARINE DRUGS
LA English
DT Review
DE fucoidan; age-related macular degeneration; diabetic retinopathy;
   oxidative stress; VEGF; complement
ID ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-WEIGHT FUCOIDAN; ACTIVATED
   PROTEIN-KINASES; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   OXIDATIVE-STRESS; SULFATED POLYSACCHARIDES; INHIBITS ANGIOGENESIS;
   ASCOPHYLLUM-NODOSUM; TUMOR ANGIOGENESIS
AB Fucoidan is a heterogeneous group of sulfated polysaccharide with a high content of l-fucose, which can be extracted from brown algae and marine invertebrates. It has many beneficial biological activities that make fucoidan an interesting candidate for therapeutic application in a variety of diseases. Age-related macular degeneration and diabetic retinopathy are major causes for vision loss and blindness in the industrialized countries and increasingly in the developing world. Some of the characteristics found in certain fucoidans, such as its anti-oxidant activity, complement inhibition or interaction with the Vascular Endothelial Growth factor, which would be of high interest for a potential application of fucoidan in age-related macular degeneration or diabetic retinopathy. However, the possible usage of fucoidan in ophthalmological diseases has received little attention so far. In this review, biological activities of fucoidan that could be of interest regarding these diseases will be discussed.
C1 [Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
EM aklettner@auge.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
FU Hermann-Wacker foundation
FX The author is funded by the Hermann-Wacker foundation.
CR Abcouwer Steven F, 2011, J Ocul Biol Dis Infor, V4, P25, DOI 10.1007/s12177-012-9086-x
   Abu R, 2013, INT J BIOL MACROMOL, V59, P305, DOI 10.1016/j.ijbiomac.2013.04.035
   Behl T, 2015, PHARMACOL RES, V99, P137, DOI 10.1016/j.phrs.2015.05.013
   Blondin C, 1996, BIOMATERIALS, V17, P597, DOI 10.1016/0142-9612(96)88710-2
   BLONDIN C, 1994, MOL IMMUNOL, V31, P247, DOI 10.1016/0161-5890(94)90121-X
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen MC, 2015, MAR DRUGS, V13, P4436, DOI 10.3390/md13074436
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cho M, 2014, CARBOHYD POLYM, V113, P507, DOI 10.1016/j.carbpol.2014.07.055
   Cui WT, 2014, LAB INVEST, V94, P382, DOI 10.1038/labinvest.2014.12
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Do H, 2010, J NUTR BIOCHEM, V21, P671, DOI 10.1016/j.jnutbio.2009.03.013
   Ehrlich R, 2010, ACTA OPHTHALMOL, V88, P279, DOI 10.1111/j.1755-3768.2008.01501.x
   Felinski EA, 2005, CURR EYE RES, V30, P949, DOI 10.1080/02713680500263598
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fitton JH, 2015, MAR DRUGS, V13, P5920, DOI 10.3390/md13095920
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   FRIBERG TR, 1985, OPHTHALMOLOGY, V92, P1051
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guo HF, 2015, J BIOL CHEM, V290, P29120, DOI 10.1074/jbc.R115.687327
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hernandez-Corona DM, 2014, J MED FOOD, V17, P830, DOI 10.1089/jmf.2013.0053
   Hong SW, 2011, BIOSCI BIOTECH BIOCH, V75, P833, DOI 10.1271/bbb.100599
   Huang S, 2000, CANCER RES, V60, P5334
   Huang TH, 2015, MAR DRUGS, V13, P1882, DOI 10.3390/md13041882
   Iraha A, 2013, WORLD J GASTROENTERO, V19, P5500, DOI 10.3748/wjg.v19.i33.5500
   Jin JO, 2015, INT J BIOL MACROMOL, V73, P65, DOI 10.1016/j.ijbiomac.2014.10.059
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kim EA, 2014, CARBOHYD POLYM, V102, P185, DOI 10.1016/j.carbpol.2013.11.022
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim KJ, 2012, FITOTERAPIA, V83, P1628, DOI 10.1016/j.fitote.2012.09.014
   Kim KJ, 2012, FITOTERAPIA, V83, P1105, DOI 10.1016/j.fitote.2012.04.027
   Kim KT, 2014, PHYTOCHEMISTRY, V98, P27, DOI 10.1016/j.phytochem.2013.12.003
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner A., 2013, VASCULAR ENDOTHELIAL, P117
   Klettner Alexa, 2015, Med Monatsschr Pharm, V38, P258
   Klettner A, 2015, MOL VIS, V21, P736
   Klettner A, 2013, MOL VIS, V19, P281
   Klettner A, 2012, OXID STRESS APPL BAS, P277, DOI 10.1007/978-1-61779-606-7_13
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Koyanagi S, 2003, BIOCHEM PHARMACOL, V65, P173, DOI 10.1016/S0006-2952(02)01478-8
   Kumar TV, 2015, INT J BIOL MACROMOL, V72, P1044, DOI 10.1016/j.ijbiomac.2014.10.013
   Lake AC, 2006, J BIOL CHEM, V281, P37844, DOI 10.1074/jbc.M600686200
   Lee SH, 2012, CARBOHYD POLYM, V89, P599, DOI 10.1016/j.carbpol.2012.03.056
   Li B, 2008, MOLECULES, V13, P1671, DOI 10.3390/molecules13081671
   Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022
   Li XX, 2015, MOL MED REP, V11, P3746, DOI 10.3892/mmr.2015.3224
   Liu F, 2012, PHYTOMEDICINE, V19, P797, DOI 10.1016/j.phymed.2012.03.015
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Marme D, 1996, WORLD J UROL, V14, P166
   Marudhupandi T, 2014, Pak J Biol Sci, V17, P402, DOI 10.3923/pjbs.2014.402.407
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morya VK, 2012, APPL MICROBIOL BIOT, V93, P71, DOI 10.1007/s00253-011-3666-8
   Narazaki M, 2008, BLOOD, V111, P4126, DOI 10.1182/blood-2007-09-112474
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032
   Park HY, 2011, FOOD CHEM TOXICOL, V49, P1745, DOI 10.1016/j.fct.2011.04.020
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Purnama A, 2015, DRUG DELIV TRANSL RE, V5, P187, DOI 10.1007/s13346-013-0177-4
   Rangasamy S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108508
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ruperez P, 2002, J AGR FOOD CHEM, V50, P840, DOI 10.1021/jf010908o
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Teruya T, 2010, BIOSCI BIOTECH BIOCH, V74, P1960, DOI 10.1271/bbb.100294
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tissot B, 2003, BBA-PROTEINS PROTEOM, V1651, P5, DOI 10.1016/S1570-9639(03)00230-9
   TUCK ML, 1988, POSTGRAD MED J, V64, P76
   Ustyuzhanina NE, 2014, GLYCOBIOLOGY, V24, P1265, DOI 10.1093/glycob/cwu063
   Wan TT, 2015, BIOMED PHARMACOTHER, V74, P145, DOI 10.1016/j.biopha.2015.08.002
   Wang J, 2008, INT J BIOL MACROMOL, V42, P127, DOI 10.1016/j.ijbiomac.2007.10.003
   Wang J, 2013, CARBOHYD POLYM, V95, P143, DOI 10.1016/j.carbpol.2013.02.076
   Wang YM, 2016, J BIOSCI BIOENG, V121, P36, DOI 10.1016/j.jbiosc.2015.05.012
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yang WZ, 2013, EXP EYE RES, V115, P96, DOI 10.1016/j.exer.2013.06.011
   Ye J, 2005, CYTOTECHNOLOGY, V47, P117, DOI 10.1007/s10616-005-3761-8
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 90
TC 24
Z9 25
U1 0
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD FEB
PY 2016
VL 14
IS 2
AR 31
DI 10.3390/md14020031
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DG2LX
UT WOS:000371899800014
PM 26848666
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Iida, Y
   Hayashi, T
   Tokuhisa, T
   Mizobuchi, K
   Omoto, S
   Nakano, T
AF Iida, Yuka
   Hayashi, Takaaki
   Tokuhisa, Teruaki
   Mizobuchi, Kei
   Omoto, Shusaku
   Nakano, Tadashi
TI Polypoidal choroidal vasculopathy in a patient with DMPK-associated
   myotonic dystrophy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Myotonic dystrophy; Electroretinography; Age-related macular
   degeneration; Polypoidal choroidal vasculopathy; DMPK gene; Retinal
   dystrophy
ID CTG REPEAT; PATTERNED DYSTROPHIES; REDUCES EXPRESSION; EXPANSION; SIX5;
   PATHOGENESIS; TYPE-1; MICE
AB Background Myotonic dystrophy type 1 (DM1) is an autosomal dominant genetic disorder that affects multiple organs, including the muscle and eye, caused by a CTG triplet expansion of the 3 ' untranslated region (UTR) of the DMPK gene. Cataracts and retinal degeneration are major eye complications in patients with DM1. We reported the case of a Japanese patient with DM1 who exhibited submacular hemorrhage unilaterally, rarely complicating DM1. Case report A 56-year-old woman presented with loss of visual acuity in the left eye (LE). The patient was diagnosed with DM1, who carried expanded CTG repeats (1100) of the 3 ' UTR of DMPK. Her corrected visual acuities were 20/100 and 20/2000 in the right eye (RE) and LE, respectively. Cataracts were observed in both eyes. Fundoscopy and angiography revealed submacular hemorrhage in the LE due to polypoidal choroidal vasculopathy (PCV, also known as aneurysmal type 1 neovascularization). The patient underwent intravitreal injections of an anti-vascular endothelial growth factor drug and sulfur hexafluoride gas in the LE. Full-field electroretinography was performed, showing that the rod and standard-flash responses were reduced to 50% and below 10% in the RE and LE, whereas the cone and 30-Hz flicker responses were reduced to 40-50% and 15-20% in the RE and LE, respectively, compared with the controls. Multifocal electroretinography revealed that the overall responses were extinguished in the LE and considerably attenuated in the RE. Conclusions This is the first patient with DM1 complicated with PCV. Widespread retinal dysfunction may be associated with expanded CTG repeats, which is significantly longer than the mean repeat number of patients with DM1.
C1 [Iida, Yuka; Hayashi, Takaaki; Tokuhisa, Teruaki] Jikei Univ, Katsushika Med Ctr, Dept Ophthalmol,Sch Med, Katsushika Ku, 6-41-2 Aoto, Tokyo 1258506, Japan.
   [Hayashi, Takaaki; Mizobuchi, Kei; Nakano, Tadashi] Jikei Univ, Dept Ophthalmol, Sch Med, Minato Ku, Tokyo 1058461, Japan.
   [Omoto, Shusaku] Jikei Univ, Katsushika Med Ctr, Dept Neurol,Sch Med, Katsushika Ku, Tokyo 1258506, Japan.
C3 Jikei University; Jikei University; Jikei University
RP Hayashi, T (通讯作者)，Jikei Univ, Katsushika Med Ctr, Dept Ophthalmol,Sch Med, Katsushika Ku, 6-41-2 Aoto, Tokyo 1258506, Japan.
EM taka@jikei.ac.jp
OI Hayashi, Takaaki/0000-0002-1535-0279; mizobuchi, kei/0000-0001-5389-6507
FU KAKENHI [21K09756]; Alcon (TH; Tokyo, Japan); Johnson Vision, AMO (TH;
   Tokyo, Japan); Daiichi Sankyo (TH; Tokyo, Japan); Chugai (TH; Tokyo,
   Japan); Mitsubishi Tanabe Pharma (TH; Osaka, Japan); Senju (TH; Osaka,
   Japan); Bayer (TH; Osaka, Japan); Ritz medical (TH; Aichi, Japan);
   Uni-hite (TH; Kanagawa, Japan); Kuribara (TH; Gunma, Japan)
FX This work was supported, in part, by the Grantsin-Aid for Scientific
   Research (KAKENHI) Grant Number 21K09756 (TH) and Research Grants from
   Alcon (TH; Tokyo, Japan), Johnson and Johnson Vision, AMO (TH; Tokyo,
   Japan), Daiichi Sankyo (TH; Tokyo, Japan), Chugai (TH; Tokyo, Japan),
   Mitsubishi Tanabe Pharma (TH; Osaka, Japan), Senju (TH; Osaka, Japan),
   Bayer (TH; Osaka, Japan), Ritz medical (TH; Aichi, Japan), Uni-hite (TH;
   Kanagawa, Japan), and Kuribara (TH; Gunma, Japan).
CR Abed E, 2020, NEUROMUSCULAR DISORD, V30, P144, DOI 10.1016/j.nmd.2019.11.012
   BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5
   Burian H M, 1966, Trans Am Ophthalmol Soc, V64, P250
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326
   Hayashi T, 2021, OPHTHALMIC GENET, V42, P412, DOI 10.1080/13816810.2021.1904422
   Hayashi T, 2021, DOC OPHTHALMOL, V143, P107, DOI 10.1007/s10633-021-09826-y
   Hayashi T, 2021, DOC OPHTHALMOL, V142, P265, DOI 10.1007/s10633-020-09798-5
   Hoffmann MB, 2021, DOC OPHTHALMOL, V142, P5, DOI 10.1007/s10633-020-09812-w
   HSIEH RC, 1977, ARCH OPHTHALMOL-CHIC, V95, P429
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Mateos-Aierdi AJ, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00125
   KIMIZUKA Y, 1993, RETINA-J RET VIT DIS, V13, P129, DOI 10.1097/00006982-199313020-00007
   Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402
   Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490
   Kohno G, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00681
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125
   Logigian EL, 2004, NEUROLOGY, V62, P1081, DOI 10.1212/01.WNL.0000118206.49652.A3
   MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325
   Makino S, 2012, INTERNAL MED, V51, P2253, DOI 10.2169/internalmedicine.51.8181
   Marano F, 2000, GRAEF ARCH CLIN EXP, V238, P760, DOI 10.1007/s004170000186
   MARMOR MF, 1977, AM J OPHTHALMOL, V84, P32, DOI 10.1016/0002-9394(77)90320-8
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Miyagi M, 2022, GRAEF ARCH CLIN EXP, V260, P1125, DOI 10.1007/s00417-021-05447-y
   Mizobuchi K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112265
   Ninomiya W, 2020, DOC OPHTHALMOL, V140, P279, DOI 10.1007/s10633-019-09743-1
   Nishihara N, 2020, JA CLIN REP, V6, DOI 10.1186/s40981-020-00388-7
   PINCKERS A, 1988, OPHTHALMIC PAED GEN, V9, P77, DOI 10.3109/13816818809031483
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Sarkar PS, 2000, NAT GENET, V25, P110, DOI 10.1038/75500
   Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407
   Wen XF, 2018, J GENE MED, V20, DOI 10.1002/jgm.3007
   Winchester CL, 1999, HUM MOL GENET, V8, P481, DOI 10.1093/hmg/8.3.481
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zinkernagel MS, 2012, EYE, V26, P1595, DOI 10.1038/eye.2012.197
NR 37
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD JUN
PY 2022
VL 144
IS 3
BP 217
EP 226
DI 10.1007/s10633-022-09867-x
EA MAR 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2C1WY
UT WOS:000768077500001
PM 35284965
DA 2022-11-30
ER

PT J
AU Jones, M
   Whitton, C
   Tan, AG
   Holliday, EG
   Oldmeadow, C
   Flood, VM
   Sim, XL
   Chai, JF
   Hamzah, H
   Klein, R
   Teo, YY
   Mitchell, P
   Wong, TY
   Tai, ES
   Van Dam, RM
   Attia, J
   Wang, JJ
AF Jones, Mark
   Whitton, Clare
   Tan, Ava G.
   Holliday, Elizabeth G.
   Oldmeadow, Christopher
   Flood, Victoria M.
   Sim, Xueling
   Chai, Jin-Fang
   Hamzah, Haslina
   Klein, Ronald
   Teo, Yik-Ying
   Mitchell, Paul
   Wong, Tien Y.
   Tai, E. Shyong
   Van Dam, Rob M.
   Attia, John
   Wang, Jie Jin
TI Exploring Factors Underlying Ethnic Difference in Age-related Macular
   Degeneration Prevalence
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Epidemiology; age-related macular degeneration; ethnic difference; diet;
   genetic risk
ID FOOD FREQUENCY QUESTIONNAIRE; LONG-TERM INCIDENCE; DIETARY PATTERNS;
   MEDIATION ANALYSIS; ZEAXANTHIN INTAKE; UNITED-STATES; RISK-FACTORS;
   LUTEIN; ANTIOXIDANTS; ASSOCIATIONS
AB Aims To assess contributions of dietary and genetic factors to ethnic differences in AMD prevalence. Design Population-based analytical study. Methods In the Blue Mountains Eye Study, Australia (European ancestry n = 2826) and Multi-Ethnic Cohort Study, Singapore (Asian ancestry, n = 1900), AMD was assessed from retinal photographs. Patterns of dietary composition and scores of the Alternative Healthy Eating Index were computed using food frequency questionnaire data. Genetic susceptibility to AMD was determined using either single nucleotide polymorphisms (SNPs) of the complement factor Handage-related maculopathy susceptibility 2genes, or combined odds-weighted genetic risk scores of 24 AMD-associated SNPs. Associations of AMD with ethnicity, diet, and genetics were assessed using logistic regression. Six potential mediators covering genetic, diet and lifestyle factors were assessed for their contributions to AMD risk difference between the two samples using mediation analyses. Results Age-standardized prevalence of any (early or late) AMD was higher in the European (16%) compared to Asian samples (9%,p< .01). Mean AMD-related genetic risk scores were also higher in European (33.3 +/- 4.4) than Asian (Chinese) samples (31.7 +/- 3.7,p< .001). In a model simultaneously adjusting for age, ethnicity, genetic susceptibility and Alternative Healthy Eating Index scores, only age and genetic susceptibility were significantly associated with AMD. Genetic risk scores contributed 19% of AMD risk difference between the two samples while intake of polyunsaturated fatty acids contributed 7.2%. Conclusion Genetic susceptibility to AMD was higher in European compared to Chinese samples and explained more of the AMD risk difference between the two samples than the dietary factors investigated.
C1 [Jones, Mark; Oldmeadow, Christopher; Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Whitton, Clare; Sim, Xueling; Chai, Jin-Fang; Teo, Yik-Ying; Tai, E. Shyong; Van Dam, Rob M.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Whitton, Clare; Sim, Xueling; Chai, Jin-Fang; Teo, Yik-Ying; Tai, E. Shyong; Van Dam, Rob M.] Natl Univ Hlth Syst, Singapore, Singapore.
   [Tan, Ava G.; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Dept Ophthalmol, Westmead, NSW, Australia.
   [Holliday, Elizabeth G.; Oldmeadow, Christopher; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW, Australia.
   [Holliday, Elizabeth G.; Oldmeadow, Christopher; Attia, John] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia.
   [Flood, Victoria M.] Univ Sydney, Fac Med & Hlth, Sch Hlth Sci, Sydney, NSW, Australia.
   [Flood, Victoria M.] Western Sydney Local Hlth Dist, Westmead Hosp, Sydney, NSW, Australia.
   [Hamzah, Haslina] Singapore Natl Eye Ctr, Ocular Reading Ctr, Singapore, Singapore.
   [Klein, Ronald] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Tai, E. Shyong; Van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
   [Tai, E. Shyong] Duke NUS Med Sch, Cardiovasc & Metab Dis Signature Res Program, Singapore, Singapore.
   [Van Dam, Rob M.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
   [Wang, Jie Jin] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore, Singapore.
C3 Hunter Medical Research Institute; University of Newcastle; National
   University of Singapore; National University of Singapore; University of
   Sydney; Westmead Institute for Medical Research; University of
   Newcastle; University of Newcastle; University of Sydney; University of
   Sydney; Singapore National Eye Center; University of Wisconsin System;
   University of Wisconsin Madison; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; National University of Singapore;
   Harvard University; Harvard T.H. Chan School of Public Health; National
   University of Singapore
RP Wang, JJ (通讯作者)，Duke NUS, Duke NUS Med Sch, 8 Coll Rd,Level 6,Room 0633, Singapore 169856, Singapore.
EM jiejin.wang@gmail.com
RI Wong, Tien Yin/AAC-9724-2020; Flood, Victoria M/A-8732-2016; Whitton,
   Clare/AFQ-5310-2022; Sim, Xueling/AAZ-6652-2020; Whitton,
   Clare/AAV-3423-2021; van Dam, Rob M/F-9674-2010
OI Wong, Tien Yin/0000-0002-8448-1264; Flood, Victoria
   M/0000-0001-5310-7221; Whitton, Clare/0000-0003-1991-2432; Sim,
   Xueling/0000-0002-1233-7642; Whitton, Clare/0000-0003-1991-2432; van
   Dam, Rob M/0000-0002-7354-8734; Tan, Ava Grace/0000-0003-3344-0339; Tai,
   E Shyong/0000-0003-2929-8966
FU National Health & Medical Research Council, Australia [590204]
FX National Health & Medical Research Council, Australia: Project grant [ID
   590204]. The sponsor or funding organization had no role in the design
   or conduct of this research.
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen GC, 2018, AM J EPIDEMIOL, V187, P2651, DOI 10.1093/aje/kwy183
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Department of Community Services and Health, 1995, NUTTAB95 NUTR DATA T
   Deurenberg-Yap M, 2000, ASIA PAC J CLIN NUTR, V9, P282, DOI 10.1046/j.1440-6047.2000.00187.x
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao X, 2004, FASEB J, V18, pA110
   Gopinath B, 2020, CLIN NUTR, V39, P580, DOI 10.1016/j.clnu.2019.03.009
   Guillermo C, 2020, J AM COLL NUTR, V39, P216, DOI 10.1080/07315724.2019.1635921
   Health Promotion Board Research & Strategic Planning Division, 2004, REP NAT NUTR SURV 20
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Lin H, 2017, OPHTHAL EPIDEMIOL, V24, P311, DOI 10.1080/09286586.2017.1290259
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McCarter RV, 2019, IRISH J MED SCI, V188, P1005, DOI 10.1007/s11845-018-1932-9
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moeller Suzen M., 2003, International Ophthalmology Clinics, V43, P47
   Neelakantan N, 2018, J NUTR, V148, P1323, DOI 10.1093/jn/nxy094
   Neelakantan N, 2016, J NUTR, V146, P1379, DOI 10.3945/jn.116.231605
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Pearl J, 2014, PSYCHOL METHODS, V19, P459, DOI 10.1037/a0036434
   Preacher KJ, 2015, ANNU REV PSYCHOL, V66, P825, DOI 10.1146/annurev-psych-010814-015258
   Richiardi L, 2013, INT J EPIDEMIOL, V42, P1511, DOI 10.1093/ije/dyt127
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sim X, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001363
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan KHX, 2018, INT J EPIDEMIOL, V47, P699, DOI 10.1093/ije/dyy014
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Whitton C, 2018, J NUTR, V148, P616, DOI 10.1093/jn/nxy016
   Wise J., 2015, BMJ, V351, ph3618
   Wong WL, 2014, LANCET GLOBAL HLTH, V2, pe106
   Wu J, 2017, AM J CLIN NUTR, V105, P1483, DOI 10.3945/ajcn.116.143453
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
NR 57
TC 3
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD SEP 2
PY 2020
VL 27
IS 5
BP 399
EP 408
DI 10.1080/09286586.2020.1762229
EA JUN 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA NA2ZD
UT WOS:000543554800001
PM 32511069
DA 2022-11-30
ER

PT J
AU Sayanagi, K
   Gomi, F
   Akiba, M
   Sawa, M
   Hara, C
   Nishida, K
AF Sayanagi, Kaori
   Gomi, Fumi
   Akiba, Masahiro
   Sawa, Miki
   Hara, Chikako
   Nishida, Kohji
TI En-face high-penetration optical coherence tomography imaging in
   polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXUDATIVE MACULAR DISEASES; INTRAVITREAL RANIBIZUMAB; THICKNESS;
   VISUALIZATION; FEATURES; LESIONS
AB Aim To observe the choroidal microstructure in polypoidal choroidal vasculopathy (PCV) using high-penetration optical coherence tomography (HP-OCT) with a long-wavelength light source that visualises tissue beneath the retinal pigment epithelium (RPE) and deep choroid, and to compare the findings with those of indocyanine green angiography (ICGA).
   Methods In this retrospective, non-invasive, observational case series, 19 eyes (18 patients) with PCV were observed using HP-OCT (swept source, 100 000 A-scans/s, 1060 nm wavelength) and ICGA. The HP-OCT scan protocol was a 3x3-mm or 6x6-mm square containing 256x256 or 512x128 A-scans. The choroidal thickness (CT) was measured using HP-OCT.
   Results ICGA showed 43 polypoidal lesions in 14 eyes and a vascular network in 17 eyes. HP-OCT showed 41 of the 43 polypoidal lesions visualised by ICGA as RPE rings with inner reflectivity and 15 eyes with a vascular network. Six eyes with RPE rings with inner reflectivity on HP-OCT were not visualised on ICGA images. The choroidal vascular network was dilated in 14 (33%) of 43 polypoidal lesions and 22 (47%) of 47 polypoidal lesions on ICGA and HP-OCT images, respectively. The mean CT at the fovea was 250 mu m. The CT at the dilated choroidal vessels beneath the polypoidal lesions was significantly (p = 0.0095) thicker than that of the undilated choroidal vessels beneath the polypoidal lesions.
   Conclusions HP-OCT can visualise choroidal vascular abnormalities in eyes with PCV and should be useful for understanding the pathogenesis of these abnormalities.
C1 [Sayanagi, Kaori; Gomi, Fumi; Sawa, Miki; Hara, Chikako; Nishida, Kohji] Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 565, Japan.
   [Gomi, Fumi] Sumitomo Hosp, Dept Ophthalmol, Osaka 5300005, Japan.
   [Akiba, Masahiro] Topcon Corp, Tokyo, Japan.
C3 Osaka University; Sumitomo Hospital; Topcon Corporation
RP Gomi, F (通讯作者)，Sumitomo Hosp, Dept Ophthalmol, Kita Ku, 5-3-20 Nakanoshima, Osaka 5300005, Japan.
EM gomi.fumi@gmail.com
OI Gomi, Fumi/0000-0003-0807-8817; Nishida, Kohji/0000-0001-9069-3610
CR Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sugano Y, 2013, JPN J OPHTHALMOL, V57, P294, DOI 10.1007/s10384-013-0230-3
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 26
TC 35
Z9 37
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2015
VL 99
IS 1
BP 29
EP 35
DI 10.1136/bjophthalmol-2013-304658
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW6CW
UT WOS:000346358000008
PM 25107899
DA 2022-11-30
ER

PT J
AU Luo, MY
   Zhao, XY
   Yang, JY
   Chen, YX
AF Luo, Mingyue
   Zhao, Xinyu
   Yang, Jingyuan
   Chen, Youxin
TI The association of polypoidal choroidal vasculopathy clinical phenotypes
   with previously reported genetic markers
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Single-nucleotide polymorphism;
   Genotype-phenotype association; Gene
ID MACULAR DEGENERATION; VARIANTS; HTRA1; CFH; SUSCEPTIBILITY
AB Purpose Genetic studies have identified the association of some single-nucleotide polymorphisms (SNPs) with polypoidal choroidal vasculopathy (PCV), but little is known about whether these SNPs are related to PCV clinical features as well. We performed this study to examine the association of 12 SNPs with PCV clinical phenotypes. Methods Sixty-nine PCV eyes of 69 patients were included. Genomic DNA was extracted from peripheral blood. Agilent SureSelect Human ALL Exon V6 was used to sequence the 12 SNPs previously reported to associate with PCV. Baseline best-corrected visual acuity (BCVA), sub-foveal choroidal thickness (SFCT), choroid maximum vascular diameter (MVD), choroidal vascular hyperpermeability (CVH), and greatest linear dimension (GLD) of entire lesion were measured and compared between patients of different genotypes. Fisher's exact test and Mann-Whitney U test were mainly used to compare categorical variables and continuous variables respectively. Results HTRA1 rs2293870 was a protective factor of PCV or AMD in the fellow eye (P = 0.040) and was related with greater SFCT in PCV eye after multiple linear regression (P = 0.043). C3 rs17030 was associated with smaller GLD (P = 0.033). CFH rs2274700 was related to lower MVD (P = 0.043) and was a protective factor for CVH (P = 0.034). Conclusion Multiple PCV-associated SNPs are associated with PCV clinical phenotypes. The involvement of several synonymous SNPs calls for further research on the role of transcriptional alterations and trans-regulation of distant signaling pathways in PCV pathogenesis.
C1 [Luo, Mingyue; Zhao, Xinyu; Yang, Jingyuan; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Luo, Mingyue; Zhao, Xinyu; Yang, Jingyuan; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
EM chenyx@pumch.cn
OI Luo, Mingyue/0000-0002-8121-7361
FU Non-profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences [2018PT32029]
FX This study was funded by the Non-profit Central Research Institute Fund
   of Chinese Academy of Medical Sciences (2018PT32029).
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Huang L, 2015, EYE, V29, P691, DOI 10.1038/eye.2015.32
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Jin EZ, 2015, INT J CLIN EXP PATHO, V8, P13928
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2020
VL 258
IS 6
BP 1199
EP 1203
DI 10.1007/s00417-020-04702-y
EA APR 2020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LR1UQ
UT WOS:000528285300002
PM 32328755
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Yamagishi, T
   Yamazaki, T
   Kinoshita, S
AF Koizumi, Hideki
   Yamagishi, Tetsuya
   Yamazaki, Taizo
   Kinoshita, Shigeru
TI Relationship Between Clinical Characteristics of Polypoidal Choroidal
   Vasculopathy and Choroidal Vascular Hyperpermeability
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; LESION SIZE;
   THICKNESS; ANGIOGRAPHY
AB PURPOSE: To investigate the relationship between the clinical characteristics of polypoidal choroidal vasculopathy (PCV) and choroidal vascular hyperpermeability seen on indocyanine green angiography.
   DESIGN: Retrospective, consecutive, interventional case series.
   METHODS: We reviewed the medical records and the angiograms of 89 patients with PCV. The relationship between choroidal vascular hyperpermeability and background factors, associated clinical manifestations, and treatment responses to intravitreal injections of ranibizumab were evaluated.
   RESULTS: Of the 89 patients with PCV, 31 patients (34.8%) demonstrated choroidal vascular hyperpermeability. The patients with choroidal vascular hyperpermeability more frequently showed bilateral neovascular membrane than those without choroidal vascular hyperpermeability (P = .009) and had a significant relationship with a history of central serous chorioretinopathy (CSC) (P = .01). Of the 98 eyes with treatment-nave PCV, 34 eyes with choroidal vascular hyperpermeability demonstrated significantly greater subfoveal thickness than the 64 eyes without choroidal vascular hyperpermeability (P < .001). However, no significant relationship was found between choroidal vascular hyperpermeability and the other biomicroscopic and angiographic phenotypes of PCV. Three monthly intravitreal injections of ranibizumab were performed on 57 patients with treatment-naive PCV, and the presence of choroidal vascular hyperpermeability was significantly related to the persistent retinal fluid 1 month after the third ranibizumab injection (P = .01).
   CONCLUSIONS: The patients with PCV associated with choroidal vascular hyperpermeability more frequently demonstrated bilateral neovascular membrane, a history of CSC, a thickened choroid, and poor responses to intravitreal injections of ranibizumab than those without choroidal vascular hyperpermeability. (Am J Ophthalmol 2013;155:305-313. (c) 2013 by Elsevier Inc. All rights reserved.)
C1 [Koizumi, Hideki] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan.
C3 Kyoto Prefectural University of Medicine
RP Koizumi, H (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM hidekoiz@koto.kpu-m.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Tokyo,
   Japan [21890226]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. The authors report no financial
   disclosures. Publication of this article was supported in part by Grant
   No. 21890226 from Ministry of Education, Culture, Sports, Science and
   Technology, Tokyo, Japan (Dr Koizumi). Involved in design and conduct of
   the study (H.K.); collection (H.K., T.Y., T.Y.), management (H.K.),
   analysis (H.K.), and interpretation of the data (H.K.); and preparation
   (H.K.), review (H.K., T.Y., T.Y., S.K.), and approval (H.K., T.Y., T.Y.,
   S.K.) of the manuscript. The Institutional Review Board at Kyoto
   Prefectural University of Medicine approved the retrospective review of
   patient data for age-related macular degeneration, and this study
   followed the tenets of the Declaration of Helsinki. Written informed
   consent was obtained from each patient for treatment.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   [Anonymous], 2005, NIHON GANKA GAKKAI Z, V109, P417
   Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Karadimas P, 2004, GRAEF ARCH CLIN EXP, V242, P800, DOI 10.1007/s00417-004-0885-z
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 122
Z9 130
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2013
VL 155
IS 2
BP 305
EP 313
DI 10.1016/j.ajo.2012.07.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 078YQ
UT WOS:000314137400014
PM 23022162
DA 2022-11-30
ER

PT J
AU Vadala, M
   Castellucci, M
   Guarrasi, G
   Cillino, G
   Bonfiglio, VME
   Casuccio, A
   Cillino, S
AF Vadala, Maria
   Castellucci, Massimo
   Guarrasi, Giulia
   Cillino, Giovanni
   Bonfiglio, Vincenza Maria Elena
   Casuccio, Alessandra
   Cillino, Salvatore
TI Polypoidal choroidal vasculopathy in pachychoroid: combined treatment
   with photodynamic therapy and aflibercept
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Pachychoroid; Photodynamic therapy; Polypoidal choroidal
   vasculopathy; Swept Source OCT
ID RANIBIZUMAB; VERTEPORFIN; THICKNESS
AB Introduction To evaluate the effects of combined therapy using intravitreal Aflibercept (IVA) and photodynamic therapy (PDT) on polypoidal choroidal vasculopathy related to pachychoroid disease (PPCV). Methods Patients with PPCV were treated with PDT combined with 3 IVA injections on a monthly basis, followed by pro re nata criteria. The 12-month follow-up consisted of multiple revaluations of visual acuity and SS-OCT parameters of clinical activity. Results Nineteen eyes were included in the study; mean age was 65.5 years. Visual acuity improved after 12 months (0.35 +/- 0.25 to 0.2 +/- 0.20 logMAR, p = 0.005). Percentage of eyes with intraretinal and subretinal fluid reduced from baseline to the 12-month follow-up (from 52.6 to 10.5%, p = 0.12, and from 89.5 to 5.3% p = 0.0009, respectively). Central retinal and mean macular thicknesses reduced (258 +/- 39.6 to 204.8 +/- 38.8 mu m p = 0.04 and 293.8 +/- 32.1 to 248.1 +/- 29.6 mu m p = 0.017, respectively). Central choroidal and mean choroidal thicknesses also displayed a reduction (328.6 +/- 54.9 to 289.8 +/- 44.6 mu m p = 0.001 and 314.5 +/- 55.3 to 287.9 +/- 47.6 mu m p = 0.015, respectively). The mean number of injections was 4.6/year. Conclusion The results support the use of a combined therapy with Aflibercept and PDT in PPCV. This treatment would act in synergy, with anti-VEGF controlling exudation and PDT closing the aneurysmal vessel and reducing choroidal congestion.
C1 [Vadala, Maria; Castellucci, Massimo] Univ Palermo, Inst Ophthalmol, Biomed Neurosci & Adv Diagnost Dept, Villa Belmonte,Via Cardinale Rampolla 1, I-90142 Palermo, Italy.
   [Casuccio, Alessandra] Univ Palermo Mother Child Care, Internal Med & Excellence, Dept Hlth Promot, Palermo, Italy.
C3 University of Palermo
RP Vadala, M; Castellucci, M (通讯作者)，Univ Palermo, Inst Ophthalmol, Biomed Neurosci & Adv Diagnost Dept, Villa Belmonte,Via Cardinale Rampolla 1, I-90142 Palermo, Italy.
EM maria.vadala@unipa.it; maria.vadala@unipa.it
OI CILLINO, Salvatore/0000-0002-5721-6772; VADALA',
   Maria/0000-0002-2726-698X; casuccio, alessandra/0000-0002-5676-9535;
   Guarrasi, Giulia/0000-0002-0819-5610; Castellucci,
   Massimo/0000-0003-2284-6552; BONFIGLIO, VINCENZA/0000-0001-5468-0978
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Lai KB, 2018, OSLI RETINA, V49, pE114, DOI 10.3928/23258160-20181002-13
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tan C., 2017, 17 EURETINA C BARC 2
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2022
VL 42
IS 2
BP 601
EP 610
DI 10.1007/s10792-021-02032-4
EA JAN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZI4CQ
UT WOS:000742806900001
PM 35034223
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Anantharaman, G
   Ramkumar, G
   Gopalakrishnan, M
   Rajput, A
AF Anantharaman, Giridhar
   Ramkumar, Gudapati
   Gopalakrishnan, Mahesh
   Rajput, Alpesh
TI Clinical features, management and visual outcome of polypoidal choroidal
   vasculopathy in Indian patients
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Greatest linear diameter; indocyanine green angiography; photodynamic
   therapy; polypoidal choroidal vasculopathy; serosanguinous maculopathy;
   submacular hemorrhage; thermal laser
ID PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION; MACULAR DEGENERATION;
   JAPANESE PATIENTS; CHINESE PATIENTS; VERTEPORFIN
AB Aims: To present the clinical, indocyanine green angiography (ICGA) features and results of treatment for polypoidal choroidal vasculopathy (PCV) in Indian patients by a retrospective chart review. Materials and Methods: Forty five patients with PCV underwent complete ocular examination, fluorescein angiography (FFA) and ICGA. Treatment was advised for patients with macular involvement and progressive loss of visual acuity. Demographic data, clinical features and results of treatment were analyzed. Results: Mean age at presentation was 61.06 years. Mean follow up was 18 months. The disease was more prevalent in males. Forty three patients had unilateral disease. The most common location of polyps in ICGA was subfoveal (42.5%). Exudative form was seen in 34 of the 47 eyes and the remaining 13 eyes had a hemorrhagic presentation. Thirty four eyes underwent treatment which included thermal laser (n = 11), photodynamic therapy (PDT) (n = 11) and transpupillary thermo therapy (TTT) (n = 12). Statistical analysis was done using the Chi-square test. Subgroup analysis of visual outcome following various modalities of treatment showed that the results of PDT (P < 0.001) and thermal laser (P < 0.001) were statistically significant. Conclusions: PCV is an important differential diagnosis in patients presenting with serosanginous maculopathy and submacular hemorrhage. The disease was more prevalent in males and was unilateral in the Indian population. Timely intervention in cases with symptomatic polyps could achieve stabilization of visual acuity. Thermal laser and PDT were safe and effective.
C1 [Anantharaman, Giridhar; Ramkumar, Gudapati; Gopalakrishnan, Mahesh; Rajput, Alpesh] Giridhar Eye Inst, Dept Vitreoretinal Serv, Cochin 682020, Kerala, India.
RP Anantharaman, G (通讯作者)，Giridhar Eye Inst, Dept Vitreoretinal Serv, Ponneth Temple Rd, Cochin 682020, Kerala, India.
EM girieye@vsnl.com
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EUR J OPHTHALMOL, V14, P264, DOI 10.1177/112067210401400313
   Lai TYY, 2004, AM J OPHTHALMOL, V138, P693, DOI 10.1016/j.ajo.2004.06.007
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Rishi P, 2009, INDIAN J OPHTHALMOL, V57, P160, DOI 10.4103/0301-4738.45514
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 15
Z9 18
U1 0
U2 3
PU ALL INDIA OPHTHALMOLOGICAL SOC
PI HYDERABAD
PA C/O L V PRASAD EYE INST, L V PRASAD MARG, BANJARA HILLS, HYDERABAD,
   ANDHRA PRADESH 00000, INDIA
SN 0301-4738
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP-OCT
PY 2010
VL 58
IS 5
BP 399
EP 405
DI 10.4103/0301-4738.67052
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646YG
UT WOS:000281581000008
PM 20689195
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maruko, I
   Iida, T
   Oyamada, H
   Sugano, Y
   Ojima, A
   Sekiryu, T
AF Maruko, Ichiro
   Iida, Tomohiro
   Oyamada, Hiroshi
   Sugano, Yukinori
   Ojima, Akira
   Sekiryu, Tetsuju
TI Choroidal Thickness Changes After Intravitreal Ranibizumab and
   Photodynamic Therapy in Recurrent Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VERTEPORFIN; BEVACIZUMAB; ANGIOGRAPHY; EFFICACY
AB PURPOSE: To evaluate subfoveal choroidal thickness changes in cases with recurrent polypoidal choroidal vasculopathy (PCV) after combination therapy with intravitreal ranibizumab and photodynamic therapy (PDT).
   DESIGN: Retrospective observational case series study.
   METHODS: We measured subfoveal choroidal thickness in PCV using optical coherence tomography (OCT) before and after PDT. In recurrent cases, the choroidal thickness was measured at the time of the recurrence. In nonrecurrent cases, choroidal thickness was measured 1 year after PDT.
   RESULTS: Combination therapy was performed in 27 eyes (27 patients). Polypoidal lesions regressed within 3 months after initial treatment in all eyes. Retreatment was needed in 10 of 27 eyes (37.0%) after more than 3 months of follow-up. In recurrent cases, subfoveal choroid decreased from 188 pm at baseline to 157 gm 3 months after PDT (P < .01); however, choroidal thickness increased to 179 mu m with recurrence (P = .54 compared to baseline; average, 8.0 months). In nonrecurrent cases, subfoveal choroid decreased from 257 gm at baseline to 210 mu m 3 months after PDT and 212 mu m 1 year after PDT (P < .01, respectively).
   CONCLUSION: Subfoveal choroidal thickness in PCV at the time of recurrence returned to the baseline level after choroidal thinning as a result of PDT treatment. Choroidal thickness changes after PDT examined using OCT may reflect disease activity in PCV. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Maruko, Ichiro; Iida, Tomohiro; Oyamada, Hiroshi; Sugano, Yukinori; Ojima, Akira; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University
RP Maruko, I (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima, Japan.
EM imaruko@fmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022
OI Maruko, Ichiro/0000-0001-5647-6372; Sekiryu, Tetsuju/0000-0001-8042-2729
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Verteporfin Roundtable 2000 and 2001 Participants Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators Verteporfin in photodynamic therapy (VIP) study group principal investigators, 2002, RETINA, V22, P6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 35
TC 42
Z9 44
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2013
VL 156
IS 3
BP 548
EP 556
DI 10.1016/j.ajo.2013.03.041
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214RM
UT WOS:000324153500017
PM 23810474
DA 2022-11-30
ER

PT J
AU Moeremans, K
   Thomas, VS
   Annemans, L
AF Moeremans, K.
   Thomas, Vince S.
   Annemans, L.
TI A model to evaluate the cost-effectiveness of ranibizumab
SO EJHP PRACTICE
LA English
DT Article
ID MACULAR DEGENERATION
AB Ranibizumab is an important development in the treatment of age-related macular degeneration (AMD) but does ranibizumab also represent "value for money?" To answer this question an economic analysis was performed which simulated the clinical evolution and costs incurred by a population with AMD.
C1 [Thomas, Vince S.] Novartis Pharma AG, CH-4056 Basel, Switzerland.
C3 Novartis
RP Thomas, VS (通讯作者)，Novartis Pharma AG, CH-4056 Basel, Switzerland.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CZOSKIMURRAY C, VALUING CONDIT UNPUB
   NEUBAUER AS, 2007, WAS DARF LEBENSQUALI
   NICE, 2008, PEG RAN TREATM AG RE
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   WALTER E, PHARMAKOOKONOMISCHE
NR 6
TC 0
Z9 0
U1 1
U2 6
PU PHARMA PUBLISHING & MEDIA EUROPE-PPM EUROPE
PI MOL
PA POSTBUS 10001, MOL, B-2400, BELGIUM
SN 1781-9989
EI 2030-3769
J9 EJHP PRACT
JI EJHP Pract.
PY 2008
VL 14
IS 6
BP 25
EP +
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 394CU
UT WOS:000262424000017
DA 2022-11-30
ER

PT J
AU Clark, AF
AF Clark, Abbot F.
TI Preclinical efficacy of anecortave acetate
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; anecortave acetate; choroidal
   neovascularization; efficacy; preclinical
ID OXYGEN-INDUCED RETINOPATHY; CHOROIDAL NEOVASCULARIZATION; CORNEAL
   NEOVASCULARIZATION; ANGIOSTATIC STEROIDS; INHIBITS ANGIOGENESIS; MACULAR
   DEGENERATION; CHICK-EMBRYO; TUMOR-GROWTH; MODEL; RAT
AB Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based antiangiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.
C1 Alcon Res Ltd, Discovery Res, Ft Worth, TX 76134 USA.
C3 Novartis; Alcon
RP Clark, AF (通讯作者)，Alcon Res Ltd, Discovery Res, R2-41,6201 S Freeway, Ft Worth, TX 76134 USA.
CR BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Ciulla Thomas A, 2004, Curr Opin Ophthalmol, V15, P211, DOI 10.1097/01.icu.0000120711.35941.76
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS26, DOI 10.1016/j.survophthal.2006.11.003
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   Dahlin DC, 2007, SURV OPHTHALMOL, V52, pS49, DOI 10.1016/j.survophthal.2006.11.002
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   DEFALLER JM, 2000, PTERYGIUM, P159
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Folkman J, 2003, CANCER BIOL THER, V2, pS127
   Folkman J, 2004, CANCER BIOL THER, V3, P338, DOI 10.4161/cbt.3.3.708
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   HAYNES WL, 1989, INVEST OPHTH VIS SCI, V30, P1588
   Heaton J, 2007, SURV OPHTHALMOL, V52, pS35, DOI 10.1016/j.survophthal.2006.11.006
   Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   LI WW, 1991, INVEST OPHTH VIS SCI, V32, P2898
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MCNATT LG, 1992, J STEROID BIOCHEM, V42, P687, DOI 10.1016/0960-0760(92)90109-V
   Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0
   Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899
   PENN JS, 1994, PEDIATR RES, V36, P724, DOI 10.1203/00006450-199412000-00007
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   PHELPS DL, 1979, ARCH OPHTHALMOL-CHIC, V97, P1522, DOI 10.1001/archopht.1979.01020020184021
   PROIA AD, 1993, EXP EYE RES, V57, P693, DOI 10.1006/exer.1993.1177
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
NR 37
TC 5
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN
PY 2007
VL 52
SU 1
BP S41
EP S48
DI 10.1016/j.survophthal.2006.11.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 135KZ
UT WOS:000244153800006
PM 17240256
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Sugiyama, A
   Tanabe, N
   Yoneyama, S
   Iijima, H
AF Kikushima, Wataru
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Yoneyama, Seigo
   Iijima, Hiroyuki
TI Retreatment of polypoidal choroidal vasculopathy after photodynamic
   therapy combined with intravitreal ranibizumab
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retreatment; Polypoidal choroidal vasculopathy; Photodynamic therapy;
   Ranibizumab; Retreatment-free period
ID MACULAR DEGENERATION; INJECTIONS; AFLIBERCEPT
AB To investigate the incidence, risk factors and effect on visual improvement of retreatment within 60 months after initial photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) in eyes with treatment-na < ve polypoidal choroidal vasculopathy (PCV).
   We retrospectively reviewed the medical records of 61 eyes from 60 patients with PCV, who were followed up for at least 12 months after undergoing combination therapy. Retreatment, including combination therapy or IVR alone, was administered if residual or recurrent exudative changes were present.
   During the follow-up period (mean 44 +/- 13 months, median 48 months), 46 eyes (75.4 %) underwent retreatment. Survival analysis revealed that the proportions of eyes that were retreatment-free were 59 % at the 12-month visit, 41 % at the 24 month, 31 % at the 36 month, and 20 % at the 60-month visit. The median retreatment-free period was 15.0 [95 % confidence interval (CI) 7.4-22.7] months, and the mean period was 24.9 (95 % CI 19.3-30.6) months. Cox regression analysis revealed that older age (P = 0.010, hazard ratio 1.06, CI 1.02-1.11) and male gender (P = 0.043, hazard ratio 2.41, CI 1.03-5.62) were associated with retreatment. Visual improvement was significantly better in eyes without retreatment compared with those with retreatment at the 12-, 24- and 48-month visits.
   About 80 % of eyes with PCV require retreatment within 5 years after combination therapy with PDT and IVR. Retreatment is associated with older age and male gender and is related to reduced improvement of visual acuity.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Sugiyama, Atsushi; Tanabe, Naohiko; Yoneyama, Seigo; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 20
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2017
VL 61
IS 1
BP 61
EP 66
DI 10.1007/s10384-016-0479-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH7BZ
UT WOS:000391929100005
PM 27663239
DA 2022-11-30
ER

PT J
AU Ooto, S
   Tsujikawa, A
   Mori, S
   Tamura, H
   Yamashiro, K
   Yoshimura, N
AF Ooto, Sotaro
   Tsujikawa, Akitaka
   Mori, Satoshi
   Tamura, Hiroshi
   Yamashiro, Kenji
   Yoshimura, Nagahisa
TI Thickness of photoreceptor layers in polypoidal choroidal vasculopathy
   and central serous chorioretinopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; Optical coherence tomography;
   Polypoidal choroidal vasculopathy; Photoreceptor inner segment;
   Photoreceptor outer segment
ID OPTICAL COHERENCE TOMOGRAPHY; EYES; FLUORESCEIN; ANGIOGRAPHY; FEATURES;
   LESIONS
AB To evaluate retinal thickness using spectral-domain optical coherence tomography (SD-OCT) with reduced speckle noise in eyes with polypoidal choroidal vasculopathy (PCV) compared to those with normal eyes and those with central serous chorioretinopathy (CSC).
   We retrospectively reviewed cases of foveal serous retinal detachment in 36 eyes of 36 patients with active CSC and 23 eyes of 23 patients with active PCV, and 44 eyes of 44 normal subjects. Patients were examined using SD-OCT with reduced speckle noise, and the thickness of the outer nuclear layer (ONL), photoreceptor inner segment (IS), and photoreceptor outer segment (OS) were measured.
   The ONL and IS were thicker in normal eyes than in eyes with CSC or PCV (P < 0.001). The OS was significantly less thick in eyes with PCV than in normal eyes (P < 0.001), whereas there was no significant difference between eyes with CSC and normal eyes. The thickness of IS and OS in eyes with PCV was related to fibrin or hemorrhage being present in the subretinal space. In eyes with PCV, best-corrected visual acuity at baseline correlated with IS thickness (P = 0.023).
   Thinning of each photoreceptor layer was observed in the eyes of PCV patients as compared to that observed in the case of normal individuals. The differentiating factors between PCV and CSC, observed using SD-OCT, include the thinning of the OS in eyes with PCV, which makes SD-OCT helpful in differentiating PCV from CSC. More severe photoreceptor alterations were seen in PCV, because fibrin and hemorrhage were present in the subretinal space, which correlated with poorer vision.
C1 [Ooto, Sotaro; Tsujikawa, Akitaka; Mori, Satoshi; Tamura, Hiroshi; Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS) [21796179]
FX This research was supported in part by a Grant-in-Aid for Scientific
   Research (21796179) from the Japan Society for the Promotion of Science
   (JSPS).
CR Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Iida T, 2000, AM J OPHTHALMOL, V129, P16, DOI 10.1016/S0002-9394(99)00272-X
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kon Y, 2008, RETINA-J RET VIT DIS, V28, P864, DOI 10.1097/IAE.0b013e3181669795
   LEVINE R, 1989, OPHTHALMOLOGY, V96, P854
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Matsumoto H, 2008, AM J OPHTHALMOL, V145, P162, DOI 10.1016/j.ajo.2007.08.024
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ojima Y, 2007, OPHTHALMOLOGY, V114, P2197, DOI 10.1016/j.ophtha.2007.02.015
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ooto S, 2010, INVEST OPHTH VIS SCI, V51, P465, DOI 10.1167/iovs.09-4047
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SCHEIDER A, 1993, AM J OPHTHALMOL, V115, P50, DOI 10.1016/S0002-9394(14)73524-X
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   YAMADA E, 1969, ARCH OPHTHALMOL-CHIC, V82, P151
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 33
TC 21
Z9 21
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2010
VL 248
IS 8
BP 1077
EP 1086
DI 10.1007/s00417-010-1338-5
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622RO
UT WOS:000279683300004
PM 20229103
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Dat, DT
   Hien, NDTN
   Quan, NN
   Tung, MQ
   Tam, HC
   Hung, BV
AF Dat, Dang Tran
   Hien, Nguyen Do Thi Ngoc
   Quan, Nguyen Nhu
   Tung, Mai Quoc
   Tam, Hoang Chi
   Hung, Bui Viet
TI Current Trends in Clinical Characteristics, Diagnosis, and Treatment of
   Polypoidal Choroidal Vasculopathy: A Perspective from Vietnam
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE polypoidal choroidal vasculopathy; Vietnam; anti-VEGF; neovascular
   age-related macular degeneration; laser therapy
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; LASER PHOTOCOAGULATION;
   RANIBIZUMAB; AFLIBERCEPT; EFFICACY; FEATURES; PATHOGENESIS
AB Polypoidal choroidal vasculopathy (PCV) is a common choroidal disease in the Asian population including Vietnam and is characterized by subretinal red-orange nodules, pigmented epithelium detachment, and massive subretinal hemorrhage. The recent focus on PCV in Vietnam can be attributed to advancements in PCV diagnosis and treatment. However, there is a scarcity of published literature and clinical data on PCV in the Vietnamese population, highlighting a key knowledge gap in this region. In order to address this gap, we gathered the opinions of experienced clinicians and retinal experts in Vietnam and reviewed available medical literature with the aim of: (i) providing an overview of PCV in the Vietnamese population-in terms of epidemiology, clinical characteristics, and management; (ii) tailoring international/national guidelines for the diagnosis and management of PCV, in line with available resources and medical equipment in Vietnam; and (iii) identifying gaps in clinical data in order to guide future PCV research in Vietnam and other countries with similar clinical conditions. The present review will enable healthcare providers and researchers to gain insight into current clinical practices and the limitations of PCV management in Vietnam and provide optimal and effective solutions.
C1 [Dat, Dang Tran] Vietnam Natl Eye Hosp, Outpatient Dept, 85 Ba Trieu, Hanoi 100000, Vietnam.
   [Hien, Nguyen Do Thi Ngoc; Tung, Mai Quoc] Hanoi Med Univ, Dept Ophthalmol, 1 Ton Tung St, Hanoi 100000, Vietnam.
   [Quan, Nguyen Nhu] Phuong Dong Int Eye Ctr, 71 Ngo Thoi Nhiem St,Dist 3, Ho Chi Minh City 700000, Vietnam.
   [Tam, Hoang Chi] FV Hosp, Ophthalmol & Refract Surg Dept, 6 Nguyen Luong Bang St,Dist 7, Ho Chi Minh City 700000, Vietnam.
   [Hung, Bui Viet] Vietnam Natl Eye Hosp, Vitreoretial Dept, 85 Ba Trieu, Hanoi 100000, Vietnam.
C3 Hanoi Medical University
RP Dat, DT (通讯作者)，Vietnam Natl Eye Hosp, Outpatient Dept, 85 Ba Trieu, Hanoi 100000, Vietnam.
EM dangtrandat.vnio@gmail.com
FU Bayer Vietnam
FX The medical writing fee and the APC were funded by Bayer Vietnam.
CR Alasil Tarek, 2017, Int J Retina Vitreous, V3, P9, DOI 10.1186/s40942-017-0060-4
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   [Anonymous], GUIDANCE TREATING PH
   Arias JD, 2021, EXPERT REV MED DEVIC, V18, P903, DOI 10.1080/17434440.2021.1963230
   Azar G, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/1637377
   Azuma K, 2016, RETINA-J RET VIT DIS, V36, P2158, DOI 10.1097/IAE.0000000000001047
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chaikitmongkol Voraporn, 2021, Asia Pac J Ophthalmol (Phila), V10, P507, DOI 10.1097/APO.0000000000000445
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen LJ, 2020, ASIA-PAC J OPHTHALMO, V9, P104, DOI 10.1097/01.APO.0000656976.47696.7d
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Chi SC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82316-y
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Choe S, 2021, INT J OPHTHALMOL-CHI, V14, P1402, DOI 10.18240/ijo.2021.09.16
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Chung YR, 2016, CAN J OPHTHALMOL, V51, P348, DOI 10.1016/j.jcjo.2016.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Nguyen CV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260415
   Dang D.T., 2022, SURVEY POLYPOIDAL CH
   Dat D., 2017, THESIS HANOI MED U
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Fenner BJ, 2022, EYE, V36, P257, DOI 10.1038/s41433-021-01688-7
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Fukuda Y, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091164
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hien N., 2021, THESIS HANOI MED U
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Ijuin N, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01443-8
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jordan-Yu JM, 2021, BRIT J OPHTHALMOL, V105, P1716, DOI 10.1136/bjophthalmol-2020-317537
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lau T, 2015, INDIAN J OPHTHALMOL, V63, P378, DOI 10.4103/0301-4738.159860
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Liu L, 2015, MOL VIS, V21, P1130
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Ma IH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99634-w
   Ma ST, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97340-1
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Meiqari L, 2019, ASIA-PAC J PUBLIC HE, V31, P101, DOI 10.1177/1010539518824810
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Mori R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011188
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Permadi AC, 2022, INT J RETINA VITR, V8, DOI 10.1186/s40942-022-00365-5
   Reddy SV, 2018, SEMIN OPHTHALMOL, V33, P83, DOI 10.1080/08820538.2017.1353820
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sen Parveen, 2016, Oman J Ophthalmol, V9, P139
   Serra R, 2021, BRIT J OPHTHALMOL, V105, P1421, DOI 10.1136/bjophthalmol-2020-317011
   Shah V.A., AFLIBERCEPT
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Teo KYC, 2019, ASIA-PAC J OPHTHALMO, V8, P165, DOI 10.22608/APO.201909
   Th Thu Trang N., 2022, VIETNAM MED J, V509, DOI [10.51298/vmj.v509i1.1760, DOI 10.51298/VMJ.V509I1.1760]
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Vietnamese Ministry of Health, DIAGN TREATM SOM COM
   Wang YL, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/6837601
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wu WC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01715-3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zeng RP, 2015, EUR J OPHTHALMOL, V25, P222, DOI 10.5301/ejo.5000532
NR 96
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2022
VL 11
IS 16
AR 4678
DI 10.3390/jcm11164678
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4B0YH
UT WOS:000845514000001
PM 36012915
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Kitamei, H
   Shioya, S
AF Hikichi, Taiichi
   Kitamei, Hirokuni
   Shioya, Shoko
TI Prognostic factors of 2-year outcomes of ranibizumab therapy for
   polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL RANIBIZUMAB; MACULAR
   DEGENERATION; VASCULAR HYPERPERMEABILITY; FUNDUS AUTOFLUORESCENCE;
   PHOTODYNAMIC THERAPY; INJECTIONS; THICKNESS
AB Purpose To determine predictors of 2-year outcomes after three, monthly, intravitreal ranibizumab (IVR) injections followed by as-needed injections for treatment-naive polypoidal choroidal vasculopathy (PCV).
   Methods This trial included 85 Japanese patients with symptomatic treatment-naive PCV who received one 0.5 mg IVR injection monthly for 3 months followed by as-needed retreatments. PCV with subfoveal leakage on fluorescein angiography with or without actual choroidal neovascularisation were included. Analyses evaluated independent baseline predictors of better and improved visual acuity (VA) and need for fewer reinjections 2 years after the first injection.
   Results After the three monthly injections, 1.3 +/- 1.4 and 1.5 +/- 2.0 (mean +/- SD) as-needed injections were administered during years 1 and 2, respectively. The baseline logarithm of the minimum angle of resolution, VA (0.60 +/- 0.49) improved significantly (p= 0.001) (0.41 +/- 0.47) 2 years after the first injection. Younger patients' eyes with a better baseline VA and no cluster of grapelike polypoidal lesions were significant independent predictors of better VA 2 years after treatment. No baseline factors predicted fewer ranibizumab reinjections during 2 years. At 2 years, resolution of polypoidal lesions 1 month after the three monthly injections did not affect VA and number of reinjections during 2 years.
   Conclusions Patient age, baseline VA and clusters of grape-like polypoidal lesions predicted VA outcomes 2 years after treatment with IVR for PCV.
C1 [Hikichi, Taiichi; Kitamei, Hirokuni; Shioya, Shoko] Ohtsuka Eye Hosp, Dept Ophthalmol, Sapporo, Hokkaido 0010016, Japan.
RP Hikichi, T (通讯作者)，Ohtsuka Eye Hosp, Kita Ku, Kita 16 Nishi 4, Sapporo, Hokkaido 0010016, Japan.
EM taiichi-hikichi@hokkaido.med.or.jp
FU Novartis Pharma Japan; Bayer Japan; Santen Pharmaceutical Co.; Ohtsuka
   Pharmaceutical Co.; Senjyu Pharmaceutical Co.
FX TH received lecture fees from Novartis Pharma Japan, Bayer Japan, Santen
   Pharmaceutical Co., Ohtsuka Pharmaceutical Co. and Senjyu Pharmaceutical
   Co. HK received lecture fee from Novartis Pharma Japan. SS received
   lecture fees from Novartis Pharma Japan.
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hikichi T, 2013, RETINA, V33, P1945
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Ijiri S, 2014, GRAEFES ARCH CLIN EX
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lam BL, 2013, INVEST OPHTH VIS SCI, V54, P193, DOI 10.1167/iovs.12-10542
   Lee YH, 2011, RETINA, V31, P1827
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 35
TC 19
Z9 19
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2015
VL 99
IS 6
BP 817
EP 822
DI 10.1136/bjophthalmol-2014-305606
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI7NO
UT WOS:000354950600019
PM 25480464
DA 2022-11-30
ER

PT J
AU Mori, R
   Yuzawa, M
   Lee, Z
   Haruyama, M
   Akaza, E
AF Mori, Ryusaburo
   Yuzawa, Mitsuko
   Lee, Zeon
   Haruyama, Miho
   Akaza, Eriko
TI Factors influencing visual outcome of polypoidal choroidal vasculopathy
   one year after photodynamic therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Photodynamic therapy; Polypoidal choroidal vasculopathy; Visual outcome
ID CHORIORETINAL ANASTOMOSIS; INTRAVITREAL BEVACIZUMAB; MACULAR
   DEGENERATION; VERTEPORFIN
AB Polypoidal choroidal vasculopathy (PCV) is considered to be a good indication for photodynamic therapy (PDT). We evaluated pre-PDT factors predicting better visual acuity (VA) 1 year after PDT in patients with PCV.
   We evaluated 181 eyes of 181 patients who underwent PDT and were followed up for 1 year. Additional treatments, if needed, were given every 3 months, with a maximum of four PDT sessions, for up to 9 months. We compared best-corrected VA (BCVA) 1 year after PDT with that before PDT. Pre-PDT factors favoring better BCVA 1 year after PDT were evaluated using stepwise multiple regression analysis.
   Mean BCVA improved from 0.29 +/- 0.15 before PDT to 0.43 +/- 0.32 1 year after PDT (p < 0.001). BCVA improved in 55 eyes (30.4%), and was maintained in 110 (60.8%). Pre-PDT factors predicting better BCVA at 1 year were better initial BCVA (beta = 0.271, p < 0.001) within our eligibility criteria up to 0.6, a relatively small diameter of a network of vessels plus polypoidal lesions on indocyanine green angiography (beta = 0.249, p < 0.001), and the absence of a polypoidal lesion under the fovea (beta = 0.175, p = 0.011).
   Better BCVA can be expected 1 year after PDT in eyes with PCV showing better initial BCVA, relatively small lesions on indocyanine green angiography, and no subfoveal polypoidal lesion before PDT.
C1 [Mori, Ryusaburo; Yuzawa, Mitsuko; Lee, Zeon; Haruyama, Miho; Akaza, Eriko] Nihon Univ, Surugadai Nihon Univ Hosp, Sch Med, Dept Ophthalmol,Chiyoda Ku, Tokyo 1018309, Japan.
C3 Nihon University
RP Yuzawa, M (通讯作者)，Nihon Univ, Surugadai Nihon Univ Hosp, Sch Med, Dept Ophthalmol,Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM yuzawam@med.nihon-u.ac.jp
FU Research Committee on Chorioretinal Degenerations and Optic Atrophy, The
   Ministry of Health and Welfare of Japan
FX This study was funded in part by the Research Committee on Chorioretinal
   Degenerations and Optic Atrophy, The Ministry of Health and Welfare of
   Japan (Mitsuko Yuzawa).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Prakash M, 2006, AM J OPHTHALMOL, V142, P1079, DOI 10.1016/j.ajo.2006.06.059
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Silva RM, 2007, GRAEF ARCH CLIN EXP, V245, P1131, DOI 10.1007/s00417-006-0532-y
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yodoi Yuko, 2008, International Ophthalmology, V28, P297, DOI 10.1007/s10792-007-9129-7
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 26
TC 20
Z9 25
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2010
VL 248
IS 9
BP 1233
EP 1239
DI 10.1007/s00417-010-1365-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 632AD
UT WOS:000280391200004
PM 20352440
DA 2022-11-30
ER

PT J
AU Storch, MW
   Hoerauf, H
AF Storch, Marcus Werner
   Hoerauf, Hans
TI Case report of a secondary macular hole closure after intravitreal
   bevacizumab therapy in a patient with retinal pigment epithelial
   detachment
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; bevacizumab; intravitreal antivascular
   endothelial growth factor therapy; macular hole; pigment epithelial
   detachment
ID DRUSEN
AB We describe a case of macular hole (MH) closure after intravitreal bevacizumab therapy for an underlying pigment epithelial detachment (PED) due to exudative age-related macular degeneration (AMD). The 73-year-old Caucasian female presented with reduced visual acuity (20/80) of the left eye and metamorphopsia for approximately 6 months. Spectral domain optical coherence tomography revealed a subfoveal PED due to AMD with an associated MH. To treat the exudative component of the pathology, we started intravitreal bevacizumab therapy, consecutively leading to reduction of the height of PED and allowing closure of the MH. Detachment recurred during further follow-up, but the MH remained closed. MHs and exudative AMD are common diseases, which rarely occur simultaneously. To the best of our knowledge (search via PubMed for "MH," " PED," " age-related macular degeneration"), no other case with the persistent closure of an MH associated with PED during intravitreal antivascular endothelial growth factor therapy and despite recurrent PED has been published to date.
C1 [Storch, Marcus Werner; Hoerauf, Hans] Univ Gottingen, Dept Ophthalmol, Robert Koch St 40, D-37075 Gottingen, Germany.
C3 University of Gottingen
RP Storch, MW (通讯作者)，Univ Gottingen, Dept Ophthalmol, Robert Koch St 40, D-37075 Gottingen, Germany.
EM marcus.storch@med.uni-goettingen.de
RI Storch, Marcus/AAN-5184-2021
OI Storch, Marcus/0000-0001-7503-3913
CR Berinstein DM, 2000, OPHTHALMOLOGY, V107, P2233, DOI 10.1016/S0161-6420(00)00417-6
   Bruggemann A, 2008, KLIN MONATSBL AUGENH, V225, P281, DOI 10.1055/s-2008-1027234
   Cazabon Sunildath, 2010, International Ophthalmology, V30, P739, DOI 10.1007/s10792-010-9376-x
   Chaudhry NA, 2000, ARCH OPHTHALMOL-CHIC, V118, P131
   Chew EY, 1999, ARCH OPHTHALMOL-CHIC, V117, P242, DOI 10.1001/archopht.117.2.242
   Clemens CR, 2010, J OCUL PHARMACOL TH, V26, P297, DOI 10.1089/jop.2009.0140
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Johnson Mark W, 2012, Retina, V32 Suppl 2, pS174, DOI 10.1097/IAE.0b013e31825bef62
   Oshima Y, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0021-3
   Raiji Veena R, 2013, Retin Cases Brief Rep, V7, P91, DOI 10.1097/ICB.0b013e31826f090d
NR 10
TC 5
Z9 5
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2017
VL 65
IS 7
BP 632
EP 633
DI 10.4103/ijo.IJO_818_16
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB8KJ
UT WOS:000406387600023
PM 28724829
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Williamson, JF
   McLure, CA
   Baird, PN
   Mate, D
   Millman, J
   Lawley, B
   Ashdown, ML
   Keating, PJ
   Dawkins, RL
AF Williamson, Joseph F.
   McLure, Craig A.
   Baird, Paul N.
   Mate, Dean
   Millman, John
   Lawley, Blair
   Ashdown, M. Luisa
   Keating, Peter J.
   Dawkins, Roger L.
TI Novel sequence elements define ancestral haplotypes of the region
   encompassing complement factor H
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE haplospecific markers; ancestral haplotypes; CFH
ID MAJOR HISTOCOMPATIBILITY COMPLEX; ACTIVATION GENE-CLUSTER; MACULAR
   DEGENERATION; JAPANESE POPULATION; CLASS-I; C4-BINDING PROTEIN; HUMAN
   REGULATOR; NO ASSOCIATION; Y402H VARIANT; MHC
AB The genomic region encompassing complement factor H (CFH) is thought to be important in determining susceptibility to inflammatory diseases such as age-related macular degeneration, but only limited polymorphism has been described. After applying the genomic matching technique to three-generation families and an ethnically diverse reference panel we have demonstrated that the polymorphism resembles that found in the major histocompatibitity complex. The different ancestral haplotypes carry either T or C at T1277C but also other more polymorphic alleles over a region of 2 Mb. Thus the association between age-related macular degeneration and T1277 or Y402 actually reflects multiple linked polymorphisms including an indel that cannot be dissected from any direct effect of Y402 and may be more important. We show for the first time that simple algorithms can identify genomic sequence elements that appear to be more useful haplospecific markers than single nucleotide polymorphism or microsatellites. (c) 2008 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Williamson, Joseph F.; McLure, Craig A.; Millman, John; Keating, Peter J.; Dawkins, Roger L.] CYO Connor ERADE Village Fdn, Canning Vale, WA, Australia.
   [Williamson, Joseph F.; McLure, Craig A.; Keating, Peter J.; Dawkins, Roger L.] Murdoch Univ, Div Hlth Sci, Murdoch, WA 6150, Australia.
   [Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Parkville, Vic 3052, Australia.
   [Williamson, Joseph F.; McLure, Craig A.; Keating, Peter J.; Dawkins, Roger L.] Univ Adelaide, Australian Ctr Ancient DNA, Adelaide, SA 5005, Australia.
   [Lawley, Blair; Ashdown, M. Luisa] Genet Technol Ltd, Fitzroy, Vic, Australia.
   [Dawkins, Roger L.] Univ Western Australia, Fac Med & Dent, Nedlands, WA 6009, Australia.
C3 Murdoch University; Centre for Eye Research Australia; University of
   Melbourne; University of Adelaide; University of Western Australia
RP Dawkins, RL (通讯作者)，CYO Connor ERADE Village Fdn, Canning Vale, WA, Australia.
EM dawkins@cyllene.uwa.edu.au
OI Baird, Paul/0000-0002-1305-3502
CR ABRAHAM LJ, 1992, TISSUE ANTIGENS, V39, P117, DOI 10.1111/j.1399-0039.1992.tb01920.x
   Alper CA, 2006, HUM IMMUNOL, V67, P73, DOI 10.1016/j.humimm.2005.11.006
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   CAMPBELL RD, 1988, BAILLIERE CLIN RHEUM, V2, P547
   CARROLL MC, 1988, J EXP MED, V167, P1271, DOI 10.1084/jem.167.4.1271
   Cattley SK, 2000, EUR J IMMUNOGENET, V27, P397, DOI 10.1046/j.1365-2370.2000.00226.x
   Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   DECORDOBA SR, 1987, IMMUNOGENETICS, V25, P267, DOI 10.1007/BF00404698
   DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V35, P355
   DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V36, P345
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gaudieri S, 1997, DNA SEQUENCE, V8, P137, DOI 10.3109/10425179709034063
   Gaudieri S, 2001, HUM IMMUNOL, V62, P279, DOI 10.1016/S0198-8859(01)00210-5
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   GROSSEWILDE H, 1997, 12 INT HIST WORKSH C, V2, P589
   Guigonis V, 2005, AM J KIDNEY DIS, V45, P588, DOI 10.1053/j.ajkd.2004.12.004
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HeineSuner D, 1997, IMMUNOGENETICS, V45, P422, DOI 10.1007/s002510050224
   HOURCADE D, 1990, J BIOL CHEM, V265, P974
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   LEELAYUWAT C, 1994, IMMUNOGENETICS, V40, P339, DOI 10.1007/BF01246675
   LEELAYUWAT C, 1991, HLA 1991, V2, P172
   LESTER S, IN PRESS ANN RHEM
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   MARTINEZ OP, 1994, EUR J IMMUNOGENET, V21, P365, DOI 10.1111/j.1744-313X.1994.tb00206.x
   McLure CA, 2005, IMMUNOGENETICS, V57, P805, DOI 10.1007/s00251-005-0049-2
   McLure CA, 2005, INT J IMMUNOGENET, V32, P407, DOI 10.1111/j.1744-313X.2005.00549.x
   Noris M, 2005, J AM SOC NEPHROL, V16, P1177, DOI 10.1681/ASN.2005010086
   Okamoto H, 2006, MOL VIS, V12, P156
   PARDOMANUEL F, 1990, P NATL ACAD SCI USA, V87, P4529, DOI 10.1073/pnas.87.12.4529
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   REYCAMPOS J, 1990, GENOMICS, V7, P644, DOI 10.1016/0888-7543(90)90213-E
   REYCAMPOS J, 1988, J EXP MED, V167, P664, DOI 10.1084/jem.167.2.664
   Romero V, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-14
   Rupprecht TA, 2007, J IMMUNOL, V178, P1861, DOI 10.4049/jimmunol.178.3.1861
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   TAY GK, 1995, BONE MARROW TRANSPL, V15, P381
   Tay GK, 1995, EXP HEMATOL, V23, P1655
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Witt C, 2000, HUM IMMUNOL, V61, P85, DOI 10.1016/S0198-8859(99)00147-0
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 52
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD MAR
PY 2008
VL 69
IS 3
BP 207
EP 219
DI 10.1016/j.humimm.2008.01.016
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 294YW
UT WOS:000255443200010
PM 18396214
DA 2022-11-30
ER

PT J
AU Huang, Z
   Ding, Q
   Yan, M
   Lian, HY
   Chen, ZS
   Chen, X
   Song, YP
AF Huang, Zhen
   Ding, Qin
   Yan, Min
   Lian, Haiyan
   Chen, Zhongshan
   Chen, Xiao
   Song, Yanping
TI SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL
   CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE antibody; angiogenesis inhibitors; Asian continental ancestry group;
   best-corrected visual acuity; central foveal thickness conbercept;
   indocyanine green angiography; intravitreal injections; optical
   coherence tomography; polypoidal choroidal vasculopathy; polypoidal
   lesion; ranibizumab; treatment outcome
ID INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL AFLIBERCEPT; PHOTODYNAMIC THERAPY; VERTEPORFIN; INJECTIONS;
   MONOTHERAPY; THICKNESS; DIAGNOSIS; EVEREST
AB Purpose: To compare the 6-month efficacy of the intravitreal injection of conbercept or ranibizumab for patients with polypoidal choroidal vasculopathy (PCV).
   Methods: This is a retrospective case-control study involved 79 PCV eyes of 77 patients. The PCV eyes were treated with an intravitreal injection of either ranibizumab (n = 44) or conbercept (n = 35). Three monthly loading doses were injected and followed by re-treatment as needed. The best-corrected visual acuity and angiographic characteristics were evaluated after 6 months.
   Results: The mean logarithm of the minimum angle of resolution best-corrected visual acuity had improved from 0.86 (Snellen equivalent, 20/145) at baseline to 0.70 (Snellen ;equivalent, 20/100) at 6 months in the conbercept group (P < 0.001), and from 0.74 (Snellen equivalent, 20/110) at baseline to 0.63 (Snellen equivalent, 20/85) at 6 months in the ranibizumab group (P = 0.032), respectively. The central foveal thickness was decreased from 407 +/- 146 mm to 230 +/- 71 mm in the conbercept group (P, 0.001), and from 394 +/- 93 mm to 208 +/- 56 mm in the ranibizumab group (P, 0.001). Polyps were completely regressed and in 21 (47.7%) eyes in the conbercept group at 6 months, significant higher than in 10 (28.6%) eyes in the ranibizumab group (P = 0.029).
   Conclusion: Both conbercept and ranibizumab effectively increased the visual acuity and regressed the polyps of PCV eyes. No significant difference was found in the visual acuity improvement of the patients with PCV between the conbercept group and ranibizumab group at 6 months. However, conbercept was superior to ranibizumab monotherapy in the regression of polyps.
C1 [Huang, Zhen; Ding, Qin; Yan, Min; Lian, Haiyan; Chen, Zhongshan; Chen, Xiao; Song, Yanping] Wuhan Gen Hosp Peoples Liberat Army, Dept Ophthalmol, 627,Wuluo Rd, Wuhan 430070, Hubei, Peoples R China.
RP Song, YP (通讯作者)，Wuhan Gen Hosp Peoples Liberat Army, Dept Ophthalmol, 627,Wuluo Rd, Wuhan 430070, Hubei, Peoples R China.
EM songyanping@medmail.com.cn
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Jacobs I, 2016, BIODRUGS, V30, P489, DOI 10.1007/s40259-016-0199-9
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 39
TC 11
Z9 13
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2019
VL 39
IS 5
BP 889
EP 895
DI 10.1097/IAE.0000000000002035
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4VP
UT WOS:000480749600020
PM 29360683
DA 2022-11-30
ER

PT J
AU Lee, K
   Park, JH
   Park, YG
   Park, YH
AF Lee, Kook
   Park, Jin-Heung
   Park, Young Gun
   Park, Young-Hoon
TI Analysis of choroidal thickness and vascularity in patients with
   unilateral polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Choroidal vascularity index; Dilated Haller vessel;
   Pachychoroid; Polypoidal choroidal vasculopathy
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; HEALTHY EYES; FEATURES
AB Purpose This study aimed to analyze the choroidal characteristics in eyes with polypoidal choroidal vasculopathy (PCV, affected eyes) and unaffected fellow eyes, and investigated the longitudinal changes in the choroidal structure of fellow eyes in patients with unilateral PCV. Methods We retrospectively reviewed the medical records of 55 treatment-naive patients with unilateral PCV. The choroidal thickness and vascularity between PCV affected eyes, unaffected fellow eyes, and normal control eyes were compared. Structural changes in the choroid of the fellow eyes were reviewed during follow-up. Results PCV eyes had thicker subfoveal choroidal thickness (SFCT) (p < 0.001), greater ratio of Haller layer to SFCT (p < 0.001), and lower choroidal vascularity index (p = 0.023), compared to controls. In unaffected fellow eyes, the ratio of the Haller layer to SFCT was greater (p < 0.001) than in controls. During a 58.91-month mean follow-up, nine (16%) fellow eyes developed new PCV. These eyes showed a greater ratio of Haller layer to SFCT at baseline (p < 0.001) compared to the other fellow eyes. We also observed a numerical change in the choroidal vascularity index during follow-up of fellow eyes that developed new PCV. Conclusion The dilation of the Haller layer was prominent in PCV eyes and fellow eyes, compared to normal controls. In the fellow eyes that developed new PCV lesions, there were changes in the choroidal vascularity during follow-up.
C1 [Lee, Kook; Park, Jin-Heung; Park, Young Gun; Park, Young-Hoon] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul, South Korea.
   [Park, Young-Hoon] Catholic Univ Korea, Catholic Inst Visual Sci, Coll Med, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea
RP Park, YH (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul, South Korea.; Park, YH (通讯作者)，Catholic Univ Korea, Catholic Inst Visual Sci, Coll Med, Seoul, South Korea.
EM parkyh@catholic.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) [2016R1A6A1A03010528]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF), funded by theMinistry
   of Education (2016R1A6A1A03010528).
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Baek J, 2019, RETINA-J RET VIT DIS, V39, P1571, DOI 10.1097/IAE.0000000000002188
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147139
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P4811, DOI 10.1167/iovs.14-14447a
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Takahashi Y, 2018, JPN J OPHTHALMOL, V62, P576, DOI 10.1007/s10384-018-0615-4
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 39
TC 14
Z9 15
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2020
VL 258
IS 6
BP 1157
EP 1164
DI 10.1007/s00417-020-04620-z
EA FEB 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LR1UQ
UT WOS:000516033700001
PM 32037487
DA 2022-11-30
ER

PT J
AU Steinmetz, A
   Bernhard, A
   Sahr, S
   Oechtering, G
AF Steinmetz, Andrea
   Bernhard, Andreas
   Sahr, Sabine
   Oechtering, Gerhard
TI Suspected macular degeneration in a captive western lowland gorilla
   (gorilla gorilla gorilla)
SO VETERINARY OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); ape; decreased near vision;
   drusen; eye; Western lowland gorilla
ID AGE-RELATED MACULOPATHY; RHESUS-MONKEYS; ANIMAL-MODEL; DISEASE; DRUSEN
AB The case of a 31-year-old captive female Western lowland gorilla (Gorilla gorilla gorilla) with decreased near vision but good distance vision is presented. Examination of the fundus revealed drusen-like bodies in the macula presumably because of an age-related macular degeneration (AMD).
C1 [Steinmetz, Andrea; Sahr, Sabine; Oechtering, Gerhard] Univ Leipzig, Dept Small Anim Med, D-04103 Leipzig, Germany.
   [Bernhard, Andreas] Zoo Leipzig, D-04105 Leipzig, Germany.
C3 Leipzig University
RP Steinmetz, A (通讯作者)，Univ Leipzig, Dept Small Anim Med, Tierkliniken 23, D-04103 Leipzig, Germany.
EM steinmetz@kleintierklinik.uni-leipzig.de
CR BELLHORN RW, 1981, INVEST OPHTH VIS SCI, V21, P771
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Dawson WW, 2008, VISION RES, V48, P360, DOI 10.1016/j.visres.2007.08.006
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   FINE BS, 1978, INVEST OPHTH VIS SCI, V17, P1059
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Grehn F, 2008, AUGENHEILKUNDE
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Knapp S, 2007, VET OPHTHALMOL, V10, P357, DOI 10.1111/j.1463-5224.2007.00568.x
   Liang D, 2005, J ZOO WILDLIFE MED, V36, P430, DOI 10.1638/03-121.1
   Liu G, 2011, MOL VIS, V17, P1405
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Morris MS, 2007, OPHTHAL EPIDEMIOL, V14, P288, DOI 10.1080/09286580601186759
   Nowak RM, 1991, WALKERS MAMMALS WORL
   Plesker R, 2005, P INT C DIS ZOO WILD, V42, P148
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Zhao L, 2008, AM J HEALTH-SYST PH, V65, P1232, DOI 10.2146/ahjp080052
NR 19
TC 3
Z9 3
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1463-5216
J9 VET OPHTHALMOL
JI Vet. Ophthalmol.
PD SEP
PY 2012
VL 15
SU 2
SI SI
BP 139
EP 141
DI 10.1111/j.1463-5224.2011.00953.x
PG 3
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 000OR
UT WOS:000308396600019
PM 22702721
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Yamagishi, T
   Yamazaki, T
   Kinoshita, S
AF Koizumi, Hideki
   Yamagishi, Tetsuya
   Yamazaki, Taizo
   Kinoshita, Shigeru
TI Predictive factors of resolved retinal fluid after intravitreal
   ranibizumab for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION;
   VERTEPORFIN; BEVACIZUMAB; NEOVASCULARIZATION; INJECTION; EFFICACY
AB Background/aims To investigate the predictive factors for the resolution of retinal fluid after intravitreal injections of ranibizumab (IVRs) for polypoidal choroidal vasculopathy (PCV).
   Methods Forty-seven eyes of 45 patients with symptomatic PCV received 0.5 mg of IVR monthly for 3 months. One month after the third IVR, the presence of dry macula, defined as absence of retinal fluid as detected by the use of optical coherence tomography, was retrospectively evaluated and correlated with clinical characteristics at baseline. Most of the eyes were followed for over 6 months.
   Results Of the 47 eyes, 31 eyes (66%) achieved the dry macula along with increased best-corrected visual acuity (BCVA) (0.64 to 0.46 logarithm of the minimum angle of resolution units, p<0.0001), while the other 16 eyes without dry macula showed no significant change of BCVA. Univariate analyses of the baseline characteristics identified the smaller size of the largest polyp (p=0.0008) and the absence of serous or haemorrhagic pigment epithelial detachment (p=0.045) as predictive factors for the dry macula. Multivariate logistic regression found the independent predictor for the dry macula to be the smaller size of the largest polyp (p=0.001). No severe systemic or ocular adverse events were observed.
   Conclusions IVR may be helpful for resolution of retinal fluid and increased BCVA in the short term, but larger polyps and pigment epithelial detachments at baseline may be negative prognostic factors for a therapeutic response. Further studies are needed to clarify the long-term efficacy of IVR for PCV.
C1 [Koizumi, Hideki] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan.
C3 Kyoto Prefectural University of Medicine
RP Koizumi, H (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM hidekoiz@koto.kpu-m.ac.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 35
TC 34
Z9 37
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2011
VL 95
IS 11
BP 1555
EP 1559
DI 10.1136/bjophthalmol-2011-300285
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 837VK
UT WOS:000296233900017
PM 21890787
DA 2022-11-30
ER

PT J
AU Fronk, AH
   Vargis, E
AF Fronk, Aaron H.
   Vargis, Elizabeth
TI Methods for culturing retinal pigment epithelial cells: a review of
   current protocols and future recommendations
SO JOURNAL OF TISSUE ENGINEERING
LA English
DT Review
DE Retinal pigment epithelium; in vitro; tissue culture; cell culture;
   age-related macular degeneration
ID STEM-CELL; MACULAR DEGENERATION; OXIDATIVE STRESS; GENE-EXPRESSION;
   CHOROIDAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; PHOTOOXIDATIVE
   DAMAGE; GEOGRAPHIC ATROPHY; COMBINED HAMARTOMA; TISSUE-CULTURE
AB The retinal pigment epithelium is an important part of the vertebrate eye, particularly in studying the causes and possible treatment of age-related macular degeneration. The retinal pigment epithelium is difficult to access in vivo due to its location at the back of the eye, making experimentation with age-related macular degeneration treatments problematic. An alternative to in vivo experimentation is cultivating the retinal pigment epithelium in vitro, a practice that has been going on since the 1970s, providing a wide range of retinal pigment epithelial culture protocols, each producing cells and tissue of varying degrees of similarity to natural retinal pigment epithelium. The purpose of this review is to provide researchers with a ready list of retinal pigment epithelial protocols, their effects on cultured tissue, and their specific possible applications. Protocols using human and animal retinal pigment epithelium cells, derived from tissue or cell lines, are discussed, and recommendations for future researchers included.
C1 [Fronk, Aaron H.; Vargis, Elizabeth] Utah State Univ, Dept Biol Engn, Logan, UT 84322 USA.
C3 Utah System of Higher Education; Utah State University
RP Vargis, E (通讯作者)，Utah State Univ, Dept Biol Engn, Logan, UT 84322 USA.
EM vargis@usu.edu
FU Career Starter Grant from the Knights Templar Eye Foundation; Ralph E.
   Powe Junior Faculty Award from the Oak Ridge Associated Universities
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   authors received financial support from a Career Starter Grant from the
   Knights Templar Eye Foundation and a Ralph E. Powe Junior Faculty Award
   from the Oak Ridge Associated Universities.
CR Abu Khamidakh AE, 2013, EXP EYE RES, V108, P129, DOI 10.1016/j.exer.2013.01.009
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Akrami Hassan, 2009, J Ophthalmic Vis Res, V4, P134
   Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Amemiya K, 2004, BIOCHEM BIOPH RES CO, V316, P1, DOI 10.1016/j.bbrc.2004.01.172
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnouk H, 2011, J PROTEOMICS, V74, P254, DOI 10.1016/j.jprot.2010.11.004
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   Baek DSH, 2015, J PHARMACOL TOX MET, V71, P77, DOI 10.1016/j.vascn.2014.09.002
   Baetz NW, 2012, INVEST OPHTH VIS SCI, V53, P2127, DOI 10.1167/iovs.11-8471
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Blenkinsop T. A, 2012, METHOD MOL BIOL, VLXIII, P45
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Cao SJ, 2013, MOL VIS, V19, P718
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Carr AJ, 2011, MOL VIS, V17, P1701
   Catalioto RM, 2015, BIOCHEM PHARMACOL, V97, P189, DOI 10.1016/j.bcp.2015.07.034
   Chang KC, 2015, CHEM-BIOL INTERACT, V234, P254, DOI 10.1016/j.cbi.2014.10.007
   Chen YH, 2012, J PROTEOMICS, V77, P111, DOI 10.1016/j.jprot.2012.07.014
   Cheng LB, 2014, INT J MOL SCI, V15, P18762, DOI 10.3390/ijms151018762
   Cheng LB, 2014, BIOCHEM BIOPH RES CO, V443, P447, DOI 10.1016/j.bbrc.2013.11.113
   Cheng ZY, 2013, NEUROSCI LETT, V539, P43, DOI 10.1016/j.neulet.2013.01.038
   Chiba C, 2014, EXP EYE RES, V123, P107, DOI 10.1016/j.exer.2013.07.009
   Cottet S, 2013, MOL VIS, V19, P2312
   Dahrouj M, 2015, EXP EYE RES, V137, P50, DOI 10.1016/j.exer.2015.06.004
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301
   El-Beltagy AEFBM, 2015, TISSUE CELL, V47, P78, DOI 10.1016/j.tice.2014.11.008
   Esumi N, 2009, HUM MOL GENET, V18, P128, DOI 10.1093/hmg/ddn323
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Ford KM, 2012, MOL VIS, V18, P519
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   Gamm DM, 2008, STEM CELLS, V26, P3182, DOI 10.1634/stemcells.2008-0300
   Gaucher D, 2012, AMINO ACIDS, V43, P1979, DOI 10.1007/s00726-012-1273-3
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Gnana-Prakasam JP, 2011, INVEST OPHTH VIS SCI, V52, P3751, DOI 10.1167/iovs.10-6722
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   GRIERSON I, 1994, EYE, V8, P255, DOI 10.1038/eye.1994.54
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Herrmann P, 2015, NEUROBIOL AGING, V36, P2637, DOI 10.1016/j.neurobiolaging.2015.05.019
   Hjelmeland LM, 2010, MOL VIS, V16, P1108
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Ho TC, 1997, EXP EYE RES, V64, P133, DOI 10.1006/exer.1996.0199
   Hu J, 2014, EXP EYE RES, V126, P46, DOI 10.1016/j.exer.2013.09.009
   Hu J, 2015, GENES DIS, V2, P293, DOI 10.1016/j.gendis.2015.07.002
   Huang J, 2009, MOL VIS, V15, P223
   HUNT RC, 1989, J CELL SCI, V92, P655
   Ibrahim AS, 2015, BBA-MOL CELL BIOL L, V1851, P290, DOI 10.1016/j.bbalip.2014.12.017
   ISRAEL P, 1980, INVEST OPHTH VIS SCI, V19, P720
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kennedy BG, 2010, MOL VIS, V16, P665
   Klettner A, 2013, MOL VIS, V19, P281
   Klimanskaya I, 2006, METHOD ENZYMOL, V418, P169, DOI 10.1016/S0076-6879(06)18011-8
   Koirala A, 2013, BIOMATERIALS, V34, P7158, DOI 10.1016/j.biomaterials.2013.06.002
   Kutty RK, 2015, CYTOKINE, V74, P335, DOI 10.1016/j.cyto.2015.03.016
   Lajunen T, 2014, EUR J PHARM SCI, V62, P23, DOI 10.1016/j.ejps.2014.04.018
   LANE C, 1989, EYE, V3, P27, DOI 10.1038/eye.1989.4
   Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083
   Lee H, 2011, INT J BIOL MACROMOL, V48, P194, DOI 10.1016/j.ijbiomac.2010.11.006
   Li FL, 2015, EXP EYE RES, V136, P78, DOI 10.1016/j.exer.2015.05.004
   Liu YX, 2014, J PHOTOCH PHOTOBIO B, V140, P85, DOI 10.1016/j.jphotobiol.2014.07.016
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Luo C, 2011, MOL VIS, V17, P1588
   Ma J, 2012, CYTOKINE, V59, P100, DOI 10.1016/j.cyto.2012.03.025
   Machalinska A, 2013, EXP EYE RES, V112, P68, DOI 10.1016/j.exer.2013.04.004
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   MANNAGH J, 1973, INVEST OPHTH VISUAL, V12, P52
   Mateos MV, 2014, INT J BIOCHEM CELL B, V55, P119, DOI 10.1016/j.biocel.2014.08.016
   Mathivanan I, 2015, EXP CELL RES, V333, P11, DOI 10.1016/j.yexcr.2015.02.001
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mizuno A, 2012, NEUROSCI LETT, V523, P39, DOI 10.1016/j.neulet.2012.06.037
   Munoz-Erazo L, 2012, MOL VIS, V18, P730
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Nishihara D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048879
   OKA MS, 1984, EXP CELL RES, V154, P537, DOI 10.1016/0014-4827(84)90178-2
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Peng SM, 2013, STEM CELL TRANSL MED, V2, P534, DOI 10.5966/sctm.2012-0134
   Pequignot MO, 2011, MOL VIS, V17, P989
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Pickl JMA, 2015, FEBS LETT, V589, P1383, DOI 10.1016/j.febslet.2015.04.018
   Reichhart N, 2014, EXP EYE RES, V126, P27, DOI 10.1016/j.exer.2014.05.005
   Reinisalo M, 2012, MOL VIS, V18, P38
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Rossi EA, 2013, BIOMED OPT EXPRESS, V4, P2527, DOI 10.1364/BOE.4.002527
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Samuels IS, 2010, J NEUROPHYSIOL, V104, P391, DOI 10.1152/jn.00088.2010
   Schmack I, 2009, MOL VIS, V15, P146
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Shelby SJ, 2015, EXP EYE RES, V140, P28, DOI 10.1016/j.exer.2015.08.006
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sivalingam MD, 2015, J AAPOS, V19, P379, DOI 10.1016/j.jaapos.2015.03.016
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492
   Thanos A, 2012, AM J PATHOL, V180, P1917, DOI 10.1016/j.ajpath.2012.01.017
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Tseng Han-Yi, 2004, Kaohsiung Journal of Medical Sciences, V20, P225
   TSO MOM, 1973, INVEST OPHTH VISUAL, V12, P554
   Uhl PB, 2014, J PROTEOMICS, V109, P50, DOI 10.1016/j.jprot.2014.06.020
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vigneswara V, 2015, MOL CELL NEUROSCI, V68, P212, DOI 10.1016/j.mcn.2015.08.001
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wolkow N, 2014, EXP EYE RES, V128, P92, DOI 10.1016/j.exer.2014.09.010
   Xia HM, 2011, EXP EYE RES, V93, P862, DOI 10.1016/j.exer.2011.09.020
   Yassin SA, 2012, SAUDI J OPHTHALMOL, V26, P229, DOI 10.1016/j.sjopt.2012.03.005
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Yuan ZD, 2015, GENE, V569, P239, DOI 10.1016/j.gene.2015.05.060
   Zhang ZY, 2012, MOL VIS, V18, P2961
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zhou WY, 2011, MOL VIS, V17, P1526
   [No title captured]
   [No title captured]
NR 150
TC 45
Z9 45
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2041-7314
J9 J TISSUE ENG
JI J. Tissue Eng.
PD JAN-DEC
PY 2016
VL 7
AR 2041731416650838
DI 10.1177/2041731416650838
PG 23
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EC8CR
UT WOS:000388368400010
PM 27493715
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Boucard, CC
   Hernowo, AT
   Maguire, RP
   Jansonius, NM
   Roerdink, JBTM
   Hooymans, JMM
   Cornelissen, FW
AF Boucard, Christine C.
   Hernowo, Aditya T.
   Maguire, R. Paul
   Jansonius, Nomdo M.
   Roerdink, Jos B. T. M.
   Hooymans, Johanna M. M.
   Cornelissen, Frans W.
TI Changes in cortical grey matter density associated with long-standing
   retinal visual field defects
SO BRAIN
LA English
DT Article
DE macular degeneration; glaucoma; visual field; visual cortex; voxel-based
   morphometry; grey matter density
ID LATERAL GENICULATE-NUCLEUS; MACULAR DEGENERATION; HUMAN GLAUCOMA;
   OPTIC-NERVE; CORTEX; REORGANIZATION; PATHOGENESIS; ATROPHY; LESIONS;
   VISION
AB Retinal lesions caused by eye diseases such as glaucoma and age-related macular degeneration can, over time, eliminate stimulation of parts of the visual cortex. This could lead to degeneration of inactive cortical neuronal tissue, but this has not been established in humans. Here, we used magnetic resonance imaging to assess the effects of prolonged sensory deprivation in human visual cortex. High-resolution anatomical magnetic resonance images were obtained in subjects with foveal (age-related macular degeneration) and peripheral (glaucoma) retinal lesions as well as age-matched controls. Comparison of grey matter between patient and control groups revealed density reductions in the approximate retinal lesion projection zones in visual cortex. This indicates that long-term cortical deprivation, due to retinal lesions acquired later in life, is associated with retinotopic-specific neuronal degeneration of visual cortex. Such degeneration could interfere with therapeutic strategies such as the future application of artificial retinal implants to overcome lesion-induced visual impairment.
C1 [Boucard, Christine C.; Hernowo, Aditya T.; Cornelissen, Frans W.] Univ Groningen, Univ Med Ctr Groningen, Lab Expt Ophthalmol, NL-9700 RB Groningen, Netherlands.
   [Hernowo, Aditya T.] Gadjah Mada Univ, Dept Ophthalmol, Yogyakarta, Indonesia.
   [Maguire, R. Paul] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands.
   [Jansonius, Nomdo M.; Hooymans, Johanna M. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, NL-9700 RB Groningen, Netherlands.
   [Roerdink, Jos B. T. M.] Univ Groningen, Inst Math & Comp Sci, NL-9700 RB Groningen, Netherlands.
   [Boucard, Christine C.; Hernowo, Aditya T.; Maguire, R. Paul; Roerdink, Jos B. T. M.; Cornelissen, Frans W.] Univ Groningen, Sch Behav & Cognit Neurosci, Groningen, Netherlands.
C3 University of Groningen; Gadjah Mada University; University of
   Groningen; University of Groningen; University of Groningen; University
   of Groningen
RP Cornelissen, FW (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Lab Expt Ophthalmol, POB 30001, NL-9700 RB Groningen, Netherlands.
EM f.w.cornelissen@rug.nl
RI Hernowo, Aditya/GPK-4884-2022; Maguire, Ralph/GYV-1278-2022; Hernowo,
   Aditya/M-9316-2017; Hernowo, Aditya/M-9651-2015; Roerdink, Jos
   B.T.M/B-3631-2008
OI Maguire, Ralph/0000-0003-3937-6622; Hernowo, Aditya/0000-0002-9212-6705;
   Boucard, Christine Claudia/0000-0003-2634-869X; Jansonius,
   Nomdo/0000-0002-6495-6568
FU Uitzicht Stichting Oogheelkundig Onderzoek Nederland; Prof. Mulder
   foundation
FX The first and the second author contributed equally to this study. A. T.
   H is supported by the 'RuG Fellowship Program' and C. C. B. is supported
   by an Ubbo Emmius grant, both from the University of Groningen, the
   Netherlands. This work was supported by Uitzicht Stichting Oogheelkundig
   Onderzoek Nederland and an equipment grant from the Prof. Mulder
   foundation. The authors thank the BCN Neuroimaging center for the use of
   their scanner, Hans Hoogduin and Anita Kuiper for assistance in magnetic
   resonance scan acquisition, Michiel Kunst for assistance in setting up
   the voxel- based morphometry analysis, Shriprakash Sinha for assistance
   with the region of interest analysis, Remco Renken for fruitful
   suggestions regarding data analysis and Martin Pavlovsky for
   contributing to the discussion.
CR Acaroglu G, 2001, NEURO-OPHTHALMOLOGY, V26, P103, DOI 10.1076/noph.26.2.103.10304
   Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582
   Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   BOUCARD CC, 2006, THESIS U GRONINGEN
   Dougherty RF, 2003, J VISION, V3, P586, DOI 10.1167/3.10.1
   FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6
   Garway-Heath DF, 2000, INVEST OPHTH VIS SCI, V41, P1774
   Gupta N, 2006, BRIT J OPHTHALMOL, V90, P674, DOI 10.1136/bjo.2005.086769
   Gupta N, 2009, BRIT J OPHTHALMOL, V93, P56, DOI 10.1136/bjo.2008.138172
   Gupta N, 2007, CAN J OPHTHALMOL, V42, P409, DOI 10.3129/i07-051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030
   Hossain P, 2005, BMJ-BRIT MED J, V330, P30, DOI 10.1136/bmj.330.7481.30
   Johansson Barbro B., 2004, Keio Journal of Medicine, V53, P231, DOI 10.2302/kjm.53.231
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Kitajima M, 1997, AM J NEURORADIOL, V18, P1291
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mendola JD, 2005, HUM BRAIN MAPP, V25, P222, DOI 10.1002/hbm.20109
   MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408
   Nickells RW, 1996, J GLAUCOMA, V5, P345
   Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Safran A B, 1996, Curr Opin Ophthalmol, V7, P53, DOI 10.1097/00055735-199612000-00009
   Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032
   Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Swanson WH, 2004, INVEST OPHTH VIS SCI, V45, P466, DOI 10.1167/iovs.03-0374
   Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754
   von dem Hagen EAH, 2005, EUR J NEUROSCI, V22, P2475, DOI 10.1111/j.1460-9568.2005.04433.x
   Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 33
TC 137
Z9 142
U1 0
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JUL
PY 2009
VL 132
BP 1898
EP 1906
DI 10.1093/brain/awp119
PN 7
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 463OE
UT WOS:000267440700026
PM 19467992
OA hybrid, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Park, DH
   Kim, IT
AF Park, Dong Ho
   Kim, In Taek
TI Association of ARMS2/HTRA1 variants with polypoidal choroidal
   vasculopathy phenotype in a Korean population
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE ARMS2; HTRA1; Polypoidal choroidal vasculopathy; Single nucleotide
   polymorphism
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; MACULAR DEGENERATION;
   CLINICAL CHARACTERISTICS; PHOTODYNAMIC THERAPY; JAPANESE POPULATION;
   LOC387715 A69S; RISK; GENE; SUSCEPTIBILITY
AB To investigate whether ARMS2 (rs10490924)/HTRA1 (rs11200638) variants are associated with polypoidal choroidal vasculopathy (PCV) in a Korean population and with various PCV phenotypes.
   A case-control study comprised of 103 patients with PCV and 112 control subjects. The PCV and control groups were genotyped for ARMS2 (rs10490924) and HTRA1 (rs11200638) polymorphisms. Clinical characteristics were evaluated, including best-corrected visual acuity (BCVA), fundus findings, and angiographic findings, at first visit.
   Two single nucleotide polymorphisms generated highly significant allelic associations with PCV. The frequency of vitreous hemorrhage (VH) was different among the genotypes with respect to both rs10490924 and rs11200638. The frequency of the T allele of rs10490924 was higher in PCV patients with VH than in PCV patients without VH. The frequency of the A allele of rs11200638 was higher in PCV patients with VH than in PCV patients without VH. In rs10490924, the mean BCVA of the GG genotype group was better than that of the TT and TG genotype groups. In rs11200638, the mean BCVA of the GG genotype group was better than that of the AA and AG genotype groups.
   The ARMS2 (rs10490924)/HTRA1 (rs11200638) variants are significantly associated with the risk of PCV in a Korean population. ARMS2/HTRA1 variants contribute significantly to the PCV phenotypes, including frequency of VH and mean BCVA at baseline.
C1 [Park, Dong Ho; Kim, In Taek] Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, Taegu 700721, South Korea.
C3 Kyungpook National University
RP Kim, IT (通讯作者)，Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, 50 Samduk Dong 2 Ga, Taegu 700721, South Korea.
EM itkim@knu.ac.kr
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chowers I, 2008, MOL VIS, V14, P2263
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
NR 36
TC 13
Z9 14
U1 0
U2 1
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2012
VL 56
IS 1
BP 60
EP 67
DI 10.1007/s10384-011-0089-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 877JS
UT WOS:000299175900010
PM 21959923
DA 2022-11-30
ER

PT J
AU Kim, D
   Ryu, G
   Sagong, M
AF Kim, Doyeon
   Ryu, Gahyung
   Sagong, Min
TI Polypoidal choroidal vasculopathy as a complication of choroidal osteoma
   A case report
SO MEDICINE
LA English
DT Article
DE bevacizumab; choroidal neovascularization; choroidal osteoma; optical
   coherence tomography angiography; polypoidal choroidal vasculopathy
ID TERM-FOLLOW-UP; NEOVASCULARIZATION; MEMBRANE
AB Introduction: Choroidal osteoma (CO) is a rare benign tumor that particularly affects young, healthy women. Its prognosis is influenced by complications, such as choroidal neovascularization (CNV), subretinal hemorrhage, subretinal fluid (SF), decalcification status, and overlying retinal pigment epithelium (RPE) atrophy. In case of CNV as the complication of CO, it is typically present in the classic form; however, reports on polypoidal choroidal vasculopathy (PCV) have been rare. Here, we report a case of an older, male patient with PCV as a complication of CO. Patient concerns: A 70-year-old male patient visited the hospital with vision impairment in the right eye since 2 weeks. Diagnosis: Fundus examination revealed a red-yellow, well-demarcated, scalloped lesion around the optic nerve in each eye; the lesions were highly reflective on ultrasound examination, and thus, CO was diagnosed. Indocyanine green fluorescence angiography and optical coherence tomography (OCT) revealed that the right eye also had PCV accompanied with SF. OCT confirmed the presence of large quiescent type 1 CNV bilaterally in decalcified areas of the lesions adjacent to the optic nerve. Interventions: Intravitreal bevacizumab (IB) injection was performed. Outcomes: Best-corrected visual acuity had improved and OCT showed a decrease in the SF, while OCT angiography showed partial regression of branching vascular network. Conclusion: CO can be accompanied by quiescent type 1 CNV; this should be closely monitored because it can progress to PCV. Optical coherence tomography, alongside indocyanine green fluorescence angiography, is useful for the diagnosis and monitoring of potential CNV as a complication of CO.
C1 [Kim, Doyeon; Ryu, Gahyung; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchungro, Daegu 42415, South Korea.
C3 Yeungnam University
RP Sagong, M (通讯作者)，Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchungro, Daegu 42415, South Korea.
EM msagong@yu.ac.kr
CR Aylward GW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1337, DOI 10.1001/archopht.116.10.1337
   Fine Howard F, 2008, Retin Cases Brief Rep, V2, P15, DOI 10.1097/ICB.0b013e318159e7e9
   Foster BS, 2003, ARCH OPHTHALMOL-CHIC, V121, P273
   GASS J D M, 1979, International Ophthalmology, V1, P71
   GASS JDM, 1978, ARCH OPHTHALMOL-CHIC, V96, P428
   Navajas EV, 2012, AM J OPHTHALMOL, V153, P890, DOI 10.1016/j.ajo.2011.10.025
   Olguin-Manriquez Francisco, 2018, Int J Retina Vitreous, V4, P30, DOI 10.1186/s40942-018-0132-0
   ROSE SJ, 1991, RETINA-J RET VIT DIS, V11, P224, DOI 10.1097/00006982-199111020-00007
   Shields CL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1658, DOI 10.1001/archopht.123.12.1658
   SHIELDS CL, 1988, SURV OPHTHALMOL, V33, P17, DOI 10.1016/0039-6257(88)90069-0
   Shukla D, 2006, EYE, V20, P845, DOI 10.1038/sj.eye.6702016
   Singh AD, 2005, EYE, V19, P482, DOI 10.1038/sj.eye.6701475
   Song JH, 2010, RETINA-J RET VIT DIS, V30, P945, DOI 10.1097/IAE.0b013e3181c720ca
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wu ZHY, 2012, CASE REP OPHTHALM, V3, P200, DOI 10.1159/000339624
NR 15
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY 15
PY 2020
VL 99
IS 20
AR e19927
DI 10.1097/MD.0000000000019927
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA MO4OD
UT WOS:000551506600008
PM 32443292
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kang, HM
   Koh, HJ
   Lee, SC
AF Kang, Hae Min
   Koh, Hyoung Jun
   Lee, Sung Chul
TI Baseline polyp size as a potential predictive factor for recurrence of
   polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor therapy; Photodynamic therapy;
   Polypoidal choroidal vasculopathy; Recurrence
ID PHOTODYNAMIC THERAPY; INTRAVITREAL RANIBIZUMAB; MACULAR DEGENERATION;
   JAPANESE PATIENTS; FOLLOW-UP; CLINICAL CHARACTERISTICS; VERTEPORFIN;
   INJECTIONS; BEVACIZUMAB; FEATURES
AB To investigate the predictive factors for recurrence of polypoidal choroidal vasculopathy (PCV).
   The medical records of 78 consecutive patients (78 eyes) with treatment-na < ve PCV who responded to first-line treatment and completed at least a 3-year follow-up after the first remission were retrospectively analyzed. In this comparative cohort study, baseline characteristics were compared between the patients who had at least one recurrence (the recurrence group) and those without recurrence (the non-recurrence group) during at least 3-year follow-up periods. In addition, possible predictive factors for recurrence of PCV were investigated by using Cox regression analysis.
   Within 3 years of the first remission, 50 eyes (64 %) showed at least one recurrence (mean 1.5; 1 to similar to 2 times). There were no significant differences in the baseline characteristics between the recurrence group and the non-recurrence group. However, the largest polyp diameter was significantly different: the mean largest polyp diameter (524 +/- 340 mu m) was significantly larger in the recurrence group compared to that of the non-recurrence group (352 +/- 173 mu m; P = 0.038). Cox regression analysis showed that the largest polyp diameter at baseline significantly correlated with recurrence of PCV (B = 1.470, P = 0.015).
   The largest polyp diameter at baseline may be predictive for PCV recurrence, as it was significantly larger in patients who had at least one recurrence.
C1 [Kang, Hae Min; Koh, Hyoung Jun; Lee, Sung Chul] Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, Seoul 120752, South Korea.
   [Kang, Hae Min] Catholic Kwandong Univ, Int St Marys Hosp, Dept Ophthalmol, Coll Med, Inchon, South Korea.
C3 Yonsei University; Yonsei University Health System; Catholic Kwandong
   University
RP Lee, SC (通讯作者)，Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, Seoul 120752, South Korea.
EM sunglee@yuhs.ac
OI , Sung Chul/0000-0001-9438-2385; Koh, Hyoung Jun/0000-0002-5932-8516
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 33
TC 9
Z9 10
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2016
VL 254
IS 8
BP 1519
EP 1527
DI 10.1007/s00417-015-3241-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS3IB
UT WOS:000380675200010
PM 26686373
DA 2022-11-30
ER

PT J
AU Fukuda, Y
   Sakurada, Y
   Sugiyama, A
   Yoneyama, S
   Matsubara, M
   Kikushima, W
   Tanabe, N
   Parikh, R
   Kashiwagi, K
AF Fukuda, Yoshiko
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Yoneyama, Seigo
   Matsubara, Mio
   Kikushima, Wataru
   Tanabe, Naohiko
   Parikh, Ravi
   Kashiwagi, Kenji
TI Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy
   in Patients with Polypoidal Choroidal Vasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE as-needed aflibercept therapy; polypoidal choroidal vasculopathy;
   pachydrusen; treatment burden
ID SIMPLIFIED SEVERITY SCALE; COMPLEMENT FACTOR-H; MACULAR DEGENERATION;
   INTRAVITREAL AFLIBERCEPT; PHOTODYNAMIC THERAPY; RANIBIZUMAB;
   POLYMORPHISM; LOC387715; REGIMEN; DISEASE
AB We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (allp< 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (allp-value < 0.003; Group 1: 0.50 +/- 1.32; Group 2: 1.73 +/- 2.08; Group 3:2.71 +/- 1.99; Group 3: 2.71 +/- 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year.
C1 [Fukuda, Yoshiko; Sakurada, Yoichi; Sugiyama, Atsushi; Yoneyama, Seigo; Matsubara, Mio; Kikushima, Wataru; Tanabe, Naohiko; Kashiwagi, Kenji] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo, Yamanashi 4093898, Japan.
   [Parikh, Ravi] NYU, Sch Med, Dept Ophthalmol, New York, NY 10016 USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY 10016 USA.
C3 University of Yamanashi; New York University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo, Yamanashi 4093898, Japan.
EM ysugiyama@yamanashi.ac.jp; sakurada@yamanashi.ac.jp;
   asugiyama@yamaanshi.ac.jp; syoneyama@yamanashi.ac.jp;
   miom@yamanashi.ac.jp; wkikushima@yamanashi.ac.jp;
   tanabe@yamanashi.ac.jp; parikh815@gmail.com; kenjik@yamanashi.ac.jp
CR Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   KIKUSHIMA W, 2017, SCI REP UK, V0007
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Sakurada Y, 2018, GRAEF ARCH CLIN EXP, V256, P99, DOI 10.1007/s00417-017-3847-y
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
NR 35
TC 5
Z9 5
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2459
DI 10.3390/jcm9082459
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NL2TO
UT WOS:000567274500001
PM 32752023
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Winther, C
   Frisen, L
AF Winther, Christina
   Frisen, Lars
TI A compact rarebit test for macular diseases
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; VISUAL-ACUITY; IDENTIFICATION; PERIMETRY;
   GLAUCOMA; ATROPHY; FOVEA; EYES
AB Background Rarebit testing implies probing for gaps in the neuro-retinal receptive field matrix, using bright microdots on a dark background. Previous reports have found rarebit testing useful for the detection of macular lesions. In its original implementation, the test requires darkroom facilities and a long test distance (2 m).
   Methods A self-contained rarebit test device was realised using a modified miniature data projector driven by a laptop computer. Its performance was assessed in normal subjects and in patients with advanced age-related macular degeneration.
   Results Normal subjects (N=49) produced test results very similar to those reported for the original rarebit fovea test. The patient group (N=12) performed significantly worse. The reproducibility was good, and the mean test time was 142 s.
   Conclusion The new test allows portable rarebit testing for neuro-macular damage, without the need for a darkroom. It may prove useful for screening for early age-related macular degeneration.
C1 [Winther, Christina; Frisen, Lars] Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci, Sahlgrenska Acad, Gothenburg, Sweden.
C3 University of Gothenburg
RP Frisen, L (通讯作者)，SU S, Neuroophthalmol Unit, Blue St 7-5, SE-41345 Gothenburg, Sweden.
EM lars.frisen@neuro.gu.se
FU Skaraborg Hospital, University of Gothenburg
FX Research Fund at Skaraborg Hospital, University of Gothenburg.
CR AGERVI P, 2009, ACTA OPHTHALMOL 0130
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Frisen L, 2002, VISION RES, V42, P1931, DOI 10.1016/S0042-6989(02)00102-5
   FRISEN L, 1981, A GRAEF ARCH KLIN EX, V215, P149, DOI 10.1007/BF00413146
   Frisen L, 2010, BRIT J OPHTHALMOL, V94, P97, DOI 10.1136/bjo.2009.160200
   Frisen L, 2009, BRIT J OPHTHALMOL, V93, P714, DOI 10.1136/bjo.2008.149088
   FRISEN L, 1984, GRAEF ARCH CLIN EXP, V222, P71, DOI 10.1007/BF02150634
   GELLER AM, 1992, J OPT SOC AM A, V9, P472, DOI 10.1364/JOSAA.9.000472
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Kerrigan-Baumrind LA, 2000, INVEST OPHTH VIS SCI, V41, P741
   Malmer L, 2005, OPHTHAL PHYSL OPT, V25, P81, DOI 10.1111/j.1475-1313.2004.00244.x
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nilsson M, 2007, BRIT J OPHTHALMOL, V91, P1596, DOI 10.1136/bjo.2007.124461
   Nilsson M, 2006, CLIN EXP OPTOM, V89, P81, DOI 10.1111/j.1444-0938.2006.00016.x
   NILSSON M, 2009, ACTA OPHTHALMOL 0423
   Nowomiejska Katarzyna, 2007, Klin Oczna, V109, P131
   QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1
   Salvetat ML, 2007, INVEST OPHTH VIS SCI, V48, P5320, DOI 10.1167/iovs.06-1495
   SEIPLE W, 1995, VISION RES, V35, P2057, DOI 10.1016/0042-6989(94)00289-X
NR 19
TC 7
Z9 7
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2010
VL 94
IS 3
BP 324
EP 327
DI 10.1136/bjo.2009.164749
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 566BZ
UT WOS:000275346200015
PM 19822915
DA 2022-11-30
ER

PT J
AU Boucard, CC
   Hoogduin, JM
   van der Grond, J
   Cornelissen, FW
AF Boucard, Christine C.
   Hoogduin, Johannes M.
   van der Grond, Jeroen
   Cornelissen, Frans W.
TI Occipital Proton Magnetic Resonance Spectroscopy (H-1-MRS) Reveals
   Normal Metabolite Concentrations in Retinal Visual Field Defects
SO PLOS ONE
LA English
DT Article
AB Background. Progressive visual field defects, such as age-related macular degeneration and glaucoma, prevent normal stimulation of visual cortex. We investigated whether in the case of visual field defects, concentrations of metabolites such as N-acetylaspartate (NAA), a marker for degenerative processes, are reduced in the occipital brain region. Methodology/ Principal Findings. Participants known with glaucoma, age-related macular degeneration (the two leading causes of visual impairment in the developed world), and controls were examined by proton MR spectroscopic (H-1-MRS) imaging. Absolute NAA, Creatine and Choline concentrations were derived from a single-voxel in the occipital region of each brain hemisphere. No significant differences in metabolites concentrations were found between the three groups. Conclusions/ Significance. We conclude that progressive retinal visual field defects do not affect metabolite concentration in visual brain areas suggesting that there is no ongoing occipital degeneration. We discuss the possibility that metabolite change is too slow to be detectable.
C1 [Boucard, Christine C.; Hoogduin, Johannes M.; Cornelissen, Frans W.] Univ Groningen, Univ Med Ctr Groningen, BCN Neuroimaging Ctr, Groningen, Netherlands.
   [Boucard, Christine C.; Cornelissen, Frans W.] Univ Groningen, Univ Med Ctr Groningen, Lab Expt Ophthalmol, Groningen, Netherlands.
   [van der Grond, Jeroen] Univ Med Ctr Leiden, Dept Radiol, Leiden, Netherlands.
C3 University of Groningen; University of Groningen; Leiden University;
   Leiden University Medical Center (LUMC)
RP Boucard, CC (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, BCN Neuroimaging Ctr, Groningen, Netherlands.
EM joyce@brain.riken.jp
OI Boucard, Christine Claudia/0000-0003-2634-869X
FU University of Groningen; Cognition program of the Netherlands
   Organization for Scientific Research (NWO) [051.02.080]
FX Author CCB was supported by an Ubbo Emmius grant from the University of
   Groningen. FWC was supported by grant 051.02.080 of the Cognition
   program of the Netherlands Organization for Scientific Research (NWO).
CR Bjartmar C, 2002, ANN NEUROL, V51, P51, DOI 10.1002/ana.10052
   Block W, 1998, ARCH NEUROL-CHICAGO, V55, P931, DOI 10.1001/archneur.55.7.931
   Block W, 2002, AMINO ACIDS, V23, P317, DOI 10.1007/s00726-001-0144-0
   Chan YL, 1999, J MAGN RESON IMAGING, V10, P130, DOI 10.1002/(SICI)1522-2586(199908)10:2<130::AID-JMRI4>3.0.CO;2-R
   De Stefano N., 2000, Neurological Sciences, V21, pS883, DOI 10.1007/s100720070031
   Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x
   DESTEFANO N, 1995, MAGN RESON MED, V34, P721
   ETTL A, 1994, INT OPHTHALMOL, V18, P171, DOI 10.1007/BF00915968
   FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6
   Gujar SK, 2005, J NEURO-OPHTHALMOL, V25, P217, DOI 10.1097/01.wno.0000177307.21081.81
   Hashimoto M, 2004, JPN J OPHTHALMOL, V48, P353, DOI 10.1007/s10384-004-0086-7
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jansonius NM, 2005, GRAEF ARCH CLIN EXP, V243, P433, DOI 10.1007/s00417-004-1065-x
   Johansson Barbro B., 2004, Keio Journal of Medicine, V53, P231, DOI 10.2302/kjm.53.231
   Karitzky J, 1999, ARCH NEUROL-CHICAGO, V56, P1465, DOI 10.1001/archneur.56.12.1465
   Kuzniecky R, 2004, NEUROIMAG CLIN N AM, V14, P507, DOI 10.1016/j.nic.2004.04.010
   MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408
   Nickells RW, 1996, J GLAUCOMA, V5, P345
   PASSE TJ, 1995, PROG NEURO-PSYCHOPH, V19, P541, DOI 10.1016/0278-5846(95)00101-Z
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schuff N, 1997, NEUROLOGY, V49, P1513, DOI 10.1212/WNL.49.6.1513
   Sijens PE, 2006, EUR RADIOL, V16, P489, DOI 10.1007/s00330-005-2839-1
   SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S
   Tedeschi G, 1997, BRAIN, V120, P1541, DOI 10.1093/brain/120.9.1541
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 20
Z9 21
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2007
VL 2
IS 2
AR e222
DI 10.1371/journal.pone.0000222
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V10DK
UT WOS:000207444500003
PM 17311099
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, JW
   Lee, DW
   Cho, SW
   Kim, CG
AF Cho, H. J.
   Kim, J. W.
   Lee, D. W.
   Cho, S. W.
   Kim, C. G.
TI Intravitreal bevacizumab and ranibizumab injections for patients with
   polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
DE bevacizumab; polypoidal choroidal vasculopathy; ranibizumab
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; FEATURES
AB Purpose To compare the effectiveness of intravitreal injection of bevacizumab and ranibizumab in patients with treatment-naive polypoidal choroidal vasculopathy (PCV).
   Methods A total of 66 and 60 eyes of 121 consecutive patients who received intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg) injection for treatment of PCV were retrospectively reviewed. After initial three loading injections by month, injection was performed as needed. Main outcome measures included best corrected visual acuity (BCVA), foveal center thickness (FCT) as assessed by spectral domain optical coherence tomography (SD-OCT), and change in polypoidal lesion on indocyanine green angiography (ICGA).
   Results At 12 months, average number of injections was 4.72 +/- 1.84 in the bevacizumab group and 5.52 +/- 1.54 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline at 12 months after injection improved by 0.11 in the bevacizumab group (P=0.02) and by 0.14 in the ranibizumab group (P=0.01). Average FCT decreased from 368 +/- 62.48 to 298 +/- 40.77 mu m in the bevacizumab group (P=0.01) and from 371 +/- 50.79 to 286 +/- 36.93 mu m in the ranibizumab group (P=0.01). Polyp regression rate was 24.2% (16 eyes out of 66 eyes) in the bevacizumab group and 23.3% (14 eyes out of 60 eyes) in the ranibizumab group. There was no statistically significant difference in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups.
   Conclusion Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilization of visual acuity, macular edema, and regression of polypoidal complex with PCV eyes. Eye (2012) 26, 426-433; doi: 10.1038/eye.2011.324; published online 16 December 2011
C1 [Cho, H. J.; Kim, J. W.; Lee, D. W.; Cho, S. W.; Kim, C. G.] Konyang Univ Coll Med, Dept Ophthalmol, Kims Eye Hosp, Seoul, South Korea.
C3 Konyang University
RP Cho, HJ (通讯作者)，Konyang Univ Coll Med, Dept Ophthalmol, Kims Eye Hosp, 156,4gA Yeoungdeungpo Dong, Seoul, South Korea.
EM -medical-@hanmail.net
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lai TY, 2010, INVEST OPHTH VIS SCI, V51
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 56
Z9 58
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2012
VL 26
IS 3
BP 426
EP 433
DI 10.1038/eye.2011.324
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907PD
UT WOS:000301428900010
PM 22173075
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Puzyeyeva, O
   Lam, WC
   Flanagan, JG
   Brent, MH
   Devenyi, RG
   Mandelcorn, MS
   Wong, T
   Hudson, C
AF Puzyeyeva, Olena
   Lam, Wai Ching
   Flanagan, John G.
   Brent, Michael H.
   Devenyi, Robert G.
   Mandelcorn, Mark S.
   Wong, Tien
   Hudson, Christopher
TI High-Resolution Optical Coherence Tomography Retinal Imaging: A Case
   Series Illustrating Potential and Limitations
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SPECTRAL-DOMAIN
AB Purpose. To present a series of retinal disease cases that were imaged by spectral domain optical coherence tomography (SD-OCT) in order to illustrate the potential and limitations of this new imaging modality. Methods. The series comprised four selected cases (one case each) of age-related macular degeneration (ARMD), diabetic retinopathy (DR), central retinal artery occlusion (CRAO), and branch retinal vein occlusion (BRVO). Patients were imaged using the Heidelberg Spectralis (Heidelberg Engineering, Germany) in SD-OCT mode. Patients also underwent digital fundus photography and clinical assessment. Results. SD-OCT imaging of a case of age-related macular degeneration revealed a subfoveal choroidal neovascular membrane with detachment of the retinal pigment epithelium (RPE) and neurosensory retina. Using SD-OCT, the cases of DR and BRVO both exhibited macular edema with cystoid spaces visible in the outer retina. Conclusions. The ability of SD-OCT to clearly and objectively elucidate subtle morphological changes within the retinal layers provides information that can be used to formulate diagnoses with greater confidence.
C1 [Puzyeyeva, Olena; Lam, Wai Ching; Flanagan, John G.; Brent, Michael H.; Devenyi, Robert G.; Mandelcorn, Mark S.; Wong, Tien; Hudson, Christopher] Univ Toronto, Dept Ophthalmol & Vis Sci, Retina Res Grp, Toronto, ON M5T 2S8, Canada.
   [Flanagan, John G.; Hudson, Christopher] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
C3 University of Toronto; University of Waterloo
RP Hudson, C (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, Retina Res Grp, Toronto, ON M5T 2S8, Canada.
EM chudson@uwaterloo.ca
FU Vision Science Research Program (VSRP); Canadian Institute of Health
   Research (CIHR)
FX This paper received funding from the Vision Science Research Program
   (VSRP), Canadian Institute of Health Research (CIHR), and an anonymous
   donor. John Flanagan is a consultant for Heidelberg Engineering. This
   study was presented at the Association for Research in Vision and
   Ophthalmology Annual Meeting (Fort Lauderdale, USA, 2009).
CR de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Drexler W, 2007, INVEST OPHTH VIS SCI, V48, P5340, DOI 10.1167/iovs.07-0895
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Heidelberg Engineering, 2007, SPECTR HARDW OP MAN, P22
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Luviano DM, 2009, OPHTHAL SURG LAS IM, V40, P325, DOI 10.3928/15428877-20090430-20
   Ma Z., 2004, P SOC PHOTO-OPT INS, V5630, P286
   Singh M, 2009, OPHTHAL SURG LAS IM, V40, P336, DOI 10.3928/15428877-20090430-23
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
NR 10
TC 23
Z9 23
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 764183
DI 10.1155/2011/764183
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979BO
UT WOS:000306790100037
PM 21969910
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Baek, J
   Lee, JH
   Jeon, S
   Lee, WK
AF Baek, Jiwon
   Lee, Jae Hyung
   Jeon, Sohee
   Lee, Won Ki
TI Choroidal morphology and short-term outcomes of combination photodynamic
   therapy in polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   MACULAR DEGENERATION; VASCULAR HYPERPERMEABILITY; THICKNESS CHANGES;
   RANIBIZUMAB; VERTEPORFIN; EYES; NEOVASCULARIZATION; CLASSIFICATION
AB Purpose To investigate outcomes of combined photodynamic therapy (PDT) and intravitreal bevacizumab in association with choroidal morphology in polypoidal choroidal vasculopathy (PCV).
   Method Eighty-six PCV eyes (83 patients) treated with PDT in combination with intravitreal bevacizumab and followed for 1 year were evaluated. Choroidal morphological features including subfoveal choroidal thicknesses, diameter of pachyvessel, and choroidal vascularity were analyzed for association with responsiveness and recurrence.
   Result Total choroid, Haller's layer, and pachyvessel were thicker in responders (n = 70) compared with non-responders (n = 16) at baseline (298 vs. 227 mu m, 213 vs. 144 mu m, and 276 vs. 210 mu m, respectively; all p <= 0.001). Choroidal vascularity was significantly higher (0.68 vs 0.60, P< 0.001) and choroidal hyperpermeability was more frequent in responders (44 vs 13%, P= 0.018). Significant thinning of total choroid was observed in both responders and non-responders at 3 months after combination PDT (both P< 0.05), but the reduction was greater in responders (-33 mu m vs. - 10 mu m, P = 0.036). In recurrent eyes (n = 26), increase in pachyvessel diameter and choroidal vascularity was observed at recurrence.
   Conclusion Choroidal morphology including characteristic features of pachychoroid and high vascularity can serve as predictive factors for outcomes after combination PDT in eyes with PCV.
C1 [Baek, Jiwon] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Gyeonggi Do, South Korea.
   [Lee, Jae Hyung; Jeon, Sohee; Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
EM wklee@catholic.ac.kr
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Isola V, 2004, RETINA-J RET VIT DIS, V24, P618, DOI 10.1097/00006982-200408000-00020
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroda Y, 2016, AM J OPHTHALMOL, V169, P199, DOI 10.1016/j.ajo.2016.06.043
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Wei Chunyi, 2014, Eye Sci, V29, P20
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 13
Z9 13
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2019
VL 33
IS 3
BP 419
EP 427
DI 10.1038/s41433-018-0228-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN9UD
UT WOS:000460544800014
PM 30305706
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Iancu, R
   Pirvulescu, R
   Istrate, S
   Cherecheanu, AP
   Iancu, G
   Burcea, M
AF Iancu, Raluca
   Pirvulescu, Ruxandra
   Istrate, Sanziana
   Cherecheanu, Alina Popa
   Iancu, George
   Burcea, Marian
TI RHO-KINASE INHIBITORS - A NEW BROAD-SPECTRUM TREATMENT IN OPHTHALMIC
   DISEASES. A REVIEW
SO FARMACIA
LA English
DT Review
DE rho-kinase inhibitors; ophthalmology; cornea; glaucoma; diabetic
   retinopathy; age related macular degeneration
ID OPEN-ANGLE GLAUCOMA; ELEVATED INTRAOCULAR-PRESSURE; CORNEAL ENDOTHELIAL
   DISEASE; FIXED-DOSE COMBINATION; ROCK INHIBITORS; SOLUTION 0.02-PERCENT;
   SIGNALING PATHWAY; RIPASUDIL K-115; RHO/RHO-KINASE; IN-VITRO
AB Rho-kinases, also called coiled-coil containing protein kinases, are proteins that belong to the guanine triphosphate-ase family. Rho-kinase (ROCK) inhibition represents a relatively new therapeutic target for many diseases as cardiovascular diseases, neuronal degeneration, asthma, cancer. Due to their involvement in multiple biological processes, these compounds are increasingly addressed in the last ten years for clinical trials related to ophthalmic pathologies like glaucoma, endothelial dysfunction and vitreoretinal diseases. ROCK inhibition pathway seems to play important roles in: promoting endothelial cell proliferation and wound healing, regulation of trabecular meshwork outflow, limiting diabetes-induced microvascular damage, inhibiting the development of neovascular choroidal membranes in wet age related macular degeneration. This review of literature explores the mechanisms of action and effects of ROCK inhibitors in a variety of ocular pathologies as corneal pathologies, glaucoma, diabetic retinopathy, age related macular degeneration; also listing clinical trials (completed or ongoing) on ROCK inhibitors administered in patients with those particular disease.
C1 [Iancu, Raluca; Pirvulescu, Ruxandra; Istrate, Sanziana; Cherecheanu, Alina Popa; Iancu, George; Burcea, Marian] Carol Davila Univ Med & Pharm, 37 Dionisie Lupu St, Bucharest 040292, Romania.
   [Iancu, Raluca; Pirvulescu, Ruxandra; Istrate, Sanziana; Cherecheanu, Alina Popa] Emergency Univ Hosp Bucharest, 169 Independence St, Bucharest 050098, Romania.
   [Iancu, George] Filantropia Clin Hosp Bucharest, 11-13 Ion Mihalache St, Bucharest 011171, Romania.
   [Burcea, Marian] Emergency Ophthalmol Hosp Bucharest, 1 Lahovari Sq, Bucharest 010464, Romania.
C3 Carol Davila University of Medicine & Pharmacy
RP Pirvulescu, R (通讯作者)，Carol Davila Univ Med & Pharm, 37 Dionisie Lupu St, Bucharest 040292, Romania.; Pirvulescu, R (通讯作者)，Emergency Univ Hosp Bucharest, 169 Independence St, Bucharest 050098, Romania.
EM ruxandra_pascu@yahoo.co.uk
RI Burcea, Marian/AAZ-2644-2021
OI Popa-Cherecheanu, Alina/0000-0003-4189-6571
CR Ahmadieh H, 2019, BRIT J OPHTHALMOL, V103, P922, DOI 10.1136/bjophthalmol-2018-312244
   Ahmadieh H, 2013, JAMA OPHTHALMOL, V131, P923, DOI 10.1001/jamaophthalmol.2013.143
   Alkharashi M, 2019, MIDDLE EAST AFR J OP, V26, P246, DOI 10.4103/meajo.MEAJO_27_19
   Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472
   Anderson S, 2004, EXP CELL RES, V298, P574, DOI 10.1016/j.yexcr.2004.05.005
   Arita R, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/175163
   Arita R, 2009, DIABETES, V58, P215, DOI 10.2337/db08-0762
   Asrani S, 2020, ADV THER, V37, P1620, DOI 10.1007/s12325-020-01277-2
   Asrani S, 2019, AM J OPHTHALMOL, V207, P248, DOI 10.1016/j.ajo.2019.06.016
   Barac IR, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9716
   Berrino E, 2019, EXPERT OPIN THER PAT, V29, P817, DOI 10.1080/13543776.2019.1670812
   Brubaker JW, 2020, OPHTHALMOL GLAUCOMA, V3, P327, DOI 10.1016/j.ogla.2020.05.008
   Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012
   Coviltir V, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/4960852
   Dasso L, 2018, CLIN OPHTHALMOL, V12, P1939, DOI 10.2147/OPTH.S154001
   Dong M, 2010, DRUG DISCOV TODAY, V15, P622, DOI 10.1016/j.drudis.2010.06.011
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Duman JG, 2015, NEUROSCI LETT, V601, P4, DOI 10.1016/j.neulet.2015.05.034
   Feng YB, 2016, J MED CHEM, V59, P2269, DOI 10.1021/acs.jmedchem.5b00683
   Futakuchi A, 2020, SCI REP-UK, V10, P1
   Futakuchi A, 2016, EXP EYE RES, V149, P107, DOI 10.1016/j.exer.2016.07.001
   Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776
   Garnock-Jones K, 2014, DRUGS, V74, P2211, DOI 10.1007/s40265-014-0333-2
   Gauthier Angela C., 2016, Yale Journal of Biology and Medicine, V89, P73
   Goda E, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1253-4
   Goldstein AS, 2018, J OCUL PHARMACOL TH, V34, P692, DOI 10.1089/jop.2018.0063
   Gonzalez LE, 2020, ANN PHARMACOTHER, V55, P1
   Guan RG, 2013, EUR J MED CHEM, V70, P613, DOI 10.1016/j.ejmech.2013.10.048
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hartmann S, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00276
   Harvey SAK, 2004, INVEST OPHTH VIS SCI, V45, P2168, DOI 10.1167/iovs.03-1218
   Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100
   Hollanders K, 2015, INVEST OPHTH VIS SCI, V56, P1335, DOI 10.1167/iovs.14-15681
   Honjo M, 2001, INVEST OPHTH VIS SCI, V42, P137
   Hoy SM, 2018, DRUGS, V78, P389, DOI 10.1007/s40265-018-0877-7
   Ibrahim DG, 2019, CELL BIOCHEM FUNCT, V37, P113, DOI 10.1002/cbf.3382
   Inazaki H, 2017, GRAEF ARCH CLIN EXP, V255, P2009, DOI 10.1007/s00417-017-3727-5
   Inazaki H, 2017, J GLAUCOMA, V26, P96, DOI 10.1097/IJG.0000000000000552
   Inoue K, 2018, JPN J OPHTHALMOL, V62, P508, DOI 10.1007/s10384-018-0599-0
   Irimia T, 2019, FARMACIA, V67, P702, DOI 10.31925/farmacia.2019.4.20
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kahook MY, 2019, AM J OPHTHALMOL, V200, P130, DOI 10.1016/j.ajo.2019.01.003
   Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459
   Khouri AS, 2019, AM J OPHTHALMOL, V204, P97, DOI 10.1016/j.ajo.2019.03.002
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Koch JC, 2018, PHARMACOL THERAPEUT, V189, P1, DOI 10.1016/j.pharmthera.2018.03.008
   Koizumi N, 2012, EXP EYE RES, V95, P60, DOI 10.1016/j.exer.2011.10.014
   Koyanagi M, 2008, J NEUROSCI RES, V86, P270, DOI 10.1002/jnr.21502
   Kusuhara S, 2020, CLIN OPHTHALMOL, V14, P1229, DOI 10.2147/OPTH.S216907
   Kusuhara S, 2018, GRAEF ARCH CLIN EXP, V256, P809, DOI 10.1007/s00417-018-3933-9
   Lin CW, 2018, J OCUL PHARMACOL TH, V34, P40, DOI 10.1089/jop.2017.0023
   Lu DW., 2020, MOLECULES, V25, P1
   Lu QY, 2014, INT J CLIN EXP PATHO, V7, P7268
   Lusthaus J, 2019, MED J AUSTRALIA, V210, P180, DOI 10.5694/mja2.50020
   Macsai MS, 2019, CORNEA, V38, P529, DOI 10.1097/ICO.0000000000001883
   Maruyama Y, 2021, BRIT J OPHTHALMOL, V105, P169, DOI 10.1136/bjophthalmol-2019-315776
   Maruyama Y, 2020, J OCUL PHARMACOL TH, V36, P229, DOI 10.1089/jop.2019.0125
   Matsubara M, 2016, ONCOTARGET, V7, P31602, DOI 10.18632/oncotarget.9395
   Matsumura R, 2017, CLIN DRUG INVEST, V37, P535, DOI 10.1007/s40261-017-0509-0
   Meekins LC, 2016, INVEST OPHTH VIS SCI, V57, P6731, DOI 10.1167/iovs.16-20414
   Meekins LC, 2012, INVEST OPHTHALMOL VI, V53, P6017
   Minami Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40194-5
   Moloney G, 2021, CORNEA, V40, P320, DOI 10.1097/ICO.0000000000002437
   Moloney G, 2017, CORNEA, V36, P642, DOI 10.1097/ICO.0000000000001209
   Moshirfar Majid, 2018, Med Hypothesis Discov Innov Ophthalmol, V7, P101
   Moura-Coelho N, 2019, GRAEF ARCH CLIN EXP, V257, P1101, DOI 10.1007/s00417-019-04283-5
   Mulherkar S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010245
   Noritake K, 2012, TOXICOL IN VITRO, V26, P849, DOI 10.1016/j.tiv.2012.04.027
   Nourinia Ramin, 2013, J Ophthalmic Vis Res, V8, P337
   Okumura N, 2016, INVEST OPHTH VIS SCI, V57, P6843, DOI 10.1167/iovs.16-20123
   Okumura N, 2016, INVEST OPHTH VIS SCI, V57, P1284, DOI 10.1167/iovs.15-18586
   Okumura N, 2015, INVEST OPHTH VIS SCI, V56, P6067, DOI 10.1167/iovs.15-17595
   Okumura N, 2014, INVEST OPHTH VIS SCI, V55, P318, DOI 10.1167/iovs.13-12225
   Okumura N, 2011, BRIT J OPHTHALMOL, V95, P1006, DOI 10.1136/bjo.2010.194571
   Okumura N, 2009, INVEST OPHTH VIS SCI, V50, P3680, DOI 10.1167/iovs.08-2634
   Ota C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77302-9
   Peh GSL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09167
   Pipparelli A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062095
   Rossig L, 2000, J BIOL CHEM, V275, P25502, DOI 10.1074/jbc.M002283200
   Rothschild PR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07329-y
   Scheau C, 2020, FARMACIA, V68, P984, DOI 10.31925/farmacia.2020.6.4
   Seccia TM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051328
   Shahsuvaryan ML., 2020, EC OPHTHALMOLOGY, V02, P04
   Shtein RM, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.025
   Singh IP, 2020, J GLAUCOMA, V29, P878, DOI 10.1097/IJG.0000000000001634
   Skaat A, 2016, J GLAUCOMA, V25, pE807, DOI 10.1097/IJG.0000000000000508
   SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Sun CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144571
   Tamura M, 2005, BBA-PROTEINS PROTEOM, V1754, P245, DOI 10.1016/j.bbapap.2005.06.015
   Tan DTH, 2012, LANCET, V379, P1749, DOI 10.1016/S0140-6736(12)60437-1
   Tanihara H, 2016, ACTA OPHTHALMOL, V94, pE26, DOI 10.1111/aos.12829
   Testa V, 2020, DRUG TODAY, V56, P599, DOI 10.1358/dot.2020.56.9.3178110
   Twa MD, 2018, OPTOMETRY VISION SCI, V95, P83, DOI 10.1097/OPX.0000000000001183
   Van de Velde S, 2015, PROG NEUROBIOL, V131, P105, DOI 10.1016/j.pneurobio.2015.06.002
   Walters TR, 2019, OPHTHALMOL GLAUCOMA, V2, P280, DOI 10.1016/j.ogla.2019.03.007
   Wang DA, 2002, AM J PHYSIOL-CELL PH, V283, pC1646, DOI 10.1152/ajpcell.00323.2002
   Watsky MA, 2000, ANN NY ACAD SCI, V905, P142
   Williams RD, 2011, AM J OPHTHALMOL, V152, P834, DOI 10.1016/j.ajo.2011.04.012
   Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P636, DOI 10.1167/iovs.06-0203
   Yasuda M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185305
   Yin J, 2008, AM J PHYSIOL-CELL PH, V295, pC378, DOI 10.1152/ajpcell.90624.2007
   Yin J, 2007, J CELL SCI, V120, P815, DOI 10.1242/jcs.03389
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zhang Y, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1134
   Zhou EHH, 2017, INVEST OPHTH VIS SCI, V58, P2991, DOI 10.1167/iovs.16-20974
NR 106
TC 1
Z9 1
U1 1
U2 12
PU SOC STIINTE FARMACEUTICE ROMANIA
PI BUCURESTI
PA BUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIA
SN 0014-8237
EI 2065-0019
J9 FARMACIA
JI Farmacia
PD MAY-JUN
PY 2021
VL 69
IS 3
BP 399
EP 409
DI 10.31925/farmacia.2021.3.2
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TA8PT
UT WOS:000667509000002
OA gold
DA 2022-11-30
ER

PT J
AU Barmas-Alamdari, D
   D'Souza, HS
   Kapoor, KG
   Wagner, AL
AF Barmas-Alamdari, Daniel
   D'Souza, Haley S.
   Kapoor, Kapil G.
   Wagner, Alan L.
TI Intravitreal Ziv-Aflibercept: A Comprehensive Review
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE AMD; anti-vascular endothelial growth factor; diabetic macular edema;
   neovascular age-related macular degeneration; Zaltrap; ziv-aflibercept
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF AGENTS; MACULAR DEGENERATION;
   BEVACIZUMAB AVASTIN; RANIBIZUMAB LUCENTIS; NEOVASCULAR MEMBRANES;
   RETINAL-DETACHMENT; ADVERSE EVENTS; EYE; INJECTION
AB Background: Age-related macular degeneration is the leading cause of blindness in adults over the age of 50 in the United States of America. Neovascular age-related macular degeneration (nAMD) is sight-threatening, but can be treated by three currently utilized, intravitreally administered drugs: aflibercept, bevacizumab, and ranibizumab. Ziv-aflibercept is an analogue of aflibercept, containing the same active molecule in a different buffer solution, and its recent availability has prompted numerous pre-clinical and clinical trials addressing its viability for intraocular use, summarized herein. Results: Trial outcomes demonstrate that ziv-aflibercept has a similar safety profile to other indicated drugs with effective maintenance or improvement of best-corrected visual acuity (BCVA) and reduction of retinal fluid or central foveal thickness (CFT). Clinical trials of ziv-aflibercept in other neovascular disorders such as diabetic macular edema (DME) and retinal vein occlusion (RVO) have shown similar results. Conclusion: Further prospective, randomized studies of ziv-aflibercept are needed, particularly in eyes with nAMD.
C1 [Barmas-Alamdari, Daniel; D'Souza, Haley S.; Kapoor, Kapil G.; Wagner, Alan L.] Eastern Virginia Med Sch, Dept Ophthalmol, Norfolk, VA 23501 USA.
   [D'Souza, Haley S.; Kapoor, Kapil G.; Wagner, Alan L.] Wagner Macula & Retina Ctr, Ophthalmol Res, Virginia Beach, VA USA.
C3 Eastern Virginia Medical School
RP Kapoor, KG (通讯作者)，Wagner Macula & Retina Ctr, Virginia Beach, VA 23454 USA.
EM Kaps2003@gmail.com
OI Barmas-Alamdari, Daniel/0000-0002-0556-2438; D'Souza,
   Haley/0000-0002-0938-1650
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2008, DRUGS R&D, V9, P261
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Ashraf M, 2017, OSLI RETINA, V48, P399, DOI 10.3928/23258160-20170428-06
   Ashraf M, 2016, ACTA OPHTHALMOL, V94, pE669, DOI 10.1111/aos.13111
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Baghi A, 2017, OPHTHALMOL RETINA, V1, P103, DOI 10.1016/j.oret.2016.08.007
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Campbell RJ, 2013, CURR OPIN OPHTHALMOL, V24, P197, DOI 10.1097/ICU.0b013e32835f8bbe
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Chung C, 2013, AM J HEALTH-SYST PH, V70, P1887, DOI 10.2146/ajhp130143
   de Andrade GC, 2018, OSLI RETINA, V49, P245, DOI 10.3928/23258160-20180329-06
   de Andrade GC, 2016, OPHTHALMOLOGICA, V236, P223, DOI 10.1159/000452677
   de Andrade GC, 2016, RETINA-J RET VIT DIS, V36, P1640, DOI 10.1097/IAE.0000000000001000
   Dias JRD, 2019, RETINA-J RET VIT DIS, V39, P648, DOI 10.1097/IAE.0000000000002001
   Dias JRDO, 2017, RETINA-J RET VIT DIS, V37, P1499, DOI 10.1097/IAE.0000000000001385
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gower EW, 2011, ARVO M, V52, P6644
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hageman GS, 1995, WEBVISION ORG RETINA, P1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   HodjatJalali K, 2017, J CURR OPHTHALMOL, V29, P228, DOI 10.1016/j.joco.2017.01.005
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Kim Ramasamy, 2007, Indian Journal of Ophthalmology, V55, P413
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Marashi A, 2016, ADV OPHTHALMOL VISUA, V4, P3, DOI [10.15406/aovs.2016.04.00114, DOI 10.15406/AOVS.2016.04.00114]
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moreno TA, 2016, SEMIN OPHTHALMOL, V31, P378, DOI 10.3109/08820538.2016.1154174
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Paulose R, 2016, CLIN OPHTHALMOL, V10, P1853, DOI 10.2147/OPTH.S116343
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Ranibizumab for Neovascular Age Related Macular Degeneration | NEJM, RAN NEOV AG REL MAC, DOI DOI 10.1056/NEJMOA054481
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shaikh AH, 2015, OSLI RETINA, V46, P62, DOI 10.3928/23258160-20150101-10
   Singh Rishi P., 2007, Indian Journal of Ophthalmology, V55, P421
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P805, DOI 10.1136/bjophthalmol-2018-312453
   Singh SR, 2017, ASIA-PAC J OPHTHALMO, V6, P561, DOI 10.22608/APO.2017263
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Tanzi MG, 2012, PHARM TODAY, V18, P43, DOI [10.1016/S1042-0991(15)32009-0, DOI 10.1016/S1042-0991(15)32009-0]
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Topal T, 2017, TURK OFTALMOL DERG, V47, P133, DOI 10.4274/tjo.34735
   van der GM, 2015, CURR PHARM DES
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   WALSH AW, 1989, ANN OPHTHALMOL, V21, P348
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yogi Rohit, 2017, Retin Cases Brief Rep, V11, P111, DOI 10.1097/ICB.0000000000000305
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 82
TC 9
Z9 9
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD AUG 18
PY 2019
VL 34
IS 6
BP 420
EP 435
DI 10.1080/08820538.2019.1641526
EA JUL 2019
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN3WT
UT WOS:000476101400001
PM 31314638
DA 2022-11-30
ER

PT J
AU Chung, YR
   Seo, EJ
   Kim, YH
   Yang, H
   Lee, K
AF Chung, Yoo-Ri
   Seo, Eoi Jong
   Kim, Yong Hyun
   Yang, Hongseok
   Lee, Kihwang
TI Hypertension as a risk factor for recurrent subretinal hemorrhage in
   polypoidal choroidal vasculopathy
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION;
   RANIBIZUMAB INJECTIONS; SUBMACULAR HEMORRHAGE; CHINESE PATIENTS;
   NATURAL-HISTORY; BLOOD-PRESSURE; COMPLICATIONS; VERTEPORFIN
AB Objective: To investigate the relationship between hypertension and recurrent subretinal hemorrhage (SRH) in eyes with polypoidal choroidal vasculopathy (PCV).
   Design: Retrospective, comparative case series.
   Participants: Thirty-eight eyes of 38 patients with PCV.
   Methods: Ocular findings and clinical features were analyzed retrospectively in patients with PCV enrolled from January 2011 to December 2013. The patients were divided into 2 groups according to the presence of recurrent SRH after successful initial treatment (rebleeding vs nonrebleeding) and were subdivided into those with and without hypertension, based on history of hypertension, systolic blood pressure (SBP) >150 mm Hg. The relationship between hypertension and recurrent SRH was analyzed.
   Results: Thirty-eight patients (38 eyes) were included in this analysis. High SBP or history of hypertension was significantly more frequent in the rebleeding group than in the nonrebleeding group (p = 0.014). Subgroup analysis showed that mean time until recurrent SRH was significantly shorter in the hypertensive group than in the nonhypertensive group (p = 0.025). The cumulative incidence of recurrent SRH at 2 years was 43% in the hypertensive group and 20% in the nonhypertensive group. Cox regression after adjustment for age showed that hypertension was associated with a 3.9 -fold greater risk of recurrent SRH (p = 0.039).
   Conclusions: Recurrent SRH in patients with PCV was more common in hypertensive subjects. Undiagnosed hypertension should be considered when assessing the prognosis of patients with PCV.
C1 [Chung, Yoo-Ri; Seo, Eoi Jong; Kim, Yong Hyun; Yang, Hongseok; Lee, Kihwang] Ajou Univ, Dept Ophthalmol, Sch Med, 164,World Cup Ro, Suwon 443380, South Korea.
C3 Ajou University
RP Lee, K (通讯作者)，Ajou Univ, Dept Ophthalmol, Sch Med, 164,World Cup Ro, Suwon 443380, South Korea.
EM kie114@hanmail.net
OI Lee, Kihwang/0000-0003-0478-8758; Chung, Yoo-Ri/0000-0002-6871-6721
FU New Faculty Research Fund of Ajou University School of Medicine
FX This study was supported by the 2014 New Faculty Research Fund of Ajou
   University School of Medicine.
CR Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Ceyhan M, 2003, CHRONOBIOL INT, V20, P337, DOI 10.1081/CBI-120019342
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Chhablani JK, 2014, INDIAN J OPHTHALMOL, V62, P97, DOI 10.4103/0301-4738.126197
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho HJ, 2012, CAN J OPHTHALMOL, V47, P170, DOI 10.1016/j.jcjo.2012.01.005
   Choo EH, 2014, INT J CARDIOL, V172, pE465, DOI 10.1016/j.ijcard.2014.01.040
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hasan DM, 2015, HYPERTENSION, V66, P324, DOI 10.1161/HYPERTENSIONAHA.115.05500
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Hwang JU, 2012, RETINA-J RET VIT DIS, V32, P652, DOI 10.1097/IAE.0b013e318233abb4
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Juvela S, 2003, STROKE, V34, P1852, DOI 10.1161/01.STR.0000080380.56799.DD
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kaplan NM, 2010, KAPLANS CLIN HYPERTE
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 46
TC 6
Z9 6
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2016
VL 51
IS 5
BP 348
EP 353
DI 10.1016/j.jcjo.2016.02.012
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA9GQ
UT WOS:000386950900019
PM 27769325
DA 2022-11-30
ER

PT J
AU Prevot, PH
   Gehere, K
   Arcizet, F
   Akolkar, H
   Khoei, MA
   Blaize, K
   Oubari, O
   Daye, P
   Lanoe, M
   Valet, M
   Dalouz, S
   Langlois, P
   Esposito, E
   Forster, V
   Dubus, E
   Wattiez, N
   Brazhnikova, E
   Nouvel-Jaillard, C
   LeMer, Y
   Demilly, J
   Fovet, CM
   Hantraye, P
   Weissenburger, M
   Lorach, H
   Bouillet, E
   Deterre, M
   Hornig, R
   Buc, G
   Sahel, JA
   Chenegros, G
   Pouget, P
   Benosman, R
   Picaud, S
AF Prevot, Paul-Henri
   Gehere, Kevin
   Arcizet, Fabrice
   Akolkar, Himanshu
   Khoei, Mina A.
   Blaize, Kevin
   Oubari, Omar
   Daye, Pierre
   Lanoe, Marion
   Valet, Manon
   Dalouz, Sami
   Langlois, Paul
   Esposito, Elric
   Forster, Valerie
   Dubus, Elisabeth
   Wattiez, Nicolas
   Brazhnikova, Elena
   Nouvel-Jaillard, Celine
   LeMer, Yannick
   Demilly, Joanna
   Fovet, Claire-Maelle
   Hantraye, Philippe
   Weissenburger, Morgane
   Lorach, Henri
   Bouillet, Elodie
   Deterre, Martin
   Hornig, Ralf
   Buc, Guillaume
   Sahel, Jose-Alain
   Chenegros, Guillaume
   Pouget, Pierre
   Benosman, Ryad
   Picaud, Serge
TI Behavioural responses to a photovoltaic subretinal prosthesis implanted
   in non-human primates
SO NATURE BIOMEDICAL ENGINEERING
LA English
DT Article
ID ARTIFICIAL VISION; SIMULATION; RESTORATION; CELLS; EYE
AB Retinal dystrophies and age-related macular degeneration related to photoreceptor degeneration can cause blindness. In blind patients, although the electrical activation of the residual retinal circuit can provide useful artificial visual perception, the resolutions of current retinal prostheses have been limited either by large electrodes or small numbers of pixels. Here we report the evaluation, in three awake non-human primates, of a previously reported near-infrared-light-sensitive photovoltaic subretinal prosthesis. We show that multipixel stimulation of the prosthesis within radiation safety limits enabled eye tracking in the animals, that they responded to stimulations directed at the implant with repeated saccades and that the implant-induced responses were present two years after device implantation. Our findings pave the way for the clinical evaluation of the prosthesis in patients affected by dry atrophic age-related macular degeneration. A near-infrared-light-sensitive photovoltaic subretinal prosthesis triggers behavioural responses in awake macaques, even two years after device implantation.
C1 [Prevot, Paul-Henri; Gehere, Kevin; Arcizet, Fabrice; Akolkar, Himanshu; Khoei, Mina A.; Blaize, Kevin; Oubari, Omar; Daye, Pierre; Lanoe, Marion; Valet, Manon; Dalouz, Sami; Langlois, Paul; Esposito, Elric; Forster, Valerie; Dubus, Elisabeth; Brazhnikova, Elena; Nouvel-Jaillard, Celine; Sahel, Jose-Alain; Chenegros, Guillaume; Benosman, Ryad; Picaud, Serge] Sorbonne Univ, INSERM, Inst Vis, Paris, France.
   [Prevot, Paul-Henri; Gehere, Kevin; Arcizet, Fabrice; Akolkar, Himanshu; Khoei, Mina A.; Blaize, Kevin; Oubari, Omar; Daye, Pierre; Lanoe, Marion; Valet, Manon; Dalouz, Sami; Langlois, Paul; Esposito, Elric; Forster, Valerie; Dubus, Elisabeth; Brazhnikova, Elena; Nouvel-Jaillard, Celine; Sahel, Jose-Alain; Chenegros, Guillaume; Benosman, Ryad; Picaud, Serge] CNRS, Paris, France.
   [Wattiez, Nicolas; Weissenburger, Morgane; Pouget, Pierre] Hop La Pitie Salpetriere, CNRS UMR 7225, Inst Cerveau & Moelle Epiniere, Paris, France.
   [LeMer, Yannick; Sahel, Jose-Alain] Fdn Ophtalmol A de Rothschild, Paris, France.
   [Demilly, Joanna; Fovet, Claire-Maelle; Hantraye, Philippe] Mol Imaging Res Ctr MIRCen, Fontenay Aux Roses, France.
   [Lorach, Henri] Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA.
   [Bouillet, Elodie; Deterre, Martin; Hornig, Ralf; Buc, Guillaume] Pixium Vis, Paris, France.
   [Sahel, Jose-Alain] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA USA.
   [Sahel, Jose-Alain] CHNO Quinze Vingts, DHU Sight Restore, INSERM, DGOS CIC 1423, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); UDICE-French Research Universities; Sorbonne Universite; CEA;
   UDICE-French Research Universities; Universite Paris Saclay; Stanford
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; CHNO des Quinze-Vingts; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite
RP Picaud, S (通讯作者)，Sorbonne Univ, INSERM, Inst Vis, Paris, France.; Picaud, S (通讯作者)，CNRS, Paris, France.
EM serge.picaud@inserm.fr
RI Akolkar, Himanshu/AAV-4896-2021; Akolkar, Himanshu/ABG-1936-2021;
   Picaud, Serge/H-4012-2014
OI Demilly, Joanna/0000-0002-8345-9567; LORACH, HENRI/0000-0003-4337-2798;
   Picaud, Serge/0000-0002-0548-5145; HANTRAYE,
   Philippe/0000-0002-5121-1831; Deterre, Martin/0000-0001-5770-7451;
   Arcizet, Fabrice/0000-0003-0385-1639
FU BPIfrance [2014-PRSP-15]; Foundation Fighting Blindness; Federation des
   Aveugles de France; LabEx LIFESENSES [ANR-10-LABX-65]; French Agence
   National pour la Recherche as part of the first Investissements d'Avenir
   programme [ANR-11-IDEX-0004-02]; European Union [785219]
FX This work was supported by BPIfrance (grant no. 2014-PRSP-15), the
   Foundation Fighting Blindness, the Federation des Aveugles de France and
   LabEx LIFESENSES (grant no. ANR-10-LABX-65) and was managed by the
   French Agence National pour la Recherche as part of the first
   Investissements d'Avenir programme (grant no. ANR-11-IDEX-0004-02). This
   project also received funding from the European Union's Horizon 2020
   research and innovation programme for the European Graphene Flagship
   under grant agreement no. 785219. The content is solely the
   responsibility of the authors and does not necessarily represent the
   views of the funders. The authors had the final say over the data
   collection and analysis, decision to publish and preparation of the
   manuscript.
CR Bendali A, 2015, BIOMATERIALS, V67, P73, DOI 10.1016/j.biomaterials.2015.07.018
   Boinagrov D, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026008
   Brandli A, 2016, EYE BRAIN, V8, P15, DOI 10.2147/EB.S70822
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   Fornos AP, 2008, VISION RES, V48, P1705, DOI 10.1016/j.visres.2008.04.027
   Freeman DK, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/035005
   Fried SI, 2006, J NEUROPHYSIOL, V95, P970, DOI 10.1152/jn.00849.2005
   Jensen RJ, 2005, INVEST OPHTH VIS SCI, V46, P1486, DOI 10.1167/iovs.04-1018
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Joucla S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004828
   Jung JH, 2015, VISION RES, V111, P182, DOI 10.1016/j.visres.2014.10.023
   LAPUERTA P, 1995, VISION RES, V35, P2245, DOI 10.1016/0042-6989(94)00320-L
   Li PH, 2015, J NEUROSCI, V35, P4663, DOI 10.1523/JNEUROSCI.3675-14.2015
   Lorach H, 2016, BIOMED OPT EXPRESS, V7, P13, DOI 10.1364/BOE.7.000013
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Picaud S, 1998, J PHYSIOL-LONDON, V513, P33, DOI 10.1111/j.1469-7793.1998.033by.x
   SCHILLER PH, 1994, VISUAL NEUROSCI, V11, P229, DOI 10.1017/S0952523800001590
   SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684
   SMITH RC, 1990, EYE, V4, P230, DOI 10.1038/eye.1990.32
   Sommerhalder J, 2004, VISION RES, V44, P1693, DOI 10.1016/j.visres.2004.01.017
   Sommerhalder J, 2003, VISION RES, V43, P269, DOI 10.1016/S0042-6989(02)00481-9
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
NR 25
TC 33
Z9 33
U1 2
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2157-846X
J9 NAT BIOMED ENG
JI Nat. Biomed. Eng
PD FEB
PY 2020
VL 4
IS 2
BP 172
EP 180
DI 10.1038/s41551-019-0484-2
PG 9
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA KN1NV
UT WOS:000514607100010
PM 31792423
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lai, E
   Levine, B
   Ciralsky, J
AF Lai, Edward
   Levine, Benjamin
   Ciralsky, Jessica
TI Ultraviolet-blocking intraocular lenses: fact or fiction
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; blue-blocking intraocular lens;
   circadian rhythm; scotopic sensitivity; ultraviolet-blocking intraocular
   lens
ID AGE-RELATED MACULOPATHY; BEAVER DAM EYE; BLUE MOUNTAINS EYE; MACULAR
   DEGENERATION; CATARACT-SURGERY; RISK-FACTORS; CONTRAST SENSITIVITY;
   COLOR-VISION; VISUAL FUNCTION; VISIBLE-LIGHT
AB Purpose of reviewUltraviolet-blocking intraocular lenses (IOLs) are used routinely in cataract surgery and are widely accepted. Blue-blocking IOLs, however, have been much debated since their inception. In this article, we will review the advantages and disadvantages of blue-blocking IOLs.Recent findingsIn experimental and animal studies, acute blue light exposure induces retinal damage and the use of blue-blocking IOLs lessens this damage. Many large epidemiologic studies have further investigated this relationship between blue light exposure and the development of age-related macular degeneration, and have shown conflicting results. Visual performance and circadian rhythm disturbances have also been explored in patients with blue-blocking IOLs; no significant negative effects have been shown.SummaryThe current literature on blue-blocking IOLs is contradictory. Studies have failed to conclusively prove that blue-blocking lenses provide photoprotection against age-related macular degeneration or cause any significant detrimental effects on visual function or circadian rhythms.
C1 [Lai, Edward; Levine, Benjamin; Ciralsky, Jessica] Weill Cornell Med Coll, New York, NY 10021 USA.
C3 Cornell University
RP Ciralsky, J (通讯作者)，Weill Cornell Med Coll, 1305 York Ave,11th Floor, New York, NY 10021 USA.
EM jbc9004@med.cornell.edu
FU Research to Prevent Blindness
FX The work of E.L., B.L., and J.C. is supported by a grant from Research
   to Prevent Blindness. There are no conflicts of interest.
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bhattacharjee H, 2006, J CATARACT REFR SURG, V32, P451, DOI 10.1016/j.jcrs.2005.12.136
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475
   Brondsted AE, 2013, ACTA OPHTHALMOL, V91, P52, DOI 10.1111/j.1755-3768.2011.02291.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Foley D, 2004, J PSYCHOSOM RES, V56, P497, DOI 10.1016/j.jpsychores.2004.02.010
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GORGELS GMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Greenstein VC, 2007, J CATARACT REFR SURG, V33, P667, DOI 10.1016/j.jcrs.2006.12.012
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Henderson BA, 2010, SURV OPHTHALMOL, V55, P284, DOI 10.1016/j.survophthal.2009.07.007
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kiser AK, 2008, CLIN EXP OPHTHALMOL, V36, P514, DOI 10.1111/j.1442-9071.2008.01824.x
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Landers J, 2007, CLIN EXP OPHTHALMOL, V35, P152, DOI 10.1111/j.1442-9071.2006.01434.x
   Landers JA, 2009, J CATARACT REFR SURG, V35, P83, DOI 10.1016/j.jcrs.2008.10.015
   Lee RMH, 2012, EYE, V26, P1400, DOI 10.1038/eye.2012.177
   Lee RMH, 2012, ACTA OPHTHALMOL, V90, pe151, DOI 10.1111/j.1755-3768.2011.02166.x
   Leibovitch I, 2006, ACTA OPHTHALMOL SCAN, V84, P95, DOI 10.1111/j.1600-0420.2005.00607.x
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   MAINSTER MA, 1978, AM J OPHTHALMOL, V85, P167, DOI 10.1016/S0002-9394(14)75943-4
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   MAINSTER MA, 1986, AM J OPHTHALMOL, V102, P727, DOI 10.1016/0002-9394(86)90400-9
   Mainster MA, 2011, OPHTHALMOLOGY, V118, P1, DOI 10.1016/j.ophtha.2010.11.016
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Mainster MA, 2009, AM J OPHTHALMOL, V147, P8, DOI 10.1016/j.ajo.2008.08.020
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   MELLERIO J, 1987, VISION RES, V27, P1581, DOI 10.1016/0042-6989(87)90166-0
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Muftuoglu O, 2007, J CATARACT REFR SURG, V33, P658, DOI 10.1016/j.jcrs.2006.12.018
   Mukai K, 2009, JPN J OPHTHALMOL, V53, P47, DOI 10.1007/s10384-008-0620-0
   Nilsson S E, 1989, Prog Clin Biol Res, V314, P539
   Niwa K, 1996, OPHTHAL PHYSL OPT, V16, P297, DOI 10.1046/j.1475-1313.1996.95001182.x
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NORREN DV, 1974, VISION RES, V14, P1237, DOI 10.1016/0042-6989(74)90222-3
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Pons A, 2007, J OPT SOC AM A, V24, P1545, DOI 10.1364/JOSAA.24.001545
   Raj SM, 2005, J CATARACT REFR SURG, V31, P2324, DOI 10.1016/j.jcrs.2005.08.052
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Schmidinger G, 2008, J CATARACT REFR SURG, V34, P769, DOI 10.1016/j.jcrs.2007.12.034
   Schwiegerling J, 2006, J CATARACT REFR SURG, V32, P141, DOI 10.1016/j.jcrs.2005.11.021
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Symes RJ, 2012, EYE, V26, P1397, DOI 10.1038/eye.2012.178
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   Tanito M, 2012, JPN J OPHTHALMOL, V56, P82, DOI 10.1007/s10384-011-0100-9
   Tanito M, 2010, J CATARACT REFR SURG, V36, P299, DOI 10.1016/j.jcrs.2009.08.036
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Turner PL, 2008, BRIT J OPHTHALMOL, V92, P1439, DOI 10.1136/bjo.2008.141747
   VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G
   Vuori ML, 2006, ACTA OPHTHALMOL SCAN, V84, P92, DOI 10.1111/j.1600-0420.2005.00579.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wirtitsch MG, 2009, OPHTHALMOLOGY, V116, P39, DOI 10.1016/j.ophtha.2008.08.035
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   Yuan ZX, 2004, AM J OPHTHALMOL, V138, P138, DOI 10.1016/j.ajo.2004.02.024
   1992, ARCH OPHTHALMOL, V110, P1701
NR 93
TC 10
Z9 10
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JAN
PY 2014
VL 25
IS 1
BP 35
EP 39
DI 10.1097/ICU.0000000000000016
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 266BF
UT WOS:000327996600006
PM 24248095
DA 2022-11-30
ER

PT J
AU Guan, BX
   Zhao, YH
   Yin, Y
   Li, Y
AF Guan, Boxin
   Zhao, Yuhai
   Yin, Ying
   Li, Yuan
TI A differential evolution based feature combination selection algorithm
   for high-dimensional data
SO INFORMATION SCIENCES
LA English
DT Article
DE Binary space partitioning; Differential evolution; Feature combination;
   High-dimensional data
ID DETECTING EPISTATIC INTERACTIONS; GENOME-WIDE ASSOCIATION; OPTIMIZATION
   ALGORITHM
AB Feature combination selection is used in object classification to select complementary features that can produce a powerful combination. One active area of selecting feature combinations is genome-wide association studies (GWAS). However, selecting feature combinations from high-dimensional GWAS data faces a serious issue of high computational complexity. In this paper, a fast evolutionary optimization method named search history-guided differential evolution (HGDE) is proposed to deal with the problem. This method applies the search history memorized in a binary space partitioning tree to enhance its power for selecting feature combinations. We perform a comparative study on the proposed HGDE algorithm and other state-of-the-art algorithms using synthetic datasets, and later employ the HGDE algorithm in experiments on a real age-related macular degeneration dataset. The experimental results show that this proposed algorithm has superior performance in the selection of feature combinations. Moreover, the results provide a reference for studying the functional mechanisms of age-related macular degeneration. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Guan, Boxin; Zhao, Yuhai; Yin, Ying] Northeastern Univ, Sch Comp Sci & Engn, Shenyang 110819, Peoples R China.
   [Guan, Boxin; Zhao, Yuhai; Yin, Ying] Northeastern Univ, Key Lab Med Image Comp, Minist Educ, Shenyang 110819, Peoples R China.
   [Li, Yuan] North China Univ Technol, Sch Informat Sci & Technol, Beijing 100144, Peoples R China.
C3 Northeastern University - China; Northeastern University - China; North
   China University of Technology
RP Zhao, YH (通讯作者)，Northeastern Univ, Sch Comp Sci & Engn, Shenyang 110819, Peoples R China.
EM zhaoyuhai@ise.neu.edu.cn
FU National Natural Science Foundation Program of China [61772124]; North
   China University of Technology
FX This work was supported by the National Natural Science Foundation
   Program of China under Grant 61772124 and the start up of North China
   University of Technology.
CR Baioletti M., 2019, INFORM SCI, V507
   Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916
   Chow CK, 2011, IEEE T EVOLUT COMPUT, V15, P741, DOI 10.1109/TEVC.2010.2040180
   Das S, 2011, IEEE T EVOLUT COMPUT, V15, P4, DOI 10.1109/TEVC.2010.2059031
   Donnelly P, 2008, NATURE, V456, P728, DOI 10.1038/nature07631
   Fish A., 2016, AM J HUM GENET, V99
   Geem ZW, 2001, SIMULATION, V76, P60, DOI 10.1177/003754970107600201
   Guan BX, 2019, IEEE ACCESS, V7, P69604, DOI 10.1109/ACCESS.2019.2917132
   Guan BX, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020114
   Jiang X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-89
   Jing PJ, 2015, BIOINFORMATICS, V31, P634, DOI 10.1093/bioinformatics/btu702
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/icnn.1995.488968
   Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee JJ, 2010, LUNG CANCER, V70, P205, DOI 10.1016/j.lungcan.2010.02.005
   Li P, 2015, BRIEF FUNCT GENOMICS, V14, P143, DOI 10.1093/bfgp/elu036
   Lin HY, 2012, ANN HUM GENET, V76, P53, DOI 10.1111/j.1469-1809.2011.00692.x
   Liu J, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060153
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Niel C, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00280
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Shang JL, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1076-8
   Shang JL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-475
   Storn R, 1997, J GLOBAL OPTIM, V11, P341, DOI 10.1023/A:1008202821328
   Sun YM, 2018, INT CONF SIGN PROCES, P1, DOI 10.1109/ICSP.2018.8652408
   Sun YX, 2017, BIODATA MIN, V10, DOI 10.1186/s13040-017-0143-7
   Tallarida R., 1987, CHI SQUARE TEST, V01, P140
   Tang R., 2016, CANC LETT, V373
   Tian M., 2018, INFORM SCI, V478, P11
   Tuo S., 2017, SCI REPORTS, V7, P12
   Tuo S.FDHE-IW, 2018, GENES, V9, P435
   Tuo SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150669
   Urbanowicz RJ, 2012, BIODATA MIN, V5, DOI 10.1186/1756-0381-5-16
   Wan XA, 2010, AM J HUM GENET, V87, P325, DOI 10.1016/j.ajhg.2010.07.021
   Wei WH, 2014, NAT REV GENET, V15, P722, DOI 10.1038/nrg3747
   Wu LT, 2015, STEM CELL REP, V5, P10, DOI 10.1016/j.stemcr.2015.05.016
   Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041
   Yang C, 2009, BIOINFORMATICS, V25, P504, DOI 10.1093/bioinformatics/btn652
   Yang JB, 2012, IEEE T SYST MAN CY B, V42, P1550, DOI 10.1109/TSMCB.2012.2195000
   Yuen JWF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105163
   Yuen SY, 2009, IEEE T EVOLUT COMPUT, V13, P454, DOI 10.1109/TEVC.2008.2003008
   Zhang X, 2010, BIOINFORMATICS, V26, pi217, DOI 10.1093/bioinformatics/btq186
   Zhang Y., 2019, INFORM SCI, V507
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
   Zhao YH, 2014, IEEE T KNOWL DATA EN, V26, P667, DOI 10.1109/TKDE.2013.31
NR 46
TC 15
Z9 16
U1 11
U2 45
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0020-0255
EI 1872-6291
J9 INFORM SCIENCES
JI Inf. Sci.
PD FEB 8
PY 2021
VL 547
BP 870
EP 886
DI 10.1016/j.ins.2020.08.081
PG 17
WC Computer Science, Information Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA OT2JS
UT WOS:000590678800004
DA 2022-11-30
ER

PT J
AU Kim, YH
   Lee, B
   Kang, E
   Oh, J
AF Kim, Young Ho
   Lee, Boram
   Kang, Edward
   Oh, Jaeryung
TI Choroidal thickness profile and clinical outcomes in eyes with
   polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Optical coherence tomography; Peripapillary
   choroidal thickness; Polypoidal choroidal vasculopathy; Subfoveal
   choroidal thickness
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; AFLIBERCEPT THERAPY;
   VASCULAR HYPERPERMEABILITY; INJECTION; FEATURES
AB Purpose To investigate the relationship between choroidal thickness (CT) profile and clinical outcomes after anti-vascular endothelial growth factor (VEGF) treatment in polypoidal choroidal vasculopathy (PCV). Methods Medical records of patients diagnosed with PCV who received anti-VEGF treatment over 12 months were reviewed. Subfoveal CT (SFCT) and peripapillary CT (PCT) were measured on swept-source optical coherence tomography images. Patients were divided into various groups based on choroidal profiles including SFCT, nasal PCT (nPCT) and ratio of SFCT to nPCT (SFCT/nPCT). Clinical outcomes were compared between the thin and thick CT groups. Results A total of 65 patients with PCV patients were included. After ant-VEGF treatment, SFCT was significantly decreased after anti-VEGF treatment (P = 0.001), but nasal PCT (nPCT) was not. Clinical outcomes were not different between the thin and thick SFCT groups. Total number of injections during the 12 months was significantly fewer in the thin nPCT group (3.4 +/- 1.3) than in the thick nPCT group (4.5 +/- 1.8) (P = 0.020). Complete resolution after loading injections was more frequently observed in the high SFCT/nPCT ratio (> 1.9) group (87.9%) than in the low SFCT/nPCT ratio (<= 1.90) group (59.4%) (P = 0.009). The ratio of SFCT/nPCT showed the best predictive ability for poor responders (area under curve = 0.771). Conclusion These results suggest that baseline nPCT and SFCT/nPCT ratio could be a good biomarker that reflects clinical outcomes after anti-VEGF treatment in PCV.
C1 [Kim, Young Ho; Lee, Boram; Kang, Edward; Oh, Jaeryung] Korea Univ, Dept Ophthalmol, Coll Med, 73 Inchon Ro, Seoul 02841, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Dept Ophthalmol, Coll Med, 73 Inchon Ro, Seoul 02841, South Korea.
EM ojr4991@korea.ac.kr
RI Kim, Young Ho/ABH-7801-2020; Oh, Jaeryung/ABD-3090-2021
OI Kim, Young Ho/0000-0002-5281-1185; Oh, Jaeryung/0000-0002-1036-6562
FU Korea University [K2011221]
FX This study was supported by the Korea University grant (K2011221).
CR Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   Jang JW, 2019, RETINA-J RET VIT DIS, V39, P1995, DOI 10.1097/IAE.0000000000002259
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230293
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lee B, 2019, GRAEF ARCH CLIN EXP, V257, P2163, DOI 10.1007/s00417-019-04432-w
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee Kyou Ho, 2017, Korean J Ophthalmol, V31, P431, DOI 10.3341/kjo.2016.0101
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nagai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47738-9
   Nam KT, 2020, RETINA-J RET VIT DIS, V40, P2270, DOI 10.1097/IAE.0000000000002758
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
NR 31
TC 5
Z9 5
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2021
VL 259
IS 7
BP 1711
EP 1721
DI 10.1007/s00417-020-05051-6
EA JAN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TI3LH
UT WOS:000606211000006
PM 33417092
DA 2022-11-30
ER

PT J
AU Chen, YT
   Yang, Z
   Xia, F
   Ning, H
   Hua, R
AF Chen, Yutong
   Yang, Zhi
   Xia, Fan
   Ning, Hong
   Hua, Rui
TI The blood flow characteristics of polypoidal choroidal vasculopathy and
   the choroidal remodelling process after photodynamic therapy
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy; choroidal remodelling; photodynamic
   therapy; enhanced-depth imaging; optical coherence tomography
   angiography
AB ObjectivesTo investigate the blood flow characteristics of polypoidal choroidal vasculopathy (PCV) using optical coherence tomography angiography (OCTA) and to analyse photodynamic therapy (PDT) effects on choroidal remodelling in PCV.
   Materials and MethodsDiagnostic indocyanine green angiography and OCTA were performed. All patients underwent PDT with full-dose verteporfin and were followed up with enhanced-depth imaging optical coherence tomography.
   ResultsAt baseline, a branching vascular network (BVN) was clearly demonstrated in all patients with PCV who underwent OCTA examinations as opposed to polyps. Additionally, the choroidal thickness (266 [range: 74-456] mu m) showed a positive relationship with polyp size (0.59 [range: 0.33-0.94] mm(2), r=0.679, P=0.0022). The subfoveal choroidal thickness and choroidal thickness at polyp sites increased within 1 day after PDT and atrophied 1-3 months after PDT.
   ConclusionsThe differences in imaging characteristics between BVNs and polyps on OCTA were presumably due to both blood turbulence (different flow orientations) within polyps and the velocities detectable on OCTA. Moreover, the choroidal remodelling effects of PDT in PCV suggested the occurrence of transitional reactive inflammatory choroidal vascular hyperpermeability and choroidal exudation. PCV involved the entire choroids rather than only focal lesions. Lasers Surg. Med. 50:427-432, 2018. (c) 2018 Wiley Periodicals, Inc.
C1 [Chen, Yutong; Ning, Hong; Hua, Rui] China Med Univ, Dept Ophthalmol, Hosp 1, 155 Nanjingbei St, Shenyang, Liaoning, Peoples R China.
   [Yang, Zhi; Xia, Fan] Fourth Hosp People, Dept Ophthalmol, Shenyang, Liaoning, Peoples R China.
C3 China Medical University
RP Ning, H; Hua, R (通讯作者)，China Med Univ, Dept Ophthalmol, Hosp 1, 155 Nanjingbei St, Shenyang, Liaoning, Peoples R China.
EM ninghong2015cmu@126.com; woodshua@126.com
RI Xia, Fan/GQP-4575-2022
FU Natural Science Foundation of Liaoning Province [20170541041]; Fund for
   Scientific Research of The First Hospital of China Medical University
   [FSFH201712]
FX Contract grant sponsor: Natural Science Foundation of Liaoning Province;
   Contract grant number: 20170541041; Contract grant sponsor: Fund for
   Scientific Research of The First Hospital of China Medical University;
   Contract grant number: FSFH201712.
CR Hua R, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/5498125
   Hua R, 2014, PHOTODIAGN PHOTODYN, V11, P519, DOI 10.1016/j.pdpdt.2014.07.005
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Muir ER, 2011, NMR BIOMED, V24, P216, DOI 10.1002/nbm.1576
   Okubo Akiko, 2013, Korean J Ophthalmol, V27, P384, DOI 10.3341/kjo.2013.27.5.384
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Srour M, 2016, DEV OPHTHALMOL, V56, P71, DOI 10.1159/000442781
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 18
TC 11
Z9 11
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD JUL
PY 2018
VL 50
IS 5
SI SI
BP 427
EP 432
DI 10.1002/lsm.22801
PG 6
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology; Surgery
GA GJ8LJ
UT WOS:000435640900004
PM 29399845
DA 2022-11-30
ER

PT J
AU Fukuda, Y
   Sakurada, Y
   Matsubara, M
   Hasebe, Y
   Sugiyama, A
   Kikushima, W
   Kashiwagi, K
AF Fukuda, Yoshiko
   Sakurada, Yoichi
   Matsubara, Mio
   Hasebe, Yuka
   Sugiyama, Atsushi
   Kikushima, Wataru
   Kashiwagi, Kenji
TI Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept
   Injections for Polypoidal Choroidal Vasculopathy
SO BIOMEDICINES
LA English
DT Article
DE polypoidal choroidal vasculopathy; brolucizumab; aflibercept;
   intraocular inflammation; resolution of polypoidal lesion(s)
ID PHOTODYNAMIC THERAPY; RANIBIZUMAB; VERTEPORFIN; MONOTHERAPY; THICKNESS
AB We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naive polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 +/- 0.34 (log MAR unit) at baseline to 0.20 +/- 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (p = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%-44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (p = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA.
C1 [Fukuda, Yoshiko; Sakurada, Yoichi; Matsubara, Mio; Hasebe, Yuka; Sugiyama, Atsushi; Kikushima, Wataru; Kashiwagi, Kenji] Univ Yamanashi, Fac Med, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093821, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093821, Japan.
EM ysugiyama@yamanashi.ac.jp; sakurada@yamanashi.ac.jp;
   miom@yamanashi.ac.jp; hyuka@yamanashi.ac.jp; asugiyama@yamanashi.ac.jp;
   wkikushima@yamanashi.ac.jp; kenjik@yamanashi.ac.jp
OI Kashiwagi, Kenji/0000-0001-8506-8503; Sakurada,
   Yoichi/0000-0002-2894-0454
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132758
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112425
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fukuda Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082459
   Hikichi T, 2021, JPN J OPHTHALMOL, V65, P208, DOI 10.1007/s10384-021-00819-7
   Kataoka K, 2021, JPN J OPHTHALMOL, V65, P199, DOI 10.1007/s10384-021-00818-8
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Matsubara M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237330
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 22
TC 10
Z9 10
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD SEP
PY 2021
VL 9
IS 9
AR 1164
DI 10.3390/biomedicines9091164
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA UV0OC
UT WOS:000699188500001
PM 34572350
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jordan-Yu, JM
   Teo, K
   Fan, Q
   Gana, JC
   Leopando, AK
   Nunes, S
   Farinha, C
   Barreto, P
   Melo, JB
   Carreira, I
   Murta, JN
   Silva, R
   Cheung, CMG
AF Jordan-Yu, Janice Marie
   Teo, Kelvin
   Fan, Qiao
   Gana, Jose Carlos
   Leopando, Anna Karina
   Nunes, Sandrina
   Farinha, Claudia
   Barreto, Patricia
   Melo, Joana Barbosa
   Carreira, Isabel
   Murta, Joaquim Neto
   Silva, Rufino
   Cheung, Chui Ming Gemmy
TI T and genetic variations between Asian and Caucasian polypoidal
   choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina
ID MACULAR DEGENERATION; ASSOCIATION; VARIANTS; DIAGNOSIS; JAPANESE;
   SUBTYPES; CHINESE
AB Purpose To compare phenotypic and genetic variations in polypoidal choroidal vasculopathy (PCV) between Caucasian and Asian patients. Methods We analysed phenotypic and genotypic data from two sites, Association for Innovation and Biomedical Research on Light and Image, Portugal and Singapore National Eye Centre, Singapore. Baseline fundus photography, spectral domain-optical coherence tomography, indocyanine green and fluorescein angiography scans were analysed by respective reading centres using a standardised grading protocol. Single nucleotide polymorphisms across 8 PCV loci were compared between cases and controls selected from each population. Results One hundred and forty treatment-naive PCV participants (35 Portuguese and 105 Singaporean) were included. The Portuguese cohort were older (72.33 +/- 8.44 vs 68.71 +/- 9.40 years, p=0.043) and were comprised of a lower proportion of males (43% vs 71%, p=0.005) compared with the Singaporean cohort. Differences in imaging features include higher prevalence of soft drusen (66% vs 30%, p=0.004), lower prevalence of subretinal haemorrhage (14% vs 67%, p<0.001), smaller polypoidal lesion (PL) area (0.09 +/- 0.09 vs 0.76 +/- 0.93 mm(2), p<0.001), lower ratio of PL to branching vascular network area (3% vs 38%, p<0.001) and lower central retinal thickness (346.48 +/- 93.74 vs 493.16 +/- 212.92 mu m, p<0.001) in the Portuguese cohort. CETP rs3764261 (OR 2.467; 95% CI 1.282 to 4.745, p=0.006) in the Portuguese population was significantly associated with PCV and CFH rs800292 (OR 1.719; 95% CI 1.139 to 2.596, p=0.010) in the Singaporean population, respectively. Conclusion Among Asian and Caucasian patients with PCV, there are significant differences in the expression of phenotype. We also identified different polymorphisms associated with PCV in the two populations.
C1 [Jordan-Yu, Janice Marie; Teo, Kelvin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Jordan-Yu, Janice Marie; Teo, Kelvin; Gana, Jose Carlos; Leopando, Anna Karina; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Fan, Qiao] Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore.
   [Nunes, Sandrina; Farinha, Claudia; Barreto, Patricia; Murta, Joaquim Neto; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AILIBI, P-3000548 Coimbra, Portugal.
   [Nunes, Sandrina; Barreto, Patricia; Murta, Joaquim Neto; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.
   [Farinha, Claudia] Ctr Hosp & Univ Coimbra CHUC, Ophthalmol Dept, Coimbra, Portugal.
   [Melo, Joana Barbosa; Carreira, Isabel] Clin Acad Ctr Coimbra CACC, Coimbra, Portugal.
   [Melo, Joana Barbosa; Carreira, Isabel] Univ Coimbra, Fac Med, Cytogenet & Genom Lab, Coimbra, Portugal.
   [Silva, Rufino] EVICRnet, ATLANTIC Study Grp, Coimbra, Portugal.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; National University of Singapore;
   Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade
   de Coimbra
RP Cheung, CMG (通讯作者)，Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.; Silva, R (通讯作者)，Assoc Innovat & Biomed Res Light & Image AILIBI, P-3000548 Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt; gemmy.cheung.c.m@snec.com.sg
RI Melo, Joana B/K-8347-2014; Melo, Joana B/AAY-8984-2020; Carreira, Isabel
   M/C-7711-2018; Farinha, Claudia/R-1392-2017; Murta, Joaquim/V-5494-2017
OI Melo, Joana B/0000-0001-5049-2670; Melo, Joana B/0000-0001-5049-2670;
   Carreira, Isabel M/0000-0001-6842-1707; Farinha,
   Claudia/0000-0003-4596-0913; Teo, Kelvin/0000-0002-7458-7081; Silva,
   Rufino/0000-0001-8676-0833; Murta, Joaquim/0000-0001-8926-5176
FU Bayer (Portugal) [ECR-AMD-2015-2019]; National Medical Research Council
   (Singapore) [NMRC/NIG/1003/2009, NMRC/OFLGC/004/2018]
FX Funding for this research includes the Investigator-Institution
   Initiated Research Grant from Bayer: ECR-AMD-2015-2019 (Portugal) and
   National Medical Research Council grant: NMRC/NIG/1003/2009 and
   NMRC/OFLGC/004/2018 (Singapore). The funding agencies have no role in
   the conduct of this study.
CR Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   El Chehab H, 2020, EUR J OPHTHALMOL, V30, P948, DOI 10.1177/1120672119874674
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Farinha C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051329
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Marques JP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015785
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuan MZ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/9538671
NR 35
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2021
VL 105
IS 12
BP 1716
EP 1723
DI 10.1136/bjophthalmol-2020-317537
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XJ6PS
UT WOS:000726907900019
PM 33037006
DA 2022-11-30
ER

PT J
AU Rasoulinejad, SA
   Karkhah, A
   Paniri, A
   Saleki, K
   Pirzadeh, M
   Nouri, HR
AF Rasoulinejad, Seyed Ahmad
   Karkhah, Ahmad
   Paniri, Alireza
   Saleki, Kiarash
   Pirzadeh, Marzieh
   Nouri, Hamid Reza
TI Contribution of inflammasome complex in inflammatory-related eye
   disorders and its implications for anti-inflammasome therapy
SO IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
LA English
DT Review
DE Diabetic retinopathy; glaucoma; IL-1 beta; inflammasome; macular
   degeneration
ID NLRP3 INFLAMMASOME; MACULAR DEGENERATION; P2X(7) RECEPTOR; OXIDATIVE
   STRESS; IL-1 FAMILY; INTERLEUKIN-1; ACTIVATION; IL-1-BETA; MECHANISM;
   GLAUCOMA
AB Inflammasome complex is regarded as a major molecular regulator that exerts a significant function in caspase-1 activation and consequently, the development of cytokines like interleukin-1 beta (IL-1 beta) and interleukin-18 (IL-18). The secretion of these cytokines may induce inflammation. The role of inflammasomes in the pathologic process of eye-related illnesses like glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy has been well studied over the past decade. However, the detailed pathogenic mechanism of inflammasomes in these retinal diseases is still unknown. Therefore, further investigation and understanding various aspects of inflammasome complexes as well as their pivotal roles in the immunopathology of human ocular illnesses are essential. The present review aims to describe the significant involvement of inflammasomes in the immunopathology of important inflammatory retinal illnesses, including glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy focusing on anti-inflammasome therapy as a promising approach in the treatment of inflammation-related eye diseases.
C1 [Rasoulinejad, Seyed Ahmad] Babol Univ Med Sci, Sch Med, Dept Ophthalmol, Babol, Iran.
   [Rasoulinejad, Seyed Ahmad] Babol Univ Med Sci, Clin Res Dev Unit, Rouhani Hosp, Babol, Iran.
   [Karkhah, Ahmad; Paniri, Alireza; Saleki, Kiarash; Pirzadeh, Marzieh] Babol Univ Med Sci, Student Res Comm, Babol, Iran.
   [Karkhah, Ahmad; Nouri, Hamid Reza] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran.
   [Nouri, Hamid Reza] Babol Univ Med Sci, Hlth Res Inst, Immunoregulat Res Ctr, Babol, Iran.
C3 Babol University of Medical Sciences; Babol University of Medical
   Sciences; Babol University of Medical Sciences; Babol University of
   Medical Sciences; Babol University of Medical Sciences
RP Nouri, HR (通讯作者)，Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran.
EM nourihr851@gmail.com
RI Karkhah, Ahmad/A-2960-2017; Saleki, Kiarash/AGR-4565-2022
OI Karkhah, Ahmad/0000-0002-9511-7839; Saleki, Kiarash/0000-0003-4159-7299;
   Paniri, Alireza/0000-0002-6004-5417
FU deputy for research and technology of Babol University of Medical
   Sciences
FX This work was supported by deputy for research and technology of Babol
   University of Medical Sciences.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arulkumaran N, 2011, EXPERT OPIN INV DRUG, V20, P897, DOI 10.1517/13543784.2011.578068
   Barclay W, 2017, BRAIN PATHOL, V27, P213, DOI 10.1111/bpa.12477
   Blumberg D, 2015, PROG BRAIN RES, V221, P81, DOI 10.1016/bs.pbr.2015.04.007
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Deuteraiou K, 2018, RHEUMATOL INT, V38, P1345, DOI 10.1007/s00296-018-4074-5
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Doyle SL, 2014, NAT MED, V20, P1376, DOI 10.1038/nm.3741
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Hu CY, 2015, P NATL ACAD SCI USA, V112, P11318, DOI 10.1073/pnas.1513509112
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Keating C, 2011, J IMMUNOL, V187, P1467, DOI 10.4049/jimmunol.1100423
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kordes M, 2011, INFECT IMMUN, V79, P3633, DOI 10.1128/IAI.05459-11
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745
   Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124
   Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213
   Leemans JC, 2011, IMMUNOL REV, V243, P152, DOI 10.1111/j.1600-065X.2011.01043.x
   Liu Y, 2015, INNATE IMMUN-LONDON, V21, P587, DOI 10.1177/1753425914566205
   Lopez-Castejon G, 2012, EXPERT OPIN INV DRUG, V21, P995, DOI 10.1517/13543784.2012.690032
   Loukovaara S, 2017, ACTA OPHTHALMOL, V95, P803, DOI 10.1111/aos.13427
   Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Nouri HR, 2016, MOL MED REP, V13, P3356, DOI 10.3892/mmr.2016.4934
   Ozaki E, 2015, J INFLAMM RES, V8, P15, DOI 10.2147/JIR.S51250
   Pelegrin P, 2008, DRUG NEWS PERSPECT, V21, P424, DOI 10.1358/dnp.2008.21.8.1265800
   Planck SR, 2012, ANN RHEUM DIS, V71, P753, DOI 10.1136/annrheumdis-2011-200556
   Pronin A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00036
   Rasoulinejad SA, 2015, J BABOLUNIV MED SCI, V17, P24
   Rasoulinejad SA, 2015, OPEN OPHTHALMOL J, V9, P149, DOI 10.2174/1874364101509010149
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P77
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Rostamtabar M, 2020, GENE, V731, DOI 10.1016/j.gene.2020.144352
   Rubsam A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040942
   Russo R, 2016, EUR J PHARMACOL, V787, P134, DOI 10.1016/j.ejphar.2016.03.064
   Saadi M, 2020, BRAIN RES BULL, V154, P81, DOI 10.1016/j.brainresbull.2019.10.010
   Sasongko MB, 2015, DIABETIC MED, V32, P686, DOI 10.1111/dme.12640
   Schallenberg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033593
   Semeraro F, 2019, DIABETES METAB, V45, P517, DOI 10.1016/j.diabet.2019.04.002
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691
   So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143
   Solomon A, 2001, INVEST OPHTH VIS SCI, V42, P2283
   Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Sutterwala FS, 2007, J LEUKOCYTE BIOL, V82, P259, DOI 10.1189/jlb.1206755
   Szabo G, 2012, J HEPATOL, V57, P642, DOI 10.1016/j.jhep.2012.03.035
   Ting DSW, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0812-9
   Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Voronov E, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00114
   Wannamaker W, 2007, J PHARMACOL EXP THER, V321, P509, DOI 10.1124/jpet.106.111344
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm2
   Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489
   Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Xu HP, 2017, VISION RES, V139, P39, DOI 10.1016/j.visres.2017.04.013
   Xu SC, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0755-0
   Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662
   Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152
NR 80
TC 8
Z9 8
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0892-3973
EI 1532-2513
J9 IMMUNOPHARM IMMUNOT
JI Immunopharmacol. Immunotoxicol.
PD SEP 2
PY 2020
VL 42
IS 5
BP 400
EP 407
DI 10.1080/08923973.2020.1808986
EA AUG 2020
PG 8
WC Immunology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA NR0PI
UT WOS:000564077000001
PM 32791926
DA 2022-11-30
ER

PT J
AU Danca, C
   Costea, CF
   Costan, VV
   Turliuc, MD
   Sava, A
   Turliuc, S
   Cucu, A
   Dragomir, RA
   Scripcariu, IS
   Dumitrescu, N
   Carauleanu, A
AF Danca, Cristina
   Costea, Claudia Florida
   Costan, Victor Vlad
   Turliuc, Mihaela Dana
   Sava, Anca
   Turliuc, Serban
   Cucu, Andrei
   Dragomir, Raluca Alina
   Scripcariu, Ioana Sadiye
   Dumitrescu, Nicoleta
   Carauleanu, Alexandru
TI Gut Microbiota and Serotonin - Biochemical Pathways in Age-Related
   Macular Disease
SO REVISTA DE CHIMIE
LA English
DT Article
DE age-related macular degeneration; microbiota; serotonin; inflammation
ID DEGENERATION
AB Age-related macular degeneration (AMD) is a multifactorial disease and is a major cause of blindness in the entire world. Current studies show a tight connection between gut microbiota and AMD. This literature review shows the positive role played by gut microbiota, which is essential in providing the optimal serotonin level in retina protection against the noxious action of various factors of the environment. Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter derived from tryptophan which is poorly expressed in the retina, but it may provide protection against retinal damage, such as light-induced retinopathy and age-related macular degeneration, due to the fact that certain serotonin receptor agonists and antagonists of those 7 classes and 17 subtypes of 5-HT receptors help prevent serum deprivation, anoxia and oxidative damage. Our study also shows the role played by other diet-related factors, which protect retina against oxidative stress and delay the onset of AMD.
C1 [Danca, Cristina; Costea, Claudia Florida] Prof Dr Nicolae Oblu Emergency Clin Hosp, Ophthalmol Clin 2, 2Ateneului Str, Iasi 700309, Romania.
   [Costea, Claudia Florida] Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, 16 Univ Str, Iasi 700115, Romania.
   [Costan, Victor Vlad; Dragomir, Raluca Alina] Grigore T Popa Univ Med & Pharm, Dept Oral & Maxillo Facial Surg, 16 Univ Str, Iasi 700115, Romania.
   [Turliuc, Mihaela Dana] Grigore T Popa Univ Med & Pharm, Dept Neurosurg, 16 Univ Str, Iasi 700115, Romania.
   [Sava, Anca] Grigore T Popa Univ Med & Pharm, Dept Anat, 16 Univ Str, Iasi 700115, Romania.
   [Turliuc, Serban] Grigore T Popa Univ Med & Pharm, Dept Psychiat, 16 Univ Str, Iasi 700115, Romania.
   [Turliuc, Mihaela Dana; Cucu, Andrei] Prof Dr Nicolae Oblu Emergency Clin Hosp, Neurosurg Clin 2, 2 Ateneului Str, Iasi 700309, Romania.
   [Scripcariu, Ioana Sadiye; Carauleanu, Alexandru] Cuza Voda Hosp Obstet & Gynecol, Clin Gynecol, Iasi, Romania.
   [Dumitrescu, Nicoleta] Grigore T Popa Univ Med & Pharm, 16 Univ Str, Iasi 700115, Romania.
   [Carauleanu, Alexandru] Grigore T Popa Univ Med & Pharm, Dept Obstet & Gynecol, 16 Univ Str, Iasi 700115, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy; Grigore T Popa
   University of Medicine & Pharmacy; Grigore T Popa University of Medicine
   & Pharmacy; Grigore T Popa University of Medicine & Pharmacy; Grigore T
   Popa University of Medicine & Pharmacy; Grigore T Popa University of
   Medicine & Pharmacy; Grigore T Popa University of Medicine & Pharmacy
RP Costea, CF (通讯作者)，Prof Dr Nicolae Oblu Emergency Clin Hosp, Ophthalmol Clin 2, 2Ateneului Str, Iasi 700309, Romania.; Costea, CF (通讯作者)，Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, 16 Univ Str, Iasi 700115, Romania.; Costan, VV (通讯作者)，Grigore T Popa Univ Med & Pharm, Dept Oral & Maxillo Facial Surg, 16 Univ Str, Iasi 700115, Romania.
EM costea10@yahoo.com; victorcostan@gmail.com
RI Alexandru, Carauleanu/AAO-2262-2020; Costan, Victor Vlad/B-6961-2018;
   Costea, Claudia Florida/AAL-4352-2020; Sava, Anca/AAL-6304-2020;
   Dragomir, Raluca Alina/AAV-7080-2020; Cucu, Andrei Ionut/AAI-1078-2020
OI Alexandru, Carauleanu/0000-0001-9112-7039; Costan, Victor
   Vlad/0000-0002-3978-5103; Dragomir, Raluca Alina/0000-0002-1572-076X;
   Cucu, Andrei Ionut/0000-0003-1441-1751
CR Anderson G, 2016, CURR PHARM DESIGN, V22, P6142, DOI 10.2174/1381612822666160906161513
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bogdanici ST, 2015, MED-SURG J, V119, P214
   Bogdanici ST, 2016, REV CERCET INTERV SO, V52, P187
   Chassaing B, 2014, TOXICOL PATHOL, V42, P49, DOI 10.1177/0192623313508481
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cowen DS, 2007, J NEUROCHEM, V101, P1161, DOI 10.1111/j.1471-4159.2006.04420.x
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   GLENN J. V., 1790, BIOCHIM BIOPHYS ACTA, V10, P1109
   Gonzalez-Flores D, 2011, J FOOD NUTR RES-SLOV, V50, P229
   Gordon JI, 2012, SCIENCE, V336, P1251, DOI 10.1126/science.1224686
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hold GL, 2016, DIGEST DIS, V34, P244, DOI 10.1159/000443358
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Nicholson JK, 2003, NAT REV DRUG DISCOV, V2, P668, DOI 10.1038/nrd1157
   Nitulescu GM, 2017, REV CHIM-BUCHAREST, V68, P754
   REMAROLI F., 2012, NATURE, P242
   RHOADES K. L., 2009, INVEST OPHTH VIS SCI, V50, P677
   SONG S. J., 2013, ELIFE, P45
   Tiutiuca C, 2016, REV CHIM-BUCHAREST, V67, P1641
   TURNBAUGH P. J., 2013, NATURE, P1027
   WANG Y. M., 2009, IVOS, V50, P585
NR 24
TC 1
Z9 1
U1 1
U2 9
PU REVISTA CHIMIE SRL
PI BUCURESTI
PA CALES PLEVNEI NR 139A, SECTOR 6, BUCURESTI, ROMANIA
SN 0034-7752
J9 REV CHIM-BUCHAREST
JI Rev. Chim.
PD OCT
PY 2018
VL 69
IS 10
BP 2823
EP 2825
PG 3
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering
GA HC6QB
UT WOS:000451925300045
DA 2022-11-30
ER

PT J
AU Thierry, M
   Pasquis, B
   Acar, N
   Gregoire, S
   Febvret, V
   Buteau, B
   Gambert-Nicot, S
   Bron, AM
   Creuzot-Garcher, CP
   Bretillon, L
AF Thierry, Magalie
   Pasquis, Bruno
   Acar, Niyazi
   Gregoire, Stephane
   Febvret, Valerie
   Buteau, Benedicte
   Gambert-Nicot, Segolene
   Bron, Alain M.
   Creuzot-Garcher, Catherine P.
   Bretillon, Lionel
TI Metabolic Syndrome Triggered by High-Fructose Diet Favors Choroidal
   Neovascularization and Impairs Retinal Light Sensitivity in the Rat
SO PLOS ONE
LA English
DT Article
ID ELECTRORETINOGRAPHIC OSCILLATORY POTENTIALS; INDUCED INSULIN-RESISTANCE;
   FATTY-ACID PROFILE; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   ANIMAL-MODELS; HEPATIC STEATOSIS; MOUSE; ASSOCIATION; ADIPOSITY
AB Diabetic retinopathy and age-related macular degeneration are the leading causes of blindness in Western populations. Although it is a matter of controversy, large-scale population-based studies have reported increased prevalence of age-related macular degeneration in patients with diabetes or diabetic retinopathy. We hypothesized that metabolic syndrome, one of the major risk factors for type 2 diabetes, would represent a favorable environment for the development of choroidal neovascularization, the main complication of age-related macular degeneration. The fructose-fed rat was used as a model for metabolic syndrome in which choroidal neovascularization was induced by laser photocoagulation. Male Brown Norway rats were fed for 1, 3, and 6 months with a standard equilibrated chow diet or a 60%-rich fructose diet (n = 24 per time point). The animals expectedly developed significant body adiposity (+17%), liver steatosis at 3 and 6 months, hyperleptinemia at 1 and 3 months (two-fold increase) and hyperinsulinemia at 3 and 6 months (up to two-fold increase), but remained normoglycemic and normolipemic. The fructose-fed animals exhibited partial loss of rod sensitivity to light stimulus and reduced amplitude of oscillatory potentials at 6 months. Fructose-fed rats developed significantly more choroidal neovascularization at 14 and 21 days post-laser photocoagulation after 1 and 3 months of diet compared to animals fed the control diet. These results were consistent with infiltration/activation of phagocytic cells and up-regulation of pro-angiogenic gene expression such as Vegf and Leptin in the retina. Our data therefore suggested that metabolic syndrome would exacerbate the development of choroidal neovascularization in our experimental model.
C1 [Thierry, Magalie; Pasquis, Bruno; Acar, Niyazi; Gregoire, Stephane; Febvret, Valerie; Buteau, Benedicte; Gambert-Nicot, Segolene; Bron, Alain M.; Creuzot-Garcher, Catherine P.; Bretillon, Lionel] INRA, Ctr Sci Gout & Alimentat, Eye & Nutr Res Grp, UMR 1324, F-21034 Dijon, France.
   [Thierry, Magalie; Pasquis, Bruno; Acar, Niyazi; Gregoire, Stephane; Febvret, Valerie; Buteau, Benedicte; Gambert-Nicot, Segolene; Bron, Alain M.; Creuzot-Garcher, Catherine P.; Bretillon, Lionel] INRA, Ctr Sci Gout & Alimentat, UMR 6265, F-21034 Dijon, France.
   [Thierry, Magalie; Pasquis, Bruno; Acar, Niyazi; Gregoire, Stephane; Febvret, Valerie; Buteau, Benedicte; Gambert-Nicot, Segolene; Bron, Alain M.; Creuzot-Garcher, Catherine P.; Bretillon, Lionel] Univ Bourgogne, Ctr Sci Gout & Alimentat, Dijon, France.
   [Gambert-Nicot, Segolene] Univ Hosp, Dept Clin Chem, Dijon, France.
   [Bron, Alain M.; Creuzot-Garcher, Catherine P.] Univ Hosp, Dept Ophthalmol, Dijon, France.
C3 INRAE; Institut Agro; AgroSup Dijon; Centre National de la Recherche
   Scientifique (CNRS); Universite de Bourgogne; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); INRAE; Institut Agro; AgroSup Dijon; Universite de Bourgogne;
   Institut Agro; AgroSup Dijon; Centre National de la Recherche
   Scientifique (CNRS); Universite de Bourgogne; CHU Dijon Bourgogne; CHU
   Dijon Bourgogne
RP Bretillon, L (通讯作者)，INRA, Ctr Sci Gout & Alimentat, Eye & Nutr Res Grp, UMR 1324, F-21034 Dijon, France.
EM lionel.bretillon@dijon.inra.fr
RI Bron, Alain/AAP-8010-2020
OI Bron, Alain/0000-0002-7265-931X; Bretillon, Lionel/0000-0002-6957-100X
FU Laboratoires Horus Pharma (Saint Laurent du Var, France); INRA-AlimH;
   CNRS; Universite de Bourgogne; Regional Council of Burgundy France (PARI
   Agrale 1); FEDER (European Funding for Regional Economic Development);
   French Government [ANR-11-LABX-0021-01-LipSTIC Labex]
FX This work was supported by Laboratoires Horus Pharma (Saint Laurent du
   Var, France), INRA-AlimH, CNRS, Universite de Bourgogne, Regional
   Council of Burgundy France (PARI Agrale 1), FEDER (European Funding for
   Regional Economic Development), and French Government grant managed by
   the French National Research Agency (ANR) under the "Investissements
   d'Avenir'' program with reference ANR-11-LABX-0021-01-LipSTIC Labex. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ackman R G, 1981, Methods Enzymol, V72, P205
   Andreoli MF, 2010, LIPIDS, V45, P1035, DOI 10.1007/s11745-010-3466-4
   Aung MH, 2013, INVEST OPHTH VIS SCI, V54, P1370, DOI 10.1167/iovs.12-10927
   Beltran-Sanchez H, 2013, J AM COLL CARDIOL, V62, P697, DOI 10.1016/j.jacc.2013.05.064
   BRESNICK GH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1307, DOI 10.1001/archopht.1984.01040031057023
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Dekker MJ, 2010, AM J PHYSIOL-ENDOC M, V299, pE685, DOI 10.1152/ajpendo.00283.2010
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Elliott SS, 2002, AM J CLIN NUTR, V76, P911, DOI 10.1093/ajcn/76.5.911
   Ferrannini E, 2011, MED CLIN N AM, V95, P327, DOI 10.1016/j.mcna.2010.11.005
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Fourgeux C, 2014, BIOCHEM BIOPH RES CO, V446, P775, DOI 10.1016/j.bbrc.2014.01.118
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Han MS, 2013, SCIENCE, V339, P218, DOI 10.1126/science.1227568
   Hancock HA, 2004, INVEST OPHTH VIS SCI, V45, P1002, DOI 10.1167/iovs.03-1080
   Holopigian K, 1997, INVEST OPHTH VIS SCI, V38, P2355
   HWANG IS, 1989, AM J HYPERTENS, V2, P424, DOI 10.1093/ajh/2.6.424
   HWANG IS, 1987, HYPERTENSION, V10, P512, DOI 10.1161/01.HYP.10.5.512
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jaissle GB, 2001, INVEST OPHTH VIS SCI, V42, P506
   Jesmin S, 2013, THROMB HAEMOSTASIS, V109, P696, DOI 10.1160/TH12-09-0654
   JUEN S, 1990, ARCH OPHTHALMOL-CHIC, V108, P372, DOI 10.1001/archopht.1990.01070050070033
   Jurgens H, 2005, OBES RES, V13, P1146, DOI 10.1038/oby.2005.136
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   LACHAPELLE P, 1989, DOC OPHTHALMOL, V73, P327, DOI 10.1007/BF00154488
   Lutty GA, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12979
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mishra S, 2013, J NUTR METAB, V2013, DOI 10.1155/2013/327079
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   MORRISON WR, 1964, J LIPID RES, V5, P600
   Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Park SH, 2003, DIABETOLOGIA, V46, P1260, DOI 10.1007/s00125-003-1177-6
   Reaven G, 2005, CIRCULATION, V112, P3030, DOI 10.1161/CIRCULATIONAHA.105.504670
   Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x
   Robinson R, 2012, DIS MODEL MECH, V5, P444, DOI 10.1242/dmm.009597
   SEBEDIO JL, 1987, J CHROMATOGR, V405, P371, DOI 10.1016/S0021-9673(01)81779-9
   Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712
   Shirao Y, 1998, PROG RETIN EYE RES, V17, P59, DOI 10.1016/S1350-9462(97)00005-0
   Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683
   Stanhope KL, 2009, J CLIN INVEST, V119, P1322, DOI 10.1172/JCI37385
   Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405
   Suganami E, 2004, DIABETES, V53, P2443, DOI 10.2337/diabetes.53.9.2443
   Tappy L, 2010, PHYSIOL REV, V90, P23, DOI 10.1152/physrev.00019.2009
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Tinsley FC, 2004, OBES RES, V12, P150, DOI 10.1038/oby.2004.20
   TOBEY TA, 1982, METABOLISM, V31, P608, DOI 10.1016/0026-0495(82)90100-7
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Vadala M, 2002, ACTA OPHTHALMOL SCAN, V80, P305, DOI 10.1034/j.1600-0420.2002.800314.x
   Vernay M, 2013, INT J PUBLIC HEALTH, V58, P855, DOI 10.1007/s00038-013-0501-2
   WACHTMEISTER L, 1978, INVEST OPHTH VIS SCI, V17, P1176
   Wu XL, 2011, J AGR FOOD CHEM, V59, P747, DOI 10.1021/jf1038426
   ZAVARONI I, 1980, METABOLISM, V29, P970, DOI 10.1016/0026-0495(80)90041-4
NR 59
TC 10
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2014
VL 9
IS 11
AR e112450
DI 10.1371/journal.pone.0112450
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AT3WF
UT WOS:000344863100097
PM 25380250
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Semoun, O
   Coscas, F
   Coscas, G
   Lalloum, F
   Srour, M
   Souied, EH
AF Semoun, Oudy
   Coscas, Florence
   Coscas, Gabriel
   Lalloum, Franck
   Srour, Mayer
   Souied, Eric H.
TI En face enhanced depth imaging optical coherence tomography of
   polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXUDATIVE MACULAR DISEASES; DEGENERATION; THICKNESS; VISUALIZATION;
   ANGIOGRAPHY; MACULOPATHY; FEATURES; LESIONS
AB Purpose To analyse retinal and choroidal changes associated with polypoidal choroidal vasculopathy (PCV) using en face spectral-domain optical coherence tomography (SD-OCT).
   Methods In this retrospective and descriptive study, we collected imaging of patients affected with PCV examined using enhanced depth imaging (EDI) SD-OCT, fluorescein and indocyanine green angiography for a qualitative analysis. The three-dimensional reconstruction of 197 transverse sections with EDI SD-OCT at 30 mu m intervals provided a virtual macular brick through which 496 sections in the coronal plane resulted in a C-scan or en face OCT image.
   Results 30 eyes of 30 patients affected with PCV were studied. En face OCT revealed polyps as roundish structures visible deeper than pigment epithelium layer, attached to its posterior face, easily detected in all cases. Hyper-reflective dots were visible on en face OCT in all cases within the retinal layers, associated to a well-defined dark area suggesting serous exudation in 27 eyes. The abnormal choroidal network was identified in four eyes. At the Bruch membrane level, all polyps were associated with a localised back shadowing, and were no more visible at the choriocapillaris layer level. Large choroidal vessels were visible in all eyes, mainly at the polypoidal lesion periphery, not directly behind.
   Conclusions En face OCT imaging using SD-OCT is an easy, reproducible, non-invasive and effective tool to visualise and to understand retinal and choroidal changes PCV. It provides complementary morphological information, describes new semiological entities and might substitute other exams in the future, without dye injection.
C1 [Semoun, Oudy; Coscas, Florence; Coscas, Gabriel; Lalloum, Franck; Srour, Mayer; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Univ Eye Clin Creteil, Paris, France.
   [Coscas, Florence; Coscas, Gabriel] Ctr Explorat Ophtalmol Odeon, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Semoun, O (通讯作者)，Ctr Hosp Intercommunal Creteil, Serv Ophtalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM oudysemoun@hotmail.com
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   Coscas F, 2011, EUR J OPHTHALMOL, V21, P331, DOI 10.5301/EJO.2010.2803
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gass JDM., 1987, STEREOSCOPIC ATLAS M, V1
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kodach VM, 2010, BIOMED OPT EXPRESS, V1, P176, DOI 10.1364/BOE.1.000176
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lau T, 2015, INDIAN J OPHTHALMOL, V63, P378, DOI 10.4103/0301-4738.159860
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Park SY, 2013, AM J OPHTHALMOL, V156, P557, DOI 10.1016/j.ajo.2013.04.027
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   Sa Ho-Seok, 2005, Korean J Ophthalmol, V19, P275
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 33
TC 12
Z9 13
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2016
VL 100
IS 8
BP 1028
EP 1034
DI 10.1136/bjophthalmol-2015-307494
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4JR
UT WOS:000380747900003
PM 26541431
DA 2022-11-30
ER

PT J
AU Shin, JY
   Lee, JM
   Byeon, SH
AF Shin, Joo Youn
   Lee, Ji-Min
   Byeon, Suk Ho
TI Anti-Vascular Endothelial Growth Factor With or Without Pneumatic
   Displacement for Submacular Hemorrhage
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; CHOROIDAL NEOVASCULAR LESIONS; SUBRETINAL
   HEMORRHAGE; INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; NATURAL-HISTORY; SECONDARY; RANIBIZUMAB; MANAGEMENT
AB PURPOSE: To compare the treatment outcomes of a combination of pneumatic displacement and intravitreal anti-vascular endothelial growth factor, and anti-vascular endothelial growth factor monotherapy for submacular hemorrhage resulting from exudative age-related macular degeneration.
   DESIGN: Retrospective, comparative, interventional case series.
   METHODS: Forty eyes treated with a combination therapy and 42 eyes treated with monotherapy for submacular hemorrhage resulting from exudative age-related macular degeneration with no significant difference in baseline central foveal thickness were compared. Central foveal thickness and best-corrected visual acuity (BCVA) at baseline, 1, 3, and 6 months after initial treatment were measured and compared between the 2 groups after adjustment of baseline central foveal thickness.
   RESULTS: Central foveal thickness (P < .0001) and BCVA (combination, P < .0001; monotherapy, P = .022) were improved after both treatments. Combination therapy showed more rapid improvement of central foveal thickness (P = .009) and BCVA (P = .007) within 1 month than monotherapy, but there was no difference at 6 months (P = .385 and P = .303, respectively). In eyes with subretinal hemorrhage thicker than 450 mu m, visual outcome at 6 months was better in the combination therapy group than in the monotherapy group (P = .021), whereas BCVA showed no significant difference between groups in eyes with subretinal hemorrhage less than 450 mu m (P = .930).
   CONCLUSIONS: Both treatments are useful options for submacular hemorrhage resulting from exudative age-related macular degeneration. Combination therapy may yield a better treatment outcome than monotherapy in eyes with thick subretinal hemorrhage. Nevertheless, the potential for adverse events resulting from pneumatic displacement should be considered. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Shin, Joo Youn; Lee, Ji-Min; Byeon, Suk Ho] Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, Seoul 120749, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Shinchon Dong, Seoul 120749, South Korea.
EM shbyeon@yuhs.ac
OI Byeon, suk ho/0000-0001-8101-0830; Shin, Joo Youn/0000-0003-4543-477X
FU Basic Science Research Program through the National Research Foundation
   of South Korea (NRF) - Ministry of Education [2013R1A1A2007865]
FX Supported by Grant 2013R1A1A2007865 from the Basic Science Research
   Program through the National Research Foundation of South Korea (NRF)
   funded by the Ministry of Education. The funding organizations had no
   role in the design or conduct of this research. The authors were
   independent in reporting the study data and interpretation of the data.
   Involved in Design of study (J.Y.S., S.H.B.); Conduct of study (J.Y.S.,
   J.L., S.H.B.); Collection, management, analysis, and interpretation of
   data (J.Y.S., J.L., S.H.B.); Preparation of manuscript (J.Y.S., J.L.,
   S.H.B.); and Review or approval of manuscript (J.Y.S., J.L., S.H.B.).
   Each author is responsible for the integrity of the entire study and
   manuscript. Each author has seen and agrees with each of the changes
   made to this manuscript in the revision and to the way his and her name
   is listed. The authors thank Jung Hwa Hong, Biostatistics Collaboration
   Unit, Yonsei University College of Medicine, for statistical support and
   Dong-Su Jang, MFA, Medical Illustrator, Medical Research Support
   Section, Yonsei University College of Medicine, for his help with the
   illustrations.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Cho HJ, 2015, RETINA-J RET VIT DIS, V35, P205, DOI 10.1097/IAE.0000000000000295
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   HILTON GF, 1987, OPHTHALMOLOGY, V94, P307
   Hohn F, 2010, OPHTHALMOLOGE, V107, P328, DOI 10.1007/s00347-009-2004-3
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881
   Obuchowska I, 2005, EUR J OPHTHALMOL, V15, P712, DOI 10.1177/112067210501500609
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
NR 32
TC 27
Z9 29
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2015
VL 159
IS 5
BP 904
EP 914
DI 10.1016/j.ajo.2015.01.024
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5VW
UT WOS:000353365000011
PM 25637179
DA 2022-11-30
ER

PT J
AU Querques, G
   Capuano, V
   Frascio, P
   Zweifel, S
   Georges, A
   Souied, EH
AF Querques, Giuseppe
   Capuano, Vittorio
   Frascio, Pietro
   Zweifel, Sandrine
   Georges, Anouk
   Souied, Eric H.
TI WEDGE-SHAPED SUBRETINAL HYPOREFLECTIVITY IN GEOGRAPHIC ATROPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION
AB Purpose:
   To describe wedge-shaped subretinal hyporeflectivity, a peculiar spectral domain optical coherence tomography finding in geographic atrophy (GA) areas of atrophic age-related macular degeneration.
   Methods:
   We reviewed the charts of consecutive patients with GA who presented between January 2012 and December 2013. A standardized imaging protocol was performed in all patients, which included blue fundus autofluorescence, and spectral domain optical coherence tomography.
   Results:
   Wedge-shaped subretinal hyporeflective lesions were found in 12 of 161 included eyes (11 of 94 consecutive patients, 6 males/5 females, mean age 79.6 +/- 9.3 years). On spectral domain optical coherence tomography, regions immediately adjacent to the wedge-shaped subretinal hyporeflective lesions were characterized by absence of the hyporeflective outer nuclear layer, the hyperreflective external limiting membrane, the ellipsoid zone, the interdigitation zone, and the retinal pigment epithelium. On "en face" images, they appeared as round-oval hyporeflectivities delimited by hyperreflective borders, which we interpreted as the outer plexiform layer. Mean GA area was significantly larger in eyes with as compared with eyes without wedge-shaped subretinal hyporeflective lesions. Overall, the dimensions of the wedge-shaped subretinal hyporeflective lesions did not change after a mean of similar to 15 months.
   Conclusion:
   Wedge-shaped subretinal hyporeflectivity, a previously unreported peculiar finding in GA areas of atrophic age-related macular degeneration eyes, appears delimited internally by the hyperreflective outer plexiform layer and externally by the hyperreflective Bruch membrane. These lesions, which are detected in eyes with large GA (even though stable over time), should be recognized and distinguished from subretinal fluid (and other exudative signs of age-related macular degeneration) because their presence should not require prompt treatment.
C1 [Querques, Giuseppe; Capuano, Vittorio; Frascio, Pietro; Zweifel, Sandrine; Georges, Anouk; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Querques, Giuseppe] Univ Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Zweifel, Sandrine/AAX-5045-2020
OI Querques, Giuseppe/0000-0002-3292-9581
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 20
TC 22
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2015
VL 35
IS 9
BP 1735
EP 1742
DI 10.1097/IAE.0000000000000553
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2YK
UT WOS:000361196600004
PM 25923956
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bereimipour, A
   Satarian, L
   Taleahmad, S
AF Bereimipour, Ahmad
   Satarian, Leila
   Taleahmad, Sara
TI Investigation of Key Signaling Pathways Associating miR-204 and Common
   Retinopathies
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OPEN-ANGLE GLAUCOMA; RETINOBLASTOMA CELLS;
   EXPRESSION; PROLIFERATION; ADHESION; DEGENERATION; MICRORNAS; JUNCTIONS;
   KINASE
AB MicroRNAs are a large group of small noncoding RNAs that work in multiple cellular pathways. miR-204, as one of the key axes in the development, maintenance, and pathogenesis of the retina, plays several roles by modulating its target genes. This study was aimed at evaluating the target genes of miR-204 involved in the development and progression of common retinopathies such as glaucoma, retinoblastoma, and age-related macular degeneration. In this study, three datasets related to retinopathies (GSE50195, GSE27276, and GSE97508) were selected from Gene Expression Omnibus. miR-204 target genes were isolated from TargeScan. The shares between retinopathy and miR-204 target genes were then categorized. Using Enrichr and STRING, we highlighted the signaling pathways and the relationships between the proteins. SHC1 events in ERBB2, adherent junction's interactions, NGF signaling via TRKA from the plasma membrane, IRF3-mediated activation of type 1 IFN, pathways in upregulated genes and G0 and early G1, RORA-activated gene expression, PERK-regulated gene expression, adherent junction's interactions, and CREB phosphorylation pathways in downregulated genes were identified in glaucoma, retinoblastoma, and age-related macular degeneration. WEE1, SMC2, HMGB1, RRM2, and POLA1 proteins were also observed to be involved in the progression and invasion of retinoblastoma; SLC24A2 and DTX4 in age-related macular degeneration; and EPHB6, EFNB3, and SHC1 in glaucoma. Continuous bioinformatics analysis has shown that miR-204 has a significant presence and expression in retinal tissue, and approximately 293 genes are controlled and regulated by miR-204 in this tissue; also, target genes of miR-204 have the potential to develop various retinopathies; thus, a study of related target genes can provide appropriate treatment strategies in the future.
C1 [Bereimipour, Ahmad; Satarian, Leila] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.
   [Bereimipour, Ahmad] Univ Sci & Culture, Fac Sci & Adv Technol Biol, Tehran, Iran.
   [Taleahmad, Sara] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Mol Syst Biol, Tehran, Iran.
C3 Academic Center for Education, Culture & Research (ACECR); Academic
   Center for Education, Culture & Research (ACECR)
RP Satarian, L (通讯作者)，ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.; Taleahmad, S (通讯作者)，ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Mol Syst Biol, Tehran, Iran.
EM ahmadlta@yahoo.com; l.satarian@royan-rc.ac.ir; sara_taleahmad@yahoo.com
RI Bereimipour, Ahmad/ABE-8857-2021
OI Bereimipour, Ahmad/0000-0002-6758-9599; Taleahmad,
   Sara/0000-0003-4666-1907
CR Ashikawa Y, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00266
   Bereimipour A, 2021, EXP CELL RES, V406, DOI 10.1016/j.yexcr.2021.112737
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cao MJ, 2020, PEERJ, V8, DOI 10.7717/peerj.8873
   Cao W, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1125-4
   Cassoux N, 2017, ASIA-PAC J OPHTHALMO, V6, P290, DOI 10.22608/APO.201778
   Chai Y, 2018, INT J MOL MED, V41, P1651, DOI 10.3892/ijmm.2018.3379
   Chehrazi P., 2017, PAPYRUS
   Chen Liwen, 2016, Vision (Basel), V1, DOI 10.3390/vision1010004
   Chen X, 2017, EXP THER MED, V14, P3651, DOI 10.3892/etm.2017.4931
   Conte I, 2013, CELL MOL LIFE SCI, V70, P4141, DOI 10.1007/s00018-013-1335-z
   Conte I, 2010, P NATL ACAD SCI USA, V107, P15491, DOI 10.1073/pnas.0914785107
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Doh SH, 2010, BRAIN RES, V1308, P158, DOI 10.1016/j.brainres.2009.10.025
   Feng J, 2019, MOL MED REP, V20, P216, DOI 10.3892/mmr.2019.10236
   Galardi A, 2020, CANCERS, V12, DOI 10.3390/cancers12061555
   Ganguly A, 2010, MOL VIS, V16, P1292
   Garcia TB, 2017, CYTOKINE GROWTH F R, V34, P43, DOI 10.1016/j.cytogfr.2016.11.005
   Gavini E, 2018, CURR DRUG DELIV, V15, P930, DOI 10.2174/1567201815666180226121020
   Geenen JJJ, 2017, CLIN CANCER RES, V23, P4540, DOI 10.1158/1078-0432.CCR-17-0520
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Honavar S.G., 2019, J RADIAT CANCER RES, V10, P85, DOI [10.4103/jrcr.jrcr_7_19, DOI 10.4103/JRCR.JRCR_7_19]
   Jo DH, 2017, ONCOTARGET, V8, P15441, DOI 10.18632/oncotarget.14487
   Katritch V, 2011, NEUROPHARMACOLOGY, V60, P108, DOI 10.1016/j.neuropharm.2010.07.009
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kwon HS, 2013, J BIOL CHEM, V288, P26357, DOI 10.1074/jbc.M112.446138
   Lazzara F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01063
   Leske MC, 2007, OPHTHAL EPIDEMIOL, V14, P166, DOI 10.1080/09286580701501931
   Liesenborghs I, 2020, ACTA OPHTHALMOL, V98, P48, DOI 10.1111/aos.14154
   Liu HJ, 2019, MOL MED REP, V19, P5321, DOI 10.3892/mmr.2019.10206
   Liu YM, 2018, INVEST OPHTH VIS SCI, V59, P2955, DOI 10.1167/iovs.17-23599
   Maisto R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00235
   Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nie C, 2021, OPHTHALMOLOGICA, V244, P51, DOI 10.1159/000506993
   Oddone F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168565
   Park YG, 2001, BIOCHEM BIOPH RES CO, V281, P1213, DOI 10.1006/bbrc.2001.4521
   Platania CBM, 2019, BRIT J PHARMACOL, V176, P2179, DOI 10.1111/bph.14665
   Qiu HY, 2018, INT OPHTHALMOL, V38, P19, DOI 10.1007/s10792-017-0704-2
   Rajasekaran S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00221
   Reh TA, 2018, ANNU REV VIS SCI, V4, P25, DOI 10.1146/annurev-vision-091517-034357
   Shekarabi M, 2005, J NEUROSCI, V25, P3132, DOI 10.1523/JNEUROSCI.1920-04.2005
   Shetty T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01015
   Siffroi-Fernandez S, 2005, ARCH OPHTHALMOL-CHIC, V123, P368, DOI 10.1001/archopht.123.3.368
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Su T, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20200776
   Valastyan S, 2011, J CELL SCI, V124, P999, DOI 10.1242/jcs.081513
   Wang JB, 2016, J BIOL CHEM, V291, P18084, DOI 10.1074/jbc.M116.732339
   Wang LL, 2017, INT J OPHTHALMOL-CHI, V10, P30, DOI 10.18240/ijo.2017.01.05
   Wang NY, 2018, MOL MED REP, V17, P3891, DOI 10.3892/mmr.2017.8341
   Wang S, 2019, CANCER MANAG RES, V11, P3111, DOI 10.2147/CMAR.S200566
   Wang YW, 2019, INVEST OPHTH VIS SCI, V60, P265, DOI 10.1167/iovs.18-25477
   Wilkerson JL, 2019, MOL NEUROBIOL, V56, P7188, DOI 10.1007/s12035-019-1599-x
   Wu C, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.2
   Wu XJ, 2015, FEBS LETT, V589, P645, DOI 10.1016/j.febslet.2015.01.030
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Xu HZ, 2012, OPHTHALMIC RES, V47, P163, DOI 10.1159/000331428
   Yang Y, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa538
   YuSu Y.Y., 2014, EXPRIMENTAL EYE RES, V203, P18, DOI [10.18632/oncotarget.1686, DOI 10.18632/ONCOTARGET.1686]
   Zeng YY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023314
   Zhang JY, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/2714746
   Zhang SH, 2019, CURR OPIN CELL BIOL, V61, P64, DOI 10.1016/j.ceb.2019.07.006
   Zhao B, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0498-z
NR 64
TC 0
Z9 0
U1 4
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD OCT 4
PY 2021
VL 2021
AR 5568113
DI 10.1155/2021/5568113
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA XP6CF
UT WOS:000730950400007
PM 34646884
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Daizumoto, E
   Mitamura, Y
   Sano, H
   Akaiwa, K
   Niki, M
   Yamanaka, C
   Kinoshita, T
   Egawa, M
   Sonoda, S
   Sakamoto, T
AF Daizumoto, Erina
   Mitamura, Yoshinori
   Sano, Hiroki
   Akaiwa, Kei
   Niki, Masanori
   Yamanaka, Chihiro
   Kinoshita, Takamasa
   Egawa, Mariko
   Sonoda, Shozo
   Sakamoto, Taiji
TI Changes of choroidal structure after intravitreal aflibercept therapy
   for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY; MACULAR
   DEGENERATION; HEALTHY EYES; MORPHOLOGIC FEATURES; VASCULARITY INDEX;
   THICKNESS; BINARIZATION; IMAGES
AB Aims To quantify the changes of the choroidal structure in the enhanced depth imaging optical coherence tomographic (EDI-OCT) images after intravitreal aflibercept (IVA) injections for polypoidal choroidal vasculopathy (PCV).
   Methods Retrospective, observational case series. Forty eyes of 40 treatment-naive patients who underwent IVA for PCV were examined by EDI-OCT before, and 3 months and 12 months after IVA. The EDI-OCT images were binarised by ImageJ software. The cross-sectional luminal and stromal areas of the inner and outer subfoveal choroid of 1500 mm width were quantified.
   Results The stromal but not the luminal area of the inner choroid was significantly decreased at 3 months and 12 months after the IVA (stromal area, both p< 0.001; luminal area, both p>0.050). On the other hand, the luminal but not the stromal area of the outer choroid was significantly decreased at 3 months and 12 months (luminal area, both p< 0.001; stromal area, both p>0.050). The Pachychoroid Index, ratio of luminal/stromal area (L/S ratio) of the outer choroid divided by the L/S ratio of the inner choroid, was significantly decreased at 3 months and 12 months (both p< 0.050). The Pachychoroid Index was increased and returned almost to the baseline level after recurrences and decreased again after successful re-treatment. The baseline Pachychoroid Index was significantly correlated with the presence of a dry macula, thinner fovea and better visual acuity at 12 months (all p< 0.050).
   Conclusion The binarisation of the EDI-OCT images can be used to quantify the activity of PCV and to predict the prognosis after IVA.
C1 [Daizumoto, Erina; Mitamura, Yoshinori; Sano, Hiroki; Akaiwa, Kei; Niki, Masanori; Yamanaka, Chihiro; Kinoshita, Takamasa; Egawa, Mariko] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Ophthalmol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.
   [Sonoda, Shozo; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan.
C3 Tokushima University; Kagoshima University
RP Mitamura, Y (通讯作者)，Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Ophthalmol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.
EM ymitaymitaymita@yahoo.co.jp
RI Kinoshita, Takamasa/S-9174-2019
OI Kinoshita, Takamasa/0000-0002-0465-2140
FU Ministry of Education, Science, Sports and Culture, Japan [16K11288];
   Bayer Japan
FX This work was supported in part by grant-in-aid 16K11288 (to YM) from
   the Ministry of Education, Science, Sports and Culture, Japan, as well
   as by the grant from Bayer Japan to the Tokushima University.
CR Adhi M, 2013, JAMA OPHTHALMOL, V131, P1267, DOI 10.1001/jamaophthalmol.2013.4321
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Egawa M, 2017, BR J OPHTHALMOL, V101, P56
   Egawa M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0127-7
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kinoshita T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163104
   Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park KA, 2014, AM J OPHTHALMOL, V158, P716, DOI 10.1016/j.ajo.2014.07.008
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2893, DOI 10.1167/iovs.12-11085
   Sonoda S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157190
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
NR 25
TC 15
Z9 16
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2017
VL 101
IS 1
BP 56
EP 61
DI 10.1136/bjophthalmol-2016-309694
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ6BP
UT WOS:000393303800011
PM 27974321
DA 2022-11-30
ER

PT J
AU Yan, YC
AF Yan, YC
TI Preserving vision with verteporfin photodynamic therapy
SO HOSPITAL MEDICINE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; CONTRAST
   SENSITIVITY
AB Wet age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. Verteporfin photodynamic therapy (PDT) is significantly effective in preventing visual loss in patients with subfoveal choroidal neovascularization caused by exudative AMD. This article reviews verteporfin PDT and discusses treatment and evolving appraisal guidance.
C1 Wolverhampton Eye Infirm, Wolverhampton, W Midlands, England.
RP Yan, YC (通讯作者)，Wolverhampton Eye Infirm, Wolverhampton, W Midlands, England.
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   [Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   *EARL TREATM DIAB, 1987, INT OPHTHALMOL CLIN, V27, P265
   EVANS J, 1993, BR J OPHTHALMOL, V80, P9
   GAFFNEY J, 1985, J CELL SCI, V79, P317
   GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97
   Harding S, 2001, EYE, V15, P407, DOI 10.1038/eye.2001.145
   *NAT I CLIN EXC, 2003, TECHN APPR GUID, V68
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   TALKS SJ, 2003, ANN C ROYAL COLL OPH
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 30
TC 1
Z9 1
U1 0
U2 0
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 1462-3935
J9 HOSP MED
JI Hosp. Med
PD JAN
PY 2004
VL 65
IS 1
BP 39
EP 43
DI 10.12968/hosp.2004.65.1.2417
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 763ZK
UT WOS:000188163400009
PM 14964795
DA 2022-11-30
ER

PT J
AU Wang, SS
   Cunnusamy, K
AF Wang, Shusheng
   Cunnusamy, Khrishen
TI Pharmaceutical composition for treating macular degeneration
   (WO2012079419)
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   traditional Chinese medicine
ID CHINESE HERB PAIRS; CHOROIDAL NEOVASCULARIZATION; ANTIINFLAMMATORY
   ACTIVITY; ANGELICA SINENSIS; PANAX-NOTOGINSENG; EXPRESSION; CELLS;
   MODEL; EXTRACT
AB A pharmaceutical composition composed of several traditional Chinese medicines is claimed to treat age-related macular degeneration (AMD). This represents a novel and alternative therapeutic solution for wet AMD, with the potential advantage of treating both the symptoms and the underlying causes of this devastating degenerative retinal disease.
C1 [Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Wang, Shusheng] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
   [Cunnusamy, Khrishen] Univ Texas SW Med Ctr, Dept Pathol, Houston, TX USA.
C3 Tulane University; Tulane University; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Wang, SS (通讯作者)，Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
EM swang1@tulane.edu
FU Tulane University; NIH [EY021862]; 'Research to prevent Blindness Career
   Development' Award; NATIONAL EYE INSTITUTE [R01EY021862] Funding Source:
   NIH RePORTER
FX This manuscript was partially supported by a start-up fund from Tulane
   University, an NIH grant (EY021862), and a 'Research to prevent
   Blindness Career Development' Award. The authors state no other conflict
   of interest.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, p[57, e55]
   Chang SH, 2007, CLIN NUTR, V26, P785, DOI 10.1016/j.clnu.2007.07.008
   Cho IH, 2011, BIOSCI BIOTECH BIOCH, V75, P1440, DOI 10.1271/bbb.110076
   Choi Roy Chi-Yan, 2010, Chin Med, V5, P38, DOI 10.1186/1749-8546-5-38
   Cunnusamy K, 2012, PHARM PAT ANAL, V1, P193, DOI 10.4155/PPA.12.12
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuchs SM, 2006, SKIN RES TECHNOL, V12, P223, DOI 10.1111/j.0909-752X.2006.00168.x
   Han CC, 2012, INFLAMMATION, V35, P913, DOI 10.1007/s10753-011-9393-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang YJ, 2011, ARCH ORAL BIOL, V56, P1319, DOI 10.1016/j.archoralbio.2011.05.010
   Jin M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-118
   Ko JKS, 2009, CYTOKINE, V47, P85, DOI 10.1016/j.cyto.2009.05.014
   Lee HS, 2010, J ENZYM INHIB MED CH, V25, P720, DOI 10.3109/14756360903555274
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Ohkura N, 2012, BLOOD COAGUL FIBRIN, V23, P254, DOI 10.1097/MBC.0b013e3283504148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seo JS, 2010, J ETHNOPHARMACOL, V130, P578, DOI 10.1016/j.jep.2010.05.055
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   Yang WJ, 2009, BIOL PHARM BULL, V32, P1021, DOI 10.1248/bpb.32.1021
   Yang XB, 2007, BIOL PHARM BULL, V30, P1884, DOI 10.1248/bpb.30.1884
   Yeh JC, 2011, ANGIOGENESIS, V14, P187, DOI 10.1007/s10456-011-9202-8
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 23
TC 4
Z9 5
U1 2
U2 20
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3776
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD FEB
PY 2013
VL 23
IS 2
BP 269
EP 272
DI 10.1517/13543776.2013.751972
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 072MS
UT WOS:000313676400008
PM 23215532
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, CG
   Lee, DW
   Han, JI
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Chul Gu
   Lee, Dong Won
   Han, Jung Il
TI Hyperpigmented spots after treatment for submacular hemorrhage secondary
   to polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Polypoidal choroidal vasculopathy; Anti-vascular endothelial growth
   factor; Hemorrhage; Hyperpigmented spots
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; VISUAL PROGNOSIS;
   RANIBIZUMAB; RECURRENCE; FEATURES; EYES
AB To investigate the characteristics and clinical course of hyperpigmented spots after submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
   This retrospective, observational study included 87 eyes initially treated with three anti-vascular endothelial growth factor (VEGF) injections for submacular hemorrhage secondary to PCV. Patients were divided into two groups according to the presence of multiple small, dark-gray or black, pigmented lesions after initial treatment: the hyperpigmented spots group and no-hyperpigmented spots group. Baseline characteristics and re-activation of the lesion were compared between the two groups.
   The mean follow-up period was 30.6 +/- 12.9 months, and 41 eyes (47.1%) were included in the hyperpigmented spots group. The hyperpigmented spots group exhibited greater extent of hemorrhage (P < 0.001) and greater central foveal thickness (P = 0.045) than did the no-hyperpigmented spots group. In the hyperpigmented spots group, re-activation of the lesion was noted in 17 eyes (41.5%) at a mean duration of 15.4 +/- 12.7 months after the third anti-VEGF injection. In the no-hyperpigmented spots group, re-activation was noted in 28 eyes (60.9%) at a mean duration of 6.4 +/- 4.0 months after the third injection. Kaplan-Meier analysis with log-rank test revealed a significant difference in the re-activation of the lesion between the two groups (P = 0.006).
   Hyperpigmented spots were associated with a large amount of submacular hemorrhage in PCV. The low incidence of re-activation and late re-activation of the lesion in eyes with hyperpigmented spots suggest that a novel follow-up and treatment strategy is required for this condition.
C1 [Kim, Jae Hui; Kim, Chul Gu; Lee, Dong Won; Han, Jung Il] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
OI Kim, Jae Hui/0000-0001-8121-6353
FU Kim's Eye Hospital (Seoul, South Korea)
FX Kim's Eye Hospital (Seoul, South Korea) provided financial support in
   the form of funding for English editing support. The sponsor had no role
   in the design or conduct of this research.
CR ANDERSON DH, 1983, INVEST OPHTH VIS SCI, V24, P906
   ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015
   Fazekas F, 1999, AM J NEURORADIOL, V20, P637
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Fujii K, 2015, JACC-CARDIOVASC IMAG, V8, P451, DOI 10.1016/j.jcmg.2014.10.015
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Kim JH, 2017, J OCUL PHARMACOL TH, V33, P445, DOI 10.1089/jop.2016.0098
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim JH, 2017, EYE LOND
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Stafanous SN, 2009, ORBIT, V28, P179, DOI 10.1080/01676830802659145
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 33
TC 8
Z9 9
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2018
VL 256
IS 3
BP 469
EP 477
DI 10.1007/s00417-017-3877-5
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX4QC
UT WOS:000426062100005
PM 29302789
DA 2022-11-30
ER

PT J
AU Yamashita, A
   Shiraga, F
   Shiragami, C
   Shirakata, Y
   Fujiwara, A
AF Yamashita, Ayana
   Shiraga, Fumio
   Shiragami, Chieko
   Shirakata, Yukari
   Fujiwara, Atsushi
TI Two-Year Results of Reduced-Fluence Photodynamic Therapy for Polypoidal
   Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; VERTEPORFIN; RANIBIZUMAB
AB PURPOSE: To report the results of a 2-year follow-up study of Japanese polypoidal choroidal vasculopathy (PCV) patients treated with reduced-fluence photodynamic therapy (PDT) monotherapy.
   DESIGN: Prospective interventional case series.
   METHODS: In the present study, 38 eyes of 38 consecutive patients underwent PDT with a reduced laser fluence of 25 J/cm(2). During the 2-year follow-up, visual acuity (VA) and optical coherence tomography measurements were performed every 3 months after the PDT procedure and then compared with baseline values. PCV vascular lesions were evaluated by indocyanine green and fluorescein angiography.
   RESULTS: At baseline, the mean logarithm of the minimal angle of resolution (logMAR) best-corrected VA (BCVA) was 0.43. There was a significant improvement of the mean logMAR BCVA to 0.28 and 0.29 at 12 and 24 months, respectively (P < .0001, P = .001). The logMAR BCVA was stable or improved by in 36 (95%) of the eyes at the 2-year follow-up. In 13 eyes in which the baseline VA was better than 20/40, there was a significant improvement of the mean logMAR BCVA at 12 months, with the acuities continuing to be stable at 24 months. The mean number of treatment sessions during the 24-month study period was 1.9.
   CONCLUSIONS: Reduced-fluence PDT monotherapy for PCV effectively improved and maintained the VA over a 24-month period, even in eyes with a baseline VA better than 20/40. In addition, the number of treatments could be much smaller as compared with intravitreal injection of anti vascular endothelial growth factor agents. (Am J Ophthalmol 2013;155:96-102. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Yamashita, Ayana; Shiraga, Fumio; Shiragami, Chieko; Shirakata, Yukari; Fujiwara, Atsushi] Kagawa Univ, Fac Med, Dept Ophthalmol, Miki, Kagawa 7610793, Japan.
C3 Kagawa University
RP Yamashita, A (通讯作者)，Kagawa Univ, Fac Med, Dept Ophthalmol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
EM bourjois@med.kagawa-u.ac.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 30
TC 32
Z9 34
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2013
VL 155
IS 1
BP 96
EP 102
DI 10.1016/j.ajo.2012.06.027
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 066ML
UT WOS:000313224800009
PM 22995028
DA 2022-11-30
ER

PT J
AU Baba, T
   Bikbova, G
   Kitahashi, M
   Yokouchi, H
   Oshitari, T
   Yamamoto, S
AF Baba, Takayuki
   Bikbova, Guzel
   Kitahashi, Masayasu
   Yokouchi, Hirotaka
   Oshitari, Toshiyuki
   Yamamoto, Shuichi
TI Level of Vascular Endothelial Growth Factor 165b in Human Aqueous Humor
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; aqueous humor; retinal vein occlusion;
   Vascular Endothelial Growth Factor 165b
ID RETINAL VEIN OCCLUSION; INHIBITORY SPLICE VARIANT; DIABETIC MACULAR
   EDEMA; VEGF TRAP-EYE; CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB
   TREATMENT; ANGIOGENIC ISOFORMS; VEGF(165)B; DEGENERATION; RANIBIZUMAB
AB Purpose: Vascular endothelial growth factor 165b (VEGF(165)b) is a splice variant of VEGF-A and is an anti-angiogenic form as opposed to a pro-angiogenic form of VEGF. We compared the level of VEGF165b in the aqueous humor of 77 eyes with exudative age-related macular degeneration (AMD) and 38 eyes with retinal vein occlusion (RVO). Design: A prospective, interventional case series.
   Methods: The concentration of aqueous VEGF(165)b was measured by enzyme-linked immunosorbent assay (ELISA), and its level in the subgroups of AMD, classic and occult choroidal neovascularization (CNV) and polypoidal choroidal vasculopathy (PCV), was compared. The relationships between the VEGF(165)b level and the greatest linear dimension (GLD), central foveal thickness (CFT), and the height of the subretinal fluid (SRF) were determined for the AMD and RVO cases.
   Results: The level of VEGF(165)b was higher than the lower limit of detection (15 pg/ml) in 57% of the AMD cases (median, 16.4; range, <15-98 pg/ml) and 63% of the controls (median, 20.6; range, <15-46 pg/ml). The percentage of eyes with 415 pg/ml of VEGF(165)b was significantly lower in eyes with RVO (32%, p = 0.038). The VEGF(165)b level was not significantly different among the AMD subtypes, and it was not significantly correlated with the GLD, CFT, and SRF. In the RVO cases, the CFT and SRF thickness were greater in eyes with a VEGF level <15 pg/ml (p = 0.006, 0.048 respectively).
   Conclusions: The anti-angiogenic VEGF(165)b was low in eyes with RVO. Therapy based on balancing the pro-and anti-angiogenic factors might be a new approach to treat ocular vascular disorders.
C1 [Baba, Takayuki; Bikbova, Guzel; Kitahashi, Masayasu; Yokouchi, Hirotaka; Oshitari, Toshiyuki; Yamamoto, Shuichi] Chiba Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Chiba 2600856, Japan.
C3 Chiba University
RP Baba, T (通讯作者)，Chiba Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2600856, Japan.
EM babatakayuki@nifty.com
RI Bikbova, Guzel/B-1751-2018
OI Bikbova, Guzel/0000-0002-7715-7466; Oshitari,
   Toshiyuki/0000-0002-8273-845X
FU Japan Society for the Promotion of Science KAKENHI [23791966]
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. The authors
   indicate no financial support or financial conflict of interest involved
   in design and conduct of study, collection of data, management, analysis
   and interpretation of data, and preparation, review, or approval of
   manuscript. This work was supported by Japan Society for the Promotion
   of Science KAKENHI 23791966, Grant-in-Aid for Young Scientists (B) (TB).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Baba T, 2012, DEV DYNAM, V241, P595, DOI 10.1002/dvdy.23743
   Bates DO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068399
   Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223
   Bates DO, 2002, CANCER RES, V62, P4123
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Carter JG, 2011, CURR EYE RES, V36, P328, DOI 10.3109/02713683.2010.548892
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Ehlken C, 2011, AM J OPHTHALMOL, V152, P298, DOI 10.1016/j.ajo.2011.01.040
   Harris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035231
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hua J, 2010, INVEST OPHTH VIS SCI, V51, P4282, DOI 10.1167/iovs.09-4360
   Konopatskaya O, 2006, MOL VIS, V12, P626
   Lee WJ, 2012, BRIT J OPHTHALMOL, V96, P1426, DOI 10.1136/bjophthalmol-2012-301913
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Manetti M, 2011, CIRC RES, V109, pE14, DOI 10.1161/CIRCRESAHA.111.242057
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410
   Park SP, 2010, RETINA-J RET VIT DIS, V30, P281, DOI 10.1097/IAE.0b013e3181b9f153
   Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Ricker LJAG, 2012, RETINA-J RET VIT DIS, V32, P54, DOI 10.1097/IAE.0b013e31821800b9
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
NR 30
TC 6
Z9 7
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG
PY 2014
VL 39
IS 8
BP 830
EP 836
DI 10.3109/02713683.2013.877935
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM8ET
UT WOS:000340105500008
PM 24502617
DA 2022-11-30
ER

PT J
AU Li, Y
   You, QS
   Wei, WB
   Xu, J
   Chen, CX
   Wang, YX
   Xu, L
   Jonas, JB
AF Li, Yang
   You, Qi Sheng
   Wei, Wen Bin
   Xu, Jie
   Chen, Chang Xi
   Wang, Ya Xing
   Xu, Liang
   Jonas, Jost B.
TI Prevalence and associations of central serous chorioretinopathy in
   elderly Chinese. The Beijing Eye Study 2011
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; Beijing Eye Study; central serous
   chorioretinopathy; optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   AGE-RELATED MACULOPATHY; CHOROIDAL THICKNESS; MACULAR THICKNESS;
   POPULATION; RETINOPATHY; CHILDREN; CHINA
AB Purpose: To determine the prevalence and associations of central serous chorioretinopathy (CSC) in elderly Chinese.
   Methods: The population-based cross-sectional Beijing Eye Study 2011 included 3468 individuals (age: 64.6 +/- 9.8 years; range: 50-93 years), who underwent enhanced depth imaging of spectral-domain optical coherence tomography (SD-OCT). CSC was defined as serous detachment of the retina in the macular region without signs of haemorrhages or signs of polypoidal choroidal vasculopathy, exudative age-related macular degeneration or other retinal vascular disorders, both on fundus photographs and on optical coherence tomography (OCT) images.
   Results: Central serous chorioretinopathy was diagnosed in 10 eyes (prevalence rate: 0.15 +/- 0.05%; 95% confidence interval (CI): 0.06%, 0.25%) of 10 subjects (prevalence rate: 0.31 +/- 0.10%; 95% CI: 0.12%, 0.50%). In five subjects, CSC was located foveally, and in five subjects, CSC was located extrafoveally. All subjects affected by foveal CSC were men, and three of the five individuals with extrafoveal CSC were men. In univariate analysis, subjects with CSC were significantly younger than the remaining study participants, and foveal CSC showed a significant (p = 0.02) predilection for men. After adjusting for age and gender, individuals with foveal CSC (383 +/- 112 mu m versus 270 +/- 47 mu m; p = 0.02) and the whole group of subjects with CSC had a significantly thicker subfoveal choroid. In a parallel manner, eyes contralateral to eyes with foveal CSC showed a significantly thicker subfoveal choroid than the age-adjusted control group (413 +/- 74 mu m versus 270 +/- 47 mu m; p = 0.001).
   Conclusions: In Chinese aged 50+ years, the prevalence of CSC was 0.14% per subject. The choroid in the CSC affected eyes and in the contralateral unaffected eyes was significantly thicker than in an age-and gender-adjusted control population-based group.
C1 [Li, Yang; Wei, Wen Bin; Xu, Jie] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
   [You, Qi Sheng; Chen, Chang Xi; Wang, Ya Xing; Xu, Liang; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Wei, WB (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM tr_weiwenbin@163.com
RI You, Qisheng/AAG-7153-2020; wang, YA XING/K-9671-2016; xu,
   jie/GQR-1913-2022; Xu, Jie/AIE-0524-2022
OI You, Qisheng/0000-0003-0743-7320; wang, YA XING/0000-0003-2749-7793; xu,
   jie/0000-0002-2039-7055; Jonas, Jost/0000-0003-2972-5227
FU National Natural Science Foundation of China [81770890, 81041018];
   Beijing NOVA Program [2011058, 2010B032]; Ministry of Science and
   Technology [2011BAH15B08, 2012BAH05F05, 2013BAH19F04]
FX Supported by the National Natural Science Foundation of China ( No.
   81770890 and 81041018); Beijing NOVA Program ( No. 2011058 and
   2010B032); and National Key Technology R&D Program of the Ministry of
   Science and Technology ( No. 2011BAH15B08 and 2012BAH05F05,
   2013BAH19F04).
CR Duan XR, 2010, OPHTHALMOLOGY, V117, P1585, DOI 10.1016/j.ophtha.2009.12.036
   Eriksson U, 2009, ACTA OPHTHALMOL, V87, P741, DOI 10.1111/j.1755-3768.2008.01357.x
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Huynh SC, 2006, INVEST OPHTH VIS SCI, V47, P2351, DOI 10.1167/iovs.05-1396
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jain I S, 1966, J All India Ophthalmol Soc, V14, P250
   Kamppeter B, 2003, ARCH OPHTHALMOL-CHIC, V121, P742, DOI 10.1001/archopht.121.5.742
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Lim Z, 2008, EYE, V22, P471, DOI 10.1038/sj.eye.6703020
   Manjunath V, 2010, RETINA-J RET VIT DIS, V30, P1320, DOI 10.1097/IAE.0b013e3181e798b1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Montero JA, 2005, BRIT J OPHTHALMOL, V89, P562, DOI 10.1136/bjo.2004.049403
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   SPITZNAS M, 1987, GRAEF ARCH CLIN EXP, V225, P437, DOI 10.1007/BF02334172
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   van Velthoven MEJ, 2005, BRIT J OPHTHALMOL, V89, P1483, DOI 10.1136/bjo.2005.073056
   WAKAKURA M, 1984, BRIT J OPHTHALMOL, V68, P329, DOI 10.1136/bjo.68.5.329
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Wang YX, 2012, BRIT J OPHTHALMOL, V96, P811, DOI 10.1136/bjophthalmol-2011-301224
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
   Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 28
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2016
VL 94
IS 4
SI SI
BP 386
EP 390
DI 10.1111/aos.12891
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO2UQ
UT WOS:000377636000012
PM 26928876
OA Bronze
DA 2022-11-30
ER

PT J
AU Yuan, MZ
   Chen, LL
   Yang, JY
   Luo, MY
   Chen, YX
AF Yuan, Ming-Zhen
   Chen, Lu-Lu
   Yang, Jing-Yuan
   Luo, Ming-Yue
   Chen, You-Xin
TI Comparison of OCT and OCTA manifestations among untreated PCV,
   neovascular AMD, and CSC in Chinese population
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; neovascular age-related macular
   degeneration; central serous chorioretinopathy; Haller's layer; vascular
   density; pigment epithelium detachment
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COHERENCE TOMOGRAPHY ANGIOGRAPHY;
   PIGMENT EPITHELIAL DETACHMENT; MACULAR DEGENERATION; THICKNESS;
   SPECTRUM; EYES; VASCULATURE; PERSPECTIVE; PREVALENCE
AB AIM: To compare the qualitative and quantitative features among untreated polypoidal choroidal vasculopathy (PCV), neovascular age-related macular degeneration (nv-AMD) and central serous chorioretinopathy (CSC) using optical coherence tomography (OCT) and OCT angiography (OCTA).
   METHODS: This retrospective study included 16 eyes with thin-choroid PCV, 18 eyes with thick-choroid PCV, 16 eyes with nv-AMD and 17 eyes with CSC, respectively. The indicators were obtained by OCT and OCTA.
   RESULTS: Sub-foveal choroidal thickness (SECT) in CSC was thicker compared to other groups (all P<0.05). SFCT in nv-AMD was thicker compared to thin-choroid PCV, but thinner compared with thick-choroid PCV (both P<0.05). As the ratio of thickness of Haller's layer to thickness of SFCT, which of thin-choroid PCV was significantly higher than CSC (P<0.001). Likewise, thick-choroid PCV had significantly higher ratio than nv-AMD (P=0.016) or CSC (P<0.001). There were differences among them in pigment epithelium detachment (PED). The whole-superficial retinal vessel density (RVD), deep RVD and choroidal capillary vessel density (CCVD) in CSC were significantly higher compared to other three groups, respectively (all P<0.05). The whole CCVD in nv-AMD was higher compared to thick-choroid PCV (P=0.032). Cross-sectional local angiographic form was 87.50%, 83.33%, 0 and 35.29% in thin-choroid PCV, thick-choroid PCV, nv-AMD and CSC, respectively. Cross-sectional diffuse angiographic form was 12.50%, 16.67%, 100% and 5.88% in thin-choroid PCV, thick-choroid PCV, nv-AMD and CSC, respectively.
   CONCLUSION: Combination of OCT and OCTA can effectively observe the significant alterations existed in PCV, CSC and nv-AMD, and there are distinctive differences among them. The pathogenesis is not exactly the same between PCV and nv-AMD, or PCV and CSC.
C1 [Yuan, Ming-Zhen; Chen, Lu-Lu; Yang, Jing-Yuan; Luo, Ming-Yue; Chen, You-Xin] Chinese Acad Med Sci & Peking Union Med Coll, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
FU National Natural Science Foundation of China [81670879]
FX Supported by National Natural Science Foundation of China (No.81670879).
CR Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Baek J, 2019, RETINA-J RET VIT DIS, V39, P1571, DOI 10.1097/IAE.0000000000002188
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kang H, 2019, RETINA-J RET VIT DIS, V39, P1551, DOI 10.1097/IAE.0000000000002201
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lai KB, 2018, OSLI RETINA, V49, pE114, DOI 10.3928/23258160-20181002-13
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Song IS, 2012, AM J OPHTHALMOL, V154, P366, DOI 10.1016/j.ajo.2012.02.031
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   V Pasyechnikova Nataliya, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P72
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 39
TC 3
Z9 4
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2020
VL 13
IS 1
BP 93
EP 103
DI 10.18240/ijo.2020.01.14
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KA3EF
UT WOS:000505680500014
PM 31956576
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Dedhia, CJ
   Peguda, HK
   Stewart, M
AF Chhablani, Jay
   Dedhia, Chintan Jethalal
   Peguda, Hari K.
   Stewart, Michael
CA Ziv-Aflibercept Study Grp
TI SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ziv-aflibercept; aflibercept; anti-VEGF; AMD; PCV; IJRT; CNVM; choroidal
   neovascularization
ID DIABETIC MACULAR EDEMA; CLINICAL-PRACTICE; VEIN OCCLUSION; RANIBIZUMAB;
   DEGENERATION; BEVACIZUMAB; SECONDARY; EFFICACY; INJECTION; RISE
AB Purpose: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM).
   Methods: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30. Primary outcome measures consisted of safety assessments (signs of clinical toxicity and electroretinographic abnormalities). Secondary outcome measures included changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) of the macula.
   Results: Twenty-one eyes of 20 patients (12 males) received injections. Etiologies responsible for the choroidal neovascular membranes included age-related macular degeneration (14), polypoidal choroidal vasculopathy (PCV) (3), myopia (2), and idiopathic juxtafoveal telangiectasia (2). None of the patients complained of worsening vision or pain after the intravitreal injections and no intraocular inflammation was seen. No significant changes in the electroretinographic b/a ratio from baseline to 1 month were measured (scotopic: P = 0.89; photopic: P = 0.13) and mean intraocular pressures were unchanged (14.2 +/- 3.6 vs. 13.7 +/- 3.0 mmHg; P = 0.62). Mean best-corrected visual acuity did not change significantly from baseline to 1 month (0.66 +/- 0.37 logMAR [Snellen equivalent: 20/100] vs. 0.61 +/- 0.35 logMAR [Snellen equivalent: 20/80]; P = 0.72) but significant improvements in central subfield thickness were seen (343 +/- 177 vs. 210 +/- 133 mu m; P = 0.01).
   Conclusion: Single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL) appear to be safe through 1 month.
C1 [Chhablani, Jay; Dedhia, Chintan Jethalal; Peguda, Hari K.] L V Prasad Eye Inst, Hyderabad Eye Res Fdn, Srimati Kanuri Santhamma Ctr Vitreoretinal Dis, Kallam Anji Reddy Campus, Hyderabad, Telangana, India.
   [Stewart, Michael] Mayo Clin, Dept Ophthalmol, Jacksonville, FL 32224 USA.
C3 L. V. Prasad Eye Institute; Mayo Clinic
RP Chhablani, J (通讯作者)，L V Prasad Eye Inst, Srimati Kanuri Santhamma Ctr Vitreoretinal Dis, Kallam Anji Reddy Campus,L V Prasad Marg, Telangana 500034, India.
EM jay.chhablani@gmail.com
RI peguda, hari kumar/AAF-2134-2021
OI peguda, hari kumar/0000-0002-1317-5040
CR Arikan G, 2011, INT J OPHTHALMOL-CHI, V4, P402, DOI 10.3980/j.issn.2222-3959.2011.04.16
   Barthelmes D, 2016, BR J OPHTHALMOL
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P469, DOI 10.4103/0301-4738.159909
   de Andrade GC, 2016, RETINA-J RET VIT DIS, V36, P1640, DOI 10.1097/IAE.0000000000001000
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Heier JS, 2016, JAMA OPHTHALMOL, V134, P95, DOI 10.1001/jamaophthalmol.2015.4110
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lehmann-Clarke L, 2015, KLIN MONATSBL AUGENH, V232, P552, DOI 10.1055/s-0035-1545783
   Liang CP, 1996, EYE, V10, P709, DOI 10.1038/eye.1996.165
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Mansour AM, 2016, BR J OPHTHALMOL
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   Patel A, 2014, BIOL-TARGETS THER, V8, P13, DOI 10.2147/BTT.S39360
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Videkar Chetan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212988
   Wells JA, 2016, JAMA OPHTHALMOL, V134, P127, DOI 10.1001/jamaophthalmol.2015.4599
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
NR 27
TC 12
Z9 12
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2017
VL 37
IS 10
BP 1859
EP 1865
DI 10.1097/IAE.0000000000001440
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GH
UT WOS:000411680300017
PM 28060148
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Kano, M
   Yamamoto, A
   Saito, M
   Maruko, I
   Sekiryu, T
   Okada, AA
   Iida, T
AF Koizumi, Hideki
   Kano, Mariko
   Yamamoto, Akiko
   Saito, Masaaki
   Maruko, Ichiro
   Sekiryu, Tetsuju
   Okada, Annabelle A.
   Iida, Tomohiro
TI Aflibercept therapy for polypoidal choroidal vasculopathy: short-term
   results of a multicentre study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina
ID VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY; VEGF
   TRAP-EYE; VASCULAR HYPERPERMEABILITY; INTRAVITREAL AFLIBERCEPT; MACULAR
   DEGENERATION; RANIBIZUMAB THERAPY; THICKNESS; EFFICACY; BEVACIZUMAB
AB Background/aims To investigate short-term outcomes of intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV).
   Methods 91 eyes of 88 consecutive patients with treatment-naive PCV examined at three university hospitals received IAI monthly for 3months. One month after the third IAI, changes in best-corrected visual acuity (BCVA) and macular morphology were retrospectively evaluated. Additionally, possible baseline characteristics predictive of persistent retinal fluid were analysed.
   Results The mean BCVA (logarithm of the minimum angle of resolution units) of the 91 eyes improved from 0.31 at baseline to 0.21 at 3months (p<0.0001). The mean central retinal thickness and mean subfoveal choroidal thickness decreased from 323 m and 270m at baseline to 185 m and 232m at 3months, respectively (p<0.0001 for both). Seventy-three eyes (80.2%) achieved a dry macula defined as absence of retinal fluid. Presence of the baseline characteristics of subretinal haemorrhage and greater size of the largest polyp were significantly associated with inability to achieve a dry macula (p=0.008 and 0.03, respectively). However, this association was not found on multivariate logistic regression. Of the 90 eyes that underwent indocyanine green angiography at 3months, 43 eyes (47.8%) showed complete and 28 eyes (31.1%) showed partial resolution of polyps. Twenty-four eyes (24.4%) also showed partial regression of branching choroidal vascular networks.
   Conclusions IAIs for the treatment of a large number of PCV eyes were found to improve both visual acuity and macular morphology over the short term.
C1 [Koizumi, Hideki; Maruko, Ichiro; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo 1628666, Japan.
   [Kano, Mariko; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Fukushima, Japan.
   [Yamamoto, Akiko; Okada, Annabelle A.] Kyorin Univ, Sch Med, Tokyo, Japan.
C3 Tokyo Women's Medical University; Fukushima Medical University; Kyorin
   University
RP Koizumi, H (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM koizumi.hideki@twmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Saito, Masaaki/ABI-2783-2020
OI Maruko, Ichiro/0000-0001-5647-6372; Saito, Masaaki/0000-0003-1494-6350;
   Sekiryu, Tetsuju/0000-0001-8042-2729
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [25670739]
FX Supported in part by grant no. 25670739 from the Ministry of Education,
   Culture, Sports, Science and Technology, Japan (HK).
CR Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Ogasawara Masashi, 2012, Nippon Ganka Gakkai Zasshi, V116, P643
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 29
Z9 29
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2015
VL 99
IS 9
BP 1284
EP 1288
DI 10.1136/bjophthalmol-2014-306432
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ2VL
UT WOS:000360460000027
PM 25777816
DA 2022-11-30
ER

PT J
AU Morimoto, M
   Matsumoto, H
   Mimura, K
   Akiyama, H
AF Morimoto, Masahiro
   Matsumoto, Hidetaka
   Mimura, Kensuke
   Akiyama, Hideo
TI Two-year results of a treat-and-extend regimen with aflibercept for
   polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Anti-vascular endothelial growth factor; Aflibercept; Treat-and-extend
   regimen; Macular thickness; Choroidal thickness; Optical coherence
   tomography; Fluorescein angiography; And indocyanine green angiography
ID VERTEPORFIN PHOTODYNAMIC THERAPY; PIGMENT EPITHELIAL DETACHMENTS;
   MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT; JAPANESE PATIENTS; RAPID
   RESPONSE; RANIBIZUMAB; THICKNESS; BEVACIZUMAB; COMBINATION
AB To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-na < ve polypoidal choroidal vasculopathy (PCV).
   In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of injections for 2 years. Polypoidal lesions were also evaluated before treatment and after the loading phase by indocyanine green angiography.
   BCVA significantly improved after the loading phase and was maintained in the maintenance phase. CMT and CCT significantly reduced after the loading phase and were maintained throughout the follow-up period. The number of injections averaged 7.72 in the first year and 4.67 in the second year. The average number of polypoidal lesions per patient was 2.43 before treatment. In 32 patients (55.2%), polypoidal lesions regressed completely after the loading phase; these patients also needed significantly fewer injections compared to other patients. CCT at baseline was positively correlated with the decreased amount of CCT after 2 years and negatively correlated with the number of injections for 2 years.
   Treat-and-extend intravitreal therapy with aflibercept may be effective for improving BCVA and exudative change in eyes with PCV. The regression of polypoidal lesions after the loading phase and thicker choroid at baseline might lead to fewer total number of intravitreal injections of aflibercept.
C1 [Morimoto, Masahiro; Matsumoto, Hidetaka; Mimura, Kensuke; Akiyama, Hideo] Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Patel KH, 2013, EYE, V27, P668
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yanai H, 2015, STATCEL USEFUL ADD S
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 36
TC 39
Z9 41
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2017
VL 255
IS 10
BP 1891
EP 1897
DI 10.1007/s00417-017-3718-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG9JV
UT WOS:000410756000004
PM 28669041
DA 2022-11-30
ER

PT J
AU Zhou, H
   Bacci, T
   Freund, KB
   Wang, RKK
AF Zhou, Hao
   Bacci, Tommaso
   Freund, K. Bailey
   Wang, Ruikang K.
TI Three-dimensional segmentation and depth-encoded visualization of
   choroidal vasculature using swept-source optical coherence tomography
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Depth-encoded choroid visualization; choroid imaging; 3D data;
   swept-source optical coherence tomography
ID INDOCYANINE GREEN ANGIOGRAPHY; FLUORESCEIN ANGIOGRAPHY; AUTOMATED
   SEGMENTATION; THICKNESS; OCT; VESSELS; ANATOMY
AB The choroid provides nutritional support for the retinal pigment epithelium and photoreceptors. Choroidal dysfunction plays a major role in several of the most important causes of vision loss including age-related macular degeneration, myopic degeneration, and pachychoroid diseases such as central serous chorioretinopathy and polypoidal choroidal vasculopathy. We describe an imaging technique using depth-resolved swept-source optical coherence tomography (SS-OCT) that provides full-thickness three-dimensional (3D) visualization of choroidal anatomy including topographical features of individual vessels. Enrolled subjects with different clinical manifestations within the pachychoroid disease spectrum underwent 15 mm x 9 mm volume scans centered on the fovea. A fully automated method segmented the choroidal vessels using their hyporeflective lumens. Binarized choroidal vessels were rendered in a 3D viewer as a vascular network within a choroidal slab. The network of choroidal vessels was color depth-encoded with a reference to the Bruch's membrane segmentation. Topographical features of the choroidal vasculature were characterized and compared with choroidal imaging obtained with indocyanine green angiography (ICGA) from the same subject. The en face SS-OCT projections of the larger choroid vessels closely resembled to that obtained with ICGA, with the automated SS-OCT approach proving additional depth-encoded 3D information. In 16 eyes with pachychoroid disease, the SS-OCT approach added clinically relevant structural details, including choroidal thickness and vessel depth, which the ICGA studies could not provide. Our technique appears to advance the in vivo visualization of the full-thickness choroid, successfully reveals the topographical features of choroidal vasculature, and shows potential for further quantitative analysis when compared with other choroidal imaging techniques. This improved visualization of choroidal vasculature and its 3D structure should provide an insight into choroid-related disease mechanisms as well as their responses to treatment.
C1 [Zhou, Hao; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98105 USA.
   [Bacci, Tommaso; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Bacci, Tommaso; Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch Med, New York, NY 10016 USA.
   [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98105 USA.
C3 University of Washington; University of Washington Seattle; Vitreous
   Retina Macula Consultants of New York; New York University; University
   of Washington; University of Washington Seattle
RP Wang, RKK (通讯作者)，Univ Washington, Dept Bioengn, Seattle, WA 98105 USA.; Wang, RKK (通讯作者)，Univ Washington, Dept Ophthalmol, Seattle, WA 98105 USA.
EM wangrk@uw.edu
RI Bacci, Tommaso/GQA-8840-2022; Wang, Ruikang/L-3889-2019; Freund, K.
   Bailey/V-7488-2018; Zhou, Hao/U-7850-2017
OI Bacci, Tommaso/0000-0001-7477-2263; Wang, Ruikang/0000-0001-5169-8822;
   Freund, K. Bailey/0000-0002-7888-9773; Zhou, Hao/0000-0003-0068-5102
FU National Eye Institute [R01EY028753]; Carl Zeiss Meditec
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research is supported by grants from the National Eye Institute
   (R01EY028753), Carl Zeiss Meditec. The funding organization had no role
   in the design or conduct of this research.
CR Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   BLOOME MA, 1980, VISION RES, V20, P1083, DOI 10.1016/0042-6989(80)90045-0
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Campos A, 2017, ACTA OPHTHALMOL, V95, P446, DOI 10.1111/aos.13210
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   DhilipKumar V, 2013, INT C 3D IM IC3D LIE, P1
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Duan L, 2013, OPT EXPRESS, V21, P15787, DOI 10.1364/OE.21.015787
   DUCREY NM, 1979, ARCH OPHTHALMOL-CHIC, V97, P288, DOI 10.1001/archopht.1979.01020010140009
   El Matri Leila, 2012, Ophthalmic Surg Lasers Imaging, V43, pS38, DOI 10.3928/15428877-20121001-02
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Fardeau C, 1999, OPHTHALMOLOGY, V106, P1928, DOI 10.1016/S0161-6420(99)90403-7
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Hong Y, 2007, OPT EXPRESS, V15, P7538, DOI 10.1364/OE.15.007538
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Kirby MA, 2018, PROC SPIE, V10474, DOI 10.1117/12.2291057
   Laviers H, 2014, GRAEF ARCH CLIN EXP, V252, P1871, DOI 10.1007/s00417-014-2840-y
   Maloca P, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.3
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Preimi B, 2008, MATH VIS, P39, DOI 10.1007/978-3-540-72630-2_3
   RING HG, 1967, ARCH OPHTHALMOL-CHIC, V78, P431
   Sekiryu T, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.5.31
   Shi YY, 2021, AM J OPHTHALMOL, V224, P321, DOI 10.1016/j.ajo.2020.12.015
   Singh SR, 2019, SURV OPHTHALMOL, V64, P312, DOI 10.1016/j.survophthal.2018.11.002
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan BY, 2020, IEEE ENG MED BIO, P1883, DOI 10.1109/EMBC44109.2020.9175242
   Toslak D, 2020, BIOMED OPT EXPRESS, V11, P6281, DOI 10.1364/BOE.406299
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yiu G, 2013, RETINA TODAY, P39
   Zhang J, 2018, OSLI RETINA, V49, pE249, DOI 10.3928/23258160-20181203-15
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zhang QQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.6.066008
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
   Zhou H, 2018, BIOMED OPT EXPRESS, V9, P6067, DOI 10.1364/BOE.9.006067
NR 44
TC 4
Z9 4
U1 1
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD OCT
PY 2021
VL 246
IS 20
SI SI
BP 2238
EP 2245
AR 15353702211028540
DI 10.1177/15353702211028540
EA JUL 2021
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA WN1CM
UT WOS:000682611400001
PM 34259053
OA Green Published
DA 2022-11-30
ER

PT J
AU Roberts, PK
   Zotter, S
   Montuoro, A
   Pircher, M
   Baumann, B
   Ritter, M
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Roberts, Philipp K.
   Zotter, Stefan
   Montuoro, Alessio
   Pircher, Michael
   Baumann, Bernhard
   Ritter, Markus
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula
TI Identification and Quantification of the Angiofibrotic Switch in
   Neovascular AMD
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   subretinal fibrosis; choroidal neovascularization; anti-VEGF
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL HYPERREFLECTIVE MATERIAL;
   MACULAR DEGENERATION; GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION;
   ANGIOGRAPHY; FIBROSIS; SEGMENTATION; ASSOCIATION; THERAPY
AB PURPOSE. We quantify volumetric changes of subretinal hyperreflective material (SHRM) and determine the conversion toward subretinal fibrosis, the angiofibrotic switch, under antiVEGF therapy using polarization-sensitive optical coherence tomography (PS-OCT).
   METHODS. A total of 50 eyes of 50 patients with treatment-naive neovascular age-related macular degeneration (AMD) were included in this prospective observational study: 26 diagnosed with type 1 choroidal neovascularization (CNV), seven with type 2 CNV, 11 with mixed type CNV, three with a retinal angiomatous proliferation (RAP) lesion and three with a polypoidal choroidal vasculopathy (PCV). Patients were imaged at baseline and at the end of the loading phase (after treatment with three intravitreal anti-VEGF injections) using a PS-OCT system with a scanning angle of 308 3 308 and a scan pattern of 1024 3 250 A-scans. The device is capable of detecting fibrosis based on birefringence and the RPE based on depolarization. The volume of SHRM was quantified by manual delineation in each PS-OCT Bscan and interpolation between B-scans using proprietary reading center certified software. The occurrence of fibrosis detected by PS-OCT was compared to the clinical presentation of subretinal fibrosis.
   RESULTS. Of 50 eyes, 28 had SHRM at baseline. Seven of these eyes had subretinal fibrosis within 3 months, six of which could be detected unambiguously based on PS-OCT imaging. SHRM thickness and volume at month 3 (P = 0.001 and P = 0.02) were significantly larger and the reduction of SHRM thickness and volume (P = 0.002 and P = 0.027) in response to therapy were significantly less pronounced in eyes with fibrosis.
   CONCLUSIONS. SHRM volume decreases significantly under anti-VEGF therapy. However, lesions unresponsive to therapy may progress to fibrosis as early as 3 months. Reduction in SHRM thickness may be a prognostic marker for treatment response.
C1 [Roberts, Philipp K.; Montuoro, Alessio; Ritter, Markus; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Zotter, Stefan; Pircher, Michael; Baumann, Bernhard; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Baumann, Bernhard/0000-0001-6419-1932; Ritter,
   Markus/0000-0003-1406-8340
FU Canon, Inc.
FX Supported by Canon, Inc.
CR Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kuiper EJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1457, DOI 10.1001/archopht.124.10.1457
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Pircher M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771560
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Shu DY, 2017, PROG RETIN EYE RES, V60, P44, DOI 10.1016/j.preteyeres.2017.08.001
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sugita M, 2014, BIOMED OPT EXPRESS, V5, P106, DOI 10.1364/BOE.5.000106
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zotter S, 2012, BIOMED OPT EXPRESS, V3, P2720, DOI 10.1364/BOE.3.002720
NR 35
TC 17
Z9 18
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2019
VL 60
IS 1
BP 304
EP 311
DI 10.1167/iovs.18-25189
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH9WS
UT WOS:000456092300028
PM 30657855
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kesarwani, S
   Sahu, SK
   Basu, S
AF Kesarwani, Siddharth
   Sahu, Srikant Kumar
   Basu, Soumyava
TI Bilateral response after unilateral subconjunctival bevacizumab
   injection in a child with Stevens-Johnson syndrome
SO JOURNAL OF AAPOS
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; MACULAR EDEMA; NEOVASCULARIZATION; AVASTIN;
   SURFACE
AB Bevacizumab is widely used for several ocular conditions, including age-related macular degeneration, diabetic retinopathy, corneal neovascularization, neovascular glaucoma, and retinopathy of prematurity. We describe a 14-year-old patient with Stevens-Johnson syndrome in whom subconjunctival injection of bevacizumab in one eye caused bilateral regression of corneal neovascularization.
C1 [Sahu, Srikant Kumar] LV Prasad Eye Inst, Cornea & Anterior Segment Serv, Bhubaneswar 751024, Orissa, India.
   [Kesarwani, Siddharth] LV Prasad Eye Inst, Miriam Hyman Childrens Eye Care Ctr, Bhubaneswar 751024, Orissa, India.
   [Basu, Soumyava] LV Prasad Eye Inst, Retina & Vitreous Serv, Bhubaneswar 751024, Orissa, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute
RP Sahu, SK (通讯作者)，LV Prasad Eye Inst, Cornea & Anterior Segment Serv, Bhubaneswar 751024, Orissa, India.
EM srikant_sahu1@yahoo.co.in
CR Al-Dhibi H, 2009, J AAPOS, V13, P400, DOI 10.1016/j.jaapos.2009.03.006
   Bahar I, 2008, CORNEA, V27, P142, DOI 10.1097/ICO.0b013e318159019f
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Joussen AM, 2003, INVEST OPHTH VIS SCI, V44, P117, DOI 10.1167/iovs.01-1277
   Kim MJ, 2010, J OCUL PHARMACOL TH, V26, P49, DOI 10.1089/jop.2009.0022
   Law JC, 2010, J AAPOS, V14, P6, DOI 10.1016/j.jaapos.2009.10.011
   Scartozzi R, 2009, EYE, V23, P1229, DOI 10.1038/eye.2008.162
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Uy HS, 2008, CORNEA, V27, P70, DOI 10.1097/ICO.0b013e318158f6ad
NR 10
TC 6
Z9 6
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
J9 J AAPOS
JI J. AAPOS
PD JUN
PY 2012
VL 16
IS 3
BP 309
EP 311
DI 10.1016/j.jaapos.2011.12.153
PG 3
WC Ophthalmology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pediatrics
GA 961CG
UT WOS:000305440900020
PM 22459106
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Iijima, H
AF Sakurada, Yoichi
   Iijima, Hiroyuki
TI Two-Year Results of Photodynamic Therapy With or Without Intravitreal
   Ranibizumab for Polypoidal Choroidal Vasculopathy
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID FOLLOW-UP; VERTEPORFIN; BEVACIZUMAB; INJECTION; EFFICACY; VEGF
AB Purpose: To compare the 2-year outcomes of photodynamic therapy (PDT) with or without intravitreal ranibizumab (IVR) for polypoidal choroidal vasculopathy (PCV). Methods: Medical charts from 58 patients with PCV, who had been followed up for more than 2 years after initial treatment, were reviewed retrospectively. Visual outcomes were compared between 2 groups, consisting of 34 patients treated with PDT monotherapy without IVR and 24 with the combination of PDT and IVR, and the factors associated with the 2-year visual outcomes were investigated using multiple regression analysis. Results: In the PDT monotherapy group, the logarithm of the minimum angle of resolution (logMAR) of the best-corrected visual acuity (BCVA) improved significantly at 12 months (P=0.026), but was not significantly different from the initial logMAR BCVA at 24 months (P=0.21). By contrast, the logMAR BCVA improved significantly at 12 months and was maintained throughout the second 12-month period (P<0.001 at all time points) in the combined PDT group. Multiple regression analysis revealed that the initial BCVA (P<0.001), the greatest linear dimension of the initial PDT (P=0.006), and the combined PDT (P=0.039) were predictors of visual outcomes at 24 months. Conclusions: Combined PDT with IVR is a better treatment modality compared with PDT monotherapy, and results in improvement of visual outcomes at 24 months after the initial treatment.
C1 [Sakurada, Yoichi; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
FU Grants-in-Aid for Scientific Research [25462707] Funding Source: KAKEN
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
NR 26
TC 24
Z9 26
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD NOV 1
PY 2013
VL 29
IS 9
BP 832
EP 836
DI 10.1089/jop.2013.0044
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 243RF
UT WOS:000326333900010
PM 23962035
DA 2022-11-30
ER

PT J
AU Lim, JY
   Lee, SY
   Kim, JG
   Lee, JY
   Chung, H
   Yoon, YH
AF Lim, Jong Yoon
   Lee, Sun Young
   Kim, June-Gone
   Lee, Joo Yong
   Chung, Hyewon
   Yoon, Young Hee
TI Intravitreal bevacizumab alone versus in combination with photodynamic
   therapy for the treatment of neovascular maculopathy in patients aged 50
   years or older: 1-year results of a prospective clinical study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; bevacizumab; optical coherence
   tomography; photodynamic therapy; polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; EPITHELIUM-DERIVED FACTOR;
   ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; AVASTIN; EFFICACY;
   SAFETY; PREVALENCE
AB Purpose: To compare the outcomes of treatment with intravitreal bevacizumab alone (BEVA group) or in combination with photodynamic therapy (PDT) (COMB group), in patients aged at least 50 years with neovascular maculopathy.
   Methods: Forty-one patients with neovascular age-related macular degeneration (AMD) (n = 31) or polypoidal choroidal vasculopathy (PCV) (n = 10) were randomized to either the BEVA group (n = 18) or the COMB group (n = 23). A total of three intravitreal bevacizumab injections (1.25 mg/0.05 ml) were given at 6-week intervals. In the COMB group, PDT was included near the time of one injection. Patients underwent best-corrected visual acuity (BCVA) measurement and optical coherence tomography (OCT) at every visit. Fluorescein angiography and indocyanine green angiography were repeated every 3 months.
   Results: Overall BCVA (p = 0.001) and central foveal thickness (CFT) (p < 0.001) measured by OCT improved significantly at 12 months, and there was no between-group difference in BCVA or CFT between the BEVA and COMB groups. Whereas AMD patients showed significant improvement in BCVA (p = 0.001) and CFT (p = 0.004), PCV patients failed to improve. The effect of bevacizumab alone on neovascular AMD was similar to that of combination therapy, when measured by both BCVA and CFT. The total number of bevacizumab injections was not reduced when PDT was given, either among all patients or in a subgroup of naive patients (p > 0.05). No serious complication was noted.
   Conclusion: The results of our 12-month prospective study indicate that intravitreal bevacizumab alone has similar efficacy and safety to bevacizumab plus PDT for treatment of patients with neovascular AMD, even treatment-naive patients. The addition of PDT did not assist in reducing the required total number of bevacizumab injections.
C1 [Lim, Jong Yoon; Lee, Sun Young; Kim, June-Gone; Lee, Joo Yong; Chung, Hyewon; Yoon, Young Hee] Univ Ulsan, Dept Ophthalmol, Coll Med, Asan Med Ctr, Seoul 138040, South Korea.
C3 University of Ulsan
RP Yoon, YH (通讯作者)，Univ Ulsan, Dept Ophthalmol, Coll Med, Asan Med Ctr, 388-1 Poongnap Dong, Seoul 138040, South Korea.
EM yhyoon@amc.seoul.kr
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frimpong-Boateng A, 2009, ACTA OPHTHALMOL, V87, P183, DOI 10.1111/j.1755-3768.2008.01213.x
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   PEDERSEN KB, 2008, ACTA OPHTHALMOL
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 20
TC 23
Z9 25
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2012
VL 90
IS 1
BP 61
EP 67
DI 10.1111/j.1755-3768.2009.01841.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883HK
UT WOS:000299624600032
PM 20337606
OA Bronze
DA 2022-11-30
ER

PT J
AU Sakai, T
   Kato, N
   Kubota, M
   Tsuneoka, H
AF Sakai, Tsutomu
   Kato, Noriko
   kubota, Masaomi
   Tsuneoka, Hiroshi
TI Effects of photodynamic therapy plus intravitreal aflibercept with
   subtenon triamcinolone injections for aflibercept-resistant polypoidal
   choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Photodynamic therapy; Triamcinolone acetonide; Polypoidal
   choroidal vasculopathy
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; ACETONIDE INJECTIONS; BEVACIZUMAB; RANIBIZUMAB;
   SUPPRESSION
AB Purpose To evaluate the outcome of triple therapy of photodynamic therapy combined with injections of intravitreal aflibercept (IVA) and subtenon triamcinolone acetonide for polypoidal choroidal vasculopathy (PCV) resistant to IVA.
   Methods A retrospective chart review at a single institution was conducted to identify patients with PCV resistant to treatment with IVA who were switched to treatment with triple therapy. In total, 13 eyes from 13 patients were included in the study. Demographic data, visual acuities, central retinal thickness (CRT) and height of pigment epithelial detachment (PED) on optical coherence tomography (OCT), complications, and number of injections were reviewed.
   Results The patients had a mean age of 68 years (range 53-83). The number of prior injections with IVA ranged from 5 to 10. At 12 months follow-up after triple therapy, there was a significant improvement in visual acuity (P = 0.0039), a significant decrease in CRT (P = 0.003), and a significant reduction of the height of PED (P = 0.015). Only one patient had retinal pigment epithelium tear.
   Conclusions Triple therapy improved visual and anatomical outcomes in patients with PCV with recurrent or resistant retinal fluid and PED after multiple injections with IVA.
C1 [Sakai, Tsutomu; Kato, Noriko; kubota, Masaomi; Tsuneoka, Hiroshi] Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.
   [Sakai, Tsutomu] Jikei Daisan Hosp, Komae, Tokyo, Japan.
C3 Jikei University; Jikei University
RP Sakai, T (通讯作者)，Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.
EM tstmski@jikei.ac.jp
CR Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Kang HM, 2013, AM J OPTHALMOL, V156, P652
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Takayama K, 2016, GRAEFE ARCH CLIN EXP, DOI [10.1007/s00417-016-3468, DOI 10.1007/S00417-016-3468]
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
NR 29
TC 1
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2017
VL 255
IS 8
BP 1565
EP 1571
DI 10.1007/s00417-017-3700-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC8GR
UT WOS:000407080300013
PM 28601912
DA 2022-11-30
ER

PT J
AU Kim, H
   Lee, SC
   Kim, SM
   Lee, JH
   Koh, HJ
   Kim, SS
   Byeon, SH
   Kim, M
   Lee, CS
AF Kim, Hyesun
   Lee, Sung Chul
   Kim, Sang Myung
   Lee, Ji Hwan
   Koh, Hyoung Jun
   Kim, Sung Soo
   Byeon, Suk Ho
   Kim, Min
   Lee, Christopher Seungkyu
TI Identification of Underlying Causes of Spontaneous Submacular Hemorrhage
   by Indocyanine Green Angiography
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Indocyanine green angiography; Lacquer
   crack; Optical coherence tomography; Polypoidal choroidal vasculopathy;
   Retinal macroaneurysnn; Submacular hemorrhage
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ARTERIAL MACROANEURYSMS;
   TISSUE-PLASMINOGEN ACTIVATOR; SUBTHRESHOLD LASER TREATMENT; ENDOTHELIAL
   GROWTH-FACTOR; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; SUBRETINAL
   HEMORRHAGE; PATHOLOGICAL MYOPIA; CASE SERIES
AB Purpose: To investigate the causes of acute spontaneous submacular hemorrhage with indocyanine green angiography (ICGA). Methods: Retrospective observation case series. A total of 51 eyes from 51 patients with newly developed spontaneous submacular hemorrhage were enrolled. Best-corrected visual acuity (BCVA),fundus photography, fluorescein angiography, spectral domain optical coherence tomography (OCT), and ICGA at baseline were analyzed. The extent of hemorrhage using fundus photography, height of hemorrhage, and central foveal thickness measured by OCT was analyzed to compare the diagnostic and nondiagnostic groups. Results:The mean logarithm of the minimum angle of resolution (logMAR) BCVA at presentation was 1.21 +/- 0.74 (Snellen equivalent, 20/324); the mean follow-up period was 23.9 +/- 23.9 months. The cause of submacular hemorrhage was diagnosed in 43 of 51 eyes (84.3%) based on ICGA at presentation. The initial diagnoses were correct in 93% of eyes. In 3 cases, the initial diagnosis of age-related macular degeneration (AMD) was changed to polypoidal choroidal vasculopathy (PCV) based on follow-up ICGA. The central foveal thickness was significantly greater in the nondiagnostic group (1,102.4 vs. 666.7 mu m, respectively; p = 0.008). The most common cause of submacular hemorrhage was neovascular AMD (52.9%), followed by PCV (37.3%), macroaneurysm (5.9%), and lacquer crack (3.9%). The mean final visual acuity was generally worse in patients with submacular hemorrhage with typical AMD (visual acuity 20/618) or PCV (visual acuity 20/240) compared to that in patients with retinal macroaneurysm (visual acuity 20/100) or lacquer crack (visual acuity 20/72). Conclusions: ICGA at initial presentation helps identify causes of subnnacular hemorrhage, allowing differential treatment approaches that may improve outcomes and safety. (C) 2015 S. Karger AG, Basel
C1 [Kim, Hyesun; Lee, Sung Chul; Kim, Sang Myung; Lee, Ji Hwan; Koh, Hyoung Jun; Kim, Sung Soo; Byeon, Suk Ho; Kim, Min; Lee, Christopher Seungkyu] Yonsei Univ, Coll Med, Severance Hosp, Inst Vis Res,Dept Ophthalmol, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Coll Med, Severance Hosp, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM sklee219@yuhs.ac
OI Kim, Min/0000-0003-1873-6959; Lee, Christopher/0000-0001-5054-9470; Kim,
   Sung Soo/0000-0002-0574-7993; Byeon, suk ho/0000-0001-8101-0830; Koh,
   Hyoung Jun/0000-0002-5932-8516; , Sung Chul/0000-0001-9438-2385; Lee, Ji
   Hwan/0000-0003-1759-8195
CR Ahmad S, 2008, AM J OPHTHALMOL, V145, P1052, DOI 10.1016/j.ajo.2008.02.008
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRINTON GS, 1982, AM J OPHTHALMOL, V93, P271, DOI 10.1016/0002-9394(82)90524-4
   BROWN DM, 1994, BRIT J OPHTHALMOL, V78, P534, DOI 10.1136/bjo.78.7.534
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Cohen SY, 2011, RETINA-J RET VIT DIS, V31, P209, DOI 10.1097/IAE.0b013e31820a69db
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   DUGAN JD, 1993, AM J OPHTHALMOL, V115, P677, DOI 10.1016/S0002-9394(14)71475-8
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Georgalas I, 2011, EUR J OPHTHALMOL, V21, P220, DOI 10.5301/EJO.2010.5685
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   HAYASAKA S, 1990, GRAEF ARCH CLIN EXP, V228, P277, DOI 10.1007/BF00920048
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Panzardi G, 1992, Eur J Ophthalmol, V2, P83
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Parodi MB, 2011, BRIT J OPHTHALMOL, V95, P534, DOI 10.1136/bjo.2009.175547
   Parodi MB, 2012, INVEST OPHTH VIS SCI, V53, P1783, DOI 10.1167/iovs.11-8772
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Townsend-Pico WA, 2000, AM J OPHTHALMOL, V129, P33, DOI 10.1016/S0002-9394(99)00337-2
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 37
TC 8
Z9 8
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 3-4
BP 146
EP 154
DI 10.1159/000380830
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK3LO
UT WOS:000356117800004
PM 25833061
DA 2022-11-30
ER

PT J
AU Yasuno, Y
   Miura, M
   Kawana, K
   Makita, S
   Sato, M
   Okamoto, F
   Yamanari, M
   Iwasaki, T
   Yatagai, T
   Oshika, T
AF Yasuno, Yoshiaki
   Miura, Masahiro
   Kawana, Keisuke
   Makita, Shuichi
   Sato, Masaki
   Okamoto, Fumiki
   Yamanari, Masahiro
   Iwasaki, Takuya
   Yatagai, Toyohiko
   Oshika, Tetsuro
TI Visualization of Sub-retinal Pigment Epithelium Morphologies of
   Exudative Macular Diseases by High-Penetration Optical Coherence
   Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID IN-VIVO; HUMAN RETINA; DEGENERATION; SIGNAL; EYE; NM
AB PURPOSE. To evaluate the clinical significance of the newly developed long-wavelength probe optical coherence tomography (LP-OCT) for the diagnosis of exudative macular diseases.
   METHODS. Fourteen eyes of 13 participants were prospectively enrolled in the study. There were seven type I and five type II choroidal neovascularization (CNV) cases associated with age-related macular degeneration and idiopathic neovascularization and one case of polypoidal choroidal vasculopathy (PCV). A custom-built LP-OCT based on swept-source OCT (SS-OCT) technology was used. This new OCT uses a probe beam with a wavelength of 1060 nm that provides deeper penetration into the choroid and higher image contrast to the structures beneath the retinal pigment epithelium (RPE) and pathologic tissues than does conventional OCT. The depth resolution is 10.4 mu m tissue and the measurement speed is 28,000 depth scans/s. All the eyes were also examined by standard short wavelength probe OCT (SP-OCT). The image contrasts of the LP- and SP-OCT were qualitatively evaluated and analyzed by Wilcoxon's paired signed rank test and Spearman's rank correlation test.
   RESULTS. In 10 of 14 eyes, high-contrast visualization of the diseases beneath the RPE, CNV, or fibrin was attained. These diseases were almost invisible in the SP-OCT images. The LP- OCT of the remaining eyes also revealed significant improvement in the image contrasts beneath the RPE and CNV. Qualitative evaluation of the image contrasts and subsequent statistical test indicated statistically significant improvement in the image penetration to the choroid of LP- OCT to that of SP-OCT.
   CONCLUSIONS. LP-OCT provided significant improvement in the image contrast of exudative macular diseases. (Invest Ophthalmol Vis Sci. 2009; 50: 405-413) DOI:10.1167/iovs.08-2272
C1 [Yasuno, Yoshiaki] Univ Tsukuba, Inst Appl Phys, Computat Opt Grp, Tsukuba, Ibaraki 3058573, Japan.
   [Kawana, Keisuke; Sato, Masaki; Okamoto, Fumiki; Oshika, Tetsuro] Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tsukuba, Ibaraki 3058573, Japan.
   [Yasuno, Yoshiaki; Miura, Masahiro; Kawana, Keisuke; Makita, Shuichi; Sato, Masaki; Okamoto, Fumiki; Yamanari, Masahiro; Iwasaki, Takuya; Yatagai, Toyohiko; Oshika, Tetsuro] Computat Opt & Ophthalmol Grp, Ibaraki, Japan.
   [Miura, Masahiro; Iwasaki, Takuya] Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 University of Tsukuba; University of Tsukuba; Tokyo Medical University
RP Yasuno, Y (通讯作者)，Univ Tsukuba, Inst Appl Phys, Computat Opt Grp, Tennodai 1-1-1, Tsukuba, Ibaraki 3058573, Japan.
EM yasuno@optlab2.bk.tsukuba.ac.jp
RI Yasuno, Yoshiaki/F-2586-2011; Makita, Shuichi/G-3806-2011; Yamanari,
   Masahiro/B-3147-2010
OI Yasuno, Yoshiaki/0000-0003-1645-7948; Makita,
   Shuichi/0000-0002-6614-3640; Yamanari, Masahiro/0000-0001-9873-2151
FU Japan Society for the Promotion of Science (JSPS) [04210026, 18.3827]
FX Supported by the Japan Society for the Promotion of Science (JSPS)
   through the contracts of KAKENHI 04210026 and 18.3827; the Japan Science
   and Technology Agency (JST) through the contract of Development of
   Systems and Technology for Advanced Measurement and Analysis; and the
   Special Research Project of Nanoscience at the University of Tsukuba.
   Shuichi Makita is supported by the postdoctoral fellow program of JSPS.
CR Bohren CF., 1983, ABSORPTION SCATTERIN
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   FERCHER AF, 1995, OPT COMMUN, V117, P43, DOI 10.1016/0030-4018(95)00119-S
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Hausler G, 1998, J BIOMED OPT, V3, P21, DOI 10.1117/1.429899
   HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555
   HAMMER M, 1995, PHYS MED BIOL, V40, P963, DOI 10.1088/0031-9155/40/6/001
   Huber R, 2007, OPT LETT, V32, P2049, DOI 10.1364/OL.32.002049
   *I ANS, 2000, AM NAT STAND SAF US
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Lee ECW, 2006, OPT EXPRESS, V14, P4403, DOI 10.1364/OE.14.004403
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Pece A, 1998, OPHTHALMOLOGICA, V212, P295, DOI 10.1159/000027311
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Smithies DJ, 1998, PHYS MED BIOL, V43, P3025, DOI 10.1088/0031-9155/43/10/024
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yao G, 1999, PHYS MED BIOL, V44, P2307, DOI 10.1088/0031-9155/44/9/316
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
   Yun SH, 2003, OPT EXPRESS, V11, P3598, DOI 10.1364/OE.11.003598
NR 31
TC 74
Z9 77
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2009
VL 50
IS 1
BP 405
EP 413
DI 10.1167/iovs.08-2272
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 390YP
UT WOS:000262199900053
PM 18676629
DA 2022-11-30
ER

PT J
AU Terasaki, H
   Miyake, Y
   Suzuki, T
   Niwa, T
   Piao, CH
   Suzuki, S
   Nakamura, M
   Kondo, M
AF Terasaki, H
   Miyake, Y
   Suzuki, T
   Niwa, T
   Piao, CH
   Suzuki, S
   Nakamura, M
   Kondo, M
TI Change in full-field ERGs after macular translocation surgery with 360
   degrees retinotomy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FOVEAL TRANSLOCATION;
   SURGICAL-MANAGEMENT; RETINAL SEPARATION; LIGHT ADAPTATION; HIGH MYOPIA;
   RABBIT EYE; AGE; DEGENERATION; RECOVERY
AB PURPOSE. One of the methods used in macular translocation (MT) surgery for subfoveal neovascularization is to create a temporary total retinal detachment followed by a 360degrees retinotomy. The whole retina is then shifted from the original surface of the retinal pigment epithelium (RPE), resulting in an unusual retina and RPE complex, The purpose of this study was to assess retinal function after MT surgery.
   METHODS. Full-field electroretinograms (ERGS) were recorded before and 4 to 8 months (mean, 5.4 months) after NIT surgery with a 360degrees retinotomy in 15 consecutive patients with age-related macular degeneration (10 eyes), high myopia (4 eyes), and polypoidal choroidal vasculopathy (I eye), Their ages ranged from 57 to 74 years. The angle of rotation of the retina ranged from 18degrees to 45degrees (mean +/- SE, 30 +/- 2degrees). In addition to the recording of the standard rod and mixed rod-cone ERGS after 30 minutes of dark adaptation, the cone single flash and 30-Hz flicker ERGS were recorded immediately after a light-adapting background was turned on (LA(0)) and also after 10 minutes of light adaptation (LA(10)).
   RESULTS. The mean amplitude of the full-field ERGs was reduced after surgery by 44% for the rod response, by 24% for the mixed rod-cone b-wave, by 12% and 35% for the cone single-flash b-wave at LA(0) and 30-Hz flicker ERGS at LA(0), respectively. The mean implicit times were delayed by 8 msec for the rod response, by 2 msec for the mixed rod-cone oscillatory potential (OP1), by 4 msec for the cone single-flash b-wave at LA(0), and by 6 msec for the 30-Hz flicker at LA(0).
   CONCLUSIONS. These results demonstrated a functional alteration in both the rod and cone components of the ERGs for the entire retina after MT surgery.
C1 Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
RI Terasaki, Hiroko/M-5054-2014
OI Nakamura, Makoto/0000-0002-6464-4302
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cekic O, 1999, LANCET, V354, P340, DOI 10.1016/S0140-6736(05)75249-1
   de Juan E, 1999, AM J OPHTHALMOL, V128, P380, DOI 10.1016/S0002-9394(99)00142-7
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   GOURAS P, 1989, INVEST OPHTH VIS SCI, V30, P625
   GUERIN CJ, 1993, INVEST OPHTH VIS SCI, V34, P175
   Horle S, 2000, OPHTHALMOLOGICA, V214, P122, DOI 10.1159/000027480
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   Kondo M, 1999, INVEST OPHTH VIS SCI, V40, P2633
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lin SB, 2000, AM J OPHTHALMOL, V130, P76, DOI 10.1016/S0002-9394(00)00394-9
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   McLeod D, 2000, BRIT J OPHTHALMOL, V84, P344, DOI 10.1136/bjo.84.4.344
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MIYAKE Y, 1987, INVEST OPHTH VIS SCI, V28, P1816
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Potter MJ, 2000, AM J OPHTHALMOL, V129, P547, DOI 10.1016/S0002-9394(99)00480-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tabandeh H, 1999, OPHTHALMOLOGY, V106, P2063, DOI 10.1016/S0161-6420(99)90484-0
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Uemura A, 2000, ARCH OPHTHALMOL-CHIC, V118, P344, DOI 10.1001/archopht.118.3.344
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wong D, 2000, BRIT J OPHTHALMOL, V84, P670
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   1993, MACULAR PHOTOCOAGULA, V111, P1200
NR 32
TC 17
Z9 18
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2002
VL 43
IS 2
BP 452
EP 457
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518PK
UT WOS:000173676900022
PM 11818390
DA 2022-11-30
ER

PT J
AU Yamashita, A
   Shiraga, F
   Shiragami, C
   Ono, A
   Tenkumo, K
AF Yamashita, Ayana
   Shiraga, Fumio
   Shiragami, Chieko
   Ono, Aoi
   Tenkumo, Kaori
TI One-Year Results of Reduced-Fluence Photodynamic Therapy for Polypoidal
   Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN
AB PURPOSE: To report 1-year results of reduced-fluence photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in Japanese patients.
   DESIGN: Prospective interventional case series.
   METHODS: In the present study, 28 treatment-naive eyes of 28 consecutive patients underwent PDT with a reduced laser fluence of 25 J/cm(2). Patients were followed up at baseline and 1 week and 3, 6, 9, and 12 months after PDT. Choroidal perfusion changes were evaluated by indocyanine green angiography (ICGA) and leakage from PCV lesions and exudative changes by fluorescein angiography and optical coherence tomography. Treatment safety was assessed according to visual acuity (VA) and adverse events. The best-corrected VA (BCVA) obtained by Landolt ring tests was converted into the logarithm of the minimal angle of resolution (IogMAR).
   RESULTS: At baseline, the mean logMAR BCVA was 0.45 (geometric mean: 7/20). At 12 months, the mean logMAR BCVA significantly improved to 0.29 (geometric mean: 10/20) (P = 0.0001). The logMAR BCVA was stable or improved by >= 0.2 in 26 eyes (93%) at 1-year follow-up. In 10 eyes with VA better than 20/40 at baseline, the mean logMAR BCVA was significantly improved compared with baseline at 12 months. Although 16 of 28 eyes (57%) showed mild to moderate nonperfusion of choriocapillaris in early ICGA at 1 week, 27 eyes (96%) showed recovery to pretreatment levels at 3 months. Mean number of treatment sessions during the 12 months was 1.3. No severe side effects related to treatment were encountered.
   CONCLUSIONS: Reduced-fluence PDT is an effective treatment for PCV and could improve vision even in eyes with VA better than 20/40. (Am J Ophthalmol 2010;149: 465-471. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Yamashita, Ayana; Shiraga, Fumio; Shiragami, Chieko; Ono, Aoi; Tenkumo, Kaori] Kagawa Univ, Dept Ophthalmol, Fac Med, Miki, Kagawa 7610793, Japan.
C3 Kagawa University
RP Yamashita, A (通讯作者)，Kagawa Univ, Dept Ophthalmol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
EM bourjois@med.kagawa-u.ac.jp
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 22
TC 36
Z9 40
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2010
VL 149
IS 3
BP 465
EP 471
DI 10.1016/j.ajo.2009.09.020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 565MD
UT WOS:000275296400017
PM 20042180
DA 2022-11-30
ER

PT J
AU Oishi, A
   Mandai, M
   Kimakura, M
   Nishida, A
   Kurimoto, Y
AF Oishi, A.
   Mandai, M.
   Kimakura, M.
   Nishida, A.
   Kurimoto, Y.
TI Characteristics of fine vascular network pattern associated with
   recurrence of polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
DE age-related macular degeneration; occult choroidal neovascularization;
   photodynamic therapy; polypoidal choroidal vasculopathy; vascular
   network
ID INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; CLINICOPATHOLOGICAL
   CORRELATION; INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION;
   VERTEPORFIN; FEATURES
AB Objective To characterize an irregular capillary-like structure in the vascular network of eyes with polypoidal choroidal vasculopathy (PCV), and to determine whether its presence after photodynamic therapy (PDT) can be used to predict the clinical course of PCV.
   Methods We reviewed the clinical records of 29 eyes of 29 patients with PCV, who underwent PDT and confocal retinal angiographic examinations every 3 months. The images obtained before the PDT were compared with those after the PDT. The correlations between angiography findings and recurrences were evaluated.
   Results An area of fine, densely packed capillary-like vessels, named the fine vascular network, was identified within the polypoidal vascular network in 25 of 29 cases at the initial examination. The fine vascular network regressed in 23 cases (92%) after the first PDT. Thereafter, the fine vascular network remained or enlarged in 19 eyes, and 17 (84.5%) of these eyes had a recurrence of the polypoidal lesions or had exudative changes. In contrast, recurrences were found in only 2 of 10 (20%) eyes, whose fine network had regressed without a subsequent enlargement (P<0.001 compared with the former group).
   Conclusions A fine irregular vascular network is present in the majority of eyes with PCV before PDT. Its presence or expansion after PDT was significantly associated with a recurrence of PCV. Thus, we recommend that this network be monitored after treatment to determine whether a polypoidal vascular network will recur. Eye (2011) 25, 1020-1026; doi:10.1038/eye.2011.110; published online 6 May 2011 Keywords: age-related macular
C1 [Mandai, M.] RIKEN, Lab Retinal Regenerat, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan.
   [Oishi, A.; Mandai, M.; Kimakura, M.; Nishida, A.; Kurimoto, Y.] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
C3 RIKEN; Kobe City Medical Center General Hospital
RP Mandai, M (通讯作者)，RIKEN, Lab Retinal Regenerat, Ctr Dev Biol, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
EM mmandai@cdb.riken.jp
RI Mandai, Michiko/E-7986-2011; Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458
FU Japanese Society for the Promotion of Science, Tokyo, Japan [22791706]
FX The study was supported in part by Grant-In-Aid for Scientific Research
   (No. 22791706) from the Japanese Society for the Promotion of Science,
   Tokyo, Japan.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   LEE MW, 2008, EYE, V218, P193
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 12
Z9 13
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD AUG
PY 2011
VL 25
IS 8
BP 1020
EP 1026
DI 10.1038/eye.2011.110
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 806BG
UT WOS:000293775400010
PM 21546915
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Takayama, K
   Ito, Y
   Kaneko, H
   Kataoka, K
   Sugita, T
   Maruko, R
   Hattori, K
   Ra, E
   Haga, F
   Terasaki, H
AF Takayama, K.
   Ito, Y.
   Kaneko, H.
   Kataoka, K.
   Sugita, T.
   Maruko, R.
   Hattori, K.
   Ra, E.
   Haga, F.
   Terasaki, H.
TI Comparison of indocyanine green angiography and optical coherence
   tomographic angiography in polypoidal choroidal vasculopathy
SO EYE
LA English
DT Article
ID MACULAR DEGENERATION; FLUORESCEIN ANGIOGRAPHY; OCT ANGIOGRAPHY;
   NEOVASCULARIZATION; COMPLICATION; THERAPY
AB Purpose To compare optical coherence tomographic angiography (OCTA) and indocyanine green angiography (ICGA) images for detecting polypoidal lesions (PLs) and branching vascular networks (BVNs), and to measure the polypoidal areas (PAs) in patients with polypoidal choroidal vasculopathy (PCV).
   Methods All patients underwent ICGA, optical coherence tomography (OCT), and OCTA. We compared the detection sensitivity for PL and BVN, as evaluated by the ICGA and OCTA images. Furthermore, PA measured by ICGA was divided into two groups: one in which the area could be measured by OCTA (ICGA(+) OCTA(+)) and the other in which the area could not be measured by OCTA (ICGA(+) OCTA(-)).
   Results Twenty-one consecutive eyes of 21 patients (mean age, 73.8 +/- 9.8 years) were included. ICGA detected PL in all eyes (100%), whereas OCTA detected PL in 16 eyes (75.2%); ICGA detected BVN in 15 eyes (71.4%), whereas OCTA detected BVN in 20 eyes (95.2%). The mean PA in ICGA(+) OCTA(+) and ICGA(+) OCTAwas 0.24 +/- 0.04 and 0.14 +/- 0.01mm2, respectively; a significant difference was observed between ICGA(+) OCTA(+) PA and ICGA(+) OCTA-PA (Po0.0001). In addition, the mean PA in the ICGA(+) OCTA(+) group measured by ICGA and OCTA was 0.24 +/- 0.04 was 0.19 +/- 0.04mm(2), respectively; these values were significantly different (P= 0.0046).
   Conclusions OCTA might detect more BVNs and fewer PLs compared with ICGA, and PL detected by OCTA might be smaller than those detected by ICGA.
C1 [Takayama, K.; Ito, Y.; Kaneko, H.; Kataoka, K.; Sugita, T.; Maruko, R.; Hattori, K.; Ra, E.; Haga, F.; Terasaki, H.] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Nagoya University
RP Takayama, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan.
EM keitaka1234@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/O-7695-2015; Kaneko, Hiroki/AHA-2461-2022; Maruko,
   Ruka/M-4929-2014; Ito, Yasuki/M-4876-2014; Kataoka, Keiko/B-2806-2016
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Maruko, Ruka/0000-0003-0208-1011; Ito, Yasuki/0000-0001-9219-9261;
   Takayama, Kei/0000-0002-1477-9014; Kataoka, Keiko/0000-0002-8795-6536
FU Ministry of Education, Culture, Sports, Science and Technology
   [23390401[SU], 25462710]; Novartis Pharma KK Novartis Co.; Santen
   Pharmaceutical Co.; Wakamoto Co.; Pfizer Inc. Co.; Bayer Healthcare AG
   Co.; Novartis Pharma KK Co.
FX We express the deepest appreciation to all patients included in the
   study and all staff working in my department. This research was
   supported by a Grant-in-Aid for Scientific Research B (No. 23390401[SU])
   and a Grant-in-Aid for Scientific Research C (No. 25462710) from the
   Ministry of Education, Culture, Sports, Science and Technology
   (http://www.jsps.go.jp/). HT has research funding from Novartis Pharma
   KK Novartis Co.; Santen Pharmaceutical Co.; Wakamoto Co.; Pfizer Inc.
   Co., and personal fees from Bayer Healthcare AG Co.; Novartis Pharma KK
   Co.; Santen Pharmaceutical Co.; Wakamoto Co.; and Pfizer Inc. Co.
CR Ang M, 2015, OPHTHALMOLOGY, V122, P1740, DOI 10.1016/j.ophtha.2015.05.017
   Bonte CA, 1998, RETINA-J RET VIT DIS, V18, P476, DOI 10.1097/00006982-199805000-00018
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Christenbury JG, 2015, OSLI RETINA, V46, P579, DOI 10.3928/23258160-20150521-11
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Kokame GT, 2015, JAMA OPHTHALMOL, V133, DOI 10.1001/jamaophthalmol.2015.1886
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   McClintic S, 2015, JAMA OPHTHALMOL, V133, P1212, DOI 10.1001/jamaophthalmol.2015.2126
   Schachat AP, 2015, OPHTHALMOLOGY, V122, P222, DOI 10.1016/j.ophtha.2014.09.015
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 24
TC 37
Z9 39
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2017
VL 31
IS 1
BP 45
EP 52
DI 10.1038/eye.2016.232
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AU
UT WOS:000394353700004
PM 27813526
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Falsini, B
   Piccardi, M
   Iarossi, G
   Fadda, A
   Merendino, E
   Valentini, P
AF Falsini, B
   Piccardi, M
   Iarossi, G
   Fadda, A
   Merendino, E
   Valentini, P
TI Influence of short-term antioxidant supplementation on macular function
   in age-related maculopathy - A pilot study including electrophysiologic
   assessment
SO OPHTHALMOLOGY
LA English
DT Article
ID SENSITIVITY LOSS; PIGMENT DENSITY; GRADING SYSTEM; FELLOW EYES;
   DEGENERATION; ELECTRORETINOGRAMS; ERG
AB Purpose: To evaluate the influence of short-term antioxidant supplementation on retinal function in age-related maculopathy (ARM) patients by recording focal electroretinograms (FERGs).
   Design: Nonrandomized, comparative clinical trial.
   Participants: Thirty patients with early ARM and visual acuity greater than or equal to20/30, divided into two groups, similar for age and disease severity: antioxidant group (ARM-A, n = 17) and no treatment group (ARM-NT, n = 13). Eight age-matched normal subjects divided into antioxidant (N-A, n = 4) or no treatment (N-NT, n = 4) groups.
   Methods: ARM-A patients and N-A patients had oral supplementation of lutein, 15 mg; vitamin E, 20 mg; and nicotinamide, 18 mg, daily for 180 days, whereas ARM-NT patients and N-NT patients had no dietary supplementation during the same period. Eight of the 17 ARM-A patients took supplementation for an additional 180-day period. In all patients and normal subjects, FERG assessment was performed at the study entry (baseline) and after 180 days. Further testing was performed at 360 days for the eight ARM-A patients taking supplements and for one ARM-A patient who had discontinued supplementation after 180 days. FERGs were recorded in response to a 41-Hz sinusoidally modulated uniform field (93.5% modulation depth) presented to the macular region (18degrees) on a light-adapting background. In a subgroup of patients (11 ARM-A and 5 ARM-NT), whose responses had suitable signal-to-noise ratios, FERGs were also recorded at different stimulus modulation depths between 8.25% and 93.5%.
   Main Outcome and Measures: Amplitude (in AV) and phase (in degrees) of the FERG fundamental harmonic component. FERG modulation thresholds, estimated from the value of log modulation depth yielding a criterion response.
   Results: At 180 days, FERGs of ARM-A patients and N-A patients were increased in amplitude (mean change, 0.11 and 0.15 log muV, respectively, P less than or equal to 0.01) compared with baseline values, whereas no significant changes in FERG amplitudes of ARM-NT patients and N-NT patients were found (mean change, -0.004. and -0.023 log muV, respectively). In all groups no changes in the FERG phase were found. FERG modulation thresholds decreased with respect to baseline values (mean change, -0.36 log units, P < 0.01) in ARM-A patients, whereas no significant change (mean change, 0.07 log units) in ARM-NT patients was seen. At 360 days, FERGs of ARM-A patients taking supplementation were still increased in amplitude with respect to baseline (P < 0.05) but did not differ from those recorded at 180 days. In the patient who had discontinued supplementation, FERG amplitude decreased from the 180 days value, approaching that recorded at baseline.
   Conclusions: Although this study provides no evidence for the long-term benefit of antioxidants in ARM, the results suggest that increasing the level of retinal antioxidants might influence macular function early in the disease process, as well as in normal aging.
C1 Univ Sacred Heart, Ist Oftalmol, I-00168 Rome, Italy.
   Ist Super Sanita, Lab Ingn Biomed, I-00161 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Istituto Superiore di Sanita (ISS)
RP Falsini, B (通讯作者)，Univ Sacred Heart, Ist Oftalmol, Lgo F Vito 1, I-00168 Rome, Italy.
RI Iarossi, giancarlo/AAB-4916-2020; Falsini, Benedetto/AAC-5907-2022;
   Falsini, Benedetto/V-1070-2019; Fadda, Antonello/J-1560-2012
OI Falsini, Benedetto/0000-0002-1694-1062; Fadda,
   Antonello/0000-0001-7004-5245; Falsini, Benedetto/0000-0002-3569-4968;
   PICCARDI, Marco/0000-0002-9836-7534
CR Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bush RA, 1996, J OPT SOC AM A, V13, P557, DOI 10.1364/JOSAA.13.000557
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Crabtree DV, 1996, INVEST OPHTH VIS SCI, V37, P61
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   FISH GE, 1986, OPHTHALMOLOGY, V93, P1177
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Kamat JP, 1996, CHEM-BIOL INTERACT, V99, P1, DOI 10.1016/0009-2797(95)03653-9
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SCHALCH W, 1992, FREE RADICALS AGING, P280
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
NR 29
TC 65
Z9 70
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2003
VL 110
IS 1
BP 51
EP 60
AR PII S0161-6420(02)01547-6
DI 10.1016/S0161-6420(02)01547-6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 633PT
UT WOS:000180292200019
PM 12511345
DA 2022-11-30
ER

PT J
AU Inoue, M
   Balaratnasingam, C
   Freund, KB
AF Inoue, Maiko
   Balaratnasingam, Chandrakumar
   Freund, K. Bailey
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF POLYPOIDAL CHOROIDAL
   VASCULOPATHY AND POLYPOIDAL CHOROIDAL NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE optical coherence tomography angiography; polypoidal choroidal
   vasculopathy; polypoidal choroidal neovascuralization; indocyanine green
   angiography; multimodal imaging; pachychoroid neovasculopathy; branching
   vascular network
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; CHORIORETINOPATHY;
   CLASSIFICATION; THICKNESS
AB Purpose: To describe the use of optical coherence tomography angiography (OCT-A) for evaluating the spectrum of polypoidal vascular diseases.
   Methods: Retrospective observational case series of seven patients with polypoidal choroidal vasculopathy (three cases) or polypoidal choroidal neovascularization (four cases). Optical coherence tomography angiography information was acquired using two different OCT-A devices (the Optovue RTVue XR Avanti SD-OCT and the Spectralis OCT angiography). Flow signals within branching vascular networks, type 1 neovascularization and polyps were evaluated. Comparisons were made between en face and cross-sectional OCT-A images. Vascular information from OCT-A was also compared with indocyanine green angiography.
   Results: En face images from OCT-A provided anatomical information about branching vascular networks that were comparable to indocyanine green angiography. Polyps were poorly resolved on en face OCT-A images but were clearly defined on cross-sectional OCT-A images. Cross-sectional OCT-A revealed flow signals within focal regions of the polyps with a significant portion of the polyp lumen being devoid of flow signal. Flow signals from cross-sectional OCT-A images also showed that branching vascular networks, type 1 neovascularization, and polyps were confined to the anatomic compartment between the retinal pigment epithelium and Bruch's membrane. It was not possible to detect leakage on en face or cross-sectional OCT-A.
   Conclusion: The combination of en face and cross-sectional OCT-A images provides anatomical information about polypoidal structures that is comparable to indocyanine green angiography. OCT-A may be a useful modality for the management of polypoidal diseases. However, the limitations of OCT-A identified in this study suggest that it is not a replacement for indocyanine green angiography.
C1 [Inoue, Maiko; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Inoue, Maiko; Balaratnasingam, Chandrakumar; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Inoue, Maiko] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa 232, Japan.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Dept Physiol & Pharmacol, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Yokohama City University; Lions Eye Institute;
   University of Western Australia; New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat
   Hospital, New York, NY; Macular Foundation, Inc, New York, NY
FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear and Throat Hospital, New York, NY, and the Macular Foundation,
   Inc, New York, NY. The funding organization had no role in the design or
   execution of this research.
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Balaratnasingam C, RETINA IN PRESS
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dansingani K, 2015, RETINA
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Mashayekhi Arman, 2013, J Ophthalmic Vis Res, V8, P264
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 33
TC 87
Z9 95
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2265
EP 2274
DI 10.1097/IAE.0000000000000777
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100014
PM 26405770
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Lee, TG
   Lew, YJ
AF Kim, Jae Hui
   Kim, Jong Woo
   Lee, Tae Gon
   Lew, Young Ju
TI Treatment Outcomes in Eyes with Polypoidal Choroidal Vasculopathy with
   Poor Baseline Visual Acuity
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID SUBMACULAR HEMORRHAGE SECONDARY; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; PNEUMATIC DISPLACEMENT; INTRAVITREAL BEVACIZUMAB;
   SUBRETINAL HEMORRHAGE; NATURAL-HISTORY; RANIBIZUMAB; MANAGEMENT;
   NEOVASCULARIZATION
AB Purpose: To evaluate treatment outcomes of intravitreal vascular endothelial growth factor (VEGF) in eyes with polypoidal choroidal vasculopathy (PCV) that exhibited poor baseline visual acuity.
   Methods: This retrospective, observational study included 47 eyes with treatment-naive PCV with baseline visual acuity of 20/200 or worse treated with intravitreal anti-VEGF. Eyes were divided into 2 groups according to the presence of submacular hemorrhage (hemorrhage and no-hemorrhage groups). The best-corrected visual acuity (BCVA) at baseline was compared with that measured at 3 and 6 months after treatment.
   Results: A mean of 3.3 +/- 0.9 intravitreal anti-VEGF injections were performed during the 6-month follow-up period. In the hemorrhage group (n=23), 6 patients additionally underwent pneumatic displacement with or without intravitreal tissue plasminogen activator. The logarithm of minimal angle of resolution BCVA at diagnosis, 3, and 6 months was 1.47 +/- 0.49, 0.91 +/- 0.79, and 0.81 +/- 0.83, respectively. Compared with baseline, BCVA was significantly better at 3 and 6 months (P=0.007 and P=0.001, respectively). In the no-hemorrhage group (n=24), the BCVA at defined time points was 1.23 +/- 0.32, 1.06 +/- 0.33, and 1.02 +/- 0.35, respectively. BCVA was significantly better at 3 and 6 months compared with baseline (P=0.006 and P=0.025, respectively).
   Conclusions: Intravitreal anti-VEGF was found to be beneficial in PCV eyes with poor baseline visual acuity, regardless of the presence of submacular hemorrhage. The magnitude of visual improvement was relatively greater in eyes with submacular hemorrhage.
C1 [Kim, Jae Hui; Kim, Jong Woo; Lee, Tae Gon; Lew, Young Ju] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, Seoul 150034, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   El Matri L, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/861384
   Galbinur T, 2009, BRIT J OPHTHALMOL, V93, P1351, DOI 10.1136/bjo.2009.158931
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Hesgaard HB, 2012, ACTA OPHTHALMOL, V90, pe498, DOI 10.1111/j.1755-3768.2011.02352.x
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Iacono P., 2014, RETINA, V34, P271
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P467, DOI 10.1089/jop.2011.0038
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nayak S, 2015, SEMIN OPHTHALMOL, V30, P53, DOI 10.3109/08820538.2013.807849
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ozkaya A, 2013, J OCUL PHARMACOL TH, V29, P865, DOI 10.1089/jop.2013.0106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 2
Z9 3
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAY 1
PY 2015
VL 31
IS 4
BP 241
EP 247
DI 10.1089/jop.2014.0145
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA CH3ZT
UT WOS:000353970700008
PM 25786032
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Chan, WM
   Liu, DTL
   Luk, FOJ
   Lam, DSC
AF Lai, T. Y. Y.
   Chan, W-M
   Liu, D. T. L.
   Luk, F. O. J.
   Lam, D. S. C.
TI Intravitreal bevacizumab (Avastin) with or without photodynamic therapy
   for the treatment of polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; NEOVASCULAR MEMBRANES; VERTEPORFIN; RANIBIZUMAB;
   PEGAPTANIB; EXPRESSION
AB Aim: To evaluate the efficacy of intravitreal bevacizumab (Avastin) with or without verteporfin photodynamic therapy (PDT) in the treatment of polypoidal choroidal vasculopathy (PCV).
   Methods: Fifteen eyes of 15 patients with symptomatic PCV who received three monthly intravitreal bevacizumab were retrospectively reviewed. Subsequent retreatments with intravitreal bevacizumab and/or PDT were performed in patients with recurrent or persistent polypoidal lesions on indocyanine green angiography (ICGA), and persistent or recurrent subretinal fluid.
   Results: The mean follow-up duration was 12.8 months. At 3 months, the mean logMAR BCVA improved from 0.61 to 0.51 (p = 0.014), and the mean CFT reduced from 347 mm to 247 mm (p = 0.015). Despite the visual and anatomical improvements, persistent polyps were present in ICGA of all eyes at 3 months. At the last follow-up, mean BCVA remained at 0.51 after additional treatment with intravitreal bevacizumab and/or PDT (p = 0.022). Patients who had subsequent PDT were less likely to have persistent polypoidal lesions on ICGA at the last visit (p = 0.041).
   Conclusions: Intravitreal bevacizumab appeared to result in stabilisation of vision and reduction of exudative retinal detachment in PCV patients. However, intravitreal bevacizumab monotherapy had limited effectiveness in causing regression of the polypoidal lesions in ICGA, and additional PDT appeared to be useful for treating these lesions.
C1 [Lai, T. Y. Y.; Chan, W-M; Luk, F. O. J.; Lam, D. S. C.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
   [Chan, W-M; Liu, D. T. L.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 3-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020; Lam, Dennis/AAL-1211-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; 
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 26
TC 126
Z9 134
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2008
VL 92
IS 5
BP 661
EP 666
DI 10.1136/bjo.2007.135103
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 293MC
UT WOS:000255338400017
PM 18356265
DA 2022-11-30
ER

PT J
AU Salceanu, SO
   Levy, S
   Cunningham, R
   Frimpong-Ansah, K
AF Salceanu, Silvia Olivia
   Levy, Sarah
   Cunningham, Richard
   Frimpong-Ansah, Kwabena
TI Severe Gemella haemolysans endophthalmitis following ranibizumab
   intravitreal injection
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Endophthalmitis; Gemella haemolysans; Gram-positive bacteria;
   ranibizumab
AB Gemella haemolysans is a commensal of the upper respiratory tract that is rarely involved in ocular pathology. We present a unique case of endophthalmitis with negative cultures and positive 16s ribosomal ribonucleic acid gene sequencing showing G. haemolysans infection after an intravitreal ranibizumab injection for wet age-related macular degeneration.
C1 [Salceanu, Silvia Olivia; Levy, Sarah; Frimpong-Ansah, Kwabena] Derriford Hosp, Dept Ophthalmol, Plymouth, Devon, England.
   [Cunningham, Richard] Derriford Hosp, Dept Microbiol, Plymouth, Devon, England.
C3 Derriford Hospital; Derriford Hospital
RP Salceanu, SO (通讯作者)，Spital Pascanu St,2B,Bl Z4,Ap 3, Iasi 700373, Romania.
EM sil.salceanu@gmail.com
CR Buu-Hoi A, 1982, Eur J Clin Microbiol, V1, P102, DOI 10.1007/BF02014200
   Raman SV, 2003, BRIT J OPHTHALMOL, V87, P1192, DOI 10.1136/bjo.87.9.1192-a
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Ritterband D, 2002, AM J OPHTHALMOL, V133, P268, DOI 10.1016/S0002-9394(01)01271-5
   Sawada A, 2009, J GLAUCOMA, V18, P496, DOI 10.1097/IJG.0b013e31818c6f07
   Simunovic MP, 2012, BRIT J OPHTHALMOL, V96, P862, DOI 10.1136/bjophthalmol-2011-301439
NR 6
TC 1
Z9 1
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD NOV
PY 2017
VL 65
IS 11
BP 1249
EP +
DI 10.4103/ijo.IJO_1007_16
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM7HP
UT WOS:000415246000044
PM 29133669
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nagai, N
   Suzuki, M
   Minami, S
   Kurihara, T
   Kamoshita, M
   Sonobe, H
   Watanabe, K
   Uchida, A
   Shinoda, H
   Tsubota, K
   Ozawa, Y
AF Nagai, Norihiro
   Suzuki, Misa
   Minami, Sakiko
   Kurihara, Toshihide
   Kamoshita, Mamoru
   Sonobe, Hideki
   Watanabe, Kazuhiro
   Uchida, Atsuro
   Shinoda, Hajime
   Tsubota, Kazuo
   Ozawa, Yoko
TI Dynamic changes in choroidal conditions during anti-vascular endothelial
   growth factor therapy in polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL
   AFLIBERCEPT; RANIBIZUMAB TREATMENT; PREDICTIVE FACTORS;
   CLINICAL-FEATURES; NEOVASCULARIZATION; THICKNESS; EYES; RECURRENCE
AB We defined the relationships between initial choroidal conditions and their dynamics and exudative changes during anti-vascular endothelial growth factor (anti-VEGF) therapy in polypoidal choroidal vasculopathy (PCV). One hundred treatment-naive eyes of 100 patients with PCV treated for 24 months at Keio University Hospital with intravitreal ranibizumab or aflibercept monotherapy (three injections and PRN thereafter) were retrospectively analyzed. Wet macula risk after three induction injections, which affected visual prognosis, was predicted by initial pachyvessels in the choroid (foveal greatest vertical choroidal vessel diameter [CVD] >= 180 mu m) and pachychoroid (central choroidal thickness [CCT] >= 220 mu m) recorded by optical coherence tomography. The risk for recurrent exudative change was greater in the pachyvessel groups irrespective of presence or absence of pachychoroid. Mean CVD and CCT decreased with anti-VEGF therapy when achieving a dry macula, suggesting that exudative changes are regulated by VEGF. Mean CVD and CCT at remission were greater in patients with initial pachyvessels and pachychoroid than in those without; the basal levels of CVD and CCT most likely represent VEGF-unrelated conditions. CVD increase preceded CCT increase and recurrent exudative changes, suggesting that the VEGF-related CVD increase may regulate CCT and exudative change; and that CVD may be a biomarker of exudative change.
C1 [Nagai, Norihiro; Suzuki, Misa; Kamoshita, Mamoru; Ozawa, Yoko] Keio Univ, Sch Med, Lab Retinal Cell Biol, Tokyo, Japan.
   [Nagai, Norihiro; Suzuki, Misa; Minami, Sakiko; Kurihara, Toshihide; Kamoshita, Mamoru; Sonobe, Hideki; Watanabe, Kazuhiro; Uchida, Atsuro; Shinoda, Hajime; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Keio University; Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Lab Retinal Cell Biol, Tokyo, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
EM ozawa@a5.kelo.jp
RI Kurihara, Toshihide/ABA-7058-2020; Uchida, Atsuro/GVT-8593-2022; Ozawa,
   Yoko/AAH-9888-2020; Tsubota, Kazuo/M-1915-2013
OI Kurihara, Toshihide/0000-0002-5457-2720; Uchida,
   Atsuro/0000-0002-1378-7151; Tsubota, Kazuo/0000-0002-8874-7111
CR Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Recchia FM, 2006, RETINA-J RET VIT DIS, V26, P1042, DOI 10.1097/01.iae.0000254894.94013.d8
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 15
Z9 15
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 6
PY 2019
VL 9
AR 11389
DI 10.1038/s41598-019-47738-9
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IN7LK
UT WOS:000478863700038
PM 31388029
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ohji, M
   Lanzetta, P
   Korobelnik, JF
   Wojciechowski, P
   Taieb, V
   Deschaseaux, C
   Janer, D
   Tuckmantel, C
AF Ohji, Masahito
   Lanzetta, Paolo
   Korobelnik, Jean-Francois
   Wojciechowski, Piotr
   Taieb, Vanessa
   Deschaseaux, Celine
   Janer, Daniel
   Tuckmantel, Claudia
TI Efficacy and Treatment Burden of Intravitreal Aflibercept Versus
   Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network
   Meta-Analysis Incorporating Individual Patient Data Meta-Regression and
   Matching-Adjusted Indirect Comparison
SO ADVANCES IN THERAPY
LA English
DT Article
DE Intravitreal anti-vascular endothelial growth factor therapy; Network
   meta-analysis; Ophthalmology; Wet age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; DISEASE BURDEN; EYE
AB Purpose To compare visual outcomes and treatment burden between intravitreally administered aflibercept (IVT-AFL) and ranibizumab (RBZ) treat-and-extend (T&E) regimens in patients with wet age-related macular degeneration (wAMD) at 2 years. Methods A systematic literature review was carried out in Medline, EMBASE, and CENTRAL in October 2018. Matching-adjusted indirect comparison (MAIC) and/or individual patient data meta-regression was used to connect ALTAIR (assessing IVT-AFL T&E) with other studies, adjusting for between-trial differences in baseline visual acuity and age or baseline visual acuity, age, and polypoidal choroidal vasculopathy (PCV) status. Sensitivity analyses were conducted to test the robustness of the results, including direct MAIC between IVT-AFL T&E (ALTAIR) and RBZ T&E (CANTREAT and TREX-AMD trials). Results Six randomized controlled trials (RCTs) (ALTAIR, VIEW 1 and 2, CATT, CANTREAT, and TREX) were included in the analysis. IVT-AFL T&E was assessed in one study, ALTAIR (n = 255), while RBZ T&E was assessed in two trials (n = 327). At 2 years, the median difference (95% credibility interval) between IVT-AFL T&E and RBZ T&E regarding the numbers of Early Treatment Diabetic Retinopathy Study (ETDRS) letters gained was not significant (M1: - 2.29 [- 8.10, 3.58]; M2: - 0.55 [- 6.34, 5.29]). IVT-AFL T&E was associated with significantly fewer injections than RBZ-T&E (M1: - 6.12 [- 7.60, - 4.65]; M2: - 5.93 [- 7.42, - 4.45]). Results of the sensitivity analyses were consistent with the main scenarios. Conclusion Patients with wAMD receiving an IVT-AFL T&E regimen achieved and maintained improvement in visual acuity with fewer injections over 2 years compared with RBZ T&E. IVT-AFL T&E may therefore serve as the optimal therapy for wAMD, as it was associated with clinical efficacy and minimized treatment burden.
C1 [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Lanzetta, Paolo] Univ Udine, Dept Med, Udine, Italy.
   [Korobelnik, Jean-Francois] Univ Bordeaux, Ctr INSERM U897 Epidemiol Biostat, ISPED, Bordeaux, France.
   [Korobelnik, Jean-Francois] CHU Bordeaux, ISPED, INSERM, Bordeaux, France.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Wojciechowski, Piotr] Creat Ceut, Krakow, Poland.
   [Taieb, Vanessa] Creat Ceut, London, England.
   [Deschaseaux, Celine; Janer, Daniel] Bayer Consumer Care AG, Basel, Switzerland.
   [Tuckmantel, Claudia] Bayer AG, Wuppertal, Germany.
C3 Shiga University of Medical Science; University of Udine; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite de Bordeaux; CHU Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux;
   Bayer AG; Bayer AG
RP Deschaseaux, C (通讯作者)，Bayer Consumer Care AG, Basel, Switzerland.
EM celine.deschaseaux@bayer.com
RI Taieb, Vanessa/AAW-7488-2020
OI Taieb, Vanessa/0000-0003-0655-8630
FU Bayer AG, Basel
FX This study was funded by Bayer AG, Basel. Bayer AG, Basel also funded
   the Journal Rapid Service and the Open Access Fees.
CR Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Dias S, 2011, NICE DSU TECHNICAL S
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Faria R., 2015, NICE DSU TECHNICAL S
   GATZ DF, 1995, ATMOS ENVIRON, V29, P1185, DOI 10.1016/1352-2310(94)00210-C
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2016, OPHTHALMOLOGE, V113, P925, DOI 10.1007/s00347-016-0275-z
   Higgins JPT., 2022, COCHRANE HDB SYSTEMA
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lanzetta P, 2019, 19 EURETINA C 5 8 SE
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   M Ohji, 2017, 17 EURETINA C BARC
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Phillippo DM, 2016, 18 ICE DSU NICE
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
NR 39
TC 12
Z9 16
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD MAY
PY 2020
VL 37
IS 5
BP 2184
EP 2198
DI 10.1007/s12325-020-01298-x
EA MAR 2020
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LK5DQ
UT WOS:000521999800001
PM 32222903
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Kano, M
   Itagaki, K
AF Saito, Masaaki
   Iida, Tomohiro
   Kano, Mariko
   Itagaki, Kanako
TI Two-year results of combined intravitreal ranibizumab and photodynamic
   therapy for polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Photodynamic therapy;
   Vascular endothelial growth factor; Indocyanine green angiography;
   Age-related macular degeneration; Retinal pigment epithelial detachment;
   Optical coherence tomography; Retinal pigment epithelium; Bevacizumab
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; JAPANESE PATIENTS;
   VERTEPORFIN; EFFICACY; NEOVASCULARIZATION; BEVACIZUMAB; EXPRESSION;
   MEMBRANES; VEGF
AB To clarify the efficacy of combined therapy with intravitreal ranibizumab injections and photodynamic therapy (PDT) in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
   We retrospectively reviewed 57 treatment-na < ve eyes of 57 patients. Thirty-two patients were treated with standard fluence PDT (PDT group), and 25 patients were treated with three consecutive monthly intravitreal injections of ranibizumab and standard fluence PDT (ranibizumab plus PDT group). All patients were followed for at least 24 months.
   In the ranibizumab plus PDT group, the mean best-corrected visual acuity (BCVA) levels of decimal (logMAR equivalent) significantly improved from 0.30 (0.52) at baseline to 0.55 (0.26) at 24 months (P < 0.001). In the PDT group, the BCVA levels stabilized from 0.26 (0.58) at baseline to 0.25 (0.60) at 24 months. The mean changes in the BCVA in the ranibizumab plus PDT group and the PDT group were improvement of 2.63 lines and decline of 0.16 lines respectively (P = 0.010). The mean number of PDTs at 24 months in the ranibizumab plus PDT group and the PDT group were 1.4 and 2.6 respectively. Increased subretinal hemorrhages were seen in eight (18.0 %) eyes, all of which were belonging to the PDT group.
   Combined intravitreal ranibizumab and PDT was significantly more effective in maintaining and improving VA for PCV patients compared with PDT monotherapy over 24 months.
C1 [Saito, Masaaki; Iida, Tomohiro; Kano, Mariko; Itagaki, Kanako] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 38
TC 32
Z9 35
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2013
VL 251
IS 9
BP 2099
EP 2110
DI 10.1007/s00417-013-2323-6
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214ES
UT WOS:000324114500004
PM 23553286
DA 2022-11-30
ER

PT J
AU Asano-Shimizu, K
   Asano, S
   Murata, H
   Azuma, K
   Nomura, Y
   Inoue, T
   Ogawa, A
   Asaoka, R
   Obata, R
AF Asano-Shimizu, Kimiko
   Asano, Shotaro
   Murata, Hiroshi
   Azuma, Keiko
   Nomura, Yoko
   Inoue, Tatsuya
   Ogawa, Asako
   Asaoka, Ryo
   Obata, Ryo
TI Early changes of vascular lesions and responses to combined photodynamic
   therapy in patients with polypoidal choroidal vasculopathy
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Branching vascular network (BVN); Indocyanine-green angiography (ICGA);
   Optical coherence tomography angiography (OCTA); Photodynamic therapy
   (PDT); Polypoidal choroidal vasculopathy (PCV)
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MACULAR DEGENERATION; EXTEND REGIMEN;
   RANIBIZUMAB; COMBINATION; AFLIBERCEPT; EFFICACY; SAFETY
AB Purpose To evaluate early changes of vascular lesions and their associations with the early responses to combined photodynamic therapy (PDT) in eyes with polypoidal choroidal vasculopathy (PCV). Methods This study evaluated 19 eyes of 19 patients with PCV who underwent PDT combined with anti-vascular endothelial growth factor injections and were followed for 3 months. All subjects were examined 1 week and 1, 2, and 3 months after combined PDT. "Active" cases were defined as recurrence or persistence of serous retinal detachment or subretinal hemorrhage detected within 3 months. Branching vascular networks (BVNs) were evaluated by optical coherence tomography angiography (OCTA) and polyps by indocyanine-green angiography. Results In total, 16%, 58%, 84%, and 89% of eyes displayed BVNs 1 week, 1, 2, and 3 months after PDT, respectively. BVNs were detected significantly more often 1 month after PDT in the "active" group than "inactive" group (89% vs. 30%, p = 0.020). There were significantly higher overall proportions of BVNs detected by OCTA in the "active" group than "inactive" group (p = 0.0058). Conclusion In most cases, BVNs disappeared once and gradually appeared again within 3 months. Detecting BVNs using OCTA from early phases could be a helpful biomarker to assess the early responses to PDT in eyes with PCV.
C1 [Asano-Shimizu, Kimiko; Asano, Shotaro; Murata, Hiroshi; Azuma, Keiko; Nomura, Yoko; Inoue, Tatsuya; Ogawa, Asako; Asaoka, Ryo; Obata, Ryo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Obata, R (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM robata-tky@umin.ac.jp
FU Japan Society For The Promotion Of Science [18K18413] Funding Source:
   Medline
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Azuma K, 2016, RETINA-J RET VIT DIS, V36, P2158, DOI 10.1097/IAE.0000000000001047
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Eris E, 2019, PHOTODIAGN PHOTODYN, V25, P1, DOI 10.1016/j.pdpdt.2018.10.007
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Iesato Y, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0952-6
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
NR 32
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2020
VL 40
IS 6
BP 1335
EP 1345
DI 10.1007/s10792-020-01299-3
EA FEB 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LQ2CJ
UT WOS:000515870900001
PM 32026179
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JY
   Lee, DW
   Kim, CG
   Kim, JW
AF Kim, Jae Hui
   Kim, Joo Yeon
   Lee, Dong Won
   Kim, Chul Gu
   Kim, Jong Woo
TI Fibrovascular pigment epithelial detachment in eyes with subretinal
   hemorrhage secondary to neovascular AMD or PCV: a morphologic predictor
   associated with poor treatment outcomes
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; TISSUE-PLASMINOGEN ACTIVATOR; MACULAR
   DEGENERATION; SUBMACULAR HEMORRHAGE; PNEUMATIC DISPLACEMENT;
   RANIBIZUMAB; MANAGEMENT; EXTEND; RECURRENCE; DISTANCE
AB To evaluate the influence of fibrovascular pigment epithelial detachment (FVPED) on treatment outcomes in eyes with subretinal hemorrhage secondary to neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). This retrospective study included 83 eyes diagnosed with fovea-involving submacular hemorrhage secondary to neovascular AMD or PCV. All the patients were treated with intravitreal anti-vascular endothelial growth factor. Eyes showing definite FVPED, which involves the subfoveal region, were included in the FVPED group. Eyes without subfoveal PED, shallow irregular PEDs, or serous/hemorrhagic PED were stratified to the non-FVPED group. The best-corrected visual acuity (BCVA) at diagnosis, at 3 months, at 12 months, and lesion re-activation after initial treatment were compared between the two groups. The mean size of hemorrhage was 8.6 +/- 7.6 disc diameter areas. In the FVPED group, the mean logarithm of minimal angle of resolution BCVA was 1.11 +/- 0.49 at diagnosis, 0.89 +/- 0.58 at 3 months, and 1.05 +/- 0.63 at 12 months. In the non-FVPED group, the values were 0.97 +/- 0.56, 0.56 +/- 0.55, and 0.45 +/- 0.50, respectively. The BCVA at 3 months (P=0.036) and at 12 months (P<0.001) was significantly worse in the FVPED group than in the non-FVPED group. In addition, the incidence of lesion reactivation was greater in the FVPED group (83.3%) than in the non-FVPED group (38.5%) (P<0.001). The presence of subfoveal FVPED was associated with a high incidence of lesion re-activation and poor treatment outcomes in eyes with subretinal hemorrhage. This result suggests that different treatment strategies are needed between eyes with and without FVPED.
C1 [Kim, Jae Hui; Kim, Joo Yeon; Lee, Dong Won; Kim, Chul Gu; Kim, Jong Woo] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong,4gaYoungdeungpo Gu, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong,4gaYoungdeungpo Gu, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Baek J, 2018, RETINA-J RET VIT DIS, V38, P1993, DOI 10.1097/IAE.0000000000001817
   Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Clemens CR, 2017, ACTA OPHTHALMOL, V95, P683, DOI 10.1111/aos.13359
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Kherani S, 2018, AM J OPHTHALMOL, V189, P86, DOI 10.1016/j.ajo.2018.02.015
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041145
   Kim JH, 2020, SEMIN OPHTHALMOL, V35, P33, DOI 10.1080/08820538.2019.1701045
   Kim JH, 2018, GRAEF ARCH CLIN EXP, V256, P469, DOI 10.1007/s00417-017-3877-5
   Kim JH, 2018, JPN J OPHTHALMOL, V62, P54, DOI 10.1007/s10384-017-0549-2
   Kim JH, 2017, J OCUL PHARMACOL TH, V33, P445, DOI 10.1089/jop.2016.0098
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Ohayon A, 2020, BRIT J OPHTHALMOL, V104, P1085, DOI 10.1136/bjophthalmol-2019-314923
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 40
TC 4
Z9 5
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 10
PY 2020
VL 10
IS 1
AR 14943
DI 10.1038/s41598-020-72030-6
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NR9XJ
UT WOS:000571915100064
PM 32913279
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nishihara, H
   Kondo, M
   Ishikawa, K
   Sugita, T
   Piao, CH
   Nakamura, Y
   Terasaki, H
AF Nishihara, Hiroaki
   Kondo, Mineo
   Ishikawa, Kohei
   Sugita, Tadasu
   Piao, Chang-Hua
   Nakamura, Yoshiharu
   Terasaki, Hiroko
TI Focal macular electroretinograms in eyes with wet-type age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL FUNCTION; MULTIFOCAL ELECTRORETINOGRAPHY; PHOTODYNAMIC THERAPY;
   RETINITIS-PIGMENTOSA; FELLOW EYES; MACULOPATHY; MORPHOLOGY; REMOVAL;
   ERGS
AB PURPOSE. To study the properties of the focal macular electroretinograms (fmERGs) in eyes with untreated wet-type agerelated macular degeneration (AMD).
   METHODS. fmERGs were recorded from 157 eyes of 157 consecutive patients with untreated wet-type AMD (113 men, 44 women; age, 71.3 +/- 8.0 years). The fmERGs were recorded under direct fundus observation using a modified infrared fundus camera and a 15 stimulus spot. Amplitudes and implicit times of the fmERGs recorded from the AMD patients were compared with those from 21 age-similar healthy controls.
   RESULTS. The amplitudes of fmERGs in the AMD patients were significantly smaller (P < 0.001) and the implicit times were significantly longer (P < 0.001) than the corresponding values in the control eyes. There was a significant correlation between amplitude and implicit time of the fmERG and visual acuity (logMAR), but the degree of correlation was weak. The difference in the b/a amplitude ratio between the AMD patients and healthy controls was not significant.
   CONCLUSIONS. The significant reduction in amplitude and the severe delay in implicit times of a-and b-waves of the fmERGs indicated significant functional alterations in the inner and the outer retinal layers of the macular area of eyes with wet-type AMD.
C1 [Kondo, Mineo] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Kondo, M (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM kondomi@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014
CR Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P635
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FISH GE, 1989, OPHTHALMOLOGY, V96, P109
   Grover S, 1999, OPHTHALMOLOGY, V106, P1780, DOI 10.1016/S0161-6420(99)90342-1
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Hood DC, 1996, VISION RES, V36, P1699, DOI 10.1016/0042-6989(95)00246-4
   Ikenoya K, 2007, INVEST OPHTH VIS SCI, V48, P3312, DOI 10.1167/iovs.06-1417
   Ishikawa K, 2005, OPHTHALMIC RES, V37, P34, DOI 10.1159/000083020
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KNAPP AG, 1984, VISION RES, V24, P1841, DOI 10.1016/0042-6989(84)90016-6
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   MIYAKE Y, 1993, INVEST OPHTH VIS SCI, V34, P512
   MIYAKE Y, 1993, AM J OPHTHALMOL, V116, P576, DOI 10.1016/S0002-9394(14)73199-X
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Niwa T, 2003, INVEST OPHTH VIS SCI, V44, P1652, DOI 10.1167/iovs.02-0404
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Robson JG, 2003, J PHYSIOL-LONDON, V547, P509, DOI 10.1113/jphysiol.2002.030304
   Ruther K, 2003, OPHTHALMOLOGE, V100, P459, DOI 10.1007/s00347-002-0757-z
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   SIEVING PA, 1994, VISUAL NEUROSCI, V11, P519, DOI 10.1017/S0952523800002431
   SOUBRANE G, 2006, OPTICAL COHERENCE TO, P109
   Tanikawa A, 1999, AM J OPHTHALMOL, V127, P559, DOI 10.1016/S0002-9394(98)00447-4
   Terasaki H, 2004, INVEST OPHTH VIS SCI, V45, P567, DOI 10.1167/iovs.03-0187
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 37
TC 15
Z9 15
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3121
EP 3125
DI 10.1167/iovs.08-1835
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000044
PM 18408182
DA 2022-11-30
ER

PT J
AU Terasaki, H
   Ishikawa, K
   Niwa, Y
   Piao, CH
   Niwa, T
   Kondo, M
   Ito, Y
   Miyake, Y
AF Terasaki, H
   Ishikawa, K
   Niwa, Y
   Piao, CH
   Niwa, T
   Kondo, M
   Ito, Y
   Miyake, Y
TI Changes in focal macular ERGs after macular translocation surgery with
   360 degrees retinotomy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; FOVEAL
   TRANSLOCATION; RETINAL SEPARATION; RABBIT EYE; DEGENERATION; MANAGEMENT;
   ELECTRORETINOGRAMS; MACULOPATHY; VERTEPORFIN
AB PURPOSE. To evaluate the short- and long-term changes of focal macular electroretinograms (fmERGs) after macular translocation with 360degrees retinotomy.
   METHODS. This was a retrospective study. fmERGs were recorded in 19 eyes of 19 consecutive patients who underwent macular translocation with 360degrees retinotomy for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD; 17 eyes) or polypoidal choroidal vasculopathy (2 eyes). The changes in the fmERGs, recorded before, shortly after (6-12 months; mean 8.3 months), and more than 18 months (18-30 months; mean 22.4 months) after surgery from 12 eyes, were analyzed. A 15degrees stimulus centered on the fovea was used to elicit the fmERGs.
   RESULTS:. The mean logarithm of minimum angle of resolution (logMAR) was 1.06 +/- 0.07 (20/230) before surgery, 0.78 +/- 0.08 (20/121) early after surgery (n = 19), and 0.64 +/- 0.07 (20/87) late after surgery (n = 12). These improvements in visual acuity were significant (P = 0.0074, P = 0.0050, respectively). Before surgery, the amplitudes of all components of the fmERGs were markedly reduced in all eyes. The mean b-wave amplitude in 17 AMD eyes recorded early after surgery was significantly larger (P = 0.0262), and the mean a-wave amplitude was also increased but not significantly (P = 0.1180). The mean amplitudes of the a- and b-waves in 10 AMD eyes recorded after 18 months were significantly larger than those before the surgery (P = 0.0218, and P = 0.0284). The mean implicit time of the b-wave in 17 AMD eyes decreased early after surgery, and a further decrease was detected at the later testing time.
   CONCLUSIONS. These results indicate that macular function is partially recoverable after macular translocation in some patients.
C1 Nagoya Univ, Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM terasaki@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Terasaki, Hiroko/M-5054-2014
OI Ito, Yasuki/0000-0001-9219-9261; 
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P635
   de Juan E, 1999, AM J OPHTHALMOL, V128, P380, DOI 10.1016/S0002-9394(99)00142-7
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hayashi Hirofumi, 1997, Nippon Ganka Gakkai Zasshi, V101, P417
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lewis GP, 2002, INVEST OPHTH VIS SCI, V43, P2412
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Macular translocation, 2000, OPHTHALMOLOGY, V107, P1015
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   MIYAKE Y, 1988, ACTA SOC OPHTHALMOL, V92, P1418
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Potter MJ, 2000, AM J OPHTHALMOL, V129, P547, DOI 10.1016/S0002-9394(99)00480-8
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P452
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
NR 27
TC 13
Z9 15
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2004
VL 45
IS 2
BP 567
EP 573
DI 10.1167/iovs.03-0187
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 771CX
UT WOS:000188769000029
PM 14744900
DA 2022-11-30
ER

PT J
AU Narita, C
   Wu, ZC
   Rosenfeld, PJ
   Yang, J
   Lyu, CC
   Caruso, E
   McGuinness, M
   Guymer, RH
AF Narita, Callum
   Wu, Zhichao
   Rosenfeld, Philip J.
   Yang, Jin
   Lyu, Cancan
   Caruso, Emily
   McGuinness, Myra
   Guymer, Robyn H.
TI Structural OCT Signs Suggestive of Subclinical Nonexudative Macular
   Neovascularization in Eyes with Large Drusen
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SWEPT-SOURCE; SPECTRAL-DOMAIN; CHOROIDAL
   NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; VISUAL OUTCOMES; FELLOW EYES;
   ANGIOGRAPHY; DEGENERATION; RANIBIZUMAB
AB Purpose: To further define the structural OCT features described as the "double-layer sign" suggestive of subclinical, nonexudative macular neovascularization (NE-MNV) in asymptomatic eyes with age-related macular degeneration (AMD).
   Design: Cross-sectional observational study.
   Participants: Participants with large drusen (>125 mu m) secondary to AMD in at least 1 eye.
   Methods: Participants in a "discovery" cohort, with known NE-MNV identified on swept-source (SS) OCT angiography (OCTA) and the "double-layer sign" on structural spectral-domain OCT (SD-OCT) imaging, were used to identify characteristic features of this sign. These features were then assessed by masked grading in an "evaluation" cohort of AMD eyes with large drusen to determine the predictive values for NE-MNV.
   Main Outcome Measures: Description of OCT features associated with an increased risk of NE-MNV and their diagnostic and predictive performance.
   Results: The discovery cohort of 4 eyes revealed that in retinal pigment epithelium (RPE) elevations with a greatest transverse linear dimension of 1000 mu m or more, an irregular RPE layer with a height of predominantly less than 100 mu m and a nonhomogenous internal reflectivity as characteristic features of the double-layer sign when NE-MNV was present. We term these collective features as a shallow, irregular RPE elevation (SIRE). Features on OCT images from 233 eyes in the evaluation cohort that were associated significantly with NE-MNV when the RPE elevation was more than 1000 mu m in length were: height of the RPE elevation, overall flat or variable morphologic features, RPE layer irregularity, and nonhomogeneous reflectivity (all P >= 0.032). Twenty-four eyes (10.3%) were identified with a SIRE. On SS-OCTA imaging, 6 of the 233 eyes were found to have definite NE-MNV, and all 6 graded positively for SIRE (sensitivity, 100%). The absence of SIRE was identified in 209 of 227 eyes without NE-MNV (specificity, 92.1 %). The positive predictive value for SIRE was 25% and the negative predictive value was 100%.
   Conclusions: Eyes whose OCT images display a SIRE sign are at higher risk of having subclinical NE-MNV. SIRE can be used as a screening tool on routine structural OCT imaging. More frequent follow-up and diligent home monitoring is recommended for those with SIRE. (C) 2019 by the American Academy of Ophthalmology
C1 [Narita, Callum; Wu, Zhichao; Caruso, Emily; McGuinness, Myra; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
   [Narita, Callum] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia.
   [Wu, Zhichao; Caruso, Emily; McGuinness, Myra; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Rosenfeld, Philip J.; Yang, Jin; Lyu, Cancan] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   Monash University; University of Melbourne; Bascom Palmer Eye Institute;
   University of Miami
RP Guymer, RH (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017; Lyu, Cancan/ABC-4635-2021
OI McGuinness, Myra/0000-0002-5422-040X; Narita,
   Callum/0000-0003-0381-5400; Lyu, Cancan/0000-0003-2078-3471
FU National Health & Medical Research Council of Australia [GNT1103013,
   APP1104985]; ARI Network
FX Supported by the National Health & Medical Research Council of Australia
   (research fellowship nos.: GNT1103013 [R.H.G.] and APP1104985 [Z.W.]).
   Carl Zeiss Meditec, Inc., Dublin, California, provided the PLEX Elite
   9000 instrument and support via the ARI Network. The Centre for Eye
   Research Australia receives operational infrastructure support from the
   Victorian Government.
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 28
TC 20
Z9 20
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2020
VL 127
IS 5
BP 637
EP 647
DI 10.1016/j.ophtha.2019.11.007
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE7XR
UT WOS:000526937900021
PM 31899036
DA 2022-11-30
ER

PT J
AU Carrasco, J
   Pietsch, GA
   Nicolas, MP
   Koerber, C
   Bennison, C
   Yoon, J
AF Carrasco, Joao
   Pietsch, Georg-Alexander
   Nicolas, Marie-Pierre
   Koerber, Cecile
   Bennison, Craig
   Yoon, Jisu
TI Real-World Effectiveness and Real-World Cost-Effectiveness of
   Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular
   Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of
   Real-World Studies
SO ADVANCES IN THERAPY
LA English
DT Review
DE Age-related macular degeneration; Intravitreally administered
   aflibercept; Ophthalmology; Ranibizumab; Real-world cost-effectiveness;
   Real-world effectiveness
ID VISUAL-ACUITY MEASUREMENTS; TREATMENT-NAIVE PATIENTS; 12-MONTH OUTCOMES;
   PRN RANIBIZUMAB; LIFE; TREAT; THERAPY; INJECTIONS; REGIMEN; AUDIT
AB Introduction Treatment of neovascular age-related macular degeneration (nAMD) has evolved with the advent of anti-vascular endothelial growth factor agents such that intravitreally administered aflibercept and ranibizumab (RBZ) have become the standard of care. Randomized clinical trials (RCTs) have demonstrated the benefits of these agents in nAMD; however, results achieved under RCT protocols may not always be replicated in clinical practice. Assessing real-world outcomes is important to estimate the effectiveness and cost-effectiveness of these two agents. Our objective was to assess the real-world effectiveness of intravitreally administered aflibercept and RBZ in treatment-naive patients with nAMD and determine the cost-effectiveness of intravitreally administered aflibercept versus RBZ in a real-world setting. Methods A multistage approach was undertaken. A systematic literature review (SLR) was completed to identify studies describing real-world outcomes in patients with nAMD treated intravitreally with aflibercept or RBZ. A meta-analysis of data identified in the SLR generated a pooled estimate of the effectiveness of intravitreally administered aflibercept and RBZ at 52 weeks and an estimate of treatment burden (injection frequency and monitoring). The impact of treatment effect modifiers, such as baseline visual acuity (VA) and age, were corrected through a multivariable meta-regression. A Markov state transition model was developed to estimate the real-world cost-effectiveness of intravitreally administered aflibercept using results from the pooled estimates for effectiveness and treatment burden as primary inputs. The analysis considered the perspective of the French National Healthcare System. Results Patients treated intravitreally with aflibercept had a mean age of 79.52 years and mean baseline VA of 55.80 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. At week 52, mean VA gain was 5.30 ETDRS letters in patients reporting an average of 7.10 intravitreal injections of aflibercept and 8.65 visits (injection and/or monitoring). RBZ-treated patients were younger (77.28 years), with a lower mean baseline VA (52.81 ETDRS letters). At week 52, mean VA gain from baseline was 4.24 ETDRS letters, with an average of 5.88 injections and 10.10 visits (injection and/or monitoring). After correcting for differences in age (77.28 years) and baseline VA (52.81 ETDRS letters) and considering the current clinical practice with aflibercept and RBZ, the mean VA gain was 6.57 ETDRS letters for patients treated intravitreally with aflibercept and 4.42 ETDRS for patients treated intravitreally with RBZ. The cost-effectiveness analysis showed that intravitreally administered aflibercept is a more effective treatment option with an incremental gain in quality-adjusted life years (QALYs) (4.918 versus 4.880) and an incremental cost-effectiveness ratio (ICER) of euro27,087 per QALY. Conclusions The analysis identified differences in the overall treatment approach and how ophthalmologists use intravitreally administered aflibercept and RBZ in clinical practice. These differences ultimately influence the mean real-world effectiveness of the two agents. Intravitreal treatment with aflibercept (injection frequency and patients follow-up) was consistent and in line with the European label recommendations. Patients treated intravitreally with aflibercept in clinical practice reported a mean gain in VA of similar magnitude to the mean VA gain reported in the pivotal RCT.
   Conversely, treatment with RBZ varied significantly across the different studies.
   On average, RBZ-treated patients reported a low injection frequency and a frequent follow-up, driven in part by the high number of patients treated with pro re nata (PRN) regimens. RBZ-treated patients reported gains in VA versus baseline; however, the magnitude of the gain in VA was not comparable to the VA gains reported in the RBZ pivotal RCT. Intravitreal treatment with aflibercept was associated with better mean VA outcomes and an incremental gain in QALYs compared with RBZ and can be considered cost-effective for the treatment of nAMD in patients in France despite a higher price for each individual intravitreal injection of aflibercept compared with RBZ. Funding Bayer AG, Basel.
C1 [Carrasco, Joao; Pietsch, Georg-Alexander] Bayer Consumer Care AG, Basel, Switzerland.
   [Nicolas, Marie-Pierre; Koerber, Cecile] Bayer HealthCare SAS, Loos, France.
   [Bennison, Craig] Pharmerit Int, York, N Yorkshire, England.
   [Yoon, Jisu] Pharmerit Int, Berlin, Germany.
C3 Bayer AG; Bayer AG; Bayer Healthcare Pharmaceuticals
RP Carrasco, J (通讯作者)，Bayer Consumer Care AG, Basel, Switzerland.
EM joao.carrasco@bayer.com
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Basheer K, 2015, CLIN OPHTHALMOL, V9, P959, DOI 10.2147/OPTH.S76754
   Boulanger-Scemama E, 2016, J FR OPHTALMOL, V39, P668, DOI 10.1016/j.jfo.2016.06.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Claxton L, 2017, PHARMACOECONOMICS, V35, P237, DOI 10.1007/s40273-016-0459-z
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Duval MV, 2017, J FR OPHTALMOL, V40, P270, DOI 10.1016/j.jfo.2016.11.012
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gungel H, 2014, CLIN OPHTHALMOL, V8, P981, DOI 10.2147/OPTH.S61871
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Guo MY, 2018, PHARMACOTHERAPY, V38, P197, DOI 10.1002/phar.2079
   Guymer RH, 2016, INVEST OPHTH VIS SCI, V57
   Haute Authorite de Sante, 2012, CHOIC METH EC EV
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Quaranta M, 2017, INVEST OPHTH VIS SCI, V58
   Rana-Rahman RL, 2015, INVEST OPHTH VIS SCI, V56
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Wickremasinghe SS, 2012, EYE, V26, P958, DOI 10.1038/eye.2012.72
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 51
TC 21
Z9 25
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD JAN
PY 2020
VL 37
IS 1
BP 300
EP 315
DI 10.1007/s12325-019-01147-6
PG 16
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KJ2XL
UT WOS:000511921200020
PM 31728825
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Cougnard-Gregoire, A
   Delyfer, MN
   Korobelnik, JF
   Rougier, MB
   Malet, F
   Le Goff, M
   Dartigues, JF
   Colin, J
   Barberger-Gateau, P
   Delcourt, C
AF Cougnard-Gregoire, Audrey
   Delyfer, Marie-Noelle
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Malet, Florence
   Le Goff, Melanie
   Dartigues, Jean-Francois
   Colin, Joseph
   Barberger-Gateau, Pascale
   Delcourt, Cecile
TI Long-Term Blood Pressure and Age-Related Macular Degeneration: The
   ALIENOR Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; CARDIOVASCULAR RISK-FACTORS; BEAVER DAM EYE;
   CHOROIDAL NEOVASCULARIZATION; FRAMINGHAM HEART; LONGITUDINAL DATA;
   5-YEAR INCIDENCE; PULSE PRESSURE; MACULOPATHY; DISEASE
AB PURPOSE. To explore the association of AMD with long-term average blood pressure (BP) parameters, including pulse pressure (PP).
   METHODS. The ALIENOR study is a population-based study on age-related eye diseases in 963 residents of Bordeaux, France, aged 73 years or older. AMD was graded from nonmydriatic color retinal photographs, in three exclusive stages: no AMD (1015 eyes), large soft distinct drusen and/or large soft indistinct drusen and/or reticular drusen and/or pigmentary abnormalities (early AMD, 276 eyes), and late AMD (66 eyes). BP parameters were measured at four occasions over a 7-year period. PP was defined as systolic BP minus diastolic BP. Associations of AMD with BP parameters were estimated using generalized estimating equation logistic regressions. Statistical analyses included 702 subjects (1357 eyes) with complete data.
   RESULTS. After adjustment for age, sex, educational level, smoking, body mass index, plasma HDL and LDL cholesterol, CFH Y402H, ApoE2, ApoE4, and ARMS2 A69S polymorphisms, elevated PP was significantly associated with an increased risk of late AMD (odds ratio [OR] 1.37 for a 10-mm Hg increase, 95% confidence interval [CI]: 1.03-1.82). Associations were similar for late atrophic and late neovascular AMD (OR 1.39, 95% CI: 1.01-1.92, P = 0.04, and OR = 1.43, 95% CI: 0.90-2.23, P = 0.13, respectively). Association with early AMD was in the same direction but did not reach statistical significance (OR 1.12, 95% CI: 0.98-1.28). Early and late AMD were not significantly associated with systolic or diastolic BP, hypertension, or use of antihypertensive medications.
   CONCLUSIONS. This study suggests that high PP may be associated with increased risk for AMD. (Invest Ophthalmol Vis Sci. 2013;54:1905-1912) DOI:10.1167/iovs.12-10192
C1 [Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] Univ Bordeaux, Bordeaux, France.
   [Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Le Goff, Melanie; Dartigues, Jean-Francois; Colin, Joseph; Barberger-Gateau, Pascale; Delcourt, Cecile] Ctr INSERM U897 Epidemiol Biostat, INSERM, ISPED, Bordeaux, France.
   [Delyfer, Marie-Noelle; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Malet, Florence; Colin, Joseph] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux
RP Delcourt, C (通讯作者)，Univ Bordeaux Segalen, Inserm U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM Cecile.Delcourt@isped.u-bordeaux2.fr
RI COUGNARD-GREGOIRE, Audrey/T-4443-2019; Delcourt, Cecile/I-2627-2013;
   DARTIGUES, Jean François/T-4513-2019; Delyfer, Marie-Noelle/T-3304-2019;
   LE GOFF, Mélanie/A-3541-2016; KOROBELNIK, Jean-Francois/A-5448-2016
OI COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Delcourt,
   Cecile/0000-0002-2099-0481; LE GOFF, Melanie/0000-0003-2848-6287
FU Laboratoires Thea, Clermont-Ferrand, France; Fondation Voir et Entendre,
   Paris, France; Association Retina France, Colomiers, France
FX Supported by Laboratoires Thea, Clermont-Ferrand, France; Fondation Voir
   et Entendre, Paris, France; and Association Retina France, Colomiers,
   France. Laboratoires Thea participated in the design of the study, but
   none of the sponsors participated in the collection, management,
   statistical analysis and interpretation of the data, nor in the
   preparation, review or approval of the present manuscript.
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1982, ARTERIAL FUNCTION HL
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Benetos A, 1998, HYPERTENSION, V32, P560, DOI 10.1161/01.HYP.32.3.560
   BIRD AC, 1995, INT ARM EPIDEMIOLOGI, V5, P367
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Franklin SS, 2001, CIRCULATION, V103, P1245
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GORDON T, 1976, INT J EPIDEMIOL, V5, P327, DOI 10.1093/ije/5.4.327
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klabunde R. E., CARDIOVASCULAR PHYSL
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P1568, DOI 10.1001/archophthalmol.2010.298
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roman MJ, 2009, J AM COLL CARDIOL, V54, P1730, DOI 10.1016/j.jacc.2009.05.070
   Sasai H, 2011, HYPERTENS RES, V34, P139, DOI 10.1038/hr.2010.173
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vasan RS, 2002, CIRCULATION, V105, P48, DOI 10.1161/hc0102.101774
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 60
TC 30
Z9 31
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2013
VL 54
IS 3
BP 1905
EP 1912
DI 10.1167/iovs.12-10192
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117GV
UT WOS:000316942400044
PM 23404120
DA 2022-11-30
ER

PT J
AU Kojima, M
   Yukawa, E
   Shimoyama, K
   Nochioka, K
   Tsujinaka, H
   Matsuura, T
AF Kojima, Masashi
   Yukawa, Eiichi
   Shimoyama, Kimie
   Nochioka, Katsunori
   Tsujinaka, Hiroki
   Matsuura, Toyoaki
TI Multifocal electroretinograms in age-related macular degeneration before
   and after photodynamic therapy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroidal neovascularization; Multifocal electroretinograms; Optical
   coherence tomography; Photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; RETINAL
   FUNCTION; EDEMA; ERG
AB PURPOSE. To evaluate multifocal electroretinograms (mfERG) and macular retinal thickness before and after photodynamic therapy (PDT) for predominantly classic choroidal neovascularization (CNV) (classic type) and occult with no classic CNV (occult type).
   METHODS. Recording of mfERG and measurement of macular retinal thickness were performed before and after PDT in 19 patients (19 eyes) with the classic type and 24 (26 eyes) with the occult type. The evaluation items were the amplitude of the first negative wave (N1), the amplitude from the peak of the negative wave to that of the following positive wave (P1), and the peak latencies of the negative and positive waves.
   RESULTS. Compared with mfERG before PDT, that after PDT showed a significant decrease in the P1 latency in the central area (31.1 +/- 1.9 ms before and 29.6 +/- 1.6 ms after PDT) for the classic type and significant decreases in both the central (32.0 +/- 2.0 ms before and 30.5 +/- 2.4 ms after PDT) and peripheral (30.2 +/- 2.0 ms before and 29.5 +/- 2.0 ms after PDT) areas for the occult type. Optical coherence tomography showed significant decreases in macular retinal thickness in both groups (464 and 314 mu m before and after PDT, respectively, for the classic type and 516 and 340 mu m for the occult type).
   CONCLUSIONS. After PDT, retinal function evaluated by mfERG improved for both the classic and occult types, and the recovery of P1 latency may be due to improvement in retinal edema.
C1 [Kojima, Masashi; Yukawa, Eiichi; Shimoyama, Kimie; Nochioka, Katsunori; Tsujinaka, Hiroki; Matsuura, Toyoaki] Nara Med Univ, Dept Ophthalmol, Kashihara, Nara 6300813, Japan.
C3 Nara Medical University
RP Kojima, M (通讯作者)，Nara Med Univ, Dept Ophthalmol, 840 Shijyotyou, Kashihara, Nara 6300813, Japan.
EM cozimasa@yahoo.co.jp
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   Karacorlu M, 2008, EUR J OPHTHALMOL, V18, P601, DOI 10.1177/112067210801800417
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Leozappa M, 2008, EUR J OPHTHALMOL, V18, P609, DOI 10.1177/112067210801800418
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Moschos MN, 2003, EUR J OPHTHALMOL, V13, P461, DOI 10.1177/112067210301300507
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Ruther K, 2003, OPHTHALMOLOGE, V100, P459, DOI 10.1007/s00347-002-0757-z
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
NR 14
TC 1
Z9 1
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2012
VL 22
IS 3
BP 412
EP 416
DI 10.5301/ejo.5000031
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 969ZZ
UT WOS:000306099200019
PM 21928263
DA 2022-11-30
ER

PT J
AU Mauget-Faysse, M
   Maftouhi, MQ
   De La Marnierre, E
   Leys, A
AF Mauget-Faysse, M.
   Quaranta-El Maftouhi, M.
   De La Marnierre, E.
   Leys, A.
TI Photodynamic therapy with verteporfin in the treatment of exudative
   idiopathic polypoidal choroidal vasculopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascular membrane; idiopathic polypoidal choroidal
   vasculopathy; photodynamic therapy; verteporfin
ID OPTICAL COHERENCE TOMOGRAPHY; LASER PHOTOCOAGULATION; MACULAR
   TRANSLOCATION; EDGE
AB PURPOSE. To determine the safety and efficacy of photodynamic therapy with verteporfin (VPDT) in the treatment of exudative idiopathic polypoidal choroidal vasculopathy (IPCV) lesions that were not suitable for laser photocoagulation.
   METHODS. This was a prospective, open label study in two centers involving 30 consecutive patients (31 eyes) diagnosed with exudative IPCV using fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). All patients underwent complete ophthalmologic examination including best-corrected visual acuity (VA) measurement, contrast sensitivity (CS) testing, FA, ICGA, and OCT OCT was used to assess the stage of the polypoidal dilations (active or scarred) and the evolution of the signs associated with exudation. Study patients were treated with V-PDT and followed up at 6 weeks and 3, 6, and 12 months. Re-treatment was applied, at an interval of 3 months, until there was an absence of leakage on FA and hyperfluorescence on ICGA.
   RESULTS. Thirty eyes (29 patients) completed the 12 months post-treatment visit and were retained for further analysis. The mean number of V-PDT treatments was 2.5 (SD 1.1). At 12 months post-treatment, the mean foveal thickness had significantly (p < 0.03) decreased to 224 (SD 104) pm from the baseline 292 (SD 124) pm while the mean VA had significantly (p < 0.02) improved to 0.50 (SD 0.38) from the baseline 0.38 (SD 0.24). Serous detachment of the macula completely resolved in 83.3% of the eyes while 73.3% of the polypoidal dilations were occluded at 12 months.
   CONCLUSIONS. The results suggest that V-PDT is effective and relatively safe in treating exudative IPCV.
C1 Ctr Ophtalmol Rabelais, F-69003 Lyon, France.
   Katholieke Univ Leuven Hosp, Dept Ophthalmol, B-3000 Louvain, Belgium.
C3 Flanders Institute for Biotechnology (VIB); KU Leuven; University
   Hospital Leuven
RP Mauget-Faysse, M (通讯作者)，Ctr Ophtalmol Rabelais, 12-14 Rue Rabelais, F-69003 Lyon, France.
EM centrerabelais@wanadoo.fr
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   COSCAS G, 2004, J FR OPHTALMOL, V27, P327
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Morizane Y, 2002, AM J OPHTHALMOL, V133, P848, DOI 10.1016/S0002-9394(02)01413-7
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SUNG CL, 2004, OPHTHALMOLOGICA, V218, P193
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 30
TC 38
Z9 41
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2006
VL 16
IS 5
BP 695
EP 704
DI 10.1177/112067210601600506
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117TJ
UT WOS:000242895900007
PM 17061220
DA 2022-11-30
ER

PT J
AU Chi, SC
   Kang, YN
   Huang, YM
AF Chi, Sheng-Chu
   Kang, Yi-No
   Huang, Yi-Ming
TI Systematic review with network meta-analysis of antivascular endothelial
   growth factor use in managing polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Review
AB Polypoidal choroidal vasculopathy (PCV) is a vision-threatening disease common in Asian populations. However, the optimal treatment for PCV remains under debate. We searched the databases with optimal searching strategy. The study included randomized clinical trials and prospective studies that recruited patients with active PCV who had received interventions, including PDT, anti-VEGF, or a combination of PDT and anti-VEGF. The Grading of Recommendations Assessment, Development, and Evaluation methodology was used for rating the quality of evidence. Our study included 11 studies involving 1277 patients. The network meta-analysis of RCTs revealed the anti-VEGF group, early combination group, and late combination group had significant BCVA changes compared with the PDT group. Early combination therapy led to a significant decrease in CRT compared with PDT, anti-VEGF, and late combination therapy. Additionally, the early combination group had a significantly higher complete polyp regression rate than the anti-VEGF group. No significant differences were detected in the analysis of the number of anti-VEGF injections and safety profile. This network meta-analysis revealed that early combination therapy exhibited better efficacy related to anatomical outcomes than other therapies. Nonetheless, no significant differences related to BCVA change could be detected between anti-VEGF and late combination therapy.
C1 [Chi, Sheng-Chu; Huang, Yi-Ming] Taipei Vet Gen Hosp, Taiwan Fac Med, Dept Ophthalmol, Taipei, Taiwan.
   [Kang, Yi-No] Taipei Med Univ, Wan Fang Hosp, Evidence Based Med Ctr, Taipei, Taiwan.
   [Kang, Yi-No] Taipei Med Univ, Wan Fang Hosp, Res Ctr Big Data & Metaanal, Taipei 115, Taiwan.
   [Kang, Yi-No] Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan.
   [Kang, Yi-No] Natl Taiwan Univ, Inst Hlth Policy & Management, Coll Publ Hlth, Taipei, Taiwan.
   [Huang, Yi-Ming] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; Taipei Medical University; Taipei
   Municipal WanFang Hospital; Taipei Medical University; Taipei Municipal
   WanFang Hospital; Taipei Medical University; National Taiwan University;
   National Yang Ming Chiao Tung University
RP Huang, YM (通讯作者)，Taipei Vet Gen Hosp, Taiwan Fac Med, Dept Ophthalmol, Taipei, Taiwan.; Huang, YM (通讯作者)，Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
EM nowaytokyo@yahoo.com.tw
CR Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Azuma K, 2018, CLIN OPHTHALMOL, V12, P1589, DOI 10.2147/OPTH.S172115
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai KB, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0801-7
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li J, 2018, EXP THER MED, V15, P1546, DOI 10.3892/etm.2017.5565
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Mitchell P, 2017, CLIN EXP OPHTHALMOL, V45, P31
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 31
TC 3
Z9 3
U1 3
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 2
PY 2021
VL 11
IS 1
AR 2735
DI 10.1038/s41598-021-82316-y
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QG6PD
UT WOS:000617704900002
PM 33531615
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lai, TM
   Tang, ZQ
   Lai, ACW
   Szeto, SKH
   Lai, R
   Cheung, CY
AF Lai, Timothy Y. Y.
   Tang, Ziqi
   Lai, Adrian C. W.
   Szeto, Simon K. H.
   Lai, Ricky Y. K.
   Cheung, Carol Y.
TI Association of Fundus Autofluorescence Abnormalities and Pachydrusen in
   Central Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE pachychoroid; pachydrusen; drusen; central serous chorioretinopathy;
   polypoidal choroidal vasculopathy; optical coherence tomography; fundus
   autofluorescence; neovascular age-related macular degeneration
ID THICKNESS; AGE
AB A specific form of drusen, known as pachydrusen, has been demonstrated to be associated with pachychoroid eye diseases, such as central serous chorioretinopathy (CSC) and polypoidal choroidal vasculopathy (PCV). These pachydrusen have been found in up to 50% of eyes with CSC and PCV and may affect the disease progression and treatment response. This study aims to investigate the association between pachydrusen and changes in fundus autofluorescence (FAF) in eyes with CSC and PCV. A total of 65 CSC patients and 32 PCV patients were evaluated. Pachydrusen were detected using both color fundus photography and spectral-domain optical coherence tomography. The relationships between pachydrusen and FAF changes were then investigated. The prevalence of pachydrusen in CSC and PCV eyes was 16.7% and 61.8%, respectively. The mean age of patients with pachydrusen was significantly older than those without pachydrusen (CSC: 56.3 vs. 45.0 years, p < 0.001; PCV: 68.8 vs. 59.5 years, p < 0.001). No significant difference was found in the mean subfoveal choroidal thickness between eyes with or without pachydrusen. Eyes with pachydrusen were significantly associated with more extensive FAF changes in both CSC and PCV (p < 0.001 and p = 0.037, respectively). The study demonstrated that pachydrusen are more prevalent in PCV than CSC. Increasing age and more extensive abnormalities in FAF are associated with the presence of pachydrusen, suggesting that dysfunction of retinal pigment epithelial cells is associated with pachydrusen.
C1 [Lai, Timothy Y. Y.; Tang, Ziqi; Szeto, Simon K. H.; Cheung, Carol Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.; Lai, Adrian C. W.; Lai, Ricky Y. K.] 2010 Retina & Macula Ctr, Tsim Sha Tsui, Kowloon, Hong Kong, Peoples R China.
   [Lai, Adrian C. W.] UNSW Sydney, Fac Med & Hlth, Kensington, NSW 2052, Australia.
C3 Chinese University of Hong Kong; University of New South Wales Sydney
RP Lai, TM (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.; Lai, TM (通讯作者)，2010 Retina & Macula Ctr, Tsim Sha Tsui, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
OI Lai, Timothy/0000-0002-7832-6428; Szeto, Simon, Ka
   Ho/0000-0001-9377-7377
CR Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Castro-Navarro V, 2021, GRAEF ARCH CLIN EXP, V259, P1385, DOI 10.1007/s00417-020-04940-0
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Fukuda Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082459
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Goyindahari V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48040-4
   Han J, 2020, RETINA-J RET VIT DIS, V40, P1387, DOI 10.1097/IAE.0000000000002580
   Kim KL, 2022, ACTA OPHTHALMOL, V100, pE710, DOI 10.1111/aos.14960
   Kim YH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158353
   Kumar V, 2022, RETINA-J RET VIT DIS, V42, P80, DOI 10.1097/IAE.0000000000003275
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Notomi S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255213
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sheth J, 2020, EYE, V34, P1501, DOI 10.1038/s41433-020-0886-0
   Shinojima A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102178
   Singh SR, 2020, INDIAN J OPHTHALMOL, V68, P118, DOI 10.4103/ijo.IJO_528_19
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi A, 2021, OPHTHALMOL RETINA, V5, P910, DOI 10.1016/j.oret.2020.12.004
   Teo KYC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87083-4
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
   Zhao XY, 2018, GRAEF ARCH CLIN EXP, V256, P1101, DOI 10.1007/s00417-018-3980-2
NR 30
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2022
VL 11
IS 18
AR 5340
DI 10.3390/jcm11185340
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4Q9QM
UT WOS:000856409100001
PM 36142987
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU O' Farrell, L
   Lewis, S
   McKenzie, A
   Jones, L
AF O' Farrell, Lauren
   Lewis, Sandra
   McKenzie, Amy
   Jones, Lynda
TI Charles Bonnet Syndrome: A Review of the Literature
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Review
ID COMPLEX VISUAL HALLUCINATIONS; MACULAR DEGENERATION; PARKINSONS-DISEASE;
   CLINICAL-EVALUATION; LOW-VISION; PEOPLE; OPHTHALMOLOGY; HYPOTHESIS;
   DEMENTIA; ANATOMY
AB Charles Bonnet syndrome (CBS) commonly occurs in older adults with visual impairments, particularly those with age-related macular degeneration. It is characterized by complex visual hallucinations in individuals without mental disorders. The authors explore diagnostic criteria, demographic characteristics, clinical features, theories of pathogenesis, and management options for people who are diagnosed with CBS.
C1 [O' Farrell, Lauren] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA.
   [Lewis, Sandra; McKenzie, Amy] Florida State Univ, Sch Teacher Educ, Tallahassee, FL 32306 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   State University System of Florida; Florida State University
RP O' Farrell, L (通讯作者)，Charlie Norwood VA Med Ctr, 1 Freedom Way, Augusta, GA 30904 USA.
EM lauren.ofarrell@va.gov; slewis@fsu.edu; armckenzie@coe.fsu.edu;
   lyndajones2414@embarqmail.com
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   Barnes J, 2001, J NEUROL NEUROSUR PS, V70, P727, DOI 10.1136/jnnp.70.6.727
   Batra A, 1997, ACTA PSYCHIAT SCAND, V96, P129, DOI 10.1111/j.1600-0447.1997.tb09917.x
   BECK J, 1994, INT J GERIATR PSYCH, V9, P531, DOI 10.1002/gps.930090705
   BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662
   BURKE W, 2005, J NEUROL PSYCHIAT, V73, P535
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Collerton D, 2005, BEHAV BRAIN SCI, V28, P737
   Crumbliss Kara E, 2008, Semin Ophthalmol, V23, P121, DOI 10.1080/08820530801888170
   Elbers N, 2007, THEOR PSYCHOL, V17, P587, DOI 10.1177/0959354307079305
   Fernandez A, 1997, J NERV MENT DIS, V185, P195, DOI 10.1097/00005053-199703000-00009
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3
   Hedges TR, 2007, SURV OPHTHALMOL, V52, P111, DOI 10.1016/j.survophthal.2006.10.007
   Holroyd S, 1996, J NERV MENT DIS, V184, P188, DOI 10.1097/00005053-199603000-00008
   HOLROYD S, 1994, J NERV MENT DIS, V182, P273, DOI 10.1097/00005053-199405000-00004
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Jackson ML, 2007, BRIT J OPHTHALMOL, V91, P296, DOI 10.1136/bjo.2006.104604
   KAHN JC, 2008, OPHTHAL EPIDEMIOL, V15, P202
   Kitayama M, 2007, ACTA NEUROL SCAND, V116, P190, DOI 10.1111/j.1600-0404.2007.00860.x
   Lang UE, 2007, J PSYCHOPHARMACOL, V21, P553, DOI 10.1177/0269881106075275
   Lannon SP, 2006, VIS IMPAIR RES, V8, P9, DOI DOI 10.1080/13882350600805761
   Manford M, 1998, BRAIN, V121, P1819, DOI 10.1093/brain/121.10.1819
   Matsui H, 2006, J GERIATR PSYCH NEUR, V19, P36, DOI 10.1177/0891988705284739
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Merabet LB, 2004, J NEURO-OPHTHALMOL, V24, P109, DOI 10.1097/00041327-200406000-00003
   Mocellin R, 2006, AUST NZ J PSYCHIAT, V40, P742
   Mosimann UP, 2008, INT J GERIATR PSYCH, V23, P712, DOI 10.1002/gps.1965
   Nadarajah J, 1998, AUST NZ J OPHTHALMOL, V26, P63, DOI 10.1111/j.1442-9071.1998.tb01444.x
   Nesher R, 2001, J GLAUCOMA, V10, P396, DOI 10.1097/00061198-200110000-00006
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   RABINS PV, 1994, INT J GERIATR PSYCH, V9, P775, DOI 10.1002/gps.930091002
   Rovner BW, 2002, GERIATRICS, V57, P45
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809
   Scott IU, 2001, AM J OPHTHALMOL, V131, P590, DOI 10.1016/S0002-9394(01)00833-9
   Shiraishi Y, 2004, J PSYCHIATR RES, V38, P207, DOI 10.1016/S0022-3956(03)00090-6
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   Terao T., 2002, PSYCHOGERIATRICS, V2, P6, DOI 10.1111/j.1479-8301.2002.tb00027.x
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1999, COMPR PSYCHIAT, V40, P315, DOI 10.1016/S0010-440X(99)90133-5
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4
NR 43
TC 20
Z9 20
U1 0
U2 22
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD MAY
PY 2010
VL 104
IS 5
BP 261
EP 274
DI 10.1177/0145482X1010400502
PG 14
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 595HM
UT WOS:000277601300002
DA 2022-11-30
ER

PT J
AU Dawson, WW
   Dawson, JC
   Lake, KP
   Gonzalez-Martinez, J
AF Dawson, William W.
   Dawson, Judyth C.
   Lake, Kenneth P.
   Gonzalez-Martinez, Janis
TI Maculas, monkeys, models, AMD and aging
SO VISION RESEARCH
LA English
DT Article
DE ARMD; macula; monkeys; drusen; models; surrogate
ID AGE-RELATED MACULOPATHY; RHESUS-MONKEYS; DRUSEN; DEGENERATION;
   PATHOGENESIS; PRIMATE
AB Age related macular degeneration (AMD) signs may be found reliably in monkeys (Macaca mulatta) bred selectively in Florida after 14 generations of inbreeding in a closed colony at the University of Puerto Rico. Progression, ultrastructure and functional losses are parallel to those found in humans. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Dawson, William W.; Dawson, Judyth C.; Lake, Kenneth P.] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Gonzalez-Martinez, Janis] Univ Puerto Rico, Caribbean Primate Res Ctr, San Juan, PR 00936 USA.
C3 State University System of Florida; University of Florida; University of
   Puerto Rico; University of Puerto Rico Mayaguez
RP Dawson, WW (通讯作者)，Univ Florida, Dept Ophthalmol, 1600 SW Archer Rd,Rm M119, Gainesville, FL 32610 USA.
EM wdawson@eye.ufl.edu
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   BERGER J, 1999, AGE RELATED MACULAR, P463
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   DAWSON WW, 2007, INVESTIGATIVE OPHTHA
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1824
   FEENEYBURNS L, 1981, ARCH OPHTHALMOL-CHIC, V99, P664, DOI 10.1001/archopht.1981.03930010664013
   Friedburg C, 2001, J PHYSIOL-LONDON, V534, P217, DOI 10.1111/j.1469-7793.2001.t01-1-00217.x
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   JOST B, 1988, RETINAL DEYSTROPHIES, P111
   MCKECHNIE J, 1968, WEBSTERS 20 CENTURY, P1154
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pepperberg DR, 1996, J OPT SOC AM A, V13, P586, DOI 10.1364/JOSAA.13.000586
   Rawlins RG., 1986, CAYO SANTIAGO MACAQU
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SIMMONS ED, 2007, INVESTIGATIVE OPHTHA, V48
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   ULSHAFER RJ, 1987, RETINA-J RET VIT DIS, V7, P198, DOI 10.1097/00006982-198700730-00011
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   YOSHIDA T, 2007, INVEST OPHTHALMOL, P48
NR 21
TC 18
Z9 18
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
J9 VISION RES
JI Vision Res.
PD FEB
PY 2008
VL 48
IS 3
BP 360
EP 365
DI 10.1016/j.visres.2007.08.006
PG 6
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 272BG
UT WOS:000253832000007
PM 17892891
OA Bronze
DA 2022-11-30
ER

PT J
AU Di Perna, L
   Melillo, P
   Gesualdo, C
   Palmieri, F
   Testa, F
   Bifani, M
   Rossi, S
   Simonelli, F
AF Di Perna, Luigi
   Melillo, Paolo
   Gesualdo, Carlo
   Palmieri, Filomena
   Testa, Francesco
   Bifani, Mario
   Rossi, Settimio
   Simonelli, Francesca
TI Correlation Between Choriocapillaris Density and Retinal Sensitivity in
   Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); optical coherence tomography
   angiography (OCT-A); microperimetry (MP); choriocapillaris (CC); mean
   macular sensitivity (MMS)
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; GEOGRAPHIC ATROPHY; OCT ANGIOGRAPHY;
   EYES; ASSOCIATION; DRUSEN
AB Purpose: The purpose of this study was to investigate the relationship between perfusion of the choriocapillaris (CC) and retinal sensitivity in eyes with intermediate agerelated macular degeneration (iAMD).
   Methods: This prospective study included patients with iAMD and healthy controls. All enrolled subjects underwent optical coherence tomography angiography (OCT-A) in order to compute the percent perfused choriocapillaris area (PPCA). In patients with iAMD, microperimetry (MP) testing was performed in order to quantify: mean retinal sensitivity (MRS), over an area of 10 degrees; mean macular sensitivity (MMS), over the macular area scanned with OCT-A; and retinal sensitivity (RS) in each macular point.
   Results: Eighteen eyes of 13 patients were included in the analysis. In addition, 18 eyes of 12 healthy subjects were enrolled as controls. No statistically significant difference (P value > 0.2) was observed in age between patients (73.9 +/- 2.0 years) and controls (70.1 +/- 2.8 years). We observed significantly lower values of PPCA between patients with iAMD and healthy controls (42.0% +/- 3.8% vs. 66.4% +/- 3.0%; -beta = 23.8%; P value < 0.001). Among iAMD eyes, higher values of PPCA were significantly associated with higher values of MRS (P value = 0.002) and MMS (P value = 0.013). Finally, higher values of RS in each macular point analyzed with MP were significantly (P value < 0.001) associated with higher values of PPCA computed in circular regions of interest (ROIs) centered in each analyzed MP point with radii of 0.5 degrees and 1.0 degree.
   Conclusions: Using OCT-A, we demonstrated a significant association between CC impairment and macular dysfunction, quantified by MP, in iAMD eyes.
   Translational Relevance: OCT-A could be a useful tool for detecting CC alterations and to monitor disease progression.
C1 [Di Perna, Luigi; Melillo, Paolo; Gesualdo, Carlo; Palmieri, Filomena; Testa, Francesco; Bifani, Mario; Rossi, Settimio; Simonelli, Francesca] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, Via S Pansini 5, Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Melillo, P (通讯作者)，Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, Via S Pansini 5, Naples, Italy.
EM paolomelillo85@gmail.com
RI Rossi, Settimio/AHI-1119-2022; Simonelli, Francesca/AHE-7571-2022
OI Simonelli, Francesca/0000-0001-8520-6769
FU Research Program VALERE - University of Campania Luigi Vanvitelli
FX Supported by the Research Program VALERE funded by the University of
   Campania Luigi Vanvitelli.
CR Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Mastropasqua R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091432
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2021, AM J OPHTHALMOL, V222, P302, DOI 10.1016/j.ajo.2020.04.018
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ro-Mase T, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.1
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUN
PY 2021
VL 10
IS 7
AR 2
DI 10.1167/tvst.10.7.2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL4SG
UT WOS:000656908600001
PM 34061948
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Saravia, M
   Zeman, L
   Ingolotti, M
   Schlaen, A
AF Saravia, Mario
   Zeman, Luis
   Ingolotti, Mariana
   Schlaen, Ariel
TI The VEGF paradox: Does diabetic retinopathy protect from age related
   macular degeneration?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; CHORIOCAPILLARIS;
   DISEASE; ADULTS; RPE; VASCULATURE; MACULOPATHY; EXPRESSION; HYPOXIA
AB Age-related macular disease (AMD) and diabetic retinopathy (DR) are prevalent diseases. Vascular endothelial growth factor (VEGF) related retinal neovascularization is a common feature in both. Consequently, both pathologies are treated with anti-VEGF therapy. We have previously reported a lower incidence of AMD in patients with DR compared to controls. The present study hypothesizes that DR in stages in which the concentration of intravitreal VEGF is increased, might have a protective role for both the onset and development of AMD.
C1 [Saravia, Mario; Ingolotti, Mariana; Schlaen, Ariel] Hosp Univ Austral, Dept Ophthalmol, Buenos Aires, DF, Argentina.
   [Zeman, Luis; Schlaen, Ariel] Univ Buenos Aires, Hosp Clin, Dept Ophthalmol, Buenos Aires, DF, Argentina.
C3 Austral University; Hospital Universitario Austral; University of Buenos
   Aires
RP Zeman, L (通讯作者)，Hosp Clin Buenos Aires, Dept Ophthalmol, 2351 Cordoba Ave, Buenos Aires, DF, Argentina.
EM luiszemanbardeci@gmail.com
RI Schlaen, Ariel/J-2986-2019
OI Schlaen, Ariel/0000-0003-1202-8660
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bearelly S, 2008, ARCH OPHTHALMOL-CHIC, V126, P986, DOI 10.1001/archopht.126.7.986
   Benson W H, 1989, W V Med J, V85, P141
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Frank RN, 2013, RETINA-J RET VIT DIS, V33, P899, DOI 10.1097/IAE.0b013e318287d882
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Huo LL, 2016, DIABETOLOGIA, V59, P1437, DOI 10.1007/s00125-016-3948-x
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Soubrane G, 2002, PRESSE MED, V31, P1282
   Srinivasan S, 2017, EYE LOND
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 34
TC 3
Z9 4
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2017
VL 109
BP 156
EP 161
DI 10.1016/j.mehy.2017.10.001
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FQ2XL
UT WOS:000418221200035
PM 29150277
DA 2022-11-30
ER

PT J
AU Smith, RT
   Merriam, JE
   Sohrab, MA
   Pumariega, NM
   Barile, G
   Blonska, AM
   Haans, R
   Madigan, D
   Allikmets, R
AF Smith, R. Theodore
   Merriam, Joanna E.
   Sohrab, Mahsa A.
   Pumariega, Nicole M.
   Barile, Gaetano
   Blonska, Anna M.
   Haans, Raymond
   Madigan, David
   Allikmets, Rando
TI Complement Factor H 402H Variant and Reticular Macular Disease
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; CHLAMYDIA-PNEUMONIAE; DEGENERATION; GENES;
   RISK; PSEUDODRUSEN; POLYMORPHISM
AB Objective: To determine the association of high-risk alleles in the complement factor H (CFH; Y402H, rs1061170) and age-related maculopathy susceptibility (ARMS2; A69S, rs10490924) genes with reticular macular disease (RMD), a major clinical subphenotype of age-related macular degeneration (AMD).
   Methods: Using retinal images from the Columbia Macular Genetics Study, we identified 67 subject individuals with RMD. A comparison group of 64 subjects with AMD without RMD was matched by ethnicity, age, sex, and AMD clinical stage.
   Results: In the RMD group, 53 of 67 subjects (79.1%) were female, the mean age was 83 years, and 47 of 67 (70.1%) had late AMD, with closely matched values in the non-RMD group. The frequencies of the CFH 402H allele were 39.6% in the RMD group (53 of 134 individuals) and 58.6% in the non-RMD group (75 of 128 individuals) (chi(2) = 8.8; P = .003; odds ratio, 0.46 [95% confidence interval, 0.28-0.76]). The corresponding frequencies of the risk allele for ARMS2 were 44.0% (40 of 128 individuals) and 31.3% (40 of 128 individuals), respectively (chi(2) = 4.0; P = .045; odds ratio, 1.73 [95% confidence interval, 1.04-2.90]). Homozygosity for 402H was particularly associated with the absence of RMD, occurring in 8 of 67 subjects (11.9%) with RMD vs 24 of 64 subjects (37.5%) without RMD(P < .001). Retinal macular disease also was associated with hypertension among male patients.
   Conclusions: The AMD-associated CFH 402H risk variant is significantly associated with the absence of RMD but enhanced risk for RMD is conferred by the ARMS2 69S AMD risk allele. These results are consistent with the hypothesis that 402H may confer a survival benefit against certain infections, some of which may cause RMD.
   Clinical Relevance: Reticular macular disease may be genetically distinct from the rest of AMD.
C1 [Smith, R. Theodore; Merriam, Joanna E.; Sohrab, Mahsa A.; Pumariega, Nicole M.; Barile, Gaetano; Blonska, Anna M.; Haans, Raymond; Allikmets, Rando] Columbia Univ, Harkness Eye Inst, Dept Ophthalmol, New York, NY 10032 USA.
   [Smith, R. Theodore; Pumariega, Nicole M.] Columbia Univ, Dept Biomed Engn, Fu Fdn, Sch Engn & Appl Sci, New York, NY 10032 USA.
   [Madigan, David] Columbia Univ, Dept Stat, New York, NY 10032 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University
RP Smith, RT (通讯作者)，Columbia Univ, Harkness Eye Inst, Dept Ophthalmol, 160 Ft Washington Ave,Room 509C, New York, NY 10032 USA.
EM rts1@columbia.edu
RI Allikmets, Rando/ABD-4533-2021
OI smith, theodore/0000-0002-1693-943X
FU New York Community Trust; National Eye Institute [R01 EY015520, R24
   EY017404, R01 EY13435]; Research to Prevent Blindness, Inc.; NATIONAL
   CENTER FOR RESEARCH RESOURCES [S10RR026748] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R24EY017404, R01EY015520, R01EY013435]
   Funding Source: NIH RePORTER
FX This study was supported by the New York Community Trust; grants R01
   EY015520 (Dr Smith), R24 EY017404 (Dr Allikmets), and R01 EY13435 (Dr
   Allikmets) from the National Eye Institute; and an unrestricted grant to
   the Department of Ophthalmology, Harkness Eye Institute, Columbia
   University, from Research to Prevent Blindness, Inc.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Nilsson HO, 2005, HELICOBACTER, V10, P54, DOI 10.1111/j.1523-5378.2005.00334.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmitz-Valckenberg S, 2011, INVEST OPHTHALMOL VI
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Sohrab MA, 2009, INVEST OPHTHALMOL VI, V50
   Walsh SJ, 2000, AM J PUBLIC HEALTH, V90, P1463, DOI 10.2105/AJPH.90.9.1463
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 25
TC 44
Z9 47
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2011
VL 129
IS 8
BP 1061
EP 1066
DI 10.1001/archophthalmol.2011.212
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804IZ
UT WOS:000293648800012
PM 21825189
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Iglicki, M
   Gonzalez, DP
   Loewenstein, A
   Zur, D
AF Iglicki, Matias
   Gonzalez, David Perez
   Loewenstein, Anat
   Zur, Dinah
TI Longer-acting treatments for neovascular age-related macular
   degeneration-present and future
SO EYE
LA English
DT Review
ID ABICIPAR-PEGOL; RANIBIZUMAB; THERAPY; OUTCOMES; HORIZON; DARPINS;
   ATROPHY; ANCHOR; GROWTH; MARINA
AB The treatment of neovascular AMD (nAMD) has been revolutionized by the introduction of anti-vascular endothelial growth factor (VEGF) agents. Though, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings, where long-term outcomes are not as good as expected. This is due to undertreatment, i.e., fewer injection and low monitoring frequency. Treatment burden due to frequent injections remains a major limitation. Long-lasting treatments provide promising solutions for this unmet need by achieving better results with less mandatory injections. This review aims to cover the current state in this field and also discuss the mechanism of action, data from pivotal trials, and safety profile of long-acting treatments in present and future, going into details about the following agents: Brolucizumab, Faricimab, Abipicar, and Conbercept.
C1 [Iglicki, Matias] Univ Buenos Aires, Private Retina Off, Buenos Aires, DF, Argentina.
   [Gonzalez, David Perez; Loewenstein, Anat; Zur, Dinah] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
C3 University of Buenos Aires; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv Sourasky Medical Center
RP Iglicki, M (通讯作者)，Univ Buenos Aires, Private Retina Off, Buenos Aires, DF, Argentina.
EM matiasiglicki@gmail.com
CR Agency EM, 2019, EMA236302020, P1
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brunton LL, 2017, GOODMAN GILMANS EDIT
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Cantor LB, 2014, RETINA VITREOUS
   ClinicalTrials.gov, STUD EV EFF SAF FAR
   ClinicalTrials.gov, EFF SAF TRIAL CONB I
   Danzig CJ, 2020, INVEST OPHTH VIS SCI, V61
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helzner Jerry, 2020, DARPIN FAILS GET APP
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Karampelas M, 2015, OPHTHALMOL THER, V4, P43, DOI 10.1007/s40123-015-0031-5
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michael Singer MD, 2020, RETINAL PHYS, V17, P38
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rajan K, COMPR OPHTHALMOL RET
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2020, AM J OPHTHALMOL, V216, pA7, DOI 10.1016/j.ajo.2020.05.012
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Sharma A, 2020, EYE, V34, P802, DOI 10.1038/s41433-019-0670-1
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 41
TC 9
Z9 9
U1 1
U2 11
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2021
VL 35
IS 4
BP 1111
EP 1116
DI 10.1038/s41433-020-01309-9
EA JAN 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RJ9QR
UT WOS:000607010200003
PM 33432165
OA Green Published
DA 2022-11-30
ER

PT J
AU Donati, G
AF Donati, Guy
TI Emerging therapies for Neovascular age-related macular degeneration:
   State of the art
SO OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; verteporfin; photodynamic therapy;
   vascular endothelial growth factor; pegaptanib; ranibizumab; cortisones;
   anecortave acetate; triamcinolone acetate; transpupillary thermotherapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; VERTEPORFIN
   THERAPY; RADIATION-THERAPY; NONINFECTIOUS ENDOPHTHALMITIS; ANECORTAVE
   ACETATE; COST-EFFECTIVENESS; SURGICAL REMOVAL
AB The cornerstone of pharmacotherapeutic treatment for agerelated macular degeneration (AMD) is photodynamic therapy with verteporfin. The recently approved pegaptanib sodium, which targets vascular endothelial growth factor ( VEGF), reduces vision loss in AMD when given by intravit-real injection every 6 weeks. The early promise of monotherapy with the corticosteroid triamcinolone acetonide has yet to be borne out in larger clinical trials, but outcomes may be improved when it is used in combination with verteporfin therapy. The angiostatic cortisone anecortave acetate was recently reported to have failed to meet the primary efficacy criterion in two large, placebo-controlled trials, and its clinical utility is uncertain. Other potential treatments with varying mechanisms of action are currently under investigation. To date, no agent has been shown to significantly restore lost vision in patients with AMD. Future treatment strategies are likely to include a combination of treatments to better manage AMD-associated choroidal neovascularisation and preserve patients' visual acuity.
C1 HUG, Clin Ophthalmol Geneve, CH-1211 Geneva 14, Switzerland.
C3 University of Geneva
RP Donati, G (通讯作者)，HUG, Clin Ophthalmol Geneve, Rue Alcide Jentzer 22, CH-1211 Geneva 14, Switzerland.
EM guy.donati@bluewin.ch
CR Aiello LP, 1997, INVEST OPHTH VIS SCI, V38, P1647
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   *AM AC OPHTH RET P, 2003, AG REL MAC DEG
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   BEAUMONT PR, 2002, RET 2002 C SAN FRANC
   BECKER B, 1965, ARCH OPHTHALMOL-CHIC, V74, P621
   BENEZRA D, 1997, INVEST OPHTH VIS SCI, V38, P1962
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   BHATTACHERJEE P, 1983, INVEST OPHTH VIS SCI, V24, P1143
   BIGGER JF, 1972, NEW ENGL J MED, V287, P992
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAUDHARY V, 2005, ASS RES VIS OPHTH AN
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   DAMICO D, 2005, ASS RES VISION OPHTH
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   DEFALLER JM, 2000, PTERYGIUM, P159
   ENGERMAN RL, 1967, LAB INVEST, V17, P738
   EVANS J, 1995, STUDIES MED POPULATI
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   FRENNESSON C, 2005, ASS RES VIS OPHTH AN
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gustavsson C, 2005, ACTA OPHTHALMOL SCAN, V83, P148, DOI 10.1111/j.1600-0420.2005.00427.x
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HEIER J, 2005, ASS RES VISION OPHTH
   HEIER J, 2004, AM ACAD OPHTHALMOL
   HEIER JS, 2003, INVEST OPHTHALMOL VI, V44
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Krummenauer F, 2005, EUR J OPHTHALMOL, V15, P74, DOI 10.1177/112067210501500112
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lees M, 2003, VALUE HEALTH, V6, P239, DOI 10.1016/S1098-3015(10)63950-2
   LEWIS GD, 1986, ENDOCRINOLOGY, V119, P62, DOI 10.1210/endo-119-1-62
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MIELER W, 2005, ASS RES VISION OPHTH
   MILLER J, 2005, AM SOC RET SPEC 23 A
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   Presta LG, 1997, CANCER RES, V57, P4593
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   REICHEL E, 2005, MAC SOC 28 ANN M
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sasai K, 1997, INT J RADIAT ONCOL, V39, P173, DOI 10.1016/S0360-3016(97)00296-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   SLAKTER J, 2004, AM ACAD OPHTH ANN M
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   TRANOS P, 2005, ASS RES VIS OPHTH AN
   *TREATM AG REL MAC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   *TREATM AG REL MAC, 2004, RETINA, V24, P1
   Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   WORMALD R, 2003, COCHRANE DB SYST REV, V2
NR 115
TC 18
Z9 52
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 6
BP 366
EP 377
DI 10.1159/000107495
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 222PN
UT WOS:000250309500001
PM 17947822
DA 2022-11-30
ER

PT J
AU Kovach, JL
   Schwartz, SG
   Flynn, HW
   Scott, IU
AF Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Flynn, Harry W., Jr.
   Scott, Ingrid U.
TI Anti-VEGF Treatment Strategies for Wet AMD
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB AVASTIN; COMPLEMENT FACTOR-H; MACULAR
   DEGENERATION; RANIBIZUMAB; THERAPY; REGIMEN; PHARMACOKINETICS;
   VERTEPORFIN
AB Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.
C1 [Kovach, Jaclyn L.; Schwartz, Stephen G.; Flynn, Harry W., Jr.] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Naples, FL 34102 USA.
   [Scott, Ingrid U.] Penn State Hershey Eye Ctr, Hershey, PA 17033 USA.
C3 Bascom Palmer Eye Institute; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health
RP Kovach, JL (通讯作者)，Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 311 9th St N, Naples, FL 34102 USA.
EM jkovach@med.miami.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], 2011, PCONSUPERSITE
   [Anonymous], 2009, OPHTHALMOLOGY TIMES
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nguyen Q. D., 2011, P ASS RES VISION OPH
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oubraham H, 2010, RETINA, V31, P26
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U., 2011, P ASS RES VISION OPH
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma S., 2010, RETINAL PHYS
   Slakter J. S., 2010, RETINAL PHYS
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 44
TC 120
Z9 124
U1 0
U2 23
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 786870
DI 10.1155/2012/786870
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979FI
UT WOS:000306801000001
PM 22523653
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Song, MH
   Ryu, HW
   Roh, YJ
AF Song, Min-Hye
   Ryu, Hyun-Wook
   Roh, Young-Jung
TI One-Year Results of Intravitreal Ranibizumab with or without
   Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Photodynamic therapy
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; NEOVASCULAR MEMBRANES; VERTEPORFIN; BEVACIZUMAB;
   MANAGEMENT; INJECTION; EFFICACY
AB Purpose: To evaluate the safety and efficacy of intravitreal ranibizumab with or without photodynamic therapy (PDT) in the treatment of polypoidal choroidal vasculopathy (PCV) in Korean patients. Methods: A retrospective chart review of 22 patients (24 eyes) with PCV was conducted. Nine eyes were treated with intravitreal ranibizumab combined with a single session of PDT (group 1), and 15 eyes were treated only with ranibizumab (group 2). Such clinical evaluations as best-corrected Snellen visual acuity, central retinal thickness (CRT) by optical coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA) were done at baseline, 1, 3, 6, 9 and 12 months after the first injections. Ranibizumab was reinjected on an as-needed basis guided by OCT, FA and ICGA, or at the doctor's discretion. Results: The mean follow-up duration was 22.5 months (range 12-37). The mean best-corrected visual acuity (log-MAR) improved, and the mean CRT decreased throughout 12 months in both groups; no statistically significant difference between the groups was found (p = 0.327, p = 0.073, respectively). The number of ranibizumab injections was not significantly different either (p = 0.555). Conclusions: Intravitreal ranibizumab with or without PDT for PCV in Korean patients resulted in visual and anatomical improvement over the 1-year follow-up period. Copyright (C) 2011 S. Karger AG, Basel
C1 [Ryu, Hyun-Wook; Roh, Young-Jung] Catholic Univ Korea, Coll Med, Dept Ophthalmol, Yeouido St Marys Hosp, Seoul 150713, South Korea.
   [Song, Min-Hye; Ryu, Hyun-Wook; Roh, Young-Jung] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul 150713, South Korea.
   [Song, Min-Hye] Hangil Eye Hosp, Gimpo, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Coll Med, Dept Ophthalmol, Yeouido St Marys Hosp, 62 Yeouido Dong, Seoul 150713, South Korea.
EM youngjungroh@hanmail.net
CR Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 29
TC 22
Z9 25
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 226
IS 3
DI 10.1159/000329466
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 821DP
UT WOS:000294955400004
PM 21757883
DA 2022-11-30
ER

PT J
AU Barbazetto, IA
   Saroj, N
   Shapiro, H
   Wong, P
   Ho, AC
   Freund, KB
AF Barbazetto, Irene A.
   Saroj, Namrata
   Shapiro, Howard
   Wong, Pamela
   Ho, Allen C.
   Freund, K. Bailey
TI Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients
   Treated in the MARINA and ANCHOR Trials
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; 5-YEAR INCIDENCE; RANIBIZUMAB;
   PHARMACOKINETICS; VERTEPORFIN; PROGRESSION
AB PURPOSE: To explore whether monthly intravitreal ranibizumab injections are associated with a lower rate of new choroidal neovascularization (CNV) in fellow eyes of patients with unilateral neovascular age-related macular degeneration.
   DESIGN: Retrospective data analysis of randomized, controlled clinical trials.
   METHODS: Incidence of new CNV in fellow eyes was calculated at 12 and 24 months from 2 clinical trials (the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration [MARINA] study and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration [ANCHOR] study), based on fluorescein angiographic reading center criteria and investigator evaluation. Patients treated with monthly ranibizumab (0.3 and 0.5 mg) were compared with those receiving a sham injection (MARINA) or photodynamic therapy (ANCHOR).
   RESULTS: In MARINA, new CNV developed in fellow eyes in 20.3% of the 0.3-mg ranibizumab group by 12 months and in 30.4% by 24 months. The conversion rate in the 0.5-mg ranibizumab group was 21.1% and 38.0% by 12 and 24 months, respectively. In the sham group, 26.4% converted by 12 months and 36.3% converted by 24 months. In ANCHOR, fellow eyes in 15.9% of the 0.3-mg ranibizumab group converted by 12 months and fellow eyes in 23.8% converted by 24 months. The conversion rate in the 0.5-mg ranibizumab group was 24.3% and 35.1% by 12 and 24 months, respectively. In the photodynamic therapy group, 25.4% converted by 12 months and 38.8% converted by 24 months. Differences in conversion rates at 12 and 24 months between the 0.3-mg or 0.5-mg ranibizumab groups and respective controls (sham or photodynamic therapy) were not statistically significant.
C1 [Barbazetto, Irene A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Saroj, Namrata; Shapiro, Howard; Wong, Pamela] Genentech Inc, San Francisco, CA 94080 USA.
   [Ho, Allen C.] Mid Atlantic Retina & Wills Eye Inst, Philadelphia, PA USA.
C3 Vitreous Retina Macula Consultants of New York; Roche Holding; Genentech
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Ho, Allen/0000-0003-3921-608X
FU GENENTECH, INC, SOUTH SAN FRANCISCO, CALIFORNIA; Novartis Pharma, AG,
   Basel, Switzerland
FX THE ANCHOR AND MARINA STUDIES WERE FUNDED BY GENENTECH, INC, SOUTH SAN
   FRANCISCO, CALIFORNIA, AND by Novartis Pharma, AG, Basel, Switzerland.
   Genentech designed and oversaw the conduct of the ANCHOR and MARINA
   studies and managed and statistically analyzed the data. Dr Barbazetto
   had complete access to the data for this manuscript and editorial
   control over its content. Namrata Saroj, Howard Shapiro, and Pamela Wong
   are Genentech employees. Allen C. Ho is a consultant for Genentech. Dr
   Ho had complete access to the data for this manuscript and editorial
   control over its content. K. Bailey Freund is a consultant for
   Genentech. Dr Freund had complete access to the data for this manuscript
   and editorial control over its content. Involved in design and concept
   (A.C.H., K.B.F.); Data collection (H.S., P.W.); Analysis and
   interpretation (I.B., N.S., H.S., P.W., A.C.H., K.B.F.); Statistical
   expertise (H.S., P.W.); Literature search (I.B.); Writing the article
   (I.B., N.S., H.S., K.B.F.); Critical revision of the article (I.B.,
   N.S., H.S., P.W., A.C.H., K.B.F.); and Final approval of the manuscript
   (I.B., N.S., H.S., P.W., A.C.H., K.B.F.). The study protocols of the
   ANCHOR and MARINA trials (primary reports of safety and efficacy
   published previously<SUP>15-17</SUP>) were approved by the institutional
   review board, national competent authority, or ethics committee at each
   participating clinical center before the start of the study. All United
   Stares sites were compliant with the Health Insurance Portability and
   Accountability Act of 1996. The 2 studies are registered at
   ClinicalTrials.gov (ANCHOR ID no., NCT0061594; MARINA ID no.,
   NCT00056836). Before determination of their full eligibility for
   enrollment, all patients provided written, informed consent for their
   study participation.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   *GEN INC, 2007, LUCENTIS RAN INJ DRU
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Neri Piergiorgio, 2008, International Ophthalmology, V28, P425, DOI 10.1007/s10792-007-9152-8
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2008, GRAEF ARCH CLIN EXP, V246, P1379, DOI 10.1007/s00417-008-0874-8
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
NR 19
TC 61
Z9 62
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2010
VL 149
IS 6
BP 939
EP 946
DI 10.1016/j.ajo.2010.01.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 610SI
UT WOS:000278755400012
PM 20378094
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Silver, RE
   Rosner, B
   Seddon, JM
AF Merle, Benedicte M. J.
   Silver, Rachel E.
   Rosner, Bernard
   Seddon, Johanna M.
TI Adherence to a Mediterranean diet, genetic susceptibility, and
   progression to advanced macular degeneration: a prospective cohort study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE AMD progression; Mediterranean diet; genetics; macular degeneration;
   nutrition
ID AGE-RELATED MACULOPATHY; FISH CONSUMPTION; RISK-FACTORS; FATTY-ACIDS;
   ASSOCIATIONS; HEALTH; LUTEIN; OMEGA-3-FATTY-ACIDS; ZEAXANTHIN; QUALITY
AB Background: Adherence to a Mediterranean-type diet is linked to a lower risk of mortality and chronic disease, but the association with the progression of age-related macular degeneration (AMD) and genetic susceptibility is unknown.
   Objective: We examined the association of adherence to the Mediterranean diet and genetic susceptibility with progression to advanced AMD.
   Design: Among 2525 subjects in the AREDS (Age-Related Eye Disease Study), 1028 eyes progressed to advanced AMD over 13 y. Baseline data for demographic and behavioral covariates were collected by using questionnaires. Dietary data were collected from food-frequency questionnaires. The alternate Mediterranean diet (aMeDi) score (range: 0-9) was constructed from individual intakes of vegetables, fruit, legumes, whole grains, nuts, fish, red and processed meats, alcohol, and the ratio of monounsaturated to saturated fats. Ten genetic loci in 7 genes [complement factor H (CFH), age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase 1 (ARMS2/HTRA1), complement component 2 (C2), complement factor B (CFB), complement component 3 (C3), collagen type VIII a 1 (COL8A1), and RAD51 paralog B (RAD51B)] were examined. Survival analysis was used to assess individual eyes for associations between incident AMD and aMeDi score, as well as interaction effects between aMeDi score and genetic variation on risk of AMD.
   Results: A high aMeDi score (score of 6-9) was significantly associated with a reduced risk of progression to advanced AMD after adjustment for demographic, behavioral, ocular, and genetic covariates (HR: 0.74; 95% CI: 0.61, 0.91; P-trend = 0.007). The aMeDi score was significantly associated with a lower risk of incident advanced AMD among subjects carrying the CFH Y402H nonrisk (T) allele (P-trend = 0.0004, P-interaction = 0.04). The aMeDi score was not associated with AMD among subjects who were homozygous for the risk (C) allele.
   Conclusion: Higher adherence to a Mediterranean diet was associated with reduced risk of progression to advanced AMD, which may be modified by genetic susceptibility.
C1 [Merle, Benedicte M. J.; Silver, Rachel E.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Rosner, Bernard] Harvard Univ, Sch Med, Channing Div Network med, Boston, MA USA.
C3 Tufts Medical Center; Tufts University; Tufts University; Harvard
   University; Harvard Medical School
RP Seddon, JM (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Merle, Benedicte MJ/F-1247-2015; Merle, Benedicte MJ/AAQ-5021-2021
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954
FU Fondation Dalloz-Institut de France; Philippe Foundation; Jean-Walter
   Zellidja-Academie Francaise; NIH [RO1-EY11309, RO1-EY022445];
   Massachusetts Lions Eye Research Fund Inc. (New Bedford, Massachusetts);
   Research to Prevent Blindness Inc. (New York, New York); American
   Macular Degeneration Foundation (Northampton, Massachusetts);
   Age-Related Macular Degeneration Research Fund, Ophthalmic Epidemiology
   and Genetics Service, Tufts Medical Center, Tufts University School of
   Medicine (Boston, Massachusetts); NATIONAL EYE INSTITUTE [R01EY022445,
   R01EY011309] Funding Source: NIH RePORTER
FX BMJM received grants from Fondation Dalloz-Institut de France, Philippe
   Foundation, and Jean-Walter Zellidja-Academie Francaise. JMS received
   support from the NIH (grant RO1-EY11309) and the Massachusetts Lions Eye
   Research Fund Inc. (New Bedford, Massachusetts), and unrestricted grants
   from Research to Prevent Blindness Inc. (New York, New York), the
   American Macular Degeneration Foundation (Northampton, Massachusetts),
   and the Age-Related Macular Degeneration Research Fund, Ophthalmic
   Epidemiology and Genetics Service, Tufts Medical Center, Tufts
   University School of Medicine (Boston, Massachusetts). BR received
   support from the NIH (grant RO1-EY022445).
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bach-Faig A, 2006, PUBLIC HEALTH NUTR, V9, P1110, DOI 10.1017/S1368980007668499
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Samieri C, 2013, ANN INTERN MED, V159, P584, DOI 10.7326/0003-4819-159-9-201311050-00004
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 51
TC 69
Z9 70
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV
PY 2015
VL 102
IS 5
BP 1196
EP 1206
DI 10.3945/ajcn.115.111047
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA CV4YV
UT WOS:000364273300028
PM 26490493
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hikichi, T
AF Hikichi, Taiichi
TI Six-year outcomes of antivascular endothelial growth factor monotherapy
   for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; CLINICOPATHOLOGICAL CORRELATION; RANIBIZUMAB
   MONOTHERAPY; MACULAR DEGENERATION; VERTEPORFIN; COMBINATION; ATROPHY
AB Objective To evaluate the 6-year outcomes of anti-VEGF (vascular endothelial growth factor) monotherapy for polypoidal choroidal vasculopathy (PCV).
   Methods The charts of 66 eyes of 66 patients with newly diagnosed, symptomatic, treatment-naive PCV were reviewed retrospectively. All patients were treated with 0.5 mg intravitreal ranibizumab (IVR) injections for 3 months followed by as-needed reinjections based on monthly examinations until 3 years after the first IVR injection. Thereafter, anti-VEGF monotherapy was continued for another 3 years.
   Results The mean best-corrected visual acuity (BCVA) improved significantly (p=0.001) 3 months after the first IVR injection (0.24 +/- 0.30 logarithm of the minimum angle of resolution (logMAR) VA; 20/35 Snellen VA) compared with the baseline BCVA (0.34 +/- 0.37 logMAR VA; 20/44 Snellen VA). However, the improved VA returned to 0.32 +/- 0.39 logMAR unit (20/42 Snellen VA), which was not significantly different at 3 years. This level was maintained to the end of 6 years (0.36 +/- 0.37 logMAR unit; 20/46 Snellen VA). The mean numbers of anti-VEGF injections administered annually during 6 years were 5.6 +/- 2.4 (including the initial three monthly injections), 3.3 +/- 2.2, 3.3 +/- 2.9, 3.6 +/- 3.2, 3.5 +/- 2.9 and 3.3 +/- 2.7, respectively. The mean total number of injections during 6 years was 21.5 +/- 10.1.
   Conclusions The results emphasised the efficacy of anti-VEGF therapy for preserving vision and the limitations of anti-VEGF therapy in that continuous treatment is required over an extended follow-up period.
C1 [Hikichi, Taiichi] Hikichi Eye Clin, Kita Sky Build, Sapporo, Hokkaido 0600807, Japan.
RP Hikichi, T (通讯作者)，Hikichi Eye Clin, Kita Sky Build, Sapporo, Hokkaido 0600807, Japan.
EM thikichi@hikichi-eye.jp
FU Novartis Pharma Japan; Bayer Japan; Santen; Alcon Japan
FX TH has received lecture fees from Novartis Pharma Japan, Bayer Japan,
   Santen and Alcon Japan.
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hikichi T, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0237-x
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 16
Z9 20
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2018
VL 102
IS 1
BP 97
EP 101
DI 10.1136/bjophthalmol-2017-310448
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ2NY
UT WOS:000418194700018
PM 28546150
DA 2022-11-30
ER

PT J
AU He, LZ
   Marneros, AG
AF He, Lizhi
   Marneros, Alexander G.
TI Doxycycline Inhibits Polarization of Macrophages to the Proangiogenic
   M2-type and Subsequent Neovascularization
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Angiogenesis; Antibiotics; Inflammation; Innate Immunity; Macrophages;
   Wound Healing; Macular Degeneration
ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; MEDIATED INHIBITION;
   ANGIOGENESIS; PREVENTS; RANIBIZUMAB; BEVACIZUMAB; PROGRESSION; MECHANISM
AB Background: M2-type macrophages are proangiogenic and protumorigenic, whereas M1-type macrophages are antiangiogenic. Results: Doxycycline is a potent inhibitor of M2-type macrophage polarization in both human and mouse macrophages in vitro and in vivo. Conclusion: Preventing M2-type macrophage polarization correlates with inhibition of pathological angiogenesis. Significance: Doxycycline may be used to enhance current antiangiogenic treatment approaches in neovascular age-related macular degeneration and in certain cancers.
   Macrophages occur along a continuum of functional states between M1-type polarized macrophages with antiangiogenic and antitumor activity and M2-type polarized macrophages, which have been implicated to promote angiogenesis and tumor growth. Proangiogenic M2-type macrophages promote various pathologic conditions, including choroidal neovascularization in models of neovascular age-related macular degeneration, or certain cancers, such as glioblastoma multiforme. Thus, a potential novel therapeutic approach to target pathological angiogenesis in these conditions would be to inhibit the polarization of macrophages toward the proangiogenic M2-type. However, no pharmacological inhibitors of M2-type macrophage polarization have been identified yet. Here we performed an unbiased pharmacological and small chemical screen to identify drugs that inhibit proangiogenic M2-type macrophage polarization and block pathologic macrophage-driven neovascularization. We identified the well tolerated and commonly used antibiotic doxycycline as a potent inhibitor of M2-type polarization of macrophages. Doxycycline inhibited, in a dose-dependent manner, M2-type polarization of human and bone marrow-derived mouse macrophages without affecting cell viability. Furthermore, doxycycline inhibited M2-type macrophage polarization and subsequent neovascularization in vivo in a laser injury model of choroidal neovascularization. Thus, doxycycline could be used to enhance current antiangiogenic treatment approaches in various conditions that are promoted by proangiogenic M2-type macrophages, including neovascular age-related macular degeneration and certain cancers.
C1 Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
   Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA 02129 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University
RP Marneros, AG (通讯作者)，CBRC, MGH East, CNY-149,Rm 3-216,13th St, Charlestown, MA 02129 USA.
EM amarneros@mgh.harvard.edu
OI Marneros, Alexander/0000-0003-3866-020X
FU NEI, National Institutes of Health [NEI R01-EY019297]; Shiseido research
   grant; Dermatology Foundation; NATIONAL EYE INSTITUTE [R01EY019297]
   Funding Source: NIH RePORTER
FX This study was supported, in whole or in part, by NEI, National
   Institutes of Health Grant NEI R01-EY019297 (to A. G. M.). This work was
   also supported by a Shiseido research grant (to A. G. M.) and by a
   Dermatology Foundation research grant (to L. H.).
CR Cox CA, 2010, OPHTHALMOLOGY, V117, P1782, DOI 10.1016/j.ophtha.2010.01.037
   Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236
   Fainaru O, 2008, FASEB J, V22, P3728, DOI 10.1096/fj.08-110494
   GILBERTSONBEADLING S, 1995, CANCER CHEMOTH PHARM, V36, P418, DOI 10.1007/BF00686191
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Liang D, 2008, CURR EYE RES, V33, P653, DOI 10.1080/02713680802245772
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Su WR, 2013, INVEST OPHTH VIS SCI, V54, P783, DOI 10.1167/iovs.12-10323
   Su WR, 2011, INVEST OPHTH VIS SCI, V52, P9108, DOI 10.1167/iovs.11-7255
   SUOMALAINEN K, 1992, ANTIMICROB AGENTS CH, V36, P227, DOI 10.1128/AAC.36.1.227
NR 18
TC 56
Z9 60
U1 3
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 21
PY 2014
VL 289
IS 12
BP 8019
EP 8028
DI 10.1074/jbc.M113.535765
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AD3PG
UT WOS:000333157500002
PM 24505138
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ishida, O
   Oku, H
   Ikeda, T
   Nishimura, M
   Kawagoe, K
   Nakamura, K
AF Ishida, O
   Oku, H
   Ikeda, T
   Nishimura, M
   Kawagoe, K
   Nakamura, K
TI Is Chlamydia pneumoniae infection a risk factor for age related macular
   degeneration?
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IN-VITRO; TWAR; ATHEROSCLEROSIS; ASSOCIATION; GENE
C1 Osaka Med Coll, Osaka, Japan.
   Kyoto Prefectural Univ Med, Kyoto, Japan.
   Hitachi Chem Co Ltd, Hitachi, Ibaraki, Japan.
   Nakamura Eye Clin, Matsumoto, Nagano, Japan.
C3 Osaka Medical College; Kyoto Prefectural University of Medicine; Hitachi
   Limited
RP Oku, H (通讯作者)，Osaka Med Coll, Osaka, Japan.
EM hidehirooku@aol.com
RI Oku, Hidehiro/AAD-5029-2019
OI Oku, Hidehiro/0000-0003-4359-4219
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Fong IW, 1997, J CLIN MICROBIOL, V35, P48, DOI 10.1128/JCM.35.1.48-52.1997
   Gaydos CA, 1996, INFECT IMMUN, V64, P1614, DOI 10.1128/IAI.64.5.1614-1620.1996
   GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724
   Kalayoglu MV, 2001, MICROBES INFECT, V3, P963, DOI 10.1016/S1286-4579(01)01458-7
   KISHIMOTO T, 1999, J JPN ASS INFECT DIS, V73, P457
   Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300
   KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Moazed TC, 1999, J INFECT DIS, V180, P238, DOI 10.1086/314855
   Quinn TC, 1999, AM HEART J, V138, pS507, DOI 10.1016/S0002-8703(99)70287-5
   SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6
   Schmidt S, 2000, MOL VIS, V6, P287
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Vecsei PV, 2002, OPHTHALMOLOGICA, V216, P215, DOI 10.1159/000059636
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weger M, 2002, OPHTHALMOLOGY, V109, P749, DOI 10.1016/S0161-6420(01)01031-4
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 26
TC 32
Z9 38
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2003
VL 87
IS 5
BP 523
EP 524
DI 10.1136/bjo.87.5.523
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 671MT
UT WOS:000182469100002
PM 12714382
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Murphy, C
   Duponsel, N
   Huang, XS
   Wittich, W
   Koenekoop, RK
   Overbury, O
AF Murphy, Caitlin
   Duponsel, Nathalie
   Huang, Xi Sheila
   Wittich, Walter
   Koenekoop, Robert K.
   Overbury, Olga
TI Retinal Disorders and Sleep Disorders: Are They Genetically Related?
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID RETINITIS-PIGMENTOSA; QUALITY INDEX; BLIND; MELANOPSIN; INSOMNIA;
   DREAMS; MEMORY; GENE; DISTURBANCES; TASIMELTEON
AB Introduction: Sleep is important for optimal physical health and vitality. Recent studies have shown that individuals with visual impairments may be at risk for sleep problems. This research examines the prevalence of sleep problems among those with retinal disorders and the possibility of a genetic link. Methods: Subjects with retinitis pigmentosa (n = 33), Stargardt's disease (n = 31) and age-related macular degeneration (n = 43) were recruited from the ophthalmology department of Montreal Children's Hospital. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS). Genetic testing was conducted by the Radboud University Medical Center in Nijmegen, Netherlands. Retinal genes were identified as having retina only or pineal and retinal expression. Results: The expression patterns of genes causing retinal disorders did not predict sleep quality. The PSQI indicated poor sleep quality in 56% of participants with retinitis pigmentosa, 48% of those with Stargardt's disease, and 53% of those with age-related macular degeneration. The ESS showed that daytime sleepiness was experienced by 20% of individuals with retinitis pigmentosa or Stargardt's disease, and by only one individual with age-related macular degeneration. Discussion: Approximately 50% of people with retinal disease have sleep problems. This number compares with up to one-third of the general population. Gene expression did not correlate with sleep quality, and the explanation for such a large percentage of sleep disorders needs further investigation. Implications for practitioners: Eye care and rehabilitation specialists need to be aware of the high prevalence of poor sleep quality in individuals with retinal disorders, since this situation may have an important impact on memory and learning, both of which are vital in successful rehabilitation.
C1 [Murphy, Caitlin] Univ Montreal, Sch Optometry, Stn Ctr Ville, POB 6128, Montreal, PQ H3C 3J7, Canada.
   [Duponsel, Nathalie] Concordia Univ, Dept Educ, Montreal, PQ H3G 1M8, Canada.
   [Huang, Xi Sheila] St Marys Hosp, CSSS Suroit, Salaberry De Valleyfield, PQ J6T 2N6, Canada.
   [Huang, Xi Sheila] Jewish Gen Hosp, Salaberry De Valleyfield, PQ J6T 2N6, Canada.
   [Wittich, Walter; Overbury, Olga] Univ Montreal, Sch Optometry, Montreal, PQ H3C 3J7, Canada.
   [Wittich, Walter] CRIR MAB Mackay Rehabil Ctr, Montreal, PQ, Canada.
   [Wittich, Walter] Concordia Univ, Dept Psychol, Montreal, PQ H3G 1M8, Canada.
   [Wittich, Walter] Univ Montreal, Sch Phys & Occupat Therapy, Montreal, PQ H3C 3J7, Canada.
   [Koenekoop, Robert K.] Montreal Childrens Hosp, Pediat Ophthalmol, Montreal, PQ H4A 3J1, Canada.
   [Koenekoop, Robert K.] Univ Montreal, McGill Ocular Genet Lab, Montreal, PQ H3C 3J7, Canada.
   [Koenekoop, Robert K.] Univ Montreal, Ophthalmol, Montreal, PQ H3C 3J7, Canada.
C3 Universite de Montreal; Concordia University - Canada; McGill
   University; Universite de Montreal; Concordia University - Canada;
   Universite de Montreal; McGill University; McGill University; Universite
   de Montreal; Universite de Montreal
RP Murphy, C (通讯作者)，Univ Montreal, Sch Optometry, Stn Ctr Ville, POB 6128, Montreal, PQ H3C 3J7, Canada.
EM caitlin.murphy@umontreal.ca; nw_de@education.concordia.ca;
   xi.huang@mail.mcgill.ca; walter.wittich@umontreal.ca;
   robert.koenekoop@mcgill.ca; olga.overbury@umontreal.ca
RI Wittich, Walter/AAH-2145-2020; Koenekoop, Robert/AAT-6676-2021
OI Wittich, Walter/0000-0003-2184-6139; 
CR Asplund R, 2005, ARCH GERONTOL GERIAT, V41, P61, DOI 10.1016/j.archger.2004.11.003
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Bailes HJ, 2010, CELL MOL LIFE SCI, V67, P99, DOI 10.1007/s00018-009-0155-7
   Bailey MJ, 2009, J BIOL CHEM, V284, P7606, DOI 10.1074/jbc.M808394200
   Bansil P, 2011, J CLIN HYPERTENS, V13, P739, DOI 10.1111/j.1751-7176.2011.00500.x
   Bittner AK, 2013, BRIT J OPHTHALMOL, V97, P145, DOI 10.1136/bjophthalmol-2012-302116
   BLANK HR, 1958, PSYCHOANAL QUART, V27, P158, DOI 10.1080/21674086.1958.11926088
   Brand S, 2012, NEUROPSYCHOBIOLOGY, V65, P109, DOI 10.1159/000330362
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Cole JC, 2006, SLEEP, V29, P112, DOI 10.1093/sleep/29.1.112
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Dijk DJ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000145
   Duffy JF, 2009, SLEEP MED CLIN, V4, P165, DOI 10.1016/j.jsmc.2009.01.004
   Fazzi E, 2008, BRAIN DEV-JPN, V30, P572, DOI 10.1016/j.braindev.2008.01.008
   Franzco A. A. M., 2005, CLIN EXPT OPHTHALMOL, V33, P117
   Gordo MA, 2001, J SLEEP RES, V10, P159, DOI 10.1046/j.1365-2869.2001.00251.x
   Hannibal J, 2002, ANN MED, V34, P401, DOI 10.1080/078538902320772151
   HENNEVIN E, 1995, BEHAV BRAIN RES, V69, P125, DOI 10.1016/0166-4328(95)00013-J
   Hu JF, 2010, BIOINFORMATICS, V26, P2289, DOI 10.1093/bioinformatics/btq408
   Ionescu D, 2001, J SLEEP RES, V10, P329, DOI 10.1046/j.1365-2869.2001.00271.x
   Jeter PE, 2012, ALTERN MED STUDIES, V2, P18
   JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376
   Johnsa JD, 2014, ANN PHARMACOTHER, V48, P1636, DOI 10.1177/1060028014550476
   KIRTLEY DD, 1979, INT J REHABIL RES, V2, P225, DOI 10.1097/00004356-197905000-00005
   Knutson KL, 2006, SLEEP, V29, P1503, DOI 10.1093/sleep/29.11.1503
   Lambertus S, 2015, OPHTHALMOLOGY, V122, P335, DOI 10.1016/j.ophtha.2014.08.032
   Lankford DA, 2011, EXPERT OPIN INV DRUG, V20, P987, DOI 10.1517/13543784.2011.583235
   Li JZ, 2013, P NATL ACAD SCI USA, V110, P9950, DOI 10.1073/pnas.1305814110
   Lockley SW, 2008, J SLEEP RES, V17, P207, DOI 10.1111/j.1365-2869.2008.00656.x
   Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505
   Lyytikainen P, 2011, INT J OBESITY, V35, P109, DOI 10.1038/ijo.2010.113
   Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856
   Mustian KM, 2013, J CLIN ONCOL, V31, P3233, DOI 10.1200/JCO.2012.43.7707
   Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186
   Ong J, 2010, J CLIN PSYCHOL, V66, P1175, DOI 10.1002/jclp.20736
   Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848
   Rasch B, 2013, PHYSIOL REV, V93, P681, DOI 10.1152/physrev.00032.2012
   Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701
   SABO KT, 1980, INT J REHABIL RES, V3, P382, DOI 10.1097/00004356-198009000-00013
   Saletin Jared M, 2012, Front Neurol, V3, P59, DOI 10.3389/fneur.2012.00059
   Salzarulo P., 1975, ELECTROENCEPHALOGRAP, V39, P86
   SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9
   Stickgold R, 2000, NAT NEUROSCI, V3, P1237, DOI 10.1038/81756
   Stores G, 1999, DEV MED CHILD NEUROL, V41, P348, DOI 10.1017/S0012162299000766
   Tabandeh H., 1998, DISTURBANCE SLEEP BL, P707
NR 45
TC 1
Z9 1
U1 0
U2 7
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD SEP-OCT
PY 2015
VL 109
IS 5
BP 359
EP 370
PG 12
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA DC7UK
UT WOS:000369425800005
DA 2022-11-30
ER

PT J
AU Delaunay, K
   Sellam, A
   Dinet, V
   Moulin, A
   Zhao, M
   Gelize, E
   Canonica, J
   Naud, MC
   Crisanti-Lassiaz, P
   Behar-Cohen, F
AF Delaunay, Kimberley
   Sellam, Alexandre
   Dinet, Virginie
   Moulin, Alexandre
   Zhao, Min
   Gelize, Emmanuelle
   Canonica, Jeremie
   Naud, Marie-Christine
   Crisanti-Lassiaz, Patricia
   Behar-Cohen, Francine
TI Meteorin Is a Novel Therapeutic Target for Wet Age-Related Macular
   Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE retina; choroidal neovascularization; angiogenesis; meteorin;
   therapeutic innovation
ID MINERALOCORTICOID RECEPTOR; ENDOTHELIAL-CELLS; GLIAL-CELLS; RAT;
   RANIBIZUMAB; EXPRESSION; THROMBOSPONDIN-1; PROMOTES; MODEL
AB The aim of this study was to evaluate the potential anti-angiogenic effect of MTRN (meteorin) in the laser-induced CNV rat model and explore its mechanisms of action. MTRN, thrompospondin-1, glial cell markers (GFAP, vimentin), and phalloidin were immuno-stained in non-human primate flat-mounted retinas and human retina cross sections. The effect of MTRN at different doses and time points was evaluated on laser-induced CNV at 14 days using in vivo fluorescein angiography and ex vivo quantification of CNV. A pan transcriptomic analysis of the retina and the RPE/choroid complex was used to explore MTRN effects mechanisms. In human retina, MTRN is enriched in the macula, expressed in and secreted by glial cells, and located in photoreceptor cells, including in nuclear bodies. Intravitreal MTRN administered preventively reduced CNV angiographic scores and CNV size in a dose-dependent manner. The highest dose, administered at day 7, also reduced CNV. MTRN, which is regulated by mineralocorticoid receptor modulators in the rat retina, regulates pathways associated with angiogenesis, oxidative stress, and neuroprotection. MTRN is a potential novel therapeutic candidate protein for wet AMD.
C1 [Delaunay, Kimberley; Sellam, Alexandre; Dinet, Virginie; Zhao, Min; Gelize, Emmanuelle; Canonica, Jeremie; Naud, Marie-Christine; Crisanti-Lassiaz, Patricia; Behar-Cohen, Francine] Univ Paris, Sorbonne Univ, Physiopathol Retinal Dis Clin Adv, INSERM,Ctr Rech Cordeliers, F-75006 Paris, France.
   [Dinet, Virginie] Univ Bordeaux, INSERM, U1034, Biol Cardiovasc Dis, F-33000 Bordeaux, France.
   [Moulin, Alexandre; Canonica, Jeremie] Univ Lausanne, Dept Ophthalmol, Jules Gonin Eye Hosp, Fdn Asile Aveugles, CH-1000 Lausanne, Switzerland.
   [Behar-Cohen, Francine] Hop Cochin Ophthalmopole, AP HP, F-75014 Paris, France.
   [Behar-Cohen, Francine] Ctr Rech Cordeliers, INSERM, UMR S 1138, Team Physiopathol Retinal Dis Clin Adv 17, F-75006 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   University of Lausanne; Assistance Publique Hopitaux Paris (APHP);
   UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite
RP Behar-Cohen, F (通讯作者)，Univ Paris, Sorbonne Univ, Physiopathol Retinal Dis Clin Adv, INSERM,Ctr Rech Cordeliers, F-75006 Paris, France.; Behar-Cohen, F (通讯作者)，Hop Cochin Ophthalmopole, AP HP, F-75014 Paris, France.; Behar-Cohen, F (通讯作者)，Ctr Rech Cordeliers, INSERM, UMR S 1138, Team Physiopathol Retinal Dis Clin Adv 17, F-75006 Paris, France.
EM kimberley.delaunay@etu.u-paris.fr; alexandresellam@gmail.com;
   virginie.dinet@inserm.fr; alexandre.moulin@fa2.ch; elodiecn@gmail.com;
   emma-nuelle.gelize@gmail.com; jerem.canonica@gmail.com;
   marie-christine.naud@crc.jussieu.fr; patricia.lassiaz@gmail.com;
   francine.behar@gmail.com
RI Zhao, Min/AAX-7664-2020
OI Zhao, Min/0000-0002-5418-7275; behar cohen, francine/0000-0001-8571-9513
CR Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Allingham MJ, 2018, INVEST OPHTH VIS SCI, V59, P3355, DOI 10.1167/iovs.17-23073
   Behar-Cohen F, 2018, OPHTHALMOLOGICA, V240, P111, DOI 10.1159/000489673
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   Canonica J, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107747
   Celen AB, 2020, FEBS J, V287, P3110, DOI 10.1111/febs.15319
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Delaunay K, 2020, MOL VIS, V26, P235
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Du SS, 2013, EXP EYE RES, V116, P151, DOI 10.1016/j.exer.2013.08.019
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hsu KS, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578-018-0204-8
   Jorgensen JR, 2012, EXP NEUROL, V237, P260, DOI 10.1016/j.expneurol.2012.06.027
   Jorgensen JR, 2009, J MOL NEUROSCI, V39, P104, DOI 10.1007/s12031-009-9189-4
   Lee HS, 2010, J CELL SCI, V123, P1959, DOI 10.1242/jcs.063784
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nishino J, 2004, EMBO J, V23, P1998, DOI 10.1038/sj.emboj.7600202
   Palibrk V, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.223
   Park JA, 2008, GLIA, V56, P247, DOI 10.1002/glia.20600
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahin U, 2014, NUCLEUS-PHILA, V5, P499, DOI 10.4161/19491034.2014.970104
   Tornoe J, 2012, RESTOR NEUROL NEUROS, V30, P225, DOI 10.3233/RNN-2012-110199
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright JL, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00177
   Xie JY, 2019, PAIN, V160, P1847, DOI 10.1097/j.pain.0000000000001569
   Yafai Y, 2014, OPHTHALMIC RES, V52, P81, DOI 10.1159/000362371
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
   Zhao M, 2017, J CONTROL RELEASE, V266, P187, DOI 10.1016/j.jconrel.2017.09.029
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhao M, 2010, FASEB J, V24, P3405, DOI 10.1096/fj.09-154344
NR 38
TC 3
Z9 3
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 13
AR 2973
DI 10.3390/jcm10132973
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TG0FR
UT WOS:000671089400001
PM 34279457
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Chang, ML
   Li, TL
   Gensler, G
   Taylor, A
AF Chiu, Chung-Jung
   Chang, Min-Lee
   Li, Tricia
   Gensler, Gary
   Taylor, Allen
TI Visualization of Dietary Patterns and Their Associations With
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retina; nutrition; diet; aging; dietary pattern; epidemiology; principle
   component analysis; qualitative comparative analysis; data visualization
ID QUALITATIVE COMPARATIVE-ANALYSIS; CARDIOVASCULAR-DISEASE; GLYCEMIC
   INDEX; HEALTH INEQUALITIES; RISK; CARBOHYDRATE; CONSUMPTION; GLYCATION;
   CELLS
AB PURPOSE. We aimed to visualize the relationship of predominant dietary patterns and their associations with AMD.
   METHODS. A total of 8103 eyes from 4088 participants in the baseline Age-Related Eye Disease Study (AREDS) were classified into three groups: control (n = 2739), early AMD (n = 4599), and advanced AMD (n = 765). Using principle component analysis, two major dietary patterns and eight minor dietary patterns were characterized. Applying logistic regression in our analysis, we related dietary patterns to the prevalence of AMD. Qualitative comparative analysis by operating Boolean algebra and drawing Venn diagrams was used to visualize our findings.
   RESULTS. In general, the eight minor patterns were subsets or extensions of either one of the two major dietary patterns (Oriental and Western patterns) and consisted of fewer characteristic foods than the two major dietary patterns. Unlike the two major patterns, which were more strongly associated with both early and advanced AMD, none of the eight minors were associated with early AMD and only four minor patterns, including the Steak pattern (odds ratio comparing the highest to lowest quintile of the pattern score = 1.73 [95% confidence interval: 1.24 to 2.41; P-trend = 0.02]), the Breakfast pattern (0.60 [0.44 to 0.82]; P-trend = 0.004]), the Caribbean pattern (0.64 [0.47 to 0.89; P-trend = 0.009]), and the Peanut pattern (0.64 [0.46 to 0.89; P-trend = 0.03]), were significantly associated with advanced AMD. Our data also suggested several potential beneficial (peanuts, pizza, coffee, and tea) and harmful (salad dressing) foods for AMD.
   CONCLUSIONS. Our data indicate that a diet of various healthy foods may be optimal for reducing AMD risk. The effects of some specific foods in the context of overall diet warrant further study.
C1 [Chiu, Chung-Jung; Chang, Min-Lee; Taylor, Allen] Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
   [Chiu, Chung-Jung; Taylor, Allen] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Li, Tricia] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA.
   [Gensler, Gary] Emmes Corp, Age Related Eye Dis Study Coordinating Ctr, Rockville, MD USA.
C3 Tufts University; United States Department of Agriculture (USDA); Tufts
   University; Harvard University; Brigham & Women's Hospital; Harvard
   Medical School; Emmes Corporation
RP Chiu, CJ (通讯作者)，Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM Chiu@tufts.edu
OI CHANG, MIN-LEE/0000-0001-9868-4030
FU National Institutes of Health [RO1EY021826, RO1EY013250, RO1EY021212];
   US Department of Agriculture [1950-5100-060-01A]; NATIONAL EYE INSTITUTE
   [R01EY021826, R01EY013250, R01EY026979, R01EY021212] Funding Source: NIH
   RePORTER
FX Supported by National Institutes of Health Grant RO1EY021826 (C-JC), US
   Department of Agriculture Agreements 1950-5100-060-01A, and National
   Institutes of Health Grants RO1EY013250 and RO1EY021212 (AT). The
   funding sources had no role in the design and conduct of the study; the
   collection, analysis, and interpretation of the data; or the
   preparation, review, or approval of the manuscript. The authors declared
   no conflict of interest. Any opinions, findings, conclusions, or
   recommendations expressed in this publication are those of the authors
   and do not necessarily reflect the views or policies of the US
   Department of Agriculture, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the US Government.
CR Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alper CM, 2003, J AM COLL NUTR, V22, P133, DOI 10.1080/07315724.2003.10719286
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Blackman T, 2008, HEALTH EDUC J, V67, P91, DOI 10.1177/0017896908089388
   Blackman T, 2011, SOC SCI MED, V72, P1965, DOI 10.1016/j.socscimed.2011.04.003
   Chang ML, 2014, ADV EXP MED BIOL, V801, P609, DOI 10.1007/978-1-4614-3209-8_77
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Fan XJ, 2011, MOL VIS, V17, P2221
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kerver JM, 2003, AM J CLIN NUTR, V78, P1103, DOI 10.1093/ajcn/78.6.1103
   Klatsky AL, 2007, PHARMACOL RES, V55, P237, DOI 10.1016/j.phrs.2007.01.011
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kurinij N, 1998, INT C DIET ASS MEAS
   Li TY, 2009, J NUTR, V139, P1333, DOI 10.3945/jn.108.103622
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moghaddam E, 2006, J NUTR, V136, P2506, DOI 10.1093/jn/136.10.2506
   PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0
   Ragin C., 1987, COMP METHOD
   Servetnick DA, 1996, AMINO ACIDS, V11, P69, DOI 10.1007/BF00805722
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   VandeBerg John L., 2009, pXVII
   Warren J, 2014, J PUBLIC HEALTH-UK, V36, P126, DOI 10.1093/pubmed/fdt047
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 39
TC 13
Z9 13
U1 2
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1404
EP 1410
DI 10.1167/iovs.16-20454
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000006
PM 28253403
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chalasani, R
   Qureshi, S
AF Chalasani, Rajeev
   Qureshi, Salmaan
TI Anticoagulation and intraocular haemorrhage in age-related macular
   degeneration: a probable link?
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
ID MACULOPATHY
C1 [Chalasani, Rajeev; Qureshi, Salmaan] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Royal Victorian Eye & Ear Hospital
RP Chalasani, R (通讯作者)，Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
EM rajeev.chalasani@eyeandear.org.au
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
NR 8
TC 2
Z9 2
U1 0
U2 0
PU AUSTRALASIAN MED PUBL CO LTD
PI PYRMONT
PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA
SN 0025-729X
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD FEB 15
PY 2010
VL 192
IS 4
BP 228
EP 229
DI 10.5694/j.1326-5377.2010.tb03485.x
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 563RH
UT WOS:000275150600013
PM 20170463
DA 2022-11-30
ER

PT J
AU Chen, HY
   Yang, ZL
   Gibbs, D
   Yang, X
   Hau, V
   Zhao, PQ
   Ma, X
   Zeng, JX
   Luo, L
   Pearson, E
   Constantine, R
   Kaminoh, Y
   Harmon, J
   Tong, ZZ
   Stratton, CA
   Cameron, DJ
   Tang, SB
   Zhang, K
AF Chen, Haoyu
   Yang, Zhenglin
   Gibbs, Daniel
   Yang, Xian
   Hau, Vincent
   Zhao, Peiquan
   Ma, Xiang
   Zeng, Jiexi
   Luo, Ling
   Pearson, Erik
   Constantine, Ryan
   Kaminoh, Yuuki
   Harmon, Jennifer
   Tong, Zongzhong
   Stratton, Charity A.
   Cameron, D. Joshua
   Tang, Shibo
   Zhang, Kang
TI Association of HTRA1 polymorphism and bilaterality in advanced
   age-related macular degeneration
SO VISION RESEARCH
LA English
DT Article
DE age-related macular degeneration; HTRA1; genetics; single nucleotide
   polymorphism
ID VISUAL IMPAIRMENT; PREVALENCE; VARIANT
AB Single nucleotide polymorphism (SNP), rs11200638, in the promoter of HTRA1 has recently been shown to increase the risk for AMD. In order to investigate the association of this HTRA1 polymorphism and the bilaterality of AMD, we genotyped rs11200638 in control, unilateral, and bilateral advanced AMD patients. The A allele for SNP rs11200638 in HTRA1, was significantly more prevalent in bilateral wet AMD and GA patients than in unilateral groups (p = .02 and p = .03, respectively). The homozygote odds ratios of bilateral wet AMD and GA are significantly greater than those seen in unilateral groups (twofold and threefold increase, respectively). This finding is consistent with the role of HTRA1 in AMD pathogenesis and will help aid in the clinical management and prognosis of AMD patients. (C) 2008 Published by Elsevier Ltd.
C1 [Chen, Haoyu; Tang, Shibo] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.
   [Chen, Haoyu; Yang, Zhenglin; Gibbs, Daniel; Yang, Xian; Hau, Vincent; Zhao, Peiquan; Ma, Xiang; Zeng, Jiexi; Luo, Ling; Pearson, Erik; Constantine, Ryan; Kaminoh, Yuuki; Harmon, Jennifer; Tong, Zongzhong; Stratton, Charity A.; Cameron, D. Joshua; Zhang, Kang] Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA.
   [Chen, Haoyu; Yang, Zhenglin; Gibbs, Daniel; Yang, Xian; Hau, Vincent; Zhao, Peiquan; Ma, Xiang; Zeng, Jiexi; Luo, Ling; Pearson, Erik; Constantine, Ryan; Kaminoh, Yuuki; Harmon, Jennifer; Tong, Zongzhong; Stratton, Charity A.; Cameron, D. Joshua; Zhang, Kang] Univ Utah, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.
   [Zhao, Peiquan] Shanghai Jiao Tong Univ, Xinhua Hosp, Shanghai 200030, Peoples R China.
C3 Sun Yat Sen University; Utah System of Higher Education; University of
   Utah; Utah System of Higher Education; University of Utah; Shanghai Jiao
   Tong University
RP Tang, SB (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.
EM tangsb@mail.sysu.edu.cn; kang.zhang@hsc.utah.edu
RI Ma, Xiang/E-4173-2013; Chu, Kai On/E-2325-2016; TANG, Shi/GXH-5719-2022;
   Chen, Haoyu/A-7432-2013; Zhang, Kang/Y-2740-2019
OI Ma, Xiang/0000-0001-9427-8385; Chen, Haoyu/0000-0003-0676-4610; Zhang,
   Kang/0000-0002-4549-1697
FU NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NEI NIH HHS
   [R01EY14448, P30EY014800, R01EY14428] Funding Source: Medline; NATIONAL
   CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY014800, R01EY014428, R01EY014448]
   Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   MACULAR P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Warpeha KM, 2003, EYE, V17, P305, DOI 10.1038/sj.eye.6700348
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 13
TC 36
Z9 37
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD FEB
PY 2008
VL 48
IS 5
BP 690
EP 694
DI 10.1016/j.visres.2007.10.014
PG 5
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 276AC
UT WOS:000254112500005
PM 18206206
OA Bronze
DA 2022-11-30
ER

PT J
AU Johnson, EJ
   Maras, JE
   Rasmussen, HM
   Tucker, KL
AF Johnson, Elizabeth J.
   Maras, Janice E.
   Rasmussen, Helen M.
   Tucker, Katherine L.
TI Intake of Lutein and Zeaxanthin Differ with Age, Sex, and Ethnicity
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; MACULAR DEGENERATION;
   CAROTENOIDS; MACULOPATHY; POPULATION; PREVALENCE; VEGETABLES; PIGMENT;
   RETINA
AB Lutein and zeaxanthin are carotenoids that are selectively taken up into the macula of the eye, where they may protect against development of age-related macular degeneration. Accurate assessment of their intakes is important in the understanding of their individual roles in eye health Current dietary databases lack the appropriate information to ascertain valid dietary intakes of these individual nutrients The purpose of this research is to determine intakes of lutein and zeaxanthin separately in the National Health and Nutrition Examination Survey (NHANES) 2003-2004. The top major food sources for lutein and zeaxanthin intake in NHANES 2003-2004 were analyzed for lutein and zeaxanthin by high-performance liquid chromatography from June to August 2006. Results were applied to dietary data from 8,525 participants in NHANES 2003-2004. Lutein and zeaxanthin food contents were separated into lutein and zeaxanthin in the nutrient database Mean intakes from two nonconsecutive 24-hour recalls were grouped into food groups based on nutrient composition, these were matched to the new database, and lutein and zeaxanthin intakes were calculated separately. Among all age groups, both sexes, and all ethnicities, intakes of lutein were greater than of zeaxanthin Relative intake of zeaxanthin to lutein decreased with age, with zeaxanthin to lutein ratios lower in females Zeaxanthin to lutein ratios in Mexican Americans was considerably greater than other ethnicities (other Hispanics, non-Hispanic white, non-Hispanic black, other races) Lower zeaxanthin to lutein ratios were measured in groups at risk for age-related macular degeneration (eg, older participants, females) Our findings suggest that the relative Intake of lutein and zeaxanthin may be important to age-related macular degeneration risk Future studies are needed to assess the individual associations of lutein and zeaxanthin in eye health. J Am. Diet Assoc 2010,110:1357-1362.
C1 [Johnson, Elizabeth J.; Rasmussen, Helen M.] Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Maras, Janice E.; Tucker, Katherine L.] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   Northeastern University
RP Johnson, EJ (通讯作者)，Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
OI Tucker, Katherine/0000-0001-7640-662X
FU US Department of Agriculture [58-1950-7-707]
FX Supported by US Department of Agriculture 58-1950-7-707. Any opinions,
   findings, conclusions, or recommendations expressed in this publication
   are those of the author(s) and do not necessarily reflect the view of
   the US Department of Agriculture
CR Bermudez OI, 2005, J NUTR, V135, P1496, DOI 10.1093/jn/135.6.1496
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1999, OPHTHALMOLOGY, V106, P1036
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Tucker KL, 1999, J NUTR, V129, P438, DOI 10.1093/jn/129.2.438
   United States Department of Agriculture, USDA TABL NUTR RET F
   *USDA, USDA NCC CAR DAT US
   *USDA, 1975, AGR HDB USDA, V102
   *USDA, WE AR WHAT WE EAT AM
   *USDA, 1998, 1994 96 CONT SURV FO
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
NR 22
TC 78
Z9 80
U1 1
U2 23
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD SEP
PY 2010
VL 110
IS 9
BP 1357
EP 1362
DI 10.1016/j.jada.2010.06.009
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 645YG
UT WOS:000281501500015
PM 20800129
DA 2022-11-30
ER

PT J
AU Bhatnagar, P
   Spaide, RF
   Takahashi, BS
   Peragallo, JH
   Freund, KB
   Klancnik, JM
   Cooney, MJ
   Slakter, JS
   Sorenson, JA
   Yannuzzi, LA
AF Bhatnagar, Pawan
   Spaide, Richard F.
   Takahashi, Beatriz S.
   Peragallo, Jason H.
   Freund, K. Bailey
   Klancnik, James M., Jr.
   Cooney, Michael J.
   Slakter, Jason S.
   Sorenson, John A.
   Yannuzzi, Lawrence A.
TI Ranibizumab for treatment of choroidal neovascularization secondary to
   age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; ranibizumab; choroidal neovascularization; age-related
   macular degeneration
ID INTRAVITREAL BEVACIZUMAB AVASTIN; ENDOTHELIAL GROWTH-FACTOR; MEMBRANES
AB Purpose: To evaluate the short-term outcomes after intravitreal ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) injection in patients with neovascular agerelated macular degeneration.
   Methods: A review of data for consecutive patients who received intravitreal ranibizumab injection was conducted. The main outcome measures were mean visual acuity and central macular thickness at 3 months compared with those at baseline. Response to ranibizumab therapy was evaluated with particular attention to prior treatment with bevacizumab (Avastin; Genentech, Inc.).
   Results: Mean baseline visual acuity of 231 eyes of 231 patients was 20/152, and 189 patients (81.8%) had undergone prior treatment, with 153 (65.4%) having received intravitreal bevacizurnab. Mean visual acuity at 3 months, available for 203 patients (88%), was 20/126 (P = 0.004). Mean visual acuity for 98 patients treated with bevacizurnab within 3 months before ranibizurnab injection was 20/100 at baseline and 20/98 at 3 months (P = 0.35). Mean baseline central macular thickness was 278 tkm for all patients and improved to 211 gm at 3 months (P < 0.001). Macular thickness decrease was noted irrespective of previous bevacizurnab therapy.
   Conclusion: Ranibizumab therapy was associated with significant improvements in mean visual acuity and central macular thickness for the group of all patients. Patients who had received bevacizurnab treatment within 3 months before initiating ranibizurnab treatment had stability of, but no improvement in, visual acuity.
C1 Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Manhattan Eye Ear & Throat Hospital
RP Spaide, RF (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM vrmny@aol.com
RI Newman, Nancy/AAB-2532-2021; Spaide, Richard/ABD-7368-2020; Freund, K.
   Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 10
TC 28
Z9 28
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 846
EP 850
DI 10.1097/IAE.0b013e31813c68b7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600007
PM 17891007
DA 2022-11-30
ER

PT J
AU Buitendijk, GHS
   Hooghart, AJ
   Brussee, C
   de Jong, PTVM
   Hofman, A
   Vingerling, JR
   Klaver, CCW
AF Buitendijk, Gabrielle H. S.
   Hooghart, Ada J.
   Brussee, Corina
   de Jong, Paulus T. V. M.
   Hofman, Albert
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
TI Epidemiology of Reticular Pseudodrusen in Age-Related Macular
   Degeneration: The Rotterdam Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE reticular pseudodrusen; near-infrared imaging; epidemiology; risk
   factors; genetics
ID SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC-ATROPHY; GRADING SYSTEM;
   DISEASE; ASSOCIATION; MACULOPATHY; RISK; PREVALENCE; FUNDUS; ARMS2
AB PURPOSE. Reticular pseudodrusen (RPD) are considered to be a distinct feature in AMD. Population studies have studied the epidemiology of RPD using standard color fundus photographs (CFP). However, recent studies have shown that RPD are better imaged using near-infrared (NIR) imaging. We studied the epidemiology of RPD in a large population-based study using NIR and CFP.
   METHODS. Participants aged 65+ years from the Rotterdam Study underwent ophthalmologic examination including NIR and CFP. Both images were graded for the presence of RPD and soft indistinct drusen (SID). Associations with demographic and environmental factors, 26 genetic variants, and total genetic risk score were analyzed using logistic regression analysis.
   RESULTS. Reticular pseudodrusen were detected in 137 (4.9%) of 2774 study participants; of these, 92.7% were detected with NIR imaging and 38% on CFP. Most eyes with RPD showed presence of SID, whereas other drusen types coincided less frequently. Reticular pseudodrusen were significantly associated with age (odds ratio [ OR] 1.21, 95% Confidence Interval [CI] 1.17-1.24) and female sex (OR 2.10, 95% CI 1.41-3.13). Environmental factors did not show a significant association with RPD. Major AMD risk variants were significantly associated with RPD and SID; however, ARMS2, C3, and VEGFA were more associated with RPD (RPD vs. SID P < 0.05). Total genetic risk score did not differ significantly (P = 0.88).
   CONCLUSION. Detection of RPD was better with NIR imaging than on CFP in a population-based setting. Presence of RPD often coincided with presence of SID; however, they showed quantitative differences in genetic risk profile.
C1 [Buitendijk, Gabrielle H. S.; Hooghart, Ada J.; Brussee, Corina; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Hooghart, Ada J.; Brussee, Corina; Hofman, Albert; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] KNAW, Netherlands Inst Neurosci, Dept Retinal Signal Proc, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Ageing, The Hague, Netherlands.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic
   Medical Center Amsterdam; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; Radboud University
   Nijmegen
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Klaver, Caroline C.W./A-2013-2016
OI Klaver, Caroline/0000-0002-2355-5258
FU MD Fonds, Utrecht, The Netherlands; Stichting Nederlands Oog Onderzoek,
   Rotterdam, The Netherlands; Netherlands Organization for Scientific
   Research, The Hague, The Netherlands; Swart van Essen, Rotterdam, The
   Netherlands; Bevordering van Volkskracht, Rotterdam, The Netherlands;
   Rotterdamse Blindenbelangen Association, Rotterdam, The Netherlands;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Doorn, The
   Netherlands; Oogfonds Nederland, Utrecht, The Netherlands; Vereniging
   Trustfonds Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands;
   Lijf en Leven, Krimpen aan de IJssel, The Netherlands; Topcon Europe BV,
   Capelle aan den IJssel, The Netherlands
FX Supported by the MD Fonds, Utrecht, The Netherlands; the Stichting
   Nederlands Oog Onderzoek, Rotterdam, The Netherlands; Netherlands
   Organization for Scientific Research, The Hague, The Netherlands; Swart
   van Essen, Rotterdam, The Netherlands; Bevordering van Volkskracht,
   Rotterdam, The Netherlands; Rotterdamse Blindenbelangen Association,
   Rotterdam, The Netherlands; Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid, Doorn, The Netherlands; Oogfonds Nederland,
   Utrecht, The Netherlands; Vereniging Trustfonds Erasmus Universiteit
   Rotterdam, Rotterdam, The Netherlands; and Lijf en Leven, Krimpen aan de
   IJssel, The Netherlands. An unrestricted grant was obtained from Topcon
   Europe BV, Capelle aan den IJssel, The Netherlands.
CR Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lally DR, 2014, JAMA OPHTHALMOL, V132, P775, DOI 10.1001/jamaophthalmol.2014.387
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 42
TC 32
Z9 32
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2016
VL 57
IS 13
BP 5593
EP 5601
DI 10.1167/iovs.15-18816
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI4ND
UT WOS:000392469600070
PM 27768796
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU VanNasdale, DA
   Elsner, AE
   Peabody, TD
   Kohne, KD
   Malinovsky, VE
   Haggerty, BP
   Weber, A
   Clark, CA
   Burns, SA
AF VanNasdale, Dean A.
   Elsner, Ann E.
   Peabody, Todd D.
   Kohne, Kimberly D.
   Malinovsky, Victor E.
   Haggerty, Bryan P.
   Weber, Anke
   Clark, Christopher A.
   Burns, Stephen A.
TI Henle Fiber Layer Phase Retardation Changes Associated With Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Henle fiber layer; scanning laser polarimetry; photoreceptors;
   age-related macular degeneration
ID PHOTORECEPTOR PACKING DENSITY; OPTICAL COHERENCE TOMOGRAPHY; IMAGING
   POLARIMETRY; CONE PHOTOPIGMENT; IMPROVED CONTRAST; VISUAL FUNCTION;
   HUMAN RETINA; IN-VIVO; POLARIZATION; BIREFRINGENCE
AB PURPOSE. To quantify and compare phase retardation amplitude and regularity associated with the Henle fiber layer (HFL) between nonexudative AMD patients and age-matched controls using scanning laser polarimetry (SLP) imaging.
   METHODS. A scanning laser polarimeter was used to collect 15 x 15 degrees macular-centered images in 25 patients with nonexudative AMD and 25 age-matched controls. Raw image data were used to compute macular phase retardation maps associated with the HFL. Consecutive, annular regions of interest from 0.5 to 3.0 degrees eccentricity, centered on the fovea, were used to generate intensity profiles from phase retardation data and analyzed with two complementary techniques: a normalized second harmonic frequency (2f) of the fast Fourier Transform (FFT) analysis and a curve fitting analysis using a 2f sine function. Paired t-tests were used to compare the normalized 2f FFT magnitude at each eccentricity between the two groups, the eccentricity that yielded the maximum normalized 2f FFT between paired individuals across the two groups, and curve fitting RMS error at each eccentricity between the two groups.
   RESULTS. Normalized 2f FFT components were lower in the AMD group at each eccentricity, with no difference between the two groups in the maximum normalized 2f FFT component eccentricity. The root-mean-square (RMS) error from curve fitting was significantly higher in the AMD group.
   CONCLUSIONS. Phase retardation changes in the central macula indicate loss and/or structural alterations to central cone photoreceptors in nonexudative AMD patients. Scanning laser polarimetry imaging is a noninvasive method for quantifying cone photoreceptor changes associated with central macular disease.
C1 [VanNasdale, Dean A.] Ohio State Univ, Coll Optometry, Columbus, OH 43210 USA.
   [Elsner, Ann E.; Peabody, Todd D.; Kohne, Kimberly D.; Malinovsky, Victor E.; Haggerty, Bryan P.; Clark, Christopher A.; Burns, Stephen A.] Indiana Univ, Sch Optometry, Bloomington, IN USA.
   [Weber, Anke] Aachen Univ Hosp, Aachen, Germany.
C3 University System of Ohio; Ohio State University; Indiana University
   System; Indiana University Bloomington; RWTH Aachen University; RWTH
   Aachen University Hospital
RP VanNasdale, DA (通讯作者)，Ohio State Univ, Coll Optometry, 338 West 10th Ave, Columbus, OH 43210 USA.
EM vannasdale.1@osu.edu
RI Burns, Stephen A/D-9259-2011; Burns, Stephen/AAN-3044-2021
OI Burns, Stephen A/0000-0001-5348-035X; 
FU National Eye Institute [K23-EY017886, RO1-EY007624, RO1-EB002346,
   P30-EY019008]; NATIONAL EYE INSTITUTE [R01EY024315, K23EY017886,
   R01EY007624, P30EY019008] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002346] Funding
   Source: NIH RePORTER
FX Supported by Grants K23-EY017886 (DAV); RO1-EY007624 (AEE); RO1-EB002346
   (AEE); and P30-EY019008 (SAB) from the National Eye Institute. The
   authors alone are responsible for the content and writing of the paper.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   BRINK HBK, 1988, J OPT SOC AM A, V5, P49, DOI 10.1364/JOSAA.5.000049
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Cense B, 2013, BIOMED OPT EXPRESS, V4, P2296, DOI 10.1364/BOE.4.002296
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   Chui TYP, 2008, J OPT SOC AM A, V25, P3021, DOI 10.1364/JOSAA.25.003021
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Elsner AE, 2008, VISION RES, V48, P2578, DOI 10.1016/j.visres.2008.04.031
   Fortune B, 2008, INVEST OPHTH VIS SCI, V49, P255, DOI 10.1167/iovs.07-0872
   Fortune B, 2013, INVEST OPHTH VIS SCI, V54, P5653, DOI 10.1167/iovs.13-12219
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Huang XR, 2003, APPL OPTICS, V42, P5726, DOI 10.1364/AO.42.005726
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Knighton RW, 2002, INVEST OPHTH VIS SCI, V43, P82
   Li KY, 2010, INVEST OPHTH VIS SCI, V51, P6858, DOI 10.1167/iovs.10-5499
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Mellem-Kairala MB, 2005, INVEST OPHTH VIS SCI, V46, P1099, DOI 10.1167/iovs.04-0574
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schutze C, 2013, INVEST OPHTH VIS SCI, V54, P739, DOI 10.1167/iovs.11-7877
   Song HX, 2011, INVEST OPHTH VIS SCI, V52, P7376, DOI 10.1167/iovs.11-7199
   VANBLOKLAND GJ, 1985, J OPT SOC AM A, V2, P72, DOI 10.1364/JOSAA.2.000072
   VanNasdale DA, 2012, OPTOMETRY VISION SCI, V89, P667, DOI 10.1097/OPX.0b013e31824eeb25
   VanNasdale DA, 2011, VISION RES, V51, P2263, DOI 10.1016/j.visres.2011.08.017
   VanNasdale DA, 2009, J VISION, V9, DOI 10.1167/9.3.21
   Weber A, 2007, EYE, V21, P353, DOI 10.1038/sj.eye.6702203
   Weber A, 2004, OPT EXPRESS, V12, P5178, DOI 10.1364/OPEX.12.005178
   Weinreb RN, 2002, ARCH OPHTHALMOL-CHIC, V120, P901, DOI 10.1001/archopht.120.7.901
   Zou WY, 2011, BIOMED OPT EXPRESS, V2, P1986, DOI 10.1364/BOE.2.001986
NR 47
TC 7
Z9 7
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 284
EP 290
DI 10.1167/iovs.14-14459
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800030
PM 25525166
OA Green Published
DA 2022-11-30
ER

PT J
AU Denniss, J
   Baggaley, HC
   Astle, AT
AF Denniss, Jonathan
   Baggaley, Helen C.
   Astle, Andrew T.
TI Predicting Visual Acuity From Visual Field Sensitivity in Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE microperimetry; fundus perimetry; AMD; visual acuity; visual field
   sensitivity
ID PREFERRED RETINAL LOCUS; CENTRAL SCOTOMA; FIXATION; VISION; LIMITS;
   PSYCHOPHYSICS; BIOFEEDBACK; RESOLUTION; AMD
AB PURPOSE. To investigate how well visual field sensitivity predicts visual acuity at the same locations in macular disease, and to assess whether such predictions may be useful for selecting an optimum area for fixation training.
   METHODS. Visual field sensitivity and acuity were measured at nine locations in the central 10 degrees in 20 people with AMD and stable foveal fixation. A linear mixed model was constructed to predict acuity from sensitivity, taking into account within-subject effects and eccentricity. Cross validation was used to test the ability to predict acuity from sensitivity in a new patient. Simulations tested whether sensitivity can predict nonfoveal regions with greatest acuity in individual patients.
   RESULTS. Visual field sensitivity (P < 0.0001), eccentricity (P = 0.007), and random effects of subject on eccentricity (P = 0.043) improved the model. For known subjects, 95% of acuity prediction errors (predicted - measured acuity) fell within -0.21 logMAR to +0.18 logMAR (median +0.00 logMAR). For unknown subjects, cross validation gave 95% of acuity prediction errors within -0.35 logMAR to +0.31 logMAR (median -0.01 logMAR). In simulations, the nonfoveal location with greatest predicted acuity had greatest "true" acuity on median 26% of occasions, and median difference in acuity between the location with greatest predicted acuity and the best possible location was +0.14 logMAR (range +0.04 to +0.17).
   CONCLUSIONS. The relationship between sensitivity and acuity in macular disease is not strongly predictive. The location with greatest sensitivity on microperimetry is unlikely to represent the location with the best visual acuity, even if eccentricity is taken into account.
C1 [Denniss, Jonathan] Univ Bradford, Sch Optometry & Vis Sci, Fac Life Sci, Bradford, W Yorkshire, England.
   [Denniss, Jonathan; Baggaley, Helen C.; Astle, Andrew T.] Univ Nottingham, Sch Psychol, Visual Neurosci Grp, Nottingham, England.
   [Baggaley, Helen C.] Univ Nottingham Hosp NHS Trust, Ophthalmol Dept, Optometry Unit, Nottingham, England.
C3 University of Bradford; University of Nottingham; Nottingham University
   Hospital NHS Trust
RP Denniss, J (通讯作者)，Univ Bradford, Sch Optometry & Vis Sci, Bradford BD7 1DP, W Yorkshire, England.
EM j.denniss@bradford.ac.uk
FU College of Optometrists Postdoctoral Research Award (London, UK);
   National Institute for Health Research (NIHR) Postdoctoral Fellowship
   (London, UK); NIHR
FX Supported by College of Optometrists Postdoctoral Research Award (JD and
   ATA; London, UK) and National Institute for Health Research (NIHR)
   Postdoctoral Fellowship (ATA; London, UK). This report presents
   independent research funded by the NIHR. The views expressed are those
   of the authors and not necessarily those of the NHS, the NIHR or the
   Department of Health.
CR Anderson DR., 1999, AUTOMATED STATIC PER, V2
   ANDERSON SJ, 1991, J PHYSIOL-LONDON, V442, P47, DOI 10.1113/jphysiol.1991.sp018781
   BANKS MS, 1991, J OPT SOC AM A, V8, P1775, DOI 10.1364/JOSAA.8.001775
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Denniss J, 2017, INVEST OPHTH VIS SCI, V58, P2652, DOI 10.1167/iovs.16-21086
   Denniss J, 2016, OPHTHAL PHYSL OPT, V36, P453, DOI 10.1111/opo.12304
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GREEN DG, 1970, J PHYSIOL-LONDON, V207, P351, DOI 10.1113/jphysiol.1970.sp009065
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Kwon MY, 2013, CURR BIOL, V23, P1663, DOI 10.1016/j.cub.2013.06.056
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Nido MD, 2018, CAN J OPHTHALMOL, V53, pE83, DOI 10.1016/j.jcjo.2017.11.003
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017
   Peirce JW, 2009, FRONT NEUROINFORM, V2, DOI 10.3389/neuro.11.010.2008
   R Core Team, 2021, R LANG ENV STAT COMP
   Ronne H., 1915, ARCH AUGENHEILKD, V78, P284
   Rose D, 2017, VISION RES, V133, P95, DOI 10.1016/j.visres.2016.10.016
   SANSBURY RV, 1973, J OPT SOC AM, V63, P612, DOI 10.1364/JOSA.63.000612
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   THIBOS LN, 1987, J OPT SOC AM A, V4, P1524, DOI 10.1364/JOSAA.4.001524
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Walsh DV, 2014, VISION RES, V96, P75, DOI 10.1016/j.visres.2014.01.005
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   Wichmann FA, 2001, PERCEPT PSYCHOPHYS, V63, P1293, DOI 10.3758/BF03194544
   Wiecek E, 2014, J VISION, V14, DOI 10.1167/14.14.1
NR 38
TC 6
Z9 6
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2018
VL 59
IS 11
BP 4590
EP 4597
DI 10.1167/iovs.18-24861
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT6VK
UT WOS:000444658800012
PM 30242359
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gabor, T
   Dorottya, S
   Laszlo, SG
   Zsolt, NZ
   Limburg, H
   Janos, N
AF Gabor, Toth
   Dorottya, Szabo
   Laszlo, Sandor Gabor
   Zsolt, Nagy Zoltan
   Limburg, Hans
   Janos, Nemeth
TI Visual impairment and blindness caused by posterior segment diseases in
   Hungary in people aged 50 years and older
SO ORVOSI HETILAP
LA English
DT Article
DE blindness; visual impairment; posterior segment disease; retina
ID AVOIDABLE BLINDNESS; RAPID ASSESSMENT; DIABETIC-RETINOPATHY; PREVALENCE;
   TRENDS
AB Introduction: Posterior segment diseases are the most common causes of blindness and visual impairment in devel-oped countries among people aged 50 years and older in Hungary. Objective: The purpose of this study was to estimate the prevalence of visual impairment and blindness caused by posterior segment diseases in the population aged 50 years and older in Hungary. Method: 105 census enumeration units were randomly selected with a probability proportional to size by the Hungar-ian Central Statistical Office. The standardised Rapid Assessment of Avoidable Blindness (RAAB) method was used. Participants underwent eye examination with a direct ophthalmoscope. Participants underwent visual acuity testing with a Snellen tumbling E-chart with or without a pinhole. Dilated fundus examination was performed in diabetic participants using an indirect binocular ophthalmoscope. Results: In total, 3523 (95.9%) out of 3675 eligible people were examined, of whom the prevalence of bilateral blind-ness and severe visual impairment was 0.7% and 0.2%, respectively. The most common causes of visual impairment caused by posterior segment diseases were age-related macular degeneration (1.419%), glaucoma (0.397%), diabetic retinopathy (0.341%) and rhegmatogenous retinal detachment (0.198%). The most common causes of blindness caused by posterior segment diseases were age-related macular degeneration (37.5%), glaucoma (16.7%), diabetic retinopathy (8.3%), high myopia (8.3%), rhegmatogenous retinal detachment (8.3%) and retinitis pigmentosa (8.3%). Conclusion: Prevalence of severe visual impairment and blindness caused by posterior segment diseases was lower compared to results of RAAB surveys in other countries. The frequency order of different posterior segment diseases was in line with developed countries. Availability of eye care should be improved and financing should be modernized due to the continuously increasing number of patients with age-related macular degeneration, glaucoma, diabetes and pathologic myopia.
C1 [Gabor, Toth; Dorottya, Szabo; Laszlo, Sandor Gabor; Zsolt, Nagy Zoltan; Janos, Nemeth] Semmelweis Egyet, Altalanos Orvostudomanyi Kar, Szemeszeti Klinika, Budapest, Hungary.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
C3 Semmelweis University
RP Gabor, T (通讯作者)，Semmelweis Egyet, Altalanos Orvostudomanyi Kar, Szemeszeti Klinika, Budapest, Hungary.
EM gabortothgabor@gmail.com
CR Castellon RIA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212660
   Al Ghamdi AH, 2012, BRIT J OPHTHALMOL, V96, P1168, DOI 10.1136/bjophthalmol-2012-301874
   Anton A, 2004, J GLAUCOMA, V13, P371
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Chiang F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011854
   Das T, 2021, EYE, V35, P2685, DOI 10.1038/s41433-021-01572-4
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   Gabor T, 2021, ORVOSI HETILAP, V162, P298, DOI 10.1556/650.2021.32031
   Goertz YHH, 2010, J VISUAL IMPAIR BLIN, V104, P404, DOI 10.1177/0145482X1010400704
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Hollo G, 2013, SZEMESZET, V150, P175
   Isipradit S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114245
   Li JQ., 2017, RETINAL DIS EUROPE
   Micskei P., 2012, AGRARTUD KOZL, V46, P63
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Mueller B, 2020, OPHTHAL EPIDEMIOL, V27, P141, DOI 10.1080/09286586.2019.1701040
   Nakamura Y, 2010, OPHTHALMOLOGY, V117, P2315, DOI 10.1016/j.ophtha.2010.03.043
   Nemeth J, 2021, EUR J OPHTHALMOL, V31, P853, DOI 10.1177/1120672121998960
   Nemeth J, 2019, EUR J OPHTHALMOL, V29, P129, DOI 10.1177/1120672118819397
   Nemeth J, 2018, OPHTHAL EPIDEMIOL, V25, P273, DOI 10.1080/09286586.2018.1438634
   Pek A, 2020, INT J OPHTHALMOL-CHI, V13, P788, DOI 10.18240/ijo.2020.05.14
   Rajavi Z, 2011, OPHTHALMOLOGY, V118, P1812, DOI 10.1016/j.ophtha.2011.01.049
   Sandor GL, 2020, INT J OPHTHALMOL-CHI, V13, P438, DOI 10.18240/ijo.2020.03.11
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Szabo D, 2017, SZEMESZET, V154, P119
   Szabo D, 2018, ACTA OPHTHALMOL, V96, P168, DOI 10.1111/aos.13542
   Taryam MO, 2020, BRIT J OPHTHALMOL, V104, P752, DOI 10.1136/bjophthalmol-2019-314572
   Toth G, 2017, ORVOSI HETILAP, V158, P363
   Toth G, 2020, LEGE ARTIS MED, V30, P441
   Toth G, 2021, SPEKTRUM AUGENHEILKD, V35, P54, DOI 10.1007/s00717-019-00433-6
   Toth G, 2021, BRIT J OPHTHALMOL, V105, P1116, DOI 10.1136/bjophthalmol-2020-316337
   Toth G, 2019, EUR J OPHTHALMOL, V29, P141, DOI 10.1177/1120672118811738
   Toth G, 2017, BRIT J OPHTHALMOL, V101, P965, DOI 10.1136/bjophthalmol-2016-309016
   World Health Organization, 1994, INT STAT CLASS DIS R
   Xiao BX, 2010, BRIT J OPHTHALMOL, V94, P1437, DOI 10.1136/bjo.2009.165308
   Zatic T, 2015, BRIT J OPHTHALMOL, V99, P832, DOI 10.1136/bjophthalmol-2014-305824
NR 36
TC 0
Z9 0
U1 5
U2 5
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD APR
PY 2022
VL 163
IS 16
BP 624
EP 630
DI 10.1556/650.2022.32440
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1C5LS
UT WOS:000793161100002
DA 2022-11-30
ER

PT J
AU Peng, YT
   Zhang, XZ
   Li, ML
   Liu, B
   Mi, L
   Zuo, CG
   Wen, F
AF Peng, Yuting
   Zhang, Xiongze
   Li, Miaoling
   Liu, Bing
   Mi, Lan
   Zuo, Chengguo
   Wen, Feng
TI Short-term efficacy of intravitreal conbercept in treatment-naive
   patients with polypoidal choroidal vasculopathy
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE conbercept; intravitreal injection; PCV; short-term efficacy; "3+PRN"
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; PROGNOSTIC-FACTORS; JAPANESE
   PATIENTS; CHINESE PATIENTS; RANIBIZUMAB; AFLIBERCEPT; VERTEPORFIN;
   SAFETY; INJECTION
AB Introduction: To evaluate the functional and morphological outcomes of intravitreal conbercept monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
   Materials and methods: In this retrospective, observational case series study, we reviewed medical records of 48 eyes (48 patients) with naive PCV that were treated with a series of 3 monthly intravitreal injections of 0.5 mg of conbercept followed by as-needed injections (3+pro re nata). All patients completed at least 6 months of monthly follow-up. Changes in the best-corrected visual acuity, optical coherence tomography, and indocyanine green angiography were retrospectively evaluated.
   Results: At 6 months, the mean best-corrected visual acuity significantly improved from 0.89 +/- 0.35 (20/160 in Snellen equivalent) at baseline to 0.58 +/- 0.26 (Snellen equivalent of 20/80; P<0.001), and 60.42% (29/48) of eyes had an improvement of three lines of vision; the mean central retinal thickness significantly decreased from 333.56 +/- 171.04 mu m at baseline to 187.65 +/- 54.46 mu m (P<0.001), and 93.75% (45/48) achieved a dry macula. At 3 months, 6 of 32 eyes (18.75%) showed partial regression of branching vascular network, 14 of 32 (43.75%) patients showed complete resolution of polyps. The mean number of injections was 3.4 +/- 0.9 through 6 months. No conbercept-related systemic or ocular adverse effects were observed.
   Conclusion: Intravitreal injection of conbercept using "3+pro re nata" regimen significantly improved visual acuity and anatomical outcomes in treatment-naive patients with PCV.
C1 [Peng, Yuting; Zhang, Xiongze; Li, Miaoling; Liu, Bing; Mi, Lan; Zuo, Chengguo; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
OI Peng, Yuting/0000-0002-8629-9167
FU National Natural Science Foundation of China [81470647]; Fundamental
   Research Funds of State Key Laboratory of Ophthalmology
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81470647) and the Fundamental Research Funds of
   State Key Laboratory of Ophthalmology.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Kang HM, 2016, GRAEF ARCH CLIN EXP, V254, P1519, DOI 10.1007/s00417-015-3241-6
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Li FJ, 2017, CURR EYE RES, V42, P1174, DOI 10.1080/02713683.2017.1285943
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Peng YT, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0481-8
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 36
TC 8
Z9 9
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2018
VL 12
BP 339
EP 345
DI 10.2147/DDDT.S158368
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FW5AW
UT WOS:000425329400002
PM 29497280
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Liang, IC
   Lin, YR
   Chien, HW
   Liu, KR
AF Liang, I-Chia
   Lin, Yi-Ru
   Chien, Hsiang-Wen
   Liu, Kwan-Rong
TI Vision Preservation in Eyes of Polypoidal Choroidal Vasculopathy with
   Low-Dose Intravitreal Triamcinolone Acetonide
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE adjunctive therapy; polypoidal choroidal vasculopathy; triamcinolone
   acetonide
ID RETINAL-VEIN-OCCLUSION; MACULAR EDEMA SECONDARY; PHOTODYNAMIC THERAPY;
   STANDARD-CARE; DEGENERATION; NEOVASCULARIZATION; RANIBIZUMAB;
   BEVACIZUMAB; EFFICACY; SAFETY
AB Purpose: To evaluate the efficacy and adverse effects of using low-dose intravitreal triamcinolone acetonide (IVTA) to preserve vision in polypoidal choroidal vasculopathy (PCV) eyes.
   Methods: This retrospective chart review study examined 8 eyes of 7 PCV patients, for whom verteporfin photodynamic therapy (vPDT) or antivascular endothelial growth factor (VEGF) therapy was not affordable/available and also with intolerable risk because of underlying cardiovascular and/or cerebrovascular ischemia. Low-dose IVTA (1 mg/0.025 mL) monotherapy was administered and repeated every 4 weeks if intraretinal edema or subretinal fluid persisted.
   Results: The median follow-up time was 26.4 months. Three eyes (3/8) maintained their initial best-corrected visual acuity and 4 eyes (4/8) exhibited improvement, whereas 1 eye (1/8) sustained some loss. The mean injection number per month was 0.7 for the first 6 months, after which it decreased to 0.4. In regard to adverse effects, intraocular pressure (IOP) of more than 21 mmHg was noted as persisting for a few weeks in 4 eyes and that of more than 30mmHg was noted once in 1 eye. The increased IOP was adequately controlled by using IOP-lowering agents. Two initially phakic eyes each underwent cataract surgery in the 12th and 14th months after treatment.
   Conclusions: Low-dose IVTA therapy may be valuable for preserving the vision of PCV patients, while vPDT or anti-VEGF is not affordable/available or of those with underlying diseases for whom anti-VEGF therapy is with intolerable risk.
C1 [Liang, I-Chia; Lin, Yi-Ru; Chien, Hsiang-Wen; Liu, Kwan-Rong] Cathay Gen Hosp, Taipei, Taiwan.
   [Liang, I-Chia] Fu Jen Catholic Univ, New Taipei, Taiwan.
   [Lin, Yi-Ru; Liu, Kwan-Rong] Taiwan Adventist Hosp, Taipei, Taiwan.
   [Liu, Kwan-Rong] Natl Taiwan Univ Hosp, Taipei, Taiwan.
C3 Cathay General Hospital; Fu Jen Catholic University; National Taiwan
   University; National Taiwan University Hospital
RP Liu, KR (通讯作者)，Taiwan Adventist Hosp, Dept Ophthalmol, 424,Sec 2,Bade Rd, Taipei 10556, Taiwan.
EM krliu56@hotmail.com
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bakri SJ, 2005, AM J OPHTHALMOL, V139, P290, DOI 10.1016/j.ajo.2004.09.038
   Cekic O, 2005, RETINA-J RET VIT DIS, V25, P846, DOI 10.1097/00006982-200510000-00005
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   FICHTE C, 1978, American Journal of Ophthalmology, V85, P509
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Jonas J.B., 2003, ARCH OPHTHALMOL-CHIC, V121, P121
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kojima A, 2006, ACTA OPHTHALMOL SCAN, V84, P749, DOI 10.1111/j.1600-0420.2006.00745.x
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martidis A, 1999, J OCUL PHARMACOL TH, V15, P425, DOI 10.1089/jop.1999.15.425
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sarao V, 2014, THESCIENTIFICWORLDJO, V2014
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233
   Selim A, 2014, TURK J MED SCI, V44, P889, DOI 10.3906/sag-1104-54
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   ZWEIFACH BW, 1953, ANN NY ACAD SCI, V56, P626, DOI 10.1111/j.1749-6632.1953.tb27383.x
NR 53
TC 3
Z9 3
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JAN-FEB
PY 2017
VL 33
IS 1
BP 42
EP 49
DI 10.1089/jop.2015.0150
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA EH4PB
UT WOS:000391752000008
PM 27991837
DA 2022-11-30
ER

PT J
AU Jeong, A
   Lim, J
   Sagong, M
AF Jeong, Areum
   Lim, Jinam
   Sagong, Min
TI Choroidal Vascular Abnormalities by Ultra-widefield Indocyanine Green
   Angiography in Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroidal hyperpermeability; choroid; choroidal vasculature; polypoidal
   choroidal vasculopathy; ultra-widefield
ID MACULAR DEGENERATION; VORTEX VEIN; THICKNESS; EYES; HYPERPERMEABILITY;
   CHORIORETINOPATHY
AB PURPOSE. To evaluate vortex vein engorgement and choroidal vascular hyperpermeability in patients with polypoidal choroidal vasculopathy (PCV) using ultra-widefield indocyanine green angiography (ICGA).
   METHODS. This retrospective case control study included 51 patients with unilateral PCV, 7 patients with bilateral PCV, and 43 age-matched controls. The number of quadrants of vortex vein engorgement was evaluated in the middle phase of ICGA, which was classified as extended engorgement if the dilated choroidal vessels expanded to the macula. The area of choroidal vascular hyperpermeability was quantified stereographically from the late-phase ICGA and correlated with clinical and optical coherence tomography findings.
   RESULTS. Affected eyes had a larger choroidal hyperpermeability area and a thicker subfoveal choroid than eyes in the control group or fellow eyes (P < 0.001, P < 0.001). More quadrants with extended vortex vein engorgement were observed in affected eyes than in fellow eyes (P < 0.001). Significant differences were observed in the area of choroidal hyperpermeability, Haller layer thickness and greatest linear dimension according to the extended vortex vein engorgement in eyes with PCV (P < 0.001, P = 0.001, and P = 0.001, respectively). The area of choroidal hyperpermeability was significantly correlated with subfoveal choroidal thickness (P < 0.001, Pearson's correlation coefficient = 0.471).
   CONCLUSIONS. Ultra-widefield ICGA results revealed that patients with PCV had vortex vein engorgement and an increased choroidal hyperpermeability area. The results from this study provide substantial information to clarify the pathogenesis and predict the prognosis in the patients with PCV.
C1 [Jeong, Areum; Lim, Jinam; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchungro, Daegu 42415, South Korea.
   [Jeong, Areum; Lim, Jinam; Sagong, Min] Yeungnam Univ Hosp, Yeungnam Eye Ctr, Daegu, South Korea.
C3 Yeungnam University; Yeungnam University; Yeungnam University Hospital
RP Sagong, M (通讯作者)，Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchungro, Daegu 42415, South Korea.
EM msagong@yu.ac.kr
FU Yeungnam University
FX Supported by a 2018 Yeungnam University Research Grant. This funding
   source had no role in the study design, collection, analysis,
   interpretation of data, or writing of the manuscript.
CR Aboshiha J, 2015, OPHTHALMOLOGY, V122, P864, DOI 10.1016/j.ophtha.2014.11.016
   Al-Rashaed S, 2008, MIDDLE EAST AFR J OP, V15, P90, DOI 10.4103/0974-9233.52000
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   DICOM Standards Committee, 2015, DIG IM COMM MED DICO
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2020, RETINA-J RET VIT DIS, V40, P1851, DOI 10.1097/IAE.0000000000002931
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhao XY, 2020, RETINA-J RET VIT DIS, V40, P477, DOI 10.1097/IAE.0000000000002389
NR 40
TC 6
Z9 6
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2021
VL 62
IS 2
AR 29
DI 10.1167/iovs.62.2.29
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ5MM
UT WOS:000624567800029
PM 33605985
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yeniad, B
   Ayranci, O
   Tuncer, S
   Kir, N
   Ovali, T
   Tugal-Tutkun, I
   Akarcay, K
AF Yeniad, Baris
   Ayranci, Ozen
   Tuncer, Samuray
   Kir, Nur
   Ovali, Tunc
   Tugal-Tutkun, Ilknur
   Akarcay, Koray
TI Assessment of anterior chamber inflammation after intravitreal
   bevacizumab injection in different ocular exudative diseases
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Flare; Inflammation; Intravitreal injection; Iritis
ID RETINAL VEIN OCCLUSION; GROWTH-FACTOR ANTIBODY; CHOROIDAL
   NEOVASCULARIZATION; AQUEOUS FLARE; INTRAOCULAR INFLAMMATION; MACULAR
   DEGENERATION; SAFETY; EYES; AVASTIN; EDEMA
AB PURPOSE. To investigate the inflammation of the anterior chamber after intravitreal bevacizumab injection in different ocular exudative diseases.
   METHODS. The study included 76 eyes from 62 consecutive patients with different ocular exudative diseases. The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). The study also included 32 age-matched control patients. Inflammation of the anterior chamber was examined with flare-cell photometry before and after an intravitreal injection of 1.25 mg of bevacizumab.
   RESULTS. There were no statistically significant differences between the measurements at baseline and postoperative day 1, 3, 7, or 30 in any of the groups (p > 0.05).
   CONCLUSIONS. The extent of inflammation in the anterior chamber did not change after intravitreal bevacizumab injection in patients with nonproliferative diabetic retinopathy, choroidal neovascularization secondary to age-related macular degeneration, or macular edema due to branch or central vein occlusion.
C1 [Yeniad, Baris; Ayranci, Ozen; Tuncer, Samuray; Kir, Nur; Ovali, Tunc; Tugal-Tutkun, Ilknur; Akarcay, Koray] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, TR-34093 Istanbul, Turkey.
C3 Istanbul University
RP Yeniad, B (通讯作者)，Istanbul Univ, Istanbul Tip Fak, Goz Hastaliklari AD, TR-34093 Istanbul, Turkey.
EM byeniad@yahoo.com
RI Kir, Nur/AAT-9664-2020; Tuncer, Samuray/J-2596-2015
CR Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Batioglu Figen, 2008, International Ophthalmology, V28, P59, DOI 10.1007/s10792-007-9105-2
   Brouzas D, 2009, CLIN OPHTHALMOL, V3, P457
   Byeon SH, 2007, J OCUL PHARMACOL TH, V23, P387, DOI 10.1089/jop.2007.0012
   Chilov MN, 2007, CLIN EXP OPHTHALMOL, V35, P494, DOI 10.1111/j.1442-9071.2007.01521.x
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kubota T, 1996, GRAEF ARCH CLIN EXP, V234, P285, DOI 10.1007/BF00220701
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   NGUYEN NX, 1993, BRIT J OPHTHALMOL, V77, P280, DOI 10.1136/bjo.77.5.280
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   TUGALTUTKUN I, INT OPHTHALMOL
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Zaczek A, 1999, EUR J OPHTHALMOL, V9, P158, DOI 10.1177/112067219900900303
NR 27
TC 9
Z9 9
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2011
VL 21
IS 2
BP 156
EP 161
DI 10.5301/EJO.2010.5239
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 760TR
UT WOS:000290347300006
PM 20658459
DA 2022-11-30
ER

PT J
AU Hanhart, J
   Comaneshter, DS
   Dror, YF
   Vinker, S
AF Hanhart, Joel
   Comaneshter, Doron S.
   Dror, Yossi Freier
   Vinker, Shlomo
TI Mortality in patients treated with intravitreal bevacizumab for
   age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Neovascular AMD; Anti-VEGF; Bevacizumab; Safety; Mortality
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; RISK; DEFINITIONS; DISORDERS;
   SURVIVAL; THERAPY; AVASTIN; EVENTS; WOMEN
AB Background: The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD.
   Methods: We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables.
   Results: During follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P <.001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C. I. 1.54-1.84), P <.001.
   Conclusions: We found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD.
C1 [Hanhart, Joel] Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Beyt St, IL-91031 Jerusalem, Israel.
   [Comaneshter, Doron S.; Vinker, Shlomo] Clalit Hlth Serv, Cent Headquarters, Tel Aviv, Israel.
   [Dror, Yossi Freier] Mashav Appl Res, Jerusalem, Israel.
   [Vinker, Shlomo] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit
   Health Services; Tel Aviv University; Sackler Faculty of Medicine
RP Hanhart, J (通讯作者)，Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Beyt St, IL-91031 Jerusalem, Israel.
EM hanhart@szmc.org.il
OI Hanhart, Joel/0000-0003-0952-3740
CR Amadio M., 2015, PHARM RES, V103, P253
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boberg-Ans G, 2006, ACTA OPHTHALMOL SCAN, V84, P613, DOI 10.1111/j.1600-0420.2006.00719.x
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6
   Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980
   Hicks KA, 2015, CIRCULATION, V132, P302, DOI 10.1161/CIR.0000000000000156
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Rennert G, 2001, ISR MED ASSOC J, V3, P404
   Richards Lisa, 2011, Nat Rev Clin Oncol, V8, P194, DOI 10.1038/nrclinonc.2011.28
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
NR 32
TC 22
Z9 25
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 10
PY 2017
VL 17
AR 189
DI 10.1186/s12886-017-0586-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ7ZX
UT WOS:000412981200001
PM 29017506
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Caballero, S
   Sengupta, N
   Crafoord, S
   Lund, R
   Kruse, FE
   Young, M
   Grant, MB
AF Caballero, S
   Sengupta, N
   Crafoord, S
   Lund, R
   Kruse, FE
   Young, M
   Grant, MB
TI The many possible roles of stem cells in age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL PROGENITOR CELLS; AMNIOTIC MEMBRANE TRANSPLANTATION;
   RETINAL-PIGMENT EPITHELIUM; BONE-MARROW; CORNEAL SURFACE; PRECURSOR
   CELLS; VISUAL FUNCTION; RCS RATS; RECONSTRUCTION; NEOVASCULARIZATION
C1 Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.
   Orebro Univ Hosp, Orebro, Sweden.
   Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
   Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
   Schepens Eye Inst, Boston, MA USA.
C3 State University System of Florida; University of Florida; Orebro
   University; Utah System of Higher Education; University of Utah;
   Ruprecht Karls University Heidelberg; Harvard University; Schepens Eye
   Research Institute
RP Grant, MB (通讯作者)，Univ Florida, Dept Pharmacol & Therapeut, POB 100276, Gainesville, FL 32610 USA.
EM grantma@pharmacology.ufl.edu
RI Crafoord, Sven/ABC-2560-2020
OI Crafoord, Sven/0000-0002-0477-5204
FU NATIONAL EYE INSTITUTE [R29EY007739, R01EY007739, R01EY012601] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY007739, EY012601] Funding Source:
   Medline
CR Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3
   Hori J, 2003, STEM CELLS, V21, P405, DOI 10.1634/stemcells.21-4-405
   Keegan DJ, 2003, INVEST OPHTH VIS SCI, V44, P3526, DOI 10.1167/iovs.02-0097
   Kern TS, 1996, ARCH OPHTHALMOL-CHIC, V114, P306, DOI 10.1001/archopht.1996.01100130302013
   Klassen H, 2003, VISION RES, V43, P947, DOI 10.1016/S0042-6989(03)00094-4
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Kruse F E, 1997, Curr Opin Ophthalmol, V8, P46, DOI 10.1097/00055735-199708000-00007
   Kruse FE, 1999, OPHTHALMOLOGY, V106, P1504, DOI 10.1016/S0161-6420(99)90444-X
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   LAWRENCE JM, 2003, IN PRESS INVEST OPHT
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Mizumoto H, 2003, VISION RES, V43, P1699, DOI 10.1016/S0042-6989(03)00235-9
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Rama P, 2001, TRANSPLANTATION, V72, P1478, DOI 10.1097/00007890-200111150-00002
   Roy S, 1996, INVEST OPHTH VIS SCI, V37, P258
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   SAUVE Y, 2003, IN PRESS VISION RES
   Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087
   SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   SENGUPTA N, 2003, ARVO ANN M ASS RES V
   SENGUPTA N, 2004, KEYST S STEM CELLS K
   SHATOS M, 2001, J REGENERATIVE MED, V2
   Shirakawa K, 2002, INT J CANCER, V99, P344, DOI 10.1002/ijc.10336
   Solomon A, 2001, BRIT J OPHTHALMOL, V85, P444, DOI 10.1136/bjo.85.4.444
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202
   Tseng SCG, 1998, ARCH OPHTHALMOL-CHIC, V116, P431, DOI 10.1001/archopht.116.4.431
   Van Hoffelen SJ, 2003, INVEST OPHTH VIS SCI, V44, P426, DOI 10.1167/iovs.02-0269
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460
NR 41
TC 6
Z9 16
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2004
VL 242
IS 1
BP 85
EP 90
DI 10.1007/s00417-003-0813-7
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 766PU
UT WOS:000188385400014
PM 14685872
DA 2022-11-30
ER

PT J
AU Chang, MY
   Velez, FG
   Demer, JL
   Isenberg, SJ
   Coleman, AL
   Pineles, SL
AF Chang, Melinda Y.
   Velez, Federico G.
   Demer, Joseph L.
   Isenberg, Sherwin J.
   Coleman, Anne L.
   Pineles, Stacy L.
TI Quality of Life in Adults With a Strabismus
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PSYCHOSOCIAL-ASPECTS; CORRECTIVE SURGERY; IMPACT
AB PURPOSE: To assess relative quality of life in patients with strabismus.
   DESIGN: Retrospective cohort study.
   METHODS: The 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) was performed in 42 strabismic adults over the age of 50 years at a single institution. Subscale scores were compared with those of patients with other ocular diseases, including diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, cataract, cytomegalovirus (CMV) retinitis, and low vision.
   RESULTS: Median visual acuity was 20/20 (range 20/12.5-20/50), and 34 patients (81%) reported diplopia. Strabismic patients performed the same or worse on nearly all vision-related subscales than did patients with diabetic retinopathy, age-related macular degeneration, glaucoma, cataract, and CMV retinitis. Additionally, strabismic patients reported significantly worse ocular pain than all comparison groups before any surgery was performed.
   CONCLUSIONS: Strabismus impacts quality of life through both functional and psychosocial factors. Physicians treating strabismic patients should recognize these quality-of-life issues and address them accordingly. (C) 2015 by Elsevier Inc. All rights reserved.
C1 Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Pineles, SL (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM Pineles@jsei.ucla.edu
OI Chang, Melinda/0000-0002-6169-1373; Velez, Federico
   G/0000-0001-8173-1304
FU National Eye Institute [EY08313]; National Institutes of Health/National
   Eye Institute [K23EY021762]; Knights Templar Eye Foundation; Oppenheimer
   Family Foundation; NATIONAL EYE INSTITUTE [K23EY021762, R01EY008313]
   Funding Source: NIH RePORTER
FX Joseph Demer: research grant reviewer for National Eye Institute,
   Knights Templar Eye Foundation; National Eye Institute EY08313 Research
   Grant; honoraria and travel reimbursements for visiting professorships
   and lectures; small royalties for book chapters; Sherwin Isenberg:
   consultant for Foresight Biotherapeutics; Stacy Pineles: National
   Institutes of Health/National Eye Institute K23EY021762 grant. The
   authors indicate funding support from National Institutes of
   Health/National Eye Institute K23EY021762 (S.L.P.), Knights Templar Eye
   Foundation (S.L.P.), and Oppenheimer Family Foundation (S.L.P.).
CR Alpak G, 2014, BRIT J OPHTHALMOL, V98, P876, DOI 10.1136/bjophthalmol-2014-304888
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Beauchamp George R, 2005, Trans Am Ophthalmol Soc, V103, P164
   Beauchamp GR, 2005, T AM OPHTHAL SOC, V103, P171
   Berna C, 2010, BIOL PSYCHIAT, V67, P1083, DOI 10.1016/j.biopsych.2010.01.014
   Burke JP, 1997, J PEDIAT OPHTH STRAB, V34, P159
   Coats DK, 2005, ARCH OPHTHALMOL-CHIC, V123, P497, DOI 10.1001/archopht.123.4.497
   Durnian JM, 2011, BRIT J OPHTHALMOL, V95, P450, DOI 10.1136/bjo.2010.188425
   Durnian JM, 2010, J AAPOS, V14, P469, DOI 10.1016/j.jaapos.2010.08.013
   Durnian JM, 2009, J AAPOS, V13, P477, DOI 10.1016/j.jaapos.2009.06.006
   Hartman Jill M, 2006, Health Qual Life Outcomes, V4, P2, DOI 10.1186/1477-7525-4-2
   Hatt SR, 2007, AM J OPHTHALMOL, V144, P643, DOI 10.1016/j.ajo.2007.06.032
   Hatt SR, 2014, OPHTHALMOLOGY, V121, P2070, DOI 10.1016/j.ophtha.2014.04.031
   Jackson S, 2006, BRIT J OPHTHALMOL, V90, P883, DOI 10.1136/bjo.2005.089516
   Kishimoto F, 2012, ACTA MED OKAYAMA, V66, P101
   Kovac SH, 2006, QUAL LIFE RES, V15, P451, DOI 10.1007/s11136-005-3213-0
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mangione CM., NATL EYE I 25 ITEM V
   McBain HB, 2014, BRIT J OPHTHALMOL, V98, P550, DOI 10.1136/bjophthalmol-2013-304220
   McBain HB, 2014, SURV OPHTHALMOL, V59, P185, DOI 10.1016/j.survophthal.2013.04.001
   Menon V, 2002, J PEDIAT OPHTH STRAB, V39, P203, DOI 10.3928/0191-3913-20020701-07
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Mohney BG, 2008, PEDIATRICS, V122, P1033, DOI 10.1542/peds.2007-3484
   Nelson BA, 2008, J AAPOS, V12, P72, DOI 10.1016/j.jaapos.2007.08.006
   Pineles SL, 2013, JAMA OPHTHALMOL, V131, P1413, DOI 10.1001/jamaophthalmol.2013.4484
   PRATTJOHNSON JA, 1976, CAN J OPHTHALMOL, V11, P37
   Quittner AL, 2010, CHEST, V137, P642, DOI 10.1378/chest.09-0345
   SATTERFIELD D, 1993, ARCH OPHTHALMOL-CHIC, V111, P1100, DOI 10.1001/archopht.1993.01090080096024
   Spiers A, 2009, LEISURE SCI, V31, P84, DOI 10.1080/01490400802558277
   Tandon AK, 2014, J AAPOS, V18, P423, DOI 10.1016/j.jaapos.2014.05.009
   Unruh M, 2004, KIDNEY INT, V65, P1482, DOI 10.1111/j.1523-1755.2004.00529.x
   Wu-Chen WY, 2011, OPHTHALMOLOGY, V118, P1481, DOI 10.1016/j.ophtha.2011.01.052
NR 33
TC 22
Z9 24
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2015
VL 159
IS 3
BP 539
EP 544
DI 10.1016/j.ajo.2014.12.003
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC1BV
UT WOS:000350077100017
PM 25498355
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Enoki, M
   Shinto, S
   Matsuoka, Y
   Otsuka, A
   Kaidzu, S
   Tanito, M
   Shibata, T
   Uchida, K
   Ohira, A
   Yamatoa, M
   Yamada, KI
AF Enoki, Masataka
   Shinto, Saki
   Matsuoka, Yuta
   Otsuka, Ayasa
   Kaidzu, Sachiko
   Tanito, Masaki
   Shibata, Takahiro
   Uchida, Koji
   Ohira, Akihiro
   Yamatoa, Mayumi
   Yamada, Ken-ichi
TI Lipid radicals cause light-induced retinal degeneration
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID MACULAR DEGENERATION; OXIDATIVE STRESS; PROTEIN MODIFICATIONS; DAMAGE;
   MALONDIALDEHYDE; NITROXIDE; RATS
AB Age-related macular degeneration (AMD) is the leading cause of blindness worldwide. Although the cause of AMD remains unknown, lipid peroxidation (LPO) end-products are critical molecules for its development. Herein, we report the imaging of lipid radicals, which are key factors in the LPO reaction, and therapeutic information using animal models.
C1 [Enoki, Masataka; Shinto, Saki; Matsuoka, Yuta; Otsuka, Ayasa; Yamatoa, Mayumi; Yamada, Ken-ichi] Kyushu Univ, Fac Pharmaceut Sci, Phys Chem Life Sci Lab, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Japan.
   [Kaidzu, Sachiko; Tanito, Masaki; Ohira, Akihiro] Shimane Univ, Sch Med, Dept Ophthalmol, 89-1 Enya Cho, Izumo, Shimane, Japan.
   [Shibata, Takahiro] Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Chikusa Ku, Furo Cho, Nagoya, Aichi, Japan.
   [Shibata, Takahiro] Nagoya Univ, Sch Agr Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi, Japan.
   [Shibata, Takahiro; Yamada, Ken-ichi] Japan Sci & Technol Agcy, PRESTO, 4-1-8 Hon Cho, Kawaguchi, Saitama, Japan.
   [Uchida, Koji] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Lab Food Chem,Bunkyo ku, 1-1-1 Yayoi, Tokyo, Japan.
C3 Kyushu University; Shimane University; Nagoya University; Nagoya
   University; Japan Science & Technology Agency (JST); University of Tokyo
RP Yamada, KI (通讯作者)，Kyushu Univ, Fac Pharmaceut Sci, Phys Chem Life Sci Lab, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Japan.; Yamada, KI (通讯作者)，Japan Sci & Technol Agcy, PRESTO, 4-1-8 Hon Cho, Kawaguchi, Saitama, Japan.
EM kenyamada@phar.kyushu-u.ac.jp
RI ohira, akihiro/G-8352-2017; Yamada, Ken-ichi/E-6318-2012; Shibata,
   Takahiro/I-6872-2014
OI ohira, akihiro/0000-0002-1307-5592; Yamada,
   Ken-ichi/0000-0003-2100-8477; Uchida, Koji/0000-0003-3894-5299; Shibata,
   Takahiro/0000-0003-3194-607X
FU JST PRESTO; JSPS KAKENHI [16H01363, 16K15109]; AMED; ONO Medical
   Research Foundation, Japan
FX This work was supported in part by JST PRESTO, JSPS KAKENHI grant
   numbers 16H01363 and 16K15109, the Platform Project for Supporting Drug
   Discovery and Life Science Research from the AMED, and the ONO Medical
   Research Foundation, Japan. We appreciate the technical support provided
   by the Research Support Center, Graduate School of Medical Sciences,
   Kyushu University. We thank J. Ludovic Croxford, PhD, from the Edanz
   Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
CR Bagryanskaya EG, 2014, CHEM REV, V114, P5011, DOI 10.1021/cr4000946
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hosoya K, 2010, PHARM RES-DORDR, V27, P2715, DOI 10.1007/s11095-010-0272-x
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Matier W. L., 2008, [No title captured], Patent No. 7442711
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Saito Y, 2016, J PHARMACOL SCI, V131, P215, DOI 10.1016/j.jphs.2016.05.009
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yamada K, 2016, NAT CHEM BIOL, V12, P608, DOI [10.1038/NCHEMBIO.2105, 10.1038/nchembio.2105]
   Yamasaki T, 2011, J ORG CHEM, V76, P4144, DOI 10.1021/jo200361p
   Yang JH, 2003, INVEST OPHTH VIS SCI, V44, P1312, DOI 10.1167/iovs.02-0768
   Ye X, 2010, TRENDS MOL MED, V16, P417, DOI 10.1016/j.molmed.2010.07.003
NR 26
TC 5
Z9 5
U1 0
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PD OCT 11
PY 2017
VL 53
IS 79
BP 10922
EP 10925
DI 10.1039/c7cc03387g
PG 4
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA FI7IF
UT WOS:000412169700015
PM 28930310
DA 2022-11-30
ER

PT J
AU Borgersen, NJ
   Moller-Lorentzen, T
   Sorensen, TL
   Subhi, Y
AF Borgersen, Nanna Jo
   Moller-Lorentzen, Thomas
   Sorensen, Torben Lykke
   Subhi, Yousif
TI Association between C-reactive protein and polypoidal choroidal
   vasculopathy: a systematic review and meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE blood; C&#8208; reactive protein; plasma; polypoidal choroidal
   vasculopathy; serum
ID REGULATORY T-CELLS; MACULAR DEGENERATION; INFLAMMATION
AB Aetiological processes of polypoidal choroidal vasculopathy (PCV) remains poorly understood, but several studies indicate that immunity may play a role and report elevated levels of systemic C-reactive protein (CRP). In this systematic review and meta-analysis, we summarize available evidence in the field. We searched the databases PubMed/MEDLINE, EMBASE, Web of Science and the Cochrane Central on 19 March 2020. Two independent authors reviewed the studies and extracted data. Two independent authors reviewed the studies, extracted data and evaluated risk of bias within individual studies. Studies were reviewed in the text qualitatively and measures of association were included for quantitative analyses. Results from univariate analyses and multivariate-adjusted analyses were included for separate meta-analyses to evaluate whether the association was only due to factors associated with PCV. Four studies (246 patients with PCV and 2861 control individuals) were identified and included for a qualitative and quantitative analysis. Increased CRP was associated with PCV when pooling both univariate measures (OR 3.54, 95% CI: 2.13-5.89, p < 0.0001) and multivariate-adjusted measures (OR 3.05, 95% CI: 1.56-5.98, p = 0.0011). Sensitivity analyses confirmed robustness of the results. Increased CRP is associated to PCV, even after adjusting for demographics, lifestyle factors and co-morbidities. Clinical value of CRP in relation to PCV remains unclear, but the association gives much needed insight into the aetiology of a poorly understood disease.
C1 [Borgersen, Nanna Jo; Sorensen, Torben Lykke; Subhi, Yousif] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Moller-Lorentzen, Thomas; Subhi, Yousif] Rigshosp Glostrup, Dept Ophthalmol, Copenhagen, Denmark.
   [Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
CR Bruunsgaard H, 2006, DAN MED BULL, V53, P285
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jonas JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204263
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lewis S, 2001, BMJ-BRIT MED J, V322, P1479, DOI 10.1136/bmj.322.7300.1479
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Shiels MS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju294
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0160-0
   Subhi Y, 2019, INVEST OPHTH VIS SCI, V60, P2583, DOI 10.1167/iovs.19-26882
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tarsilla M., 2010, COCHRANE HDB SYSTEMA, V6, P142, DOI [DOI 10.1002/9781119536604, 10.1002/9781119536604.ch23]
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 1982, MAC SOC M FEBR 5 198
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
NR 33
TC 3
Z9 3
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2021
VL 99
IS 5
BP 470
EP 477
DI 10.1111/aos.14655
EA OCT 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD5RN
UT WOS:000585007500001
PM 33124181
DA 2022-11-30
ER

PT J
AU Marcus, DM
   Singh, H
   Fechter, CM
   Chamberlain, DP
AF Marcus, D. M.
   Singh, H.
   Fechter, C. M.
   Chamberlain, D. P.
TI High-dose ranibizumab monotherapy for neovascular polypoidal choroidal
   vasculopathy in a predominantly non-Asian population
SO EYE
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; OBSTRUCTIVE
   SLEEP-APNEA; 2.0 MG RANIBIZUMAB; INTRAVITREAL RANIBIZUMAB; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; BLOOD-FLOW; RESIDUAL EXUDATION;
   EFFICACY
AB Purpose To determine safety and efficacy of intravitreal high-dose ranibizumab in the treatment of active neovascular polypoidal choroidal vasculopathy (PCV).
   Methods In this Phase I/II, single-center, randomized, controlled, double-masked study, predominantly non-Asian, previously treated or treatment-naive, male and female adult patients were randomized to receive high-dose (1.0/0.1 ml or 2.0 mg/0.05 ml; n = 15) or standard-dose (0.5 mg/0.05 ml; n = 5) ranibizumab in 3 monthly loading doses, followed by 9 months of criteria-based, as-needed retreatment. Safety was evaluated by a descriptive analysis of all non-serious and serious adverse events, angiographic assessments, physical examinations, vital signs, ocular examinations, and visual acuity measurements. Visual acuity and anatomic outcomes are described for the high-dose group.
   Results Twenty patients (aged 35-76 years; 8 Black, 11 White, 1 Asian) were enrolled. At baseline, in the high-dose group, mean best-corrected visual acuity (BCVA) was 63.5 letters (Snellen equivalent similar to 20/50), and mean baseline central foveal thickness (CFT) was 253.7 mu m. High-dose ranibizumab was generally well tolerated without evidence of ocular or systemic severe adverse events, including arterial thromboembolic events. At month 12, in the high-dose group, the mean overall change from baseline in BCVA was +6.7 letters and in CFT was -49.7 mu m.
   Conclusion High-dose ranibizumab monotherapy is safe and efficacious for treating patients with PCV.
C1 [Marcus, D. M.; Singh, H.] Southeast Retina Ctr, Augusta, GA 30909 USA.
   [Fechter, C. M.] Mercer Univ, Sch Med, Macon, GA 31207 USA.
   [Chamberlain, D. P.] Harvard Univ, Boston, MA 02115 USA.
C3 Mercer University; Harvard University
RP Marcus, DM (通讯作者)，Southeast Retina Ctr, 3685 Wheeler Rd, Augusta, GA 30909 USA.
EM dmarcus@southeastretina.com
FU Genentech, Inc.; Genentech, Inc., South San Francisco, CA
FX Courtney Roberts, Allison Foster, Jared Gardner, and Siobhan Ortiz
   provided technical and data support. Support for third-party writing
   assistance for this manuscript was provided by Grace H. Lee at Envision
   Scientific Solutions and funded by Genentech, Inc. This study was funded
   as an investigator-initiated trial by Genentech, Inc., South San
   Francisco, CA, and conducted at Southeast Retina Center, Augusta, GA.
   The authors have no proprietary interest. Genentech, Inc., participated
   in the review of the manuscript. Genentech, Inc., did not participate in
   the study design; conducting the study; data collection, management,
   analysis, and interpretation; or approval of the manuscript.
CR Abraham A, 2013, CLIN NEUROL NEUROSUR, V115, P1379, DOI 10.1016/j.clineuro.2012.12.037
   Birnbaum AD, 2014, JAMA OPHTHALMOL, V132, P929, DOI 10.1001/jamaophthalmol.2014.877
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kergoat H, 1999, INVEST OPHTH VIS SCI, V40, P2906
   Khayi H, 2011, INVEST OPHTH VIS SCI, V52, P9489, DOI 10.1167/iovs.11-7936
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Saito M, 2013, EYE, V27, P931, DOI 10.1038/eye.2013.114
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tonini M, 2010, SLEEP, V33, P811, DOI 10.1093/sleep/33.6.811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yonekawa Y, 2013, CAN J OPHTHALMOL, V48, pE59, DOI 10.1016/j.jcjo.2012.12.015
NR 34
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2015
VL 29
IS 11
BP 1428
EP 1436
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW5HZ
UT WOS:000365027600004
DA 2022-11-30
ER

PT J
AU Orellana-Rios, J
   Yokoyama, S
   Bhuiyan, A
   Gao, L
   Otero-Marquez, O
   Smith, RT
AF Orellana-Rios, Jorge
   Yokoyama, Sho
   Bhuiyan, Alauddin
   Gao, Liang
   Otero-Marquez, Oscar
   Smith, R. Theodore
TI Translational Retinal Imaging
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE endoscopic surgery; hyperspectral imaging; quantitative
   autofluorescence; telemedicine; translational medicine
ID QUANTITATIVE FUNDUS AUTOFLUORESCENCE; ENDOSCOPE-ASSISTED VITRECTOMY;
   OPTICAL COHERENCE TOMOGRAPHY; DISEASE; DRUSEN; EYE
AB The diagnosis and treatment of medical retinal disease is now inseparable from retinal imaging in all its multimodal incarnations. The purpose of this article is to present a selection of very different retinal imaging techniques that are truly translational, in the sense that they are not only new, but can guide us to new understandings of disease processes or interventions that are not accessible by present methods. Quantitative autofluorescence imaging, now available for clinical investigation, has already fundamentally changed our understanding of the role of lipofuscin in age-related macular degeneration. Hyperspectral autofluorescence imaging is bench science poised not only to unravel the molecular basis of retinal pigment epithelium fluorescence, but also to be translated into a clinical camera for earliest detection of age-related macular degeneration. The ophthalmic endoscope for vitreous surgery is a radically new retinal imaging system that enables surgical approaches heretofore impossible while it captures subretinal images of living tissue. Remote retinal imaging coupled with deep learning artificial intelligence will transform the very fabric of future medical care.
C1 [Orellana-Rios, Jorge] Fdn Oftalmol Los Andes, Vitacura, Santiago De Chi, Chile.
   [Yokoyama, Sho] Chukyo Hosp, Dept Ophthalmol, Japan Community Healthcare Org, Nagoya, Aichi, Japan.
   [Bhuiyan, Alauddin] iHealthScreen Inc, New York, NY USA.
   [Gao, Liang] Univ Calif Los Angeles, Dept Biomed Engn, Los Angeles, CA USA.
   [Otero-Marquez, Oscar; Smith, R. Theodore] Icahn Sch Med Mt Sinai, Dept Ophthalmol, 1 Gustave L Levy Pl, New York, NY 10029 USA.
C3 University of California System; University of California Los Angeles;
   Icahn School of Medicine at Mount Sinai
RP Smith, RT (通讯作者)，Icahn Sch Med Mt Sinai, Dept Ophthalmol, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM rtslmd@gmail.com
OI Yokoyama, Sho/0000-0002-5962-3179; smith, theodore/0000-0002-1693-943X
FU NIH [R01 EY015520]
FX NIH R01 EY015520 (RTS).
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Al Sabti K, 2012, BRIT J OPHTHALMOL, V96, P1399, DOI 10.1136/bjophthalmol-2012-302187
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Zapata MA, 2020, CLIN OPHTHALMOL, V14, P419, DOI 10.2147/OPTH.S235751
   Ben Ami T, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.5
   Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P3159, DOI 10.1167/iovs.14-16343
   Duncker T, 2015, OPHTHALMOLOGY, V122, P345, DOI 10.1016/j.ophtha.2014.08.017
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   Duncker T, 2013, INVEST OPHTH VIS SCI, V54, P6820, DOI 10.1167/iovs.13-12895
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Gao L, 2012, BIOMED OPT EXPRESS, V3, P48, DOI 10.1364/BOE.3.000048
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gliem M, 2017, INVEST OPHTH VIS SCI, V58, P6159, DOI 10.1167/iovs.17-22007
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P101, DOI 10.1167/iovs.10-5799
   Kaga T, 2019, RETINA-J RET VIT DIS, V39, P896, DOI 10.1097/IAE.0000000000002031
   Mohammed Taariq, 2018, Vision (Basel), V2, DOI 10.3390/vision2040038
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P1937, DOI 10.1167/iovs.19-26566
   Reiter GS, 2019, ACTA OPHTHALMOL, V97, pE526, DOI 10.1111/aos.13987
   Ren H, 2013, GRAEF ARCH CLIN EXP, V251, P1797, DOI 10.1007/s00417-013-2297-4
   Schuerch K, 2017, INVEST OPHTH VIS SCI, V58, P1843, DOI 10.1167/iovs.16-21302
   Smith RT, 2014, BIOMED OPT EXPRESS, V5, P4171, DOI 10.1364/BOE.5.004171
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith RT, 2009, INVEST OPHTH VIS SCI, V50, P3907, DOI 10.1167/iovs.08-2448
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Wang Y, 2019, EXP EYE RES, V184, P48, DOI 10.1016/j.exer.2019.04.004
   Yokoyama S, 2017, CLIN OPHTHALMOL, V11, P2003, DOI 10.2147/OPTH.S147690
   Yoshitake S, 2012, JPN J OPHTHALMOL, V56, P613, DOI 10.1007/s10384-012-0176-x
NR 37
TC 2
Z9 3
U1 0
U2 2
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAY-JUN
PY 2020
VL 9
IS 3
BP 269
EP 277
DI 10.1097/APO.0000000000000292
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LY2AH
UT WOS:000540322300013
PM 32487917
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Payne, AJ
   Kaja, S
   Naumchuk, Y
   Kunjukunju, N
   Koulen, P
AF Payne, Andrew J.
   Kaja, Simon
   Naumchuk, Yuliya
   Kunjukunju, Nancy
   Koulen, Peter
TI Antioxidant Drug Therapy Approaches for Neuroprotection in Chronic
   Diseases of the Retina
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE reactive oxygen species; oxidative stress; neuroprotection; age-related
   macular degeneration; diabetic retinopathy; glaucoma
ID GLYCATION END-PRODUCTS; GANGLION-CELL LAYER; OXIDATIVE STRESS; MACULAR
   DEGENERATION; POLY(ADP-RIBOSE) POLYMERASE; DIABETIC-RETINOPATHY;
   MITOCHONDRIAL-DNA; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY;
   GLUTAMATE TOXICITY
AB The molecular pathways contributing to visual signal transduction in the retina generate a high energy demand that has functional and structural consequences such as vascularization and high metabolic rates contributing to oxidative stress. Multiple signaling cascades are involved to actively regulate the redox state of the retina. Age-related processes increase the oxidative load, resulting in chronically elevated levels of oxidative stress and reactive oxygen species, which in the retina ultimately result in pathologies such as glaucoma or age-related macular degeneration, as well as the neuropathic complications of diabetes in the eye. Specifically, oxidative stress results in deleterious changes to the retina through dysregulation of its intracellular physiology, ultimately leading to neurodegenerative and potentially also vascular dysfunction. Herein we will review the evidence for oxidative stress-induced contributions to each of the three major ocular pathologies, glaucoma, age-related macular degeneration, and diabetic retinopathy. The premise for neuroprotective strategies for these ocular disorders will be discussed in the context of recent clinical and preclinical research pursuing novel therapy development approaches.
C1 [Payne, Andrew J.; Kaja, Simon; Naumchuk, Yuliya; Kunjukunju, Nancy; Koulen, Peter] Univ Missouri, Sch Med, Dept Ophthalmol, Vis Res Ctr, Kansas City, MO 64108 USA.
   [Koulen, Peter] Univ Missouri, Sch Med, Dept Basic Med Sci, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City
RP Koulen, P (通讯作者)，Univ Missouri, Sch Med, Dept Ophthalmol, Vis Res Ctr, Kansas City, MO 64108 USA.
EM paynea@umkc.edu; kajas@umkc.edu; yn8r4@umkc.edu; kunjukunjun@umkc.edu;
   koulenp@umkc.edu
RI ; Kaja, Simon/C-2267-2015
OI Naumchuk, Yuliya/0000-0001-6498-1627; Kaja, Simon/0000-0001-6878-521X
FU National Eye Institute [EY014227, EY022774]; National Institute on Aging
   [AG010485, AG022550, AG027956]; National Center for Research Resources;
   National Institute of General Medical Sciences of the National
   Institutes of Health [RR022570, RR027093]; Felix and Carmen Sabates
   Missouri Endowed Chair in Vision Research; Vision Research Foundation of
   Kansas City; Research to Prevent Blindness Challenge Grant; NATIONAL
   CENTER FOR RESEARCH RESOURCES [S10RR022570, S10RR027093] Funding Source:
   NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY022774, R01EY014227] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022550,
   P01AG027956, P01AG010485] Funding Source: NIH RePORTER
FX Research reported in this publication was supported by grants from the
   National Eye Institute (EY014227 and EY022774); the National Institute
   on Aging (AG010485, AG022550 and AG027956); the National Center for
   Research Resources and National Institute of General Medical Sciences
   (RR022570 and RR027093) of the National Institutes of Health (to PK).
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health. Additional support by the Felix and Carmen Sabates Missouri
   Endowed Chair in Vision Research, the Vision Research Foundation of
   Kansas City and a Research to Prevent Blindness Challenge Grant (to PK)
   is gratefully acknowledged. The authors thank Margaret, Richard and Sara
   Koulen for generous support and encouragement.
CR Abu El-Asrar A. M., 2011, J OPHTHALMOL, V25, P113
   Albrecht P, 2010, CNS NEUROL DISORD-DR, V9, P373, DOI 10.2174/187152710791292567
   American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   Annweiler C, 2012, DRUG AGING, V29, P81, DOI 10.2165/11597550-000000000-00000
   Arden GB, 2011, CURR DIABETES REV, V7, P291, DOI 10.2174/157339911797415620
   Arentoft A, 2009, BRAIN COGNITION, V71, P147, DOI 10.1016/j.bandc.2009.04.009
   Barbosa AM, 2012, GENET MOL RES, V11, P3256, DOI 10.4238/2012.September.12.8
   Baskol G, 2008, EUR J OPHTHALMOL, V18, P792, DOI 10.1177/112067210801800521
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Burroughs SL, 2011, INVEST OPHTH VIS SCI, V52, P3654, DOI 10.1167/iovs.10-7106
   Carrasco E, 2008, MOL VIS, V14, P1496
   Chang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027218
   Chang EE, 2012, OPHTHALMOLOGY, V119, P979, DOI 10.1016/j.ophtha.2011.11.003
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   Cook C, 2012, CAN J OPHTHALMOL, V47, P223, DOI 10.1016/j.jcjo.2012.02.003
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Drel VR, 2009, INVEST OPHTH VIS SCI, V50, P1778, DOI 10.1167/iovs.08-2191
   Duncan RS, 2011, CLIN OPHTHALMOL, V5, P543, DOI 10.2147/OPTH.S18309
   Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50
   Dutcher JP, 2004, CLIN CANCER RES, V10, p6382S, DOI 10.1158/1078-0432.CCR-050008
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Engin KN, 2010, MOL VIS, V16, P1260
   Erdurmus M, 2011, CURR EYE RES, V36, P713, DOI 10.3109/02713683.2011.584370
   Fang JH, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-31
   Feilchenfeld Z, 2008, EXP EYE RES, V87, P409, DOI 10.1016/j.exer.2008.07.011
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Foster MT, 2009, ENDOCRINOLOGY, V150, P2325, DOI 10.1210/en.2008-1426
   Fride E, 2002, PROSTAG LEUKOTR ESS, V66, P221, DOI 10.1054/plef.2001.0360
   Fujinami A, 2008, CLIN BIOCHEM, V41, P812, DOI 10.1016/j.clinbiochem.2008.03.003
   Garg P, 2010, NEUROSCIENCE, V166, P252, DOI 10.1016/j.neuroscience.2009.11.069
   Garg P, 2011, NEUROSCI LETT, V492, P134, DOI 10.1016/j.neulet.2011.01.073
   Giangiacomo A, 2009, GLAUCOMA, P13, DOI DOI 10.1007/978-3-540-69475-5_2
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Gupta Madhur M, 2005, Indian J Physiol Pharmacol, V49, P187
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hartnett ME, 2000, DIABETES CARE, V23, P234, DOI 10.2337/diacare.23.2.234
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu MK, 2002, J MED CHEM, V45, P2277, DOI 10.1021/jm010308g
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Garcia-Medina JJ, 2011, EUR J OPHTHALMOL, V21, P637, DOI 10.5301/EJO.2010.6212
   Kaja S, 2003, INVEST OPHTH VIS SCI, V44, P3155, DOI 10.1167/iovs.02-1204
   Kaja S, 2011, NEUROSCIENCE, V175, P281, DOI 10.1016/j.neuroscience.2010.11.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kern TS, 2008, J PHYSIOL-LONDON, V586, P4401, DOI 10.1113/jphysiol.2008.156695
   King A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3518
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kubota R., 2013, RETINA
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Lee DA, 2005, AM J HEALTH-SYST PH, V62, P691, DOI 10.1093/ajhp/62.7.691
   LEVENE RZ, 1980, SURV OPHTHALMOL, V24, P621, DOI 10.1016/0039-6257(80)90123-X
   Li Q, 2002, INVEST OPHTH VIS SCI, V43, P3109
   Li WM, 2007, MOL PHARMACOL, V71, P1258, DOI 10.1124/mol.106.029108
   Li WM, 2005, J BIOL CHEM, V280, P18179, DOI 10.1074/jbc.M411085200
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lombardi G, 2007, J PHARMACOL EXP THER, V320, P599, DOI 10.1124/jpet.106.112987
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   Mancino R, 2011, MOL VIS, V17, P1298
   Manea A, 2004, J CELL MOL MED, V8, P117, DOI 10.1111/j.1582-4934.2004.tb00266.x
   McElnea EM, 2011, MOL VIS, V17, P1182
   Milne R, 2013, AMINO ACIDS, V44, P1397, DOI 10.1007/s00726-011-1071-3
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Mochimaru H, 2007, INVEST OPHTH VIS SCI, V48, P4795, DOI 10.1167/iovs.07-0425
   MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3
   Mustata GT, 2005, DIABETES, V54, P517, DOI 10.2337/diabetes.54.2.517
   Mysona B, 2009, CELL TISSUE RES, V335, P477, DOI 10.1007/s00441-008-0742-1
   Nowak M, 2010, CLIN EXP MED, V10, P185, DOI 10.1007/s10238-009-0084-7
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Ola MS, 2012, J DIABETES COMPLICAT, V26, P56, DOI 10.1016/j.jdiacomp.2011.11.004
   Osborne NN, 2013, CURR OPIN PHARMACOL, V13, P16, DOI 10.1016/j.coph.2012.09.002
   Osborne NN, 2009, ACTA OPHTHALMOL, V87, P450, DOI 10.1111/j.1755-3768.2008.01459.x
   Pan HZ, 2008, BRIT J OPHTHALMOL, V92, P548, DOI 10.1136/bjo.2007.130542
   Panfoli I, 2011, BIOCHIMIE, V93, P1565, DOI 10.1016/j.biochi.2011.05.020
   Panfoli I, 2009, INT J BIOCHEM CELL B, V41, P2555, DOI 10.1016/j.biocel.2009.08.013
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100
   Prokai-Tatrai K, 2013, MOL PHARMACEUT, V10, P3253, DOI 10.1021/mp400313u
   Quigley HA, 2012, CURR OPIN OPHTHALMOL, V23, P144, DOI 10.1097/ICU.0b013e32834ff490
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105
   Silva KC, 2013, INVEST OPHTH VIS SCI, V54, P1325, DOI 10.1167/iovs.12-10647
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sozio P, 2013, EUR J PHARM SCI, V49, P187, DOI 10.1016/j.ejps.2013.02.013
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sugawara R, 2004, CURR EYE RES, V29, P11, DOI 10.1080/02713680490513146
   Suzuki S, 1999, DIABETES RES CLIN PR, V45, P161, DOI 10.1016/S0168-8227(99)00046-7
   Takahashi H, 2008, INVEST OPHTH VIS SCI, V49, P2143, DOI 10.1167/iovs.07-0523
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Tuncay E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071014
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Valverde AM, 2013, MOL VIS, V19, P47
   Villarroel M, 2010, WORLD J DIABETES, V1, P57, DOI 10.4239/wjd.v1.i2.57
   Wang AL, 2008, MOL VIS, V14, P644
   Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446
   Wilkinson D, 2012, INT J GERIATR PSYCH, V27, P769, DOI 10.1002/gps.2788
   Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Xie L, 2008, INVEST OPHTH VIS SCI, V49, P4203, DOI 10.1167/iovs.07-1364
   Yamagishi S, 2005, CURR DIABETES REV, V1, P93, DOI 10.2174/1573399052952631
   Yazulla S, 2008, PROG RETIN EYE RES, V27, P501, DOI 10.1016/j.preteyeres.2008.07.002
   Yildirim Z, 2007, ANN NY ACAD SCI, V1100, P199, DOI 10.1196/annals.1395.019
   Zhang XY, 2013, INT J BIOCHEM CELL B, V45, P1525, DOI 10.1016/j.biocel.2013.03.002
   Zhang ZH, 2011, INT J OPHTHALMOL-CHI, V4, P125, DOI 10.3980/j.issn.2222-3959.2011.02.03
   Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960
   Zhou JL, 2008, PHOTOCHEM PHOTOBIOL, V84, P75, DOI 10.1111/j.1751-1097.2007.00205.x
NR 122
TC 45
Z9 46
U1 1
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2014
VL 15
IS 2
BP 1865
EP 1886
DI 10.3390/ijms15021865
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AG9YP
UT WOS:000335776400011
PM 24473138
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Sugiyama, A
   Yoneyama, S
   Tanabe, N
   Matsubara, M
   Mabuchi, F
   Iijima, H
AF Kikushima, Wataru
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Yoneyama, Seigo
   Tanabe, Naohiko
   Matsubara, Mio
   Mabuchi, Fumihiko
   Iijima, Hiroyuki
TI Comparison of two-year outcomes after photodynamic therapy with
   ranibizumab or aflibercept for polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT; LESION SIZE; THICKNESS;
   ASSOCIATION; VERTEPORFIN; POPULATION; INJECTION; VEGF
AB Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the first-line treatment for polypoidal choroidal vasculopathy (PCV), along with anti-VEGF monotherapy. In this study, 100 eyes with treatment-naive PCV were initially treated with PDT combined with intravitreal ranibizumab (IVR; n = 57) or aflibercept (IVA; n = 43). We compared two-year outcomes between these two groups and investigated factors associated with visual improvement and retreatment over 24 months. Best-corrected visual acuity (BCVA) was significantly improved in both groups (P < 0.001) at 24 months. Multiple regression analysis revealed that visual improvement at 24 months was associated with female (P = 0.030), worse baseline BCVA (P = 3.0 x 10(-6)), smaller greatest linear dimension (GLD; P = 2.0 x 10(-4)), and treatment with IVA rather than IVR (P = 0.016). Multiple logistic regression analysis revealed that absence of retreatment was associated with younger age (P = 2.2 x 10(-4)), female (P = 1.2 x 10(-3)), and the non-risk variants of ARMS2 A69S (P = 6.0 x 10(-4)). Although there were no significant differences in the retreatment rate between the two groups, PDT/IVA may be superior to PDT/IVR in terms of visual improvement at 24 months.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Sugiyama, Atsushi; Yoneyama, Seigo; Tanabe, Naohiko; Matsubara, Mio; Mabuchi, Fumihiko; Iijima, Hiroyuki] Yamanashi Univ, Dept Ophthalmol, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Yamanashi Univ, Dept Ophthalmol, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
FU Japan Society for the Promotion of Science KAKENHI Grant [23791972]
FX This work was supported by Japan Society for the Promotion of Science
   KAKENHI Grant Number 23791972 (Y.S.).
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sato T., 2013, AM J OPHTHALMOL, V156
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 37
TC 20
Z9 20
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 28
PY 2017
VL 7
AR 16461
DI 10.1038/s41598-017-16476-1
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FN9YF
UT WOS:000416398100011
PM 29184088
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lois, N
   Abdelkader, E
   Reglitz, K
   Garden, C
   Ayres, JG
AF Lois, N.
   Abdelkader, E.
   Reglitz, K.
   Garden, C.
   Ayres, J. G.
TI Environmental tobacco smoke exposure and eye disease
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID FACTOR-H POLYMORPHISM; AGE-RELATED MACULOPATHY; CIGARETTE-SMOKING;
   MACULAR DEGENERATION; PASSIVE SMOKING; RISK-FACTOR; GRAVES
   OPHTHALMOPATHY; ALCOHOL AMBLYOPIA; OCULAR GROWTH; LENS
AB Aim: To undertake a systematic review of the literature on the effect of environmental tobacco smoke (ETS) and eye disease.
   Methods: Medline (1950-January Week 2 2007), EMBASE (1980 to 2007 Week 07), SCOPUS and Science Direct were searched on ETS exposure and eye disease using various combinations of the following terms: passive smoking, environmental tobacco smoke, sidestream smoke, involuntary smoking, secondhand smoke; with eye, conjunctiva, sclera, episclera, cornea, lens, iris, retina, choroid, uvea, optic nerve, uveitis, iritis, blindness, visual loss, cataract, thyroid eye disease, conjunctivitis, age-related macular degeneration, dry eye, tears. The above terms were also used to search abstracts published on The Association for Research in Vision and Ophthalmology Annual Meeting abstracts, from 1995 to 2006, and the grey literature, including PhD and MSc theses/dissertations. A search was further conducted specifically on eye diseases where active smoking has been proposed to be a risk factor, including age-related macular degeneration, Graves ophthalmology, glaucoma, uveitis, refractive errors, strabismus, tobacco-alcohol amblyopia, non-arteritic ischaemic optic neuropathy, Leber optic neuropathy and diabetic retinopathy. Given the scarce number of studies found through the above search, all articles found on ETS and eye disease were included in this review.
   Results: Seven studies evaluated the possible relationship between ETS and an eye disease. These studies referred to refractive errors in children (n=2), cataract (n=1), age-related macular degeneration (n=3) and Grave ophthalmopathy (n=1). The data available were insufficient to establish conclusive relationships between ETS and these eye diseases.
   Conclusion: Very scarce data exist in the literature on the effect of ETS on diseases of the eye. It seems appropriate that ETS should be included in future studies addressing the effect of smoking on eye disease.
C1 [Lois, N.; Abdelkader, E.] Grampian Univ Hosp NHS Trust, Dept Ophthalmol, Aberdeen, Scotland.
   [Reglitz, K.; Garden, C.; Ayres, J. G.] Univ Aberdeen, Dept Environm & Occupat Med, Aberdeen AB25 2ZD, Scotland.
C3 University of Aberdeen; University of Aberdeen
RP Lois, N (通讯作者)，Univ Aberdeen, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland.
EM noemilois@aol.com
FU Royal National Institute
FX The authors wish to thank the Royal National Institute for the Blind for
   their support for this research.
CR Altinors DD, 2006, AM J OPHTHALMOL, V141, P1016, DOI 10.1016/j.ajo.2005.12.047
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Annesi-Maesano I, 2004, CLIN EXP ALLERGY, V34, P1017, DOI 10.1111/j.1365-2222.2004.02002.x
   Avunduk AM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1368, DOI 10.1001/archopht.117.10.1368
   Avunduk AM, 1997, OPHTHALMOLOGICA, V211, P296, DOI 10.1159/000310812
   BAKER RR, 1990, ENVIRON INT, V16, P231, DOI 10.1016/0160-4120(90)90117-O
   Bartalena L, 1998, ANN INTERN MED, V129, P632, DOI 10.7326/0003-4819-129-8-199810150-00010
   BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304, DOI 10.1164/ajrccm/143.6.1304
   Bates MN, 2002, TOB CONTROL, V11, P125, DOI 10.1136/tc.11.2.125
   BERTELSEN JB, 1994, THYROID, V4, P327, DOI 10.1089/thy.1994.4.327
   BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188
   Bonovas S, 2004, PUBLIC HEALTH, V118, P256, DOI 10.1016/j.puhe.2003.09.009
   Burch HB, 1997, EXP EYE RES, V65, P311, DOI 10.1006/exer.1997.0353
   Cawood T, 2004, BRIT MED J, V329, P385, DOI 10.1136/bmj.329.7462.385
   Cawood TJ, 2007, J CLIN ENDOCR METAB, V92, P59, DOI 10.1210/jc.2006-1824
   Chapman S, 2007, BMJ-BRIT MED J, V335, P521, DOI 10.1136/bmj.39315.616169.BE
   Cherrie J W, 1999, Appl Occup Environ Hyg, V14, P539, DOI 10.1080/104732299302530
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   CHUNG SM, 1994, OPHTHALMOLOGY, V101, P779
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cumming RG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1296, DOI 10.1001/archopht.1997.01100160466015
   Cutter Gary R., 1996, CLAO Journal, V22, P30
   DANG CV, 1981, MED HYPOTHESES, V7, P1317, DOI 10.1016/0306-9877(81)90122-5
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Eckstein A, 2003, BRIT J OPHTHALMOL, V87, P773, DOI 10.1136/bjo.87.6.773
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisner MD, 2002, CHEST, V122, P826, DOI 10.1378/chest.122.3.826
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980
   Hahn EJ, 2006, J OCCUP ENVIRON MED, V48, P906, DOI 10.1097/01.jom.0000215709.09305.01
   HAHN H, 2005, SECONDHAND SMOKE EXP
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAKIM RB, 1992, ARCH OPHTHALMOL-CHIC, V110, P1459, DOI 10.1001/archopht.1992.01080220121033
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Haw SJ, 2006, J PUBLIC HEALTH-UK, V28, P24, DOI 10.1093/pubmed/fdi080
   Hiller R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1113, DOI 10.1001/archopht.1997.01100160283003
   IUVONE PM, 1991, INVEST OPHTH VIS SCI, V32, P1674
   Jarvis MJ, 2001, TOB CONTROL, V10, P368, DOI 10.1136/tc.10.4.368
   Johansson A, 2005, ANN EPIDEMIOL, V15, P453, DOI 10.1016/j.annepidem.2004.09.012
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kimata H, 2004, HUM EXP TOXICOL, V23, P215, DOI 10.1191/0960327104ht445oa
   Klein B E, 1999, Ophthalmic Epidemiol, V6, P247
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krassas GE, 2005, EUR J ENDOCRINOL, V153, P515, DOI 10.1530/eje.1.01991
   KRUMSIEK J, 1985, ACTA NEUROL SCAND, V72, P180
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973
   Lee SI, 2001, J KOREAN MED SCI, V16, P155, DOI 10.3346/jkms.2001.16.2.155
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Monso E, 2004, AM J IND MED, V46, P357, DOI 10.1002/ajim.20077
   MUHLHAUSER I, 1986, DIABETOLOGIA, V29, P500, DOI 10.1007/BF00453501
   Muhlhauser I, 1996, DIABETIC MED, V13, P536, DOI 10.1002/(SICI)1096-9136(199606)13:6<536::AID-DIA110>3.0.CO;2-J
   MUSSALORAUHAMAA H, 1986, ARCH ENVIRON HEALTH, V41, P49, DOI 10.1080/00039896.1986.9935765
   Pfeilschifter J, 1996, CLIN ENDOCRINOL, V45, P477, DOI 10.1046/j.1365-2265.1996.8220832.x
   Prabhakar BS, 2003, ENDOCR REV, V24, P802, DOI 10.1210/er.2002-0020
   PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479
   RAMAKRISHNAN S, 1995, BRIT J OPHTHALMOL, V79, P202, DOI 10.1136/bjo.79.3.202
   Repace J, 2004, TOB CONTROL, V13, P8, DOI 10.1136/tc.2003.003111
   RODENSTEIN DO, 1985, AM REV RESPIR DIS, V132, P628
   ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0
   ROY H, 1993, JAMA-J AM MED ASSOC, V269, P748, DOI 10.1001/jama.269.6.748
   Ryder MI, 2002, ORAL MICROBIOL IMMUN, V17, P331, DOI 10.1034/j.1399-302X.2002.170601.x
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Satici A, 2003, ACTA OPHTHALMOL SCAN, V81, P583, DOI 10.1111/j.1395-3907.2003.00158.x
   Saw SM, 2004, BRIT J OPHTHALMOL, V88, P934, DOI 10.1136/bjo.2003.033175
   SCHEIN OD, 1990, CORNEA, V9, pS55
   Schick S, 2005, TOB CONTROL, V14, P396, DOI 10.1136/tc.2005.011288
   SCHWARTZ DA, 1992, ANN INTERN MED, V116, P630, DOI 10.7326/0003-4819-116-8-630
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEMPLE S, 2006, FOCUS RES
   SHALINI VK, 1994, INDIAN J BIOCHEM BIO, V31, P261
   SHINE B, 1990, LANCET, V335, P1261, DOI 10.1016/0140-6736(90)91315-2
   Singh J, 2005, J ALLERGY CLIN IMMUN, V115, P330, DOI 10.1016/j.jaci.2004.11.021
   Siverio CD, 2001, INVEST OPHTH VIS SCI, V42, pS708
   SLINEY DH, 1986, INVEST OPHTH VIS SCI, V27, P781
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   STEWART E, 2004, DEV PASSIVE SAMPLERS
   Stone RA, 2003, INVEST OPHTH VIS SCI, V44, P3933, DOI 10.1167/iovs.02-0774
   Stone RA, 2001, INVEST OPHTH VIS SCI, V42, P557
   Stone RA, 2006, INVEST OPHTH VIS SCI, V47, P4277, DOI 10.1167/iovs.05-1625
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2007, EYE, V21, P1135, DOI 10.1038/sj.eye.6702603
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsao K, 1999, BRIT J OPHTHALMOL, V83, P577, DOI 10.1136/bjo.83.5.577
   Utiger RD, 1998, EUR J ENDOCRINOL, V138, P368, DOI 10.1530/eje.0.1380368
   VARMA SD, 1984, CURR EYE RES, V3, P35, DOI 10.3109/02713688408997186
   Vestergaard P, 2002, EUR J ENDOCRINOL, V146, P153, DOI 10.1530/eje.0.1460153
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023
   Wegener A, 2002, OPHTHALMIC RES, V34, P273, DOI 10.1159/000065598
   Wegener A, 2002, OPHTHALMIC RES, V34, P281, DOI 10.1159/000065599
   WESSELIUS LJ, 1994, AM J RESP CRIT CARE, V150, P690, DOI 10.1164/ajrccm.150.3.8087339
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yolton K, 2005, ENVIRON HEALTH PERSP, V113, P98, DOI 10.1289/ehp.7210
   Yoon Kyung-Chul, 2005, Korean J Ophthalmol, V19, P18
   Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8
   1986, REPORT HLTH EFFECTS
   1992, DISCOMFORT ENV TOBAC
NR 108
TC 69
Z9 73
U1 0
U2 20
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2008
VL 92
IS 10
BP 1304
EP 1310
DI 10.1136/bjo.2008.141168
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 352NJ
UT WOS:000259503600002
PM 18658170
DA 2022-11-30
ER

EF